Torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
during O O
low O O
dose O O
intermittent O O
dobutamine O O
treatment O O
in O O
a O O
patient O O
with O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
and O O
congestive B-Disease B-Disease
heart I-Disease I-Disease
failure I-Disease I-Disease
. O O

The O O
authors O O
describe O O
the O O
case O O
of O O
a O O
56-year O O
- O O
old O O
woman O O
with O O
chronic O O
, O O
severe O O
heart B-Disease B-Disease
failure I-Disease I-Disease
secondary O O
to O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
and O O
absence O O
of O O
significant O O
ventricular B-Disease B-Disease
arrhythmias I-Disease I-Disease
who O O
developed O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
and O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
during O O
one O O
cycle O O
of O O
intermittent O O
low O O
dose O O
( O O
2.5 O O
mcg O O
/ O O
kg O O
per O O
min O O
) O O
dobutamine O O
. O O

This O O
report O O
of O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
during O O
intermittent O O
dobutamine O O
supports O O
the O O
hypothesis O O
that O O
unpredictable O O
fatal O O
arrhythmias B-Disease B-Disease
may O O
occur O O
even O O
with O O
low O O
doses O O
and O O
in O O
patients O O
with O O
no O O
history O O
of O O
significant O O
rhythm O O
disturbances O O
. O O

The O O
mechanisms O O
of O O
proarrhythmic O O
effects O O
of O O
Dubutamine O O
are O O
discussed O O
. O O

Positive O O
skin O O
tests O O
in O O
late O O
reactions O O
to O O
radiographic O O
contrast O O
media O O
. O O

In O O
the O O
last O O
few O O
years O O
delayed O O
reactions O O
several O O
hours O O
after O O
the O O
injection O O
of O O
radiographic O O
and O O
contrast O O
materials O O
( O O
PRC O O
) O O
have O O
been O O
described O O
with O O
increasing O O
frequency O O
. O O

The O O
authors O O
report O O
two O O
observations O O
on O O
patients O O
with O O
delayed O O
reactions O O
in O O
whom O O
intradermoreactions O O
( O O
IDR O O
) O O
and O O
patch O O
tests O O
to O O
a O O
series O O
of O O
ionic O O
and O O
non O O
ionic O O
PRC O O
were O O
studied O O
. O O

After O O
angiography O O
by O O
the O O
venous O O
route O O
in O O
patient O O
n O O
degree O O
1 O O
a O O
biphasic O O
reaction O O
with O O
an O O
immediate O O
reaction O O
( O O
dyspnea B-Disease B-Disease
, O O
loss B-Disease B-Disease
of I-Disease I-Disease
consciousness I-Disease I-Disease
) O O
and O O
delayed O O
macro B-Disease B-Disease
- I-Disease I-Disease
papular I-Disease I-Disease
rash I-Disease I-Disease
appeared O O
, O O
whilst O O
patient O O
n O O
degree O O
2 O O
developed O O
a O O
generalised O O
sensation O O
of O O
heat O O
, O O
persistent O O
pain B-Disease B-Disease
at O O
the O O
site O O
of O O
injection O O
immediately O O
and O O
a O O
generalised O O
macro O O
- O O
papular O O
reaction O O
after O O
24 O O
hours O O
. O O

The O O
skin O O
tests O O
revealed O O
positive O O
delayed O O
reactions O O
of O O
24 O O
hours O O
and O O
48 O O
hours O O
by O O
IDR O O
and O O
patch O O
tests O O
to O O
only O O
some O O
PRC O O
with O O
common O O
chains O O
in O O
their O O
structures O O
. O O

The O O
positive O O
skin O O
tests O O
are O O
in O O
favour O O
of O O
immunological O O
reactions O O
and O O
may O O
help O O
in O O
diagnosis O O
of O O
allergy B-Disease B-Disease
in O O
the O O
patients O O
. O O

Risk O O
of O O
transient O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
in O O
cancer B-Disease B-Disease
patients O O
who O O
received O O
continuous O O
infusion O O
of O O
5-fluorouracil O O
with O O
the O O
complication O O
of O O
dehydration B-Disease B-Disease
and O O
infection B-Disease B-Disease
. O O

From O O
1986 O O
to O O
1998 O O
, O O
29 O O
cancer B-Disease B-Disease
patients O O
who O O
had O O
32 O O
episodes O O
of O O
transient O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
related O O
to O O
continuous O O
infusion O O
of O O
5-fluorouracil O O
( O O
5-FU O O
) O O
were O O
identified O O
. O O

None O O
of O O
the O O
patients O O
had O O
decompensated O O
liver B-Disease B-Disease
disease I-Disease I-Disease
. O O

Onset O O
of O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
varied O O
from O O
0.5 O O
to O O
5 O O
days O O
( O O
mean O O
: O O
2.6 O O
+ O O
/- O O

1.3 O O
days O O
) O O
after O O
the O O
initiation O O
of O O
chemotherapy O O
. O O

Plasma O O
ammonium O O
level O O
ranged O O
from O O
248 O O
to O O
2387 O O
microg% O O
( O O
mean O O
: O O
626 O O
+ O O
/- O O

431 O O
microg% O O
) O O
. O O

Among O O
the O O
32 O O
episodes O O
, O O
26 O O
( O O
81 O O
% O O
) O O
had O O
various O O
degrees O O
of O O
azotemia B-Disease B-Disease
, O O
18 O O
( O O
56 O O
% O O
) O O
occurred O O
during O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
and O O
14 O O
( O O
44 O O
% O O
) O O
without O O
infection B-Disease B-Disease
occurred O O
during O O
periods O O
of O O
dehydration B-Disease B-Disease
. O O

Higher O O
plasma O O
ammonium O O
levels O O
and O O
more O O
rapid O O
onset O O
of O O
hyperammonemia B-Disease B-Disease
were O O
seen O O
in O O
18 O O
patients O O
with O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
( O O
p=0.003 O O
and O O
0.0006 O O
, O O
respectively O O
) O O
and O O
in O O
nine O O
patients O O
receiving O O
high O O
daily O O
doses O O
( O O
2600 O O
or O O
1800 O O
mg O O
/ O O
m2 O O
) O O
of O O
5-FU O O
( O O
p=0.0001 O O
and O O
< O O
0.0001 O O
, O O
respectively O O
) O O
. O O

In O O
25 O O
out O O
of O O
32 O O
episodes O O
( O O
78 O O
% O O
) O O
, O O
plasma O O
ammonium O O
levels O O
and O O
mental O O
status O O
returned O O
to O O
normal O O
within O O
2 O O
days O O
after O O
adequate O O
management O O
. O O

In O O
conclusion O O
, O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
can O O
occur O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5-FU O O
. O O

Azotemia B-Disease B-Disease
, O O
body O B-Disease
fluid O I-Disease
insufficiency O I-Disease
and O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
were O O
frequently O O
found O O
in O O
these O O
patients O O
. O O

It O O
is O O
therefore O O
important O O
to O O
recognize O O
this O O
condition O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5-FU O O
. O O

The O O
effects O O
of O O
quinine O O
and O O
4-aminopyridine O O
on O O
conditioned O O
place O O
preference O O
and O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine O O
in O O
rats O O
. O O

1 O O
. O O

The O O
effects O O
of O O
two O O
unselective O O
potassium O O
( O O
K O O
( O O
+ O O
) O O
- O O
) O O
channel O O
blockers O O
, O O
quinine O O
( O O
12.5 O O
, O O
25 O O
and O O
50 O O
mg O O
/ O O
kg O O
) O O
and O O
4-aminopyridine O O
( O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
) O O
, O O
on O O
conditioned O O
place O O
preference O O
and O O
biphasic O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
were O O
tested O O
in O O
Wistar O O
rats O O
. O O

Quinine O O
is O O
known O O
to O O
block O O
voltage- O O
, O O
calcium- O O
and O O
ATP O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
-channels O O
while O O
4-aminopyridine O O
is O O
known O O
to O O
block O O
voltage O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
-channels O O
. O O

2 O O
. O O

In O O
the O O
counterbalanced O O
method O O
, O O
quinine O O
attenuated O O
morphine O O
- O O
induced O O
place O O
preference O O
, O O
whereas O O
4-aminopyridine O O
was O O
ineffective O O
. O O

In O O
the O O
motor O O
activity O O
test O O
measured O O
with O O
an O O
Animex O O
- O O
activity O O
meter O O
neither O O
of O O
the O O
K O O
( O O
+ O O
) O O
-channel O O
blockers O O
affected O O
morphine O O
- O O
induced O O
hypoactivity B-Disease B-Disease
, O O
but O O
both O O
K O O
( O O
+ O O
) O O
-channel O O
blockers O O
prevented O O
morphine O O
- O O
induced O O
secondary O O
hyperactivity B-Disease B-Disease
. O O

3 O O
. O O

These O O
results O O
suggest O O
the O O
involvement O O
of O O
quinine O O
- O O
sensitive O O
but O O
not O O
4-aminopyridine O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
-channels O O
in O O
morphine O O
reward O O
. O O

It O O
is O O
also O O
suggested O O
that O O
the O O
blockade O O
of O O
K O O
( O O
+ O O
) O O
-channels O O
sensitive O O
to O O
these O O
blockers O O
is O O
not O O
sufficient O O
to O O
prevent O O
morphine O O
- O O
induced O O
hypoactivity B-Disease B-Disease
whereas O O
morphine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
seems O O
to O O
be O O
connected O O
to O O
both O O
quinine- O O
and O O
4-aminopyridine O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
-channels O O
. O O

Nociceptin O O
/ O O
orphanin O O
FQ O O
and O O
nocistatin O O
on O O
learning B-Disease B-Disease
and I-Disease I-Disease
memory I-Disease I-Disease
impairment I-Disease I-Disease
induced O O
by O O
scopolamine O O
in O O
mice O O
. O O

1 O O
. O O
Nociceptin O O
, O O
also O O
known O O
as O O
orphanin O O
FQ O O
, O O
is O O
an O O
endogenous O O
ligand O O
for O O
the O O
orphan O O
opioid O O
receptor O O
- O O
like O O
receptor O O
1 O O
( O O
ORL1 O O
) O O
and O O
involves O O
in O O
various O O
functions O O
in O O
the O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
. O O

On O O
the O O
other O O
hand O O
, O O
nocistatin O O
is O O
recently O O
isolated O O
from O O
the O O
same O O
precursor O O
as O O
nociceptin O O
and O O
blocks O O
nociceptin O O
- O O
induced O O
allodynia B-Disease B-Disease
and O O
hyperalgesia B-Disease B-Disease
. O O

2 O O
. O O

Although O O
ORL1 O O
receptors O O
which O O
display O O
a O O
high O O
degree O O
of O O
sequence O O
homology O O
with O O
classical O O
opioid O O
receptors O O
are O O
abundant O O
in O O
the O O
hippocampus O O
, O O
little O O
is O O
known O O
regarding O O
their O O
role O O
in O O
learning O O
and O O
memory O O
. O O

3 O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
whether O O
nociceptin O O
/ O O
orphanin O O
FQ O O
and O O
nocistatin O O
could O O
modulate O O
impairment B-Disease B-Disease
of I-Disease I-Disease
learning I-Disease I-Disease
and I-Disease I-Disease
memory I-Disease I-Disease
induced O O
by O O
scopolamine O O
, O O
a O O
muscarinic O O
cholinergic O O
receptor O O
antagonist O O
, O O
using O O
spontaneous O O
alternation O O
of O O
Y O O
- O O
maze O O
and O O
step O O
- O O
down O O
type O O
passive O O
avoidance O O
tasks O O
in O O
mice O O
. O O

4 O O
. O O
While O O
nocistatin O O
( O O
0.5 O O
- O O
5.0 O O
nmol O O
mouse-1 O O
, O O
i.c.v O O
. O O
) O O
administered O O
30 O O
min O O
before O O
spontaneous O O
alternation O O
performance O O
or O O
the O O
training O O
session O O
of O O
the O O
passive O O
avoidance O O
task O O
, O O
had O O
no O O
effect O O
on O O
spontaneous O O
alternation O O
or O O
passive O O
avoidance O O
behaviours O O
, O O
a O O
lower O O
per O O
cent O O
alternation O O
and O O
shorter O O
median O O
step O O
- O O
down O O
latency O O
in O O
the O O
retention O O
test O O
were O O
obtained O O
in O O
nociceptin O O
( O O
1.5 O O
and/or O O
5.0 O O
nmol O O
mouse-1 O O
, O O
i.c.v. O O
) O O
-treated O O
normal O O
mice O O
. O O

5 O O
. O O
Administration O O
of O O
nocistatin O O
( O O
1.5 O O
and/or O O
5.0 O O
nmol O O
mouse-1 O O
, O O
i.c.v O O
. O O
) O O
30 O O
min O O
before O O
spontaneous O O
alternation O O
performance O O
or O O
the O O
training O O
session O O
of O O
the O O
passive O O
avoidance O O
task O O
, O O
attenuated O O
the O O
scopolamine O O
- O O
induced O O
impairment O B-Disease
of O I-Disease
spontaneous O I-Disease
alternation O I-Disease
and O O
passive O O
avoidance O O
behaviours O O
. O O

6 O O
. O O

These O O
results O O
indicated O O
that O O
nocistatin O O
, O O
a O O
new O O
biologically O O
active O O
peptide O O
, O O
ameliorates O O
impairments O O
of O O
spontaneous O O
alternation O O
and O O
passive O O
avoidance O O
induced O O
by O O
scopolamine O O
, O O
and O O
suggested O O
that O O
these O O
peptides O O
play O O
opposite O O
roles O O
in O O
learning O O
and O O
memory O O
. O O

Meloxicam O O
- O O
induced O O
liver B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

We O O
report O O
the O O
case O O
of O O
a O O
female O O
patient O O
with O O
rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
who O O
developed O O
acute O O
cytolytic O O
hepatitis B-Disease B-Disease
due O O
to O O
meloxicam O O
. O O

Recently O O
introduced O O
in O O
Belgium O O
, O O
meloxicam O O
is O O
the O O
first O O
nonsteroidal O O
antiinflammatory O O
drug O O
with O O
selective O O
action O O
on O O
the O O
inducible O O
form O O
of O O
cyclooxygenase O O
2 O O
. O O

The O O
acute O O
cytolytic O O
hepatitis B-Disease B-Disease
occurred O O
rapidly O O
after O O
meloxicam O O
administration O O
and O O
was O O
associated O O
with O O
the O O
development O O
of O O
antinuclear O O
antibodies O O
suggesting O O
a O O
hypersensitivity B-Disease B-Disease
mechanism O O
. O O

This O O
first O O
case O O
of O O
meloxicam O O
related O O
liver B-Disease B-Disease
toxicity I-Disease I-Disease
demonstrates O O
the O O
potential O O
of O O
this O O
drug O O
to O O
induce O O
hepatic B-Disease B-Disease
damage I-Disease I-Disease
. O O

Induction O O
of O O
apoptosis O O
by O O
remoxipride O O
metabolites O O
in O O
HL60 O O
and O O
CD34+ O O
/ O O
CD19- O O
human O O
bone O O
marrow O O
progenitor O O
cells O O
: O O
potential O O
relevance O O
to O O
remoxipride O O
- O O
induced O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
. O O

The O O
antipsychotic O O
agent O O
, O O
remoxipride O O
[ O O
( O O
S O O
) O O
- O O
( O O
- O O
) O O
-3-bromo O O
- O O
N- O O
[ O O
( O O
1-ethyl-2-pyrrolidinyl O O
) O O
methyl O O
] O O
-2,6-dimethoxybenz O O
amide O O
] O O
has O O
been O O
associated O O
with O O
acquired O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
. O O

We O O
have O O
examined O O
the O O
ability O O
of O O
remoxipride O O
, O O
three O O
pyrrolidine O O
ring O O
metabolites O O
and O O
five O O
aromatic O O
ring O O
metabolites O O
of O O
the O O
parent O O
compound O O
to O O
induce O O
apoptosis O O
in O O
HL60 O O
cells O O
and O O
human O O
bone O O
marrow O O
progenitor O O
( O O
HBMP O O
) O O
cells O O
. O O

Cells O O
were O O
treated O O
for O O
0 O O
- O O
24 O O
h O O
with O O
each O O
compound O O
( O O
0 O O
- O O
200 O O
microM O O
) O O
. O O

Apoptosis O O
was O O
assessed O O
by O O
fluorescence O O
microscopy O O
in O O
Hoechst O O
33342- O O
and O O
propidium O O
iodide O O
stained O O
cell O O
samples O O
. O O

Results O O
were O O
confirmed O O
by O O
determination O O
of O O
internucleosomal O O
DNA O O
fragmentation O O
using O O
gel O O
electrophoresis O O
for O O
HL60 O O
cell O O
samples O O
and O O
terminal O O
deoxynucleotidyl O O
transferase O O
assay O O
in O O
HBMP O O
cells O O
. O O

The O O
catechol O O
and O O
hydroquinone O O
metabolites O O
, O O
NCQ436 O O
and O O
NCQ344 O O
, O O
induced O O
apoptosis O O
in O O
HL60 O O
and O O
HBMP O O
cells O O
in O O
a O O
time- O O
and O O
concentration O O
dependent O O
manner O O
, O O
while O O
the O O
phenols O O
, O O
NCR181 O O
, O O
FLA873 O O
, O O
and O O
FLA797 O O
, O O
and O O
the O O
derivatives O O
formed O O
by O O
oxidation O O
of O O
the O O
pyrrolidine O O
ring O O
, O O
FLA838 O O
, O O
NCM001 O O
, O O
and O O
NCL118 O O
, O O
had O O
no O O
effect O O
. O O

No O O
necrosis B-Disease B-Disease
was O O
observed O O
in O O
cells O O
treated O O
with O O
NCQ436 O O
but O O
NCQ344 O O
had O O
a O O
biphasic O O
effect O O
in O O
both O O
cell O O
types O O
, O O
inducing O O
apoptosis O O
at O O
lower O O
concentrations O O
and O O
necrosis B-Disease B-Disease
at O O
higher O O
concentrations O O
. O O

These O O
data O O
show O O
that O O
the O O
catechol O O
and O O
hydroquinone O O
metabolites O O
of O O
remoxipride O O
have O O
direct O O
toxic O O
effects O O
in O O
HL60 O O
and O O
HBMP O O
cells O O
, O O
leading O O
to O O
apoptosis O O
, O O
while O O
the O O
phenol O O
metabolites O O
were O O
inactive O O
. O O

Similarly O O
, O O
benzene O O
- O O
derived O O
catechol O O
and O O
hydroquinone O O
, O O
but O O
not O O
phenol O O
, O O
induce O O
apoptosis O O
in O O
HBMP O O
cells O O
[ O O
Moran O O
et O O
al. O O
, O O
Mol O O
. O O

Pharmacol O O
. O O
, O O
50 O O
( O O
1996 O O
) O O
610 O O
- O O
615 O O
] O O
. O O

We O O
propose O O
that O O
remoxipride O O
and O O
benzene O O
may O O
induce O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
via O O
production O O
of O O
similar O O
reactive O O
metabolites O O
and O O
that O O
the O O
ability O O
of O O
NCQ436 O O
and O O
NCQ344 O O
to O O
induce O O
apoptosis O O
in O O
HBMP O O
cells O O
may O O
contribute O O
to O O
the O O
mechanism O O
underlying O O
acquired O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
that O O
has O O
been O O
associated O O
with O O
remoxipride O O
. O O

Synthesis O O
and O O
preliminary O O
pharmacological O O
investigations O O
of O O
1- O O
( O O
1,2-dihydro-2-acenaphthylenyl O O
) O O
piperazine O O
derivatives O O
as O O
potential O O
atypical O O
antipsychotic O O
agents O O
in O O
mice O O
. O O

In O O
research O O
towards O O
the O O
development O O
of O O
new O O
atypical O O
antipsychotic O O
agents O O
, O O
one O O
strategy O O
is O O
that O O
the O O
dopaminergic O O
system O O
can O O
be O O
modulated O O
through O O
manipulation O O
of O O
the O O
serotonergic O O
system O O
. O O

The O O
synthesis O O
and O O
preliminary O O
pharmacological O O
evaluation O O
of O O
a O O
series O O
of O O
potential O O
atypical O O
antipsychotic O O
agents O O
based O O
on O O
the O O
structure O O
of O O
1- O O
( O O
1,2-dihydro-2-acenaphthylenyl O O
) O O
piperazine O O
( O O
7 O O
) O O
is O O
described O O
. O O

Compound O O
7e O O
, O O
5- O O
{ O O
2- O O
[ O O
4- O O
( O O
1,2-dihydro-2-acenaphthylenyl O O
) O O
piperazinyl O O
] O O
ethyl O O
} O O
-2,3-dihy O O
dro-1H- O O
indol-2-one O O
, O O
from O O
this O O
series O O
showed O O
significant O O
affinities O O
at O O
the O O
5-HT1A O O
and O O
5-HT2A O O
receptors O O
and O O
moderate O O
affinity O O
at O O
the O O
D2 O O
receptor O O
. O O

7e O O
exhibits O O
a O O
high O O
reversal O O
of O O
catalepsy B-Disease B-Disease
induced O O
by O O
haloperidol O O
indicating O O
its O O
atypical O O
antipsychotic O O
nature O O
. O O

Sub O O
- O O
chronic O O
inhibition O O
of O O
nitric O O
- O O
oxide O O
synthesis O O
modifies O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
and O O
the O O
number O O
of O O
NADPH O O
- O O
diaphorase O O
neurons O O
in O O
mice O O
. O O

RATIONALE O O
: O O
NG O O
- O O
nitro O O
- O O
L O O
- O O
arginine O O
( O O
L O O
- O O
NOARG O O
) O O
, O O
an O O
inhibitor O O
of O O
nitric O O
- O O
oxide O O
synthase O O
( O O
NOS O O
) O O
, O O
induces O O
catalepsy B-Disease B-Disease
in O O
mice O O
. O O

This O O
effect O O
undergoes O O
rapid O O
tolerance O O
, O O
showing O O
a O O
significant O O
decrease O O
after O O
2 O O
days O O
of O O
sub O O
- O O
chronic O O
L O O
- O O
NOARG O O
treatment O O
. O O

Nitric O O
oxide O O
( O O
NO O O
) O O
has O O
been O O
shown O O
to O O
influence O O
dopaminergic O O
neurotransmission O O
in O O
the O O
striatum O O
. O O

Neuroleptic O O
drugs O O
such O O
as O O
haloperidol O O
, O O
which O O
block O O
dopamine O O
receptors O O
, O O
also O O
cause O O
catalepsy B-Disease B-Disease
in O O
rodents O O
. O O

OBJECTIVES O O
: O O
To O O
investigate O O
the O O
effects O O
of O O
subchronic O O
L O O
- O O
NOARG O O
treatment O O
in O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
and O O
the O O
number O O
of O O
NOS O O
neurons O O
in O O
areas O O
related O O
to O O
motor O O
control O O
. O O

METHODS O O
: O O
Male O O
albino O O
Swiss O O
mice O O
were O O
treated O O
sub O O
- O O
chronically O O
( O O
twice O O
a O O
day O O
for O O
4 O O
days O O
) O O
with O O
L O O
- O O
NOARG O O
( O O
40 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
or O O
haloperidol O O
( O O
1 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
. O O

Catalepsy B-Disease B-Disease
was O O
evaluated O O
at O O
the O O
beginning O O
and O O
the O O
end O O
of O O
the O O
treatments O O
. O O

Reduced O O
nicotinamide O O
adenine O O
dinucleotide O O
phosphate O O
- O O
diaphorase O O
( O O
NADPH O O
- O O
d O O
) O O
histochemistry O O
was O O
also O O
employed O O
to O O
visualize O O
NOS O O
as O O
an O O
index O O
of O O
enzyme O O
expression O O
in O O
mice O O
brain O O
regions O O
related O O
to O O
motor O O
control O O
. O O

RESULTS O O
: O O
L O O
- O O
NOARG O O
sub O O
- O O
chronic O O
administration O O
produced O O
tolerance O O
of O O
L O O
- O O
NOARG O O
and O O
of O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
. O O

It O O
also O O
induced O O
an O O
increase O O
in O O
the O O
number O O
of O O
NADPH O O
- O O
d O O
- O O
positive O O
cells O O
in O O
the O O
dorsal O O
part O O
of O O
the O O
caudate O O
and O O
accumbens O O
nuclei O O
compared O O
with O O
haloperidol O O
and O O
in O O
the O O
pedunculopontine O O
tegmental O O
nucleus O O
compared O O
with O O
saline O O
. O O

In O O
contrast O O
, O O
there O O
was O O
a O O
decrease O O
in O O
NADPH O O
- O O
d O O
neuron O O
number O O
in O O
the O O
substantia O O
nigra O O
, O O
pars O O
compacta O O
in O O
both O O
haloperidol O O
- O O
treated O O
and O O
L O O
- O O
NOARG O O
- O O
treated O O
animals O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
give O O
further O O
support O O
to O O
the O O
hypothesis O O
that O O
NO O O
plays O O
a O O
role O O
in O O
motor O O
behavior O O
control O O
and O O
suggest O O
that O O
it O O
may O O
take O O
part O O
in O O
the O O
synaptic O O
changes O O
produced O O
by O O
antipsychotic O O
treatment O O
. O O

Prolonged O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
occurs O O
in O O
patients O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
after O O
both O O
dobutamine O O
and O O
exercise O O
induced O O
myocardial B-Disease B-Disease
ischaemia I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
To O O
determine O O
whether O O
pharmacological O O
stress O O
leads O O
to O O
prolonged O O
but O O
reversible O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
in O O
patients O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
, O O
similar O O
to O O
that O O
seen O O
after O O
exercise O O
. O O

DESIGN O O
: O O
A O O
randomised O O
crossover O O
study O O
of O O
recovery O O
time O O
of O O
systolic O O
and O O
diastolic O O
left O O
ventricular O O
function O O
after O O
exercise O O
and O O
dobutamine O O
induced O O
ischaemia B-Disease B-Disease
. O O

SUBJECTS O O
: O O
10 O O
patients O O
with O O
stable B-Disease B-Disease
angina I-Disease I-Disease
, O O
angiographically O O
proven O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
, O O
and O O
normal O O
left O O
ventricular O O
function O O
. O O

INTERVENTIONS O O
: O O
Treadmill O O
exercise O O
and O O
dobutamine O O
stress O O
were O O
performed O O
on O O
different O O
days O O
. O O

Quantitative O O
assessment O O
of O O
systolic O O
and O O
diastolic O O
left O O
ventricular O O
function O O
was O O
performed O O
using O O
transthoracic O O
echocardiography O O
at O O
baseline O O
and O O
at O O
regular O O
intervals O O
after O O
each O O
test O O
. O O

RESULTS O O
: O O
Both O O
forms O O
of O O
stress O O
led O O
to O O
prolonged O O
but O O
reversible O O
systolic O B-Disease
and O I-Disease
diastolic O I-Disease
dysfunction O I-Disease
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
maximum O O
double O O
product O O
( O O
p O O
= O O
0.53 O O
) O O
or O O
ST O O
depression B-Disease B-Disease
( O O
p O O
= O O
0.63 O O
) O O
with O O
either O O
form O O
of O O
stress O O
. O O

After O O
exercise O O
, O O
ejection O O
fraction O O
was O O
reduced O O
at O O
15 O O
and O O
30 O O
minutes O O
compared O O
with O O
baseline O O
( O O
mean O O
( O O
SEM O O
) O O
, O O
-5.6 O O
( O O
1.5 O O
) O O
% O O
, O O
p O O
< O O
0.05 O O
; O O
and O O
-6.1 O O
( O O
2.2 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
at O O
30 O O
and O O
45 O O
minutes O O
after O O
dobutamine O O
( O O
-10.8 O O
( O O
1.8 O O
) O O
% O O
and O O
-5 O O
. O O

5 O O
( O O
1.8 O O
) O O
% O O
, O O
both O O
p O O
< O O
0.01 O O
) O O
. O O

Regional O O
analysis O O
showed O O
a O O
reduction O O
in O O
the O O
worst O O
affected O O
segment O O
15 O O
and O O
30 O O
minutes O O
after O O
exercise O O
( O O
-27.9 O O
( O O
7.2 O O
) O O
% O O
and O O
-28.6 O O
( O O
5.7 O O
) O O
% O O
, O O
both O O
p O O
< O O
0.01 O O
) O O
, O O
and O O
at O O
30 O O
minutes O O
after O O
dobutamine O O
( O O
-32 O O
( O O
5.3 O O
) O O
% O O
, O O
p O O
< O O
0.01 O O
) O O
. O O

The O O
isovolumic O O
relaxation O O
period O O
was O O
prolonged O O
45 O O
minutes O O
after O O
each O O
form O O
of O O
stress O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

CONCLUSIONS O O
: O O
In O O
patients O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
, O O
dobutamine O O
induced O O
ischaemia B-Disease B-Disease
results O O
in O O
prolonged O O
reversible O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
, O O
presumed O O
to O O
be O O
myocardial B-Disease B-Disease
stunning I-Disease I-Disease
, O O
similar O O
to O O
that O O
seen O O
after O O
exercise O O
. O O

Dobutamine O O
induced O O
ischaemia B-Disease B-Disease
could O O
therefore O O
be O O
used O O
to O O
study O O
the O O
pathophysiology O O
of O O
this O O
phenomenon O O
further O O
in O O
patients O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
. O O

Anorexigens O O
and O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
in O O
the O O
United O O
States O O
: O O
results O O
from O O
the O O
surveillance O O
of O O
North O O
American O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
. O O

BACKGROUND O O
: O O
The O O
use O O
of O O
appetite O O
suppressants O O
in O O
Europe O O
has O O
been O O
associated O O
with O O
the O O
development O O
of O O
primary B-Disease B-Disease
pulmonary I-Disease I-Disease
hypertension I-Disease I-Disease
( O O
PPH B-Disease B-Disease
) O O
. O O

Recently O O
, O O
fenfluramine O O
appetite O O
suppressants O O
became O O
widely O O
used O O
in O O
the O O
United O O
States O O
but O O
were O O
withdrawn O O
in O O
September O O
1997 O O
because O O
of O O
concerns O O
over O O
adverse O O
effects O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
conducted O O
a O O
prospective O O
surveillance O O
study O O
on O O
patients O O
diagnosed O O
with O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
at O O
12 O O
large O O
referral O O
centers O O
in O O
North O O
America O O
. O O

Data O O
collected O O
on O O
patients O O
seen O O
from O O
September O O
1 O O
, O O
1996 O O
, O O
to O O
December O O
31 O O
, O O
1997 O O
, O O
included O O
the O O
cause O O
of O O
the O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
and O O
its O O
severity O O
. O O

Patients O O
with O O
no O O
identifiable O O
cause O O
of O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
were O O
classed O O
as O O
PPH B-Disease B-Disease
. O O

A O O
history O O
of O O
drug O O
exposure O O
also O O
was O O
taken O O
with O O
special O O
attention O O
on O O
the O O
use O O
of O O
antidepressants O O
, O O
anorexigens O O
, O O
and O O
amphetamines O O
. O O

RESULTS O O
: O O
Five O O
hundred O O
seventy O O
- O O
nine O O
patients O O
were O O
studied O O
, O O
205 O O
with O O
PPH B-Disease B-Disease
and O O
374 O O
with O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
from O O
other O O
causes O O
( O O
secondary O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
[ O O
SPH O B-Disease
] O O
) O O
. O O

The O O
use O O
of O O
anorexigens O O
was O O
common O O
in O O
both O O
groups O O
. O O

However O O
, O O
of O O
the O O
medications O O
surveyed O O
, O O
only O O
the O O
fenfluramines O O
had O O
a O O
significant O O
preferential O O
association O O
with O O
PPH B-Disease B-Disease
as O O
compared O O
with O O
SPH O O
( O O
adjusted O O
odds O O
ratio O O
for O O
use O O
> O O
6 O O
months O O
, O O
7.5 O O
; O O
95 O O
% O O
confidence O O
interval O O
, O O
1.7 O O
to O O
32.4 O O
) O O
. O O

The O O
association O O
was O O
stronger O O
with O O
longer O O
duration O O
of O O
use O O
when O O
compared O O
to O O
shorter O O
duration O O
of O O
use O O
and O O
was O O
more O O
pronounced O O
in O O
recent O O
users O O
than O O
in O O
remote O O
users O O
. O O

An O O
unexpectedly O O
high O O
( O O
11.4 O O
% O O
) O O
number O O
of O O
patients O O
with O O
SPH O O
had O O
used O O
anorexigens O O
. O O

CONCLUSION O O
: O O
The O O
magnitude O O
of O O
the O O
association O O
with O O
PPH B-Disease B-Disease
, O O
the O O
increase O O
of O O
association O O
with O O
increasing O O
duration O O
of O O
use O O
, O O
and O O
the O O
specificity O O
for O O
fenfluramines O O
are O O
consistent O O
with O O
previous O O
studies O O
indicating O O
that O O
fenfluramines O O
are O O
causally O O
related O O
to O O
PPH B-Disease B-Disease
. O O

The O O
high O O
prevalence O O
of O O
anorexigen O O
use O O
in O O
patients O O
with O O
SPH O O
also O O
raises O O
the O O
possibility O O
that O O
these O O
drugs O O
precipitate O O
pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
in O O
patients O O
with O O
underlying O O
conditions O O
associated O O
with O O
SPH O O
. O O

Clinical O O
aspects O O
of O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
and O O
thrombosis B-Disease B-Disease
and O O
other O O
side O O
effects O O
of O O
heparin O O
therapy O O
. O O

Heparin O O
, O O
first O O
used O O
to O O
prevent O O
the O O
clotting O O
of O O
blood O O
in O O
vitro O O
, O O
has O O
been O O
clinically O O
used O O
to O O
treat O O
thrombosis B-Disease B-Disease
for O O
more O O
than O O
50 O O
years O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin O O
remains O O
the O O
anticoagulant O O
of O O
choice O O
to O O
treat O O
acute O O
thrombotic B-Disease B-Disease
episodes O O
. O O

The O O
clinical O O
effects O O
of O O
heparin O O
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Bleeding B-Disease B-Disease
is O O
the O O
primary O O
untoward O O
effect O O
of O O
heparin O O
. O O

Major O O
bleeding B-Disease B-Disease
is O O
of O O
primary O O
concern O O
in O O
patients O O
receiving O O
heparin O O
therapy O O
. O O

However O O
, O O
additional O O
important O O
untoward O O
effects O O
of O O
heparin O O
therapy O O
include O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
, O O
heparin O O
- O O
associated O O
osteoporosis B-Disease B-Disease
, O O
eosinophilia B-Disease B-Disease
, O O
skin B-Disease B-Disease
reactions I-Disease I-Disease
, O O
allergic B-Disease B-Disease
reactions I-Disease I-Disease
other O O
than O O
thrombocytopenia B-Disease B-Disease
, O O
alopecia B-Disease B-Disease
, O O
transaminasemia O B-Disease
, O O
hyperkalemia B-Disease B-Disease
, O O
hypoaldosteronism B-Disease B-Disease
, O O
and O O
priapism B-Disease B-Disease
. O O

These O O
side O O
effects O O
are O O
relatively O O
rare O O
in O O
a O O
given O O
individual O O
, O O
but O O
given O O
the O O
extremely O O
widespread O O
use O O
of O O
heparin O O
, O O
some O O
are O O
quite O O
common O O
, O O
particularly O O
HITT B-Disease B-Disease
and O O
osteoporosis B-Disease B-Disease
. O O

Although O O
reasonable O O
incidences O O
of O O
many O O
of O O
these O O
side O O
effects O O
can O O
be O O
" O O
softly O O
" O O
deduced O O
from O O
current O O
reports O O
dealing O O
with O O
unfractionated O O
heparin O O
, O O
at O O
present O O
the O O
incidences O O
of O O
these O O
side O O
effects O O
with O O
newer O O
low O O
molecular O O
weight O O
heparins O O
appear O O
to O O
be O O
much O O
less O O
common O O
. O O

However O O
, O O
only O O
longer O O
experience O O
will O O
more O O
clearly O O
define O O
the O O
incidence O O
of O O
each O O
side O O
effect O O
with O O
low O O
molecular O O
weight O O
preparations O O
. O O

A O O
case O O
of O O
bilateral O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
in O O
a O O
patient O O
on O O
tacrolimus O O
( O O
FK506 O O
) O O
therapy O O
after O O
liver O O
transplantation O O
. O O

PURPOSE O O
: O O
To O O
report O O
a O O
case O O
of O O
bilateral O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
in O O
a O O
patient O O
receiving O O
tacrolimus O O
( O O
FK O O
506 O O
, O O
Prograf O O
; O O
Fujisawa O O
USA O O
, O O
Inc O O
, O O
Deerfield O O
, O O
Illinois O O
) O O
for O O
immunosuppression O O
after O O
orthotropic O O
liver O O
transplantation O O
. O O

METHOD O O
: O O
Case O O
report O O
. O O

In O O
a O O
58-year O O
- O O
old O O
man O O
receiving O O
tacrolimus O O
after O O
orthotropic O O
liver O O
transplantation O O
, O O
serial O O
neuro O O
- O O
ophthalmologic O O
examinations O O
and O O
laboratory O O
studies O O
were O O
performed O O
. O O

RESULTS O O
: O O
The O O
patient O O
had O O
episodic O O
deterioration O B-Disease
of O I-Disease
vision O I-Disease
in O O
both O O
eyes O O
, O O
with O O
clinical O O
features O O
resembling O O
ischemic B-Disease B-Disease
optic I-Disease I-Disease
neuropathies I-Disease I-Disease
. O O

Deterioration B-Disease B-Disease
of I-Disease I-Disease
vision I-Disease I-Disease
occurred O O
despite O O
discontinuation O O
of O O
the O O
tacrolimus O O
. O O

CONCLUSION O O
: O O
Tacrolimus O O
and O O
other O O
immunosuppressive O O
agents O O
may O O
be O O
associated O O
with O O
optic B-Disease B-Disease
nerve I-Disease I-Disease
toxicity I-Disease I-Disease
. O O

Hypercalcemia B-Disease B-Disease
, O O
arrhythmia B-Disease B-Disease
, O O
and O O
mood O O
stabilizers O O
. O O

Recent O O
findings O O
in O O
a O O
bipolar B-Disease B-Disease
patient O O
receiving O O
maintenance O O
lithium O O
therapy O O
who O O
developed O O
hypercalcemia B-Disease B-Disease
and O O
severe O O
bradyarrhythmia B-Disease B-Disease
prompted O O
the O O
authors O O
to O O
conduct O O
a O O
retrospective O O
study O O
of O O
bipolar B-Disease B-Disease
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B-Disease B-Disease
. O O

A O O
printout O O
of O O
all O O
cases O O
of O O
hypercalcemia B-Disease B-Disease
that O O
presented O O
during O O
a O O
1-year O O
period O O
was O O
generated O O
. O O

After O O
eliminating O O
spurious O O
hypercalcemias B-Disease B-Disease
or O O
those O O
associated O O
with O O
intravenous O O
fluids O O
, O O
the O O
authors O O
identified O O
18 O O
non O O
- O O
lithium O O
- O O
treated O O
patients O O
with O O
hypercalcemias B-Disease B-Disease
related O O
to O O
malignancies B-Disease B-Disease
and O O
other O O
medical O O
conditions O O
( O O
group O O
A O O
) O O
and O O
12 O O
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B-Disease B-Disease
( O O
group O O
B O O
) O O
. O O

Patients O O
in O O
group O O
B O O
were O O
not O O
comparable O O
to O O
those O O
in O O
group O O
A O O
, O O
as O O
the O O
latter O O
were O O
medically O O
compromised O O
and O O
were O O
receiving O O
multiple O O
pharmacotherapies O O
. O O

Thus O O
, O O
two O O
control O O
groups O O
were O O
generated O O
: O O
group O O
C1 O O
, O O
which O O
included O O
age- O O
and O O
sex O O
- O O
comparable O O
lithium O O
- O O
treated O O
bipolar B-Disease B-Disease
normocalcemic O O
patients O O
, O O
and O O
group O O
C2 O O
, O O
which O O
included O O
bipolar B-Disease B-Disease
normocalcemic O O
patients O O
treated O O
with O O
anticonvulsant O O
mood O O
stabilizers O O
. O O

The O O
electrocardiographic O O
( O O
ECG O O
) O O
findings O O
for O O
patients O O
in O O
group O O
B O O
were O O
compared O O
with O O
those O O
of O O
patients O O
in O O
groups O O
C1 O O
and O O
C2 O O
. O O

It O O
was O O
found O O
that O O
these O O
groups O O
did O O
not O O
differ O O
in O O
their O O
overall O O
frequency O O
of O O
ECG O O
abnormalities O O
; O O
however O O
, O O
there O O
were O O
significant O O
differences O O
in O O
the O O
frequency O O
of O O
conduction O O
defects O O
. O O

Patients O O
with O O
hypercalcemia B-Disease B-Disease
resulting O O
from O O
medical O O
diseases O O
and O O
bipolar B-Disease B-Disease
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B-Disease B-Disease
had O O
significantly O O
higher O O
frequencies O O
of O O
conduction O O
defects O O
. O O

Patients O O
in O O
group O O
A O O
had O O
significant O O
mortality O O
at O O
2-year O O
follow O O
- O O
up O O
( O O
28 O O
% O O
) O O
, O O
in O O
contrast O O
to O O
zero O O
mortality O O
in O O
the O O
other O O
three O O
groups O O
. O O

The O O
clinical O O
implications O O
of O O
these O O
findings O O
are O O
discussed O O
. O O

Attenuation O O
of O O
nephrotoxicity B-Disease B-Disease
by O O
a O O
novel O O
lipid O O
nanosphere O O
( O O
NS-718 O O
) O O
incorporating O O
amphotericin O O
B. O O
NS-718 O O
, O O
a O O
lipid O O
nanosphere O O
incorporating O O
amphotericin O O
B O O
, O O
is O O
effective O O
against O O
pathogenic O O
fungi O O
and O O
has O O
low O O
toxicity B-Disease O
. O O

We O O
compared O O
the O O
toxicity B-Disease B-Disease
of O O
NS-718 O O
with O O
that O O
of O O
Fungizone O O
( O O
amphotericin O O
B O O
- O O
sodium O O
deoxycholate O O
; O O
D O O
- O O
AmB O O
) O O
in O O
vitro O O
using O O
renal O O
cell O O
cultures O O
and O O
in O O
vivo O O
by O O
biochemical O O
analysis O O
, O O
histopathological O O
study O O
of O O
the O O
kidney O O
and O O
pharmacokinetic O O
study O O
of O O
amphotericin O O
B O O
following O O
intravenous O O
infusion O O
of O O
the O O
formulation O O
in O O
rats O O
. O O

Incubation O O
with O O
NS-718 O O
resulted O O
in O O
significantly O O
less O O
damage O O
of O O
cultured O O
human O O
renal O O
proximal O O
tubular O O
epithelial O O
cells O O
compared O O
with O O
D O O
- O O
AmB. O O
Serum O O
blood O O
urea O O
and O O
creatinine O O
concentrations O O
increased O O
significantly O O
in O O
rats O O
given O O
an O O
iv O O
infusion O O
of O O
D O O
- O O
AmB O O
3 O O
mg O O
/ O O
kg O O
but O O
not O O
in O O
those O O
given O O
the O O
same O O
dose O O
of O O
NS-718 O O
. O O

Histopathological O O
examination O O
of O O
the O O
kidney O O
showed O O
tubular B-Disease B-Disease
necrosis I-Disease I-Disease
in O O
D O O
- O O
AmB O O
- O O
treated O O
rats O O
but O O
no O O
change O O
in O O
NS-718-treated O O
rats O O
. O O

Amphotericin O O
B O O
concentrations O O
in O O
the O O
kidney O O
in O O
NS-718-treated O O
rats O O
were O O
higher O O
than O O
those O O
in O O
D O O
- O O
AmB O O
- O O
treated O O
rats O O
. O O

Our O O
in O O
vitro O O
and O O
in O O
vivo O O
results O O
suggest O O
that O O
incorporation O O
of O O
amphotericin O O
B O O
into O O
lipid O O
nanospheres O O
of O O
NS-718 O O
attenuates O O
the O O
nephrotoxicity B-Disease B-Disease
of O O
amphotericin O O
B. O O

Patterns O O
of O O
sulfadiazine O O
acute B-Disease O
nephrotoxicity I-Disease B-Disease
. O O

Sulfadiazine O O
acute B-Disease O
nephrotoxicity I-Disease B-Disease
is O O
reviving O O
specially O O
because O O
of O O
its O O
use O O
in O O
toxoplasmosis B-Disease B-Disease
in O O
HIV O O
- O O
positive O O
patients O O
. O O

We O O
report O O
4 O O
cases O O
, O O
one O O
of O O
them O O
in O O
a O O
previously O O
healthy O O
person O O
. O O

Under O O
treatment O O
with O O
sulfadiazine O O
they O O
developed O O
oliguria B-Disease B-Disease
, O O
abdominal B-Disease B-Disease
pain I-Disease I-Disease
, O O
renal B-Disease B-Disease
failure I-Disease I-Disease
and O O
showed O O
multiple O O
radiolucent O O
renal B-Disease B-Disease
calculi I-Disease I-Disease
in O O
echography O O
. O O

All O O
patients O O
recovered O O
their O O
previous O O
normal O O
renal O O
function O O
after O O
adequate O O
hydration O O
and O O
alcalinization O O
. O O

A O O
nephrostomy O O
tube O O
had O O
to O O
be O O
placed O O
in O O
one O O
of O O
the O O
patients O O
for O O
ureteral B-Disease B-Disease
lithiasis I-Disease I-Disease
in O O
a O O
single O O
functional O O
kidney O O
. O O

None O O
of O O
them O O
needed O O
dialysis O O
or O O
a O O
renal O O
biopsy O O
because O O
of O O
a O O
typical O O
benign O O
course O O
. O O

Treatment O O
with O O
sulfadiazine O O
requires O O
exquisite O O
control O O
of O O
renal O O
function O O
, O O
an O O
increase O O
in O O
water O O
ingestion O O
and O O
possibly O O
the O O
alcalinization O O
of O O
the O O
urine O O
. O O

We O O
communicate O O
a O O
case O O
in O O
a O O
previously O O
healthy O O
person O O
, O O
a O O
fact O O
not O O
found O O
in O O
the O O
recent O O
literature O O
. O O

Probably O O
many O O
more O O
cases O O
are O O
not O O
detected O O
. O O

We O O
think O O
that O O
a O O
prospective O O
study O O
would O O
be O O
useful O O
. O O

Downbeat B-Disease B-Disease
nystagmus I-Disease I-Disease
associated O O
with O O
intravenous O O
patient O O
- O O
controlled O O
administration O O
of O O
morphine O O
. O O

IMPLICATIONS O O
: O O
This O O
case O O
documents O O
a O O
patient O O
who O O
developed O O
dizziness B-Disease B-Disease
with O O
downbeating B-Disease O
nystagmus I-Disease B-Disease
while O O
receiving O O
a O O
relatively O O
large O O
dose O O
of O O
IV O O
patient O O
- O O
controlled O O
analgesia O O
morphine O O
. O O

Although O O
there O O
have O O
been O O
case O O
reports O O
of O O
epidural O O
morphine O O
with O O
these O O
symptoms O O
and O O
signs O O
, O O
this O O
has O O
not O O
been O O
previously O O
documented O O
with O O
IV O O
or O O
patient O O
- O O
controlled O O
analgesia O O
morphine O O
. O O

Hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone O O
and O O
amiodarone O O
in O O
animals O O
with O O
a O O
healed O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

The O O
hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone O O
, O O
a O O
noniodinated O O
compound O O
structurally O O
related O O
to O O
amiodarone O O
, O O
were O O
compared O O
with O O
those O O
of O O
amiodarone O O
after O O
prolonged O O
oral O O
administration O O
, O O
both O O
at O O
rest O O
and O O
during O O
sympathetic O O
stimulation O O
in O O
conscious O O
dogs O O
with O O
a O O
healed O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

All O O
dogs O O
( O O
n O O
= O O
6 O O
) O O
randomly O O
received O O
orally O O
dronedarone O O
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
amiodarone O O
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
and O O
placebo O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
with O O
a O O
3-week O O
washout O O
between O O
consecutive O O
treatments O O
. O O

Heart O O
rate O O
( O O
HR O O
) O O
, O O
mean O O
arterial O O
pressure O O
( O O
MBP O O
) O O
, O O
positive O O
rate O O
of O O
increase O O
of O O
left O O
ventricular O O
pressure O O
( O O
+ O O
LVdP O O
/ O O
dt O O
) O O
, O O
echocardiographically O O
assessed O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
, O O
and O O
fractional O O
shortening O O
( O O
FS O O
) O O
, O O
as O O
well O O
as O O
chronotropic O O
response O O
to O O
isoproterenol O O
and O O
exercise O O
- O O
induced O O
sympathetic O O
stimulation O O
were O O
evaluated O O
under O O
baseline O O
and O O
posttreatment O O
conditions O O
. O O

Resting O O
values O O
of O O
LVEF O O
, O O
FS O O
, O O
+ O O
LVdP O O
/ O O
dt O O
, O O
and O O
MBP O O
remained O O
unchanged O O
whatever O O
the O O
drug O O
and O O
the O O
dosing O O
regimen O O
, O O
whereas O O
resting O O
HR O O
was O O
significantly O O
and O O
dose O O
- O O
dependently O O
lowered O O
after O O
dronedarone O O
and O O
to O O
a O O
lesser O O
extent O O
after O O
amiodarone O O
. O O

Both O O
dronedarone O O
and O O
amiodarone O O
significantly O O
reduced O O
the O O
exercise O O
- O O
induced O O
tachycardia B-Disease B-Disease
and O O
, O O
at O O
the O O
highest O O
dose O O
, O O
decreased O O
the O O
isoproterenol O O
- O O
induced O O
tachycardia B-Disease B-Disease
. O O

Thus O O
, O O
dronedarone O O
and O O
amiodarone O O
displayed O O
a O O
similar O O
level O O
of O O
antiadrenergic O O
effect O O
and O O
did O O
not O O
impair O O
the O O
resting O O
left O O
ventricular O O
function O O
. O O

Consequently O O
, O O
dronedarone O O
might O O
be O O
particularly O O
suitable O O
for O O
the O O
treatment O O
and O O
prevention O O
of O O
various O O
clinical O O
arrhythmias B-Disease B-Disease
, O O
without O O
compromising O O
the O O
left O O
ventricular O O
function O O
. O O

Phase O O
2 O O
trial O O
of O O
liposomal O O
doxorubicin O O
( O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
in O O
platinum O O
/ O O
paclitaxel O O
- O O
refractory O O
ovarian B-Disease B-Disease
and I-Disease I-Disease
fallopian I-Disease I-Disease
tube I-Disease I-Disease
cancers I-Disease I-Disease
and O O
primary O O
carcinoma B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
peritoneum I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Several O O
studies O O
have O O
demonstrated O O
liposomal O O
doxorubicin O O
( O O
Doxil O O
) O O
to O O
be O O
an O O
active O O
antineoplastic O O
agent O O
in O O
platinum O O
- O O
resistant O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
, O O
with O O
dose O O
limiting O O
toxicity B-Disease B-Disease
of O O
the O O
standard O O
dosing O O
regimen O O
( O O
50 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
) O O
being O O
severe O O
erythrodysesthesia B-Disease B-Disease
( O O
" O O
hand B-Disease B-Disease
- I-Disease I-Disease
foot I-Disease I-Disease
syndrome I-Disease I-Disease
" O O
) O O
and O O
stomatitis B-Disease B-Disease
. O O

We O O
wished O O
to O O
develop O O
a O O
more O O
tolerable O O
liposomal O O
doxorubicin O O
treatment O O
regimen O O
and O O
document O O
its O O
level O O
of O O
activity O O
in O O
a O O
well O O
- O O
defined O O
patient O O
population O O
with O O
platinum O O
/ O O
paclitaxel O O
- O O
refractory O O
disease O O
. O O

METHODS O O
AND O O
MATERIALS O O
: O O
Patients O O
with O O
ovarian B-Disease B-Disease
or I-Disease I-Disease
fallopian I-Disease I-Disease
tube I-Disease I-Disease
cancers I-Disease I-Disease
or O O
primary O O
peritoneal B-Disease B-Disease
carcinoma I-Disease I-Disease
with O O
platinum O O
/ O O
paclitaxel O O
- O O
refractory O O
disease O O
( O O
stable O O
or O O
progressive O O
disease O O
following O O
treatment O O
with O O
these O O
agents O O
or O O
previous O O
objective O O
response O O
<3 O O
months O O
in O O
duration O O
) O O
were O O
treated O O
with O O
liposomal O O
doxorubicin O O
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
49 O O
patients O O
( O O
median O O
age O O
: O O
60 O O
; O O
range O O
41 O O
- O O
81 O O
) O O
entered O O
this O O
phase O O
2 O O
trial O O
. O O

The O O
median O O
number O O
of O O
prior O O
regimens O O
was O O
2 O O
( O O
range O O
: O O
1 O O
- O O
6 O O
) O O
. O O

Six O O
( O O
12 O O
% O O
) O O
and O O
4 O O
( O O
8 O O
% O O
) O O
patients O O
experienced O O
grade O O
2 O O
hand B-Disease B-Disease
- I-Disease I-Disease
foot I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
stomatitis B-Disease B-Disease
, O O
respectively O O
( O O
no O O
episodes O O
of O O
grade O O
3 O O
) O O
. O O

One O O
patient O O
developed O O
grade O O
3 O O
diarrhea B-Disease B-Disease
requiring O O
hospitalization O O
for O O
hydration O O
. O O

Six O O
( O O
12 O O
% O O
) O O
individuals O O
required O O
dose O O
reductions O O
. O O

The O O
median O O
number O O
of O O
courses O O
of O O
liposomal O O
doxorubicin O O
administered O O
on O O
this O O
protocol O O
was O O
2 O O
( O O
range O O
: O O
1 O O
- O O
12 O O
) O O
. O O

Four O O
of O O
44 O O
patients O O
( O O
9 O O
% O O
) O O
evaluable O O
for O O
response O O
exhibited O O
objective O O
and O O
subjective O O
evidence O O
of O O
an O O
antineoplastic O O
effect O O
of O O
therapy O O
. O O

CONCLUSION O O
: O O
This O O
modified O O
liposomal O O
doxorubicin O O
regimen O O
results O O
in O O
less O O
toxicity B-Disease O
( O O
stomatitis B-Disease B-Disease
, O O
hand B-Disease B-Disease
- I-Disease I-Disease
foot I-Disease I-Disease
syndrome I-Disease I-Disease
) O O
than O O
the O O
standard O O
FDA O O
- O O
approved O O
dose O O
schedule O O
. O O

Definite O O
, O O
although O O
limited O O
, O O
antineoplastic O O
activity O O
is O O
observed O O
in O O
patients O O
with O O
well O O
- O O
defined O O
platinum- O O
and O O
paclitaxel O O
- O O
refractory O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Efficacy O O
of O O
olanzapine O O
in O O
acute O O
bipolar B-Disease B-Disease
mania I-Disease I-Disease
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
. O O

The O O
Olanzipine O O
HGGW O O
Study O O
Group O O
. O O

BACKGROUND O O
: O O
We O O
compared O O
the O O
efficacy O O
and O O
safety O O
of O O
olanzapine O O
vs O O
placebo O O
for O O
the O O
treatment O O
of O O
acute O O
bipolar B-Disease B-Disease
mania I-Disease I-Disease
. O O

METHODS O O
: O O
Four O O
- O O
week O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
parallel O O
study O O
. O O

A O O
total O O
of O O
115 O O
patients O O
with O O
a O O
DSM O O
- O O
IV O O
diagnosis O O
of O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
, O O
manic B-Disease B-Disease
or O O
mixed O O
, O O
were O O
randomized O O
to O O
olanzapine O O
, O O
5 O O
to O O
20 O O
mg O O
/ O O
d O O
( O O
n O O
= O O
55 O O
) O O
, O O
or O O
placebo O O
( O O
n O O
= O O
60 O O
) O O
. O O

The O O
primary O O
efficacy O O
measure O O
was O O
the O O
Young O O
- O O
Mania B-Disease B-Disease
Rating O O
Scale O O
( O O
Y O O
- O O
MRS O O
) O O
total O O
score O O
. O O

Response O O
and O O
euthymia O B-Disease
were O O
defined O O
, O O
a O O
priori O O
, O O
as O O
at O O
least O O
a O O
50 O O
% O O
improvement O O
from O O
baseline O O
to O O
end O O
point O O
and O O
as O O
a O O
score O O
of O O
no O O
less O O
than O O
12 O O
at O O
end O O
point O O
in O O
the O O
Y O O
- O O
MRS O O
total O O
score O O
, O O
respectively O O
. O O

Safety O O
was O O
assessed O O
using O O
adverse O O
events O O
, O O
Extrapyramidal B-Disease B-Disease
Symptom I-Disease I-Disease
( O O
EPS B-Disease B-Disease
) O O
rating O O
scales O O
, O O
laboratory O O
values O O
, O O
electrocardiograms O O
, O O
vital O O
signs O O
, O O
and O O
weight O O
change O O
. O O

RESULTS O O
: O O
Olanzapine O O
- O O
treated O O
patients O O
demonstrated O O
a O O
statistically O O
significant O O
greater O O
mean O O
( O O
+ O O
/- O O

SD O O
) O O
improvement O O
in O O
Y O O
- O O
MRS O O
total O O
score O O
than O O
placebo O O
- O O
treated O O
patients O O
( O O
-14.8 O O
+ O O
/- O O

12.5 O O
and O O
-8.1 O O
+ O O
/- O O

12.7 O O
, O O
respectively O O
; O O
P<.001 O O
) O O
, O O
which O O
was O O
evident O O
at O O
the O O
first O O
postbaseline O O
observation O O
1 O O
week O O
after O O
randomization O O
and O O
was O O
maintained O O
throughout O O
the O O
study O O
( O O
last O O
observation O O
carried O O
forward O O
) O O
. O O

Olanzapine O O
- O O
treated O O
patients O O
demonstrated O O
a O O
higher O O
rate O O
of O O
response O O
( O O
65 O O
% O O
vs O O
43 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
.02 O O
) O O
and O O
euthymia O B-Disease
( O O
61 O O
% O O
vs O O
36 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
. O O
01 O O
) O O
than O O
placebo O O
- O O
treated O O
patients O O
. O O

There O O
were O O
no O O
statistically O O
significant O O
differences O O
in O O
EPSs B-Disease O
between O O
groups O O
. O O

However O O
, O O
olanzapine O O
- O O
treated O O
patients O O
had O O
a O O
statistically O O
significant O O
greater O O
mean O O
( O O
+ O O
/- O O

SD O O
) O O
weight B-Disease O
gain I-Disease O
than O O
placebo O O
- O O
treated O O
patients O O
( O O
2.1 O O
+ O O
/- O O
2.8 O O
vs O O
0.45 O O
+ O O
/- O O

2.3 O O
kg O O
, O O
respectively O O
) O O
and O O
also O O
experienced O O
more O O
treatment O O
- O O
emergent O O
somnolence B-Disease B-Disease
( O O
21 O O
patients O O
[ O O
38.2 O O
% O O
] O O
vs O O
5 O O
[ O O
8.3 O O
% O O
] O O
, O O
respectively O O
) O O
. O O

CONCLUSION O O
: O O
Olanzapine O O
demonstrated O O
greater O O
efficacy O O
than O O
placebo O O
in O O
the O O
treatment O O
of O O
acute O O
bipolar B-Disease B-Disease
mania I-Disease I-Disease
and O O
was O O
generally O O
well O O
tolerated O O
. O O

The O O
effect O O
of O O
pupil B-Disease B-Disease
dilation I-Disease I-Disease
with O O
tropicamide O O
on O O
vision O O
and O O
driving O O
simulator O O
performance O O
. O O

PURPOSE O O
: O O
To O O
assess O O
the O O
effect O O
of O O
pupil B-Disease B-Disease
dilation I-Disease I-Disease
on O O
vision O O
and O O
driving O O
ability O O
. O O

METHODS O O
: O O
A O O
series O O
of O O
tests O O
on O O
various O O
parameters O O
of O O
visual O O
function O O
and O O
driving O O
simulator O O
performance O O
were O O
performed O O
on O O
12 O O
healthy O O
drivers O O
, O O
before O O
and O O
after O O
pupil B-Disease B-Disease
dilation I-Disease I-Disease
using O O
guttae O O
tropicamide O O
1 O O
% O O
. O O

A O O
driving O O
simulator O O
( O O
Transport O O
Research O O
Laboratory O O
) O O
was O O
used O O
to O O
measure O O
reaction O O
time O O
( O O
RT O O
) O O
, O O
speed O O
maintenance O O
and O O
steering O O
accuracy O O
. O O

Tests O O
of O O
basic O O
visual O O
function O O
included O O
high- O O
and O O
low O O
- O O
contrast O O
visual O O
acuity O O
( O O
HCVA O O
and O O
LCVA O O
) O O
, O O
Pelli O O
- O O
Robson O O
contrast O O
threshold O O
( O O
CT O O
) O O
and O O
Goldmann O O
perimetry O O
( O O
FIELDS O O
) O O
. O O

Useful O O
Field O O
of O O
View O O
( O O
UFOV O O
-- O O
a O O
test O O
of O O
visual O O
attention O O
) O O
was O O
also O O
undertaken O O
. O O

The O O
mean O O
differences O O
in O O
the O O
pre- O O
and O O
post O O
- O O
dilatation O O
measurements O O
were O O
tested O O
for O O
statistical O O
significance O O
at O O
the O O
95 O O
% O O
level O O
using O O
one O O
- O O
tail O O
paired O O
t O O
- O O
tests O O
. O O

RESULTS O O
: O O
Pupillary B-Disease B-Disease
dilation I-Disease I-Disease
resulted O O
in O O
a O O
statistically O O
significant O O
deterioration O O
in O O
CT O O
and O O
HCVA O O
only O O
. O O

Five O O
of O O
12 O O
drivers O O
also O O
exhibited O O
deterioration O O
in O O
LCVA O O
, O O
CT O O
and O O
RT O O
. O O

Little O O
evidence O O
emerged O O
for O O
deterioration O O
in O O
FIELDS O O
and O O
UFOV O O
. O O

Also O O
, O O
7 O O
of O O
12 O O
drivers O O
appeared O O
to O O
adjust O O
their O O
driving O O
behaviour O O
by O O
reducing O O
their O O
speed O O
on O O
the O O
driving O O
simulator O O
, O O
leading O O
to O O
improved O O
steering O O
accuracy O O
. O O

CONCLUSIONS O O
: O O
Pupillary B-Disease B-Disease
dilation I-Disease I-Disease
may O O
lead O O
to O O
a O O
decrease O O
in O O
vision O O
and O O
daylight O O
driving O O
performance O O
in O O
young O O
people O O
. O O

A O O
larger O O
study O O
, O O
including O O
a O O
broader O O
spectrum O O
of O O
subjects O O
, O O
is O O
warranted O O
before O O
guidelines O O
can O O
be O O
recommended O O
. O O

A O O
case O O
of O O
isotretinoin B-Disease O
embryopathy I-Disease B-Disease
with O O
bilateral O O
anotia B-Disease B-Disease
and O O
Taussig B-Disease B-Disease
- I-Disease I-Disease
Bing I-Disease I-Disease
malformation I-Disease I-Disease
. O O

We O O
report O O
a O O
newborn O O
infant O O
with O O
multiple O O
congenital O B-Disease
anomalies O I-Disease
( O O
anotia B-Disease B-Disease
and O O
Taussig B-Disease B-Disease
- I-Disease I-Disease
Bing I-Disease I-Disease
malformation I-Disease I-Disease
) O O
due O O
to O O
exposure O O
to O O
isotretinoin O O
within O O
the O O
first O O
trimester O O
. O O

In O O
this O O
paper O O
we O O
aim O O
to O O
draw O O
to O O
the O O
fact O O
that O O
caution O O
is O O
needed O O
when O O
prescribing O O
vitamin O O
A O O
- O O
containing O O
drugs O O
to O O
women O O
of O O
childbearing O O
years O O
. O O

Effect O O
of O O
methoxamine O O
on O O
maximum O O
urethral O O
pressure O O
in O O
women O O
with O O
genuine O O
stress B-Disease B-Disease
incontinence I-Disease I-Disease
: O O
a O O
placebo O O
- O O
controlled O O
, O O
double O O
- O O
blind O O
crossover O O
study O O
. O O

The O O
aim O O
of O O
the O O
study O O
was O O
to O O
evaluate O O
the O O
potential O O
role O O
for O O
a O O
selective O O
alpha1-adrenoceptor O O
agonist O O
in O O
the O O
treatment O O
of O O
urinary B-Disease B-Disease
stress I-Disease I-Disease
incontinence I-Disease I-Disease
. O O

A O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
crossover O O
study O O
design O O
was O O
employed O O
. O O

Half O O
log O O
incremental O O
doses O O
of O O
intravenous O O
methoxamine O O
or O O
placebo O O
( O O
saline O O
) O O
were O O
administered O O
to O O
a O O
group O O
of O O
women O O
with O O
genuine O O
stress B-Disease B-Disease
incontinence I-Disease I-Disease
while O O
measuring O O
maximum O O
urethral O O
pressure O O
( O O
MUP O O
) O O
, O O
blood O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
symptomatic O O
side O O
effects O O
. O O

Methoxamine O O
evoked O O
non O O
- O O
significant O O
increases O O
in O O
MUP O O
and O O
diastolic O O
blood O O
pressure O O
but O O
caused O O
a B-Disease O
significant I-Disease O
rise I-Disease O
in I-Disease O
systolic I-Disease O
blood I-Disease O
pressure I-Disease O
and O O
significant O O
fall O O
in O O
heart O O
rate O O
at O O
maximum O O
dosage O O
. O O

Systemic O O
side O O
effects O O
including O O
piloerection O B-Disease
, O O
headache B-Disease B-Disease
, O O
and O O
cold O O
extremities O O
were O O
experienced O O
in O O
all O O
subjects O O
. O O

The O O
results O O
indicate O O
that O O
the O O
clinical O O
usefulness O O
of O O
direct O O
, O O
peripherally O O
acting O O
sub O O
- O O
type O O
- O O
selective O O
alpha1-adrenoceptor O O
agonists O O
in O O
the O O
medical O O
treatment O O
of O O
stress B-Disease B-Disease
incontinence I-Disease I-Disease
may O O
be O O
limited O O
by O O
associated O O
piloerection O O
and O O
cardiovascular O O
side O O
effects O O
. O O

Hyperglycemic B-Disease B-Disease
effect O O
of O O
amino O O
compounds O O
structurally O O
related O O
to O O
caproate O O
in O O
rats O O
. O O

The O O
chronic O O
feeding O O
of O O
small O O
amounts O O
( O O
0.3 O O
- O O
3 O O
% O O
of O O
diet O O
weight O O
) O O
of O O
certain O O
amino O O
derivatives O O
of O O
caproate O O
resulted O O
in O O
hyperglycemia B-Disease B-Disease
, O O
an O O
elevated O O
glucose O O
tolerance O O
curve O O
and O O
, O O
occasionally O O
, O O
glucosuria B-Disease B-Disease
. O O

Effective O O
compounds O O
included O O
norleucine O O
, O O
norvaline O O
, O O
glutamate O O
, O O
epsilon O O
- O O
aminocaproate O O
, O O
methionine O O
, O O
and O O
leucine O O
. O O

Toleration O O
of O O
high O O
doses O O
of O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitors O O
in O O
patients O O
with O O
chronic O O
heart B-Disease B-Disease
failure I-Disease I-Disease
: O O
results O O
from O O
the O O
ATLAS O O
trial O O
. O O

The O O
Assessment O O
of O O
Treatment O O
with O O
Lisinopril O O
and O O
Survival O O
. O O

BACKGROUND O O
: O O
Treatment O O
with O O
angiotensin O O
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
reduces O O
mortality O O
and O O
morbidity O O
in O O
patients O O
with O O
chronic O O
heart B-Disease B-Disease
failure I-Disease I-Disease
( O O
CHF B-Disease B-Disease
) O O
, O O
but O O
most O O
affected O O
patients O O
are O O
not O O
receiving O O
these O O
agents O O
or O O
are O O
being O O
treated O O
with O O
doses O O
lower O O
than O O
those O O
found O O
to O O
be O O
efficacious O O
in O O
trials O O
, O O
primarily O O
because O O
of O O
concerns O O
about O O
the O O
safety O O
and O O
tolerability O O
of O O
these O O
agents O O
, O O
especially O O
at O O
the O O
recommended O O
doses O O
. O O

The O O
present O O
study O O
examines O O
the O O
safety O O
and O O
tolerability O O
of O O
high- O O
compared O O
with O O
low O O
- O O
dose O O
lisinopril O O
in O O
CHF B-Disease B-Disease
. O O

METHODS O O
: O O
The O O
Assessment O O
of O O
Lisinopril O O
and O O
Survival O O
study O O
was O O
a O O
multicenter O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
trial O O
in O O
which O O
patients O O
with O O
or O O
without O O
previous O O
ACE O O
inhibitor O O
treatment O O
were O O
stabilized O O
receiving O O
medium O O
- O O
dose O O
lisinopril O O
( O O
12.5 O O
or O O
15.0 O O
mg O O
once O O
daily O O
[ O O
OD O O
] O O
) O O
for O O
2 O O
to O O
4 O O
weeks O O
and O O
then O O
randomized O O
to O O
high- O O
( O O
35.0 O O
or O O
32.5 O O
mg O O
OD O O
) O O
or O O
low O O
- O O
dose O O
( O O
5.0 O O
or O O
2.5 O O
mg O O
OD O O
) O O
groups O O
. O O

Patients O O
with O O
New O O
York O O
Heart O O
Association O O
classes O O
II O O
to O O
IV O O
CHF B-Disease B-Disease
and O O
left O O
ventricular O O
ejection O O
fractions O O
of O O
no O O
greater O O
than O O
0.30 O O
( O O
n O O
= O O
3164 O O
) O O
were O O
randomized O O
and O O
followed O O
up O O
for O O
a O O
median O O
of O O
46 O O
months O O
. O O

We O O
examined O O
the O O
occurrence O O
of O O
adverse O O
events O O
and O O
the O O
need O O
for O O
discontinuation O O
and O O
dose O O
reduction O O
during O O
treatment O O
, O O
with O O
a O O
focus O O
on O O
hypotension B-Disease B-Disease
and O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

RESULTS O O
: O O
Of O O
405 O O
patients O O
not O O
previously O O
receiving O O
an O O
ACE O O
inhibitor O O
, O O
doses O O
in O O
only O O
4.2 O O
% O O
could O O
not O O
be O O
titrated O O
to O O
the O O
medium O O
doses O O
required O O
for O O
randomization O O
because O O
of O O
symptoms O O
possibly O O
related O O
to O O
hypotension B-Disease B-Disease
( O O
2.0 O O
% O O
) O O
or O O
because O O
of O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
or O O
hyperkalemia B-Disease B-Disease
( O O
2.3 O O
% O O
) O O
. O O

Doses O O
in O O
more O O
than O O
90 O O
% O O
of O O
randomized O O
patients O O
in O O
the O O
high- O O
and O O
low O O
- O O
dose O O
groups O O
were O O
titrated O O
to O O
their O O
assigned O O
target O O
, O O
and O O
the O O
mean O O
doses O O
of O O
blinded O O
medication O O
in O O
both O O
groups O O
remained O O
similar O O
throughout O O
the O O
study O O
. O O

Withdrawals O O
occurred O O
in O O
27.1 O O
% O O
of O O
the O O
high- O O
and O O
30.7 O O
% O O
of O O
the O O
low O O
- O O
dose O O
groups O O
. O O

Subgroups O O
presumed O O
to O O
be O O
at O O
higher O O
risk O O
for O O
ACE O O
inhibitor O O
intolerance O O
( O O
blood O O
pressure O O
, O O
< O O
120 O O
mm O O
Hg O O
; O O
creatinine O O
, O O
> O O
or O O
= O O
132.6 O O
micromol O O
/ O O
L O O
[ O O
> O O
or O O
= O O
1.5 O O
mg O O
/ O O
dL O O
] O O
; O O
age O O
, O O
> O O
or O O
= O O
70 O O
years O O
; O O
and O O
patients O O
with O O
diabetes B-Disease B-Disease
) O O
generally O O
tolerated O O
the O O
high O O
- O O
dose O O
strategy O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
demonstrate O O
that O O
ACE O O
inhibitor O O
therapy O O
in O O
most O O
patients O O
with O O
CHF B-Disease B-Disease
can O O
be O O
successfully O O
titrated O O
to O O
and O O
maintained O O
at O O
high O O
doses O O
, O O
and O O
that O O
more O O
aggressive O O
use O O
of O O
these O O
agents O O
is O O
warranted O O
. O O

Cocaine O O
, O O
ethanol O O
, O O
and O O
cocaethylene O O
cardiotoxity B-Disease B-Disease
in O O
an O O
animal O O
model O O
of O O
cocaine B-Disease B-Disease
and I-Disease I-Disease
ethanol I-Disease I-Disease
abuse I-Disease I-Disease
. O O

OBJECTIVES O O
: O O
Simultaneous O O
abuse B-Disease O
of I-Disease O
cocaine I-Disease O
and B-Disease O
ethanol I-Disease O
affects O O
12 O O
million O O
Americans O O
annually O O
. O O

In O O
combination O O
, O O
these O O
substances O O
are O O
substantially O O
more O O
toxic O O
than O O
either O O
drug O O
alone O O
. O O

Their O O
combined O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
may O O
be O O
due O O
to O O
independent O O
effects O O
of O O
each O O
drug O O
; O O
however O O
, O O
they O O
may O O
also O O
be O O
due O O
to O O
cocaethylene O O
( O O
CE O O
) O O
, O O
a O O
cocaine O O
metabolite O O
formed O O
only O O
in O O
the O O
presence O O
of O O
ethanol O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
delineate O O
the O O
role O O
of O O
CE O O
in O O
the O O
combined O O
cardiotoxicity B-Disease B-Disease
of O O
cocaine O O
and O O
ethanol O O
in O O
a O O
model O O
simulating O O
their O O
abuse O O
. O O

METHODS O O
: O O
Twenty O O
- O O
three O O
dogs O O
were O O
randomized O O
to O O
receive O O
either O O
1 O O
) O O
three O O
intravenous O O
( O O
IV O O
) O O
boluses O O
of O O
cocaine O O
7.5 O O
mg O O
/ O O
kg O O
with O O
ethanol O O
( O O
1 O O
g O O
/ O O
kg O O
) O O
as O O
an O O
IV O O
infusion O O
( O O
C+E O O
, O O
n O O
= O O
8) O O
, O O
2 O O
) O O
three O O
cocaine O O
boluses O O
only O O
( O O
C O O
, O O
n O O
= O O
6 O O
) O O
, O O
3 O O
) O O
ethanol O O
infusion O O
only O O
( O O
E O O
, O O
n O O
= O O
5 O O
) O O
, O O
or O O
4 O O
) O O
placebo O O
boluses O O
and O O
infusion O O
( O O
n O O
= O O
4 O O
) O O
. O O

Hemodynamic O O
measurements O O
, O O
electrocardiograms O O
, O O
and O O
serum O O
drug O O
concentrations O O
were O O
obtained O O
at O O
baseline O O
, O O
and O O
then O O
at O O
fixed O O
time O O
intervals O O
after O O
each O O
drug O O
was O O
administered O O
. O O

RESULTS O O
: O O
Two O O
of O O
eight O O
dogs O O
in O O
the O O
C+E O O
group O O
experienced O O
cardiovascular B-Disease B-Disease
collapse I-Disease I-Disease
. O O

The O O
most O O
dramatic O O
hemodynamic O O
changes O O
occurred O O
after O O
each O O
cocaine O O
bolus O O
in O O
the O O
C+E O O
and O O
C O O
only O O
groups O O
; O O
however O O
, O O
persistent O O
hemodynamic O O
changes O O
occurred O O
in O O
the O O
C+E O O
group O O
. O O

Peak O O
CE O O
levels O O
were O O
associated O O
with O O
a O O
45 O O
% O O
( O O
SD O O
+ O O
/- O O

22 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
22 O O
% O O
to O O
69 O O
% O O
) O O
decrease B-Disease O
in I-Disease O
cardiac I-Disease O
output I-Disease O
( O O
p O O
< O O
0.05 O O
) O O
, O O
a O O
56 O O
% O O
( O O
SD O O
+ O O
/- O O

23 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
32 O O
% O O
to O O
80 O O
% O O
) O O
decrease O O
in O O
dP O O
/ O O
dt O O
( O O
max O O
) O O
( O O
p O O
< O O
.006 O O
) O O
, O O
and O O
a O O
23 O O
% O O
( O O
SD O O
+ O O
/- O O

15 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
7 O O
% O O
to O O
49 O O
% O O
) O O
decrease O O
in O O
SVO O O
( O O
2 O O
) O O
( O O
p O O
< O O
0.025 O O
) O O
. O O

Ventricular B-Disease B-Disease
arrhythmias I-Disease I-Disease
were O O
primarily O O
observed O O
in O O
the O O
C+E O O
group O O
, O O
in O O
which O O
four O O
of O O
eight O O
dogs O O
experienced O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
. O O

CONCLUSIONS O O
: O O
Cocaine O O
and O O
ethanol O O
in O O
combination O O
were O O
more O O
toxic O O
than O O
either O O
substance O O
alone O O
. O O

Co O O
- O O
administration O O
resulted O O
in O O
prolonged O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
and O O
was O O
dysrhythmogenic O O
. O O

Peak O O
serum O O
cocaethylene O O
concentrations O O
were O O
associated O O
with O O
prolonged O O
myocardial B-Disease B-Disease
depression I-Disease I-Disease
. O O

Worsening O O
of O O
Parkinsonism B-Disease B-Disease
after O O
the O O
use O O
of O O
veralipride O O
for O O
treatment O O
of O O
menopause O O
: O O
case O O
report O O
. O O

We O O
describe O O
a O O
female O O
patient O O
with O O
stable O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
who O O
has O O
shown O O
a O O
marked O O
worsening O O
of O O
her O O
motor O O
functions O O
following O O
therapy O O
of O O
menopause O O
related O O
symptoms O O
with O O
veralipride O O
, O O
as O O
well O O
as O O
the O O
improvement O O
of O O
her O O
symptoms O O
back O O
to O O
baseline O O
after O O
discontinuation O O
of O O
the O O
drug O O
. O O

We O O
emphasize O O
the O O
anti O O
- O O
dopaminergic O O
effect O O
of O O
veralipride O O
. O O

Viracept O O
and O O
irregular B-Disease O
heartbeat I-Disease O
warning O O
. O O

A O O
group O O
of O O
doctors O O
in O O
Boston O O
warn O O
that O O
the O O
protease O O
inhibitor O O
Viracept O O
may O O
cause O O
an O O
irregular B-Disease B-Disease
heart I-Disease I-Disease
beat I-Disease I-Disease
, O O
known O O
as O O
bradycardia B-Disease B-Disease
, O O
in O O
people O O
with O O
HIV O O
. O O

Bradycardia B-Disease B-Disease
occurred O O
in O O
a O O
45-year O O
- O O
old O O
male O O
patient O O
who O O
was O O
Viracept O O
in O O
combination O O
with O O
other O O
anti O O
- O O
HIV O O
drugs O O
. O O

The O O
symptoms O O
ceased O O
after O O
switching O O
to O O
another O O
drug O O
combination O O
. O O

Frequency O O
of O O
appearance O O
of O O
myeloperoxidase O O
- O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
in O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
patients O O
treated O O
with O O
propylthiouracil O O
and O O
the O O
relationship O O
between O O
MPO O O
- O O
ANCA O O
and O O
clinical O O
manifestations O O
. O O

OBJECTIVE O O
: O O
Myeloperoxidase O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
-positive O O
vasculitis B-Disease B-Disease
has O O
been O O
reported O O
in O O
patients O O
with O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
who O O
were O O
treated O O
with O O
propylthiouracil O O
( O O
PTU O O
) O O
. O O

The O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
in O O
these O O
cases O O
was O O
suspected O O
of O O
being O O
related O O
to O O
PTU O O
because O O
the O O
titres O O
of O O
MPO O O
- O O
ANCA O O
decreased O O
when O O
PTU O O
was O O
stopped O O
. O O

Nevertheless O O
, O O
there O O
have O O
been O O
no O O
studies O O
on O O
the O O
temporal O O
relationship O O
between O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
and O O
vasculitis B-Disease B-Disease
during O O
PTU O O
therapy O O
, O O
or O O
on O O
the O O
incidence O O
of O O
MPO O O
- O O
ANCA O O
in O O
untreated O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
patients O O
. O O

Therefore O O
, O O
we O O
sought O O
to O O
address O O
these O O
parameters O O
in O O
patients O O
with O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
. O O

PATIENTS O O
: O O
We O O
investigated O O
102 O O
untreated O O
patients O O
with O O
hyperthyroidism B-Disease B-Disease
due O O
to O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
for O O
the O O
presence O O
of O O
MPO O O
- O O
ANCA O O
, O O
and O O
for O O
the O O
development O O
vasculitis B-Disease B-Disease
after O O
starting O O
PTU O O
therapy O O
. O O

Twenty O O
- O O
nine O O
of O O
them O O
were O O
later O O
excluded O O
because O O
of O O
adverse O O
effects O O
of O O
PTU O O
or O O
because O O
the O O
observation O O
period O O
was O O
less O O
than O O
3 O O
months O O
. O O

The O O
remaining O O
73 O O
patients O O
( O O
55 O O
women O O
and O O
18 O O
men O O
) O O
, O O
all O O
of O O
whom O O
were O O
examined O O
for O O
more O O
than O O
3 O O
months O O
, O O
were O O
adopted O O
as O O
the O O
subjects O O
of O O
the O O
investigation O O
. O O

The O O
median O O
observation O O
period O O
was O O
23.6 O O
months O O
( O O
range O O
: O O
3 O O
- O O
37 O O
months O O
) O O
. O O

MEASUREMENTS O O
: O O
MPO O O
- O O
ANCA O O
was O O
measured O O
at O O
intervals O O
of O O
2 O O
- O O
6 O O
months O O
. O O

RESULTS O O
: O O
Before O O
treatment O O
, O O
the O O
MPO O O
- O O
ANCA O O
titres O O
of O O
all O O
102 O O
untreated O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
patients O O
were O O
within O O
the O O
reference O O
range O O
( O O
below O O
10 O O
U O O
/ O O
ml O O
) O O
. O O

Three O O
( O O
4.1 O O
% O O
) O O
of O O
the O O
73 O O
patients O O
were O O
positive O O
for O O
MPO O O
- O O
ANCA O O
at O O
13 O O
, O O
16 O O
and O O
17 O O
months O O
, O O
respectively O O
, O O
after O O
the O O
start O O
of O O
PTU O O
therapy O O
. O O

In O O
two O O
of O O
them O O
, O O
the O O
MPO O O
- O O
ANCA O O
titres O O
transiently O O
increased O O
to O O
12.8 O O
and O O
15.0 O O
U O O
/ O O
ml O O
, O O
respectively O O
, O O
despite O O
continued O O
PTU O O
therapy O O
, O O
but O O
no O O
vasculitic B-Disease B-Disease
disorders I-Disease I-Disease
developed O O
. O O

In O O
the O O
third O O
patient O O
, O O
the O O
MPO O O
- O O
ANCA O O
titre O O
increased O O
to O O
204 O O
U O O
/ O O
ml O O
and O O
she O O
developed O O
a O O
higher O O
fever B-Disease B-Disease
, O O
oral B-Disease B-Disease
ulcers I-Disease I-Disease
and O O
polyarthralgia B-Disease B-Disease
, O O
but O O
the O O
symptoms O O
resolved O O
2 O O
weeks O O
after O O
stopping O O
PTU O O
therapy O O
, O O
and O O
the O O
MPO O O
- O O
ANCA O O
titre O O
decreased O O
to O O
20.7 O O
U O O
/ O O
ml O O
by O O
4 O O
months O O
after O O
discontinuing O O
PTU O O
. O O

CONCLUSIONS O O
: O O
PTU O O
therapy O O
may O O
be O O
related O O
to O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
, O O
but O O
MPO O O
- O O
ANCA O O
does O O
not O O
appear O O
to O O
be O O
closely O O
related O O
to O O
vasculitis B-Disease B-Disease
. O O

Prevalence O O
of O O
heart B-Disease B-Disease
disease I-Disease I-Disease
in O O
asymptomatic O O
chronic O O
cocaine O O
users O O
. O O

To O O
determine O O
the O O
prevalence O O
of O O
heart B-Disease B-Disease
disease I-Disease I-Disease
in O O
outpatient O O
young O O
asymptomatic O O
chronic O O
cocaine O O
users O O
, O O
35 O O
cocaine O O
users O O
and O O
32 O O
age O O
- O O
matched O O
controls O O
underwent O O
resting O O
and O O
exercise O O
electrocardiography O O
( O O
ECG O O
) O O
and O O
Doppler O O
echocardiography O O
. O O

Findings O O
consistent O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
were O O
detected O O
in O O
12 O O
( O O
34 O O
% O O
) O O
patients O O
and O O
3 O O
( O O
9 O O
% O O
) O O
controls O O
( O O
p O O
= O O
0.01 O O
) O O
. O O

Decreased O O
left O O
ventricular O O
systolic O O
function O O
was O O
demonstrated O O
in O O
5 O O
( O O
14 O O
% O O
) O O
patients O O
, O O
but O O
in O O
none O O
of O O
the O O
controls O O
( O O
p O O
= O O
0.055 O O
) O O
. O O

Finally O O
, O O
resting O O
and O O
peak O O
exercise O O
abnormal B-Disease O
left I-Disease O
ventricular I-Disease O
filling I-Disease O
was O O
detected O O
in O O
38 O O
and O O
35 O O
% O O
of O O
patients O O
as O O
compared O O
to O O
19 O O
and O O
9 O O
% O O
of O O
controls O O
, O O
respectively O O
( O O
p O O
= O O
0.11 O O
and O O
0.02 O O
, O O
respectively O O
) O O
. O O

We O O
conclude O O
that O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
or I-Disease I-Disease
myocardial I-Disease I-Disease
disease I-Disease I-Disease
is O O
common O O
( O O
38 O O
% O O
) O O
in O O
young O O
asymptomatic O O
chronic O O
cocaine O O
users O O
. O O

Therefore O O
, O O
screening O O
ECG O O
and O O
echocardiography O O
may O O
be O O
warranted O O
in O O
these O O
patients O O
. O O

Cardioprotective O O
effects O O
of O O
Picrorrhiza O O
kurroa O O
against O O
isoproterenol O O
- O O
induced O O
myocardial O O
stress O O
in O O
rats O O
. O O

The O O
cardioprotective O O
effect O O
of O O
the O O
ethanol O O
extract O O
of O O
Picrorrhiza O O
kurroa O O
rhizomes O O
and O O
roots O O
( O O
PK O O
) O O
on O O
isoproterenol O O
- O O
induced O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
in O O
rats O O
with O O
respect O O
to O O
lipid O O
metabolism O O
in O O
serum O O
and O O
heart O O
tissue O O
has O O
been O O
investigated O O
. O O

Oral O O
pre O O
- O O
treatment O O
with O O
PK O O
( O O
80 O O
mg O O
kg O O
( O O
-1 O O
) O O
day O O
( O O
-1 O O
) O O
for O O
15 O O
days O O
) O O
significantly O O
prevented O O
the O O
isoproterenol O O
- O O
induced O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
and O O
maintained O O
the O O
rats O O
at O O
near O O
normal O O
status O O
. O O

Phase O O
2 O O
early O O
afterdepolarization O O
as O O
a O O
trigger O O
of O O
polymorphic O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
in O O
acquired O O
long B-Disease B-Disease
- I-Disease I-Disease
QT I-Disease I-Disease
syndrome I-Disease I-Disease
: O O
direct O O
evidence O O
from O O
intracellular O O
recordings O O
in O O
the O O
intact O O
left O O
ventricular O O
wall O O
. O O

BACKGROUND O O
: O O
This O O
study O O
examined O O
the O O
role O O
of O O
phase O O
2 O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
in O O
producing O O
a O O
trigger O O
to O O
initiate O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
( O O
TdP B-Disease B-Disease
) O O
with O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
induced O O
by O O
dl O O
- O O
sotalol O O
and O O
azimilide O O
. O O

The O O
contribution O O
of O O
transmural O O
dispersion O O
of O O
repolarization O O
( O O
TDR O O
) O O
to O O
transmural O O
propagation O O
of O O
EAD O O
and O O
the O O
maintenance O O
of O O
TdP B-Disease B-Disease
was O O
also O O
evaluated O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Transmembrane O O
action O O
potentials O O
from O O
epicardium O O
, O O
midmyocardium O O
, O O
and O O
endocardium O O
were O O
recorded O O
simultaneously O O
, O O
together O O
with O O
a O O
transmural O O
ECG O O
, O O
in O O
arterially O O
perfused O O
canine O O
and O O
rabbit O O
left O O
ventricular O O
preparations O O
. O O

dl O O
- O O
Sotalol O O
preferentially O O
prolonged O O
action O O
potential O O
duration O O
( O O
APD O O
) O O
in O O
M O O
cells O O
dose O O
- O O
dependently O O
( O O
1 O O
to O O
100 O O
micromol O O
/ O O
L O O
) O O
, O O
leading O O
to O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
and O O
an O O
increase O O
in O O
TDR O O
. O O

Azimilide O O
, O O
however O O
, O O
significantly O O
prolonged O O
APD O O
and O O
QT O O
interval O O
at O O
concentrations O O
from O O
0.1 O O
to O O
10 O O
micromol O O
/ O O
L O O
but O O
shortened O O
them O O
at O O
30 O O
micromol O O
/ O O
L. O O
Unlike O O
dl O O
- O O
sotalol O O
, O O
azimilide O O
( O O
> O O
3 O O
micromol O O
/ O O
L O O
) O O
increased O O
epicardial O O
APD O O
markedly O O
, O O
causing O O
a O O
diminished O O
TDR O O
. O O

Although O O
both O O
dl O O
- O O
sotalol O O
and O O
azimilide O O
rarely O O
induced O O
EADs O O
in O O
canine O O
left O O
ventricles O O
, O O
they O O
produced O O
frequent O O
EADs O O
in O O
rabbits O O
, O O
in O O
which O O
more O O
pronounced O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
was O O
seen O O
. O O

An O O
increase O O
in O O
TDR O O
by O O
dl O O
- O O
sotalol O O
facilitated O O
transmural O O
propagation O O
of O O
EADs O O
that O O
initiated O O
multiple O O
episodes O O
of O O
spontaneous O O
TdP B-Disease B-Disease
in O O
3 O O
of O O
6 O O
rabbit O O
left O O
ventricles O O
. O O

Of O O
note O O
, O O
although O O
azimilide O O
( O O
3 O O
to O O
10 O O
micromol O O
/ O O
L O O
) O O
increased O O
APD O O
more O O
than O O
dl O O
- O O
sotalol O O
, O O
its O O
EADs O O
often O O
failed O O
to O O
propagate O O
transmurally O O
, O O
probably O O
because O O
of O O
a O O
diminished O O
TDR O O
. O O

CONCLUSIONS O O
: O O
This O O
study O O
provides O O
the O O
first O O
direct O O
evidence O O
from O O
intracellular O O
action O O
potential O O
recordings O O
that O O
phase O O
2 O O
EAD O O
can O O
be O O
generated O O
from O O
intact O O
ventricular O O
wall O O
and O O
produce O O
a O O
trigger O O
to O O
initiate O O
the O O
onset O O
of O O
TdP B-Disease B-Disease
under O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
. O O

A O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
dobutamine O O
stress O O
echocardiography O O
in O O
the O O
emergency O O
department O O
evaluation O O
of O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

STUDY O O
OBJECTIVE O O
: O O
Chest B-Disease B-Disease
pain I-Disease I-Disease
in O O
the O O
setting O O
of O O
cocaine O O
use O O
poses O O
a O O
diagnostic O O
dilemma O O
. O O

Dobutamine O O
stress O O
echocardiography O O
( O O
DSE O O
) O O
is O O
a O O
widely O O
available O O
and O O
sensitive O O
test O O
for O O
evaluating O O
cardiac O B-Disease
ischemia B-Disease I-Disease
. O O

Because O O
of O O
the O O
theoretical O O
concern O O
regarding O O
administration O O
of O O
dobutamine O O
in O O
the O O
setting O O
of O O
cocaine O O
use O O
, O O
we O O
conducted O O
a O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
DSE O O
in O O
emergency O O
department O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

METHODS O O
: O O
A O O
prospective O O
case O O
series O O
was O O
conducted O O
in O O
the O O
intensive O O
diagnostic O O
and O O
treatment O O
unit O O
in O O
the O O
ED O O
of O O
an O O
urban O O
tertiary O O
- O O
care O O
teaching O O
hospital O O
. O O

Patients O O
were O O
eligible O O
for O O
DSE O O
if O O
they O O
had O O
used O O
cocaine O O
within O O
24 O O
hours O O
preceding O O
the O O
onset O O
of O O
chest B-Disease B-Disease
pain I-Disease I-Disease
and O O
had O O
a O O
normal O O
ECG O O
and O O
tropinin O O
I O O
level O O
. O O

Patients O O
exhibiting O O
signs O O
of O O
continuing O O
cocaine O B-Disease
toxicity B-Disease I-Disease
were O O
excluded O O
from O O
the O O
study O O
. O O

All O O
patients O O
were O O
admitted O O
to O O
the O O
hospital O O
for O O
serial O O
testing O O
after O O
the O O
DSE O O
testing O O
in O O
the O O
intensive O O
diagnostic O O
and O O
treatment O O
unit O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
four O O
patients O O
were O O
enrolled O O
. O O

Two O O
patients O O
had O O
inadequate O O
resting O O
images O O
, O O
one O O
DSE O O
was O O
terminated O O
because O O
of O O
inferior O O
hypokinesis B-Disease B-Disease
, O O
another O O
DSE O B-Disease
was O O
terminated O O
because O O
of O O
a O O
rate O O
- O O
related O O
atrial O B-Disease
conduction O I-Disease
deficit O I-Disease
, O O
and O O
1 O O
patient O O
did O O
not O O
reach O O
the O O
target O O
heart O O
rate O O
. O O

Thus O O
, O O
19 O O
patients O O
completed O O
a O O
DSE O O
and O O
reached O O
their O O
target O O
heart O O
rates O O
. O O

None O O
of O O
the O O
patients O O
experienced O O
signs O O
of O O
exaggerated O O
adrenergic O O
response O O
, O O
which O O
was O O
defined O O
as O O
a O O
systolic O O
blood O O
pressure O O
of O O
greater O O
than O O
200 O O
mm O O
Hg O O
or O O
the O O
occurrence O O
of O O
tachydysrhythmias B-Disease B-Disease
( O O
excluding O O
sinus B-Disease B-Disease
tachycardia I-Disease I-Disease
) O O
. O O

Further O O
suggesting O O
lack O O
of O O
exaggerated O O
adrenergic O O
response O O
, O O
13 O O
( O O
65 O O
% O O
) O O
of O O
20 O O
patients O O
required O O
supplemental O O
atropine O O
to O O
reach O O
their O O
target O O
heart O O
rates O O
. O O

CONCLUSION O O
: O O
No O O
exaggerated O O
adrenergic O O
response O O
was O O
detected O O
when O O
dobutamine O O
was O O
administered O O
to O O
patients O O
with O O
cocaine O O
- O O
related O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

Prenatal O O
cocaine O O
exposure O O
and O O
cranial O O
sonographic O O
findings O O
in O O
preterm B-Disease O
infants I-Disease O
. O O

PURPOSE O O
: O O
Prenatal O O
cocaine O O
exposure O O
has O O
been O O
linked O O
with O O
subependymal O B-Disease
hemorrhage B-Disease I-Disease
and O O
the O O
formation O O
of O O
cysts B-Disease B-Disease
that O O
are O O
detectable O O
on O O
cranial O O
sonography O O
in O O
neonates O O
born O O
at O O
term O O
. O O

We O O
sought O O
to O O
determine O O
if O O
prenatal O O
cocaine O O
exposure O O
increases O O
the O O
incidence O O
of O O
subependymal B-Disease B-Disease
cysts I-Disease I-Disease
in O O
preterm B-Disease O
infants I-Disease O
. O O

METHODS O O
: O O
We O O
retrospectively O O
reviewed O O
the O O
medical O O
records O O
and O O
cranial O O
sonograms O O
obtained O O
during O O
a O O
1-year O O
period O O
on O O
122 O O
premature B-Disease O
( I-Disease O
< I-Disease O
36 I-Disease O
weeks I-Disease O
of I-Disease O
gestation I-Disease O
) I-Disease O
infants I-Disease O
. O O

Infants O O
were O O
categorized O O
into O O
1 O O
of O O
2 O O
groups O O
: O O
those O O
exposed O O
to O O
cocaine O O
and O O
those O O
not O O
exposed O O
to O O
cocaine O O
. O O

Infants O O
were O O
assigned O O
to O O
the O O
cocaine O O
- O O
exposed O O
group O O
if O O
there O O
was O O
a O O
maternal O O
history O O
of O O
cocaine B-Disease B-Disease
abuse I-Disease I-Disease
during O O
pregnancy O O
or O O
if O O
maternal O O
or O O
neonatal O O
urine O O
toxicology O O
results O O
were O O
positive O O
at O O
the O O
time O O
of O O
delivery O O
. O O

RESULTS O O
: O O
Five O O
of O O
the O O
122 O O
infants O O
were O O
excluded O O
from O O
the O O
study O O
because O O
of O O
insufficient O O
medical O O
and O O
drug O O
histories O O
. O O

The O O
incidence O O
of O O
subependymal B-Disease B-Disease
cysts I-Disease I-Disease
in O O
the O O
117 O O
remaining O O
infants O O
was O O
14 O O
% O O
( O O
16 O O
of O O
117 O O
) O O
. O O

The O O
incidence O O
of O O
subependymal B-Disease B-Disease
cysts I-Disease I-Disease
in O O
infants O O
exposed O O
to O O
cocaine O O
prenatally O O
was O O
44 O O
% O O
( O O
8 O O
of O O
18 O O
) O O
compared O O
with O O
8 O O
% O O
( O O
8 O O
of O O
99 O O
) O O
in O O
the O O
unexposed O O
group O O
( O O
p O O
< O O
0.01 O O
) O O
. O O

CONCLUSIONS O O
: O O
We O O
found O O
an O O
increased O O
incidence O O
of O O
subependymal B-Disease B-Disease
cyst I-Disease I-Disease
formation O O
in O O
preterm B-Disease O
infants I-Disease O
who O O
were O O
exposed O O
to O O
cocaine O O
prenatally O O
. O O

This O O
result O O
is O O
consistent O O
with O O
results O O
of O O
similar O O
studies O O
in O O
term O O
infants O O
. O O

Thalidomide O O
neuropathy B-Disease B-Disease
in O O
patients O O
treated O O
for O O
metastatic O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

We O O
prospectively O O
evaluated O O
thalidomide O O
- O O
induced O O
neuropathy B-Disease B-Disease
using O O
electrodiagnostic O O
studies O O
. O O

Sixty O O
- O O
seven O O
men O O
with O O
metastatic O O
androgen O O
- O O
independent O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
in O O
an O O
open O O
- O O
label O O
trial O O
of O O
oral O O
thalidomide O O
underwent O O
neurologic O O
examinations O O
and O O
nerve O O
conduction O O
studies O O
( O O
NCS O O
) O O
prior O O
to O O
and O O
at O O
3-month O O
intervals O O
during O O
treatment O O
. O O

NCS O O
included O O
recording O O
of O O
sensory O O
nerve O O
action O O
potentials O O
( O O
SNAPs O O
) O O
from O O
median O O
, O O
radial O O
, O O
ulnar O O
, O O
and O O
sural O O
nerves O O
. O O

SNAP O O
amplitudes O O
for O O
each O O
nerve O O
were O O
expressed O O
as O O
the O O
percentage O O
of O O
its O O
baseline O O
, O O
and O O
the O O
mean O O
of O O
the O O
four O O
was O O
termed O O
the O O
SNAP O O
index O O
. O O

A O O
40 O O
% O O
decline O O
in O O
the O O
SNAP O O
index O O
was O O
considered O O
clinically O O
significant O O
. O O

Thalidomide O O
was O O
discontinued O O
in O O
55 O O
patients O O
for O O
lack O O
of O O
therapeutic O O
response O O
. O O

Of O O
67 O O
patients O O
initially O O
enrolled O O
, O O
24 O O
remained O O
on O O
thalidomide O O
for O O
3 O O
months O O
, O O
8 O O
remained O O
at O O
6 O O
months O O
, O O
and O O
3 O O
remained O O
at O O
9 O O
months O O
. O O

Six O O
patients O O
developed O O
neuropathy B-Disease B-Disease
. O O

Clinical O O
symptoms O O
and O O
a O O
decline O O
in O O
the O O
SNAP O O
index O O
occurred O O
concurrently O O
. O O

Older O O
age O O
and O O
cumulative O O
dose O O
were O O
possible O O
contributing O O
factors O O
. O O

Neuropathy B-Disease B-Disease
may O O
thus O O
be O O
a O O
common O O
complication O O
of O O
thalidomide O O
in O O
older O O
patients O O
. O O

The O O
SNAP O O
index O O
can O O
be O O
used O O
to O O
monitor O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
, O O
but O O
not O O
for O O
early O O
detection O O
. O O

Overexpression O O
of O O
copper O O
/ O O
zinc O O
- O O
superoxide O O
dismutase O O
protects O O
from O O
kanamycin O O
- O O
induced O O
hearing B-Disease B-Disease
loss I-Disease I-Disease
. O O

The O O
participation O O
of O O
reactive O O
oxygen O O
species O O
in O O
aminoglycoside O O
- O O
induced O O
ototoxicity B-Disease B-Disease
has O O
been O O
deduced O O
from O O
observations O O
that O O
aminoglycoside O O
- O O
iron O O
complexes O O
catalyze O O
the O O
formation O O
of O O
superoxide O O
radicals O O
in O O
vitro O O
and O O
that O O
antioxidants O O
attenuate O O
ototoxicity B-Disease B-Disease
in O O
vivo O O
. O O

We O O
therefore O O
hypothesized O O
that O O
overexpression O O
of O O
Cu O O
/ O O
Zn O O
- O O
superoxide O O
dismutase O O
( O O
h O O
- O O
SOD1 O O
) O O
should O O
protect O O
transgenic O O
mice O O
from O O
ototoxicity B-Disease B-Disease
. O O

Immunocytochemistry O O
confirmed O O
expression O O
of O O
h O O
- O O
SOD1 O O
in O O
inner O O
ear O O
tissues O O
of O O
transgenic O O
C57BL O O
/ O O
6-TgN O O
[ O O
SOD1 O O
] O O
3Cje O O
mice O O
. O O

Transgenic O O
and O O
nontransgenic O O
littermates O O
received O O
kanamycin O O
( O O
400 O O
mg O O
/ O O
kg O O
body O O
weight O O
/ O O
day O O
) O O
for O O
10 O O
days O O
beginning O O
on O O
day O O
10 O O
after O O
birth O O
. O O

Auditory O O
thresholds O O
were O O
tested O O
by O O
evoked O O
auditory O O
brain O O
stem O O
responses O O
at O O
1 O O
month O O
after O O
birth O O
. O O

In O O
nontransgenic O O
animals O O
, O O
the O O
threshold O O
in O O
the O O
kanamycin O O
- O O
treated O O
group O O
was O O
45 O O
- O O
50 O O
dB O O
higher O O
than O O
in O O
saline O O
- O O
injected O O
controls O O
. O O

In O O
the O O
transgenic O O
group O O
, O O
kanamycin O O
increased O O
the O O
threshold O O
by O O
only O O
15 O O
dB O O
over O O
the O O
respective O O
controls O O
. O O

The O O
effects O O
were O O
similar O O
at O O
12 O O
and O O
24 O O
kHz O O
. O O

The O O
protection O O
by O O
overexpression O O
of O O
superoxide O O
dismutase O O
supports O O
the O O
hypothesis O O
that O O
oxidant O O
stress O O
plays O O
a O O
significant O O
role O O
in O O
aminoglycoside O O
- O O
induced O O
ototoxicity B-Disease B-Disease
. O O

The O O
results O O
also O O
suggest O O
transgenic O O
animals O O
as O O
suitable O O
models O O
to O O
investigate O O
the O O
underlying O O
mechanisms O O
and O O
possible O O
strategies O O
for O O
prevention O O
. O O

Fatty B-Disease B-Disease
liver I-Disease I-Disease
induced O O
by O O
tetracycline O O
in O O
the O O
rat O O
. O O

Dose O O
- O O
response O O
relationships O O
and O O
effect O O
of O O
sex O O
. O O

Dose O O
- O O
response O O
relationships O O
, O O
biochemical O O
mechanisms O O
, O O
and O O
sex O O
differences O O
in O O
the O O
experimental O O
fatty B-Disease B-Disease
liver I-Disease I-Disease
induced O O
by O O
tetracycline O O
were O O
studied O O
in O O
the O O
intact O O
rat O O
and O O
with O O
the O O
isolated O O
perfused O O
rat O O
liver O O
in O O
vitro O O
. O O

In O O
the O O
intact O O
male O O
and O O
female O O
rat O O
, O O
no O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline O O
and O O
hepatic O O
accumulation O O
of O O
triglyceride O O
. O O

With O O
provision O O
of O O
adequate O O
oleic O O
acid O O
as O O
a O O
substrate O O
for O O
the O O
isolated O O
perfused O O
liver O O
, O O
a O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline O O
and O O
both O O
accumulation O O
of O O
triglyceride O O
in O O
the O O
liver O O
and O O
depression B-Disease B-Disease
of O O
output O O
of O O
triglyceride O O
by O O
livers O O
from O O
male O O
and O O
female O O
rats O O
. O O

Marked O O
differences O O
were O O
observed O O
between O O
female O O
and O O
male O O
rats O O
with O O
regard O O
to O O
base O O
line O O
( O O
control O O
) O O
hepatic O O
concentration O O
of O O
triglyceride O O
and O O
output O O
of O O
triglyceride O O
. O O

Accumulation O O
of O O
hepatic O O
triglyceride O O
, O O
as O O
a O O
per O O
cent O O
of O O
control O O
values O O
, O O
in O O
response O O
to O O
graded O O
doses O O
of O O
tetracycline O O
, O O
did O O
not O O
differ O O
significantly O O
between O O
male O O
, O O
female O O
and O O
pregnant O O
rat O O
livers O O
. O O

However O O
, O O
livers O O
from O O
female O O
, O O
and O O
especially O O
pregnant O O
female O O
rats O O
, O O
were O O
strikingly O O
resistant O O
to O O
the O O
effects O O
of O O
tetracycline O O
on O O
depression B-Disease B-Disease
of O O
output O O
of O O
triglyceride O O
under O O
these O O
experimental O O
conditions O O
. O O

These O O
differences O O
between O O
the O O
sexes O O
could O O
not O O
be O O
related O O
to O O
altered O O
disposition O O
of O O
tetracycline O O
or O O
altered O O
uptake O O
of O O
oleic O O
acid O O
. O O

Depressed O O
hepatic O O
secretion O O
of O O
triglyceride O O
accounted O O
only O O
for O O
30 O O
to O O
50 O O
% O O
of O O
accumulated O O
hepatic O O
triglyceride O O
, O O
indicating O O
that O O
additional O O
mechanisms O O
must O O
be O O
involved O O
in O O
the O O
production O O
of O O
the O O
triglyceride O O
- O O
rich O O
fatty B-Disease B-Disease
liver I-Disease I-Disease
in O O
response O O
to O O
tetracycline O O
. O O

Prednisone O O
induces O O
anxiety B-Disease B-Disease
and O O
glial O O
cerebral O O
changes O O
in O O
rats O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
whether O O
prednisone O O
( O O
PDN O O
) O O
produces O O
anxiety B-Disease B-Disease
and/or O O
cerebral O O
glial O O
changes O O
in O O
rats O O
. O O

METHODS O O
: O O
Male O O
Wistar O O
rats O O
were O O
studied O O
and O O
3 O O
groups O O
were O O
formed O O
( O O
8 O O
rats O O
per O O
group O O
) O O
. O O

The O O
moderate O O
- O O
dose O O
group O O
received O O
5 O O
mg O O
/ O O
kg O O
/ O O
day O O
PDN O O
released O O
from O O
a O O
subcutaneous O O
implant O O
. O O

In O O
the O O
high O O
- O O
dose O O
group O O
, O O
implants O O
containing O O
PDN O O
equivalent O O
to O O
60 O O
mg O O
/ O O
kg O O
/ O O
day O O
were O O
applied O O
. O O

In O O
the O O
control O O
group O O
implants O O
contained O O
no O O
PDN O O
. O O

Anxiety B-Disease B-Disease
was O O
assessed O O
using O O
an O O
open O O
field O O
and O O
elevated O O
plus O O
- O O
maze O O
devices O O
. O O

The O O
number O O
of O O
cells O O
and O O
cytoplasmic O O
transformation O O
of O O
astrocytes O O
and O O
microglia O O
cells O O
were O O
assessed O O
by O O
immunohistochemical O O
analyses O O
. O O

RESULTS O O
: O O
Anxiety B-Disease B-Disease
was O O
documented O O
in O O
both O O
groups O O
of O O
PDN O O
treated O O
rats O O
compared O O
with O O
controls O O
. O O

The O O
magnitude O O
of O O
transformation O O
of O O
the O O
microglia O O
assessed O O
by O O
the O O
number O O
of O O
intersections O O
was O O
significantly O O
higher O O
in O O
the O O
PDN O O
groups O O
than O O
in O O
controls O O
in O O
the O O
prefrontal O O
cortex O O
( O O
moderate O O
- O O
dose O O
, O O
24.1 O O
; O O
high O O
- O O
dose O O
, O O
23.6 O O
; O O
controls O O
18.7 O O
; O O
p O O
< O O
0.01 O O
) O O
and O O
striatum O O
( O O
moderate O O
- O O
dose O O
25.6 O O
; O O
high O O
- O O
dose O O
26.3 O O
; O O
controls O O
18.9 O O
; O O
p O O
< O O
0.01 O O
) O O
, O O
but O O
not O O
in O O
hippocampus O O
. O O

The O O
number O O
of O O
stained O O
microglia O O
cells O O
was O O
significantly O O
higher O O
in O O
the O O
PDN O O
treated O O
groups O O
in O O
the O O
prefrontal O O
cortex O O
than O O
in O O
controls O O
( O O
moderate O O
- O O
dose O O
, O O
29.1 O O
; O O
high O O
- O O
dose O O
, O O
28.4 O O
; O O
control O O
, O O
17.7 O O
cells O O
per O O
field O O
; O O
p O O
< O O
0.01 O O
) O O
. O O

Stained O O
microglia O O
cells O O
were O O
significantly O O
more O O
numerous O O
striatum O O
and O O
hippocampus O O
in O O
the O O
high O O
- O O
dose O O
group O O
compared O O
to O O
controls O O
. O O

CONCLUSION O O
: O O
Subacute O O
exposure O O
to O O
PDN O O
induced O O
anxiety B-Disease B-Disease
and O O
reactivity O O
of O O
microglia O O
. O O

The O O
relevance O O
of O O
these O O
features O O
for O O
patients O O
using O O
PDN O O
remains O O
to O O
be O O
elucidated O O
. O O

Phase O O
II O O
study O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
in O O
patients O O
with O O
recurrent O O
squamous B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
of B-Disease I-Disease
the I-Disease I-Disease
cervix I-Disease I-Disease
. O O

BACKGROUND O O
: O O
The O O
activity O O
of O O
the O O
combination O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
was O O
tested O O
in O O
a O O
Phase O O
II O O
study O O
of O O
patients O O
with O O
recurrent O O
cervical B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

METHODS O O
: O O
The O O
combination O O
of O O
carboplatin O O
( O O
area O O
under O O
the O O
concentration O O
curve O O
[ O O
AUC O O
] O O
, O O
5 O O
) O O
and O O
liposomal O O
doxorubicin O O
( O O
Doxil O O
; O O
starting O O
dose O O
, O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
was O O
administered O O
intravenously O O
every O O
28 O O
days O O
to O O
37 O O
patients O O
with O O
recurrent O O
squamous B-Disease B-Disease
cell I-Disease I-Disease
cervical I-Disease I-Disease
carcinoma I-Disease I-Disease
to O O
determine O O
antitumor O O
activity O O
and O O
toxicity B-Disease O
profile O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
nine O O
patients O O
were O O
assessable O O
for O O
response O O
, O O
and O O
35 O O
patients O O
were O O
assessable O O
for O O
toxicity B-Disease O
. O O

The O O
overall O O
response O O
rate O O
was O O
38 O O
% O O
, O O
the O O
median O O
time O O
to O O
response O O
was O O
10 O O
weeks O O
, O O
the O O
median O O
duration O O
of O O
response O O
was O O
26 O O
weeks O O
, O O
and O O
the O O
median O O
survival O O
was O O
37 O O
weeks O O
. O O

The O O
main O O
toxic O O
effect O O
was O O
myelosuppression B-Disease B-Disease
, O O
with O O
Grade O O
3 O O
and O O
4 O O
neutropenia B-Disease B-Disease
in O O
16 O O
patients O O
, O O
anemia B-Disease B-Disease
in O O
12 O O
patients O O
, O O
thrombocytopenia B-Disease B-Disease
in O O
11 O O
patients O O
, O O
and O O
neutropenic B-Disease B-Disease
fever B-Disease B-Disease
in O O
3 O O
patients O O
. O O

Four O O
patients O O
had O O
five O O
infusion O O
- O O
related O O
reactions O O
during O O
the O O
infusion O O
of O O
liposomal O O
doxorubicin O O
, O O
leading O O
to O O
treatment O O
discontinuation O O
in O O
three O O
patients O O
. O O

Grade O O
> O O
or O O
= O O
2 O O
nonhematologic O O
toxicity B-Disease B-Disease
included O O
nausea B-Disease B-Disease
in O O
17 O O
patients O O
, O O
emesis B-Disease B-Disease
in O O
14 O O
patients O O
, O O
fatigue B-Disease B-Disease
in O O
9 O O
patients O O
, O O
mucositis B-Disease B-Disease
and/or O O
stomatitis B-Disease B-Disease
in O O
8 O O
patients O O
, O O
constipation B-Disease B-Disease
in O O
6 O O
patients O O
, O O
weight B-Disease B-Disease
loss I-Disease I-Disease
in O O
5 O O
patients O O
, O O
hand B-Disease B-Disease
- I-Disease I-Disease
foot I-Disease I-Disease
syndrome I-Disease I-Disease
in O O
2 O O
patients O O
, O O
and O O
skin B-Disease B-Disease
reactions I-Disease I-Disease
in O O
3 O O
patients O O
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
has O O
modest O O
activity O O
in O O
patients O O
with O O
recurrent O O
cervical B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

Antimicrobial O O
- O O
induced O O
mania B-Disease B-Disease
( O O
antibiomania B-Disease B-Disease
) O O
: O O
a O O
review O O
of O O
spontaneous O O
reports O O
. O O

The O O
authors O O
reviewed O O
reported O O
cases O O
of O O
antibiotic O O
- O O
induced O O
manic B-Disease B-Disease
episodes O O
by O O
means O O
of O O
a O O
MEDLINE O O
and O O
PsychLit O O
search O O
for O O
reports O O
of O O
antibiotic O O
- O O
induced O O
mania B-Disease B-Disease
. O O

Unpublished O O
reports O O
were O O
requested O O
from O O
the O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
and O O
the O O
Food O O
and O O
Drug O O
Administration O O
( O O
FDA O O
) O O
. O O

Twenty O O
- O O
one O O
reports O O
of O O
antimicrobial O O
- O O
induced O O
mania B-Disease B-Disease
were O O
found O O
in O O
the O O
literature O O
. O O

There O O
were O O
6 O O
cases O O
implicating O O
clarithromycin O O
, O O
13 O O
implicating O O
isoniazid O O
, O O
and O O
1 O O
case O O
each O O
implicating O O
erythromycin O O
and O O
amoxicillin O O
. O O

The O O
WHO O O
reported O O
82 O O
cases O O
. O O

Of O O
these O O
, O O
clarithromycin O O
was O O
implicated O O
in O O
23 O O
( O O
27.6 O O
% O O
) O O
cases O O
, O O
ciprofloxacin O O
in O O
12 O O
( O O
14.4 O O
% O O
) O O
cases O O
, O O
and O O
ofloxacin O O
in O O
10 O O
( O O
12 O O
% O O
) O O
cases O O
. O O

Cotrimoxazole O O
, O O
metronidazole O O
, O O
and O O
erythromycin O O
were O O
involved O O
in O O
15 O O
reported O O
manic B-Disease B-Disease
episodes O O
. O O

Cases O O
reported O O
by O O
the O O
FDA O O
showed O O
clarithromycin O O
and O O
ciprofloxacin O O
to O O
be O O
the O O
most O O
frequently O O
associated O O
with O O
the O O
development O O
of O O
mania B-Disease B-Disease
. O O

Statistical O O
analysis O O
of O O
the O O
data O O
would O O
not O O
have O O
demonstrated O O
a O O
significant O O
statistical O O
correlative O O
risk O O
and O O
was O O
therefore O O
not O O
undertaken O O
. O O

Patients O O
have O O
an O O
increased O O
risk O O
of O O
developing O O
mania B-Disease B-Disease
while O O
being O O
treated O O
with O O
antimicrobials O O
. O O

Although O O
this O O
is O O
not O O
a O O
statistically O O
significant O O
risk O O
, O O
physicians O O
must O O
be O O
aware O O
of O O
the O O
effect O O
and O O
reversibility O O
. O O

Further O O
research O O
clearly O O
is O O
required O O
to O O
determine O O
the O O
incidence O O
of O O
antimicrobial O O
- O O
induced O O
mania B-Disease B-Disease
, O O
the O O
relative O O
risk O O
factors O O
of O O
developing O O
an O O
antimicrobial O O
- O O
induced O O
manic B-Disease B-Disease
episode O O
among O O
various O O
demographic O O
populations O O
, O O
and O O
the O O
incidence O O
of O O
patients O O
who O O
continue O O
to O O
have O O
persistent O O
affective O B-Disease
disorders O I-Disease
once O O
the O O
initial O O
episode O O
, O O
which O O
occurs O O
while O O
the O O
patient O O
is O O
taking O O
antibiotics O O
, O O
subsides O O
. O O

The O O
authors O O
elected O O
to O O
name O O
this O O
syndrome O O
" O O
antibiomania B-Disease B-Disease
. O O
" O O

Levodopa O O
- O O
induced O O
ocular B-Disease B-Disease
dyskinesias I-Disease I-Disease
in O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

Levodopa O O
- O O
induced O O
ocular B-Disease B-Disease
dyskinesias I-Disease I-Disease
are O O
very O O
uncommon O O
. O O

Usually O O
they O O
occur O O
simultaneously O O
with O O
limb O O
peak O O
- O O
dose O O
choreatic B-Disease B-Disease
dyskinesias I-Disease I-Disease
. O O

We O O
report O O
on O O
a O O
patient O O
with O O
leftward O O
and O O
upward O O
deviations O O
of O O
gaze O O
during O O
the O O
peak O O
effect O O
of O O
levodopa O O
, O O
and O O
hypothesize O O
that O O
a O O
severe O O
dopaminergic O O
denervation O O
in O O
the O O
caudate O O
nucleus O O
is O O
needed O O
for O O
the O O
appearance O O
of O O
these O O
levodopa O O
- O O
induce O O
ocular B-Disease B-Disease
dyskinesias I-Disease I-Disease
. O O

A O O
comparison O O
of O O
glyceryl O O
trinitrate O O
with O O
diclofenac O O
for O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea B-Disease B-Disease
: O O
an O O
open O O
, O O
randomized O O
, O O
cross O O
- O O
over O O
trial O O
. O O

Primary O O
dysmenorrhea B-Disease B-Disease
is O O
a O O
syndrome O O
characterized O O
by O O
painful O O
uterine O O
contractility O O
caused O O
by O O
a O O
hypersecretion O O
of O O
endometrial O O
prostaglandins O O
; O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
are O O
the O O
first O O
choice O O
for O O
its O O
treatment O O
. O O

However O O
, O O
in O O
vivo O O
and O O
in O O
vitro O O
studies O O
have O O
demonstrated O O
that O O
myometrial O O
cells O O
are O O
also O O
targets O O
of O O
the O O
relaxant O O
effects O O
of O O
nitric O O
oxide O O
( O O
NO O O
) O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
the O O
efficacy O O
of O O
glyceryl O O
trinitrate O O
( O O
GTN O O
) O O
, O O
an O O
NO O O
donor O O
, O O
in O O
the O O
resolution O O
of O O
primary O O
dysmenorrhea B-Disease B-Disease
in O O
comparison O O
with O O
diclofenac O O
( O O
DCF O O
) O O
. O O

A O O
total O O
of O O
24 O O
patients O O
with O O
the O O
diagnosis O O
of O O
severe O O
primary O O
dysmenorrhea B-Disease B-Disease
were O O
studied O O
during O O
two O O
consecutive O O
menstrual O O
cycles O O
. O O

In O O
an O O
open O O
, O O
cross O O
- O O
over O O
, O O
controlled O O
design O O
, O O
patients O O
were O O
randomized O O
to O O
receive O O
either O O
DCF O O
per O O
os O O
or O O
GTN O O
patches O O
the O O
first O O
days O O
of O O
menses O O
, O O
when O O
menstrual O B-Disease
cramps O I-Disease
became O O
unendurable O O
. O O

In O O
the O O
subsequent O O
cycle O O
the O O
other O O
treatment O O
was O O
used O O
. O O

Patients O O
received O O
up O O
to O O
3 O O
doses O O
/ O O
day O O
of O O
50 O O
mg O O
DCF O O
or O O
2.5 O O
mg O O
/ O O
24 O O
h O O
transdermal O O
GTN O O
for O O
the O O
first O O
3 O O
days O O
of O O
the O O
cycle O O
, O O
according O O
to O O
their O O
needs O O
. O O

The O O
participants O O
recorded O O
menstrual O O
symptoms O O
and O O
possible O O
side O O
- O O
effects O O
at O O
different O O
times O O
( O O
0 O O
, O O
30 O O
, O O
60 O O
, O O
120 O O
minutes O O
) O O
after O O
the O O
first O O
dose O O
of O O
medication O O
on O O
the O O
first O O
day O O
of O O
the O O
cycle O O
, O O
with O O
both O O
drugs O O
. O O

The O O
difference O O
in O O
pain B-Disease B-Disease
intensity O O
score O O
( O O
DPI O O
) O O
was O O
the O O
main O O
outcome O O
variable O O
. O O

Both O O
treatments O O
significantly O O
reduced O O
DPI O O
by O O
the O O
30th O O
minute O O
( O O
GTN O O
, O O
-12.8 O O
+ O O
/- O O

17.9 O O
; O O
DCF O O
, O O
-18.9 O O
+ O O
/- O O

16.6 O O
) O O
. O O

However O O
, O O
DCF O O
continued O O
to O O
be O O
effective O O
in O O
reducing O O
pelvic B-Disease B-Disease
pain I-Disease I-Disease
for O O
two O O
hours O O
, O O
whereas O O
GTN O O
scores O O
remained O O
more O O
or O O
less O O
stable O O
after O O
30 O O
min O O
and O O
significantly O O
higher O O
than O O
those O O
for O O
DFC O O
( O O
after O O
one O O
hour O O
: O O
GTN O O
, O O
-12.8 O O
+ O O
/- O O

17.9 O O
; O O
DFC O O
, O O
-18.9 O O
+ O O
/- O O

16.6 O O
and O O
after O O
two O O
hours O O
: O O
GTN O O
, O O
-23.7 O O
+ O O
/- O O

20.5 O O
; O O
DFC O O
, O O
-59.7 O O
+ O O
/- O O

17.9 O O
, O O
p O O
= O O
0.0001 O O
) O O
. O O

Low B-Disease B-Disease
back I-Disease I-Disease
pain I-Disease I-Disease
was O O
also O O
relieved O O
by O O
both O O
drugs O O
. O O

Headache B-Disease B-Disease
was O O
significantly O O
increased O O
by O O
GTN O O
but O O
not O O
by O O
DCF O O
. O O

Eight O O
patients O O
stopped O O
using O O
GTN O O
because O O
headache B-Disease B-Disease
-- O O
attributed O O
to O O
its O O
use O O
-- O O
became O O
intolerable O O
. O O

These O O
findings O O
indicate O O
that O O
GTN O O
has O O
a O O
reduced O O
efficacy O O
and O O
tolerability O O
by O O
comparison O O
with O O
DCF O O
in O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea B-Disease B-Disease
. O O

Temocapril O O
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin O O
converting O O
enzyme O O
inhibitor O O
, O O
modulates O O
glomerular B-Disease B-Disease
injury I-Disease I-Disease
in O O
chronic O O
puromycin O O
aminonucleoside O O
nephrosis B-Disease B-Disease
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
whether O O
chronic O O
administration O O
of O O
temocapril O O
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitor O O
, O O
reduced O O
proteinuria B-Disease B-Disease
, O O
inhibited O O
glomerular O B-Disease
hypertrophy B-Disease I-Disease
and O O
prevented O O
glomerulosclerosis B-Disease B-Disease
in O O
chronic O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
- O O
induced O O
nephrotic B-Disease B-Disease
rats O O
. O O

Nephrosis B-Disease B-Disease
was O O
induced O O
by O O
injection O O
of O O
PAN O O
( O O
15mg O O
/ O O
100 O O
g O O
body O O
weight O O
) O O
in O O
male O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

Four O O
groups O O
were O O
used O O
, O O
i O O
) O O
the O O
PAN O O
group O O
( O O
14 O O
) O O
, O O
ii O O
) O O
PAN O O
/ O O
temocapril O O
( O O
13 O O
) O O
, O O
iii O O
) O O
temocapril O O
( O O
14 O O
) O O
and O O
iv O O
) O O
untreated O O
controls O O
( O O
15 O O
) O O
. O O

Temocapril O O
( O O
8 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
was O O
administered O O
to O O
the O O
rats O O
which O O
were O O
killed O O
at O O
weeks O O
4 O O
, O O
14 O O
or O O
20 O O
. O O

At O O
each O O
time O O
point O O
, O O
systolic O O
blood O O
pressure O O
( O O
BP O O
) O O
, O O
urinary O O
protein O O
excretion O O
and O O
renal O O
histopathological O O
findings O O
were O O
evaluated O O
, O O
and O O
morphometric O O
image O O
analysis O O
was O O
done O O
. O O

Systolic O O
BP O O
in O O
the O O
PAN O O
group O O
was O O
significantly O O
high O O
at O O
4 O O
, O O
14 O O
and O O
20 O O
weeks O O
, O O
but O O
was O O
normal O O
in O O
the O O
PAN O O
/ O O
temocapril O O
group O O
. O O

Urinary O O
protein O O
excretion O O
in O O
the O O
PAN O O
group O O
increased O O
significantly O O
, O O
peaking O O
at O O
8 O O
days O O
, O O
then O O
decreased O O
at O O
4 O O
weeks O O
, O O
but O O
rose O O
again O O
significantly O O
at O O
14 O O
and O O
20 O O
weeks O O
. O O

Temocapril O O
did O O
not O O
attenuate O O
proteinuria B-Disease B-Disease
at O O
8 O O
days O O
, O O
but O O
it O O
did O O
markedly O O
lower O O
it O O
from O O
weeks O O
4 O O
to O O
20 O O
. O O

The O O
glomerulosclerosis B-Disease B-Disease
index O O
( O O
GSI O O
) O O
was O O
6.21 O O
% O O
at O O
4 O O
weeks O O
and O O
respectively O O
25.35 O O
% O O
and O O
30.49 O O
% O O
at O O
14 O O
and O O
20 O O
weeks O O
in O O
the O O
PAN O O
group O O
. O O

There O O
was O O
a O O
significant O O
correlation O O
between O O
urinary O O
protein O O
excretion O O
and O O
GSI O O
( O O
r O O
= O O
0.808 O O
, O O
p O O
< O O
0.0001 O O
) O O
. O O

The O O
ratio O O
of O O
glomerular O O
tuft O O
area O O
to O O
the O O
area O O
of O O
Bowman O O
's O O
capsules O O
( O O
GT O O
/ O O
BC O O
) O O
in O O
the O O
PAN O O
group O O
was O O
significantly O O
increased O O
, O O
but O O
it O O
was O O
significantly O O
lower O O
in O O
the O O
PAN O O
/ O O
temocapril O O
group O O
. O O

It O O
appears O O
that O O
temocapril O O
was O O
effective O O
in O O
retarding O O
renal O O
progression O O
and O O
protected O O
renal O O
function O O
in O O
PAN O O
neprotic B-Disease B-Disease
rats O O
. O O

Pulmonary B-Disease B-Disease
hypertension I-Disease I-Disease
after O O
ibuprofen O O
prophylaxis O O
in O O
very O O
preterm O O
infants O O
. O O

We O O
report O O
three O O
cases O O
of O O
severe O O
hypoxaemia B-Disease B-Disease
after O O
ibuprofen O O
administration O O
during O O
a O O
randomised O O
controlled O O
trial O O
of O O
prophylactic O O
treatment O O
of O O
patent B-Disease B-Disease
ductus I-Disease I-Disease
arteriosus I-Disease I-Disease
with O O
ibuprofen O O
in O O
premature O O
infants O O
born O O
at O O
less O O
than O O
28 O O
weeks O O
of O O
gestation O O
. O O

Echocardiography O O
showed O O
severely O O
decreased O O
pulmonary O O
blood O O
flow O O
. O O

Hypoxaemia B-Disease B-Disease
resolved O O
quickly O O
on O O
inhaled O O
nitric O O
oxide O O
therapy O O
. O O

We O O
suggest O O
that O O
investigators O O
involved O O
in O O
similar O O
trials O O
pay O O
close O O
attention O O
to O O
pulmonary O O
pressure O O
if O O
hypoxaemia B-Disease B-Disease
occurs O O
after O O
prophylactic O O
administration O O
of O O
ibuprofen O O
. O O

Hyponatremia B-Disease B-Disease
and O O
syndrome B-Disease B-Disease
of I-Disease I-Disease
inappropriate I-Disease I-Disease
anti I-Disease I-Disease
- I-Disease I-Disease
diuretic I-Disease I-Disease
hormone I-Disease I-Disease
reported O O
with O O
the O O
use O O
of O O
Vincristine O O
: O O
an O O
over O O
- O O
representation O O
of O O
Asians O O
? O O

PURPOSE O O
: O O
This O O
retrospective O O
study O O
used O O
a O O
pharmaceutical O O
company O O
's O O
global O O
safety O O
database O O
to O O
determine O O
the O O
reporting O O
rate O O
of O O
hyponatremia B-Disease B-Disease
and/or O O
syndrome B-Disease B-Disease
of I-Disease I-Disease
inappropriate I-Disease I-Disease
secretion I-Disease I-Disease
of I-Disease I-Disease
anti I-Disease I-Disease
- I-Disease I-Disease
diuretic I-Disease I-Disease
hormone I-Disease I-Disease
( O O
SIADH B-Disease B-Disease
) O O
among O O
vincristine O O
- O O
treated O O
patients O O
and O O
to O O
explore O O
the O O
possibility O O
of O O
at O O
- O O
risk O O
population O O
subgroups O O
. O O

METHOD O O
: O O
We O O
searched O O
the O O
Eli O O
Lilly O O
and O O
Company O O
's O O
computerized O O
adverse O O
event O O
database O O
for O O
all O O
reported O O
cases O O
of O O
hyponatremia B-Disease B-Disease
and/or O O
SIADH B-Disease B-Disease
as O O
of O O
1 O O
November O O
1999 O O
that O O
had O O
been O O
reported O O
during O O
the O O
use O O
of O O
vincristine O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
76 O O
cases O O
of O O
hyponatremia B-Disease B-Disease
and/or O O
SIADH B-Disease B-Disease
associated O O
with O O
vincristine O O
use O O
were O O
identified O O
. O O

The O O
overall O O
reporting O O
rate O O
was O O
estimated O O
to O O
be O O
1.3 O O
/ O O
100,000 O O
treated O O
patients O O
. O O

The O O
average O O
age O O
of O O
patients O O
was O O
35.6 O O
+ O O
/- O O

28.3 O O
years O O
, O O
and O O
62 O O
% O O
were O O
males O O
. O O

Approximately O O
75 O O
% O O
of O O
the O O
patients O O
were O O
receiving O O
treatment O O
for O O
leukemia B-Disease B-Disease
or O O
lymphoma B-Disease B-Disease
. O O

Among O O
the O O
39 O O
reports O O
that O O
included O O
information O O
on O O
race O O
, O O
the O O
racial O O
distribution O O
was O O
: O O
1 O O
Black O O
, O O
3 O O
Caucasian O O
, O O
and O O
35 O O
Asian O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
Asian O O
patients O O
may O O
be O O
at O O
increased O O
risk O O
of O O
hyponatremia B-Disease B-Disease
and/or O O
SIADH B-Disease B-Disease
associated O O
with O O
vincristine O O
use O O
. O O

Although O O
the O O
overall O O
reported O O
rate O O
of O O
SIADH B-Disease B-Disease
associated O O
with O O
vincristine O O
is O O
very O O
low O O
, O O
physicians O O
caring O O
for O O
Asian O O
oncology O O
patients O O
should O O
be O O
aware O O
of O O
this O O
potential O O
serious O O
but O O
reversible O O
adverse O O
event O O
. O O

Delayed O O
toxicity B-Disease B-Disease
of O O
cyclophosphamide O O
on O O
the O O
bladder O O
of O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mouse O O
. O O

The O O
present O O
study O O
describes O O
the O O
delayed O O
development O O
of O O
a O O
severe O O
bladder O O
pathology O O
in O O
a O O
susceptible O O
strain O O
of O O
mice O O
( O O
DBA O O
/ O O
2 O O
) O O
but O O
not O O
in O O
a O O
resistant O O
strain O O
( O O
C57BL O O
/ O O
6 O O
) O O
when O O
both O O
were O O
treated O O
with O O
a O O
single O O
300 O O
mg O O
/ O O
kg O O
dose O O
of O O
cyclophosphamide O O
( O O
CY O O
) O O
. O O

Inbred O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mice O O
were O O
injected O O
with O O
CY O O
, O O
and O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
bladder O O
was O O
assessed O O
during O O
100 O O
days O O
by O O
light O O
microscopy O O
using O O
different O O
staining O O
procedures O O
, O O
and O O
after O O
30 O O
days O O
by O O
conventional O O
electron O O
microscopy O O
. O O

Early O O
CY O O
toxicity B-Disease B-Disease
caused O O
a O O
typical O O
haemorrhagic B-Disease B-Disease
cystitis B-Disease B-Disease
in O O
both O O
strains O O
that O O
was O O
completely O O
repaired O O
in O O
about O O
7 O O
- O O
10 O O
days O O
. O O

After O O
30 O O
days O O
of O O
CY O O
injection O O
ulcerous O O
and O O
non O O
- O O
ulcerous O O
forms O O
of O O
chronic O O
cystitis B-Disease B-Disease
appeared O O
in O O
86 O O
% O O
of O O
DBA O O
/ O O
2 O O
mice O O
but O O
only O O
in O O
4 O O
% O O
of O O
C57BL O O
/ O O
6 O O
mice O O
. O O

Delayed O O
cystitis B-Disease B-Disease
was O O
characterized O O
by O O
infiltration O O
and O O
transepithelial O O
passage O O
into O O
the O O
lumen O O
of O O
inflammatory O O
cells O O
and O O
by O O
frequent O O
exfoliation O O
of O O
the O O
urothelium O O
. O O

Mast O O
cells O O
appeared O O
in O O
the O O
connective O O
and O O
muscular O O
layers O O
of O O
the O O
bladder O O
at O O
a O O
much O O
higher O O
number O O
in O O
DBA O O
/ O O
2 O O
mice O O
than O O
in O O
C57BL O O
/ O O
6 O O
mice O O
or O O
untreated O O
controls O O
. O O

Electron O O
microscopy O O
disclosed O O
the O O
absence O O
of O O
the O O
typical O O
discoidal O O
vesicles O O
normally O O
present O O
in O O
the O O
cytoplasm O O
of O O
surface O O
cells O O
. O O

Instead O O
, O O
numerous O O
abnormal O O
vesicles O O
containing O O
one O O
or O O
several O O
dark O O
granules O O
were O O
observed O O
in O O
the O O
cytoplasm O O
of O O
cells O O
from O O
all O O
the O O
epithelial O O
layers O O
. O O

Delayed O O
cystitis B-Disease B-Disease
still O O
persisted O O
in O O
DBA O O
/ O O
2 O O
mice O O
100 O O
days O O
after O O
treatment O O
. O O

These O O
results O O
indicate O O
that O O
delayed O O
toxicity B-Disease B-Disease
of O O
CY O O
in O O
female O O
DBA O O
/ O O
2 O O
mice O O
causes O O
a O O
bladder O O
pathology O O
that O O
is O O
not O O
observed O O
in O O
C57BL O O
/ O O
6 O O
mice O O
. O O

This O O
pathology O O
resembles O O
interstitial B-Disease B-Disease
cystitis I-Disease I-Disease
in O O
humans O O
and O O
could O O
perhaps O O
be O O
used O O
as O O
an O O
animal O O
model O O
for O O
studies O O
on O O
the O O
disease O O
. O O

High O O
- O O
dose O O
5-fluorouracil O O
/ O O
folinic O O
acid O O
in O O
combination O O
with O O
three O O
- O O
weekly O O
mitomycin O O
C O O
in O O
the O O
treatment O O
of O O
advanced O O
gastric B-Disease B-Disease
cancer I-Disease I-Disease
. O O

A O O
phase O O
II O O
study O O
. O O

BACKGROUND O O
: O O
The O O
24-hour O O
continuous O O
infusion O O
of O O
5-fluorouracil O O
( O O
5-FU O O
) O O
and O O
folinic O O
acid O O
( O O
FA O O
) O O
as O O
part O O
of O O
several O O
new O O
multidrug O O
chemotherapy O O
regimens O O
in O O
advanced O O
gastric B-Disease B-Disease
cancer I-Disease I-Disease
( O O
AGC B-Disease B-Disease
) O O
has O O
shown O O
to O O
be O O
effective O O
, O O
with O O
low O O
toxicity B-Disease O
. O O

In O O
a O O
previous O O
phase O O
II O O
study O O
with O O
3-weekly O O
bolus O O
5-FU O O
, O O
FA O O
and O O
mitomycin O O
C O O
( O O
MMC O O
) O O
we O O
found O O
a O O
low O O
toxicity B-Disease O
rate O O
and O O
response O O
rates O O
comparable O O
to O O
those O O
of O O
regimens O O
such O O
as O O
ELF O O
, O O
FAM O O
or O O
FAMTX O O
, O O
and O O
a O O
promising O O
median O O
overall O O
survival O O
. O O

In O O
order O O
to O O
improve O O
this O O
MMC O O
- O O
dependent O O
schedule O O
we O O
initiated O O
a O O
phase O O
II O O
study O O
with O O
high O O
- O O
dose O O
5-FU O O
/ O O
FA O O
and O O
3-weekly O O
bolus O O
MMC O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
From O O
February O O
, O O
1998 O O
to O O
September O O
, O O
2000 O O
we O O
recruited O O
33 O O
patients O O
with O O
AGC B-Disease B-Disease
to O O
receive O O
weekly O O
24-hour O O
5-FU O O
2,600 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
preceded O O
by O O
2-hour O O
FA O O
500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
for O O
6 O O
weeks O O
, O O
followed O O
by O O
a O O
2-week O O
rest O O
period O O
. O O

Bolus O O
MMC O O
10 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
was O O
added O O
in O O
3-weekly O O
intervals O O
. O O

Treatment O O
given O O
on O O
an O O
outpatient O O
basis O O
, O O
using O O
portable O O
pump O O
systems O O
, O O
was O O
repeated O O
on O O
day O O
57 O O
. O O

Patients O O
' O O
characteristics O O
were O O
: O O
male O O
/ O O
female O O
ratio O O
20 O O
/ O O
13 O O
; O O
median O O
age O O
57 O O
( O O
27 O O
- O O
75 O O
) O O
years O O
; O O
median O O
WHO O O
status O O
1 O O
( O O
0 O O
- O O
2 O O
) O O
. O O

18 O O
patients O O
had O O
a O O
primary O O
AGC B-Disease B-Disease
, O O
and O O
15 O O
showed O O
a O O
relapsed O O
AGC B-Disease B-Disease
. O O

Median O O
follow O O
- O O
up O O
was O O
11.8 O O
months O O
( O O
range O O
of O O
those O O
surviving O O
: O O
2.7 O O
- O O
11.8 O O
months O O
) O O
. O O

RESULTS O O
: O O
32 O O
patients O O
were O O
evaluable O O
for O O
response O O
- O O
complete O O
remission O O
9.1 O O
% O O
( O O
n O O
= O O
3 O O
) O O
, O O
partial O O
remission O O
45.5 O O
% O O
( O O
n O O
= O O
15 O O
) O O
, O O
no O O
change O O
27.3 O O
% O O
( O O
n O O
= O O
9 O O
) O O
, O O
progressive O O
disease O O
15.1 O O
% O O
( O O
n O O
= O O
5 O O
) O O
. O O

Median O O
overall O O
survival O O
time O O
was O O
10.2 O O
months O O
[ O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
: O O
8.7 O O
- O O
11.6 O O
] O O
, O O
and O O
median O O
progression O O
- O O
free O O
survival O O
time O O
was O O
7.6 O O
months O O
( O O
95 O O
% O O
CI O O
: O O
4.4 O O
- O O
10.9 O O
) O O
. O O

The O O
worst O O
toxicities B-Disease O
( O O
% O O
) O O
observed O O
were O O
( O O
CTC O O
- O O
NCI O O
1 O O
/ O O
2 O O
/ O O
3 O O
) O O
: O O
leukopenia B-Disease B-Disease
45.5 O O
/ O O
18.2 O O
/ O O
6.1 O O
, O O
thrombocytopenia B-Disease B-Disease
33.3 O O
/ O O
9.1 O O
/ O O
6.1 O O
, O O
vomitus B-Disease B-Disease
24.2 O O
/ O O
9.1 O O
/ O O
0 O O
, O O
diarrhea B-Disease B-Disease
36.4 O O
/ O O
6.1 O O
/ O O
3.0 O O
, O O
stomatitis B-Disease B-Disease
18.2 O O
/ O O
9.1 O O
/ O O
0 O O
, O O
hand B-Disease B-Disease
- I-Disease I-Disease
foot I-Disease I-Disease
syndrome I-Disease I-Disease
12.1 O O
/ O O
0 O O
/ O O
0 O O
. O O

Two O O
patients O O
developed O O
hemolytic B-Disease B-Disease
- I-Disease I-Disease
uremic I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
HUS B-Disease B-Disease
) O O
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
5-FU O O
/ O O
FA O O
/ O O
MMC O O
is O O
an O O
effective O O
and O O
well O O
- O O
tolerated O O
outpatient O O
regimen O O
for O O
AGC B-Disease B-Disease
( O O
objective O O
response O O
rate O O
54.6 O O
% O O
) O O
. O O

It O O
may O O
serve O O
as O O
an O O
alternative O O
to O O
cisplatin O O
- O O
containing O O
regimens O O
; O O
however O O
, O O
it O O
has O O
to O O
be O O
considered O O
that O O
possibly O O
HUS B-Disease B-Disease
may O O
occur O O
. O O

Persistent O O
sterile O O
leukocyturia B-Disease B-Disease
is O O
associated O O
with O O
impaired B-Disease B-Disease
renal I-Disease I-Disease
function I-Disease I-Disease
in O O
human B-Disease B-Disease
immunodeficiency I-Disease I-Disease
virus I-Disease I-Disease
type I-Disease I-Disease
1-infected I-Disease I-Disease
children O O
treated O O
with O O
indinavir O O
. O O

BACKGROUND O O
: O O
Prolonged O O
administration O O
of O O
indinavir O O
is O O
associated O O
with O O
the O O
occurrence O O
of O O
a O O
variety O O
of O O
renal O O
complications O O
in O O
adults O O
. O O

These O O
well O O
- O O
documented O O
side O O
effects O O
have O O
restricted O O
the O O
use O O
of O O
this O O
potent O O
protease O O
inhibitor O O
in O O
children O O
. O O

DESIGN O O
: O O
A O O
prospective O O
study O O
to O O
monitor O O
indinavir O O
- O O
related O O
nephrotoxicity B-Disease B-Disease
in O O
a O O
cohort O O
of O O
30 O O
human B-Disease B-Disease
immunodeficiency I-Disease I-Disease
virus I-Disease I-Disease
type I-Disease I-Disease
1-infected I-Disease I-Disease
children O O
treated O O
with O O
indinavir O O
. O O

METHODS O O
: O O
Urinary O O
pH O O
, O O
albumin O O
, O O
creatinine O O
, O O
the O O
presence O O
of O O
erythrocytes O O
, O O
leukocytes O O
, O O
bacteria O O
and O O
crystals O O
, O O
and O O
culture O O
were O O
analyzed O O
every O O
3 O O
months O O
for O O
96 O O
weeks O O
. O O

Serum O O
creatinine O O
levels O O
were O O
routinely O O
determined O O
at O O
the O O
same O O
time O O
points O O
. O O

Steady O O
- O O
state O O
pharmacokinetics O O
of O O
indinavir O O
were O O
done O O
at O O
week O O
4 O O
after O O
the O O
initiation O O
of O O
indinavir O O
. O O

RESULTS O O
: O O
The O O
cumulative O O
incidence O O
of O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
( O O
> O O
or O O
= O O
75 O O
cells O O
/ O O
micro O O
L O O
in O O
at O O
least O O
2 O O
consecutive O O
visits O O
) O O
after O O
96 O O
weeks O O
was O O
53 O O
% O O
. O O

Persistent O O
sterile O O
leukocyturia B-Disease B-Disease
was O O
frequently O O
associated O O
with O O
a O O
mild O O
increase O O
in O O
the O O
urine O O
albumin O O
/ O O
creatinine O O
ratio O O
and O O
by O O
microscopic O O
hematuria B-Disease B-Disease
. O O

The O O
cumulative O O
incidence O O
of O O
serum O O
creatinine O O
levels O O
> O O
50 O O
% O O
above O O
normal O O
was O O
33 O O
% O O
after O O
96 O O
weeks O O
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
more O O
frequently O O
had O O
serum O O
creatinine O O
levels O O
of O O
50 O O
% O O
above O O
normal O O
than O O
those O O
children O O
without O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
. O O

In O O
children O O
younger O O
than O O
5.6 O O
years O O
, O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
was O O
significantly O O
more O O
frequent O O
than O O
in O O
older O O
children O O
. O O

A O O
higher O O
cumulative O O
incidence O O
of O O
persistent O O
leukocyturia B-Disease B-Disease
was O O
found O O
in O O
children O O
with O O
an O O
area O O
under O O
the O O
curve O O
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
or O O
a O O
peak O O
serum O O
level O O
of O O
indinavir O O
> O O
12 O O
mg O O
/ O O
L. O O
In O O
4 O O
children O O
, O O
indinavir O O
was O O
discontinued O O
because O O
of O O
nephrotoxicity B-Disease B-Disease
. O O

Subsequently O O
, O O
the O O
serum O O
creatinine O O
levels O O
decreased O O
, O O
the O O
urine O O
albumin O O
/ O O
creatinine O O
ratios O O
returned O O
to O O
zero O O
, O O
and O O
the O O
leukocyturia B-Disease B-Disease
disappeared O O
within O O
3 O O
months O O
. O O

CONCLUSIONS O O
: O O
Children O O
treated O O
with O O
indinavir O O
have O O
a O O
high O O
cumulative O O
incidence O O
of O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
more O O
frequently O O
had O O
an O O
increase O O
in O O
serum O O
creatinine O O
levels O O
of O O
> O O
50 O O
% O O
above O O
normal O O
. O O

Younger O O
children O O
have O O
an O O
additional O O
risk O O
for O O
renal O O
complications O O
. O O

The O O
impairment B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
renal I-Disease I-Disease
function I-Disease I-Disease
in O O
these O O
children O O
occurred O O
in O O
the O O
absence O O
of O O
clinical O O
symptoms O O
of O O
nephrolithiasis B-Disease B-Disease
. O O

Indinavir O O
- O O
associated O O
nephrotoxicity B-Disease B-Disease
must O O
be O O
monitored O O
closely O O
, O O
especially O O
in O O
children O O
with O O
risk O O
factors O O
such O O
as O O
persistent O O
sterile O O
leukocyturia B-Disease B-Disease
, O O
age O O
< O O
5.6 O O
years O O
, O O
an O O
area O O
under O O
the O O
curve O O
of O O
indinavir O O
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
, O O
and O O
a O O
C O O
( O O
max O O
) O O
> O O
12 O O
mg O O
/ O O
L. O O

Utility O O
of O O
troponin O O
I O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

Baseline O O
electrocardiogram O O
abnormalities O O
and O O
market O O
elevations O O
not O O
associated O O
with O O
myocardial B-Disease B-Disease
necrosis I-Disease I-Disease
make O O
accurate O O
diagnosis O O
of O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
MI B-Disease B-Disease
) O O
difficult O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

Troponin O O
sampling O O
may O O
offer O O
greater O O
diagnostic O O
utility O O
in O O
these O O
patients O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
outcomes O O
based O O
on O O
troponin O O
positivity O O
in O O
patients O O
with O O
cocaine O O
chest B-Disease B-Disease
pain I-Disease I-Disease
admitted O O
for O O
exclusion O O
of O O
MI B-Disease B-Disease
. O O

METHODS O O
: O O
Outcomes O O
were O O
examined O O
in O O
patients O O
admitted O O
for O O
possible O O
MI B-Disease B-Disease
after O O
cocaine O O
use O O
. O O

All O O
patients O O
underwent O O
a O O
rapid O O
rule O O
- O O
in O O
protocol O O
that O O
included O O
serial O O
sampling O O
of O O
creatine O O
kinase O O
( O O
CK O O
) O O
, O O
CK O O
- O O
MB O O
, O O
and O O
cardiac O O
troponin O O
I O O
( O O
cTnI O O
) O O
over O O
eight O O
hours O O
. O O

Outcomes O O
included O O
CK O O
- O O
MB O O
MI B-Disease B-Disease
( O O
CK O O
- O O
MB O O
> O O
or= O O
8 O O
ng O O
/ O O
mL O O
with O O
a O O
relative O O
index O O
[ O O
( O O
CK O O
- O O
MB O O
x O O
100 O O
) O O
/ O O
total O O
CK O O
] O O
> O O
or= O O
4 O O
, O O
cardiac B-Disease B-Disease
death I-Disease I-Disease
, O O
and O O
significant O O
coronary B-Disease B-Disease
disease I-Disease I-Disease
( O O
> O O
or=50 O O
% O O
) O O
. O O

RESULTS O O
: O O
Of O O
the O O
246 O O
admitted O O
patients O O
, O O
34 O O
( O O
14 O O
% O O
) O O
met O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B-Disease B-Disease
and O O
38 O O
( O O
16 O O
% O O
) O O
had O O
cTnI O O
elevations O O
. O O

Angiography O O
was O O
performed O O
in O O
29 O O
of O O
38 O O
patients O O
who O O
were O O
cTnI O O
- O O
positive O O
, O O
with O O
significant O O
disease O O
present O O
in O O
25 O O
( O O
86 O O
% O O
) O O
. O O

Three O O
of O O
the O O
four O O
patients O O
without O O
significant O O
disease O O
who O O
had O O
cTnI O O
elevations O O
met O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B-Disease B-Disease
, O O
and O O
the O O
other O O
had O O
a O O
peak O O
CK O O
- O O
MB O O
level O O
of O O
13 O O
ng O O
/ O O
mL. O O
Sensitivities O O
, O O
specificities O O
, O O
and O O
positive O O
and O O
negative O O
likelihood O O
ratios O O
for O O
predicting O O
cardiac B-Disease B-Disease
death I-Disease I-Disease
or O O
significant O O
disease O O
were O O
high O O
for O O
both O O
CK O O
- O O
MB O O
MI B-Disease B-Disease
and O O
cTnI O O
and O O
were O O
not O O
significantly O O
different O O
. O O

CONCLUSIONS O O
: O O
Most O O
patients O O
with O O
cTnI O O
elevations O O
meet O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B-Disease B-Disease
, O O
as O O
well O O
as O O
have O O
a O O
high O O
incidence O O
of O O
underlying O O
significant O O
disease O O
. O O

Troponin O O
appears O O
to O O
have O O
an O O
equivalent O O
diagnostic O O
accuracy O O
compared O O
with O O
CK O O
- O O
MB O O
for O O
diagnosing O O
necrosis B-Disease B-Disease
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
and O O
suspected O O
MI B-Disease B-Disease
. O O

Acute O O
interstitial B-Disease B-Disease
nephritis I-Disease I-Disease
due O O
to O O
nicergoline O O
( O O
Sermion O O
) O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
interstitial B-Disease B-Disease
nephritis I-Disease I-Disease
( O O
AIN B-Disease B-Disease
) O O
due O O
to O O
nicergoline O O
( O O
Sermion O O
) O O
. O O

A O O
50-year O O
- O O
old O O
patient O O
admitted O O
to O O
our O O
hospital O O
for O O
fever B-Disease B-Disease
and O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
. O O

Before O O
admission O O
, O O
he O O
had O O
been O O
taking O O
nicergoline O O
and O O
bendazac O O
lysine O O
due O O
to O O
retinal B-Disease B-Disease
vein I-Disease I-Disease
occlusion I-Disease I-Disease
at O O
ophthalmologic O O
department O O
. O O

Thereafter O O
, O O
he O O
experienced O O
intermittent O O
fever B-Disease B-Disease
and O O
skin B-Disease B-Disease
rash I-Disease I-Disease
. O O

On O O
admission O O
, O O
clinical O O
symptoms O O
( O O
i.e. O O
arthralgia B-Disease B-Disease
and O O
fever B-Disease B-Disease
) O O
and O O
laboratory O O
findings O O
( O O
i.e. O O
eosinophilia B-Disease B-Disease
and O O
renal B-Disease B-Disease
failure I-Disease I-Disease
) O O
suggested O O
AIN B-Disease B-Disease
, O O
and O O
which O O
was O O
confirmed O O
by O O
pathologic O O
findings O O
on O O
renal O O
biopsy O O
. O O

A O O
lymphocyte O O
transformation O O
test O O
demonstrated O O
a O O
positive O O
result O O
against O O
nicergoline O O
. O O

Treatment O O
was O O
consisted O O
of O O
withdrawal O O
of O O
nicergoline O O
and O O
intravenous O O
methylprednisolone O O
, O O
and O O
his O O
renal O O
function O O
was O O
completely O O
recovered O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
of O O
nicergoline O O
- O O
associated O O
AIN B-Disease B-Disease
. O O

Neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
complicated O O
by O O
massive O O
intestinal O B-Disease
bleeding B-Disease I-Disease
in O O
a O O
patient O O
with O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
. O O

A O O
patient O O
with O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
( O O
CRF B-Disease B-Disease
) O O
developed O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
NMS B-Disease B-Disease
) O O
after O O
administration O O
of O O
risperidone O O
and O O
levomepromazine O O
. O O

In O O
addition O O
to O O
the O O
typical O O
symptoms O O
of O O
NMS B-Disease B-Disease
, O O
massive O O
intestinal O B-Disease
bleeding B-Disease I-Disease
was O O
observed O O
during O O
the O O
episode O O
. O O

This O O
report O O
suggests O O
that O O
NMS B-Disease B-Disease
in O O
a O O
patient O O
with O O
CRF B-Disease B-Disease
may O O
be O O
complicated O O
by O O
intestinal O B-Disease
bleeding B-Disease I-Disease
and O O
needs O O
special O O
caution O O
for O O
this O O
complication O O
. O O

Blood O O
brain O O
barrier O O
in O O
right- O O
and O O
left O O
- O O
pawed O O
female O O
rats O O
assessed O O
by O O
a O O
new O O
staining O O
method O O
. O O

The O O
asymmetrical O O
breakdown O O
of O O
the O O
blood O O
- O O
brain O O
barrier O O
( O O
BBB O O
) O O
was O O
studied O O
in O O
female O O
rats O O
. O O

Paw O O
preference O O
was O O
assessed O O
by O O
a O O
food O O
reaching O O
test O O
. O O

Adrenaline O O
- O O
induced O O
hypertension B-Disease B-Disease
was O O
used O O
to O O
destroy O O
the O O
BBB O O
, O O
which O O
was O O
evaluated O O
using O O
triphenyltetrazolium O O
( O O
TTC O O
) O O
staining O O
of O O
the O O
brain O O
slices O O
just O O
after O O
giving O O
adrenaline O O
for O O
30 O O
s. O O
In O O
normal O O
rats O O
, O O
the O O
whole O O
brain O O
sections O O
exhibited O O
complete O O
staining O O
with O O
TTC O O
. O O

After O O
adrenaline O O
infusion O O
for O O
30 O O
s O O
, O O
there O O
were O O
large O O
unstained O O
areas O O
in O O
the O O
left O O
brain O O
in O O
right O O
- O O
pawed O O
animals O O
, O O
and O O
vice O O
versa O O
in O O
left O O
- O O
pawed O O
animals O O
. O O

Similar O O
results O O
were O O
obtained O O
in O O
seizure B-Disease B-Disease
- O O
induced O O
breakdown O O
of O O
BBB O O
. O O

These O O
results O O
were O O
explained O O
by O O
an O O
asymmetric O O
cerebral O O
blood O O
flow O O
depending O O
upon O O
the O O
paw O O
preference O O
in O O
rats O O
. O O

It O O
was O O
suggested O O
that O O
this O O
new O O
method O O
and O O
the O O
results O O
are O O
consistent O O
with O O
contralateral O O
motor O O
control O O
that O O
may O O
be O O
important O O
in O O
determining O O
the O O
dominant O O
cerebral O O
hemisphere O O
in O O
animals O O
. O O

Carvedilol O O
protects O O
against O O
doxorubicin O O
- O O
induced O O
mitochondrial O B-Disease
cardiomyopathy B-Disease I-Disease
. O O

Several O O
cytopathic O O
mechanisms O O
have O O
been O O
suggested O O
to O O
mediate O O
the O O
dose O O
- O O
limiting O O
cumulative O O
and O O
irreversible O O
cardiomyopathy B-Disease B-Disease
caused O O
by O O
doxorubicin O O
. O O

Recent O O
evidence O O
indicates O O
that O O
oxidative O O
stress O O
and O O
mitochondrial B-Disease B-Disease
dysfunction I-Disease I-Disease
are O O
key O O
factors O O
in O O
the O O
pathogenic O O
process O O
. O O

The O O
objective O O
of O O
this O O
investigation O O
was O O
to O O
test O O
the O O
hypothesis O O
that O O
carvedilol O O
, O O
a O O
nonselective O O
beta O O
- O O
adrenergic O O
receptor O O
antagonist O O
with O O
potent O O
antioxidant O O
properties O O
, O O
protects O O
against O O
the O O
cardiac O B-Disease
and O I-Disease
hepatic O I-Disease
mitochondrial O I-Disease
bioenergetic O I-Disease
dysfunction O I-Disease
associated O O
with O O
subchronic O O
doxorubicin O O
toxicity B-Disease B-Disease
. O O

Heart O O
and O O
liver O O
mitochondria O O
were O O
isolated O O
from O O
rats O O
treated O O
for O O
7 O O
weeks O O
with O O
doxorubicin O O
( O O
2 O O
mg O O
/ O O
kg O O
sc O O
/ O O
week O O
) O O
, O O
carvedilol O O
( O O
1 O O
mg O O
/ O O
kg O O
ip O O
/ O O
week O O
) O O
, O O
or O O
the O O
combination O O
of O O
the O O
two O O
drugs O O
. O O

Heart O O
mitochondria O O
isolated O O
from O O
doxorubicin O O
- O O
treated O O
rats O O
exhibited O O
depressed O O
rates O O
for O O
state O O
3 O O
respiration O O
( O O
336 O O
+ O O
/- O O

26 O O
versus O O
425 O O
+ O O
/- O O

53 O O
natom O O
O O O
/ O O
min O O
/ O O
mg O O
protein O O
) O O
and O O
a O O
lower O O
respiratory O O
control O O
ratio O O
( O O
RCR O O
) O O
( O O
4.3 O O
+ O O
/- O O

0.6 O O
versus O O
5.8 O O
+ O O
/- O O

0.4 O O
) O O
compared O O
with O O
cardiac O O
mitochondria O O
isolated O O
from O O
saline O O
- O O
treated O O
rats O O
. O O

Mitochondrial O O
calcium O O
- O O
loading O O
capacity O O
and O O
the O O
activity O O
of O O
NADH O O
- O O
dehydrogenase O O
were O O
also O O
suppressed O O
in O O
cardiac O O
mitochondria O O
from O O
doxorubicin O O
- O O
treated O O
rats O O
. O O

Doxorubicin O O
treatment O O
also O O
caused O O
a O O
decrease O O
in O O
RCR O O
for O O
liver O O
mitochondria O O
( O O
3.9 O O
+ O O
/- O O

0.9 O O
versus O O
5.6 O O
+ O O
/- O O

0.7 O O
for O O
control O O
rats O O
) O O
and O O
inhibition O O
of O O
hepatic O O
cytochrome O O
oxidase O O
activity O O
. O O

Coadministration O O
of O O
carvedilol O O
decreased O O
the O O
extent O O
of O O
cellular O O
vacuolization O O
in O O
cardiac O O
myocytes O O
and O O
prevented O O
the O O
inhibitory O O
effect O O
of O O
doxorubicin O O
on O O
mitochondrial O O
respiration O O
in O O
both O O
heart O O
and O O
liver O O
. O O

Carvedilol O O
also O O
prevented O O
the O O
decrease O O
in O O
mitochondrial O O
Ca O O
( O O
2 O O
+ O O
) O O
loading O O
capacity O O
and O O
the O O
inhibition O O
of O O
the O O
respiratory O O
complexes O O
of O O
heart O O
mitochondria O O
caused O O
by O O
doxorubicin O O
. O O

Carvedilol O O
by O O
itself O O
did O O
not O O
affect O O
any O O
of O O
the O O
parameters O O
measured O O
for O O
heart O O
or O O
liver O O
mitochondria O O
. O O

It O O
is O O
concluded O O
that O O
this O O
protection O O
by O O
carvedilol O O
against O O
both O O
the O O
structural O O
and O O
functional O O
cardiac O B-Disease
tissue O I-Disease
damage O I-Disease
may O O
afford O O
significant O O
clinical O O
advantage O O
in O O
minimizing O O
the O O
dose O O
- O O
limiting O O
mitochondrial B-Disease B-Disease
dysfunction I-Disease I-Disease
and O O
cardiomyopathy B-Disease B-Disease
that O O
accompanies O O
long O O
- O O
term O O
doxorubicin O O
therapy O O
in O O
cancer B-Disease B-Disease
patients O O
. O O

Cocaine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
is O O
more O O
influenced O O
by O O
adenosine O O
receptor O O
agonists O O
than O O
amphetamine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
. O O

The O O
influence O O
of O O
adenosine O O
receptor O O
agonists O O
and O O
antagonists O O
on O O
cocaine O O
- O O
and O O
amphetamine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
was O O
examined O O
in O O
mice O O
. O O

All O O
adenosine O O
receptor O O
agonists O O
significantly O O
decreased B-Disease O
the I-Disease O
locomotor I-Disease O
activity I-Disease O
in O O
mice O O
, O O
and O O
the O O
effects O O
were O O
dose O O
- O O
dependent O O
. O O

It O O
seems O O
that O O
adenosine O O
A1 O O
and O O
A2 O O
receptors O O
might O O
be O O
involved O O
in O O
this O O
reaction O O
. O O

Moreover O O
, O O
all O O
adenosine O O
receptor O O
agonists O O
: O O
2-p- O O
( O O
2-carboxyethyl O O
) O O
phenethylamino-5'-N O O
- O O
ethylcarboxamidoadenosine O O
( O O
CGS O O
21680 O O
) O O
, O O
A2A O O
receptor O O
agonist O O
, O O
N6-cyclopentyladenosine O O
( O O
CPA O O
) O O
, O O
A1 O O
receptor O O
agonist O O
, O O
and O O
5'-N O O
- O O
ethylcarboxamidoadenosine O O
( O O
NECA O O
) O O
, O O
A2 O O
/ O O
A1 O O
receptor O O
agonist O O
significantly O O
and O O
dose O O
- O O
dependently O O
decreased O O
cocaine O O
- O O
induced O O
locomotor O O
activity O O
. O O

CPA O O
reduced O O
cocaine O O
action O O
at O O
the O O
doses O O
which O O
, O O
given O O
alone O O
, O O
did O O
not O O
influence O O
motility O O
, O O
while O O
CGS O O
21680 O O
and O O
NECA O O
decreased O O
the O O
action O O
of O O
cocaine O O
at O O
the O O
doses O O
which O O
, O O
given O O
alone O O
, O O
decreased O O
locomotor O O
activity O O
in O O
animals O O
. O O

These O O
results O O
suggest O O
the O O
involvement O O
of O O
both O O
adenosine O O
receptors O O
in O O
the O O
action O O
of O O
cocaine O O
although O O
agonists O O
of O O
A1 O O
receptors O O
seem O O
to O O
have O O
stronger O O
influence O O
on O O
it O O
. O O

The O O
selective O O
blockade O O
of O O
A2 O O
adenosine O O
receptor O O
by O O
DMPX O O
( O O
3,7-dimethyl-1-propargylxanthine O O
) O O
significantly O O
enhanced O O
cocaine O O
- O O
induced O O
locomotor O O
activity O O
of O O
animals O O
. O O

Caffeine O O
had O O
similar O O
action O O
but O O
the O O
effect O O
was O O
not O O
significant O O
. O O

CPT O O
( O O
8-cyclopentyltheophylline O O
) O O
--A1 O O
receptor O O
antagonist O O
, O O
did O O
not O O
show O O
any O O
influence O O
in O O
this O O
test O O
. O O

Similarly O O
, O O
all O O
adenosine O O
receptor O O
agonists O O
decreased O O
amphetamine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
, O O
but O O
at O O
the O O
higher O O
doses O O
than O O
those O O
which O O
were O O
active O O
in O O
cocaine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
. O O

The O O
selective O O
blockade O O
of O O
A2 O O
adenosine O O
receptors O O
( O O
DMPX O O
) O O
and O O
non O O
- O O
selective O O
blockade O O
of O O
adenosine O O
receptors O O
( O O
caffeine O O
) O O
significantly O O
increased O O
the O O
action O O
of O O
amphetamine O O
in O O
the O O
locomotor O O
activity O O
test O O
. O O

Our O O
results O O
have O O
shown O O
that O O
all O O
adenosine O O
receptor O O
agonists O O
( O O
A1 O O
and O O
A2 O O
) O O
reduce O O
cocaine- O O
and O O
amphetamine O O
- O O
induced O O
locomotor O O
activity O O
and O O
indicate O O
that O O
cocaine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
is O O
more O O
influenced O O
by O O
adenosine O O
receptor O O
agonists O O
( O O
particularly O O
A1 O O
receptors O O
) O O
than O O
amphetamine O O
- O O
induced O O
hyperactivity B-Disease B-Disease
. O O

Amiodarone O O
and O O
the O O
risk O O
of O O
bradyarrhythmia B-Disease B-Disease
requiring O O
permanent O O
pacemaker O O
in O O
elderly O O
patients O O
with O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
and O O
prior O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

OBJECTIVES O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
the O O
use O O
of O O
amiodarone O O
in O O
patients O O
with O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
( O O
AF B-Disease B-Disease
) O O
increases O O
the O O
risk O O
of O O
bradyarrhythmia B-Disease B-Disease
requiring O O
a O O
permanent O O
pacemaker O O
. O O

BACKGROUND O O
: O O
Reports O O
of O O
severe O O
bradyarrhythmia B-Disease B-Disease
during O O
amiodarone O O
therapy O O
are O O
infrequent O O
and O O
limited O O
to O O
studies O O
assessing O O
the O O
therapy O O
's O O
use O O
in O O
the O O
management O O
of O O
patients O O
with O O
ventricular B-Disease B-Disease
arrhythmias I-Disease I-Disease
. O O

METHODS O O
: O O
A O O
study O O
cohort O O
of O O
8,770 O O
patients O O
age O O
> O O
or O O
= O O
65 O O
years O O
with O O
a O O
new O O
diagnosis O O
of O O
AF B-Disease B-Disease
was O O
identified O O
from O O
a O O
provincewide O O
database O O
of O O
Quebec O O
residents O O
with O O
a O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
MI B-Disease B-Disease
) O O
between O O
1991 O O
and O O
1999 O O
. O O

Using O O
a O O
nested O O
case O O
- O O
control O O
design O O
, O O
477 O O
cases O O
of O O
bradyarrhythmia B-Disease B-Disease
requiring O O
a O O
permanent O O
pacemaker O O
were O O
matched O O
( O O
1:4 O O
) O O
to O O
1,908 O O
controls O O
. O O

Multivariable O O
logistic O O
regression O O
was O O
used O O
to O O
estimate O O
the O O
odds O O
ratio O O
( O O
OR O O
) O O
of O O
pacemaker O O
insertion O O
associated O O
with O O
amiodarone O O
use O O
, O O
controlling O O
for O O
baseline O O
risk O O
factors O O
and O O
exposure O O
to O O
sotalol O O
, O O
Class O O
I O O
antiarrhythmic O O
agents O O
, O O
beta O O
- O O
blockers O O
, O O
calcium O O
channel O O
blockers O O
, O O
and O O
digoxin O O
. O O

RESULTS O O
: O O
amiodarone O O
use O O
was O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
pacemaker O O
insertion O O
( O O
OR O O
: O O
2.14 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
: O O
1.30 O O
to O O
3.54 O O
) O O
. O O

This O O
effect O O
was O O
modified O O
by O O
gender O O
, O O
with O O
a O O
greater O O
risk O O
in O O
women O O
versus O O
men O O
( O O
OR O O
: O O
3.86 O O
, O O
95 O O
% O O
CI O O
: O O
1.70 O O
to O O
8.75 O O
vs. O O
OR O O
: O O
1.52 O O
, O O
95 O O
% O O
CI O O
: O O
0.80 O O
to O O
2.89 O O
) O O
. O O

Digoxin O O
was O O
the O O
only O O
other O O
medication O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
pacemaker O O
insertion O O
( O O
OR O O
: O O
1.78 O O
, O O
95 O O
% O O
CI O O
: O O
1.37 O O
to O O
2.31 O O
) O O
. O O

CONCLUSIONS O O
: O O
This O O
study O O
suggests O O
that O O
the O O
use O O
of O O
amiodarone O O
in O O
elderly O O
patients O O
with O O
AF B-Disease B-Disease
and O O
a O O
previous O O
MI B-Disease B-Disease
increases O O
the O O
risk O O
of O O
bradyarrhythmia B-Disease B-Disease
requiring O O
a O O
permanent O O
pacemaker O O
. O O

The O O
finding O O
of O O
an O O
augmented O O
risk O O
of O O
pacemaker O O
insertion O O
in O O
elderly O O
women O O
receiving O O
amiodarone O O
requires O O
further O O
investigation O O
. O O

Indomethacin O O
- O O
induced O O
morphologic O O
changes O O
in O O
the O O
rat O O
urinary O O
bladder O O
epithelium O O
. O O

OBJECTIVES O O
: O O
To O O
evaluate O O
the O O
morphologic O O
changes O O
in O O
rat O O
urothelium O O
induced O O
by O O
indomethacin O O
. O O

Nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
- O O
induced O O
cystitis B-Disease B-Disease
is O O
a O O
poorly O O
recognized O O
and O O
under O O
- O O
reported O O
condition O O
. O O

In O O
addition O O
to O O
tiaprofenic O O
acid O O
, O O
indomethacin O O
has O O
been O O
reported O O
to O O
be O O
associated O O
with O O
this O O
condition O O
. O O

METHODS O O
: O O
Three O O
groups O O
were O O
established O O
: O O
a O O
control O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
a O O
high O O
- O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
treated O O
with O O
one O O
intraperitoneal O O
injection O O
of O O
indomethacin O O
20 O O
mg O O
/ O O
kg O O
, O O
and O O
a O O
therapeutic O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
in O O
which O O
oral O O
indomethacin O O
was O O
administered O O
3.25 O O
mg O O
/ O O
kg O O
body O O
weight O O
daily O O
for O O
3 O O
weeks O O
. O O

The O O
animals O O
were O O
then O O
killed O O
and O O
the O O
bladders O O
removed O O
for O O
light O O
and O O
electron O O
microscopic O O
studies O O
. O O

RESULTS O O
: O O
The O O
light O O
microscopic O O
findings O O
showed O O
some O O
focal O O
epithelial O O
degeneration O O
that O O
was O O
more O O
prominent O O
in O O
the O O
high O O
- O O
dose O O
group O O
. O O

When O O
compared O O
with O O
the O O
control O O
group O O
, O O
both O O
indomethacin O O
groups O O
revealed O O
statistically O O
increased O O
numbers O O
of O O
mast O O
cells O O
in O O
the O O
mucosa O O
( O O
P O O
< O O
0.0001 O O
) O O
and O O
penetration O O
of O O
lanthanum O O
nitrate O O
through O O
intercellular O O
areas O O
of O O
the O O
epithelium O O
. O O

Furthermore O O
, O O
the O O
difference O O
in O O
mast O O
cell O O
counts O O
between O O
the O O
high O O
and O O
therapeutic O O
dose O O
groups O O
was O O
also O O
statistically O O
significant O O
( O O
P O O
< O O
0.0001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Indomethacin O O
resulted O O
in O O
histopathologic O O
findings O O
typical O O
of O O
interstitial B-Disease B-Disease
cystitis I-Disease I-Disease
, O O
such O O
as O O
leaky O O
bladder O O
epithelium O O
and O O
mucosal O O
mastocytosis B-Disease B-Disease
. O O

The O O
true O O
incidence O O
of O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
- O O
induced O O
cystitis B-Disease B-Disease
in O O
humans O O
must O O
be O O
clarified O O
by O O
prospective O O
clinical O O
trials O O
. O O

An O O
open O O
- O O
label O O
phase O O
II O O
study O O
of O O
low O O
- O O
dose O O
thalidomide O O
in O O
androgen O O
- O O
independent O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
antiangiogenic O O
effects O O
of O O
thalidomide O O
have O O
been O O
assessed O O
in O O
clinical O O
trials O O
in O O
patients O O
with O O
various O O
solid O O
and O O
haematological B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

Thalidomide O O
blocks O O
the O O
activity O O
of O O
angiogenic O O
agents O O
including O O
bFGF O O
, O O
VEGF O O
and O O
IL-6 O O
. O O

We O O
undertook O O
an O O
open O O
- O O
label O O
study O O
using O O
thalidomide O O
100 O O
mg O O
once O O
daily O O
for O O
up O O
to O O
6 O O
months O O
in O O
20 O O
men O O
with O O
androgen O O
- O O
independent O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
mean O O
time O O
of O O
study O O
was O O
109 O O
days O O
( O O
median O O
107 O O
, O O
range O O
4 O O
- O O
184 O O
days O O
) O O
. O O

Patients O O
underwent O O
regular O O
measurement O O
of O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
, O O
urea O O
and O O
electrolytes O O
, O O
serum O O
bFGF O O
and O O
VEGF O O
. O O

Three O O
men O O
( O O
15 O O
% O O
) O O
showed O O
a O O
decline O O
in O O
serum O O
PSA O O
of O O
at O O
least O O
50 O O
% O O
, O O
sustained O O
throughout O O
treatment O O
. O O

Of O O
16 O O
men O O
treated O O
for O O
at O O
least O O
2 O O
months O O
, O O
six O O
( O O
37.5 O O
% O O
) O O
showed O O
a O O
fall O O
in O O
absolute O O
PSA O O
by O O
a O O
median O O
of O O
48 O O
% O O
. O O

Increasing O O
levels O O
of O O
serum O O
bFGF O O
and O O
VEGF O O
were O O
associated O O
with O O
progressive O O
disease O O
; O O
five O O
of O O
six O O
men O O
who O O
demonstrated O O
a O O
fall O O
in O O
PSA O O
also O O
showed O O
a O O
decline O O
in O O
bFGF O O
and O O
VEGF O O
levels O O
, O O
and O O
three O O
of O O
four O O
men O O
with O O
a O O
rising O O
PSA O O
showed O O
an O O
increase O O
in O O
both O O
growth O O
factors O O
. O O

Adverse O O
effects O O
included O O
constipation B-Disease B-Disease
, O O
morning O O
drowsiness B-Disease B-Disease
, O O
dizziness B-Disease B-Disease
and O O
rash B-Disease B-Disease
, O O
and O O
resulted O O
in O O
withdrawal O O
from O O
the O O
study O O
by O O
three O O
men O O
. O O

Evidence O O
of O O
peripheral B-Disease B-Disease
sensory I-Disease I-Disease
neuropathy I-Disease I-Disease
was O O
found O O
in O O
nine O O
of O O
13 O O
men O O
before O O
treatment O O
. O O

In O O
the O O
seven O O
men O O
who O O
completed O O
six O O
months O O
on O O
thalidomide O O
, O O
subclinical O O
evidence O O
of O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
was O O
found O O
in O O
four O O
before O O
treatment O O
, O O
but O O
in O O
all O O
seven O O
at O O
repeat O O
testing O O
. O O

The O O
findings O O
indicate O O
that O O
thalidomide O O
may O O
be O O
an O O
option O O
for O O
patients O O
who O O
have O O
failed O O
other O O
forms O O
of O O
therapy O O
, O O
provided O O
close O O
follow O O
- O O
up O O
is O O
maintained O O
for O O
development O O
of O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

Central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
toxicity I-Disease I-Disease
following O O
the O O
administration O O
of O O
levobupivacaine O O
for O O
lumbar O O
plexus O O
block O O
: O O
A O O
report O O
of O O
two O O
cases O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
Central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
and I-Disease I-Disease
cardiac I-Disease I-Disease
toxicity I-Disease I-Disease
following O O
the O O
administration O O
of O O
local O O
anesthetics O O
is O O
a O O
recognized O O
complication O O
of O O
regional O O
anesthesia O O
. O O

Levobupivacaine O O
, O O
the O O
pure O O
S O O
( O O
- O O
) O O
enantiomer O O
of O O
bupivacaine O O
, O O
was O O
developed O O
to O O
improve O O
the O O
cardiac O O
safety O O
profile O O
of O O
bupivacaine O O
. O O

We O O
describe O O
2 O O
cases O O
of O O
grand B-Disease B-Disease
mal I-Disease I-Disease
seizures I-Disease I-Disease
following O O
accidental O O
intravascular O O
injection O O
of O O
levobupivacaine O O
. O O

CASE O O
REPORT O O
: O O
Two O O
patients O O
presenting O O
for O O
elective O O
orthopedic O O
surgery O O
of O O
the O O
lower O O
limb O O
underwent O O
blockade O O
of O O
the O O
lumbar O O
plexus O O
via O O
the O O
posterior O O
approach O O
. O O

Immediately O O
after O O
the O O
administration O O
of O O
levobupivacaine O O
0.5 O O
% O O
with O O
epinephrine O O
2.5 O O
microgram O O
/ O O
mL O O
, O O
the O O
patients O O
developed O O
grand B-Disease B-Disease
mal I-Disease I-Disease
seizures I-Disease I-Disease
, O O
despite O O
negative O O
aspiration O O
for O O
blood O O
and O O
no O O
clinical O O
signs O O
of O O
intravenous O O
epinephrine O O
administration O O
. O O

The O O
seizures B-Disease B-Disease
were O O
successfully O O
treated O O
with O O
sodium O O
thiopental O O
in O O
addition O O
to O O
succinylcholine O O
in O O
1 O O
patient O O
. O O

Neither O O
patient O O
developed O O
signs O O
of O O
cardiovascular B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

Both O O
patients O O
were O O
treated O O
preoperatively O O
with O O
beta O O
- O O
adrenergic O O
antagonist O O
medications O O
, O O
which O O
may O O
have O O
masked O O
the O O
cardiovascular O O
signs O O
of O O
the O O
unintentional O O
intravascular O O
administration O O
of O O
levobupivacaine O O
with O O
epinephrine O O
. O O

CONCLUSIONS O O
: O O
Although O O
levobupivacaine O O
may O O
have O O
a O O
safer O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
profile O O
than O O
racemic O O
bupivacaine O O
, O O
if O O
adequate O O
amounts O O
of O O
levobupivacaine O O
reach O O
the O O
circulation O O
, O O
it O O
will O O
result O O
in O O
convulsions B-Disease B-Disease
. O O

Plasma O O
concentrations O O
sufficient O O
to O O
result O O
in O O
central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
toxicity I-Disease I-Disease
did O O
not O O
produce O O
manifestations O O
of O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
in O O
these O O
2 O O
patients O O
. O O

Amiodarone O O
- O O
induced O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
during O O
bladder O O
irrigation O O
: O O
an O O
unusual O O
presentation O O
-- O O
a O O
case O O
report O O
. O O

The O O
authors O O
present O O
a O O
case O O
of O O
early O O
( O O
within O O
4 O O
days O O
) O O
development O O
of O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
( O O
TdP B-Disease B-Disease
) O O
associated O O
with O O
oral O O
amiodarone O O
therapy O O
. O O

Consistent O O
with O O
other O O
reports O O
this O O
case O O
of O O
TdP B-Disease B-Disease
occurred O O
in O O
the O O
context O O
of O O
multiple O O
exacerbating O O
factors O O
including O O
hypokalemia B-Disease B-Disease
and O O
digoxin O O
excess O O
. O O

Transient O O
prolongation O O
of O O
the O O
QT O O
during O O
bladder O O
irrigation O O
prompted O O
the O O
episode O O
of O O
TdP. B-Disease B-Disease
It O O
is O O
well O O
known O O
that O O
bradycardia B-Disease B-Disease
exacerbates O O
acquired O O
TdP. B-Disease B-Disease
The O O
authors O O
speculate O O
that O O
the O O
increased O O
vagal O O
tone O O
during O O
bladder O O
irrigation O O
, O O
a O O
vagal O O
maneuver O O
, O O
in O O
the O O
context O O
of O O
amiodarone O O
therapy O O
resulted O O
in O O
amiodarone O O
- O O
induced O O
proarrhythmia B-Disease B-Disease
. O O

In O O
the O O
absence O O
of O O
amiodarone O O
therapy O O
, O O
a O O
second O O
bladder O O
irrigation O O
did O O
not O O
induce O O
TdP B-Disease B-Disease
despite O O
hypokalemia B-Disease B-Disease
and O O
hypomagnesemia B-Disease B-Disease
. O O

Anaesthetic O O
complications O O
associated O O
with O O
myotonia B-Disease B-Disease
congenita I-Disease I-Disease
: O O
case O O
study O O
and O O
comparison O O
with O O
other O O
myotonic B-Disease B-Disease
disorders I-Disease I-Disease
. O O

Myotonia B-Disease B-Disease
congenita I-Disease I-Disease
( O O
MC B-Disease B-Disease
) O O
is O O
caused O O
by O O
a O O
defect O O
in O O
the O O
skeletal O O
muscle O O
chloride O O
channel O O
function O O
, O O
which O O
may O O
cause O O
sustained B-Disease O
membrane I-Disease O
depolarisation I-Disease O
. O O

We O O
describe O O
a O O
previously O O
healthy O O
32-year O O
- O O
old O O
woman O O
who O O
developed O O
a O O
life O O
- O O
threatening O O
muscle B-Disease B-Disease
spasm I-Disease I-Disease
and O O
secondary O O
ventilation O O
difficulties O O
following O O
a O O
preoperative O O
injection O O
of O O
suxamethonium O O
. O O

The O O
muscle B-Disease B-Disease
spasms I-Disease I-Disease
disappeared O O
spontaneously O O
and O O
the O O
surgery O O
proceeded O O
without O O
further O O
problems O O
. O O

When O O
subsequently O O
questioned O O
, O O
she O O
reported O O
minor O O
symptoms O O
suggesting O O
a O O
myotonic B-Disease B-Disease
condition I-Disease I-Disease
. O O

Myotonia B-Disease B-Disease
was O O
found O O
on O O
clinical O O
examination O O
and O O
EMG O O
. O O

The O O
diagnosis O O
MC B-Disease B-Disease
was O O
confirmed O O
genetically O O
. O O

Neither O O
the O O
patient O O
nor O O
the O O
anaesthetist O O
were O O
aware O O
of O O
the O O
diagnosis O O
before O O
this O O
potentially O O
lethal O O
complication O O
occurred O O
. O O

We O O
give O O
a O O
brief O O
overview O O
of O O
ion B-Disease B-Disease
channel I-Disease I-Disease
disorders I-Disease I-Disease
including O O
malignant B-Disease B-Disease
hyperthermia I-Disease I-Disease
and O O
their O O
anaesthetic O O
considerations O O
. O O

Respiratory O O
pattern O O
in O O
a O O
rat O O
model O O
of O O
epilepsy B-Disease B-Disease
. O O

PURPOSE O O
: O O
Apnea B-Disease B-Disease
is O O
known O O
to O O
occur O O
during O O
seizures B-Disease B-Disease
, O O
but O O
systematic O O
studies O O
of O O
ictal O O
respiratory O O
changes O O
in O O
adults O O
are O O
few O O
. O O

Data O O
regarding O O
respiratory O O
pattern O O
defects O O
during O O
interictal O O
periods O O
also O O
are O O
scarce O O
. O O

Here O O
we O O
sought O O
to O O
generate O O
information O O
with O O
regard O O
to O O
the O O
interictal O O
period O O
in O O
animals O O
with O O
pilocarpine O O
- O O
induced O O
epilepsy B-Disease B-Disease
. O O

METHODS O O
: O O
Twelve O O
rats O O
( O O
six O O
chronically O O
epileptic B-Disease B-Disease
animals O O
and O O
six O O
controls O O
) O O
were O O
anesthetized O O
, O O
given O O
tracheotomies O O
, O O
and O O
subjected O O
to O O
hyperventilation B-Disease O
or O O
hypoventilation O B-Disease
conditions O O
. O O

Breathing O O
movements O O
caused O O
changes O O
in O O
thoracic O O
volume O O
and O O
forced O O
air O O
to O O
flow O O
tidally O O
through O O
a O O
pneumotachograph O O
. O O

This O O
flow O O
was O O
measured O O
by O O
using O O
a O O
differential O O
pressure O O
transducer O O
, O O
passed O O
through O O
a O O
polygraph O O
, O O
and O O
from O O
this O O
to O O
a O O
computer O O
with O O
custom O O
software O O
that O O
derived O O
ventilation O O
( O O
VE O O
) O O
, O O
tidal O O
volume O O
( O O
VT O O
) O O
, O O
inspiratory O O
time O O
( O O
TI O O
) O O
, O O
expiratory O O
time O O
( O O
TE O O
) O O
, O O
breathing O O
frequency O O
( O O
f O O
) O O
, O O
and O O
mean O O
inspiratory O O
flow O O
( O O
VT O O
/ O O
TI O O
) O O
on O O
a O O
breath O O
- O O
by O O
- O O
breath O O
basis O O
. O O

RESULTS O O
: O O
The O O
hyperventilation B-Disease B-Disease
maneuver O O
caused O O
a O O
decrease O O
in O O
spontaneous O O
ventilation O O
in O O
pilocarpine O O
- O O
treated O O
and O O
control O O
rats O O
. O O

Although O O
VE O O
had O O
a O O
similar O O
decrease O O
in O O
both O O
groups O O
, O O
in O O
the O O
epileptic B-Disease B-Disease
group O O
, O O
the O O
decrease O O
in O O
VE O O
was O O
due O O
to O O
a O O
significant O O
( O O
p O O
< O O
0.05 O O
) O O
increase O O
in O O
TE O O
peak O O
in O O
relation O O
to O O
that O O
of O O
the O O
control O O
animals O O
. O O

The O O
hypoventilation O B-Disease
maneuver O O
led O O
to O O
an O O
increase O O
in O O
the O O
arterial O O
Paco2 O O
, O O
followed O O
by O O
an O O
increase O O
in O O
VE O O
. O O

In O O
the O O
epileptic B-Disease B-Disease
group O O
, O O
the O O
increase O O
in O O
VE O O
was O O
mediated O O
by O O
a O O
significant O O
( O O
p O O
< O O
0.05 O O
) O O
decrease O O
in O O
TE O O
peak O O
compared O O
with O O
the O O
control O O
group O O
. O O

Systemic O O
application O O
of O O
KCN O O
, O O
to O O
evaluate O O
the O O
effects O O
of O O
peripheral O O
chemoreception O O
activation O O
on O O
ventilation O O
, O O
led O O
to O O
a O O
similar O O
increase O O
in O O
VE O O
for O O
both O O
groups O O
. O O

CONCLUSIONS O O
: O O
The O O
data O O
indicate O O
that O O
pilocarpine O O
- O O
treated O O
animals O O
have O O
an O O
altered O O
ability O O
to O O
react O O
to O O
( O O
or O O
compensate O O
for O O
) O O
blood O O
gas O O
changes O O
with O O
changes O O
in O O
ventilation O O
and O O
suggest O O
that O O
it O O
is O O
centrally O O
determined O O
. O O

We O O
speculate O O
on O O
the O O
possible O O
relation O O
of O O
the O O
current O O
findings O O
on O O
treating O O
different O O
epilepsy B-Disease B-Disease
- O O
associated O O
conditions O O
. O O

Fatal O O
myeloencephalopathy B-Disease B-Disease
due O O
to O O
intrathecal O O
vincristine O O
administration O O
. O O

Vincristine O O
was O O
accidentally O O
given O O
intrathecally O O
to O O
a O O
child O O
with O O
leukaemia B-Disease B-Disease
, O O
producing O O
sensory B-Disease B-Disease
and I-Disease I-Disease
motor I-Disease I-Disease
dysfunction I-Disease I-Disease
followed O O
by O O
encephalopathy B-Disease B-Disease
and O O
death O O
. O O

Separate O O
times O O
for O O
administering O O
vincristine O O
and O O
intrathecal O O
therapy O O
is O O
recommended O O
. O O

Progesterone O O
potentiation O O
of O O
bupivacaine O O
arrhythmogenicity O O
in O O
pentobarbital O O
- O O
anesthetized O O
rats O O
and O O
beating O O
rat O O
heart O O
cell O O
cultures O O
. O O

The O O
effects O O
of O O
progesterone O O
treatment O O
on O O
bupivacaine O O
arrhythmogenicity O O
in O O
beating O O
rat O O
heart O O
myocyte O O
cultures O O
and O O
on O O
anesthetized O O
rats O O
were O O
determined O O
. O O

After O O
determining O O
the O O
bupivacaine O O
AD50 O O
( O O
the O O
concentration O O
of O O
bupivacaine O O
that O O
caused O O
50 O O
% O O
of O O
all O O
beating O O
rat O O
heart O O
myocyte O O
cultures O O
to O O
become O O
arrhythmic B-Disease B-Disease
) O O
, O O
we O O
determined O O
the O O
effect O O
of O O
1-hour O O
progesterone O O
HCl O O
exposure O O
on O O
myocyte O O
contractile O O
rhythm O O
. O O

Each O O
concentration O O
of O O
progesterone O O
( O O
6.25 O O
, O O
12.5 O O
, O O
25 O O
, O O
and O O
50 O O
micrograms O O
/ O O
ml O O
) O O
caused O O
a O O
significant O O
and O O
concentration O O
- O O
dependent O O
reduction O O
in O O
the O O
AD50 O O
for O O
bupivacaine O O
. O O

Estradiol O O
treatment O O
also O O
increased O O
the O O
arrhythmogenicity O O
of O O
bupivacaine O O
in O O
myocyte O O
cultures O O
, O O
but O O
was O O
only O O
one O O
fourth O O
as O O
potent O O
as O O
progesterone O O
. O O

Neither O O
progesterone O O
nor O O
estradiol O O
effects O O
on O O
bupivacaine O O
arrhythmogenicity O O
were O O
potentiated O O
by O O
epinephrine O O
. O O

Chronic O O
progesterone O O
pretreatment O O
( O O
5 O O
mg O O
/ O O
kg O O
/ O O
day O O
for O O
21 O O
days O O
) O O
caused O O
a O O
significant O O
increase O O
in O O
bupivacaine O O
arrhythmogenicity O O
in O O
intact O O
pentobarbital O O
- O O
anesthetized O O
rats O O
. O O

There O O
was O O
a O O
significant O O
decrease O O
in O O
the O O
time O O
to O O
onset O O
of O O
arrhythmia B-Disease B-Disease
as O O
compared O O
with O O
control O O
nonprogesterone O O
- O O
treated O O
rats O O
( O O
6.2 O O
+ O O
/- O O

1.3 O O
vs. O O
30.8 O O
+ O O
/- O O

2.5 O O
min O O
, O O
mean O O
+ O O
/- O O

SE O O
) O O
. O O

The O O
results O O
of O O
this O O
study O O
indicate O O
that O O
progesterone O O
can O O
potentiate O O
bupivacaine O O
arrhythmogenicity O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

Potentiation O O
of O O
bupivacaine O O
arrhythmia B-Disease B-Disease
in O O
myocyte O O
cultures O O
suggests O O
that O O
this O O
effect O O
is O O
at O O
least O O
partly O O
mediated O O
at O O
the O O
myocyte O O
level O O
. O O

Increased O O
serum O O
soluble O O
Fas O O
in O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
due O O
to O O
paracetamol O O
overdose B-Disease B-Disease
. O O

BACKGROUND O O
/ O O
AIMS O O
: O O
Experimental O O
studies O O
have O O
suggested O O
that O O
apoptosis O O
via O O
the O O
Fas O O
/ O O
Fas O O
Ligand O O
signaling O O
system O O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
development O O
of O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
. O O

The O O
aim O O
of O O
the O O
study O O
was O O
to O O
investigate O O
the O O
soluble O O
form O O
of O O
Fas O O
in O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
. O O

METHODOLOGY O O
: O O
Serum O O
levels O O
of O O
sFas O O
( O O
soluble O O
Fas O O
) O O
were O O
measured O O
by O O
ELISA O O
in O O
24 O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
and O O
10 O O
normal O O
control O O
subjects O O
. O O

Serum O O
levels O O
of O O
tumor B-Disease B-Disease
necrosis B-Disease B-Disease
factor O O
- O O
alpha O O
and O O
interferon O O
- O O
gamma O O
were O O
also O O
determined O O
by O O
ELISA O O
. O O

RESULTS O O
: O O
Serum O O
sFas O O
was O O
significantly O O
increased O O
in O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
( O O
median O O
, O O
26.8 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6.9 O O
- O O
52.7 O O
U O O
/ O O
mL O O
) O O
compared O O
to O O
the O O
normal O O
controls O O
( O O
median O O
, O O
8.6 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6.5 O O
- O O
12.0 O O
U O O
/ O O
mL O O
, O O
P O O
< O O
0.0001 O O
) O O
. O O

Levels O O
were O O
significantly O O
greater O O
in O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
due O O
to O O
paracetamol O O
overdose B-Disease B-Disease
( O O
median O O
, O O
28.7 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
12.8 O O
- O O
52.7 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
17 O O
) O O
than O O
those O O
due O O
to O O
non O O
- O O
A O O
to O O
E O O
hepatitis B-Disease B-Disease
( O O
median O O
, O O
12.5 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6.9 O O
- O O
46.0 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
7 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

There O O
was O O
no O O
relationship O O
of O O
sFas O O
to O O
eventual O O
outcome O O
in O O
the O O
patients O O
. O O

A O O
significant O O
correlation O O
was O O
observed O O
between O O
serum O O
sFas O O
levels O O
and O O
aspartate O O
aminotransferase O O
( O O
r O O
= O O
0.613 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
increased O O
concentration O O
of O O
sFas O O
in O O
serum O O
of O O
patients O O
with O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
may O O
reflect O O
activation O O
of O O
Fas O O
- O O
mediated O O
apoptosis O O
in O O
the O O
liver O O
and O O
this O O
together O O
with O O
increased O O
tumor B-Disease B-Disease
necrosis B-Disease B-Disease
factor O O
- O O
alpha O O
may O O
be O O
an O O
important O O
factor O O
in O O
liver O O
cell O O
loss O O
. O O

Bilateral O O
subthalamic O O
nucleus O O
stimulation O O
for O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

High O O
frequency O O
stimulation O O
of O O
the O O
subthalamic O O
nucleus O O
( O O
STN O O
) O O
is O O
known O O
to O O
ameliorate O O
the O O
signs O O
and O O
symptoms O O
of O O
advanced O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

AIM O O
: O O
We O O
studied O O
the O O
effect O O
of O O
high O O
frequency O O
STN O O
stimulation O O
in O O
23 O O
patients O O
. O O

METHOD O O
: O O
Twenty O O
- O O
three O O
patients O O
suffering O O
from O O
severe O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
( O O
Stages O O
III O O
- O O
V O O
on O O
Hoehn O O
and O O
Yahr O O
scale O O
) O O
and O O
, O O
particularly O O
bradykinesia B-Disease B-Disease
, O O
rigidity B-Disease B-Disease
, O O
and O O
levodopa O O
- O O
induced O O
dyskinesias B-Disease B-Disease
underwent O O
bilateral O O
implantation O O
of O O
electrodes O O
in O O
the O O
STN O O
. O O

Preoperative O O
and O O
postoperative O O
assessments O O
of O O
these O O
patients O O
at O O
1 O O
, O O
3 O O
, O O
6 O O
and O O
12 O O
months O O
follow O O
- O O
up O O
, O O
in O O
" O O
on O O
" O O
and O O
" O O
off O O
" O O
drug O O
conditions O O
, O O
was O O
carried O O
out O O
using O O
Unified O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
Disease I-Disease I-Disease
Rating O O
Scale O O
, O O
Hoehn O O
and O O
Yahr O O
staging O O
, O O
England O O
activities O O
of O O
daily O O
living O O
score O O
and O O
video O O
recordings O O
. O O

RESULTS O O
: O O
After O O
one O O
year O O
of O O
electrical O O
stimulation O O
of O O
the O O
STN O O
, O O
the O O
patients O O
' O O
scores O O
for O O
activities O O
of O O
daily O O
living O O
and O O
motor O O
examination O O
scores O O
( O O
Unified O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
Disease I-Disease I-Disease
Rating O O
Scale O O
parts O O
II O O
and O O
III O O
) O O
off O O
medication O O
improved O O
by O O
62 O O
% O O
and O O
61 O O
% O O
respectively O O
( O O
p<0.0005 O O
) O O
. O O

The O O
subscores O O
for O O
the O O
akinesia B-Disease B-Disease
, O O
rigidity B-Disease B-Disease
, O O
tremor B-Disease B-Disease
and O O
gait O O
also O O
improved O O
. O O

( O O
p<0.0005 O O
) O O
. O O

The O O
average O O
levodopa O O
dose O O
decreased O O
from O O
813 O O
mg O O
to O O
359 O O
mg O O
. O O

The O O
cognitive O O
functions O O
remained O O
unchanged O O
. O O

Two O O
patients O O
developed O O
device O O
- O O
related O O
complications O O
and O O
two O O
patients O O
experienced O O
abnormal O O
weight O O
gain O O
. O O

CONCLUSION O O
: O O
Bilateral O O
subthalamic O O
nucleus O O
stimulation O O
is O O
an O O
effective O O
treatment O O
for O O
advanced O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

It O O
reduces O O
the O O
severity O O
of O O
" O O
off O O
" O O
phase O O
symptoms O O
, O O
improves O O
the O O
axial O O
symptoms O O
and O O
reduces O O
levodopa O O
requirements O O
. O O

The O O
reduction O O
in O O
the O O
levodopa O O
dose O O
is O O
useful O O
in O O
controlling O O
drug B-Disease O
- I-Disease O
induced I-Disease O
dyskinesias I-Disease B-Disease
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
occurring O O
during O O
intravenous O O
desferrioxamine O O
therapy O O
: O O
recovery O O
after O O
haemodialysis O O
. O O

A O O
patient O O
with O O
transfusion O O
- O O
dependent O O
thalassemia B-Disease B-Disease
was O O
undergoing O O
home O O
intravenous O O
desferrioxamine O O
( O O
DFX O O
) O O
treatment O O
by O O
means O O
of O O
a O O
totally O O
implanted O O
system O O
because O O
of O O
his O O
poor O O
compliance O O
with O O
the O O
nightly O O
subcutaneous O O
therapy O O
. O O

Due O O
to O O
an O O
accidental O O
malfunctioning O O
of O O
the O O
infusion O O
pump O O
, O O
the O O
patient O O
was O O
inadvertently O O
administered O O
a O O
toxic O O
dosage O O
of O O
the O O
drug O O
which O O
caused O O
renal B-Disease B-Disease
insufficiency I-Disease I-Disease
. O O

Given O O
the O O
progressive O O
deterioration O O
of O O
the O O
symptoms O O
and O O
of O O
the O O
laboratory O O
values O O
, O O
despite O O
adequate O O
medical O O
treatment O O
, O O
a O O
decision O O
was O O
made O O
to O O
introduce O O
haemodialytical O O
therapy O O
in O O
order O O
to O O
remove O O
the O O
drug O O
and O O
therapy O O
reduce O O
the O O
nephrotoxicity B-Disease B-Disease
. O O

From O O
the O O
results O O
obtained O O
, O O
haemodialysis O O
can O O
therefore O O
be O O
suggested O O
as O O
a O O
useful O O
therapy O O
in O O
rare O O
cases O O
of O O
progressive O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
caused O O
by O O
desferrioxamine O O
. O O

Ocular O O
motility O O
changes O O
after O O
subtenon O O
carboplatin O O
chemotherapy O O
for O O
retinoblastoma B-Disease B-Disease
. O O

BACKGROUND O O
: O O
Focal O O
subtenon O O
carboplatin O O
injections O O
have O O
recently O O
been O O
used O O
as O O
a O O
presumably O O
toxicity B-Disease O
- O O
free O O
adjunct O O
to O O
systemic O O
chemotherapy O O
for O O
intraocular O B-Disease
retinoblastoma B-Disease I-Disease
. O O

OBJECTIVE O O
: O O
To O O
report O O
our O O
clinical O O
experience O O
with O O
abnormal B-Disease B-Disease
ocular I-Disease I-Disease
motility I-Disease I-Disease
in O O
patients O O
treated O O
with O O
subtenon O O
carboplatin O O
chemotherapy O O
. O O

METHODS O O
: O O
We O O
noted O O
abnormal B-Disease B-Disease
ocular I-Disease I-Disease
motility I-Disease I-Disease
in O O
10 O O
consecutive O O
patients O O
with O O
retinoblastoma B-Disease B-Disease
who O O
had O O
received O O
subtenon O O
carboplatin O O
. O O

During O O
ocular O O
manipulation O O
under O O
general O O
anesthesia O O
, O O
we O O
assessed O O
their O O
eyes O O
by O O
forced O O
duction O O
testing O O
, O O
comparing O O
ocular O O
motility O O
after O O
tumor B-Disease B-Disease
control O O
with O O
ocular O O
motility O O
at O O
diagnosis O O
. O O

Eyes O O
subsequently O O
enucleated O O
because O O
of O O
treatment O O
failure O O
( O O
n O O
= O O
4 O O
) O O
were O O
examined O O
histologically O O
. O O

RESULTS O O
: O O
Limitation O O
of O O
ocular O O
motility O O
was O O
detected O O
in O O
all O O
12 O O
eyes O O
of O O
10 O O
patients O O
treated O O
for O O
intraocular O B-Disease
retinoblastoma B-Disease I-Disease
with O O
1 O O
to O O
6 O O
injections O O
of O O
subtenon O O
carboplatin O O
as O O
part O O
of O O
multimodality O O
therapy O O
. O O

Histopathological O O
examination O O
revealed O O
many O O
lipophages O O
in O O
the O O
periorbital O O
fat O O
surrounding O O
the O O
optic O O
nerve O O
in O O
1 O O
eye O O
, O O
indicative O O
of O O
phagocytosis O O
of O O
previously O O
existing O O
fat O O
cells O O
and O O
suggesting O O
prior O O
fat O B-Disease
necrosis B-Disease I-Disease
. O O

The O O
enucleations O O
were O O
technically O O
difficult O O
and O O
hazardous O O
for O O
globe O O
rupture B-Disease O
because O O
of O O
extensive O O
orbital O O
soft O O
tissue O O
adhesions O O
. O O

CONCLUSIONS O O
: O O
Subtenon O O
carboplatin O O
chemotherapy O O
is O O
associated O O
with O O
significant O O
fibrosis B-Disease B-Disease
of O O
orbital O O
soft O O
tissues O O
, O O
leading O O
to O O
mechanical O O
restriction O O
of O O
eye O O
movements O O
and O O
making O O
subsequent O O
enucleation O O
difficult O O
. O O

Subtenon O O
carboplatin O O
is O O
not O O
free O O
of O O
toxicity B-Disease B-Disease
, O O
and O O
its O O
use O O
is O O
best O O
restricted O O
to O O
specific O O
indications O O
. O O

Ethambutol O O
and O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

PURPOSE O O
: O O
To O O
demonstrate O O
the O O
association O O
between O O
ethambutol O O
and O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

METHOD O O
: O O
Thirteen O O
patients O O
who O O
developed O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
after O O
being O O
treated O O
with O O
ethambutol O O
for O O
tuberculosis B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
lung I-Disease I-Disease
or B-Disease O
lymph I-Disease O
node I-Disease O
at O O
Siriraj O O
Hospital O O
between O O
1997 O O
and O O
2001 O O
were O O
retrospectively O O
reviewed O O
. O O

The O O
clinical O O
characteristics O O
and O O
initial O O
and O O
final O O
visual O O
acuity O O
were O O
analyzed O O
to O O
determine O O
visual O O
outcome O O
. O O

RESULTS O O
: O O
All O O
patients O O
had O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
between O O
1 O O
to O O
6 O O
months O O
( O O
mean O O
= O O
2.9 O O
months O O
) O O
after O O
starting O O
ethambutol O O
therapy O O
at O O
a O O
dosage O O
ranging O O
from O O
13 O O
to O O
20 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
mean O O
= O O
17 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
. O O

Seven O O
( O O
54 O O
% O O
) O O
of O O
the O O
13 O O
patients O O
experienced O O
visual O O
recovery O O
after O O
stopping O O
the O O
drug O O
. O O

Of O O
6 O O
patients O O
with O O
irreversible O O
visual B-Disease B-Disease
impairment I-Disease I-Disease
, O O
4 O O
patients O O
had O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
, O O
glaucoma B-Disease B-Disease
and O O
a O O
history O O
of O O
heavy O O
smoking O O
. O O

CONCLUSION O O
: O O
Early O O
recognition O O
of O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
should O O
be O O
considered O O
in O O
patients O O
with O O
ethambutol O O
therapy O O
. O O

A O O
low O O
dose O O
and O O
prompt O O
discontinuation O O
of O O
the O O
drug O O
is O O
recommended O O
particularly O O
in O O
individuals O O
with O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
, O O
glaucoma B-Disease B-Disease
or O O
who O O
are O O
heavy O O
smokers O O
. O O

Treatment O O
of O O
compensatory O O
gustatory B-Disease B-Disease
hyperhidrosis I-Disease I-Disease
with O O
topical O O
glycopyrrolate O O
. O O

Gustatory B-Disease B-Disease
hyperhidrosis I-Disease I-Disease
is O O
facial O O
sweating B-Disease B-Disease
usually O O
associated O O
with O O
the O O
eating O O
of O O
hot O O
spicy O O
food O O
or O O
even O O
smelling O O
this O O
food O O
. O O

Current O O
options O O
of O O
treatment O O
include O O
oral O O
anticholinergic O O
drugs O O
, O O
the O O
topical O O
application O O
of O O
anticholinergics O O
or O O
aluminum O O
chloride O O
, O O
and O O
the O O
injection O O
of O O
botulinum O O
toxin O O
. O O

Thirteen O O
patients O O
have O O
been O O
treated O O
to O O
date O O
with O O
1.5 O O
% O O
or O O
2 O O
% O O
topical O O
glycopyrrolate O O
. O O

All O O
patients O O
had O O
gustatory B-Disease B-Disease
hyperhidrosis I-Disease I-Disease
, O O
which O O
interfered O O
with O O
their O O
social O O
activities O O
, O O
after O O
transthroacic O O
endoscopic O O
sympathectomy O O
, O O
and O O
which O O
was O O
associated O O
with O O
compensatory O O
focal O O
hyperhidrosis B-Disease B-Disease
. O O

After O O
applying O O
topical O O
glycopyrrolate O O
, O O
the O O
subjective O O
effect O O
was O O
excellent O O
( O O
no O O
sweating B-Disease B-Disease
after O O
eating O O
hot O O
spicy O O
food O O
) O O
in O O
10 O O
patients O O
( O O
77 O O
% O O
) O O
, O O
and O O
fair O O
( O O
clearly O O
reduced O O
sweating B-Disease B-Disease
) O O
in O O
3 O O
patients O O
( O O
23 O O
% O O
) O O
. O O

All O O
had O O
reported O O
incidents O O
of O O
being O O
very O O
embarrassed O O
whilst O O
eating O O
hot O O
spicy O O
foods O O
. O O

Adverse O O
effects O O
included O O
a O O
mildly O O
dry B-Disease B-Disease
mouth I-Disease I-Disease
and O O
a O O
sore B-Disease B-Disease
throat I-Disease I-Disease
in O O
2 O O
patients O O
( O O
2 O O
% O O
glycopyrrolate O O
) O O
, O O
a O O
light O O
headache B-Disease B-Disease
in O O
1 O O
patient O O
( O O
1.5 O O
% O O
glycopyrrolate O O
) O O
. O O

The O O
topical O O
application O O
of O O
a O O
glycopyrrolate O O
pad O O
appeared O O
to O O
be O O
safe O O
, O O
efficacious O O
, O O
well O O
tolerated O O
, O O
and O O
a O O
convenient O O
method O O
of O O
treatment O O
for O O
moderate O O
to O O
severe O O
symptoms O O
of O O
gustatory B-Disease B-Disease
hyperhidrosis I-Disease I-Disease
in O O
post O O
transthoracic O O
endoscopic O O
sympathectomy O O
or O O
sympathicotomy O O
patients O O
, O O
with O O
few O O
side O O
effects O O
. O O

Neuroleptic O O
- O O
associated O O
hyperprolactinemia B-Disease B-Disease
. O O

Can O O
it O O
be O O
treated O O
with O O
bromocriptine O O
? O O

Six O O
stable O O
psychiatric O O
outpatients O O
with O O
hyperprolactinemia B-Disease B-Disease
and O O
amenorrhea B-Disease B-Disease
/ O O
oligomenorrhea B-Disease B-Disease
associated O O
with O O
their O O
neuroleptic O O
medications O O
were O O
treated O O
with O O
bromocriptine O O
. O O

Daily O O
dosages O O
of O O
5 O O
- O O
10 O O
mg O O
corrected O O
the O O
hyperprolactinemia B-Disease B-Disease
and O O
restored O O
menstruation O O
in O O
four O O
of O O
the O O
six O O
patients O O
. O O

One O O
woman O O
, O O
however O O
, O O
developed O O
worsened O O
psychiatric B-Disease O
symptoms I-Disease O
while O O
taking O O
bromocriptine O O
, O O
and O O
it O O
was O O
discontinued O O
. O O

Thus O O
, O O
three O O
of O O
six O O
patients O O
had O O
their O O
menstrual O B-Disease
irregularity O I-Disease
successfully O O
corrected O O
with O O
bromocriptine O O
. O O

This O O
suggests O O
that O O
bromocriptine O O
should O O
be O O
further O O
evaluated O O
as O O
potential O O
therapy O O
for O O
neuroleptic O O
- O O
associated O O
hyperprolactinemia B-Disease B-Disease
and O O
amenorrhea B-Disease B-Disease
/ O O
galactorrhea B-Disease B-Disease
. O O

Ethacrynic O O
acid O O
- O O
induced O O
convulsions B-Disease B-Disease
and O O
brain O O
neurotransmitters O O
in O O
mice O O
. O O

Intracerebroventricular O O
injection O O
of O O
ethacrynic O O
acid O O
( O O
50 O O
% O O
convulsive B-Disease B-Disease
dose O O
; O O
50 O O
micrograms O O
/ O O
mouse O O
) O O
accelerated O O
the O O
synthesis O O
/ O O
turnover O O
of O O
5-hydroxytryptamine O O
( O O
5-HT O O
) O O
but O O
suppressed O O
the O O
synthesis O O
of O O
gamma O O
- O O
aminobutyric O O
acid O O
and O O
acetylcholine O O
in O O
mouse O O
brain O O
. O O

These O O
effects O O
were O O
completely O O
antagonized O O
by O O
pretreatment O O
with O O
a O O
glutamate O O
/ O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
antagonist O O
, O O
aminophosphonovaleric O O
acid O O
. O O

In O O
ethacrynic O O
acid O O
- O O
induced O O
convulsions B-Disease B-Disease
, O O
these O O
neurotransmitter O O
systems O O
may O O
be O O
differentially O O
modulated O O
, O O
probably O O
through O O
activation O O
of O O
glutaminergic O O
neurons O O
in O O
the O O
brain O O
. O O

Pharmacology O O
of O O
gamma O O
- O O
aminobutyric O O
acidA O O
receptor O O
complex O O
after O O
the O O
in O O
vivo O O
administration O O
of O O
the O O
anxioselective O O
and O O
anticonvulsant O O
beta O O
- O O
carboline O O
derivative O O
abecarnil O O
. O O

In O O
rodents O O
, O O
the O O
effect O O
of O O
the O O
beta O O
- O O
carboline O O
derivative O O
isopropyl-6- O O
benzyloxy-4-methoxymethyl O O
- O O
beta O O
- O O
carboline-3-carboxylate O O
( O O
abecarrnil O O
) O O
, O O
a O O
new O O
ligand O O
for O O
benzodiazepine O O
receptors O O
possessing O O
anxiolytic O O
and O O
anticonvulsant O O
properties O O
, O O
was O O
evaluated O O
on O O
the O O
function O O
of O O
central O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
A O O
receptor O O
complex O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Added O O
in O O
vitro O O
to O O
rat O O
cortical O O
membrane O O
preparation O O
, O O
abecarnil O O
increased O O
[ O O
3H O O
] O O
GABA O O
binding O O
, O O
enhanced O O
muscimol O O
- O O
stimulated O O
36Cl- O O
uptake O O
and O O
reduced O O
the O O
binding O O
of O O
t- O O
[ O O
35S O O
] O O
butylbicyclophosphorothionate O O
( O O
[ O O
35S O O
] O O
TBPS O O
) O O
. O O

These O O
effects O O
were O O
similar O O
to O O
those O O
induced O O
by O O
diazepam O O
, O O
whereas O O
the O O
partial O O
agonist O O
Ro O O
16 O O
- O O
6028 O O
( O O
tert O O
- O O
butyl- O O
( O O
S O O
) O O
-8-bromo-11,12,13,13a O O
- O O
tetrahydro-9-oxo-9H- O O
imidazo O O
[ O O
1,5-a O O
] O O
-pyrrolo- O O
[ O O
2,1-c O O
] O O
[ O O
1,4 O O
] O O
benzodiazepine-1-carboxylate O O
) O O
showed O O
very O O
weak O O
efficacy O O
in O O
these O O
biochemical O O
tests O O
. O O

After O O
i.p O O
. O O

injection O O
to O O
rats O O
, O O
abecarnil O O
and O O
diazepam O O
decreased O O
in O O
a O O
time O O
- O O
dependent O O
and O O
dose O O
- O O
related O O
( O O
0.25 O O
- O O
20 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
manner O O
[ O O
35S O O
] O O
TBPS O O
binding O O
measured O O
ex O O
vivo O O
in O O
the O O
cerebral O O
cortex O O
. O O

Moreover O O
, O O
both O O
drugs O O
at O O
the O O
dose O O
of O O
0.5 O O
mg O O
/ O O
kg O O
antagonized O O
completely O O
the O O
convulsant O O
activity O O
and O O
the O O
increase O O
of O O
[ O O
35S O O
] O O
TBPS O O
binding O O
induced O O
by O O
isoniazide O O
( O O
350 O O
mg O O
/ O O
kg O O
s.c O O
. O O
) O O
as O O
well O O
as O O
the O O
increase O O
of O O
[ O O
35S O O
] O O
TBPS O O
binding O O
induced O O
by O O
foot O O
- O O
shock O B-Disease
stress O O
. O O

To O O
better O O
correlate O O
the O O
biochemical O O
and O O
the O O
pharmacological O O
effects O O
, O O
we O O
studied O O
the O O
action O O
of O O
abecarnil O O
on O O
[ O O
35S O O
] O O
TBPS O O
binding O O
, O O
exploratory O O
motility O O
and O O
on O O
isoniazid O O
- O O
induced O O
biochemical O O
and O O
pharmacological O O
effects O O
in O O
mice O O
. O O

In O O
these O O
animals O O
, O O
abecarnil O O
produced O O
a O O
paralleled O O
dose O O
- O O
dependent O O
( O O
0.05 O O
- O O
1 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
reduction O O
of O O
both O O
motor O O
behavior O O
and O O
cortical O O
[ O O
35S O O
] O O
TBPS O O
binding O O
. O O

Moreover O O
, O O
0.05 O O
mg O O
/ O O
kg O O
of O O
this O O
beta O O
- O O
carboline O O
reduced O O
markedly O O
the O O
increase O O
of O O
[ O O
35S O O
] O O
TBPS O O
binding O O
and O O
the O O
convulsions B-Disease B-Disease
induced O O
by O O
isoniazid O O
( O O
200 O O
mg O O
/ O O
kg O O
s.c. O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Recurrent O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
in O O
a O O
postpartum O O
patient O O
receiving O O
bromocriptine O O
. O O

Myocardial B-Disease B-Disease
infarction I-Disease I-Disease
in O O
puerperium O O
is O O
infrequently O O
reported O O
. O O

Spasm B-Disease B-Disease
, O O
coronary O O
dissection O O
, O O
or O O
atheromatous O O
etiology O O
has O O
been O O
described O O
. O O

Bromocriptine O O
has O O
been O O
implicated O O
in O O
several O O
previous O O
case O O
reports O O
of O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
in O O
the O O
puerperium O O
. O O

Our O O
case O O
( O O
including O O
an O O
inadvertent O O
rechallenge O O
) O O
suggests O O
such O O
a O O
relationship O O
. O O

Although O O
generally O O
regarded O O
as O O
" O O
safe O O
, O O
" O O
possible O O
serious O O
cardiac O O
effects O O
of O O
bromocriptine O O
should O O
be O O
acknowledged O O
. O O

Asterixis B-Disease B-Disease
induced O O
by O O
carbamazepine O O
therapy O O
. O O

There O O
are O O
very O O
few O O
reports O O
about O O
asterixis B-Disease B-Disease
as O O
a O O
side O O
effect O O
of O O
treatment O O
with O O
psychopharmacologic O O
agents O O
. O O

In O O
this O O
report O O
we O O
present O O
four O O
patients O O
treated O O
with O O
a O O
combination O O
of O O
different O O
psychotropic O O
drugs O O
, O O
in O O
whom O O
asterixis B-Disease B-Disease
was O O
triggered O O
either O O
by O O
adding O O
carbamazepine O O
( O O
CBZ O O
) O O
to O O
a O O
treatment O O
regimen O O
, O O
or O O
by O O
increasing O O
its O O
dosage O O
. O O

Neither O O
dosage O O
nor O O
serum O O
levels O O
of O O
CBZ O O
were O O
in O O
a O O
higher O O
range O O
. O O

We O O
consider O O
asterixis B-Disease B-Disease
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity B-Disease B-Disease
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium O O
or O O
clozapine O O
are O O
used O O
in O O
combination O O
with O O
CBZ O O
. O O

Pharmacodynamics O O
of O O
the O O
hypotensive B-Disease B-Disease
effect O O
of O O
levodopa O O
in O O
parkinsonian B-Disease B-Disease
patients O O
. O O

Blood O O
pressure O O
effects O O
of O O
i.v O O
. O O

levodopa O O
were O O
examined O O
in O O
parkinsonian B-Disease B-Disease
patients O O
with O O
stable O O
and O O
fluctuating O O
responses O O
to O O
levodopa O O
. O O

The O O
magnitude O O
of O O
the O O
hypotensive B-Disease B-Disease
effect O O
of O O
levodopa O O
was O O
concentration O O
dependent O O
and O O
was O O
fit O O
to O O
an O O
Emax O O
model O O
in O O
fluctuating O O
responders O O
. O O

Stable O O
responders O O
demonstrated O O
a O O
small O O
hypotensive B-Disease B-Disease
response O O
. O O

Baseline O O
blood O O
pressures O O
were O O
higher O O
in O O
fluctuating O O
patients O O
; O O
a O O
higher O O
baseline O O
blood O O
pressure O O
correlated O O
with O O
greater O O
hypotensive B-Disease B-Disease
effects O O
. O O

Antiparkinsonian O O
effects O O
of O O
levodopa O O
temporally O O
correlated O O
with O O
blood O O
pressure O O
changes O O
. O O

Phenylalanine O O
, O O
a O O
large O O
neutral O O
amino O O
acid O O
( O O
LNAA O O
) O O
competing O O
with O O
levodopa O O
for O O
transport O O
across O O
the O O
blood O O
- O O
brain O O
barrier O O
, O O
reduced O O
the O O
hypotensive B-Disease B-Disease
and O O
antiparkinsonian O O
effects O O
of O O
levodopa O O
. O O

We O O
conclude O O
that O O
levodopa O O
has O O
a O O
central O O
hypotensive B-Disease B-Disease
action O O
that O O
parallels O O
the O O
motor O O
effects O O
in O O
fluctuating O O
patients O O
. O O

The O O
hypotensive B-Disease B-Disease
effect O O
appears O O
to O O
be O O
related O O
to O O
the O O
higher O O
baseline O O
blood O O
pressure O O
we O O
observed O O
in O O
fluctuating O O
patients O O
relative O O
to O O
stable O O
patients O O
. O O

Syndrome B-Disease B-Disease
of I-Disease I-Disease
inappropriate I-Disease I-Disease
secretion I-Disease I-Disease
of I-Disease I-Disease
antidiuretic I-Disease I-Disease
hormone I-Disease I-Disease
after O O
infusional O O
vincristine O O
. O O

A O O
77-year O O
- O O
old O O
woman O O
with O O
refractory O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
was O O
treated O O
with O O
a O O
4-day O O
continuous O O
intravenous O O
infusion O O
of O O
vincristine O O
and O O
doxorubicin O O
and O O
4 O O
days O O
of O O
oral O O
dexamethasone O O
. O O

Nine O O
days O O
after O O
her O O
second O O
cycle O O
she O O
presented O O
with O O
lethargy B-Disease B-Disease
and O O
weakness B-Disease B-Disease
associated O O
with O O
hyponatremia B-Disease B-Disease
. O O

Evaluation O O
revealed O O
the O O
syndrome B-Disease B-Disease
of I-Disease I-Disease
inappropriate I-Disease I-Disease
secretion I-Disease I-Disease
of I-Disease I-Disease
antidiuretic I-Disease I-Disease
hormone I-Disease I-Disease
, O O
which O O
was O O
attributed O O
to O O
the O O
vincristine O O
infusion O O
. O O

After O O
normal O O
serum O O
sodium O O
levels O O
returned O O
, O O
further O O
doxorubicin O O
and O O
dexamethasone O O
chemotherapy O O
without O O
vincristine O O
did O O
not O O
produce O O
this O O
complication O O
. O O

Heart B-Disease B-Disease
failure I-Disease I-Disease
: O O
to O O
digitalise O O
or O O
not O O
? O O

The O O
view O O
against O O
. O O

Despite O O
extensive O O
clinical O O
experience O O
the O O
role O O
of O O
digoxin O O
is O O
still O O
not O O
well O O
defined O O
. O O

In O O
patients O O
with O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
digoxin O O
is O O
beneficial O O
for O O
ventricular O O
rate O O
control O O
. O O

For O O
patients O O
in O O
sinus O O
rhythm O O
and O O
heart B-Disease B-Disease
failure I-Disease I-Disease
the O O
situation O O
is O O
less O O
clear O O
. O O

Digoxin O O
has O O
a O O
narrow O O
therapeutic O O
: O O
toxic O O
ratio O O
and O O
concentrations O O
are O O
affected O O
by O O
a O O
number O O
of O O
drugs O O
. O O

Also O O
, O O
digoxin O O
has O O
undesirable O O
effects O O
such O O
as O O
increasing O O
peripheral O O
resistance O O
and O O
myocardial O O
demands O O
, O O
and O O
causing O O
arrhythmias B-Disease B-Disease
. O O

There O O
is O O
a O O
paucity O O
of O O
data O O
from O O
well O O
- O O
designed O O
trials O O
. O O

The O O
trials O O
that O O
are O O
available O O
are O O
generally O O
small O O
with O O
limitations O O
in O O
design O O
and O O
these O O
show O O
variation O O
in O O
patient O O
benefit O O
. O O

More O O
convincing O O
evidence O O
is O O
required O O
showing O O
that O O
digoxin O O
improves O O
symptoms O O
or O O
exercise O O
capacity O O
. O O

Furthermore O O
, O O
no O O
trial O O
has O O
had O O
sufficient O O
power O O
to O O
evaluate O O
mortality O O
. O O

Pooled O O
analysis O O
of O O
the O O
effects O O
of O O
other O O
inotropic O O
drugs O O
shows O O
an O O
excess O O
mortality O O
and O O
there O O
is O O
a O O
possibility O O
that O O
digoxin O O
may O O
increase O O
mortality O O
after O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
MI B-Disease B-Disease
) O O
. O O

Angiotensin O O
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
should O O
be O O
used O O
first O O
as O O
they O O
are O O
safer O O
, O O
do O O
not O O
require O O
blood O O
level O O
monitoring O O
, O O
modify O O
progression O O
of O O
disease O O
, O O
relieve O O
symptoms O O
, O O
improve O O
exercise O O
tolerance O O
and O O
reduce O O
mortality O O
. O O

Caution O O
should O O
be O O
exercised O O
in O O
using O O
digoxin O O
until O O
large O O
mortality O O
trials O O
are O O
completed O O
showing O O
either O O
benefit O O
or O O
harm O O
. O O

Until O O
then O O
digoxin O O
should O O
be O O
considered O O
a O O
third O O
- O O
line O O
therapy O O
. O O

Isradipine O O
treatment O O
for O O
hypertension B-Disease B-Disease
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

A O O
6-week O O
open O O
study O O
of O O
the O O
introduction O O
of O O
isradipine O O
treatment O O
was O O
conducted O O
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

303 O O
Chinese O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension B-Disease B-Disease
entered O O
the O O
study O O
. O O

Side O O
effects O O
were O O
reported O O
in O O
21 O O
% O O
of O O
patients O O
and O O
caused O O
withdrawal O O
from O O
the O O
study O O
in O O
3 O O
patients O O
. O O

The O O
main O O
side O O
- O O
effects O O
were O O
headache B-Disease B-Disease
, O O
dizziness B-Disease B-Disease
, O O
palpitation B-Disease B-Disease
and O O
flushing B-Disease B-Disease
and O O
these O O
were O O
not O O
more O O
frequent O O
than O O
reported O O
in O O
other O O
studies O O
with O O
isradipine O O
or O O
with O O
placebo O O
. O O

Supine O O
blood O O
pressure O O
was O O
reduced O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
from O O
170 O O
+ O O
/- O O

20 O O
/ O O
102 O O
+ O O
/- O O

6 O O
mmHg O O
to O O
153 O O
+ O O
/- O O

19 O O
/ O O
92 O O
+ O O
/- O O

8 O O
, O O
147 O O
+ O O
/- O O

18 O O
/ O O
88 O O
+ O O
/- O O

7 O O
and O O
144 O O
+ O O
/- O O

14 O O
/ O O
87 O O
+ O O
/- O O

6 O O
mmHg O O
at O O
2 O O
, O O
4 O O
and O O
6 O O
weeks O O
respectively O O
in O O
evaluable O O
patients O O
. O O

Similar O O
reductions O O
occurred O O
in O O
standing O O
blood O O
pressure O O
and O O
there O O
was O O
no O O
evidence O O
of O O
postural B-Disease B-Disease
hypotension I-Disease I-Disease
. O O

Normalization O O
and O O
responder O O
rates O O
at O O
6 O O
weeks O O
were O O
86 O O
% O O
and O O
69 O O
% O O
respectively O O
. O O

Dosage O O
was O O
increased O O
from O O
2.5 O O
mg O O
b.d O O
. O O

to O O
5 O O
mg O O
b.d O O
. O O

at O O
4 O O
weeks O O
in O O
patients O O
with O O
diastolic O O
blood O O
pressure O O
greater O O
than O O
90 O O
mmHg O O
and O O
their O O
further O O
response O O
was O O
greater O O
than O O
those O O
remaining O O
on O O
2.5 O O
mg O O
b.d O O
. O O

Pharmacological O O
characteristics O O
and O O
side O O
effects O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol O O
without O O
soyabean O O
oil O O
. O O

We O O
compared O O
the O O
pharmacokinetics O O
, O O
pharmacodynamics O O
and O O
safety O O
profile O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol O O
( O O
AM149 O O
1 O O
% O O
) O O
, O O
which O O
does O O
not O O
contain O O
soyabean O O
oil O O
, O O
with O O
a O O
standard O O
formulation O O
of O O
propofol O O
( O O
Disoprivan O O
1 O O
% O O
) O O
. O O

In O O
a O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
cross O O
- O O
over O O
study O O
, O O
30 O O
healthy O O
volunteers O O
received O O
a O O
single O O
intravenous O O
bolus O O
injection O O
of O O
2.5 O O
mg.kg-1 O O
propofol O O
. O O

Plasma O O
propofol O O
levels O O
were O O
measured O O
for O O
48 O O
h O O
following O O
drug O O
administration O O
and O O
evaluated O O
according O O
to O O
a O O
three O O
- O O
compartment O O
model O O
. O O

The O O
pharmacodynamic O O
parameters O O
assessed O O
included O O
induction O O
and O O
emergence O O
times O O
, O O
respiratory O O
and O O
cardiovascular O O
effects O O
, O O
and O O
pain B-Disease B-Disease
on O O
injection O O
. O O

Patients O O
were O O
monitored O O
for O O
side O O
effects O O
over O O
48 O O
h. O O
Owing O O
to O O
a O O
high O O
incidence O O
of O O
thrombophlebitis B-Disease B-Disease
, O O
the O O
study O O
was O O
terminated O O
prematurely O O
and O O
only O O
the O O
data O O
of O O
the O O
two O O
parallel O O
treatment O O
groups O O
( O O
15 O O
patients O O
in O O
each O O
group O O
) O O
were O O
analysed O O
. O O

Plasma O O
concentrations O O
did O O
not O O
differ O O
significantly O O
between O O
the O O
two O O
formulations O O
. O O

Anaesthesia O O
induction O O
and O O
emergence O O
times O O
, O O
respiratory O O
and O O
cardiovascular O O
variables O O
showed O O
no O O
significant O O
differences O O
between O O
the O O
two O O
treatment O O
groups O O
. O O

Pain B-Disease B-Disease
on O O
injection O O
( O O
80 O O
vs. O O
20 O O
% O O
, O O
p O O
< O O
0.01 O O
) O O
and O O
thrombophlebitis B-Disease B-Disease
( O O
93.3 O O
vs. O O
6.6 O O
% O O
, O O
p O O
< O O
0.001 O O
) O O
occurred O O
more O O
frequently O O
with O O
AM149 O O
than O O
with O O
Disoprivan O O
. O O

Although O O
both O O
formulations O O
had O O
similar O O
pharmacokinetic O O
and O O
pharmacodynamic O O
profiles O O
the O O
new O O
formulation O O
is O O
not O O
suitable O O
for O O
clinical O O
use O O
due O O
to O O
the O O
high O O
incidence O O
of O O
thrombophlebitis B-Disease B-Disease
produced O O
. O O

Pure B-Disease B-Disease
red I-Disease I-Disease
cell I-Disease I-Disease
aplasia I-Disease I-Disease
, O O
toxic B-Disease B-Disease
dermatitis I-Disease I-Disease
and O O
lymphadenopathy B-Disease B-Disease
in O O
a O O
patient O O
taking O O
diphenylhydantoin O O
. O O

A O O
patient O O
taking O O
diphenylhydantoin O O
for O O
3 O O
weeks O O
developed O O
a O O
generalized O O
skin B-Disease B-Disease
rash I-Disease I-Disease
, O O
lymphadenopathy B-Disease B-Disease
and O O
pure B-Disease B-Disease
red I-Disease I-Disease
cell I-Disease I-Disease
aplasia I-Disease I-Disease
. O O

After O O
withdrawal O O
of O O
the O O
pharmacon O O
all O O
symptoms O O
disappeared O O
spontaneously O O
. O O

Skin B-Disease B-Disease
rash I-Disease I-Disease
is O O
a O O
well O O
- O O
known O O
complication O O
of O O
diphenylhydantoin O O
treatment O O
as O O
is O O
benign O O
and O O
malignant O B-Disease
lymphadenopathy B-Disease I-Disease
. O O

Pure B-Disease B-Disease
red I-Disease I-Disease
cell I-Disease I-Disease
aplasia I-Disease I-Disease
associated O O
with O O
diphenylhydantoin O O
medication O O
has O O
been O O
reported O O
in O O
3 O O
patients O O
. O O

The O O
exact O O
mechanism O O
by O O
which O O
diphenylhydantoin O O
exerts O O
its O O
toxic O O
effects O O
is O O
not O O
known O O
. O O

In O O
this O O
patient O O
the O O
time O O
relation O O
between O O
the O O
ingestion O O
of O O
diphenylhydantoin O O
and O O
the O O
occurrence O O
of O O
the O O
skin B-Disease B-Disease
rash I-Disease I-Disease
, O O
lymphadenopathy B-Disease B-Disease
and O O
pure B-Disease B-Disease
red I-Disease I-Disease
cell I-Disease I-Disease
aplasia I-Disease I-Disease
is O O
very O O
suggestive O O
of O O
a O O
direct O O
connection O O
. O O

Vinorelbine O O
- O O
related O O
cardiac O O
events O O
: O O
a O O
meta O O
- O O
analysis O O
of O O
randomized O O
clinical O O
trials O O
. O O

Several O O
cases O O
of O O
cardiac O O
adverse O O
reactions O O
related O O
to O O
vinorelbine O O
( O O
VNR O O
) O O
have O O
been O O
reported O O
in O O
the O O
literature O O
. O O

In O O
order O O
to O O
quantify O O
the O O
incidence O O
of O O
these O O
cardiac O O
events O O
, O O
we O O
performed O O
a O O
meta O O
- O O
analysis O O
of O O
clinical O O
trials O O
comparing O O
VNR O O
with O O
other O O
chemotherapeutic O O
agents O O
in O O
the O O
treatment O O
of O O
various O O
malignancies B-Disease B-Disease
. O O

Randomized O O
clinical O O
trials O O
comparing O O
VNR O O
with O O
other O O
drugs O O
in O O
the O O
treatment O O
of O O
cancer B-Disease B-Disease
were O O
searched O O
in O O
Medline O O
, O O
Embase O O
, O O
Evidence O O
- O O
based O O
Medicine O O
Reviews O O
databases O O
and O O
the O O
Cochrane O O
library O O
from O O
1987 O O
to O O
2002 O O
. O O

Outcomes O O
of O O
interest O O
were O O
severe O O
cardiac O O
events O O
, O O
toxic O O
deaths O O
and O O
cardiac O O
event O O
- O O
related O O
deaths O O
reported O O
in O O
each O O
publication O O
. O O

We O O
found O O
19 O O
trials O O
, O O
involving O O
2441 O O
patients O O
treated O O
by O O
VNR O O
and O O
2050 O O
control O O
patients O O
. O O

The O O
incidence O O
of O O
cardiac O O
events O O
with O O
VNR O O
was O O
1.19 O O
% O O
[ O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
( O O
0.75 O O
; O O
1.67 O O
) O O
] O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
risk O O
of O O
cardiac O O
events O O
between O O
VNR O O
and O O
other O O
drugs O O
[ O O
odds O O
ratio O O
: O O
0.92 O O
, O O
95 O O
% O O
CI O O
( O O
0.54 O O
; O O
1.55 O O
) O O
] O O
. O O

The O O
risk O O
of O O
VNR O O
cardiac O O
events O O
was O O
similar O O
to O O
vindesine O O
( O O
VDS O O
) O O
and O O
other O O
cardiotoxic B-Disease B-Disease
drugs O O
[ O O
fluorouracil O O
, O O
anthracyclines O O
, O O
gemcitabine O O
( O O
GEM O O
) O O
em O O
leader O O
] O O
. O O

Even O O
if O O
it O O
did O O
not O O
reach O O
statistical O O
significance O O
because O O
of O O
a O O
few O O
number O O
of O O
cases O O
, O O
the O O
risk O O
was O O
lower O O
in O O
trials O O
excluding O O
patients O O
with O O
cardiac O O
history O O
, O O
and O O
seemed O O
to O O
be O O
higher O O
in O O
trials O O
including O O
patients O O
with O O
pre O O
- O O
existing O O
cardiac B-Disease B-Disease
diseases I-Disease I-Disease
. O O

Vinorelbine O O
- O O
related O O
cardiac O O
events O O
concern O O
about O O
1 O O
% O O
of O O
treated O O
patients O O
in O O
clinical O O
trials O O
. O O

However O O
, O O
the O O
risk O O
associated O O
with O O
VNR O O
seems O O
to O O
be O O
similar O O
to O O
that O O
of O O
other O O
chemotherapeutic O O
agents O O
in O O
the O O
same O O
indications O O
. O O

MRI O O
findings O O
of O O
hypoxic O B-Disease
cortical O O
laminar O O
necrosis B-Disease B-Disease
in O O
a O O
child O O
with O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
crisis O O
. O O

We O O
present O O
magnetic O O
resonance O O
imaging O O
findings O O
of O O
a O O
5-year O O
- O O
old O O
girl O O
who O O
had O O
a O O
rapidly O O
installing O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
crisis O O
induced O O
by O O
trimethoprim O O
- O O
sulfomethoxazole O O
, O O
resulting O O
in O O
cerebral B-Disease B-Disease
anoxia I-Disease I-Disease
leading O O
to O O
permanent O O
damage O O
. O O

Magnetic O O
Resonance O O
imaging O O
revealed O O
cortical O O
laminar O O
necrosis B-Disease B-Disease
in O O
arterial O O
border O O
zones O O
in O O
both O O
cerebral O O
hemispheres O O
, O O
ischemic O B-Disease
changes O O
in O O
subcortical O O
white O O
matter O O
of O O
left O O
cerebral O O
hemisphere O O
, O O
and O O
in O O
the O O
left O O
putamen O O
. O O

Although O O
cortical O O
laminar O O
necrosis B-Disease B-Disease
is O O
a O O
classic O O
entity O O
in O O
adulthood O O
related O O
to O O
conditions O O
of O O
energy O O
depletions O O
, O O
there O O
are O O
few O O
reports O O
available O O
in O O
children O O
. O O

A O O
wide O O
review O O
of O O
the O O
literature O O
is O O
also O O
presented O O
. O O

The O O
natural O O
history O O
of O O
Vigabatrin O O
associated O O
visual B-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
in O O
patients O O
electing O O
to O O
continue O O
their O O
medication O O
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
natural O O
history O O
of O O
visual B-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
in O O
a O O
group O O
of O O
patients O O
known O O
to O O
have O O
Vigabatrin O O
- O O
associated O O
changes O O
who O O
elected O O
to O O
continue O O
the O O
medication O O
because O O
of O O
good O O
seizure B-Disease B-Disease
control O O
. O O

METHODS O O
: O O
All O O
patients O O
taking O O
Vigabatrin O O
alone O O
or O O
in O O
combination O O
with O O
other O O
antiepileptic O O
drugs O O
for O O
at O O
least O O
5 O O
years O O
( O O
range O O
5 O O
- O O
12 O O
years O O
) O O
were O O
entered O O
into O O
a O O
visual O O
surveillance O O
programme O O
. O O

Patients O O
were O O
followed O O
up O O
at O O
6-monthly O O
intervals O O
for O O
not O O
less O O
than O O
18 O O
months O O
( O O
range O O
18 O O
- O O
43 O O
months O O
) O O
. O O

In O O
all O O
, O O
16 O O
patients O O
with O O
unequivocal O O
defects O O
continued O O
the O O
medication O O
. O O

Following O O
already O O
published O O
methodology O O
( O O
Eye O O
2002 O O
; O O
16;567 O O
- O O
571 O O
) O O
monocular O O
mean O O
radial O O
degrees O O
( O O
MRDs O O
) O O
to O O
the O O
I O O
/ O O
4e O O
isopter O O
on O O
Goldmann O O
perimetry O O
was O O
calculated O O
for O O
the O O
right O O
eye O O
at O O
the O O
time O O
of O O
discovery O O
of O O
a O O
visual B-Disease B-Disease
field I-Disease I-Disease
defect I-Disease I-Disease
and O O
again O O
after O O
not O O
less O O
than O O
18 O O
months O O
follow O O
- O O
up O O
. O O

RESULTS O O
: O O
Mean O O
right O O
eye O O
MRD O O
at O O
presentation O O
was O O
36.98 O O
degrees O O
( O O
range O O
22.25 O O
- O O
51.0 O O
) O O
, O O
compared O O
to O O
38.40 O O
degrees O O
( O O
range O O
22.5 O O
- O O
49.75 O O
) O O
after O O
follow O O
- O O
up O O
; O O
P=0.338 O O
unpaired O O
t O O
- O O
test O O
. O O

Only O O
one O O
patient O O
demonstrated O O
a O O
deterioration B-Disease B-Disease
in I-Disease I-Disease
visual I-Disease I-Disease
field I-Disease I-Disease
during O O
the O O
study O O
period O O
and O O
discontinued O O
treatment O O
. O O

CONCLUSION O O
: O O
Established O O
visual B-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
presumed O O
to O O
be O O
due O O
to O O
Vigabatrin O O
therapy O O
did O O
not O O
usually O O
progress O O
in O O
spite O O
of O O
continuing O O
use O O
of O O
the O O
medication O O
. O O

These O O
data O O
give O O
support O O
to O O
the O O
hypothesis O O
that O O
the O O
pathogenesis O O
of O O
Vigabatrin O O
- O O
associated O O
visual B-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
may O O
be O O
an O O
idiosyncratic O O
adverse O O
drug O O
reaction O O
rather O O
than O O
dose O O
- O O
dependent O O
toxicity B-Disease B-Disease
. O O

Induction O O
of O O
rosaceiform O O
dermatitis B-Disease B-Disease
during O O
treatment O O
of O O
facial B-Disease B-Disease
inflammatory I-Disease I-Disease
dermatoses I-Disease I-Disease
with O O
tacrolimus O O
ointment O O
. O O

BACKGROUND O O
: O O
Tacrolimus O O
ointment O O
is O O
increasingly O O
used O O
for O O
anti O O
- O O
inflammatory O O
treatment O O
of O O
sensitive O O
areas O O
such O O
as O O
the O O
face O O
, O O
and O O
recent O O
observations O O
indicate O O
that O O
the O O
treatment O O
is O O
effective O O
in O O
steroid O O
- O O
aggravated O O
rosacea B-Disease B-Disease
and O O
perioral B-Disease B-Disease
dermatitis I-Disease I-Disease
. O O

We O O
report O O
on O O
rosaceiform O O
dermatitis B-Disease B-Disease
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus O O
ointment O O
. O O

OBSERVATIONS O O
: O O
Six O O
adult O O
patients O O
with O O
inflammatory B-Disease B-Disease
facial I-Disease I-Disease
dermatoses I-Disease I-Disease
were O O
treated O O
with O O
tacrolimus O O
ointment O O
because O O
of O O
the O O
ineffectiveness O O
of O O
standard O O
treatments O O
. O O

Within O O
2 O O
to O O
3 O O
weeks O O
of O O
initially O O
effective O O
and O O
well O O
- O O
tolerated O O
treatment O O
, O O
3 O O
patients O O
with O O
a O O
history O O
of O O
rosacea B-Disease B-Disease
and O O
1 O O
with O O
a O O
history O O
of O O
acne B-Disease B-Disease
experienced O O
sudden O O
worsening O O
with O O
pustular O O
rosaceiform O O
lesions O O
. O O

Biopsy O O
revealed O O
an O O
abundance O O
of O O
Demodex O O
mites O O
in O O
2 O O
of O O
these O O
patients O O
. O O

In O O
1 O O
patient O O
with O O
eyelid O B-Disease
eczema B-Disease I-Disease
, O O
rosaceiform O O
periocular B-Disease B-Disease
dermatitis I-Disease I-Disease
gradually O O
appeared O O
after O O
3 O O
weeks O O
of O O
treatment O O
. O O

In O O
1 O O
patient O O
with O O
atopic B-Disease B-Disease
dermatitis I-Disease I-Disease
, O O
telangiectatic O B-Disease
and O O
papular B-Disease B-Disease
rosacea I-Disease I-Disease
insidiously O O
appeared O O
after O O
5 O O
months O O
of O O
treatment O O
. O O

CONCLUSIONS O O
: O O
Our O O
observations O O
suggest O O
that O O
the O O
spectrum O O
of O O
rosaceiform O O
dermatitis B-Disease B-Disease
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus O O
ointment O O
is O O
heterogeneous O O
. O O

A O O
variety O O
of O O
factors O O
, O O
such O O
as O O
vasoactive O O
properties O O
of O O
tacrolimus O O
, O O
proliferation O O
of O O
Demodex O O
due O O
to O O
local O O
immunosuppression O O
, O O
and O O
the O O
occlusive O O
properties O O
of O O
the O O
ointment O O
, O O
may O O
be O O
involved O O
in O O
the O O
observed O O
phenomena O O
. O O

Future O O
studies O O
are O O
needed O O
to O O
identify O O
individual O O
risk O O
factors O O
. O O

Intravascular O O
hemolysis B-Disease B-Disease
and O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
following O O
intermittent O O
rifampin O O
therapy O O
. O O

Renal B-Disease B-Disease
failure I-Disease I-Disease
is O O
a O O
rare O O
complication O O
associated O O
with O O
the O O
use O O
of O O
rifampin O O
. O O

Intravascular O O
hemolysis B-Disease B-Disease
leading O O
to O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
following O O
rifampin O O
therapy O O
is O O
extremely O O
rare O O
. O O

Two O O
patients O O
with O O
leprosy B-Disease B-Disease
who O O
developed O O
hemolysis B-Disease B-Disease
and O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
following O O
rifampin O O
are O O
reported O O
. O O

Structural O O
abnormalities O O
in O O
the O O
brains O O
of O O
human O O
subjects O O
who O O
use O O
methamphetamine O O
. O O

We O O
visualize O O
, O O
for O O
the O O
first O O
time O O
, O O
the O O
profile O O
of O O
structural B-Disease O
deficits I-Disease O
in I-Disease O
the I-Disease O
human I-Disease O
brain I-Disease O
associated O O
with O O
chronic O O
methamphetamine O O
( O O
MA O O
) O O
abuse O O
. O O

Studies O O
of O O
human O O
subjects O O
who O O
have O O
used O O
MA O O
chronically O O
have O O
revealed O O
deficits O O
in O O
dopaminergic O O
and O O
serotonergic O O
systems O O
and O O
cerebral O B-Disease
metabolic B-Disease I-Disease
abnormalities I-Disease I-Disease
. O O

Using O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
and O O
new O O
computational O O
brain O O
- O O
mapping O O
techniques O O
, O O
we O O
determined O O
the O O
pattern O O
of O O
structural O O
brain O O
alterations O O
associated O O
with O O
chronic O O
MA O O
abuse O O
in O O
human O O
subjects O O
and O O
related O O
these O O
deficits O O
to O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
. O O

We O O
used O O
high O O
- O O
resolution O O
MRI O O
and O O
surface O O
- O O
based O O
computational O O
image O O
analyses O O
to O O
map O O
regional O O
abnormalities B-Disease O
in I-Disease O
the I-Disease O
cortex I-Disease O
, I-Disease O
hippocampus I-Disease O
, I-Disease O
white I-Disease O
matter I-Disease O
, I-Disease O
and I-Disease O
ventricles I-Disease O
in O O
22 O O
human O O
subjects O O
who O O
used O O
MA O O
and O O
21 O O
age O O
- O O
matched O O
, O O
healthy O O
controls O O
. O O

Cortical O O
maps O O
revealed O O
severe O O
gray O O
- O O
matter O O
deficits O O
in O O
the O O
cingulate O O
, O O
limbic O O
, O O
and O O
paralimbic O O
cortices O O
of O O
MA O O
abusers O O
( O O
averaging O O
11.3 O O
% O O
below O O
control O O
; O O
p O O
< O O
0.05 O O
) O O
. O O

On O O
average O O
, O O
MA O O
abusers O O
had O O
7.8 O O
% O O
smaller O O
hippocampal O O
volumes O O
than O O
control O O
subjects O O
( O O
p O O
< O O
0.01 O O
; O O
left O O
, O O
p O O
= O O
0.01 O O
; O O
right O O
, O O
p O O
< O O
0.05 O O
) O O
and O O
significant O O
white O O
- O O
matter O O
hypertrophy B-Disease B-Disease
( O O
7.0 O O
% O O
; O O
p O O
< O O
0.01 O O
) O O
. O O

Hippocampal O B-Disease
deficits O I-Disease
were O O
mapped O O
and O O
correlated O O
with O O
memory O O
performance O O
on O O
a O O
word O O
- O O
recall O O
test O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

MRI O O
- O O
based O O
maps O O
suggest O O
that O O
chronic O B-Disease
methamphetamine O I-Disease
abuse O I-Disease
causes O O
a O O
selective O O
pattern O O
of O O
cerebral O B-Disease
deterioration O I-Disease
that O O
contributes O O
to O O
impaired B-Disease B-Disease
memory I-Disease I-Disease
performance I-Disease I-Disease
. O O

MA O O
may O O
selectively O O
damage O O
the O O
medial O O
temporal O O
lobe O O
and O O
, O O
consistent O O
with O O
metabolic O O
studies O O
, O O
the O O
cingulate O O
- O O
limbic O O
cortex O O
, O O
inducing O O
neuroadaptation O O
, O O
neuropil O O
reduction O O
, O O
or O O
cell O O
death O O
. O O

Prominent O O
white O O
- O O
matter O O
hypertrophy B-Disease B-Disease
may O O
result O O
from O O
altered O O
myelination O O
and O O
adaptive O O
glial O O
changes O O
, O O
including O O
gliosis B-Disease B-Disease
secondary O O
to O O
neuronal B-Disease B-Disease
damage I-Disease I-Disease
. O O

These O O
brain O O
substrates O O
may O O
help O O
account O O
for O O
the O O
symptoms O O
of O O
MA O B-Disease
abuse O I-Disease
, O O
providing O O
therapeutic O O
targets O O
for O O
drug O O
- O O
induced O O
brain B-Disease B-Disease
injury I-Disease I-Disease
. O O

Disruption O O
of O O
hepatic O O
lipid O O
homeostasis O O
in O O
mice O O
after O O
amiodarone O O
treatment O O
is O O
associated O O
with O O
peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
- O O
alpha O O
target O O
gene O O
activation O O
. O O

Amiodarone O O
, O O
an O O
efficacious O O
and O O
widely O O
used O O
antiarrhythmic O O
agent O O
, O O
has O O
been O O
reported O O
to O O
cause O O
hepatotoxicity B-Disease B-Disease
in O O
some O O
patients O O
. O O

To O O
gain O O
insight O O
into O O
the O O
mechanism O O
of O O
this O O
unwanted O O
effect O O
, O O
mice O O
were O O
administered O O
various O O
doses O O
of O O
amiodarone O O
and O O
examined O O
for O O
changes O O
in O O
hepatic O O
histology O O
and O O
gene O O
regulation O O
. O O

Amiodarone O O
induced O O
hepatomegaly B-Disease B-Disease
, O O
hepatocyte O O
microvesicular O O
lipid O O
accumulation O O
, O O
and O O
a O O
significant O O
decrease O O
in O O
serum O O
triglycerides O O
and O O
glucose O O
. O O

Northern O O
blot O O
analysis O O
of O O
hepatic O O
RNA O O
revealed O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
expression O O
of O O
a O O
number O O
of O O
genes O O
critical O O
for O O
fatty O O
acid O O
oxidation O O
, O O
lipoprotein O O
assembly O O
, O O
and O O
lipid O O
transport O O
. O O

Many O O
of O O
these O O
genes O O
are O O
regulated O O
by O O
the O O
peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
- O O
alpha O O
( O O
PPARalpha O O
) O O
, O O
a O O
ligand O O
- O O
activated O O
nuclear O O
hormone O O
receptor O O
transcription O O
factor O O
. O O

The O O
absence O O
of O O
induction O O
of O O
these O O
genes O O
as O O
well O O
as O O
hepatomegaly B-Disease B-Disease
in O O
PPARalpha O O
knockout O O
[ O O
PPARalpha- O O
/ O O
- O O
] O O
mice O O
indicated O O
that O O
the O O
effects O O
of O O
amiodarone O O
were O O
dependent O O
upon O O
the O O
presence O O
of O O
a O O
functional O O
PPARalpha O O
gene O O
. O O

Compared O O
to O O
wild O O
- O O
type O O
mice O O
, O O
treatment O O
of O O
PPARalpha- O O
/ O O
- O O
mice O O
with O O
amiodarone O O
resulted O O
in O O
an O O
increased O O
rate O O
and O O
extent O O
of O O
total O O
body O O
weight B-Disease O
loss I-Disease O
. O O

The O O
inability O O
of O O
amiodarone O O
to O O
directly O O
activate O O
either O O
human O O
or O O
mouse O O
PPARalpha O O
transiently O O
expressed O O
in O O
human O O
HepG2 O O
hepatoma B-Disease O
cells O O
indicates O O
that O O
the O O
effects O O
of O O
amiodarone O O
on O O
the O O
function O O
of O O
this O O
receptor O O
were O O
indirect O O
. O O

Based O O
upon O O
these O O
results O O
, O O
we O O
conclude O O
that O O
amiodarone O O
disrupts O O
hepatic O O
lipid O O
homeostasis O O
and O O
that O O
the O O
increased O O
expression O O
of O O
PPARalpha O O
target O O
genes O O
is O O
secondary O O
to O O
this O O
toxic O O
effect O O
. O O

These O O
results O O
provide O O
important O O
new O O
mechanistic O O
information O O
regarding O O
the O O
hepatotoxic B-Disease B-Disease
effects O O
of O O
amiodarone O O
and O O
indicate O O
that O O
PPARalpha O O
protects O O
against O O
amiodarone O O
- O O
induced O O
hepatotoxicity B-Disease B-Disease
. O O

Safety O O
and O O
compliance O O
with O O
once O O
- O O
daily O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
as O O
initial O O
therapy O O
in O O
the O O
Impact O O
of O O
Medical O O
Subspecialty O O
on O O
Patient O O
Compliance O O
to O O
Treatment O O
( O O
IMPACT O O
) O O
study O O
. O O

Niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
is O O
a O O
new O O
combination O O
product O O
approved O O
for O O
treatment O O
of O O
primary O B-Disease
hypercholesterolemia B-Disease I-Disease
and O O
mixed O O
dyslipidemia B-Disease B-Disease
. O O

This O O
open O O
- O O
labeled O O
, O O
multicenter O O
study O O
evaluated O O
the O O
safety O O
of O O
bedtime O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
when O O
dosed O O
as O O
initial O O
therapy O O
and O O
patient O O
compliance O O
to O O
treatment O O
in O O
various O O
clinical O O
practice O O
settings O O
. O O

A O O
total O O
of O O
4,499 O O
patients O O
with O O
dyslipidemia B-Disease B-Disease
requiring O O
drug O O
intervention O O
was O O
enrolled O O
at O O
1,081 O O
sites O O
. O O

Patients O O
were O O
treated O O
with O O
1 O O
tablet O O
( O O
500 O O
mg O O
of O O
niacin O O
extended O O
- O O
release O O
/ O O
20 O O
mg O O
of O O
lovastatin O O
) O O
once O O
nightly O O
for O O
4 O O
weeks O O
and O O
then O O
2 O O
tablets O O
for O O
8 O O
weeks O O
. O O

Patients O O
also O O
received O O
dietary O O
counseling O O
, O O
educational O O
materials O O
, O O
and O O
reminders O O
to O O
call O O
a O O
toll O O
- O O
free O O
number O O
that O O
provided O O
further O O
education O O
about O O
dyslipidemia B-Disease B-Disease
and O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
. O O

Primary O O
end O O
points O O
were O O
study O O
compliance O O
, O O
increases O O
in O O
liver O O
transaminases O O
to O O
> O O
3 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
, O O
and O O
clinical O O
myopathy B-Disease B-Disease
. O O

Final O O
study O O
status O O
was O O
available O O
for O O
4,217 O O
patients O O
( O O
94 O O
% O O
) O O
. O O

Compliance O O
to O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
was O O
77 O O
% O O
, O O
with O O
3,245 O O
patients O O
completing O O
the O O
study O O
. O O

Patients O O
in O O
the O O
southeast O O
and O O
those O O
enrolled O O
by O O
endocrinologists O O
had O O
the O O
lowest O O
compliance O O
and O O
highest O O
adverse O O
event O O
rates O O
. O O

Flushing B-Disease O
was O O
the O O
most O O
common O O
adverse O O
event O O
, O O
reported O O
by O O
18 O O
% O O
of O O
patients O O
and O O
leading O O
to O O
discontinuation O O
by O O
6 O O
% O O
. O O

Incidence O O
of O O
increased O O
aspartate O O
aminotransferase O O
and/or O O
alanine O O
aminotransferase O O
> O O
3 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
was O O
< O O
0.3 O O
% O O
. O O

An O O
increase O O
of O O
creatine O O
phosphokinase O O
to O O
> O O
5 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
occurred O O
in O O
0.24 O O
% O O
of O O
patients O O
, O O
and O O
no O O
cases O O
of O O
drug O O
- O O
induced O O
myopathy B-Disease B-Disease
were O O
observed O O
. O O

Niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
1,000 O O
/ O O
40 O O
mg O O
, O O
dosed O O
as O O
initial O O
therapy O O
, O O
was O O
associated O O
with O O
good O O
compliance O O
and O O
safety O O
and O O
had O O
very O O
low O O
incidences O O
of O O
increased O O
liver O O
and O O
muscle O O
enzymes O O
. O O

Protective O O
effect O O
of O O
Terminalia O O
chebula O O
against O O
experimental O O
myocardial B-Disease B-Disease
injury I-Disease I-Disease
induced O O
by O O
isoproterenol O O
. O O

Cardioprotective O O
effect O O
of O O
ethanolic O O
extract O O
of O O
Terminalia O O
chebula O O
fruits O O
( O O
500 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
was O O
examined O O
in O O
isoproterenol O O
( O O
200 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
induced O O
myocardial B-Disease B-Disease
damage I-Disease I-Disease
in O O
rats O O
. O O

In O O
isoproterenol O O
administered O O
rats O O
, O O
the O O
level O O
of O O
lipid O O
peroxides O O
increased O O
significantly O O
in O O
the O O
serum O O
and O O
heart O O
. O O

A O O
significant O O
decrease O O
was O O
observed O O
in O O
the O O
activity O O
of O O
the O O
myocardial O O
marker O O
enzymes O O
with O O
a O O
concomitant O O
increase O O
in O O
their O O
activity O O
in O O
serum O O
. O O

Histopathological O O
examination O O
was O O
carried O O
out O O
to O O
confirm O O
the O O
myocardial O B-Disease
necrosis B-Disease I-Disease
. O O

T. O O
chebula O O
extract O O
pretreatment O O
was O O
found O O
to O O
ameliorate O O
the O O
effect O O
of O O
isoproterenol O O
on O O
lipid O O
peroxide O O
formation O O
and O O
retained O O
the O O
activities O O
of O O
the O O
diagnostic O O
marker O O
enzymes O O
. O O

A O O
case O O
of O O
postoperative O O
anxiety B-Disease B-Disease
due O O
to O O
low O O
dose O O
droperidol O O
used O O
with O O
patient O O
- O O
controlled O O
analgesia O O
. O O

A O O
multiparous O O
woman O O
in O O
good O O
psychological O O
health O O
underwent O O
urgent O O
caesarean O O
section O O
in O O
labour O O
. O O

Postoperatively O O
, O O
she O O
was O O
given O O
a O O
patient O O
- O O
controlled O O
analgesia O O
device O O
delivering O O
boluses O O
of O O
diamorphine O O
0.5 O O
mg O O
and O O
droperidol O O
0.025 O O
mg O O
. O O

Whilst O O
using O O
the O O
device O O
she O O
gradually O O
became O O
anxious O O
, O O
the O O
feeling O O
worsening O O
after O O
each O O
bolus O O
. O O

The O O
diagnosis O O
of O O
droperidol O O
- O O
induced O O
psychological B-Disease B-Disease
disturbance I-Disease I-Disease
was O O
not O O
made O O
straight O O
away O O
although O O
on O O
subsequent O O
close O O
questioning O O
the O O
patient O O
gave O O
a O O
very O O
clear O O
history O O
. O O

After O O
she O O
had O O
received O O
a O O
total O O
of O O
only O O
0.9 O O
mg O O
droperidol O O
, O O
a O O
syringe O O
containing O O
diamorphine O O
only O O
was O O
substituted O O
and O O
her O O
unease O O
resolved O O
completely O O
. O O

We O O
feel O O
that O O
, O O
although O O
the O O
dramatic O O
extrapyramidal O O
side O O
effects O O
of O O
dopaminergic O O
antiemetics O O
are O O
well O O
known O O
, O O
more O O
subtle O O
manifestations O O
may O O
easily O O
be O O
overlooked O O
. O O

Accurate O O
patient O O
history O O
contributes O O
to O O
differentiating O O
diabetes B-Disease B-Disease
insipidus I-Disease I-Disease
: O O
a O O
case O O
study O O
. O O

This O O
case O O
study O O
highlights O O
the O O
important O O
contribution O O
of O O
nursing O O
in O O
obtaining O O
an O O
accurate O O
health O O
history O O
. O O

The O O
case O O
discussed O O
herein O O
initially O O
appeared O O
to O O
be O O
neurogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
( O O
DI B-Disease B-Disease
) O O
secondary O O
to O O
a O O
traumatic B-Disease B-Disease
brain I-Disease I-Disease
injury I-Disease I-Disease
. O O

The O O
nursing O O
staff O O
, O O
by O O
reviewing O O
the O O
patient O O
's O O
health O O
history O O
with O O
his O O
family O O
, O O
discovered O O
a O O
history O O
of O O
polydipsia B-Disease B-Disease
and O O
long O O
- O O
standing O O
lithium O O
use O O
. O O

Lithium O O
is O O
implicated O O
in O O
drug O O
- O O
induced O O
nephrogenic B-Disease B-Disease
DI I-Disease I-Disease
, O O
and O O
because O O
the O O
patient O O
had O O
not O O
received O O
lithium O O
since O O
being O O
admitted O O
to O O
the O O
hospital O O
, O O
his O O
treatment O O
changed O O
to O O
focus O O
on O O
nephrogenic B-Disease B-Disease
DI I-Disease I-Disease
. O O

By O O
combining O O
information O O
from O O
the O O
patient O O
history O O
, O O
the O O
physical O O
examination O O
, O O
and O O
radiologic O O
and O O
laboratory O O
studies O O
, O O
the O O
critical O O
care O O
team O O
demonstrated O O
that O O
the O O
patient O O
had O O
been O O
self O O
- O O
treating O O
his O O
lithium O O
- O O
induced O O
nephrogenic B-Disease B-Disease
DI I-Disease I-Disease
and O O
developed O O
neurogenic B-Disease B-Disease
DI I-Disease I-Disease
secondary O O
to O O
brain B-Disease B-Disease
trauma I-Disease I-Disease
. O O

Thus O O
successful O O
treatment O O
required O O
that O O
nephrogenic O O
and O O
neurogenic B-Disease B-Disease
DI I-Disease I-Disease
be O O
treated O O
concomitantly O O
. O O

Factors O O
contributing O O
to O O
ribavirin O O
- O O
induced O O
anemia B-Disease B-Disease
. O O

BACKGROUND O O
AND O O
AIM O O
: O O
Interferon O O
and O O
ribavirin O O
combination O O
therapy O O
for O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
C I-Disease I-Disease
produces O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
. O O

This O O
study O O
was O O
conducted O O
to O O
identify O O
the O O
factors O O
contributing O O
to O O
ribavirin O O
- O O
induced O O
anemia B-Disease B-Disease
. O O

METHODS O O
: O O
Eighty O O
- O O
eight O O
patients O O
with O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
C I-Disease I-Disease
who O O
received O O
interferon O O
- O O
alpha-2b O O
at O O
a O O
dose O O
of O O
6 O O
MU O O
administered O O
intramuscularly O O
for O O
24 O O
weeks O O
in O O
combination O O
with O O
ribavirin O O
administered O O
orally O O
at O O
a O O
dose O O
of O O
600 O O
mg O O
or O O
800 O O
mg O O
participated O O
in O O
the O O
study O O
. O O

A O O
hemoglobin O O
concentration O O
of O O
< O O
10 O O
g O O
/ O O
dL O O
was O O
defined O O
as O O
ribavirin O O
- O O
induced O O
anemia B-Disease B-Disease
. O O

RESULTS O O
: O O
Ribavirin O O
- O O
induced O O
anemia B-Disease B-Disease
occurred O O
in O O
18 O O
( O O
20.5 O O
% O O
) O O
patients O O
during O O
treatment O O
. O O

A O O
2 O O
g O O
/ O O
dL O O
decrease O O
in O O
hemoglobin O O
concentrations O O
in O O
patients O O
with O O
anemia B-Disease B-Disease
was O O
observed O O
at O O
week O O
2 O O
after O O
the O O
start O O
of O O
treatment O O
. O O

The O O
hemoglobin O O
concentration O O
in O O
patients O O
with O O
> O O
or O O
= O O
2 O O
g O O
/ O O
dL O O
decrease O O
at O O
week O O
2 O O
was O O
observed O O
to O O
be O O
significantly O O
lower O O
even O O
after O O
week O O
2 O O
than O O
in O O
patients O O
with O O
< O O
2 O O
g O O
/ O O
dL O O
decrease O O
( O O
P O O
< O O
0.01 O O
) O O
. O O

A O O
significant O O
relationship O O
was O O
observed O O
between O O
the O O
rate O O
of O O
reduction O O
of O O
hemoglobin O O
concentrations O O
at O O
week O O
2 O O
and O O
the O O
severity O O
of O O
anemia B-Disease B-Disease
( O O
P O O
< O O
0.01 O O
) O O
. O O

Such O O
factors O O
as O O
sex O O
( O O
female O O
) O O
, O O
age O O
( O O
> O O
or O O
= O O
60 O O
years O O
old O O
) O O
, O O
and O O
the O O
ribavirin O O
dose O O
by O O
body O O
weight O O
( O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
) O O
were O O
significant O O
by O O
univariate O O
analysis O O
. O O

CONCLUSIONS O O
: O O
Careful O O
administration O O
is O O
necessary O O
in O O
patients O O
> O O
or O O
= O O
60 O O
years O O
old O O
, O O
in O O
female O O
patients O O
, O O
and O O
in O O
patients O O
receiving O O
a O O
ribavirin O O
dose O O
of O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
. O O

Patients O O
who O O
experience O O
a O O
fall O O
in O O
hemoglobin O O
concentrations O O
of O O
2 O O
g O O
/ O O
dL O O
or O O
more O O
at O O
week O O
2 O O
after O O
the O O
start O O
of O O
treatment O O
should O O
be O O
monitored O O
with O O
particular O O
care O O
. O O

Zidovudine O O
- O O
induced O O
hepatitis B-Disease B-Disease
. O O

A O O
case O O
of O O
acute O O
hepatitis B-Disease B-Disease
induced O O
by O O
zidovudine O O
in O O
a O O
38-year O O
- O O
old O O
patient O O
with O O
AIDS B-Disease B-Disease
is O O
presented O O
. O O

The O O
mechanism O O
whereby O O
the O O
hepatitis B-Disease B-Disease
was O O
induced O O
is O O
not O O
known O O
. O O

However O O
, O O
the O O
patient O O
tolerated O O
well O O
an O O
alternative O O
reverse O O
transcriptase O O
inhibitor O O
, O O
2'3 O O
' O O
dideoxyinosine O O
. O O

Physicians O O
caring O O
for O O
patients O O
with O O
AIDS B-Disease B-Disease
should O O
be O O
aware O O
of O O
this O O
hitherto O O
rarely O O
reported O O
complication O O
. O O

Oxidative O O
damage O O
precedes O O
nitrative O O
damage O O
in O O
adriamycin O O
- O O
induced O O
cardiac O B-Disease
mitochondrial B-Disease I-Disease
injury I-Disease I-Disease
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
if O O
elevated O O
reactive O O
oxygen O O
( O O
ROS O O
) O O
/ O O
nitrogen O O
species O O
( O O
RNS O O
) O O
reported O O
to O O
be O O
present O O
in O O
adriamycin O O
( O O
ADR O O
) O O
-induced O O
cardiotoxicity B-Disease B-Disease
actually O O
resulted O O
in O O
cardiomyocyte O O
oxidative O O
/ O O
nitrative O O
damage O O
, O O
and O O
to O O
quantitatively O O
determine O O
the O O
time O O
course O O
and O O
subcellular O O
localization O O
of O O
these O O
postulated O O
damage O O
products O O
using O O
an O O
in O O
vivo O O
approach O O
. O O

B6C3 O O
mice O O
were O O
treated O O
with O O
a O O
single O O
dose O O
of O O
20 O O
mg O O
/ O O
kg O O
ADR O O
. O O

Ultrastructural O O
damage O O
and O O
levels O O
of O O
4-hydroxy-2-nonenal O O
( O O
4HNE O O
) O O
-protein O O
adducts O O
and O O
3-nitrotyrosine O O
( O O
3NT O O
) O O
were O O
analyzed O O
. O O

Quantitative O O
ultrastructural O O
damage O O
using O O
computerized O O
image O O
techniques O O
showed O O
cardiomyocyte O B-Disease
injury O I-Disease
as O O
early O O
as O O
3 O O
hours O O
, O O
with O O
mitochondria O O
being O O
the O O
most O O
extensively O O
and O O
progressively O O
injured O O
subcellular O O
organelle O O
. O O

Analysis O O
of O O
4HNE O O
protein O O
adducts O O
by O O
immunogold O O
electron O O
microscopy O O
showed O O
appearance O O
of O O
4HNE O O
protein O O
adducts O O
in O O
mitochondria O O
as O O
early O O
as O O
3 O O
hours O O
, O O
with O O
a O O
peak O O
at O O
6 O O
hours O O
and O O
subsequent O O
decline O O
at O O
24 O O
hours O O
. O O

3NT O O
levels O O
were O O
significantly O O
increased O O
in O O
all O O
subcellular O O
compartments O O
at O O
6 O O
hours O O
and O O
subsequently O O
declined O O
at O O
24 O O
hours O O
. O O

Our O O
data O O
showed O O
ADR O O
induced O O
4HNE O O
- O O
protein O O
adducts O O
in O O
mitochondria O O
at O O
the O O
same O O
time O O
point O O
as O O
when O O
mitochondrial B-Disease B-Disease
injury I-Disease I-Disease
initially O O
appeared O O
. O O

These O O
results O O
document O O
for O O
the O O
first O O
time O O
in O O
vivo O O
that O O
mitochondrial B-Disease O
oxidative I-Disease O
damage I-Disease O
precedes O O
nitrative O O
damage O O
. O O

The O O
progressive O O
nature O O
of O O
mitochondrial B-Disease B-Disease
injury I-Disease I-Disease
suggests O O
that O O
mitochondria O O
, O O
not O O
other O O
subcellular O O
organelles O O
, O O
are O O
the O O
major O O
site O O
of O O
intracellular O O
injury O O
. O O

Sotalol O O
- O O
induced O O
coronary B-Disease B-Disease
spasm I-Disease I-Disease
in O O
a O O
patient O O
with O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
associated O O
with O O
sustained O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
. O O

A O O
54-year O O
- O O
old O O
man O O
with O O
severe O O
left O B-Disease
ventricular B-Disease I-Disease
dysfunction I-Disease I-Disease
due O O
to O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
was O O
referred O O
to O O
our O O
hospital O O
for O O
symptomatic O O
incessant O O
sustained O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
( O O
VT B-Disease B-Disease
) O O
. O O

After O O
the O O
administration O O
of O O
nifekalant O O
hydrochloride O O
, O O
sustained O O
VT B-Disease B-Disease
was O O
terminated O O
. O O

An O O
alternate O O
class O O
III O O
agent O O
, O O
sotalol O O
, O O
was O O
also O O
effective O O
for O O
the O O
prevention O O
of O O
VT B-Disease B-Disease
. O O

However O O
, O O
one O O
month O O
after O O
switching O O
over O O
nifekalant O O
to O O
sotalol O O
, O O
a O O
short O O
duration O O
of O O
ST O O
elevation O O
was O O
documented O O
in O O
ECG O O
monitoring O O
at O O
almost O O
the O O
same O O
time O O
for O O
three O O
consecutive O O
days O O
. O O

ST O O
elevation O O
with O O
chest O B-Disease
discomfort O I-Disease
disappeared O O
since O O
he O O
began O O
taking O O
long O O
- O O
acting O O
diltiazem O O
. O O

Coronary B-Disease B-Disease
vasospasm I-Disease I-Disease
may O O
be O O
induced O O
by O O
the O O
non O O
- O O
selective O O
beta O O
- O O
blocking O O
properties O O
of O O
sotalol O O
. O O

Effects O O
of O O
the O O
antidepressant O O
trazodone O O
, O O
a O O
5-HT O O
2A O O
/ O O
2C O O
receptor O O
antagonist O O
, O O
on O O
dopamine O O
- O O
dependent O O
behaviors O O
in O O
rats O O
. O O

RATIONALE O O
: O O
5-Hydroxytryptamine O O
, O O
via O O
stimulation O O
of O O
5-HT O O
2C O O
receptors O O
, O O
exerts O O
a O O
tonic O O
inhibitory O O
influence O O
on O O
dopaminergic O O
neurotransmission O O
, O O
whereas O O
activation O O
of O O
5-HT O O
2A O O
receptors O O
enhances O O
stimulated O O
DAergic O O
neurotransmission O O
. O O

The O O
antidepressant O O
trazodone O O
is O O
a O O
5-HT O O
2A O O
/ O O
2C O O
receptor O O
antagonist O O
. O O

OBJECTIVES O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
trazodone O O
treatment O O
on O O
behaviors O O
dependent O O
on O O
the O O
functional O O
status O O
of O O
the O O
nigrostriatal O O
DAergic O O
system O O
. O O

METHODS O O
: O O
The O O
effect O O
of O O
pretreatment O O
with O O
trazodone O O
on O O
dexamphetamine- O O
and O O
apomorphine O O
- O O
induced O O
oral B-Disease B-Disease
stereotypies I-Disease I-Disease
, O O
on O O
catalepsy B-Disease B-Disease
induced O O
by O O
haloperidol O O
and O O
apomorphine O O
( O O
0.05 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
, O O
on O O
ergometrine O O
- O O
induced O O
wet O O
dog O O
shake O O
( O O
WDS O O
) O O
behavior O O
and O O
fluoxetine O O
- O O
induced O O
penile O O
erections O O
was O O
studied O O
in O O
rats O O
. O O

We O O
also O O
investigated O O
whether O O
trazodone O O
induces O O
catalepsy B-Disease B-Disease
in O O
rats O O
. O O

RESULTS O O
: O O
Trazodone O O
at O O
2.5 O O
- O O
20 O O
mg O O
/ O O
kg O O
i.p O O
. O O
did O O
not O O
induce O O
catalepsy B-Disease B-Disease
, O O
and O O
did O O
not O O
antagonize O O
apomorphine O O
( O O
1.5 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
stereotypy O O
and O O
apomorphine O O
( O O
0.05 O O
mg O O
/ O O
kg O O
) O O
-induced O O
catalepsy B-Disease B-Disease
. O O

However O O
, O O
pretreatment O O
with O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
i.p O O
. O O

trazodone O O
enhanced O O
dexamphetamine O O
stereotypy O O
, O O
and O O
antagonized O O
haloperidol O O
catalepsy B-Disease B-Disease
, O O
ergometrine O O
- O O
induced O O
WDS O O
behavior O O
and O O
fluoxetine O O
- O O
induced O O
penile O O
erections O O
. O O

Trazodone O O
at O O
30 O O
, O O
40 O O
and O O
50 O O
mg O O
/ O O
kg O O
i.p O O
. O O

induced O O
catalepsy B-Disease B-Disease
and O O
antagonized O O
apomorphine O O
and O O
dexamphetamine O O
stereotypies O O
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
indicate O O
that O O
trazodone O O
at O O
2.5 O O
- O O
20 O O
mg O O
/ O O
kg O O
does O O
not O O
block O O
pre- O O
and O O
postsynaptic O O
striatal O O
D2 O O
DA O O
receptors O O
, O O
while O O
at O O
30 O O
, O O
40 O O
and O O
50 O O
mg O O
/ O O
kg O O
it O O
blocks O O
postsynaptic O O
striatal O O
D2 O O
DA O O
receptors O O
. O O

Furthermore O O
, O O
at O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
, O O
trazodone O O
blocks O O
5-HT O O
2A O O
and O O
5-HT O O
2C O O
receptors O O
. O O

We O O
suggest O O
that O O
trazodone O O
( O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
) O O
, O O
by O O
blocking O O
the O O
5-HT O O
2C O O
receptors O O
, O O
releases O O
the O O
nigrostriatal O O
DAergic O O
neurons O O
from O O
tonic O O
inhibition O O
caused O O
by O O
5-HT O O
, O O
and O O
thereby O O
potentiates O O
dexamphetamine O O
stereotypy O O
and O O
antagonizes O O
haloperidol O O
catalepsy B-Disease B-Disease
. O O

Swallowing B-Disease B-Disease
abnormalities I-Disease I-Disease
and O O
dyskinesia B-Disease B-Disease
in O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

Gastrointestinal B-Disease B-Disease
abnormalities I-Disease I-Disease
in O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
( O O
PD B-Disease B-Disease
) O O
have O O
been O O
known O O
for O O
almost O O
two O O
centuries O O
, O O
but O O
many O O
aspects O O
concerning O O
their O O
pathophysiology O O
have O O
not O O
been O O
completely O O
clarified O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
characterize O O
the O O
oropharyngeal O O
dynamics O O
in O O
PD B-Disease B-Disease
patients O O
with O O
and O O
without O O
levodopa O O
- O O
induced O O
dyskinesia B-Disease B-Disease
. O O

Fifteen O O
dyskinetic B-Disease B-Disease
, O O
12 O O
nondyskinetic O O
patients O O
, O O
and O O
a O O
control O O
group O O
were O O
included O O
. O O

Patients O O
were O O
asked O O
about O O
dysphagia B-Disease B-Disease
and O O
evaluated O O
with O O
the O O
Unified O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
Disease I-Disease I-Disease
Rating O O
Scale O O
Parts O O
II O O
and O O
III O O
and O O
the O O
Hoehn O O
and O O
Yahr O O
scale O O
. O O

Deglutition O B-Disease
was O O
assessed O O
using O O
modified O O
barium O O
swallow O O
with O O
videofluoroscopy O O
. O O

Nondyskinetic O B-Disease
patients O O
, O O
but O O
not O O
the O O
dyskinetic B-Disease B-Disease
ones O O
, O O
showed O O
less O O
oropharyngeal O O
swallowing O O
efficiency O O
( O O
OPSE O O
) O O
for O O
liquid O O
food O O
than O O
controls O O
( O O
Dunnett O O
, O O
P O O
= O O
0.02 O O
) O O
. O O

Dyskinetic B-Disease B-Disease
patients O O
tended O O
to O O
have O O
a O O
greater O O
OPSE O O
than O O
nondyskinetic O O
( O O
Dunnett O O
, O O
P O O
= O O
0.06 O O
) O O
. O O

Patients O O
who O O
were O O
using O O
a O O
higher O O
dose O O
of O O
levodopa O O
had O O
a O O
greater O O
OPSE O O
and O O
a O O
trend O O
toward O O
a O O
smaller O O
oral O O
transit O O
time O O
( O O
Pearson O O
's O O
correlation O O
, O O
P O O
= O O
0.01 O O
and O O
0.08 O O
, O O
respectively O O
) O O
. O O

Neither O O
the O O
report O O
of O O
dysphagia B-Disease B-Disease
nor O O
any O O
of O O
the O O
PD B-Disease B-Disease
severity O O
parameters O O
correlated O O
to O O
the O O
videofluoroscopic O O
variables O O
. O O

In O O
the O O
current O O
study O O
, O O
dyskinetic B-Disease B-Disease
patients O O
performed O O
better O O
in O O
swallowing O O
function O O
, O O
which O O
could O O
be O O
explained O O
on O O
the O O
basis O O
of O O
a O O
greater O O
levodopa O O
dose O O
. O O

Our O O
results O O
suggest O O
a O O
role O O
for O O
levodopa O O
in O O
the O O
oral O O
phase O O
of O O
deglutition O B-Disease
and O O
confirm O O
that O O
dysphagia B-Disease B-Disease
is O O
not O O
a O O
good O O
predictor O O
of O O
deglutition O O
alterations O O
in O O
PD B-Disease B-Disease
. O O

Inhibition O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial B-Disease B-Disease
nephritis I-Disease I-Disease
induced O O
by O O
gentamicin O O
. O O

BACKGROUND O O
: O O
Animals O O
treated O O
with O O
gentamicin O O
can O O
show O O
residual O O
areas O O
of O O
interstitial O O
fibrosis B-Disease B-Disease
in O O
the O O
renal O O
cortex O O
. O O

This O O
study O O
investigated O O
the O O
expression O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
, O O
mitogen O O
- O O
activated O O
protein O O
( O O
MAP O O
) O O
kinases O O
and O O
macrophages O O
in O O
the O O
renal O O
cortex O O
and O O
structural O O
and O O
functional O O
renal O O
changes O O
of O O
rats O O
treated O O
with O O
gentamicin O O
or O O
gentamicin O O
+ O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
, O O
an O O
NF O O
- O O
kappaB O O
inhibitor O O
. O O

METHODS O O
: O O
38 O O
female O O
Wistar O O
rats O O
were O O
injected O O
with O O
gentamicin O O
, O O
40 O O
mg O O
/ O O
kg O O
, O O
twice O O
a O O
day O O
for O O
9 O O
days O O
, O O
38 O O
with O O
gentamicin O O
+ O O
PDTC O O
, O O
and O O
28 O O
with O O
0.15 O O
M O O
NaCl O O
solution O O
. O O

The O O
animals O O
were O O
killed O O
5 O O
and O O
30 O O
days O O
after O O
these O O
injections O O
and O O
the O O
kidneys O O
were O O
removed O O
for O O
histological O O
and O O
immunohistochemical O O
studies O O
. O O

The O O
results O O
of O O
the O O
immunohistochemical O O
studies O O
were O O
scored O O
according O O
to O O
the O O
extent O O
of O O
staining O O
. O O

The O O
fractional O O
interstitial O O
area O O
was O O
determined O O
by O O
morphometry O O
. O O

RESULTS O O
: O O
Gentamicin O O
- O O
treated O O
rats O O
presented O O
a O O
transitory O O
increase O O
in O O
plasma O O
creatinine O O
levels O O
. O O

Increased O O
ED-1 O O
, O O
MAP O O
kinases O O
and O O
NF O O
- O O
kappaB O O
staining O O
were O O
also O O
observed O O
in O O
the O O
renal O O
cortex O O
from O O
all O O
gentamicin O O
- O O
treated O O
rats O O
compared O O
to O O
control O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

The O O
animals O O
killed O O
on O O
day O O
30 O O
also O O
presented O O
fibrosis B-Disease B-Disease
in O O
the O O
renal O O
cortex O O
despite O O
the O O
recovery O O
of O O
renal O O
function O O
. O O

Treatment O O
with O O
PDTC O O
reduced O O
the O O
functional O O
and O O
structural O O
changes O O
induced O O
by O O
gentamicin O O
. O O

CONCLUSIONS O O
: O O
These O O
data O O
show O O
that O O
inhibition O O
of O O
NF O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial B-Disease B-Disease
nephritis I-Disease I-Disease
induced O O
by O O
gentamicin O O
. O O

Glucose O O
metabolism O O
in O O
patients O O
with O O
schizophrenia B-Disease B-Disease
treated O O
with O O
atypical O O
antipsychotic O O
agents O O
: O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
and O O
minimal O O
model O O
analysis O O
. O O

BACKGROUND O O
: O O
While O O
the O O
incidence O O
of O O
new O O
- O O
onset O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
may O O
be O O
increasing O O
in O O
patients O O
with O O
schizophrenia B-Disease B-Disease
treated O O
with O O
certain O O
atypical O O
antipsychotic O O
agents O O
, O O
it O O
remains O O
unclear O O
whether O O
atypical O O
agents O O
are O O
directly O O
affecting O O
glucose O O
metabolism O O
or O O
simply O O
increasing O O
known O O
risk O O
factors O O
for O O
diabetes B-Disease B-Disease
. O O

OBJECTIVE O O
: O O
To O O
study O O
the O O
2 O O
drugs O O
most O O
clearly O O
implicated O O
( O O
clozapine O O
and O O
olanzapine O O
) O O
and O O
risperidone O O
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
. O O

DESIGN O O
: O O
A O O
cross O O
- O O
sectional O O
design O O
in O O
stable O O
, O O
treated O O
patients O O
with O O
schizophrenia B-Disease B-Disease
evaluated O O
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
and O O
the O O
Bergman O O
minimal O O
model O O
analysis O O
. O O

SETTING O O
: O O
Subjects O O
were O O
recruited O O
from O O
an O O
urban O O
community O O
mental O O
health O O
clinic O O
and O O
were O O
studied O O
at O O
a O O
general O O
clinical O O
research O O
center O O
. O O

Patients O O
Fifty O O
subjects O O
signed O O
informed O O
consent O O
and O O
41 O O
underwent O O
the O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
. O O

Thirty O O
- O O
six O O
nonobese O O
subjects O O
with O O
schizophrenia B-Disease B-Disease
or O O
schizoaffective B-Disease B-Disease
disorder I-Disease I-Disease
, O O
matched O O
by O O
body O O
mass O O
index O O
and O O
treated O O
with O O
either O O
clozapine O O
, O O
olanzapine O O
, O O
or O O
risperidone O O
, O O
were O O
included O O
in O O
the O O
analysis O O
. O O

MAIN O O
OUTCOME O O
MEASURES O O
: O O
Fasting O O
plasma O O
glucose O O
and O O
fasting O O
serum O O
insulin O O
levels O O
, O O
insulin B-Disease O
sensitivity I-Disease O
index O O
, O O
homeostasis O O
model O O
assessment O O
of O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
, O O
and O O
glucose O O
effectiveness O O
. O O

RESULTS O O
: O O
The O O
mean O O
+ O O
/- O O

SD O O
duration O O
of O O
treatment O O
with O O
the O O
identified O O
atypical O O
antipsychotic O O
agent O O
was O O
68.3 O O
+ O O
/- O O

28.9 O O
months O O
( O O
clozapine O O
) O O
, O O
29.5 O O
+ O O
/- O O

17.5 O O
months O O
( O O
olanzapine O O
) O O
, O O
and O O
40.9 O O
+ O O
/- O O

33.7 O O
( O O
risperidone O O
) O O
. O O

Fasting O O
serum O O
insulin O O
concentrations O O
differed O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
3.35 O O
; O O
P O O
= O O
.047 O O
) O O
( O O
clozapine O O
> O O
olanzapine O O
> O O
risperidone O O
) O O
with O O
significant O O
differences O O
between O O
clozapine O O
and O O
risperidone O O
( O O
t O O
( O O
33 O O
) O O
= O O
2.32 O O
; O O
P O O
= O O
.03 O O
) O O
and O O
olanzapine O O
and O O
risperidone O O
( O O
t O O
( O O
33 O O
) O O
= O O
2.15 O O
; O O
P O O
= O O
.04 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
in O O
insulin B-Disease O
sensitivity I-Disease O
index O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
10.66 O O
; O O
P<.001 O O
) O O
( O O
clozapine O O
< O O
olanzapine O O
< O O
risperidone O O
) O O
, O O
with O O
subjects O O
who O O
received O O
clozapine O O
and O O
olanzapine O O
exhibiting O O
significant O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
compared O O
with O O
subjects O O
who O O
were O O
treated O O
with O O
risperidone O O
( O O
clozapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
-4.29 O O
; O O
P<.001 O O
; O O
olanzapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
-3.62 O O
; O O
P O O
= O O
.001 O O
[ O O
P<.001 O O
] O O
) O O
. O O

The O O
homeostasis O O
model O O
assessment O O
of O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
also O O
differed O O
significantly O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
4.92 O O
; O O
P O O
= O O
.01 O O
) O O
( O O
clozapine O O
> O O
olanzapine O O
> O O
risperidone O O
) O O
( O O
clozapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
2.94 O O
; O O
P O O
= O O
.006 O O
; O O
olanzapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
2.42 O O
; O O
P O O
= O O
.02 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
among O O
groups O O
in O O
glucose O O
effectiveness O O
( O O
F O O
( O O
30 O O
) O O
= O O
4.18 O O
; O O
P O O
= O O
.02 O O
) O O
( O O
clozapine O O
< O O
olanzapine O O
< O O
risperidone O O
) O O
with O O
significant O O
differences O O
between O O
clozapine O O
and O O
risperidone O O
( O O
t O O
( O O
30 O O
) O O
= O O
-2.59 O O
; O O
P O O
= O O
.02 O O
) O O
and O O
olanzapine O O
and O O
risperidone O O
( O O
t O O
( O O
30 O O
) O O
= O O
-2.34 O O
, O O
P O O
= O O
.03 O O
) O O
. O O

CONCLUSIONS O O
: O O
Both O O
nonobese O O
clozapine- O O
and O O
olanzapine O O
- O O
treated O O
groups O O
displayed O O
significant O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
and O O
impairment O O
of O O
glucose O O
effectiveness O O
compared O O
with O O
risperidone O O
- O O
treated O O
subjects O O
. O O

Patients O O
taking O O
clozapine O O
and O O
olanzapine O O
must O O
be O O
examined O O
for O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
and O O
its O O
consequences O O
. O O

Thoracic B-Disease B-Disease
hematomyelia I-Disease I-Disease
secondary O O
to O O
coumadin O O
anticoagulant O O
therapy O O
: O O
a O O
case O O
report O O
. O O

A O O
case O O
of O O
thoracic B-Disease B-Disease
hematomyelia I-Disease I-Disease
secondary O O
to O O
anticoagulant O O
therapy O O
is O O
presented O O
. O O

Clinical O O
features O O
, O O
similar O O
to O O
2 O O
other O O
previously O O
reported O O
cases O O
, O O
are O O
discussed O O
. O O

A O O
high O O
index O O
of O O
suspicion O O
may O O
lead O O
to O O
a O O
quick O O
diagnostic O O
procedure O O
and O O
successful O O
decompressive O O
surgery O O
. O O

Mania B-Disease B-Disease
associated O O
with O O
fluoxetine O O
treatment O O
in O O
adolescents O O
. O O

Fluoxetine O O
, O O
a O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
, O O
is O O
gaining O O
increased O O
acceptance O O
in O O
the O O
treatment O O
of O O
adolescent O B-Disease
depression B-Disease I-Disease
. O O

Generally O O
safe O O
and O O
well O O
tolerated O O
by O O
adults O O
, O O
fluoxetine O O
has O O
been O O
reported O O
to O O
induce O O
mania B-Disease B-Disease
. O O

The O O
cases O O
of O O
five O O
depressed B-Disease B-Disease
adolescents O O
, O O
14 O O
- O O
16 O O
years O O
of O O
age O O
, O O
who O O
developed O O
mania B-Disease B-Disease
during O O
pharmacotherapy O O
with O O
fluoxetine O O
, O O
are O O
reported O O
here O O
. O O

Apparent O O
risk O O
factors O O
for O O
the O O
development O O
of O O
mania B-Disease B-Disease
or O O
hypomania B-Disease B-Disease
during O O
fluoxetine O O
pharmacotherapy O O
in O O
this O O
population O O
were O O
the O O
combination O O
of O O
attention B-Disease B-Disease
- I-Disease I-Disease
deficit I-Disease I-Disease
hyperactivity I-Disease I-Disease
disorder I-Disease I-Disease
and O O
affective O B-Disease
instability O I-Disease
; O O
major O O
depression B-Disease B-Disease
with O O
psychotic B-Disease B-Disease
features O O
; O O
a O O
family O O
history O O
of O O
affective B-Disease B-Disease
disorder I-Disease I-Disease
, O O
especially O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
; O O
and O O
a O O
diagnosis O O
of O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
. O O

Further O O
study O O
is O O
needed O O
to O O
determine O O
the O O
optimal O O
dosage O O
and O O
to O O
identify O O
risk O O
factors O O
that O O
increase O O
individual O O
vulnerability O O
to O O
fluoxetine O O
induced O O
mania B-Disease B-Disease
in O O
adolescents O O
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
insufficiency I-Disease I-Disease
after O O
high O O
- O O
dose O O
melphalan O O
in O O
patients O O
with O O
primary B-Disease B-Disease
systemic I-Disease I-Disease
amyloidosis I-Disease I-Disease
during O O
stem O O
cell O O
transplantation O O
. O O

BACKGROUND O O
: O O
Patients O O
with O O
primary B-Disease B-Disease
systemic I-Disease I-Disease
amyloidosis I-Disease I-Disease
( O O
AL B-Disease B-Disease
) O O
have O O
a O O
poor O O
prognosis O O
. O O

Median O O
survival O O
time O O
from O O
standard O O
treatments O O
is O O
only O O
17 O O
months O O
. O O

High O O
- O O
dose O O
intravenous O O
melphalan O O
followed O O
by O O
peripheral O O
blood O O
stem O O
cell O O
transplant O O
( O O
PBSCT O O
) O O
appears O O
to O O
be O O
the O O
most O O
promising O O
therapy O O
, O O
but O O
treatment O O
mortality O O
can O O
be O O
high O O
. O O

The O O
authors O O
have O O
noted O O
the O O
development O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
insufficiency I-Disease I-Disease
immediately O O
after O O
melphalan O O
conditioning O O
. O O

This O O
study O O
was O O
undertaken O O
to O O
further O O
examine O O
its O O
risk O O
factors O O
and O O
impact O O
on O O
posttransplant O O
mortality O O
. O O

METHODS O O
: O O
Consecutive O O
AL B-Disease B-Disease
patients O O
who O O
underwent O O
PBSCT O O
were O O
studied O O
retrospectively O O
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
insufficiency I-Disease I-Disease
( O O
ARI B-Disease B-Disease
) O O
after O O
high O O
- O O
dose O O
melphalan O O
was O O
defined O O
by O O
a O O
minimum O O
increase O O
of O O
0.5 O O
mg O O
/ O O
dL O O
( O O
44 O O
micromol O O
/ O O
L O O
) O O
in O O
the O O
serum O O
creatinine O O
level O O
that O O
is O O
greater O O
than O O
50 O O
% O O
of O O
baseline O O
immediately O O
after O O
conditioning O O
. O O

Urine O O
sediment O O
score O O
was O O
the O O
sum O O
of O O
the O O
individual O O
types O O
of O O
sediment O O
identified O O
on O O
urine O O
microscopy O O
. O O

RESULTS O O
: O O
Of O O
the O O
80 O O
patients O O
studied O O
, O O
ARI B-Disease B-Disease
developed O O
in O O
18.8 O O
% O O
of O O
the O O
patients O O
after O O
high O O
- O O
dose O O
melphalan O O
. O O

Univariate O O
analysis O O
identified O O
age O O
, O O
hypoalbuminemia B-Disease B-Disease
, O O
heavy O O
proteinuria B-Disease B-Disease
, O O
diuretic O O
use O O
, O O
and O O
urine O O
sediment O O
score O O
( O O
> O O
3 O O
) O O
as O O
risk O O
factors O O
. O O

Age O O
and O O
urine O O
sediment O O
score O O
remained O O
independently O O
significant O O
risk O O
factors O O
in O O
the O O
multivariate O O
analysis O O
. O O

Patients O O
who O O
had O O
ARI B-Disease B-Disease
after O O
high O O
- O O
dose O O
melphalan O O
underwent O O
dialysis O O
more O O
often O O
( O O
P O O
= O O
0.007 O O
) O O
, O O
and O O
had O O
a O O
worse O O
1-year O O
survival O O
( O O
P O O
= O O
0.03 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
timing O O
of O O
renal B-Disease B-Disease
injury I-Disease I-Disease
strongly O O
suggests O O
melphalan O O
as O O
the O O
causative O O
agent O O
. O O

Ongoing O O
tubular B-Disease B-Disease
injury I-Disease I-Disease
may O O
be O O
a O O
prerequisite O O
for O O
renal B-Disease B-Disease
injury I-Disease I-Disease
by O O
melphalan O O
as O O
evidenced O O
by O O
the O O
active O O
urinary O O
sediment O O
. O O

Development O O
of O O
ARI B-Disease B-Disease
adversely O O
affected O O
the O O
outcome O O
after O O
PBSCT O O
. O O

Effective O O
preventive O O
measures O O
may O O
help O O
decrease O O
the O O
treatment O O
mortality O O
of O O
PBSCT O O
in O O
AL B-Disease B-Disease
patients O O
. O O

Focal O O
cerebral B-Disease B-Disease
ischemia I-Disease I-Disease
in O O
rats O O
: O O
effect O O
of O O
phenylephrine O O
- O O
induced O O
hypertension B-Disease B-Disease
during O O
reperfusion O O
. O O

After O O
180 O O
min O O
of O O
temporary O O
middle B-Disease B-Disease
cerebral I-Disease I-Disease
artery I-Disease I-Disease
occlusion I-Disease I-Disease
in O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
, O O
the O O
effect O O
of O O
phenylephrine O O
- O O
induced O O
hypertension B-Disease B-Disease
on O O
ischemic B-Disease B-Disease
brain I-Disease I-Disease
injury I-Disease I-Disease
and O O
blood O O
- O O
brain O O
barrier O O
permeability O O
was O O
determined O O
. O O

Blood O O
pressure O O
was O O
manipulated O O
by O O
one O O
of O O
the O O
following O O
schedules O O
during O O
120 O O
min O O
of O O
reperfusion O O
: O O
Control O O
, O O
normotensive O O
reperfusion O O
; O O
90 O O
/ O O
hypertension B-Disease B-Disease
( O O
90 O O
/ O O
HTN B-Disease B-Disease
) O O
, O O
blood O O
pressure O O
was O O
increased O O
by O O
35 O O
mm O O
Hg O O
during O O
the O O
initial O O
90 O O
min O O
of O O
reperfusion O O
only O O
; O O
15 O O
/ O O
hypertension B-Disease B-Disease
( O O
15 O O
/ O O
HTN B-Disease B-Disease
) O O
, O O
normotensive O O
reperfusion O O
for O O
30 O O
min O O
followed O O
by O O
15 O O
min O O
of O O
hypertension B-Disease B-Disease
and O O
75 O O
min O O
of O O
normotension O O
. O O

Part O O
A O O
, O O
for O O
eight O O
rats O O
in O O
each O O
group O O
brain B-Disease B-Disease
injury I-Disease I-Disease
was O O
evaluated O O
by O O
staining O O
tissue O O
using O O
2,3,5-triphenyltetrazolium O O
chloride O O
and O O
edema B-Disease B-Disease
was O O
evaluated O O
by O O
microgravimetry O O
. O O

Part O O
B O O
, O O
for O O
eight O O
different O O
rats O O
in O O
each O O
group O O
blood O O
- O O
brain O O
barrier O O
permeability O O
was O O
evaluated O O
by O O
measuring O O
the O O
amount O O
and O O
extent O O
of O O
extravasation O O
of O O
Evans O O
Blue O O
dye O O
. O O

Brain B-Disease B-Disease
injury I-Disease I-Disease
( O O
percentage O O
of O O
the O O
ischemic B-Disease B-Disease
hemisphere I-Disease I-Disease
) O O
was O O
less O O
in O O
the O O
15 O O
/ O O
HTN B-Disease B-Disease
group O O
( O O
16 O O
+ O O
/- O O

6 O O
, O O
mean O O
+ O O
/- O O

SD O O
) O O
versus O O
the O O
90 O O
/ O O
HTN B-Disease B-Disease
group O O
( O O
30 O O
+ O O
/- O O

6 O O
) O O
, O O
which O O
was O O
in O O
turn O O
less O O
than O O
the O O
control O O
group O O
( O O
42 O O
+ O O
/- O O

5 O O
) O O
. O O

Specific O O
gravity O O
was O O
greater O O
in O O
the O O
15 O O
/ O O
HTN B-Disease B-Disease
group O O
( O O
1.043 O O
+ O O
/- O O
0.002 O O
) O O
versus O O
the O O
90 O O
/ O O
HTN B-Disease B-Disease
( O O
1.036 O O
+ O O
/- O O

0.003 O O
) O O
and O O
control O O
( O O
1.037 O O
+ O O
/- O O

0.003 O O
) O O
groups O O
. O O

Evans O O
Blue O O
( O O
mug O O
g-1 O O
of O O
brain O O
tissue O O
) O O
was O O
greater O O
in O O
the O O
90 O O
/ O O
HTN B-Disease B-Disease
group O O
( O O
24.4 O O
+ O O
/- O O

6.0 O O
) O O
versus O O
the O O
control O O
group O O
( O O
12.3 O O
+ O O
/- O O

4.1 O O
) O O
, O O
which O O
was O O
in O O
turn O O
greater O O
than O O
the O O
15 O O
/ O O
HTN B-Disease B-Disease
group O O
( O O
7.3 O O
+ O O
/- O O

3.2 O O
) O O
. O O

This O O
study O O
supports O O
a O O
hypothesis O O
that O O
during O O
reperfusion O O
, O O
a O O
short O O
interval O O
of O O
hypertension B-Disease B-Disease
decreases O O
brain B-Disease B-Disease
injury I-Disease I-Disease
and O O
edema B-Disease B-Disease
; O O
and O O
that O O
sustained O O
hypertension B-Disease B-Disease
increases O O
the O O
risk O O
of O O
vasogenic B-Disease B-Disease
edema I-Disease I-Disease
. O O

People O O
aged O O
over O O
75 O O
in O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
on O O
warfarin O O
: O O
the O O
rate O O
of O O
major O O
hemorrhage B-Disease B-Disease
and O O
stroke B-Disease B-Disease
in O O
more O O
than O O
500 O O
patient O O
- O O
years O O
of O O
follow O O
- O O
up O O
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
incidence O O
of O O
major O O
hemorrhage B-Disease B-Disease
and O O
stroke B-Disease B-Disease
in O O
people O O
aged O O
76 O O
and O O
older O O
with O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
on O O
adjusted O O
- O O
dose O O
warfarin O O
who O O
had O O
been O O
recently O O
been O O
admitted O O
to O O
hospital O O
. O O

DESIGN O O
: O O
A O O
retrospective O O
observational O O
cohort O O
study O O
. O O

SETTING O O
: O O
A O O
major O O
healthcare O O
network O O
involving O O
four O O
tertiary O O
hospitals O O
. O O

PARTICIPANTS O O
: O O
Two O O
hundred O O
thirty O O
- O O
five O O
patients O O
aged O O
76 O O
and O O
older O O
admitted O O
to O O
a O O
major O O
healthcare O O
network O O
between O O
July O O
1 O O
, O O
2001 O O
, O O
and O O
June O O
30 O O
, O O
2002 O O
, O O
with O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
on O O
warfarin O O
were O O
enrolled O O
. O O

MEASUREMENTS O O
: O O
Information O O
regarding O O
major O O
bleeding B-Disease B-Disease
episodes O O
, O O
strokes B-Disease B-Disease
, O O
and O O
warfarin O O
use O O
was O O
obtained O O
from O O
patients O O
, O O
relatives O O
, O O
primary O O
physicians O O
, O O
and O O
medical O O
records O O
. O O

RESULTS O O
: O O
Two O O
hundred O O
twenty O O
- O O
eight O O
patients O O
( O O
42 O O
% O O
men O O
) O O
with O O
a O O
mean O O
age O O
of O O
81.1 O O
( O O
range O O
76 O O
- O O
94 O O
) O O
were O O
included O O
in O O
the O O
analysis O O
. O O

Total O O
follow O O
- O O
up O O
on O O
warfarin O O
was O O
530 O O
years O O
( O O
mean O O
28 O O
months O O
) O O
. O O

There O O
were O O
53 O O
major O O
hemorrhages B-Disease B-Disease
, O O
for O O
an O O
annual O O
rate O O
of O O
10.0 O O
% O O
, O O
including O O
24 O O
( O O
45.3 O O
% O O
) O O
life O O
- O O
threatening O O
and O O
five O O
( O O
9.4 O O
% O O
) O O
fatal O O
bleeds O B-Disease
. O O

The O O
annual O O
stroke B-Disease B-Disease
rate O O
after O O
initiation O O
of O O
warfarin O O
was O O
2.6 O O
% O O
. O O

CONCLUSION O O
: O O
The O O
rate O O
of O O
major O O
hemorrhage B-Disease B-Disease
was O O
high O O
in O O
this O O
old O O
, O O
frail O O
group O O
, O O
but O O
excluding O O
fatalities O O
, O O
resulted O O
in O O
no O O
long O O
- O O
term O O
sequelae O O
, O O
and O O
the O O
stroke B-Disease B-Disease
rate O O
on O O
warfarin O O
was O O
low O O
, O O
demonstrating O O
how O O
effective O O
warfarin O O
treatment O O
is O O
. O O

Safety O O
of O O
celecoxib O O
in O O
patients O O
with O O
adverse O O
skin B-Disease O
reactions I-Disease O
to O O
acetaminophen O O
( O O
paracetamol O O
) O O
and O O
nimesulide O O
associated O O
or O O
not O O
with O O
common O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

BACKGROUND O O
: O O
Acetaminophen O O
( O O
paracetamol O O
-- O O
P O O
) O O
and O O
Nimesulide O O
( O O
N O O
) O O
are O O
widely O O
used O O
analgesic O O
- O O
antipyretic O O
/ O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

The O O
rate O O
of O O
adverse O O
hypersensitivity B-Disease B-Disease
reactions O O
to O O
these O O
agents O O
is O O
generally O O
low O O
. O O

On O O
the O O
contrary O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
are O O
commonly O O
involved O O
in O O
such O O
reactions O O
. O O

Celecoxib O O
( O O
CE O O
) O O
is O O
a O O
novel O O
drug O O
, O O
with O O
high O O
selectivity O O
and O O
affinity O O
for O O
COX-2 O O
enzyme O O
. O O

OBJECTIVE O O
: O O
We O O
evaluated O O
the O O
tolerability O O
of O O
CE O O
in O O
a O O
group O O
of O O
patients O O
with O O
documented O O
history O O
of O O
adverse O O
cutaneous B-Disease O
reactions I-Disease O
to O O
P O O
and O O
N O O
associated O O
or O O
not O O
to O O
classic O O
NSAIDs O O
. O O

METHODS O O
: O O
We O O
studied O O
9 O O
patients O O
with O O
hypersensitivity B-Disease B-Disease
to O O
P O O
and O O
N O O
with O O
or O O
without O O
associated O O
reactions O O
to O O
classic O O
NSAIDs O O
. O O

The O O
diagnosis O O
of O O
P O O
and O O
N O O
- O O
induced O O
skin B-Disease B-Disease
reactions I-Disease I-Disease
was O O
based O O
in O O
vivo O O
challenge O O
. O O

The O O
placebo O O
was O O
blindly O O
administered O O
at O O
the O O
beginning O O
of O O
each O O
challenge O O
. O O

After O O
three O O
days O O
, O O
a O O
cumulative O O
dosage O O
of O O
200 O O
mg O O
of O O
CE O O
in O O
refracted O O
doses O O
were O O
given O O
. O O

After O O
2 O O
- O O
3 O O
days O O
, O O
a O O
single O O
dose O O
of O O
200 O O
mg O O
was O O
administered O O
. O O

All O O
patients O O
were O O
observed O O
for O O
6 O O
hours O O
after O O
each O O
challenge O O
, O O
and O O
controlled O O
again O O
after O O
24 O O
hours O O
to O O
exclude O O
delayed O O
reactions O O
. O O

The O O
challenge O O
was O O
considered O O
positive O O
if O O
one O O
or O O
more O O
of O O
the O O
following O O
appeared O O
: O O
erythema B-Disease B-Disease
, O O
rush O O
or O O
urticaria B-Disease B-Disease
- O O
angioedema B-Disease B-Disease
. O O

RESULTS O O
: O O
No O O
reaction O O
was O O
observed O O
with O O
placebo O O
and O O
eight O O
patients O O
( O O
88.8 O O
% O O
) O O
tolerated O O
CE O O
. O O

Only O O
one O O
patient O O
developed O O
a O O
moderate O O
angioedema B-Disease B-Disease
of O O
the O O
lips O O
. O O

CONCLUSION O O
: O O
Only O O
one O O
hypersensitivity B-Disease B-Disease
reaction O O
to O O
CE O O
was O O
documented O O
among O O
9 O O
P O O
and O O
N O O
- O O
highly O O
NSAIDs O O
intolerant O O
patients O O
. O O

Thus O O
, O O
we O O
conclude O O
that O O
CE O O
is O O
a O O
reasonably O O
safe O O
alternative O O
to O O
be O O
used O O
in O O
subjects O O
who O O
do O O
not O O
tolerate O O
P O O
and O O
N. O O

Case O O
- O O
control O O
study O O
of O O
regular O O
analgesic O O
and O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
use O O
and O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Studies O O
on O O
the O O
association O O
between O O
the O O
long O O
- O O
term O O
use O O
of O O
aspirin O O
and O O
other O O
analgesic O O
and O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
and O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
( O O
ESRD B-Disease B-Disease
) O O
have O O
given O O
conflicting O O
results O O
. O O

In O O
order O O
to O O
examine O O
this O O
association O O
, O O
a O O
case O O
- O O
control O O
study O O
with O O
incident O O
cases O O
of O O
ESRD B-Disease B-Disease
was O O
carried O O
out O O
. O O

METHODS O O
: O O
The O O
cases O O
were O O
all O O
patients O O
entering O O
the O O
local O O
dialysis O O
program O O
because O O
of O O
ESRD B-Disease B-Disease
in O O
the O O
study O O
area O O
between O O
June O O
1 O O
, O O
1995 O O
and O O
November O O
30 O O
, O O
1997 O O
. O O

They O O
were O O
classified O O
according O O
to O O
the O O
underlying O O
disease O O
, O O
which O O
had O O
presumably O O
led O O
them O O
to O O
ESRD B-Disease B-Disease
. O O

Controls O O
were O O
patients O O
admitted O O
to O O
the O O
same O O
hospitals O O
from O O
where O O
the O O
cases O O
arose O O
, O O
also O O
matched O O
by O O
age O O
and O O
sex O O
. O O

Odds O O
ratios O O
were O O
calculated O O
using O O
a O O
conditional O O
logistic O O
model O O
, O O
including O O
potential O O
confounding O O
factors O O
, O O
both O O
for O O
the O O
whole O O
study O O
population O O
and O O
for O O
the O O
various O O
underlying O O
diseases O O
. O O

RESULTS O O
: O O
Five O O
hundred O O
and O O
eighty O O
- O O
three O O
cases O O
and O O
1190 O O
controls O O
were O O
included O O
in O O
the O O
analysis O O
. O O

Long O O
- O O
term O O
use O O
of O O
any O O
analgesic O O
was O O
associated O O
with O O
an O O
overall O O
odds O O
ratio O O
of O O
1.22 O O
( O O
95 O O
% O O
CI O O
, O O
0.89 O O
- O O
1.66 O O
) O O
. O O

For O O
specific O O
groups O O
of O O
drugs O O
, O O
the O O
risks O O
were O O
1.56 O O
( O O
1.05 O O
- O O
2.30 O O
) O O
for O O
aspirin O O
, O O
1.03 O O
( O O
0.60 O O
- O O
1.76 O O
) O O
for O O
pyrazolones O O
, O O
0.80 O O
( O O
0.39 O O
- O O
1.63 O O
) O O
for O O
paracetamol O O
, O O
and O O
0.94 O O
( O O
0.57 O O
- O O
1.56 O O
) O O
for O O
nonaspirin O O
NSAIDs O O
. O O

The O O
risk O O
of O O
ESRD B-Disease B-Disease
associated O O
with O O
aspirin O O
was O O
related O O
to O O
the O O
cumulated O O
dose O O
and O O
duration O O
of O O
use O O
, O O
and O O
it O O
was O O
particularly O O
high O O
among O O
the O O
subset O O
of O O
patients O O
with O O
vascular O O
nephropathy B-Disease B-Disease
as O O
underlying O O
disease O O
[ O O
2.35 O O
( O O
1.17 O O
- O O
4.72 O O
) O O
] O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
indicate O O
that O O
long O O
- O O
term O O
use O O
of O O
nonaspirin O O
analgesic O O
drugs O O
and O O
NSAIDs O O
is O O
not O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
ESRD B-Disease B-Disease
. O O

However O O
, O O
the O O
chronic O O
use O O
of O O
aspirin O O
may O O
increase O O
the O O
risk O O
of O O
ESRD B-Disease B-Disease
. O O

Two O O
cases O O
of O O
amisulpride O O
overdose B-Disease B-Disease
: O O
a O O
cause O O
for O O
prolonged B-Disease B-Disease
QT I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Two O O
cases O O
of O O
deliberate O O
self O O
- O O
poisoning B-Disease B-Disease
with O O
5 O O
g O O
and O O
3.6 O O
g O O
of O O
amisulpride O O
, O O
respectively O O
, O O
are O O
reported O O
. O O

In O O
both O O
cases O O
, O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
and O O
hypocalcaemia B-Disease B-Disease
were O O
noted O O
. O O

The O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
appeared O O
to O O
respond O O
to O O
administration O O
of O O
i.v O O
. O O

calcium O O
gluconate O O
. O O

Growth O O
- O O
associated O O
protein O O
43 O O
expression O O
in O O
hippocampal O O
molecular O O
layer O O
of O O
chronic O O
epileptic B-Disease B-Disease
rats O O
treated O O
with O O
cycloheximide O O
. O O

PURPOSE O O
: O O
GAP43 O O
has O O
been O O
thought O O
to O O
be O O
linked O O
with O O
mossy O O
fiber O O
sprouting O O
( O O
MFS O O
) O O
in O O
various O O
experimental O O
models O O
of O O
epilepsy B-Disease B-Disease
. O O

To O O
investigate O O
how O O
GAP43 O O
expression O O
( O O
GAP43-ir O O
) O O
correlates O O
with O O
MFS O B-Disease
, O O
we O O
assessed O O
the O O
intensity O O
( O O
densitometry O O
) O O
and O O
extension O O
( O O
width O O
) O O
of O O
GAP43-ir O O
in O O
the O O
inner O O
molecular O O
layer O O
of O O
the O O
dentate O O
gyrus O O
( O O
IML O O
) O O
of O O
rats O O
subject O O
to O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
induced O O
by O O
pilocarpine O O
( O O
Pilo O O
) O O
, O O
previously O O
injected O O
or O O
not O O
with O O
cycloheximide O O
( O O
CHX O O
) O O
, O O
which O O
has O O
been O O
shown O O
to O O
inhibit O O
MFS O O
. O O

METHODS O O
: O O
CHX O O
was O O
injected O O
before O O
the O O
Pilo O O
injection O O
in O O
adult O O
Wistar O O
rats O O
. O O

The O O
Pilo O O
group O O
was O O
injected O O
with O O
the O O
same O O
drugs O O
, O O
except O O
for O O
CHX O O
. O O

Animals O O
were O O
killed O O
between O O
30 O O
and O O
60 O O
days O O
later O O
, O O
and O O
brain O O
sections O O
were O O
processed O O
for O O
GAP43 O O
immunohistochemistry O O
. O O

RESULTS O O
: O O
Densitometry O O
showed O O
no O O
significant O O
difference O O
regarding O O
GAP43-ir O O
in O O
the O O
IML O O
between O O
Pilo O O
, O O
CHX+Pilo O O
, O O
and O O
control O O
groups O O
. O O

However O O
, O O
the O O
results O O
of O O
the O O
width O O
of O O
the O O
GAP43-ir O O
band O O
in O O
the O O
IML O O
showed O O
that O O
CHX+Pilo O O
and O O
control O O
animals O O
had O O
a O O
significantly O O
larger O O
band O O
( O O
p O O
= O O
0.03 O O
) O O
as O O
compared O O
with O O
that O O
in O O
the O O
Pilo O O
group O O
. O O

CONCLUSIONS O O
: O O
Our O O
current O O
finding O O
that O O
animals O O
in O O
the O O
CHX+Pilo O O
group O O
have O O
a O O
GAP43-ir O O
band O O
in O O
the O O
IML O O
, O O
similar O O
to O O
that O O
of O O
controls O O
, O O
reinforces O O
prior O O
data O O
on O O
the O O
blockade O O
of O O
MFS O O
in O O
these O O
animals O O
. O O

The O O
change O O
in O O
GAP43-ir O O
present O O
in O O
Pilo O O
- O O
treated O O
animals O O
was O O
a O O
thinning O O
of O O
the O O
band O O
to O O
a O O
very O O
narrow O O
layer O O
just O O
above O O
the O O
granule O O
cell O O
layer O O
that O O
is O O
likely O O
to O O
be O O
associated O O
with O O
the O O
loss O O
of O O
hilar O O
cell O O
projections O O
that O O
express O O
GAP-43 O O
. O O

Nicotine O O
antagonizes O O
caffeine- O O
but O O
not O O
pentylenetetrazole O O
- O O
induced O O
anxiogenic O O
effect O O
in O O
mice O O
. O O

RATIONALE O O
: O O
Nicotine O O
and O O
caffeine O O
are O O
widely O O
consumed O O
licit O O
psychoactive O O
drugs O O
worldwide O O
. O O

Epidemiological O O
studies O O
showed O O
that O O
they O O
were O O
generally O O
used O O
concurrently O O
. O O

Although O O
some O O
studies O O
in O O
experimental O O
animals O O
indicate O O
clear O O
pharmacological O O
interactions O O
between O O
them O O
, O O
no O O
studies O O
have O O
shown O O
a O O
specific O O
interaction O O
on O O
anxiety B-Disease B-Disease
responses O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
investigates O O
the O O
effects O O
of O O
nicotine O O
on O O
anxiety B-Disease B-Disease
induced O O
by O O
caffeine O O
and O O
another O O
anxiogenic O O
drug O O
, O O
pentylenetetrazole O O
, O O
in O O
mice O O
. O O

The O O
elevated O O
plus O O
- O O
maze O O
( O O
EPM O O
) O O
test O O
was O O
used O O
to O O
evaluate O O
the O O
effects O O
of O O
drugs O O
on O O
anxiety B-Disease B-Disease
. O O

METHODS O O
: O O
Adult O O
male O O
Swiss O O
Webster O O
mice O O
( O O
25 O O
- O O
32 O O
g O O
) O O
were O O
given O O
nicotine O O
( O O
0.05 O O
- O O
0.25 O O
mg O O
/ O O
kg O O
s.c O O
. O O
) O O
or O O
saline O O
10 O O
min O O
before O O
caffeine O O
( O O
70 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
or O O
pentylenetetrazole O O
( O O
15 O O
and O O
30 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
injections O O
. O O

After O O
15 O O
min O O
, O O
mice O O
were O O
evaluated O O
for O O
their O O
open- O O
and O O
closed O O
- O O
arm O O
time O O
and O O
entries O O
on O O
the O O
EPM O O
for O O
a O O
10-min O O
session O O
. O O

Locomotor O O
activity O O
was O O
recorded O O
for O O
individual O O
groups O O
by O O
using O O
the O O
same O O
treatment O O
protocol O O
with O O
the O O
EPM O O
test O O
. O O

RESULTS O O
: O O
Nicotine O O
( O O
0.05 O O
- O O
0.25 O O
mg O O
/ O O
kg O O
) O O
itself O O
did O O
not O O
produce O O
any O O
significant O O
effect O O
in O O
the O O
EPM O O
test O O
, O O
whereas O O
caffeine O O
( O O
70 O O
mg O O
/ O O
kg O O
) O O
and O O
pentylenetetrazole O O
( O O
30 O O
mg O O
/ O O
kg O O
) O O
produced O O
an O O
anxiogenic O O
effect O O
, O O
apparent O O
with O O
decreases O O
in O O
open O O
- O O
arm O O
time O O
and O O
entry O O
. O O

Nicotine O O
( O O
0.25 O O
mg O O
/ O O
kg O O
) O O
pretreatment O O
blocked O O
the O O
caffeine- O O
but O O
not O O
pentylenetetrazole O O
- O O
induced O O
anxiety B-Disease B-Disease
. O O

Administration O O
of O O
each O O
drug O O
and O O
their O O
combinations O O
did O O
not O O
produce O O
any O O
effect O O
on O O
locomotor O O
activity O O
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
suggest O O
that O O
the O O
antagonistic O O
effect O O
of O O
nicotine O O
on O O
caffeine O O
- O O
induced O O
anxiety B-Disease B-Disease
is O O
specific O O
to O O
caffeine O O
, O O
instead O O
of O O
a O O
non O O
- O O
specific O O
anxiolytic O O
effect O O
. O O

Thus O O
, O O
it O O
may O O
extend O O
the O O
current O O
findings O O
on O O
the O O
interaction O O
between O O
nicotine O O
and O O
caffeine O O
. O O

Long O O
term O O
hormone O O
therapy O O
for O O
perimenopausal O O
and O O
postmenopausal O O
women O O
. O O

BACKGROUND O O
: O O
Hormone O O
therapy O O
( O O
HT O O
) O O
is O O
widely O O
used O O
for O O
controlling O O
menopausal B-Disease O
symptoms I-Disease O
. O O

It O O
has O O
also O O
been O O
used O O
for O O
the O O
management O O
and O O
prevention O O
of O O
cardiovascular B-Disease B-Disease
disease I-Disease I-Disease
, O O
osteoporosis B-Disease B-Disease
and O O
dementia B-Disease B-Disease
in O O
older O O
women O O
but O O
the O O
evidence O O
supporting O O
its O O
use O O
for O O
these O O
indications O O
is O O
largely O O
observational O O
. O O

OBJECTIVES O O
: O O
To O O
assess O O
the O O
effect O O
of O O
long O O
- O O
term O O
HT O O
on O O
mortality O O
, O O
heart B-Disease B-Disease
disease I-Disease I-Disease
, O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
, O O
stroke B-Disease B-Disease
, O O
transient B-Disease B-Disease
ischaemic I-Disease I-Disease
attacks I-Disease I-Disease
, O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
, O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
, O O
endometrial B-Disease B-Disease
cancer I-Disease I-Disease
, O O
gallbladder B-Disease B-Disease
disease I-Disease I-Disease
, O O
cognitive O O
function O O
, O O
dementia B-Disease B-Disease
, O O
fractures B-Disease B-Disease
and O O
quality O O
of O O
life O O
. O O

SEARCH O O
STRATEGY O O
: O O
We O O
searched O O
the O O
following O O
databases O O
up O O
to O O
November O O
2004 O O
: O O
the O O
Cochrane O O
Menstrual O B-Disease
Disorders O I-Disease
and O O
Subfertility O O
Group O O
Trials O O
Register O O
, O O
Cochrane O O
Central O O
Register O O
of O O
Controlled O O
Trials O O
( O O
CENTRAL O O
) O O
, O O
MEDLINE O O
, O O
EMBASE O O
, O O
Biological O O
Abstracts O O
. O O

Relevant O O
non O O
- O O
indexed O O
journals O O
and O O
conference O O
abstracts O O
were O O
also O O
searched O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
double O O
- O O
blind O O
trials O O
of O O
HT O O
( O O
oestrogens O O
with O O
or O O
without O O
progestogens O O
) O O
versus O O
placebo O O
, O O
taken O O
for O O
at O O
least O O
one O O
year O O
by O O
perimenopausal O O
or O O
postmenopausal O O
women O O
. O O

DATA O O
COLLECTION O O
AND O O
ANALYSIS O O
: O O

Fifteen O O
RCTs O O
were O O
included O O
. O O

Trials O O
were O O
assessed O O
for O O
quality O O
and O O
two O O
review O O
authors O O
extracted O O
data O O
independently O O
. O O

They O O
calculated O O
risk O O
ratios O O
for O O
dichotomous O O
outcomes O O
and O O
weighted O O
mean O O
differences O O
for O O
continuous O O
outcomes O O
. O O

Clinical O O
heterogeneity O O
precluded O O
meta O O
- O O
analysis O O
for O O
most O O
outcomes O O
. O O

MAIN O O
RESULTS O O
: O O
All O O
the O O
statistically O O
significant O O
results O O
were O O
derived O O
from O O
the O O
two O O
biggest O O
trials O O
. O O

In O O
relatively O O
healthy O O
women O O
, O O
combined O O
continuous O O
HT O O
significantly O O
increased O O
the O O
risk O O
of O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
or O O
coronary O O
event O O
( O O
after O O
one O O
year O O
's O O
use O O
) O O
, O O
stroke B-Disease B-Disease
( O O
after O O
3 O O
years O O
) O O
, O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
( O O
after O O
5 O O
years O O
) O O
and O O
gallbladder B-Disease B-Disease
disease I-Disease I-Disease
. O O

Long O O
- O O
term O O
oestrogen O O
- O O
only O O
HT O O
also O O
significantly O O
increased O O
the O O
risk O O
of O O
stroke B-Disease B-Disease
and O O
gallbladder B-Disease B-Disease
disease I-Disease I-Disease
. O O

Overall O O
, O O
the O O
only O O
statistically O O
significant O O
benefits O O
of O O
HT O O
were O O
a O O
decreased O O
incidence O O
of O O
fractures B-Disease B-Disease
and O O
colon B-Disease B-Disease
cancer I-Disease I-Disease
with O O
long O O
- O O
term O O
use O O
. O O

Among O O
relatively O O
healthy O O
women O O
over O O
65 O O
years O O
taking O O
continuous O O
combined O O
HT O O
, O O
there O O
was O O
a O O
statistically O O
significant O O
increase O O
in O O
the O O
incidence O O
of O O
dementia B-Disease B-Disease
. O O

Among O O
women O O
with O O
cardiovascular B-Disease B-Disease
disease I-Disease I-Disease
, O O
long O O
- O O
term O O
use O O
of O O
combined O O
continuous O O
HT O O
significantly O O
increased O O
the O O
risk O O
of O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
. O O

No O O
trials O O
focussed O O
specifically O O
on O O
younger O O
women O O
. O O

However O O
, O O
one O O
trial O O
analysed O O
subgroups O O
of O O
2839 O O
relatively O O
healthy O O
50 O O
to O O
59 O O
year O O
- O O
old O O
women O O
taking O O
combined O O
continuous O O
HT O O
and O O
1637 O O
taking O O
oestrogen O O
- O O
only O O
HT O O
, O O
versus O O
similar O O
- O O
sized O O
placebo O O
groups O O
. O O

The O O
only O O
significantly O O
increased O O
risk O O
reported O O
was O O
for O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
in O O
women O O
taking O O
combined O O
continuous O O
HT O O
; O O
their O O
absolute O O
risk O O
remained O O
very O O
low O O
. O O

AUTHORS O O
' O O
CONCLUSIONS O O
: O O
HT O O
is O O
not O O
indicated O O
for O O
the O O
routine O O
management O O
of O O
chronic B-Disease O
disease I-Disease O
. O O

We O O
need O O
more O O
evidence O O
on O O
the O O
safety O O
of O O
HT O O
for O O
menopausal O O
symptom O O
control O O
, O O
though O O
short O O
- O O
term O O
use O O
appears O O
to O O
be O O
relatively O O
safe O O
for O O
healthy O O
younger O O
women O O
. O O

Drug B-Disease O
- I-Disease O
induced I-Disease O
liver I-Disease B-Disease
injury I-Disease I-Disease
: O O
an O O
analysis O O
of O O
461 O O
incidences O O
submitted O O
to O O
the O O
Spanish O O
registry O O
over O O
a O O
10-year O O
period O O
. O O

BACKGROUND O O
& O O
AIMS O O
: O O
Progress O O
in O O
the O O
understanding O O
of O O
susceptibility O O
factors O O
to O O
drug B-Disease O
- I-Disease O
induced I-Disease O
liver I-Disease B-Disease
injury I-Disease I-Disease
( O O
DILI B-Disease B-Disease
) O O
and O O
outcome O O
predictability O O
are O O
hampered O O
by O O
the O O
lack O O
of O O
systematic O O
programs O O
to O O
detect O O
bona O O
fide O O
cases O O
. O O

METHODS O O
: O O
A O O
cooperative O O
network O O
was O O
created O O
in O O
1994 O O
in O O
Spain O O
to O O
identify O O
all O O
suspicions O O
of O O
DILI B-Disease B-Disease
following O O
a O O
prospective O O
structured O O
report O O
form O O
. O O

The O O
liver B-Disease B-Disease
damage I-Disease I-Disease
was O O
characterized O O
according O O
to O O
hepatocellular O O
, O O
cholestatic B-Disease B-Disease
, O O
and O O
mixed O O
laboratory O O
criteria O O
and O O
to O O
histologic O O
criteria O O
when O O
available O O
. O O

Further O O
evaluation O O
of O O
causality O O
assessment O O
was O O
centrally O O
performed O O
. O O

RESULTS O O
: O O
Since O O
April O O
1994 O O
to O O
August O O
2004 O O
, O O
461 O O
out O O
of O O
570 O O
submitted O O
cases O O
, O O
involving O O
505 O O
drugs O O
, O O
were O O
deemed O O
to O O
be O O
related O O
to O O
DILI B-Disease B-Disease
. O O

The O O
antiinfective O O
group O O
of O O
drugs O O
was O O
the O O
more O O
frequently O O
incriminated O O
, O O
amoxicillin O O
- O O
clavulanate O O
accounting O O
for O O
the O O
12.8 O O
% O O
of O O
the O O
whole O O
series O O
. O O

The O O
hepatocellular O O
pattern O O
of O O
damage O O
was O O
the O O
most O O
common O O
( O O
58 O O
% O O
) O O
, O O
was O O
inversely O O
correlated O O
with O O
age O O
( O O
P O O
< O O
.0001 O O
) O O
, O O
and O O
had O O
the O O
worst O O
outcome O O
( O O
Cox O O
regression O O
, O O
P O O
< O O
.034 O O
) O O
. O O

Indeed O O
, O O
the O O
incidence O O
of O O
liver O O
transplantation O O
and O O
death O O
in O O
this O O
group O O
was O O
11.7 O O
% O O
if O O
patients O O
had O O
jaundice B-Disease B-Disease
at O O
presentation O O
, O O
whereas O O
the O O
corresponding O O
figure O O
was O O
3.8 O O
% O O
in O O
nonjaundiced O O
patients O O
( O O
P O O
< O O
.04 O O
) O O
. O O

Factors O O
associated O O
with O O
the O O
development O O
of O O
fulminant B-Disease B-Disease
hepatic I-Disease I-Disease
failure I-Disease I-Disease
were O O
female O O
sex O O
( O O
OR O O
= O O
25 O O
; O O
95 O O
% O O
CI O O
: O O
4.1 O O
- O O
151 O O
; O O
P O O
< O O
.0001 O O
) O O
, O O
hepatocellular O B-Disease
damage O I-Disease
( O O
OR O O
= O O
7.9 O O
; O O
95 O O
% O O
CI O O
: O O
1.6 O O
- O O
37 O O
; O O
P O O
< O O
.009 O O
) O O
, O O
and O O
higher O O
baseline O O
plasma O O
bilirubin O O
value O O
( O O
OR O O
= O O
1.15 O O
; O O
95 O O
% O O
CI O O
: O O
1.09 O O
- O O
1.22 O O
; O O
P O O
< O O
.0001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Patients O O
with O O
drug O O
- O O
induced O O
hepatocellular O B-Disease
jaundice B-Disease I-Disease
have O O
11.7 O O
% O O
chance O O
of O O
progressing O O
to O O
death O O
or O O
transplantation O O
. O O

Amoxicillin O O
- O O
clavulanate O O
stands O O
out O O
as O O
the O O
most O O
common O O
drug O O
related O O
to O O
DILI B-Disease B-Disease
. O O

Morphological O O
evaluation O O
of O O
the O O
effect O O
of O O
d O O
- O O
ribose O O
on O O
adriamycin O O
- O O
evoked O O
cardiotoxicity B-Disease B-Disease
in O O
rats O O
. O O

The O O
influence O O
of O O
d O O
- O O
ribose O O
on O O
adriamycin O O
- O O
induced O O
myocardiopathy B-Disease B-Disease
in O O
rats O O
was O O
studied O O
. O O

Adriamycin O O
in O O
the O O
cumulative O O
dose O O
of O O
25 O O
mg O O
/ O O
kg O O
evoked O O
fully O O
developed O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

D O O
- O O
ribose O O
in O O
the O O
multiple O O
doses O O
of O O
200 O O
mg O O
/ O O
kg O O
did O O
not O O
influence O O
ADR O O
cardiotoxicity B-Disease B-Disease
. O O

In O O
vivo O O
evidences O O
suggesting O O
the O O
role O O
of O O
oxidative O O
stress O O
in O O
pathogenesis O O
of O O
vancomycin O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
: O O
protection O O
by O O
erdosteine O O
. O O

The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
vancomycin O O
( O O
VCM O O
) O O
-induced O O
oxidative O O
stress O O
that O O
promotes O O
production O O
of O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
and O O
to O O
investigate O O
the O O
role O O
of O O
erdosteine O O
, O O
an O O
expectorant O O
agent O O
, O O
which O O
has O O
also O O
antioxidant O O
properties O O
, O O
on O O
kidney O O
tissue O O
against O O
the O O
possible O O
VCM O O
- O O
induced O O
renal B-Disease B-Disease
impairment I-Disease I-Disease
in O O
rats O O
. O O

Rats O O
were O O
divided O O
into O O
three O O
groups O O
: O O
sham O O
, O O
VCM O O
and O O
VCM O O
plus O O
erdosteine O O
. O O

VCM O O
was O O
administrated O O
intraperitoneally O O
( O O
i.p O O
. O O
) O O
with O O
200mgkg O O
( O O
-1 O O
) O O
twice O O
daily O O
for O O
7 O O
days O O
. O O

Erdosteine O O
was O O
administered O O
orally O O
. O O

VCM O O
administration O O
to O O
control O O
rats O O
significantly O O
increased O O
renal O O
malondialdehyde O O
( O O
MDA O O
) O O
and O O
urinary O O
N O O
- O O
acetyl O O
- O O
beta O O
- O O
d O O
- O O
glucosaminidase O O
( O O
NAG O O
, O O
a O O
marker O O
of O O
renal B-Disease B-Disease
tubular I-Disease I-Disease
injury I-Disease I-Disease
) O O
excretion O O
but O O
decreased O O
superoxide O O
dismutase O O
( O O
SOD O O
) O O
and O O
catalase O O
( O O
CAT O O
) O O
activities O O
. O O

Erdosteine O O
administration O O
with O O
VCM O O
injections O O
caused O O
significantly O O
decreased O O
renal O O
MDA O O
and O O
urinary O O
NAG O O
excretion O O
, O O
and O O
increased O O
SOD O O
activity O O
, O O
but O O
not O O
CAT O O
activity O O
in O O
renal O O
tissue O O
when O O
compared O O
with O O
VCM O O
alone O O
. O O

Erdosteine O O
showed O O
histopathological O O
protection O O
against O O
VCM O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
. O O

There O O
were O O
a O O
significant O O
dilatation O O
of O O
tubular O O
lumens O O
, O O
extensive O O
epithelial O O
cell O O
vacuolization O O
, O O
atrophy B-Disease B-Disease
, O O
desquamation B-Disease B-Disease
, O O
and O O
necrosis B-Disease B-Disease
in O O
VCM O O
- O O
treated O O
rats O O
more O O
than O O
those O O
of O O
the O O
control O O
and O O
the O O
erdosteine O O
groups O O
. O O

Erdosteine O O
caused O O
a O O
marked O O
reduction O O
in O O
the O O
extent O O
of O O
tubular O B-Disease
damage O I-Disease
. O O

It O O
is O O
concluded O O
that O O
oxidative O O
tubular O O
damage O O
plays O O
an O O
important O O
role O O
in O O
the O O
VCM O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
and O O
the O O
modulation O O
of O O
oxidative O O
stress O O
with O O
erdosteine O O
reduces O O
the O O
VCM O O
- O O
induced O O
kidney B-Disease B-Disease
damage I-Disease I-Disease
both O O
at O O
the O O
biochemical O O
and O O
histological O O
levels O O
. O O

Gemfibrozil O O
- O O
lovastatin O O
therapy O O
for O O
primary O B-Disease
hyperlipoproteinemias B-Disease I-Disease
. O O

The O O
specific O O
aim O O
of O O
this O O
retrospective O O
, O O
observational O O
study O O
was O O
to O O
assess O O
safety O O
and O O
efficacy O O
of O O
long O O
- O O
term O O
( O O
21 O O
months O O
/ O O
patient O O
) O O
, O O
open O O
- O O
label O O
, O O
gemfibrozil O O
- O O
lovastatin O O
treatment O O
in O O
80 O O
patients O O
with O O
primary O O
mixed O O
hyperlipidemia B-Disease B-Disease
( O O
68 O O
% O O
of O O
whom O O
had O O
atherosclerotic B-Disease B-Disease
vascular I-Disease I-Disease
disease I-Disease I-Disease
) O O
. O O

Because O O
ideal O O
lipid O O
targets O O
were O O
not O O
reached O O
( O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
cholesterol O O
less O O
than O O
130 O O
mg O O
/ O O
dl O O
, O O
high O O
- O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
cholesterol O O
greater O O
than O O
35 O O
mg O O
/ O O
dl O O
, O O
or O O
total O O
cholesterol O O
/ O O
HDL O O
cholesterol O O
less O O
than O O
4.5 O O
mg O O
/ O O
dl O O
) O O
with O O
diet O O
plus O O
a O O
single O O
drug O O
, O O
gemfibrozil O O
( O O
1.2 O O
g O O
/ O O
day O O
) O O
-lovastatin O O
( O O
primarily O O
20 O O
or O O
40 O O
mg O O
) O O
treatment O O
was O O
given O O
. O O

Follow O O
- O O
up O O
visits O O
were O O
scheduled O O
with O O
2-drug O O
therapy O O
every O O
6 O O
to O O
8 O O
weeks O O
, O O
an O O
average O O
of O O
10.3 O O
visits O O
per O O
patient O O
, O O
with O O
741 O O
batteries O O
of O O
6 O O
liver O O
function O O
tests O O
and O O
714 O O
creatine O O
phosphokinase O O
levels O O
measured O O
. O O

Only O O
1 O O
of O O
the O O
4,446 O O
liver O O
function O O
tests O O
( O O
0.02 O O
% O O
) O O
, O O
a O O
gamma O O
glutamyl O O
transferase O O
, O O
was O O
greater O O
than O O
or O O
equal O O
to O O
3 O O
times O O
the O O
upper O O
normal O O
limit O O
. O O

Of O O
the O O
714 O O
creatine O O
phosphokinase O O
levels O O
, O O
9 O O
% O O
were O O
high O O
; O O
only O O
1 O O
( O O
0.1 O O
% O O
) O O
was O O
greater O O
than O O
or O O
equal O O
to O O
3 O O
times O O
the O O
upper O O
normal O O
limit O O
. O O

With O O
2-drug O O
therapy O O
, O O
mean O O
total O O
cholesterol O O
decreased O O
22 O O
% O O
from O O
255 O O
to O O
200 O O
mg O O
/ O O
dl O O
, O O
triglyceride O O
levels O O
decreased O O
35 O O
% O O
from O O
236 O O
to O O
154 O O
mg O O
/ O O
dl O O
, O O
LDL O O
cholesterol O O
decreased O O
26 O O
% O O
from O O
176 O O
to O O
131 O O
mg O O
/ O O
dl O O
, O O
and O O
the O O
total O O
cholesterol O O
/ O O
HDL O O
cholesterol O O
ratio O O
decreased O O
24 O O
% O O
from O O
7.1 O O
to O O
5.4 O O
, O O
all O O
p O O
less O O
than O O
or O O
equal O O
to O O
0.0001 O O
. O O

Myositis B-Disease B-Disease
, O O
attributable O O
to O O
the O O
drug O O
combination O O
and O O
symptomatic O O
enough O O
to O O
discontinue O O
it O O
, O O
occurred O O
in O O
3 O O
% O O
of O O
patients O O
, O O
and O O
in O O
1 O O
% O O
with O O
concurrent O O
high O O
creatine O O
phosphokinase O O
( O O
769 O O
U O O
/ O O
liter O O
) O O
; O O
no O O
patients O O
had O O
rhabdomyolysis B-Disease B-Disease
or O O
myoglobinuria. B-Disease B-Disease
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Does O O
domperidone O O
potentiate O O
mirtazapine O O
- O O
associated O O
restless B-Disease B-Disease
legs I-Disease I-Disease
syndrome I-Disease I-Disease
? O O

There O O
is O O
now O O
evidence O O
to O O
suggest O O
a O O
central O O
role O O
for O O
the O O
dopaminergic O O
system O O
in O O
restless B-Disease B-Disease
legs I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
RLS B-Disease B-Disease
) O O
. O O

For O O
example O O
, O O
the O O
symptoms O O
of O O
RLS B-Disease B-Disease
can O O
be O O
dramatically O O
improved O O
by O O
levodopa O O
and O O
dopamine O O
agonists O O
, O O
whereas O O
central O O
dopamine O O
D2 O O
receptor O O
antagonists O O
can O O
induce O O
or O O
aggravate O O
RLS B-Disease B-Disease
symptoms O O
. O O

To O O
our O O
knowledge O O
, O O
there O O
is O O
no O O
previous O O
report O O
regarding O O
whether O O
domperidone O O
, O O
a O O
peripheral O O
dopamine O O
D2 O O
receptor O O
antagonist O O
, O O
can O O
also O O
induce O O
or O O
aggravate O O
symptoms O O
of O O
RLS B-Disease B-Disease
. O O

Mirtazapine O O
, O O
the O O
first O O
noradrenergic O O
and O O
specific O O
serotonergic O O
antidepressant O O
( O O
NaSSA O O
) O O
, O O
has O O
been O O
associated O O
with O O
RLS B-Disease B-Disease
in O O
several O O
recent O O
publications O O
. O O

The O O
authors O O
report O O
here O O
a O O
depressed O B-Disease
patient O O
comorbid O O
with O O
postprandial B-Disease B-Disease
dyspepsia I-Disease I-Disease
who O O
developed O O
RLS B-Disease B-Disease
after O O
mirtazapine O O
had O O
been O O
added O O
to O O
his O O
domperidone O O
therapy O O
. O O

Our O O
patient O O
started O O
to O O
have O O
symptoms O O
of O O
RLS B-Disease B-Disease
only O O
after O O
he O O
had O O
been O O
treated O O
with O O
mirtazapine O O
, O O
and O O
his O O
RLS B-Disease B-Disease
symptoms O O
resolved O O
completely O O
upon O O
discontinuation O O
of O O
his O O
mirtazapine O O
. O O

Such O O
a O O
temporal O O
relationship O O
between O O
the O O
use O O
of O O
mirtazapine O O
and O O
the O O
symptoms O O
of O O
RLS B-Disease B-Disease
in O O
our O O
patient O O
did O O
not O O
support O O
a O O
potentiating O O
effect O O
of O O
domperione O O
on O O
mirtazapine O O
- O O
associated O O
RLS B-Disease B-Disease
. O O

However O O
, O O
physicians O O
should O O
be O O
aware O O
of O O
the O O
possibility O O
that O O
mirtazapine O O
can O O
be O O
associated O O
with O O
RLS B-Disease B-Disease
in O O
some O O
individuals O O
, O O
especially O O
those O O
receiving O O
concomitant O O
dopamine O O
D2 O O
receptor O O
antagonists O O
. O O

Antiandrogenic O O
therapy O O
can O O
cause O O
coronary B-Disease B-Disease
arterial I-Disease I-Disease
disease I-Disease I-Disease
. O O

AIM O O
: O O
To O O
study O O
the O O
change O O
of O O
lipid O O
metabolism O O
by O O
antiandrogen O O
therapy O O
in O O
patients O O
with O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
studied O O
with O O
a O O
2.5 O O
years O O
follow O O
- O O
up O O
the O O
changes O O
in O O
plasma O O
cholesterols O O
( O O
C O O
) O O
, O O
triglycerides O O
( O O
TG O O
) O O
, O O
lipoproteins O O
( O O
LP O O
) O O
, O O
and O O
apolipoproteins O O
( O O
Apo O O
) O O
B-100 O O
, O O
A O O
- O O
I O O
, O O
and O O
A O O
- O O
II O O
pro O O
fi O O
les O O
in O O
24 O O
patients O O
of O O
mean O O
age O O
60 O O
years O O
with O O
low O O
risk O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
( O O
stage O O
: O O
T1cN0M0 O O
, O O
Gleason O O
score O O
: O O
2 O O
- O O
5 O O
) O O
during O O
treatment O O
with O O
cyproterone O O
acetate O O
( O O
CPA O O
) O O
without O O
surgical O O
management O O
or O O
radiation O O
therapy O O
. O O

RESULTS O O
: O O
Significant O O
decreases O O
of O O
HDL O O
- O O
C O O
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
and O O
an O O
increase O O
of O O
triglyceride O O
levels O O
in O O
VLDL O O
were O O
induced O O
by O O
CPA O O
. O O

After O O
a O O
period O O
of O O
2.5 O O
years O O
on O O
CPA O O
treatment O O
, O O
four O O
patients O O
out O O
of O O
twenty O O
- O O
four O O
were O O
found O O
to O O
be O O
affected O O
by O O
coronary B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
. O O

CONCLUSIONS O O
: O O
Ischaemic O B-Disease
coronary B-Disease I-Disease
arteriosclerosis I-Disease I-Disease
with O O
an O O
incidence O O
rate O O
of O O
16.6 O O
% O O
as O O
caused O O
by O O
prolonged O O
CPA O O
therapy O O
is O O
mediated O O
through O O
changes O O
in O O
HDL O O
cholesterol O O
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
pro O O
fi O O
les O O
, O O
other O O
than O O
the O O
well O O
- O O
known O O
hyperglyceridemic B-Disease B-Disease
effect I-Disease O
caused O O
by O O
estrogen O O
. O O

5-Fluorouracil O O
cardiotoxicity B-Disease B-Disease
induced O O
by O O
alpha O O
- O O
fluoro O O
- O O
beta O O
- O O
alanine O O
. O O

Cardiotoxicity B-Disease B-Disease
is O O
a O O
rare O O
complication O O
occurring O O
during O O
5-fluorouracil O O
( O O
5-FU O O
) O O
treatment O O
for O O
malignancies B-Disease B-Disease
. O O

We O O
herein O O
report O O
the O O
case O O
of O O
a O O
70-year O O
- O O
old O O
man O O
with O O
5-FU O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
, O O
in O O
whom O O
a O O
high O O
serum O O
level O O
of O O
alpha O O
- O O
fluoro O O
- O O
beta O O
- O O
alanine O O
( O O
FBAL O O
) O O
was O O
observed O O
. O O

The O O
patient O O
, O O
who O O
had O O
unresectable O O
colon B-Disease B-Disease
cancer I-Disease I-Disease
metastases O B-Disease
to O I-Disease
the O I-Disease
liver O I-Disease
and O I-Disease
lung O I-Disease
, O O
was O O
referred O O
to O O
us O O
for O O
chemotherapy O O
from O O
an O O
affiliated O O
hospital O O
; O O
he O O
had O O
no O O
cardiac O O
history O O
. O O

After O O
admission O O
, O O
the O O
patient O O
received O O
a O O
continuous O O
intravenous O O
infusion O O
of O O
5-FU O O
( O O
1000 O O
mg O O
/ O O
day O O
) O O
, O O
during O O
which O O
precordial B-Disease B-Disease
pain I-Disease I-Disease
with O O
right B-Disease B-Disease
bundle I-Disease I-Disease
branch I-Disease I-Disease
block I-Disease I-Disease
occurred O O
concomitantly O O
with O O
a O O
high O O
serum O O
FBAL O O
concentration O O
of O O
1955 O O
ng O O
/ O O
ml O O
. O O

Both O O
the O O
precordial B-Disease B-Disease
pain I-Disease I-Disease
and O O
the O O
electrocardiographic O O
changes O O
disappeared O O
spontaneously O O
after O O
the O O
discontinuation O O
of O O
5-FU O O
. O O

As O O
the O O
precordial B-Disease B-Disease
pain I-Disease I-Disease
in O O
this O O
patient O O
was O O
considered O O
to O O
have O O
been O O
due O O
to O O
5-FU O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
, O O
the O O
administration O O
of O O
5-FU O O
was O O
abandoned O O
. O O

Instead O O
, O O
oral O O
administration O O
of O O
S-1 O O
( O O
a O O
derivative O O
of O O
5-FU O O
) O O
, O O
at O O
200 O O
mg O O
/ O O
day O O
twice O O
a O O
week O O
, O O
was O O
instituted O O
, O O
because O O
S-1 O O
has O O
a O O
strong O O
inhibitory O O
effect O O
on O O
dihydropyrimidine O O
dehydrogenase O O
, O O
which O O
catalyzes O O
the O O
degradative O O
of O O
5-FU O O
into O O
FBAL O O
. O O

The O O
serum O O
FBAL O O
concentration O O
subsequently O O
decreased O O
to O O
352 O O
ng O O
/ O O
ml O O
, O O
the O O
same O O
as O O
the O O
value O O
measured O O
on O O
the O O
first O O
day O O
of O O
S-1 O O
administration O O
. O O

Thereafter O O
, O O
no O O
cardiac B-Disease B-Disease
symptoms I-Disease I-Disease
were O O
observed O O
. O O

The O O
patient O O
achieved O O
a O O
partial O O
response O O
6 O O
months O O
after O O
the O O
initiation O O
of O O
the O O
S-1 O O
treatment O O
. O O

The O O
experience O O
of O O
this O O
case O O
, O O
together O O
with O O
a O O
review O O
of O O
the O O
literature O O
, O O
suggests O O
that O O
FBAL O O
is O O
related O O
to O O
5-FU O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
. O O

S-1 O O
may O O
be O O
administered O O
safely O O
to O O
patients O O
with O O
5-FU O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
. O O

Hepatocellular B-Disease B-Disease
carcinoma I-Disease I-Disease
in O O
Fanconi B-Disease B-Disease
's I-Disease I-Disease
anemia I-Disease I-Disease
treated O O
with O O
androgen O O
and O O
corticosteroid O O
. O O

The O O
case O O
of O O
an O O
11-year O O
- O O
old O O
boy O O
is O O
reported O O
who O O
was O O
known O O
to O O
have O O
Fanconi B-Disease B-Disease
's I-Disease I-Disease
anemia I-Disease I-Disease
for O O
3 O O
years O O
and O O
was O O
treated O O
with O O
androgens O O
, O O
corticosteroids O O
and O O
transfusions O O
. O O

Two O O
weeks O O
before O O
his O O
death O O
he O O
was O O
readmitted O O
because O O
of O O
aplastic O B-Disease
crisis O I-Disease
with O O
septicemia B-Disease B-Disease
and O O
marked O O
abnormalities O O
in O O
liver O O
function O O
and O O
died O O
of O O
hemorrhagic B-Disease B-Disease
bronchopneumonia I-Disease B-Disease
. O O

At O O
autopsy O O
peliosis B-Disease B-Disease
and O O
multiple O O
hepatic B-Disease B-Disease
tumors I-Disease I-Disease
were O O
found O O
which O O
histologically O O
proved O O
to O O
be O O
well O O
- O O
differentiated O O
hepatocellular B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

This O O
case O O
contributes O O
to O O
the O O
previous O O
observations O O
that O O
non O B-Disease
- O I-Disease
metastasizing O I-Disease
hepatic B-Disease I-Disease
neoplasms I-Disease I-Disease
and O O
peliosis B-Disease B-Disease
can O O
develop O O
in O O
patients O O
with O O
androgen- O O
and O O
corticosteroid O O
- O O
treated O O
Fanconi B-Disease B-Disease
's I-Disease I-Disease
anemia I-Disease I-Disease
. O O

The O O
influence O O
of O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
doxorubicin O O
administration O O
on O O
the O O
protection O O
against O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
in O O
mice O O
. O O

PURPOSE O O
: O O
Despite O O
its O O
well O O
- O O
known O O
cardiotoxicity B-Disease B-Disease
, O O
the O O
anthracyclin O O
doxorubicin O O
( O O
DOX O O
) O O
continues O O
to O O
be O O
an O O
effective O O
and O O
widely O O
used O O
chemotherapeutic O O
agent O O
. O O

DOX O O
- O O
induced O O
cardiac B-Disease B-Disease
damage I-Disease I-Disease
presumably O O
results O O
from O O
the O O
formation O O
of O O
free O O
radicals O O
by O O
DOX O O
. O O

Reactive O O
oxygen O O
species O O
particularly O O
affect O O
the O O
cardiac O O
myocytes O O
because O O
these O O
cells O O
seem O O
to O O
have O O
a O O
relatively O O
poor O O
antioxidant O O
defense O O
system O O
. O O

The O O
semisynthetic O O
flavonoid O O
monohydroxyethylrutoside O O
( O O
monoHER O O
) O O
showed O O
cardioprotection O O
against O O
DOX O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
through O O
its O O
radical O O
scavenging O O
and O O
iron O O
chelating O O
properties O O
. O O

Because O O
of O O
the O O
relatively O O
short O O
final O O
half O O
- O O
life O O
of O O
monoHER O O
( O O
about O O
30 O O
min O O
) O O
, O O
it O O
is O O
expected O O
that O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
DOX O O
might O O
be O O
of O O
influence O O
on O O
the O O
cardioprotective O O
effect O O
of O O
monoHER O O
. O O

Therefore O O
, O O
the O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
this O O
possible O O
effect O O
. O O

METHODS O O
: O O
Six O O
groups O O
of O O
6 O O
BALB O O
/ O O
c O O
mice O O
were O O
treated O O
with O O
saline O O
, O O
DOX O O
alone O O
or O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
i.v O O
. O O
) O O
preceded O O
by O O
monoHER O O
( O O
500 O O
mg O O
/ O O
kg O O
i.p O O
. O O
) O O
with O O
an O O
interval O O
of O O
10 O O
, O O
30 O O
, O O
60 O O
or O O
120 O O
min O O
. O O

After O O
a O O
6-week O O
treatment O O
period O O
and O O
additional O O
observation O O
for O O
2 O O
weeks O O
, O O
the O O
mice O O
were O O
sacrificed O O
. O O

Their O O
cardiac O O
tissues O O
were O O
processed O O
for O O
light O O
microscopy O O
, O O
after O O
which O O
cardiomyocyte B-Disease B-Disease
damage I-Disease I-Disease
was O O
evaluated O O
according O O
to O O
Billingham O O
( O O
in O O
Cancer B-Disease B-Disease
Treat O O
Rep O O
62 O O
( O O
6 O O
) O O
:865 O O
- O O
872 O O
, O O
1978 O O
) O O
. O O

Microscopic O O
evaluation O O
revealed O O
that O O
treatment O O
with O O
DOX O O
alone O O
induced O O
significant O O
cardiac B-Disease B-Disease
damage I-Disease I-Disease
in O O
comparison O O
to O O
the O O
saline O O
control O O
group O O
( O O
P<0.001 O O
) O O
. O O

RESULTS O O
: O O
The O O
number O O
of O O
damaged O O
cardiomyocytes O O
was O O
9.6-fold O O
( O O
95 O O
% O O
CI O O
4.4 O O
- O O
21.0 O O
) O O
higher O O
in O O
mice O O
treated O O
with O O
DOX O O
alone O O
than O O
that O O
in O O
animals O O
of O O
the O O
control O O
group O O
. O O

The O O
ratio O O
of O O
aberrant O O
cardiomyocytes O O
in O O
mice O O
treated O O
with O O
DOX O O
preceded O O
by O O
monoHER O O
and O O
those O O
in O O
mice O O
treated O O
with O O
saline O O
ranged O O
from O O
1.6 O O
to O O
2.8 O O
( O O
mean O O
2.2 O O
, O O
95 O O
% O O
CI O O
1.2 O O
- O O
4.1 O O
, O O
P=0.019 O O
) O O
. O O

The O O
mean O O
protective O O
effect O O
by O O
adding O O
monoHER O O
before O O
DOX O O
led O O
to O O
a O O
significant O O
4.4-fold O O
reduction O O
( O O
P<0.001 O O
, O O
95 O O
% O O
CI O O
2.3 O O
- O O
8.2 O O
) O O
of O O
abnormal O O
cardiomyocytes O O
. O O

This O O
protective O O
effect O O
did O O
not O O
depend O O
on O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
DOX O O
administration O O
( O O
P=0.345 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
in O O
an O O
outpatient O O
clinical O O
setting O O
monoHER O O
may O O
be O O
administered O O
shortly O O
before O O
DOX O O
. O O

Clinical O O
evaluation O O
of O O
adverse O O
effects O O
during O O
bepridil O O
administration O O
for O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
and B-Disease O
flutter I-Disease B-Disease
. O O

BACKGROUND O O
: O O
Bepridil O O
hydrochloride O O
( O O
Bpd O O
) O O
has O O
attracted O O
attention O O
as O O
an O O
effective O O
drug O O
for O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
( O O
AF B-Disease B-Disease
) O O
and O O
atrial B-Disease B-Disease
flutter I-Disease I-Disease
( O O
AFL B-Disease B-Disease
) O O
. O O

However O O
, O O
serious O O
adverse O O
effects O O
, O O
including O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
( O O
Tdp B-Disease B-Disease
) O O
, O O
have O O
been O O
reported O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Adverse O O
effects O O
of O O
Bpd O O
requiring O O
discontinuation O O
of O O
treatment O O
were O O
evaluated O O
. O O

Bpd O O
was O O
administered O O
to O O
459 O O
patients O O
( O O
361 O O
males O O
, O O
63+ O O
/ O O
-12 O O
years O O
old O O
) O O
comprising O O
378 O O
AF B-Disease B-Disease
and O O
81 O O
AFL B-Disease B-Disease
cases O O
. O O

Mean O O
left O O
ventricular O O
ejection O O
fraction O O
and O O
atrial O O
dimension O O
( O O
LAD O O
) O O
were O O
66+ O O
/ O O
-11 O O
% O O
and O O
40+ O O
/ O O
-6 O O
mm O O
, O O
respectively O O
. O O

Adverse O O
effects O O
were O O
observed O O
in O O
19 O O
patients O O
( O O
4 O O
% O O
) O O
during O O
an O O
average O O
follow O O
- O O
up O O
of O O
20 O O
months O O
. O O

There O O
was O O
marked O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
greater O O
than O O
0.55 O O
s O O
in O O
13 O O
patients O O
, O O
bradycardia B-Disease B-Disease
less O O
than O O
40 O O
beats O O
/ O O
min O O
in O O
6 O O
patients O O
, O O
dizziness B-Disease B-Disease
and O O
general O O
fatigue B-Disease B-Disease
in O O
1 O O
patient O O
each O O
. O O

In O O
4 O O
of O O
13 O O
patients O O
with O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
, O O
Tdp B-Disease B-Disease
occurred O O
. O O

The O O
major O O
triggering O O
factors O O
of O O
Tdp B-Disease B-Disease
were O O
hypokalemia B-Disease B-Disease
and O O
sudden O O
decrease O O
in O O
heart O O
rate O O
. O O

There O O
were O O
no O O
differences O O
in O O
the O O
clinical O O
backgrounds O O
of O O
the O O
patients O O
with O O
and O O
without O O
Tdp B-Disease B-Disease
other O O
than O O
LAD O O
and O O
age O O
, O O
which O O
were O O
larger O O
and O O
older O O
in O O
the O O
patients O O
with O O
Tdp B-Disease B-Disease
. O O

CONCLUSION O O
: O O
Careful O O
observation O O
of O O
serum O O
potassium O O
concentration O O
and O O
the O O
ECG O O
should O O
always O O
be O O
done O O
during O O
Bpd O O
administration O O
, O O
particularly O O
in O O
elderly O O
patients O O
. O O

Enhanced O O
isoproterenol O O
- O O
induced O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
in O O
transgenic O O
rats O O
with O O
low O O
brain O O
angiotensinogen O O
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
permanent O O
deficiency O O
in O O
the O O
brain O O
renin O O
- O O
angiotensin O O
system O O
( O O
RAS O O
) O O
may O O
increase O O
the O O
sensitivity O O
of O O
the O O
baroreflex O O
control O O
of O O
heart O O
rate O O
. O O

In O O
this O O
study O O
we O O
aimed O O
at O O
studying O O
the O O
involvement O O
of O O
the O O
brain O O
RAS O O
in O O
the O O
cardiac O O
reactivity O O
to O O
the O O
beta O O
- O O
adrenoceptor O O
( O O
beta O O
- O O
AR O O
) O O
agonist O O
isoproterenol O O
( O O
Iso O O
) O O
. O O

Transgenic O O
rats O O
with O O
low O O
brain O O
angiotensinogen O O
( O O
TGR O O
) O O
were O O
used O O
. O O

In O O
isolated O O
hearts O O
, O O
Iso O O
induced O O
a O O
significantly O O
greater O O
increase O O
in O O
left O O
ventricular O O
( O O
LV O O
) O O
pressure O O
and O O
maximal O O
contraction O O
( O O
+ O O
dP O O
/ O O
dt O O
( O O
max O O
) O O
) O O
in O O
the O O
TGR O O
than O O
in O O
the O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

LV B-Disease B-Disease
hypertrophy I-Disease I-Disease
induced O O
by O O
Iso O O
treatment O O
was O O
significantly O O
higher O O
in O O
TGR O O
than O O
in O O
SD O O
rats O O
( O O
in O O
g O O
LV O O
wt O O
/ O O
100 O O
g O O
body O O
wt O O
, O O
0.28 O O
+ O O
/- O O

0.004 O O
vs. O O
0.24 O O
+ O O
/- O O

0.004 O O
, O O
respectively O O
) O O
. O O

The O O
greater O O
LV B-Disease B-Disease
hypertrophy I-Disease I-Disease
in O O
TGR O O
rats O O
was O O
associated O O
with O O
more O O
pronounced O O
downregulation O O
of O O
beta O O
- O O
AR O O
and O O
upregulation O O
of O O
LV O O
beta O O
- O O
AR O O
kinase-1 O O
mRNA O O
levels O O
compared O O
with O O
those O O
in O O
SD O O
rats O O
. O O

The O O
decrease O O
in O O
the O O
heart O O
rate O O
( O O
HR O O
) O O
induced O O
by O O
the O O
beta O O
- O O
AR O O
antagonist O O
metoprolol O O
in O O
conscious O O
rats O O
was O O
significantly O O
attenuated O O
in O O
TGR O O
compared O O
with O O
SD O O
rats O O
( O O
-9.9 O O
+ O O
/- O O

1.7 O O
% O O
vs. O O
-18.1 O O
+ O O
/- O O

1.5 O O
% O O
) O O
, O O
whereas O O
the O O
effect O O
of O O
parasympathetic O O
blockade O O
by O O
atropine O O
on O O
HR O O
was O O
similar O O
in O O
both O O
strains O O
. O O

These O O
results O O
indicate O O
that O O
TGR O O
are O O
more O O
sensitive O O
to O O
beta O O
- O O
AR O O
agonist O O
- O O
induced O O
cardiac B-Disease O
inotropic I-Disease O
response O O
and O O
hypertrophy B-Disease B-Disease
, O O
possibly O O
due O O
to O O
chronically O O
low O O
sympathetic O O
outflow O O
directed O O
to O O
the O O
heart O O
. O O

Drug O O
- O O
induced O O
long B-Disease B-Disease
QT I-Disease I-Disease
syndrome I-Disease I-Disease
in O O
injection O O
drug O O
users O O
receiving O O
methadone O O
: O O
high O O
frequency O O
in O O
hospitalized O O
patients O O
and O O
risk O O
factors O O
. O O

BACKGROUND O O
: O O
Drug O O
- O O
induced O O
long B-Disease B-Disease
QT I-Disease I-Disease
syndrome I-Disease I-Disease
is O O
a O O
serious O O
adverse O O
drug O O
reaction O O
. O O

Methadone O O
prolongs O O
the O O
QT O O
interval O O
in O O
vitro O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

In O O
the O O
inpatient O O
setting O O
, O O
the O O
frequency O O
of O O
QT B-Disease B-Disease
interval I-Disease I-Disease
prolongation I-Disease I-Disease
with O O
methadone O O
treatment O O
, O O
its O O
dose O O
dependence O O
, O O
and O O
the O O
importance O O
of O O
cofactors O O
such O O
as O O
drug O O
- O O
drug O O
interactions O O
remain O O
unknown O O
. O O

METHODS O O
: O O
We O O
performed O O
a O O
systematic O O
, O O
retrospective O O
study O O
comparing O O
active O O
or O O
former O O
intravenous O O
drug O O
users O O
receiving O O
methadone O O
and O O
those O O
not O O
receiving O O
methadone O O
among O O
all O O
patients O O
hospitalized O O
over O O
a O O
5-year O O
period O O
in O O
a O O
tertiary O O
care O O
hospital O O
. O O

A O O
total O O
of O O
167 O O
patients O O
receiving O O
methadone O O
fulfilled O O
the O O
inclusion O O
criteria O O
and O O
were O O
compared O O
with O O
a O O
control O O
group O O
of O O
80 O O
injection O O
drug O O
users O O
not O O
receiving O O
methadone O O
. O O

In O O
addition O O
to O O
methadone O O
dose O O
, O O
15 O O
demographic O O
, O O
biological O O
, O O
and O O
pharmacological O O
variables O O
were O O
considered O O
as O O
potential O O
risk O O
factors O O
for O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
. O O

RESULTS O O
: O O
Among O O
167 O O
methadone O O
maintenance O O
patients O O
, O O
the O O
prevalence O O
of O O
QTc O B-Disease
prolongation O I-Disease
to O O
0.50 O O
second O O
( O O
( O O
1 O O
/ O O
2 O O
) O O
) O O
or O O
longer O O
was O O
16.2 O O
% O O
compared O O
with O O
0 O O
% O O
in O O
80 O O
control O O
subjects O O
. O O

Six O O
patients O O
( O O
3.6 O O
% O O
) O O
in O O
the O O
methadone O O
group O O
presented O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
. O O

QTc O O
length O O
was O O
weakly O O
but O O
significantly O O
associated O O
with O O
methadone O O
daily O O
dose O O
( O O
Spearman O O
rank O O
correlation O O
coefficient O O
, O O
0.20 O O
; O O
P<.01 O O
) O O
. O O

Multivariate O O
regression O O
analysis O O
allowed O O
attribution O O
of O O
31.8 O O
% O O
of O O
QTc O O
variability O O
to O O
methadone O O
dose O O
, O O
cytochrome O O
P-450 O O
3A4 O O
drug O O
- O O
drug O O
interactions O O
, O O
hypokalemia B-Disease B-Disease
, O O
and O O
altered O B-Disease
liver O I-Disease
function O I-Disease
. O O

CONCLUSIONS O O
: O O
QT B-Disease B-Disease
interval I-Disease I-Disease
prolongation I-Disease I-Disease
in O O
methadone O O
maintenance O O
patients O O
hospitalized O O
in O O
a O O
tertiary O O
care O O
center O O
is O O
a O O
frequent O O
finding O O
. O O

Methadone O O
dose O O
, O O
presence O O
of O O
cytochrome O O
P-450 O O
3A4 O O
inhibitors O O
, O O
potassium O O
level O O
, O O
and O O
liver O O
function O O
contribute O O
to O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
. O O

Long B-Disease B-Disease
QT I-Disease I-Disease
syndrome I-Disease I-Disease
can O O
occur O O
with O O
low O O
doses O O
of O O
methadone O O
. O O

Mechanisms O O
of O O
hypertension B-Disease B-Disease
induced O O
by O O
nitric O O
oxide O O
( O O
NO O O
) O O
deficiency O O
: O O
focus O O
on O O
venous O O
function O O
. O O

Loss O O
of O O
endothelial O O
cell O O
- O O
derived O O
nitric O O
oxide O O
( O O
NO O O
) O O
in O O
hypertension B-Disease B-Disease
is O O
a O O
hallmark O O
of O O
arterial B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

Experimental O O
hypertension B-Disease B-Disease
created O O
by O O
the O O
removal O O
of O O
NO O O
, O O
however O O
, O O
involves O O
mechanisms O O
in O O
addition O O
to O O
decreased O O
arterial O O
vasodilator O O
activity O O
. O O

These O O
include O O
augmented O O
endothelin-1 O O
( O O
ET-1 O O
) O O
release O O
, O O
increased O O
sympathetic O O
nervous O O
system O O
activity O O
, O O
and O O
elevated O O
tissue O O
oxidative O O
stress O O
. O O

We O O
hypothesized O O
that O O
increased O O
venous O O
smooth O O
muscle O O
( O O
venomotor O O
) O O
tone O O
plays O O
a O O
role O O
in O O
Nomega O O
- O O
nitro O O
- O O
L O O
- O O
arginine O O
( O O
LNNA O O
) O O
hypertension B-Disease B-Disease
through O O
these O O
mechanisms O O
. O O

Rats O O
were O O
treated O O
with O O
the O O
NO O O
synthase O O
inhibitor O O
LNNA O O
( O O
0.5 O O
g O O
/ O O
L O O
in O O
drinking O O
water O O
) O O
for O O
2 O O
weeks O O
. O O

Mean O O
arterial O O
pressure O O
of O O
conscious O O
rats O O
was O O
119 O O
+ O O
/- O O

2 O O
mm O O
Hg O O
in O O
control O O
and O O
194 O O
+ O O
/- O O

5 O O
mm O O
Hg O O
in O O
LNNA O O
rats O O
( O O
P<0.05 O O
) O O
. O O

Carotid O O
arteries O O
and O O
vena O O
cava O O
were O O
removed O O
for O O
measurement O O
of O O
isometric O O
contraction O O
. O O

Maximal O O
contraction O O
to O O
norepinephrine O O
was O O
modestly O O
reduced O O
in O O
arteries O O
from O O
LNNA O O
compared O O
with O O
control O O
rats O O
whereas O O
the O O
maximum O O
contraction O O
to O O
ET-1 O O
was O O
significantly O O
reduced O O
( O O
54 O O
% O O
control O O
) O O
. O O

Maximum O O
contraction O O
of O O
vena O O
cava O O
to O O
norepinephrine O O
( O O
37 O O
% O O
control O O
) O O
also O O
was O O
reduced O O
but O O
no O O
change O O
in O O
response O O
to O O
ET-1 O O
was O O
observed O O
. O O

Mean O O
circulatory O O
filling O O
pressure O O
, O O
an O O
in O O
vivo O O
measure O O
of O O
venomotor O O
tone O O
, O O
was O O
not O O
elevated O O
in O O
LNNA O O
hypertension B-Disease B-Disease
at O O
1 O O
or O O
2 O O
weeks O O
after O O
LNNA O O
. O O

The O O
superoxide O O
scavenger O O
tempol O O
( O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
micromol O O
kg O O
( O O
-1 O O
) O O
, O O
IV O O
) O O
did O O
not O O
change O O
arterial O O
pressure O O
in O O
control O O
rats O O
but O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
LNNA O O
rats O O
( O O
-18 O O
+ O O
/- O O

8 O O
, O O
-26 O O
+ O O
/- O O

15 O O
, O O
and O O
-54 O O
+ O O
/- O O

11 O O
mm O O
Hg O O
) O O
. O O

Similarly O O
, O O
ganglionic O O
blockade O O
with O O
hexamethonium O O
caused O O
a O O
significantly O O
greater O O
fall O O
in O O
LNNA O O
hypertensive B-Disease B-Disease
rats O O
( O O
76 O O
+ O O
/- O O

9 O O
mm O O
Hg O O
) O O
compared O O
with O O
control O O
rats O O
( O O
35 O O
+ O O
/- O O

10 O O
mm O O
Hg O O
) O O
. O O

Carotid O O
arteries O O
, O O
vena O O
cava O O
, O O
and O O
sympathetic O O
ganglia O O
from O O
LNNA O O
rats O O
had O O
higher O O
basal O O
levels O O
of O O
superoxide O O
compared O O
with O O
those O O
from O O
control O O
rats O O
. O O

These O O
data O O
suggest O O
that O O
while O O
NO O O
deficiency O O
increases O O
oxidative O O
stress O O
and O O
sympathetic O O
activity O O
in O O
both O O
arterial O O
and O O
venous O O
vessels O O
, O O
the O O
impact O O
on O O
veins O O
does O O
not O O
make O O
a O O
major O O
contribution O O
to O O
this O O
form O O
of O O
hypertension B-Disease B-Disease
. O O

Association O O
of O O
DRD2 O O
polymorphisms O O
and O O
chlorpromazine O O
- O O
induced O O
extrapyramidal B-Disease B-Disease
syndrome I-Disease I-Disease
in O O
Chinese O O
schizophrenic B-Disease B-Disease
patients O O
. O O

AIM O O
: O O
Extrapyramidal B-Disease B-Disease
syndrome I-Disease I-Disease
( O O
EPS B-Disease B-Disease
) O O
is O O
most O O
commonly O O
affected O O
by O O
typical O O
antipsychotic O O
drugs O O
that O O
have O O
a O O
high O O
affinity O O
with O O
the O O
D2 O O
receptor O O
. O O

Recently O O
, O O
many O O
research O O
groups O O
have O O
reported O O
on O O
the O O
positive O O
relationship O O
between O O
the O O
genetic O O
variations O O
in O O
the O O
DRD2 O O
gene O O
and O O
the O O
therapeutic O O
response O O
in O O
schizophrenia B-Disease B-Disease
patients O O
as O O
a O O
result O O
of O O
the O O
role O O
of O O
variations O O
in O O
the O O
receptor O O
in O O
modulating O O
receptor O O
expression O O
. O O

In O O
this O O
study O O
, O O
we O O
evaluate O O
the O O
role O O
DRD2 O O
plays O O
in O O
chlorpromazine O O
- O O
induced O O
EPS B-Disease B-Disease
in O O
schizophrenic B-Disease B-Disease
patients O O
. O O

METHODS O O
: O O
We O O
identified O O
seven O O
SNP O O
( O O
single O O
nucleotide O O
polymorphism O O
) O O
( O O
-141Cins O O
> O O
del O O
, O O
TaqIB O O
, O O
TaqID O O
, O O
Ser311Cys O O
, O O
rs6275 O O
, O O
rs6277 O O
and O O
TaqIA O O
) O O
in O O
the O O
DRD2 O O
gene O O
in O O
146 O O
schizophrenic B-Disease B-Disease
inpatients O O
( O O
59 O O
with O O
EPS B-Disease B-Disease
and O O
87 O O
without O O
EPS B-Disease B-Disease
according O O
to O O
the O O
Simpson O O
- O O
Angus O O
Scale O O
) O O
treated O O
with O O
chlorpromazine O O
after O O
8 O O
weeks O O
. O O

The O O
alleles O O
of O O
all O O
loci O O
were O O
determined O O
by O O
PCR O O
( O O
polymerase O O
chain O O
reaction O O
) O O
. O O

RESULTS O O
: O O
Polymorphisms O O
TaqID O O
, O O
Ser311Cys O O
and O O
rs6277 O O
were O O
not O O
polymorphic O O
in O O
the O O
population O O
recruited O O
in O O
the O O
present O O
study O O
. O O

No O O
statistical O O
significance O O
was O O
found O O
in O O
the O O
allele O O
distribution O O
of O O
-141Cins O O
> O O
del O O
, O O
TaqIB O O
, O O
rs6275 O O
and O O
TaqIA O O
or O O
in O O
the O O
estimated O O
haplotypes O O
( O O
constituted O O
by O O
TaqIB O O
, O O
rs6275 O O
and O O
TaqIA O O
) O O
in O O
linkage O O
disequilibrium O O
between O O
the O O
two O O
groups O O
. O O

CONCLUSION O O
: O O
Our O O
results O O
did O O
not O O
lend O O
strong O O
support O O
to O O
the O O
view O O
that O O
the O O
genetic O O
variation O O
of O O
the O O
DRD2 O O
gene O O
plays O O
a O O
major O O
role O O
in O O
the O O
individually O O
variable O O
adverse O O
effect O O
induced O O
by O O
chlorpromazine O O
, O O
at O O
least O O
in O O
Chinese O O
patients O O
with O O
schizophrenia B-Disease B-Disease
. O O

Our O O
results O O
confirmed O O
a O O
previous O O
study O O
on O O
the O O
relationship O O
between O O
DRD2 O O
and O O
EPS B-Disease B-Disease
in O O
Caucasians O O
. O O

Physical O O
training O O
decreases O O
susceptibility O O
to O O
subsequent O O
pilocarpine O O
- O O
induced O O
seizures B-Disease B-Disease
in O O
the O O
rat O O
. O O

Regular O O
motor O O
activity O O
has O O
many O O
benefits O O
for O O
mental O O
and O O
physical O O
condition O O
but O O
its O O
implications O O
for O O
epilepsy B-Disease B-Disease
are O O
still O O
controversial O O
. O O

In O O
order O O
to O O
elucidate O O
this O O
problem O O
, O O
we O O
have O O
studied O O
the O O
effect O O
of O O
long O O
- O O
term O O
physical O O
activity O O
on O O
susceptibility O O
to O O
subsequent O O
seizures B-Disease B-Disease
. O O

Male O O
Wistar O O
rats O O
were O O
subjected O O
to O O
repeated O O
training O O
sessions O O
in O O
a O O
treadmill O O
and O O
swimming O O
pool O O
. O O

Thereafter O O
, O O
seizures B-Disease B-Disease
were O O
induced O O
by O O
pilocarpine O O
injections O O
in O O
trained O O
and O O
non O O
- O O
trained O O
control O O
groups O O
. O O

During O O
the O O
acute O O
period O O
of O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
, O O
we O O
measured O O
: O O
( O O
1 O O
) O O
the O O
latency O O
of O O
the O O
first O O
motor O O
sign O O
, O O
( O O
2 O O
) O O
the O O
intensity O O
of O O
seizures B-Disease B-Disease
, O O
( O O
3 O O
) O O
the O O
time O O
when O O
it O O
occurred O O
within O O
the O O
6-h O O
observation O O
period O O
, O O
and O O
( O O
4 O O
) O O
the O O
time O O
when O O
the O O
acute O O
period O O
ended O O
. O O

All O O
these O O
behavioral O O
parameters O O
showed O O
statistically O O
significant O O
changes O O
suggesting O O
that O O
regular O O
physical O O
exercises O O
decrease O O
susceptibility O O
to O O
subsequently O O
induced O O
seizures B-Disease B-Disease
and O O
ameliorate O O
the O O
course O O
of O O
experimentally O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

Tonic O O
dopaminergic O O
stimulation O O
impairs B-Disease B-Disease
associative I-Disease I-Disease
learning I-Disease I-Disease
in O O
healthy O O
subjects O O
. O O

Endogenous O O
dopamine O O
plays O O
a O O
central O O
role O O
in O O
salience O O
coding O O
during O O
associative O O
learning O O
. O O

Administration O O
of O O
the O O
dopamine O O
precursor O O
levodopa O O
enhances O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke B-Disease B-Disease
patients O O
. O O

Because O O
levodopa O O
increases O O
both O O
phasic O O
and O O
tonic O O
dopaminergic O O
neurotransmission O O
, O O
the O O
critical O O
mechanism O O
mediating O O
the O O
enhancement O O
of O O
learning O O
is O O
unresolved O O
. O O

We O O
here O O
probed O O
how O O
selective O O
tonic O O
dopaminergic O O
stimulation O O
affects O O
associative O O
learning O O
. O O

Forty O O
healthy O O
subjects O O
were O O
trained O O
in O O
a O O
novel O O
vocabulary O O
of O O
45 O O
concrete O O
nouns O O
over O O
the O O
course O O
of O O
5 O O
consecutive O O
training O O
days O O
in O O
a O O
prospective O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
design O O
. O O

Subjects O O
received O O
the O O
tonically O O
stimulating O O
dopamine O O
- O O
receptor O O
agonist O O
pergolide O O
( O O
0.1 O O
mg O O
) O O
vs O O
placebo O O
120 O O
min O O
before O O
training O O
on O O
each O O
training O O
day O O
. O O

The O O
dopamine O O
agonist O O
significantly O O
impaired B-Disease B-Disease
novel I-Disease I-Disease
word I-Disease I-Disease
learning I-Disease I-Disease
compared O O
to O O
placebo O O
. O O

This O O
learning O O
decrement O O
persisted O O
up O O
to O O
the O O
last O O
follow O O
- O O
up O O
4 O O
weeks O O
post O O
- O O
training O O
. O O

Subjects O O
treated O O
with O O
pergolide O O
also O O
showed O O
restricted O O
emotional O O
responses O O
compared O O
to O O
the O O
PLACEBO O O
group O O
. O O

The O O
extent O O
of O O
' O O
flattened O O
' O O
affect O O
with O O
pergolide O O
was O O
related O O
to O O
the O O
degree O O
of O O
learning O O
inhibition O O
. O O

These O O
findings O O
suggest O O
that O O
tonic O O
occupation O O
of O O
dopamine O O
receptors O O
impairs O O
learning O O
by O O
competition O O
with O O
phasic O O
dopamine O O
signals O O
. O O

Thus O O
, O O
phasic O O
signaling O O
seems O O
to O O
be O O
the O O
critical O O
mechanism O O
by O O
which O O
dopamine O O
enhances O O
associative O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke B-Disease B-Disease
patients O O
. O O

Minocycline O O
- O O
induced O O
vasculitis B-Disease B-Disease
fulfilling O O
the O O
criteria O O
of O O
polyarteritis B-Disease B-Disease
nodosa I-Disease I-Disease
. O O

A O O
47-year O O
- O O
old O O
man O O
who O O
had O O
been O O
taking O O
minocycline O O
for O O
palmoplantar B-Disease B-Disease
pustulosis I-Disease I-Disease
developed O O
fever B-Disease B-Disease
, O O
myalgias B-Disease B-Disease
, O O
polyneuropathy B-Disease B-Disease
, O O
and O O
testicular B-Disease B-Disease
pain I-Disease I-Disease
, O O
with O O
elevated O O
C O O
- O O
reactive O O
protein O O
( O O
CRP O O
) O O
. O O

Neither O O
myeloperoxidase- O O
nor O O
proteinase-3-antineutrophil O O
cytoplasmic O O
antibody O O
was O O
positive O O
. O O

These O O
manifestations O O
met O O
the O O
American O O
College O O
of O O
Rheumatology O O
1990 O O
criteria O O
for O O
the O O
classification O O
of O O
polyarteritis B-Disease B-Disease
nodosa I-Disease I-Disease
. O O

Stopping O O
minocycline O O
led O O
to O O
amelioration O O
of O O
symptoms O O
and O O
normalization O O
of O O
CRP O O
level O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
second O O
case O O
of O O
minocycline O O
- O O
induced O O
vasculitis B-Disease B-Disease
satisfying O O
the O O
criteria O O
. O O

Differential O O
diagnosis O O
for O O
drug O O
- O O
induced O O
disease O O
is O O
invaluable O O
even O O
for O O
patients O O
with O O
classical O O
polyarteritis B-Disease B-Disease
nodosa I-Disease I-Disease
. O O

Intramuscular O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
immune O O
globulin O O
combined O O
with O O
lamivudine O O
in O O
prevention O O
of O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
recurrence O O
after O O
liver O O
transplantation O O
. O O

BACKGROUND O O
: O O
Combined O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
immune O O
globulin O O
( O O
HBIg O O
) O O
and O O
lamivudine O O
in O O
prophylaxis O O
of O O
the O O
recurrence O O
of O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
after O O
liver O O
transplantation O O
has O O
significantly O O
improved O O
the O O
survival O O
of O O
HBsAg O O
positive O O
patients O O
. O O

This O O
study O O
was O O
undertaken O O
to O O
evaluate O O
the O O
outcomes O O
of O O
liver O O
transplantation O O
for O O
patients O O
with O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
virus O O
( O O
HBV O O
) O O
. O O

METHODS O O
: O O
A O O
retrospective O O
chart O O
analysis O O
and O O
a O O
review O O
of O O
the O O
organ O O
transplant O O
database O O
identified O O
51 O O
patients O O
( O O
43 O O
men O O
and O O
8 O O
women O O
) O O
transplanted O O
for O O
benign O O
HBV O O
- O O
related O O
cirrhotic B-Disease B-Disease
diseases I-Disease I-Disease
between O O
June O O
2002 O O
and O O
December O O
2004 O O
who O O
had O O
survived O O
more O O
than O O
3 O O
months O O
. O O

HBIg O O
was O O
administered O O
intravenously O O
during O O
the O O
first O O
week O O
and O O
intramuscularly O O
thereafter O O
. O O

RESULTS O O
: O O
At O O
a O O
median O O
follow O O
- O O
up O O
of O O
14.1 O O
months O O
, O O
the O O
overall O O
recurrence O O
rate O O
in O O
the O O
51 O O
patients O O
was O O
3.9 O O
% O O
( O O
2 O O
/ O O
51 O O
) O O
. O O

The O O
overall O O
patient O O
survival O O
was O O
88.3 O O
% O O
, O O
and O O
82.4 O O
% O O
after O O
1 O O
and O O
2 O O
years O O
, O O
respectively O O
. O O

A O O
daily O O
oral O O
dose O O
of O O
100 O O
mg O O
lamivudine O O
for O O
2 O O
weeks O O
before O O
transplantation O O
for O O
10 O O
patients O O
enabled O O
57.1 O O
% O O
( O O
4 O O
/ O O
7 O O
) O O
and O O
62.5 O O
% O O
( O O
5 O O
/ O O
8 O O
) O O
of O O
HBV O O
- O O
DNA O O
and O O
HBeAg O O
positive O O
patients O O
respectively O O
to O O
convert O O
to O O
be O O
negative O O
. O O

Intramuscular O O
HBIg O O
was O O
well O O
tolerated O O
in O O
all O O
patients O O
. O O

CONCLUSION O O
: O O
Lamivudine O O
combined O O
with O O
intramuscular O O
HBIg O O
can O O
effectively O O
prevent O O
allograft O O
from O O
the O O
recurrence O O
of O O
HBV O O
after O O
liver O O
transplantation O O
. O O

Anticonvulsant O O
effect O O
of O O
eslicarbazepine O O
acetate O O
( O O
BIA O O
2 O O
- O O
093 O O
) O O
on O O
seizures B-Disease B-Disease
induced O O
by O O
microperfusion O O
of O O
picrotoxin O O
in O O
the O O
hippocampus O O
of O O
freely O O
moving O O
rats O O
. O O

Eslicarbazepine O O
acetate O O
( O O
BIA O O
2 O O
- O O
093 O O
, O O
S- O O
( O O
- O O
) O O
-10-acetoxy-10,11-dihydro-5H O O
- O O
dibenzo O O
/ O O
b O O
, O O
f O O
/ O O
azepine-5-carboxamide O O
) O O
is O O
a O O
novel O O
antiepileptic O O
drug O O
, O O
now O O
in O O
Phase O O
III O O
clinical O O
trials O O
, O O
designed O O
with O O
the O O
aim O O
of O O
improving O O
efficacy O O
and O O
safety O O
in O O
comparison O O
with O O
the O O
structurally O O
related O O
drugs O O
carbamazepine O O
( O O
CBZ O O
) O O
and O O
oxcarbazepine O O
( O O
OXC O O
) O O
. O O

We O O
have O O
studied O O
the O O
effects O O
of O O
oral O O
treatment O O
with O O
eslicarbazepine O O
acetate O O
on O O
a O O
whole O O
- O O
animal O O
model O O
in O O
which O O
partial O O
seizures B-Disease B-Disease
can O O
be O O
elicited O O
repeatedly O O
on O O
different O O
days O O
without O O
changes O O
in O O
threshold O O
or O O
seizure B-Disease B-Disease
patterns O O
. O O

In O O
the O O
animals O O
treated O O
with O O
threshold O O
doses O O
of O O
picrotoxin O O
, O O
the O O
average O O
number O O
of O O
seizures B-Disease B-Disease
was O O
2.3+ O O
/ O O
-1.2 O O
, O O
and O O
average O O
seizure B-Disease B-Disease
duration O O
was O O
39.5+ O O
/ O O
-8.4s O O
. O O

Pre O O
- O O
treatment O O
with O O
a O O
dose O O
of O O
30 O O
mg O O
/ O O
kg O O
2h O O
before O O
picrotoxin O O
microperfusion O O
prevented O O
seizures B-Disease B-Disease
in O O
the O O
75 O O
% O O
of O O
the O O
rats O O
. O O

Lower O O
doses O O
( O O
3 O O
and O O
10mg O O
/ O O
kg O O
) O O
did O O
not O O
suppress O O
seizures B-Disease B-Disease
, O O
however O O
, O O
after O O
administration O O
of O O
10mg O O
/ O O
kg O O
, O O
significant O O
reductions O O
in O O
seizures B-Disease B-Disease
duration O O
( O O
24.3+ O O
/ O O
-6.8s O O
) O O
and O O
seizure B-Disease B-Disease
number O O
( O O
1.6+ O O
/ O O
-0.34 O O
) O O
were O O
found O O
. O O

No O O
adverse O O
effects O O
of O O
eslicarbazepine O O
acetate O O
were O O
observed O O
in O O
the O O
behavioral O O
/ O O
EEG O O
patterns O O
studied O O
, O O
including O O
sleep O O
/ O O
wakefulness O O
cycle O O
, O O
at O O
the O O
doses O O
studied O O
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
associated O O
with O O
prolonged O O
intake O O
of O O
slimming O O
pills O O
containing O O
anthraquinones O O
. O O

Chinese O O
herbal O O
medicine O O
preparations O O
are O O
widely O O
available O O
and O O
often O O
regarded O O
by O O
the O O
public O O
as O O
natural O O
and O O
safe O O
remedies O O
for O O
a O O
variety O O
of O O
medical O O
conditions O O
. O O

Nephropathy B-Disease B-Disease
caused O O
by O O
Chinese O O
herbs O O
has O O
previously O O
been O O
reported O O
, O O
usually O O
involving O O
the O O
use O O
of O O
aristolochic O O
acids O O
. O O

We O O
report O O
a O O
23-year O O
- O O
old O O
woman O O
who O O
developed O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
following O O
prolonged O O
use O O
of O O
a O O
proprietary O O
Chinese O O
herbal O O
slimming O O
pill O O
that O O
contained O O
anthraquinone O O
derivatives O O
, O O
extracted O O
from O O
Rhizoma O O
Rhei O O
( O O
rhubarb O O
) O O
. O O

The O O
renal B-Disease B-Disease
injury I-Disease I-Disease
was O O
probably O O
aggravated O O
by O O
the O O
concomitant O O
intake O O
of O O
a O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drug O O
, O O
diclofenac O O
. O O

Renal O O
pathology O O
was O O
that O O
of O O
hypocellular O O
interstitial O O
fibrosis B-Disease B-Disease
. O O

Spontaneous O O
renal O O
recovery O O
occurred O O
upon O O
cessation O O
of O O
the O O
slimming O O
pills O O
, O O
but O O
mild O O
interstitial O O
fibrosis B-Disease B-Disease
and O O
tubular O O
atrophy B-Disease B-Disease
was O O
still O O
evident O O
histologically O O
4 O O
months O O
later O O
. O O

Although O O
a O O
causal O O
relationship O O
between O O
the O O
use O O
of O O
an O O
anthraquinone O O
- O O
containing O O
herbal O O
agent O O
and O O
renal B-Disease B-Disease
injury I-Disease I-Disease
remains O O
to O O
be O O
proven O O
, O O
phytotherapy O O
- O O
associated O O
interstitial O B-Disease
nephropathy B-Disease I-Disease
should O O
be O O
considered O O
in O O
patients O O
who O O
present O O
with O O
unexplained O O
renal B-Disease B-Disease
failure I-Disease I-Disease
. O O

Chloroacetaldehyde O O
as O O
a O O
sulfhydryl O O
reagent O O
: O O
the O O
role O O
of O O
critical O O
thiol O O
groups O O
in O O
ifosfamide O O
nephropathy B-Disease B-Disease
. O O

Chloroacetaldehyde O O
( O O
CAA O O
) O O
is O O
a O O
metabolite O O
of O O
the O O
alkylating O O
agent O O
ifosfamide O O
( O O
IFO O O
) O O
and O O
putatively O O
responsible O O
for O O
renal B-Disease B-Disease
damage I-Disease I-Disease
following O O
anti O O
- O O
tumor B-Disease B-Disease
therapy O O
with O O
IFO O O
. O O

Depletion O O
of O O
sulfhydryl O O
( O O
SH O O
) O O
groups O O
has O O
been O O
reported O O
from O O
cell O O
culture O O
, O O
animal O O
and O O
clinical O O
studies O O
. O O

In O O
this O O
work O O
the O O
effect O O
of O O
CAA O O
on O O
human O O
proximal O O
tubule O O
cells O O
in O O
primary O O
culture O O
( O O
hRPTEC O O
) O O
was O O
investigated O O
. O O

Toxicity B-Disease B-Disease
of O O
CAA O O
was O O
determined O O
by O O
protein O O
content O O
, O O
cell O O
number O O
, O O
LDH O O
release O O
, O O
trypan O O
blue O O
exclusion O O
assay O O
and O O
caspase-3 O O
activity O O
. O O

Free O O
thiols O O
were O O
measured O O
by O O
the O O
method O O
of O O
Ellman O O
. O O

CAA O O
reduced O O
hRPTEC O O
cell O O
number O O
and O O
protein O O
, O O
induced O O
a O O
loss O O
in O O
free O O
intracellular O O
thiols O O
and O O
an O O
increase O O
in O O
necrosis B-Disease B-Disease
markers O O
. O O

CAA O O
but O O
not O O
acrolein O O
inhibited O O
the O O
cysteine O O
proteases O O
caspase-3 O O
, O O
caspase-8 O O
and O O
cathepsin O O
B. O O
Caspase O O
activation O O
by O O
cisplatin O O
was O O
inhibited O O
by O O
CAA O O
. O O

In O O
cells O O
stained O O
with O O
fluorescent O O
dyes O O
targeting O O
lysosomes O O
, O O
CAA O O
induced O O
an O O
increase O O
in O O
lysosomal O O
size O O
and O O
lysosomal O O
leakage O O
. O O

The O O
effects O O
of O O
CAA O O
on O O
cysteine O O
protease O O
activities O O
and O O
thiols O O
could O O
be O O
reproduced O O
in O O
cell O O
lysate O O
. O O

Acidification O O
, O O
which O O
slowed O O
the O O
reaction O O
of O O
CAA O O
with O O
thiol O O
donors O O
, O O
could O O
also O O
attenuate O O
effects O O
of O O
CAA O O
on O O
necrosis B-Disease B-Disease
markers O O
, O O
thiol O O
depletion O O
and O O
cysteine O O
protease O O
inhibition O O
in O O
living O O
cells O O
. O O

Thus O O
, O O
CAA O O
directly O O
reacts O O
with O O
cellular O O
protein O O
and O O
non O O
- O O
protein O O
thiols O O
, O O
mediating O O
its O O
toxicity B-Disease O
on O O
hRPTEC O O
. O O

This O O
effect O O
can O O
be O O
reduced O O
by O O
acidification O O
. O O

Therefore O O
, O O
urinary O O
acidification O O
could O O
be O O
an O O
option O O
to O O
prevent O O
IFO O O
nephropathy B-Disease B-Disease
in O O
patients O O
. O O

Stereological O O
methods O O
reveal O O
the O O
robust O O
size O O
and O O
stability O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
after O O
pilocarpine O O
- O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
in O O
the O O
adult O O
rat O O
. O O

Following O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
in O O
the O O
rat O O
, O O
dentate O O
granule O O
cell O O
neurogenesis O O
increases O O
greatly O O
, O O
and O O
many O O
of O O
the O O
new O O
neurons O O
appear O O
to O O
develop O O
ectopically O O
, O O
in O O
the O O
hilar O O
region O O
of O O
the O O
hippocampal O O
formation O O
. O O

It O O
has O O
been O O
suggested O O
that O O
the O O
ectopic O O
hilar O O
granule O O
cells O O
could O O
contribute O O
to O O
the O O
spontaneous O O
seizures B-Disease B-Disease
that O O
ultimately O O
develop O O
after O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

However O O
, O O
the O O
population O O
has O O
never O O
been O O
quantified O O
, O O
so O O
it O O
is O O
unclear O O
whether O O
it O O
is O O
substantial O O
enough O O
to O O
have O O
a O O
strong O O
influence O O
on O O
epileptogenesis O O
. O O

To O O
quantify O O
this O O
population O O
, O O
the O O
total O O
number O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
was O O
estimated O O
using O O
unbiased O O
stereology O O
at O O
different O O
times O O
after O O
pilocarpine O O
- O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

The O O
number O O
of O O
hilar O O
neurons O O
immunoreactive O O
for O O
Prox-1 O O
, O O
a O O
granule O O
- O O
cell O O
- O O
specific O O
marker O O
, O O
was O O
estimated O O
using O O
the O O
optical O O
fractionator O O
method O O
. O O

The O O
results O O
indicate O O
that O O
the O O
size O O
of O O
the O O
hilar O O
ectopic O O
granule O O
cell O O
population O O
after O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
is O O
substantial O O
, O O
and O O
stable O O
over O O
time O O
. O O

Interestingly O O
, O O
the O O
size O O
of O O
the O O
population O O
appears O O
to O O
be O O
correlated O O
with O O
the O O
frequency O O
of O O
behavioral O O
seizures B-Disease B-Disease
, O O
because O O
animals O O
with O O
more O O
ectopic O O
granule O O
cells O O
in O O
the O O
hilus O O
have O O
more O O
frequent O O
behavioral O O
seizures B-Disease B-Disease
. O O

The O O
hilar O O
ectopic O O
granule O O
cell O O
population O O
does O O
not O O
appear O O
to O O
vary O O
systematically O O
across O O
the O O
septotemporal O O
axis O O
, O O
although O O
it O O
is O O
associated O O
with O O
an O O
increase O O
in O O
volume O O
of O O
the O O
hilus O O
. O O

The O O
results O O
provide O O
new O O
insight O O
into O O
the O O
potential O O
role O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
in O O
the O O
pilocarpine O O
model O O
of O O
temporal B-Disease B-Disease
lobe I-Disease I-Disease
epilepsy I-Disease I-Disease
. O O

A O O
prospective O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine O O
in O O
autistic B-Disease B-Disease
disorder I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
Post O O
- O O
mortem O O
studies O O
have O O
reported O O
abnormalities O O
of O O
the O O
cholinergic O O
system O O
in O O
autism B-Disease B-Disease
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
assess O O
the O O
use O O
of O O
galantamine O O
, O O
an O O
acetylcholinesterase O O
inhibitor O O
and O O
nicotinic O O
receptor O O
modulator O O
, O O
in O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism B-Disease B-Disease
. O O

METHODS O O
: O O
Thirteen O O
medication O O
- O O
free O O
children O O
with O O
autism B-Disease B-Disease
( O O
mean O O
age O O
, O O
8.8 O O
+ O O
/- O O

3.5 O O
years O O
) O O
participated O O
in O O
a O O
12-week O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine O O
. O O

Patients O O
were O O
rated O O
monthly O O
by O O
parents O O
on O O
the O O
Aberrant O O
Behavior O O
Checklist O O
( O O
ABC O O
) O O
and O O
the O O
Conners O O
' O O
Parent O O
Rating O O
Scale O O
- O O
Revised O O
, O O
and O O
by O O
a O O
physician O O
using O O
the O O
Children O O
's O O
Psychiatric O O
Rating O O
Scale O O
and O O
the O O
Clinical O O
Global O O
Impressions O O
scale O O
. O O

RESULTS O O
: O O
Patients O O
showed O O
a O O
significant O O
reduction O O
in O O
parent O O
- O O
rated O O
irritability B-Disease B-Disease
and O O
social O O
withdrawal O O
on O O
the O O
ABC O O
as O O
well O O
as O O
significant O O
improvements O O
in O O
emotional O O
lability O O
and O O
inattention O B-Disease
on O O
the O O
Conners O O
' O O
Parent O O
Rating O O
Scale O O
-- O O
Revised O O
. O O

Similarly O O
, O O
clinician O O
ratings O O
showed O O
reductions O O
in O O
the O O
anger O O
subscale O O
of O O
the O O
Children O O
's O O
Psychiatric O O
Rating O O
Scale O O
. O O

Eight O O
of O O
13 O O
participants O O
were O O
rated O O
as O O
responders O O
on O O
the O O
basis O O
of O O
their O O
improvement O O
scores O O
on O O
the O O
Clinical O O
Global O O
Impressions O O
scale O O
. O O

Overall O O
, O O
galantamine O O
was O O
well O O
- O O
tolerated O O
, O O
with O O
no O O
significant O O
adverse O O
effects O O
apart O O
from O O
headaches B-Disease B-Disease
in O O
one O O
patient O O
. O O

CONCLUSION O O
: O O
In O O
this O O
open O O
trial O O
, O O
galantamine O O
was O O
well O O
- O O
tolerated O O
and O O
appeared O O
to O O
be O O
beneficial O O
for O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism B-Disease B-Disease
, O O
particularly O O
aggression B-Disease B-Disease
, O O
behavioral B-Disease B-Disease
dyscontrol I-Disease I-Disease
, O O
and O O
inattention B-Disease B-Disease
. O O

Further O O
controlled O O
trials O O
are O O
warranted O O
. O O

Randomized O O
comparison O O
of O O
olanzapine O O
versus O O
risperidone O O
for O O
the O O
treatment O O
of O O
first O O
- O O
episode O O
schizophrenia B-Disease B-Disease
: O O
4-month O O
outcomes O O
. O O

OBJECTIVE O O
: O O
The O O
authors O O
compared O O
4-month O O
treatment O O
outcomes O O
for O O
olanzapine O O
versus O O
risperidone O O
in O O
patients O O
with O O
first O O
- O O
episode O O
schizophrenia B-Disease B-Disease
spectrum O O
disorders O O
. O O

METHOD O O
: O O
One O O
hundred O O
twelve O O
subjects O O
( O O
70 O O
% O O
male O O
; O O
mean O O
age=23.3 O O
years O O
[ O O
SD O O
= O O
5.1 O O
] O O
) O O
with O O
first O O
- O O
episode O O
schizophrenia B-Disease B-Disease
( O O
75 O O
% O O
) O O
, O O
schizophreniform B-Disease B-Disease
disorder I-Disease I-Disease
( O O
17 O O
% O O
) O O
, O O
or O O
schizoaffective B-Disease B-Disease
disorder I-Disease I-Disease
( O O
8 O O
% O O
) O O
were O O
randomly O O
assigned O O
to O O
treatment O O
with O O
olanzapine O O
( O O
2.5 O O
- O O
20 O O
mg O O
/ O O
day O O
) O O
or O O
risperidone O O
( O O
1 O O
- O O
6 O O
mg O O
/ O O
day O O
) O O
. O O

RESULTS O O
: O O
Response O O
rates O O
did O O
not O O
significantly O O
differ O O
between O O
olanzapine O O
( O O
43.7 O O
% O O
, O O
95 O O
% O O
CI=28.8%-58.6 O O
% O O
) O O
and O O
risperidone O O
( O O
54.3 O O
% O O
, O O
95 O O
% O O
CI=39.9%-68.7 O O
% O O
) O O
. O O

Among O O
those O O
responding O O
to O O
treatment O O
, O O
more O O
subjects O O
in O O
the O O
olanzapine O O
group O O
( O O
40.9 O O
% O O
, O O
95 O O
% O O
CI=16.8%-65.0 O O
% O O
) O O
than O O
in O O
the O O
risperidone O O
group O O
( O O
18.9 O O
% O O
, O O
95 O O
% O O
CI=0%-39.2 O O
% O O
) O O
had O O
subsequent O O
ratings O O
not O O
meeting O O
response O O
criteria O O
. O O

Negative O O
symptom O O
outcomes O O
and O O
measures O O
of O O
parkinsonism B-Disease B-Disease
and O O
akathisia B-Disease B-Disease
did O O
not O O
differ O O
between O O
medications O O
. O O

Extrapyramidal B-Disease B-Disease
symptom I-Disease I-Disease
severity O O
scores O O
were O O
1.4 O O
( O O
95 O O
% O O
CI=1.2 O O
- O O
1.6 O O
) O O
with O O
risperidone O O
and O O
1.2 O O
( O O
95 O O
% O O
CI=1.0 O O
- O O
1.4 O O
) O O
with O O
olanzapine O O
. O O

Significantly O O
more O O
weight B-Disease B-Disease
gain I-Disease I-Disease
occurred O O
with O O
olanzapine O O
than O O
with O O
risperidone O O
: O O
the O O
increase O O
in O O
weight O O
at O O
4 O O
months O O
relative O O
to O O
baseline O O
weight O O
was O O
17.3 O O
% O O
( O O
95 O O
% O O
CI=14.2%-20.5 O O
% O O
) O O
with O O
olanzapine O O
and O O
11.3 O O
% O O
( O O
95 O O
% O O
CI=8.4%-14.3 O O
% O O
) O O
with O O
risperidone O O
. O O

Body O O
mass O O
index O O
at O O
baseline O O
and O O
at O O
4 O O
months O O
was O O
24.3 O O
( O O
95 O O
% O O
CI=22.8 O O
- O O
25.7 O O
) O O
versus O O
28.2 O O
( O O
95 O O
% O O
CI=26.7 O O
- O O
29.7 O O
) O O
with O O
olanzapine O O
and O O
23.9 O O
( O O
95 O O
% O O
CI=22.5 O O
- O O
25.3 O O
) O O
versus O O
26.7 O O
( O O
95 O O
% O O
CI=25.2 O O
- O O
28.2 O O
) O O
with O O
risperidone O O
. O O

CONCLUSIONS O O
: O O
Clinical O O
outcomes O O
with O O
risperidone O O
were O O
equal O O
to O O
those O O
with O O
olanzapine O O
, O O
and O O
response O O
may O O
be O O
more O O
stable O O
. O O

Olanzapine O O
may O O
have O O
an O O
advantage O O
for O O
motor O O
side O O
effects O O
. O O

Both O O
medications O O
caused O O
substantial O O
rapid O O
weight B-Disease O
gain I-Disease O
, O O
but O O
weight B-Disease B-Disease
gain I-Disease I-Disease
was O O
greater O O
with O O
olanzapine O O
. O O

Early O O
paracentral O O
visual B-Disease B-Disease
field I-Disease I-Disease
loss I-Disease I-Disease
in O O
patients O O
taking O O
hydroxychloroquine O O
. O O

OBJECTIVE O O
: O O
To O O
review O O
the O O
natural O O
history O O
and O O
ocular O O
and O O
systemic O O
adverse O O
effects O O
of O O
patients O O
taking O O
hydroxychloroquine O O
sulfate O O
who O O
attended O O
an O O
ophthalmic O O
screening O O
program O O
. O O

DESIGN O O
: O O
Retrospective O O
study O O
. O O

RESULTS O O
: O O
Records O O
of O O
262 O O
patients O O
who O O
were O O
taking O O
hydroxychloroquine O O
and O O
screened O O
in O O
the O O
Department O O
of O O
Ophthalmology O O
were O O
reviewed O O
. O O

Of O O
the O O
262 O O
patients O O
, O O
14 O O
( O O
18 O O
% O O
) O O
of O O
76 O O
who O O
had O O
stopped O O
treatment O O
at O O
the O O
time O O
of O O
the O O
study O O
experienced O O
documented O O
adverse O O
effects O O
. O O

Systemic O O
adverse O O
effects O O
occurred O O
in O O
8 O O
patients O O
( O O
10.5 O O
% O O
) O O
and O O
ocular O O
adverse O O
effects O O
, O O
in O O
5 O O
( O O
6.5 O O
% O O
) O O
. O O

Thirty O O
- O O
five O O
patients O O
( O O
13.4 O O
% O O
) O O
had O O
visual B-Disease B-Disease
field I-Disease I-Disease
abnormalities I-Disease I-Disease
, O O
which O O
were O O
attributed O O
to O O
hydroxychloroquine O O
treatment O O
in O O
4 O O
patients O O
( O O
1.5 O O
% O O
) O O
. O O

Three O O
of O O
the O O
4 O O
patients O O
were O O
taking O O
less O O
than O O
6.5 O O
mg O O
/ O O
kg O O
per O O
day O O
and O O
all O O
patients O O
had O O
normal O O
renal O O
and O O
liver O O
function O O
test O O
results O O
. O O

CONCLUSIONS O O
: O O
The O O
current O O
study O O
used O O
a O O
protocol O O
of O O
visual O O
acuity O O
and O O
color O O
vision O O
assessment O O
, O O
funduscopy O O
, O O
and O O
Humphrey O O
10 O O
- O O
2 O O
visual O O
field O O
testing O O
and O O
shows O O
that O O
visual B-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
appeared O O
before O O
any O O
corresponding O O
changes O O
in O O
any O O
other O O
tested O O
clinical O O
parameters O O
; O O
the O O
defects O O
were O O
reproducible O O
and O O
the O O
test O O
parameters O O
were O O
reliable O O
. O O

Patients O O
taking O O
hydroxychloroquine O O
can O O
demonstrate O O
a O O
toxic O O
reaction O O
in O O
the O O
retina O O
despite O O
the O O
absence O O
of O O
known O O
risk O O
factors O O
. O O

Screening O O
, O O
including O O
Humphrey O O
10 O O
- O O
2 O O
visual O O
field O O
assessment O O
, O O
is O O
recommended O O
2 O O
years O O
after O O
the O O
initial O O
baseline O O
and O O
yearly O O
thereafter O O
. O O

Peri O O
- O O
operative O O
atrioventricular B-Disease B-Disease
block I-Disease I-Disease
as O O
a O O
result O O
of O O
chemotherapy O O
with O O
epirubicin O O
and O O
paclitaxel O O
. O O

A O O
47-year O O
- O O
old O O
woman O O
presented O O
for O O
mastectomy O O
and O O
immediate O O
latissimus O O
dorsi O O
flap O O
reconstruction O O
having O O
been O O
diagnosed O O
with O O
carcinoma B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
breast I-Disease I-Disease
6 O O
months O O
previously O O
. O O

In O O
the O O
preceding O O
months O O
she O O
had O O
received O O
neo O O
- O O
adjuvant O O
chemotherapy O O
with O O
epirubicin O O
, O O
paclitaxel O O
( O O
Taxol O O
) O O
and O O
cyclophosphamide O O
. O O

This O O
had O O
been O O
apparently O O
uncomplicated O O
and O O
she O O
had O O
maintained O O
a O O
remarkably O O
high O O
level O O
of O O
physical O O
activity O O
. O O

She O O
was O O
found O O
to O O
be O O
bradycardic B-Disease B-Disease
at O O
pre O O
- O O
operative O O
assessment O O
but O O
had O O
no O O
cardiac O B-Disease
symptoms O I-Disease
. O O

Second O O
degree O O
Mobitz O O
type O O
II O O
atrioventricular B-Disease B-Disease
block I-Disease I-Disease
was O O
diagnosed O O
on O O
electrocardiogram O O
, O O
and O O
temporary O O
transvenous O O
ventricular O O
pacing O O
instituted O O
in O O
the O O
peri O O
- O O
operative O O
period O O
. O O

We O O
discuss O O
how O O
evidence O O
- O O
based O O
guidelines O O
would O O
not O O
have O O
been O O
helpful O O
in O O
this O O
case O O
, O O
and O O
how O O
chemotherapy O O
can O O
exhibit O O
substantial O O
cardiotoxicity B-Disease B-Disease
that O O
may O O
develop O O
over O O
many O O
years O O
. O O

We O O
suggest O O
that O O
patients O O
who O O
have O O
received O O
chemotherapy O O
at O O
any O O
time O O
should O O
have O O
a O O
pre O O
- O O
operative O O
electrocardiogram O O
even O O
if O O
they O O
are O O
asymptomatic O O
. O O

Risks O O
and O O
benefits O O
of O O
COX-2 O O
inhibitors O O
vs O O
non O O
- O O
selective O O
NSAIDs O O
: O O
does O O
their O O
cardiovascular O O
risk O O
exceed O O
their O O
gastrointestinal O O
benefit O O
? O O

A O O
retrospective O O
cohort O O
study O O
. O O

OBJECTIVES O O
: O O
The O O
risk O O
of O O
acute B-Disease O
myocardial I-Disease B-Disease
infarction I-Disease I-Disease
( O O
AMI B-Disease B-Disease
) O O
with O O
COX-2 O O
inhibitors O O
may O O
offset O O
their O O
gastrointestinal O O
( O O
GI O O
) O O
benefit O O
compared O O
with O O
non O O
- O O
selective O O
( O O
NS O O
) O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
. O O

We O O
aimed O O
to O O
compare O O
the O O
risks O O
of O O
hospitalization O O
for O O
AMI B-Disease B-Disease
and O O
GI B-Disease B-Disease
bleeding I-Disease I-Disease
among O O
elderly O O
patients O O
using O O
COX-2 O O
inhibitors O O
, O O
NS O O
- O O
NSAIDs O O
and O O
acetaminophen O O
. O O

METHODS O O
: O O
We O O
conducted O O
a O O
retrospective O O
cohort O O
study O O
using O O
administrative O O
data O O
of O O
patients O O
> O O
or O O
= O O
65 O O
years O O
of O O
age O O
who O O
filled O O
a O O
prescription O O
for O O
NSAID O O
or O O
acetaminophen O O
during O O
1999 O O
- O O
2002 O O
. O O

Outcomes O O
were O O
compared O O
using O O
Cox O O
regression O O
models O O
with O O
time O O
- O O
dependent O O
exposures O O
. O O

RESULTS O O
: O O
Person O O
- O O
years O O
of O O
exposure O O
among O O
non O O
- O O
users O O
of O O
aspirin O O
were O O
: O O
75,761 O O
to O O
acetaminophen O O
, O O
42,671 O O
to O O
rofecoxib O O
65,860 O O
to O O
celecoxib O O
, O O
and O O
37,495 O O
to O O
NS O O
- O O
NSAIDs O O
. O O

Among O O
users O O
of O O
aspirin O O
, O O
they O O
were O O
: O O
14,671 O O
to O O
rofecoxib O O
, O O
22,875 O O
to O O
celecoxib O O
, O O
9,832 O O
to O O
NS O O
- O O
NSAIDs O O
and O O
38,048 O O
to O O
acetaminophen O O
. O O

Among O O
non O O
- O O
users O O
of O O
aspirin O O
, O O
the O O
adjusted O O
hazard O O
ratios O O
( O O
95 O O
% O O
confidence O O
interval O O
) O O
of O O
hospitalization O O
for O O
AMI B-Disease B-Disease
/ O O
GI O O
vs O O
the O O
acetaminophen O O
( O O
with O O
no O O
aspirin O O
) O O
group O O
were O O
: O O
rofecoxib O O
1.27 O O
( O O
1.13 O O
, O O
1.42 O O
) O O
, O O
celecoxib O O
0.93 O O
( O O
0.83 O O
, O O
1.03 O O
) O O
, O O
naproxen O O
1.59 O O
( O O
1.31 O O
, O O
1.93 O O
) O O
, O O
diclofenac O O
1.17 O O
( O O
0.99 O O
, O O
1.38 O O
) O O
and O O
ibuprofen O O
1.05 O O
( O O
0.74 O O
, O O
1.51 O O
) O O
. O O

Among O O
users O O
of O O
aspirin O O
, O O
they O O
were O O
: O O
rofecoxib O O
1.73 O O
( O O
1.52 O O
, O O
1.98 O O
) O O
, O O
celecoxib O O
1.34 O O
( O O
1.19 O O
, O O
1.52 O O
) O O
, O O
ibuprofen O O
1.51 O O
( O O
0.95 O O
, O O
2.41 O O
) O O
, O O
diclofenac O O
1.69 O O
( O O
1.35 O O
, O O
2.10 O O
) O O
, O O
naproxen O O
1.35 O O
( O O
0.97 O O
, O O
1.88 O O
) O O
and O O
acetaminophen O O
1.29 O O
( O O
1.17 O O
, O O
1.42 O O
) O O
. O O

CONCLUSION O O
: O O
Among O O
non O O
- O O
users O O
of O O
aspirin O O
, O O
naproxen O O
seemed O O
to O O
carry O O
the O O
highest O O
risk O O
for O O
AMI B-Disease B-Disease
/ O O
GI B-Disease B-Disease
bleeding I-Disease I-Disease
. O O

The O O
AMI B-Disease B-Disease
/ O O
GI O B-Disease
toxicity B-Disease I-Disease
of O O
celecoxib O O
was O O
similar O O
to O O
that O O
of O O
acetaminophen O O
and O O
seemed O O
to O O
be O O
better O O
than O O
those O O
of O O
rofecoxib O O
and O O
NS O O
- O O
NSAIDs O O
. O O

Among O O
users O O
of O O
aspirin O O
, O O
both O O
celecoxib O O
and O O
naproxen O O
seemed O O
to O O
be O O
the O O
least O O
toxic O O
. O O

Quinine O O
- O O
induced O O
arrhythmia B-Disease B-Disease
in O O
a O O
patient O O
with O O
severe B-Disease O
malaria I-Disease B-Disease
. O O

It O O
was O O
reported O O
that O O
there O O
was O O
a O O
case O O
of O O
severe B-Disease O
malaria I-Disease B-Disease
patient O O
with O O
jaundice B-Disease B-Disease
who O O
presented O O
with O O
arrhythmia B-Disease B-Disease
( O O
premature B-Disease B-Disease
ventricular I-Disease I-Disease
contraction I-Disease I-Disease
) O O
while O O
getting O O
quinine O O
infusion O O
was O O
reported O O
. O O

A O O
man O O
, O O
25 O O
years O O
old O O
, O O
was O O
admitted O O
to O O
hospital O O
with O O
high O O
fever B-Disease B-Disease
, O O
chill B-Disease B-Disease
, O O
vomiting B-Disease B-Disease
, O O
jaundice B-Disease B-Disease
. O O

The O O
patient O O
was O O
fully O O
conscious O O
, O O
blood O O
pressure O O
120 O O
/ O O
80 O O
mmHg O O
, O O
pulse O O
rate O O
100 O O
x O O
/ O O
minute O O
, O O
regular O O
. O O

On O O
admission O O
, O O
laboratory O O
examination O O
showed O O
Plasmodium O O
falciparum O O
( O O
+ O O
+ O O
+ O O
+ O O
) O O
, O O
total O O
bilirubin O O
8.25 O O
mg O O
/ O O
dL O O
, O O
conjugated O O
bilirubin O O
4.36 O O
mg O O
/ O O
dL O O
, O O
unconjugated O O
bilirubin O O
3.89 O O
mg O O
/ O O
dL O O
, O O
potassium O O
3.52 O O
meq O O
/ O O
L O O
Patient O O
was O O
diagnosed O O
as O O
severe B-Disease O
malaria I-Disease B-Disease
with O O
jaundice B-Disease B-Disease
and O O
got O O
quinine O O
infusion O O
in O O
dextrose O O
5 O O
% O O
500 O O
mg O O
/ O O
8 O O
hour O O
. O O

On O O
the O O
second O O
day O O
the O O
patient O O
had O O
vomitus B-Disease B-Disease
, O O
diarrhea B-Disease B-Disease
, O O
tinnitus B-Disease B-Disease
, O O
loss B-Disease B-Disease
of I-Disease I-Disease
hearing I-Disease I-Disease
. O O

After O O
30 O O
hours O O
of O O
quinine O O
infusion O O
the O O
patient O O
felt O O
palpitation B-Disease B-Disease
and O O
electrocardiography O O
( O O
ECG O O
) O O
recording O O
showed O O
premature B-Disease O
ventricular I-Disease B-Disease
contraction I-Disease I-Disease
( O O
PVC B-Disease B-Disease
) O O
> O O
5 O O
x O O
/ O O
minute O O
, O O
trigemini O O
, O O
constant O O
type O O
-- O O
sinoatrial B-Disease B-Disease
block I-Disease I-Disease
, O O
positive O O
U O O
wave O O
. O O

He O O
was O O
treated O O
with O O
lidocaine O O
50 O O
mg O O
intravenously O O
followed O O
by O O
infusion O O
1500 O O
mg O O
in O O
dextrose O O
5% O O
/ O O
24 O O
hour O O
and O O
potassium O O
aspartate O O
tablet O O
. O O

Quinine O O
infusion O O
was O O
discontinued O O
and O O
changed O O
with O O
sulfate O O
quinine O O
tablets O O
. O O

Three O O
hours O O
later O O
the O O
patient O O
felt O O
better O O
, O O
the O O
frequency O O
of O O
PVC B-Disease O
reduced O O
to O O
4 O O
- O O
5 O O
x O O
/ O O
minute O O
and O O
on O O
the O O
third O O
day O O
ECG O O
was O O
normal O O
, O O
potassium O O
level O O
was O O
3.34 O O
meq O O
/ O O
L. O O
He O O
was O O
discharged O O
on O O
7th O O
day O O
in O O
good O O
condition O O
. O O

Quinine O O
, O O
like O O
quinidine O O
, O O
is O O
a O O
chincona O O
alkaloid O O
that O O
has O O
anti O O
- O O
arrhythmic B-Disease B-Disease
property O O
, O O
although O O
it O O
also O O
pro O O
- O O
arrhythmic B-Disease B-Disease
that O O
can O O
cause O O
various O O
arrhythmias B-Disease B-Disease
, O O
including O O
severe O O
arrhythmia B-Disease B-Disease
such O O
as O O
multiple O O
PVC B-Disease B-Disease
. O O

Administration O O
of O O
parenteral O O
quinine O O
must O O
be O O
done O O
carefully O O
and O O
with O O
good O O
observation O O
because O O
of O O
its O O
pro O O
- O O
arrhythmic B-Disease B-Disease
effect O O
, O O
especially O O
in O O
older O O
patients O O
who O O
have O O
heart B-Disease B-Disease
diseases I-Disease I-Disease
or O O
patients O O
with O O
electrolyte B-Disease B-Disease
disorder I-Disease I-Disease
( O O
hypokalemia B-Disease B-Disease
) O O
which O O
frequently O O
occurs O O
due O O
to O O
vomiting B-Disease B-Disease
and O O
or O O
diarrhea B-Disease B-Disease
in O O
malaria B-Disease B-Disease
cases O O
. O O

Penicillamine O O
- O O
related O O
lichenoid B-Disease B-Disease
dermatitis I-Disease I-Disease
and O O
utility O O
of O O
zinc O O
acetate O O
in O O
a O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
patient O O
with O O
hepatic O O
presentation O O
, O O
anxiety B-Disease B-Disease
and O O
SPECT O O
abnormalities O O
. O O

Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
is O O
an O O
autosomal O B-Disease
recessive O I-Disease
disorder O I-Disease
of O I-Disease
hepatic O I-Disease
copper O I-Disease
metabolism O I-Disease
with O O
consequent O O
copper O O
accumulation O O
and O O
toxicity B-Disease O
in O O
many O O
tissues O O
and O O
consequent O O
hepatic B-Disease B-Disease
, I-Disease I-Disease
neurologic I-Disease I-Disease
and I-Disease I-Disease
psychiatric I-Disease I-Disease
disorders I-Disease I-Disease
. O O

We O O
report O O
a O O
case O O
of O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
with O O
chronic B-Disease B-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
; O O
moreover O O
, O O
in O O
our O O
patient O O
, O O
presenting O O
also O O
with O O
high O O
levels O O
of O O
state O O
anxiety B-Disease B-Disease
without O O
depression B-Disease B-Disease
, O O
99mTc O O
- O O
ECD O O
- O O
SPECT O O
showed O O
cortical O O
hypoperfusion O B-Disease
in O O
frontal O O
lobes O O
, O O
more O O
marked O O
on O O
the O O
left O O
frontal O O
lobe O O
. O O

During O O
the O O
follow O O
- O O
up O O
of O O
our O O
patient O O
, O O
penicillamine O O
was O O
interrupted O O
after O O
the O O
appearance O O
of O O
a O O
lichenoid B-Disease B-Disease
dermatitis I-Disease I-Disease
, O O
and O O
zinc O O
acetate O O
permitted O O
to O O
continue O O
the O O
successful O O
treatment O O
of O O
the O O
patient O O
without O O
side O O
- O O
effects O O
. O O

In O O
our O O
case O O
the O O
therapy O O
with O O
zinc O O
acetate O O
represented O O
an O O
effective O O
treatment O O
for O O
a O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
patient O O
in O O
which O O
penicillamine O O
- O O
related O O
side O O
effects O O
appeared O O
. O O

The O O
safety O O
of O O
the O O
zinc O O
acetate O O
allowed O O
us O O
to O O
avoid O O
other O O
potentially O O
toxic O O
chelating O O
drugs O O
; O O
this O O
observation O O
is O O
in O O
line O O
with O O
the O O
growing O O
evidence O O
on O O
the O O
efficacy O O
of O O
the O O
drug O O
in O O
the O O
treatment O O
of O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

Since O O
most O O
of O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
penicillamine O O
- O O
treated O O
patients O O
do O O
not O O
seem O O
to O O
develop O O
this O O
skin B-Disease B-Disease
lesion I-Disease I-Disease
, O O
it O O
could O O
be O O
conceivable O O
that O O
a O O
specific O O
genetic O O
factor O O
is O O
involved O O
in O O
drug O O
response O O
. O O

Further O O
studies O O
are O O
needed O O
for O O
a O O
better O O
clarification O O
of O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
therapy O O
, O O
and O O
in O O
particular O O
to O O
differentiate O O
specific O O
therapies O O
for O O
different O O
Wilson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
phenotypes O O
. O O

A O O
dramatic O O
drop B-Disease O
in I-Disease O
blood I-Disease O
pressure I-Disease O
following O O
prehospital O O
GTN O O
administration O O
. O O

A O O
male O O
in O O
his O O
sixties O O
with O O
no O O
history O O
of O O
cardiac O B-Disease
chest B-Disease I-Disease
pain I-Disease I-Disease
awoke O O
with O O
chest B-Disease B-Disease
pain I-Disease I-Disease
following O O
an O O
afternoon O O
sleep O O
. O O

The O O
patient O O
did O O
not O O
self O O
medicate O O
. O O

The O O
patient O O
's O O
observations O O
were O O
within O O
normal O O
limits O O
, O O
he O O
was O O
administered O O
oxygen O O
via O O
a O O
face O O
mask O O
and O O
glyceryl O O
trinitrate O O
( O O
GTN O O
) O O
. O O

Several O O
minutes O O
after O O
the O O
GTN O O
the O O
patient O O
experienced O O
a O O
sudden O O
drop B-Disease O
in I-Disease O
blood I-Disease O
pressure I-Disease O
and O O
heart O O
rate O O
, O O
this O O
was O O
rectified O O
by O O
atropine O O
sulphate O O
and O O
a O O
fluid O O
challenge O O
. O O

There O O
was O O
no O O
further O O
deterioration O O
in O O
the O O
patient O O
's O O
condition O O
during O O
transport O O
to O O
hospital O O
. O O

There O O
are O O
very O O
few O O
documented O O
case O O
like O O
this O O
in O O
the O O
prehospital O O
scientific O O
literature O O
. O O

The O O
cause O O
appears O O
to O O
be O O
the O O
Bezold O O
- O O
Jarish O O
reflex O O
, O O
stimulation O O
of O O
the O O
ventricular O O
walls O O
which O O
in O O
turn O O
decreases O O
sympathetic O O
outflow O O
from O O
the O O
vasomotor O O
centre O O
. O O

Prehospital O O
care O O
providers O O
who O O
are O O
managing O O
any O O
patient O O
with O O
a O O
syncopal B-Disease O
episode I-Disease O
that O O
fails O O
to O O
recover O O
within O O
a O O
reasonable O O
time O O
frame O O
should O O
consider O O
the O O
Bezold O O
- O O
Jarisch O O
reflex O O
as O O
the O O
cause O O
and O O
manage O O
the O O
patient O O
accordingly O O
. O O

Chronic O O
lesion O O
of O O
rostral O O
ventrolateral O O
medulla O O
in O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
. O O

We O O
studied O O
the O O
effects O O
of O O
chronic O O
selective O O
neuronal O O
lesion O O
of O O
rostral O O
ventrolateral O O
medulla O O
on O O
mean O O
arterial O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
neurogenic O O
tone O O
in O O
conscious O O
, O O
unrestrained O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
. O O

The O O
lesions O O
were O O
placed O O
via O O
bilateral O O
microinjections O O
of O O
30 O O
nmol O O
/ O O
200 O O
nl O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartic O O
acid O O
. O O

The O O
restimulation O O
of O O
this O O
area O O
with O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartic O O
acid O O
15 O O
days O O
postlesion O O
failed O O
to O O
produce O O
a O O
pressor O O
response O O
. O O

One O O
day O O
postlesion O O
, O O
the O O
resting O O
mean O O
arterial O O
pressure O O
was O O
significantly O O
decreased O O
in O O
lesioned O O
rats O O
when O O
compared O O
with O O
sham O O
rats O O
( O O
100 O O
+ O O
/- O O

7 O O
versus O O
173 O O
+ O O
/- O O

4 O O
mm O O
Hg O O
, O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

Fifteen O O
days O O
later O O
, O O
the O O
lesioned O O
group O O
still O O
showed O O
values O O
significantly O O
lower O O
than O O
the O O
sham O O
group O O
( O O
150 O O
+ O O
/- O O

6 O O
versus O O
167 O O
+ O O
/- O O

5 O O
mm O O
Hg O O
, O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

No O O
significant O O
heart O O
rate O O
differences O O
were O O
observed O O
between O O
the O O
sham O O
and O O
lesioned O O
groups O O
. O O

The O O
ganglionic O O
blocker O O
trimethaphan O O
( O O
5 O O
mg O O
/ O O
kg O O
i.v O O
. O O
) O O
caused O O
similar O O
reductions O O
in O O
mean O O
arterial O O
pressure O O
in O O
both O O
lesioned O O
and O O
sham O O
groups O O
. O O

The O O
trimethaphan O O
- O O
induced O O
hypotension B-Disease B-Disease
was O O
accompanied O O
by O O
a O O
significant O O
bradycardia B-Disease B-Disease
in O O
lesioned O O
rats O O
( O O
-32 O O
+ O O
/- O O

13 O O
beats O O
per O O
minute O O
) O O
but O O
a O O
tachycardia B-Disease B-Disease
in O O
sham O O
rats O O
( O O
+ O O
33 O O
+ O O
/- O O

12 O O
beats O O
per O O
minute O O
) O O
1 O O
day O O
postlesion O O
. O O

Therefore O O
, O O
rostral O O
ventrolateral O O
medulla O O
neurons O O
appear O O
to O O
play O O
a O O
significant O O
role O O
in O O
maintaining O O
hypertension B-Disease B-Disease
in O O
conscious O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
. O O

Spinal O O
or O O
suprabulbar O O
structures O O
could O O
be O O
responsible O O
for O O
the O O
gradual O O
recovery O O
of O O
the O O
hypertension B-Disease B-Disease
in O O
the O O
lesioned O O
rats O O
. O O

Acute B-Disease O
encephalopathy I-Disease B-Disease
and O O
cerebral B-Disease B-Disease
vasospasm I-Disease I-Disease
after O O
multiagent O O
chemotherapy O O
including O O
PEG O O
- O O
asparaginase O O
and O O
intrathecal O O
cytarabine O O
for O O
the O O
treatment O O
of O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

A O O
7-year O O
- O O
old O O
girl O O
with O O
an O O
unusual O O
reaction O O
to O O
induction O O
chemotherapy O O
for O O
precursor O O
B O O
- O O
cell O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
ALL B-Disease B-Disease
) O O
is O O
described O O
. O O

The O O
patient O O
developed O O
acute B-Disease O
encephalopathy I-Disease B-Disease
evidenced O O
by O O
behavioral O O
changes O O
, O O
aphasia B-Disease B-Disease
, O O
incontinence B-Disease B-Disease
, O O
visual B-Disease B-Disease
hallucinations I-Disease I-Disease
, O O
and O O
right O O
- O O
sided O O
weakness B-Disease B-Disease
with O O
diffuse O O
cerebral B-Disease B-Disease
vasospasm I-Disease I-Disease
on O O
magnetic O O
resonance O O
angiography O O
after O O
the O O
administration O O
of O O
intrathecal O O
cytarabine O O
. O O

Vincristine O O
, O O
dexamethasone O O
, O O
and O O
polyethylene O O
glycol O O
- O O
asparaginase O O
were O O
also O O
administered O O
before O O
the O O
episode O O
as O O
part O O
of O O
induction O O
therapy O O
. O O

Neurologic O O
status O O
returned O O
to O O
baseline O O
within O O
10 O O
days O O
of O O
the O O
acute O O
event O O
, O O
and O O
magnetic O O
resonance O O
angiography O O
findings O O
returned O O
to O O
normal O O
4 O O
months O O
later O O
. O O

Comparison O O
of O O
valsartan O O
/ O O
hydrochlorothiazide O O
combination O O
therapy O O
at O O
doses O O
up O O
to O O
320 O O
/ O O
25 O O
mg O O
versus O O
monotherapy O O
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
followed O O
by O O
long O O
- O O
term O O
combination O O
therapy O O
in O O
hypertensive B-Disease B-Disease
adults O O
. O O

BACKGROUND O O
: O O
One O O
third O O
of O O
patients O O
treated O O
for O O
hypertension B-Disease B-Disease
attain O O
adequate O O
blood O O
pressure O O
( O O
BP O O
) O O
control O O
, O O
and O O
multidrug O O
regimens O O
are O O
often O O
required O O
. O O

Given O O
the O O
lifelong O O
nature O O
of O O
hypertension B-Disease B-Disease
, O O
there O O
is O O
a O O
need O O
to O O
evaluate O O
the O O
long O O
- O O
term O O
efficacy O O
and O O
tolerability O O
of O O
higher O O
doses O O
of O O
combination O O
anti O O
- O O
hypertensive B-Disease B-Disease
therapies O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
investigated O O
the O O
efficacy O O
and O O
tolerability O O
of O O
valsartan O O
( O O
VAL O O
) O O
or O O
hydrochlorothiazide O O
( O O
HCTZ O O
) O O
-monotherapy O O
and O O
higher O O
- O O
dose O O
combinations O O
in O O
patients O O
with O O
essential B-Disease B-Disease
hypertension I-Disease I-Disease
. O O

METHODS O O
: O O
The O O
first O O
part O O
of O O
this O O
study O O
was O O
an O O
8-week O O
, O O
multicenter O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
controlled O O
, O O
parallel O O
- O O
group O O
trial O O
. O O

Patients O O
with O O
essential B-Disease B-Disease
hypertension I-Disease I-Disease
( O O
mean O O
sitting O O
diastolic O O
BP O O
[ O O
MSDBP O O
] O O
, O O
> O O
or O O
= O O
95 O O
mm O O
Hg O O
and O O
< O O
110 O O
mm O O
Hg O O
) O O
were O O
randomized O O
to O O
1 O O
of O O
8 O O
treatment O O
groups O O
: O O
VAL O O
160 O O
or O O
320 O O
mg O O
; O O
HCTZ O O
12.5 O O
or O O
25 O O
mg O O
; O O
VAL O O
/ O O
HCTZ O O
160 O O
/ O O
12.5 O O
, O O
320 O O
/ O O
12.5 O O
, O O
or O O
320 O O
/ O O
25 O O
mg O O
; O O
or O O
placebo O O
. O O

Mean O O
changes O O
in O O
MSDBP O O
and O O
mean O O
sitting O O
systolic O O
BP O O
( O O
MSSBP O O
) O O
were O O
analyzed O O
at O O
the O O
8-week O O
core O O
study O O
end O O
point O O
. O O

VAL O O
/ O O
HCTZ O O
320 O O
/ O O
12.5 O O
and O O
320 O O
/ O O
25 O O
mg O O
were O O
further O O
investigated O O
in O O
a O O
54-week O O
, O O
open O O
- O O
label O O
extension O O
. O O

Response O O
was O O
defined O O
as O O
MSDBP O O
< O O
90 O O
mm O O
Hg O O
or O O
a O O
> O O
or O O
= O O
10 O O
mm O O
Hg O O
decrease O O
compared O O
to O O
baseline O O
. O O

Control O O
was O O
defined O O
as O O
MSDBP O O
< O O
90 O O
mm O O
Hg O O
compared O O
with O O
baseline O O
. O O

Tolerability O O
was O O
assessed O O
by O O
monitoring O O
adverse O O
events O O
at O O
randomization O O
and O O
all O O
subsequent O O
study O O
visits O O
and O O
regular O O
evaluation O O
of O O
hematology O O
and O O
blood O O
chemistry O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
1346 O O
patients O O
were O O
randomized O O
into O O
the O O
8-week O O
core O O
study O O
( O O
734 O O
men O O
, O O
612 O O
women O O
; O O
924 O O
white O O
, O O
291 O O
black O O
, O O
23 O O
Asian O O
, O O
108 O O
other O O
; O O
mean O O
age O O
, O O
52.7 O O
years O O
; O O
mean O O
weight O O
, O O
92.6 O O
kg O O
) O O
. O O

All O O
active O O
treatments O O
were O O
associated O O
with O O
significantly O O
reduced O O
MSSBP O O
and O O
MSDBP O O
during O O
the O O
core O O
8-week O O
study O O
, O O
with O O
each O O
monotherapy O O
significantly O O
contributing O O
to O O
the O O
overall O O
effect O O
of O O
combination O O
therapy O O
( O O
VAL O O
and O O
HCTZ O O
, O O
P O O
< O O
0.001 O O
) O O
. O O

Each O O
combination O O
was O O
associated O O
with O O
significantly O O
greater O O
reductions O O
in O O
MSSBP O O
and O O
MSDBP O O
compared O O
with O O
the O O
monotherapies O O
and O O
placebo O O
( O O
all O O
, O O
P O O
< O O
0.001 O O
) O O
. O O

The O O
mean O O
reduction O O
in O O
MSSBP O O
/ O O
MSDBP O O
with O O
VAL O O
/ O O
HCTZ O O
320 O O
/ O O
25 O O
mg O O
was O O
24.7 O O
/ O O
16.6 O O
mm O O
Hg O O
, O O
compared O O
with O O
5.9 O O
/ O O
7.0 O O
mm O O
Hg O O
with O O
placebo O O
. O O

The O O
reduction O O
in O O
MSSBP O O
was O O
significantly O O
greater O O
with O O
VAL O O
/ O O
HCTZ O O
320 O O
/ O O
25 O O
mg O O
compared O O
with O O
VAL O O
/ O O
HCTZ O O
160 O O
/ O O
12.5 O O
mg O O
( O O
P O O
< O O
0.002 O O
) O O
. O O

Rates O O
of O O
response O O
and O O
BP O O
control O O
were O O
significantly O O
higher O O
in O O
the O O
groups O O
that O O
received O O
combination O O
treatment O O
compared O O
with O O
those O O
that O O
received O O
monotherapy O O
. O O

The O O
incidence O O
of O O
hypokalemia B-Disease B-Disease
was O O
lower O O
with O O
VAL O O
/ O O
HCTZ O O
combinations O O
( O O
1.8%-6.1 O O
% O O
) O O
than O O
with O O
HCTZ O O
monotherapies O O
( O O
7.1%-13.3 O O
% O O
) O O
. O O

The O O
majority O O
of O O
adverse O O
events O O
in O O
the O O
core O O
study O O
were O O
of O O
mild O O
to O O
moderate O O
severity O O
. O O

The O O
efficacy O O
and O O
tolerability O O
of O O
VAL O O
/ O O
HCTZ O O
combinations O O
were O O
maintained O O
during O O
the O O
extension O O
( O O
797 O O
patients O O
) O O
. O O

CONCLUSIONS O O
: O O
In O O
this O O
study O O
population O O
, O O
combination O O
therapies O O
with O O
VAL O O
/ O O
HCTZ O O
were O O
associated O O
with O O
significantly O O
greater O O
BP O O
reductions O O
compared O O
with O O
either O O
monotherapy O O
, O O
were O O
well O O
tolerated O O
, O O
and O O
were O O
associated O O
with O O
less O O
hypokalemia B-Disease B-Disease
than O O
HCTZ O O
alone O O
. O O

Succimer O O
chelation O O
improves O O
learning O O
, O O
attention O O
, O O
and O O
arousal O O
regulation O O
in O O
lead O O
- O O
exposed O O
rats O O
but O O
produces O O
lasting O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
in O O
the O O
absence O O
of O O
lead O O
exposure O O
. O O

BACKGROUND O O
: O O
There O O
is O O
growing O O
pressure O O
for O O
clinicians O O
to O O
prescribe O O
chelation O O
therapy O O
at O O
only O O
slightly O O
elevated O O
blood O O
lead O O
levels O O
. O O

However O O
, O O
very O O
few O O
studies O O
have O O
evaluated O O
whether O O
chelation O O
improves O O
cognitive O O
outcomes O O
in O O
Pb O O
- O O
exposed O O
children O O
, O O
or O O
whether O O
these O O
agents O O
have O O
adverse O O
effects O O
that O O
may O O
affect O O
brain O O
development O O
in O O
the O O
absence O O
of O O
Pb O O
exposure O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
was O O
designed O O
to O O
answer O O
these O O
questions O O
, O O
using O O
a O O
rodent O O
model O O
of O O
early O O
childhood O O
Pb O O
exposure O O
and O O
treatment O O
with O O
succimer O O
, O O
a O O
widely O O
used O O
chelating O O
agent O O
for O O
the O O
treatment O O
of O O
Pb B-Disease B-Disease
poisoning I-Disease I-Disease
. O O

RESULTS O O
: O O
Pb O O
exposure O O
produced O O
lasting O O
impairments B-Disease B-Disease
in I-Disease I-Disease
learning I-Disease I-Disease
, B-Disease O
attention I-Disease O
, I-Disease O
inhibitory I-Disease O
control I-Disease O
, I-Disease O
and I-Disease O
arousal I-Disease O
regulation I-Disease O
, O O
paralleling O O
the O O
areas O O
of O O
dysfunction O O
seen O O
in O O
Pb O O
- O O
exposed O O
children O O
. O O

Succimer O O
treatment O O
of O O
the O O
Pb O O
- O O
exposed O O
rats O O
significantly O O
improved O O
learning O O
, O O
attention O O
, O O
and O O
arousal O O
regulation O O
, O O
although O O
the O O
efficacy O O
of O O
the O O
treatment O O
varied O O
as O O
a O O
function O O
of O O
the O O
Pb O O
exposure O O
level O O
and O O
the O O
specific O O
functional O O
deficit O O
. O O

In O O
contrast O O
, O O
succimer O O
treatment O O
of O O
rats O O
not O O
previously O O
exposed O O
to O O
Pb O O
produced O O
lasting O O
and O O
pervasive O O
cognitive B-Disease B-Disease
and I-Disease I-Disease
affective I-Disease I-Disease
dysfunction I-Disease I-Disease
comparable O O
in O O
magnitude O O
to O O
that O O
produced O O
by O O
the O O
higher O O
Pb O O
exposure O O
regimen O O
. O O

CONCLUSIONS O O
: O O
These O O
are O O
the O O
first O O
data O O
, O O
to O O
our O O
knowledge O O
, O O
to O O
show O O
that O O
treatment O O
with O O
any O O
chelating O O
agent O O
can O O
alleviate O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
due O O
to O O
Pb O O
exposure O O
. O O

These O O
findings O O
suggest O O
that O O
it O O
may O O
be O O
possible O O
to O O
identify O O
a O O
succimer O O
treatment O O
protocol O O
that O O
improves O O
cognitive O O
outcomes O O
in O O
Pb O O
- O O
exposed O O
children O O
. O O

However O O
, O O
they O O
also O O
suggest O O
that O O
succimer O O
treatment O O
should O O
be O O
strongly O O
discouraged O O
for O O
children O O
who O O
do O O
not O O
have O O
elevated O O
tissue O O
levels O O
of O O
Pb O O
or O O
other O O
heavy O O
metals O O
. O O

Caffeine O O
challenge O O
test O O
in O O
panic B-Disease B-Disease
disorder I-Disease I-Disease
and O O
depression B-Disease B-Disease
with O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
. O O

Our O O
aim O O
was O O
to O O
observe O O
if O O
patients O O
with O O
panic B-Disease B-Disease
disorder I-Disease I-Disease
( O O
PD B-Disease B-Disease
) O O
and O O
patients O O
with O O
major B-Disease B-Disease
depression I-Disease I-Disease
with O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
( O O
MDP B-Disease B-Disease
) O O
( O O
Diagnostic O O
and O O
Statistical O O
Manual O O
of O O
Mental B-Disease B-Disease
Disorders I-Disease I-Disease
, O O
Fourth O O
Edition O O
criteria O O
) O O
respond O O
in O O
a O O
similar O O
way O O
to O O
the O O
induction O O
of O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
by O O
an O O
oral O O
caffeine O O
challenge O O
test O O
. O O

We O O
randomly O O
selected O O
29 O O
patients O O
with O O
PD B-Disease B-Disease
, O O
27 O O
with O O
MDP B-Disease B-Disease
, O O
25 O O
with O O
major B-Disease B-Disease
depression I-Disease I-Disease
without O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
( O O
MD B-Disease B-Disease
) O O
, O O
and O O
28 O O
healthy O O
volunteers O O
. O O

The O O
patients O O
had O O
no O O
psychotropic O O
drug O O
for O O
at O O
least O O
a O O
4-week O O
period O O
. O O

In O O
a O O
randomized O O
double O O
- O O
blind O O
experiment O O
performed O O
in O O
2 O O
occasions O O
7 O O
days O O
apart O O
, O O
480 O O
mg O O
caffeine O O
and O O
a O O
caffeine O O
- O O
free O O
( O O
placebo O O
) O O
solution O O
were O O
administered O O
in O O
a O O
coffee O O
form O O
and O O
anxiety B-Disease B-Disease
scales O O
were O O
applied O O
before O O
and O O
after O O
each O O
test O O
. O O

A O O
total O O
of O O
58.6 O O
% O O
( O O
n O O
= O O
17 O O
) O O
of O O
patients O O
with O O
PD B-Disease B-Disease
, O O
44.4 O O
% O O
( O O
n O O
= O O
12 O O
) O O
of O O
patients O O
with O O
MDP B-Disease B-Disease
, O O
12.0 O O
% O O
( O O
n O O
= O O
3 O O
) O O
of O O
patients O O
with O O
MD B-Disease B-Disease
, O O
and O O
7.1 O O
% O O
( O O
n= O O
2 O O
) O O
of O O
control O O
subjects O O
had O O
a O O
panic B-Disease B-Disease
attack I-Disease I-Disease
after O O
the O O
480-mg O O
caffeine O O
challenge O O
test O O
( O O
chi O O
( O O
2 O O
) O O
( O O
3 O O
) O O
= O O
16.22 O O
, O O
P O O
= O O
.001 O O
) O O
. O O

The O O
patients O O
with O O
PD B-Disease B-Disease
and O O
MDP B-Disease B-Disease
were O O
more O O
sensitive O O
to O O
caffeine O O
than O O
were O O
patients O O
with O O
MD B-Disease B-Disease
and O O
healthy O O
volunteers O O
. O O

No O O
panic B-Disease B-Disease
attack I-Disease I-Disease
was O O
observed O O
after O O
the O O
caffeine O O
- O O
free O O
solution O O
intake O O
. O O

The O O
patients O O
with O O
MD B-Disease B-Disease
had O O
a O O
lower O O
heart O O
rate O O
response O O
to O O
the O O
test O O
than O O
all O O
the O O
other O O
groups O O
( O O
2-way O O
analysis O O
of O O
variance O O
, O O
group O O
by O O
time O O
interaction O O
with O O
Greenhouse O O
- O O
Geisser O O
correction O O
: O O
F O O
( O O
3,762 O O
) O O
= O O
2.85 O O
, O O
P O O
= O O
.026 O O
) O O
. O O

Our O O
data O O
suggest O O
that O O
there O O
is O O
an O O
association O O
between O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
, O O
no O O
matter O O
if O O
associated O O
with O O
PD B-Disease B-Disease
or O O
MDP B-Disease B-Disease
, O O
and O O
hyperreactivity O O
to O O
an O O
oral O O
caffeine O O
challenge O O
test O O
. O O

Mitral O O
annuloplasty O O
as O O
a O O
ventricular O O
restoration O O
method O O
for O O
the O O
failing B-Disease O
left I-Disease O
ventricle I-Disease O
: O O
a O O
pilot O O
study O O
. O O

BACKGROUND O O
AND O O
AIM O O
OF O O
THE O O
STUDY O O
: O O
Undersized O O
mitral O O
annuloplasty O O
( O O
MAP O O
) O O
is O O
effective O O
in O O
patients O O
with O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
and O O
functional O O
mitral B-Disease B-Disease
regurgitation I-Disease I-Disease
( O O
MR B-Disease B-Disease
) O O
since O O
, O O
as O O
well O O
as O O
addressing O O
the O O
MR B-Disease B-Disease
, O O
the O O
MAP O O
may O O
also O O
reshape O O
the O O
dilated O O
left O O
ventricular O O
( O O
LV O O
) O O
base O O
. O O

However O O
, O O
the O O
direct O O
benefits O O
of O O
this O O
possible O O
reshaping O O
on O O
LV O O
function O O
in O O
the O O
absence O O
of O O
underlying O O
MR B-Disease B-Disease
remain O O
incompletely O O
understood O O
. O O

The O O
study O O
aim O O
was O O
to O O
identify O O
these O O
benefits O O
in O O
a O O
canine O O
model O O
of O O
acute O O
heart B-Disease B-Disease
failure I-Disease I-Disease
. O O

METHODS O O
: O O
Six O O
dogs O O
underwent O O
MAP O O
with O O
a O O
prosthetic O O
band O O
on O O
the O O
posterior O O
mitral O O
annulus O O
, O O
using O O
four O O
mattress O O
sutures O O
. O O

The O O
sutures O O
were O O
passed O O
individually O O
through O O
four O O
tourniquets O O
and O O
exteriorized O O
untied O O
via O O
the O O
left O O
atriotomy O O
. O O

Sonomicrometry O O
crystals O O
were O O
implanted O O
around O O
the O O
mitral O O
annulus O O
and O O
left O O
ventricle O O
to O O
measure O O
geometry O O
and O O
regional O O
function O O
. O O

Acute O O
heart B-Disease B-Disease
failure I-Disease I-Disease
was O O
induced O O
by O O
propranolol O O
and O O
volume O O
loading O O
after O O
weaning O O
from O O
cardiopulmonary O O
bypass O O
; O O
an O O
absence O O
of O O
MR B-Disease B-Disease
was O O
confirmed O O
by O O
echocardiography O O
. O O

MAP O O
was O O
accomplished O O
by O O
cinching O O
the O O
tourniquets O O
. O O

Data O O
were O O
acquired O O
at O O
baseline O O
, O O
after O O
induction O O
of O O
acute O O
heart B-Disease B-Disease
failure I-Disease I-Disease
, O O
and O O
after O O
MAP O O
. O O

RESULTS O O
: O O
MAP O O
decreased O O
mitral O O
annular O O
dimensions O O
in O O
both O O
commissure O O
- O O
commissure O O
and O O
septal O O
- O O
lateral O O
directions O O
. O O

Concomitantly O O
, O O
the O O
diastolic O O
diameter O O
of O O
the O O
LV O O
base O O
and O O
LV O O
sphericity O O
decreased O O
( O O
i.e. O O
, O O
improved O O
) O O
from O O
37.4 O O
+ O O
/- O O

9.3 O O
to O O
35.9 O O
+ O O
/- O O

10 O O
mm O O
( O O
p O O
= O O
0.063 O O
) O O
, O O
and O O
from O O
67.9 O O
+ O O
/- O O

18.6 O O
% O O
to O O
65.3 O O
+ O O
/- O O

18.9 O O
% O O
( O O
p O O
= O O
0.016 O O
) O O
, O O
respectively O O
. O O

Decreases O O
were O O
evident O O
in O O
both O O
LV O O
end O O
- O O
diastolic O O
pressure O O
( O O
from O O
17 O O
+ O O
/- O O

7 O O
to O O
15 O O
+ O O
/- O O

6 O O
mmHg O O
, O O
p O O
= O O
0.0480 O O
and O O
Tau O O
( O O
from O O
48 O O
+ O O
/- O O

8 O O
to O O
45 O O
+ O O
/- O O

8 O O
ms O O
, O O
p O O
< O O
0.01 O O
) O O
, O O
while O O
fractional O O
shortening O O
at O O
the O O
LV O O
base O O
increased O O
from O O
7.7 O O
+ O O
/- O O

4.5 O O
% O O
to O O
9.4 O O
+ O O
/- O O

4.5 O O
% O O
( O O
p O O
= O O
0.045 O O
) O O
. O O

After O O
MAP O O
, O O
increases O O
were O O
identified O O
in O O
both O O
cardiac O O
output O O
( O O
from O O
1.54 O O
+ O O
/- O O

0.57 O O
to O O
1.65 O O
+ O O
/- O O

0.57 O O
1 O O
/ O O
min O O
) O O
and O O
Emax O O
( O O
from O O
1.86 O O
+ O O
/- O O

0.9 O O
to O O
2.41 O O
+ O O
/- O O

1.31 O O
mmHg O O
/ O O
ml O O
) O O
. O O

CONCLUSION O O
: O O
The O O
data O O
acquired O O
suggest O O
that O O
isolated O O
MAP O O
may O O
have O O
certain O O
benefits O O
on O O
LV O O
dimension O O
/ O O
function O O
in O O
acute O O
heart B-Disease B-Disease
failure I-Disease I-Disease
, O O
even O O
in O O
the O O
absence O O
of O O
MR B-Disease B-Disease
. O O

However O O
, O O
further O O
investigations O O
are O O
warranted O O
in O O
a O O
model O O
of O O
chronic O O
heart B-Disease B-Disease
failure I-Disease I-Disease
. O O

Piperacillin O O
/ O O
tazobactam O O
- O O
induced O O
seizure B-Disease B-Disease
rapidly O O
reversed O O
by O O
high O O
flux O O
hemodialysis O O
in O O
a O O
patient O O
on O O
peritoneal O O
dialysis O O
. O O

Despite O O
popular O O
use O O
of O O
piperacillin O O
, O O
the O O
dire O O
neurotoxicity B-Disease B-Disease
associated O O
with O O
piperacillin O O
still O O
goes O O
unrecognized O O
, O O
leading O O
to O O
a O O
delay O O
in O O
appropriate O O
management O O
. O O

We O O
report O O
a O O
57-year O O
- O O
old O O
woman O O
with O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
receiving O O
continuous O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
CAPD O O
) O O
, O O
who O O
developed O O
slurred O B-Disease
speech O I-Disease
, O O
tremor B-Disease B-Disease
, O O
bizarre O B-Disease
behavior O I-Disease
, O O
progressive O O
mental O O
confusion B-Disease B-Disease
, O O
and O O
2 O O
episodes O O
of O O
generalized O O
tonic B-Disease B-Disease
- I-Disease I-Disease
clonic I-Disease I-Disease
seizure I-Disease I-Disease
( O O
GTCS B-Disease B-Disease
) O O
after O O
5 O O
doses O O
of O O
piperacillin O O
/ O O
tazobactam O O
( O O
2 O O
g O O
/ O O
250 O O
mg O O
) O O
were O O
given O O
for O O
bronchiectasis B-Disease B-Disease
with O O
secondary B-Disease B-Disease
infection I-Disease I-Disease
. O O

The O O
laboratory O O
data O O
revealed O O
normal O O
plasma O O
electrolyte O O
and O O
ammonia O O
levels O O
but O O
leukocytosis B-Disease B-Disease
. O O

Neurologic O O
examinations O O
showed O O
dysarthria B-Disease B-Disease
and O O
bilateral O O
Babinski O O
sign O O
. O O

Computed O O
tomography O O
of O O
brain O O
and O O
electroencephalogram O O
were O O
unremarkable O O
. O O

Despite O O
the O O
use O O
of O O
antiepileptic O O
agents O O
, O O
another O O
GTCS B-Disease B-Disease
episode O O
recurred O O
after O O
the O O
sixth O O
dose O O
of O O
piperacillin O O
/ O O
tazobactam O O
. O O

Brain O O
magnetic O O
resonance O O
imaging O O
did O O
not O O
demonstrate O O
acute O O
infarction B-Disease B-Disease
and O O
organic B-Disease B-Disease
brain I-Disease I-Disease
lesions I-Disease I-Disease
. O O

Initiation O O
of O O
high O O
- O O
flux O O
hemodialysis O O
rapidly O O
reversed O O
the O O
neurologic O B-Disease
symptoms O I-Disease
within O O
4 O O
hours O O
. O O

Piperacillin O O
- O O
induced O O
encephalopathy B-Disease B-Disease
should O O
be O O
considered O O
in O O
any O O
uremic B-Disease B-Disease
patients O O
with O O
unexplained O O
neurological O O
manifestations O O
. O O

CAPD O O
is O O
inefficient O O
in O O
removing O O
piperacillin O O
, O O
whereas O O
hemodialysis O O
can O O
rapidly O O
terminate O O
the O O
piperacillin O O
- O O
induced O O
encephalopathy B-Disease B-Disease
. O O

Frequency O O
of O O
transient O O
ipsilateral O O
vocal B-Disease B-Disease
cord I-Disease I-Disease
paralysis I-Disease I-Disease
in O O
patients O O
undergoing O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
. O O

BACKGROUND O O
: O O
Especially O O
because O O
of O O
improvements O O
in O O
clinical O O
neurologic O O
monitoring O O
, O O
carotid O O
endarterectomy O O
done O O
under O O
local O O
anesthesia O O
has O O
become O O
the O O
technique O O
of O O
choice O O
in O O
several O O
centers O O
. O O

Temporary O O
ipsilateral O O
vocal B-Disease B-Disease
nerve I-Disease I-Disease
palsies I-Disease I-Disease
due O O
to O O
local O O
anesthetics O O
have O O
been O O
described O O
, O O
however O O
. O O

Such O O
complications O O
are O O
most O O
important O O
in O O
situations O O
where O O
there O O
is O O
a O O
pre O O
- O O
existing O O
contralateral O O
paralysis B-Disease B-Disease
. O O

We O O
therefore O O
examined O O
the O O
effect O O
of O O
local O O
anesthesia O O
on O O
vocal O O
cord O O
function O O
to O O
better O O
understand O O
its O O
possible O O
consequences O O
. O O

METHODS O O
: O O
This O O
prospective O O
study O O
included O O
28 O O
patients O O
undergoing O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
. O O

Vocal O O
cord O O
function O O
was O O
evaluated O O
before O O
, O O
during O O
, O O
and O O
after O O
surgery O O
( O O
postoperative O O
day O O
1 O O
) O O
using O O
flexible O O
laryngoscopy O O
. O O

Anesthesia O O
was O O
performed O O
by O O
injecting O O
20 O O
to O O
40 O O
mL O O
of O O
a O O
mixture O O
of O O
long O O
- O O
acting O O
( O O
ropivacaine O O
) O O
and O O
short O O
- O O
acting O O
( O O
prilocaine O O
) O O
anesthetic O O
. O O

RESULTS O O
: O O
All O O
patients O O
had O O
normal O O
vocal O O
cord O O
function O O
preoperatively O O
. O O

Twelve O O
patients O O
( O O
43 O O
% O O
) O O
were O O
found O O
to O O
have O O
intraoperative O O
ipsilateral O O
vocal B-Disease B-Disease
cord I-Disease I-Disease
paralysis I-Disease I-Disease
. O O

It O O
resolved O O
in O O
all O O
cases O O
< O O
or O O
= O O
24 O O
hours O O
. O O

There O O
were O O
no O O
significant O O
differences O O
in O O
operating O O
time O O
or O O
volume O O
or O O
frequency O O
of O O
anesthetic O O
administration O O
in O O
patients O O
with O O
temporary O O
vocal B-Disease B-Disease
cord I-Disease I-Disease
paralysis I-Disease I-Disease
compared O O
with O O
those O O
without O O
. O O

CONCLUSION O O
: O O
Local O O
anesthesia O O
led O O
to O O
temporary O O
ipsilateral O O
vocal B-Disease B-Disease
cord I-Disease I-Disease
paralysis I-Disease I-Disease
in O O
almost O O
half O O
of O O
these O O
patients O O
. O O

Because O O
pre O O
- O O
existing O O
paralysis B-Disease B-Disease
is O O
of O O
a O O
relevant O O
frequency O O
( O O
up O O
to O O
3 O O
% O O
) O O
, O O
a O O
preoperative O O
evaluation O O
of O O
vocal O O
cord O O
function O O
before O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
is O O
recommended O O
to O O
avoid O O
intraoperative O O
bilateral O O
paralysis B-Disease B-Disease
. O O

In O O
patients O O
with O O
preoperative O O
contralateral O O
vocal B-Disease B-Disease
cord I-Disease I-Disease
paralysis I-Disease I-Disease
, O O
surgery O O
under O O
general O O
anesthesia O O
should O O
be O O
considered O O
. O O

Impaired B-Disease B-Disease
fear I-Disease I-Disease
recognition I-Disease I-Disease
in O O
regular O O
recreational O O
cocaine O O
users O O
. O O

INTRODUCTION O O
: O O
The O O
ability O O
to O O
read O O
facial O O
expressions O O
is O O
essential O O
for O O
normal O O
human O O
social O O
interaction O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
conduct O O
the O O
first O O
investigation O O
of O O
facial O O
expression O O
recognition O O
performance O O
in O O
recreational O O
cocaine O O
users O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Three O O
groups O O
, O O
comprised O O
of O O
21 O O
cocaine O O
naive O O
participants O O
( O O
CN O O
) O O
, O O
30 O O
occasional O O
cocaine O O
( O O
OC O O
) O O
, O O
and O O
48 O O
regular O O
recreational O O
cocaine O O
( O O
RC O O
) O O
users O O
, O O
were O O
compared O O
. O O

An O O
emotional O O
facial O O
expression O O
( O O
EFE O O
) O O
task O O
consisting O O
of O O
a O O
male O O
and O O
female O O
face O O
expressing O O
six O O
basic O O
emotions O O
( O O
happiness O O
, O O
surprise O O
, O O
sadness O O
, O O
anger O O
, O O
fear O O
, O O
and O O
disgust O O
) O O
was O O
administered O O
. O O

Mean O O
percent O O
accuracy O O
and O O
latencies O O
for O O
correct O O
responses O O
across O O
eight O O
presentations O O
of O O
each O O
basic O O
emotion O O
were O O
derived O O
. O O

Participants O O
were O O
also O O
assessed O O
with O O
the O O
" O O
Eyes O O
task O O
" O O
to O O
investigate O O
their O O
ability O O
to O O
recognize O O
more O O
complex O O
emotional O O
states O O
and O O
the O O
Symptom O O
CheckList-90-Revised O O
to O O
measure O O
psychopathology O O
. O O

RESULTS O O
: O O
There O O
were O O
no O O
group O O
differences O O
in O O
psychopathology O O
or O O
" O O
eyes O O
task O O
" O O
performance O O
, O O
but O O
the O O
RC O O
group O O
, O O
who O O
otherwise O O
had O O
similar O O
illicit O O
substance O O
use O O
histories O O
to O O
the O O
OC O O
group O O
, O O
exhibited O O
impaired B-Disease B-Disease
fear I-Disease I-Disease
recognition I-Disease I-Disease
accuracy O O
compared O O
to O O
the O O
OC O O
and O O
CN O O
groups O O
. O O

The O O
RC O O
group O O
also O O
correctly O O
identified O O
anger O O
, O O
fear O O
, O O
happiness O O
, O O
and O O
surprise O O
, O O
more O O
slowly O O
than O O
CN O O
, O O
but O O
not O O
OC O O
participants O O
. O O

The O O
OC O O
group O O
was O O
slower O O
than O O
CN O O
when O O
correctly O O
identifying O O
disgust O O
. O O

The O O
selective O O
deficit B-Disease B-Disease
in I-Disease I-Disease
fear I-Disease I-Disease
recognition I-Disease I-Disease
accuracy O O
manifested O O
by O O
the O O
RC O O
group O O
can O O
not O O
be O O
explained O O
by O O
the O O
subacute O O
effects O O
of O O
cocaine O O
, O O
or O O
ecstasy O O
, O O
because O O
recent O O
and O O
less O O
recent O O
users O O
of O O
these O O
drugs O O
within O O
this O O
group O O
were O O
similarly O O
impaired O O
. O O

Possible O O
parallels O O
between O O
RC O O
users O O
and O O
psychopaths B-Disease O
with O O
respect O O
to O O
impaired B-Disease B-Disease
fear I-Disease I-Disease
recognition I-Disease I-Disease
, O O
amygdala B-Disease B-Disease
dysfunction I-Disease I-Disease
, O O
and O O
etiology O O
are O O
discussed O O
. O O

Damage B-Disease B-Disease
of I-Disease I-Disease
substantia I-Disease I-Disease
nigra I-Disease I-Disease
pars I-Disease I-Disease
reticulata I-Disease I-Disease
during O O
pilocarpine O O
- O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
in O O
the O O
rat O O
: O O
immunohistochemical O O
study O O
of O O
neurons O O
, O O
astrocytes O O
and O O
serum O O
- O O
protein O O
extravasation O O
. O O

The O O
substantia O O
nigra O O
has O O
a O O
gating O O
function O O
controlling O O
the O O
spread O O
of O O
epileptic B-Disease B-Disease
seizure I-Disease B-Disease
activity O O
. O O

Additionally O O
, O O
in O O
models O O
of O O
prolonged B-Disease O
status I-Disease B-Disease
epilepticus I-Disease I-Disease
the O O
pars O O
reticulata O O
of O O
substantia O O
nigra O O
( O O
SNR O O
) O O
suffers O O
from O O
a O O
massive O O
lesion O O
which O O
may O O
arise O O
from O O
a O O
massive O O
metabolic B-Disease O
derangement I-Disease O
and O O
hyperexcitation O O
developing O O
in O O
the O O
activated O O
SNR O O
. O O

In O O
this O O
study O O
, O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
was O O
induced O O
by O O
systemic O O
injection O O
of O O
pilocarpine O O
in O O
rats O O
. O O

The O O
neuropathology O O
of O O
SNR O O
was O O
investigated O O
using O O
immunohistochemical O O
techniques O O
with O O
the O O
major O O
emphasis O O
on O O
the O O
time O O
- O O
course O O
of O O
changes O O
in O O
neurons O O
and O O
astrocytes O O
. O O

Animals O O
surviving O O
20 O O
, O O
30 O O
, O O
40 O O
, O O
60 O O
min O O
, O O
2 O O
, O O
3 O O
, O O
6 O O
hours O O
, O O
1 O O
, O O
2 O O
, O O
and O O
3 O O
days O O
after O O
induction O O
of O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
were O O
perfusion O O
- O O
fixed O O
, O O
and O O
brains O O
processed O O
for O O
immunohistochemical O O
staining O O
of O O
SNR O O
. O O

Nissl O O
- O O
staining O O
and O O
antibodies O O
against O O
the O O
neuron O O
- O O
specific O O
calcium O O
- O O
binding O O
protein O O
, O O
parvalbumin O O
, O O
served O O
to O O
detect O O
neuronal B-Disease B-Disease
damage I-Disease I-Disease
in O O
SNR O O
. O O

Antibodies O O
against O O
the O O
astroglia O O
- O O
specific O O
cytoskeletal O O
protein O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
( O O
GFAP O O
) O O
, O O
and O O
against O O
the O O
glial O O
calcium O O
- O O
binding O O
protein O O
, O O
S-100 O O
protein O O
, O O
were O O
used O O
to O O
assess O O
the O O
status O O
of O O
astrocytes O O
. O O

Immunohistochemical O O
staining O O
for O O
serum O O
- O O
albumin O O
and O O
immunoglobulins O O
in O O
brain O O
tissue O O
was O O
taken O O
as O O
indicator O O
of O O
blood O O
- O O
brain O O
barrier O O
disturbances O O
and O O
vasogenic B-Disease B-Disease
edema I-Disease I-Disease
formation O O
. O O

Immunohistochemical O O
staining O O
indicated O O
loss O O
of O O
GFAP O O
- O O
staining O O
already O O
at O O
30 O O
min O O
after O O
induction O O
of O O
seizures B-Disease B-Disease
in O O
an O O
oval O O
focus O O
situated O O
in O O
the O O
center O O
of O O
SNR O O
while O O
sparing O O
medial O O
and O O
lateral O O
aspects O O
. O O

At O O
1 O O
h O O
there O O
was O O
additional O O
vacuolation O O
in O O
S-100 O O
protein O O
staining O O
. O O

By O O
2 O O
hours O O
, O O
parvalbumin O O
- O O
staining O O
changed O O
in O O
the O O
central O O
SNR O O
indicating O O
neuronal B-Disease B-Disease
damage I-Disease I-Disease
, O O
and O O
Nissl O O
- O O
staining O O
visualized O O
some O O
neuronal O O
distortion O O
. O O

Staining O O
for O O
serum O O
- O O
proteins O O
occurred O O
in O O
a O O
patchy O O
manner O O
throughout O O
the O O
forebrain O O
during O O
the O O
first O O
hours O O
. O O

By O O
6 O O
h O O
, O O
vasogenic B-Disease B-Disease
edema I-Disease I-Disease
covered O O
the O O
lesioned B-Disease O
SNR I-Disease O
. O O

By O O
24 O O
h O O
, O O
glial O O
and O O
neuronal O O
markers O O
indicated O O
a O O
massive O O
lesion O O
in O O
the O O
center O O
of O O
SNR O O
. O O

By O O
48 O O
- O O
72 O O
h O O
, O O
astrocytes O O
surrounding O O
the O O
lesion O O
increased O O
in O O
size O O
, O O
and O O
polymorphic O O
phagocytotic O O
cells O O
invaded O O
the O O
damaged O O
area O O
. O O

In O O
a O O
further O O
group O O
of O O
animals O O
surviving O O
1 O O
to O O
5 O O
days O O
, O O
conventional O O
paraffin O O
- O O
sections O O
confirmed O O
the O O
neuronal O O
and O O
glial O O
damage B-Disease O
of I-Disease O
SNR I-Disease O
. O O

Additional O O
pathology O O
of O O
similar O O
quality O O
was O O
found O O
in O O
the O O
globus O O
pallidus O O
. O O

Since O O
astrocytes O O
were O O
always O O
damaged O O
in O O
parallel O O
with O O
neurons O O
in O O
SNR O O
it O O
is O O
proposed O O
that O O
the O O
anatomical O O
and O O
functional O O
interrelationship O O
between O O
neurons O O
and O O
astrocytes O O
is O O
particularly O O
tight O O
in O O
SNR O O
. O O

Both O O
cell O O
elements O O
may O O
suffer O O
in O O
common O O
from O O
metabolic O O
disturbance O O
and O O
neurotransmitter B-Disease B-Disease
dysfunction I-Disease I-Disease
as O O
occur O O
during O O
massive O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

Neuroprotective O O
effects O O
of O O
melatonin O O
upon O O
the O O
offspring O O
cerebellar O O
cortex O O
in O O
the O O
rat O O
model O O
of O O
BCNU O O
- O O
induced O O
cortical B-Disease B-Disease
dysplasia I-Disease I-Disease
. O O

Cortical B-Disease B-Disease
dysplasia I-Disease I-Disease
is O O
a O O
malformation O O
characterized O O
by O O
defects O O
in O O
proliferation O O
, O O
migration O O
and O O
maturation O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
alterations O O
in O O
offspring O O
rat O O
cerebellum O O
induced O O
by O O
maternal O O
exposure O O
to O O
carmustine- O O
[ O O
1,3-bis O O
( O O
2-chloroethyl O O
) O O
-1-nitrosoure O O
] O O
( O O
BCNU O O
) O O
and O O
to O O
investigate O O
the O O
effects O O
of O O
exogenous O O
melatonin O O
upon O O
cerebellar O O
BCNU O O
- O O
induced O O
cortical B-Disease B-Disease
dysplasia I-Disease I-Disease
, O O
using O O
histological O O
and O O
biochemical O O
analyses O O
. O O

Pregnant O O
Wistar O O
rats O O
were O O
assigned O O
to O O
five O O
groups O O
: O O
intact O O
- O O
control O O
, O O
saline O O
- O O
control O O
, O O
melatonin O O
- O O
treated O O
, O O
BCNU O O
- O O
exposed O O
and O O
BCNU O O
- O O
exposed O O
plus O O
melatonin O O
. O O

Rats O O
were O O
exposed O O
to O O
BCNU O O
on O O
embryonic O O
day O O
15 O O
and O O
melatonin O O
was O O
given O O
until O O
delivery O O
. O O

Immuno O O
/ O O
histochemistry O O
and O O
electron O O
microscopy O O
were O O
carried O O
out O O
on O O
the O O
offspring O O
cerebellum O O
, O O
and O O
levels O O
of O O
malondialdehyde O O
and O O
superoxide O O
dismutase O O
were O O
determined O O
. O O

Histopathologically O O
, O O
typical O O
findings O O
were O O
observed O O
in O O
the O O
cerebella O O
from O O
the O O
control O O
groups O O
, O O
but O O
the O O
findings O O
consistent O O
with O O
early O O
embryonic O O
development O O
were O O
noted O O
in O O
BCNU O O
- O O
exposed O O
cortical B-Disease B-Disease
dysplasia I-Disease I-Disease
group O O
. O O

There O O
was O O
a O O
marked O O
increase O O
in O O
the O O
number O O
of O O
TUNEL O O
positive O O
cells O O
and O O
nestin O O
positive O O
cells O O
in O O
BCNU O O
- O O
exposed O O
group O O
, O O
but O O
a O O
decreased O O
immunoreactivity O O
to O O
glial O O
fibrillary O O
acidic O O
protein O O
, O O
synaptophysin O O
and O O
transforming O O
growth O O
factor O O
beta1 O O
was O O
observed O O
, O O
indicating O O
a O O
delayed O O
maturation O O
, O O
and O O
melatonin O O
significantly O O
reversed O O
these O O
changes O O
. O O

Malondialdehyde O O
level O O
in O O
BCNU O O
- O O
exposed O O
group O O
was O O
higher O O
than O O
those O O
in O O
control O O
groups O O
and O O
melatonin O O
decreased O O
malondialdehyde O O
levels O O
in O O
BCNU O O
group O O
( O O
P<0.01 O O
) O O
, O O
while O O
there O O
were O O
no O O
significant O O
differences O O
in O O
the O O
superoxide O O
dismutase O O
levels O O
between O O
these O O
groups O O
. O O

These O O
data O O
suggest O O
that O O
exposure O O
of O O
animals O O
to O O
BCNU O O
during O O
pregnancy O O
leads O O
to O O
delayed O O
maturation O O
of O O
offspring O O
cerebellum O O
and O O
melatonin O O
protects O O
the O O
cerebellum O O
against O O
the O O
effects O O
of O O
BCNU O O
. O O

Reduced O O
cardiotoxicity B-Disease B-Disease
of O O
doxorubicin O O
given O O
in O O
the O O
form O O
of O O
N- O O
( O O
2-hydroxypropyl O O
) O O
methacrylamide O O
conjugates O O
: O O
and O O
experimental O O
study O O
in O O
the O O
rat O O
. O O

A O O
rat O O
model O O
was O O
used O O
to O O
evaluate O O
the O O
general O O
acute O O
toxicity B-Disease B-Disease
and O O
the O O
late O O
cardiotoxicity B-Disease B-Disease
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
( O O
DOX O O
) O O
given O O
either O O
as O O
free O O
drug O O
or O O
in O O
the O O
form O O
of O O
three O O
N- O O
( O O
2-hydroxypropyl O O
) O O
methacrylamide O O
( O O
HPMA O O
) O O
copolymer O O
conjugates O O
. O O

In O O
these O O
HPMA O O
copolymers O O
, O O
DOX O O
was O O
covalently O O
bound O O
via O O
peptide O O
linkages O O
that O O
were O O
either O O
non O O
- O O
biodegradable O O
( O O
Gly O O
- O O
Gly O O
) O O
or O O
degradable O O
by O O
lysosomal O O
proteinases O O
( O O
Gly O O
- O O
Phe O O
- O O
Leu O O
- O O
Gly O O
) O O
. O O

In O O
addition O O
, O O
one O O
biodegradable O O
conjugate O O
containing O O
galactosamine O O
was O O
used O O
; O O
this O O
residue O O
was O O
targeted O O
to O O
the O O
liver O O
. O O

Over O O
the O O
first O O
3 O O
weeks O O
after O O
the O O
i.v O O
. O O

administration O O
of O O
free O O
and O O
polymer O O
- O O
bound O O
DOX O O
, O O
all O O
animals O O
showed O O
a O O
transient O O
reduction O O
in O O
body O O
weight O O
. O O

However O O
, O O
the O O
maximal O O
reduction O O
in O O
body O O
weight O O
seen O O
in O O
animals O O
that O O
received O O
polymer O O
- O O
bound O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
) O O
was O O
significantly O O
lower O O
than O O
that O O
observed O O
in O O
those O O
that O O
received O O
free O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
) O O
or O O
a O O
mixture O O
of O O
the O O
unmodified O O
parent O O
HPMA O O
copolymer O O
and O O
free O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
; O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

Throughout O O
the O O
study O O
( O O
20 O O
weeks O O
) O O
, O O
deaths O O
related O O
to O O
cardiotoxicity B-Disease B-Disease
were O O
observed O O
only O O
in O O
animals O O
that O O
received O O
either O O
free O O
DOX O O
or O O
the O O
mixture O O
of O O
HPMA O O
copolymer O O
and O O
free O O
DOX O O
; O O
in O O
these O O
cases O O
, O O
histological O O
investigations O O
revealed O O
marked O O
changes O O
in O O
the O O
heart O O
that O O
were O O
consistent O O
with O O
DOX O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
. O O

Sequential O O
measurements O O
of O O
cardiac O O
output O O
in O O
surviving O O
animals O O
that O O
received O O
either O O
free O O
DOX O O
or O O
the O O
mixture O O
of O O
HPMA O O
copolymer O O
and O O
free O O
DOX O O
showed O O
a O O
reduction O O
of O O
approximately O O
30 O O
% O O
in O O
function O O
beginning O O
at O O
the O O
4th O O
week O O
after O O
drug O O
administration O O
. O O

The O O
heart O O
rate O O
in O O
these O O
animals O O
was O O
approximately O O
12 O O
% O O
lower O O
than O O
that O O
measured O O
in O O
age O O
- O O
matched O O
control O O
rats O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

Animals O O
that O O
were O O
given O O
the O O
HPMA O O
copolymer O O
conjugates O O
containing O O
DOX O O
exhibited O O
no O O
significant O O
change O O
in O O
cardiac O O
output O O
throughout O O
the O O
study O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

In O O
addition O O
, O O
no O O
significant O O
histological O O
change O O
was O O
observed O O
in O O
the O O
heart O O
of O O
animals O O
that O O
received O O
DOX O O
in O O
the O O
form O O
of O O
HPMA O O
copolymer O O
conjugates O O
and O O
were O O
killed O O
at O O
the O O
end O O
of O O
the O O
study O O
. O O

However O O
, O O
these O O
animals O O
had O O
shown O O
a O O
significant O O
increase O O
in O O
heart O O
rate O O
beginning O O
at O O
8 O O
weeks O O
after O O
drug O O
administration O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

Corneal B-Disease B-Disease
ulcers I-Disease I-Disease
associated O O
with O O
aerosolized O O
crack O O
cocaine O O
use O O
. O O

PURPOSE O O
: O O
We O O
report O O
4 O O
cases O O
of O O
corneal B-Disease B-Disease
ulcers I-Disease I-Disease
associated O O
with O O
drug B-Disease B-Disease
abuse I-Disease I-Disease
. O O

The O O
pathogenesis O O
of O O
these O O
ulcers B-Disease B-Disease
and O O
management O O
of O O
these O O
patients O O
are O O
also O O
reviewed O O
. O O

METHODS O O
: O O
Review O O
of O O
all O O
cases O O
of O O
corneal B-Disease B-Disease
ulcers I-Disease I-Disease
associated O O
with O O
drug B-Disease B-Disease
abuse I-Disease I-Disease
seen O O
at O O
our O O
institution O O
from O O
July O O
2006 O O
to O O
December O O
2006 O O
. O O

RESULTS O O
: O O
Four O O
patients O O
with O O
corneal B-Disease B-Disease
ulcers I-Disease I-Disease
associated O O
with O O
crack O O
cocaine O O
use O O
were O O
reviewed O O
. O O

All O O
corneal B-Disease B-Disease
ulcers I-Disease I-Disease
were O O
cultured O O
, O O
and O O
the O O
patients O O
were O O
admitted O O
to O O
the O O
hospital O O
for O O
intensive O O
topical O O
antibiotic O O
treatment O O
. O O

Each O O
patient O O
received O O
comprehensive O O
health O O
care O O
, O O
including O O
medical O O
and O O
substance B-Disease B-Disease
abuse I-Disease I-Disease
consultations O O
. O O

Streptococcal O O
organisms O O
were O O
found O O
in O O
3 O O
cases O O
and O O
Capnocytophaga O O
and O O
Brevibacterium O O
casei O O
in O O
1 O O
patient O O
. O O

The O O
infections B-Disease B-Disease
responded O O
to O O
antibiotic O O
treatment O O
. O O

Two O O
patients O O
needed O O
a O O
lateral O O
tarsorrhaphy O O
for O O
persistent O O
epithelial B-Disease B-Disease
defects I-Disease I-Disease
. O O

CONCLUSIONS O O
: O O
Aerosolized O O
crack O O
cocaine O O
use O O
can O O
be O O
associated O O
with O O
the O O
development O O
of O O
corneal B-Disease B-Disease
ulcers I-Disease I-Disease
. O O

Drug B-Disease B-Disease
abuse I-Disease I-Disease
provides O O
additional O O
challenges O O
for O O
management O O
. O O

Not O O
only O O
treatment O O
of O O
their O O
infections B-Disease B-Disease
but O O
also O O
the O O
overall O O
poor O O
health O O
of O O
the O O
patients O O
and O O
increased O O
risk O O
of O O
noncompliance O O
need O O
to O O
be O O
addressed O O
. O O

Comprehensive O O
care O O
may O O
provide O O
the O O
patient O O
the O O
opportunity O O
to O O
discontinue O O
their O O
substance B-Disease B-Disease
abuse I-Disease I-Disease
, O O
improve O O
their O O
overall O O
health O O
, O O
and O O
prevent O O
future O O
corneal O B-Disease
complications O I-Disease
. O O

Topical O O
0.025 O O
% O O
capsaicin O O
in O O
chronic O O
post B-Disease B-Disease
- I-Disease I-Disease
herpetic I-Disease I-Disease
neuralgia I-Disease I-Disease
: O O
efficacy O O
, O O
predictors O O
of O O
response O O
and O O
long O O
- O O
term O O
course O O
. O O

In O O
order O O
to O O
evaluate O O
the O O
efficacy O O
, O O
time O O
- O O
course O O
of O O
action O O
and O O
predictors O O
of O O
response O O
to O O
topical O O
capsaicin O O
, O O
39 O O
patients O O
with O O
chronic O O
post B-Disease B-Disease
- I-Disease I-Disease
herpetic I-Disease I-Disease
neuralgia I-Disease I-Disease
( O O
PHN B-Disease B-Disease
) O O
, O O
median O O
duration O O
24 O O
months O O
, O O
were O O
treated O O
with O O
0.025 O O
% O O
capsaicin O O
cream O O
for O O
8 O O
weeks O O
. O O

During O O
therapy O O
the O O
patients O O
rated O O
their O O
pain B-Disease B-Disease
on O O
a O O
visual O O
analogue O O
scale O O
( O O
VAS O O
) O O
and O O
a O O
verbal O O
outcome O O
scale O O
. O O

A O O
follow O O
- O O
up O O
investigation O O
was O O
performed O O
10 O O
- O O
12 O O
months O O
after O O
study O O
onset O O
on O O
the O O
patients O O
who O O
had O O
improved O O
. O O

Nineteen O O
patients O O
( O O
48.7 O O
% O O
) O O
substantially O O
improved O O
after O O
the O O
8-week O O
trial O O
; O O
5 O O
( O O
12.8 O O
% O O
) O O
discontinued O O
therapy O O
due O O
to O O
side O O
- O O
effects O O
such O O
as O O
intolerable O O
capsaicin O O
- O O
induced O O
burning O B-Disease
sensations O I-Disease
( O O
4 O O
) O O
or O O
mastitis B-Disease B-Disease
( O O
1 O O
) O O
; O O
15 O O
( O O
38.5 O O
% O O
) O O
reported O O
no O O
benefit O O
. O O

The O O
decrease O O
in O O
VAS O O
ratings O O
was O O
significant O O
after O O
2 O O
weeks O O
of O O
continuous O O
application O O
. O O

Of O O
the O O
responders O O
72.2 O O
% O O
were O O
still O O
improved O O
at O O
the O O
follow O O
- O O
up O O
; O O
only O O
one O O
- O O
third O O
of O O
them O O
had O O
continued O O
application O O
irregularly O O
. O O

Treatment O O
effect O O
was O O
not O O
dependent O O
on O O
patient O O
's O O
age O O
, O O
duration O O
or O O
localization O O
of O O
PHN B-Disease B-Disease
( O O
trigeminal O O
involvement O O
was O O
excluded O O
) O O
, O O
sensory B-Disease B-Disease
disturbance I-Disease I-Disease
or O O
pain B-Disease B-Disease
character O O
. O O

Treatment O O
response O O
was O O
not O O
correlated O O
with O O
the O O
incidence O O
, O O
time O O
- O O
course O O
or O O
severity O O
of O O
capsaicin O O
- O O
induced O O
burning O O
. O O

If O O
confirmed O O
in O O
controlled O O
trials O O
, O O
the O O
long O O
- O O
term O O
results O O
of O O
this O O
open O O
, O O
non O O
- O O
randomized O O
study O O
might O O
indicate O O
that O O
the O O
analgesic O O
effect O O
of O O
capsaicin O O
in O O
PHN B-Disease B-Disease
is O O
mediated O O
by O O
both O O
interference O O
with O O
neuropeptide O O
metabolism O O
and O O
morphological O O
changes O O
( O O
perhaps O O
degeneration O O
) O O
of O O
nociceptive O O
afferents O O
. O O

Myo O O
- O O
inositol-1-phosphate O O
( O O
MIP O O
) O O
synthase O O
inhibition O O
: O O
in O O
- O O
vivo O O
study O O
in O O
rats O O
. O O

Lithium O O
and O O
valproate O O
are O O
the O O
prototypic O O
mood O O
stabilizers O O
and O O
have O O
diverse O O
structures O O
and O O
targets O O
. O O

Both O O
drugs O O
influence O O
inositol O O
metabolism O O
. O O

Lithium O O
inhibits O O
IMPase O O
and O O
valproate O O
inhibits O O
MIP O O
synthase O O
. O O

This O O
study O O
shows O O
that O O
MIP O O
synthase O O
inhibition O O
does O O
not O O
replicate O O
or O O
augment O O
the O O
effects O O
of O O
lithium O O
in O O
the O O
inositol O O
sensitive O O
pilocarpine O O
- O O
induced O O
seizures B-Disease B-Disease
model O O
. O O

This O O
lack O O
of O O
effects O O
may O O
stem O O
from O O
the O O
low O O
contribution O O
of O O
de O O
- O O
novo O O
synthesis O O
to O O
cellular O O
inositol O O
supply O O
or O O
to O O
the O O
inhibition O O
of O O
the O O
de O O
- O O
novo O O
synthesis O O
by O O
lithium O O
itself O O
. O O

Non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
- O O
associated O O
acute O O
interstitial B-Disease B-Disease
nephritis I-Disease I-Disease
with O O
granular O O
tubular O O
basement O O
membrane O O
deposits O O
. O O

Acute B-Disease B-Disease
tubulo I-Disease I-Disease
- I-Disease I-Disease
interstitial I-Disease I-Disease
nephritis I-Disease I-Disease
( O O
ATIN B-Disease B-Disease
) O O
is O O
an O O
important O O
cause O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
resulting O O
from O O
a O O
variety O O
of O O
insults O O
, O O
including O O
immune O O
complex O O
- O O
mediated O O
tubulo B-Disease O
- I-Disease O
interstitial I-Disease B-Disease
injury I-Disease I-Disease
, O O
but O O
drugs O O
such O O
as O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
are O O
a O O
far O O
more O O
frequent O O
cause O O
. O O

Overall O O
, O O
as O O
an O O
entity O O
, O O
ATIN B-Disease B-Disease
remains O O
under O O
- O O
diagnosed O O
, O O
as O O
symptoms O O
resolve O O
spontaneously O O
if O O
the O O
medication O O
is O O
stopped O O
. O O

We O O
report O O
on O O
a O O
14-year O O
- O O
old O O
boy O O
who O O
developed O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
2 O O
weeks O O
after O O
aortic O O
valve O O
surgery O O
. O O

He O O
was O O
put O O
on O O
aspirin O O
following O O
surgery O O
and O O
took O O
ibuprofen O O
for O O
fever B-Disease B-Disease
for O O
nearly O O
a O O
week O O
prior O O
to O O
presentation O O
. O O

He O O
then O O
presented O O
to O O
the O O
emergency O O
department O O
feeling O O
quite O O
ill O O
and O O
was O O
found O O
to O O
have O O
a O O
blood O O
urea O O
nitrogen O O
( O O
BUN O O
) O O
concentration O O
of O O
of O O
147 O O
mg O O
/ O O
dl O O
, O O
creatinine O O
of O O
15.3 O O
mg O O
/ O O
dl O O
and O O
serum O O
potassium O O
of O O
8.7 O O
mEq O O
/ O O
l O O
. O O

Dialysis O O
was O O
immediately O O
initiated O O
. O O

A O O
kidney O O
biopsy O O
showed O O
inflammatory O O
infiltrate O O
consistent O O
with O O
ATIN B-Disease B-Disease
. O O

However O O
, O O
in O O
the O O
tubular O O
basement O O
membrane O O
( O O
TBM O O
) O O
, O O
very O O
intense O O
granular O O
deposits O O
of O O
polyclonal O O
IgG O O
and O O
C3 O O
were O O
noted O O
. O O

He O O
needed O O
dialysis O O
for O O
2 O O
weeks O O
and O O
was O O
treated O O
successfully O O
with O O
steroids O O
for O O
6 O O
months O O
. O O

His O O
renal O O
recovery O O
and O O
disappearance O O
of O O
proteinuria B-Disease B-Disease
took O O
a O O
year O O
. O O

In O O
conclusion O O
, O O
this O O
is O O
a O O
first O O
report O O
of O O
NSAIDs O O
- O O
associated O O
ATIN B-Disease B-Disease
, O O
showing O O
deposits O O
of O O
granular O O
immune O O
complex O O
present O O
only O O
in O O
the O O
TBM O O
and O O
not O O
in O O
the O O
glomeruli O O
. O O

Rifampicin O O
- O O
associated O O
segmental O O
necrotizing O O
glomerulonephritis B-Disease B-Disease
in O O
staphylococcal B-Disease B-Disease
endocarditis B-Disease I-Disease
. O O

Segmental O O
necrotising O O
glomerulonephritis B-Disease B-Disease
has O O
been O O
reported O O
as O O
complication O O
of O O
rifampicin O O
therapy O O
in O O
patients O O
receiving O O
treatment O O
for O O
tuberculosis B-Disease B-Disease
. O O

Changing O O
epidemiology O O
of O O
infections B-Disease B-Disease
such O O
as O O
infective B-Disease B-Disease
endocarditis I-Disease I-Disease
( O O
IE B-Disease B-Disease
) O O
has O O
led O O
to O O
an O O
increase O O
in O O
the O O
use O O
of O O
rifampicin O O
for O O
Staphylococcal B-Disease B-Disease
infections I-Disease I-Disease
. O O

We O O
describe O O
a O O
case O O
of O O
a O O
patient O O
with O O
Staphylococcal B-Disease B-Disease
IE B-Disease I-Disease
who O O
developed O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
secondary O O
to O O
a O O
segmental O O
necrotising O O
glomerulonephritis B-Disease B-Disease
while O O
being O O
treated O O
with O O
rifampicin O O
, O O
and O O
review O O
the O O
literature O O
regarding O O
this O O
complication O O
of O O
rifampicin O O
therapy O O
. O O

Rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
Iranian O O
patients O O
with O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
virus I-Disease I-Disease
infection I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Lamivudine O O
is O O
used O O
for O O
the O O
treatment O O
of O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
patients O O
. O O

Recent O O
studies O O
show O O
that O O
the O O
YMDD O O
motif O O
mutants O O
( O O
resistant O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
virus O O
) O O
occur O O
as O O
natural O O
genome O O
variability O O
in O O
lamivudine O O
- O O
untreated O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
patients O O
. O O

In O O
this O O
study O O
we O O
aimed O O
to O O
determine O O
the O O
rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
patients O O
in O O
Iran O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
77 O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
patients O O
who O O
had O O
not O O
been O O
treated O O
with O O
lamivudine O O
were O O
included O O
in O O
the O O
study O O
. O O

Serum O O
samples O O
from O O
patients O O
were O O
tested O O
by O O
polymerase O O
chain O O
reaction O O
- O O
restriction O O
fragment O O
length O O
polymorphism O O
( O O
PCR O O
- O O
RFLP O O
) O O
for O O
detection O O
of O O
YMDD O O
motif O O
mutants O O
. O O

All O O
patients O O
were O O
also O O
tested O O
for O O
liver O O
enzymes O O
, O O
anti O O
- O O
HCV O O
, O O
HBeAg O O
, O O
and O O
anti O O
- O O
HBe O O
. O O

RESULTS O O
: O O
Of O O
the O O
77 O O
patients O O
enrolled O O
in O O
the O O
study O O
, O O
73 O O
% O O
were O O
male O O
and O O
27 O O
% O O
were O O
female O O
. O O

Mean O O
ALT O O
and O O
AST O O
levels O O
were O O
124.4+ O O
/ O O
-73.4 O O
and O O
103.1+ O O
/ O O
-81 O O
IU O O
/ O O
l O O
, O O
respectively O O
. O O

HBeAg O O
was O O
positive O O
in O O
40 O O
% O O
and O O
anti O O
- O O
HBe O O
in O O
60 O O
% O O
of O O
the O O
patients O O
. O O

Anti O O
- O O
HCV O O
was O O
negative O O
in O O
all O O
of O O
them O O
. O O

YMDD O O
motif O O
mutants O O
were O O
not O O
detected O O
in O O
any O O
of O O
the O O
patients O O
despite O O
the O O
liver O O
enzyme O O
levels O O
and O O
the O O
presence O O
of O O
HBeAg O O
or O O
anti O O
- O O
HBe O O
. O O

CONCLUSION O O
: O O
Although O O
the O O
natural O O
occurrence O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
patients O O
with O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
has O O
been O O
reported O O
, O O
these O O
mutants O O
were O O
not O O
detected O O
in O O
Iranian O O
lamivudine O O
- O O
untreated O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
B I-Disease I-Disease
patients O O
. O O

Branch O B-Disease
retinal B-Disease I-Disease
vein I-Disease I-Disease
occlusion I-Disease I-Disease
and O O
fluoxetine O O
. O O

A O O
case O O
of O O
branch O O
retinal B-Disease B-Disease
vein I-Disease I-Disease
occlusion I-Disease I-Disease
associated O O
with O O
fluoxetine O O
- O O
induced O O
secondary O O
hypertension B-Disease B-Disease
is O O
described O O
. O O

Although O O
an O O
infrequent O O
complication O O
of O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
therapy O O
, O O
it O O
is O O
important O O
that O O
ophthalmologists O O
are O O
aware O O
that O O
these O O
agents O O
can O O
cause O O
hypertension B-Disease B-Disease
because O O
this O O
class O O
of O O
drugs O O
is O O
widely O O
prescribed O O
. O O

The O O
differential O O
effects O O
of O O
bupivacaine O O
and O O
lidocaine O O
on O O
prostaglandin O O
E2 O O
release O O
, O O
cyclooxygenase O O
gene O O
expression O O
and O O
pain B-Disease B-Disease
in O O
a O O
clinical O O
pain B-Disease B-Disease
model O O
. O O

BACKGROUND O O
: O O
In O O
addition O O
to O O
blocking O O
nociceptive O O
input O O
from O O
surgical O O
sites O O
, O O
long O O
- O O
acting O O
local O O
anesthetics O O
might O O
directly O O
modulate O O
inflammation B-Disease B-Disease
. O O

In O O
the O O
present O O
study O O
, O O
we O O
describe O O
the O O
proinflammatory O O
effects O O
of O O
bupivacaine O O
on O O
local O O
prostaglandin O O
E2 O O
( O O
PGE2 O O
) O O
production O O
and O O
cyclooxygenase O O
( O O
COX O O
) O O
gene O O
expression O O
that O O
increases O O
postoperative B-Disease B-Disease
pain I-Disease I-Disease
in O O
human O O
subjects O O
. O O

METHODS O O
: O O
Subjects O O
( O O
n O O
= O O
114 O O
) O O
undergoing O O
extraction O O
of O O
impacted O O
third O O
molars O O
received O O
either O O
2 O O
% O O
lidocaine O O
or O O
0.5 O O
% O O
bupivacaine O O
before O O
surgery O O
and O O
either O O
rofecoxib O O
50 O O
mg O O
or O O
placebo O O
orally O O
90 O O
min O O
before O O
surgery O O
and O O
for O O
the O O
following O O
48 O O
h. O O
Oral O O
mucosal O O
biopsies O O
were O O
taken O O
before O O
surgery O O
and O O
48 O O
h O O
after O O
surgery O O
. O O

After O O
extraction O O
, O O
a O O
microdialysis O O
probe O O
was O O
placed O O
at O O
the O O
surgical O O
site O O
for O O
PGE2 O O
and O O
thromboxane O O
B2 O O
( O O
TXB2 O O
) O O
measurements O O
. O O

RESULTS O O
: O O
The O O
bupivacaine O O
/ O O
rofecoxib O O
group O O
reported O O
significantly O O
less O O
pain B-Disease B-Disease
, O O
as O O
assessed O O
by O O
a O O
visual O O
analog O O
scale O O
, O O
compared O O
with O O
the O O
other O O
three O O
treatment O O
groups O O
over O O
the O O
first O O
4 O O
h. O O
However O O
, O O
the O O
bupivacaine O O
/ O O
placebo O O
group O O
reported O O
significantly O O
more O O
pain B-Disease B-Disease
at O O
24 O O
h O O
and O O
PGE2 O O
levels O O
during O O
the O O
first O O
4 O O
h O O
were O O
significantly O O
higher O O
than O O
the O O
other O O
three O O
treatment O O
groups O O
. O O

Moreover O O
, O O
bupivacaine O O
significantly O O
increased O O
COX-2 O O
gene O O
expression O O
at O O
48 O O
h O O
as O O
compared O O
with O O
the O O
lidocaine O O
/ O O
placebo O O
group O O
. O O

Thromboxane O O
levels O O
were O O
not O O
significantly O O
affected O O
by O O
any O O
of O O
the O O
treatments O O
, O O
indicating O O
that O O
the O O
effects O O
seen O O
were O O
attributable O O
to O O
inhibition O O
of O O
COX-2 O O
, O O
but O O
not O O
COX-1 O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
bupivacaine O O
stimulates O O
COX-2 O O
gene O O
expression O O
after O O
tissue B-Disease B-Disease
injury I-Disease I-Disease
, O O
which O O
is O O
associated O O
with O O
higher O O
PGE2 O O
production O O
and O O
pain B-Disease B-Disease
after O O
the O O
local O O
anesthetic O O
effect O O
dissipates O O
. O O

p75NTR O O
expression O O
in O O
rat O O
urinary O O
bladder O O
sensory O O
neurons O O
and O O
spinal O O
cord O O
with O O
cyclophosphamide O O
- O O
induced O O
cystitis B-Disease B-Disease
. O O

A O O
role O O
for O O
nerve O O
growth O O
factor O O
( O O
NGF O O
) O O
in O O
contributing O O
to O O
increased O O
voiding O O
frequency O O
and O O
altered O O
sensation O O
from O O
the O O
urinary O O
bladder O O
has O O
been O O
suggested O O
. O O

Previous O O
studies O O
have O O
examined O O
the O O
expression O O
and O O
regulation O O
of O O
tyrosine O O
kinase O O
receptors O O
( O O
Trks O O
) O O
in O O
micturition O O
reflexes O O
with O O
urinary B-Disease B-Disease
bladder I-Disease I-Disease
inflammation I-Disease I-Disease
. O O

The O O
present O O
studies O O
examine O O
the O O
expression O O
and O O
regulation O O
of O O
another O O
receptor O O
known O O
to O O
bind O O
NGF O O
, O O
p75 O O
( O O
NTR O O
) O O
, O O
after O O
various O O
durations O O
of O O
bladder B-Disease B-Disease
inflammation I-Disease I-Disease
induced O O
by O O
cyclophosphamide O O
( O O
CYP O O
) O O
. O O

CYP O O
- O O
induced O O
cystitis B-Disease B-Disease
increased O O
( O O
P O O
< O O
or O O
= O O
0.001 O O
) O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
the O O
superficial O O
lateral O O
and O O
medial O O
dorsal O O
horn O O
in O O
L1-L2 O O
and O O
L6-S1 O O
spinal O O
segments O O
. O O

The O O
number O O
of O O
p75 O O
( O O
NTR O O
) O O
-immunoreactive O O
( O O
-IR O O
) O O
cells O O
in O O
the O O
lumbosacral O O
dorsal O O
root O O
ganglia O O
( O O
DRG O O
) O O
also O O
increased O O
( O O
P O O
< O O
or O O
= O O
0.05 O O
) O O
with O O
CYP O O
- O O
induced O O
cystitis B-Disease B-Disease
( O O
acute O O
, O O
intermediate O O
, O O
and O O
chronic O O
) O O
. O O

Quantitative O O
, O O
real O O
- O O
time O O
polymerase O O
chain O O
reaction O O
also O O
demonstrated O O
significant O O
increases O O
( O O
P O O
< O O
or O O
= O O
0.01 O O
) O O
in O O
p75 O O
( O O
NTR O O
) O O
mRNA O O
in O O
DRG O O
with O O
intermediate O O
and O O
chronic O O
CYP O O
- O O
induced O O
cystitis B-Disease B-Disease
. O O

Retrograde O O
dye O O
- O O
tracing O O
techniques O O
with O O
Fastblue O O
were O O
used O O
to O O
identify O O
presumptive O O
bladder O O
afferent O O
cells O O
in O O
the O O
lumbosacral O O
DRG O O
. O O

In O O
bladder O O
afferent O O
cells O O
in O O
DRG O O
, O O
p75 O O
( O O
NTR O O
) O O
-IR O O
was O O
also O O
increased O O
( O O
P O O
< O O
or O O
= O O
0.01 O O
) O O
with O O
cystitis B-Disease B-Disease
. O O

In O O
addition O O
to O O
increases O O
in O O
p75 O O
( O O
NTR O O
) O O
-IR O O
in O O
DRG O O
cell O O
bodies O O
, O O
increases O O
( O O
P O O
< O O
or O O
= O O
0.001 O O
) O O
in O O
pericellular O O
( O O
encircling O O
DRG O O
cells O O
) O O
p75 O O
( O O
NTR O O
) O O
-IR O O
in O O
DRG O O
also O O
increased O O
. O O

Confocal O O
analyses O O
demonstrated O O
that O O
pericellular O O
p75 O O
( O O
NTR O O
) O O
-IR O O
was O O
not O O
colocalized O O
with O O
the O O
glial O O
marker O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
( O O
GFAP O O
) O O
. O O

These O O
studies O O
demonstrate O O
that O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
micturition O O
reflexes O O
is O O
present O O
constitutively O O
and O O
modified O O
by O O
bladder B-Disease B-Disease
inflammation I-Disease I-Disease
. O O

The O O
functional O O
significance O O
of O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
micturition O O
reflexes O O
remains O O
to O O
be O O
determined O O
. O O

Azathioprine O O
- O O
induced O O
suicidal O O
erythrocyte O O
death O O
. O O

BACKGROUND O O
: O O
Azathioprine O O
is O O
widely O O
used O O
as O O
an O O
immunosuppressive O O
drug O O
. O O

The O O
side O O
effects O O
of O O
azathioprine O O
include O O
anemia B-Disease B-Disease
, O O
which O O
has O O
been O O
attributed O O
to O O
bone O B-Disease
marrow O I-Disease
suppression O I-Disease
. O O

Alternatively O O
, O O
anemia B-Disease B-Disease
could O O
result O O
from O O
accelerated O O
suicidal O O
erythrocyte O O
death O O
or O O
eryptosis O O
, O O
which O O
is O O
characterized O O
by O O
exposure O O
of O O
phosphatidylserine O O
( O O
PS O O
) O O
at O O
the O O
erythrocyte O O
surface O O
and O O
by O O
cell O O
shrinkage O O
. O O

METHODS O O
: O O
The O O
present O O
experiments O O
explored O O
whether O O
azathioprine O O
influences O O
eryptosis O B-Disease
. O O

According O O
to O O
annexin O O
V O O
binding O O
, O O
erythrocytes O O
from O O
patients O O
indeed O O
showed O O
a O O
significant O O
increase O O
of O O
PS O O
exposure O O
within O O
1 O O
week O O
of O O
treatment O O
with O O
azathioprine O O
. O O

In O O
a O O
second O O
series O O
, O O
cytosolic O O
Ca2 O O
+ O O
activity O O
( O O
Fluo3 O O
fluorescence O O
) O O
, O O
cell O O
volume O O
( O O
forward O O
scatter O O
) O O
, O O
and O O
PS O O
- O O
exposure O O
( O O
annexin O O
V O O
binding O O
) O O
were O O
determined O O
by O O
FACS O O
analysis O O
in O O
erythrocytes O O
from O O
healthy O O
volunteers O O
. O O

RESULTS O O
: O O
Exposure O O
to O O
azathioprine O O
( O O
> O O
or O O
= O O
2 O O
microg O O
/ O O
mL O O
) O O
for O O
48 O O
hours O O
increased O O
cytosolic O O
Ca2 O O
+ O O
activity O O
and O O
annexin O O
V O O
binding O O
and O O
decreased O O
forward O O
scatter O O
. O O

The O O
effect O O
of O O
azathioprine O O
on O O
both O O
annexin O O
V O O
binding O O
and O O
forward O O
scatter O O
was O O
significantly O O
blunted O O
in O O
the O O
nominal O O
absence O O
of O O
extracellular O O
Ca2 O O
+ O O
. O O

CONCLUSIONS O O
: O O
Azathioprine O O
triggers O O
suicidal O O
erythrocyte O O
death O O
, O O
an O O
effect O O
presumably O O
contributing O O
to O O
azathioprine O O
- O O
induced O O
anemia B-Disease B-Disease
. O O

Levetiracetam O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
suspected O O
idiopathic B-Disease B-Disease
epilepsy I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
To O O
assess O O
pharmacokinetics O O
, O O
efficacy O O
, O O
and O O
tolerability O O
of O O
oral O O
levetiracetam O O
administered O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
poorly O O
controlled O O
suspected O O
idiopathic B-Disease B-Disease
epilepsy I-Disease I-Disease
. O O

DESIGN O O
- O O
Open O O
- O O
label O O
, O O
noncomparative O O
clinical O O
trial O O
. O O

ANIMALS O O
: O O
12 O O
cats O O
suspected O O
to O O
have O O
idiopathic B-Disease B-Disease
epilepsy I-Disease I-Disease
that O O
was O O
poorly O O
controlled O O
with O O
phenobarbital O O
or O O
that O O
had O O
unacceptable O O
adverse O O
effects O O
when O O
treated O O
with O O
phenobarbital O O
. O O

PROCEDURES O O
: O O
Cats O O
were O O
treated O O
with O O
levetiracetam O O
( O O
20 O O
mg O O
/ O O
kg O O
[ O O
9.1 O O
mg O O
/ O O
lb O O
] O O
, O O
PO O O
, O O
q O O
8 O O
h O O
) O O
. O O

After O O
a O O
minimum O O
of O O
1 O O
week O O
of O O
treatment O O
, O O
serum O O
levetiracetam O O
concentrations O O
were O O
measured O O
before O O
and O O
2 O O
, O O
4 O O
, O O
and O O
6 O O
hours O O
after O O
drug O O
administration O O
, O O
and O O
maximum O O
and O O
minimum O O
serum O O
concentrations O O
and O O
elimination O O
half O O
- O O
life O O
were O O
calculated O O
. O O

Seizure B-Disease B-Disease
frequencies O O
before O O
and O O
after O O
initiation O O
of O O
levetiracetam O O
treatment O O
were O O
compared O O
, O O
and O O
adverse O O
effects O O
were O O
recorded O O
. O O

RESULTS O O
: O O
Median O O
maximum O O
serum O O
levetiracetam O O
concentration O O
was O O
25.5 O O
microg O O
/ O O
mL O O
, O O
median O O
minimum O O
serum O O
levetiracetam O O
concentration O O
was O O
8.3 O O
microg O O
/ O O
mL O O
, O O
and O O
median O O
elimination O O
half O O
- O O
life O O
was O O
2.9 O O
hours O O
. O O

Median O O
seizure B-Disease B-Disease
frequency O O
prior O O
to O O
treatment O O
with O O
levetiracetam O O
( O O
2.1 O O
seizures B-Disease B-Disease
/ O O
mo O O
) O O
was O O
significantly O O
higher O O
than O O
median O O
seizure B-Disease B-Disease
frequency O O
after O O
initiation O O
of O O
levetiracetam O O
treatment O O
( O O
0.42 O O
seizures B-Disease B-Disease
/ O O
mo O O
) O O
, O O
and O O
7 O O
of O O
10 O O
cats O O
were O O
classified O O
as O O
having O O
responded O O
to O O
levetiracetam O O
treatment O O
( O O
ie O O
, O O
reduction O O
in O O
seizure B-Disease B-Disease
frequency O O
of O O
> O O
or=50 O O
% O O
) O O
. O O

Two O O
cats O O
had O O
transient O O
lethargy B-Disease B-Disease
and O O
inappetence B-Disease B-Disease
. O O

CONCLUSIONS O O
AND O O
CLINICAL O O
RELEVANCE O O
: O O
Results O O
suggested O O
that O O
levetiracetam O O
is O O
well O O
tolerated O O
in O O
cats O O
and O O
may O O
be O O
useful O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
idiopathic B-Disease B-Disease
epilepsy I-Disease I-Disease
. O O

Serotonin O O
reuptake O O
inhibitors O O
, O O
paranoia B-Disease B-Disease
, O O
and O O
the O O
ventral O O
basal O O
ganglia O O
. O O

Antidepressants O O
have O O
previously O O
been O O
associated O O
with O O
paranoid B-Disease B-Disease
reactions O O
in O O
psychiatric O O
patients O O
. O O

Five O O
cases O O
of O O
paranoid B-Disease B-Disease
exacerbation O O
with O O
the O O
serotonin O O
reuptake O O
inhibitors O O
fluoxetine O O
and O O
amitriptyline O O
are O O
reported O O
here O O
. O O

Elements O O
common O O
to O O
these O O
cases O O
included O O
a O O
history O O
of O O
paranoid B-Disease B-Disease
symptomatology O O
and O O
the O O
concomitant O O
occurrence O O
of O O
depressive B-Disease B-Disease
and I-Disease I-Disease
psychotic I-Disease I-Disease
symptoms I-Disease I-Disease
. O O

Complicated O O
depressive B-Disease B-Disease
disorders I-Disease I-Disease
( O O
including O O
atypicality O O
of O O
course O O
and O O
symptomatology O O
, O O
chronicity O O
, O O
psychosis B-Disease B-Disease
, O O
bipolarity O B-Disease
, O O
and O O
secondary O O
onset O O
in O O
the O O
course O O
of O O
a O O
primary O O
psychosis B-Disease B-Disease
) O O
may O O
present O O
particular O O
vulnerability O O
to O O
paranoid B-Disease B-Disease
exacerbations O O
associated O O
with O O
serotonin O O
reuptake O O
inhibitors O O
. O O

Although O O
the O O
pharmacology O O
and O O
neurobiology O O
of O O
paranoia B-Disease B-Disease
remain O O
cryptic O O
, O O
several O O
mechanisms O O
, O O
including O O
5HT3 O O
receptor O O
- O O
mediated O O
dopamine O O
release O O
, O O
beta O O
- O O
noradrenergic O O
receptor O O
downregulation O O
, O O
or O O
GABAB O O
receptor O O
upregulation O O
acting O O
in O O
the O O
vicinity O O
of O O
the O O
ventral O O
basal O O
ganglia O O
( O O
possibly O O
in O O
lateral O O
orbitofrontal O O
or O O
anterior O O
cingulate O O
circuits O O
) O O
, O O
might O O
apply O O
to O O
this O O
phenomenon O O
. O O

These O O
cases O O
call O O
attention O O
to O O
possible O O
paranoid B-Disease B-Disease
exacerbations O O
with O O
serotonin O O
reuptake O O
blockers O O
in O O
select O O
patients O O
and O O
raise O O
neurobiological O O
considerations O O
regarding O O
paranoia B-Disease B-Disease
. O O

Clinical O O
comparison O O
of O O
cardiorespiratory O O
effects O O
during O O
unilateral O O
and O O
conventional O O
spinal O O
anaesthesia O O
. O O

BACKGROUND O O
: O O
Spinal O O
anaesthesia O O
is O O
widely O O
employed O O
in O O
clinical O O
practice O O
but O O
has O O
the O O
main O O
drawback O O
of O O
post O O
- O O
spinal O O
block O O
hypotension B-Disease B-Disease
. O O

Efforts O O
must O O
therefore O O
continue O O
to O O
be O O
made O O
to O O
obviate O O
this O O
setback O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
cardiovascular O O
and O O
respiratory O O
changes O O
during O O
unilateral O O
and O O
conventional O O
spinal O O
anaesthesia O O
. O O

METHODS O O
: O O
With O O
ethical O O
approval O O
, O O
we O O
studied O O
74 O O
American O O
Society O O
of O O
Anesthesiologists O O
( O O
ASA O O
) O O
, O O
physical O O
status O O
class O O
1 O O
and O O
2 O O
patients O O
scheduled O O
for O O
elective O O
unilateral O O
lower O O
limb O O
surgery O O
. O O

Patients O O
were O O
randomly O O
allocated O O
into O O
one O O
of O O
two O O
groups O O
: O O
lateral O O
and O O
conventional O O
spinal O O
anaesthesia O O
groups O O
. O O

In O O
the O O
lateral O O
position O O
with O O
operative O O
side O O
down O O
, O O
patients O O
recived O O
10 O O
mg O O
( O O
2mls O O
) O O
of O O
0.5 O O
% O O
hyperbaric O O
bupivacaine O O
through O O
a O O
25-gauge O O
spinal O O
needle O O
. O O

Patients O O
in O O
the O O
unilateral O O
group O O
were O O
maintained O O
in O O
the O O
lateral O O
position O O
for O O
15 O O
minutes O O
following O O
spinal O O
injection O O
while O O
those O O
in O O
the O O
conventional O O
group O O
were O O
turned O O
supine O O
immediately O O
after O O
injection O O
. O O

Blood O O
pressure O O
, O O
heart O O
rate O O
, O O
respiratory O O
rate O O
and O O
oxygen O O
saturation O O
were O O
monitored O O
over O O
1 O O
hour O O
. O O

RESULTS O O
: O O
Three O O
patients O O
( O O
8.1 O O
% O O
) O O
in O O
the O O
unilateral O O
group O O
and O O
5 O O
( O O
13.5 O O
% O O
) O O
in O O
the O O
conventional O O
group O O
developed O O
hypotension B-Disease B-Disease
, O O
P= O O
0.71 O O
. O O

Four O O
( O O
10.8 O O
% O O
) O O
patients O O
in O O
the O O
conventional O O
group O O
and O O
1 O O
( O O
2.7 O O
% O O
) O O
in O O
the O O
unilateral O O
group O O
, O O
P= O O
0.17 O O
required O O
epinephrine O O
infusion O O
to O O
treat O O
hypotension B-Disease B-Disease
. O O

Patients O O
in O O
the O O
conventional O O
group O O
had O O
statistically O O
significant O O
greater O O
fall O O
in O O
the O O
systolic O O
blood O O
pressures O O
at O O
15 O O
, O O
30 O O
and O O
45 O O
minutes O O
when O O
compared O O
to O O
the O O
baseline O O
( O O
P= O O
0.003 O O
, O O
0.001 O O
and O O
0.004 O O
) O O
. O O

The O O
mean O O
respiratory O O
rate O O
and O O
oxygen O O
saturations O O
in O O
the O O
two O O
groups O O
were O O
similar O O
. O O

CONCLUSION O O
: O O
Compared O O
to O O
conventional O O
spinal O O
anaesthesia O O
, O O
unilateral O O
spinal O O
anaesthesia O O
was O O
associated O O
with O O
fewer O O
cardiovascular O O
perturbations O O
. O O

Also O O
, O O
the O O
type O O
of O O
spinal O O
block O O
instituted O O
affected O O
neither O O
the O O
respiratory O O
rate O O
nor O O
the O O
arterial O O
oxygen O O
saturation O O
. O O

Spectrum O O
of O O
adverse O O
events O O
after O O
generic O O
HAART O O
in O O
southern O O
Indian O O
HIV B-Disease B-Disease
- I-Disease I-Disease
infected I-Disease I-Disease
patients O O
. O O

To O O
determine O O
the O O
incidence O O
of O O
clinically O O
significant O O
adverse O O
events O O
after O O
long O O
- O O
term O O
, O O
fixed O O
- O O
dose O O
, O O
generic O O
highly O O
active O O
antiretroviral O O
therapy O O
( O O
HAART O O
) O O
use O O
among O O
HIV B-Disease B-Disease
- I-Disease I-Disease
infected I-Disease I-Disease
individuals O O
in O O
South O O
India O O
, O O
we O O
examined O O
the O O
experiences O O
of O O
3154 O O
HIV B-Disease B-Disease
- I-Disease I-Disease
infected I-Disease I-Disease
individuals O O
who O O
received O O
a O O
minimum O O
of O O
3 O O
months O O
of O O
generic O O
HAART O O
between O O
February O O
1996 O O
and O O
December O O
2006 O O
at O O
a O O
tertiary O O
HIV O O
care O O
referral O O
center O O
in O O
South O O
India O O
. O O

The O O
most O O
common O O
regimens O O
were O O
3TC O O
+ O O
d4 O O
T O O
+ O O
nevirapine O O
( O O
NVP O O
) O O
( O O
54.8 O O
% O O
) O O
, O O
zidovudine O O
( O O
AZT O O
) O O
+ O O
3TC O O
+ O O
NVP O O
( O O
14.5 O O
% O O
) O O
, O O
3TC O O
+ O O
d4 O O
T O O
+ O O
efavirenz O O
( O O
EFV O O
) O O
( O O
20.1 O O
% O O
) O O
, O O
and O O
AZT O O
+ O O
3TC O O
+ O O
EFV O O
( O O
5.4 O O
% O O
) O O
. O O

The O O
most O O
common O O
adverse O O
events O O
and O O
median O O
CD4 O O
at O O
time O O
of O O
event O O
were O O
rash B-Disease B-Disease
( O O
15.2 O O
% O O
; O O
CD4 O O
, O O
285 O O
cells O O
/ O O
microL O O
) O O
and O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
( O O
9.0 O O
% O O
and O O
348 O O
cells O O
/ O O
microL O O
) O O
. O O

Clinically O O
significant O O
anemia B-Disease B-Disease
( O O
hemoglobin O O
< O O
7 O O
g O O
/ O O
dL O O
) O O
was O O
observed O O
in O O
5.4 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
165 O O
cells O O
/ O O
microL O O
) O O
and O O
hepatitis B-Disease B-Disease
( O O
clinical O O
jaundice B-Disease B-Disease
with O O
alanine O O
aminotransferase O O
> O O
5 O O
times O O
upper O O
limits O O
of O O
normal O O
) O O
in O O
3.5 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
260 O O
cells O O
/ O O
microL O O
) O O
. O O

Women O O
were O O
significantly O O
more O O
likely O O
to O O
experience O O
lactic B-Disease B-Disease
acidosis I-Disease I-Disease
, O O
while O O
men O O
were O O
significantly O O
more O O
likely O O
to O O
experience O O
immune B-Disease B-Disease
reconstitution I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
p O O
< O O
0.05 O O
) O O
. O O

Among O O
the O O
patients O O
with O O
1 O O
year O O
of O O
follow O O
- O O
up O O
, O O
NVP O O
therapy O O
was O O
significantly O O
associated O O
with O O
developing O O
rash B-Disease B-Disease
and O O
d4 O O
T O O
therapy O O
with O O
developing O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
( O O
p O O
< O O
0.05 O O
) O O
. O O

Anemia B-Disease B-Disease
and O O
hepatitis B-Disease B-Disease
often O O
occur O O
within O O
12 O O
weeks O O
of O O
initiating O O
generic O O
HAART O O
. O O

Frequent O O
and O O
early O O
monitoring O O
for O O
these O O
toxicities B-Disease O
is O O
warranted O O
in O O
developing O O
countries O O
where O O
generic O O
HAART O O
is O O
increasingly O O
available O O
. O O

Thalidomide O O
and O O
sensory B-Disease B-Disease
neurotoxicity I-Disease I-Disease
: O O
a O O
neurophysiological O O
study O O
. O O

BACKGROUND O O
: O O
Recent O O
studies O O
confirmed O O
a O O
high O O
incidence O O
of O O
sensory B-Disease B-Disease
axonal I-Disease I-Disease
neuropathy I-Disease I-Disease
in O O
patients O O
treated O O
with O O
different O O
doses O O
of O O
thalidomide O O
. O O

The O O
study O O
's O O
aims O O
were O O
to O O
measure O O
variations O O
in O O
sural O O
nerve O O
sensory O O
action O O
potential O O
( O O
SAP O O
) O O
amplitude O O
in O O
patients O O
with O O
refractory O O
cutaneous B-Disease B-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
( O O
CLE B-Disease B-Disease
) O O
treated O O
with O O
thalidomide O O
and O O
use O O
these O O
findings O O
to O O
identify O O
the O O
neurotoxic B-Disease B-Disease
potential O O
of O O
thalidomide O O
and O O
the O O
recovery O O
capacity O O
of O O
sensory O O
fibres O O
after O O
discontinuation O O
of O O
treatment O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Clinical O O
and O O
electrophysiological O O
data O O
in O O
12 O O
female O O
patients O O
with O O
CLE B-Disease B-Disease
during O O
treatment O O
with O O
thalidomide O O
and O O
up O O
to O O
47 O O
months O O
after O O
discontinuation O O
of O O
treatment O O
were O O
analysed O O
. O O

Sural O O
nerve O O
SAP O O
amplitude O O
reduction O O
> O O
or O O
= O O
40 O O
% O O
was O O
the O O
criteria O O
for O O
discontinuing O O
therapy O O
. O O

RESULTS O O
: O O
During O O
treatment O O
, O O
11 O O
patients O O
showed O O
a O O
reduction O O
in O O
sural O O
nerve O O
SAP O O
amplitude O O
compared O O
to O O
baseline O O
values O O
( O O
9 O O
with O O
a O O
reduction O O
> O O
or O O
= O O
50 O O
% O O
and O O
2 O O
< O O
50 O O
% O O
) O O
. O O

One O O
patient O O
showed O O
no O O
changes O O
in O O
SAP O O
amplitude O O
. O O

Five O O
patients O O
complained O O
of O O
paresthesias B-Disease B-Disease
and O O
leg O B-Disease
cramps B-Disease I-Disease
. O O

After O O
thalidomide O O
treatment O O
, O O
sural O O
SAP O O
amplitude O O
recovered O O
in O O
3 O O
patients O O
. O O

At O O
detection O O
of O O
reduction O O
in O O
sural O O
nerve O O
SAP O O
amplitude O O
, O O
the O O
median O O
thalidomide O O
cumulative O O
dose O O
was O O
21.4 O O
g. O O
The O O
threshold O O
neurotoxic B-Disease B-Disease
dosage O O
is O O
lower O O
than O O
previously O O
reported O O
. O O

CONCLUSIONS O O
: O O
Sural O O
nerve O O
SAP O O
amplitude O O
reduction O O
is O O
a O O
reliable O O
and O O
sensitive O O
marker O O
of O O
degeneration O O
and O O
recovery O O
of O O
sensory O O
fibres O O
. O O

This O O
electrophysiological O O
parameter O O
provides O O
information O O
about O O
subclinical O O
neurotoxic B-Disease B-Disease
potential O O
of O O
thalidomide O O
but O O
is O O
not O O
helpful O O
in O O
predicting O O
the O O
appearance O O
of O O
sensory O O
symptoms O O
. O O

Five O O
cases O O
of O O
encephalitis B-Disease B-Disease
during O O
treatment O O
of O O
loiasis B-Disease B-Disease
with O O
diethylcarbamazine O O
. O O

Five O O
cases O O
of O O
encephalitis B-Disease B-Disease
following O O
treatment O O
with O O
diethylcarbamazine O O
( O O
DEC O O
) O O
were O O
observed O O
in O O
Congolese O O
patients O O
with O O
Loa O O
loa O O
filariasis B-Disease B-Disease
. O O

Two O O
cases O O
had O O
a O O
fatal O O
outcome O O
and O O
one O O
resulted O O
in O O
severe O O
sequelae O O
. O O

The O O
notable O O
fact O O
was O O
that O O
this O O
complication O O
occurred O O
in O O
three O O
patients O O
hospitalized O O
before O O
treatment O O
began O O
, O O
with O O
whom O O
particularly O O
strict O O
therapeutic O O
precautions O O
were O O
taken O O
, O O
i.e. O O
, O O
initial O O
dose O O
less O O
than O O
10 O O
mg O O
of O O
DEC O O
, O O
very O O
gradual O O
dose O O
increases O O
, O O
and O O
associated O O
anti O O
- O O
allergic O O
treatment O O
. O O

This O O
type O O
of O O
drug O O
- O O
induced O O
complication O O
may O O
not O O
be O O
that O O
uncommon O O
in O O
highly O O
endemic O O
regions O O
. O O

It O O
occurs O O
primarily O O
, O O
but O O
not O O
exclusively O O
, O O
in O O
subjects O O
presenting O O
with O O
a O O
high O O
microfilarial O O
load O O
. O O

The O O
relationship O O
between O O
the O O
occurrence O O
of O O
encephalitis B-Disease B-Disease
and O O
the O O
decrease O O
in O O
microfilaremia B-Disease B-Disease
is O O
evident O O
. O O

The O O
pathophysiological O O
mechanisms O O
are O O
discussed O O
in O O
the O O
light O O
of O O
these O O
observations O O
and O O
the O O
few O O
other O O
comments O O
on O O
this O O
subject O O
published O O
in O O
the O O
literature O O
. O O

Amiodarone O O
- O O
related O O
pulmonary B-Disease B-Disease
mass I-Disease I-Disease
and O O
unique O O
membranous B-Disease O
glomerulonephritis I-Disease B-Disease
in O O
a O O
patient O O
with O O
valvular B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
: O O
Diagnostic O O
pitfall O O
and O O
new O O
findings O O
. O O

Amiodarone O O
is O O
an O O
anti O O
- O O
arrhythmic B-Disease B-Disease
drug O O
for O O
life O O
- O O
threatening O O
tachycardia B-Disease B-Disease
, O O
but O O
various O O
adverse O O
effects O O
have O O
been O O
reported O O
. O O

Reported O O
herein O O
is O O
an O O
autopsy O O
case O O
of O O
valvular B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
, O O
in O O
a O O
patient O O
who O O
developed O O
a O O
lung B-Disease B-Disease
mass I-Disease I-Disease
( O O
1.5 O O
cm O O
in O O
diameter O O
) O O
and O O
proteinuria B-Disease B-Disease
( O O
2.76 O O
g O O
/ O O
day O O
) O O
after O O
treatment O O
with O O
amiodarone O O
for O O
a O O
long O O
time O O
. O O

The O O
lung B-Disease O
mass I-Disease O
was O O
highly O O
suspected O O
to O O
be O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
on O O
CT O O
and O O
positron O O
emission O O
tomography O O
, O O
but O O
histologically O O
the O O
lesion O O
was O O
composed O O
of O O
lymphoplasmacytic O O
infiltrates O O
in O O
alveolar O O
walls O O
and O O
intra O O
- O O
alveolar O O
accumulation O O
of O O
foamy O O
macrophages O O
containing O O
characteristic O O
myelinoid O O
bodies O O
, O O
indicating O O
that O O
it O O
was O O
an O O
amiodarone O O
- O O
related O O
lesion O O
. O O

In O O
addition O O
, O O
the O O
lung O O
tissue O O
had O O
unevenly O O
distributed O O
hemosiderin B-Disease O
deposition O O
, O O
and O O
abnormally O O
tortuous O O
capillaries O O
were O O
seen O O
in O O
the O O
mass O O
and O O
in O O
heavily O O
hemosiderotic B-Disease B-Disease
lung O O
portions O O
outside O O
the O O
mass O O
. O O

In O O
the O O
kidneys O O
, O O
glomeruli O O
had O O
membrane O O
spikes O O
, O O
prominent O O
swelling O O
of O O
podocytes O O
and O O
subepithelial O O
deposits O O
, O O
which O O
were O O
sometimes O O
large O O
and O O
hump O O
- O O
like O O
. O O

Autoimmune B-Disease B-Disease
diseases I-Disease I-Disease
, O O
viral B-Disease B-Disease
hepatitis I-Disease I-Disease
, O O
malignant O B-Disease
neoplasms B-Disease I-Disease
or O O
other O O
diseases O O
with O O
a O O
known O O
relationship O O
to O O
membranous B-Disease B-Disease
glomerulonephritis I-Disease I-Disease
were O O
not O O
found O O
. O O

The O O
present O O
case O O
highlights O O
the O O
possibility O O
that O O
differential O O
diagnosis O O
between O O
an O O
amiodarone O O
- O O
related O O
pulmonary B-Disease B-Disease
lesion I-Disease I-Disease
and O O
a O O
neoplasm B-Disease B-Disease
can O O
be O O
very O O
difficult O O
radiologically O O
, O O
and O O
suggests O O
that O O
membranous B-Disease B-Disease
glomerulonephritis I-Disease I-Disease
might O O
be O O
another O O
possible O O
complication O O
of O O
amiodarone O O
treatment O O
. O O

Risk O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
associated O O
with O O
initial O O
sulphonylurea O O
treatment O O
of O O
patients O O
with O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
: O O
a O O
matched O O
case O O
- O O
control O O
study O O
. O O

AIMS O O
: O O
This O O
study O O
sought O O
to O O
assess O O
the O O
risk O O
of O O
developing O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
( O O
CAD B-Disease B-Disease
) O O
associated O O
with O O
initial O O
treatment O O
of O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
with O O
different O O
sulphonylureas O O
. O O

METHODS O O
: O O
In O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetic I-Disease I-Disease
patients O O
, O O
cases O O
who O O
developed O O
CAD B-Disease B-Disease
were O O
compared O O
retrospectively O O
with O O
controls O O
that O O
did O O
not O O
. O O

The O O
20-year O O
risk O O
of O O
CAD B-Disease B-Disease
at O O
diagnosis O O
of O O
diabetes B-Disease B-Disease
, O O
using O O
the O O
UKPDS O O
risk O O
engine O O
, O O
was O O
used O O
to O O
match O O
cases O O
with O O
controls O O
. O O

RESULTS O O
: O O
The O O
76 O O
cases O O
of O O
CAD B-Disease B-Disease
were O O
compared O O
with O O
152 O O
controls O O
. O O

The O O
hazard O O
of O O
developing O O
CAD B-Disease B-Disease
( O O
95 O O
% O O
CI O O
) O O
associated O O
with O O
initial O O
treatment O O
increased O O
by O O
2.4-fold O O
( O O
1.3 O O
- O O
4.3 O O
, O O
P=0.004 O O
) O O
with O O
glibenclamide O O
; O O
2-fold O O
( O O
0.9 O O
- O O
4.6 O O
, O O
P=0.099 O O
) O O
with O O
glipizide O O
; O O
2.9-fold O O
( O O
1.6 O O
- O O
5.1 O O
, O O
P=0.000 O O
) O O
with O O
either O O
, O O
and O O
was O O
unchanged O O
with O O
metformin O O
. O O

The O O
hazard O O
decreased O O
0.3-fold O O
( O O
0.7 O O
- O O
1.7 O O
, O O
P=0.385 O O
) O O
with O O
glimepiride O O
, O O
0.4-fold O O
( O O
0.7 O O
- O O
1.3 O O
, O O
P=0.192 O O
) O O
with O O
gliclazide O O
, O O
and O O
0.4-fold O O
( O O
0.7 O O
- O O
1.1 O O
, O O
P=0.09 O O
) O O
with O O
either O O
. O O

CONCLUSIONS O O
: O O
Initiating O O
treatment O O
of O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
with O O
glibenclamide O O
or O O
glipizide O O
is O O
associated O O
with O O
increased O O
risk O O
of O O
CAD B-Disease B-Disease
in O O
comparison O O
to O O
gliclazide O O
or O O
glimepiride O O
. O O

If O O
confirmed O O
, O O
this O O
may O O
be O O
important O O
because O O
most O O
Indian O O
patients O O
receive O O
the O O
cheaper O O
older O O
sulphonylureas O O
, O O
and O O
present O O
guidelines O O
do O O
not O O
distinguish O O
between O O
individual O O
agents O O
. O O

Reduced O O
progression O O
of O O
adriamycin O O
nephropathy B-Disease B-Disease
in O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
treated O O
by O O
losartan O O
. O O

BACKGROUND O O
: O O
The O O
aim O O
of O O
the O O
study O O
was O O
to O O
investigate O O
the O O
antihypertensive O O
effects O O
of O O
angiotensin O O
II O O
type-1 O O
receptor O O
blocker O O
, O O
losartan O O
, O O
and O O
its O O
potential O O
in O O
slowing O O
down O O
renal B-Disease B-Disease
disease I-Disease I-Disease
progression O O
in O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
( O O
SHR O O
) O O
with O O
adriamycin O O
( O O
ADR O O
) O O
nephropathy B-Disease B-Disease
. O O

METHODS O O
: O O
Six O O
- O O
month O O
- O O
old O O
female O O
SHR O O
were O O
randomly O O
selected O O
in O O
six O O
groups O O
. O O

Two O O
control O O
groups O O
( O O
SH O O
( O O
6 O O
) O O
, O O
SH O O
( O O
12 O O
) O O
) O O
received O O
vehicle O O
. O O

Groups O O
ADR O O
( O O
6 O O
) O O
, O O
ADR+LOS O O
( O O
6 O O
) O O
and O O
ADR O O
( O O
12 O O
) O O
, O O
and O O
ADR+LOS O O
( O O
12 O O
) O O
received O O
ADR O O
( O O
2 O O
mg O O
/ O O
kg O O
/ O O
b.w O O
. O O

i.v O O
. O O
) O O
twice O O
in O O
a O O
3-week O O
interval O O
. O O

Group O O
ADR+LOS O O
( O O
6 O O
) O O
received O O
losartan O O
( O O
10 O O
mg O O
/ O O
kg O O
/ O O
b.w. O O
/ O O
day O O
by O O
gavages O O
) O O
for O O
6 O O
weeks O O
and O O
group O O
ADR+LOS O O
( O O
12 O O
) O O
for O O
12 O O
weeks O O
after O O
second O O
injection O O
of O O
ADR O O
. O O

Animals O O
were O O
killed O O
after O O
6 O O
or O O
12 O O
weeks O O
, O O
respectively O O
. O O

Haemodynamic O O
measurements O O
were O O
performed O O
on O O
anaesthetized O O
animals O O
, O O
blood O O
and O O
urine O O
samples O O
were O O
taken O O
for O O
biochemical O O
analysis O O
and O O
the O O
left O O
kidney O O
was O O
processed O O
for O O
morphological O O
studies O O
. O O

RESULTS O O
: O O
Short O O
- O O
term O O
losartan O O
treatment O O
, O O
besides O O
antihypertensive O O
effect O O
, O O
improved O O
glomerular O O
filtration O O
rate O O
and O O
ameliorated O O
glomerulosclerosis B-Disease B-Disease
resulting O O
in O O
decreased O O
proteinuria B-Disease B-Disease
. O O

Prolonged O O
treatment O O
with O O
losartan O O
showed O O
further O O
reduction O O
of O O
glomerulosclerosis B-Disease B-Disease
associated O O
with O O
reduced O O
progression O O
of O O
tubular O O
atrophy B-Disease B-Disease
and O O
interstitial B-Disease O
fibrosis I-Disease B-Disease
, O O
thus O O
preventing O O
heavy O O
proteinuria B-Disease B-Disease
and O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
. O O

Losartan O O
reduced O O
uraemia B-Disease B-Disease
and O O
increased O O
urea O O
clearance O O
in O O
advanced O O
ADR O O
nephropathy B-Disease B-Disease
in O O
SHR O O
. O O

Histological O O
examination O O
showed O O
that O O
losartan O O
could O O
prevent O O
tubular O O
atrophy B-Disease B-Disease
, O O
interstitial O O
infiltration O O
and O O
fibrosis B-Disease B-Disease
in O O
ADR O O
nephropathy B-Disease B-Disease
. O O

CONCLUSION O O
: O O
Losartan O O
reduces O O
the O O
rate O O
of O O
progression O O
of O O
ADR O O
- O O
induced O O
focal B-Disease B-Disease
segmental I-Disease I-Disease
glomerulosclerosis I-Disease I-Disease
to O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
in O O
SHR O O
. O O

The O O
risks O O
of O O
aprotinin O O
and O O
tranexamic O O
acid O O
in O O
cardiac O O
surgery O O
: O O
a O O
one O O
- O O
year O O
follow O O
- O O
up O O
of O O
1188 O O
consecutive O O
patients O O
. O O

BACKGROUND O O
: O O
Our O O
aim O O
was O O
to O O
investigate O O
postoperative O O
complications O O
and O O
mortality O O
after O O
administration O O
of O O
aprotinin O O
compared O O
to O O
tranexamic O O
acid O O
in O O
an O O
unselected O O
, O O
consecutive O O
cohort O O
. O O

METHODS O O
: O O
Perioperative O O
data O O
from O O
consecutive O O
cardiac O O
surgery O O
patients O O
were O O
prospectively O O
collected O O
between O O
September O O
2005 O O
and O O
June O O
2006 O O
in O O
a O O
university O O
- O O
affiliated O O
clinic O O
( O O
n O O
= O O
1188 O O
) O O
. O O

During O O
the O O
first O O
5 O O
mo O O
, O O
596 O O
patients O O
received O O
aprotinin O O
( O O
Group O O
A O O
) O O
; O O
in O O
the O O
next O O
5 O O
mo O O
, O O
592 O O
patients O O
were O O
treated O O
with O O
tranexamic O O
acid O O
( O O
Group O O
T O O
) O O
. O O

Except O O
for O O
antifibrinolytic O O
therapy O O
, O O
the O O
anesthetic O O
and O O
surgical O O
protocols O O
remained O O
unchanged O O
. O O

RESULTS O O
: O O
The O O
pre- O O
and O O
intraoperative O O
variables O O
were O O
comparable O O
between O O
the O O
treatment O O
groups O O
. O O

Postoperatively O O
, O O
a O O
significantly O O
higher O O
incidence O O
of O O
seizures B-Disease B-Disease
was O O
found O O
in O O
Group O O
T O O
( O O
4.6 O O
% O O
vs O O
1.2 O O
% O O
, O O
P O O
< O O
0.001 O O
) O O
. O O

This O O
difference O O
was O O
also O O
significant O O
in O O
the O O
primary O O
valve O O
surgery O O
and O O
the O O
high O O
risk O O
surgery O O
subgroups O O
( O O
7.9 O O
% O O
vs O O
1.2 O O
% O O
, O O
P O O
= O O
0.003 O O
; O O
7.3 O O
% O O
vs O O
2.4 O O
% O O
, O O
P O O
= O O
0.035 O O
, O O
respectively O O
) O O
. O O

Persistent O O
atrial O B-Disease
fibrillation O I-Disease
( O O
7.9 O O
% O O
vs O O
2.3 O O
% O O
, O O
P O O
= O O
0.020 O O
) O O
and O O
renal B-Disease B-Disease
failure I-Disease I-Disease
( O O
9.7 O O
% O O
vs O O
1.7 O O
% O O
, O O
P O O
= O O
0.002 O O
) O O
were O O
also O O
more O O
common O O
in O O
Group O O
T O O
, O O
in O O
the O O
primary O O
valve O O
surgery O O
subgroup O O
. O O

On O O
the O O
contrary O O
, O O
among O O
primary O O
coronary O O
artery O O
bypass O O
surgery O O
patients O O
, O O
there O O
were O O
more O O
acute O O
myocardial B-Disease B-Disease
infarctions I-Disease I-Disease
and O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
in O O
Group O O
A O O
( O O
5.8 O O
% O O
vs O O
2.0 O O
% O O
, O O
P O O
= O O
0.027 O O
; O O
22.5 O O
% O O
vs O O
15.2 O O
% O O
, O O
P O O
= O O
0.036 O O
, O O
respectively O O
) O O
. O O

The O O
1-yr O O
mortality O O
was O O
significantly O O
higher O O
after O O
aprotinin O O
treatment O O
in O O
the O O
high O O
risk O O
surgery O O
group O O
( O O
17.7 O O
% O O
vs O O
9.8 O O
% O O
, O O
P O O
= O O
0.034 O O
) O O
. O O

CONCLUSION O O
: O O
Both O O
antifibrinolytic O O
drugs O O
bear O O
the O O
risk O O
of O O
adverse O O
outcome O O
depending O O
on O O
the O O
type O O
of O O
cardiac O O
surgery O O
. O O

Administration O O
of O O
aprotinin O O
should O O
be O O
avoided O O
in O O
coronary O O
artery O O
bypass O O
graft O O
and O O
high O O
risk O O
patients O O
, O O
whereas O O
administration O O
of O O
tranexamic O O
acid O O
is O O
not O O
recommended O O
in O O
valve O O
surgery O O
. O O

Delirium B-Disease B-Disease
in O O
an O O
elderly O O
woman O O
possibly O O
associated O O
with O O
administration O O
of O O
misoprostol O O
. O O

Misoprostol O O
has O O
been O O
associated O O
with O O
adverse O O
reactions O O
, O O
including O O
gastrointestinal O B-Disease
symptoms O I-Disease
, O O
gynecologic O O
problems O O
, O O
and O O
headache B-Disease B-Disease
. O O

Changes O O
in O O
mental O O
status O O
, O O
however O O
, O O
have O O
not O O
been O O
reported O O
. O O

We O O
present O O
a O O
case O O
in O O
which O O
an O O
89-year O O
- O O
old O O
woman O O
in O O
a O O
long O O
- O O
term O O
care O O
facility O O
became O O
confused O O
after O O
the O O
initiation O O
of O O
misoprostol O O
therapy O O
. O O

The O O
patient O O
's O O
change O O
in O O
mental O O
status O O
was O O
first O O
reported O O
nine O O
days O O
after O O
the O O
initiation O O
of O O
therapy O O
. O O

Her O O
delirium B-Disease B-Disease
significantly O O
improved O O
after O O
misoprostol O O
was O O
discontinued O O
and O O
her O O
mental O O
status O O
returned O O
to O O
normal O O
within O O
a O O
week O O
. O O

Because O O
no O O
other O O
factors O O
related O O
to O O
this O O
patient O O
changed O O
significantly O O
, O O
the O O
delirium B-Disease B-Disease
experienced O O
by O O
this O O
patient O O
possibly O O
resulted O O
from O O
misoprostol O O
therapy O O
. O O

The O O
biological O O
properties O O
of O O
the O O
optical O O
isomers O O
of O O
propranolol O O
and O O
their O O
effects O O
on O O
cardiac B-Disease B-Disease
arrhythmias I-Disease I-Disease
. O O

1 O O
. O O

The O O
optical O O
isomers O O
of O O
propranolol O O
have O O
been O O
compared O O
for O O
their O O
beta O O
- O O
blocking O O
and O O
antiarrhythmic O O
activities.2 O O
. O O

In O O
blocking O O
the O O
positive O O
inotropic O O
and O O
chronotropic O O
responses O O
to O O
isoprenaline O O
, O O
( O O
+ O O
) O O
-propranolol O O
had O O
less O O
than O O
one O O
hundredth O O
the O O
potency O O
of O O
( O O
- O O
) O O
-propranolol O O
. O O

At O O
dose O O
levels O O
of O O
( O O
+ O O
) O O
-propranolol O O
which O O
attenuated O O
the O O
responses O O
to O O
isoprenaline O O
, O O
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram.3 O O
. O O

The O O
metabolic O O
responses O O
to O O
isoprenaline O O
in O O
dogs O O
( O O
an O O
increase O O
in O O
circulating O O
glucose O O
, O O
lactate O O
and O O
free O O
fatty O O
acids O O
) O O
were O O
all O O
blocked O O
by O O
( O O
- O O
) O O
-propranolol O O
. O O

( O O
+ O O
) O O
-Propranolol O O
had O O
no O O
effect O O
on O O
fatty O O
acid O O
mobilization O O
but O O
significantly O O
reduced O O
the O O
increments O O
in O O
both O O
lactate O O
and O O
glucose.4 O O
. O O

Both O O
isomers O O
of O O
propranolol O O
possessed O O
similar O O
depressant O O
potency O O
on O O
isolated O O
atrial O O
muscle O O
taken O O
from O O
guinea O O
- O O
pigs.5 O O
. O O

The O O
isomers O O
of O O
propranolol O O
exhibited O O
similar O O
local O O
anaesthetic O O
potencies O O
on O O
an O O
isolated O O
frog O O
nerve O O
preparation O O
at O O
a O O
level O O
approximately O O
three O O
times O O
that O O
of O O
procaine O O
. O O

The O O
racemic O O
compound O O
was O O
significantly O O
less O O
potent O O
than O O
either O O
isomer.6 O O
. O O

Both O O
isomers O O
of O O
propranolol O O
were O O
capable O O
of O O
preventing O O
adrenaline O O
- O O
induced O O
cardiac B-Disease B-Disease
arrhythmias I-Disease I-Disease
in O O
cats O O
anaesthetized O O
with O O
halothane O O
, O O
but O O
the O O
mean O O
dose O O
of O O
( O O
- O O
) O O
-propranolol O O
was O O
0.09+ O O
/ O O
-0.02 O O
mg O O
/ O O
kg O O
whereas O O
that O O
of O O
( O O
+ O O
) O O
-propranolol O O
was O O
4.2+ O O
/ O O
-1.2 O O
mg O O
/ O O
kg O O
. O O

At O O
the O O
effective O O
dose O O
level O O
of O O
( O O
+ O O
) O O
-propranolol O O
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram O O
. O O

Blockade O O
of O O
arrhythmias B-Disease B-Disease
with O O
both O O
isomers O O
was O O
surmountable O O
by O O
increasing O O
the O O
dose O O
of O O
adrenaline.7 O O
. O O

Both O O
isomers O O
of O O
propranolol O O
were O O
also O O
capable O O
of O O
reversing O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
caused O O
by O O
ouabain O O
in O O
anaesthetized O O
cats O O
and O O
dogs O O
. O O

The O O
dose O O
of O O
( O O
- O O
) O O
-propranolol O O
was O O
significantly O O
smaller O O
than O O
that O O
of O O
( O O
+ O O
) O O
-propranolol O O
in O O
both O O
species O O
but O O
much O O
higher O O
than O O
that O O
required O O
to O O
produce O O
evidence O O
of O O
beta O O
- O O
blockade.8 O O
. O O

The O O
implications O O
of O O
these O O
results O O
are O O
discussed O O
. O O

Topotecan O O
in O O
combination O O
with O O
radiotherapy O O
in O O
unresectable O O
glioblastoma B-Disease B-Disease
: O O
a O O
phase O O
2 O O
study O O
. O O

Improving O O
glioblastoma B-Disease B-Disease
multiforme I-Disease I-Disease
( O O
GBM B-Disease B-Disease
) O O
treatment O O
with O O
radio O O
- O O
chemotherapy O O
remains O O
a O O
challenge O O
. O O

Topotecan O O
is O O
an O O
attractive O O
option O O
as O O
it O O
exhibits O O
growth O O
inhibition O O
of O O
human O O
glioma B-Disease B-Disease
as O O
well O O
as O O
brain O O
penetration O O
. O O

The O O
present O O
study O O
assessed O O
the O O
combination O O
of O O
radiotherapy O O
( O O
60 O O
Gy O O
/ O O
30 O O
fractions O O
/ O O
40 O O
days O O
) O O
and O O
topotecan O O
( O O
0.9 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
on O O
days O O
1 O O
- O O
5 O O
on O O
weeks O O
1 O O
, O O
3 O O
and O O
5 O O
) O O
in O O
50 O O
adults O O
with O O
histologically O O
proven O O
and O O
untreated O O
GBM B-Disease B-Disease
. O O

The O O
incidence O O
of O O
non O B-Disease
- O I-Disease
hematological O I-Disease
toxicities B-Disease I-Disease
was O O
low O O
and O O
grade O O
3 O O
- O O
4 O O
hematological O O
toxicities B-Disease B-Disease
were O O
reported O O
in O O
20 O O
patients O O
( O O
mainly O O
lymphopenia B-Disease B-Disease
and O O
neutropenia B-Disease B-Disease
) O O
. O O

Partial O O
response O O
and O O
stabilization O O
rates O O
were O O
2 O O
% O O
and O O
32 O O
% O O
, O O
respectively O O
, O O
with O O
an O O
overall O O
time O O
to O O
progression O O
of O O
12 O O
weeks O O
. O O

One O O
- O O
year O O
overall O O
survival O O
( O O
OS O O
) O O
rate O O
was O O
42 O O
% O O
, O O
with O O
a O O
median O O
OS O O
of O O
40 O O
weeks O O
. O O

Topotecan O O
in O O
combination O O
with O O
radiotherapy O O
was O O
well O O
tolerated O O
. O O

However O O
, O O
while O O
response O O
and O O
stabilization O O
concerned O O
one O O
- O O
third O O
of O O
the O O
patients O O
, O O
the O O
study O O
did O O
not O O
show O O
increased O O
benefits O O
in O O
terms O O
of O O
survival O O
in O O
patients O O
with O O
unresectable O O
GBM B-Disease B-Disease
. O O

Long O O
- O O
term O O
lithium O O
therapy O O
leading O O
to O O
hyperparathyroidism B-Disease B-Disease
: O O
a O O
case O O
report O O
. O O

PURPOSE O O
: O O
This O O
paper O O
reviews O O
the O O
effect O O
of O O
chronic O O
lithium O O
therapy O O
on O O
serum O O
calcium O O
level O O
and O O
parathyroid O O
glands O O
, O O
its O O
pathogenesis O O
, O O
and O O
treatment O O
options O O
. O O

We O O
examined O O
the O O
case O O
of O O
a O O
lithium O O
- O O
treated O O
patient O O
who O O
had O O
recurrent O O
hypercalcemia B-Disease B-Disease
to O O
better O O
understand O O
the O O
disease O O
process O O
. O O

CONCLUSION O O
: O O
Primary B-Disease B-Disease
hyperparathyroidism I-Disease I-Disease
is O O
a O O
rare O O
but O O
potentially O O
life O O
- O O
threatening O O
side O O
effect O O
of O O
long O O
- O O
term O O
lithium O O
therapy O O
. O O

Careful O O
patient O O
selection O O
and O O
long O O
- O O
term O O
follow O O
- O O
up O O
can O O
reduce O O
morbidity O O
. O O

PRACTICAL O O
IMPLICATIONS O O
: O O
As O O
much O O
as O O
15 O O
% O O
of O O
lithium O O
- O O
treated O O
patients O O
become O O
hypercalcemic B-Disease B-Disease
. O O

By O O
routinely O O
monitoring O O
serum O O
calcium O O
levels O O
, O O
healthcare O O
providers O O
can O O
improve O O
the O O
quality O O
of O O
life O O
of O O
this O O
patient O O
group O O
. O O

Comparison O O
of O O
laryngeal O O
mask O O
with O O
endotracheal O O
tube O O
for O O
anesthesia O O
in O O
endoscopic O O
sinus O O
surgery O O
. O O

BACKGROUND O O
: O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
compare O O
surgical O O
conditions O O
, O O
including O O
the O O
amount O O
of O O
intraoperative O O
bleeding B-Disease B-Disease
as O O
well O O
as O O
intraoperative O O
blood O O
pressure O O
, O O
during O O
functional O O
endoscopic O O
sinus O O
surgery O O
( O O
FESS O O
) O O
using O O
flexible O O
reinforced O O
laryngeal O O
mask O O
airway O O
( O O
FRLMA O O
) O O
versus O O
endotracheal O O
tube O O
( O O
ETT O O
) O O
in O O
maintaining O O
controlled O O
hypotension B-Disease B-Disease
anesthesia O O
induced O O
by O O
propofol O O
- O O
remifentanil O O
total O O
i.v O O
. O O

anesthesia O O
( O O
TIVA O O
) O O
. O O

METHODS O O
: O O
Sixty O O
normotensive O O
American O O
Society O O
of O O
Anesthesiologists O O
I O O
- O O
II O O
adult O O
patients O O
undergoing O O
FESS O O
under O O
controlled O O
hypotension B-Disease B-Disease
anesthesia O O
caused O O
by O O
propofol O O
- O O
remifentanil O O
- O O
TIVA O O
were O O
randomly O O
assigned O O
into O O
two O O
groups O O
: O O
group O O
I O O
, O O
FRLMA O O
; O O
group O O
II O O
, O O
ETT O O
. O O

Hemorrhage B-Disease B-Disease
was O O
measured O O
and O O
the O O
visibility O O
of O O
the O O
operative O O
field O O
was O O
evaluated O O
according O O
to O O
a O O
six O O
- O O
point O O
scale O O
. O O

RESULTS O O
: O O
Controlled O O
hypotension B-Disease B-Disease
was O O
achieved O O
within O O
a O O
shorter O O
period O O
using O O
laryngeal O O
mask O O
using O O
lower O O
rates O O
of O O
remifentanil O O
infusion O O
and O O
lower O O
total O O
dose O O
of O O
remifentanil O O
. O O

CONCLUSION O O
: O O
In O O
summary O O
, O O
our O O
results O O
indicate O O
that O O
airway O O
management O O
using O O
FRLMA O O
during O O
controlled O O
hypotension B-Disease B-Disease
anesthesia O O
provided O O
better O O
surgical O O
conditions O O
in O O
terms O O
of O O
quality O O
of O O
operative O O
field O O
and O O
blood O O
loss O O
and O O
allowed O O
for O O
convenient O O
induced O O
hypotension B-Disease B-Disease
with O O
low O O
doses O O
of O O
remifentanil O O
during O O
TIVA O O
in O O
patients O O
undergoing O O
FESS O O
. O O

Nonalcoholic B-Disease B-Disease
fatty I-Disease I-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
during O O
valproate O O
therapy O O
. O O

Valproic O O
acid O O
( O O
VPA O O
) O O
is O O
effective O O
for O O
the O O
treatment O O
of O O
many O O
types O O
of O O
epilepsy B-Disease B-Disease
, O O
but O O
its O O
use O O
can O O
be O O
associated O O
with O O
an O O
increase O O
in O O
body O O
weight O O
. O O

We O O
report O O
a O O
case O O
of O O
nonalcoholic B-Disease B-Disease
fatty I-Disease I-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
( O O
NAFLD B-Disease B-Disease
) O O
arising O O
in O O
a O O
child O O
who O O
developed O O
obesity B-Disease B-Disease
during O O
VPA O O
treatment O O
. O O

Laboratory O O
data O O
revealed O O
hyperinsulinemia B-Disease B-Disease
with O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
. O O

After O O
the O O
withdrawal O O
of O O
VPA O O
therapy O O
, O O
our O O
patient O O
showed O O
a O O
significant O O
weight B-Disease B-Disease
loss I-Disease I-Disease
, O O
a O O
decrease O O
of O O
body O O
mass O O
index O O
, O O
and O O
normalization O O
of O O
metabolic O O
and O O
endocrine O O
parameters O O
; O O
moreover O O
, O O
ultrasound O O
measurements O O
showed O O
a O O
complete O O
normalization O O
. O O

The O O
present O O
case O O
suggests O O
that O O
obesity B-Disease B-Disease
, O O
hyperinsulinemia B-Disease B-Disease
, O O
insulin B-Disease B-Disease
resistance I-Disease I-Disease
, O O
and O O
long O O
- O O
term O O
treatment O O
with O O
VPA O O
may O O
be O O
all O O
associated O O
with O O
the O O
development O O
of O O
NAFLD B-Disease B-Disease
; O O
this O O
side O O
effect O O
is O O
reversible O O
after O O
VPA O O
withdrawal O O
. O O

Carbimazole O O
induced O O
ANCA B-Disease O
positive I-Disease O
vasculitis I-Disease B-Disease
. O O

Anti O O
- O O
thyroid O O
drugs O O
, O O
like O O
carbimazole O O
and O O
propylthiouracil O O
( O O
PTU O O
) O O
are O O
commonly O O
prescribed O O
for O O
the O O
treatment O O
of O O
hyperthyroidism B-Disease B-Disease
. O O

One O O
should O O
be O O
aware O O
of O O
the O O
side O O
effects O O
of O O
antithyroid O O
medications O O
. O O

Antineutrophil B-Disease B-Disease
cytoplasmic I-Disease I-Disease
antibody I-Disease I-Disease
( I-Disease I-Disease
ANCA I-Disease I-Disease
) I-Disease I-Disease
--associated I-Disease I-Disease
vasculitis I-Disease I-Disease
is O O
a O O
potentially O O
life O O
- O O
threatening O O
adverse O O
effect O O
of O O
antithyroidmedications O O
. O O

We O O
report O O
a O O
patient O O
with O O
Graves B-Disease B-Disease
' I-Disease I-Disease
disease I-Disease I-Disease
who O O
developed O O
ANCA O O
positive O O
carbimazole O O
induced O O
vasculitis B-Disease B-Disease
. O O

The O O
episode O O
was O O
characterized O O
by O O
a O O
vasculitic B-Disease B-Disease
skin B-Disease I-Disease
rash I-Disease I-Disease
associated O O
with O O
large O O
joint O O
arthritis B-Disease B-Disease
, O O
pyrexia B-Disease B-Disease
and O O
parotiditis B-Disease B-Disease
but O O
no O O
renal O O
or O O
pulmonary O O
involvement O O
. O O

He O O
was O O
referred O O
to O O
us O O
for O O
neurological O O
evaluation O O
because O O
he O O
had O O
difficulty O O
in O O
getting O O
up O O
from O O
squatting O O
position O O
and O O
was O O
suspected O O
to O O
have O O
myositis B-Disease B-Disease
. O O

Carbimazole O O
and O O
methimazole O O
have O O
a O O
lower O O
incidence O O
of O O
reported O O
ANCA O O
positive O O
side O O
effects O O
than O O
PUT O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
ANCA O O
positive O O
carbimazole O O
induced O O
vasculitis B-Disease B-Disease
case O O
reported O O
from O O
India O O
. O O

Aspirin O O
for O O
the O O
primary O O
prevention O O
of O O
cardiovascular O O
events O O
: O O
an O O
update O O
of O O
the O O
evidence O O
for O O
the O O
U.S. O O
Preventive O O
Services O O
Task O O
Force O O
. O O

BACKGROUND O O
: O O
Coronary B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
and O O
cerebrovascular B-Disease B-Disease
disease I-Disease I-Disease
are O O
leading O O
causes O O
of O O
death O O
in O O
the O O
United O O
States O O
. O O

In O O
2002 O O
, O O
the O O
U.S. O O
Preventive O O
Services O O
Task O O
Force O O
( O O
USPSTF O O
) O O
strongly O O
recommended O O
that O O
clinicians O O
discuss O O
aspirin O O
with O O
adults O O
who O O
are O O
at O O
increased O O
risk O O
for O O
coronary B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
benefits O O
and O O
harms O O
of O O
taking O O
aspirin O O
for O O
the O O
primary O O
prevention O O
of O O
myocardial B-Disease B-Disease
infarctions I-Disease I-Disease
, O O
strokes B-Disease B-Disease
, O O
and O O
death O O
. O O

DATA O O
SOURCES O O
: O O
MEDLINE O O
and O O
Cochrane O O
Library O O
( O O
search O O
dates O O
, O O
1 O O
January O O
2001 O O
to O O
28 O O
August O O
2008 O O
) O O
, O O
recent O O
systematic O O
reviews O O
, O O
reference O O
lists O O
of O O
retrieved O O
articles O O
, O O
and O O
suggestions O O
from O O
experts O O
. O O

STUDY O O
SELECTION O O
: O O
English O O
- O O
language O O
randomized O O
, O O
controlled O O
trials O O
( O O
RCTs O O
) O O
; O O
case O O
- O O
control O O
studies O O
; O O
meta O O
- O O
analyses O O
; O O
and O O
systematic O O
reviews O O
of O O
aspirin O O
versus O O
control O O
for O O
the O O
primary O O
prevention O O
of O O
cardiovascular B-Disease B-Disease
disease I-Disease I-Disease
( O O
CVD B-Disease B-Disease
) O O
were O O
selected O O
to O O
answer O O
the O O
following O O
questions O O
: O O
Does O O
aspirin O O
decrease O O
coronary O O
heart O O
events O O
, O O
strokes B-Disease B-Disease
, O O
death O O
from O O
coronary O O
heart O O
events O O
or O O
stroke B-Disease B-Disease
, O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
adults O O
without O O
known O O
CVD B-Disease B-Disease
? O O

Does O O
aspirin O O
increase O O
gastrointestinal B-Disease B-Disease
bleeding I-Disease I-Disease
or O O
hemorrhagic B-Disease B-Disease
strokes B-Disease B-Disease
? O O

DATA O O
EXTRACTION O O
: O O
All O O
studies O O
were O O
reviewed O O
, O O
abstracted O O
, O O
and O O
rated O O
for O O
quality O O
by O O
using O O
predefined O O
USPSTF O O
criteria O O
. O O

DATA O O
SYNTHESIS O O
: O O
New O O
evidence O O
from O O
1 O O
good O O
- O O
quality O O
RCT O O
, O O
1 O O
good O O
- O O
quality O O
meta O O
- O O
analysis O O
, O O
and O O
2 O O
fair O O
- O O
quality O O
subanalyses O O
of O O
RCTs O O
demonstrates O O
that O O
aspirin O O
use O O
reduces O O
the O O
number O O
of O O
CVD B-Disease B-Disease
events O O
in O O
patients O O
without O O
known O O
CVD B-Disease B-Disease
. O O

Men O O
in O O
these O O
studies O O
experienced O O
fewer O O
myocardial B-Disease B-Disease
infarctions I-Disease I-Disease
and O O
women O O
experienced O O
fewer O O
ischemic O B-Disease
strokes B-Disease I-Disease
. O O

Aspirin O O
does O O
not O O
seem O O
to O O
affect O O
CVD B-Disease B-Disease
mortality O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
either O O
men O O
or O O
women O O
. O O

The O O
use O O
of O O
aspirin O O
for O O
primary O O
prevention O O
increases O O
the O O
risk O O
for O O
major O O
bleeding B-Disease B-Disease
events O O
, O O
primarily O O
gastrointestinal B-Disease B-Disease
bleeding I-Disease I-Disease
events O O
, O O
in O O
both O O
men O O
and O O
women O O
. O O

Men O O
have O O
an O O
increased O O
risk O O
for O O
hemorrhagic B-Disease B-Disease
strokes B-Disease B-Disease
with O O
aspirin O O
use O O
. O O

A O O
new O O
RCT O O
and O O
meta O O
- O O
analysis O O
suggest O O
that O O
the O O
risk O O
for O O
hemorrhagic B-Disease B-Disease
strokes B-Disease B-Disease
in O O
women O O
is O O
not O O
statistically O O
significantly O O
increased O O
. O O

LIMITATIONS O O
: O O
New O O
evidence O O
on O O
aspirin O O
for O O
the O O
primary O O
prevention O O
of O O
CVD B-Disease B-Disease
is O O
limited O O
. O O

The O O
dose O O
of O O
aspirin O O
used O O
in O O
the O O
RCTs O O
varied O O
, O O
which O O
prevented O O
the O O
estimation O O
of O O
the O O
most O O
appropriate O O
dose O O
for O O
primary O O
prevention O O
. O O

Several O O
of O O
the O O
RCTs O O
were O O
conducted O O
within O O
populations O O
of O O
health O O
professionals O O
, O O
which O O
potentially O O
limits O O
generalizability O O
. O O

CONCLUSION O O
: O O
Aspirin O O
reduces O O
the O O
risk O O
for O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
in O O
men O O
and O O
strokes B-Disease B-Disease
in O O
women O O
. O O

Aspirin O O
use O O
increases O O
the O O
risk O O
for O O
serious O O
bleeding B-Disease B-Disease
events O O
. O O

Reducing O O
harm O O
associated O O
with O O
anticoagulation O O
: O O
practical O O
considerations O O
of O O
argatroban O O
therapy O O
in O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
. O O

Argatroban O O
is O O
a O O
hepatically O O
metabolized O O
, O O
direct O O
thrombin O O
inhibitor O O
used O O
for O O
prophylaxis O O
or O O
treatment O O
of O O
thrombosis B-Disease B-Disease
in O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
( O O
HIT B-Disease B-Disease
) O O
and O O
for O O
patients O O
with O O
or O O
at O O
risk O O
of O O
HIT B-Disease B-Disease
undergoing O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

The O O
objective O O
of O O
this O O
review O O
is O O
to O O
summarize O O
practical O O
considerations O O
of O O
argatroban O O
therapy O O
in O O
HIT B-Disease B-Disease
. O O

The O O
US O O
FDA O O
- O O
recommended O O
argatroban O O
dose O O
in O O
HIT B-Disease B-Disease
is O O
2 O O
microg O O
/ O O
kg O O
/ O O
min O O
( O O
reduced O O
in O O
patients O O
with O O
hepatic B-Disease B-Disease
impairment I-Disease I-Disease
and O O
in O O
paediatric O O
patients O O
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
partial O O
thromboplastin O O
times O O
( O O
aPTTs O O
) O O
1.5 O O
- O O
3 O O
times O O
baseline O O
( O O
not O O
> O O
100 O O
seconds O O
) O O
. O O

Contemporary O O
experiences O O
indicate O O
that O O
reduced O O
doses O O
are O O
also O O
needed O O
in O O
patients O O
with O O
conditions O O
associated O O
with O O
hepatic O B-Disease
hypoperfusion O I-Disease
, O O
e.g. O O
heart B-Disease B-Disease
failure I-Disease I-Disease
, O O
yet O O
are O O
unnecessary O O
for O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
, O O
adult O O
age O O
, O O
sex O O
, O O
race O O
/ O O
ethnicity O O
or O O
obesity B-Disease B-Disease
. O O

Argatroban O O
0.5 O O
- O O
1.2 O O
microg O O
/ O O
kg O O
/ O O
min O O
typically O O
supports O O
therapeutic O O
aPTTs O O
. O O

The O O
FDA O O
- O O
recommended O O
dose O O
during O O
PCI O O
is O O
25 O O
microg O O
/ O O
kg O O
/ O O
min O O
( O O
350 O O
microg O O
/ O O
kg O O
initial O O
bolus O O
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
clotting O O
times O O
( O O
ACTs O O
) O O
of O O
300 O O
- O O
450 O O
sec. O O
For O O
PCI O O
, O O
argatroban O O
has O O
not O O
been O O
investigated O O
in O O
hepatically O O
impaired O O
patients O O
; O O
dose O O
adjustment O O
is O O
unnecessary O O
for O O
adult O O
age O O
, O O
sex O O
, O O
race O O
/ O O
ethnicity O O
or O O
obesity B-Disease B-Disease
, O O
and O O
lesser O O
doses O O
may O O
be O O
adequate O O
with O O
concurrent O O
glycoprotein O O
IIb O O
/ O O
IIIa O O
inhibition O O
. O O

Argatroban O O
prolongs O O
the O O
International O O
Normalized O O
Ratio O O
, O O
and O O
published O O
approaches O O
for O O
monitoring O O
the O O
argatroban O O
- O O
to O O
- O O
warfarin O O
transition O O
should O O
be O O
followed O O
. O O

Major O O
bleeding B-Disease B-Disease
with O O
argatroban O O
is O O
0 O O
- O O
10 O O
% O O
in O O
the O O
non O O
- O O
interventional O O
setting O O
and O O
0 O O
- O O
5.8 O O
% O O
periprocedurally O O
. O O

Argatroban O O
has O O
no O O
specific O O
antidote O O
, O O
and O O
if O O
excessive O O
anticoagulation O O
occurs O O
, O O
argatroban O O
infusion O O
should O O
be O O
stopped O O
or O O
reduced O O
. O O

Improved O O
familiarity O O
of O O
healthcare O O
professionals O O
with O O
argatroban O O
therapy O O
in O O
HIT B-Disease B-Disease
, O O
including O O
in O O
special O O
populations O O
and O O
during O O
PCI O O
, O O
may O O
facilitate O O
reduction O O
of O O
harm O O
associated O O
with O O
HIT B-Disease B-Disease
( O O
e.g. O O
fewer O O
thromboses O B-Disease
) O O
or O O
its O O
treatment O O
( O O
e.g. O O
fewer O O
argatroban O O
medication O O
errors O O
) O O
. O O

Rhabdomyolysis B-Disease B-Disease
and O O
brain O B-Disease
ischemic B-Disease I-Disease
stroke I-Disease I-Disease
in O O
a O O
heroin O O
- O O
dependent O O
male O O
under O O
methadone O O
maintenance O O
therapy O O
. O O

OBJECTIVE O O
: O O
There O O
are O O
several O O
complications O O
associated O O
with O O
heroin B-Disease B-Disease
abuse I-Disease I-Disease
, O O
some O O
of O O
which O O
are O O
life O O
- O O
threatening O O
. O O

Methadone O O
may O O
aggravate O O
this O O
problem O O
. O O

METHOD O O
: O O
A O O
clinical O O
case O O
description O O
. O O

RESULTS O O
: O O
A O O
33-year O O
- O O
old O O
man O O
presented O O
with O O
rhabdomyolysis B-Disease B-Disease
and O O
cerebral O B-Disease
ischemic B-Disease I-Disease
stroke I-Disease I-Disease
after O O
intravenous O O
heroin O O
. O O

He O O
had O O
used O O
heroin O O
since O O
age O O
20 O O
, O O
and O O
had O O
used O O
150 O O
mg O O
methadone O O
daily O O
for O O
6 O O
months O O
. O O

He O O
was O O
found O O
unconsciousness B-Disease B-Disease
at O O
home O O
and O O
was O O
sent O O
to O O
our O O
hospital O O
. O O

In O O
the O O
ER O O
, O O
his O O
opiate O O
level O O
was O O
4497 O O
ng O O
/ O O
ml O O
. O O

In O O
the O O
ICU O O
, O O
we O O
found O O
rhabdomyolysis B-Disease B-Disease
, O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
and O O
acute O O
respiratory B-Disease B-Disease
failure I-Disease I-Disease
. O O

After O O
transfer O O
to O O
an O O
internal O O
ward O O
, O O
we O O
noted O O
aphasia B-Disease B-Disease
and O O
weakness B-Disease B-Disease
of O O
his O O
left O O
limbs O O
. O O

After O O
MRI O O
, O O
we O O
found O O
cerebral B-Disease B-Disease
ischemic I-Disease I-Disease
infarction I-Disease I-Disease
. O O

CONCLUSION O O
: O O
Those O O
using O O
methadone O O
and O O
heroin O O
simultaneously O O
may O O
increase O O
risk O O
of O O
rhabdomyolysis B-Disease B-Disease
and O O
ischemic B-Disease B-Disease
stroke I-Disease I-Disease
. O O

Patients O O
under O O
methadone O O
maintenance O O
therapy O O
should O O
be O O
warned O O
regarding O O
these O O
serious O O
adverse O O
events O O
. O O

Hypotheses O O
of O O
heroin O O
- O O
related O O
rhabdomyolysis B-Disease B-Disease
and O O
stroke B-Disease B-Disease
in O O
heroin O O
abusers O O
are O O
discussed O O
. O O

Increased O O
vulnerability O O
to O O
6-hydroxydopamine O O
lesion O O
and O O
reduced O O
development O O
of O O
dyskinesias B-Disease B-Disease
in O O
mice O O
lacking O O
CB1 O O
cannabinoid O O
receptors O O
. O O

Motor O B-Disease
impairment O I-Disease
, O O
dopamine O O
( O O
DA O O
) O O
neuronal O O
activity O O
and O O
proenkephalin O O
( O O
PENK O O
) O O
gene O O
expression O O
in O O
the O O
caudate O O
- O O
putamen O O
( O O
CPu O O
) O O
were O O
measured O O
in O O
6-OHDA O O
- O O
lesioned O O
and O O
treated O O
( O O
L O O
- O O
DOPA+benserazide O O
) O O
CB1 O O
KO O O
and O O
WT O O
mice O O
. O O

A O O
lesion O O
induced O O
by O O
6-OHDA O O
produced O O
more O O
severe O O
motor O O
deterioration O O
in O O
CB1 O O
KO O O
mice O O
accompanied O O
by O O
more O O
loss O O
of O O
DA O O
neurons O O
and O O
increased O O
PENK O O
gene O O
expression O O
in O O
the O O
CPu O O
. O O

Oxidative O O
/ O O
nitrosative O O
and O O
neuroinflammatory O O
parameters O O
were O O
estimated O O
in O O
the O O
CPu O O
and O O
cingulate O O
cortex O O
( O O
Cg O O
) O O
. O O

CB1 O O
KO O O
mice O O
exhibited O O
higher O O
MDA O O
levels O O
and O O
iNOS O O
protein O O
expression O O
in O O
the O O
CPu O O
and O O
Cg O O
compared O O
to O O
WT O O
mice O O
. O O

Treatment O O
with O O
L O O
- O O
DOPA+benserazide O O
( O O
12 O O
weeks O O
) O O
resulted O O
in O O
less O O
severe O O
dyskinesias B-Disease B-Disease
in O O
CB1 O O
KO O O
than O O
in O O
WT O O
mice O O
. O O

The O O
results O O
revealed O O
that O O
the O O
lack O O
of O O
cannabinoid O O
CB1 O O
receptors O O
increased O O
the O O
severity O O
of O O
motor O B-Disease
impairment O I-Disease
and O O
DA O O
lesion O O
, O O
and O O
reduced O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B-Disease B-Disease
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
CB1 O O
receptors O O
offers O O
neuroprotection O O
against O O
dopaminergic O O
lesion O O
and O O
the O O
development O O
of O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B-Disease B-Disease
. O O

Hepatocellular O O
oxidant O O
stress O O
following O O
intestinal O O
ischemia B-Disease B-Disease
- O O
reperfusion B-Disease B-Disease
injury I-Disease I-Disease
. O O

Reperfusion O O
of O O
ischemic B-Disease B-Disease
intestine O O
results O O
in O O
acute O B-Disease
liver B-Disease I-Disease
dysfunction I-Disease I-Disease
characterized O O
by O O
hepatocellular O O
enzyme O O
release O O
into O O
plasma O O
, O O
reduction O O
in O O
bile O O
flow O O
rate O O
, O O
and O O
neutrophil O O
sequestration O O
within O O
the O O
liver O O
. O O

The O O
pathophysiology O O
underlying O O
this O O
acute O B-Disease
hepatic B-Disease I-Disease
injury I-Disease I-Disease
is O O
unknown O O
. O O

This O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
oxidants O O
are O O
associated O O
with O O
the O O
hepatic B-Disease B-Disease
injury I-Disease I-Disease
and O O
to O O
determine O O
the O O
relative O O
value O O
of O O
several O O
indirect O O
methods O O
of O O
assessing O O
oxidant O O
exposure O O
in O O
vivo O O
. O O

Rats O O
were O O
subjected O O
to O O
a O O
standardized O O
intestinal O O
ischemia B-Disease B-Disease
- O O
reperfusion B-Disease B-Disease
injury I-Disease I-Disease
. O O

Hepatic O O
tissue O O
was O O
assayed O O
for O O
lipid O O
peroxidation O O
products O O
and O O
oxidized O O
and O O
reduced O O
glutathione O O
. O O

There O O
was O O
no O O
change O O
in O O
hepatic O O
tissue O O
total O O
glutathione O O
following O O
intestinal O O
ischemia B-Disease B-Disease
- O O
reperfusion B-Disease B-Disease
injury I-Disease I-Disease
. O O

Oxidized O O
glutathione O O
( O O
GSSG O O
) O O
increased O O
significantly O O
following O O
30 O O
and O O
60 O O
min O O
of O O
reperfusion O O
. O O

There O O
was O O
no O O
increase O O
in O O
any O O
of O O
the O O
products O O
of O O
lipid O O
peroxidation O O
associated O O
with O O
this O O
injury O O
. O O

An O O
increase O O
in O O
GSSG O O
within O O
hepatic O O
tissue O O
during O O
intestinal O O
reperfusion O O
suggests O O
exposure O O
of O O
hepatocytes O O
to O O
an O O
oxidant O O
stress O O
. O O

The O O
lack O O
of O O
a O O
significant O O
increase O O
in O O
products O O
of O O
lipid O O
peroxidation O O
suggests O O
that O O
the O O
oxidant O O
stress O O
is O O
of O O
insufficient O O
magnitude O O
to O O
result O O
in O O
irreversible O O
injury O O
to O O
hepatocyte O O
cell O O
membranes O O
. O O

These O O
data O O
also O O
suggest O O
that O O
the O O
measurement O O
of O O
tissue O O
GSSG O O
may O O
be O O
a O O
more O O
sensitive O O
indicator O O
of O O
oxidant O O
stress O O
than O O
measurement O O
of O O
products O O
of O O
lipid O O
peroxidation O O
. O O

Animal O O
model O O
of O O
mania B-Disease B-Disease
induced O O
by O O
ouabain O O
: O O
Evidence O O
of O O
oxidative O O
stress O O
in O O
submitochondrial O O
particles O O
of O O
the O O
rat O O
brain O O
. O O

The O O
intracerebroventricular O O
( O O
ICV O O
) O O
administration O O
of O O
ouabain O O
( O O
a O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
-ATPase O O
inhibitor O O
) O O
in O O
rats O O
has O O
been O O
suggested O O
to O O
mimic O O
some O O
symptoms O O
of O O
human O O
bipolar B-Disease B-Disease
mania I-Disease I-Disease
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
may O O
be O O
related O O
to O O
mitochondrial B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

Herein O O
, O O
we O O
investigated O O
the O O
behavioral O O
and O O
biochemical O O
effects O O
induced O O
by O O
the O O
ICV O O
administration O O
of O O
ouabain O O
in O O
rats O O
. O O

To O O
achieve O O
this O O
aim O O
, O O
the O O
effects O O
of O O
ouabain O O
injection O O
immediately O O
after O O
and O O
7 O O
days O O
following O O
a O O
single O O
ICV O O
administration O O
( O O
at O O
concentrations O O
of O O
10 O O
( O O
-2 O O
) O O
and O O
10 O O
( O O
-3 O O
) O O
M O O
) O O
on O O
locomotion O O
was O O
measured O O
using O O
the O O
open O O
- O O
field O O
test O O
. O O

Additionally O O
, O O
thiobarbituric O O
acid O O
reactive O O
substances O O
( O O
TBARSs O O
) O O
and O O
superoxide O O
production O O
were O O
measured O O
in O O
submitochondrial O O
particles O O
of O O
the O O
prefrontal O O
cortex O O
, O O
hippocampus O O
, O O
striatum O O
and O O
amygdala O O
. O O

Our O O
findings O O
demonstrated O O
that O O
ouabain O O
at O O
10 O O
( O O
-2 O O
) O O
and O O
10 O O
( O O
-3 O O
) O O
M O O
induced O O
hyperlocomotion B-Disease B-Disease
in O O
rats O O
, O O
and O O
this O O
response O O
remained O O
up O O
to O O
7 O O
days O O
following O O
a O O
single O O
ICV O O
injection O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
the O O
persistent O O
increase O O
in O O
the O O
rat O O
spontaneous O O
locomotion O O
is O O
associated O O
with O O
increased O O
TBARS O O
levels O O
and O O
superoxide O O
generation O O
in O O
submitochondrial O O
particles O O
in O O
the O O
prefrontal O O
cortex O O
, O O
striatum O O
and O O
amygdala O O
. O O

In O O
conclusion O O
, O O
ouabain O O
- O O
induced O O
mania B-Disease B-Disease
- O O
like O O
behavior O O
may O O
provide O O
a O O
useful O O
animal O O
model O O
to O O
test O O
the O O
hypothesis O O
of O O
the O O
involvement O O
of O O
oxidative O O
stress O O
in O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
. O O

Intraoperative O O
dialysis O O
during O O
liver O O
transplantation O O
with O O
citrate O O
dialysate O O
. O O

Liver O O
transplantation O O
for O O
acutely O O
ill O O
patients O O
with O O
fulminant B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
carries O O
high O O
intraoperative O O
and O O
immediate O O
postoperative O O
risks O O
. O O

These O O
are O O
increased O O
with O O
the O O
presence O O
of O O
concomitant O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
( O O
AKI B-Disease B-Disease
) O O
and O O
intraoperative O O
dialysis O O
is O O
sometimes O O
required O O
to O O
allow O O
the O O
transplant O O
to O O
proceed O O
. O O

The O O
derangements O O
in O O
the O O
procoagulant O O
and O O
anticoagulant O O
pathways O O
during O O
fulminant B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
can O O
lead O O
to O O
difficulties O O
with O O
anticoagulation O O
during O O
dialysis O O
, O O
especially O O
when O O
continued O O
in O O
the O O
operating O O
room O O
. O O

Systemic O O
anticoagulation O O
is O O
unsafe O O
and O O
regional O O
citrate O O
anticoagulation O O
in O O
the O O
absence O O
of O O
a O O
functional O O
liver O O
carries O O
the O O
risk O O
of O O
citrate O O
toxicity B-Disease B-Disease
. O O

Citrate O O
dialysate O O
, O O
a O O
new O O
dialysate O O
with O O
citric O O
acid O O
can O O
be O O
used O O
for O O
anticoagulation O O
in O O
patients O O
who O O
can O O
not O O
tolerate O O
heparin O O
or O O
regional O O
citrate O O
. O O

We O O
report O O
a O O
case O O
of O O
a O O
40-year O O
- O O
old O O
female O O
with O O
acetaminophen O O
- O O
induced O O
fulminant B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
with O O
associated O O
AKI B-Disease B-Disease
who O O
underwent O O
intraoperative O O
dialytic O O
support O O
during O O
liver O O
transplantation O O
anticoagulated O O
with O O
citrate O O
dialysate O O
during O O
the O O
entire O O
procedure O O
. O O

The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
without O O
any O O
signs O O
of O O
citrate O O
toxicity B-Disease B-Disease
and O O
maintained O O
adequate O O
anticoagulation O O
for O O
patency O O
of O O
the O O
dialysis O O
circuit O O
. O O

Citrate O O
dialysate O O
is O O
a O O
safe O O
alternative O O
for O O
intradialytic O O
support O O
of O O
liver O O
transplantation O O
in O O
fulminant B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
. O O

Delirium B-Disease B-Disease
in O O
a O O
patient O O
with O O
toxic O O
flecainide O O
plasma O O
concentrations O O
: O O
the O O
role O O
of O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine O O
. O O

OBJECTIVE O O
: O O
To O O
describe O O
a O O
case O O
of O O
flecainide O O
- O O
induced O O
delirium B-Disease B-Disease
associated O O
with O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
69-year O O
- O O
old O O
white O O
female O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
a O O
history O O
of O O
confusion B-Disease B-Disease
and O O
paranoia B-Disease B-Disease
over O O
the O O
past O O
several O O
days O O
. O O

On O O
admission O O
the O O
patient O O
was O O
taking O O
carvedilol O O
12 O O
mg O O
twice O O
daily O O
, O O
warfarin O O
2 O O
mg O O
/ O O
day O O
, O O
folic O O
acid O O
1 O O
mg O O
/ O O
day O O
, O O
levothyroxine O O
100 O O
microg O O
/ O O
day O O
, O O
pantoprazole O O
40 O O
mg O O
/ O O
day O O
, O O
paroxetine O O
40 O O
mg O O
/ O O
day O O
, O O
and O O
flecainide O O
100 O O
mg O O
twice O O
daily O O
. O O

Flecainide O O
had O O
been O O
started O O
2 O O
weeks O O
prior O O
for O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
. O O

Laboratory O O
test O O
findings O O
on O O
admission O O
were O O
notable O O
only O O
for O O
a O O
flecainide O O
plasma O O
concentration O O
of O O
1360 O O
microg O O
/ O O
L O O
( O O
reference O O
range O O
200 O O
- O O
1000 O O
) O O
. O O

A O O
metabolic O O
drug O O
interaction O O
between O O
flecainide O O
and O O
paroxetine O O
, O O
which O O
the O O
patient O O
had O O
been O O
taking O O
for O O
more O O
than O O
5 O O
years O O
, O O
was O O
considered O O
. O O

Paroxetine O O
was O O
discontinued O O
and O O
the O O
dose O O
of O O
flecainide O O
was O O
reduced O O
to O O
50 O O
mg O O
twice O O
daily O O
. O O

Her O O
delirium B-Disease B-Disease
resolved O O
3 O O
days O O
later O O
. O O

DISCUSSION O O
: O O
Flecainide O O
and O O
pharmacologically O O
similar O O
agents O O
that O O
interact O O
with O O
sodium O O
channels O O
may O O
cause O O
delirium B-Disease B-Disease
in O O
susceptible O O
patients O O
. O O

A O O
MEDLINE O O
search O O
( O O
1966-January O O
2009 O O
) O O
revealed O O
one O O
in O O
vivo O O
pharmacokinetic O O
study O O
on O O
the O O
interaction O O
between O O
flecainide O O
, O O
a O O
CYP2D6 O O
substrate O O
, O O
and O O
paroxetine O O
, O O
a O O
CYP2D6 O O
inhibitor O O
, O O
as O O
well O O
as O O
3 O O
case O O
reports O O
of O O
flecainide O O
- O O
induced O O
delirium B-Disease B-Disease
. O O

According O O
to O O
the O O
Naranjo O O
probability O O
scale O O
, O O
flecainide O O
was O O
the O O
probable O O
cause O O
of O O
the O O
patient O O
's O O
delirium B-Disease B-Disease
; O O
the O O
Horn O O
Drug O O
Interaction O O
Probability O O
Scale O O
indicates O O
a O O
possible O O
pharmacokinetic O O
drug O O
interaction O O
between O O
flecainide O O
and O O
paroxetine O O
. O O

CONCLUSIONS O O
: O O
Supratherapeutic O O
flecainide O O
plasma O O
concentrations O O
may O O
cause O O
delirium B-Disease B-Disease
. O O

Because O O
toxicity B-Disease B-Disease
may O O
occur O O
when O O
flecainide O O
is O O
prescribed O O
with O O
paroxetine O O
and O O
other O O
potent O O
CYP2D6 O O
inhibitors O O
, O O
flecainide O O
plasma O O
concentrations O O
should O O
be O O
monitored O O
closely O O
with O O
commencement O O
of O O
CYP2D6 O O
inhibitors O O
. O O

Efficacy O O
of O O
everolimus O O
( O O
RAD001 O O
) O O
in O O
patients O O
with O O
advanced O O
NSCLC B-Disease B-Disease
previously O O
treated O O
with O O
chemotherapy O O
alone O O
or O O
with O O
chemotherapy O O
and O O
EGFR O O
inhibitors O O
. O O

BACKGROUND O O
: O O
Treatment O O
options O O
are O O
scarce O O
in O O
pretreated O O
advanced O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
( O O
NSCLC B-Disease B-Disease
) O O
patients O O
. O O

RAD001 O O
, O O
an O O
oral O O
inhibitor O O
of O O
the O O
mammalian O O
target O O
of O O
rapamycin O O
( O O
mTOR O O
) O O
, O O
has O O
shown O O
phase O O
I O O
efficacy O O
in O O
NSCLC B-Disease B-Disease
. O O

METHODS O O
: O O
Stage O O
IIIb O O
or O O
IV O O
NSCLC B-Disease B-Disease
patients O O
, O O
with O O
two O O
or O O
fewer O O
prior O O
chemotherapy O O
regimens O O
, O O
one O O
platinum O O
based O O
( O O
stratum O O
1 O O
) O O
or O O
both O O
chemotherapy O O
and O O
epidermal O O
growth O O
factor O O
receptor O O
tyrosine O O
kinase O O
inhibitors O O
( O O
stratum O O
2 O O
) O O
, O O
received O O
RAD001 O O
10 O O
mg O O
/ O O
day O O
until O O
progression O O
or O O
unacceptable O O
toxicity B-Disease O
. O O

Primary O O
objective O O
was O O
overall O O
response O O
rate O O
( O O
ORR O O
) O O
. O O

Analyses O O
of O O
markers O O
associated O O
with O O
the O O
mTOR O O
pathway O O
were O O
carried O O
out O O
on O O
archival O O
tumor B-Disease B-Disease
from O O
a O O
subgroup O O
using O O
immunohistochemistry O O
( O O
IHC O O
) O O
and O O
direct O O
mutation O O
sequencing O O
. O O

RESULTS O O
: O O
Eighty O O
- O O
five O O
patients O O
were O O
enrolled O O
, O O
42 O O
in O O
stratum O O
1 O O
and O O
43 O O
in O O
stratum O O
. O O

ORR O O
was O O
4.7 O O
% O O
( O O
7.1 O O
% O O
stratum O O
1 O O
; O O
2.3 O O
% O O
stratum O O
2 O O
) O O
. O O

Overall O O
disease O O
control O O
rate O O
was O O
47.1 O O
% O O
. O O

Median O O
progression O O
- O O
free O O
survivals O O
( O O
PFSs O O
) O O
were O O
2.6 O O
( O O
stratum O O
1 O O
) O O
and O O
2.7 O O
months O O
( O O
stratum O O
2 O O
) O O
. O O

Common O O
> O O
or O O
= O O
grade O O
3 O O
events O O
were O O
fatigue B-Disease B-Disease
, O O
dyspnea B-Disease B-Disease
, O O
stomatitis B-Disease B-Disease
, O O
anemia B-Disease B-Disease
, O O
and O O
thrombocytopenia B-Disease B-Disease
. O O

Pneumonitis B-Disease B-Disease
, O O
probably O O
or O O
possibly O O
related O O
, O O
mainly O O
grade O O
1 O O
/ O O
2 O O
, O O
occurred O O
in O O
25 O O
% O O
. O O

Cox O O
regression O O
analysis O O
of O O
IHC O O
scores O O
found O O
that O O
only O O
phospho O O
AKT O O
( O O
pAKT O O
) O O
was O O
a O O
significant O O
independent O O
predictor O O
of O O
worse O O
PFS O O
. O O

CONCLUSIONS O O
: O O
RAD001 O O
10 O O
mg O O
/ O O
day O O
was O O
well O O
tolerated O O
, O O
showing O O
modest O O
clinical O O
activity O O
in O O
pretreated O O
NSCLC B-Disease B-Disease
. O O

Evaluation O O
of O O
RAD001 O O
plus O O
standard O O
therapy O O
for O O
metastatic O O
NSCLC B-Disease B-Disease
continues O O
. O O

Posttransplant O O
anemia B-Disease B-Disease
: O O
the O O
role O O
of O O
sirolimus O O
. O O

Posttransplant O O
anemia B-Disease B-Disease
is O O
a O O
common O O
problem O O
that O O
may O O
hinder O O
patients O O
' O O
quality O O
of O O
life O O
. O O

It O O
occurs O O
in O O
12 O O
to O O
76 O O
% O O
of O O
patients O O
, O O
and O O
is O O
most O O
common O O
in O O
the O O
immediate O O
posttransplant O O
period O O
. O O

A O O
variety O O
of O O
factors O O
have O O
been O O
identified O O
that O O
increase O O
the O O
risk O O
of O O
posttransplant O B-Disease
anemia B-Disease I-Disease
, O O
of O O
which O O
the O O
level O O
of O O
renal O O
function O O
is O O
most O O
important O O
. O O

Sirolimus O O
, O O
a O O
mammalian O O
target O O
of O O
rapamycin O O
inhibitor O O
, O O
has O O
been O O
implicated O O
as O O
playing O O
a O O
special O O
role O O
in O O
posttransplant O B-Disease
anemia B-Disease I-Disease
. O O

This O O
review O O
considers O O
anemia B-Disease B-Disease
associated O O
with O O
sirolimus O O
, O O
including O O
its O O
presentation O O
, O O
mechanisms O O
, O O
and O O
management O O
. O O

Coronary O O
computerized O O
tomography O O
angiography O O
for O O
rapid O O
discharge O O
of O O
low O O
- O O
risk O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Most O O
patients O O
presenting O O
to O O
emergency O O
departments O O
( O O
EDs O O
) O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
are O O
admitted O O
for O O
at O O
least O O
12 O O
hours O O
and O O
receive O O
a O O
" O O
rule O O
out O O
acute B-Disease B-Disease
coronary I-Disease I-Disease
syndrome I-Disease I-Disease
" O O
protocol O O
, O O
often O O
with O O
noninvasive O O
testing O O
prior O O
to O O
discharge O O
. O O

In O O
patients O O
without O O
cocaine O O
use O O
, O O
coronary O O
computerized O O
tomography O O
angiography O O
( O O
CTA O O
) O O
has O O
been O O
shown O O
to O O
be O O
useful O O
for O O
identifying O O
a O O
group O O
of O O
patients O O
at O O
low O O
risk O O
for O O
cardiac O O
events O O
who O O
can O O
be O O
safely O O
discharged O O
. O O

It O O
is O O
unclear O O
whether O O
a O O
coronary O O
CTA O O
strategy O O
would O O
be O O
efficacious O O
in O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
, O O
as O O
coronary B-Disease B-Disease
vasospasm I-Disease I-Disease
may O O
account O O
for O O
some O O
of O O
the O O
ischemia B-Disease B-Disease
. O O

We O O
studied O O
whether O O
a O O
negative O O
coronary O O
CTA O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
could O O
identify O O
a O O
subset O O
safe O O
for O O
discharge O O
. O O

METHODS O O
: O O
We O O
prospectively O O
evaluated O O
the O O
safety O O
of O O
coronary O O
CTA O O
for O O
low O O
- O O
risk O O
patients O O
who O O
presented O O
to O O
the O O
ED O O
with O O
cocaineassociated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
( O O
self O O
- O O
reported O O
or O O
positive O O
urine O O
test O O
) O O
. O O

Consecutive O O
patients O O
received O O
either O O
immediate O O
coronary O O
CTA O O
in O O
the O O
ED O O
( O O
without O O
serial O O
markers O O
) O O
or O O
underwent O O
coronary O O
CTA O O
after O O
a O O
brief O O
observation O O
period O O
with O O
serial O O
cardiac O O
marker O O
measurements O O
. O O

Patients O O
with O O
negative O O
coronary O O
CTA O O
( O O
maximal O O
stenosis B-Disease B-Disease
less O O
than O O
50 O O
% O O
) O O
were O O
discharged O O
. O O

The O O
main O O
outcome O O
was O O
30-day O O
cardiovascular O B-Disease
death O I-Disease
or O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

RESULTS O O
: O O
A O O
total O O
of O O
59 O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
were O O
evaluated O O
. O O

Patients O O
had O O
a O O
mean O O
age O O
of O O
45.6 O O
+ O O
/- O O

6.6 O O
yrs O O
and O O
were O O
86 O O
% O O
black O O
, O O
66 O O
% O O
male O O
. O O

Seventy O O
- O O
nine O O
percent O O
had O O
a O O
normal O O
or O O
nonspecific O O
ECG O O
and O O
85 O O
% O O
had O O
a O O
TIMI O O
score O O
< O O
2 O O
. O O

Twenty O O
patients O O
received O O
coronary O O
CTA O O
immediately O O
in O O
the O O
ED O O
, O O
18 O O
of O O
whom O O
were O O
discharged O O
following O O
CTA O O
( O O
90 O O
% O O
) O O
. O O

Thirty O O
- O O
nine O O
received O O
coronary O O
CTA O O
after O O
a O O
brief O O
observation O O
period O O
, O O
with O O
37 O O
discharged O O
home O O
following O O
CTA O O
( O O
95 O O
% O O
) O O
. O O

Six O O
patients O O
had O O
coronary B-Disease B-Disease
stenosis I-Disease I-Disease
> O O
or=50 O O
% O O
. O O

During O O
the O O
30-day O O
follow O O
- O O
up O O
period O O
, O O
no O O
patients O O
died O O
of O O
a O O
cardiovascular O O
event O O
( O O
0 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
- O O
6.1 O O
% O O
) O O
and O O
no O O
patient O O
sustained O O
a O O
nonfatal O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
0 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
- O O
6.1 O O
% O O
) O O
. O O

CONCLUSIONS O O
: O O
Although O O
cocaine O O
- O O
associated O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
can O O
result O O
from O O
coronary O O
vasoconstriction O O
, O O
patients O O
with O O
cocaine O O
associated O O
chest B-Disease B-Disease
pain I-Disease I-Disease
, O O
a O O
non O O
- O O
ischemic B-Disease B-Disease
ECG O O
, O O
and O O
a O O
TIMI O O
risk O O
score O O
< O O
2 O O
may O O
be O O
safely O O
discharged O O
from O O
the O O
ED O O
after O O
a O O
negative O O
coronary O O
CTA O O
with O O
a O O
low O O
risk O O
of O O
30-day O O
adverse O O
events O O
. O O

Bilateral O O
haemorrhagic B-Disease B-Disease
infarction B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
globus I-Disease I-Disease
pallidus I-Disease I-Disease
after O O
cocaine O O
and O O
alcohol O O
intoxication O O
. O O

Cocaine O O
is O O
a O O
risk O O
factor O O
for O O
both O O
ischemic B-Disease B-Disease
and I-Disease I-Disease
haemorrhagic I-Disease I-Disease
stroke I-Disease I-Disease
. O O

We O O
present O O
the O O
case O O
of O O
a O O
31-year O O
- O O
old O O
man O O
with O O
bilateral O O
ischemia B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
globus I-Disease I-Disease
pallidus I-Disease I-Disease
after O O
excessive O O
alcohol O O
and O O
intranasal O O
cocaine O O
use O O
. O O

Drug O O
- O O
related O O
globus B-Disease B-Disease
pallidus I-Disease I-Disease
infarctions I-Disease I-Disease
are O O
most O O
often O O
associated O O
with O O
heroin O O
. O O

Bilateral O O
basal B-Disease B-Disease
ganglia I-Disease I-Disease
infarcts I-Disease I-Disease
after O O
the O O
use O O
of O O
cocaine O O
, O O
without O O
concurrent O O
heroin O O
use O O
, O O
have O O
never O O
been O O
reported O O
. O O

In O O
our O O
patient O O
, O O
transient O O
cardiac B-Disease B-Disease
arrhythmia I-Disease I-Disease
or O O
respiratory B-Disease B-Disease
dysfunction I-Disease I-Disease
related O O
to O O
cocaine O O
and/or O O
ethanol O O
use O O
were O O
the O O
most O O
likely O O
causes O O
of O O
cerebral B-Disease B-Disease
hypoperfusion I-Disease I-Disease
. O O

Late O O
fulminant O O
posterior B-Disease B-Disease
reversible I-Disease I-Disease
encephalopathy I-Disease I-Disease
syndrome I-Disease I-Disease
after O O
liver O O
transplant O O
. O O

OBJECTIVES O O
: O O
Posterior B-Disease B-Disease
leukoencephalopathy I-Disease I-Disease
due O O
to O O
calcineurin O O
- O O
inhibitor O O
- O O
related O O
neurotoxicity B-Disease B-Disease
is O O
a O O
rare O O
but O O
severe O O
complication O O
that O O
results O O
from O O
treatment O O
with O O
immunosuppressive O O
agents O O
( O O
primarily O O
those O O
administered O O
after O O
a O O
liver O O
or O O
kidney O O
transplant O O
) O O
. O O

The O O
pathophysiologic O O
mechanisms O O
of O O
that O O
disorder O O
remain O O
unknown O O
. O O

CASE O O
: O O
We O O
report O O
the O O
case O O
of O O
a O O
46-year O O
- O O
old O O
woman O O
who O O
received O O
a O O
liver O O
transplant O O
in O O
our O O
center O O
as O O
treatment O O
for O O
alcoholic B-Disease B-Disease
cirrhosis I-Disease I-Disease
and O O
in O O
whom O O
either O O
a O O
fulminant O O
course O O
of O O
posterior B-Disease B-Disease
leukoencephalopathy I-Disease I-Disease
or O O
posterior B-Disease B-Disease
reversible I-Disease I-Disease
encephalopathy I-Disease I-Disease
syndrome I-Disease I-Disease
developed O O
110 O O
days O O
after O O
transplant O O
. O O

After O O
an O O
initially O O
uneventful O O
course O O
after O O
the O O
transplant O O
, O O
the O O
patient O O
rapidly O O
fell O O
into O O
deep O O
coma O B-Disease
. O O

RESULTS O O
: O O
Cerebral O O
MRI O O
scan O O
showed O O
typical O O
signs O O
of O O
enhancement O O
in O O
the O O
pontine O O
and O O
posterior O O
regions O O
. O O

Switching O O
the O O
immunosuppressive O O
regimen O O
from O O
tacrolimus O O
to O O
cyclosporine O O
did O O
not O O
improve O O
the O O
clinical O O
situation O O
. O O

The O O
termination O O
of O O
treatment O O
with O O
any O O
calcineurin O O
inhibitor O O
resulted O O
in O O
a O O
complete O O
resolution O O
of O O
that O O
complication O O
. O O

CONCLUSIONS O O
: O O
Posterior B-Disease B-Disease
reversible I-Disease I-Disease
encephalopathy I-Disease I-Disease
syndrome I-Disease I-Disease
after O O
liver O O
transplant O O
is O O
rare O O
. O O

We O O
recommend O O
a O O
complete O O
cessation O O
of O O
any O O
calcineurin O O
inhibitor O O
rather O O
than O O
a O O
dose O O
reduction O O
. O O

Prolonged O O
hypothermia B-Disease B-Disease
as O O
a O O
bridge O O
to O O
recovery O O
for O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
and O O
intracranial B-Disease B-Disease
hypertension I-Disease I-Disease
associated O O
with O O
fulminant B-Disease B-Disease
hepatic I-Disease I-Disease
failure I-Disease I-Disease
. O O

BACKGROUND O O
: O O
To O O
review O O
evidence O O
- O O
based O O
treatment O O
options O O
in O O
patients O O
with O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
complicating O O
fulminant B-Disease B-Disease
hepatic I-Disease I-Disease
failure I-Disease I-Disease
( O O
FHF B-Disease B-Disease
) O O
and O O
discuss O O
the O O
potential O O
applications O O
of O O
hypothermia B-Disease B-Disease
. O O

METHOD O O
: O O
Case O O
- O O
based O O
observations O O
from O O
a O O
medical O O
intensive O O
care O O
unit O O
( O O
MICU O O
) O O
in O O
a O O
tertiary O O
care O O
facility O O
in O O
a O O
27-year O O
- O O
old O O
female O O
with O O
FHF B-Disease B-Disease
from O O
acetaminophen O O
and O O
resultant O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
. O O

RESULTS O O
: O O
Our O O
patient O O
was O O
admitted O O
to O O
the O O
MICU O O
after O O
being O O
found O O
unresponsive O O
with O O
presumed O O
toxicity B-Disease B-Disease
from O O
acetaminophen O O
which O O
was O O
ingested O O
over O O
a O O
2-day O O
period O O
. O O

The O O
patient O O
had O O
depressed O O
of O O
mental O O
status O O
lasting O O
at O O
least O O
24 O O
h O O
prior O O
to O O
admission O O
. O O

Initial O O
evaluation O O
confirmed O O
FHF B-Disease B-Disease
from O O
acetaminophen O O
and O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
. O O

The O O
patient O O
was O O
treated O O
with O O
hyperosmolar O O
therapy O O
, O O
hyperventilation B-Disease B-Disease
, O O
sedation O O
, O O
and O O
chemical O O
paralysis B-Disease B-Disease
. O O

Her O O
intracranial O O
pressure O O
remained O O
elevated O O
despite O O
maximal O O
medical O O
therapy O O
. O O

We O O
then O O
initiated O O
therapeutic O O
hypothermia B-Disease B-Disease
which O O
was O O
continued O O
for O O
5 O O
days O O
. O O

At O O
re O O
- O O
warming O O
, O O
patient O O
had O O
resolution O O
of O O
her O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
and O O
intracranial B-Disease B-Disease
hypertension I-Disease I-Disease
. O O

At O O
discharge O O
, O O
she O O
had O O
complete O O
recovery O O
of O O
neurological O O
and O O
hepatic O O
functions O O
. O O

CONCLUSION O O
: O O
In O O
patients O O
with O O
FHF B-Disease B-Disease
and O O
cerebral B-Disease B-Disease
edema I-Disease I-Disease
from O O
acetaminophen O O
overdose B-Disease B-Disease
, O O
prolonged O O
therapeutic O O
hypothermia B-Disease B-Disease
could O O
potentially O O
be O O
used O O
as O O
a O O
life O O
saving O O
therapy O O
and O O
a O O
bridge O O
to O O
hepatic O O
and O O
neurological O O
recovery O O
. O O

A O O
clinical O O
trial O O
of O O
hypothermia B-Disease B-Disease
in O O
patients O O
with O O
this O O
condition O O
is O O
warranted O O
. O O

Binasal B-Disease O
visual I-Disease B-Disease
field I-Disease I-Disease
defects I-Disease I-Disease
are O O
not O O
specific O O
to O O
vigabatrin O O
. O O

This O O
study O O
investigated O O
the O O
visual B-Disease B-Disease
defects I-Disease I-Disease
associated O O
with O O
the O O
antiepileptic O O
drug O O
vigabatrin O O
( O O
VGB O O
) O O
. O O

Two O O
hundred O O
four O O
people O O
with O O
epilepsy B-Disease B-Disease
were O O
grouped O O
on O O
the O O
basis O O
of O O
antiepileptic O O
drug O O
therapy O O
( O O
current O O
, O O
previous O O
, O O
or O O
no O O
exposure O O
to O O
VGB O O
) O O
. O O

Groups O O
were O O
matched O O
with O O
respect O O
to O O
age O O
, O O
gender O O
, O O
and O O
seizure B-Disease B-Disease
frequency O O
. O O

All O O
patients O O
underwent O O
objective O O
assessment O O
of O O
electrophysiological O O
function O O
( O O
wide O O
- O O
field O O
multifocal O O
electroretinography O O
) O O
and O O
conventional O O
visual O O
field O O
testing O O
( O O
static O O
perimetry O O
) O O
. O O

Bilateral O O
visual O B-Disease
field O I-Disease
constriction O I-Disease
was O O
observed O O
in O O
59 O O
% O O
of O O
patients O O
currently O O
taking O O
VGB O O
, O O
43 O O
% O O
of O O
patients O O
who O O
previously O O
took O O
VGB O O
, O O
and O O
24 O O
% O O
of O O
patients O O
with O O
no O O
exposure O O
to O O
VGB O O
. O O

Assessment O O
of O O
retinal O O
function O O
revealed O O
abnormal O O
responses O O
in O O
48 O O
% O O
of O O
current O O
VGB O O
users O O
and O O
22 O O
% O O
of O O
prior O O
VGB O O
users O O
, O O
but O O
in O O
none O O
of O O
the O O
patients O O
without O O
previous O O
exposure O O
to O O
VGB O O
. O O

Bilateral B-Disease O
visual I-Disease B-Disease
field I-Disease I-Disease
abnormalities I-Disease I-Disease
are O O
common O O
in O O
the O O
treated O O
epilepsy B-Disease B-Disease
population O O
, O O
irrespective O O
of O O
drug O O
history O O
. O O

Assessment O O
by O O
conventional O O
static O O
perimetry O O
may O O
neither O O
be O O
sufficiently O O
sensitive O O
nor O O
specific O O
to O O
reliably O O
identify O O
retinal B-Disease B-Disease
toxicity I-Disease I-Disease
associated O O
with O O
VGB O O
. O O

Smoking O O
of O O
crack O O
cocaine O O
as O O
a O O
risk O O
factor O O
for O O
HIV B-Disease B-Disease
infection I-Disease I-Disease
among O O
people O O
who O O
use O O
injection O O
drugs O O
. O O

BACKGROUND O O
: O O
Little O O
is O O
known O O
about O O
the O O
possible O O
role O O
that O O
smoking O O
crack O O
cocaine O O
has O O
on O O
the O O
incidence O O
of O O
HIV B-Disease B-Disease
infection I-Disease I-Disease
. O O

Given O O
the O O
increasing O O
use O O
of O O
crack O O
cocaine O O
, O O
we O O
sought O O
to O O
examine O O
whether O O
use O O
of O O
this O O
illicit O O
drug O O
has O O
become O O
a O O
risk O O
factor O O
for O O
HIV B-Disease B-Disease
infection I-Disease I-Disease
. O O

METHODS O O
: O O
We O O
included O O
data O O
from O O
people O O
participating O O
in O O
the O O
Vancouver O O
Injection O O
Drug O O
Users O O
Study O O
who O O
reported O O
injecting O O
illicit O O
drugs O O
at O O
least O O
once O O
in O O
the O O
month O O
before O O
enrolment O O
, O O
lived O O
in O O
the O O
greater O O
Vancouver O O
area O O
, O O
were O O
HIV O O
- O O
negative O O
at O O
enrolment O O
and O O
completed O O
at O O
least O O
1 O O
follow O O
- O O
up O O
study O O
visit O O
. O O

To O O
determine O O
whether O O
the O O
risk O O
of O O
HIV B-Disease B-Disease
seroconversion I-Disease I-Disease
among O O
daily O O
smokers O O
of O O
crack O O
cocaine O O
changed O O
over O O
time O O
, O O
we O O
used O O
Cox O O
proportional O O
hazards O O
regression O O
and O O
divided O O
the O O
study O O
into O O
3 O O
periods O O
: O O
May O O
1 O O
, O O
1996-Nov O O
. O O
30 O O
, O O
1999 O O
( O O
period O O
1 O O
) O O
, O O
Dec. O O
1 O O
, O O
1999-Nov O O
. O O
30 O O
, O O
2002 O O
( O O
period O O
2 O O
) O O
, O O
and O O
Dec. O O
1 O O
, O O
2002-Dec O O
. O O
30 O O
, O O
2005 O O
( O O
period O O
3 O O
) O O
. O O

RESULTS O O
: O O
Overall O O
, O O
1048 O O
eligible O O
injection O O
drug O O
users O O
were O O
included O O
in O O
our O O
study O O
. O O

Of O O
these O O
, O O
137 O O
acquired O O
HIV B-Disease B-Disease
infection I-Disease I-Disease
during O O
follow O O
- O O
up O O
. O O

The O O
mean O O
proportion O O
of O O
participants O O
who O O
reported O O
daily O O
smoking O O
of O O
crack O O
cocaine O O
increased O O
from O O
11.6 O O
% O O
in O O
period O O
1 O O
to O O
39.7 O O
% O O
in O O
period O O
3 O O
. O O

After O O
adjusting O O
for O O
potential O O
confounders O O
, O O
we O O
found O O
that O O
the O O
risk O O
of O O
HIV B-Disease B-Disease
seroconversion I-Disease I-Disease
among O O
participants O O
who O O
were O O
daily O O
smokers O O
of O O
crack O O
cocaine O O
increased O O
over O O
time O O
( O O
period O O
1 O O
: O O
hazard O O
ratio O O
[ O O
HR O O
] O O
1.03 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
0.57 O O
- O O
1.85 O O
; O O
period O O
2 O O
: O O
HR O O
1.68 O O
, O O
95 O O
% O O
CI O O
1.01 O O
- O O
2.80 O O
; O O
and O O
period O O
3 O O
: O O
HR O O
2.74 O O
, O O
95 O O
% O O
CI O O
1.06 O O
- O O
7.11 O O
) O O
. O O

INTERPRETATION O O
: O O
Smoking O O
of O O
crack O O
cocaine O O
was O O
found O O
to O O
be O O
an O O
independent O O
risk O O
factor O O
for O O
HIV B-Disease B-Disease
seroconversion I-Disease I-Disease
among O O
people O O
who O O
were O O
injection O O
drug O O
users O O
. O O

This O O
finding O O
points O O
to O O
the O O
urgent O O
need O O
for O O
evidence O O
- O O
based O O
public O O
health O O
initiatives O O
targeted O O
at O O
people O O
who O O
smoke O O
crack O O
cocaine O O
. O O

Fluoxetine O O
improves O O
the O O
memory B-Disease B-Disease
deficits I-Disease I-Disease
caused O O
by O O
the O O
chemotherapy O O
agent O O
5-fluorouracil O O
. O O

Cancer B-Disease B-Disease
patients O O
who O O
have O O
been O O
treated O O
with O O
systemic O O
adjuvant O O
chemotherapy O O
have O O
described O O
experiencing O O
deteriorations O O
in O O
cognition O O
. O O

A O O
widely O O
used O O
chemotherapeutic O O
agent O O
, O O
5-fluorouracil O O
( O O
5-FU O O
) O O
, O O
readily O O
crosses O O
the O O
blood O O
- O O
brain O O
barrier O O
and O O
so O O
could O O
have O O
a O O
direct O O
effect O O
on O O
brain O O
function O O
. O O

In O O
particular O O
this O O
anti O O
mitotic O O
drug O O
could O O
reduce O O
cell O O
proliferation O O
in O O
the O O
neurogenic O O
regions O O
of O O
the O O
adult O O
brain O O
. O O

In O O
contrast O O
reports O O
indicate O O
that O O
hippocampal O O
dependent O O
neurogenesis O O
and O O
cognition O O
are O O
enhanced O O
by O O
the O O
SSRI O O
antidepressant O O
Fluoxetine O O
. O O

In O O
this O O
investigation O O
the O O
behavioural O O
effects O O
of O O
chronic O O
( O O
two O O
week O O
) O O
treatment O O
with O O
5-FU O O
and O O
( O O
three O O
weeks O O
) O O
with O O
Fluoxetine O O
either O O
separately O O
or O O
in O O
combination O O
with O O
5-FU O O
were O O
tested O O
on O O
adult O O
Lister O O
hooded O O
rats O O
. O O

Behavioural O O
effects O O
were O O
tested O O
using O O
a O O
context O O
dependent O O
conditioned O O
emotional O O
response O O
test O O
( O O
CER O O
) O O
which O O
showed O O
that O O
animals O O
treated O O
with O O
5-FU O O
had O O
a O O
significant O O
reduction O O
in O O
freezing O O
time O O
compared O O
to O O
controls O O
. O O

A O O
separate O O
group O O
of O O
animals O O
was O O
tested O O
using O O
a O O
hippocampal O O
dependent O O
spatial O O
working O O
memory O O
test O O
, O O
the O O
object O O
location O O
recognition O O
test O O
( O O
OLR O O
) O O
. O O

Animals O O
treated O O
only O O
with O O
5-FU O O
showed O O
significant O O
deficits O O
in O O
their O O
ability O O
to O O
carry O O
out O O
the O O
OLR O O
task O O
but O O
co O O
administration O O
of O O
Fluoxetine O O
improved O O
their O O
performance O O
. O O

5-FU O O
chemotherapy O O
caused O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
proliferating O O
cells O O
in O O
the O O
sub O O
granular O O
zone O O
of O O
the O O
dentate O O
gyrus O O
compared O O
to O O
controls O O
. O O

This O O
reduction O O
was O O
eliminated O O
when O O
Fluoxetine O O
was O O
co O O
administered O O
with O O
5-FU O O
. O O

Fluoxetine O O
on O O
its O O
own O O
had O O
no O O
effect O O
on O O
proliferating O O
cell O O
number O O
or O O
behaviour O O
. O O

These O O
findings O O
suggest O O
that O O
5-FU O O
can O O
negatively O O
affect O O
both O O
cell O O
proliferation O O
and O O
hippocampal O O
dependent O O
working O O
memory O O
and O O
that O O
these O O
deficits O O
can O O
be O O
reversed O O
by O O
the O O
simultaneous O O
administration O O
of O O
the O O
antidepressant O O
Fluoxetine O O
. O O

Liver O O
- O O
specific O O
ablation O O
of O O
integrin O O
- O O
linked O O
kinase O O
in O O
mice O O
results O O
in O O
enhanced O O
and O O
prolonged O O
cell O O
proliferation O O
and O O
hepatomegaly B-Disease B-Disease
after O O
phenobarbital O O
administration O O
. O O

We O O
have O O
recently O O
demonstrated O O
that O O
disruption O O
of O O
extracellular O O
matrix O O
( O O
ECM O O
) O O
/ O O
integrin O O
signaling O O
via O O
elimination O O
of O O
integrin O O
- O O
linked O O
kinase O O
( O O
ILK O O
) O O
in O O
hepatocytes O O
interferes O O
with O O
signals O O
leading O O
to O O
termination O O
of O O
liver O O
regeneration O O
. O O

This O O
study O O
investigates O O
the O O
role O O
of O O
ILK O O
in O O
liver O B-Disease
enlargement O I-Disease
induced O O
by O O
phenobarbital O O
( O O
PB O O
) O O
. O O

Wild O O
- O O
type O O
( O O
WT O O
) O O
and O O
ILK O O
: O O
liver- O O
/ O O
- O O
mice O O
were O O
given O O
PB O O
( O O
0.1 O O
% O O
in O O
drinking O O
water O O
) O O
for O O
10 O O
days O O
. O O

Livers O O
were O O
harvested O O
on O O
2 O O
, O O
5 O O
, O O
and O O
10 O O
days O O
during O O
PB O O
administration O O
. O O

In O O
the O O
hepatocyte O O
- O O
specific O O
ILK O O
/ O O
liver- O O
/ O O
- O O
mice O O
, O O
the O O
liver O O
: O O
body O O
weight O O
ratio O O
was O O
more O O
than O O
double O O
as O O
compared O O
to O O
0 O O
h O O
at O O
day O O
2 O O
( O O
2.5 O O
times O O
) O O
, O O
while O O
at O O
days O O
5 O O
and O O
10 O O
, O O
it O O
was O O
enlarged O O
three O O
times O O
. O O

In O O
the O O
WT O O
mice O O
, O O
the O O
increase O O
was O O
as O O
expected O O
from O O
previous O O
literature O O
( O O
1.8 O O
times O O
) O O
and O O
seems O O
to O O
have O O
leveled O O
off O O
after O O
day O O
2 O O
. O O

There O O
were O O
slightly O O
increased O O
proliferating O O
cell O O
nuclear O O
antigen O O
- O O
positive O O
cells O O
in O O
the O O
ILK O O
/ O O
liver- O O
/ O O
- O O
animals O O
at O O
day O O
2 O O
as O O
compared O O
to O O
WT O O
after O O
PB O O
administration O O
. O O

In O O
the O O
WT O O
animals O O
, O O
the O O
proliferative O O
response O O
had O O
come O O
back O O
to O O
normal O O
by O O
days O O
5 O O
and O O
10 O O
. O O

Hepatocytes O O
of O O
the O O
ILK O O
/ O O
liver- O O
/ O O
- O O
mice O O
continued O O
to O O
proliferate O O
up O O
until O O
day O O
10 O O
. O O

ILK O O
/ O O
liver- O O
/ O O
- O O
mice O O
also O O
showed O O
increased O O
expression O O
of O O
key O O
genes O O
involved O O
in O O
hepatocyte O O
proliferation O O
at O O
different O O
time O O
points O O
during O O
PB O O
administration O O
. O O

In O O
summary O O
, O O
ECM O O
proteins O O
communicate O O
with O O
the O O
signaling O O
machinery O O
of O O
dividing O O
cells O O
via O O
ILK O O
to O O
regulate O O
hepatocyte O O
proliferation O O
and O O
termination O O
of O O
the O O
proliferative O O
response O O
. O O

Lack O O
of O O
ILK O O
in O O
the O O
hepatocytes O O
imparts O O
prolonged O O
proliferative O O
response O O
not O O
only O O
to O O
stimuli O O
related O O
to O O
liver O O
regeneration O O
but O O
also O O
to O O
xenobiotic O O
chemical O O
mitogens O O
, O O
such O O
as O O
PB O O
. O O

Decreased O O
Expression O O
of O O
Na O O
/ O O
K O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
in O O
Gentamicin O O
- O O
induced O O
Nephropathy B-Disease B-Disease
. O O

The O O
present O O
study O O
was O O
aimed O O
to O O
determine O O
whether O O
there O O
is O O
an O O
altered O O
regulation O O
of O O
tubular O O
transporters O O
in O O
gentamicin O O
- O O
induced O O
nephropathy B-Disease B-Disease
. O O

Sprague O O
- O O
Dawley O O
male O O
rats O O
( O O
200~250 O O
g O O
) O O
were O O
subcutaneously O O
injected O O
with O O
gentamicin O O
( O O
100 O O
mg O O
/ O O
kg O O
per O O
day O O
) O O
for O O
7 O O
days O O
, O O
and O O
the O O
expression O O
of O O
tubular O O
transporters O O
was O O
determined O O
by O O
immunoblotting O O
and O O
immunohistochemistry O O
. O O

The O O
mRNA O O
and O O
protein O O
expression O O
of O O
OAT O O
was O O
also O O
determined O O
. O O

Gentamicin O O
- O O
treated O O
rats O O
exhibited O O
significantly O O
decreased O O
creatinine O O
clearance O O
along O O
with O O
increased O O
plasma O O
creatinine O O
levels O O
. O O

Accordingly O O
, O O
the O O
fractional O O
excretion O O
of O O
sodium O O
increased O O
. O O

Urine O O
volume O O
was O O
increased O O
, O O
while O O
urine O O
osmolality O O
and O O
free O O
water O O
reabsorption O O
were O O
decreased O O
. O O

Immunoblotting O O
and O O
immunohistochemistry O O
revealed O O
decreased O O
expression O O
of O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
-ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
and O O
AQP1 O O
in O O
the O O
kidney O O
of O O
gentamicin O O
- O O
treated O O
rats O O
. O O

The O O
expression O O
of O O
OAT1 O O
and O O
OAT3 O O
was O O
also O O
decreased O O
. O O

Gentamicin O O
- O O
induced O O
nephropathy B-Disease B-Disease
may O O
at O O
least O O
in O O
part O O
be O O
causally O O
related O O
with O O
a O O
decreased O O
expression O O
of O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
-ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
after O O
high O O
- O O
dose O O
methotrexate O O
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
. O O

High O O
- O O
dose O O
methotrexate O O
( O O
HD O O
- O O
MTX O O
) O O
is O O
an O O
important O O
treatment O O
for O O
Burkitt B-Disease B-Disease
lymphoma I-Disease I-Disease
, O O
but O O
can O O
cause O O
hepatic B-Disease B-Disease
and I-Disease I-Disease
renal I-Disease I-Disease
toxicity I-Disease I-Disease
when O O
its O O
clearance O O
is O O
delayed O O
. O O

We O O
report O O
a O O
case O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
after O O
HD O O
- O O
MTX O O
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
, O O
The O O
patient O O
was O O
a O O
3-year O O
- O O
old O O
boy O O
who O O
had O O
received O O
a O O
living O O
- O O
related O O
liver O O
transplantation O O
for O O
congenital O B-Disease
biliary B-Disease I-Disease
atresia I-Disease I-Disease
. O O

At O O
day O O
833 O O
after O O
the O O
transplantation O O
, O O
he O O
was O O
diagnosed O O
with O O
PTLD B-Disease B-Disease
( O O
post B-Disease B-Disease
- I-Disease I-Disease
transplantation I-Disease I-Disease
lymphoproliferative I-Disease I-Disease
disorder I-Disease I-Disease
, O O
Burkitt B-Disease B-Disease
- I-Disease I-Disease
type I-Disease I-Disease
malignant I-Disease I-Disease
lymphoma I-Disease I-Disease
) O O
. O O

During O O
induction O O
therapy O O
, O O
he O O
suffered O O
ileal O B-Disease
perforation O I-Disease
and O O
ileostomy O O
was O O
performed O O
. O O

Subsequent O O
HD O O
- O O
MTX O O
therapy O O
caused O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
that O O
required O O
continuous O O
hemodialysis O O
. O O

We O O
supposed O O
that O O
intravascular O O
hypovolemia B-Disease B-Disease
due O O
to O O
substantial O O
drainage O O
from O O
the O O
ileostoma O O
caused O O
acute B-Disease B-Disease
prerenal I-Disease I-Disease
failure I-Disease I-Disease
. O O

After O O
recovery O O
of O O
his O O
renal O O
function O O
, O O
we O O
could O O
safely O O
treat O O
the O O
patient O O
with O O
HD O O
- O O
MTX O O
therapy O O
by O O
controlling O O
drainage O O
from O O
ileostoma O O
with O O
total O O
parenteral O O
nutrition O O
. O O

Longitudinal O O
association O O
of O O
alcohol O O
use O O
with O O
HIV B-Disease B-Disease
disease I-Disease I-Disease
progression O O
and O O
psychological O O
health O O
of O O
women O O
with O O
HIV O O
. O O

We O O
evaluated O O
the O O
association O O
of O O
alcohol O O
consumption O O
and O O
depression B-Disease B-Disease
, O O
and O O
their O O
effects O O
on O O
HIV B-Disease B-Disease
disease I-Disease I-Disease
progression O O
among O O
women O O
with O O
HIV O O
. O O

The O O
study O O
included O O
871 O O
women O O
with O O
HIV O B-Disease
who O O
were O O
recruited O O
from O O
1993 O O
- O O
1995 O O
in O O
four O O
US O O
cities O O
. O O

The O O
participants O O
had O O
physical O O
examination O O
, O O
medical O O
record O O
extraction O O
, O O
and O O
venipuncture O O
, O O
CD4+T O O
- O O
cell O O
counts O O
determination O O
, O O
measurement O O
of O O
depression B-Disease B-Disease
symptoms O O
( O O
using O O
the O O
self O O
- O O
report O O
Center O O
for O O
Epidemiological O O
Studies O O
- O O
Depression B-Disease B-Disease
Scale O O
) O O
, O O
and O O
alcohol O O
use O O
assessment O O
at O O
enrollment O O
, O O
and O O
semiannually O O
until O O
March O O
2000 O O
. O O

Multilevel O O
random O O
coefficient O O
ordinal O O
models O O
as O O
well O O
as O O
multilevel O O
models O O
with O O
joint O O
responses O O
were O O
used O O
in O O
the O O
analysis O O
. O O

There O O
was O O
no O O
significant O O
association O O
between O O
level O O
of O O
alcohol O O
use O O
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
. O O

When O O
participants O O
were O O
stratified O O
by O O
antiretroviral O O
therapy O O
( O O
ART O O
) O O
use O O
, O O
the O O
association O O
between O O
alcohol O O
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
did O O
not O O
reach O O
statistical O O
significance O O
. O O

The O O
association O O
between O O
alcohol O O
consumption O O
and O O
depression B-Disease B-Disease
was O O
significant O O
( O O
p<0.001 O O
) O O
. O O

Depression B-Disease B-Disease
had O O
a O O
significant O O
negative O O
effect O O
on O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
over O O
time O O
regardless O O
of O O
ART O O
use O O
. O O

Our O O
findings O O
suggest O O
that O O
alcohol O O
consumption O O
has O O
a O O
direct O O
association O O
with O O
depression B-Disease B-Disease
. O O

Moreover O O
, O O
depression B-Disease B-Disease
is O O
associated O O
with O O
HIV B-Disease B-Disease
disease I-Disease I-Disease
progression O O
. O O

Our O O
findings O O
have O O
implications O O
for O O
the O O
provision O O
of O O
alcohol O O
use O O
interventions O O
and O O
psychological O O
resources O O
to O O
improve O O
the O O
health O O
of O O
women O O
with O O
HIV O O
. O O

Chemokine O O
CCL2 O O
and O O
its O O
receptor O O
CCR2 O O
are O O
increased O O
in O O
the O O
hippocampus O O
following O O
pilocarpine O O
- O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Neuroinflammation B-Disease B-Disease
occurs O O
after O O
seizures B-Disease B-Disease
and O O
is O O
implicated O O
in O O
epileptogenesis O O
. O O

CCR2 O O
is O O
a O O
chemokine O O
receptor O O
for O O
CCL2 O O
and O O
their O O
interaction O O
mediates O O
monocyte O O
infiltration O O
in O O
the O O
neuroinflammatory B-Disease O
cascade O O
triggered O O
in O O
different O O
brain O O
pathologies O O
. O O

In O O
this O O
work O O
CCR2 O O
and O O
CCL2 O O
expression O O
were O O
examined O O
following O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
( O O
SE B-Disease B-Disease
) O O
induced O O
by O O
pilocarpine O O
injection O O
. O O

METHODS O O
: O O
SE B-Disease B-Disease
was O O
induced O O
by O O
pilocarpine O O
injection O O
. O O

Control O O
rats O O
were O O
injected O O
with O O
saline O O
instead O O
of O O
pilocarpine O O
. O O

Five O O
days O O
after O O
SE B-Disease B-Disease
, O O
CCR2 O O
staining O O
in O O
neurons O O
and O O
glial O O
cells O O
was O O
examined O O
using O O
imunohistochemical O O
analyses O O
. O O

The O O
number O O
of O O
CCR2 O O
positive O O
cells O O
was O O
determined O O
using O O
stereology O O
probes O O
in O O
the O O
hippocampus O O
. O O

CCL2 O O
expression O O
in O O
the O O
hippocampus O O
was O O
examined O O
by O O
molecular O O
assay O O
. O O

RESULTS O O
: O O
Increased O O
CCR2 O O
was O O
observed O O
in O O
the O O
hippocampus O O
after O O
SE B-Disease B-Disease
. O O

Seizures B-Disease B-Disease
also O O
resulted O O
in O O
alterations O O
to O O
the O O
cell O O
types O O
expressing O O
CCR2 O O
. O O

Increased O O
numbers O O
of O O
neurons O O
that O O
expressed O O
CCR2 O O
was O O
observed O O
following O O
SE B-Disease B-Disease
. O O

Microglial O O
cells O O
were O O
more O O
closely O O
apposed O O
to O O
the O O
CCR2-labeled O O
cells O O
in O O
SE B-Disease B-Disease
rats O O
. O O

In O O
addition O O
, O O
rats O O
that O O
experienced O O
SE B-Disease B-Disease
exhibited O O
CCR2-labeling O O
in O O
populations O O
of O O
hypertrophied B-Disease O
astrocytes O O
, O O
especially O O
in O O
CA1 O O
and O O
dentate O O
gyrus O O
. O O

These O O
CCR2 O O
+ O O
astroctytes O O
were O O
not O O
observed O O
in O O
control O O
rats O O
. O O

Examination O O
of O O
CCL2 O O
expression O O
showed O O
that O O
it O O
was O O
elevated O O
in O O
the O O
hippocampus O O
following O O
SE B-Disease B-Disease
. O O

CONCLUSION O O
: O O
The O O
data O O
show O O
that O O
CCR2 O O
and O O
CCL2 O O
are O O
up O O
- O O
regulated O O
in O O
the O O
hippocampus O O
after O O
pilocarpine O O
- O O
induced O O
SE B-Disease B-Disease
. O O

Seizures B-Disease B-Disease
also O O
result O O
in O O
changes O O
to O O
CCR2 O O
receptor O O
expression O O
in O O
neurons O O
and O O
astrocytes O O
. O O

These O O
changes O O
might O O
be O O
involved O O
in O O
detrimental O O
neuroplasticity O O
and O O
neuroinflammatory B-Disease O
changes O O
that O O
occur O O
following O O
seizures B-Disease B-Disease
. O O

Metallothionein O O
induction O O
reduces O O
caspase-3 O O
activity O O
and O O
TNFalpha O O
levels O O
with O O
preservation O O
of O O
cognitive O O
function O O
and O O
intact O O
hippocampal O O
neurons O O
in O O
carmustine O O
- O O
treated O O
rats O O
. O O

Hippocampal O O
integrity O O
is O O
essential O O
for O O
cognitive O O
functions O O
. O O

On O O
the O O
other O O
hand O O
, O O
induction O O
of O O
metallothionein O O
( O O
MT O O
) O O
by O O
ZnSO O O
( O O
4 O O
) O O
and O O
its O O
role O O
in O O
neuroprotection O O
has O O
been O O
documented O O
. O O

The O O
present O O
study O O
aimed O O
to O O
explore O O
the O O
effect O O
of O O
MT O O
induction O O
on O O
carmustine O O
( O O
BCNU O O
) O O
-induced O O
hippocampal O O
cognitive B-Disease B-Disease
dysfunction I-Disease I-Disease
in O O
rats O O
. O O

A O O
total O O
of O O
60 O O
male O O
Wistar O O
albino O O
rats O O
were O O
randomly O O
divided O O
into O O
four O O
groups O O
( O O
15 O O
/ O O
group O O
) O O
: O O
The O O
control O O
group O O
injected O O
with O O
single O O
doses O O
of O O
normal O O
saline O O
( O O
i.c.v O O
) O O
followed O O
24 O O
h O O
later O O
by O O
BCNU O O
solvent O O
( O O
i.v O O
) O O
. O O

The O O
second O O
group O O
administered O O
ZnSO O O
( O O
4 O O
) O O
( O O
0.1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i.c.v O O
, O O
once O O
) O O
then O O
BCNU O O
solvent O O
( O O
i.v O O
) O O
after O O
24 O O
h. O O
Third O O
group O O
received O O
BCNU O O
( O O
20 O O
mg O O
/ O O
kg O O
, O O
i.v O O
, O O
once O O
) O O
24 O O
h O O
after O O
injection O O
with O O
normal O O
saline O O
( O O
i.c.v O O
) O O
. O O

Fourth O O
group O O
received O O
a O O
single O O
dose O O
of O O
ZnSO O O
( O O
4 O O
) O O
( O O
0.1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i.c.v O O
) O O
then O O
BCNU O O
( O O
20 O O
mg O O
/ O O
kg O O
, O O
i.v O O
, O O
once O O
) O O
after O O
24 O O
h. O O
The O O
obtained O O
data O O
revealed O O
that O O
BCNU O O
administration O O
resulted O O
in O O
deterioration B-Disease B-Disease
of I-Disease I-Disease
learning I-Disease I-Disease
and B-Disease I-Disease
short I-Disease I-Disease
- I-Disease I-Disease
term I-Disease I-Disease
memory I-Disease I-Disease
( O O
STM O O
) O O
, O O
as O O
measured O O
by O O
using O O
radial O O
arm O O
water O O
maze O O
, O O
accompanied O O
with O O
decreased O O
hippocampal O O
glutathione O O
reductase O O
( O O
GR O O
) O O
activity O O
and O O
reduced O O
glutathione O O
( O O
GSH O O
) O O
content O O
. O O

Also O O
, O O
BCNU O O
administration O O
increased O O
serum O O
tumor B-Disease B-Disease
necrosis B-Disease B-Disease
factor O O
- O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
hippocampal O O
MT O O
and O O
malondialdehyde O O
( O O
MDA O O
) O O
contents O O
as O O
well O O
as O O
caspase-3 O O
activity O O
in O O
addition O O
to O O
histological O O
alterations O O
. O O

ZnSO O O
( O O
4 O O
) O O
pretreatment O O
counteracted O O
BCNU O O
- O O
induced O O
inhibition O O
of O O
GR O O
and O O
depletion O O
of O O
GSH O O
and O O
resulted O O
in O O
significant O O
reduction O O
in O O
the O O
levels O O
of O O
MDA O O
and O O
TNFalpha O O
as O O
well O O
as O O
the O O
activity O O
of O O
caspase-3 O O
. O O

The O O
histological O O
features O O
were O O
improved O O
in O O
hippocampus O O
of O O
rats O O
treated O O
with O O
ZnSO O O
( O O
4 O O
) O O
+ O O
BCNU O O
compared O O
to O O
only O O
BCNU O O
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
MT O O
induction O O
halts O O
BCNU O O
- O O
induced O O
hippocampal O B-Disease
toxicity B-Disease I-Disease
as O O
it O O
prevented O O
GR O O
inhibition O O
and O O
GSH O O
depletion O O
and O O
counteracted O O
the O O
increased O O
levels O O
of O O
TNFalpha O O
, O O
MDA O O
and O O
caspase-3 O O
activity O O
with O O
subsequent O O
preservation O O
of O O
cognition O O
. O O

Fatal O O
carbamazepine O O
induced O O
fulminant B-Disease O
eosinophilic I-Disease O
( O O
hypersensitivity B-Disease B-Disease
) O O
myocarditis B-Disease B-Disease
: O O
emphasis O O
on O O
anatomical O O
and O O
histological O O
characteristics O O
, O O
mechanisms O O
and O O
genetics O O
of O O
drug B-Disease B-Disease
hypersensitivity I-Disease I-Disease
and O O
differential O O
diagnosis O O
. O O

The O O
most O O
severe O O
adverse O O
reactions O O
to O O
carbamazepine O O
have O O
been O O
observed O O
in O O
the O O
haemopoietic O O
system O O
, O O
the O O
liver O O
and O O
the O O
cardiovascular O O
system O O
. O O

A O O
frequently O O
fatal O O
, O O
although O O
exceptionally O O
rare O O
side O O
effect O O
of O O
carbamazepine O O
is O O
necrotizing O O
eosinophilic O O
( O O
hypersensitivity B-Disease B-Disease
) O O
myocarditis B-Disease B-Disease
. O O

We O O
report O O
a O O
case O O
of O O
hypersensitivity B-Disease B-Disease
myocarditis B-Disease B-Disease
secondary O O
to O O
administration O O
of O O
carbamazepine O O
. O O

Acute O O
hypersensitivity B-Disease B-Disease
myocarditis B-Disease B-Disease
was O O
not O O
suspected O O
clinically O O
, O O
and O O
the O O
diagnosis O O
was O O
made O O
post O O
- O O
mortem O O
. O O

Histology O O
revealed O O
diffuse O O
infiltration O O
of O O
the O O
myocardium O O
by O O
eosinophils O O
and O O
lymphocytes O O
with O O
myocyte O O
damage O O
. O O

Clinically O O
, O O
death O O
was O O
due O O
to O O
cardiogenic B-Disease B-Disease
shock I-Disease I-Disease
. O O

To O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
second O O
case O O
of O O
fatal O O
carbamazepine O O
induced O O
myocarditis B-Disease B-Disease
reported O O
in O O
English O O
literature O O
. O O

Neuropsychiatric O B-Disease
behaviors O I-Disease
in O O
the O O
MPTP O O
marmoset O O
model O O
of O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

OBJECTIVES O O
: O O
Neuropsychiatric O O
symptoms O O
are O O
increasingly O O
recognised O O
as O O
a O O
significant O O
problem O O
in O O
patients O O
with O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
( O O
PD B-Disease B-Disease
) O O
. O O

These O O
symptoms O O
may O O
be O O
due O O
to O O
' O O
sensitisation O O
' O O
following O O
repeated O O
levodopa O O
treatment O O
or O O
a O O
direct O O
effect O O
of O O
dopamine O O
on O O
the O O
disease O O
state O O
. O O

The O O
levodopa O O
- O O
treated O O
MPTP O O
- O O
lesioned O O
marmoset O O
was O O
used O O
as O O
a O O
model O O
of O O
neuropsychiatric B-Disease B-Disease
symptoms I-Disease I-Disease
in O O
PD B-Disease B-Disease
patients O O
. O O

Here O O
we O O
compare O O
the O O
time O O
course O O
of O O
levodopa O O
- O O
induced O O
motor O O
fluctuations O O
and O O
neuropsychiatric B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
behaviors I-Disease I-Disease
to O O
determine O O
the O O
relationship O O
between O O
duration O O
of O O
treatment O O
and O O
onset O O
of O O
symptoms O O
. O O

METHODS O O
: O O
Marmosets O O
were O O
administered O O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O O
( O O
2.0 O O
mg O O
/ O O
kg O O
s.c O O
. O O
) O O
for O O
five O O
days O O
, O O
resulting O O
in O O
stable O O
parkinsonism B-Disease B-Disease
. O O

Levodopa O O
( O O
15 O O
mg O O
/ O O
kg O O
and O O
benserazide O O
, O O
3.75 O O
mg O O
/ O O
kg O O
) O O
p.o O O
. O O

b.i.d O O
, O O
was O O
administered O O
for O O
30 O O
days O O
. O O

Animals O O
were O O
evaluated O O
for O O
parkinsonian B-Disease B-Disease
disability I-Disease I-Disease
, O O
dyskinesia B-Disease B-Disease
and O O
on O O
- O O
time O O
( O O
motor O O
fluctuations O O
) O O
and O O
neuropsychiatric B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
behaviors I-Disease I-Disease
on O O
Day O O
0 O O
( O O
prior O O
to O O
levodopa O O
) O O
and O O
on O O
Days O O
1 O O
, O O
7 O O
, O O
13 O O
, O O
27 O O
and O O
30 O O
of O O
treatment O O
using O O
post O O
hoc O O
DVD O O
analysis O O
by O O
a O O
trained O O
rater O O
, O O
blind O O
to O O
the O O
treatment O O
day O O
. O O

RESULTS O O
: O O
The O O
neuropsychiatric B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
behavior I-Disease I-Disease
rating O O
scale O O
demonstrated O O
high O O
interrater O O
reliability O O
between O O
three O O
trained O O
raters O O
of O O
differing O O
professional O O
backgrounds O O
. O O

As O O
anticipated O O
, O O
animals O O
exhibited O O
a O O
progressive O O
increase O O
in O O
levodopa O O
- O O
induced O O
motor O O
fluctuations O O
, O O
dyskinesia B-Disease B-Disease
and O O
wearing O O
- O O
off O O
, O O
that O O
correlated O O
with O O
the O O
duration O O
of O O
levodopa O O
therapy O O
. O O

In O O
contrast O O
, O O
levodopa O O
- O O
induced O O
neuropsychiatric B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
behaviors I-Disease I-Disease
were O O
present O O
on O O
Day O O
1 O O
of O O
levodopa O O
treatment O O
and O O
their O O
severity O O
did O O
not O O
correlate O O
with O O
duration O O
of O O
treatment O O
. O O

CONCLUSIONS O O
: O O
The O O
data O O
suggest O O
that O O
neuropsychiatric B-Disease B-Disease
disorders I-Disease I-Disease
in O O
PD B-Disease B-Disease
are O O
more O O
likely O O
an O O
interaction O O
between O O
levodopa O O
and O O
the O O
disease O O
state O O
than O O
a O O
consequence O O
of O O
sensitisation O O
to O O
repeated O O
dopaminergic O O
therapy O O
. O O

Contrast O O
medium O O
nephrotoxicity B-Disease B-Disease
after O O
renal O O
artery O O
and O O
coronary O O
angioplasty O O
. O O

BACKGROUND O O
: O O
Renal B-Disease B-Disease
dysfunction I-Disease I-Disease
induced O O
by O O
iodinated O O
contrast O O
medium O O
( O O
CM O O
) O O
administration O O
can O O
minimize O O
the O O
benefit O O
of O O
the O O
interventional O O
procedure O O
in O O
patients O O
undergoing O O
renal O O
angioplasty O O
( O O
PTRA O O
) O O
. O O

PURPOSE O O
: O O
To O O
compare O O
the O O
susceptibility O O
to O O
nephrotoxic B-Disease B-Disease
effect O O
of O O
CM O O
in O O
patients O O
undergoing O O
PTRA O O
with O O
that O O
of O O
patients O O
submitted O O
to O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
33 O O
patients O O
successfully O O
treated O O
with O O
PTRA O O
( O O
PTRA O O
group O O
, O O
mean O O
age O O
70+ O O
/ O O
-12 O O
years O O
, O O
23 O O
female O O
, O O
basal O O
creatinine O O
1.46+ O O
/ O O
-0.79 O O
, O O
range O O
0.7 O O
- O O
4.9 O O
mg O O
/ O O
dl O O
) O O
were O O
compared O O
with O O
33 O O
patients O O
undergoing O O
successful O O
PCI O O
( O O
PCI O O
group O O
) O O
, O O
matched O O
for O O
basal O O
creatinine O O
( O O
1.44+ O O
/ O O
-0.6 O O
, O O
range O O
0.7 O O
- O O
3.4 O O
mg O O
/ O O
dl O O
) O O
, O O
gender O O
, O O
and O O
age O O
. O O

In O O
both O O
groups O O
postprocedural O O
( O O
48 O O
h O O
) O O
serum O O
creatinine O O
was O O
measured O O
. O O

RESULTS O O
: O O
Postprocedural O O
creatinine O O
level O O
decreased O O
nonsignificantly O O
in O O
the O O
PTRA O O
group O O
( O O
1.46+ O O
/ O O
-0.8 O O
vs. O O
1.34+ O O
/ O O
-0.5 O O
mg O O
/ O O
dl O O
, O O
P O O
= O O
NS O O
) O O
and O O
increased O O
significantly O O
in O O
the O O
PCI O O
group O O
( O O
1.44+ O O
/ O O
-0.6 O O
vs. O O
1.57+ O O
/ O O
-0.7 O O
mg O O
/ O O
dl O O
, O O
P<0.02 O O
) O O
. O O

Changes O O
in O O
serum O O
creatinine O O
after O O
intervention O O
( O O
after O O
- O O
before O O
) O O
were O O
significantly O O
different O O
between O O
the O O
PTRA O O
and O O
PCI O O
groups O O
( O O
-0.12+ O O
/ O O
-0.5 O O
vs. O O
0.13+ O O
/ O O
-0.3 O O
, O O
P=0.014 O O
) O O
. O O

This O O
difference O O
was O O
not O O
related O O
to O O
either O O
a O O
different O O
clinical O O
risk O O
profile O O
or O O
to O O
the O O
volume O O
of O O
CM O O
administered O O
. O O

CONCLUSION O O
: O O
In O O
this O O
preliminary O O
study O O
patients O O
submitted O O
to O O
PTRA O O
showed O O
a O O
lower O O
susceptibility O O
to O O
renal B-Disease B-Disease
damage I-Disease I-Disease
induced O O
by O O
CM O O
administration O O
than O O
PCI O O
patients O O
. O O

The O O
effectiveness O O
of O O
PTRA O O
on O O
renal O O
function O O
seems O O
to O O
be O O
barely O O
influenced O O
by O O
CM O O
toxicity B-Disease B-Disease
. O O

Diphenhydramine O O
prevents O O
the O O
haemodynamic O O
changes O O
of O O
cimetidine O O
in O O
ICU O O
patients O O
. O O

Cimetidine O O
, O O
a O O
histamine O O
2 O O
( O O
H2 O O
) O O
antagonist O O
, O O
produces O O
a O O
decrease O O
in O O
arterial O O
pressure O O
due O O
to O O
vasodilatation O O
, O O
especially O O
in O O
critically O O
ill O O
patients O O
. O O

This O O
may O O
be O O
because O O
cimetidine O O
acts O O
as O O
a O O
histamine O O
agonist O O
. O O

We O O
, O O
therefore O O
, O O
investigated O O
the O O
effects O O
of O O
the O O
histamine O O
1 O O
( O O
H1 O O
) O O
receptor O O
antagonist O O
, O O
diphenhydramine O O
, O O
on O O
the O O
haemodynamic O O
changes O O
observed O O
after O O
cimetidine O O
in O O
ICU O O
patients O O
. O O

Each O O
patient O O
was O O
studied O O
on O O
two O O
separate O O
days O O
. O O

In O O
a O O
random O O
fashion O O
, O O
they O O
received O O
cimetidine O O
200 O O
mg O O
iv O O
on O O
one O O
day O O
, O O
and O O
on O O
the O O
other O O
, O O
a O O
pretreatment O O
of O O
diphenhydramine O O
40 O O
mg O O
iv O O
with O O
cimetidine O O
200 O O
mg O O
iv O O
. O O

In O O
the O O
non O O
- O O
pretreatment O O
group O O
, O O
mean O O
arterial O O
pressure O O
( O O
MAP O O
) O O
decreased O O
from O O
107.4 O O
+ O O
/- O O

8.4 O O
mmHg O O
to O O
86.7 O O
+ O O
/- O O

11.4 O O
mmHg O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
two O O
minutes O O
after O O
cimetidine O O
. O O

Also O O
, O O
systemic O O
vascular O O
resistance O O
( O O
SVR O O
) O O
decreased O O
during O O
the O O
eight O O
- O O
minute O O
observation O O
period O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

In O O
contrast O O
, O O
in O O
the O O
pretreatment O O
group O O
, O O
little O O
haemodynamic O O
change O O
was O O
seen O O
. O O

We O O
conclude O O
that O O
an O O
H1 O O
antagonist O O
may O O
be O O
useful O O
in O O
preventing O O
hypotension B-Disease B-Disease
caused O O
by O O
iv O O
cimetidine O O
, O O
since O O
the O O
vasodilating O O
activity O O
of O O
cimetidine O O
is O O
mediated O O
, O O
in O O
part O O
, O O
through O O
the O O
H1 O O
receptor O O
. O O

Medical O O
and O O
psychiatric O O
outcomes O O
for O O
patients O O
transplanted O O
for O O
acetaminophen O O
- O O
induced O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
: O O
a O O
case O O
- O O
control O O
study O O
. O O

BACKGROUND O O
: O O
Acetaminophen O O
- O O
induced O O
hepatotoxicity B-Disease B-Disease
is O O
the O O
most O O
common O O
cause O O
of O O
acute B-Disease B-Disease
liver I-Disease I-Disease
failure I-Disease I-Disease
( O O
ALF B-Disease B-Disease
) O O
in O O
the O O
UK O O
. O O

Patients O O
often O O
consume O O
the O O
drug O O
with O O
suicidal O O
intent O O
or O O
with O O
a O O
background O O
of O O
substance O B-Disease
dependence O I-Disease
. O O

AIMS O O
AND O O
METHODS O O
: O O
We O O
compared O O
the O O
severity O O
of O O
pretransplant O O
illness O O
, O O
psychiatric O O
co O O
- O O
morbidity O O
, O O
medical O O
and O O
psychosocial O O
outcomes O O
of O O
all O O
patients O O
who O O
had O O
undergone O O
liver O O
transplantation O O
( O O
LT O O
) O O
emergently O O
between O O
1999 O O
- O O
2004 O O
for O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
( O O
n=36 O O
) O O
with O O
age- O O
and O O
sex O O
- O O
matched O O
patients O O
undergoing O O
emergent O O
LT O O
for O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
( O O
n=35 O O
) O O
and O O
elective O O
LT O O
for O O
chronic B-Disease B-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
( O O
CLD B-Disease B-Disease
, O O
n=34 O O
) O O
. O O

RESULTS O O
: O O
Acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
patients O O
undergoing O O
LT O O
had O O
a O O
greater O O
severity O O
of O O
pre O O
- O O
LT O O
illness O O
reflected O O
by O O
higher O O
Acute O O
Physiology O O
and O O
Chronic O O
Health O O
Evaluation O O
II O O
scores O O
and O O
requirement O O
for O O
organ O O
support O O
compared O O
with O O
the O O
other O O
two O O
groups O O
. O O

Twenty O O
( O O
56 O O
% O O
) O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
patients O O
had O O
a O O
formal O O
psychiatric O O
diagnosis O O
before O O
LT O O
( O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF=0 B-Disease B-Disease
/ O O
35 O O
, O O
CLD=2 B-Disease O
/ O O
34 O O
; O O
P<0.01 O O
for O O
all O O
) O O
and O O
nine O O
( O O
25 O O
% O O
) O O
had O O
a O O
previous O O
suicide O O
attempt O O
. O O

During O O
follow O O
- O O
up O O
( O O
median O O
5 O O
years O O
) O O
, O O
there O O
were O O
no O O
significant O O
differences O O
in O O
rejection O O
( O O
acute O O
and O O
chronic O O
) O O
, O O
graft O O
failure O O
or O O
survival O O
between O O
the O O
groups O O
( O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
1 O O
year O O
87 O O
% O O
, O O
5 O O
years O O
75 O O
% O O
; O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
88 O O
% O O
, O O
78 O O
% O O
; O O
CLD B-Disease B-Disease
93 O O
% O O
, O O
82 O O
% O O
: O O
P>0.6 O O
log O O
rank O O
) O O
. O O

Two O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
patients O O
reattempted O O
suicide O O
post O O
- O O
LT O O
( O O
one O O
died O O
8 O O
years O O
post O O
- O O
LT O O
) O O
. O O

CONCLUSIONS O O
: O O
Despite O O
a O O
high O O
prevalence O O
of O O
psychiatric O B-Disease
disturbance O I-Disease
, O O
outcomes O O
for O O
patients O O
transplanted O O
emergently O O
for O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
were O O
comparable O O
to O O
those O O
transplanted O O
for O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B-Disease B-Disease
and O O
electively O O
for O O
CLD B-Disease B-Disease
. O O

Multidisciplinary O O
approaches O O
with O O
long O O
- O O
term O O
psychiatric O O
follow O O
- O O
up O O
may O O
contribute O O
to O O
low O O
post O O
- O O
transplant O O
suicide O O
rates O O
seen O O
and O O
low O O
rates O O
of O O
graft O O
loss O O
because O O
of O O
non O O
- O O
compliance O O
. O O

Antithrombotic O O
drug O O
use O O
, O O
cerebral B-Disease B-Disease
microbleeds I-Disease I-Disease
, O O
and O O
intracerebral B-Disease B-Disease
hemorrhage I-Disease I-Disease
: O O
a O O
systematic O O
review O O
of O O
published O O
and O O
unpublished O O
studies O O
. O O

BACKGROUND O O
AND O O
PURPOSE O O
: O O
Cerebral B-Disease B-Disease
microbleeds I-Disease I-Disease
( O O
MB B-Disease B-Disease
) O O
are O O
potential O O
risk O O
factors O O
for O O
intracerebral B-Disease B-Disease
hemorrhage I-Disease I-Disease
( O O
ICH B-Disease B-Disease
) O O
, O O
but O O
it O O
is O O
unclear O O
if O O
they O O
are O O
a O O
contraindication O O
to O O
using O O
antithrombotic O O
drugs O O
. O O

Insights O O
could O O
be O O
gained O O
by O O
pooling O O
data O O
on O O
MB B-Disease B-Disease
frequency O O
stratified O O
by O O
antithrombotic O O
use O O
in O O
cohorts O O
with O O
ICH B-Disease B-Disease
and O O
ischemic B-Disease B-Disease
stroke I-Disease I-Disease
( O O
IS B-Disease B-Disease
) O O
/ O O
transient B-Disease B-Disease
ischemic I-Disease I-Disease
attack I-Disease I-Disease
( O O
TIA B-Disease B-Disease
) O O
. O O

METHODS O O
: O O
We O O
performed O O
a O O
systematic O O
review O O
of O O
published O O
and O O
unpublished O O
data O O
from O O
cohorts O O
with O O
stroke B-Disease B-Disease
or O O
TIA B-Disease B-Disease
to O O
compare O O
the O O
presence O O
of O O
MB B-Disease B-Disease
in O O
: O O
( O O
1 O O
) O O
antithrombotic O O
users O O
vs O O
nonantithrombotic O O
users O O
with O O
ICH B-Disease B-Disease
; O O
( O O
2 O O
) O O
antithrombotic O O
users O O
vs O O
nonusers O O
with O O
IS B-Disease B-Disease
/ O O
TIA B-Disease B-Disease
; O O
and O O
( O O
3 O O
) O O
ICH B-Disease B-Disease
vs O O
ischemic B-Disease B-Disease
events O O
stratified O O
by O O
antithrombotic O O
use O O
. O O

We O O
also O O
analyzed O O
published O O
and O O
unpublished O O
follow O O
- O O
up O O
data O O
to O O
determine O O
the O O
risk O O
of O O
ICH B-Disease B-Disease
in O O
antithrombotic O O
users O O
with O O
MB B-Disease B-Disease
. O O

RESULTS O O
: O O
In O O
a O O
pooled O O
analysis O O
of O O
1460 O O
ICH B-Disease B-Disease
and O O
3817 O O
IS B-Disease B-Disease
/ O O
TIA B-Disease B-Disease
, O O
MB B-Disease B-Disease
were O O
more O O
frequent O O
in O O
ICH B-Disease B-Disease
vs O O
IS B-Disease B-Disease
/ O O
TIA B-Disease B-Disease
in O O
all O O
treatment O O
groups O O
, O O
but O O
the O O
excess O O
increased O O
from O O
2.8 O O
( O O
odds O O
ratio O O
; O O
range O O
, O O
2.3 O O
- O O
3.5 O O
) O O
in O O
nonantithrombotic O O
users O O
to O O
5.7 O O
( O O
range O O
, O O
3.4 O O
- O O
9.7 O O
) O O
in O O
antiplatelet O O
users O O
and O O
8.0 O O
( O O
range O O
, O O
3.5 O O
- O O
17.8 O O
) O O
in O O
warfarin O O
users O O
( O O
P O O
difference=0.01 O O
) O O
. O O

There O O
was O O
also O O
an O O
excess O O
of O O
MB B-Disease B-Disease
in O O
warfarin O O
users O O
vs O O
nonusers O O
with O O
ICH B-Disease B-Disease
( O O
OR O O
, O O
2.7 O O
; O O
95 O O
% O O
CI O O
, O O
1.6 O O
- O O
4.4 O O
; O O
P<0.001 O O
) O O
but O O
none O O
in O O
warfarin O O
users O O
with O O
IS B-Disease B-Disease
/ O O
TIA B-Disease B-Disease
( O O
OR O O
, O O
1.3 O O
; O O
95 O O
% O O
CI O O
, O O
0.9 O O
- O O
1.7 O O
; O O
P=0.33 O O
; O O
P O O
difference=0.01 O O
) O O
. O O

There O O
was O O
a O O
smaller O O
excess O O
of O O
MB B-Disease B-Disease
in O O
antiplatelet O O
users O O
vs O O
nonusers O O
with O O
ICH B-Disease B-Disease
( O O
OR O O
, O O
1.7 O O
; O O
95 O O
% O O
CI O O
, O O
1.3 O O
- O O
2.3 O O
; O O
P<0.001 O O
) O O
, O O
but O O
findings O O
were O O
similar O O
for O O
antiplatelet O O
users O O
with O O
IS B-Disease B-Disease
/ O O
TIA B-Disease B-Disease
( O O
OR O O
, O O
1.4 O O
; O O
95 O O
% O O
CI O O
, O O
1.2 O O
- O O
1.7 O O
; O O
P<0.001 O O
; O O
P O O
difference=0.25 O O
) O O
. O O

In O O
pooled O O
follow O O
- O O
up O O
data O O
for O O
768 O O
antithrombotic O O
users O O
, O O
presence O O
of O O
MB B-Disease B-Disease
at O O
baseline O O
was O O
associated O O
with O O
a O O
substantially O O
increased O O
risk O O
of O O
subsequent O O
ICH B-Disease B-Disease
( O O
OR O O
, O O
12.1 O O
; O O
95 O O
% O O
CI O O
, O O
3.4 O O
- O O
42.5 O O
; O O
P<0.001 O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
excess O O
of O O
MB B-Disease B-Disease
in O O
warfarin O O
users O O
with O O
ICH B-Disease B-Disease
compared O O
to O O
other O O
groups O O
suggests O O
that O O
MB B-Disease O
increase O O
the O O
risk O O
of O O
warfarin O O
- O O
associated O O
ICH B-Disease B-Disease
. O O

Limited O O
prospective O O
data O O
corroborate O O
these O O
findings O O
, O O
but O O
larger O O
prospective O O
studies O O
are O O
urgently O O
required O O
. O O

Studies O O
of O O
synergy O O
between O O
morphine O O
and O O
a O O
novel O O
sodium O O
channel O O
blocker O O
, O O
CNSB002 O O
, O O
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic B-Disease B-Disease
pain I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
This O O
study O O
determined O O
the O O
antihyperalgesic O O
effect O O
of O O
CNSB002 O O
, O O
a O O
sodium O O
channel O O
blocker O O
with O O
antioxidant O O
properties O O
given O O
alone O O
and O O
in O O
combinations O O
with O O
morphine O O
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic B-Disease B-Disease
pain I-Disease I-Disease
. O O

DESIGN O O
: O O
Dose O O
response O O
curves O O
for O O
nonsedating O O
doses O O
of O O
morphine O O
and O O
CNSB002 O O
given O O
intraperitoneally O O
alone O O
and O O
together O O
in O O
combinations O O
were O O
constructed O O
for O O
antihyperalgesic O O
effect O O
using O O
paw O O
withdrawal O O
from O O
noxious O O
heat O O
in O O
two O O
rat O O
pain B-Disease B-Disease
models O O
: O O
carrageenan O O
- O O
induced O O
paw O O
inflammation B-Disease B-Disease
and O O
streptozotocin O O
( O O
STZ O O
) O O
-induced O O
diabetic B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

RESULTS O O
: O O
The O O
maximum O O
nonsedating O O
doses O O
were O O
: O O
morphine O O
, O O
3.2 O O
mg O O
/ O O
kg O O
; O O
CNSB002 O O
10.0 O O
mg O O
/ O O
kg O O
; O O
5.0 O O
mg O O
/ O O
kg O O
CNSB002 O O
with O O
morphine O O
3.2 O O
mg O O
/ O O
kg O O
in O O
combination O O
. O O

The O O
doses O O
calculated O O
to O O
cause O O
50 O O
% O O
reversal O O
of O O
hyperalgesia B-Disease B-Disease
( O O
ED50 O O
) O O
were O O
7.54 O O
( O O
1.81 O O
) O O
and O O
4.83 O O
( O O
1.54 O O
) O O
in O O
the O O
carrageenan O O
model O O
and O O
44.18 O O
( O O
1.37 O O
) O O
and O O
9.14 O O
( O O
1.24 O O
) O O
in O O
the O O
STZ O O
- O O
induced O O
neuropathy B-Disease B-Disease
model O O
for O O
CNSB002 O O
and O O
morphine O O
, O O
respectively O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

These O O
values O O
were O O
greater O O
than O O
the O O
maximum O O
nonsedating O O
doses O O
. O O

The O O
ED50 O O
values O O
for O O
morphine O O
when O O
given O O
in O O
combination O O
with O O
CNSB002 O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
less O O
than O O
the O O
maximum O O
nonsedating O O
dose O O
: O O
0.56 O O
( O O
1.55 O O
) O O
in O O
the O O
carrageenan O O
model O O
and O O
1.37 O O
( O O
1.23 O O
) O O
in O O
the O O
neuropathy B-Disease B-Disease
model O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

The O O
antinociception O O
after O O
morphine O O
( O O
3.2 O O
mg O O
/ O O
kg O O
) O O
was O O
increased O O
by O O
co O O
- O O
administration O O
with O O
CNSB002 O O
from O O
28.0 O O
and O O
31.7 O O
% O O
to O O
114.6 O O
and O O
56.9 O O
% O O
reversal O O
of O O
hyperalgesia B-Disease B-Disease
in O O
the O O
inflammatory O O
and O O
neuropathic B-Disease B-Disease
models O O
, O O
respectively O O
( O O
P O O
< O O
0.01 O O
; O O
one O O
- O O
way O O
analysis O O
of O O
variance O O
- O O
significantly O O
greater O O
than O O
either O O
drug O O
given O O
alone O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
maximum O O
antihyperalgesic O O
effect O O
achievable O O
with O O
nonsedating O O
doses O O
of O O
morphine O O
may O O
be O O
increased O O
significantly O O
when O O
the O O
drug O O
is O O
used O O
in O O
combination O O
with O O
CNSB002 O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
: O O
a O O
practical O O
review O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
( O O
HIT B-Disease B-Disease
) O O
remains O O
under O O
- O O
recognized O O
despite O O
its O O
potentially O O
devastating O O
outcomes O O
. O O

It O O
begins O O
when O O
heparin O O
exposure O O
stimulates O O
the O O
formation O O
of O O
heparin O O
- O O
platelet O O
factor O O
4 O O
antibodies O O
, O O
which O O
in O O
turn O O
triggers O O
the O O
release O O
of O O
procoagulant O O
platelet O O
particles O O
. O O

Thrombosis B-Disease B-Disease
and O O
thrombocytopenia B-Disease B-Disease
that O O
follow O O
comprise O O
the O O
2 O O
hallmark O O
traits O O
of O O
HIT B-Disease B-Disease
, O O
with O O
the O O
former O O
largely O O
responsible O O
for O O
significant O O
vascular O O
complications O O
. O O

The O O
prevalence O O
of O O
HIT B-Disease B-Disease
varies O O
among O O
several O O
subgroups O O
, O O
with O O
greater O O
incidence O O
in O O
surgical O O
as O O
compared O O
with O O
medical O O
populations O O
. O O

HIT B-Disease B-Disease
must O O
be O O
acknowledged O O
for O O
its O O
intense O O
predilection O O
for O O
thrombosis B-Disease B-Disease
and O O
suspected O O
whenever O O
thrombosis B-Disease B-Disease
occurs O O
after O O
heparin O O
exposure O O
. O O

Early O O
recognition O O
that O O
incorporates O O
the O O
clinical O O
and O O
serologic O O
clues O O
is O O
paramount O O
to O O
timely O O
institution O O
of O O
treatment O O
, O O
as O O
its O O
delay O O
may O O
result O O
in O O
catastrophic O O
outcomes O O
. O O

The O O
treatment O O
of O O
HIT B-Disease B-Disease
mandates O O
an O O
immediate O O
cessation O O
of O O
all O O
heparin O O
exposure O O
and O O
the O O
institution O O
of O O
an O O
antithrombotic O O
therapy O O
, O O
most O O
commonly O O
using O O
a O O
direct O O
thrombin O O
inhibitor O O
. O O

Current O O
" O O
diagnostic O O
" O O
tests O O
, O O
which O O
primarily O O
include O O
functional O O
and O O
antigenic O O
assays O O
, O O
have O O
more O O
of O O
a O O
confirmatory O O
than O O
diagnostic O O
role O O
in O O
the O O
management O O
of O O
HIT B-Disease B-Disease
. O O

Special O O
attention O O
must O O
be O O
paid O O
to O O
cardiac O O
patients O O
who O O
are O O
often O O
exposed O O
to O O
heparin O O
multiple O O
times O O
during O O
their O O
course O O
of O O
treatment O O
. O O

Direct O O
thrombin O O
inhibitors O O
are O O
appropriate O O
, O O
evidence O O
- O O
based O O
alternatives O O
to O O
heparin O O
in O O
patients O O
with O O
a O O
history O O
of O O
HIT B-Disease B-Disease
, O O
who O O
need O O
to O O
undergo O O
percutaneous O O
coronary O O
intervention O O
. O O

As O O
heparin O O
remains O O
one O O
of O O
the O O
most O O
frequently O O
used O O
medications O O
today O O
with O O
potential O O
for O O
HIT B-Disease B-Disease
with O O
every O O
heparin O O
exposure O O
, O O
a O O
close O O
vigilance O O
of O O
platelet O O
counts O O
must O O
be O O
practiced O O
whenever O O
heparin O O
is O O
initiated O O
. O O

Abductor O O
paralysis B-Disease B-Disease
after O O
botox O O
injection O O
for O O
adductor B-Disease B-Disease
spasmodic I-Disease I-Disease
dysphonia I-Disease I-Disease
. O O

OBJECTIVES O O
/ O O
HYPOTHESIS O O
: O O
Botulinum O O
toxin O O
( O O
Botox O O
) O O
injections O O
into O O
the O O
thyroarytenoid O O
muscles O O
are O O
the O O
current O O
standard O O
of O O
care O O
for O O
adductor B-Disease B-Disease
spasmodic I-Disease I-Disease
dysphonia I-Disease I-Disease
( O O
ADSD B-Disease B-Disease
) O O
. O O

Reported O O
adverse O O
effects O O
include O O
a O O
period O O
of O O
breathiness O B-Disease
, O O
throat B-Disease B-Disease
pain I-Disease I-Disease
, O O
and O O
difficulty O O
with O O
swallowing O O
liquids O O
. O O

Here O O
we O O
report O O
multiple O O
cases O O
of O O
bilateral O O
abductor O O
paralysis B-Disease B-Disease
following O O
Botox O O
injections O O
for O O
ADSD B-Disease B-Disease
, O O
a O O
complication O O
previously O O
unreported O O
. O O

STUDY O O
DESIGN O O
: O O
Retrospective O O
case O O
series O O
. O O

METHODS O O
: O O
Patients O O
that O O
received O O
Botox O O
injections O O
for O O
spasmodic B-Disease B-Disease
dysphonia I-Disease I-Disease
between O O
January O O
2000 O O
and O O
October O O
2009 O O
were O O
evaluated O O
. O O

Patients O O
with O O
ADSD B-Disease B-Disease
were O O
identified O O
. O O

The O O
number O O
of O O
treatments O O
received O O
and O O
adverse O O
effects O O
were O O
noted O O
. O O

For O O
patients O O
with O O
bilateral O O
abductor O O
paralysis B-Disease B-Disease
, O O
age O O
, O O
sex O O
, O O
paralytic O O
Botox O O
dose O O
, O O
prior O O
Botox O O
dose O O
, O O
and O O
course O O
following O O
paralysis B-Disease B-Disease
were O O
noted O O
. O O

RESULTS O O
: O O
From O O
a O O
database O O
of O O
452 O O
patients O O
receiving O O
Botox O O
, O O
352 O O
patients O O
had O O
been O O
diagnosed O O
with O O
ADSD B-Disease B-Disease
. O O

Of O O
these O O
352 O O
patients O O
, O O
eight O O
patients O O
suffered O O
bilateral O O
abductor O O
paralysis B-Disease B-Disease
, O O
and O O
two O O
suffered O O
this O O
complication O O
twice O O
. O O

All O O
affected O O
patients O O
were O O
females O O
over O O
the O O
age O O
of O O
50 O O
years O O
. O O

Most O O
patients O O
had O O
received O O
treatments O O
prior O O
to O O
abductor O O
paralysis B-Disease B-Disease
and O O
continued O O
receiving O O
after O O
paralysis B-Disease B-Disease
. O O

Seven O O
patients O O
recovered O O
after O O
a O O
brief O O
period O O
of O O
activity O O
restrictions O O
, O O
and O O
one O O
underwent O O
a O O
tracheotomy O O
. O O

The O O
incidence O O
of O O
abductor O O
paralysis B-Disease B-Disease
after O O
Botox O O
injection O O
for O O
ADSD B-Disease B-Disease
was O O
0.34 O O
% O O
. O O

CONCLUSIONS O O
: O O
Bilateral O O
abductor O O
paralysis B-Disease B-Disease
is O O
a O O
rare O O
complication O O
of O O
Botox O O
injections O O
for O O
ADSD B-Disease B-Disease
, O O
causing O O
difficulty O O
with O O
breathing O O
upon O O
exertion O O
. O O

The O O
likely O O
mechanism O O
of O O
paralysis B-Disease B-Disease
is O O
diffusion O O
of O O
Botox O O
around O O
the O O
muscular O O
process O O
of O O
the O O
arytenoid O O
to O O
the O O
posterior O O
cricoarytenoid O O
muscles O O
. O O

The O O
paralysis B-Disease B-Disease
is O O
temporary O O
, O O
and O O
watchful O O
waiting O O
with O O
restriction O O
of O O
activity O O
is O O
the O O
recommended O O
management O O
. O O

Mitochondrial B-Disease B-Disease
impairment I-Disease I-Disease
contributes O O
to O O
cocaine O O
- O O
induced O O
cardiac B-Disease B-Disease
dysfunction I-Disease I-Disease
: O O
Prevention O O
by O O
the O O
targeted O O
antioxidant O O
MitoQ. O O
The O O
goal O O
of O O
this O O
study O O
was O O
to O O
assess O O
mitochondrial O O
function O O
and O O
ROS O O
production O O
in O O
an O O
experimental O O
model O O
of O O
cocaine O O
- O O
induced O O
cardiac B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

We O O
hypothesized O O
that O O
cocaine B-Disease B-Disease
abuse I-Disease I-Disease
may O O
lead O O
to O O
altered O O
mitochondrial O O
function O O
that O O
in O O
turn O O
may O O
cause O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
. O O

Seven O O
days O O
of O O
cocaine O O
administration O O
to O O
rats O O
led O O
to O O
an O O
increased O O
oxygen O O
consumption O O
detected O O
in O O
cardiac O O
fibers O O
, O O
specifically O O
through O O
complex O O
I O O
and O O
complex O O
III O O
. O O

ROS O O
levels O O
were O O
increased O O
, O O
specifically O O
in O O
interfibrillar O O
mitochondria O O
. O O

In O O
parallel O O
there O O
was O O
a O O
decrease O O
in O O
ATP O O
synthesis O O
, O O
whereas O O
no O O
difference O O
was O O
observed O O
in O O
subsarcolemmal O O
mitochondria O O
. O O

This O O
uncoupling O O
effect O O
on O O
oxidative O O
phosphorylation O O
was O O
not O O
detectable O O
after O O
short O O
- O O
term O O
exposure O O
to O O
cocaine O O
, O O
suggesting O O
that O O
these O O
mitochondrial B-Disease B-Disease
abnormalities I-Disease I-Disease
were O O
a O O
late O O
rather O O
than O O
a O O
primary O O
event O O
in O O
the O O
pathological O O
response O O
to O O
cocaine O O
. O O

MitoQ O O
, O O
a O O
mitochondrial O O
- O O
targeted O O
antioxidant O O
, O O
was O O
shown O O
to O O
completely O O
prevent O O
these O O
mitochondrial B-Disease B-Disease
abnormalities I-Disease I-Disease
as O O
well O O
as O O
cardiac B-Disease B-Disease
dysfunction I-Disease I-Disease
characterized O O
here O O
by O O
a O O
diastolic B-Disease B-Disease
dysfunction I-Disease I-Disease
studied O O
with O O
a O O
conductance O O
catheter O O
to O O
obtain O O
pressure O O
- O O
volume O O
data O O
. O O

Taken O O
together O O
, O O
these O O
results O O
extend O O
previous O O
studies O O
and O O
demonstrate O O
that O O
cocaine O O
- O O
induced O O
cardiac B-Disease B-Disease
dysfunction I-Disease I-Disease
may O O
be O O
due O O
to O O
a O O
mitochondrial B-Disease B-Disease
defect I-Disease I-Disease
. O O

Trimethoprim O O
- O O
induced O O
immune O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
in O O
a O O
pediatric O O
oncology O O
patient O O
presenting O O
as O O
an O O
acute O O
hemolytic O B-Disease
transfusion O I-Disease
reaction O I-Disease
. O O

A O O
10-year O O
- O O
old O O
male O O
with O O
acute B-Disease B-Disease
leukemia I-Disease I-Disease
presented O O
with O O
post O O
- O O
chemotherapy O O
anemia B-Disease B-Disease
. O O

During O O
red O O
cell O O
transfusion O O
, O O
he O O
developed O O
hemoglobinuria B-Disease B-Disease
. O O

Transfusion O O
reaction O O
workup O O
was O O
negative O O
. O O

Drug O O
- O O
induced O O
immune O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
was O O
suspected O O
because O O
of O O
positive O O
direct O O
antiglobulin O O
test O O
, O O
negative O O
eluate O O
, O O
and O O
microspherocytes O O
on O O
smear O O
pre- O O
and O O
post O O
- O O
transfusion O O
. O O

Drug O O
studies O O
using O O
the O O
indirect O O
antiglobulin O O
test O O
were O O
strongly O O
positive O O
with O O
trimethoprim O O
and O O
trimethoprim O O
- O O
sulfamethoxazole O O
but O O
negative O O
with O O
sulfamethoxazole O O
. O O

The O O
patient O O
recovered O O
after O O
discontinuing O O
the O O
drug O O
, O O
with O O
no O O
recurrence O O
in O O
2 O O
years O O
. O O

Other O O
causes O O
of O O
anemia B-Disease B-Disease
should O O
be O O
considered O O
in O O
patients O O
with O O
worse O O
- O O
than O O
- O O
expected O O
anemia B-Disease B-Disease
after O O
chemotherapy O O
. O O

Furthermore O O
, O O
hemolysis B-Disease B-Disease
during O O
transfusion O O
is O O
not O O
always O O
a O O
transfusion O O
reaction O O
. O O

Verapamil O O
stimulation O O
test O O
in O O
hyperprolactinemia B-Disease B-Disease
: O O
loss O O
of O O
prolactin O O
response O O
in O O
anatomic O O
or O O
functional O O
stalk O O
effect O O
. O O

AIM O O
: O O
Verapamil O O
stimulation O O
test O O
was O O
previously O O
investigated O O
as O O
a O O
tool O O
for O O
differential O O
diagnosis O O
of O O
hyperprolactinemia B-Disease B-Disease
, O O
but O O
with O O
conflicting O O
results O O
. O O

Macroprolactinemia B-Disease B-Disease
was O O
never O O
considered O O
in O O
those O O
previous O O
studies O O
. O O

Here O O
, O O
we O O
aimed O O
to O O
re O O
- O O
investigate O O
the O O
diagnostic O O
value O O
of O O
verapamil O O
in O O
a O O
population O O
who O O
were O O
all O O
screened O O
for O O
macroprolactinemia B-Disease B-Disease
. O O

Prolactin O O
responses O O
to O O
verapamil O O
in O O
65 O O
female O O
patients O O
( O O
age O O
: O O
29.9 O O
+ O O
/- O O
8.1 O O
years O O
) O O
with O O
hyperprolactinemia B-Disease B-Disease
were O O
tested O O
in O O
a O O
descriptive O O
, O O
matched O O
case O O
- O O
control O O
study O O
. O O

METHODS O O
: O O
Verapamil O O
80 O O
mg O O
, O O
p.o O O
. O O
was O O
administered O O
, O O
and O O
then O O
PRL O O
levels O O
were O O
measured O O
at O O
8th O O
and O O
16th O O
hours O O
, O O
by O O
immunometric O O
chemiluminescence O O
. O O

Verapamil O O
responsiveness O O
was O O
determined O O
by O O
peak O O
percent O O
change O O
in O O
basal O O
prolactin O O
levels O O
( O O
PRL O O
) O O
. O O

RESULTS O O
: O O
Verapamil O O
significantly O O
increased O O
PRL O O
levels O O
in O O
healthy O O
controls O O
( O O
N. O O
8 O O
, O O
PRL O O
: O O
183 O O
% O O
) O O
, O O
macroprolactinoma B-Disease B-Disease
( O O
N. O O
8 O O
, O O
PRL O O
: O O
7 O O
% O O
) O O
, O O
microprolactinoma B-Disease B-Disease
( O O
N. O O
19 O O
, O O
PRL O O
: O O
21 O O
% O O
) O O
, O O
macroprolactinemia B-Disease B-Disease
( O O
N. O O
23 O O
, O O
PRL O O
: O O
126 O O
% O O
) O O
, O O
but O O
not O O
in O O
pseudoprolactinoma B-Disease B-Disease
( O O
N. O O
8 O O
, O O
PRL O O
: O O
0.8 O O
% O O
) O O
, O O
and O O
risperidone O O
- O O
induced O O
hyperprolactinemia B-Disease B-Disease
( O O
N. O O
7 O O
, O O
PRL O O
: O O
3 O O
% O O
) O O
. O O

ROC O O
curve O O
analysis O O
revealed O O
that O O
unresponsiveness O O
to O O
verapamil O O
defined O O
as O O
PRL O O
< O O
7 O O
% O O
, O O
discriminated O O
anatomical O O
or O O
functional O O
stalk O O
effect O O
( O O
sensitivity O O
: O O
74 O O
% O O
, O O
specificity O O
: O O
73 O O
% O O
, O O
AUC O O
: O O
0.855+ O O
/ O O
-0.04 O O
, O O
P O O
< O O
0.001 O O
, O O
CI O O
: O O
0.768 O O
- O O
0.942 O O
) O O
associated O O
with O O
pseudoprolactinoma B-Disease B-Disease
or O O
risperidone O O
- O O
induced O O
hyperprolactinemia B-Disease B-Disease
, O O
respectively O O
. O O

CONCLUSION O O
: O O
Verapamil O O
responsiveness O O
is O O
not O O
a O O
reliable O O
finding O O
for O O
the O O
differential O O
diagnosis O O
of O O
hyperprolactinemia B-Disease B-Disease
. O O

However O O
, O O
verapamil O O
unresponsiveness O O
discriminates O O
stalk O O
effect O O
( O O
i.e. O O
, O O
anatomically O O
or O O
functionally O O
inhibited O O
dopaminergic O O
tonus O O
) O O
from O O
other O O
causes O O
of O O
hyperprolactinemia B-Disease B-Disease
with O O
varying O O
degrees O O
of O O
responsiveness O O
. O O

Blockade O O
of O O
endothelial O O
- O O
mesenchymal O O
transition O O
by O O
a O O
Smad3 O O
inhibitor O O
delays O O
the O O
early O O
development O O
of O O
streptozotocin O O
- O O
induced O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
A O O
multicenter O O
, O O
controlled O O
trial O O
showed O O
that O O
early O O
blockade O O
of O O
the O O
renin O O
- O O
angiotensin O O
system O O
in O O
patients O O
with O O
type B-Disease B-Disease
1 I-Disease I-Disease
diabetes I-Disease I-Disease
and O O
normoalbuminuria O B-Disease
did O O
not O O
retard O O
the O O
progression O O
of O O
nephropathy B-Disease B-Disease
, O O
suggesting O O
that O O
other O O
mechanism O O
( O O
s O O
) O O
are O O
involved O O
in O O
the O O
pathogenesis O O
of O O
early O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
( O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
) O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
endothelial O O
- O O
mesenchymal O O
- O O
transition O O
( O O
EndoMT O O
) O O
contributes O O
to O O
the O O
early O O
development O O
of O O
renal O O
interstitial O O
fibrosis B-Disease B-Disease
independently O O
of O O
microalbuminuria O B-Disease
in O O
mice O O
with O O
streptozotocin O O
( O O
STZ O O
) O O
-induced O O
diabetes B-Disease B-Disease
. O O

In O O
the O O
present O O
study O O
, O O
we O O
hypothesized O O
that O O
blocking O O
EndoMT O O
reduces O O
the O O
early O O
development O O
of O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
EndoMT O O
was O O
induced O O
in O O
a O O
mouse O O
pancreatic O O
microvascular O O
endothelial O O
cell O O
line O O
( O O
MMEC O O
) O O
in O O
the O O
presence O O
of O O
advanced O O
glycation O O
end O O
products O O
( O O
AGEs O O
) O O
and O O
in O O
the O O
endothelial O O
lineage O O
- O O
traceble O O
mouse O O
line O O
Tie2-Cre;Loxp O O
- O O
EGFP O O
by O O
administration O O
of O O
AGEs O O
, O O
with O O
nonglycated O O
mouse O O
albumin O O
serving O O
as O O
a O O
control O O
. O O

Phosphorylated O O
Smad3 O O
was O O
detected O O
by O O
immunoprecipitation O O
/ O O
Western O O
blotting O O
and O O
confocal O O
microscopy O O
. O O

Blocking O O
studies O O
using O O
receptor O O
for O O
AGE O O
siRNA O O
and O O
a O O
specific O O
inhibitor O O
of O O
Smad3 O O
( O O
SIS3 O O
) O O
were O O
performed O O
in O O
MMECs O O
and O O
in O O
STZ O O
- O O
induced O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
in O O
Tie2-Cre;Loxp O O
- O O
EGFP O O
mice O O
. O O

RESULTS O O
: O O
Confocal O O
microscopy O O
and O O
real O O
- O O
time O O
PCR O O
demonstrated O O
that O O
AGEs O O
induced O O
EndoMT O O
in O O
MMECs O O
and O O
in O O
Tie2-Cre;Loxp O O
- O O
EGFP O O
mice O O
. O O

Immunoprecipitation O O
/ O O
Western O O
blotting O O
showed O O
that O O
Smad3 O O
was O O
activated O O
by O O
AGEs O O
but O O
was O O
inhibited O O
by O O
SIS3 O O
in O O
MMECs O O
and O O
in O O
STZ O O
- O O
induced O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
. O O

Confocal O O
microscopy O O
and O O
real O O
- O O
time O O
PCR O O
further O O
demonstrated O O
that O O
SIS3 O O
abrogated O O
EndoMT O O
, O O
reduced O O
renal O O
fibrosis B-Disease B-Disease
, O O
and O O
retarded O O
progression O O
of O O
nephropathy B-Disease B-Disease
. O O

CONCLUSIONS O O
: O O
EndoMT O O
is O O
a O O
novel O O
pathway O O
leading O O
to O O
early O O
development O O
of O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
. O O

Blockade O O
of O O
EndoMT O O
by O O
SIS3 O O
may O O
provide O O
a O O
new O O
strategy O O
to O O
retard O O
the O O
progression O O
of O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
and O O
other O O
diabetes B-Disease B-Disease
complications I-Disease O
. O O

Cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
of O O
temsirolimus O O
in O O
refractory O O
mantle B-Disease B-Disease
cell I-Disease I-Disease
lymphoma I-Disease I-Disease
. O O

Mantle B-Disease B-Disease
cell I-Disease I-Disease
lymphoma I-Disease I-Disease
( O O
MCL B-Disease B-Disease
) O O
is O O
a O O
rare O O
and O O
aggressive O O
type O O
of O O
B B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
non I-Disease I-Disease
- I-Disease I-Disease
Hodgkin I-Disease I-Disease
's I-Disease I-Disease
lymphoma I-Disease I-Disease
. O O

Patients O O
become O O
progressively O O
refractory O O
to O O
conventional O O
chemotherapy O O
, O O
and O O
their O O
prognosis O O
is O O
poor O O
. O O

However O O
, O O
a O O
38 O O
% O O
remission O O
rate O O
has O O
been O O
recently O O
reported O O
in O O
refractory O O
MCL B-Disease B-Disease
treated O O
with O O
temsirolimus O O
, O O
a O O
mTOR O O
inhibitor O O
. O O

Here O O
we O O
had O O
the O O
opportunity O O
to O O
study O O
a O O
case O O
of O O
refractory O O
MCL B-Disease B-Disease
who O O
had O O
tumor B-Disease B-Disease
regression O O
two O O
months O O
after O O
temsirolimus O O
treatment O O
, O O
and O O
a O O
progression O O
- O O
free O O
survival O O
of O O
10 O O
months O O
. O O

In O O
this O O
case O O
, O O
lymph O O
node O O
biopsies O O
were O O
performed O O
before O O
and O O
six O O
months O O
after O O
temsirolimus O O
therapy O O
. O O

Comparison O O
of O O
the O O
two O O
biopsies O O
showed O O
that O O
temsirolimus O O
inhibited O O
tumor B-Disease B-Disease
cell O O
proliferation O O
through O O
cell O O
cycle O O
arrest O O
, O O
but O O
did O O
not O O
induce O O
any O O
change O O
in O O
the O O
number O O
of O O
apoptotic O O
tumor B-Disease B-Disease
cells O O
. O O

Apart O O
from O O
this O O
cytostatic O O
effect O O
, O O
temsirolimus O O
had O O
an O O
antiangiogenic O O
effect O O
with O O
decrease O O
of O O
tumor B-Disease B-Disease
microvessel O O
density O O
and O O
of O O
VEGF O O
expression O O
. O O

Moreover O O
, O O
numerous O O
patchy O O
, O O
well O O
- O O
limited O O
fibrotic O O
areas O O
, O O
compatible O O
with O O
post O O
- O O
necrotic B-Disease O
tissue O O
repair O O
, O O
were O O
found O O
after O O
6-month O O
temsirolimus O O
therapy O O
. O O

Thus O O
, O O
temsirolimus O O
reduced O O
tumor B-Disease B-Disease
burden O O
through O O
associated O O
cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
. O O

This O O
dual O O
effect O O
of O O
temsirolimus O O
on O O
tumor B-Disease B-Disease
tissue O O
could O O
contribute O O
to O O
its O O
recently O O
reported O O
efficiency O O
in O O
refractory O O
MCL B-Disease B-Disease
resistant O O
to O O
conventional O O
chemotherapy O O
. O O

Acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
due O O
to O O
rifampicin O O
. O O

A O O
23-year O O
- O O
old O O
male O O
patient O O
with O O
bacteriologically O O
proven O O
pulmonary B-Disease B-Disease
tuberculosis I-Disease I-Disease
was O O
treated O O
with O O
the O O
various O O
regimens O O
of O O
antituberculosis O O
drugs O O
for O O
nearly O O
15 O O
months O O
. O O

Rifampicin O O
was O O
administered O O
thrice O O
as O O
one O O
of O O
the O O
3 O O
- O O
4 O O
drug O O
regimen O O
and O O
each O O
time O O
he O O
developed O O
untoward O O
side O O
effects O O
like O O
nausea B-Disease B-Disease
, O O
vomiting B-Disease B-Disease
and O O
fever B-Disease B-Disease
with O O
chills O B-Disease
and O O
rigors O O
. O O

The O O
last O O
such O O
episode O O
was O O
of O O
acute O B-Disease
renal O I-Disease
failure O I-Disease
at O O
which O O
stage O O
the O O
patient O O
was O O
seen O O
by O O
the O O
authors O O
of O O
this O O
report O O
. O O

The O O
patient O O
, O O
however O O
, O O
made O O
a O O
full O O
recovery O O
. O O

Syncope B-Disease B-Disease
caused O O
by O O
hyperkalemia B-Disease B-Disease
during O O
use O O
of O O
a O O
combined O O
therapy O O
with O O
the O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitor O O
and O O
spironolactone O O
. O O

A O O
76 O O
year O O
- O O
old O O
woman O O
with O O
a O O
history O O
of O O
coronary O O
artery O O
bypass O O
grafting O O
and O O
prior O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
was O O
transferred O O
to O O
the O O
emergency O O
room O O
with O O
loss B-Disease B-Disease
of I-Disease I-Disease
consciousness I-Disease I-Disease
due O O
to O O
marked O O
bradycardia B-Disease B-Disease
caused O O
by O O
hyperkalemia B-Disease B-Disease
. O O

The O O
concentration O O
of O O
serum O O
potassium O O
was O O
high O O
, O O
and O O
normal O O
sinus O O
rhythm O O
was O O
restored O O
after O O
correction O O
of O O
the O O
serum O O
potassium O O
level O O
. O O

The O O
cause O O
of O O
hyperkalemia B-Disease B-Disease
was O O
considered O O
to O O
be O O
several O O
doses O O
of O O
spiranolactone O O
, O O
an O O
aldosterone O O
antagonist O O
, O O
in O O
addition O O
to O O
the O O
long O O
- O O
term O O
intake O O
of O O
ramipril O O
, O O
an O O
ACE O O
inhibitor O O
. O O

This O O
case O O
is O O
a O O
good O O
example O O
of O O
electrolyte O O
imbalance O O
causing O O
acute O O
life O O
- O O
threatening O O
cardiac O O
events O O
. O O

Clinicians O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
of O O
hyperkalemia B-Disease B-Disease
, O O
especially O O
in O O
elderly O O
patients O O
using O O
ACE O O
/ O O
ARB O O
in O O
combination O O
with O O
potassium O O
sparing O O
agents O O
and O O
who O O
have O O
mild O O
renal B-Disease B-Disease
disturbance I-Disease I-Disease
. O O

Diffuse O O
skeletal O B-Disease
pain B-Disease I-Disease
after O O
administration O O
of O O
alendronate O O
. O O

BACKGROUND O O
: O O
Osteoporosis B-Disease B-Disease
is O O
caused O O
by O O
bone O O
resorption O O
in O O
excess O O
of O O
bone O O
formation O O
, O O
and O O
bisphosphonates O O
, O O
are O O
used O O
to O O
inhibit O O
bone O O
resorption O O
. O O

Alendronate O O
, O O
a O O
biphosphonate O O
, O O
is O O
effective O O
for O O
both O O
the O O
treatment O O
and O O
prevention O O
of O O
osteoporosis B-Disease B-Disease
in O O
postmenopausal O O
women O O
. O O

Side O O
effects O O
are O O
relatively O O
few O O
and O O
prominently O O
gastrointestinal O O
. O O

Musculoskeletal B-Disease B-Disease
pain I-Disease I-Disease
may O O
be O O
an O O
important O O
side O O
effect O O
in O O
these O O
patients O O
. O O

We O O
presented O O
a O O
patient O O
admitted O O
to O O
our O O
out O O
- O O
patient O O
clinic O O
with O O
diffuse O O
skeletal O B-Disease
pain B-Disease I-Disease
after O O
three O O
consecutive O O
administration O O
of O O
alendronate O O
. O O

CONCLUSION O O
: O O
We O O
conclude O O
that O O
patients O O
with O O
osteoporosis B-Disease B-Disease
can O O
report O O
pain B-Disease B-Disease
, O O
and O O
bisphosphonate O O
- O O
related O O
pain B-Disease B-Disease
should O O
also O O
be O O
considered O O
before O O
ascribing O O
this O O
complaint O O
to O O
osteoporosis B-Disease B-Disease
. O O

Cerebrospinal O O
fluid O O
penetration O O
of O O
high O O
- O O
dose O O
daptomycin O O
in O O
suspected O O
Staphylococcus O O
aureus O O
meningitis B-Disease B-Disease
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
methicillin O O
- O O
sensitive O O
Staphylococcus O O
aureus O O
( O O
MSSA O O
) O O
bacteremia B-Disease B-Disease
with O O
suspected O O
MSSA O O
meningitis B-Disease B-Disease
treated O O
with O O
high O O
- O O
dose O O
daptomycin O O
assessed O O
with O O
concurrent O O
serum O O
and O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
concentrations O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
54-year O O
- O O
old O O
male O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
generalized O O
weakness B-Disease B-Disease
and O O
presumed O O
health O O
- O O
care O O
- O O
associated O O
pneumonia B-Disease B-Disease
shown O O
on O O
chest O O
radiograph O O
. O O

Treatment O O
was O O
empirically O O
initiated O O
with O O
vancomycin O O
, O O
levofloxacin O O
, O O
and O O
piperacillin O O
/ O O
tazobactam O O
. O O

Blood O O
cultures O O
revealed O O
S. O O
aureus O O
susceptible O O
to O O
oxacillin O O
. O O

Empiric O O
antibiotic O O
treatment O O
was O O
narrowed O O
to O O
nafcillin O O
on O O
day O O
4 O O
. O O

On O O
day O O
8 O O
, O O
the O O
patient O O
developed O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
( O O
serum O O
creatinine O O
1.9 O O
mg O O
/ O O
dL O O
, O O
increased O O
from O O
1.2 O O
mg O O
/ O O
dL O O
the O O
previous O O
day O O
and O O
0.8 O O
mg O O
/ O O
dL O O
on O O
admission O O
) O O
. O O

The O O
patient O O
's O O
Glasgow O O
Coma O O
Score O O
was O O
3 O O
, O O
with O O
normal O O
findings O O
shown O O
on O O
computed O O
tomography O O
scan O O
of O O
the O O
head O O
72 O O
hours O O
following O O
an O O
episode O O
of O O
cardiac B-Disease B-Disease
arrest I-Disease I-Disease
on O O
day O O
10 O O
. O O

The O O
patient O O
experienced O O
relapsing O O
MSSA O O
bacteremia B-Disease B-Disease
on O O
day O O
9 O O
, O O
increasing O O
the O O
suspicion O O
for O O
a O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
infection B-Disease B-Disease
. O O

Nafcillin O O
was O O
discontinued O O
and O O
daptomycin O O
9 O O
mg O O
/ O O
kg O O
daily O O
was O O
initiated O O
for O O
suspected O O
meningitis B-Disease B-Disease
and O O
was O O
continued O O
until O O
the O O
patient O O
's O O
death O O
on O O
day O O
16 O O
. O O

Daptomycin O O
serum O O
and O O
CSF O O
trough O O
concentrations O O
were O O
11.21 O O
ug O O
/ O O
mL O O
and O O
0.52 O O
ug O O
/ O O
mL O O
, O O
respectively O O
, O O
prior O O
to O O
the O O
third O O
dose O O
. O O

Lumbar O O
puncture O O
results O O
were O O
inconclusive O O
and O O
no O O
further O O
blood O O
cultures O O
were O O
positive O O
for O O
MSSA O O
. O O

Creatine O O
kinase O O
levels O O
were O O
normal O O
prior O O
to O O
daptomycin O O
therapy O O
and O O
were O O
not O O
reassessed O O
. O O

DISCUSSION O O
: O O
Daptomycin O O
was O O
initiated O O
in O O
our O O
patient O O
secondary O O
to O O
possible O O
nafcillin O O
- O O
induced O O
acute O O
interstitial B-Disease B-Disease
nephritis I-Disease I-Disease
and O O
relapsing O O
bacteremia B-Disease B-Disease
. O O

At O O
a O O
dose O O
of O O
9 O O
mg O O
/ O O
kg O O
, O O
resultant O O
penetration O O
of O O
5 O O
% O O
was O O
higher O O
than O O
in O O
previous O O
reports O O
, O O
more O O
consistent O O
with O O
inflamed O O
meninges O O
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
daptomycin O O
may O O
be O O
an O O
alternative O O
option O O
for O O
MSSA O O
bacteremia B-Disease B-Disease
with O O
or O O
without O O
a O O
CNS O O
source O O
in O O
patients O O
who O O
have O O
failed O O
or O O
can O O
not O O
tolerate O O
standard O O
therapy O O
. O O

Further O O
clinical O O
evaluation O O
in O O
patients O O
with O O
confirmed O O
meningitis B-Disease B-Disease
is O O
warranted O O
. O O

The O O
role O O
of O O
nitric O O
oxide O O
in O O
convulsions B-Disease B-Disease
induced O O
by O O
lindane O O
in O O
rats O O
. O O

Lindane O O
is O O
an O O
organochloride O O
pesticide O O
and O O
scabicide O O
. O O

It O O
evokes O O
convulsions B-Disease B-Disease
mainly O O
trough O O
the O O
blockage O O
of O O
GABA O O
( O O
A O O
) O O
receptors O O
. O O

Nitric O O
oxide O O
( O O
NO O O
) O O
, O O
gaseous O O
neurotransmitter O O
, O O
has O O
contradictor O O
role O O
in O O
epileptogenesis O O
due O O
to O O
opposite O O
effects O O
of O O
L O O
- O O
arginine O O
, O O
precursor O O
of O O
NO O O
syntheses O O
( O O
NOS O O
) O O
, O O
and O O
L O O
- O O
NAME O O
( O O
NOS O O
inhibitor O O
) O O
observed O O
in O O
different O O
epilepsy B-Disease B-Disease
models O O
. O O

The O O
aim O O
of O O
the O O
current O O
study O O
was O O
to O O
determine O O
the O O
effects O O
of O O
NO O O
on O O
the O O
behavioral O O
and O O
EEG O O
characteristics O O
of O O
lindane O O
- O O
induced O O
epilepsy B-Disease B-Disease
in O O
male O O
Wistar O O
albino O O
rats O O
. O O

The O O
administration O O
of O O
L O O
- O O
arginine O O
( O O
600 O O
, O O
800 O O
and O O
1000 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
in O O
dose O O
- O O
dependent O O
manner O O
significantly O O
increased O O
convulsion B-Disease B-Disease
incidence O O
and O O
severity O O
and O O
shortened O O
latency O O
time O O
to O O
first O O
convulsion B-Disease B-Disease
elicited O O
by O O
lower O O
lindane O O
dose O O
( O O
4 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
. O O

On O O
the O O
contrary O O
, O O
pretreatment O O
with O O
L O O
- O O
NAME O O
( O O
500 O O
, O O
700 O O
and O O
900 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
decreased O O
convulsion B-Disease B-Disease
incidence O O
and O O
severity O O
and O O
prolonged O O
latency O O
time O O
to O O
convulsion B-Disease B-Disease
following O O
injection O O
with O O
a O O
convulsive B-Disease B-Disease
dose O O
of O O
lindane O O
( O O
8 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
. O O

EEG O O
analyses O O
showed O O
increase O O
of O O
number O O
and O O
duration O O
of O O
ictal O O
periods O O
in O O
EEG O O
of O O
rats O O
receiving O O
l O O
- O O
arginine O O
prior O O
to O O
lindane O O
and O O
decrease O O
of O O
this O O
number O O
in O O
rats O O
pretreated O O
with O O
L O O
- O O
NAME O O
. O O

These O O
results O O
support O O
the O O
conclusion O O
that O O
NO O O
plays O O
a O O
role O O
of O O
endogenous O O
convulsant O O
in O O
rat O O
model O O
of O O
lindane O O
seizures B-Disease B-Disease
. O O

Severe O O
polyneuropathy B-Disease B-Disease
and O O
motor O B-Disease
loss O I-Disease
after O O
intrathecal O O
thiotepa O O
combination O O
chemotherapy O O
: O O
description O O
of O O
two O O
cases O O
. O O

Two O O
cases O O
of O O
severe O O
delayed O O
neurologic B-Disease B-Disease
toxicity I-Disease I-Disease
related O O
to O O
the O O
administration O O
of O O
intrathecal O O
( O O
IT O O
) O O
combination O O
chemotherapy O O
including O O
thiotepa O O
( O O
TSPA O O
) O O
are O O
presented O O
. O O

Both O O
cases O O
developed O O
axonal B-Disease B-Disease
neuropathy I-Disease I-Disease
with O O
motor O O
predominance O O
in O O
the O O
lower O O
extremities O O
1 O O
and O O
6 O O
months O O
after O O
IT O O
chemotherapy O O
was O O
administered O O
. O O

Neurologic B-Disease B-Disease
toxicities I-Disease I-Disease
have O O
been O O
described O O
with O O
IT O O
- O O
methotrexate O O
, O O
IT O O
- O O
cytosine O O
arabinoside O O
and O O
IT O O
- O O
TSPA O O
. O O

To O O
our O O
knowledge O O
, O O
however O O
, O O
axonal B-Disease B-Disease
neuropathy I-Disease I-Disease
following O O
administration O O
of O O
these O O
three O O
agents O O
has O O
not O O
been O O
previously O O
described O O
. O O

In O O
spite O O
of O O
the O O
fact O O
that O O
TSPA O O
is O O
a O O
useful O O
IT O O
agent O O
, O O
its O O
combination O O
with O O
MTX O O
, O O
ara O O
- O O
C O O
and O O
radiotherapy O O
could O O
cause O O
severe O O
neurotoxicity B-Disease B-Disease
. O O

This O O
unexpected O O
complication O O
indicates O O
the O O
need O O
for O O
further O O
toxicology O O
research O O
on O O
IT O O
- O O
TSPA O O
. O O

Effects O O
of O O
cromakalim O O
and O O
pinacidil O O
on O O
large O O
epicardial O O
and O O
small O O
coronary O O
arteries O O
in O O
conscious O O
dogs O O
. O O

The O O
effects O O
of O O
i.v O O
. O O

bolus O O
administration O O
of O O
cromakalim O O
( O O
1 O O
- O O
10 O O
micrograms O O
/ O O
kg O O
) O O
and O O
pinacidil O O
( O O
3 O O
- O O
100 O O
micrograms O O
/ O O
kg O O
) O O
on O O
large O O
( O O
circumflex O O
artery O O
) O O
and O O
small O O
coronary O O
arteries O O
and O O
on O O
systemic O O
hemodynamics O O
were O O
investigated O O
in O O
chronically O O
instrumented O O
conscious O O
dogs O O
and O O
compared O O
to O O
those O O
of O O
nitroglycerin O O
( O O
0.03 O O
- O O
10 O O
micrograms O O
/ O O
kg O O
) O O
. O O

Nitroglycerin O O
, O O
up O O
to O O
0.3 O O
micrograms O O
/ O O
kg O O
, O O
selectively O O
increased O O
circumflex O O
artery O O
diameter O O
( O O
CxAD O O
) O O
without O O
simultaneously O O
affecting O O
any O O
other O O
cardiac O O
or O O
systemic O O
hemodynamic O O
parameter O O
. O O

In O O
contrast O O
, O O
cromakalim O O
and O O
pinacidil O O
at O O
all O O
doses O O
and O O
nitroglycerin O O
at O O
doses O O
higher O O
than O O
0.3 O O
micrograms O O
/ O O
kg O O
simultaneously O O
and O O
dose O O
- O O
dependently O O
increased O O
CxAD O O
, O O
coronary O O
blood O O
flow O O
and O O
heart O O
rate O O
and O O
decreased O O
coronary O O
vascular O O
resistance O O
and O O
aortic O O
pressure O O
. O O

Cromakalim O O
was O O
approximately O O
8- O O
to O O
9.5-fold O O
more O O
potent O O
than O O
pinacidil O O
in O O
increasing O O
CxAD O O
. O O

Vasodilation O O
of O O
large O O
and O O
small O O
coronary O O
vessels O O
and O O
hypotension B-Disease B-Disease
induced O O
by O O
cromakalim O O
and O O
pinacidil O O
were O O
not O O
affected O O
by O O
prior O O
combined O O
beta O O
adrenergic O O
and O O
muscarinic O O
receptors O O
blockade O O
but O O
drug O O
- O O
induced O O
tachycardia B-Disease B-Disease
was O O
abolished O O
. O O

When O O
circumflex O O
artery O O
blood O O
flow O O
was O O
maintained O O
constant O O
, O O
the O O
increases O O
in O O
CxAD O O
induced O O
by O O
cromakalim O O
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
, O O
pinacidil O O
( O O
30 O O
micrograms O O
/ O O
kg O O
) O O
and O O
nitroglycerin O O
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
were O O
reduced O O
by O O
68 O O
+ O O
/- O O

7 O O
, O O
54 O O
+ O O
/- O O

9 O O
and O O
1 O O
+ O O
/- O O

1 O O
% O O
, O O
respectively O O
. O O

Thus O O
, O O
whereas O O
nitroglycerin O O
preferentially O O
and O O
flow O O
- O O
independently O O
dilates O O
large O O
coronary O O
arteries O O
, O O
cromakalim O O
and O O
pinacidil O O
dilate O O
both O O
large O O
and O O
small O O
coronary O O
arteries O O
and O O
this O O
effect O O
is O O
not O O
dependent O O
upon O O
the O O
simultaneous O O
beta O O
adrenoceptors O O
- O O
mediated O O
rise O O
in O O
myocardial O O
metabolic O O
demand O O
. O O

Finally O O
, O O
two O O
mechanisms O O
at O O
least O O
, O O
direct O O
vasodilation O O
and O O
flow O O
dependency O O
, O O
are O O
involved O O
in O O
the O O
cromakalim- O O
and O O
pinacidil O O
- O O
induced O O
increase O O
in O O
CxAD O O
. O O

Mefenamic O O
acid O O
- O O
induced O O
neutropenia B-Disease B-Disease
and O O
renal B-Disease B-Disease
failure I-Disease I-Disease
in O O
elderly O O
females O O
with O O
hypothyroidism B-Disease B-Disease
. O O

We O O
report O O
mefenamic O O
acid O O
- O O
induced O O
non O B-Disease
- O I-Disease
oliguric O I-Disease
renal B-Disease I-Disease
failure I-Disease I-Disease
and O O
severe O O
neutropenia B-Disease B-Disease
occurring O O
simultaneously O O
in O O
two O O
elderly O O
females O O
. O O

The O O
neutropenia B-Disease B-Disease
was O O
due O O
to O O
maturation O O
arrest O O
of O O
the O O
myeloid O O
series O O
in O O
one O O
patient O O
. O O

Both O O
patients O O
were O O
also O O
hypothyroid B-Disease B-Disease
, O O
but O O
it O O
is O O
not O O
clear O O
whether O O
this O O
was O O
a O O
predisposing O O
factor O O
to O O
the O O
development O O
of O O
these O O
adverse O O
reactions O O
. O O

However O O
, O O
it O O
would O O
seem O O
prudent O O
not O O
to O O
use O O
mefenamic O O
acid O O
in O O
hypothyroid B-Disease B-Disease
patients O O
until O O
the O O
hypothyroidism B-Disease B-Disease
has O O
been O O
corrected O O
. O O

Etiology O O
of O O
hypercalcemia B-Disease B-Disease
in O O
hemodialysis O O
patients O O
on O O
calcium O O
carbonate O O
therapy O O
. O O

Fourteen O O
of O O
39 O O
dialysis O O
patients O O
( O O
36 O O
% O O
) O O
became O O
hypercalcemic B-Disease B-Disease
after O O
switching O O
to O O
calcium O O
carbonate O O
as O O
their O O
principal O O
phosphate O O
binder O O
. O O

In O O
order O O
to O O
identify O O
risk O O
factors O O
associated O O
with O O
the O O
development O O
of O O
hypercalcemia B-Disease B-Disease
, O O
indirect O O
parameters O O
of O O
intestinal O O
calcium O O
reabsorption O O
and O O
bone O O
turnover O O
rate O O
in O O
these O O
14 O O
patients O O
were O O
compared O O
with O O
results O O
in O O
14 O O
eucalcemic O O
patients O O
matched O O
for O O
age O O
, O O
sex O O
, O O
length O O
of O O
time O O
on O O
dialysis O O
, O O
and O O
etiology O O
of O O
renal B-Disease B-Disease
disease I-Disease I-Disease
. O O

In O O
addition O O
to O O
experiencing O O
hypercalcemic B-Disease B-Disease
episodes O O
with O O
peak O O
calcium O O
values O O
of O O
2.7 O O
to O O
3.8 O O
mmol O O
/ O O
L O O
( O O
10.7 O O
to O O
15.0 O O
mg O O
/ O O
dL O O
) O O
, O O
patients O O
in O O
the O O
hypercalcemic B-Disease B-Disease
group O O
exhibited O O
a O O
significant O O
increase O O
in O O
the O O
mean O O
calcium O O
concentration O O
obtained O O
during O O
6 O O
months O O
before O O
the O O
switch O O
, O O
compared O O
with O O
the O O
mean O O
value O O
obtained O O
during O O
the O O
7 O O
months O O
of O O
observation O O
after O O
the O O
switch O O
( O O
2.4 O O
+ O O
/- O O

0.03 O O
to O O
2.5 O O
+ O O
/- O O

0.03 O O
mmol O O
/ O O
L O O
[ O O
9.7 O O
+ O O
/- O O

0.2 O O
to O O
10.2 O O
+ O O
/- O O

0.1 O O
mg O O
/ O O
dL O O
] O O
, O O
P O O
= O O
0.006 O O
) O O
. O O

In O O
contrast O O
, O O
eucalcemic O O
patients O O
exhibited O O
no O O
change O O
in O O
mean O O
calcium O O
values O O
over O O
the O O
same O O
time O O
period O O
( O O
2.3 O O
+ O O
/- O O

0.05 O O
to O O
2.3 O O
+ O O
/- O O

0.05 O O
mmol O O
/ O O
L O O
[ O O
9.2 O O
+ O O
/- O O

0.2 O O
to O O
9.2 O O
+ O O
/- O O

0.2 O O
mg O O
/ O O
dL O O
] O O
) O O
. O O

CaCO3 O O
dosage O O
, O O
calculated O O
dietary O O
calcium O O
intake O O
, O O
and O O
circulating O O
levels O O
of O O
vitamin O O
D O O
metabolites O O
were O O
similar O O
in O O
both O O
groups O O
. O O

Physical O O
activity O O
index O O
and O O
predialysis O O
serum O O
bicarbonate O O
levels O O
also O O
were O O
similar O O
in O O
both O O
groups O O
. O O

However O O
, O O
there O O
was O O
a O O
significant O O
difference O O
in O O
parameters O O
reflecting O O
bone O O
turnover O O
rates O O
between O O
groups. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Methyldopa O O
- O O
induced O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
in O O
a O O
15 O O
year O O
old O O
presenting O O
as O O
near O O
- O O
syncope B-Disease B-Disease
. O O

Methyldopa O O
is O O
an O O
antihypertensive O O
medication O O
which O O
is O O
available O O
generically O O
and O O
under O O
the O O
trade O O
name O O
Aldomet O O
that O O
is O O
widely O O
prescribed O O
in O O
the O O
adult O O
population O O
and O O
infrequently O O
used O O
in O O
children O O
. O O

Methyldopa O O
causes O O
an O O
autoimmune B-Disease B-Disease
hemolytic I-Disease I-Disease
anemia I-Disease I-Disease
in O O
a O O
small O O
percentage O O
of O O
patients O O
who O O
take O O
the O O
drug O O
. O O

We O O
report O O
a O O
case O O
of O O
methyldopa O O
- O O
induced O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
in O O
a O O
15-year O O
- O O
old O O
boy O O
who O O
presented O O
to O O
the O O
emergency B-Disease O
department I-Disease O
with O O
near O O
- O O
syncope B-Disease B-Disease
. O O

The O O
boy O O
had O O
been O O
treated O O
with O O
intravenous O O
methyldopa O O
during O O
a O O
trauma B-Disease B-Disease
admission O O
seven O O
weeks O O
prior O O
to O O
presentation O O
. O O

Evaluation O O
revealed O O
a O O
hemoglobin O O
of O O
three O O
grams O O
, O O
3 O O
+ O O
Coombs O O
' O O
test O O
with O O
polyspecific O O
anti O O
- O O
human O O
globulin O O
and O O
monospecific O O
IgG O O
reagents O O
, O O
and O O
a O O
warm O O
reacting O O
autoantibody O O
. O O

Transfusion O O
and O O
corticosteroid O O
therapy O O
resulted O O
in O O
a O O
complete O O
recovery O O
of O O
the O O
patient O O
. O O

Emergency O O
physicians O O
treating O O
children O O
must O O
be O O
aware O O
of O O
this O O
syndrome O O
in O O
order O O
to O O
diagnose O O
and O O
treat O O
it O O
correctly O O
. O O

A O O
brief O O
review O O
of O O
autoimmune O O
and O O
drug O O
- O O
induced O O
hemolytic B-Disease B-Disease
anemias I-Disease I-Disease
is O O
provided O O
. O O

The O O
long O O
- O O
term O O
safety O O
of O O
danazol O O
in O O
women O O
with O O
hereditary B-Disease B-Disease
angioedema I-Disease I-Disease
. O O

Although O O
the O O
short O O
- O O
term O O
safety O O
( O O
less O O
than O O
or O O
equal O O
to O O
6 O O
months O O
) O O
of O O
danazol O O
has O O
been O O
established O O
in O O
a O O
variety O O
of O O
settings O O
, O O
no O O
information O O
exists O O
as O O
to O O
its O O
long O O
- O O
term O O
safety O O
. O O

We O O
therefore O O
investigated O O
the O O
long O O
- O O
term O O
safety O O
of O O
danazol O O
by O O
performing O O
a O O
retrospective O O
chart O O
review O O
of O O
60 O O
female O O
patients O O
with O O
hereditary B-Disease B-Disease
angioedema I-Disease I-Disease
treated O O
with O O
danazol O O
for O O
a O O
continuous O O
period O O
of O O
6 O O
months O O
or O O
longer O O
. O O

The O O
mean O O
age O O
of O O
the O O
patients O O
was O O
35.2 O O
years O O
and O O
the O O
mean O O
duration O O
of O O
therapy O O
was O O
59.7 O O
months O O
. O O

Virtually O O
all O O
patients O O
experienced O O
one O O
or O O
more O O
adverse O O
reactions O O
. O O

Menstrual B-Disease B-Disease
abnormalities I-Disease I-Disease
( O O
79 O O
% O O
) O O
, O O
weight B-Disease B-Disease
gain I-Disease I-Disease
( O O
60 O O
% O O
) O O
, O O
muscle B-Disease B-Disease
cramps I-Disease I-Disease
/ O O
myalgias B-Disease B-Disease
( O O
40 O O
% O O
) O O
, O O
and O O
transaminase O O
elevations O O
( O O
40 O O
% O O
) O O
were O O
the O O
most O O
common O O
adverse O O
reactions O O
. O O

The O O
drug O O
was O O
discontinued O O
due O O
to O O
adverse O O
reactions O O
in O O
8 O O
patients O O
. O O

No O O
patient O O
has O O
died O O
or O O
suffered O O
any O O
apparent O O
long O O
- O O
term O O
sequelae O O
that O O
were O O
directly O O
attributable O O
to O O
the O O
drug O O
. O O

We O O
conclude O O
that O O
, O O
despite O O
a O O
relatively O O
high O O
incidence O O
of O O
adverse O O
reactions O O
, O O
danazol O O
has O O
proven O O
to O O
be O O
remarkably O O
safe O O
over O O
the O O
long O O
- O O
term O O
in O O
this O O
group O O
of O O
patients O O
. O O

Patient O O
tolerance O O
study O O
of O O
topical O O
chlorhexidine O O
diphosphanilate O O
: O O
a O O
new O O
topical O O
agent O O
for O O
burns B-Disease B-Disease
. O O

Effective O O
topical O O
antimicrobial O O
agents O O
decrease O O
infection B-Disease B-Disease
and O O
mortality O O
in O O
burn B-Disease B-Disease
patients O O
. O O

Chlorhexidine O O
phosphanilate O O
( O O
CHP O O
) O O
, O O
a O O
new O O
broad O O
- O O
spectrum O O
antimicrobial O O
agent O O
, O O
has O O
been O O
evaluated O O
as O O
a O O
topical O O
burn B-Disease B-Disease
wound O O
dressing O O
in O O
cream O O
form O O
, O O
but O O
preliminary O O
clinical O O
trials O O
reported O O
that O O
it O O
was O O
painful O O
upon O O
application O O
. O O

This O O
study O O
compared O O
various O O
concentrations O O
of O O
CHP O O
to O O
determine O O
if O O
a O O
tolerable O O
concentration O O
could O O
be O O
identified O O
with O O
retention O O
of O O
antimicrobial O O
efficacy O O
. O O

Twenty O O
- O O
nine O O
burn B-Disease B-Disease
patients O O
, O O
each O O
with O O
two O O
similar O O
burns B-Disease B-Disease
which O O
could O O
be O O
separately O O
treated O O
, O O
were O O
given O O
pairs O O
of O O
treatments O O
at O O
successive O O
12-h O O
intervals O O
over O O
a O O
3-day O O
period O O
. O O

One O O
burn B-Disease B-Disease
site O O
was O O
treated O O
with O O
each O O
of O O
four O O
different O O
CHP O O
concentrations O O
, O O
from O O
0.25 O O
per O O
cent O O
to O O
2 O O
per O O
cent O O
, O O
their O O
vehicle O O
, O O
and O O
1 O O
per O O
cent O O
silver O O
sulphadiazine O O
( O O
AgSD O O
) O O
cream O O
, O O
an O O
antimicrobial O O
agent O O
frequently O O
used O O
for O O
topical O O
treatment O O
of O O
burn B-Disease B-Disease
wounds O O
. O O

The O O
other O O
site O O
was O O
always O O
treated O O
with O O
AgSD O O
cream O O
. O O

There O O
was O O
a O O
direct O O
relationship O O
between O O
CHP O O
concentration O O
and O O
patients O O
' O O
ratings O O
of O O
pain B-Disease B-Disease
on O O
an O O
analogue O O
scale O O
. O O

The O O
0.25 O O
per O O
cent O O
CHP O O
cream O O
was O O
closest O O
to O O
AgSD O O
in O O
pain B-Disease B-Disease
tolerance O O
; O O
however O O
, O O
none O O
of O O
the O O
treatments O O
differed O O
statistically O O
from O O
AgSD O O
or O O
from O O
each O O
other O O
. O O

In O O
addition O O
, O O
ease O O
of O O
application O O
of O O
CHP O O
creams O O
was O O
less O O
satisfactory O O
than O O
that O O
of O O
AgSD O O
. O O

It O O
was O O
concluded O O
that O O
formulations O O
at O O
or O O
below O O
0.5 O O
per O O
cent O O
CHP O O
may O O
prove O O
acceptable O O
for O O
wound O B-Disease
care O O
, O O
but O O
the O O
vehicle O O
system O O
needs O O
pharmaceutical O O
improvement O O
to O O
render O O
it O O
more O O
tolerable O O
and O O
easier O O
to O O
use O O
. O O

Dose O O
- O O
dependent O O
neurotoxicity B-Disease B-Disease
of O O
high O O
- O O
dose O O
busulfan O O
in O O
children O O
: O O
a O O
clinical O O
and O O
pharmacological O O
study O O
. O O

Busulfan O O
is O O
known O O
to O O
be O O
neurotoxic B-Disease B-Disease
in O O
animals O O
and O O
humans O O
, O O
but O O
its O O
acute O O
neurotoxicity B-Disease B-Disease
remains O O
poorly O O
characterized O O
in O O
children O O
. O O

We O O
report O O
here O O
a O O
retrospective O O
study O O
of O O
123 O O
children O O
( O O
median O O
age O O
, O O
6.5 O O
years O O
) O O
receiving O O
high O O
- O O
dose O O
busulfan O O
in O O
combined O O
chemotherapy O O
before O O
bone O O
marrow O O
transplantation O O
for O O
malignant O B-Disease
solid O I-Disease
tumors B-Disease I-Disease
, O O
brain B-Disease B-Disease
tumors I-Disease I-Disease
excluded O O
. O O

Busulfan O O
was O O
given O O
p.o O O
. O O
, O O
every O O
6 O O
hours O O
for O O
16 O O
doses O O
over O O
4 O O
days O O
. O O

Two O O
total O O
doses O O
were O O
consecutively O O
used O O
: O O
16 O O
mg O O
/ O O
kg O O
, O O
then O O
600 O O
mg O O
/ O O
m2 O O
. O O

The O O
dose O O
calculation O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
results O O
in O O
higher O O
doses O O
in O O
young O O
children O O
than O O
in O O
older O O
patients O O
( O O
16 O O
to O O
28 O O
mg O O
/ O O
kg O O
) O O
. O O

Ninety O O
- O O
six O O
patients O O
were O O
not O O
given O O
anticonvulsive O O
prophylaxis O O
; O O
7 O O
( O O
7.5 O O
% O O
) O O
developed O O
seizures B-Disease B-Disease
during O O
the O O
4 O O
days O O
of O O
the O O
busulfan O O
course O O
or O O
within O O
24 O O
h O O
after O O
the O O
last O O
dosing O O
. O O

When O O
the O O
total O O
busulfan O O
dose O O
was O O
taken O O
into O O
account O O
, O O
there O O
was O O
a O O
significant O O
difference O O
in O O
terms O O
of O O
neurotoxicity B-Disease B-Disease
incidence O O
among O O
patients O O
under O O
16 O O
mg O O
/ O O
kg O O
( O O
1 O O
of O O
57 O O
, O O
1.7 O O
% O O
) O O
and O O
patients O O
under O O
600 O O
mg O O
/ O O
m2 O O
( O O
6 O O
of O O
39 O O
, O O
15.4 O O
% O O
) O O
( O O
P O O
less O O
than O O
0.02 O O
) O O
. O O

Twenty O O
- O O
seven O O
patients O O
were O O
given O O
a O O
600-mg O O
/ O O
m2 O O
busulfan O O
total O O
dose O O
with O O
continuous O O
i.v O O
. O O

infusion O O
of O O
clonazepam O O
; O O
none O O
had O O
any O O
neurological B-Disease B-Disease
symptoms I-Disease I-Disease
. O O

Busulfan O O
levels O O
were O O
measured O O
by O O
a O O
gas O O
chromatographic O O
- O O
mass O O
spectrometry O O
assay O O
in O O
the O O
plasma O O
and O O
cerebrospinal O O
fluid O O
of O O
9 O O
children O O
without O O
central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
disease I-Disease I-Disease
under O O
600 O O
mg O O
/ O O
m2 O O
busulfan O O
with O O
clonazepam O O
: O O
busulfan O O
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
was O O
1.39 O O
. O O

This O O
was O O
significantly O O
different O O
( O O
P O O
less O O
than O O
0.02 O O
) O O
from O O
the O O
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
previously O O
defined O O
in O O
children O O
receiving O O
a O O
16-mg O O
/ O O
kg O O
total O O
dose O O
of O O
busulfan O O
. O O

This O O
study O O
shows O O
that O O
busulfan O O
neurotoxicity B-Disease B-Disease
is O O
dose O O
- O O
dependent O O
in O O
children O O
and O O
efficiently O O
prevented O O
by O O
clonazepam O O
. O O

A O O
busulfan O O
dose O O
calculated O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
, O O
resulting O O
in O O
higher O O
doses O O
in O O
young O O
children O O
, O O
was O O
followed O O
by O O
increased O O
neurotoxicity B-Disease B-Disease
, O O
close O O
to O O
neurotoxicity B-Disease B-Disease
incidence O O
observed O O
in O O
adults O O
. O O

Since O O
plasma O O
pharmacokinetic O O
studies O O
showed O O
a O O
faster O O
busulfan O O
clearance O O
in O O
children O O
than O O
in O O
adults O O
, O O
this O O
new O O
dose O O
may O O
approximate O O
more O O
closely O O
the O O
adult O O
systemic O O
exposure O O
obtained O O
after O O
the O O
usual O O
16-mg O O
/ O O
kg O O
total O O
dose O O
, O O
with O O
potential O O
inferences O O
in O O
terms O O
of O O
anticancer O O
or O O
myeloablative O O
effects O O
. O O

The O O
busulfan O O
dose O O
in O O
children O O
and O O
infants O O
undergoing O O
bone O O
marrow O O
transplantation O O
should O O
be O O
reconsidered O O
on O O
the O O
basis O O
of O O
pharmacokinetic O O
studies O O
. O O

Long O O
- O O
term O O
oral O O
galactose O O
treatment O O
prevents O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
in O O
male O O
Wistar O O
rats O O
treated O O
intracerebroventricularly O O
with O O
streptozotocin O O
. O O

Basic O O
and O O
clinical O O
research O O
has O O
demonstrated O O
that O O
dementia B-Disease B-Disease
of O O
sporadic O O
Alzheimer B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
( O O
sAD O B-Disease
) O O
type O O
is O O
associated O O
with O O
dysfunction O O
of O O
the O O
insulin O O
- O O
receptor O O
( O O
IR O O
) O O
system O O
followed O O
by O O
decreased O O
glucose O O
transport O O
via O O
glucose O O
transporter O O
GLUT4 O O
and O O
decreased O O
glucose O O
metabolism O O
in O O
brain O O
cells O O
. O O

An O O
alternative O O
source O O
of O O
energy O O
is O O
d O O
- O O
galactose O O
( O O
the O O
C-4-epimer O O
of O O
d O O
- O O
glucose O O
) O O
which O O
is O O
transported O O
into O O
the O O
brain O O
by O O
insulin O O
- O O
independent O O
GLUT3 O O
transporter O O
where O O
it O O
might O O
be O O
metabolized O O
to O O
glucose O O
via O O
the O O
Leloir O O
pathway O O
. O O

Exclusively O O
parenteral O O
daily O O
injections O O
of O O
galactose O O
induce O O
memory B-Disease B-Disease
deterioration I-Disease I-Disease
in O O
rodents O O
and O O
are O O
used O O
to O O
generate O O
animal O O
aging O O
model O O
, O O
but O O
the O O
effects O O
of O O
oral O O
galactose O O
treatment O O
on O O
cognitive O O
functions O O
have O O
never O O
been O O
tested O O
. O O

We O O
have O O
investigated O O
the O O
effects O O
of O O
continuous O O
daily O O
oral O O
galactose O O
( O O
200 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
treatment O O
on O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
in O O
streptozotocin O O
- O O
induced O O
( O O
STZ O O
- O O
icv O O
) O O
rat O O
model O O
of O O
sAD O B-Disease
, O O
tested O O
by O O
Morris O O
Water O O
Maze O O
and O O
Passive O O
Avoidance O O
test O O
, O O
respectively O O
. O O

One O O
month O O
of O O
oral O O
galactose O O
treatment O O
initiated O O
immediately O O
after O O
the O O
STZ O O
- O O
icv O O
administration O O
, O O
successfully O O
prevented O O
development O O
of O O
the O O
STZ O O
- O O
icv O O
- O O
induced O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
. O O

Beneficial O O
effect O O
of O O
oral O O
galactose O O
was O O
independent O O
of O O
the O O
rat O O
age O O
and O O
of O O
the O O
galactose O O
dose O O
ranging O O
from O O
100 O O
to O O
300 O O
mg O O
/ O O
kg O O
/ O O
day O O
. O O

Additionally O O
, O O
oral O O
galactose O O
administration O O
led O O
to O O
the O O
appearance O O
of O O
galactose O O
in O O
the O O
blood O O
. O O

The O O
increase O O
of O O
galactose O O
concentration O O
in O O
the O O
cerebrospinal O O
fluid O O
was O O
several O O
times O O
lower O O
after O O
oral O O
than O O
after O O
parenteral O O
administration O O
of O O
the O O
same O O
galactose O O
dose O O
. O O

Oral O O
galactose O O
exposure O O
might O O
have O O
beneficial O O
effects O O
on O O
learning O O
and O O
memory O O
ability O O
and O O
could O O
be O O
worth O O
investigating O O
for O O
improvement O O
of O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
associated O O
with O O
glucose B-Disease B-Disease
hypometabolism I-Disease I-Disease
in O O
AD B-Disease B-Disease
. O O

Histamine O O
antagonists O O
and O O
d O O
- O O
tubocurarine O O
- O O
induced O O
hypotension B-Disease B-Disease
in O O
cardiac O O
surgical O O
patients O O
. O O

Hemodynamic O O
effects O O
and O O
histamine O O
release O O
by O O
bolus O O
injection O O
of O O
0.35 O O
mg O O
/ O O
kg O O
of O O
d O O
- O O
tubocurarine O O
were O O
studied O O
in O O
24 O O
patients O O
. O O

H1- O O
and O O
H2-histamine O O
antagonists O O
or O O
placebo O O
were O O
given O O
before O O
dosing O O
with O O
d O O
- O O
tubocurarine O O
in O O
a O O
randomized O O
double O O
- O O
blind O O
fashion O O
to O O
four O O
groups O O
: O O
group O O
1 O O
- O O
-placebo O O
; O O
group O O
2 O O
- O O
-cimetidine O O
, O O
4 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
group O O
3 O O
- O O
-chlorpheniramine O O
, O O
0.1 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
and O O
group O O
4 O O
- O O
-cimetidine O O
plus O O
chlorpheniramine O O
. O O

Histamine O O
release O O
occurred O O
in O O
most O O
patients O O
, O O
the O O
highest O O
level O O
2 O O
minutes O O
after O O
d O O
- O O
tubocurarine O O
dosing O O
. O O

Group O O
1 O O
had O O
a O O
moderate O O
negative O O
correlation O O
between O O
plasma O O
histamine O O
change O O
and O O
systemic O O
vascular O O
resistance O O
( O O
r O O
= O O
0.58 O O
; O O
P O O
less O O
than O O
0.05 O O
) O O
not O O
present O O
in O O
group O O
4 O O
. O O

Prior O O
dosing O O
with O O
antagonists O O
partially O O
prevented O O
the O O
fall O O
in O O
systemic O O
vascular O O
resistance O O
. O O

These O O
data O O
demonstrate O O
that O O
the O O
hemodynamic O O
changes O O
associated O O
with O O
d O O
- O O
tubocurarine O O
dosing O O
are O O
only O O
partially O O
explained O O
by O O
histamine O O
release O O
. O O

Thus O O
prior O O
dosing O O
with O O
H1- O O
and O O
H2-antagonists O O
provides O O
only O O
partial O O
protection O O
. O O

Convulsant O O
effect O O
of O O
lindane O O
and O O
regional O O
brain O O
concentration O O
of O O
GABA O O
and O O
dopamine O O
. O O

Lindane O O
( O O
gamma O O
- O O
hexachlorocyclohexane O O
) O O
is O O
an O O
organochlorine O O
insecticide O O
with O O
known O O
neurotoxic B-Disease B-Disease
effects O O
. O O

Its O O
mechanism O O
of O O
action O O
is O O
not O O
well O O
understood O O
although O O
it O O
has O O
been O O
proposed O O
that O O
lindane O O
acts O O
as O O
a O O
non O O
- O O
competitive O O
antagonist O O
at O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
-A O O
receptor O O
. O O

We O O
studied O O
the O O
effect O O
of O O
lindane O O
( O O
150 O O
mg O O
/ O O
kg O O
) O O
on O O
the O O
GABAergic O O
and O O
dopaminergic O O
systems O O
by O O
measuring O O
the O O
concentration O O
of O O
GABA O O
, O O
dopamine O O
and O O
its O O
metabolites O O
in O O
7 O O
brain O O
areas O O
at O O
the O O
onset O O
of O O
seizures B-Disease B-Disease
. O O

All O O
animals O O
suffered O O
tonic O O
convulsions B-Disease B-Disease
at O O
18.3 O O
+ O O
/- O O

1.4 O O
min O O
after O O
lindane O O
administration O O
. O O

The O O
concentration O O
of O O
GABA O O
was O O
only O O
slightly O O
but O O
significantly O O
decreased O O
in O O
the O O
colliculi O O
without O O
modifications O O
in O O
the O O
other O O
areas O O
. O O

The O O
concentration O O
of O O
dopamine O O
was O O
increased O O
in O O
the O O
mesencephalon O O
and O O
that O O
of O O
its O O
metabolite O O
DOPAC O O
was O O
also O O
increased O O
in O O
the O O
mesencephalon O O
and O O
the O O
striatum O O
. O O

Baboon B-Disease B-Disease
syndrome I-Disease I-Disease
induced O O
by O O
ketoconazole O O
. O O

A O O
27-year O O
- O O
old O O
male O O
patient O O
presented O O
with O O
a O O
maculopapular B-Disease B-Disease
eruption I-Disease I-Disease
on O O
the O O
flexural O O
areas O O
and O O
buttocks O O
after O O
using O O
oral O O
ketoconazole O O
. O O

The O O
patient O O
was O O
diagnosed O O
with O O
drug O O
- O O
induced O O
baboon B-Disease B-Disease
syndrome I-Disease I-Disease
based O O
on O O
his O O
history O O
, O O
which O O
included O O
prior O O
sensitivity O O
to O O
topical O O
ketoconazole O O
, O O
a O O
physical O O
examination O O
, O O
and O O
histopathological O O
findings O O
. O O

Baboon B-Disease B-Disease
syndrome I-Disease I-Disease
is O O
a O O
drug- O O
or O O
contact O O
allergen O O
- O O
related O O
maculopapular B-Disease B-Disease
eruption I-Disease I-Disease
that O O
typically O O
involves O O
the O O
flexural O O
and O O
gluteal O O
areas O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
ketoconazole O O
- O O
induced O O
baboon B-Disease B-Disease
syndrome I-Disease I-Disease
in O O
the O O
English O O
literature O O
. O O

A O O
Case O O
of O O
Sudden B-Disease B-Disease
Cardiac I-Disease I-Disease
Death I-Disease I-Disease
due O O
to O O
Pilsicainide O O
- O O
Induced O O
Torsades B-Disease B-Disease
de I-Disease I-Disease
Pointes I-Disease I-Disease
. O O

An O O
84-year O O
- O O
old O O
male O O
received O O
oral O O
pilsicainide O O
, O O
a O O
pure O O
sodium O O
channel O O
blocker O O
with O O
slow O O
recovery O O
kinetics O O
, O O
to O O
convert O O
his O O
paroxysmal O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
to O O
a O O
sinus O O
rhythm O O
; O O
the O O
patient O O
developed O O
sudden B-Disease B-Disease
cardiac I-Disease I-Disease
death I-Disease I-Disease
two O O
days O O
later O O
. O O

The O O
Holter O O
electrocardiogram O O
, O O
which O O
was O O
worn O O
by O O
chance O O
, O O
revealed O O
torsade B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
with O O
gradually O O
prolonged O O
QT O O
intervals O O
. O O

This O O
drug O O
is O O
rapidly O O
absorbed O O
from O O
the O O
gastrointestinal O O
tract O O
, O O
and O O
most O O
of O O
it O O
is O O
excreted O O
from O O
the O O
kidney O O
. O O

Although O O
the O O
patient O O
's O O
renal O O
function O O
was O O
not O O
highly O O
impaired O O
and O O
the O O
dose O O
of O O
pilsicainide O O
was O O
low O O
, O O
the O O
plasma O O
concentration O O
of O O
pilsicainide O O
may O O
have O O
been O O
high O O
, O O
which O O
can O O
produce O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
in O O
the O O
octogenarian O O
. O O

Although O O
the O O
oral O O
administration O O
of O O
class O O
IC O O
drugs O O
, O O
including O O
pilsicainide O O
, O O
is O O
effective O O
to O O
terminate O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
, O O
careful O O
consideration O O
must O O
be O O
taken O O
before O O
giving O O
these O O
drugs O O
to O O
octogenarians O O
. O O

All O O
- O O
trans O O
retinoic O O
acid O O
- O O
induced O O
inflammatory O O
myositis B-Disease B-Disease
in O O
a O O
patient O O
with O O
acute B-Disease B-Disease
promyelocytic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

All O O
- O O
trans O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
, O O
a O O
component O O
of O O
standard O O
therapy O O
for O O
acute B-Disease B-Disease
promyelocytic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
APL B-Disease B-Disease
) O O
, O O
is O O
associated O O
with O O
potentially O O
serious O O
but O O
treatable O O
adverse O O
effects O O
involving O O
numerous O O
organ O O
systems O O
, O O
including O O
rare O O
skeletal O O
muscle O O
involvement O O
. O O

Only O O
a O O
handful O O
of O O
cases O O
of O O
ATRA O O
- O O
induced O O
myositis B-Disease B-Disease
in O O
children O O
have O O
been O O
reported O O
, O O
and O O
none O O
in O O
the O O
radiology O O
literature O O
. O O

We O O
present O O
such O O
a O O
case O O
in O O
a O O
15-year O O
- O O
old O O
boy O O
with O O
APL B-Disease B-Disease
, O O
where O O
recognition O O
of O O
imaging O O
findings O O
played O O
a O O
crucial O O
role O O
in O O
making O O
the O O
diagnosis O O
and O O
facilitated O O
prompt O O
, O O
effective O O
treatment O O
. O O

Tolerability O O
of O O
lomustine O O
in O O
combination O O
with O O
cyclophosphamide O O
in O O
dogs O O
with O O
lymphoma B-Disease B-Disease
. O O

This O O
retrospective O O
study O O
describes O O
toxicity B-Disease B-Disease
associated O O
with O O
a O O
protocol O O
of O O
lomustine O O
( O O
CCNU O O
) O O
and O O
cyclophosphamide O O
( O O
CTX O O
) O O
in O O
dogs O O
with O O
lymphoma B-Disease B-Disease
. O O

CCNU O O
was O O
administered O O
per O O
os O O
( O O
PO O O
) O O
at O O
a O O
targeted O O
dosage O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
body O O
surface O O
area O O
on O O
day O O
0 O O
, O O
CTX O O
was O O
administered O O
PO O O
at O O
a O O
targeted O O
dosage O O
of O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
divided O O
over O O
days O O
0 O O
through O O
4 O O
, O O
and O O
all O O
dogs O O
received O O
prophylactic O O
antibiotics O O
. O O

Ninety O O
treatments O O
were O O
given O O
to O O
the O O
57 O O
dogs O O
included O O
in O O
the O O
study O O
. O O

Neutropenia B-Disease B-Disease
was O O
the O O
principal O O
toxic O O
effect O O
, O O
and O O
the O O
overall O O
frequency O O
of O O
grade O O
4 O O
neutropenia B-Disease B-Disease
after O O
the O O
first O O
treatment O O
of O O
CCNU O O
/ O O
CTX O O
was O O
30 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
19 O O
- O O
43 O O
% O O
) O O
. O O

The O O
mean O O
body O O
weight O O
of O O
dogs O O
with O O
grade O O
4 O O
neutropenia B-Disease B-Disease
( O O
19.7 O O
kg O O
+ O O
13.4 O O
kg O O
) O O
was O O
significantly O O
less O O
than O O
the O O
mean O O
body O O
weight O O
of O O
dogs O O
that O O
did O O
not O O
develop O O
grade O O
4 O O
neutropenia B-Disease B-Disease
( O O
31.7 O O
kg O O
+ O O
12.4 O O
kg O O
; O O
P O O
= O O
.005 O O
) O O
. O O

One O O
dog O O
( O O
3 O O
% O O
) O O
developed O O
hematologic O O
changes O O
suggestive O O
of O O
hepatotoxicity B-Disease B-Disease
. O O

No O O
dogs O O
had O O
evidence O O
of O O
either O O
renal B-Disease B-Disease
toxicity I-Disease I-Disease
or O O
hemorrhagic B-Disease B-Disease
cystitis B-Disease B-Disease
. O O

Adverse O O
gastrointestinal O O
effects O O
were O O
uncommon O O
. O O

On O O
the O O
basis O O
of O O
the O O
findings O O
reported O O
herein O O
, O O
a O O
dose O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CCNU O O
combined O O
with O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CTX O O
( O O
divided O O
over O O
5 O O
days O O
) O O
q O O
4 O O
wk O O
is O O
tolerable O O
in O O
tumor B-Disease B-Disease
- O O
bearing O O
dogs O O
. O O

Nelarabine O O
neurotoxicity B-Disease B-Disease
with O O
concurrent O O
intrathecal O O
chemotherapy O O
: O O

Case O O
report O O
and O O
review O O
of O O
literature O O
. O O

Severe O O
nelarabine O O
neurotoxicity B-Disease B-Disease
in O O
a O O
patient O O
who O O
received O O
concurrent O O
intrathecal O O
( O O
IT O O
) O O
chemotherapy O O
is O O
reported O O
. O O

A O O
37-year O O
- O O
old O O
Caucasian O O
woman O O
with O O
a O O
history O O
of O O
T B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
lymphoblastic I-Disease I-Disease
lymphoma I-Disease I-Disease
was O O
admitted O O
for O O
relapsed O O
disease O O
. O O

She O O
was O O
originally O O
treated O O
with O O
induction O O
chemotherapy O O
followed O O
by O O
an O O
autologous O O
transplant O O
. O O

She O O
developed O O
relapsed O O
disease O O
10 O O
months O O
later O O
with O O
leukemic B-Disease O
involvement O O
. O O

She O O
was O O
re O O
- O O
induced O O
with O O
nelarabine O O
1500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
on O O
days O O
1 O O
, O O
3 O O
, O O
and O O
5 O O
with O O
1 O O
dose O O
of O O
IT O O
cytarabine O O
100 O O
mg O O
on O O
day O O
2 O O
as O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
prophylaxis O O
. O O

At O O
the O O
time O O
of O O
treatment O O
, O O
she O O
was O O
on O O
continuous O O
renal O O
replacement O O
therapy O O
due O O
to O O
sequelae O O
of O O
tumor B-Disease B-Disease
lysis I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
TLS B-Disease B-Disease
) O O
. O O

She O O
tolerated O O
therapy O O
well O O
, O O
entered O O
a O O
complete O O
remission O O
, O O
and O O
recovered O O
her O O
renal O O
function O O
. O O

She O O
received O O
a O O
second O O
cycle O O
of O O
nelarabine O O
without O O
additional O O
IT O O
prophylaxis O O
one O O
month O O
later O O
. O O

A O O
week O O
after O O
this O O
second O O
cycle O O
, O O
she O O
noted O O
numbness O B-Disease
in O O
her O O
lower O O
extremities O O
. O O

Predominantly O O
sensory O O
, O O
though O O
also O O
motor O O
and O O
autonomic O O
, O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
started O O
in O O
her O O
feet O O
, O O
ascended O O
proximally O O
to O O
the O O
mid O O
- O O
thoracic O O
region O O
, O O
and O O
eventually O O
included O O
her O O
distal O O
upper O O
extremities O O
. O O

A O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
of O O
her O O
spine O O
demonstrated O O
changes O O
from O O
C2 O O
to O O
C6 O O
consistent O O
with O O
subacute O O
combined O O
degeneration O O
. O O

Nelarabine O O
was O O
felt O O
to O O
be O O
the O O
cause O O
of O O
her O O
symptoms O O
. O O

Her O O
neuropathy B-Disease B-Disease
stabilized O O
and O O
showed O O
slight O O
improvement O O
and O O
ultimately O O
received O O
an O O
unrelated O O
, O O
reduced O O
- O O
intensity O O
allogeneic O O
transplant O O
while O O
in O O
complete O O
remission O O
, O O
but O O
relapsed O O
disease O O
10 O O
weeks O O
later O O
. O O

She O O
is O O
currently O O
being O O
treated O O
with O O
best O O
supportive O O
care O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
published O O
case O O
report O O
of O O
severe O O
neurotoxicity B-Disease B-Disease
caused O O
by O O
nelarabine O O
in O O
a O O
patient O O
who O O
received O O
concurrent O O
IT O O
chemotherapy O O
. O O

Valproate O O
- O O
induced O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
in O O
a O O
renal O O
transplanted O O
patient O O
. O O

Neurological B-Disease O
complications I-Disease O
after O O
renal O O
transplantation O O
constitute O O
an O O
important O O
cause O O
of O O
morbidity O O
and O O
mortality O O
. O O

Their O O
differential O O
diagnosis O O
is O O
difficult O O
and O O
essential O O
for O O
subsequent O O
patient O O
's O O
management O O
. O O

Valproate O O
- O O
induced O O
hyperammonemic B-Disease B-Disease
encephalopathy B-Disease B-Disease
is O O
an O O
uncommon O O
but O O
serious O O
effect O O
of O O
valproate O O
treatment O O
. O O

Here O O
, O O
we O O
describe O O
the O O
case O O
of O O
a O O
15-year O O
- O O
old O O
girl O O
who O O
was O O
on O O
a O O
long O O
- O O
term O O
therapy O O
with O O
valproate O O
due O O
to O O
epilepsy B-Disease B-Disease
and O O
revealed O O
impaired B-Disease B-Disease
consciousness I-Disease I-Disease
with O O
hyperammonemia B-Disease B-Disease
12 O O
days O O
after O O
renal O O
transplantation O O
. O O

After O O
withdraw O O
of O O
valproate O O
, O O
patients O O
' O O
symptoms O O
resolved O O
within O O
24 O O
h. O O
Clinicians O O
should O O
increase O O
their O O
awareness O O
for O O
potential O O
complication O O
of O O
valproate O O
, O O
especially O O
in O O
transplanted O O
patients O O
. O O

Necrotising B-Disease B-Disease
fasciitis I-Disease I-Disease
after O O
bortezomib O O
and O O
dexamethasone O O
- O O
containing O O
regimen O O
in O O
an O O
elderly O O
patient O O
of O O
Waldenstrom B-Disease B-Disease
macroglobulinaemia I-Disease I-Disease
. O O

Bortezomib O O
and O O
high O O
- O O
dose O O
dexamethasone O O
- O O
containing O O
regimens O O
are O O
considered O O
to O O
be O O
generally O O
tolerable O O
with O O
few O O
severe O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
in O O
patients O O
with O O
B O B-Disease
- O I-Disease
cell O I-Disease
malignancies B-Disease I-Disease
. O O

However O O
, O O
information O O
is O O
limited O O
concerning O O
the O O
safety O O
of O O
the O O
regimen O O
in O O
elderly O O
patients O O
. O O

We O O
report O O
a O O
case O O
of O O
a O O
76-year O O
- O O
old O O
man O O
with O O
Waldenstrom B-Disease B-Disease
macroglobulinaemia I-Disease I-Disease
who O O
suffered O O
necrotising B-Disease B-Disease
fasciitis I-Disease I-Disease
without O O
neutropenia B-Disease B-Disease
after O O
the O O
combination O O
treatment O O
with O O
bortezomib O O
, O O
high O O
- O O
dose O O
dexamethasone O O
and O O
rituximab O O
. O O

Despite O O
immediate O O
intravenous O O
antimicrobial O O
therapy O O
, O O
he O O
succumbed O O
23 O O
h O O
after O O
the O O
onset O O
. O O

Physicians O O
should O O
recognise O O
the O O
possibility O O
of O O
fatal O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
related O O
to O O
bortezomib O O
plus O O
high O O
- O O
dose O O
dexamethasone O O
in O O
elderly O O
patients O O
, O O
and O O
we O O
believe O O
this O O
case O O
warrants O O
further O O
investigation O O
. O O

An O O
integrated O O
characterization O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
in O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
. O O

Many O O
efficacious O O
cancer B-Disease B-Disease
treatments O O
cause O O
significant O O
cardiac O O
morbidity O O
, O O
yet O O
biomarkers O O
or O O
functional O O
indices O O
of O O
early O O
damage O O
, O O
which O O
would O O
allow O O
monitoring O O
and O O
intervention O O
, O O
are O O
lacking O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
utilized O O
a O O
rat O O
model O O
of O O
progressive O O
doxorubicin O O
( O O
DOX O O
) O O
-induced O O
cardiomyopathy B-Disease B-Disease
, O O
applying O O
multiple O O
approaches O O
, O O
including O O
cardiac O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
, O O
to O O
provide O O
the O O
most O O
comprehensive O O
characterization O O
to O O
date O O
of O O
the O O
timecourse O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
underlying O O
this O O
toxicity B-Disease O
. O O

Hannover O O
Wistar O O
rats O O
were O O
dosed O O
with O O
1.25 O O
mg O O
/ O O
kg O O
DOX O O
weekly O O
for O O
8 O O
weeks O O
followed O O
by O O
a O O
4 O O
week O O
off O O
- O O
dosing O O
" O O
recovery O O
" O O
period O O
. O O

Electron O O
microscopy O O
of O O
the O O
myocardium O O
revealed O O
subcellular B-Disease O
degeneration I-Disease O
and O O
marked O O
mitochondrial O O
changes O O
after O O
a O O
single O O
dose O O
. O O

Histopathological O O
analysis O O
revealed O O
progressive O O
cardiomyocyte B-Disease B-Disease
degeneration I-Disease I-Disease
, O O
hypertrophy B-Disease B-Disease
/ O O
cytomegaly O B-Disease
, O O
and O O
extensive O O
vacuolation O O
after O O
two O O
doses O O
. O O

Extensive O O
replacement O O
fibrosis B-Disease B-Disease
( O O
quantified O O
by O O
Sirius O O
red O O
staining O O
) O O
developed O O
during O O
the O O
off O O
- O O
dosing O O
period O O
. O O

Functional O O
indices O O
assessed O O
by O O
cardiac O O
MRI O O
( O O
including O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
, O O
cardiac O O
output O O
, O O
and O O
E O O
/ O O
A O O
ratio O O
) O O
declined O O
progressively O O
, O O
reaching O O
statistical O O
significance O O
after O O
two O O
doses O O
and O O
culminating O O
in O O
" O O
clinical O O
" O O
LV B-Disease B-Disease
dysfunction I-Disease I-Disease
by O O
12 O O
weeks O O
. O O

Significant O O
increases O O
in O O
peak O O
myocardial O O
contrast O O
enhancement O O
and O O
serological O O
cardiac O O
troponin O O
I O O
( O O
cTnI O O
) O O
emerged O O
after O O
eight O O
doses O O
, O O
importantly O O
preceding O O
the O O
LVEF O O
decline O O
to O O
< O O
50 O O
% O O
. O O

Troponin O O
I O O
levels O O
positively O O
correlated O O
with O O
delayed O O
and O O
peak O O
gadolinium O O
contrast O O
enhancement O O
, O O
histopathological O O
grading O O
, O O
and O O
diastolic B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

In O O
summary O O
, O O
subcellular O O
cardiomyocyte B-Disease B-Disease
degeneration I-Disease I-Disease
was O O
the O O
earliest O O
marker O O
, O O
followed O O
by O O
progressive O O
functional O O
decline O O
and O O
histopathological O O
manifestations O O
. O O

Myocardial O O
contrast O O
enhancement O O
and O O
elevations O O
in O O
cTnI O O
occurred O O
later O O
. O O

However O O
, O O
all O O
indices O O
predated O O
" O O
clinical O O
" O O
LV B-Disease B-Disease
dysfunction I-Disease I-Disease
and O O
thus O O
warrant O O
further O O
evaluation O O
as O O
predictive O O
biomarkers O O
. O O

Intradermal O O
glutamate O O
and O O
capsaicin O O
injections O O
: O O
intra- O O
and O O
interindividual O O
variability O O
of O O
provoked O O
hyperalgesia B-Disease B-Disease
and O O
allodynia B-Disease B-Disease
. O O

Intradermal O O
injections O O
of O O
glutamate O O
and O O
capsaicin O O
are O O
attractive O O
to O O
use O O
in O O
human O O
experimental O O
pain B-Disease B-Disease
models O O
because O O
hyperalgesia B-Disease B-Disease
and O O
allodynia B-Disease B-Disease
mimic O O
isolated O O
aspects O O
of O O
clinical O O
pain B-Disease B-Disease
disorders I-Disease O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
reproducibility O O
of O O
these O O
models O O
. O O

Twenty O O
healthy O O
male O O
volunteers O O
( O O
mean O O
age O O
24 O O
years O O
; O O
range O O
18 O O
- O O
38 O O
years O O
) O O
received O O
intradermal O O
injections O O
of O O
glutamate O O
and O O
capsaicin O O
in O O
the O O
volar O O
forearm O O
. O O

Magnitudes O O
of O O
secondary O O
pinprick O O
hyperalgesia B-Disease B-Disease
and O O
brush O O
- O O
evoked O O
allodynia B-Disease B-Disease
were O O
investigated O O
using O O
von O O
Frey O O
filaments O O
( O O
gauges O O
10 O O
, O O
15 O O
, O O
60 O O
and O O
100 O O
g O O
) O O
and O O
brush O O
strokes O B-Disease
. O O

Areas O O
of O O
secondary B-Disease B-Disease
hyperalgesia I-Disease I-Disease
and O O
allodynia B-Disease B-Disease
were O O
quantified O O
immediately O O
after O O
injection O O
and O O
after O O
15 O O
, O O
30 O O
and O O
60 O O
min O O
. O O

Two O O
identical O O
experiments O O
separated O O
by O O
at O O
least O O
7 O O
days O O
were O O
performed O O
. O O

Reproducibility O O
across O O
and O O
within O O
volunteers O O
( O O
inter- O O
and O O
intra O O
- O O
individual O O
variation O O
, O O
respectively O O
) O O
was O O
assessed O O
using O O
intraclass O O
correlation O O
coefficient O O
( O O
ICC O O
) O O
and O O
coefficient O O
of O O
variation O O
( O O
CV O O
) O O
. O O

Secondary O O
pinprick O O
hyperalgesia B-Disease B-Disease
was O O
observed O O
as O O
a O O
marked O O
increase O O
in O O
the O O
visual O O
analogue O O
scale O O
( O O
VAS O O
) O O
response O O
to O O
von O O
Frey O O
gauges O O
60 O O
and O O
100 O O
g O O
( O O
P O O
< O O
0.001 O O
) O O
after O O
glutamate O O
injection O O
. O O

For O O
capsaicin O O
, O O
secondary O O
pinprick O O
hyperalgesia B-Disease B-Disease
was O O
detected O O
with O O
all O O
von O O
Frey O O
gauges O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

Glutamate O O
evoked O O
reproducible O O
VAS O O
response O O
to O O
all O O
von O O
Frey O O
gauges O O
( O O
ICC O O
> O O
0.60 O O
) O O
and O O
brush O O
strokes O B-Disease
( O O
ICC O O
> O O
0.83 O O
) O O
. O O

Capsaicin O O
injection O O
was O O
reproducible O O
for O O
secondary B-Disease B-Disease
hyperalgesia I-Disease I-Disease
( O O
ICC O O
> O O
0.70 O O
) O O
and O O
allodynia B-Disease B-Disease
( O O
ICC O O
> O O
0.71 O O
) O O
. O O

Intra O O
- O O
individual O O
variability O O
was O O
generally O O
lower O O
for O O
the O O
VAS O O
response O O
to O O
von O O
Frey O O
and O O
brush O O
compared O O
with O O
areas O O
of O O
secondary B-Disease B-Disease
hyperalgesia I-Disease I-Disease
and O O
allodynia B-Disease B-Disease
. O O

In O O
conclusion O O
, O O
glutamate O O
and O O
capsaicin O O
yield O O
reproducible O O
hyperalgesic B-Disease B-Disease
and O O
allodynic B-Disease O
responses O O
, O O
and O O
the O O
present O O
model O O
is O O
well O O
suited O O
for O O
basic O O
research O O
, O O
as O O
well O O
as O O
for O O
assessing O O
the O O
modulation O O
of O O
central O O
phenomena O O
. O O

Ocular O O
- O O
specific O O
ER O O
stress O O
reduction O O
rescues O O
glaucoma B-Disease B-Disease
in O O
murine O O
glucocorticoid O O
- O O
induced O O
glaucoma B-Disease B-Disease
. O O

Administration O O
of O O
glucocorticoids O O
induces O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
in O O
some O O
patients O O
. O O

If O O
untreated O O
, O O
these O O
patients O O
can O O
develop O O
a O O
secondary O O
glaucoma B-Disease B-Disease
that O O
resembles O O
primary B-Disease O
open I-Disease B-Disease
- I-Disease I-Disease
angle I-Disease I-Disease
glaucoma I-Disease I-Disease
( O O
POAG B-Disease B-Disease
) O O
. O O

The O O
underlying O O
pathology O O
of O O
glucocorticoid O O
- O O
induced O O
glaucoma B-Disease B-Disease
is O O
not O O
fully O O
understood O O
, O O
due O O
in O O
part O O
to O O
lack O O
of O O
an O O
appropriate O O
animal O O
model O O
. O O

Here O O
, O O
we O O
developed O O
a O O
murine O O
model O O
of O O
glucocorticoid O O
- O O
induced O O
glaucoma B-Disease B-Disease
that O O
exhibits O O
glaucoma B-Disease B-Disease
features O O
that O O
are O O
observed O O
in O O
patients O O
. O O

Treatment O O
of O O
WT O O
mice O O
with O O
topical O O
ocular O O
0.1 O O
% O O
dexamethasone O O
led O O
to O O
elevation O O
of O O
intraocular O O
pressure O O
( O O
IOP O O
) O O
, O O
functional O O
and O O
structural O O
loss O O
of O O
retinal B-Disease O
ganglion I-Disease O
cells O O
, O O
and O O
axonal B-Disease B-Disease
degeneration I-Disease I-Disease
, O O
resembling O O
glucocorticoid O O
- O O
induced O O
glaucoma B-Disease B-Disease
in O O
human O O
patients O O
. O O

Furthermore O O
, O O
dexamethasone O O
- O O
induced O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
was O O
associated O O
with O O
chronic O O
ER O O
stress O O
of O O
the O O
trabecular O O
meshwork O O
( O O
TM O O
) O O
. O O

Similar O O
to O O
patients O O
, O O
withdrawal O O
of O O
dexamethasone O O
treatment O O
reduced O O
elevated O O
IOP O O
and O O
ER O O
stress O O
in O O
this O O
animal O O
model O O
. O O

Dexamethasone O O
induced O O
the O O
transcriptional O O
factor O O
CHOP O O
, O O
a O O
marker O O
for O O
chronic O O
ER O O
stress O O
, O O
in O O
the O O
anterior O O
segment O O
tissues O O
, O O
and O O
Chop O O
deletion O O
reduced O O
ER O O
stress O O
in O O
these O O
tissues O O
and O O
prevented O O
dexamethasone O O
- O O
induced O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
. O O

Furthermore O O
, O O
reduction O O
of O O
ER O O
stress O O
in O O
the O O
TM O O
with O O
sodium O O
4-phenylbutyrate O O
prevented O O
dexamethasone O O
- O O
induced O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
in O O
WT O O
mice O O
. O O

Our O O
data O O
indicate O O
that O O
ER O O
stress O O
contributes O O
to O O
glucocorticoid O O
- O O
induced O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
and O O
suggest O O
that O O
reducing O O
ER O O
stress O O
has O O
potential O O
as O O
a O O
therapeutic O O
strategy O O
for O O
treating O O
glucocorticoid O O
- O O
induced O O
glaucoma B-Disease B-Disease
. O O

Effects O O
of O O
ginsenosides O O
on O O
opioid O O
- O O
induced O O
hyperalgesia B-Disease B-Disease
in O O
mice O O
. O O

Opioid O O
- O O
induced O O
hyperalgesia B-Disease B-Disease
( O O
OIH B-Disease B-Disease
) O O
is O O
characterized O O
by O O
nociceptive O O
sensitization O O
caused O O
by O O
the O O
cessation O O
of O O
chronic O O
opioid O O
use O O
. O O

OIH B-Disease B-Disease
can O O
limit O O
the O O
clinical O O
use O O
of O O
opioid O O
analgesics O O
and O O
complicate O O
withdrawal O O
from O O
opioid B-Disease B-Disease
addiction I-Disease I-Disease
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
Re O O
, O O
Rg1 O O
, O O
and O O
Rb1 O O
ginsenosides O O
, O O
the O O
bioactive O O
components O O
of O O
ginseng O O
, O O
on O O
OIH B-Disease B-Disease
. O O

OIH B-Disease B-Disease
was O O
achieved O O
in O O
mice O O
after O O
subcutaneous O O
administration O O
of O O
morphine O O
for O O
7 O O
consecutive O O
days O O
three O O
times O O
per O O
day O O
. O O

During O O
withdrawal O O
( O O
days O O
8 O O
and O O
9 O O
) O O
, O O
these O O
mice O O
were O O
administered O O
Re O O
, O O
Rg1 O O
, O O
or O O
Rb1 O O
intragastrically O O
two O O
times O O
per O O
day O O
. O O

On O O
the O O
test O O
day O O
( O O
day O O
10 O O
) O O
, O O
mice O O
were O O
subjected O O
to O O
the O O
thermal O O
sensitivity O O
test O O
and O O
the O O
acetic O O
acid O O
- O O
induced O O
writhing O O
test O O
. O O

Re O O
( O O
300 O O
mg O O
/ O O
kg O O
) O O
inhibited O O
OIH B-Disease B-Disease
in O O
both O O
the O O
thermal O O
sensitivity O O
test O O
and O O
the O O
acetic O O
acid O O
- O O
induced O O
writhing O O
test O O
. O O

However O O
, O O
the O O
Rg1 O O
and O O
Rb1 O O
ginsenosides O O
failed O O
to O O
prevent O O
OIH B-Disease B-Disease
in O O
either O O
test O O
. O O

Furthermore O O
, O O
Rg1 O O
showed O O
a O O
tendency O O
to O O
aggravate O O
OIH B-Disease B-Disease
in O O
the O O
acetic O O
acid O O
- O O
induced O O
writhing O O
test O O
. O O

Our O O
data O O
suggested O O
that O O
the O O
ginsenoside O O
Re O O
, O O
but O O
not O O
Rg1 O O
or O O
Rb1 O O
, O O
may O O
contribute O O
toward O O
reversal O O
of O O
OIH B-Disease B-Disease
. O O

A O O
comparison O O
of O O
severe O O
hemodynamic O O
disturbances O O
between O O
dexmedetomidine O O
and O O
propofol O O
for O O
sedation O O
in O O
neurocritical O O
care O O
patients O O
. O O

OBJECTIVE O O
: O O
Dexmedetomidine O O
and O O
propofol O O
are O O
commonly O O
used O O
sedatives O O
in O O
neurocritical O O
care O O
as O O
they O O
allow O O
for O O
frequent O O
neurologic O O
examinations O O
. O O

However O O
, O O
both O O
agents O O
are O O
associated O O
with O O
significant O O
hemodynamic O O
side O O
effects O O
. O O

The O O
primary O O
objective O O
of O O
this O O
study O O
is O O
to O O
compare O O
the O O
prevalence O O
of O O
severe O O
hemodynamic O O
effects O O
in O O
neurocritical O O
care O O
patients O O
receiving O O
dexmedetomidine O O
and O O
propofol O O
. O O

DESIGN O O
: O O
Multicenter O O
, O O
retrospective O O
, O O
propensity O O
- O O
matched O O
cohort O O
study O O
. O O

SETTING O O
: O O
Neurocritical O O
care O O
units O O
at O O
two O O
academic O O
medical O O
centers O O
with O O
dedicated O O
neurocritical O O
care O O
teams O O
and O O
board O O
- O O
certified O O
neurointensivists O O
. O O

PATIENTS O O
: O O
Neurocritical O O
care O O
patients O O
admitted O O
between O O
July O O
2009 O O
and O O
September O O
2012 O O
were O O
evaluated O O
and O O
then O O
matched O O
1:1 O O
based O O
on O O
propensity O O
scoring O O
of O O
baseline O O
characteristics O O
. O O

INTERVENTIONS O O
: O O
Continuous O O
sedation O O
with O O
dexmedetomidine O O
or O O
propofol O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
A O O
total O O
of O O
342 O O
patients O O
( O O
105 O O
dexmedetomidine O O
and O O
237 O O
propofol O O
) O O
were O O
included O O
in O O
the O O
analysis O O
, O O
with O O
190 O O
matched O O
( O O
95 O O
in O O
each O O
group O O
) O O
by O O
propensity O O
score O O
. O O

The O O
primary O O
outcome O O
of O O
this O O
study O O
was O O
a O O
composite O O
of O O
severe O O
hypotension B-Disease B-Disease
( O O
mean O O
arterial O O
pressure O O
< O O
60 O O
mm O O
Hg O O
) O O
and O O
bradycardia B-Disease B-Disease
( O O
heart O O
rate O O
< O O
50 O O
beats O O
/ O O
min O O
) O O
during O O
sedative O O
infusion O O
. O O

No O O
difference O O
in O O
the O O
primary O O
composite O O
outcome O O
in O O
both O O
the O O
unmatched O O
( O O
30 O O
% O O
vs O O
30 O O
% O O
, O O
p O O
= O O
0.94 O O
) O O
or O O
matched O O
cohorts O O
( O O
28 O O
% O O
vs O O
34 O O
% O O
, O O
p O O
= O O
0.35 O O
) O O
could O O
be O O
found O O
. O O

When O O
analyzed O O
separately O O
, O O
no O O
differences O O
could O O
be O O
found O O
in O O
the O O
prevalence O O
of O O
severe O O
hypotension B-Disease B-Disease
or O O
bradycardia B-Disease B-Disease
in O O
either O O
the O O
unmatched O O
or O O
matched O O
cohorts O O
. O O

CONCLUSIONS O O
: O O
Severe O O
hypotension B-Disease B-Disease
and O O
bradycardia B-Disease B-Disease
occur O O
at O O
similar O O
prevalence O O
in O O
neurocritical O O
care O O
patients O O
who O O
receive O O
dexmedetomidine O O
or O O
propofol O O
. O O

Providers O O
should O O
similarly O O
consider O O
the O O
likelihood O O
of O O
hypotension B-Disease B-Disease
or O O
bradycardia B-Disease B-Disease
before O O
starting O O
either O O
sedative O O
. O O

Hydroxytyrosol O O
ameliorates O O
oxidative O O
stress O O
and O O
mitochondrial B-Disease B-Disease
dysfunction I-Disease I-Disease
in O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
in O O
rats O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Oxidative O O
stress O O
is O O
involved O O
in O O
several O O
processes O O
including O O
cancer B-Disease B-Disease
, O O
aging O O
and O O
cardiovascular B-Disease B-Disease
disease I-Disease I-Disease
, O O
and O O
has O O
been O O
shown O O
to O O
potentiate O O
the O O
therapeutic O O
effect O O
of O O
drugs O O
such O O
as O O
doxorubicin O O
. O O

Doxorubicin O O
causes O O
significant O O
cardiotoxicity B-Disease B-Disease
characterized O O
by O O
marked O O
increases O O
in O O
oxidative O O
stress O O
and O O
mitochondrial B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

Herein O O
, O O
we O O
investigate O O
whether O O
doxorubicin O O
- O O
associated O O
chronic O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
can O O
be O O
ameliorated O O
with O O
the O O
antioxidant O O
hydroxytyrosol O O
in O O
rats O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Thirty O O
- O O
six O O
rats O O
bearing O O
breast B-Disease B-Disease
tumors I-Disease I-Disease
induced O O
chemically O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
control O O
, O O
hydroxytyrosol O O
( O O
0.5mg O O
/ O O
kg O O
, O O
5days O O
/ O O
week O O
) O O
, O O
doxorubicin O O
( O O
1mg O O
/ O O
kg O O
/ O O
week O O
) O O
, O O
and O O
doxorubicin O O
plus O O
hydroxytyrosol O O
. O O

Cardiac B-Disease B-Disease
disturbances I-Disease I-Disease
at O O
the O O
cellular O O
and O O
mitochondrial O O
level O O
, O O
mitochondrial O O
electron O O
transport O O
chain O O
complexes O O
I O O
- O O
IV O O
and O O
apoptosis O O
- O O
inducing O O
factor O O
, O O
and O O
oxidative O O
stress O O
markers O O
have O O
been O O
analyzed O O
. O O

Hydroxytyrosol O O
improved O O
the O O
cardiac B-Disease B-Disease
disturbances I-Disease I-Disease
enhanced O O
by O O
doxorubicin O O
by O O
significantly O O
reducing O O
the O O
percentage O O
of O O
altered O O
mitochondria O O
and O O
oxidative O O
damage O O
. O O

These O O
results O O
suggest O O
that O O
hydroxytyrosol O O
improve O O
the O O
mitochondrial O O
electron O O
transport O O
chain O O
. O O

This O O
study O O
demonstrates O O
that O O
hydroxytyrosol O O
protect O O
rat O O
heart B-Disease B-Disease
damage I-Disease I-Disease
provoked O O
by O O
doxorubicin O O
decreasing O O
oxidative O O
damage O O
and O O
mitochondrial O O
alterations O O
. O O

Amiodarone O O
- O O
induced O O
myxoedema B-Disease B-Disease
coma B-Disease B-Disease
. O O

A O O
62-year O O
- O O
old O O
man O O
was O O
found O O
to O O
have O O
bradycardia B-Disease B-Disease
, O O
hypothermia B-Disease B-Disease
and O O
respiratory B-Disease B-Disease
failure I-Disease I-Disease
3 O O
weeks O O
after O O
initiation O O
of O O
amiodarone O O
therapy O O
for O O
atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
. O O

Thyroid O O
- O O
stimulating O O
hormone O O
was O O
found O O
to O O
be O O
168 O O
uIU O O
/ O O
mL O O
( O O
nl O O
. O O

0.3 O O
- O O
5 O O
uIU O O
/ O O
mL O O
) O O
and O O
free O O
thyroxine O O
( O O
FT4 O O
) O O
was O O
< O O
0.2 O O
ng O O
/ O O
dL O O
( O O
nl O O
. O O
0.8 O O
- O O
1.8 O O
ng O O
/ O O
dL O O
) O O
. O O

He O O
received O O
intravenous O O
fluids O O
, O O
vasopressor O O
therapy O O
and O O
stress O O
dose O O
steroids O O
; O O
he O O
was O O
intubated O O
and O O
admitted O O
to O O
the O O
intensive O O
care O O
unit O O
. O O

He O O
received O O
500 O O
ug O O
of O O
intravenous O O
levothyroxine O O
in O O
the O O
first O O
18 O O
h O O
of O O
therapy O O
, O O
and O O
150 O O
ug O O
intravenous O O
daily O O
thereafter O O
. O O

Haemodynamic O O
improvement O O
, O O
along O O
with O O
complete O O
recovery O O
of O O
mental O O
status O O
, O O
occurred O O
after O O
48 O O
h. O O
Twelve O O
hours O O
after O O
the O O
initiation O O
of O O
therapy O O
, O O
FT4 O O
was O O
0.96 O O
ng O O
/ O O
dL. O O
The O O
patient O O
was O O
maintained O O
on O O
levothyroxine O O
175 O O
( O O
g O O
POorally O O
daily O O
. O O

A O O
thyroid O O
ultrasound O O
showed O O
diffuse O O
heterogeneity O O
. O O

The O O
24 O O
hour O O
excretion O O
of O O
iodine O O
was O O
3657 O O
( O O
mcg O O
( O O
25 O O
- O O
756 O O
( O O
mcg O O
) O O
. O O

The O O
only O O
two O O
cases O O
of O O
amiodarone O O
- O O
induced O O
myxoedema B-Disease B-Disease
coma B-Disease B-Disease
in O O
the O O
literature O O
report O O
patient O O
death O O
despite O O
supportive O O
therapy O O
and O O
thyroid O O
hormone O O
replacement O O
. O O

This O O
case O O
represents O O
the O O
most O O
thoroughly O O
investigated O O
case O O
of O O
amiodarone O O
- O O
induced O O
myxoedema B-Disease B-Disease
coma B-Disease B-Disease
with O O
a O O
history O O
significant O O
for O O
subclinical O O
thyroid B-Disease B-Disease
disease I-Disease I-Disease
. O O

Use O O
of O O
argatroban O O
and O O
catheter O O
- O O
directed O O
thrombolysis B-Disease O
with O O
alteplase O O
in O O
an O O
oncology O O
patient O O
with O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
with O O
thrombosis B-Disease B-Disease
. O O

PURPOSE O O
: O O
The O O
case O O
of O O
an O O
oncology O O
patient O O
who O O
developed O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
with O O
thrombosis B-Disease B-Disease
( O O
HITT B-Disease B-Disease
) O O
and O O
was O O
treated O O
with O O
argatroban O O
plus O O
catheter O O
- O O
directed O O
thrombolysis B-Disease O
( O O
CDT O O
) O O
with O O
alteplase O O
is O O
presented O O
. O O

SUMMARY O O
: O O
A O O
63-year O O
- O O
old O O
Caucasian O O
man O O
with O O
renal O B-Disease
amyloidosis B-Disease I-Disease
undergoing O O
peripheral O O
blood O O
stem O O
cell O O
collection O O
for O O
an O O
autologous O O
stem O O
cell O O
transplant O O
developed O O
extensive O O
bilateral O O
upper B-Disease B-Disease
- I-Disease I-Disease
extremity I-Disease I-Disease
deep I-Disease I-Disease
venous I-Disease I-Disease
thrombosis I-Disease I-Disease
( O O
DVT B-Disease B-Disease
) O O
and O O
pulmonary B-Disease B-Disease
embolism I-Disease I-Disease
secondary O O
to O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
. O O

A O O
continuous O O
i.v O O
. O O

infusion O O
of O O
argatroban O O
was O O
initiated O O
, O O
and O O
the O O
patient O O
was O O
managed O O
on O O
the O O
general O O
medical O O
floor O O
. O O

After O O
one O O
week O O
of O O
therapy O O
, O O
he O O
was O O
transferred O O
to O O
the O O
intensive O O
care O O
unit O O
with O O
cardiopulmonary O O
compromise O O
related O O
to O O
superior B-Disease B-Disease
vena I-Disease I-Disease
cava I-Disease I-Disease
( I-Disease I-Disease
SVC I-Disease I-Disease
) I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

A O O
percutaneous O O
mechanical O O
thrombectomy O O
and O O
CDT O O
with O O
alteplase O O
were O O
attempted O O
, O O
but O O
the O O
procedure O O
was O O
aborted O O
due O O
to O O
epistaxis B-Disease B-Disease
. O O

The O O
epistaxis B-Disease B-Disease
resolved O O
the O O
next O O
day O O
, O O
and O O
the O O
patient O O
was O O
restarted O O
on O O
argatroban O O
. O O

A O O
second O O
percutaneous O O
mechanical O O
thrombectomy O O
was O O
performed O O
six O O
days O O
later O O
and O O
resulted O O
in O O
partial O O
revascularization O O
of O O
the O O
SVC O O
and O O
central O O
veins O O
. O O

Postthrombectomy O O
continuous O O
CDT O O
with O O
alteplase O O
was O O
commenced O O
while O O
argatroban O O
was O O
withheld O O
, O O
and O O
complete O O
patency O O
of O O
the O O
SVC O O
and O O
central O O
veins O O
was O O
achieved O O
after O O
three O O
days O O
of O O
therapy O O
. O O

Alteplase O O
was O O
discontinued O O
, O O
and O O
the O O
patient O O
was O O
reinitiated O O
on O O
argatroban O O
; O O
ultimately O O
, O O
he O O
was O O
transitioned O O
to O O
warfarin O O
for O O
long O O
- O O
term O O
anticoagulation O O
. O O

Although O O
the O O
patient O O
recovered O O
, O O
he O O
experienced O O
permanent O O
vision B-Disease O
and I-Disease O
hearing I-Disease B-Disease
loss I-Disease I-Disease
, O O
as O O
well O O
as O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
. O O

CONCLUSION O O
: O O
A O O
63-year O O
- O O
old O O
man O O
with O O
renal O B-Disease
amyloidosis B-Disease I-Disease
and O O
SVC B-Disease B-Disease
syndrome I-Disease I-Disease
secondary O O
to O O
HITT B-Disease B-Disease
was O O
successfully O O
treated O O
with O O
argatroban O O
and O O
CDT O O
with O O
alteplase O O
. O O

Effects O O
of O O
dehydroepiandrosterone O O
in O O
amphetamine O O
- O O
induced O O
schizophrenia B-Disease B-Disease
models O O
in O O
mice O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
effects O O
of O O
dehydroepiandrosterone O O
( O O
DHEA O O
) O O
on O O
animal O O
models O O
of O O
schizophrenia B-Disease B-Disease
. O O

METHODS O O
: O O
Seventy O O
Swiss O O
albino O O
female O O
mice O O
( O O
25 O O
- O O
35 O O
g O O
) O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
amphetamine O O
- O O
free O O
( O O
control O O
) O O
, O O
amphetamine O O
, O O
50 O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
DHEA O O
. O O

The O O
DHEA O O
was O O
administered O O
intraperitoneally O O
( O O
ip O O
) O O
for O O
5 O O
days O O
. O O

Amphetamine O O
( O O
3 O O
mg O O
/ O O
kg O O
ip O O
) O O
induced O O
hyper B-Disease O
locomotion O O
, O O
apomorphine O O
( O O
1.5 O O
mg O O
/ O O
kg O O
subcutaneously O O
[ O O
sc O O
] O O
) O O
induced O O
climbing O O
, O O
and O O
haloperidol O O
( O O
1.5 O O
mg O O
/ O O
kg O O
sc O O
) O O
induced O O
catalepsy B-Disease B-Disease
tests O O
were O O
used O O
as O O
animal O O
models O O
of O O
schizophrenia B-Disease B-Disease
. O O

The O O
study O O
was O O
conducted O O
at O O
the O O
Animal O O
Experiment O O
Laboratories O O
, O O
Department O O
of O O
Pharmacology O O
, O O
Medical O O
School O O
, O O
Eskisehir O O
Osmangazi O O
University O O
, O O
Eskisehir O O
, O O
Turkey O O
between O O
March O O
and O O
May O O
2012 O O
. O O

Statistical O O
analysis O O
was O O
carried O O
out O O
using O O
Kruskal O O
- O O
Wallis O O
test O O
for O O
hyper B-Disease O
locomotion O O
, O O
and O O
one O O
- O O
way O O
ANOVA O O
for O O
climbing O O
and O O
catalepsy B-Disease B-Disease
tests O O
. O O

RESULTS O O
: O O
In O O
the O O
amphetamine O O
- O O
induced O O
locomotion O O
test O O
, O O
there O O
were O O
significant O O
increases O O
in O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine O O
- O O
free O O
group O O
. O O

Both O O
DHEA O O
50 O O
mg O O
/ O O
kg O O
( O O
p<0.05 O O
) O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
( O O
p<0.01 O O
) O O
significantly O O
decreased O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine O O
- O O
induced O O
locomotion O O
group O O
. O O

There O O
was O O
a O O
significant O O
difference O O
between O O
groups O O
in O O
the O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
test O O
( O O
p<0.05 O O
) O O
. O O

There O O
was O O
no O O
significant O O
difference O O
between O O
groups O O
in O O
terms O O
of O O
total O O
climbing O O
time O O
in O O
the O O
apomorphine O O
- O O
induced O O
climbing O O
test O O
( O O
p>0.05 O O
) O O
. O O

CONCLUSION O O
: O O
We O O
observed O O
that O O
DHEA O O
reduced O O
locomotor O O
activity O O
and O O
increased O O
catalepsy B-Disease B-Disease
at O O
both O O
doses O O
, O O
while O O
it O O
had O O
no O O
effect O O
on O O
climbing O O
behavior O O
. O O

We O O
suggest O O
that O O
DHEA O O
displays O O
typical O O
neuroleptic O O
- O O
like O O
effects O O
, O O
and O O
may O O
be O O
used O O
in O O
the O O
treatment O O
of O O
schizophrenia B-Disease B-Disease
. O O

Availability O O
of O O
human O O
induced O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
cardiomyocytes O O
in O O
assessment O O
of O O
drug O O
potential O O
for O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
. O O

Field O O
potential O O
duration O O
( O O
FPD O O
) O O
in O O
human O O
- O O
induced O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
cardiomyocytes O O
( O O
hiPS O O
- O O
CMs O O
) O O
, O O
which O O
can O O
express O O
QT O O
interval O O
in O O
an O O
electrocardiogram O O
, O O
is O O
reported O O
to O O
be O O
a O O
useful O O
tool O O
to O O
predict O O
K O O
( O O
+ O O
) O O
channel O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
channel O O
blocker O O
effects O O
on O O
QT O O
interval O O
. O O

However O O
, O O
there O O
is O O
no O O
report O O
showing O O
that O O
this O O
technique O O
can O O
be O O
used O O
to O O
predict O O
multichannel O O
blocker O O
potential O O
for O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
show O O
that O O
FPD O B-Disease
from O O
MEA O O
( O O
Multielectrode O O
array O O
) O O
of O O
hiPS O O
- O O
CMs O O
can O O
detect O O
QT B-Disease B-Disease
prolongation I-Disease I-Disease
induced O O
by O O
multichannel O O
blockers O O
. O O

hiPS O O
- O O
CMs O O
were O O
seeded O O
onto O O
MEA O O
and O O
FPD O O
was O O
measured O O
for O O
2min O O
every O O
10min O O
for O O
30min O O
after O O
drug O O
exposure O O
for O O
the O O
vehicle O O
and O O
each O O
drug O O
concentration O O
. O O

IKr O O
and O O
IKs O O
blockers O O
concentration O O
- O O
dependently O O
prolonged O O
corrected O O
FPD O O
( O O
FPDc O O
) O O
, O O
whereas O O
Ca O O
( O O
2 O O
+ O O
) O O
channel O O
blockers O O
concentration O O
- O O
dependently O O
shortened O O
FPDc O O
. O O

Also O O
, O O
the O O
multichannel O O
blockers O O
Amiodarone O O
, O O
Paroxetine O O
, O O
Terfenadine O O
and O O
Citalopram O O
prolonged O O
FPDc O O
in O O
a O O
concentration O O
dependent O O
manner O O
. O O

Finally O O
, O O
the O O
IKr O O
blockers O O
, O O
Terfenadine O O
and O O
Citalopram O O
, O O
which O O
are O O
reported O O
to O O
cause O O
Torsade B-Disease B-Disease
de I-Disease I-Disease
Pointes I-Disease I-Disease
( O O
TdP B-Disease B-Disease
) O O
in O O
clinical O O
practice O O
, O O
produced O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
. O O

hiPS O O
- O O
CMs O O
using O O
MEA O O
system O O
and O O
FPDc O O
can O O
predict O O
the O O
effects O O
of O O
drug O O
candidates O O
on O O
QT O O
interval O O
. O O

This O O
study O O
also O O
shows O O
that O O
this O O
assay O O
can O O
help O O
detect O O
EAD O O
for O O
drugs O O
with O O
TdP B-Disease B-Disease
potential O O
. O O

Dermal O O
developmental O O
toxicity B-Disease B-Disease
of O O
N O O
- O O
phenylimide O O
herbicides O O
in O O
rats O O
. O O

BACKGROUND O O
: O O
S-53482 O O
and O O
S-23121 O O
are O O
N O O
- O O
phenylimide O O
herbicides O O
and O O
produced O O
embryolethality B-Disease B-Disease
, O O
teratogenicity B-Disease B-Disease
( O O
mainly O O
ventricular B-Disease B-Disease
septal I-Disease I-Disease
defects I-Disease I-Disease
and O O
wavy O B-Disease
ribs O I-Disease
) O O
, O O
and O O
growth B-Disease B-Disease
retardation I-Disease I-Disease
in O O
rats O O
in O O
conventional O O
oral O O
developmental O B-Disease
toxicity B-Disease I-Disease
studies O O
. O O

Our O O
objective O O
in O O
this O O
study O O
was O O
to O O
investigate O O
whether O O
the O O
compounds O O
induce O O
developmental O B-Disease
toxicity B-Disease I-Disease
via O O
the O O
dermal O O
route O O
, O O
which O O
is O O
more O O
relevant O O
to O O
occupational O O
exposure O O
, O O
hence O O
better O O
addressing O O
human O O
health O O
risks O O
. O O

METHODS O O
: O O
S-53482 O O
was O O
administered O O
dermally O O
to O O
rats O O
at O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
mg O O
/ O O
kg O O
during O O
organogenesis O O
, O O
and O O
S-23121 O O
was O O
administered O O
at O O
200 O O
, O O
400 O O
, O O
and O O
800 O O
mg O O
/ O O
kg O O
( O O
the O O
maximum O O
applicable O O
dose O O
level O O
) O O
. O O

Fetuses O O
were O O
obtained O O
by O O
a O O
Cesarean O O
section O O
and O O
examined O O
for O O
external O O
, O O
visceral O O
, O O
and O O
skeletal O O
alterations O O
. O O

RESULTS O O
: O O
Dermal O O
exposure O O
of O O
rats O O
to O O
S-53482 O O
at O O
300 O O
mg O O
/ O O
kg O O
produced O O
patterns O O
of O O
developmental O B-Disease
toxicity B-Disease I-Disease
similar O O
to O O
those O O
resulting O O
from O O
oral O O
exposure O O
. O O

Toxicity B-Disease B-Disease
included O O
embryolethality B-Disease B-Disease
, O O
teratogenicity B-Disease B-Disease
, O O
and O O
growth B-Disease B-Disease
retardation I-Disease I-Disease
. O O

Dermal O O
administration O O
of O O
S-23121 O O
at O O
800 O O
mg O O
/ O O
kg O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
embryonic B-Disease B-Disease
death I-Disease I-Disease
and O O
ventricular B-Disease B-Disease
septal I-Disease I-Disease
defect I-Disease I-Disease
, O O
but O O
retarded O O
fetal O O
growth O O
was O O
not O O
observed O O
as O O
it O O
was O O
following O O
oral O O
exposure O O
to O O
S-23121 O O
. O O

CONCLUSIONS O O
: O O
Based O O
on O O
the O O
results O O
, O O
S-53482 O O
and O O
S-23121 O O
were O O
teratogenic B-Disease B-Disease
when O O
administered O O
dermally O O
to O O
pregnant O O
rats O O
as O O
were O O
the O O
compounds O O
administered O O
orally O O
. O O

Thus O O
, O O
investigation O O
of O O
the O O
mechanism O O
and O O
its O O
human O O
relevancy O O
become O O
more O O
important O O
. O O

Rates O O
of O O
Renal B-Disease B-Disease
Toxicity I-Disease I-Disease
in O O
Cancer B-Disease B-Disease
Patients O O
Receiving O O
Cisplatin O O
With O O
and O O
Without O O
Mannitol O O
. O O

BACKGROUND O O
: O O
Cisplatin O O
is O O
a O O
widely O O
used O O
antineoplastic O O
. O O

One O O
of O O
the O O
major O O
complications O O
of O O
cisplatin O O
use O O
is O O
dose O O
- O O
limiting O O
nephrotoxicity B-Disease B-Disease
. O O

There O O
are O O
many O O
strategies O O
to O O
prevent O O
this O O
toxicity B-Disease B-Disease
, O O
including O O
the O O
use O O
of O O
mannitol O O
as O O
a O O
nephroprotectant O O
in O O
combination O O
with O O
hydration O O
. O O

OBJECTIVE O O
: O O
We O O
aimed O O
to O O
evaluate O O
the O O
rates O O
of O O
cisplatin O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
in O O
cancer B-Disease B-Disease
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin O O
with O O
and O O
without O O
mannitol O O
. O O

METHODS O O
: O O
This O O
single O O
- O O
center O O
retrospective O O
analysis O O
was O O
a O O
quasi O O
experiment O O
created O O
by O O
the O O
national O O
mannitol O O
shortage O O
. O O

Data O O
were O O
collected O O
on O O
adult O O
cancer B-Disease B-Disease
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin O O
as O O
an O O
outpatient O O
from O O
January O O
2011 O O
to O O
September O O
2012 O O
. O O

The O O
primary O O
outcome O O
was O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
( O O
AKI B-Disease B-Disease
) O O
. O O

RESULTS O O
: O O
We O O
evaluated O O
143 O O
patients O O
who O O
received O O
single O O
- O O
agent O O
cisplatin O O
; O O
97.2 O O
% O O
of O O
patients O O
had O O
head B-Disease B-Disease
and I-Disease I-Disease
neck I-Disease I-Disease
cancer I-Disease I-Disease
as O O
their O O
primary O O
malignancy B-Disease B-Disease
. O O

Patients O O
who O O
did O O
not O O
receive O O
mannitol O O
were O O
more O O
likely O O
to O O
develop O O
nephrotoxicity B-Disease B-Disease
: O O
odds O O
ratio O O
[ O O
OR O O
] O O
= O O
2.646 O O
( O O
95 O O
% O O
CI O O
= O O
1.008 O O
, O O
6.944 O O
; O O
P O O
= O O
0.048 O O
) O O
. O O

Patients O O
who O O
received O O
the O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
dosing O O
and O O
patients O O
who O O
had O O
a O O
history O O
of O O
hypertension B-Disease B-Disease
also O O
had O O
a O O
higher O O
likelihood O O
of O O
developing O O
nephrotoxicity B-Disease B-Disease
: O O
OR O O
= O O
11.494 O O
( O O
95 O O
% O O
CI O O
= O O
4.149 O O
, O O
32.258 O O
; O O
P O O
< O O
0.0001 O O
) O O
and O O
OR O O
= O O
3.219 O O
( O O
95 O O
% O O
CI O O
= O O
1.228 O O
, O O
8.439 O O
; O O
P O O
= O O
0.017 O O
) O O
, O O
respectively O O
. O O

CONCLUSIONS O O
: O O
When O O
limited O O
quantities O O
of O O
mannitol O O
are O O
available O O
, O O
it O O
should O O
preferentially O O
be O O
given O O
to O O
patients O O
at O O
particularly O O
high O O
risk O O
of O O
nephrotoxicity B-Disease B-Disease
. O O

Our O O
analysis O O
suggests O O
that O O
those O O
patients O O
receiving O O
the O O
dosing O O
schedule O O
of O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
cisplatin O O
every O O
3 O O
weeks O O
and O O
those O O
with O O
hypertension B-Disease B-Disease
are O O
at O O
the O O
greatest O O
risk O O
of O O
nephrotoxicity B-Disease B-Disease
and O O
would O O
benefit O O
from O O
the O O
addition O O
of O O
mannitol O O
. O O

Metformin O O
protects O O
against O O
seizures B-Disease B-Disease
, O O
learning B-Disease B-Disease
and I-Disease I-Disease
memory I-Disease I-Disease
impairments I-Disease I-Disease
and O O
oxidative O O
damage O O
induced O O
by O O
pentylenetetrazole O O
- O O
induced O O
kindling O O
in O O
mice O O
. O O

Cognitive B-Disease B-Disease
impairment I-Disease I-Disease
, O O
the O O
most O O
common O O
and O O
severe O O
comorbidity O O
of O O
epilepsy B-Disease B-Disease
, O O
greatly O O
diminishes O O
the O O
quality O O
of O O
life O O
. O O

However O O
, O O
current O O
therapeutic O O
interventions O O
for O O
epilepsy B-Disease B-Disease
can O O
also O O
cause O O
untoward O O
cognitive O O
effects O O
. O O

Thus O O
, O O
there O O
is O O
an O O
urgent O O
need O O
for O O
new O O
kinds O O
of O O
agents O O
targeting O O
both O O
seizures B-Disease B-Disease
and O O
cognition B-Disease B-Disease
deficits I-Disease I-Disease
. O O

Oxidative O O
stress O O
is O O
considered O O
to O O
play O O
an O O
important O O
role O O
in O O
epileptogenesis O O
and O O
cognitive B-Disease B-Disease
deficits I-Disease I-Disease
, O O
and O O
antioxidants O O
have O O
a O O
putative O O
antiepileptic O O
potential O O
. O O

Metformin O O
, O O
the O O
most O O
commonly O O
prescribed O O
antidiabetic O O
oral O O
drug O O
, O O
has O O
antioxidant O O
properties O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
ameliorative O O
effects O O
of O O
metformin O O
on O O
seizures B-Disease B-Disease
, O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
and O O
brain O O
oxidative O O
stress O O
markers O O
observed O O
in O O
pentylenetetrazole O O
- O O
induced O O
kindling O O
animals O O
. O O

Male O O
C57BL O O
/ O O
6 O O
mice O O
were O O
administered O O
with O O
subconvulsive O O
dose O O
of O O
pentylenetetrazole O O
( O O
37 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
every O O
other O O
day O O
for O O
14 O O
injections O O
. O O

Metformin O O
was O O
injected O O
intraperitoneally O O
in O O
dose O O
of O O
200mg O O
/ O O
kg O O
along O O
with O O
alternate O O
- O O
day O O
PTZ O O
. O O

We O O
found O O
that O O
metformin O O
suppressed O O
the O O
progression O O
of O O
kindling O O
, O O
ameliorated O O
the O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
and O O
decreased O O
brain O O
oxidative O O
stress O O
. O O

Thus O O
the O O
present O O
study O O
concluded O O
that O O
metformin O O
may O O
be O O
a O O
potential O O
agent O O
for O O
the O O
treatment O O
of O O
epilepsy B-Disease B-Disease
as O O
well O O
as O O
a O O
protective O O
medicine O O
against O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
induced O O
by O O
seizures B-Disease B-Disease
. O O

P53 O O
inhibition O O
exacerbates O O
late O O
- O O
stage O O
anthracycline O O
cardiotoxicity B-Disease B-Disease
. O O

AIMS O O
: O O
Doxorubicin O O
( O O
DOX O O
) O O
is O O
an O O
effective O O
anti O O
- O O
cancer B-Disease O
therapeutic O O
, O O
but O O
is O O
associated O O
with O O
both O O
acute O O
and O O
late O O
- O O
stage O O
cardiotoxicity B-Disease B-Disease
. O O

Children O O
are O O
particularly O O
sensitive O O
to O O
DOX O O
- O O
induced O O
heart B-Disease B-Disease
failure I-Disease I-Disease
. O O

Here O O
, O O
the O O
impact O O
of O O
p53 O O
inhibition O O
on O O
acute O O
vs. O O
late O O
- O O
stage O O
DOX O O
cardiotoxicity B-Disease B-Disease
was O O
examined O O
in O O
a O O
juvenile O O
model O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Two O O
- O O
week O O
- O O
old O O
MHC O O
- O O
CB7 O O
mice O O
( O O
which O O
express O O
dominant O O
- O O
interfering O O
p53 O O
in O O
cardiomyocytes O O
) O O
and O O
their O O
non O O
- O O
transgenic O O
( O O
NON O O
- O O
TXG O O
) O O
littermates O O
received O O
weekly O O
DOX O O
injections O O
for O O
5 O O
weeks O O
( O O
25 O O
mg O O
/ O O
kg O O
cumulative O O
dose O O
) O O
. O O

One O O
week O O
after O O
the O O
last O O
DOX O O
treatment O O
( O O
acute O O
stage O O
) O O
, O O
MHC O O
- O O
CB7 O O
mice O O
exhibited O O
improved O O
cardiac O O
function O O
and O O
lower O O
levels O O
of O O
cardiomyocyte O O
apoptosis O O
when O O
compared O O
with O O
the O O
NON O O
- O O
TXG O O
mice O O
. O O

Surprisingly O O
, O O
by O O
13 O O
weeks O O
following O O
the O O
last O O
DOX O O
treatment O O
( O O
late O O
stage O O
) O O
, O O
MHC O O
- O O
CB7 O O
exhibited O O
a O O
progressive O O
decrease O O
in O O
cardiac O O
function O O
and O O
higher O O
rates O O
of O O
cardiomyocyte O O
apoptosis O O
when O O
compared O O
with O O
NON O O
- O O
TXG O O
mice O O
. O O

p53 O O
inhibition O O
blocked O O
transient O O
DOX O O
- O O
induced O O
STAT3 O O
activation O O
in O O
MHC O O
- O O
CB7 O O
mice O O
, O O
which O O
was O O
associated O O
with O O
enhanced O O
induction O O
of O O
the O O
DNA O O
repair O O
proteins O O
Ku70 O O
and O O
Ku80 O O
. O O

Mice O O
with O O
cardiomyocyte O O
- O O
restricted O O
deletion O O
of O O
STAT3 O O
exhibited O O
worse O O
cardiac O O
function O O
, O O
higher O O
levels O O
of O O
cardiomyocyte O O
apoptosis O O
, O O
and O O
a O O
greater O O
induction O O
of O O
Ku70 O O
and O O
Ku80 O O
in O O
response O O
to O O
DOX O O
treatment O O
during O O
the O O
acute O O
stage O O
when O O
compared O O
with O O
control O O
animals O O
. O O

CONCLUSION O O
: O O
These O O
data O O
support O O
a O O
model O O
wherein O O
a O O
p53-dependent O O
cardioprotective O O
pathway O O
, O O
mediated O O
via O O
STAT3 O O
activation O O
, O O
mitigates O O
DOX O O
- O O
induced O O
myocardial O O
stress O O
during O O
drug O O
delivery O O
. O O

Furthermore O O
, O O
these O O
data O O
suggest O O
an O O
explanation O O
as O O
to O O
how O O
p53 O O
inhibition O O
can O O
result O O
in O O
cardioprotection O O
during O O
drug O O
treatment O O
and O O
, O O
paradoxically O O
, O O
enhanced O O
cardiotoxicity B-Disease B-Disease
long O O
after O O
the O O
cessation O O
of O O
drug O O
treatment O O
. O O

Metronidazole O O
- O O
induced O O
encephalopathy B-Disease B-Disease
: O O
an O O
uncommon O O
scenario O O
. O O

Metronidazole O O
can O O
produce O O
neurological O O
complications O O
although O O
it O O
is O O
not O O
a O O
common O O
scenario O O
. O O

We O O
present O O
a O O
case O O
where O O
a O O
patient O O
developed O O
features O O
of O O
encephalopathy B-Disease B-Disease
following O O
prolonged O O
metronidazole O O
intake O O
. O O

Magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
brain O O
showed O O
abnormal O O
signal O O
intensity O O
involving O O
both O O
dentate O O
nuclei O O
of O O
cerebellum O O
and O O
splenium O O
of O O
corpus O O
callosum O O
. O O

The O O
diagnosis O O
of O O
metronidazole O O
toxicity B-Disease B-Disease
was O O
made O O
by O O
the O O
MRI O O
findings O O
and O O
supported O O
clinically O O
. O O

Aconitine O O
- O O
induced O O
Ca2 O O
+ O O
overload O O
causes O O
arrhythmia B-Disease B-Disease
and O O
triggers O O
apoptosis O O
through O O
p38 O O
MAPK O O
signaling O O
pathway O O
in O O
rats O O
. O O

Aconitine O O
is O O
a O O
major O O
bioactive O O
diterpenoid O O
alkaloid O O
with O O
high O O
content O O
derived O O
from O O
herbal O O
aconitum O O
plants O O
. O O

Emerging O O
evidence O O
indicates O O
that O O
voltage O O
- O O
dependent O O
Na O O
( O O
+ O O
) O O
channels O O
have O O
pivotal O O
roles O O
in O O
the O O
cardiotoxicity B-Disease B-Disease
of O O
aconitine O O
. O O

However O O
, O O
no O O
reports O O
are O O
available O O
on O O
the O O
role O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
in O O
aconitine O O
poisoning B-Disease B-Disease
. O O

In O O
this O O
study O O
, O O
we O O
explored O O
the O O
importance O O
of O O
pathological O O
Ca O O
( O O
2 O O
+ O O
) O O
signaling O O
in O O
aconitine O O
poisoning B-Disease B-Disease
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
found O O
that O O
Ca O O
( O O
2 O O
+ O O
) O O
overload O O
lead O O
to O O
accelerated O O
beating O O
rhythm O O
in O O
adult O O
rat O O
ventricular O O
myocytes O O
and O O
caused O O
arrhythmia B-Disease B-Disease
in O O
conscious O O
freely O O
moving O O
rats O O
. O O

To O O
investigate O O
effects O O
of O O
aconitine O O
on O O
myocardial B-Disease B-Disease
injury I-Disease I-Disease
, O O
we O O
performed O O
cytotoxicity B-Disease B-Disease
assay O O
in O O
neonatal O O
rat O O
ventricular O O
myocytes O O
( O O
NRVMs O O
) O O
, O O
as O O
well O O
as O O
measured O O
lactate O O
dehydrogenase O O
level O O
in O O
the O O
culture O O
medium O O
of O O
NRVMs O O
and O O
activities O O
of O O
serum O O
cardiac O O
enzymes O O
in O O
rats O O
. O O

The O O
results O O
showed O O
that O O
aconitine O O
resulted O O
in O O
myocardial B-Disease B-Disease
injury I-Disease I-Disease
and O O
reduced O O
NRVMs O O
viability O O
dose O O
- O O
dependently O O
. O O

To O O
confirm O O
the O O
pro O O
- O O
apoptotic O O
effects O O
, O O
we O O
performed O O
flow O O
cytometric O O
detection O O
, O O
cardiac O O
histology O O
, O O
transmission O O
electron O O
microscopy O O
and O O
terminal O O
deoxynucleotidyl O O
transferase O O
- O O
mediated O O
dUTP O O
- O O
biotin O O
nick O O
end O O
labeling O O
assay O O
. O O

The O O
results O O
showed O O
that O O
aconitine O O
stimulated O O
apoptosis O O
time O O
- O O
dependently O O
. O O

The O O
expression O O
analysis O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
demonstrated O O
that O O
aconitine O O
promoted O O
Ca O O
( O O
2 O O
+ O O
) O O
overload O O
through O O
the O O
expression O O
regulation O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
. O O

The O O
expression O O
analysis O O
of O O
apoptosis O O
- O O
related O O
proteins O O
revealed O O
that O O
pro O O
- O O
apoptotic O O
protein O O
expression O O
was O O
upregulated O O
, O O
and O O
anti O O
- O O
apoptotic O O
protein O O
BCL-2 O O
expression O O
was O O
downregulated O O
. O O

Furthermore O O
, O O
increased O O
phosphorylation O O
of O O
MAPK O O
family O O
members O O
, O O
especially O O
the O O
P O O
- O O
P38 O O
/ O O
P38 O O
ratio O O
was O O
found O O
in O O
cardiac O O
tissues O O
. O O

Hence O O
, O O
our O O
results O O
suggest O O
that O O
aconitine O O
significantly O O
aggravates O O
Ca O O
( O O
2 O O
+ O O
) O O
overload O O
and O O
causes O O
arrhythmia B-Disease B-Disease
and O O
finally O O
promotes O O
apoptotic O O
development O O
via O O
phosphorylation O O
of O O
P38 O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
. O O

Chronic O O
treatment O O
with O O
metformin O O
suppresses O O
toll O O
- O O
like O O
receptor O O
4 O O
signaling O O
and O O
attenuates O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
following O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

Acute O O
treatment O O
with O O
metformin O O
has O O
a O O
protective O O
effect O O
in O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
by O O
suppression O O
of O O
inflammatory O O
responses O O
due O O
to O O
activation O O
of O O
AMP O O
- O O
activated O O
protein O O
kinase O O
( O O
AMPK O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effect O O
of O O
chronic O O
pre O O
- O O
treatment O O
with O O
metformin O O
on O O
cardiac B-Disease B-Disease
dysfunction I-Disease I-Disease
and O O
toll O O
- O O
like O O
receptor O O
4 O O
( O O
TLR4 O O
) O O
activities O O
following O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
and O O
their O O
relation O O
with O O
AMPK O O
were O O
assessed O O
. O O

Male O O
Wistar O O
rats O O
were O O
randomly O O
assigned O O
to O O
one O O
of O O
5 O O
groups O O
( O O
n=6 O O
) O O
: O O
normal O O
control O O
and O O
groups O O
were O O
injected O O
isoproterenol O O
after O O
chronic O O
pre O O
- O O
treatment O O
with O O
0 O O
, O O
25 O O
, O O
50 O O
, O O
or O O
100mg O O
/ O O
kg O O
of O O
metformin O O
twice O O
daily O O
for O O
14 O O
days O O
. O O

Isoproterenol O O
( O O
100mg O O
/ O O
kg O O
) O O
was O O
injected O O
subcutaneously O O
on O O
the O O
13th O O
and O O
14th O O
days O O
to O O
induce O O
acute B-Disease O
myocardial I-Disease B-Disease
infarction I-Disease I-Disease
. O O

Isoproterenol O O
alone O O
decreased O O
left O O
ventricular O O
systolic O O
pressure O O
and O O
myocardial O O
contractility O O
indexed O O
as O O
LVdp O O
/ O O
dtmax O O
and O O
LVdp O O
/ O O
dtmin O O
. O O

The O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
was O O
significantly O O
lower O O
in O O
the O O
groups O O
treated O O
with O O
25 O O
and O O
50mg O O
/ O O
kg O O
of O O
metformin O O
. O O

Metfromin O O
markedly O O
lowered O O
isoproterenol O O
- O O
induced O O
elevation O O
in O O
the O O
levels O O
of O O
TLR4 O O
mRNA O O
, O O
myeloid O O
differentiation O O
protein O O
88 O O
( O O
MyD88 O O
) O O
, O O
tumor B-Disease B-Disease
necrosis B-Disease B-Disease
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
a O O
) O O
, O O
and O O
interleukin O O
6 O O
( O O
IL-6 O O
) O O
in O O
the O O
heart O O
tissues O O
. O O

Similar O O
changes O O
were O O
also O O
seen O O
in O O
the O O
serum O O
levels O O
of O O
TNF O O
- O O
a O O
and O O
IL-6 O O
. O O

However O O
, O O
the O O
lower O O
doses O O
of O O
25 O O
and O O
50mg O O
/ O O
kg O O
were O O
more O O
effective O O
than O O
100mg O O
/ O O
kg O O
. O O

Phosphorylated O O
AMPKa O O
( O O
p O O
- O O
AMPK O O
) O O
in O O
the O O
myocardium O O
was O O
significantly O O
elevated O O
by O O
25mg O O
/ O O
kg O O
of O O
metformin O O
, O O
slightly O O
by O O
50mg O O
/ O O
kg O O
, O O
but O O
not O O
by O O
100mg O O
/ O O
kg O O
. O O

Chronic O O
pre O O
- O O
treatment O O
with O O
metformin O O
reduces O O
post O O
- O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
cardiac O B-Disease
dysfunction O I-Disease
and O O
suppresses O O
inflammatory O O
responses O O
, O O
possibly O O
through O O
inhibition O O
of O O
TLR4 O O
activities O O
. O O

This O O
mechanism O O
can O O
be O O
considered O O
as O O
a O O
target O O
to O O
protect O O
infarcted O O
myocardium O O
. O O

Unusual O O
complications O O
of O O
antithyroid O O
drug O O
therapy O O
: O O
four O O
case O O
reports O O
and O O
review O O
of O O
literature O O
. O O

Two O O
cases O O
of O O
propylthiouracil O O
- O O
associated O O
acute O O
hepatitis B-Disease B-Disease
, O O
one O O
case O O
of O O
fatal O O
methimazole O O
- O O
associated O O
hepatocellular B-Disease B-Disease
necrosis I-Disease I-Disease
and O O
one O O
case O O
of O O
propylthiouracil O O
- O O
associated O O
lupus B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
syndrome I-Disease I-Disease
are O O
described O O
. O O

The O O
literature O O
related O O
to O O
antithyroid O O
drug O O
side O O
effects O O
and O O
the O O
mechanisms O O
for O O
their O O
occurrence O O
are O O
reviewed O O
and O O
the O O
efficacy O O
and O O
complications O O
of O O
thyroidectomy O O
and O O
radioiodine O O
compared O O
to O O
those O O
of O O
antithyroid O O
drugs O O
. O O

It O O
is O O
concluded O O
that O O
in O O
most O O
circumstances O O
131I O O
is O O
the O O
therapy O O
of O O
choice O O
for O O
hyperthyroidism B-Disease B-Disease
. O O

Neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
induced O O
by O O
combination O O
therapy O O
with O O
tetrabenazine O O
and O O
tiapride O O
in O O
a O O
Japanese O O
patient O O
with O O
Huntington B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
at O O
the O O
terminal O O
stage O O
of O O
recurrent O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

We O O
herein O O
describe O O
the O O
case O O
of O O
an O O
81-year O O
- O O
old O O
Japanese O O
woman O O
with O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
that O O
occurred O O
36 O O
days O O
after O O
the O O
initiation O O
of O O
combination O O
therapy O O
with O O
tiapride O O
( O O
75 O O
mg O O
/ O O
day O O
) O O
and O O
tetrabenazine O O
( O O
12.5 O O
mg O O
/ O O
day O O
) O O
for O O
Huntington B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

The O O
patient O O
had O O
been O O
treated O O
with O O
tiapride O O
or O O
tetrabenazine O O
alone O O
without O O
any O O
adverse O O
effects O O
before O O
the O O
administration O O
of O O
the O O
combination O O
therapy O O
. O O

She O O
also O O
had O O
advanced O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
when O O
the O O
combination O O
therapy O O
was O O
initiated O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
the O O
occurrence O O
of O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
due O O
to O O
combination O O
therapy O O
with O O
tetrabenazine O O
and O O
tiapride O O
has O O
not O O
been O O
previously O O
reported O O
. O O

Tetrabenazine O O
should O O
be O O
administered O O
very O O
carefully O O
in O O
combination O O
with O O
other O O
neuroleptic O O
drugs O O
, O O
particularly O O
in O O
patients O O
with O O
a O O
worsening O O
general O O
condition O O
. O O

A O O
metoprolol O O
- O O
terbinafine O O
combination O O
induced O O
bradycardia B-Disease B-Disease
. O O

To O O
report O O
a O O
sinus B-Disease B-Disease
bradycardia I-Disease I-Disease
induced O O
by O O
metoprolol O O
and O O
terbinafine O O
drug O O
- O O
drug O O
interaction O O
and O O
its O O
management O O
. O O

A O O
63 O O
year O O
- O O
old O O
Caucasian O O
man O O
on O O
metoprolol O O
200 O O
mg O O
/ O O
day O O
for O O
stable O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
was O O
prescribed O O
a O O
90-day O O
course O O
of O O
oral O O
terbinafine O O
250 O O
mg O O
/ O O
day O O
for O O
onychomycosis B-Disease B-Disease
. O O

On O O
the O O
49th O O
day O O
of O O
terbinafine O O
therapy O O
, O O
he O O
was O O
brought O O
to O O
the O O
emergency O O
room O O
for O O
a O O
decrease O O
of O O
his O O
global O O
health O O
status O O
, O O
confusion B-Disease B-Disease
and O O
falls O O
. O O

The O O
electrocardiogram O O
revealed O O
a O O
37 O O
beats O O
/ O O
min O O
sinus B-Disease O
bradycardia I-Disease B-Disease
. O O

A O O
score O O
of O O
7 O O
on O O
the O O
Naranjo O O
adverse B-Disease O
drug I-Disease O
reaction I-Disease O
probability O O
scale O O
indicates O O
a O O
probable O O
relationship O O
between O O
the O O
patient O O
's O O
sinus B-Disease B-Disease
bradycardia I-Disease I-Disease
and O O
the O O
drug O O
interaction O O
between O O
metoprolol O O
and O O
terbinafine O O
. O O

The O O
heart O O
rate O O
ameliorated O O
first O O
with O O
a O O
decrease O O
in O O
the O O
dose O O
of O O
metoprolol O O
. O O

It O O
was O O
subsequently O O
changed O O
to O O
bisoprolol O O
and O O
the O O
heart O O
rate O O
remained O O
normal O O
. O O

By O O
inhibiting O O
the O O
cytochrome O O
P450 O O
2D6 O O
, O O
terbinafine O O
had O O
decreased O O
metoprolol O O
's O O
clearance O O
, O O
leading O O
in O O
metoprolol O O
accumulation O O
which O O
has O O
resulted O O
in O O
clinically O O
significant O O
sinus B-Disease B-Disease
bradycardia I-Disease I-Disease
. O O

Optochiasmatic O O
and O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
due O O
to O O
ethambutol O O
overtreatment O O
. O O

Ethambutol O O
is O O
known O O
to O O
cause O O
optic B-Disease B-Disease
neuropathy I-Disease I-Disease
and O O
, O O
more O O
rarely O O
, O O
axonal O B-Disease
polyneuropathy B-Disease I-Disease
. O O

We O O
characterize O O
the O O
clinical O O
, O O
neurophysiological O O
, O O
and O O
neuroimaging O O
findings O O
in O O
a O O
72-year O O
- O O
old O O
man O O
who O O
developed O O
visual B-Disease B-Disease
loss I-Disease I-Disease
and O O
paresthesias B-Disease B-Disease
after O O
11 O O
weeks O O
of O O
exposure O O
to O O
a O O
supratherapeutic O O
dose O O
of O O
ethambutol O O
. O O

This O O
case O O
demonstrates O O
the O O
selective O O
vulnerability O O
of O O
the O O
anterior O O
visual O O
pathways O O
and O O
peripheral O O
nerves O O
to O O
ethambutol O O
toxicity B-Disease B-Disease
. O O

Testosterone O O
ameliorates O O
streptozotocin O O
- O O
induced O O
memory B-Disease B-Disease
impairment I-Disease I-Disease
in O O
male O O
rats O O
. O O

AIM O O
: O O
To O O
study O O
the O O
effects O O
of O O
testosterone O O
on O O
streptozotocin O O
( O O
STZ O O
) O O
-induced O O
memory B-Disease B-Disease
impairment I-Disease I-Disease
in O O
male O O
rats O O
. O O

METHODS O O
: O O
Adult O O
male O O
Wistar O O
rats O O
were O O
intracerebroventricularly O O
( O O
icv O O
) O O
infused O O
with O O
STZ O O
( O O
750 O O
ug O O
) O O
on O O
d O O
1 O O
and O O
d O O
3 O O
, O O
and O O
a O O
passive O O
avoidance O O
task O O
was O O
assessed O O
2 O O
weeks O O
after O O
the O O
first O O
injection O O
of O O
STZ O O
. O O

Castration O O
surgery O O
was O O
performed O O
in O O
another O O
group O O
of O O
rats O O
, O O
and O O
the O O
passive O O
avoidance O O
task O O
was O O
assessed O O
4 O O
weeks O O
after O O
the O O
operation O O
. O O

Testosterone O O
( O O
1 O O
mg.kg O O
( O O
-1 O O
) O O
.d O O
( O O
-1 O O
) O O
, O O
sc O O
) O O
, O O
the O O
androgen O O
receptor O O
antagonist O O
flutamide O O
( O O
10 O O
mg.kg O O
( O O
-1 O O
) O O
.d O O
( O O
-1 O O
) O O
, O O
ip O O
) O O
, O O
the O O
estrogen O O
receptor O O
antagonist O O
tamoxifen O O
( O O
1 O O
mg.kg O O
( O O
-1 O O
) O O
.d O O
( O O
-1 O O
) O O
, O O
ip O O
) O O
or O O
the O O
aromatase O O
inhibitor O O
letrozole O O
( O O
4 O O
mg.kg O O
( O O
-1 O O
) O O
.d O O
( O O
-1 O O
) O O
, O O
ip O O
) O O
were O O
administered O O
for O O
6 O O
d O O
after O O
the O O
first O O
injection O O
of O O
STZ O O
. O O

RESULTS O O
: O O
STZ O O
administration O O
and O O
castration O O
markedly O O
decreased O O
both O O
STL1 O O
( O O
the O O
short O O
memory O O
) O O
and O O
STL2 O O
( O O
the O O
long O O
memory O O
) O O
in O O
passive O O
avoidance O O
tests O O
. O O

Testosterone O O
replacement O O
almost O O
restored O O
the O O
STL1 O O
and O O
STL2 O O
in O O
castrated O O
rats O O
, O O
and O O
significantly O O
prolonged O O
the O O
STL1 O O
and O O
STL2 O O
in O O
STZ O O
- O O
treated O O
rats O O
. O O

Administration O O
of O O
flutamide O O
, O O
letrozole O O
or O O
tamoxifen O O
significantly O O
impaired B-Disease B-Disease
the I-Disease I-Disease
memory I-Disease I-Disease
in O O
intact O O
rats O O
, O O
and O O
significantly O O
attenuated O O
the O O
testosterone O O
replacement O O
in O O
improving O O
STZ- O O
and O O
castration O O
- O O
induced O O
memory B-Disease B-Disease
impairment I-Disease I-Disease
. O O

CONCLUSION O O
: O O
Testosterone O O
administration O O
ameliorates O O
STZ- O O
and O O
castration O O
- O O
induced O O
memory B-Disease B-Disease
impairment I-Disease I-Disease
in O O
male O O
Wistar O O
rats O O
. O O

Behavioral O O
and O O
neurochemical O O
studies O O
in O O
mice O O
pretreated O O
with O O
garcinielliptone O O
FC O O
in O O
pilocarpine O O
- O O
induced O O
seizures B-Disease B-Disease
. O O

Garcinielliptone O O
FC O O
( O O
GFC O O
) O O
isolated O O
from O O
hexanic O O
fraction O O
seed O O
extract O O
of O O
species O O
Platonia O O
insignis O O
Mart O O
. O O

It O O
is O O
widely O O
used O O
in O O
folk O O
medicine O O
to O O
treat O O
skin B-Disease B-Disease
diseases I-Disease I-Disease
in O O
both O O
humans O O
and O O
animals O O
as O O
well O O
as O O
the O O
seed O O
decoction O O
has O O
been O O
used O O
to O O
treat O O
diarrheas B-Disease B-Disease
and O O
inflammatory B-Disease B-Disease
diseases I-Disease I-Disease
. O O

However O O
, O O
there O O
is O O
no O O
research O O
on O O
GFC O O
effects O O
in O O
the O O
central O O
nervous O O
system O O
of O O
rodents O O
. O O

The O O
present O O
study O O
aimed O O
to O O
evaluate O O
the O O
GFC O O
effects O O
at O O
doses O O
of O O
25 O O
, O O
50 O O
or O O
75 O O
mg O O
/ O O
kg O O
on O O
seizure B-Disease B-Disease
parameters O O
to O O
determine O O
their O O
anticonvulsant O O
activity O O
and O O
its O O
effects O O
on O O
amino O O
acid O O
( O O
r O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
, O O
glutamine O O
, O O
aspartate O O
and O O
glutathione O O
) O O
levels O O
as O O
well O O
as O O
on O O
acetylcholinesterase O O
( O O
AChE O O
) O O
activity O O
in O O
mice O O
hippocampus O O
after O O
seizures B-Disease B-Disease
. O O

GFC O O
produced O O
an O O
increased O O
latency O O
to O O
first O O
seizure B-Disease B-Disease
, O O
at O O
doses O O
25mg O O
/ O O
kg O O
( O O
20.12 O O
+ O O
2.20 O O
min O O
) O O
, O O
50mg O O
/ O O
kg O O
( O O
20.95 O O
+ O O
2.21 O O
min O O
) O O
or O O
75 O O
mg O O
/ O O
kg O O
( O O
23.43 O O
+ O O
1.99 O O
min O O
) O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

In O O
addition O O
, O O
GABA O O
content O O
of O O
mice O O
hippocampus O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
showed O O
an O O
increase O O
of O O
46.90 O O
% O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

In O O
aspartate O O
, O O
glutamine O O
and O O
glutamate O O
levels O O
detected O O
a O O
decrease O O
of O O
5.21 O O
% O O
, O O
13.55 O O
% O O
and O O
21.80 O O
% O O
, O O
respectively O O
in O O
mice O O
hippocampus O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

Hippocampus O O
mice O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
showed O O
an O O
increase O O
in O O
AChE O O
activity O O
( O O
63.30 O O
% O O
) O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

The O O
results O O
indicate O O
that O O
GFC O O
can O O
exert O O
anticonvulsant O O
activity O O
and O O
reduce O O
the O O
frequency O O
of O O
installation O O
of O O
pilocarpine O O
- O O
induced O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
, O O
as O O
demonstrated O O
by O O
increase O O
in O O
latency O O
to O O
first O O
seizure B-Disease B-Disease
and O O
decrease O O
in O O
mortality O O
rate O O
of O O
animals O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
GFC O O
may O O
influence O O
in O O
epileptogenesis O O
and O O
promote O O
anticonvulsant O O
actions O O
in O O
pilocarpine O O
model O O
by O O
modulating O O
the O O
GABA O O
and O O
glutamate O O
contents O O
and O O
of O O
AChE O O
activity O O
in O O
seized O O
mice O O
hippocampus O O
. O O

This O O
compound O O
may O O
be O O
useful O O
to O O
produce O O
neuronal O O
protection O O
and O O
it O O
can O O
be O O
considered O O
as O O
an O O
anticonvulsant O O
agent O O
. O O

Standard O O
operating O O
procedures O O
for O O
antibiotic O O
therapy O O
and O O
the O O
occurrence O O
of O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
: O O
a O O
prospective O O
, O O
clinical O O
, O O
non O O
- O O
interventional O O
, O O
observational O O
study O O
. O O

INTRODUCTION O O
: O O
Acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
( O O
AKI B-Disease B-Disease
) O O
occurs O O
in O O
7 O O
% O O
of O O
hospitalized O O
and O O
66 O O
% O O
of O O
Intensive O O
Care O O
Unit O O
( O O
ICU O O
) O O
patients O O
. O O

It O O
increases O O
mortality O O
, O O
hospital O O
length O O
of O O
stay O O
, O O
and O O
costs O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
, O O
whether O O
there O O
is O O
an O O
association O O
between O O
adherence O O
to O O
guidelines O O
( O O
standard O O
operating O O
procedures O O
( O O
SOP O O
) O O
) O O
for O O
potentially O O
nephrotoxic B-Disease B-Disease
antibiotics O O
and O O
the O O
occurrence O O
of O O
AKI B-Disease B-Disease
. O O

METHODS O O
: O O
This O O
study O O
was O O
carried O O
out O O
as O O
a O O
prospective O O
, O O
clinical O O
, O O
non O O
- O O
interventional O O
, O O
observational O O
study O O
. O O

Data O O
collection O O
was O O
performed O O
over O O
a O O
total O O
of O O
170 O O
days O O
in O O
three O O
ICUs O O
at O O
Charite O O
- O O
Universitaetsmedizin O O
Berlin O O
. O O

A O O
total O O
of O O
675 O O
patients O O
were O O
included O O
; O O
163 O O
of O O
these O O
had O O
therapy O O
with O O
vancomycin O O
, O O
gentamicin O O
, O O
or O O
tobramycin O O
; O O
were O O
> O O
18 O O
years O O
; O O
and O O
treated O O
in O O
the O O
ICU O O
for O O
> O O
24 O O
hours O O
. O O

Patients O O
with O O
an O O
adherence O O
to O O
SOP O O
> O O
70 O O
% O O
were O O
classified O O
into O O
the O O
high O O
adherence O O
group O O
( O O
HAG O O
) O O
and O O
patients O O
with O O
an O O
adherence O O
of O O
< O O
70 O O
% O O
into O O
the O O
low O O
adherence O O
group O O
( O O
LAG O O
) O O
. O O

AKI B-Disease B-Disease
was O O
defined O O
according O O
to O O
RIFLE O O
criteria O O
. O O

Adherence O O
to O O
SOPs O O
was O O
evaluated O O
by O O
retrospective O O
expert O O
audit O O
. O O

Development O O
of O O
AKI B-Disease B-Disease
was O O
compared O O
between O O
groups O O
with O O
exact O O
Chi2-test O O
and O O
multivariate O O
logistic O O
regression O O
analysis O O
( O O
two O O
- O O
sided O O
P O O
< O O
0.05 O O
) O O
. O O

RESULTS O O
: O O
LAG O O
consisted O O
of O O
75 O O
patients O O
( O O
46 O O
% O O
) O O
versus O O
88 O O
HAG O B-Disease
patients O O
( O O
54 O O
% O O
) O O
. O O

AKI B-Disease B-Disease
occurred O O
significantly O O
more O O
often O O
in O O
LAG O O
with O O
36 O O
% O O
versus O O
21 O O
% O O
in O O
HAG O O
( O O
P O O
= O O
0.035 O O
) O O
. O O

Basic O O
characteristics O O
were O O
comparable O O
, O O
except O O
an O O
increased O O
rate O O
of O O
soft O B-Disease
tissue O I-Disease
infections B-Disease I-Disease
in O O
LAG O O
. O O

Multivariate O O
analysis O O
revealed O O
an O O
odds O O
ratio O O
of O O
2.5-fold O O
for O O
LAG O O
to O O
develop O O
AKI B-Disease B-Disease
compared O O
with O O
HAG O O
( O O
95 O O
% O O
confidence O O
interval O O
1.195 O O
to O O
5.124 O O
, O O
P O O
= O O
0.039 O O
) O O
. O O

CONCLUSION O O
: O O
Low O O
adherence O O
to O O
SOPs O O
for O O
potentially O O
nephrotoxic B-Disease B-Disease
antibiotics O O
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
AKI B-Disease B-Disease
. O O

TRIAL O O
REGISTRATION O O
: O O
Current O O
Controlled O O
Trials O O
ISRCTN54598675 O O
. O O

Registered O O
17 O O
August O O
2007 O O
. O O

Rhabdomyolysis B-Disease B-Disease
in O O
a O O
hepatitis B-Disease B-Disease
C I-Disease I-Disease
virus I-Disease I-Disease
infected I-Disease I-Disease
patient O O
treated O O
with O O
telaprevir O O
and O O
simvastatin O O
. O O

A O O
46-year O O
old O O
man O O
with O O
a O O
chronic O B-Disease
hepatitis B-Disease I-Disease
C I-Disease I-Disease
virus I-Disease I-Disease
infection I-Disease I-Disease
received O O
triple O O
therapy O O
with O O
ribavirin O O
, O O
pegylated O O
interferon O O
and O O
telaprevir O O
. O O

The O O
patient O O
also O O
received O O
simvastatin O O
. O O

One O O
month O O
after O O
starting O O
the O O
antiviral O O
therapy O O
, O O
the O O
patient O O
was O O
admitted O O
to O O
the O O
hospital O O
because O O
he O O
developed O O
rhabdomyolysis B-Disease B-Disease
. O O

At O O
admission O O
simvastatin O O
and O O
all O O
antiviral O O
drugs O O
were O O
discontinued O O
because O O
toxicity B-Disease B-Disease
due O O
to O O
a O O
drug O O
- O O
drug O O
interaction O O
was O O
suspected O O
. O O

The O O
creatine O O
kinase O O
peaked O O
at O O
62,246 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
treated O O
with O O
intravenous O O
normal O O
saline O O
. O O

The O O
patient O O
's O O
renal O O
function O O
remained O O
unaffected O O
. O O

Fourteen O O
days O O
after O O
hospitalization O O
, O O
creatine O O
kinase O O
level O O
had O O
returned O O
to O O
230 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
discharged O O
. O O

Telaprevir O O
was O O
considered O O
the O O
probable O O
causative O O
agent O O
of O O
an O O
interaction O O
with O O
simvastatin O O
according O O
to O O
the O O
Drug O O
Interaction O O
Probability O O
Scale O O
. O O

The O O
interaction O O
is O O
due O O
to O O
inhibition O O
of O O
CYP3A4-mediated O O
simvastatin O O
clearance O O
. O O

Simvastatin O O
plasma O O
concentration O O
increased O O
30 O O
times O O
in O O
this O O
patient O O
and O O
statin O O
induced O O
muscle B-Disease B-Disease
toxicity I-Disease I-Disease
is O O
related O O
to O O
the O O
concentration O O
of O O
the O O
statin O O
in O O
blood O O
. O O

In O O
conclusion O O
, O O
with O O
this O O
case O O
we O O
illustrate O O
that O O
telaprevir O O
as O O
well O O
as O O
statins O O
are O O
susceptible O O
to O O
clinical O O
relevant O O
drug O O
- O O
drug O O
interactions O O
. O O

Combination O O
of O O
bortezomib O O
, O O
thalidomide O O
, O O
and O O
dexamethasone O O
( O O
VTD O O
) O O
as O O
a O O
consolidation O O
therapy O O
after O O
autologous O O
stem O O
cell O O
transplantation O O
for O O
symptomatic O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
in O O
Japanese O O
patients O O
. O O

Consolidation O O
therapy O O
for O O
patients O O
with O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
( O O
MM B-Disease B-Disease
) O O
has O O
been O O
widely O O
adopted O O
to O O
improve O O
treatment O O
response O O
following O O
autologous O O
stem O O
cell O O
transplantation O O
. O O

In O O
this O O
study O O
, O O
we O O
retrospectively O O
analyzed O O
the O O
safety O O
and O O
efficacy O O
of O O
combination O O
regimen O O
of O O
bortezomib O O
, O O
thalidomide O O
, O O
and O O
dexamethasone O O
( O O
VTD O O
) O O
as O O
consolidation O O
therapy O O
in O O
24 O O
Japanese O O
patients O O
with O O
newly O O
diagnosed O O
MM B-Disease B-Disease
. O O

VTD O O
consisted O O
of O O
bortezomib O O
at O O
a O O
dose O O
of O O
1.3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
and O O
dexamethasone O O
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
day O O
on O O
days O O
1 O O
, O O
8 O O
, O O
15 O O
, O O
and O O
22 O O
of O O
a O O
35-day O O
cycle O O
, O O
with O O
daily O O
oral O O
thalidomide O O
at O O
a O O
dose O O
of O O
100 O O
mg O O
/ O O
day O O
. O O

Grade O O
3 O O
- O O
4 O O
neutropenia B-Disease B-Disease
and O O
thrombocytopenia B-Disease B-Disease
were O O
documented O O
in O O
four O O
and O O
three O O
patients O O
( O O
17 O O
and O O
13 O O
% O O
) O O
, O O
respectively O O
, O O
but O O
drug O O
dose O O
reduction O O
due O O
to O O
cytopenia B-Disease B-Disease
was O O
not O O
required O O
in O O
any O O
case O O
. O O

Peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
was O O
common O O
( O O
63 O O
% O O
) O O
, O O
but O O
severe O O
grade O O
3 O O
- O O
4 O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
was O O
not O O
observed O O
. O O

Very O O
good O O
partial O O
response O O
or O O
better O O
response O O
( O O
> O O
VGPR O O
) O O
rates O O
before O O
and O O
after O O
consolidation O O
therapy O O
were O O
54 O O
and O O
79 O O
% O O
, O O
respectively O O
. O O

Patients O O
had O O
a O O
significant O O
probability O O
of O O
improving O O
from O O
< O O
VGPR O O
before O O
consolidation O O
therapy O O
to O O
> O O
VGPR O O
after O O
consolidation O O
therapy O O
( O O
p O O
= O O
0.041 O O
) O O
. O O

The O O
VTD O O
regimen O O
may O O
be O O
safe O O
and O O
effective O O
as O O
a O O
consolidation O O
therapy O O
in O O
the O O
treatment O O
of O O
MM O B-Disease
in O O
Japanese O O
population O O
. O O

Conversion O O
to O O
sirolimus O O
ameliorates O O
cyclosporine O O
- O O
induced O O
nephropathy B-Disease B-Disease
in O O
the O O
rat O O
: O O
focus O O
on O O
serum O O
, O O
urine O O
, O O
gene O O
, O O
and O O
protein O O
renal O O
expression O O
biomarkers O O
. O O

Protocols O O
of O O
conversion O O
from O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
to O O
sirolimus O O
( O O
SRL O O
) O O
have O O
been O O
widely O O
used O O
in O O
immunotherapy O O
after O O
transplantation O O
to O O
prevent O O
CsA O O
- O O
induced O O
nephropathy B-Disease B-Disease
, O O
but O O
the O O
molecular O O
mechanisms O O
underlying O O
these O O
protocols O O
remain O O
nuclear O O
. O O

This O O
study O O
aimed O O
to O O
identify O O
the O O
molecular O O
pathways O O
and O O
putative O O
biomarkers O O
of O O
CsA O O
- O O
to O O
- O O
SRL O O
conversion O O
in O O
a O O
rat O O
model O O
. O O

Four O O
animal O O
groups O O
( O O
n O O
= O O
6 O O
) O O
were O O
tested O O
during O O
9 O O
weeks O O
: O O
control O O
, O O
CsA O O
, O O
SRL O O
, O O
and O O
conversion O O
( O O
CsA O O
for O O
3 O O
weeks O O
followed O O
by O O
SRL O O
for O O
6 O O
weeks O O
) O O
. O O

Classical O O
and O O
emergent O O
serum O O
, O O
urinary O O
, O O
and O O
kidney O O
tissue O O
( O O
gene O O
and O O
protein O O
expression O O
) O O
markers O O
were O O
assessed O O
. O O

Renal B-Disease B-Disease
lesions I-Disease I-Disease
were O O
analyzed O O
in O O
hematoxylin O O
and O O
eosin O O
, O O
periodic O O
acid O O
- O O
Schiff O O
, O O
and O O
Masson O O
's O O
trichrome O O
stains O O
. O O

SRL O O
- O O
treated O O
rats O O
presented O O
proteinuria B-Disease B-Disease
and O O
NGAL O O
( O O
serum O O
and O O
urinary O O
) O O
as O O
the O O
best O O
markers O O
of O O
renal B-Disease B-Disease
impairment I-Disease I-Disease
. O O

Short O O
CsA O O
treatment O O
presented O O
slight O O
or O O
even O O
absent O O
kidney B-Disease B-Disease
lesions I-Disease I-Disease
and O O
TGF O O
- O O
b O O
, O O
NF- O O
kb O O
, O O
mTOR O O
, O O
PCNA O O
, O O
TP53 O O
, O O
KIM-1 O O
, O O
and O O
CTGF O O
as O O
relevant O O
gene O O
and O O
protein O O
changes O O
. O O

Prolonged O O
CsA O O
exposure O O
aggravated O O
renal B-Disease B-Disease
damage I-Disease I-Disease
, O O
without O O
clear O O
changes O O
on O O
the O O
traditional O O
markers O O
, O O
but O O
with O O
changes O O
in O O
serums O O
TGF- O O
b O O
and O O
IL-7 O O
, O O
TBARs O O
clearance O O
, O O
and O O
kidney O O
TGF O O
- O O
b O O
and O O
mTOR O O
. O O

Conversion O O
to O O
SRL O O
prevented O O
CsA O O
- O O
induced O O
renal B-Disease B-Disease
damage I-Disease I-Disease
evolution O O
( O O
absent O O
/ O O
mild O O
grade O O
lesions O O
) O O
, O O
while O O
NGAL O O
( O O
serum O O
versus O O
urine O O
) O O
seems O O
to O O
be O O
a O O
feasible O O
biomarker O O
of O O
CsA O O
replacement O O
to O O
SRL O O
. O O

Kinin O O
B2 O O
receptor O O
deletion O O
and O O
blockage O O
ameliorates O O
cisplatin O O
- O O
induced O O
acute B-Disease B-Disease
renal I-Disease I-Disease
injury I-Disease I-Disease
. O O

Cisplatin O O
treatment O O
has O O
been O O
adopted O O
in O O
some O O
chemotherapies O O
; O O
however O O
, O O
this O O
drug O O
can O O
induce O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
due O O
its O O
ability O O
to O O
negatively O O
affect O O
renal O O
function O O
, O O
augment O O
serum O O
levels O O
of O O
creatinine O O
and O O
urea O O
, O O
increase O O
the O O
acute B-Disease B-Disease
tubular I-Disease I-Disease
necrosis I-Disease I-Disease
score O O
and O O
up O O
- O O
regulate O O
cytokines O O
( O O
e.g. O O
, O O
IL-1b O O
and O O
TNF O O
- O O
a O O
) O O
. O O

The O O
kinin O O
B2 O O
receptor O O
has O O
been O O
associated O O
with O O
the O O
inflammation B-Disease B-Disease
process O O
, O O
as O O
well O O
as O O
the O O
regulation O O
of O O
cytokine O O
expression O O
, O O
and O O
its O O
deletion O O
resulted O O
in O O
an O O
improvement O O
in O O
the O O
diabetic B-Disease B-Disease
nephropathy I-Disease I-Disease
status O O
. O O

To O O
examine O O
the O O
role O O
of O O
the O O
kinin O O
B2 O O
receptor O O
in O O
cisplatin O O
- O O
induced O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
, O O
kinin O O
B2 O O
receptor O O
knockout O O
mice O O
were O O
challenged O O
with O O
cisplatin O O
. O O

Additionally O O
, O O
WT O O
mice O O
were O O
treated O O
with O O
a O O
B2 O O
receptor O O
antagonist O O
after O O
cisplatin O O
administration O O
. O O

B2 O O
receptor O O
- O O
deficient O O
mice O O
were O O
less O O
sensitive O O
to O O
this O O
drug O O
than O O
the O O
WT O O
mice O O
, O O
as O O
shown O O
by O O
reduced O O
weight B-Disease O
loss I-Disease O
, O O
better O O
preservation O O
of O O
kidney O O
function O O
, O O
down O O
regulation O O
of O O
inflammatory O O
cytokines O O
and O O
less O O
acute B-Disease B-Disease
tubular I-Disease I-Disease
necrosis I-Disease I-Disease
. O O

Moreover O O
, O O
treatment O O
with O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
effectively O O
reduced O O
the O O
levels O O
of O O
serum O O
creatinine O O
and O O
blood O O
urea O O
after O O
cisplatin O O
administration O O
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
the O O
kinin O O
B2 O O
receptor O O
is O O
involved O O
in O O
cisplatin O O
- O O
induced O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
by O O
mediating O O
the O O
necrotic B-Disease B-Disease
process O O
and O O
the O O
expression O O
of O O
inflammatory O O
cytokines O O
, O O
thus O O
resulting O O
in O O
declined O O
renal O O
function O O
. O O

These O O
results O O
highlight O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
treatment O O
in O O
amelioration O O
of O O
nephrotoxicity B-Disease B-Disease
induced O O
by O O
cisplatin O O
therapy O O
. O O

Safety O O
and O O
efficacy O O
of O O
fluocinolone O O
acetonide O O
intravitreal O O
implant O O
( O O
0.59 O O
mg O O
) O O
in O O
birdshot B-Disease B-Disease
retinochoroidopathy I-Disease I-Disease
. O O

PURPOSE O O
: O O
To O O
report O O
the O O
treatment O O
outcomes O O
of O O
the O O
fluocinolone O O
acetonide O O
intravitreal O O
implant O O
( O O
0.59 O O
mg O O
) O O
in O O
patients O O
with O O
birdshot B-Disease B-Disease
retinochoroidopathy I-Disease I-Disease
whose O O
disease O O
is O O
refractory O O
or O O
intolerant O O
to O O
conventional O O
immunomodulatory O O
therapy O O
. O O

METHODS O O
: O O
A O O
retrospective O O
case O O
series O O
involving O O
11 O O
birdshot B-Disease B-Disease
retinochoroidopathy I-Disease I-Disease
patients O O
( O O
11 O O
eyes O O
) O O
. O O

Eleven O O
patients O O
( O O
11 O O
eyes O O
) O O
underwent O O
surgery O O
for O O
fluocinolone O O
acetonide O O
implant O O
( O O
0.59 O O
mg O O
) O O
. O O

Treatment O O
outcomes O O
of O O
interest O O
were O O
noted O O
at O O
baseline O O
, O O
before O O
fluocinolone O O
acetonide O O
implant O O
, O O
and O O
then O O
at O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
3 O O
years O O
, O O
and O O
beyond O O
3 O O
years O O
. O O

Disease O O
activity O O
markers O O
, O O
including O O
signs O O
of O O
ocular O B-Disease
inflammation B-Disease I-Disease
, O O
evidence O O
of O O
retinal B-Disease B-Disease
vasculitis I-Disease I-Disease
, O O
Swedish O O
interactive O O
threshold O O
algorithm O O
- O O
short O O
wavelength O O
automated O O
perimetry O O
Humphrey O O
visual O O
field O O
analysis O O
, O O
electroretinographic O O
parameters O O
, O O
and O O
optical O O
coherence O O
tomography O O
were O O
recorded O O
. O O

Data O O
on O O
occurrence O O
of O O
cataract B-Disease B-Disease
and O O
raised B-Disease B-Disease
intraocular I-Disease I-Disease
pressure I-Disease I-Disease
were O O
collected O O
in O O
all O O
eyes O O
. O O

RESULTS O O
: O O
Intraocular O B-Disease
inflammation B-Disease I-Disease
was O O
present O O
in O O
54.5 O O
, O O
9.9 O O
, O O
11.1 O O
, O O
and O O
0 O O
% O O
of O O
patients O O
at O O
baseline O O
, O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
3 O O
years O O
, O O
and O O
beyond O O
3 O O
years O O
after O O
receiving O O
the O O
implant O O
, O O
respectively O O
. O O

Active O O
vasculitis B-Disease B-Disease
was O O
noted O O
in O O
36.3 O O
% O O
patients O O
at O O
baseline O O
and O O
0 O O
% O O
at O O
3 O O
years O O
of O O
follow O O
- O O
up O O
. O O

More O O
than O O
20 O O
% O O
( O O
47.61 O O
- O O
67.2 O O
% O O
) O O
reduction O O
in O O
central O O
retinal O O
thickness O O
was O O
noted O O
in O O
all O O
patients O O
with O O
cystoid B-Disease B-Disease
macular I-Disease I-Disease
edema I-Disease I-Disease
at O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
and O O
3 O O
years O O
postimplant O O
. O O

At O O
baseline O O
, O O
54.5 O O
% O O
patients O O
were O O
on O O
immunomodulatory O O
agents O O
. O O

This O O
percentage O O
decreased O O
to O O
45.45 O O
, O O
44.4 O O
, O O
and O O
14.28 O O
% O O
at O O
1 O O
year O O
, O O
2 O O
years O O
, O O
and O O
3 O O
years O O
postimplant O O
, O O
respectively O O
. O O

Adverse O O
events O O
included O O
increased B-Disease O
intraocular I-Disease O
pressure I-Disease O
( O O
54.5 O O
% O O
) O O
and O O
cataract B-Disease B-Disease
formation O O
( O O
100 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
The O O
data O O
suggest O O
that O O
fluocinolone O O
acetonide O O
implant O O
( O O
0.59 O O
mg O O
) O O
helps O O
to O O
control O O
inflammation B-Disease B-Disease
in O O
otherwise O O
treatment O O
- O O
refractory O O
cases O O
of O O
birdshot B-Disease B-Disease
retinochoroidopathy I-Disease I-Disease
. O O

It O O
is O O
associated O O
with O O
significant O O
side O O
effects O O
of O O
cataract B-Disease B-Disease
and O O
ocular B-Disease B-Disease
hypertension I-Disease I-Disease
requiring O O
treatment O O
. O O

Optimal O O
precurarizing O O
dose O O
of O O
rocuronium O O
to O O
decrease O O
fasciculation B-Disease B-Disease
and O O
myalgia B-Disease B-Disease
following O O
succinylcholine O O
administration O O
. O O

BACKGROUND O O
: O O
Succinylcholine O O
commonly O O
produces O O
frequent O O
adverse O O
effects O O
, O O
including O O
muscle B-Disease B-Disease
fasciculation I-Disease I-Disease
and O O
myalgia B-Disease B-Disease
. O O

The O O
current O O
study O O
identified O O
the O O
optimal O O
dose O O
of O O
rocuronium O O
to O O
prevent O O
succinylcholine O O
- O O
induced O O
fasciculation B-Disease B-Disease
and O O
myalgia B-Disease B-Disease
and O O
evaluated O O
the O O
influence O O
of O O
rocuronium O O
on O O
the O O
speed O O
of O O
onset O O
produced O O
by O O
succinylcholine O O
. O O

METHODS O O
: O O
This O O
randomized O O
, O O
double O O
- O O
blinded O O
study O O
was O O
conducted O O
in O O
100 O O
patients O O
randomly O O
allocated O O
into O O
five O O
groups O O
of O O
20 O O
patients O O
each O O
. O O

Patients O O
were O O
randomized O O
to O O
receive O O
0.02 O O
, O O
0.03 O O
, O O
0.04 O O
, O O
0.05 O O
and O O
0.06 O O
mg O O
/ O O
kg O O
rocuronium O O
as O O
a O O
precurarizing O O
dose O O
. O O

Neuromuscular O O
monitoring O O
after O O
each O O
precurarizing O O
dose O O
was O O
recorded O O
from O O
the O O
adductor O O
pollicis O O
muscle O O
using O O
acceleromyography O O
with O O
train O O
- O O
of O O
- O O
four O O
stimulation O O
of O O
the O O
ulnar O O
nerve O O
. O O

All O O
patients O O
received O O
succinylcholine O O
1.5 O O
mg O O
/ O O
kg O O
at O O
2 O O
minutes O O
after O O
the O O
precurarization O O
, O O
and O O
were O O
assessed O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculations B-Disease B-Disease
, O O
while O O
myalgia B-Disease B-Disease
was O O
assessed O O
at O O
24 O O
hours O O
after O O
surgery O O
. O O

RESULTS O O
: O O
The O O
incidence O O
and O O
severity O O
of O O
visible O O
muscle B-Disease B-Disease
fasciculation I-Disease I-Disease
was O O
significantly O O
less O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

Those O O
of O O
myalgia B-Disease B-Disease
tend O O
to O O
decrease O O
according O O
to O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
, O O
but O O
there O O
was O O
no O O
significance O O
( O O
P O O
= O O
0.072 O O
) O O
. O O

The O O
onset O O
time O O
of O O
succinylcholine O O
was O O
significantly O O
longer O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Precurarization O O
with O O
0.04 O O
mg O O
/ O O
kg O O
rocuronium O O
was O O
the O O
optimal O O
dose O O
considering O O
the O O
reduction O O
in O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculation B-Disease B-Disease
and O O
myalgia B-Disease B-Disease
with O O
acceptable O O
onset O O
time O O
, O O
and O O
the O O
safe O O
and O O
effective O O
precurarization O O
. O O

Absence O O
of O O
PKC O O
- O O
alpha O O
attenuates O O
lithium O O
- O O
induced O O
nephrogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
. O O

Lithium O O
, O O
an O O
effective O O
antipsychotic O O
, O O
induces O O
nephrogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
( O O
NDI B-Disease B-Disease
) O O
in O O
40 O O
% O O
of O O
patients O O
. O O

The O O
decreased O O
capacity O O
to O O
concentrate O O
urine O O
is O O
likely O O
due O O
to O O
lithium O O
acutely O O
disrupting O O
the O O
cAMP O O
pathway O O
and O O
chronically O O
reducing O O
urea O O
transporter O O
( O O
UT O O
- O O
A1 O O
) O O
and O O
water O O
channel O O
( O O
AQP2 O O
) O O
expression O O
in O O
the O O
inner O O
medulla O O
. O O

Targeting O O
an O O
alternative O O
signaling O O
pathway O O
, O O
such O O
as O O
PKC O O
- O O
mediated O O
signaling O O
, O O
may O O
be O O
an O O
effective O O
method O O
of O O
treating O O
lithium O O
- O O
induced O O
polyuria B-Disease B-Disease
. O O

PKC O O
- O O
alpha O O
null O O
mice O O
( O O
PKCa O O
KO O O
) O O
and O O
strain O O
- O O
matched O O
wild O O
type O O
( O O
WT O O
) O O
controls O O
were O O
treated O O
with O O
lithium O O
for O O
0 O O
, O O
3 O O
or O O
5 O O
days O O
. O O

WT O O
mice O O
had O O
increased O O
urine O O
output O O
and O O
lowered O O
urine O O
osmolality O O
after O O
3 O O
and O O
5 O O
days O O
of O O
treatment O O
whereas O O
PKCa O O
KO O O
mice O O
had O O
no O O
change O O
in O O
urine O O
output O O
or O O
concentration O O
. O O

Western O O
blot O O
analysis O O
revealed O O
that O O
AQP2 O O
expression O O
in O O
medullary O O
tissues O O
was O O
lowered O O
after O O
3 O O
and O O
5 O O
days O O
in O O
WT O O
mice O O
; O O
however O O
, O O
AQP2 O O
was O O
unchanged O O
in O O
PKCa O O
KO O O
. O O

Similar O O
results O O
were O O
observed O O
with O O
UT O O
- O O
A1 O O
expression O O
. O O

Animals O O
were O O
also O O
treated O O
with O O
lithium O O
for O O
6 O O
weeks O O
. O O

Lithium O O
- O O
treated O O
WT O O
mice O O
had O O
19-fold O O
increased O O
urine O O
output O O
whereas O O
treated O O
PKCa O O
KO O O
animals O O
had O O
a O O
4-fold O O
increase O O
in O O
output O O
. O O

AQP2 O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
lowered O O
in O O
6 O O
week O O
lithium O O
- O O
treated O O
WT O O
animals O O
whereas O O
in O O
treated O O
PKCa O O
KO O O
mice O O
, O O
AQP2 O O
was O O
only O O
reduced O O
by O O
2-fold O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
unaffected O O
. O O

Urinary O O
sodium O O
, O O
potassium O O
and O O
calcium O O
were O O
elevated O O
in O O
lithium O O
- O O
fed O O
WT O O
but O O
not O O
in O O
lithium O O
- O O
fed O O
PKCa O O
KO O O
mice O O
. O O

Our O O
data O O
show O O
that O O
ablation O O
of O O
PKCa O O
preserves O O
AQP2 O O
and O O
UT O O
- O O
A1 O O
protein O O
expression O O
and O O
localization O O
in O O
lithium O O
- O O
induced O O
NDI B-Disease B-Disease
, O O
and O O
prevents O O
the O O
development O O
of O O
the O O
severe O O
polyuria B-Disease B-Disease
associated O O
with O O
lithium O O
therapy O O
. O O

Is O O
Dysguesia B-Disease B-Disease
Going O O
to O O
be O O
a O O
Rare O O
or O O
a O O
Common O O
Side O O
- O O
effect O O
of O O
Amlodipine O O
? O O

A O O
very O O
rare O O
side O O
- O O
effect O O
of O O
amlodipine O O
is O O
dysguesia B-Disease B-Disease
. O O

A O O
review O O
of O O
the O O
literature O O
produced O O
only O O
one O O
case O O
. O O

We O O
report O O
a O O
case O O
about O O
a O O
female O O
with O O
essential O B-Disease
hypertension B-Disease I-Disease
on O O
drug O O
treatment O O
with O O
amlodipine O O
developed O O
loss B-Disease B-Disease
of I-Disease I-Disease
taste I-Disease I-Disease
sensation I-Disease I-Disease
. O O

Condition O O
moderately O O
improved O O
on O O
stoppage O O
of O O
the O O
drug O O
for O O
25 O O
days O O
. O O

We O O
conclude O O
that O O
amlodipine O O
can O O
cause O O
dysguesia B-Disease B-Disease
. O O

Here O O
, O O
we O O
describe O O
the O O
clinical O O
presentation O O
and O O
review O O
the O O
relevant O O
literature O O
on O O
amlodipine O O
and O O
dysguesia B-Disease B-Disease
. O O

Rhabdomyolysis B-Disease B-Disease
in O O
association O O
with O O
simvastatin O O
and O O
dosage O O
increment O O
in O O
clarithromycin O O
. O O

Clarithromycin O O
is O O
the O O
most O O
documented O O
cytochrome O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
inhibitor O O
to O O
cause O O
an O O
adverse O O
interaction O O
with O O
simvastatin O O
. O O

This O O
particular O O
case O O
is O O
of O O
interest O O
as O O
rhabdomyolysis B-Disease B-Disease
only O O
occurred O O
after O O
an O O
increase O O
in O O
the O O
dose O O
of O O
clarithromycin O O
. O O

The O O
patient O O
developed O O
raised O O
cardiac O O
biomarkers O O
without O O
any O O
obvious O O
cardiac O O
issues O O
, O O
a O O
phenomenon O O
that O O
has O O
been O O
linked O O
to O O
rhabdomyolysis B-Disease B-Disease
previously O O
. O O

To O O
date O O
, O O
there O O
has O O
been O O
no O O
reported O O
effect O O
of O O
rhabdomyolysis B-Disease B-Disease
on O O
the O O
structure O O
and O O
function O O
of O O
cardiac O O
muscle O O
. O O

Clinicians O O
need O O
to O O
be O O
aware O O
of O O
prescribing O O
concomitant O O
medications O O
that O O
increase O O
the O O
risk O O
of O O
myopathy B-Disease B-Disease
or O O
inhibit O O
the O O
CYP3A4 O O
enzyme O O
. O O

Our O O
case O O
suggests O O
that O O
troponin O O
elevation O O
could O O
be O O
associated O O
with O O
statin O O
induced O O
rhabdomyolysis B-Disease B-Disease
, O O
which O O
may O O
warrant O O
further O O
studies O O
. O O

Characterization O O
of O O
a O O
novel O O
BCHE O O
" O O
silent O O
" O O
allele O O
: O O
point O O
mutation O O
( O O
p. O O

Val204Asp O O
) O O
causes O O
loss O O
of O O
activity O O
and O O
prolonged O O
apnea B-Disease B-Disease
with O O
suxamethonium O O
. O O

Butyrylcholinesterase B-Disease B-Disease
deficiency I-Disease I-Disease
is O O
characterized O O
by O O
prolonged O O
apnea B-Disease B-Disease
after O O
the O O
use O O
of O O
muscle O O
relaxants O O
( O O
suxamethonium O O
or O O
mivacurium O O
) O O
in O O
patients O O
who O O
have O O
mutations O O
in O O
the O O
BCHE O O
gene O O
. O O

Here O O
, O O
we O O
report O O
a O O
case O O
of O O
prolonged O O
neuromuscular O B-Disease
block O I-Disease
after O O
administration O O
of O O
suxamethonium O O
leading O O
to O O
the O O
discovery O O
of O O
a O O
novel O O
BCHE O O
variant O O
( O O
c.695T O O
> O O
A O O
, O O
p. O O

Val204Asp O O
) O O
. O O

Inhibition O O
studies O O
, O O
kinetic O O
analysis O O
and O O
molecular O O
dynamics O O
were O O
undertaken O O
to O O
understand O O
how O O
this O O
mutation O O
disrupts O O
the O O
catalytic O O
triad O O
and O O
determines O O
a O O
" O O
silent O O
" O O
phenotype O O
. O O

Low O O
activity O O
of O O
patient O O
plasma O O
butyrylcholinesterase O O
with O O
butyrylthiocholine O O
( O O
BTC O O
) O O
and O O
benzoylcholine O O
, O O
and O O
values O O
of O O
dibucaine O O
and O O
fluoride O O
numbers O O
fit O O
with O O
heterozygous O O
atypical O O
silent O O
genotype O O
. O O

Electrophoretic O O
analysis O O
of O O
plasma O O
BChE O O
of O O
the O O
proband O O
and O O
his O O
mother O O
showed O O
that O O
patient O O
has O O
a O O
reduced O O
amount O O
of O O
tetrameric O O
enzyme O O
in O O
plasma O O
and O O
that O O
minor O O
fast O O
- O O
moving O O
BChE O O
components O O
: O O
monomer O O
, O O
dimer O O
, O O
and O O
monomer O O
- O O
albumin O O
conjugate O O
are O O
missing O O
. O O

Kinetic O O
analysis O O
showed O O
that O O
the O O
p. O O

Val204Asp O O
/ O O
p O O
. O O

Asp70Gly O O
- O O
p O O
. O O

Ala539Thr O O
BChE O O
displays O O
a O O
pure O O
Michaelian O O
behavior O O
with O O
BTC O O
as O O
the O O
substrate O O
. O O

Both O O
catalytic O O
parameters O O
Km O O
= O O
265 O O
uM O O
for O O
BTC O O
, O O
two O O
times O O
higher O O
than O O
that O O
of O O
the O O
atypical O O
enzyme O O
, O O
and O O
a O O
low O O
Vmax O O
are O O
consistent O O
with O O
the O O
absence O O
of O O
activity O O
against O O
suxamethonium O O
. O O

Molecular O O
dynamic O O
( O O
MD O O
) O O
simulations O O
showed O O
that O O
the O O
overall O O
effect O O
of O O
the O O
mutation O O
p. O O

Val204Asp O O
is O O
disruption O O
of O O
hydrogen O O
bonding O O
between O O
Gln223 O O
and O O
Glu441 O O
, O O
leading O O
Ser198 O O
and O O
His438 O O
to O O
move O O
away O O
from O O
each O O
other O O
with O O
subsequent O O
disruption O O
of O O
the O O
catalytic O O
triad O O
functionality O O
regardless O O
of O O
the O O
type O O
of O O
substrate O O
. O O

MD O O
also O O
showed O O
that O O
the O O
enzyme O O
volume O O
is O O
increased O O
, O O
suggesting O O
a O O
pre O O
- O O
denaturation O O
state O O
. O O

This O O
fits O O
with O O
the O O
reduced O O
concentration O O
of O O
p. O O

Ala204Asp O O
/ O O
p O O
. O O

Asp70Gly O O
- O O
p O O
. O O

Ala539Thr O O
tetrameric O O
enzyme O O
in O O
the O O
plasma O O
and O O
non O O
- O O
detectable O O
fast O O
moving O O
- O O
bands O O
on O O
electrophoresis O O
gels O O
. O O

Delayed O O
anemia B-Disease B-Disease
after O O
treatment O O
with O O
injectable O O
artesunate O O
in O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
: O O
a O O
manageable O O
issue O O
. O O

Cases O O
of O O
delayed O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
have O O
been O O
described O O
after O O
treatment O O
with O O
injectable O O
artesunate O O
, O O
the O O
current O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
-recommended O O
first O O
- O O
line O O
drug O O
for O O
the O O
treatment O O
of O O
severe O O
malaria B-Disease B-Disease
. O O

A O O
total O O
of O O
350 O O
patients O O
( O O
215 O O
[ O O
61.4 O O
% O O
] O O
< O O
5 O O
years O O
of O O
age O O
and O O
135 O O
[ O O
38.6 O O
% O O
] O O
> O O
5 O O
years O O
of O O
age O O
) O O
were O O
followed O O
- O O
up O O
after O O
treatment O O
with O O
injectable O O
artesunate O O
for O O
severe O O
malaria B-Disease B-Disease
in O O
hospitals O O
and O O
health O O
centers O O
of O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
. O O

Complete O O
series O O
of O O
hemoglobin O O
( O O
Hb O O
) O O
measurements O O
were O O
available O O
for O O
201 O O
patients O O
. O O

A O O
decrease O O
in O O
Hb O O
levels O O
between O O
2 O O
and O O
5 O O
g O O
/ O O
dL O O
was O O
detected O O
in O O
23 O O
( O O
11.4 O O
% O O
) O O
patients O O
during O O
the O O
follow O O
- O O
up O O
period O O
. O O

For O O
five O O
patients O O
, O O
Hb O O
levels O O
decreased O O
below O O
5 O O
g O O
/ O O
dL O O
during O O
at O O
least O O
one O O
follow O O
- O O
up O O
visit O O
. O O

All O O
cases O O
of O O
delayed O O
anemia B-Disease B-Disease
were O O
clinically O O
manageable O O
and O O
resolved O O
within O O
one O O
month O O
. O O

Regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
and O O
apoptotic O O
pathways O O
by O O
betaine O O
attenuates O O
isoproterenol O O
- O O
induced O O
acute O O
myocardial B-Disease B-Disease
injury I-Disease I-Disease
in O O
rats O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
cardioprotective O O
effects O O
of O O
betaine O O
on O O
acute O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
induced O O
experimentally O O
in O O
rats O O
focusing O O
on O O
regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
( O O
STAT3 O O
) O O
and O O
apoptotic O O
pathways O O
as O O
the O O
potential O O
mechanism O O
underlying O O
the O O
drug O O
effect O O
. O O

Male O O
Sprague O O
Dawley O O
rats O O
were O O
treated O O
with O O
betaine O O
( O O
100 O O
, O O
200 O O
, O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
orally O O
for O O
40 O O
days O O
. O O

Acute O O
myocardial B-Disease B-Disease
ischemic I-Disease I-Disease
injury I-Disease I-Disease
was O O
induced O O
in O O
rats O O
by O O
subcutaneous O O
injection O O
of O O
isoproterenol O O
( O O
85 O O
mg O O
/ O O
kg O O
) O O
, O O
for O O
two O O
consecutive O O
days O O
. O O

Serum O O
cardiac O O
marker O O
enzyme O O
, O O
histopathological O O
variables O O
and O O
expression O O
of O O
protein O O
levels O O
were O O
analyzed O O
. O O

Oral O O
administration O O
of O O
betaine O O
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
significantly O O
reduced O O
the O O
level O O
of O O
cardiac O O
marker O O
enzyme O O
in O O
the O O
serum O O
and O O
prevented O O
left O O
ventricular B-Disease O
remodeling I-Disease O
. O O

Western O O
blot O O
analysis O O
showed O O
that O O
isoproterenol O O
- O O
induced O O
phosphorylation O O
of O O
STAT3 O O
was O O
maintained O O
or O O
further O O
enhanced O O
by O O
betaine O O
treatment O O
in O O
myocardium O O
. O O

Furthermore O O
, O O
betaine O O
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
treatment O O
increased O O
the O O
ventricular O O
expression O O
of O O
Bcl-2 O O
and O O
reduced O O
the O O
level O O
of O O
Bax O O
, O O
therefore O O
causing O O
a O O
significant O O
increase O O
in O O
the O O
ratio O O
of O O
Bcl-2 O O
/ O O
Bax O O
. O O

The O O
protective O O
role O O
of O O
betaine O O
on O O
myocardial B-Disease B-Disease
damage I-Disease I-Disease
was O O
further O O
confirmed O O
by O O
histopathological O O
examination O O
. O O

In O O
summary O O
, O O
our O O
results O O
showed O O
that O O
betaine O O
pretreatment O O
attenuated O O
isoproterenol O O
- O O
induced O O
acute O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
via O O
the O O
regulation O O
of O O
STAT3 O O
and O O
apoptotic O O
pathways O O
. O O

Quetiapine O O
- O O
induced O O
neutropenia B-Disease B-Disease
in O O
a O O
bipolar B-Disease B-Disease
patient O O
with O O
hepatocellular B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
Quetiapine O O
is O O
a O O
dibenzothiazepine O O
derivative O O
, O O
similar O O
to O O
clozapine O O
, O O
which O O
has O O
the O O
highest O O
risk O O
of O O
causing O O
blood B-Disease B-Disease
dyscrasias I-Disease I-Disease
, O O
especially O O
neutropenia B-Disease B-Disease
. O O

There O O
are O O
some O O
case O O
reports O O
about O O
this O O
side O O
effect O O
of O O
quetiapine O O
, O O
but O O
possible O O
risk O O
factors O O
are O O
seldom O O
discussed O O
and O O
identified O O
. O O

A O O
case O O
of O O
a O O
patient O O
with O O
hepatocellular B-Disease B-Disease
carcinoma I-Disease I-Disease
that O O
developed O O
neutropenia B-Disease B-Disease
after O O
treatment O O
with O O
quetiapine O O
is O O
described O O
here O O
. O O

CASE O O
REPORT O O
: O O
A O O
62-year O O
- O O
old O O
Taiwanese O O
widow O O
with O O
bipolar B-Disease B-Disease
disorder I-Disease I-Disease
was O O
diagnosed O O
with O O
hepatocellular B-Disease B-Disease
carcinoma I-Disease I-Disease
at O O
age O O
60 O O
. O O

She O O
developed O O
leucopenia B-Disease B-Disease
after O O
being O O
treated O O
with O O
quetiapine O O
. O O

After O O
quetiapine O O
was O O
discontinued O O
, O O
her O O
white O O
blood O O
cell O O
count O O
returned O O
to O O
normal O O
. O O

CONCLUSIONS O O
: O O
Although O O
neutropenia B-Disease B-Disease
is O O
not O O
a O O
common O O
side O O
effect O O
of O O
quetiapine O O
, O O
physicians O O
should O O
be O O
cautious O O
about O O
its O O
presentation O O
and O O
associated O O
risk O O
factors O O
. O O

Hepatic B-Disease B-Disease
dysfunction I-Disease I-Disease
may O O
be O O
one O O
of O O
the O O
possible O O
risk O O
factors O O
, O O
and O O
concomitant O O
fever B-Disease B-Disease
may O O
be O O
a O O
diagnostic O O
marker O O
for O O
adverse O O
reaction O O
to O O
quetiapine O O
. O O

Lateral O O
antebrachial O O
cutaneous O B-Disease
neuropathy B-Disease I-Disease
after O O
steroid O O
injection O O
at O O
lateral O O
epicondyle O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
This O O
report O O
aimed O O
to O O
present O O
a O O
case O O
of O O
lateral O B-Disease
antebrachial O I-Disease
cutaneous O I-Disease
neuropathy B-Disease I-Disease
( O O
LACNP O B-Disease
) O O
that O O
occurred O O
after O O
a O O
steroid O O
injection O O
in O O
the O O
lateral O O
epicondyle O O
to O O
treat O O
lateral B-Disease B-Disease
epicondylitis I-Disease I-Disease
in O O
a O O
40-year O O
- O O
old O O
woman O O
. O O

MATERIAL O O
AND O O
METHOD O O
: O O
A O O
40-year O O
- O O
old O O
woman O O
presented O O
with O O
decreased O O
sensation O O
and O O
paresthesia B-Disease B-Disease
over O O
her O O
right O O
lateral O O
forearm O O
; O O
the O O
paresthesia B-Disease B-Disease
had O O
occurred O O
after O O
a O O
steroid O O
injection O O
in O O
the O O
right O O
lateral O O
epicondyle O O
3 O O
months O O
before O O
. O O

Her O O
sensation O O
of O O
light O O
touch O O
and O O
pain B-Disease B-Disease
was O O
diminished O O
over O O
the O O
lateral O O
side O O
of O O
the O O
right O O
forearm O O
and O O
wrist O O
area O O
. O O

RESULTS O O
: O O
The O O
sensory O O
action O O
potential O O
amplitude O O
of O O
the O O
right O O
lateral O O
antebrachial O O
cutaneous O O
nerve O O
( O O
LACN O O
) O O
( O O
6.2 O O
uV O O
) O O
was O O
lower O O
than O O
that O O
of O O
the O O
left O O
( O O
13.1 O O
uV O O
) O O
. O O

The O O
difference O O
of O O
amplitude O O
between O O
both O O
sides O O
was O O
significant O O
because O O
there O O
was O O
more O O
than O O
a O O
50 O O
% O O
reduction O O
. O O

She O O
was O O
diagnosed O O
with O O
right O O
LACNP O O
( O O
mainly O O
axonal O O
involvement O O
) O O
on O O
the O O
basis O O
of O O
the O O
clinical O O
manifestation O O
and O O
the O O
electrodiagnostic O O
findings O O
. O O

Her O O
symptoms O O
improved O O
through O O
physical O O
therapy O O
but O O
persisted O O
to O O
some O O
degree O O
. O O

CONCLUSION O O
: O O
This O O
report O O
describes O O
the O O
case O O
of O O
a O O
woman O O
with O O
LACNP O B-Disease
that O O
developed O O
after O O
a O O
steroid O O
injection O O
for O O
the O O
treatment O O
of O O
lateral B-Disease B-Disease
epicondylitis I-Disease I-Disease
. O O

An O O
electrodiagnostic O O
study O O
, O O
including O O
a O O
nerve O O
conduction O O
study O O
of O O
the O O
LACN O O
, O O
was O O
helpful O O
to O O
diagnose O O
right O O
LACNP O O
and O O
to O O
find O O
the O O
passage O O
of O O
the O O
LACN O O
on O O
the O O
lateral O O
epicondyle O O
. O O

Curcumin O O
prevents O O
maleate O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
: O O
relation O O
to O O
hemodynamic O O
alterations O O
, O O
oxidative O O
stress O O
, O O
mitochondrial O O
oxygen O O
consumption O O
and O O
activity O O
of O O
respiratory O O
complex O O
I. O O
The O O
potential O O
protective O O
effect O O
of O O
the O O
dietary O O
antioxidant O O
curcumin O O
( O O
120 O O
mg O O
/ O O
Kg O O
/ O O
day O O
for O O
6 O O
days O O
) O O
against O O
the O O
renal B-Disease B-Disease
injury I-Disease I-Disease
induced O O
by O O
maleate O O
was O O
evaluated O O
. O O

Tubular O O
proteinuria B-Disease B-Disease
and O O
oxidative O O
stress O O
were O O
induced O O
by O O
a O O
single O O
injection O O
of O O
maleate O O
( O O
400 O O
mg O O
/ O O
kg O O
) O O
in O O
rats O O
. O O

Maleate O O
- O O
induced O O
renal B-Disease B-Disease
injury I-Disease I-Disease
included O O
increase O O
in O O
renal O O
vascular O O
resistance O O
and O O
in O O
the O O
urinary O O
excretion O O
of O O
total O O
protein O O
, O O
glucose O O
, O O
sodium O O
, O O
neutrophil O O
gelatinase O O
- O O
associated O O
lipocalin O O
( O O
NGAL O O
) O O
and O O
N O O
- O O
acetyl O O
b O O
- O O
D O O
- O O
glucosaminidase O O
( O O
NAG O O
) O O
, O O
upregulation O O
of O O
kidney B-Disease B-Disease
injury I-Disease I-Disease
molecule O O
( O O
KIM O O
) O O
-1 O O
, O O
decrease O O
in O O
renal O O
blood O O
flow O O
and O O
claudin-2 O O
expression O O
besides O O
of O O
necrosis B-Disease B-Disease
and O O
apoptosis O O
of O O
tubular O O
cells O O
on O O
24 O O
h. O O
Oxidative O O
stress O O
was O O
determined O O
by O O
measuring O O
the O O
oxidation O O
of O O
lipids O O
and O O
proteins O O
and O O
diminution O O
in O O
renal O O
Nrf2 O O
levels O O
. O O

Studies O O
were O O
also O O
conducted O O
in O O
renal O O
epithelial O O
LLC O O
- O O
PK1 O O
cells O O
and O O
in O O
mitochondria O O
isolated O O
from O O
kidneys O O
of O O
all O O
the O O
experimental O O
groups O O
. O O

Maleate O O
induced O O
cell O O
damage O O
and O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
production O O
in O O
LLC O O
- O O
PK1 O O
cells O O
in O O
culture O O
. O O

In O O
addition O O
, O O
maleate O O
treatment O O
reduced O O
oxygen O O
consumption O O
in O O
ADP O O
- O O
stimulated O O
mitochondria O O
and O O
diminished O O
respiratory O O
control O O
index O O
when O O
using O O
malate O O
/ O O
glutamate O O
as O O
substrate O O
. O O

The O O
activities O O
of O O
both O O
complex O O
I O O
and O O
aconitase O O
were O O
also O O
diminished O O
. O O

All O O
the O O
above O O
- O O
described O O
alterations O O
were O O
prevented O O
by O O
curcumin O O
. O O

It O O
is O O
concluded O O
that O O
curcumin O O
is O O
able O O
to O O
attenuate O O
in O O
vivo O O
maleate O O
- O O
induced O O
nephropathy B-Disease B-Disease
and O O
in O O
vitro O O
cell O O
damage O O
. O O

The O O
in O O
vivo O O
protection O O
was O O
associated O O
to O O
the O O
prevention O O
of O O
oxidative O O
stress O O
and O O
preservation O O
of O O
mitochondrial O O
oxygen O O
consumption O O
and O O
activity O O
of O O
respiratory O O
complex O O
I O O
, O O
and O O
the O O
in O O
vitro O O
protection O O
was O O
associated O O
to O O
the O O
prevention O O
of O O
ROS O O
production O O
. O O

Anticonvulsant O O
actions O O
of O O
MK-801 O O
on O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
of O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
in O O
rats O O
. O O

MK-801 O O
, O O
a O O
noncompetitive O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
( O O
NMDA O O
) O O
receptor O O
antagonist O O
, O O
was O O
tested O O
for O O
anticonvulsant O O
effects O O
in O O
rats O O
using O O
two O O
seizure B-Disease B-Disease
models O O
, O O
coadministration O O
of O O
lithium O O
and O O
pilocarpine O O
and O O
administration O O
of O O
a O O
high O O
dose O O
of O O
pilocarpine O O
alone O O
. O O

Three O O
major O O
results O O
are O O
reported O O
. O O

First O O
, O O
pretreatment O O
with O O
MK-801 O O
produced O O
an O O
effective O O
and O O
dose O O
- O O
dependent O O
anticonvulsant O O
action O O
with O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
but O O
not O O
with O O
rats O O
treated O O
with O O
pilocarpine O O
alone O O
, O O
suggesting O O
that O O
different O O
biochemical O O
mechanisms O O
control O O
seizures B-Disease B-Disease
in O O
these O O
two O O
models O O
. O O

Second O O
, O O
the O O
anticonvulsant O O
effect O O
of O O
MK-801 O O
in O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
only O O
occurred O O
after O O
initial O O
periods O O
of O O
seizure B-Disease B-Disease
activity O O
. O O

This O O
observation O O
is O O
suggested O O
to O O
be O O
an O O
in O O
vivo O O
demonstration O O
of O O
the O O
conclusion O O
derived O O
from O O
in O O
vitro O O
experiments O O
that O O
MK-801 O O
binding O O
requires O O
agonist O O
- O O
induced O O
opening O O
of O O
the O O
channel O O
sites O O
of O O
the O O
NMDA O O
receptor O O
. O O

Third O O
, O O
although O O
it O O
is O O
relatively O O
easy O O
to O O
block O O
seizures B-Disease B-Disease
induced O O
by O O
lithium O O
and O O
pilocarpine O O
by O O
administration O O
of O O
anticonvulsants O O
prior O O
to O O
pilocarpine O O
, O O
it O O
is O O
more O O
difficult O O
to O O
terminate O O
ongoing O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
and O O
block O O
the O O
lethality O O
of O O
the O O
seizures B-Disease B-Disease
. O O

Administration O O
of O O
MK-801 O O
30 O O
or O O
60 O O
min O O
after O O
pilocarpine O O
, O O
i.e. O O
, O O
during O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
, O O
gradually O O
reduced O O
electrical O O
and O O
behavioral O O
seizure B-Disease B-Disease
activity O O
and O O
greatly O O
enhanced O O
the O O
survival O O
rate O O
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
NMDA O O
receptors O O
plays O O
an O O
important O O
role O O
in O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
and O O
brain B-Disease B-Disease
damage I-Disease I-Disease
in O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
. O O

This O O
was O O
further O O
supported O O
by O O
results O O
showing O O
that O O
nonconvulsive O O
doses O O
of O O
NMDA O O
and O O
pilocarpine O O
were O O
synergistic O O
, O O
resulting O O
in O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
and O O
subsequent O O
mortality O O
. O O

Continuous O O
infusion O O
tobramycin O O
combined O O
with O O
carbenicillin O O
for O O
infections B-Disease B-Disease
in O O
cancer B-Disease B-Disease
patients O O
. O O

The O O
cure O O
rate O O
of O O
infections B-Disease B-Disease
in O O
cancer B-Disease B-Disease
patients O O
is O O
adversely O O
affected O O
by O O
neutropenia B-Disease B-Disease
( O O
less O O
than O O
1,000 O O
/ O O
mm3 O O
) O O
. O O

In O O
particular O O
, O O
patients O O
with O O
severe O O
neutropenia B-Disease B-Disease
( O O
less O O
than O O
100 O O
/ O O
mm3 O O
) O O
have O O
shown O O
a O O
poor O O
response O O
to O O
antibiotics O O
. O O

To O O
overcome O O
the O O
adverse O O
effects O O
of O O
neutropenia B-Disease B-Disease
, O O
tobramycin O O
was O O
given O O
by O O
continuous O O
infusion O O
and O O
combined O O
with O O
intermittent O O
carbenicillin O O
. O O

Tobramycin O O
was O O
given O O
to O O
a O O
total O O
daily O O
dose O O
of O O
300 O O
mg O O
/ O O
m2 O O
and O O
carbenicillin O O
was O O
given O O
at O O
a O O
dose O O
of O O
5 O O
gm O O
every O O
four O O
hours O O
. O O

There O O
were O O
125 O O
infectious O O
episodes O O
in O O
116 O O
cancer B-Disease B-Disease
patients O O
receiving O O
myelosuppressive O O
chemotherapy O O
. O O

The O O
overall O O
cure O O
rate O O
was O O
70 O O
% O O
. O O

Pneumonia B-Disease B-Disease
was O O
the O O
most O O
common O O
infection B-Disease B-Disease
and O O
61 O O
% O O
of O O
59 O O
episodes O O
were O O
cured O O
. O O

Gram O O
- O O
negative O O
bacilli O O
were O O
the O O
most O O
common O O
causative O O
organisms O O
and O O
69 O O
% O O
of O O
these O O
infections B-Disease B-Disease
were O O
cured O O
. O O

The O O
most O O
common O O
pathogen O O
was O O
Klebsiella O O
pneumoniae B-Disease O
and O O
this O O
, O O
together O O
with O O
Escherichia O O
coli O O
and O O
Pseudomonas O O
aeruginosa O O
, O O
accounted O O
for O O
74 O O
% O O
of O O
all O O
gram B-Disease O
- I-Disease O
negative I-Disease O
bacillary I-Disease B-Disease
infections I-Disease I-Disease
. O O

Response O O
was O O
not O O
influenced O O
by O O
the O O
initial O O
neutrophil O O
count O O
, O O
with O O
a O O
62 O O
% O O
cure O O
rate O O
for O O
39 O O
episodes O O
associated O O
with O O
severe O O
neutropenia B-Disease B-Disease
. O O

However O O
, O O
failure O O
of O O
the O O
neutrophil O O
count O O
to O O
increase O O
during O O
therapy O O
adversely O O
affected O O
response O O
. O O

Azotemia B-Disease B-Disease
was O O
the O O
major O O
side O O
effect O O
recognized O O
, O O
and O O
it O O
occurred O O
in O O
11 O O
% O O
of O O
episodes O O
. O O

Major O O
azotemia B-Disease B-Disease
( O O
serum O O
creatinine O O
greater O O
than O O
2.5 O O
mg O O
/ O O
dl O O
or O O
BUN O O
greater O O
than O O
50 O O
mg O O
/ O O
dl O O
) O O
occurred O O
in O O
only O O
2 O O
% O O
. O O

Azotemia B-Disease B-Disease
was O O
not O O
related O O
to O O
duration O O
of O O
therapy O O
or O O
serum O O
tobramycin O O
concentration O O
. O O

This O O
antibiotic O O
regimen O O
showed O O
both O O
therapeutic O O
efficacy O O
and O O
acceptable O O
renal B-Disease B-Disease
toxicity I-Disease I-Disease
for O O
these O O
patients O O
. O O

Incidence O O
of O O
solid O B-Disease
tumours B-Disease I-Disease
among O O
pesticide O O
applicators O O
exposed O O
to O O
the O O
organophosphate O O
insecticide O O
diazinon O O
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
an O O
updated O O
analysis O O
. O O

OBJECTIVE O O
: O O
Diazinon O O
, O O
a O O
common O O
organophosphate O O
insecticide O O
with O O
genotoxic O O
properties O O
, O O
was O O
previously O O
associated O O
with O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
in O O
the O O
Agricultural O O
Health O O
Study O O
( O O
AHS O O
) O O
cohort O O
, O O
but O O
few O O
other O O
epidemiological O O
studies O O
have O O
examined O O
diazinon O O
- O O
associated O O
cancer B-Disease B-Disease
risk O O
. O O

We O O
used O O
updated O O
diazinon O O
exposure O O
and O O
cancer B-Disease B-Disease
incidence O O
information O O
to O O
evaluate O O
solid O O
tumour B-Disease B-Disease
risk O O
in O O
the O O
AHS O O
. O O

METHODS O O
: O O
Male O O
pesticide O O
applicators O O
in O O
Iowa O O
and O O
North O O
Carolina O O
reported O O
lifetime O O
diazinon O O
use O O
at O O
enrolment O O
( O O
1993 O O
- O O
1997 O O
) O O
and O O
follow O O
- O O
up O O
( O O
1998 O O
- O O
2005 O O
) O O
; O O
cancer B-Disease B-Disease
incidence O O
was O O
assessed O O
through O O
2010 O O
( O O
North O O
Carolina O O
) O O
/ O O
2011 O O
( O O
Iowa O O
) O O
. O O

Among O O
applicators O O
with O O
usage O O
information O O
sufficient O O
to O O
evaluate O O
exposure O O
- O O
response O O
patterns O O
, O O
we O O
used O O
Poisson O O
regression O O
to O O
estimate O O
adjusted O O
rate O O
ratios O O
( O O
RRs O O
) O O
and O O
95 O O
% O O
CI O O
for O O
cancer B-Disease B-Disease
sites O O
with O O
> O O
10 O O
exposed O O
cases O O
for O O
both O O
lifetime O O
( O O
LT O O
) O O
exposure O O
days O O
and O O
intensity O O
- O O
weighted O O
( O O
IW O O
) O O
lifetime O O
exposure O O
days O O
( O O
accounting O O
for O O
factors O O
impacting O O
exposure O O
) O O
. O O

RESULTS O O
: O O
We O O
observed O O
elevated O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
risks O O
( O O
N=283 O O
) O O
among O O
applicators O O
with O O
the O O
greatest O O
number O O
of O O
LT O O
( O O
RR=1.60 O O
; O O
95 O O
% O O
CI O O
1.11 O O
to O O
2.31 O O
; O O
Ptrend=0.02 O O
) O O
and O O
IW O O
days O O
of O O
diazinon O O
use O O
( O O
RR=1.41 O O
; O O
95 O O
% O O
CI O O
0.98 O O
to O O
2.04 O O
; O O
Ptrend=0.08 O O
) O O
. O O

Kidney B-Disease B-Disease
cancer I-Disease I-Disease
( O O
N=94 O O
) O O
risks O O
were O O
non O O
- O O
significantly O O
elevated O O
( O O
RRLT O O
days=1.77 O O
; O O
95 O O
% O O
CI O O
0.90 O O
to O O
3.51 O O
; O O
Ptrend=0.09 O O
; O O
RRIW O O
days O O
1.37 O O
; O O
95 O O
% O O
CI O O
0.64 O O
to O O
2.92 O O
; O O
Ptrend=0.50 O O
) O O
, O O
as O O
were O O
risks O O
for O O
aggressive O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
( O O
N=656 O O
) O O
. O O

CONCLUSIONS O O
: O O
Our O O
updated O O
evaluation O O
of O O
diazinon O O
provides O O
additional O O
evidence O O
of O O
an O O
association O O
with O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
risk O O
. O O

Newly O O
identified O O
links O O
to O O
kidney B-Disease B-Disease
cancer I-Disease I-Disease
and O O
associations O O
with O O
aggressive O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
require O O
further O O
evaluation O O
. O O

Associations O O
of O O
Ozone O O
and O O
PM2.5 O O
Concentrations O O
With O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
Disease I-Disease I-Disease
Among O O
Participants O O
in O O
the O O
Agricultural O O
Health O O
Study O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
describes O O
associations O O
of O O
ozone O O
and O O
fine O O
particulate O O
matter O O
with O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
observed O O
among O O
farmers O O
in O O
North O O
Carolina O O
and O O
Iowa O O
. O O

METHODS O O
: O O
We O O
used O O
logistic O O
regression O O
to O O
determine O O
the O O
associations O O
of O O
these O O
pollutants O O
with O O
self O O
- O O
reported O O
, O O
doctor O O
- O O
diagnosed O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

Daily O O
predicted O O
pollutant O O
concentrations O O
were O O
used O O
to O O
derive O O
surrogates O O
of O O
long O O
- O O
term O O
exposure O O
and O O
link O O
them O O
to O O
study O O
participants O O
' O O
geocoded O O
addresses O O
. O O

RESULTS O O
: O O
We O O
observed O O
positive O O
associations O O
of O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
with O O
ozone O O
( O O
odds O O
ratio O O
= O O
1.39 O O
; O O
95 O O
% O O
CI O O
: O O
0.98 O O
to O O
1.98 O O
) O O
and O O
fine O O
particulate O O
matter O O
( O O
odds O O
ratio O O
= O O
1.34 O O
; O O
95 O O
% O O
CI O O
: O O
0.93 O O
to O O
1.93 O O
) O O
in O O
North O O
Carolina O O
but O O
not O O
in O O
Iowa O O
. O O

CONCLUSIONS O O
: O O
The O O
plausibility O O
of O O
an O O
effect O O
of O O
ambient O O
concentrations O O
of O O
these O O
pollutants O O
on O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
risk O O
is O O
supported O O
by O O
experimental O O
data O O
demonstrating O O
damage O O
to O O
dopaminergic O O
neurons O O
at O O
relevant O O
concentrations O O
. O O

Additional O O
studies O O
are O O
needed O O
to O O
address O O
uncertainties O O
related O O
to O O
confounding O O
and O O
to O O
examine O O
temporal O O
aspects O O
of O O
the O O
associations O O
we O O
observed O O
. O O

Low O O
functional O O
programming O O
of O O
renal O O
AT2R O O
mediates O O
the O O
developmental O O
origin O O
of O O
glomerulosclerosis B-Disease B-Disease
in O O
adult O O
offspring O O
induced O O
by O O
prenatal O O
caffeine O O
exposure O O
. O O

UNASSIGNED O O
: O O
Our O O
previous O O
study O O
has O O
indicated O O
that O O
prenatal O O
caffeine O O
exposure O O
( O O
PCE O O
) O O
could O O
induce O O
intrauterine B-Disease B-Disease
growth I-Disease I-Disease
retardation I-Disease I-Disease
( O O
IUGR B-Disease B-Disease
) O O
of O O
offspring O O
. O O

Recent O O
research O O
suggested O O
that O O
IUGR B-Disease B-Disease
is O O
a O O
risk O O
factor O O
for O O
glomerulosclerosis B-Disease B-Disease
. O O

However O O
, O O
whether O O
PCE O O
could O O
induce O O
glomerulosclerosis B-Disease B-Disease
and O O
its O O
underlying O O
mechanisms O O
remain O O
unknown O O
. O O

This O O
study O O
aimed O O
to O O
demonstrate O O
the O O
induction O O
to O O
glomerulosclerosis B-Disease B-Disease
in O O
adult O O
offspring O O
by O O
PCE O O
and O O
its O O
intrauterine O O
programming O O
mechanisms O O
. O O

A O O
rat O O
model O O
of O O
IUGR B-Disease B-Disease
was O O
established O O
by O O
PCE O O
, O O
male O O
fetuses O O
and O O
adult O O
offspring O O
at O O
the O O
age O O
of O O
postnatal O O
week O O
24 O O
were O O
euthanized O O
. O O

The O O
results O O
revealed O O
that O O
the O O
adult O O
offspring O O
kidneys O O
in O O
the O O
PCE O O
group O O
exhibited O O
glomerulosclerosis B-Disease B-Disease
as O O
well O O
as O O
interstitial B-Disease O
fibrosis I-Disease B-Disease
, O O
accompanied O O
by O O
elevated O O
levels O O
of O O
serum O O
creatinine O O
and O O
urine O O
protein O O
. O O

Renal O O
angiotensin O O
II O O
receptor O O
type O O
2 O O
( O O
AT2R O O
) O O
gene O O
expression O O
in O O
adult O O
offspring O O
was O O
reduced O O
by O O
PCE O O
, O O
whereas O O
the O O
renal O O
angiotensin O O
II O O
receptor O O
type O O
1a O O
( O O
AT1aR O O
) O O
/ O O
AT2R O O
expression O O
ratio O O
was O O
increased O O
. O O

The O O
fetal O O
kidneys O O
in O O
the O O
PCE O O
group O O
displayed O O
an O O
enlarged O O
Bowman O O
's O O
space O O
and O O
a O O
shrunken O O
glomerular O O
tuft O O
, O O
accompanied O O
by O O
a O O
reduced O O
cortex O O
width O O
and O O
an O O
increase O O
in O O
the O O
nephrogenic O O
zone O O
/ O O
cortical O O
zone O O
ratio O O
. O O

Observation O O
by O O
electronic O O
microscope O O
revealed O O
structural O O
damage O O
of O O
podocytes O O
; O O
the O O
reduced O O
expression O O
level O O
of O O
podocyte O O
marker O O
genes O O
, O O
nephrin O O
and O O
podocin O O
, O O
was O O
also O O
detected O O
by O O
q O O
- O O
PCR O O
. O O

Moreover O O
, O O
AT2R O O
gene O O
and O O
protein O O
expressions O O
in O O
fetal O O
kidneys O O
were O O
inhibited O O
by O O
PCE O O
, O O
associated O O
with O O
the O O
repression O O
of O O
the O O
gene O O
expression O O
of O O
glial O O
- O O
cell O O
- O O
line O O
- O O
derived O O
neurotrophic O O
factor O O
( O O
GDNF O O
) O O
/ O O
tyrosine O O
kinase O O
receptor O O
( O O
c O O
- O O
Ret O O
) O O
signaling O O
pathway O O
. O O

These O O
results O O
demonstrated O O
that O O
PCE O O
could O O
induce O O
dysplasia B-Disease B-Disease
of I-Disease I-Disease
fetal I-Disease I-Disease
kidneys I-Disease I-Disease
as O O
well O O
as O O
glomerulosclerosis B-Disease B-Disease
of O O
adult O O
offspring O O
, O O
and O O
the O O
low O O
functional O O
programming O O
of O O
renal O O
AT2R O O
might O O
mediate O O
the O O
developmental O O
origin O O
of O O
adult O O
glomerulosclerosis B-Disease B-Disease
. O O

1,3-Butadiene O O
, O O
CML B-Disease B-Disease
and O O
the O O
t O O
( O O
9:22 O O
) O O
translocation O O
: O O
A O O
reality O O
check O O
. O O

UNASSIGNED O O
: O O
Epidemiological O O
studies O O
of O O
1,3-butadiene O O
have O O
suggest O O
that O O
exposures O O
to O O
humans O O
are O O
associated O O
with O O
chronic B-Disease B-Disease
myeloid I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
CML B-Disease B-Disease
) O O
. O O

CML B-Disease B-Disease
has O O
a O O
well O O
- O O
documented O O
association O O
with O O
ionizing O O
radiation O O
, O O
but O O
reports O O
of O O
associations O O
with O O
chemical O O
exposures O O
have O O
been O O
questioned O O
. O O

Ionizing O O
radiation O O
is O O
capable O O
of O O
inducing O O
the O O
requisite O O
CML B-Disease B-Disease
- O O
associated O O
t O O
( O O
9:22 O O
) O O
translocation O O
( O O
Philadelphia B-Disease O
chromosome I-Disease O
) O O
in O O
appropriate O O
cells O O
in O O
vitro O O
but O O
, O O
thus O O
far O O
, O O
chemicals O O
have O O
not O O
shown O O
this O O
capacity O O
. O O

We O O
have O O
proposed O O
that O O
1,3-butadiene O O
metabolites O O
be O O
so O O
tested O O
as O O
a O O
reality O O
check O O
on O O
the O O
epidemiological O O
reports O O
. O O

In O O
order O O
to O O
conduct O O
reliable O O
testing O O
in O O
this O O
regard O O
, O O
it O O
is O O
essential O O
that O O
a O O
positive O O
control O O
for O O
induction O O
be O O
available O O
. O O

We O O
have O O
used O O
ionizing O O
radiation O O
to O O
develop O O
such O O
a O O
control O O
. O O

Results O O
described O O
here O O
demonstrate O O
that O O
this O O
agent O O
does O O
in O O
fact O O
induce O O
pathogenic O O
t O O
( O O
9:22 O O
) O O
translocations O O
in O O
a O O
human O O
myeloid O O
cell O O
line O O
in O O
vitro O O
, O O
but O O
does O O
so O O
at O O
low O O
frequencies O O
. O O

Conditions O O
that O O
will O O
be O O
required O O
for O O
studies O O
of O O
1,3-butadiene O O
are O O
discussed O O
. O O

Cancer B-Disease B-Disease
incidence O O
and O O
metolachlor O O
use O O
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
An O O
update O O
. O O

UNASSIGNED O O
: O O
Metolachlor O O
, O O
a O O
widely O O
used O O
herbicide O O
, O O
is O O
classified O O
as O O
a O O
Group O O
C O O
carcinogen O O
by O O
the O O
U.S. O O
Environmental O O
Protection O O
Agency O O
based O O
on O O
increased O O
liver B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
female O O
rats O O
. O O

Epidemiologic O O
studies O O
of O O
the O O
health O O
effects O O
of O O
metolachlor O O
have O O
been O O
limited O O
. O O

The O O
Agricultural O O
Health O O
Study O O
( O O
AHS O O
) O O
is O O
a O O
prospective O O
cohort O O
study O O
including O O
licensed O O
private O O
and O O
commercial O O
pesticide O O
applicators O O
in O O
Iowa O O
and O O
North O O
Carolina O O
enrolled O O
1993 O O
- O O
1997 O O
. O O

We O O
evaluated O O
cancer B-Disease B-Disease
incidence O O
through O O
2010 O O
/ O O
2011 O O
( O O
NC O O
/ O O
IA O O
) O O
for O O
49,616 O O
applicators O O
, O O
53 O O
% O O
of O O
whom O O
reported O O
ever O O
using O O
metolachlor O O
. O O

We O O
used O O
Poisson O O
regression O O
to O O
evaluate O O
relations O O
between O O
two O O
metrics O O
of O O
metolachlor O O
use O O
( O O
lifetime O O
days O O
, O O
intensity O O
- O O
weighted O O
lifetime O O
days O O
) O O
and O O
cancer B-Disease B-Disease
incidence O O
. O O

We O O
saw O O
no O O
association O O
between O O
metolachlor O O
use O O
and O O
incidence O O
of O O
all O O
cancers B-Disease B-Disease
combined O O
( O O
n O O
= O O
5,701 O O
with O O
a O O
5-year O O
lag O O
) O O
or O O
most O O
site O O
- O O
specific O O
cancers B-Disease B-Disease
. O O

For O O
liver B-Disease B-Disease
cancer I-Disease I-Disease
, O O
in O O
analyses O O
restricted O O
to O O
exposed O O
workers O O
, O O
elevations O O
observed O O
at O O
higher O O
categories O O
of O O
use O O
were O O
not O O
statistically O O
significant O O
. O O

However O O
, O O
trends O O
for O O
both O O
lifetime O O
and O O
intensity O O
- O O
weighted O O
lifetime O O
days O O
of O O
metolachor O O
use O O
were O O
positive O O
and O O
statistically O O
significant O O
with O O
an O O
unexposed O O
reference O O
group O O
. O O

A O O
similar O O
pattern O O
was O O
observed O O
for O O
follicular B-Disease B-Disease
cell I-Disease I-Disease
lymphoma I-Disease I-Disease
, O O
but O O
no O O
other O O
lymphoma B-Disease B-Disease
subtypes O O
. O O

An O O
earlier O O
suggestion O O
of O O
increased O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
risk O O
at O O
high O O
levels O O
of O O
metolachlor O O
use O O
in O O
this O O
cohort O O
was O O
not O O
confirmed O O
in O O
this O O
update O O
. O O

This O O
suggestion O O
of O O
an O O
association O O
between O O
metolachlor O O
and O O
liver B-Disease B-Disease
cancer I-Disease I-Disease
among O O
pesticide O O
applicators O O
is O O
a O O
novel O O
finding O O
and O O
echoes O O
observation O O
of O O
increased O O
liver B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
some O O
animal O O
studies O O
. O O

However O O
, O O
our O O
findings O O
for O O
both O O
liver B-Disease B-Disease
cancer I-Disease I-Disease
and O O
follicular O B-Disease
cell O I-Disease
lymphoma B-Disease I-Disease
warrant O O
follow O O
- O O
up O O
to O O
better O O
differentiate O O
effects O O
of O O
metolachlor O O
use O O
from O O
other O O
factors O O
. O O

Mechanisms O O
Underlying O O
Latent O O
Disease O O
Risk O O
Associated O O
with O O
Early O O
- O O
Life O O
Arsenic O O
Exposure O O
: O O
Current O O
Research O O
Trends O O
and O O
Scientific O O
Gaps O O
. O O

BACKGROUND O O
: O O
Millions O O
of O O
individuals O O
worldwide O O
, O O
particularly O O
those O O
living O O
in O O
rural O O
and O O
developing O O
areas O O
, O O
are O O
exposed O O
to O O
harmful O O
levels O O
of O O
inorganic O O
arsenic O O
( O O
iAs O O
) O O
in O O
their O O
drinking O O
water O O
. O O

Inorganic O O
As O O
exposure O O
during O O
key O O
developmental O O
periods O O
is O O
associated O O
with O O
a O O
variety O O
of O O
adverse O O
health O O
effects O O
including O O
those O O
that O O
are O O
evident O O
in O O
adulthood O O
. O O

There O O
is O O
considerable O O
interest O O
in O O
identifying O O
the O O
molecular O O
mechanisms O O
that O O
relate O O
early O O
- O O
life O O
iAs O O
exposure O O
to O O
the O O
development O O
of O O
these O O
latent O O
diseases O O
, O O
particularly O O
in O O
relationship O O
to O O
cancer B-Disease B-Disease
. O O

OBJECTIVES O O
: O O
This O O
work O O
summarizes O O
research O O
on O O
the O O
molecular O O
mechanisms O O
that O O
underlie O O
the O O
increased O O
risk O O
of O O
cancer B-Disease B-Disease
development O O
in O O
adulthood O O
that O O
is O O
associated O O
with O O
early O O
- O O
life O O
iAs O O
exposure O O
. O O

DISCUSSION O O
: O O
Epigenetic O O
reprogramming O O
that O O
imparts O O
functional O O
changes O O
in O O
gene O O
expression O O
, O O
the O O
development O O
of O O
cancer B-Disease B-Disease
stem O O
cells O O
, O O
and O O
immunomodulation O O
are O O
plausible O O
underlying O O
mechanisms O O
by O O
which O O
early O O
- O O
life O O
iAs O O
exposure O O
elicits O O
latent O O
carcinogenic O O
effects O O
. O O

CONCLUSIONS O O
: O O
Evidence O O
is O O
mounting O O
that O O
relates O O
early O O
- O O
life O O
iAs O O
exposure O O
and O O
cancer B-Disease B-Disease
development O O
later O O
in O O
life O O
. O O

Future O O
research O O
should O O
include O O
animal O O
studies O O
that O O
address O O
mechanistic O O
hypotheses O O
and O O
studies O O
of O O
human O O
populations O O
that O O
integrate O O
early O O
- O O
life O O
exposure O O
, O O
molecular O O
alterations O O
, O O
and O O
latent O O
disease O O
outcomes O O
. O O

Nifedipine O O
induced O O
bradycardia B-Disease B-Disease
in O O
a O O
patient O O
with O O
autonomic B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

An O O
80 O O
year O O
old O O
diabetic B-Disease B-Disease
male O O
with O O
evidence O O
of O O
peripheral B-Disease B-Disease
and I-Disease I-Disease
autonomic I-Disease I-Disease
neuropathy I-Disease I-Disease
was O O
admitted O O
with O O
chest B-Disease B-Disease
pain I-Disease I-Disease
. O O

He O O
was O O
found O O
to O O
have O O
atrial B-Disease B-Disease
flutter I-Disease I-Disease
at O O
a O O
ventricular O O
rate O O
of O O
70 O O
/ O O
min O O
which O O
slowed O O
down O O
to O O
30 O O
- O O
40 O O
/ O O
min O O
when O O
nifedipine O O
( O O
60 O O
mg O O
) O O
in O O
3 O O
divided O O
doses O O
, O O
during O O
which O O
he O O
was O O
paced O O
at O O
a O O
rate O O
of O O
70 O O
/ O O
min O O
. O O

This O O
is O O
inconsistent O O
with O O
the O O
well O O
- O O
established O O
finding O O
that O O
nifedipine O O
induces O O
tachycardia B-Disease B-Disease
in O O
normally O O
innervated O O
hearts O O
. O O

However O O
, O O
in O O
hearts O O
deprived O O
of O O
compensatory O O
sympathetic O O
drive O O
, O O
it O O
may O O
lead O O
to O O
bradycardia B-Disease B-Disease
. O O

The O O
effect O O
of O O
haloperidol O O
in O O
cocaine O O
and O O
amphetamine O O
intoxication O O
. O O

The O O
effectiveness O O
of O O
haloperidol O O
pretreatment O O
in O O
preventing O O
the O O
toxic O O
effects O O
of O O
high O O
doses O O
of O O
amphetamine O O
and O O
cocaine O O
was O O
studied O O
in O O
rats O O
. O O

In O O
this O O
model O O
, O O
toxic O O
effects O O
were O O
induced O O
by O O
intraperitoneal O O
( O O
i.p O O
. O O
) O O
injection O O
of O O
amphetamine O O
75 O O
mg O O
/ O O
kg O O
( O O
100 O O
% O O
death O O
rate O O
) O O
or O O
cocaine O O
70 O O
mg O O
/ O O
kg O O
( O O
82 O O
% O O
death O O
rate O O
) O O
. O O

Haloperidol O O
failed O O
to O O
prevent O O
amphetamine O O
- O O
induced O O
seizures B-Disease B-Disease
, O O
but O O
did O O
lower O O
the O O
mortality O O
rate O O
at O O
most O O
doses O O
tested O O
. O O

Haloperidol O O
decreased O O
the O O
incidence O O
of O O
cocaine O O
- O O
induced O O
seizures B-Disease B-Disease
at O O
the O O
two O O
highest O O
doses O O
, O O
but O O
the O O
lowering O O
of O O
the O O
mortality O O
rate O O
did O O
not O O
reach O O
statistical O O
significance O O
at O O
any O O
dose O O
. O O

These O O
data O O
suggest O O
a O O
protective O O
role O O
for O O
the O O
central O O
dopamine O O
blocker O O
haloperidol O O
against O O
death O O
from O O
high O O
- O O
dose O O
amphetamine O O
exposure O O
without O O
reducing O O
the O O
incidence O O
of O O
seizures B-Disease B-Disease
. O O

In O O
contrast O O
, O O
haloperidol O O
demonstrated O O
an O O
ability O O
to O O
reduce O O
cocaine O O
- O O
induced O O
seizures B-Disease B-Disease
without O O
significantly O O
reducing O O
mortality O O
. O O

Autoradiographic O O
evidence O O
of O O
estrogen O O
binding O O
sites O O
in O O
nuclei O O
of O O
diethylstilbesterol O O
induced O O
hamster O O
renal B-Disease B-Disease
carcinomas I-Disease I-Disease
. O O

Estrogen O O
binding O O
sites O O
were O O
demonstrated O O
by O O
autoradiography O O
in O O
one O O
transplantable O O
and O O
five O O
primary O O
diethylstilbesterol O O
induced O O
renal B-Disease B-Disease
carcinomas I-Disease I-Disease
in O O
three O O
hamsters O O
. O O

Radiolabelling O O
, O O
following O O
the O O
in O O
vivo O O
injection O O
of O O
3H-17 O O
beta O O
estradiol O O
, O O
was O O
increased O O
only O O
over O O
the O O
nuclei O O
of O O
tumor B-Disease B-Disease
cells O O
; O O
stereologic O O
analysis O O
revealed O O
a O O
4.5- O O
to O O
6.7-times O O
higher O O
concentration O O
of O O
reduced O O
silver O O
grains O O
over O O
nuclei O O
than O O
cytoplasm O O
of O O
these O O
cells O O
. O O

Despite O O
rapid O O
tubular O O
excretion O O
of O O
estradiol O O
which O O
peaked O O
in O O
less O O
than O O
1 O O
h O O
, O O
the O O
normal O O
cells O O
did O O
not O O
appear O O
to O O
bind O O
the O O
ligand O O
. O O

This O O
is O O
the O O
first O O
published O O
report O O
documenting O O
the O O
preferential O O
in O O
vivo O O
binding O O
of O O
estrogen O O
to O O
nuclei O O
of O O
cells O O
in O O
estrogen O O
induced O O
hamster O O
renal B-Disease B-Disease
carcinomas I-Disease I-Disease
. O O

Bradycardia B-Disease B-Disease
due O O
to O O
biperiden O O
. O O

In O O
a O O
38-year O O
- O O
old O O
male O O
patient O O
suffering O O
from O O
a O O
severe O O
postzosteric B-Disease O
trigeminal B-Disease B-Disease
neuralgia I-Disease I-Disease
, O O
intravenous O O
application O O
of O O
10 O O
mg O O
biperiden O O
lactate O O
led O O
to O O
a O O
long O O
- O O
lasting O O
paradoxical O O
reaction O O
characterized O O
by O O
considerable O O
bradycardia B-Disease B-Disease
, O O
dysarthria B-Disease B-Disease
, O O
and O O
dysphagia B-Disease B-Disease
. O O

The O O
heart O O
rate O O
was O O
back O O
to O O
normal O O
within O O
12 O O
hours O O
upon O O
administration O O
of O O
orciprenaline O O
under O O
cardiac O O
monitoring O O
in O O
an O O
intensive O O
care O O
unit O O
. O O

Bradycardia B-Disease B-Disease
induced O O
by O O
biperiden O O
is O O
attributed O O
to O O
the O O
speed O O
of O O
injection O O
and O O
to O O
a O O
dose O O
- O O
related O O
dual O O
effect O O
of O O
atropine O O
- O O
like O O
drugs O O
on O O
muscarine O O
receptors O O
. O O

Deliberate O O
hypotension B-Disease B-Disease
induced O O
by O O
labetalol O O
with O O
halothane O O
, O O
enflurane O O
or O O
isoflurane O O
for O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
feasibility O O
of O O
using O O
labetalol O O
, O O
an O O
alpha- O O
and O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
as O O
a O O
hypotensive B-Disease B-Disease
agent O O
in O O
combination O O
with O O
inhalation O O
anaesthetics O O
( O O
halothane O O
, O O
enflurane O O
or O O
isoflurane O O
) O O
was O O
studied O O
in O O
23 O O
adult O O
patients O O
undergoing O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
mean O O
arterial O O
pressure O O
was O O
decreased O O
from O O
86 O O
+ O O
/- O O

5 O O
( O O
s.e O O
. O O
mean O O
) O O
mmHg O O
to O O
52 O O
+ O O
/- O O

1 O O
mmHg O O
( O O
11.5 O O
+ O O
/- O O

0.7 O O
to O O
6.9 O O
+ O O
/- O O

0.1 O O
kPa O O
) O O
for O O
98 O O
+ O O
/- O O

10 O O
min O O
in O O
the O O
halothane O O
( O O
H O O
) O O
group O O
, O O
from O O
79 O O
+ O O
/- O O

5 O O
to O O
53 O O
+ O O
/- O O

1 O O
mmHg O O
( O O
10.5 O O
+ O O
/- O O

0.7 O O
to O O
7.1 O O
+ O O
/- O O

0.1 O O
kPa O O
) O O
for O O
129 O O
+ O O
/- O O

11 O O
min O O
in O O
the O O
enflurane O O
( O O
E O O
) O O
group O O
, O O
and O O
from O O
80 O O
+ O O
/- O O

4 O O
to O O
49 O O
+ O O
/- O O

1 O O
mmHg O O
( O O
10.7 O O
+ O O
/- O O

0.5 O O
to O O
6.5 O O
+ O O
/- O O

0.1 O O
kPa O O
) O O
for O O
135 O O
+ O O
/- O O

15 O O
min O O
in O O
the O O
isoflurane O O
( O O
I O O
) O O
group O O
. O O

The O O
mean O O
H O O
concentration O O
during O O
hypotension B-Disease B-Disease
in O O
the O O
inspiratory O O
gas O O
was O O
0.7 O O
+ O O
/- O O

0.1 O O
vol% O O
, O O
the O O
mean O O
E O O
concentration O O
1.6 O O
+ O O
/- O O

0.2 O O
vol% O O
, O O
and O O
the O O
mean O O
I O O
concentration O O
1.0 O O
+ O O
/- O O

0.1 O O
vol% O O
. O O

In O O
addition O O
, O O
the O O
patients O O
received O O
fentanyl O O
and O O
d O O
- O O
tubocurarine O O
. O O

The O O
initial O O
dose O O
of O O
labetalol O O
for O O
lowering O O
blood O O
pressure O O
was O O
similar O O
, O O
0.52 O O
- O O
0.59 O O
mg O O
/ O O
kg O O
, O O
in O O
all O O
the O O
groups O O
. O O

During O O
hypotension B-Disease B-Disease
, O O
the O O
heart O O
rate O O
was O O
stable O O
without O O
tachy- B-Disease O
or I-Disease O
bradycardia I-Disease B-Disease
. O O

The O O
operating O O
conditions O O
regarding O O
bleeding B-Disease B-Disease
were O O
estimated O O
in O O
a O O
double O O
- O O
blind O O
manner O O
, O O
and O O
did O O
not O O
differ O O
significantly O O
between O O
the O O
groups O O
. O O

During O O
hypotension B-Disease B-Disease
, O O
the O O
serum O O
creatinine O O
concentration O O
rose O O
significantly O O
in O O
all O O
groups O O
from O O
the O O
values O O
before O O
hypotension B-Disease B-Disease
and O O
returned O O
postoperatively O O
to O O
the O O
initial O O
level O O
in O O
the O O
other O O
groups O O
, O O
except O O
the O O
isoflurane O O
group O O
. O O

After O O
hypotension B-Disease B-Disease
there O O
was O O
no O O
rebound O O
phenomenon O O
in O O
either O O
blood O O
pressure O O
or O O
heart O O
rate O O
. O O

These O O
results O O
indicate O O
that O O
labetalol O O
induces O O
easily O O
adjustable O O
hypotension B-Disease B-Disease
without O O
compensatory O O
tachycardia B-Disease B-Disease
and O O
rebound O O
hypertension B-Disease B-Disease
. O O

Convulsion B-Disease B-Disease
following O O
intravenous O O
fluorescein O O
angiography O O
. O O

Tonic B-Disease B-Disease
- I-Disease I-Disease
clonic I-Disease I-Disease
seizures I-Disease I-Disease
followed O O
intravenous O O
fluorescein O O
injection O O
for O O
fundus O O
angiography O O
in O O
a O O
47-year O O
- O O
old O O
male O O
. O O

Despite O O
precautions O O
this O O
adverse O O
reaction O O
recurred O O
on O O
re O O
- O O
exposure O O
to O O
intravenous O O
fluorescein O O
. O O

Pharmacology O O
of O O
ACC-9653 O O
( O O
phenytoin O O
prodrug O O
) O O
. O O

ACC-9653 O O
, O O
the O O
disodium O O
phosphate O O
ester O O
of O O
3-hydroxymethyl-5,5-diphenylhydantoin O O
, O O
is O O
a O O
prodrug O O
of O O
phenytoin O O
with O O
advantageous O O
physicochemical O O
properties O O
. O O

ACC-9653 O O
is O O
rapidly O O
converted O O
enzymatically O O
to O O
phenytoin O O
in O O
vivo O O
. O O

ACC-9653 O O
and O O
phenytoin O O
sodium O O
have O O
equivalent O O
anticonvulsant O O
activity O O
against O O
seizures B-Disease B-Disease
induced O O
by O O
maximal O O
electroshock O O
( O O
MES O O
) O O
in O O
mice O O
following O O
i.p O O
. O O
, O O
oral O O
, O O
or O O
i.v O O
. O O

administration O O
. O O

The O O
ED50 O O
doses O O
were O O
16 O O
mg O O
/ O O
kg O O
for O O
i.v O O
. O O

ACC-9653 O O
and O O
8 O O
mg O O
/ O O
kg O O
for O O
i.v O O
. O O

phenytoin O O
sodium O O
. O O

ACC-9653 O O
and O O
phenytoin O O
sodium O O
have O O
similar O O
antiarrhythmic O O
activity O O
against O O
ouabain O O
- O O
induced O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
in O O
anesthetized O O
dogs O O
. O O

The O O
total O O
doses O O
of O O
ACC-9653 O O
or O O
phenytoin O O
sodium O O
necessary O O
to O O
convert O O
the O O
arrhythmia B-Disease B-Disease
to O O
a O O
normal O O
sinus O O
rhythm O O
were O O
24 O O
+ O O
/- O O

6 O O
and O O
14 O O
+ O O
/- O O

3 O O
mg O O
/ O O
kg O O
, O O
respectively O O
. O O

Only O O
phenytoin O O
sodium O O
displayed O O
in O O
vitro O O
antiarrhythmic O O
activity O O
against O O
strophanthidin O O
- O O
induced O O
arrhythmias B-Disease B-Disease
in O O
guinea O O
pig O O
right O O
atria O O
. O O

In O O
anesthetized O O
dogs O O
, O O
a O O
high O O
dose O O
of O O
ACC-9653 O O
( O O
31 O O
mg O O
/ O O
kg O O
) O O
was O O
infused O O
over O O
15 O O
, O O
20 O O
, O O
and O O
30 O O
min O O
and O O
the O O
responses O O
were O O
compared O O
to O O
an O O
equimolar O O
dose O O
of O O
phenytoin O O
sodium O O
( O O
21 O O
mg O O
/ O O
kg O O
) O O
. O O

The O O
ACC-9653 O O
and O O
phenytoin O O
sodium O O
treatments O O
produced O O
similar O O
marked O O
reductions O O
in O O
diastolic O O
blood O O
pressure O O
and O O
contractile O O
force O O
( O O
LVdP O O
/ O O
dt O O
) O O
. O O

The O O
maximum O O
effects O O
of O O
each O O
treatment O O
occurred O O
at O O
the O O
time O O
of O O
maximum O O
phenytoin O O
sodium O O
levels O O
. O O

Acute O O
toxicity B-Disease B-Disease
studies O O
of O O
ACC-9653 O O
and O O
phenytoin O O
sodium O O
were O O
carried O O
out O O
in O O
mice O O
, O O
rats O O
, O O
rabbits O O
, O O
and O O
dogs O O
by O O
i.v O O
. O O
, O O
i.m O O
. O O
, O O
and O O
i.p O O
. O O

routes O O
of O O
administration O O
. O O

The O O
systemic O O
toxic O O
signs O O
of O O
both O O
agents O O
were O O
similar O O
and O O
occurred O O
at O O
approximately O O
equivalent O O
doses O O
. O O

Importantly O O
, O O
the O O
local O O
irritation O B-Disease
of O O
ACC-9653 O O
was O O
markedly O O
less O O
than O O
phenytoin O O
sodium O O
following O O
i.m O O
. O O

administration. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Tachyphylaxis O B-Disease
to O O
systemic O O
but O O
not O O
to O O
airway O O
responses O O
during O O
prolonged O O
therapy O O
with O O
high O O
dose O O
inhaled O O
salbutamol O O
in O O
asthmatics B-Disease B-Disease
. O O

High O O
doses O O
of O O
inhaled O O
salbutamol O O
produce O O
substantial O O
improvements O O
in O O
airway O O
response O O
in O O
patients O O
with O O
asthma B-Disease B-Disease
, O O
and O O
are O O
associated O O
with O O
dose O O
- O O
dependent O O
systemic O O
beta O O
- O O
adrenoceptor O O
responses O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
whether O O
tachyphylaxis O O
occurs O O
during O O
prolonged O O
treatment O O
with O O
high O O
dose O O
inhaled O O
salbutamol O O
. O O

Twelve O O
asthmatic B-Disease B-Disease
patients O O
( O O
FEV1 O O
, O O
81 O O
+ O O
/- O O

4 O O
% O O
predicted O O
) O O
, O O
requiring O O
only O O
occasional O O
inhaled O O
beta O O
- O O
agonists O O
as O O
their O O
sole O O
therapy O O
, O O
were O O
given O O
a O O
14-day O O
treatment O O
with O O
high O O
dose O O
inhaled O O
salbutamol O O
( O O
HDS O O
) O O
, O O
4,000 O O
micrograms O O
daily O O
, O O
low O O
dose O O
inhaled O O
salbutamol O O
( O O
LDS O O
) O O
, O O
800 O O
micrograms O O
daily O O
, O O
or O O
placebo O O
( O O
PI O O
) O O
by O O
metered O O
- O O
dose O O
inhaler O O
in O O
a O O
double O O
- O O
blind O O
, O O
randomized O O
crossover O O
design O O
. O O

During O O
the O O
14-day O O
run O O
- O O
in O O
and O O
during O O
washout O O
periods O O
, O O
inhaled O O
beta O O
- O O
agonists O O
were O O
withheld O O
and O O
ipratropium O O
bromide O O
was O O
substituted O O
for O O
rescue O O
purposes O O
. O O

At O O
the O O
end O O
of O O
each O O
14-day O O
treatment O O
, O O
a O O
dose O O
- O O
response O O
curve O O
( O O
DRC O O
) O O
was O O
performed O O
, O O
and O O
airway O O
( O O
FEV1 O O
, O O
FEF25 O O
- O O
75 O O
) O O
chronotropic O O
( O O
HR O O
) O O
, O O
tremor B-Disease B-Disease
, O O
and O O
metabolic O O
( O O
K O O
, O O
Glu O O
) O O
responses O O
were O O
measured O O
at O O
each O O
step O O
( O O
from O O
100 O O
to O O
4,000 O O
micrograms O O
) O O
. O O

Treatment O O
had O O
no O O
significant O O
effect O O
on O O
baseline O O
values O O
. O O

There O O
were O O
dose O O
- O O
dependent O O
increases O O
in O O
FEV1 O O
and O O
FEF25 O O
- O O
75 O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
and O O
pretreatment O O
with O O
HDS O O
did O O
not O O
displace O O
the O O
DRC O O
to O O
the O O
right O O
. O O

DRC O O
for O O
HR O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
K O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
and O O
Glu O O
( O O
p O O
less O O
than O O
0.005 O O
) O O
were O O
attenuated O O
after O O
treatment O O
with O O
HDS O O
compared O O
with O O
PI O O
. O O

There O O
were O O
also O O
differences O O
between O O
HDS O O
and O O
LDS O O
for O O
HR O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
and O O
Glu O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
responses O O
. O O

Frequency O O
and O O
severity O O
of O O
subjective O O
adverse O O
effects O O
were O O
also O O
reduced O O
after O O
HDS O O
: O O
tremor B-Disease B-Disease
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
palpitations B-Disease B-Disease
( O O
p O O
less O O
than O O
0.001 O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Phenytoin O O
induced O O
fatal O O
hepatic B-Disease B-Disease
injury I-Disease I-Disease
. O O

A O O
61 O O
year O O
old O O
female O O
developed O O
fatal O O
hepatic B-Disease B-Disease
failure I-Disease I-Disease
after O O
phenytoin O O
administration O O
. O O

A O O
typical O O
multisystem O O
clinical O O
pattern O O
precedes O O
the O O
manifestations O O
of O O
hepatic B-Disease B-Disease
injury I-Disease I-Disease
. O O

The O O
hematologic O O
, O O
biochemical O O
and O O
pathologic O O
features O O
indicate O O
a O O
mixed O O
hepatocellular B-Disease B-Disease
damage I-Disease I-Disease
due O O
to O O
drug B-Disease B-Disease
hypersensitivity I-Disease I-Disease
. O O

In O O
a O O
patient O O
receiving O O
phenytoin O O
who O O
presents O O
a O O
viral O O
- O O
like O O
illness O O
, O O
early O O
recognition O O
and O O
discontinuation O O
of O O
the O O
drug O O
are O O
mandatory O O
. O O

Treatment O O
of O O
lethal O O
pertussis O O
vaccine O O
reaction O O
with O O
histamine O O
H1 O O
antagonists O O
. O O

We O O
studied O O
mortality O O
after O O
pertussis B-Disease B-Disease
immunization O O
in O O
the O O
mouse O O
. O O

Without O O
treatment O O
, O O
73 O O
of O O
92 O O
animals O O
( O O
80 O O
% O O
) O O
died O O
after O O
injection O O
of O O
bovine O O
serum O O
albumin O O
( O O
BSA O O
) O O
on O O
day O O
+ O O
7 O O
of O O
pertussis B-Disease B-Disease
immunization O O
. O O

After O O
pretreatment O O
with O O
3 O O
mg O O
of O O
cyproheptadine O O
, O O
2 O O
mg O O
mianserin O O
, O O
or O O
2 O O
mg O O
chlorpheniramine O O
, O O
only O O
5 O O
of O O
105 O O
animals O O
( O O
5 O O
% O O
) O O
died O O
after O O
receiving O O
BSA O O
on O O
day O O
+ O O
7 O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
. O O

Blockade O O
of O O
histamine O O
H1 O O
receptors O O
may O O
reduce O O
mortality O O
in O O
pertussis B-Disease B-Disease
immunization O O
- O O
induced O O
encephalopathy B-Disease B-Disease
in O O
mice O O
. O O

Support O O
for O O
adrenaline O O
- O O
hypertension B-Disease B-Disease
hypothesis O O
: O O
18 O O
hour O O
pressor O O
effect O O
after O O
6 O O
hours O O
adrenaline O O
infusion O O
. O O

In O O
a O O
double O O
blind O O
, O O
crossover O O
study O O
6 O O
h O O
infusions O O
of O O
adrenaline O O
( O O
15 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5.458 O O
pmol O O
) O O
, O O
noradrenaline O O
( O O
30 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5.911 O O
pmol O O
) O O
, O O
and O O
a O O
5 O O
% O O
dextrose O O
solution O O
( O O
5.4 O O
ml O O
/ O O
h O O
) O O
, O O
were O O
given O O
to O O
ten O O
healthy O O
volunteers O O
in O O
random O O
order O O
2 O O
weeks O O
apart O O
. O O

By O O
means O O
of O O
intra O O
- O O
arterial O O
ambulatory O O
monitoring O O
the O O
haemodynamic O O
effects O O
were O O
followed O O
for O O
18 O O
h O O
after O O
the O O
infusions O O
were O O
stopped O O
. O O

Adrenaline O O
, O O
but O O
not O O
noradrenaline O O
, O O
caused O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

Over O O
the O O
total O O
postinfusion O O
period O O
systolic O O
and O O
diastolic O O
arterial O O
pressure O O
were O O
6 O O
( O O
SEM O O
2 O O
) O O
% O O
and O O
7 O O
( O O
2 O O
) O O
% O O
, O O
respectively O O
, O O
higher O O
than O O
after O O
dextrose O O
infusion O O
( O O
ANOVA O O
, O O
p O O
less O O
than O O
0.001 O O
) O O
. O O

Thus O O
, O O
" O O
stress O O
" O O
levels O O
of O O
adrenaline O O
( O O
230 O O
pg O O
/ O O
ml O O
) O O
for O O
6 O O
h O O
cause O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

These O O
findings O O
are O O
strong O O
support O O
for O O
the O O
adrenaline O O
- O O
hypertension B-Disease B-Disease
hypothesis O O
in O O
man O O
. O O

Effect O O
of O O
alkylxanthines O O
on O O
gentamicin O O
- O O
induced O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
in O O
the O O
rat O O
. O O

Adenosine O O
antagonists O O
have O O
been O O
previously O O
shown O O
to O O
be O O
of O O
benefit O O
in O O
some O O
ischaemic B-Disease B-Disease
and O O
nephrotoxic B-Disease B-Disease
models O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
( O O
ARF B-Disease B-Disease
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
three O O
alkylxanthines O O
with O O
different O O
potencies O O
as O O
adenosine O O
antagonists O O
8-phenyltheophylline O O
, O O
theophylline O O
and O O
enprofylline O O
, O O
were O O
examined O O
in O O
rats O O
developing O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
after O O
4 O O
daily O O
injections O O
of O O
gentamicin O O
( O O
200 O O
mg O O
kg-1 O O
) O O
. O O

Renal O O
function O O
was O O
assessed O O
by O O
biochemical O O
( O O
plasma O O
urea O O
and O O
creatinine O O
) O O
, O O
functional O O
( O O
urine O O
analysis O O
and O O
[ O O
3H O O
] O O
inulin O O
and O O
[ O O
14C O O
] O O
p O O
- O O
aminohippuric O O
acid O O
clearances O O
) O O
and O O
morphological O O
( O O
degree O O
of O O
necrosis B-Disease B-Disease
) O O
indices O O
. O O

The O O
various O O
drug O O
treatments O O
produced O O
improvements O O
in O O
some O O
, O O
but O O
not O O
all O O
, O O
measurements O O
of O O
renal O O
function O O
. O O

However O O
, O O
any O O
improvement O O
produced O O
by O O
drug O O
treatment O O
was O O
largely O O
a O O
result O O
of O O
a O O
beneficial O O
effect O O
exerted O O
by O O
its O O
vehicle O O
( O O
polyethylene O O
glycol O O
and O O
NaOH O O
) O O
. O O

The O O
lack O O
of O O
any O O
consistent O O
protective O O
effect O O
noted O O
with O O
the O O
alkylxanthines O O
tested O O
in O O
the O O
present O O
study O O
indicates O O
that O O
adenosine O O
plays O O
little O O
, O O
if O O
any O O
, O O
pathophysiological O O
role O O
in O O
gentamicin O O
- O O
induced O O
ARF B-Disease B-Disease
. O O

Adverse O O
ocular O O
reactions O O
possibly O O
associated O O
with O O
isotretinoin O O
. O O

A O O
total O O
of O O
261 O O
adverse O O
ocular O O
reactions O O
occurred O O
in O O
237 O O
patients O O
who O O
received O O
isotretinoin O O
, O O
a O O
commonly O O
used O O
drug O O
in O O
the O O
treatment O O
of O O
severe O O
cystic O O
acne B-Disease B-Disease
. O O

Blepharoconjunctivitis B-Disease B-Disease
, O O
subjective O O
complaints O O
of O O
dry B-Disease B-Disease
eyes I-Disease I-Disease
, O O
blurred B-Disease B-Disease
vision I-Disease I-Disease
, O O
contact O B-Disease
lens O I-Disease
intolerance O I-Disease
, O O
and O O
photodermatitis B-Disease B-Disease
are O O
reversible O O
side O O
effects O O
. O O

More O O
serious O O
ocular O O
adverse O O
reactions O O
include O O
papilledema B-Disease B-Disease
, O O
pseudotumor B-Disease B-Disease
cerebri I-Disease I-Disease
, O O
and O O
white O O
or O O
gray O O
subepithelial O O
corneal B-Disease B-Disease
opacities I-Disease I-Disease
; O O
all O O
of O O
these O O
are O O
reversible O O
if O O
the O O
drug O O
is O O
discontinued O O
. O O

Reported O O
cases O O
of O O
decreased O O
dark O O
adaptation O O
are O O
under O O
investigation O O
. O O

Isotretinoin O O
is O O
contraindicated O O
in O O
pregnancy O O
because O O
of O O
the O O
many O O
reported O O
congenital B-Disease B-Disease
abnormalities I-Disease I-Disease
after O O
maternal O O
use O O
( O O
including O O
microphthalmos B-Disease B-Disease
, O O
orbital O O
hypertelorism B-Disease B-Disease
, O O
and O O
optic B-Disease B-Disease
nerve I-Disease I-Disease
hypoplasia I-Disease I-Disease
) O O
. O O

Procaterol O O
and O O
terbutaline O O
in O O
bronchial B-Disease B-Disease
asthma I-Disease I-Disease
. O O

A O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
cross O O
- O O
over O O
study O O
. O O

Procaterol O O
, O O
a O O
new O O
beta-2 O O
adrenoceptor O O
stimulant O O
, O O
was O O
studied O O
in O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
cross O O
- O O
over O O
trial O O
in O O
patients O O
with O O
bronchial B-Disease B-Disease
asthma I-Disease I-Disease
. O O

Oral O O
procaterol O O
50 O O
micrograms O O
b.d O O
. O O
, O O
procaterol O O
100 O O
micrograms O O
b.d O O
. O O
, O O
and O O
terbutaline O O
5 O O
mg O O
t.i.d O O
. O O
, O O
were O O
compared O O
when O O
given O O
randomly O O
in O O
1-week O O
treatment O O
periods O O
. O O

The O O
best O O
clinical O O
effect O O
was O O
found O O
with O O
terbutaline O O
. O O

Both O O
anti O O
- O O
asthmatic B-Disease B-Disease
and O O
tremorgenic B-Disease B-Disease
effects O O
of O O
procaterol O O
were O O
dose O O
- O O
related O O
. O O

Procaterol O O
appeared O O
effective O O
in O O
the O O
doses O O
tested O O
, O O
and O O
a O O
twice O O
daily O O
regimen O O
would O O
appear O O
to O O
be O O
suitable O O
with O O
this O O
drug O O
. O O

Subacute O O
effects O O
of O O
propranolol O O
and O O
B O O
24 O O
/ O O
76 O O
on O O
isoproterenol O O
- O O
induced O O
rat O O
heart B-Disease B-Disease
hypertrophy I-Disease I-Disease
in O O
correlation O O
with O O
blood O O
pressure O O
. O O

We O O
compared O O
the O O
potential O O
beta O O
- O O
receptor O O
blocker O O
, O O
B O O
24 O O
/ O O
76 O O
i.e. O O
1- O O
( O O
2,4-dichlorophenoxy O O
) O O
-3 O O
[ O O
2 O O
- O O
3,4-dimethoxyphenyl O O
) O O
ethanolamino O O
] O O
-prop O O
an-2-ol O O
, O O
which O O
is O O
characterized O O
by O O
beta O O
1-adrenoceptor O O
blocking O O
and O O
beta O O
2-adrenoceptor O O
stimulating O O
properties O O
with O O
propranolol O O
. O O

The O O
studies O O
were O O
performed O O
using O O
an O O
experimental O O
model O O
of O O
isoproterenol O O
- O O
induced O O
heart B-Disease B-Disease
hypertrophy I-Disease I-Disease
in O O
rats O O
. O O

A O O
correlation O O
of O O
the O O
blood O O
pressure O O
was O O
neither O O
found O O
in O O
the O O
development O O
nor O O
in O O
the O O
attempt O O
to O O
suppress O O
the O O
development O O
of O O
heart B-Disease B-Disease
hypertrophy I-Disease I-Disease
with O O
the O O
two O O
beta O O
- O O
receptor O O
blockers O O
. O O

Both O O
beta O O
- O O
blockers O O
influenced O O
the O O
development O O
of O O
hypertrophy B-Disease B-Disease
to O O
a O O
different O O
, O O
but O O
not O O
reproducible O O
extent O O
. O O

It O O
was O O
possible O O
to O O
suppress O O
the O O
increased O O
ornithine O O
decarboxylase O O
activity O O
with O O
both O O
beta O O
- O O
blockers O O
in O O
hypertrophied B-Disease O
hearts I-Disease O
, O O
but O O
there O O
was O O
no O O
effect O O
on O O
the O O
heart O O
mass O O
. O O

Neither O O
propranolol O O
nor O O
B O O
24 O O
/ O O
76 O O
could O O
stop O O
the O O
changes O O
in O O
the O O
characteristic O O
myosin O O
isoenzyme O O
pattern O O
of O O
the O O
hypertrophied B-Disease O
rat O O
heart O O
. O O

Thus O O
, O O
the O O
investigations O O
did O O
not O O
provide O O
any O O
evidence O O
that O O
the O O
beta O O
- O O
receptor O O
blockers O O
propranolol O O
and O O
B O O
24 O O
/ O O
76 O O
have O O
the O O
potency O O
to O O
prevent O O
isoproterenol O O
from O O
producing O O
heart B-Disease B-Disease
hypertrophy I-Disease I-Disease
. O O

Increased O O
anxiogenic O O
effects O O
of O O
caffeine O O
in O O
panic B-Disease B-Disease
disorders I-Disease I-Disease
. O O

The O O
effects O O
of O O
oral O O
administration O O
of O O
caffeine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
on O O
behavioral O O
ratings O O
, O O
somatic O O
symptoms O O
, O O
blood O O
pressure O O
and O O
plasma O O
levels O O
of O O
3-methoxy-4-hydroxyphenethyleneglycol O O
( O O
MHPG O O
) O O
and O O
cortisol O O
were O O
determined O O
in O O
17 O O
healthy O O
subjects O O
and O O
21 O O
patients O O
meeting O O
DSM O O
- O O
III O O
criteria O O
for O O
agoraphobia B-Disease B-Disease
with O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
or O O
panic B-Disease B-Disease
disorder I-Disease I-Disease
. O O

Caffeine O O
produced O O
significantly O O
greater O O
increases O O
in O O
subject O O
- O O
rated O O
anxiety B-Disease B-Disease
, O O
nervousness O B-Disease
, O O
fear O O
, O O
nausea B-Disease B-Disease
, O O
palpitations B-Disease B-Disease
, O O
restlessness B-Disease B-Disease
, O O
and O O
tremors B-Disease B-Disease
in O O
the O O
patients O O
compared O O
with O O
healthy O O
subjects O O
. O O

In O O
the O O
patients O O
, O O
but O O
not O O
the O O
healthy O O
subjects O O
, O O
these O O
symptoms O O
were O O
significantly O O
correlated O O
with O O
plasma O O
caffeine O O
levels O O
. O O

Seventy O O
- O O
one O O
percent O O
of O O
the O O
patients O O
reported O O
that O O
the O O
behavioral O O
effects O O
of O O
caffeine O O
were O O
similar O O
to O O
those O O
experienced O O
during O O
panic B-Disease B-Disease
attacks I-Disease I-Disease
. O O

Caffeine O O
did O O
not O O
alter O O
plasma O O
MHPG O O
levels O O
in O O
either O O
the O O
healthy O O
subjects O O
or O O
patients O O
. O O

Caffeine O O
increased O O
plasma O O
cortisol O O
levels O O
equally O O
in O O
the O O
patient O O
and O O
healthy O O
groups O O
. O O

Because O O
caffeine O O
is O O
an O O
adenosine O O
receptor O O
antagonist O O
, O O
these O O
results O O
suggest O O
that O O
some O O
panic B-Disease B-Disease
disorder I-Disease I-Disease
patients O O
may O O
have O O
abnormalities B-Disease O
in I-Disease O
neuronal I-Disease O
systems I-Disease O
involving O O
adenosine O O
. O O

Patients O O
with O O
anxiety B-Disease B-Disease
disorders I-Disease I-Disease
may O O
benefit O O
by O O
avoiding O O
caffeine O O
- O O
containing O O
foods O O
and O O
beverages O O
. O O

Comparison O O
of O O
the O O
effect O O
of O O
oxitropium O O
bromide O O
and O O
of O O
slow O O
- O O
release O O
theophylline O O
on O O
nocturnal O O
asthma B-Disease B-Disease
. O O

The O O
effects O O
of O O
a O O
new O O
inhaled O O
antimuscarinic O O
drug O O
, O O
oxitropium O O
bromide O O
, O O
and O O
of O O
a O O
slow O O
- O O
release O O
theophylline O O
preparation O O
upon O O
nocturnal O O
asthma B-Disease B-Disease
were O O
compared O O
in O O
a O O
placebo O O
- O O
controlled O O
double O O
- O O
blind O O
study O O
. O O

Two O O
samples O O
were O O
studied O O
: O O
12 O O
patients O O
received O O
oxitropium O O
at O O
600 O O
micrograms O O
( O O
6 O O
subjects O O
) O O
or O O
at O O
400 O O
micrograms O O
t.i.d O O
. O O

( O O
6 O O
subjects O O
) O O
whereas O O
11 O O
received O O
theophylline O O
at O O
300 O O
mg O O
b.i.d O O
. O O

Morning O O
dipping O O
, O O
assessed O O
by O O
the O O
fall O O
in O O
peak O O
flow O O
overnight O O
, O O
was O O
significantly O O
reduced O O
in O O
the O O
periods O O
when O O
either O O
active O O
drug O O
was O O
taken O O
, O O
whereas O O
no O O
difference O O
was O O
noticed O O
during O O
the O O
placebo O O
administration O O
. O O

No O O
significant O O
difference O O
was O O
noticed O O
between O O
results O O
obtained O O
with O O
either O O
active O O
drug O O
, O O
as O O
well O O
as O O
with O O
either O O
dosage O O
of O O
oxitropium O O
. O O

No O O
subject O O
reported O O
side O O
effects O O
of O O
oxitropium O O
, O O
as O O
compared O O
to O O
three O O
subjects O O
reporting O O
nausea B-Disease B-Disease
, O O
vomiting B-Disease B-Disease
and O O
tremors B-Disease B-Disease
after O O
theophylline O O
. O O

Oxitropium O O
proves O O
to O O
be O O
a O O
valuable O O
alternative O O
to O O
theophylline O O
in O O
nocturnal O O
asthma B-Disease B-Disease
, O O
since O O
it O O
is O O
equally O O
potent O O
, O O
safer O O
and O O
does O O
not O O
require O O
the O O
titration O O
of O O
dosage O O
. O O

Penicillin O O
anaphylaxis B-Disease B-Disease
. O O

A O O
case O O
of O O
oral O O
penicillin O O
anaphylaxis B-Disease B-Disease
is O O
described O O
, O O
and O O
the O O
terminology O O
, O O
occurrence O O
, O O
clinical O O
manifestations O O
, O O
pathogenesis O O
, O O
prevention O O
, O O
and O O
treatment O O
of O O
anaphylaxis B-Disease B-Disease
are O O
reviewed O O
. O O

Emergency O O
physicians O O
should O O
be O O
aware O O
of O O
oral O O
penicillin O O
anaphylaxis B-Disease B-Disease
in O O
order O O
to O O
prevent O O
its O O
occurrence O O
by O O
prescribing O O
the O O
antibiotic O O
judiciously O O
and O O
knowledgeably O O
and O O
to O O
offer O O
optimal O O
medical O O
therapy O O
once O O
this O O
life O O
- O O
threatening O O
reaction O O
has O O
begun O O
. O O

Reversible O O
valproic O O
acid O O
- O O
induced O O
dementia B-Disease B-Disease
: O O
a O O
case O O
report O O
. O O

Reversible O O
valproic O O
acid O O
- O O
induced O O
dementia B-Disease B-Disease
was O O
documented O O
in O O
a O O
21-year O O
- O O
old O O
man O O
with O O
epilepsy B-Disease B-Disease
who O O
had O O
a O O
3-year O O
history O O
of O O
insidious O O
progressive O O
decline O O
in O O
global O O
cognitive O O
abilities O O
documented O O
by O O
serial O O
neuropsychological O O
studies O O
. O O

Repeat O O
neuropsychological O O
testing O O
7 O O
weeks O O
after O O
discontinuation O O
of O O
the O O
drug O O
revealed O O
dramatic O O
improvement O O
in O O
IQ O O
, O O
memory O O
, O O
naming O O
, O O
and O O
other O O
tasks O O
commensurate O O
with O O
clinical O O
recovery O O
in O O
his O O
intellectual O O
capacity O O
. O O

Possible O O
pathophysiological O O
mechanisms O O
which O O
may O O
have O O
been O O
operative O O
in O O
this O O
case O O
include O O
: O O
a O O
direct O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
toxic O O
effect O O
of O O
valproic O O
acid O O
; O O
a O O
paradoxical O O
epileptogenic O O
effect O O
secondary O O
to O O
the O O
drug O O
; O O
and O O
an O O
indirect O O
CNS O O
toxic O O
effect O O
mediated O O
through O O
valproic O O
acid O O
- O O
induced O O
hyperammonemia B-Disease B-Disease
. O O

Reversal O O
of O O
scopolamine O O
- O O
induced O O
amnesia B-Disease B-Disease
of O O
passive O O
avoidance O O
by O O
pre- O O
and O O
post O O
- O O
training O O
naloxone O O
. O O

In O O
a O O
series O O
of O O
five O O
experiments O O
, O O
the O O
modulating O O
role O O
of O O
naloxone O O
on O O
a O O
scopolamine O O
- O O
induced O O
retention B-Disease B-Disease
deficit I-Disease I-Disease
in O O
a O O
passive O O
avoidance O O
paradigm O O
was O O
investigated O O
in O O
mice O O
. O O

Scopolamine O O
, O O
but O O
not O O
methyl O O
scopolamine O O
( O O
1 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
, O O
induced O O
an O O
amnesia B-Disease B-Disease
as O O
measured O O
by O O
latency O O
and O O
duration O O
parameters O O
. O O

Naloxone O O
( O O
0.3 O O
, O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
injected O O
prior O O
to O O
training O O
attenuated O O
the O O
retention B-Disease O
deficit I-Disease O
with O O
a O O
peak O O
of O O
activity O O
at O O
3 O O
mg O O
/ O O
kg O O
. O O

The O O
effect O O
of O O
naloxone O O
could O O
be O O
antagonized O O
with O O
morphine O O
( O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
, O O
demonstrating O O
the O O
opioid O O
specificity O O
of O O
the O O
naloxone O O
effect O O
. O O

Post O O
- O O
training O O
administration O O
of O O
naloxone O O
( O O
3 O O
mg O O
/ O O
kg O O
) O O
as O O
a O O
single O O
or O O
as O O
a O O
split O O
dose O O
also O O
attenuated O O
the O O
scopolamine O O
- O O
induced O O
amnesia B-Disease B-Disease
. O O

Control O O
experiments O O
indicated O O
that O O
neither O O
an O O
increase O O
in O O
pain B-Disease B-Disease
sensitivity O O
( O O
pre O O
- O O
training O O
naloxone O O
) O O
nor O O
an O O
induced O O
aversive O O
state O O
( O O
post O O
- O O
training O O
naloxone O O
) O O
appear O O
to O O
be O O
responsible O O
for O O
the O O
influence O O
of O O
naloxone O O
on O O
the O O
scopolamine O O
- O O
induced O O
retention B-Disease B-Disease
deficit I-Disease I-Disease
. O O

These O O
results O O
extend O O
previous O O
findings O O
implicating O O
a O O
cholinergic O O
- O O
opioid O O
interaction O O
in O O
memory O O
processes O O
. O O

A O O
possible O O
mechanism O O
for O O
this O O
interaction O O
involving O O
the O O
septo O O
- O O
hippocampal O O
cholinergic O O
pathway O O
is O O
discussed O O
. O O

Electron O O
microscopic O O
investigations O O
of O O
the O O
cyclophosphamide O O
- O O
induced O O
lesions B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
urinary I-Disease I-Disease
bladder I-Disease I-Disease
of O O
the O O
rat O O
and O O
their O O
prevention O O
by O O
mesna O O
. O O

Fully O O
developed O O
cyclophosphamide O O
- O O
induced O O
cystitis B-Disease B-Disease
is O O
characterized O O
by O O
nearly O O
complete O O
detachment O O
of O O
the O O
urothelium O O
, O O
severe O O
submucosal O B-Disease
edema B-Disease I-Disease
owing O O
to O O
damage O O
to O O
the O O
microvascular O O
bed O O
and O O
focal O O
muscle O B-Disease
necroses B-Disease I-Disease
. O O

The O O
initial O O
response O O
to O O
the O O
primary O O
attack O O
by O O
the O O
cyclophosphamide O O
metabolites O O
seems O O
to O O
be O O
fragmentation O O
of O O
the O O
luminal O O
membrane O O
. O O

This O O
damages O O
the O O
cellular O O
barrier O O
against O O
the O O
hypertonic O O
urine O O
. O O

Subsequent O O
breaks O O
in O O
the O O
lateral O O
cell O O
membranes O O
of O O
the O O
superficial O O
cells O O
and O O
in O O
all O O
the O O
plasma O O
membranes O O
of O O
the O O
intermediate O O
and O O
basal O O
cells O O
, O O
intercellular O O
and O O
intracellular O O
edema B-Disease B-Disease
and O O
disintegration O O
of O O
the O O
desmosomes O O
and O O
hemidesmosomes O O
lead O O
to O O
progressive O O
degeneration O O
and O O
detachment O O
of O O
the O O
epithelial O O
cells O O
with O O
exposure O O
and O O
splitting O O
of O O
the O O
basal O O
membrane O O
. O O

The O O
morphological O O
changes O O
of O O
the O O
endothelial O O
cells O O
, O O
which O O
become O O
more O O
pronounced O O
in O O
the O O
later O O
stages O O
of O O
the O O
experiment O O
, O O
the O O
involvement O O
of O O
blood O O
vessels O O
regardless O O
of O O
their O O
diameter O O
and O O
the O O
location O O
- O O
dependent O O
extent O O
of O O
the O O
damage O O
indicate O O
a O O
direct O O
type O O
of O O
damage O O
which O O
is O O
preceded O O
by O O
a O O
mediator O O
- O O
induced O O
increase O O
in O O
permeability O O
, O O
the O O
morphological O O
correlate O O
of O O
which O O
is O O
the O O
formation O O
of O O
gaps O O
in O O
the O O
interendothelial O O
cell O O
connections O O
on O O
the O O
venules O O
. O O

These O O
changes O O
can O O
be O O
effectively O O
prevented O O
by O O
mesna O O
. O O

The O O
only O O
sign O O
of O O
a O O
possible O O
involvement O O
is O O
the O O
increase O O
in O O
the O O
number O O
of O O
specific O O
granules O O
with O O
a O O
presumed O O
lysosomal O O
function O O
in O O
the O O
superficial O O
cells O O
. O O

Increase O O
in O O
intragastric O O
pressure O O
during O O
suxamethonium O O
- O O
induced O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
in O O
children O O
: O O
inhibition O O
by O O
alfentanil O O
. O O

Changes O O
in O O
intragastric O O
pressure O O
after O O
the O O
administration O O
of O O
suxamethonium O O
1.5 O O
mg O O
kg-1 O O
i.v O O
. O O
were O O
studied O O
in O O
32 O O
children O O
( O O
mean O O
age O O
6.9 O O
yr O O
) O O
pretreated O O
with O O
either O O
physiological O O
saline O O
or O O
alfentanil O O
50 O O
micrograms O O
kg-1 O O
. O O

Anaesthesia O O
was O O
induced O O
with O O
thiopentone O O
5 O O
mg O O
kg-1 O O
. O O

The O O
incidence O O
and O O
intensity O O
of O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
caused O O
by O O
suxamethonium O O
were O O
significantly O O
greater O O
in O O
the O O
control O O
than O O
in O O
the O O
alfentanil O O
group O O
. O O

The O O
intragastric O O
pressure O O
during O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
was O O
significantly O O
higher O O
in O O
the O O
control O O
group O O
( O O
16 O O
+ O O
/- O O

0.7 O O
( O O
SEM O O
) O O
cm O O
H2O O O
) O O
than O O
in O O
the O O
alfentanil O O
group O O
( O O
7.7 O O
+ O O
/- O O

1.5 O O
( O O
SEM O O
) O O
cm O O
H2O O O
) O O
. O O

The O O
increase O O
in O O
intragastric O O
pressure O O
was O O
directly O O
related O O
to O O
the O O
intensity O O
of O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
( O O
regression O O
line O O
: O O
y O O
= O O
0.5 O O
+ O O
4.78x O O
with O O
r O O
of O O
0.78 O O
) O O
. O O

It O O
is O O
concluded O O
that O O
intragastric O O
pressure O O
increases O O
significantly O O
during O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
caused O O
by O O
suxamethonium O O
in O O
healthy O O
children O O
. O O

Alfentanil O O
50 O O
micrograms O O
kg-1 O O
effectively O O
inhibits O O
the O O
incidence O O
and O O
intensity O O
of O O
suxamethonium O O
- O O
induced O O
muscle B-Disease B-Disease
fasciculations I-Disease I-Disease
; O O
moreover O O
, O O
intragastric O O
pressure O O
remains O O
at O O
its O O
control O O
value O O
. O O

Acute O O
insulin O O
treatment O O
normalizes O O
the O O
resistance O O
to O O
the O O
cardiotoxic B-Disease B-Disease
effect O O
of O O
isoproterenol O O
in O O
streptozotocin O O
diabetic B-Disease B-Disease
rats O O
. O O

A O O
morphometric O O
study O O
of O O
isoproterenol O O
induced O O
myocardial O B-Disease
fibrosis B-Disease I-Disease
. O O

The O O
acute O O
effect O O
of O O
insulin O O
treatment O O
on O O
the O O
earlier O O
reported O O
protective O O
effect O O
of O O
streptozotocin O O
diabetes B-Disease B-Disease
against O O
the O O
cardiotoxic B-Disease B-Disease
effect O O
of O O
high O O
doses O O
of O O
isoproterenol O O
( O O
ISO O O
) O O
was O O
investigated O O
in O O
rats O O
. O O

Thirty O O
to O O
135 O O
min O O
after O O
the O O
injection O O
of O O
crystalline O O
insulin O O
, O O
ISO O O
was O O
given O O
subcutaneously O O
and O O
when O O
ISO O O
induced O O
fibrosis B-Disease B-Disease
in O O
the O O
myocardium O O
was O O
morphometrically O O
analyzed O O
7 O O
days O O
later O O
, O O
a O O
highly O O
significant O O
correlation O O
( O O
r O O
= O O
0.83 O O
, O O
2 O O
p O O
= O O
0.006 O O
) O O
to O O
the O O
slope O O
of O O
the O O
fall O O
in O O
blood O O
glucose O O
after O O
insulin O O
treatment O O
appeared O O
. O O

The O O
myocardial O O
content O O
of O O
catecholamines O O
was O O
estimated O O
in O O
these O O
8 O O
day O O
diabetic B-Disease B-Disease
rats O O
. O O

The O O
norepinephrine O O
content O O
was O O
significantly O O
increased O O
while O O
epinephrine O O
remained O O
unchanged O O
. O O

An O O
enhanced O O
sympathetic O O
nervous O O
system O O
activity O O
with O O
a O O
consequent O O
down O O
regulation O O
of O O
the O O
myocardial O O
beta O O
- O O
adrenergic O O
receptors O O
could O O
, O O
therefore O O
, O O
explain O O
this O O
catecholamine O O
resistance O O
. O O

The O O
rapid O O
reversion O O
after O O
insulin O O
treatment O O
excludes O O
the O O
possibility O O
that O O
streptozotocin O O
in O O
itself O O
causes O O
the O O
ISO O O
resistance O O
and O O
points O O
towards O O
a O O
direct O O
insulin O O
effect O O
on O O
myocardial O O
catecholamine O O
sensitivity O O
in O O
diabetic B-Disease B-Disease
rats O O
. O O

The O O
phenomenon O O
described O O
might O O
elucidate O O
pathogenetic O O
mechanisms O O
behind O O
toxic O O
myocardial O O
cell O O
degeneration O O
and O O
may O O
possibly O O
have O O
relevance O O
for O O
acute O O
cardiovascular O B-Disease
complications O I-Disease
in O O
diabetic B-Disease B-Disease
patients O O
. O O

Differential O O
effects O O
of O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
on O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
in O O
rats O O
. O O

The O O
muscarinic O O
cholinergic O O
agonist O O
pilocarpine O O
induces O O
in O O
rats O O
seizures B-Disease B-Disease
and O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
followed O O
by O O
widespread O O
damage O O
to O O
the O O
forebrain O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
effect O O
of O O
5 O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
, O O
sodium O O
salicylate O O
, O O
phenylbutazone O O
, O O
indomethacin O O
, O O
ibuprofen O O
and O O
mefenamic O O
acid O O
, O O
on O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
. O O

Pretreatment O O
of O O
rats O O
with O O
sodium O O
salicylate O O
, O O
ED50 O O
103 O O
mg O O
/ O O
kg O O
( O O
60 O O
- O O
174 O O
) O O
, O O
and O O
phenylbutazone O O
, O O
59 O O
mg O O
/ O O
kg O O
( O O
50 O O
- O O
70 O O
) O O
converted O O
the O O
non O O
- O O
convulsant O O
dose O O
of O O
pilocarpine O O
, O O
200 O O
mg O O
/ O O
kg O O
, O O
to O O
a O O
convulsant O O
one O O
. O O

Indomethacin O O
, O O
1 O O
- O O
10 O O
mg O O
/ O O
kg O O
, O O
and O O
ibuprofen O O
, O O
10 O O
- O O
100 O O
mg O O
/ O O
kg O O
, O O
failed O O
to O O
modulate O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
. O O

Mefenamic O O
acid O O
, O O
26 O O
( O O
22 O O
- O O
30 O O
) O O
mg O O
/ O O
kg O O
, O O
prevented O O
seizures B-Disease B-Disease
and O O
protected O O
rats O O
from O O
seizure B-Disease B-Disease
- O O
related O O
brain B-Disease B-Disease
damage I-Disease I-Disease
induced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

These O O
results O O
indicate O O
that O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
differentially O O
modulate O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
seizures B-Disease B-Disease
. O O

Acute B-Disease B-Disease
neurologic I-Disease I-Disease
dysfunction I-Disease I-Disease
after O O
high O O
- O O
dose O O
etoposide O O
therapy O O
for O O
malignant B-Disease B-Disease
glioma I-Disease I-Disease
. O O

Etoposide O O
( O O
VP-16 O O
- O O
213 O O
) O O
has O O
been O O
used O O
in O O
the O O
treatment O O
of O O
many O O
solid O B-Disease
tumors B-Disease I-Disease
and O O
hematologic B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

When O O
used O O
in O O
high O O
doses O O
and O O
in O O
conjunction O O
with O O
autologous O O
bone O O
marrow O O
transplantation O O
, O O
this O O
agent O O
has O O
activity O O
against O O
several O O
treatment O O
- O O
resistant O O
cancers B-Disease B-Disease
including O O
malignant B-Disease B-Disease
glioma I-Disease I-Disease
. O O

In O O
six O O
of O O
eight O O
patients O O
( O O
75 O O
% O O
) O O
who O O
we O O
treated O O
for O O
recurrent O O
or O O
resistant O O
glioma B-Disease B-Disease
, O O
sudden O O
severe O O
neurologic B-Disease B-Disease
deterioration I-Disease I-Disease
occurred O O
. O O

This O O
developed O O
a O O
median O O
of O O
9 O O
days O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
etoposide O O
therapy O O
. O O

Significant O O
clinical O O
manifestations O O
have O O
included O O
confusion B-Disease B-Disease
, O O
papilledema B-Disease B-Disease
, O O
somnolence B-Disease B-Disease
, O O
exacerbation O O
of O O
motor B-Disease B-Disease
deficits I-Disease I-Disease
, O O
and O O
sharp O O
increase O O
in O O
seizure B-Disease B-Disease
activity O O
. O O

These O O
abnormalities O O
resolved O O
rapidly O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
intravenous O O
dexamethasone O O
therapy O O
. O O

In O O
all O O
patients O O
, O O
computerized O O
tomographic O O
( O O
CT O O
) O O
brain O O
scans O O
demonstrated O O
stability O O
in O O
tumor B-Disease B-Disease
size O O
and O O
peritumor O O
edema B-Disease B-Disease
when O O
compared O O
with O O
pretransplant O O
scans O O
. O O

This O O
complication O O
appears O O
to O O
represent O O
a O O
significant O O
new O O
toxicity B-Disease B-Disease
of O O
high O O
- O O
dose O O
etoposide O O
therapy O O
for O O
malignant B-Disease B-Disease
glioma I-Disease I-Disease
. O O

Progressive O O
bile B-Disease B-Disease
duct I-Disease I-Disease
injury I-Disease I-Disease
after O O
thiabendazole O O
administration O O
. O O

A O O
27-yr O O
- O O
old O O
man O O
developed O O
jaundice B-Disease B-Disease
2 O O
wk O O
after O O
exposure O O
to O O
thiabendazole O O
. O O

Cholestasis B-Disease B-Disease
persisted O O
for O O
3 O O
yr O O
, O O
at O O
which O O
time O O
a O O
liver O O
transplant O O
was O O
performed O O
. O O

Two O O
liver O O
biopsy O O
specimens O O
and O O
the O O
hepatectomy O O
specimen O O
were O O
remarkable O O
for O O
almost O O
complete O O
disappearance O O
of O O
interlobular O O
bile O O
ducts O O
. O O

Prominent O O
fibrosis B-Disease B-Disease
and O O
hepatocellular O O
regeneration O O
were O O
also O O
present O O
; O O
however O O
, O O
the O O
lobular O O
architecture O O
was O O
preserved O O
. O O

This O O
case O O
represents O O
an O O
example O O
of O O
" O O
idiosyncratic O O
" O O
drug B-Disease O
- I-Disease O
induced I-Disease O
liver I-Disease B-Disease
damage I-Disease I-Disease
in O O
which O O
the O O
primary O O
target O O
of O O
injury O O
is O O
the O O
bile O O
duct O O
. O O

An O O
autoimmune O O
pathogenesis O O
of O O
the O O
bile B-Disease B-Disease
duct I-Disease I-Disease
destruction I-Disease I-Disease
is O O
suggested O O
. O O

Differential O O
effects O O
of O O
1,4-dihydropyridine O O
calcium O O
channel O O
blockers O O
: O O
therapeutic O O
implications O O
. O O

Increasing O O
recognition O O
of O O
the O O
importance O O
of O O
calcium O O
in O O
the O O
pathogenesis O O
of O O
cardiovascular B-Disease B-Disease
disease I-Disease I-Disease
has O O
stimulated O O
research O O
into O O
the O O
use O O
of O O
calcium O O
channel O O
blocking O O
agents O O
for O O
treatment O O
of O O
a O O
variety O O
of O O
cardiovascular B-Disease B-Disease
diseases I-Disease I-Disease
. O O

The O O
favorable O O
efficacy O O
and O O
tolerability O O
profiles O O
of O O
these O O
agents O O
make O O
them O O
attractive O O
therapeutic O O
modalities O O
. O O

Clinical O O
applications O O
of O O
calcium O O
channel O O
blockers O O
parallel O O
their O O
tissue O O
selectivity O O
. O O

In O O
contrast O O
to O O
verapamil O O
and O O
diltiazem O O
, O O
which O O
are O O
roughly O O
equipotent O O
in O O
their O O
actions O O
on O O
the O O
heart O O
and O O
vascular O O
smooth O O
muscle O O
, O O
the O O
dihydropyridine O O
calcium O O
channel O O
blockers O O
are O O
a O O
group O O
of O O
potent O O
peripheral O O
vasodilator O O
agents O O
that O O
exert O O
minimal O O
electrophysiologic O O
effects O O
on O O
cardiac O O
nodal O O
or O O
conduction O O
tissue O O
. O O

As O O
the O O
first O O
dihydropyridine O O
available O O
for O O
use O O
in O O
the O O
United O O
States O O
, O O
nifedipine O O
controls O O
angina B-Disease B-Disease
and O O
hypertension B-Disease B-Disease
with O O
minimal O O
depression O B-Disease
of O I-Disease
cardiac O I-Disease
function O I-Disease
. O O

Additional O O
members O O
of O O
this O O
group O O
of O O
calcium O O
channel O O
blockers O O
have O O
been O O
studied O O
for O O
a O O
variety O O
of O O
indications O O
for O O
which O O
they O O
may O O
offer O O
advantages O O
over O O
current O O
therapy O O
. O O

Once O O
or O O
twice O O
daily O O
dosage O O
possible O O
with O O
nitrendipine O O
and O O
nisoldipine O O
offers O O
a O O
convenient O O
administration O O
schedule O O
, O O
which O O
encourages O O
patient O O
compliance O O
in O O
long O O
- O O
term O O
therapy O O
of O O
hypertension B-Disease B-Disease
. O O

The O O
coronary O O
vasodilating O O
properties O O
of O O
nisoldipine O O
have O O
led O O
to O O
the O O
investigation O O
of O O
this O O
agent O O
for O O
use O O
in O O
angina B-Disease B-Disease
. O O

Selectivity O O
for O O
the O O
cerebrovascular O O
bed O O
makes O O
nimodipine O O
potentially O O
useful O O
in O O
the O O
treatment O O
of O O
subarachnoid B-Disease B-Disease
hemorrhage I-Disease I-Disease
, O O
migraine B-Disease B-Disease
headache I-Disease I-Disease
, O O
dementia B-Disease B-Disease
, O O
and O O
stroke B-Disease B-Disease
. O O

In O O
general O O
, O O
the O O
dihydropyridine O O
calcium O O
channel O O
blockers O O
are O O
usually O O
well O O
tolerated O O
, O O
with O O
headache B-Disease B-Disease
, O O
facial O B-Disease
flushing B-Disease I-Disease
, O O
palpitations B-Disease B-Disease
, O O
edema B-Disease B-Disease
, O O
nausea B-Disease B-Disease
, O O
anorexia B-Disease B-Disease
, O O
and O O
dizziness B-Disease B-Disease
being O O
the O O
more O O
common O O
adverse O O
effects O O
. O O

The O O
enhancement O O
of O O
aminonucleoside O O
nephrosis B-Disease B-Disease
by O O
the O O
co O O
- O O
administration O O
of O O
protamine O O
. O O

An O O
experimental O O
model O O
of O O
focal B-Disease B-Disease
segmental I-Disease I-Disease
glomerular I-Disease I-Disease
sclerosis I-Disease I-Disease
( O O
FSGS B-Disease B-Disease
) O O
was O O
developed O O
in O O
rats O O
by O O
the O O
combined O O
administration O O
of O O
puromycin O O
- O O
aminonucleoside O O
( O O
AMNS O O
) O O
and O O
protamine O O
sulfate O O
( O O
PS O O
) O O
. O O

Male O O
Sprague O O
- O O
Dawley O O
rats O O
, O O
uninephrectomized O O
three O O
weeks O O
before O O
, O O
received O O
daily O O
injections O O
of O O
subcutaneous O O
AMNS O O
( O O
1 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
and O O
intravenous O O
PS O O
( O O
2 O O
separated O O
doses O O
of O O
2.5 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
for O O
four O O
days O O
. O O

The O O
series O O
of O O
injections O O
were O O
repeated O O
another O O
three O O
times O O
at O O
10 O O
day O O
intervals O O
. O O

The O O
animals O O
were O O
sacrificed O O
on O O
days O O
24 O O
, O O
52 O O
, O O
and O O
80 O O
. O O

They O O
developed O O
nephrotic B-Disease B-Disease
syndrome I-Disease I-Disease
and O O
finally O O
renal B-Disease B-Disease
failure I-Disease I-Disease
. O O

The O O
time O O
- O O
course O O
curve O O
of O O
creatinine O O
clearance O O
dropped O O
and O O
showed O O
significant O O
difference O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
from O O
that O O
of O O
each O O
control O O
group O O
, O O
such O O
as O O
, O O
AMNS O O
alone O O
, O O
PS O O
alone O O
or O O
saline O O
injected O O
. O O

Their O O
glomeruli O O
showed O O
changes O O
of O O
progressive O O
FSGS B-Disease B-Disease
. O O

The O O
ultrastructural O O
studies O O
in O O
the O O
initial O O
stage O O
revealed O O
significant O O
lack O O
of O O
particles O O
of O O
perfused O O
ruthenium O O
red O O
on O O
the O O
lamina O O
rara O O
externa O O
and O O
marked O O
changes O O
in O O
epithelial O O
cell O O
cytoplasm O O
. O O

Therefore O O
, O O
it O O
is O O
suggested O O
that O O
the O O
administration O O
of O O
PS O O
enhances O O
the O O
toxicity B-Disease O
of O O
AMNS O O
on O O
the O O
glomerulus O O
and O O
readily O O
produces O O
progressive O O
FSGS B-Disease B-Disease
in O O
rats O O
resulting O O
in O O
the O O
end B-Disease B-Disease
- I-Disease I-Disease
stage I-Disease I-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
. O O

Theophylline O O
neurotoxicity B-Disease B-Disease
in O O
pregnant O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
investigation O O
was O O
to O O
determine O O
whether O O
the O O
neurotoxicity B-Disease B-Disease
of O O
theophylline O O
is O O
altered O O
in O O
advanced O O
pregnancy O O
. O O

Sprague O O
- O O
Dawley O O
rats O O
that O O
were O O
20 O O
days O O
pregnant O O
and O O
nonpregnant O O
rats O O
of O O
the O O
same O O
age O O
and O O
strain O O
received O O
infusions O O
of O O
aminophylline O O
until O O
onset O O
of O O
maximal O O
seizures B-Disease B-Disease
which O O
occurred O O
after O O
28 O O
and O O
30 O O
minutes O O
respectively O O
. O O

Theophylline O O
concentrations O O
at O O
this O O
endpoint O O
in O O
serum O O
( O O
total O O
) O O
and O O
CSF O O
were O O
similar O O
but O O
serum O O
( O O
free O O
) O O
and O O
brain O O
concentrations O O
were O O
slightly O O
different O O
in O O
pregnant O O
rats O O
. O O

Theophylline O O
serum O O
protein O O
binding O O
determined O O
by O O
equilibrium O O
dialysis O O
was O O
lower O O
in O O
pregnant O O
rats O O
. O O

Fetal O O
serum O O
concentrations O O
at O O
onset O O
of O O
seizures B-Disease B-Disease
in O O
the O O
mother O O
were O O
similar O O
to O O
maternal O O
brain O O
and O O
CSF O O
concentrations O O
and O O
correlated O O
significantly O O
with O O
the O O
former O O
. O O

It O O
is O O
concluded O O
that O O
advanced O O
pregnancy O O
has O O
a O O
negligible O O
effect O O
on O O
the O O
neurotoxic B-Disease B-Disease
response O O
to O O
theophylline O O
in O O
rats O O
. O O

Hyperkalemia B-Disease B-Disease
induced O O
by O O
indomethacin O O
and O O
naproxen O O
and O O
reversed O O
by O O
fludrocortisone O O
. O O

We O O
have O O
described O O
a O O
patient O O
with O O
severe O O
rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
and O O
a O O
history O O
of O O
mefenamic O O
acid O O
nephropathy B-Disease B-Disease
in O O
whom O O
hyperkalemia B-Disease B-Disease
and O O
inappropriate O O
hypoaldosteronism B-Disease B-Disease
were O O
caused O O
by O O
both O O
indomethacin O O
and O O
naproxen O O
, O O
without O O
major O O
decline O O
in O O
renal O O
function O O
. O O

It O O
is O O
likely O O
that O O
preexisting O O
renal B-Disease B-Disease
disease I-Disease I-Disease
predisposed O O
this O O
patient O O
to O O
type B-Disease B-Disease
IV I-Disease I-Disease
renal I-Disease I-Disease
tubular I-Disease I-Disease
acidosis I-Disease I-Disease
with O O
prostaglandin O O
synthetase O O
inhibitors O O
. O O

Because O O
he O O
was O O
unable O O
to O O
discontinue O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
therapy O O
, O O
fludrocortisone O O
was O O
added O O
, O O
correcting O O
the O O
hyperkalemia B-Disease B-Disease
and O O
allowing O O
indomethacin O O
therapy O O
to O O
be O O
continued O O
safely O O
. O O

Hypotension B-Disease B-Disease
as O O
a O O
manifestation O O
of O O
cardiotoxicity B-Disease B-Disease
in O O
three O O
patients O O
receiving O O
cisplatin O O
and O O
5-fluorouracil O O
. O O

Cardiac O B-Disease
symptoms O I-Disease
, O O
including O O
hypotension B-Disease B-Disease
, O O
developed O O
in O O
three O O
patients O O
with O O
advanced O O
colorectal B-Disease B-Disease
carcinoma I-Disease I-Disease
while O O
being O O
treated O O
with O O
cisplatin O O
( O O
CDDP O O
) O O
and O O
5-fluorouracil O O
( O O
5-FU O O
) O O
. O O

In O O
two O O
patients O O
, O O
hypotension B-Disease B-Disease
was O O
associated O O
with O O
severe O O
left B-Disease B-Disease
ventricular I-Disease I-Disease
dysfunction I-Disease I-Disease
. O O

All O O
three O O
patients O O
required O O
therapy O O
discontinuation O O
. O O

Cardiac O O
enzymes O O
remained O O
normal O O
despite O O
transient O O
electrocardiographic O O
( O O
EKG O O
) O O
changes O O
. O O

The O O
presentation O O
and O O
cardiac O O
evaluation O O
( O O
hemodynamic O O
, O O
echocardiographic O O
, O O
and O O
scintigraphic O O
) O O
of O O
these O O
patients O O
suggest O O
new O O
manifestations O O
of O O
5-FU O O
cardiotoxicity B-Disease B-Disease
that O O
may O O
be O O
influenced O O
by O O
CDDP O O
. O O

The O O
possible O O
pathophysiologic O O
mechanisms O O
are O O
discussed O O
. O O

Fatal O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
in O O
a O O
patient O O
treated O O
with O O
carbamazepine O O
. O O

A O O
case O O
of O O
fatal O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
due O O
to O O
carbamazepine O O
treatment O O
in O O
an O O
epileptic B-Disease B-Disease
woman O O
is O O
reported O O
. O O

Despite O O
concerns O O
of O O
fatal O O
bone B-Disease B-Disease
marrow I-Disease I-Disease
toxicity I-Disease I-Disease
due O O
to O O
carbamazepine O O
, O O
this O O
is O O
only O O
the O O
fourth O O
documented O O
and O O
published O O
report O O
. O O

Carbamazepine O O
is O O
a O O
safe O O
drug O O
, O O
but O O
physicians O O
and O O
patients O O
should O O
be O O
aware O O
of O O
the O O
exceedingly O O
rare O O
but O O
potentially O O
fatal O O
side O O
effects O O
, O O
better O O
prevented O O
by O O
clinical O O
than O O
by O O
laboratory O O
monitoring O O
. O O

Participation O O
of O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
in O O
the O O
rat O O
brain O O
in O O
clonidine O O
- O O
induced O O
hypotension B-Disease B-Disease
and O O
bradycardia B-Disease B-Disease
. O O

The O O
effects O O
of O O
microinjection O O
of O O
clonidine O O
( O O
1 O O
- O O
10 O O
micrograms O O
in O O
1 O O
microliter O O
) O O
into O O
a O O
region O O
adjacent O O
to O O
the O O
ventrolateral O O
surface O O
of O O
the O O
medulla O O
oblongata O O
on O O
cardiovascular O O
function O O
were O O
assessed O O
in O O
urethane O O
- O O
anesthetized O O
rats O O
. O O

Intramedullary O O
administration O O
of O O
clonidine O O
, O O
but O O
not O O
saline O O
vehicle O O
, O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
both O O
the O O
mean O O
arterial O O
pressure O O
and O O
the O O
heart O O
rate O O
. O O

The O O
clonidine O O
- O O
induced O O
hypotension B-Disease B-Disease
was O O
antagonized O O
by O O
prior O O
spinal O O
transection O O
, O O
but O O
not O O
bilateral O O
vagotomy O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
clonidine O O
- O O
induced O O
bradycardia B-Disease B-Disease
was O O
antagonized O O
by O O
prior O O
bilateral O O
vagotomy O O
, O O
but O O
not O O
spinal O O
transection O O
. O O

Furthermore O O
, O O
selective O O
destruction O O
of O O
the O O
spinal O O
5-HT O O
nerves O O
, O O
produced O O
by O O
bilateral O O
spinal O O
injection O O
of O O
5,7-dihydroxytryptamine O O
, O O
reduced O O
the O O
magnitude O O
of O O
the O O
vasodepressor O O
or O O
the O O
bradycardiac B-Disease B-Disease
responses O O
to O O
clonidine O O
microinjected O O
into O O
the O O
area O O
near O O
the O O
ventrolateral O O
surface O O
of O O
the O O
medulla O O
oblongata O O
in O O
rats O O
. O O

The O O
data O O
indicate O O
that O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
is O O
involved O O
in O O
development O O
of O O
clonidine O O
- O O
induced O O
hypotension B-Disease B-Disease
and O O
bradycardia B-Disease B-Disease
. O O

The O O
induced O O
hypotension B-Disease B-Disease
is O O
brought O O
about O O
by O O
a O O
decrease O O
in O O
sympathetic O O
efferent O O
activity O O
, O O
whereas O O
the O O
induced O O
bradycardia B-Disease B-Disease
was O O
due O O
to O O
an O O
increase O O
in O O
vagal O O
efferent O O
activity O O
. O O

Hypertension B-Disease B-Disease
in O O
neuroblastoma B-Disease B-Disease
induced O O
by O O
imipramine O O
. O O

Hypertension B-Disease B-Disease
is O O
a O O
well O O
- O O
known O O
finding O O
in O O
some O O
patients O O
with O O
neuroblastoma B-Disease B-Disease
. O O

However O O
, O O
it O O
has O O
not O O
previously O O
been O O
described O O
in O O
association O O
with O O
the O O
use O O
of O O
Imipramine O O
. O O

We O O
report O O
the O O
occurrence O O
of O O
severe O O
hypertension B-Disease B-Disease
( O O
blood O O
pressure O O
190 O O
/ O O
160 O O
) O O
in O O
a O O
4-year O O
- O O
old O O
girl O O
with O O
neuroblastoma B-Disease B-Disease
who O O
was O O
given O O
Imipramine O O
to O O
control O O
a O O
behavior B-Disease B-Disease
disorder I-Disease I-Disease
. O O

It O O
was O O
determined O O
later O O
that O O
this O O
patient O O
's O O
tumor B-Disease B-Disease
was O O
recurring O O
at O O
the O O
time O O
of O O
her O O
hypertensive B-Disease B-Disease
episode O O
. O O

Since O O
she O O
had O O
no O O
blood O O
pressure O O
elevation O O
at O O
initial O O
diagnosis O O
and O O
none O O
following O O
discontinuation O O
of O O
the O O
Imipramine O O
( O O
when O O
she O O
was O O
in O O
florid O O
relapse O O
) O O
, O O
we O O
believe O O
that O O
this O O
drug O O
rather O O
than O O
her O O
underlying O O
disease O O
alone O O
caused O O
her O O
hypertension B-Disease B-Disease
. O O

The O O
mechanism O O
for O O
this O O
reaction O O
is O O
believed O O
to O O
be O O
increased O O
levels O O
of O O
vasoactive O O
catecholamines O O
due O O
to O O
interference O O
of O O
their O O
physiologic O O
inactivation O O
by O O
Imipramine O O
. O O

From O O
this O O
experience O O
, O O
we O O
urge O O
extreme O O
caution O O
in O O
the O O
use O O
of O O
tricyclic O O
antidepressants O O
in O O
children O O
with O O
active O O
neuroblastoma B-Disease B-Disease
. O O

Rechallenge O O
of O O
patients O O
who O O
developed O O
oral B-Disease B-Disease
candidiasis I-Disease I-Disease
or O O
hoarseness B-Disease B-Disease
with O O
beclomethasone O O
dipropionate O O
. O O

Of O O
158 O O
asthmatic B-Disease B-Disease
patients O O
who O O
were O O
placed O O
on O O
inhaled O O
beclomethasone O O
, O O
15 O O
( O O
9.5 O O
% O O
) O O
developed O O
either O O
hoarseness B-Disease B-Disease
( O O
8) O O
, O O
oral O O
thrush B-Disease B-Disease
( O O
6 O O
) O O
, O O
or O O
both O O
( O O
1 O O
) O O
. O O

When O O
their O O
adverse O O
reactions O O
subsided O O
, O O
seven O O
of O O
these O O
15 O O
patients O O
were O O
rechallenged O O
with O O
inhaled O O
beclomethasone O O
. O O

These O O
included O O
five O O
cases O O
who O O
developed O O
hoarseness B-Disease B-Disease
and O O
three O O
who O O
developed O O
Candidiasis B-Disease B-Disease
. O O

One O O
patient O O
had O O
both O O
. O O

Oral O B-Disease
thrush B-Disease I-Disease
did O O
not O O
recur O O
, O O
but O O
60 O O
% O O
( O O
3 O O
/ O O
5 O O
) O O
of O O
patients O O
with O O
hoarseness B-Disease B-Disease
had O O
recurrence O O
. O O

We O O
conclude O O
that O O
patients O O
may O O
be O O
restarted O O
on O O
inhaled O O
beclomethasone O O
when O O
clinically O O
indicated O O
; O O
however O O
, O O
because O O
of O O
the O O
high O O
recurrence O O
rate O O
, O O
patients O O
who O O
develop O O
hoarseness B-Disease B-Disease
should O O
not O O
be O O
re O O
- O O
challenged O O
. O O

Concomitant O O
use O O
of O O
oral O O
prednisone O O
and O O
topical O O
beclomethasone O O
may O O
increase O O
the O O
risk O O
of O O
developing O O
hoarseness B-Disease B-Disease
or O O
candidiasis B-Disease B-Disease
. O O

Cyclophosphamide O O
cardiotoxicity B-Disease B-Disease
: O O
an O O
analysis O O
of O O
dosing O O
as O O
a O O
risk O O
factor O O
. O O

Patients O O
who O O
undergo O O
bone O O
marrow O O
transplantation O O
are O O
generally O O
immunosuppressed O O
with O O
a O O
dose O O
of O O
cyclophosphamide O O
( O O
CYA O O
) O O
which O O
is O O
usually O O
calculated O O
based O O
on O O
the O O
patient O O
's O O
weight O O
. O O

At O O
these O O
high O O
doses O O
of O O
CYA O O
, O O
serious O O
cardiotoxicity B-Disease B-Disease
may O O
occur O O
, O O
but O O
definitive O O
risk O O
factors O O
for O O
the O O
development O O
of O O
such O O
cardiotoxicity B-Disease B-Disease
have O O
not O O
been O O
described O O
. O O

Since O O
chemotherapeutic O O
agent O O
toxicity B-Disease B-Disease
generally O O
correlates O O
with O O
dose O O
per O O
body O O
surface O O
area O O
, O O
we O O
retrospectively O O
calculated O O
the O O
dose O O
of O O
CYA O O
in O O
patients O O
transplanted O O
at O O
our O O
institution O O
to O O
determine O O
whether O O
the O O
incidence O O
of O O
CYA O O
cardiotoxicity B-Disease B-Disease
correlated O O
with O O
the O O
dose O O
per O O
body O O
surface O O
area O O
. O O

Eighty O O
patients O O
who O O
were O O
to O O
receive O O
CYA O O
50 O O
mg O O
/ O O
kg O O
/ O O
d O O
for O O
four O O
days O O
as O O
preparation O O
for O O
marrow O O
grafting O O
underwent O O
a O O
total O O
of O O
84 O O
transplants O O
for O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
, O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
or O O
severe B-Disease B-Disease
combined I-Disease I-Disease
immunodeficiency I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Fourteen O O
of O O
84 O O
( O O
17 O O
% O O
) O O
patients O O
had O O
symptoms O O
and O O
signs O O
consistent O O
with O O
CYA O O
cardiotoxicity B-Disease B-Disease
within O O
ten O O
days O O
of O O
receiving O O
1 O O
to O O
4 O O
doses O O
of O O
CYA O O
. O O

Six O O
of O O
the O O
14 O O
patients O O
died O O
with O O
congestive B-Disease B-Disease
heart I-Disease I-Disease
failure I-Disease I-Disease
. O O

The O O
dose O O
of O O
CYA O O
per O O
body O O
surface O O
area O O
was O O
calculated O O
for O O
all O O
patients O O
and O O
the O O
patients O O
were O O
divided O O
into O O
two O O
groups O O
based O O
on O O
daily O O
CYA O O
dose O O
: O O
Group O O
1 O O
, O O
CYA O O
less O O
than O O
or O O
equal O O
to O O
1.55 O O
g O O
/ O O
m2 O O
/ O O
d O O
; O O
Group O O
2 O O
, O O
CYA O O
greater O O
than O O
1.55 O O
g O O
/ O O
m2 O O
/ O O
d O O
. O O

Cardiotoxicity B-Disease B-Disease
that O O
was O O
thought O O
to O O
be O O
related O O
to O O
CYA O O
occurred O O
in O O
1 O O
/ O O
32 O O
( O O
3 O O
% O O
) O O
of O O
patients O O
in O O
Group O O
1 O O
and O O
in O O
13 O O
/ O O
52 O O
( O O
25 O O
% O O
) O O
patients O O
in O O
Group O O
2 O O
( O O
P O O
less O O
than O O
0.025 O O
) O O
. O O

Congestive B-Disease B-Disease
heart I-Disease I-Disease
failure I-Disease I-Disease
caused O O
or O O
contributed O O
to O O
death O O
in O O
0 O O
/ O O
32 O O
patients O O
in O O
Group O O
1 O O
v O O
6 O O
/ O O
52 O O
( O O
12 O O
% O O
) O O
of O O
patients O O
in O O
Group O O
2 O O
( O O
P O O
less O O
than O O
0.25 O O
) O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
rate O O
of O O
engraftment O O
of O O
evaluable O O
patients O O
in O O
the O O
two O O
groups O O
( O O
P O O
greater O O
than O O
0.5 O O
) O O
. O O

We O O
conclude O O
that O O
the O O
CYA O O
cardiotoxicity B-Disease B-Disease
correlates O O
with O O
CYA O O
dosage O O
as O O
calculated O O
by O O
body O O
surface O O
area O O
, O O
and O O
that O O
patients O O
with O O
aplastic B-Disease B-Disease
anemia I-Disease I-Disease
and O O
immunodeficiencies B-Disease B-Disease
can O O
be O O
effectively O O
prepared O O
for O O
bone O O
marrow O O
grafting O O
at O O
a O O
CYA O O
dose O O
of O O
1.55 O O
g O O
/ O O
m2 O O
/ O O
d O O
for O O
four O O
days O O
with O O
a O O
lower O O
incidence O O
of O O
cardiotoxicity B-Disease B-Disease
than O O
patients O O
whose O O
CYA O O
dosage O O
is O O
calculated O O
based O O
on O O
weight O O
. O O

This O O
study O O
reaffirms O O
the O O
principle O O
that O O
drug O B-Disease
toxicity B-Disease I-Disease
correlates O O
with O O
dose O O
per O O
body O O
surface O O
area O O
. O O

Studies O O
of O O
risk O O
factors O O
for O O
aminoglycoside O O
nephrotoxicity B-Disease B-Disease
. O O

The O O
epidemiology O O
of O O
aminoglycoside O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
is O O
not O O
fully O O
understood O O
. O O

Experimental O O
studies O O
in O O
healthy O O
human O O
volunteers O O
indicate O O
aminoglycosides O O
cause O O
proximal O O
tubular O B-Disease
damage O I-Disease
in O O
most O O
patients O O
, O O
but O O
rarely O O
, O O
if O O
ever O O
, O O
cause O O
glomerular B-Disease B-Disease
or I-Disease I-Disease
tubular I-Disease I-Disease
dysfunction I-Disease I-Disease
. O O

Clinical O O
trials O O
of O O
aminoglycosides O O
in O O
seriously O O
ill O O
patients O O
indicate O O
that O O
the O O
relative O O
risk O O
for O O
developing O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
during O O
therapy O O
ranges O O
from O O
8 O O
to O O
10 O O
and O O
that O O
the O O
attributable O O
risk O O
is O O
70 O O
% O O
to O O
80 O O
% O O
. O O

Further O O
analysis O O
of O O
these O O
data O O
suggests O O
that O O
the O O
duration O O
of O O
therapy O O
, O O
plasma O O
aminoglycoside O O
levels O O
, O O
liver B-Disease B-Disease
disease I-Disease I-Disease
, O O
advanced O O
age O O
, O O
high O O
initial O O
estimated O O
creatinine O O
clearance O O
and O O
, O O
possibly O O
, O O
female O O
gender O O
all O O
increase O O
the O O
risk O O
for O O
nephrotoxicity B-Disease B-Disease
. O O

Other O O
causes O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
, O O
such O O
as O O
shock B-Disease B-Disease
, O O
appear O O
to O O
have O O
an O O
additive O O
effect O O
. O O

Predictive O O
models O O
have O O
been O O
developed O O
from O O
these O O
analyses O O
that O O
should O O
be O O
useful O O
for O O
identifying O O
patients O O
at O O
high O O
risk O O
. O O

These O O
models O O
may O O
also O O
be O O
useful O O
in O O
developing O O
insights O O
into O O
the O O
pathophysiology O O
of O O
aminoglycoside O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
. O O

Central O O
action O O
of O O
narcotic O O
analgesics O O
. O O

Part O O
IV O O
. O O

Noradrenergic O O
influences O O
on O O
the O O
activity O O
of O O
analgesics O O
in O O
rats O O
. O O

The O O
effect O O
of O O
clonidine O O
, O O
naphazoline O O
and O O
xylometazoline O O
on O O
analgesia O O
induced O O
by O O
morphine O O
, O O
codeine O O
, O O
fentanyl O O
and O O
pentazocine O O
, O O
and O O
on O O
cataleptic B-Disease B-Disease
effect O O
of O O
morphine O O
, O O
codine O O
and O O
fentanyl O O
was O O
studied O O
in O O
rats O O
. O O

The O O
biochemical O O
assays O O
on O O
the O O
influence O O
of O O
four O O
analgesics O O
on O O
the O O
brain O O
concentration O O
and O O
turnover O O
of O O
noradrenaline O O
( O O
NA O O
) O O
were O O
also O O
performed O O
. O O

It O O
was O O
found O O
that O O
three O O
drugs O O
stimulating O O
central O O
NA O O
receptors O O
failed O O
to O O
affect O O
the O O
analgesic O O
ED50 O O
of O O
all O O
antinociceptive O O
agents O O
and O O
they O O
enhanced O O
catalepsy B-Disease B-Disease
induced O O
by O O
morphine O O
and O O
fentanyl O O
. O O

Codeine O O
catalepsy B-Disease B-Disease
was O O
increased O O
by O O
clonidine O O
and O O
decreased O O
by O O
naphazoline O O
and O O
xylometazoline O O
. O O

The O O
brain O O
concentration O O
of O O
NA O O
was O O
not O O
changed O O
by O O
morphine O O
and O O
fentanyl O O
, O O
but O O
one O O
of O O
the O O
doses O O
of O O
codeine O O
( O O
45 O O
mg O O
/ O O
kg O O
) O O
slightly O O
enhanced O O
it O O
. O O

Pentazocine O O
dose O O
- O O
dependently O O
decreased O O
the O O
brain O O
level O O
of O O
NA O O
. O O

The O O
rate O O
of O O
NA O O
turnover O O
was O O
not O O
altered O O
by O O
analgesics O O
except O O
for O O
the O O
higher O O
dose O O
of O O
fentanyl O O
( O O
0.2 O O
mg O O
/ O O
kg O O
) O O
following O O
which O O
the O O
disappearance O O
of O O
NA O O
from O O
the O O
brain O O
was O O
diminished O O
. O O

The O O
results O O
are O O
discussed O O
in O O
the O O
light O O
of O O
various O O
and O O
non O O
- O O
uniform O O
data O O
from O O
the O O
literature O O
. O O

It O O
is O O
suggested O O
that O O
in O O
rats O O
the O O
brain O O
NA O O
plays O O
a O O
less O O
important O O
function O O
than O O
the O O
other O O
monoamines O O
in O O
the O O
behavioural O O
activity O O
of O O
potent O O
analgesics O O
. O O

Flurothyl O O
seizure B-Disease B-Disease
thresholds O O
in O O
mice O O
treated O O
neonatally O O
with O O
a O O
single O O
injection O O
of O O
monosodium O O
glutamate O O
( O O
MSG O O
) O O
: O O
evaluation O O
of O O
experimental O O
parameters O O
in O O
flurothyl O O
seizure B-Disease B-Disease
testing O O
. O O

Monosodium O O
glutamate O O
( O O
MSG O O
) O O
administration O O
to O O
neonatal O O
rodents O O
produces O O
convulsions B-Disease B-Disease
and O O
results O O
in O O
numerous O O
biochemical O O
and O O
behavioral O B-Disease
deficits O I-Disease
. O O

These O O
studies O O
were O O
undertaken O O
to O O
determine O O
if O O
neonatal O O
administration O O
of O O
MSG O O
produced O O
permanent O O
alterations O O
in O O
seizure B-Disease B-Disease
susceptibility O O
, O O
since O O
previous O O
investigations O O
were O O
inconclusive O O
. O O

A O O
flurothyl O O
ether O O
seizure B-Disease B-Disease
screening O O
technique O O
was O O
used O O
to O O
evaluate O O
seizure B-Disease B-Disease
susceptibility O O
in O O
adult O O
mice O O
that O O
received O O
neonatal O O
injections O O
of O O
MSG O O
( O O
4 O O
mg O O
/ O O
g O O
and O O
1 O O
mg O O
/ O O
g O O
) O O
. O O

MSG O O
treatment O O
resulted O O
in O O
significant O O
reductions O O
in O O
whole O O
brain O O
weight O O
but O O
did O O
not O O
alter O O
seizure B-Disease B-Disease
threshold O O
. O O

A O O
naloxone O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
challenge O O
was O O
also O O
ineffective O O
in O O
altering O O
the O O
seizure B-Disease B-Disease
thresholds O O
of O O
either O O
control O O
of O O
MSG O O
- O O
treated O O
mice O O
. O O

Flurothyl O O
ether O O
produced O O
hypothermia B-Disease B-Disease
which O O
was O O
correlated O O
with O O
the O O
duration O O
of O O
flurothyl O O
exposure O O
; O O
however O O
, O O
the O O
relationship O O
of O O
hypothermia B-Disease B-Disease
to O O
seizure B-Disease B-Disease
induction O O
was O O
unclear O O
. O O

Flurothyl O O
seizure B-Disease B-Disease
testing O O
proved O O
to O O
be O O
a O O
rapid O O
and O O
reliable O O
technique O O
with O O
which O O
to O O
evaluate O O
seizure B-Disease B-Disease
susceptibility O O
. O O

Susceptibility O O
to O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
in O O
rats O O
after O O
microinjection O O
of O O
isoniazid O O
or O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
into O O
the O O
substantia O O
nigra O O
. O O

Pilocarpine O O
, O O
given O O
intraperitoneally O O
to O O
rats O O
, O O
reproduces O O
the O O
neuropathological O O
sequelae O O
of O O
temporal B-Disease B-Disease
lobe I-Disease I-Disease
epilepsy I-Disease I-Disease
and O O
provides O O
a O O
relevant O O
animal O O
model O O
for O O
studying O O
mechanisms O O
of O O
buildup O O
of O O
convulsive B-Disease B-Disease
activity O O
and O O
pathways O O
operative O O
in O O
the O O
generalization O O
and O O
propagation O O
of O O
seizures B-Disease B-Disease
within O O
the O O
forebrain O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
manipulating O O
the O O
activity O O
of O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
-mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
on O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
in O O
rats O O
, O O
were O O
investigated O O
. O O

In O O
animals O O
pretreated O O
with O O
microinjections O O
of O O
isoniazid O O
, O O
150 O O
micrograms O O
, O O
an O O
inhibitor O O
of O O
activity O O
of O O
the O O
GABA O O
- O O
synthesizing O O
enzyme O O
, O O
L O O
- O O
glutamic O O
acid O O
decarboxylase O O
, O O
into O O
the O O
substantia O O
nigra O O
pars O O
reticulata O O
( O O
SNR O O
) O O
, O O
bilaterally O O
, O O
non O O
- O O
convulsant O O
doses O O
of O O
pilocarpine O O
, O O
100 O O
and O O
200 O O
mg O O
/ O O
kg O O
, O O
resulted O O
in O O
severe O O
motor O O
limbic O O
seizures B-Disease B-Disease
and O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
. O O

Electroencephalographic O O
and O O
behavioral O O
monitoring O O
revealed O O
a O O
profound O O
reduction O O
of O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
convulsions B-Disease B-Disease
. O O

Morphological O O
analysis O O
of O O
frontal O O
forebrain O O
sections O O
with O O
light O O
microscopy O O
revealed O O
seizure B-Disease B-Disease
- O O
related O O
damage O O
to O O
the O O
hippocampal O O
formation O O
, O O
thalamus O O
, O O
amygdala O O
, O O
olfactory O O
cortex O O
, O O
substantia O O
nigra O O
and O O
neocortex O O
, O O
which O O
is O O
typically O O
observed O O
with O O
pilocarpine O O
in O O
doses O O
exceeding O O
350 O O
mg O O
/ O O
kg O O
. O O

Bilateral O O
intrastriatal O O
injections O O
of O O
isoniazid O O
did O O
not O O
augment O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
, O O
200 O O
mg O O
/ O O
kg O O
. O O

Application O O
of O O
an O O
irreversible O O
inhibitor O O
of O O
GABA O O
transaminase O O
, O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
( O O
D O O
, O O
L-4-amino O O
- O O
hex-5-enoic O O
acid O O
) O O
, O O
5 O O
micrograms O O
, O O
into O O
the O O
SNR O O
, O O
bilaterally O O
, O O
suppressed O O
the O O
appearance O O
of O O
electrographic O O
and O O
behavioral O O
seizures B-Disease B-Disease
produced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

This O O
treatment O O
was O O
also O O
sufficient O O
to O O
protect O O
animals O O
from O O
the O O
occurrence O O
of O O
brain B-Disease B-Disease
damage I-Disease I-Disease
. O O

Microinjections O O
of O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
, O O
5 O O
micrograms O O
, O O
into O O
the O O
dorsal O O
striatum O O
, O O
bilaterally O O
, O O
failed O O
to O O
prevent O O
the O O
development O O
of O O
convulsions B-Disease B-Disease
produced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

The O O
results O O
demonstrate O O
that O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
seizures B-Disease B-Disease
in O O
rats O O
is O O
subjected O O
to O O
the O O
regulation O O
of O O
the O O
GABA O O
- O O
mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
. O O

Human O O
and O O
canine O O
ventricular O O
vasoactive O O
intestinal O O
polypeptide O O
: O O
decrease O O
with O O
heart B-Disease B-Disease
failure I-Disease I-Disease
. O O

Vasoactive O O
intestinal O O
polypeptide O O
( O O
VIP O O
) O O
is O O
a O O
systemic O O
and O O
coronary O O
vasodilator O O
that O O
may O O
have O O
positive O O
inotropic O O
properties O O
. O O

Myocardial O O
levels O O
of O O
VIP O O
were O O
assayed O O
before O O
and O O
after O O
the O O
development O O
of O O
heart B-Disease B-Disease
failure I-Disease I-Disease
in O O
two O O
canine O O
models O O
. O O

In O O
the O O
first O O
, O O
cobalt O O
cardiomyopathy B-Disease B-Disease
was O O
induced O O
in O O
eight O O
dogs O O
; O O
VIP O O
( O O
by O O
radioimmunoassay O O
) O O
decreased O O
from O O
35 O O
+ O O
/- O O

11 O O
pg O O
/ O O
mg O O
protein O O
( O O
mean O O
+ O O
/- O O
SD O O
) O O
to O O
5 O O
+ O O
/- O O

4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

In O O
six O O
dogs O O
with O O
doxorubicin O O
- O O
induced O O
heart B-Disease B-Disease
failure I-Disease I-Disease
, O O
VIP O O
decreased O O
from O O
31 O O
+ O O
/- O O

7 O O
to O O
11 O O
+ O O
/- O O

4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

In O O
addition O O
, O O
VIP O O
content O O
of O O
left O O
ventricular O O
muscle O O
of O O
resected O O
failing O O
hearts O O
in O O
10 O O
patients O O
receiving O O
a O O
heart O O
transplant O O
was O O
compared O O
with O O
the O O
papillary O O
muscles O O
in O O
14 O O
patients O O
( O O
five O O
with O O
rheumatic B-Disease B-Disease
disease I-Disease I-Disease
, O O
nine O O
with O O
myxomatous B-Disease B-Disease
degeneration I-Disease I-Disease
) O O
receiving O O
mitral O O
valve O O
prostheses O O
. O O

The O O
lowest O O
myocardial O O
VIP O O
concentration O O
was O O
found O O
in O O
the O O
hearts O O
of O O
patients O O
with O O
coronary B-Disease B-Disease
disease I-Disease I-Disease
( O O
one O O
patient O O
receiving O O
a O O
transplant O O
and O O
three O O
receiving O O
mitral O O
prostheses O O
) O O
( O O
6.3 O O
+ O O
/- O O

1.9 O O
pg O O
/ O O
mg O O
protein O O
) O O
. O O

The O O
other O O
patients O O
undergoing O O
transplantation O O
had O O
an O O
average O O
ejection O O
fraction O O
of O O
17 O O
% O O
+ O O
/- O O

6 O O
% O O
and O O
a O O
VIP O O
level O O
of O O
8.8 O O
+ O O
/- O O

3.9 O O
pg O O
/ O O
mg O O
protein O O
. O O

The O O
hearts O O
without O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
( O O
average O O
ejection O O
fraction O O
of O O
this O O
group O O
62 O O
% O O
+ O O
/- O O

10 O O
% O O
) O O
had O O
a O O
VIP O O
concentration O O
of O O
14.1 O O
+ O O
/- O O

7.9 O O
pg O O
/ O O
mg O O
protein O O
, O O
and O O
this O O
was O O
greater O O
than O O
in O O
hearts O O
of O O
the O O
patients O O
with O O
coronary B-Disease B-Disease
disease I-Disease I-Disease
and O O
the O O
hearts O O
of O O
patients O O
receiving O O
a O O
transplant O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

Myocardial O O
catecholamines O O
were O O
also O O
determined O O
in O O
14 O O
subjects O O
; O O
a O O
weak O O
correlation O O
( O O
r O O
= O O
0.57 O O
, O O
P O O
less O O
than O O
0.05 O O
) O O
between O O
the O O
tissue O O
concentrations O O
of O O
VIP O O
and O O
norepinephrine O O
was O O
noted. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Non O O
- O O
invasive O O
detection O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
by O O
body O O
surface O O
electrocardiographic O O
mapping O O
after O O
dipyridamole O O
infusion O O
. O O

Electrocardiographic O O
changes O O
after O O
dipyridamole O O
infusion O O
( O O
0.568 O O
mg O O
/ O O
kg O O
/ O O
4 O O
min O O
) O O
were O O
studied O O
in O O
41 O O
patients O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
and O O
compared O O
with O O
those O O
after O O
submaximal O O
treadmill O O
exercise O O
by O O
use O O
of O O
the O O
body O O
surface O O
mapping O O
technique O O
. O O

Patients O O
were O O
divided O O
into O O
three O O
groups O O
; O O
19 O O
patients O O
without O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
non O O
- O O
MI B-Disease B-Disease
group O O
) O O
, O O
14 O O
with O O
anterior B-Disease B-Disease
infarction I-Disease I-Disease
( O O
ANT B-Disease B-Disease
- I-Disease I-Disease
MI I-Disease I-Disease
) O O
and O O
eight O O
with O O
inferior B-Disease B-Disease
infarction I-Disease I-Disease
( O O
INF B-Disease B-Disease
- I-Disease I-Disease
MI I-Disease I-Disease
) O O
. O O

Eighty O O
- O O
seven O O
unipolar O O
electrocardiograms O O
( O O
ECGs O O
) O O
distributed O O
over O O
the O O
entire O O
thoracic O O
surface O O
were O O
simultaneously O O
recorded O O
. O O

After O O
dipyridamole O O
, O O
ischemic B-Disease B-Disease
ST O I-Disease
- O I-Disease
segment O I-Disease
depression B-Disease I-Disease
( O O
0.05 O O
mV O O
or O O
more O O
) O O
was O O
observed O O
in O O
84 O O
% O O
of O O
the O O
non O O
- O O
MI B-Disease B-Disease
group O O
, O O
29 O O
% O O
of O O
the O O
ANT B-Disease O
- I-Disease O
MI I-Disease B-Disease
group O O
, O O
63 O O
% O O
of O O
the O O
INF B-Disease B-Disease
- I-Disease I-Disease
MI I-Disease I-Disease
group O O
and O O
61 O O
% O O
of O O
the O O
total O O
population O O
. O O

Exercise O O
- O O
induced O O
ST O O
depression B-Disease B-Disease
was O O
observed O O
in O O
84 O O
% O O
of O O
the O O
non O O
- O O
MI B-Disease B-Disease
group O O
, O O
43 O O
% O O
of O O
the O O
ANT B-Disease O
- I-Disease O
MI I-Disease B-Disease
group O O
, O O
38 O O
% O O
of O O
the O O
INF B-Disease O
- I-Disease O
MI I-Disease B-Disease
group O O
and O O
61 O O
% O O
of O O
the O O
total O O
. O O

For O O
individual O O
patients O O
, O O
there O O
were O O
no O O
obvious O O
differences O O
between O O
the O O
body O O
surface O O
distribution O O
of O O
ST O O
depression B-Disease B-Disease
in O O
both O O
tests O O
. O O

The O O
increase O O
in O O
pressure O O
rate O O
product O O
after O O
dipyridamole O O
was O O
significantly O O
less O O
than O O
that O O
during O O
the O O
treadmill O O
exercise O O
. O O

The O O
data O O
suggest O O
that O O
the O O
dipyridamole O O
- O O
induced O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
is O O
caused O O
by O O
the O O
inhomogenous O O
distribution O O
of O O
myocardial O O
blood O O
flow O O
. O O

We O O
conclude O O
that O O
the O O
dipyridamole O O
ECG O O
test O O
is O O
as O O
useful O O
as O O
the O O
exercise O O
ECG O O
test O O
for O O
the O O
assessment O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
. O O

Bradycardia B-Disease B-Disease
after O O
high O O
- O O
dose O O
intravenous O O
methylprednisolone O O
therapy O O
. O O

In O O
5 O O
consecutive O O
patients O O
with O O
rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
who O O
received O O
intravenous O O
high O O
- O O
dose O O
methylprednisolone O O
( O O
MP O O
) O O
therapy O O
( O O
1 O O
g O O
daily O O
for O O
2 O O
or O O
3 O O
consecutive O O
days O O
) O O
, O O
a O O
decline O O
in O O
pulse O O
rate O O
was O O
observed O O
, O O
most O O
pronounced O O
on O O
day O O
4 O O
. O O

In O O
one O O
of O O
the O O
5 O O
patients O O
the O O
bradycardia B-Disease B-Disease
was O O
associated O O
with O O
complaints O O
of O O
substernal O O
pressure O O
. O O

Reversal O O
to O O
normal O O
heart O O
rate O O
was O O
found O O
on O O
day O O
7 O O
. O O

Electrocardiographic O O
registrations O O
showed O O
sinus B-Disease B-Disease
bradycardia I-Disease I-Disease
in O O
all O O
cases O O
. O O

No O O
significant O O
changes O O
in O O
plasma O O
concentrations O O
of O O
electrolytes O O
were O O
found O O
. O O

Careful O O
observation O O
of O O
patients O O
receiving O O
high O O
- O O
dose O O
MP O O
is O O
recommended O O
. O O

High O O
- O O
dose O O
MP O O
may O O
be O O
contraindicated O O
in O O
patients O O
with O O
known O O
heart B-Disease B-Disease
disease I-Disease I-Disease
. O O

Two O O
cases O O
of O O
downbeat B-Disease B-Disease
nystagmus I-Disease I-Disease
and O O
oscillopsia B-Disease B-Disease
associated O O
with O O
carbamazepine O O
. O O

Downbeat B-Disease B-Disease
nystagmus I-Disease I-Disease
is O O
often O O
associated O O
with O O
structural O O
lesions O O
at O O
the O O
craniocervical O O
junction O O
, O O
but O O
has O O
occasionally O O
been O O
reported O O
as O O
a O O
manifestation O O
of O O
metabolic O O
imbalance O O
or O O
drug O O
intoxication O O
. O O

We O O
recorded O O
the O O
eye O O
movements O O
of O O
two O O
patients O O
with O O
reversible O O
downbeat B-Disease B-Disease
nystagmus I-Disease I-Disease
related O O
to O O
carbamazepine O O
therapy O O
. O O

The O O
nystagmus B-Disease B-Disease
of O O
both O O
patients O O
resolved O O
after O O
reduction O O
of O O
the O O
serum O O
carbamazepine O O
levels O O
. O O

Neuroradiologic O O
investigations O O
including O O
magnetic O O
resonance O O
imaging O O
scans O O
in O O
both O O
patients O O
showed O O
no O O
evidence O O
of O O
intracranial O B-Disease
abnormality O I-Disease
. O O

In O O
patients O O
with O O
downbeat B-Disease B-Disease
nystagmus I-Disease I-Disease
who O O
are O O
taking O O
anticonvulsant O O
medications O O
, O O
consideration O O
should O O
be O O
given O O
to O O
reduction O O
in O O
dose O O
before O O
further O O
investigation O O
is O O
undertaken O O
. O O

Improvement O O
by O O
denopamine O O
( O O
TA-064 O O
) O O
of O O
pentobarbital O O
- O O
induced O O
cardiac B-Disease B-Disease
failure I-Disease I-Disease
in O O
the O O
dog O O
heart O O
- O O
lung O O
preparation O O
. O O

The O O
efficacy O O
of O O
denopamine O O
, O O
an O O
orally O O
active O O
beta O O
1-adrenoceptor O O
agonist O O
, O O
in O O
improving O O
cardiac B-Disease B-Disease
failure I-Disease I-Disease
was O O
assessed O O
in O O
dog O O
heart O O
- O O
lung O O
preparations O O
. O O

Cardiac O O
functions O O
depressed O O
by O O
pentobarbital O O
( O O
118 O O
+ O O
/- O O

28 O O
mg O O
; O O
mean O O
value O O
+ O O
/- O O

SD O O
) O O
such O O
that O O
cardiac O O
output O O
and O O
maximum O O
rate O O
of O O
rise O O
of O O
left O O
ventricular O O
pressure O O
( O O
LV O O
dP O O
/ O O
dt O O
max O O
) O O
had O O
been O O
reduced O O
by O O
about O O
35 O O
% O O
and O O
26 O O
% O O
of O O
the O O
respective O O
controls O O
were O O
improved O O
by O O
denopamine O O
( O O
10 O O
- O O
300 O O
micrograms O O
) O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

With O O
100 O O
micrograms O O
denopamine O O
, O O
almost O O
complete O O
restoration O O
of O O
cardiac O O
performance O O
was O O
attained O O
, O O
associated O O
with O O
a O O
slight O O
increase O O
in O O
heart O O
rate O O
. O O

No O O
arrhythmias B-Disease B-Disease
were O O
induced O O
by O O
these O O
doses O O
of O O
denopamine O O
. O O

The O O
results O O
warrant O O
clinical O O
trials O O
of O O
denopamine O O
in O O
the O O
treatment O O
of O O
cardiac B-Disease B-Disease
failure I-Disease I-Disease
. O O

Clonazepam O O
monotherapy O O
for O O
epilepsy B-Disease B-Disease
in O O
childhood O O
. O O

Sixty O O
patients O O
( O O
age O O
- O O
range O O
one O O
month O O
to O O
14 O O
years O O
) O O
with O O
other O O
types O O
of O O
epilepsy B-Disease B-Disease
than O O
infantile B-Disease B-Disease
spasms I-Disease I-Disease
were O O
treated O O
with O O
clonazepam O O
. O O

Disappearance O O
of O O
seizures B-Disease B-Disease
and O O
normalization O O
of O O
abnormal O O
EEG O O
with O O
disappearance O O
of O O
seizures B-Disease B-Disease
were O O
recognized O O
in O O
77 O O
% O O
and O O
50 O O
% O O
, O O
respectively O O
. O O

Seizures B-Disease B-Disease
disappeared O O
in O O
71 O O
% O O
of O O
the O O
patients O O
with O O
generalized O O
seizures B-Disease B-Disease
and O O
89 O O
% O O
of O O
partial O O
seizures B-Disease B-Disease
. O O

Improvement O O
of O O
abnormal O O
EEG O O
was O O
noticed O O
in O O
76 O O
% O O
of O O
diffuse O O
paroxysms O O
and O O
in O O
67 O O
% O O
of O O
focal O O
paroxysms O O
. O O

In O O
excellent O O
cases O O
, O O
mean O O
effective O O
dosages O O
were O O
0.086 O O
+ O O
/- O O

0.021 O O
mg O O
/ O O
kg O O
/ O O
day O O
in O O
infants O O
and O O
0.057 O O
+ O O
/- O O

0.022 O O
mg O O
/ O O
kg O O
/ O O
day O O
in O O
schoolchildren O O
, O O
this O O
difference O O
was O O
statistically O O
significant O O
( O O
p O O
less O O
than O O
0.005 O O
) O O
. O O

The O O
incidence O O
of O O
side O O
effects O O
such O O
as O O
drowsiness B-Disease B-Disease
and O O
ataxia B-Disease B-Disease
was O O
only O O
5 O O
% O O
. O O

Postmarketing O O
study O O
of O O
timolol O O
- O O
hydrochlorothiazide O O
antihypertensive O O
therapy O O
. O O

A O O
postmarketing O O
surveillance O O
study O O
was O O
conducted O O
to O O
determine O O
the O O
safety O O
and O O
efficacy O O
of O O
a O O
fixed O O
- O O
ratio O O
combination O O
containing O O
10 O O
mg O O
of O O
timolol O O
maleate O O
and O O
25 O O
mg O O
of O O
hydrochlorothiazide O O
, O O
administered O O
twice O O
daily O O
for O O
one O O
month O O
to O O
hypertensive B-Disease B-Disease
patients O O
. O O

Data O O
on O O
9,037 O O
patients O O
were O O
collected O O
by O O
1,455 O O
participating O O
physicians O O
. O O

Mean O O
systolic O O
blood O O
pressure O O
decreased O O
25 O O
mmHg O O
and O O
mean O O
diastolic O O
blood O O
pressure O O
declined O O
15 O O
mmHg O O
after O O
one O O
month O O
of O O
timolol O O
- O O
hydrochlorothiazide O O
therapy O O
( O O
P O O
less O O
than O O
0.01 O O
, O O
both O O
comparisons O O
) O O
. O O

Age O O
, O O
race O O
, O O
and O O
sex O O
appeared O O
to O O
have O O
no O O
influence O O
on O O
the O O
decrease O O
in O O
blood O O
pressure O O
. O O

The O O
antihypertensive O O
effect O O
of O O
the O O
drug O O
was O O
greater O O
in O O
patients O O
with O O
more O O
severe O O
hypertension B-Disease B-Disease
. O O

Overall O O
, O O
1,453 O O
patients O O
experienced O O
a O O
total O O
of O O
2,658 O O
adverse O O
events O O
, O O
the O O
most O O
common O O
being O O
fatigue B-Disease B-Disease
, O O
dizziness B-Disease B-Disease
, O O
and O O
weakness B-Disease B-Disease
. O O

Treatment O O
in O O
590 O O
patients O O
was O O
discontinued O O
because O O
of O O
adverse O O
events O O
. O O

Salicylate O O
nephropathy B-Disease B-Disease
in O O
the O O
Gunn O O
rat O O
: O O
potential O O
role O O
of O O
prostaglandins O O
. O O

We O O
examined O O
the O O
potential O O
role O O
of O O
prostaglandins O O
in O O
the O O
development O O
of O O
analgesic O O
nephropathy B-Disease B-Disease
in O O
the O O
Gunn O O
strain O O
of O O
rat O O
. O O

The O O
homozygous O O
Gunn O O
rats O O
have O O
unconjugated O O
hyperbilirubinemia B-Disease B-Disease
due O O
to O O
the O O
absence O O
of O O
glucuronyl O O
transferase O O
, O O
leading O O
to O O
marked O O
bilirubin O O
deposition O O
in O O
renal O O
medulla O O
and O O
papilla O O
. O O

These O O
rats O O
are O O
also O O
highly O O
susceptible O O
to O O
develop O O
papillary B-Disease B-Disease
necrosis I-Disease I-Disease
with O O
analgesic O O
administration O O
. O O

We O O
used O O
homozygous O O
( O O
jj O O
) O O
and O O
phenotypically O O
normal O O
heterozygous O O
( O O
jJ O O
) O O
animals O O
. O O

Four O O
groups O O
of O O
rats O O
( O O
n O O
= O O
7 O O
) O O
were O O
studied O O
: O O
jj O O
and O O
jJ O O
rats O O
treated O O
either O O
with O O
aspirin O O
300 O O
mg O O
/ O O
kg O O
every O O
other O O
day O O
or O O
sham O O
- O O
treated O O
. O O

After O O
one O O
week O O
, O O
slices O O
of O O
cortex O O
, O O
outer O O
and O O
inner O O
medulla O O
from O O
one O O
kidney O O
were O O
incubated O O
in O O
buffer O O
and O O
prostaglandin O O
synthesis O O
was O O
determined O O
by O O
radioimmunoassay O O
. O O

The O O
other O O
kidney O O
was O O
examined O O
histologically O O
. O O

A O O
marked O O
corticomedullary O O
gradient O O
of O O
prostaglandin O O
synthesis O O
was O O
observed O O
in O O
all O O
groups O O
. O O

PGE2 O O
synthesis O O
was O O
significantly O O
higher O O
in O O
outer O O
medulla O O
, O O
but O O
not O O
cortex O O
or O O
inner O O
medulla O O
, O O
of O O
jj O O
( O O
38 O O
+ O O
/- O O

6 O O
ng O O
/ O O
mg O O
prot O O
) O O
than O O
jJ O O
rats O O
( O O
15 O O
+ O O
/- O O

3 O O
) O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
. O O

Aspirin O O
treatment O O
reduced O O
PGE2 O O
synthesis O O
in O O
all O O
regions O O
, O O
but O O
outer O O
medullary O O
PGE2 O O
remained O O
higher O O
in O O
jj O O
( O O
18 O O
+ O O
/- O O

3 O O
) O O
than O O
jJ O O
rats O O
( O O
9 O O
+ O O
/- O O

2 O O
) O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

PGF2 O O
alpha O O
was O O
also O O
significantly O O
higher O O
in O O
the O O
outer O O
medulla O O
of O O
jj O O
rats O O
with O O
and O O
without O O
aspirin O O
administration O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

The O O
changes O O
in O O
renal O O
prostaglandin O O
synthesis O O
were O O
accompanied O O
by O O
evidence O O
of O O
renal B-Disease B-Disease
damage I-Disease I-Disease
in O O
aspirin O O
- O O
treated O O
jj O O
but O O
not O O
jJ O O
rats O O
as O O
evidenced O O
by O O
: O O
increased O O
incidence O O
and O O
severity O O
of O O
hematuria B-Disease B-Disease
( O O
p O O
less O O
than O O
0.01 O O
) O O
; O O
increased O O
serum O O
creatinine O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
; O O
and O O
increase O O
in O O
outer O O
medullary O O
histopathologic O O
lesions O O
( O O
p O O
less O O
than O O
0.005 O O
compared O O
to O O
either O O
sham O O
- O O
treated O O
jj O O
or O O
aspirin O O
- O O
treated O O
jJ O O
) O O
. O O

These O O
results O O
suggest O O
that O O
enhanced O O
prostaglandin O O
synthesis O O
contributes O O
to O O
maintenance O O
of O O
renal O O
function O O
and O O
morphological O O
integrity O O
, O O
and O O
that O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
may O O
lead O O
to O O
pathological B-Disease O
renal I-Disease B-Disease
medullary I-Disease I-Disease
lesions I-Disease I-Disease
and O O
deterioration B-Disease B-Disease
of I-Disease I-Disease
renal I-Disease I-Disease
function I-Disease I-Disease
. O O

Prophylactic O O
lidocaine O O
in O O
the O O
early O O
phase O O
of O O
suspected O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

Four O O
hundred O O
two O O
patients O O
with O O
suspected O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
seen O O
within O O
6 O O
hours O O
of O O
the O O
onset O O
of O O
symptoms O O
entered O O
a O O
double O O
- O O
blind O O
randomized O O
trial O O
of O O
lidocaine O O
vs O O
placebo O O
. O O

During O O
the O O
1 O O
hour O O
after O O
administration O O
of O O
the O O
drug O O
the O O
incidence O O
of O O
ventricular B-Disease B-Disease
fibrillation I-Disease I-Disease
or O O
sustained O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
among O O
the O O
204 O O
patients O O
with O O
acute O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
was O O
low O O
, O O
1.5 O O
% O O
. O O

Lidocaine O O
, O O
given O O
in O O
a O O
300 O O
mg O O
dose O O
intramuscularly O O
followed O O
by O O
100 O O
mg O O
intravenously O O
, O O
did O O
not O O
prevent O O
sustained O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
, O O
although O O
there O O
was O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
patients O O
with O O
warning O O
arrhythmias B-Disease B-Disease
between O O
15 O O
and O O
45 O O
minutes O O
after O O
the O O
administration O O
of O O
lidocaine O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
. O O

The O O
average O O
plasma O O
lidocaine O O
level O O
10 O O
minutes O O
after O O
administration O O
for O O
patients O O
without O O
a O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
was O O
significantly O O
higher O O
than O O
that O O
for O O
patients O O
with O O
an O O
acute O O
infarction B-Disease B-Disease
. O O

The O O
mean O O
plasma O O
lidocaine O O
level O O
of O O
patients O O
on O O
beta O O
- O O
blocking O O
agents O O
was O O
no O O
different O O
from O O
that O O
in O O
patients O O
not O O
on O O
beta O O
blocking O O
agents O O
. O O

During O O
the O O
1-hour O O
study O O
period O O
, O O
the O O
incidence O O
of O O
central O O
nervous O O
system O O
side O O
effects O O
was O O
significantly O O
greater O O
in O O
the O O
lidocaine O O
group O O
, O O
hypotension B-Disease B-Disease
occurred O O
in O O
11 O O
patients O O
, O O
nine O O
of O O
whom O O
had O O
received O O
lidocaine O O
, O O
and O O
four O O
patients O O
died O O
from O O
asystole B-Disease B-Disease
, O O
three O O
of O O
whom O O
had O O
had O O
lidocaine O O
. O O

We O O
can O O
not O O
advocate O O
the O O
administration O O
of O O
lidocaine O O
prophylactically O O
in O O
the O O
early O O
hours O O
of O O
suspected O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

Evidence O O
for O O
a O O
cholinergic O O
role O O
in O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
. O O

Experiments O O
in O O
mice O O
tested O O
previous O O
evidence O O
that O O
activation O O
of O O
cholinergic O O
systems O O
promotes O O
catalepsy B-Disease B-Disease
and O O
that O O
cholinergic O O
mechanisms O O
need O O
to O O
be O O
intact O O
for O O
full O O
expression O O
of O O
neuroleptic O O
- O O
induced O O
catalepsy B-Disease B-Disease
. O O

Large O O
doses O O
of O O
the O O
cholinomimetic O O
, O O
pilocarpine O O
, O O
could O O
induce O O
catalepsy B-Disease B-Disease
when O O
peripheral O O
cholinergic O O
receptors O O
were O O
blocked O O
. O O

Low O O
doses O O
of O O
pilocarpine O O
caused O O
a O O
pronounced O O
enhancement O O
of O O
the O O
catalepsy B-Disease B-Disease
that O O
was O O
induced O O
by O O
the O O
dopaminergic O O
blocker O O
, O O
haloperidol O O
. O O

A O O
muscarinic O O
receptor O O
blocker O O
, O O
atropine O O
, O O
disrupted O O
haloperidol O O
- O O
induced O O
catalepsy B-Disease B-Disease
. O O

Intracranial O O
injection O O
of O O
an O O
acetylcholine O O
- O O
synthesis O O
inhibitor O O
, O O
hemicholinium O O
, O O
prevented O O
the O O
catalepsy B-Disease B-Disease
that O O
is O O
usually O O
induced O O
by O O
haloperidol O O
. O O

These O O
findings O O
suggest O O
the O O
hypothesis O O
that O O
the O O
catalepsy B-Disease B-Disease
that O O
is O O
produced O O
by O O
neuroleptics O O
such O O
as O O
haloperidol O O
is O O
actually O O
mediated O O
by O O
intrinsic O O
central O O
cholinergic O O
systems O O
. O O

Alternatively O O
, O O
activation O O
of O O
central O O
cholinergic O O
systems O O
could O O
promote O O
catalepsy B-Disease B-Disease
by O O
suppression O O
of O O
dopaminergic O O
systems O O
. O O

Cardiovascular B-Disease B-Disease
dysfunction I-Disease I-Disease
and O O
hypersensitivity B-Disease B-Disease
to O O
sodium O O
pentobarbital O O
induced O O
by O O
chronic O O
barium O O
chloride O O
ingestion O O
. O O

Barium O O
- O O
supplemented O O
Long O O
- O O
Evans O O
hooded O O
rats O O
were O O
characterized O O
by O O
a O O
persistent O O
hypertension B-Disease B-Disease
that O O
was O O
evident O O
after O O
1 O O
month O O
of O O
barium O O
( O O
100 O O
micrograms O O
/ O O
ml O O
mineral O O
fortified O O
water O O
) O O
treatment O O
. O O

Analysis O O
of O O
in O O
vivo O O
myocardial O O
excitability O O
, O O
contractility O O
, O O
and O O
metabolic O O
characteristics O O
at O O
16 O O
months O O
revealed O O
other O O
significant O O
barium O O
- O O
induced O O
disturbances B-Disease B-Disease
within I-Disease I-Disease
the I-Disease I-Disease
cardiovascular I-Disease I-Disease
system I-Disease I-Disease
. O O

The O O
most O O
distinctive O O
aspect O O
of O O
the O O
barium O O
effect O O
was O O
a O O
demonstrated O O
hypersensitivity B-Disease B-Disease
of O O
the O O
cardiovascular O O
system O O
to O O
sodium O O
pentobarbital O O
. O O

Under O O
barbiturate O O
anesthesia O O
, O O
virtually O O
all O O
of O O
the O O
myocardial O O
contractile O O
indices O O
were O O
depressed O O
significantly O O
in O O
barium O O
- O O
exposed O O
rats O O
relative O O
to O O
the O O
corresponding O O
control O O
- O O
fed O O
rats O O
. O O

The O O
lack O O
of O O
a O O
similar O O
response O O
to O O
ketamine O O
and O O
xylazine O O
anesthesia O O
revealed O O
that O O
the O O
cardiovascular O O
actions O O
of O O
sodium O O
pentobarbital O O
in O O
barium O O
- O O
treated O O
rats O O
were O O
linked O O
specifically O O
to O O
this O O
anesthetic O O
, O O
and O O
were O O
not O O
representative O O
of O O
a O O
generalized O O
anesthetic O O
response O O
. O O

Other O O
myocardial O O
pathophysiologic O O
and O O
metabolic O O
changes O O
induced O O
by O O
barium O O
were O O
manifest O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
employed O O
. O O

The O O
contractile O O
element O O
shortening O O
velocity O O
of O O
the O O
cardiac O O
muscle O O
fibers O O
was O O
significantly O O
slower O O
in O O
both O O
groups O O
of O O
barium O O
- O O
treated O O
rats O O
relative O O
to O O
the O O
control O O
groups O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
regimen O O
. O O

Similarly O O
, O O
significant O O
disturbances O O
in O O
myocardial O O
energy O O
metabolism O O
were O O
detected O O
in O O
the O O
barium O O
- O O
exposed O O
rats O O
which O O
were O O
consistent O O
with O O
the O O
reduced O O
contractile O O
element O O
shortening O O
velocity O O
. O O

In O O
addition O O
, O O
the O O
excitability O O
of O O
the O O
cardiac O O
conduction O O
system O O
was O O
depressed O O
preferentially O O
in O O
the O O
atrioventricular O O
nodal O O
region O O
of O O
hearts O O
from O O
barium O O
- O O
exposed O O
rats O O
. O O

Overall O O
, O O
the O O
altered O O
cardiac O O
contractility O O
and O O
excitability O O
characteristics O O
, O O
the O O
myocardial O B-Disease
metabolic B-Disease I-Disease
disturbances I-Disease I-Disease
, O O
and O O
the O O
hypersensitivity B-Disease B-Disease
of O O
the O O
cardiovascular O O
system O O
to O O
sodium O O
pentobarbital O O
suggest O O
the O O
existence O O
of O O
a O O
heretofore O O
undescribed O O
cardiomyopathic B-Disease B-Disease
disorder I-Disease I-Disease
induced O O
by O O
chronic O O
barium O O
exposure O O
. O O

These O O
experimental O O
findings O O
represent O O
the O O
first O O
indication O O
that O O
life O O
- O O
long O O
barium O O
ingestion O O
may O O
have O O
significant O O
adverse O O
effects O O
on O O
the O O
mammalian O O
cardiovascular O O
system O O
. O O

Propranolol O O
antagonism O O
of O O
phenylpropanolamine O O
- O O
induced O O
hypertension B-Disease B-Disease
. O O

Phenylpropanolamine O O
( O O
PPA O O
) O O
overdose B-Disease B-Disease
can O O
cause O O
severe O O
hypertension B-Disease B-Disease
, O O
intracerebral B-Disease B-Disease
hemorrhage I-Disease I-Disease
, O O
and O O
death O O
. O O

We O O
studied O O
the O O
efficacy O O
and O O
safety O O
of O O
propranolol O O
in O O
the O O
treatment O O
of O O
PPA O O
- O O
induced O O
hypertension B-Disease B-Disease
. O O

Subjects O O
received O O
propranolol O O
either O O
by O O
mouth O O
for O O
48 O O
hours O O
before O O
PPA O O
or O O
as O O
a O O
rapid O O
intravenous O O
infusion O O
after O O
PPA O O
. O O

PPA O O
, O O
75 O O
mg O O
alone O O
, O O
increased O O
blood O O
pressure O O
( O O
31 O O
+ O O
/- O O

14 O O
mm O O
Hg O O
systolic O O
, O O
20 O O
+ O O
/- O O

5 O O
mm O O
Hg O O
diastolic O O
) O O
, O O
and O O
propranolol O O
pretreatment O O
antagonized O O
this O O
increase O O
( O O
12 O O
+ O O
/- O O

10 O O
mm O O
Hg O O
systolic O O
, O O
10 O O
+ O O
/- O O

7 O O
mm O O
Hg O O
diastolic O O
) O O
. O O

Intravenous O O
propranolol O O
after O O
PPA O O
also O O
decreased O O
blood O O
pressure O O
. O O

Left O O
ventricular O O
function O O
( O O
assessed O O
by O O
echocardiography O O
) O O
showed O O
that O O
PPA O O
increased O O
the O O
stroke B-Disease B-Disease
volume O O
30 O O
% O O
( O O
from O O
62.5 O O
+ O O
/- O O

20.9 O O
to O O
80.8 O O
+ O O
/- O O

22.4 O O
ml O O
) O O
, O O
the O O
ejection O O
fraction O O
9 O O
% O O
( O O
from O O
64 O O
% O O
+ O O
/- O O

10 O O
% O O
to O O
70 O O
% O O
+ O O
/- O O

7 O O
% O O
) O O
, O O
and O O
cardiac O O
output O O
14 O O
% O O
( O O
from O O
3.6 O O
+ O O
/- O O

0.6 O O
to O O
4.1 O O
+ O O
/- O O

1.0 O O
L O O
/ O O
min O O
) O O
. O O

Intravenous O O
propranolol O O
reversed O O
these O O
effects O O
. O O

Systemic O O
vascular O O
resistance O O
was O O
increased O O
by O O
PPA O O
28 O O
% O O
( O O
from O O
1710 O O
+ O O
/- O O

200 O O
to O O
2190 O O
+ O O
/- O O

700 O O
dyne O O
X O O
sec O O
/ O O
cm5 O O
) O O
and O O
was O O
further O O
increased O O
by O O
propranolol O O
22 O O
% O O
( O O
to O O
2660 O O
+ O O
/- O O

1200 O O
dyne O O
X O O
sec O O
/ O O
cm5 O O
) O O
. O O

We O O
conclude O O
that O O
PPA O O
increases O O
blood O O
pressure O O
by O O
increasing O O
systemic O O
vascular O O
resistance O O
and O O
cardiac O O
output O O
, O O
and O O
that O O
propranolol O O
antagonizes O O
this O O
increase O O
by O O
reversing O O
the O O
effect O O
of O O
PPA O O
on O O
cardiac O O
output O O
. O O

That O O
propranolol O O
antagonizes O O
the O O
pressor O O
effect O O
of O O
PPA O O
is O O
in O O
contrast O O
to O O
the O O
interaction O O
in O O
which O O
propranolol O O
enhances O O
the O O
pressor O O
effect O O
of O O
norepinephrine O O
. O O

This O O
is O O
probably O O
because O O
PPA O O
has O O
less O O
beta O O
2 O O
activity O O
than O O
does O O
norepinephrine O O
. O O

Mesangial O O
function O O
and O O
glomerular B-Disease B-Disease
sclerosis I-Disease I-Disease
in O O
rats O O
with O O
aminonucleoside O O
nephrosis B-Disease B-Disease
. O O

The O O
possible O O
relationship O O
between O O
mesangial B-Disease B-Disease
dysfunction I-Disease I-Disease
and O O
development O O
of O O
glomerular B-Disease B-Disease
sclerosis I-Disease I-Disease
was O O
studied O O
in O O
the O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
model O O
. O O

Five O O
male O O
Wistar O O
rats O O
received O O
repeated O O
subcutaneous O O
PAN O O
injections O O
; O O
five O O
controls O O
received O O
saline O O
only O O
. O O

After O O
4 O O
weeks O O
the O O
PAN O O
rats O O
were O O
severely O O
proteinuric B-Disease B-Disease
( O O
190 O O
+ O O
/- O O

80 O O
mg O O
/ O O
24 O O
hr O O
) O O
, O O
and O O
all O O
rats O O
were O O
given O O
colloidal O O
carbon O O
( O O
CC O O
) O O
intravenously O O
. O O

At O O
5 O O
months O O
glomerular B-Disease B-Disease
sclerosis I-Disease I-Disease
was O O
found O O
in O O
7.6 O O
+ O O
/- O O

3.4 O O
% O O
of O O
the O O
glomeruli O O
of O O
PAN O O
rats O O
; O O
glomeruli O O
of O O
the O O
controls O O
were O O
normal O O
. O O

Glomeruli O O
of O O
PAN O O
rats O O
contained O O
significantly O O
more O O
CC O O
than O O
glomeruli O O
of O O
controls O O
. O O

Glomeruli O O
with O O
sclerosis B-Disease B-Disease
contained O O
significantly O O
more O O
CC O O
than O O
non O O
- O O
sclerotic O O
glomeruli O O
in O O
the O O
same O O
kidneys O O
. O O

CC O O
was O O
preferentially O O
localized O O
within O O
the O O
sclerotic O O
areas O O
of O O
the O O
affected O O
glomeruli O O
. O O

Since O O
mesangial O O
CC O O
clearance O O
from O O
the O O
mesangium O O
did O O
not O O
change O O
during O O
chronic O O
PAN O O
treatment O O
, O O
we O O
conclude O O
that O O
this O O
preferential O O
CC O O
localization O O
within O O
the O O
lesions O O
is O O
caused O O
by O O
an O O
increased O O
CC O O
uptake O O
shortly O O
after O O
injection O O
in O O
apparent O O
vulnerable O O
areas O O
where O O
sclerosis B-Disease B-Disease
will O O
develop O O
subsequently O O
. O O

Cluster O O
analysis O O
showed O O
a O O
random O O
distribution O O
of O O
lesions O O
in O O
the O O
PAN O O
glomeruli O O
in O O
concordance O O
with O O
the O O
random O O
localization O O
of O O
mesangial O O
areas O O
with O O
dysfunction O O
in O O
this O O
model O O
. O O

Similar O O
to O O
the O O
remnant O O
kidney O O
model O O
in O O
PAN O O
nephrosis B-Disease B-Disease
the O O
development O O
of O O
glomerular B-Disease B-Disease
sclerosis I-Disease I-Disease
may O O
be O O
related O O
to O O
" O O
mesangial O O
overloading O O
. O O
" O O

Relationship O O
between O O
nicotine O O
- O O
induced O O
seizures B-Disease B-Disease
and O O
hippocampal O O
nicotinic O O
receptors O O
. O O

A O O
controversy O O
has O O
existed O O
for O O
several O O
years O O
concerning O O
the O O
physiological O O
relevance O O
of O O
the O O
nicotinic O O
receptor O O
measured O O
by O O
alpha O O
- O O
bungarotoxin O O
binding O O
. O O

Using O O
mice O O
derived O O
from O O
a O O
classical O O
F2 O O
and O O
backcross O O
genetic O O
design O O
, O O
a O O
relationship O O
between O O
nicotine O O
- O O
induced O O
seizures B-Disease B-Disease
and O O
alpha O O
- O O
bungarotoxin O O
nicotinic O O
receptor O O
concentration O O
was O O
found O O
. O O

Mice O O
sensitive O O
to O O
the O O
convulsant O O
effects O O
of O O
nicotine O O
had O O
greater O O
alpha O O
- O O
bungarotoxin O O
binding O O
in O O
the O O
hippocampus O O
than O O
seizure B-Disease B-Disease
insensitive O O
mice O O
. O O

The O O
binding O O
sites O O
from O O
seizure B-Disease B-Disease
sensitive O O
and O O
resistant O O
mice O O
were O O
equally O O
affected O O
by O O
treatment O O
with O O
dithiothreitol O O
, O O
trypsin O O
or O O
heat O O
. O O

Thus O O
it O O
appears O O
that O O
the O O
difference O O
between O O
seizure B-Disease B-Disease
sensitive O O
and O O
insensitive O O
animals O O
may O O
be O O
due O O
to O O
a O O
difference O O
in O O
hippocampal O O
nicotinic O O
receptor O O
concentration O O
as O O
measured O O
with O O
alpha O O
- O O
bungarotoxin O O
binding O O
. O O

The O O
role O O
of O O
p O O
- O O
aminophenol O O
in O O
acetaminophen O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
: O O
effect O O
of O O
bis O O
( O O
p O O
- O O
nitrophenyl O O
) O O
phosphate O O
on O O
acetaminophen O O
and O O
p O O
- O O
aminophenol O O
nephrotoxicity B-Disease B-Disease
and O O
metabolism O O
in O O
Fischer O O
344 O O
rats O O
. O O

Acetaminophen O O
( O O
APAP O O
) O O
produces O O
proximal O O
tubular B-Disease B-Disease
necrosis I-Disease I-Disease
in O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rats O O
. O O

Recently O O
, O O
p O O
- O O
aminophenol O O
( O O
PAP O O
) O O
, O O
a O O
known O O
potent O O
nephrotoxicant O O
, O O
was O O
identified O O
as O O
a O O
metabolite O O
of O O
APAP O O
in O O
F344 O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
PAP O O
formation O O
is O O
a O O
requisite O O
step O O
in O O
APAP O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
. O O

Therefore O O
, O O
the O O
effect O O
of O O
bis O O
( O O
p O O
- O O
nitrophenyl O O
) O O
phosphate O O
( O O
BNPP O O
) O O
, O O
an O O
acylamidase O O
inhibitor O O
, O O
on O O
APAP O O
and O O
PAP O O
nephrotoxicity B-Disease B-Disease
and O O
metabolism O O
was O O
determined O O
. O O

BNPP O O
( O O
1 O O
to O O
8 O O
mM O O
) O O
reduced O O
APAP O O
deacetylation O O
and O O
covalent O O
binding O O
in O O
F344 O O
renal O O
cortical O O
homogenates O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Pretreatment O O
of O O
animals O O
with O O
BNPP O O
prior O O
to O O
APAP O O
or O O
PAP O O
administration O O
resulted O O
in O O
marked O O
reduction O O
of O O
APAP O O
( O O
900 O O
mg O O
/ O O
kg O O
) O O
nephrotoxicity B-Disease B-Disease
but O O
not O O
PAP O O
nephrotoxicity B-Disease B-Disease
. O O

This O O
result O O
was O O
not O O
due O O
to O O
altered O O
disposition O O
of O O
either O O
APAP O O
or O O
acetylated O O
metabolites O O
in O O
plasma O O
or O O
renal O O
cortical O O
and O O
hepatic O O
tissue O O
. O O

Rather O O
, O O
BNPP O O
pretreatment O O
reduced O O
the O O
fraction O O
of O O
APAP O O
excreted O O
as O O
PAP O O
by O O
64 O O
and O O
75 O O
% O O
after O O
APAP O O
doses O O
of O O
750 O O
and O O
900 O O
mg O O
/ O O
kg O O
. O O

BNPP O O
did O O
not O O
alter O O
the O O
excretion O O
of O O
APAP O O
or O O
any O O
of O O
its O O
non O O
- O O
deacetylated O O
metabolites O O
nor O O
did O O
BNPP O O
alter O O
excretion O O
of O O
PAP O O
or O O
its O O
metabolites O O
after O O
PAP O O
doses O O
of O O
150 O O
and O O
300 O O
mg O O
/ O O
kg O O
. O O

Therefore O O
, O O
the O O
BNPP O O
- O O
induced O O
reduction O O
in O O
APAP O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
appears O O
to O O
be O O
due O O
to O O
inhibition O O
of O O
APAP O O
deacetylation O O
. O O

It O O
is O O
concluded O O
that O O
PAP O O
formation O O
, O O
in O O
vivo O O
, O O
accounts O O
, O O
at O O
least O O
in O O
part O O
, O O
for O O
APAP O O
- O O
induced O O
renal B-Disease B-Disease
tubular I-Disease I-Disease
necrosis I-Disease I-Disease
. O O

Morphine O O
- O O
induced O O
seizures B-Disease B-Disease
in O O
newborn O O
infants O O
. O O

Two O O
neonates O O
suffered O O
from O O
generalized O O
seizures B-Disease B-Disease
during O O
the O O
course O O
of O O
intravenous O O
morphine O O
sulfate O O
for O O
post O O
- O O
operative O O
analgesia O O
. O O

They O O
received O O
morphine O O
in O O
doses O O
of O O
32 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
40 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
larger O O
than O O
a O O
group O O
of O O
10 O O
neonates O O
who O O
received O O
6 O O
- O O
24 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
had O O
no O O
seizures B-Disease B-Disease
. O O

Plasma O O
concentrations O O
of O O
morphine O O
in O O
these O O
neonates O O
was O O
excessive O O
( O O
60 O O
and O O
90 O O
mg O O
/ O O
ml O O
) O O
. O O

Other O O
known O O
reasons O O
for O O
seizures B-Disease B-Disease
were O O
ruled O O
out O O
and O O
the O O
convulsions B-Disease B-Disease
stopped O O
a O O
few O O
hours O O
after O O
cessation O O
of O O
morphine O O
and O O
did O O
not O O
reoccur O O
in O O
the O O
subsequent O O
8 O O
months O O
. O O

It O O
is O O
suggested O O
that O O
post O O
- O O
operative O O
intravenous O O
morphine O O
should O O
not O O
exceed O O
20 O O
micrograms O O
/ O O
kg O O
/ O O
ml O O
in O O
neonates O O
. O O

On O O
the O O
antiarrhythmic O O
activity O O
of O O
one O O
N O O
- O O
substituted O O
piperazine O O
derivative O O
of O O
trans-2-amino-3-hydroxy-1 O O
, O O
2 O O
, O O
3 O O
, O O
4-tetrahydroanaphthalene O O
. O O

The O O
antiarrhythmic O O
activity O O
of O O
the O O
compound O O
N- O O
( O O
trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl O O
) O O
-N- O O
( O O
3-oxo-3-phenyl-2-methylpropyl O O
) O O
-piperazine O O
hydrochloride O O
, O O
referred O O
to O O
as O O
P11 O O
, O O
is O O
studied O O
on O O
anaesthesized O O
cats O O
and O O
Wistar O O
albino O O
rats O O
, O O
as O O
well O O
as O O
on O O
non O O
- O O
anaesthesized O O
rabbits O O
. O O

Four O O
types O O
of O O
experimental O O
arrhythmia B-Disease B-Disease
are O O
used O O
-- O O
with O O
BaCl2 O O
, O O
with O O
chloroform O O
- O O
adrenaline O O
, O O
with O O
strophantine O O
G O O
and O O
with O O
aconitine O O
. O O

The O O
compound O O
P11 O O
is O O
introduced O O
in O O
doses O O
of O O
0.25 O O
and O O
0.50 O O
mg O O
/ O O
kg O O
intravenously O O
and O O
10 O O
mg O O
/ O O
kg O O
orally O O
. O O

The O O
compound O O
manifests O O
antiarrhythmic O O
activity O O
in O O
all O O
models O O
of O O
experimental O O
arrhythmia B-Disease B-Disease
used O O
, O O
causing O O
greatest O O
inhibition O O
on O O
the O O
arrhythmia B-Disease B-Disease
induced O O
by O O
chloroform O O
- O O
adrenaline O O
( O O
in O O
90 O O
per O O
cent O O
) O O
and O O
with O O
BaCl2 O O
( O O
in O O
84 O O
per O O
cent O O
) O O
. O O

The O O
results O O
obtained O O
are O O
associated O O
with O O
the O O
beta O O
- O O
adrenoblocking O O
and O O
with O O
the O O
membrane O O
- O O
stabilizing O O
action O O
of O O
the O O
compound O O
. O O

Recurrent O O
subarachnoid B-Disease B-Disease
hemorrhage I-Disease I-Disease
associated O O
with O O
aminocaproic O O
acid O O
therapy O O
and O O
acute B-Disease B-Disease
renal I-Disease I-Disease
artery I-Disease I-Disease
thrombosis I-Disease I-Disease
. O O

Case O O
report O O
. O O

Epsilon O O
aminocaproic O O
acid O O
( O O
EACA O O
) O O
has O O
been O O
used O O
to O O
prevent O O
rebleeding O O
in O O
patients O O
with O O
subarachnoid B-Disease B-Disease
hemorrhage I-Disease I-Disease
( O O
SAH B-Disease B-Disease
) O O
. O O

Although O O
this O O
agent O O
does O O
decrease O O
the O O
frequency O O
of O O
rebleeding O B-Disease
, O O
several O O
reports O O
have O O
described O O
thrombotic B-Disease B-Disease
complications O O
of O O
EACA O O
therapy O O
. O O

These O O
complications O O
have O O
included O O
clinical O O
deterioration O O
and O O
intracranial B-Disease B-Disease
vascular I-Disease I-Disease
thrombosis I-Disease I-Disease
in O O
patients O O
with O O
SAH B-Disease B-Disease
, O O
arteriolar O O
and O O
capillary O O
fibrin O O
thrombi B-Disease B-Disease
in O O
patients O O
with O O
fibrinolytic O B-Disease
syndromes O I-Disease
treated O O
with O O
EACA O O
, O O
or O O
other O O
thromboembolic B-Disease B-Disease
phenomena I-Disease I-Disease
. O O

Since O O
intravascular O O
fibrin O O
thrombi B-Disease B-Disease
are O O
often O O
observed O O
in O O
patients O O
with O O
fibrinolytic O B-Disease
disorders O I-Disease
, O O
EACA O O
should O O
not O O
be O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
fibrin O O
thrombi B-Disease B-Disease
in O O
patients O O
with O O
disseminated B-Disease B-Disease
intravascular I-Disease I-Disease
coagulation I-Disease I-Disease
or O O
other O O
" O O
consumption B-Disease B-Disease
coagulopathies I-Disease I-Disease
. O O
" O O

This O O
report O O
describes O O
subtotal O O
infarction B-Disease B-Disease
of O O
the O O
kidney O O
due O O
to O O
thrombosis B-Disease B-Disease
of I-Disease O
a I-Disease O
normal I-Disease O
renal I-Disease O
artery I-Disease O
. O O

This O O
occlusion O O
occurred O O
after O O
EACA O O
therapy O O
in O O
a O O
patient O O
with O O
SAH B-Disease B-Disease
and O O
histopathological O O
documentation O O
of O O
recurrent O O
SAH B-Disease B-Disease
. O O

The O O
corresponding O O
clinical O O
event O O
was O O
characterized O O
by O O
marked O O
hypertension B-Disease B-Disease
and O O
abrupt O O
neurological O B-Disease
deterioration O I-Disease
. O O

Effect O O
of O O
vincristine O O
sulfate O O
on O O
Pseudomonas B-Disease B-Disease
infections I-Disease I-Disease
in O O
monkeys O O
. O O

In O O
rhesus O O
monkeys O O
, O O
intravenous O O
challenge O O
with O O
0.6 O O
x O O
10 O O
( O O
10 O O
) O O
to O O
2.2 O O
x O O
10 O O
( O O
10 O O
) O O
Pseudomonas O O
aeruginosa O O
organisms O O
caused O O
acute O O
illness O O
of O O
4 O O
to O O
5 O O
days O O
' O O
duration O O
with O O
spontaneous O O
recovery O O
in O O
13 O O
of O O
15 O O
monkeys O O
; O O
blood O O
cultures O O
became O O
negative O O
3 O O
to O O
17 O O
days O O
after O O
challenge O O
. O O

Leukocytosis B-Disease B-Disease
was O O
observed O O
in O O
all O O
monkeys O O
. O O

Intravenous O O
or O O
intratracheal O O
inoculation O O
of O O
2.0 O O
to O O
2.5 O O
mg O O
of O O
vincristine O O
sulfate O O
was O O
followed O O
by O O
leukopenia B-Disease B-Disease
in O O
4 O O
to O O
5 O O
days O O
. O O

Intravenous O O
inoculation O O
of O O
4.2 O O
x O O
10 O O
( O O
10 O O
) O O
to O O
7.8 O O
x O O
10 O O
( O O
10 O O
) O O
pyocin O O
type O O
6 O O
Pseudomonas O O
organisms O O
in O O
monkeys O O
given O O
vincristine O O
sulfate O O
4 O O
days O O
previously O O
resulted O O
in O O
fatal O O
infection B-Disease B-Disease
in O O
11 O O
of O O
14 O O
monkeys O O
, O O
whereas O O
none O O
of O O
four O O
receiving O O
Pseudomonas O O
alone O O
died O O
. O O

These O O
studies O O
suggest O O
that O O
an O O
antimetabolite O O
- O O
induced O O
leukopenia B-Disease B-Disease
predisposes O O
to O O
severe O O
Pseudomonas O B-Disease
sepsis B-Disease I-Disease
and O O
that O O
such O O
monkeys O O
may O O
serve O O
as O O
a O O
biological O O
model O O
for O O
study O O
of O O
comparative O O
efficacy O O
of O O
antimicrobial O O
agents O O
. O O

Modification O O
by O O
propranolol O O
of O O
cardiovascular O O
effects O O
of O O
induced O O
hypoglycaemia B-Disease B-Disease
. O O

The O O
cardiovascular O O
effects O O
of O O
hypoglycaemia B-Disease B-Disease
, O O
with O O
and O O
without O O
beta O O
- O O
blockade O O
, O O
were O O
compared O O
in O O
fourteen O O
healthy O O
men O O
. O O

Eight O O
received O O
insulin O O
alone O O
, O O
and O O
eight O O
, O O
including O O
two O O
of O O
the O O
original O O
insulin O O
- O O
only O O
group O O
, O O
were O O
given O O
propranolol O O
and O O
insulin O O
. O O

In O O
the O O
insulin O O
- O O
group O O
the O O
period O O
of O O
hypoglycaemia B-Disease B-Disease
was O O
associated O O
with O O
an O O
increase O O
in O O
heart O O
- O O
rate O O
and O O
a O O
fall O O
in O O
diastolic O O
blood O O
- O O
pressure O O
. O O

In O O
the O O
propranolol O O
- O O
insulin O O
group O O
there O O
was O O
a O O
significant O O
fall O O
in O O
heart O O
- O O
rate O O
in O O
most O O
subjects O O
and O O
an O O
increase O O
in O O
diastolic O O
pressure O O
. O O

Typical O O
S O O
- O O
T O O
/ O O
T O O
changes O O
occurred O O
in O O
the O O
insulin O O
- O O
group O O
but O O
in O O
none O O
of O O
the O O
propranolol O O
- O O
insulin O O
group O O
. O O

Hypertension B-Disease B-Disease
in O O
diabetics B-Disease B-Disease
prone O O
to O O
hypoglycaemia B-Disease B-Disease
attacks O O
should O O
not O O
be O O
treated O O
with O O
beta O O
- O O
blockers O O
because O O
these O O
drugs O O
may O O
cause O O
a O O
sharp O O
rise O O
in O O
blood O O
- O O
pressure O O
in O O
such O O
patients O O
. O O

Long O O
- O O
term O O
propranolol O O
therapy O O
in O O
pregnancy O O
: O O
maternal O O
and O O
fetal O O
outcome O O
. O O

Propranolol O O
, O O
a O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
has O O
found O O
an O O
important O O
position O O
in O O
the O O
practice O O
of O O
medicine O O
. O O

Its O O
use O O
in O O
pregnancy O O
, O O
however O O
, O O
is O O
an O O
open O O
question O O
as O O
a O O
number O O
of O O
detrimental O O
side O O
effects O O
have O O
been O O
reported O O
in O O
the O O
fetus O O
and O O
neonate O O
. O O

Ten O O
patients O O
and O O
12 O O
pregnancies O O
are O O
reported O O
where O O
chronic O O
propranolol O O
has O O
been O O
administered O O
. O O

Five O O
patients O O
with O O
serial O O
pregnancies O O
with O O
and O O
without O O
propranolol O O
therapy O O
are O O
also O O
examined O O
. O O

Maternal O O
, O O
fetal O O
, O O
and O O
neonatal O O
complications O O
are O O
examined O O
. O O

An O O
attempt O O
is O O
made O O
to O O
differentiate O O
drug O O
- O O
related O O
complications O O
from O O
maternal O O
disease O O
-- O O
related O O
complications O O
. O O

We O O
conclude O O
that O O
previously O O
reported O O
hypoglycemia B-Disease B-Disease
, O O
hyperbilirubinemia B-Disease B-Disease
, O O
polycythemia B-Disease B-Disease
, O O
neonatal B-Disease O
apnea I-Disease B-Disease
, O O
and O O
bradycardia B-Disease B-Disease
are O O
not O O
invariable O O
and O O
can O O
not O O
be O O
statistically O O
correlated O O
with O O
chronic O O
propranolol O O
therapy O O
. O O

Growth B-Disease B-Disease
retardation I-Disease I-Disease
, O O
however O O
, O O
appears O O
to O O
be O O
significant O O
in O O
both O O
of O O
our O O
series O O
. O O

Central O O
excitatory O O
actions O O
of O O
flurazepam O O
. O O

Toxic O O
actions O O
of O O
flurazepam O O
( O O
FZP O O
) O O
were O O
studied O O
in O O
cats O O
, O O
mice O O
and O O
rats O O
. O O

High O O
doses O O
caused O O
an O O
apparent O O
central O O
excitation O O
, O O
most O O
clearly O O
seen O O
as O O
clonic O B-Disease
convulsions B-Disease I-Disease
, O O
superimposed O O
on O O
general O O
depression B-Disease B-Disease
. O O

Following O O
a O O
lethal O O
dose O O
, O O
death O O
was O O
always O O
associated O O
with O O
convulsions B-Disease B-Disease
. O O

Comparing O O
the O O
relative O O
sensitivity O O
to O O
central O O
depression B-Disease B-Disease
and O O
excitation O O
revealed O O
that O O
rats O O
were O O
least O O
likely O O
to O O
have O O
convulsions B-Disease B-Disease
at O O
doses O O
that O O
did O O
not O O
first O O
cause O O
loss B-Disease B-Disease
of I-Disease I-Disease
consciousness I-Disease I-Disease
, O O
while O O
cats O O
most O O
clearly O O
showed O O
marked O O
central O O
excitatory O O
actions O O
. O O

Signs O O
of O O
FZP O O
toxocity B-Disease B-Disease
in O O
cats O O
included O O
excessive O O
salivation B-Disease O
, O O
extreme O O
apprehensive O O
behavior O O
, O O
retching O O
, O O
muscle B-Disease B-Disease
tremors I-Disease I-Disease
and O O
convulsions B-Disease B-Disease
. O O

An O O
interaction O O
between O O
FZP O O
and O O
pentylenetetrazol O O
( O O
PTZ O O
) O O
was O O
shown O O
by O O
pretreating O O
mice O O
with O O
FZP O O
before O O
PTZ O O
challenge O O
. O O

As O O
a O O
function O O
of O O
dose O O
, O O
FZP O O
first O O
protected O O
against O O
convulsions B-Disease B-Disease
and O O
death O O
. O O

At O O
higher O O
doses O O
, O O
however O O
, O O
convulsions B-Disease B-Disease
again O O
emerged O O
. O O

These O O
doses O O
of O O
FZP O O
were O O
lower O O
than O O
those O O
that O O
would O O
alone O O
cause O O
convulsions B-Disease B-Disease
. O O

These O O
results O O
may O O
be O O
relevant O O
to O O
the O O
use O O
of O O
FZP O O
in O O
clinical O O
situations O O
in O O
which O O
there O O
is O O
increased O O
neural O O
excitability O O
, O O
such O O
as O O
epilepsy B-Disease B-Disease
or O O
sedative O O
- O O
hypnotic O O
drug O O
withdrawal O O
. O O

Use O O
of O O
propranolol O O
in O O
the O O
treatment O O
of O O
idiopathic B-Disease B-Disease
orthostatic I-Disease I-Disease
hypotension I-Disease I-Disease
. O O

Five O O
patients O O
with O O
idiopathic B-Disease B-Disease
orthostatic I-Disease I-Disease
hypotension I-Disease I-Disease
who O O
had O O
physiologic O O
and O O
biochemical O O
evidence O O
of O O
severe O O
autonomic O B-Disease
dysfunction O I-Disease
were O O
included O O
in O O
the O O
study O O
. O O

They O O
all O O
exhibited O O
markedly O O
reduced O O
plasma O O
catecholamines O O
and O O
plasma O O
renin O O
activity O O
in O O
both O O
recumbent O O
and O O
upright O O
positions O O
and O O
had O O
marked O O
hypersensitivity B-Disease B-Disease
to O O
the O O
pressor O O
effects O O
of O O
infused O O
norepinephrine O O
. O O

Treatment O O
with O O
propanolol O O
administered O O
intravenously O O
( O O
1 O O
- O O
5 O O
mg O O
) O O
produced O O
increases O O
in O O
supine O O
and O O
upright O O
blood O O
pressure O O
in O O
4 O O
of O O
the O O
5 O O
individuals O O
with O O
rises O O
ranging O O
from O O
11 O O
/ O O
6 O O
to O O
22 O O
/ O O
11 O O
mmHg O O
. O O

Chronic O O
oral O O
administration O O
of O O
propranolol O O
( O O
40 O O
- O O
160 O O
mg O O
/ O O
day O O
) O O
also O O
elevated O O
the O O
blood O O
pressures O O
of O O
these O O
individuals O O
with O O
increases O O
in O O
the O O
order O O
of O O
20 O O
- O O
35 O O
/ O O
15 O O
- O O
25 O O
mmg O O
being O O
observed O O
. O O

In O O
1 O O
patient O O
, O O
marked O O
hypertension B-Disease B-Disease
was O O
induced O O
by O O
propranolol O O
and O O
the O O
drug O O
had O O
to O O
be O O
withdrawn O O
. O O

It O O
otherwise O O
was O O
well O O
tolerated O O
and O O
no O O
important O O
side O O
effects O O
were O O
observed O O
. O O

Treatment O O
has O O
been O O
continued O O
in O O
3 O O
individuals O O
for O O
6 O O
- O O
13 O O
months O O
with O O
persistence O O
of O O
the O O
pressor O O
effect O O
, O O
although O O
there O O
appears O O
to O O
have O O
been O O
some O O
decrease O O
in O O
the O O
degree O O
of O O
response O O
with O O
time O O
. O O

Hemodynamic O O
measurements O O
in O O
1 O O
of O O
the O O
patients O O
demonstrated O O
an O O
increase O O
in O O
total O O
peripheral O O
resistance O O
and O O
essentially O O
no O O
change O O
in O O
cardiac O O
output O O
following O O
propranolol O O
therapy O O
. O O

The O O
studies O O
suggest O O
that O O
propranolol O O
is O O
a O O
useful O O
drug O O
in O O
selected O O
patients O O
with O O
severe O O
idiopathic B-Disease B-Disease
orthostatic I-Disease I-Disease
hypotension I-Disease I-Disease
. O O

Total O O
intravenous O O
anesthesia O O
with O O
etomidate O O
. O O

III O O
. O O

Some O O
observations O O
in O O
adults O O
. O O

An O O
investigation O O
was O O
undertaken O O
to O O
determine O O
the O O
dosage O O
of O O
etomidate O O
required O O
to O O
maintain O O
sleep O O
in O O
adults O O
undergoing O O
surgery O O
under O O
regional O O
local O O
anesthesia O O
. O O

Premedication O O
of O O
diazepam O O
10 O O
mg O O
and O O
atropine O O
0.5 O O
mg O O
was O O
given O O
, O O
and O O
sleep O O
was O O
induced O O
and O O
maintained O O
by O O
intermittent O O
intravenous O O
injections O O
of O O
etomidate O O
0.1 O O
/ O O
mg O O
/ O O
kg O O
, O O
given O O
whenever O O
the O O
patient O O
would O O
open O O
his O O
eyes O O
on O O
request O O
. O O

A O O
mean O O
overall O O
dose O O
of O O
etomidate O O
17.4 O O
microgram O O
/ O O
kg O O
/ O O
min O O
. O O
was O O
required O O
to O O
maintain O O
sleep O O
, O O
but O O
great O O
individual O O
variation O O
occurred O O
, O O
with O O
older O O
patients O O
requiring O O
less O O
drug O O
. O O

The O O
investigation O O
was O O
discontinued O O
after O O
18 O O
patients O O
because O O
of O O
the O O
frequency O O
and O O
intensity O O
of O O
side O O
- O O
effects O O
, O O
particularly O O
pain B-Disease B-Disease
and O O
myoclonia B-Disease B-Disease
, O O
which O O
caused O O
the O O
technique O O
to O O
be O O
abandoned O O
in O O
two O O
cases O O
. O O

It O O
is O O
considered O O
unlikely O O
that O O
etomidate O O
will O O
prove O O
to O O
be O O
the O O
hypnotic O O
of O O
choice O O
for O O
a O O
totally O O
intravenous O O
anesthetic O O
technique O O
in O O
adults O O
because O O
of O O
the O O
high O O
incidence O O
of O O
myoclonia B-Disease B-Disease
after O O
prolonged O O
administration O O
. O O

In O O
several O O
patients O O
uncontrollable O O
muscle O B-Disease
movements O I-Disease
persisted O O
for O O
many O O
minutes O O
after O O
complete O O
recovery O O
of O O
consciousness O O
. O O

Evidence O O
for O O
cardiac O O
beta O O
2-adrenoceptors O O
in O O
man O O
. O O

We O O
compared O O
the O O
effects O O
of O O
single O O
doses O O
of O O
50 O O
mg O O
atenolol O O
( O O
cardioselective O O
) O O
, O O
40 O O
mg O O
propranolol O O
( O O
nonselective O O
) O O
, O O
and O O
placebo O O
on O O
both O O
exercise- O O
and O O
isoproterenol O O
- O O
induced O O
tachycardia B-Disease B-Disease
in O O
two O O
experiments O O
involving O O
nine O O
normal O O
subjects O O
. O O

Maximal O O
exercise O O
heart O O
rate O O
was O O
reduced O O
from O O
187 O O
+ O O
/- O O

4 O O
( O O
SEM O O
) O O
after O O
placebo O O
to O O
146 O O
+ O O
/- O O

7 O O
bpm O O
after O O
atenolol O O
and O O
138 O O
+ O O
/- O O

6 O O
bpm O O
after O O
propranolol O O
, O O
but O O
there O O
were O O
no O O
differences O O
between O O
the O O
drugs O O
. O O

The O O
effects O O
on O O
isoproterenol O O
tachycardia B-Disease B-Disease
were O O
determined O O
before O O
and O O
after O O
atropine O O
( O O
0.04 O O
mg O O
/ O O
kg O O
IV O O
) O O
. O O

Isoproterenol O O
sensitivity O O
was O O
determined O O
as O O
the O O
intravenous O O
dose O O
that O O
increased O O
heart O O
rate O O
by O O
25 O O
bpm O O
( O O
CD25 O O
) O O
and O O
this O O
was O O
increased O O
from O O
1.8 O O
+ O O
/- O O

0.3 O O
micrograms O O
after O O
placebo O O
to O O
38.9 O O
+ O O
/- O O

8.3 O O
micrograms O O
after O O
propranolol O O
and O O
8.3 O O
+ O O
/- O O

1.7 O O
micrograms O O
after O O
atenolol O O
. O O

The O O
difference O O
in O O
the O O
effects O O
of O O
the O O
two O O
was O O
significant O O
. O O

After O O
atropine O O
the O O
CD25 O O
was O O
unchanged O O
after O O
placebo O O
( O O
2.3 O O
+ O O
/- O O

0.3 O O
micrograms O O
) O O
and O O
atenolol O O
( O O
7.7 O O
+ O O
/- O O

1.3 O O
micrograms O O
) O O
; O O
it O O
was O O
reduced O O
after O O
propranolol O O
( O O
24.8 O O
+ O O
/- O O

5.0 O O
micrograms O O
) O O
, O O
but O O
remained O O
different O O
from O O
atenolol O O
. O O

This O O
change O O
with O O
propranolol O O
sensitivity O O
was O O
calculated O O
as O O
the O O
apparent O O
Ka O O
, O O
this O O
was O O
unchanged O O
by O O
atropine O O
( O O
11.7 O O
+ O O
/- O O

2.1 O O
and O O
10.1 O O
+ O O
/- O O

2.5 O O
ml O O
/ O O
ng O O
) O O
. O O

These O O
data O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
exercise O O
- O O
induced O O
tachycardia B-Disease B-Disease
results O O
largely O O
from O O
beta O O
1-receptor O O
activation O O
that O O
is O O
blocked O O
by O O
both O O
cardioselective O O
and O O
nonselective O O
drugs O O
, O O
whereas O O
isoproterenol O O
activates O O
both O O
beta O O
1- O O
and O O
beta O O
2-receptors O O
so O O
that O O
after O O
cardioselective O O
blockade O O
there O O
remains O O
a O O
beta O O
2-component O O
that O O
can O O
be O O
blocked O O
with O O
a O O
nonselective O O
drug O O
. O O

While O O
there O O
appear O O
to O O
be O O
beta O O
2-receptors O O
in O O
the O O
human O O
heart O O
, O O
their O O
physiologic O O
or O O
pathologic O O
roles O O
remain O O
to O O
be O O
defined O O
. O O

Hormones O O
and O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

This O O
paper O O
reports O O
the O O
results O O
of O O
a O O
study O O
of O O
50 O O
menopausal O O
women O O
receiving O O
hormonal O O
replacement O O
therapy O O
. O O

The O O
majority O O
( O O
29 O O
) O O
had O O
surgical O O
menopause O O
; O O
their O O
mean O O
age O O
was O O
45.7 O O
years O O
. O O

It O O
was O O
hypothesized O O
that O O
progestins O O
could O O
equilibrate O O
the O O
effects O O
of O O
the O O
estrogenic O O
stimulation O O
on O O
the O O
mammary O O
and O O
endometrial O O
target O O
tissues O O
of O O
women O O
on O O
hormonal O O
replacement O O
therapy O O
. O O

The O O
treatment O O
schedule O O
consisted O O
of O O
conjugated O O
estrogens O O
( O O
Premarin O O
) O O
1.25 O O
mg O O
/ O O
day O O
for O O
21 O O
days O O
and O O
Medroxyprogesterone O O
acetate O O
10 O O
mg O O
/ O O
day O O
for O O
10 O O
days O O
in O O
each O O
month O O
. O O

The O O
mean O O
treatment O O
period O O
was O O
18 O O
months O O
. O O

During O O
the O O
follow O O
- O O
up O O
period O O
, O O
attention O O
was O O
paid O O
to O O
breast O O
modifications O O
as O O
evidenced O O
by O O
symptomatology O O
, O O
physical O O
examination O O
, O O
and O O
plate O O
thermography O O
. O O

Mastodynia B-Disease B-Disease
was O O
reported O O
by O O
21 O O
patients O O
, O O
and O O
physical O O
examination O O
revealed O O
a O O
light O O
increase O O
in O O
breast O O
firmness O O
in O O
12 O O
women O O
and O O
a O O
moderate O O
increase O O
in O O
breast O B-Disease
nodularity O I-Disease
in O O
2 O O
women O O
. O O

Themography O O
confirmed O O
the O O
existence O O
of O O
an O O
excessive O O
breast O O
stimulation O O
in O O
1 O O
women O O
who O O
complained O O
of O O
moderate O O
mastodynia B-Disease B-Disease
and O O
in O O
5 O O
of O O
the O O
7 O O
women O O
who O O
complained O O
of O O
severe O O
mastodynia B-Disease B-Disease
. O O

Normalization O O
was O O
obtained O O
by O O
halving O O
the O O
estrogen O O
dose O O
. O O

These O O
results O O
suggest O O
that O O
hormonal O O
replacement O O
therapy O O
can O O
be O O
safely O O
prescribed O O
if O O
the O O
following O O
criteria O O
are O O
satisfied O O
: O O
1 O O
) O O
preliminary O O
evaluation O O
of O O
patients O O
from O O
a O O
clinical O O
, O O
metabolic O O
, O O
cytologic O O
, O O
and O O
mammographic O O
perspective O O
; O O
2 O O
) O O
cyclic O O
treatment O O
schedule O O
, O O
with O O
a O O
progestative O O
phase O O
of O O
10 O O
days O O
; O O
and O O
3 O O
) O O
periodic O O
complete O O
follow O O
- O O
up O O
, O O
with O O
accurate O O
thermographic O O
evaluation O O
of O O
the O O
breast O O
target O O
tissues O O
. O O

Early O O
infections B-Disease B-Disease
in O O
kidney O O
, O O
heart O O
, O O
and O O
liver O O
transplant O O
recipients O O
on O O
cyclosporine O O
. O O

Eighty O O
- O O
one O O
renal O O
, O O
seventeen O O
heart O O
, O O
and O O
twenty O O
- O O
four O O
liver O O
transplant O O
patients O O
were O O
followed O O
for O O
infection B-Disease B-Disease
. O O

Seventeen O O
renal O O
patients O O
received O O
azathioprine O O
( O O
Aza O O
) O O
and O O
prednisone O O
as O O
part O O
of O O
a O O
randomized O O
trial O O
of O O
immunosuppression O O
with O O
21 O O
cyclosporine O O
- O O
and O O
- O O
prednisone O O
- O O
treated O O
renal O O
transplant O O
patients O O
. O O

All O O
others O O
received O O
cyclosporine O O
and O O
prednisone O O
. O O

The O O
randomized O O
Aza O O
patients O O
had O O
more O O
overall O O
infections B-Disease B-Disease
( O O
P O O
less O O
than O O
0.05 O O
) O O
and O O
more O O
nonviral O B-Disease
infections B-Disease I-Disease
( O O
P O O
less O O
than O O
0.02 O O
) O O
than O O
the O O
randomized O O
cyclosporine O O
patients O O
. O O

Heart O O
and O O
liver O O
patients O O
had O O
more O O
infections B-Disease B-Disease
than O O
cyclosporine O O
renal O O
patients O O
but O O
fewer O O
infections B-Disease B-Disease
than O O
the O O
Aza O O
renal O O
patients O O
. O O

There O O
were O O
no O O
infectious O O
deaths O O
in O O
renal O O
transplant O O
patients O O
on O O
cyclosporine O O
or O O
Aza O O
, O O
but O O
infection B-Disease B-Disease
played O O
a O O
major O O
role O O
in O O
3 O O
out O O
of O O
6 O O
cardiac O O
transplant O O
deaths O O
and O O
in O O
8 O O
out O O
of O O
9 O O
liver O O
transplant O O
deaths O O
. O O

Renal O O
patients O O
on O O
cyclosporine O O
had O O
the O O
fewest O O
bacteremias B-Disease B-Disease
. O O

Analysis O O
of O O
site O O
of O O
infection B-Disease B-Disease
showed O O
a O O
preponderance O O
of O O
abdominal B-Disease B-Disease
infections I-Disease I-Disease
in O O
liver O O
patients O O
, O O
intrathoracic O B-Disease
infections B-Disease I-Disease
in O O
heart O O
patients O O
, O O
and O O
urinary B-Disease B-Disease
tract I-Disease I-Disease
infections I-Disease I-Disease
in O O
renal O O
patients O O
. O O

Pulmonary O B-Disease
infections B-Disease I-Disease
were O O
less O O
common O O
in O O
cyclosporine O O
- O O
treated O O
renal O O
patients O O
than O O
in O O
Aza O O
- O O
treated O O
patients O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
. O O

Aza O O
patients O O
had O O
significantly O O
more O O
staphylococcal B-Disease B-Disease
infections I-Disease I-Disease
than O O
all O O
other O O
transplant O O
groups O O
( O O
P O O
less O O
than O O
0.005 O O
) O O
, O O
and O O
systemic O O
fungal B-Disease B-Disease
infections I-Disease I-Disease
occurred O O
only O O
in O O
the O O
liver O O
transplant O O
group O O
. O O

Cytomegalovirus O O
( O O
CMV O O
) O O
shedding O O
or O O
serological O O
rises O O
in O O
antibody O O
titer O O
, O O
or O O
both O O
occurred O O
in O O
78 O O
% O O
of O O
cyclosporine O O
patients O O
and O O
76 O O
% O O
of O O
Aza O O
patients O O
. O O

Of O O
the O O
cyclosporine O O
patients O O
, O O
15 O O
% O O
had O O
symptoms O O
related O O
to O O
CMV B-Disease B-Disease
infection I-Disease I-Disease
. O O

Serological O O
evidence O O
for O O
Epstein B-Disease B-Disease
Barr I-Disease I-Disease
Virus I-Disease I-Disease
infection I-Disease I-Disease
was O O
found O O
in O O
20 O O
% O O
of O O
65 O O
cyclosporine O O
patients O O
studied O O
. O O

Three O O
had O O
associated O O
symptoms O O
, O O
and O O
one O O
developed O O
a O O
lymphoma B-Disease B-Disease
. O O

Structure O O
- O O
activity O O
and O O
dose O O
- O O
effect O O
relationships O O
of O O
the O O
antagonism O O
of O O
picrotoxin O O
- O O
induced O O
seizures B-Disease B-Disease
by O O
cholecystokinin O O
, O O
fragments O O
and O O
analogues O O
of O O
cholecystokinin O O
in O O
mice O O
. O O

Intraperitoneal O O
administration O O
of O O
cholecystokinin O O
octapeptide O O
sulphate O O
ester O O
( O O
CCK-8-SE O O
) O O
and O O
nonsulphated O O
cholecystokinin O O
octapeptide O O
( O O
CCK-8-NS O O
) O O
enhanced O O
the O O
latency O O
of O O
seizures B-Disease B-Disease
induced O O
by O O
picrotoxin O O
in O O
mice O O
. O O

Experiments O O
with O O
N- O O
and O O
C O O
- O O
terminal O O
fragments O O
revealed O O
that O O
the O O
C O O
- O O
terminal O O
tetrapeptide O O
( O O
CCK-5 O O
- O O
8 O O
) O O
was O O
the O O
active O O
centre O O
of O O
the O O
CCK O O
octapeptide O O
molecule O O
. O O

The O O
analogues O O
CCK-8-SE O O
and O O
CCK-8-NS O O
( O O
dose O O
range O O
0.2 O O
- O O
6.4 O O
mumol O O
/ O O
kg O O
) O O
and O O
caerulein O O
dose O O
range O O
0.1 O O
- O O
0.8 O O
mumol O O
/ O O
kg O O
) O O
showed O O
bell O O
- O O
shaped O O
dose O O
- O O
effect O O
curves O O
, O O
with O O
the O O
greatest O O
maximum O O
inhibition O O
for O O
CCK-8-NS O O
. O O

The O O
peptide O O
CCK-5 O O
- O O
8 O O
had O O
weak O O
anticonvulsant O O
activity O O
in O O
comparison O O
to O O
the O O
octapeptides O O
, O O
3.2 O O
mumol O O
/ O O
kg O O
and O O
larger O O
doses O O
of O O
the O O
reference O O
drug O O
, O O
diazepam O O
, O O
totally O O
prevented O O
picrotoxin O O
- O O
induced O O
seizures B-Disease B-Disease
and O O
mortality O O
. O O

The O O
maximum O O
effect O O
of O O
the O O
peptides O O
tested O O
was O O
less O O
than O O
that O O
of O O
diazepam O O
. O O

Experiments O O
with O O
analogues O O
and O O
derivatives O O
of O O
CCK-5 O O
- O O
8 O O
demonstrated O O
that O O
the O O
effectiveness O O
of O O
the O O
beta O O
- O O
alanyl O O
derivatives O O
of O O
CCK-5 O O
- O O
8 O O
were O O
enhanced O O
and O O
that O O
they O O
were O O
equipotent O O
with O O
CCK-8-SE O O
. O O

Of O O
the O O
CCK-2 O O
- O O
8 O O
analogues O O
, O O
Ser O O
( O O
SO3H O O
) O O
7-Ac O O
- O O
CCK-2 O O
- O O
8-SE O O
and O O
Thr O O
( O O
SO3H O O
) O O
7-Ac O O
- O O
CCK-2 O O
- O O
8-SE O O
and O O
Hyp O O
( O O
SO3H O O
) O O
-Ac O O
- O O
CCK-2 O O
- O O
8-SE O O
were O O
slightly O O
more O O
active O O
than O O
CCK-8-SE O O
. O O

Vasopressin O O
as O O
a O O
possible O O
contributor O O
to O O
hypertension B-Disease B-Disease
. O O

The O O
role O O
of O O
vasopressin O O
as O O
a O O
pressor O O
agent O O
to O O
the O O
hypertensive B-Disease B-Disease
process O O
was O O
examined O O
. O O

Vasopressin O O
plays O O
a O O
major O O
role O O
in O O
the O O
pathogenesis O O
of O O
DOCA O O
- O O
salt O O
hypertension B-Disease B-Disease
, O O
since O O
the O O
elevation O O
of O O
blood O O
pressure O O
was O O
not O O
substantial O O
in O O
the O O
rats O O
with O O
lithium O O
- O O
treated O O
diabetes B-Disease B-Disease
insipidus I-Disease I-Disease
after O O
DOCA O O
- O O
salt O O
treatment O O
. O O

Administration O O
of O O
DDAVP O O
which O O
has O O
antidiuretic O O
action O O
but O O
minimal O O
vasopressor O O
effect O O
failed O O
to O O
increase O O
blood O O
pressure O O
to O O
the O O
levels O O
observed O O
after O O
administration O O
of O O
AVP O O
. O O

Furthermore O O
, O O
the O O
pressor O O
action O O
of O O
vasopressin O O
appears O O
to O O
be O O
important O O
in O O
the O O
development O O
of O O
this O O
model O O
of O O
hypertension B-Disease B-Disease
, O O
since O O
the O O
enhanced O O
pressor O O
responsiveness O O
to O O
the O O
hormone O O
was O O
observed O O
in O O
the O O
initial O O
stage O O
of O O
hypertension B-Disease B-Disease
. O O

Increased O O
secretion O O
of O O
vasopressin O O
from O O
neurohypophysis O O
also O O
promotes O O
the O O
function O O
of O O
the O O
hormone O O
as O O
a O O
pathogenetic O O
factor O O
in O O
hypertension B-Disease B-Disease
. O O

An O O
unproportional O O
release O O
of O O
vasopressin O O
compared O O
to O O
plasma O O
osmolality O O
may O O
be O O
induced O O
by O O
the O O
absence O O
of O O
an O O
adjusting O O
control O O
of O O
angiotensin O O
II O O
forming O O
and O O
receptor O O
binding O O
capacity O O
for O O
sodium O O
balance O O
in O O
the O O
brain O O
. O O

However O O
, O O
the O O
role O O
of O O
vasopressin O O
remains O O
to O O
be O O
determined O O
in O O
human O O
essential O B-Disease
hypertension B-Disease I-Disease
. O O

Toxic B-Disease O
hepatitis I-Disease B-Disease
induced O O
by O O
disulfiram O O
in O O
a O O
non O O
- O O
alcoholic O O
. O O

A O O
reversible O O
toxic B-Disease O
liver I-Disease B-Disease
damage I-Disease I-Disease
was O O
observed O O
in O O
a O O
non O O
- O O
alcoholic O O
woman O O
treated O O
with O O
disulfiram O O
. O O

The O O
causative O O
relationship O O
was O O
proven O O
by O O
challenge O O
. O O

Atrial B-Disease B-Disease
thrombosis I-Disease I-Disease
involving O O
the O O
heart O O
of O O
F-344 O O
rats O O
ingesting O O
quinacrine O O
hydrochloride O O
. O O

Quinacrine O O
hydrochloride O O
is O O
toxic O O
for O O
the O O
heart O O
of O O
F-344 O O
rats O O
. O O

Rats O O
treated O O
with O O
500 O O
ppm O O
quinacrine O O
hydrochloride O O
in O O
the O O
diet O O
all O O
developed O O
a O O
high O O
incidence O O
of O O
left O O
atrial B-Disease B-Disease
thrombosis I-Disease I-Disease
. O O

The O O
lesion O O
was O O
associated O O
with O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
and O O
dilatation O O
and O O
focal O O
myocardial B-Disease B-Disease
degeneration I-Disease I-Disease
. O O

Rats O O
died O O
from O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
with O O
severe O O
acute O O
and O O
chronic O O
congestion O O
of O O
the O O
lungs O O
, O O
liver O O
, O O
and O O
other O O
organs O O
. O O

Seventy O O
percent O O
of O O
rats O O
given O O
250 O O
ppm O O
quinacrine O O
hydrochloride O O
and O O
1,000 O O
ppm O O
sodium O O
nitrite O O
simultaneously O O
in O O
the O O
diet O O
had O O
thrombosis B-Disease B-Disease
of O O
the O O
atria O O
of O O
the O O
heart O O
, O O
while O O
untreated O O
control O O
rats O O
in O O
this O O
laboratory O O
did O O
not O O
have O O
atrial B-Disease B-Disease
thrombosis I-Disease I-Disease
. O O

Sodium O O
nitrite O O
in O O
combination O O
with O O
quinacrine O O
hydrochloride O O
appeared O O
to O O
have O O
no O O
additional O O
effect O O
. O O

Alternating B-Disease O
sinus I-Disease O
rhythm I-Disease O
and O O
intermittent O O
sinoatrial B-Disease B-Disease
block I-Disease I-Disease
induced O O
by O O
propranolol O O
. O O

Alternating B-Disease B-Disease
sinus I-Disease I-Disease
rhythm I-Disease I-Disease
and O O
intermittent O O
sinoatrial B-Disease B-Disease
( I-Disease I-Disease
S I-Disease I-Disease
- I-Disease I-Disease
A I-Disease I-Disease
) I-Disease I-Disease
block I-Disease I-Disease
was O O
observed O O
in O O
a O O
57-year O O
- O O
old O O
woman O O
, O O
under O O
treatment O O
for O O
angina B-Disease B-Disease
with O O
80 O O
mg O O
propranolol O O
daily O O
. O O

The O O
electrocardiogram O O
showed O O
alternation O O
of O O
long O O
and O O
short O O
P O O
- O O
P O O
intervals O O
and O O
occasional O O
pauses O O
. O O

These O O
pauses O O
were O O
always O O
preceded O O
by O O
the O O
short O O
P O O
- O O
P O O
intervals O O
and O O
were O O
usually O O
followed O O
by O O
one O O
or O O
two O O
P O O
- O O
P O O
intervals O O
of O O
0.92 O O
- O O
0.95 O O
s O O
representing O O
the O O
basic O O
sinus O O
cycle O O
. O O

Following O O
these O O
basic O O
sinus O O
cycles O O
, O O
alternating B-Disease O
rhythm I-Disease O
started O O
with O O
the O O
longer O O
P O O
- O O
P O O
interval O O
. O O

The O O
long O O
P O O
- O O
P O O
intervals O O
ranged O O
between O O
1.04 O O
- O O
1.12 O O
s O O
and O O
the O O
short O O
P O O
- O O
P O O
intervals O O
between O O
0.80 O O
- O O
0.84 O O
s O O
, O O
respectively O O
. O O

The O O
duration O O
of O O
the O O
pauses O O
were O O
equal O O
or O O
almost O O
equal O O
to O O
one O O
short O O
plus O O
one O O
long O O
P O O
- O O
P O O
interval O O
or O O
to O O
twice O O
the O O
basic O O
sinus O O
cycle O O
. O O

In O O
one O O
recording O O
a O O
short O O
period O O
of O O
regular O O
sinus O O
rhythm O O
with O O
intermittent O O
2 O O
/ O O
1 O O
S B-Disease O
- I-Disease O
A I-Disease O
block I-Disease O
was O O
observed O O
. O O

This O O
short O O
period O O
of O O
sinus O O
rhythm O O
was O O
interrupted O O
by O O
sudden O O
prolongation O O
of O O
the O O
P O O
- O O
P O O
interval O O
starting O O
the O O
alternative O O
rhythm O O
. O O

There O O
were O O
small O O
changes O O
in O O
the O O
shape O O
of O O
the O O
P O O
waves O O
and O O
P O O
- O O
R O O
intervals O O
. O O

S O O
- O O
A O O
conduction O O
through O O
two O O
pathways O O
, O O
the O O
first O O
with O O
2 O O
/ O O
1 O O
block O O
the O O
second O O
having O O
0.12 O O
- O O
0.14 O O
s O O
longer O O
conduction O O
time O O
and O O
with O O
occasional O O
2 O O
/ O O
1 O O
block O O
was O O
proposed O O
for O O
the O O
explanation O O
of O O
the O O
alternating O O
P O O
- O O
P O O
interval O O
and O O
other O O
electrocardiographic O O
features O O
seen O O
. O O

Atropine O O
1 O O
mg O O
given O O
intravenously O O
resulted O O
in O O
shortening O O
of O O
all O O
P O O
- O O
P O O
intervals O O
without O O
changing O O
the O O
rhythm O O
. O O

The O O
abnormal O O
rhythm O O
disappeared O O
with O O
the O O
withdrawal O O
of O O
propranolol O O
and O O
when O O
the O O
drug O O
was O O
restarted O O
a O O
2 O O
/ O O
1 O O
S B-Disease O
- I-Disease O
A I-Disease O
block I-Disease O
was O O
seen O O
. O O

This O O
was O O
accepted O O
as O O
evidence O O
for O O
propranolol O O
being O O
the O O
cause O O
of O O
this O O
conduction B-Disease B-Disease
disorder I-Disease I-Disease
. O O

Antitumor O O
effect O O
, O O
cardiotoxicity B-Disease B-Disease
, O O
and O O
nephrotoxicity B-Disease B-Disease
of O O
doxorubicin O O
in O O
the O O
IgM O O
solid O O
immunocytoma B-Disease B-Disease
- O O
bearing O O
LOU O O
/ O O
M O O
/ O O
WSL O O
rat O O
. O O

Antitumor O O
activity O O
, O O
cardiotoxicity B-Disease B-Disease
, O O
and O O
nephrotoxicity B-Disease B-Disease
induced O O
by O O
doxorubicin O O
were O O
studied O O
in O O
LOU O O
/ O O
M O O
/ O O
WSL O O
inbred O O
rats O O
each O O
bearing O O
a O O
transplantable O O
solid O O
IgM O O
immunocytoma B-Disease B-Disease
. O O

Animals O O
with O O
a O O
tumor B-Disease B-Disease
( O O
diameter O O
, O O
15.8 O O
+ O O
/- O O

3.3 O O
mm O O
) O O
were O O
treated O O
with O O
iv O O
injections O O
of O O
doxorubicin O O
on O O
5 O O
consecutive O O
days O O
, O O
followed O O
by O O
1 O O
weekly O O
injection O O
for O O
7 O O
weeks O O
( O O
dose O O
range O O
, O O
0.015 O O
- O O
4.0 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
. O O

Tumor B-Disease B-Disease
regression O O
was O O
observed O O
with O O
0.5 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Complete O O
disappearance O O
of O O
the O O
tumor B-Disease B-Disease
was O O
induced O O
with O O
1.0 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Histologic O O
evidence O O
of O O
cardiotoxicity B-Disease B-Disease
scored O O
as O O
grade O O
III O O
was O O
only O O
observed O O
at O O
a O O
dose O O
of O O
1.0 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Light O O
microscopic O O
evidence O O
of O O
renal B-Disease B-Disease
damage I-Disease I-Disease
was O O
seen O O
above O O
a O O
dose O O
of O O
0.5 O O
mg O O
doxorubicin O O
/ O O
kg O O
, O O
which O O
resulted O O
in O O
albuminuria B-Disease B-Disease
and O O
very O O
low O O
serum O O
albumin O O
levels O O
. O O

In O O
the O O
group O O
that O O
received O O
1.0 O O
mg O O
doxorubicin O O
/ O O
kg O O
, O O
the O O
serum O O
albumin O O
level O O
decreased O O
from O O
33.6 O O
+ O O
/- O O

4.1 O O
to O O
1.5 O O
+ O O
/- O O

0.5 O O
g O O
/ O O
liter O O
. O O

Ascites B-Disease B-Disease
and O O
hydrothorax B-Disease B-Disease
were O O
observed O O
simultaneously O O
. O O

The O O
same O O
experiments O O
were O O
performed O O
with O O
non O O
- O O
tumor B-Disease B-Disease
- O O
bearing O O
rats O O
, O O
in O O
which O O
no O O
major O O
differences O O
were O O
observed O O
. O O

In O O
conclusion O O
, O O
antitumor O O
activity O O
, O O
cardiotoxicity B-Disease B-Disease
, O O
and O O
nephrotoxicity B-Disease B-Disease
were O O
studied O O
simultaneously O O
in O O
the O O
same O O
LOU O O
/ O O
M O O
/ O O
WSL O O
rat O O
. O O

Albuminuria B-Disease B-Disease
due O O
to O O
renal B-Disease B-Disease
damage I-Disease I-Disease
led O O
to O O
extremely O O
low O O
serum O O
albumin O O
levels O O
, O O
so O O
ascites B-Disease B-Disease
and O O
hydrothorax B-Disease B-Disease
were O O
not O O
necessarily O O
a O O
consequence O O
of O O
the O O
observed O O
cardiomyopathy B-Disease B-Disease
. O O

Intraoperative O O
bradycardia B-Disease B-Disease
and O O
hypotension B-Disease B-Disease
associated O O
with O O
timolol O O
and O O
pilocarpine O O
eye O O
drops O O
. O O

A O O
69-yr O O
- O O
old O O
man O O
, O O
who O O
was O O
concurrently O O
being O O
treated O O
with O O
pilocarpine O O
nitrate O O
and O O
timolol O O
maleate O O
eye O O
drops O O
, O O
developed O O
a O O
bradycardia B-Disease B-Disease
and O O
became O O
hypotensive B-Disease B-Disease
during O O
halothane O O
anaesthesia O O
. O O

Both O O
timolol O O
and O O
pilocarpine O O
were O O
subsequently O O
identified O O
in O O
a O O
24-h O O
collection O O
of O O
urine O O
. O O

Timolol O O
( O O
but O O
not O O
pilocarpine O O
) O O
was O O
detected O O
in O O
a O O
sample O O
of O O
plasma O O
removed O O
during O O
surgery O O
; O O
the O O
plasma O O
concentration O O
of O O
timolol O O
( O O
2.6 O O
ng O O
ml-1 O O
) O O
was O O
consistent O O
with O O
partial O O
beta O O
- O O
adrenoceptor O O
blockade O O
. O O

It O O
is O O
postulated O O
that O O
this O O
action O O
may O O
have O O
been O O
enhanced O O
during O O
halothane O O
anaesthesia O O
with O O
resultant O O
bradycardia B-Disease B-Disease
and O O
hypotension B-Disease B-Disease
. O O

Pilocarpine O O
may O O
have O O
had O O
a O O
contributory O O
effect O O
. O O

Succinylcholine O O
apnoea B-Disease B-Disease
: O O
attempted O O
reversal O O
with O O
anticholinesterases O O
. O O

Anticholinesterases O O
were O O
administered O O
in O O
an O O
attempt O O
to O O
antagonize O O
prolonged O O
neuromuscular B-Disease B-Disease
blockade I-Disease I-Disease
following O O
the O O
administration O O
of O O
succinylcholine O O
in O O
a O O
patient O O
later O O
found O O
to O O
be O O
homozygous O O
for O O
atypical O O
plasma O O
cholinesterase O O
. O O

Edrophonium O O
10 O O
mg O O
, O O
given O O
74 O O
min O O
after O O
succinylcholine O O
, O O
when O O
train O O
- O O
of O O
- O O
four O O
stimulation O O
was O O
characteristic O O
of O O
phase O O
II O O
block O O
, O O
produced O O
partial O O
antagonism O O
which O O
was O O
not O O
sustained O O
. O O

Repeated O O
doses O O
of O O
edrophonium O O
to O O
70 O O
mg O O
and O O
neostigmine O O
to O O
2.5 O O
mg O O
did O O
not O O
antagonize O O
or O O
augment O O
the O O
block O O
. O O

Spontaneous O O
respiration O O
recommenced O O
200 O O
min O O
after O O
succinylcholine O O
administration O O
. O O

It O O
is O O
concluded O O
that O O
anticholinesterases O O
are O O
only O O
partially O O
effective O O
in O O
restoring O O
neuromuscular O O
function O O
in O O
succinylcholine O O
apnoea B-Disease B-Disease
despite O O
muscle O O
twitch O O
activity O O
typical O O
of O O
phase O O
II O O
block O O
. O O

Effect O O
of O O
doxorubicin O O
on O O
[ O O
omega O O
- O O
I-131 O O
] O O
heptadecanoic O O
acid O O
myocardial O O
scintigraphy O O
and O O
echocardiography O O
in O O
dogs O O
. O O

The O O
effects O O
of O O
serial O O
treatment O O
with O O
doxorubicin O O
on O O
dynamic O O
myocardial O O
scintigraphy O O
with O O
[ O O
omega O O
- O O
I-131 O O
] O O
heptadecanoic O O
acid O O
( O O
I-131 O O
HA O O
) O O
, O O
and O O
on O O
global O O
left O O
- O O
ventricular O O
function O O
determined O O
echocardiographically O O
, O O
were O O
studied O O
in O O
a O O
group O O
of O O
nine O O
mongrel O O
dogs O O
. O O

Total O O
extractable O O
myocardial O O
lipid O O
was O O
compared O O
postmortem O O
between O O
a O O
group O O
of O O
control O O
dogs O O
and O O
doxorubicin O O
- O O
treated O O
dogs O O
. O O

A O O
significant O O
and O O
then O O
progressive O O
fall O O
in O O
global O O
LV O O
function O O
was O O
observed O O
at O O
a O O
cumulative O O
doxorubicin O O
dose O O
of O O
4 O O
mg O O
/ O O
kg O O
. O O

A O O
significant O O
increase O O
in O O
the O O
myocardial O O
t1 O O
/ O O
2 O O
of O O
the O O
I-131 O O
HA O O
was O O
observed O O
only O O
at O O
a O O
higher O O
cumulative O O
dose O O
, O O
10 O O
mg O O
/ O O
kg O O
. O O

No O O
significant O O
alteration O O
in O O
total O O
extractable O O
myocardial O O
lipids O O
was O O
observed O O
between O O
control O O
dogs O O
and O O
those O O
treated O O
with O O
doxorubicin O O
. O O

Our O O
findings O O
suggest O O
that O O
the O O
changes O O
leading O O
to O O
an O O
alteration O O
of O O
myocardial O O
dynamic O O
imaging O O
with O O
I-131 O O
HA O O
are O O
not O O
the O O
initiating O O
factor O O
in O O
doxorubicin O O
cardiotoxicity B-Disease B-Disease
. O O

Hemodynamics O O
and O O
myocardial O O
metabolism O O
under O O
deliberate O O
hypotension B-Disease B-Disease
. O O

An O O
experimental O O
study O O
in O O
dogs O O
. O O

Coronary O O
blood O O
flow O O
, O O
cardiac O O
work O O
and O O
metabolism O O
were O O
studied O O
in O O
dogs O O
under O O
sodium O O
nitroprusside O O
( O O
SNP O O
) O O
and O O
trimetaphan O O
( O O
TMP O O
) O O
deliberate O O
hypotension B-Disease B-Disease
( O O
20 O O
% O O
and O O
40 O O
% O O
mean O O
pressure O O
decrease O O
from O O
baseline O O
) O O
. O O

Regarding O O
the O O
effects O O
of O O
drug O O
- O O
induced O O
hypotension B-Disease B-Disease
on O O
coronary O O
blood O O
flow O O
, O O
aortic O O
and O O
coronary O O
sinus O O
metabolic O O
data O O
( O O
pH O O
, O O
pO2 O O
, O O
pCO2 O O
) O O
we O O
could O O
confirm O O
that O O
nitroprusside O O
hypotension B-Disease B-Disease
could O O
be O O
safely O O
used O O
to O O
30 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
from O O
control O O
, O O
trimetaphan O O
hypotension B-Disease B-Disease
to O O
20 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
. O O

Cardiac O O
work O O
was O O
significantly O O
reduced O O
during O O
SNP O O
hypotension B-Disease B-Disease
. O O

Myocardial O O
O2 O O
consumption O O
and O O
O2 O O
availability O O
were O O
directly O O
dependent O O
on O O
the O O
coronary O O
perfusion O O
. O O

Careful O O
invasive O O
monitoring O O
of O O
the O O
blood O O
pressure O O
, O O
blood O O
gases O O
and O O
of O O
the O O
ECG O O
ST O O
- O O
T O O
segment O O
is O O
mandatory O O
. O O

Evidence O O
for O O
a O O
selective O O
brain O O
noradrenergic O O
involvement O O
in O O
the O O
locomotor O O
stimulant O O
effects O O
of O O
amphetamine O O
in O O
the O O
rat O O
. O O

Male O O
rats O O
received O O
the O O
noradrenaline O O
neurotoxin O O
DSP4 O O
( O O
50 O O
mg O O
/ O O
kg O O
) O O
7 O O
days O O
prior O O
to O O
injection O O
of O O
D O O
- O O
amphetamine O O
( O O
10 O O
or O O
40 O O
mumol O O
/ O O
kg O O
i.p O O
. O O
) O O
. O O

The O O
hyperactivity B-Disease B-Disease
induced O O
by O O
D O O
- O O
amphetamine O O
( O O
10 O O
mumol O O
/ O O
kg O O
) O O
was O O
significantly O O
reduced O O
by O O
DSP4 O O
pretreatment O O
. O O

However O O
, O O
the O O
increased O O
rearings O O
and O O
the O O
amphetamine O O
- O O
induced O O
stereotypies B-Disease B-Disease
were O O
not O O
blocked O O
by O O
pretreatment O O
with O O
DSP4 O O
. O O

The O O
reduction O O
of O O
amphetamine O O
hyperactivity B-Disease B-Disease
induced O O
by O O
DSP4 O O
was O O
blocked O O
by O O
pretreatment O O
with O O
the O O
noradrenaline O O
- O O
uptake O O
blocking O O
agent O O
, O O
desipramine O O
, O O
which O O
prevents O O
the O O
neurotoxic B-Disease B-Disease
action O O
of O O
DSP4 O O
. O O

The O O
present O O
results O O
suggest O O
a O O
selective O O
involvement O O
of O O
central O O
noradrenergic O O
neurones O O
in O O
the O O
locomotor O O
stimulant O O
effect O O
of O O
amphetamine O O
in O O
the O O
rat O O
. O O

Accelerated B-Disease O
junctional I-Disease O
rhythms I-Disease O
during O O
oral O O
verapamil O O
therapy O O
. O O

This O O
study O O
examined O O
the O O
frequency O O
of O O
atrioventricular O B-Disease
( O I-Disease
AV O I-Disease
) O I-Disease
dissociation O I-Disease
and O O
accelerated B-Disease O
junctional I-Disease O
rhythms I-Disease O
in O O
59 O O
patients O O
receiving O O
oral O O
verapamil O O
. O O

Accelerated B-Disease O
junctional I-Disease O
rhythms I-Disease O
and O O
AV O O
dissociation O O
were O O
frequent O O
in O O
patients O O
with O O
supraventricular B-Disease B-Disease
tachyarrhythmias I-Disease I-Disease
, O O
particularly O O
AV O O
nodal O O
reentry O O
. O O

Verapamil O O
administration O O
to O O
these O O
patients O O
led O O
to O O
an O O
asymptomatic O O
increase O O
in O O
activity O O
of O O
these O O
junctional O O
pacemakers O O
. O O

In O O
patients O O
with O O
various O O
chest B-Disease B-Disease
pain I-Disease I-Disease
syndromes O O
, O O
verapamil O O
neither O O
increased O O
the O O
frequency O O
of O O
junctional O O
rhythms O O
nor O O
suppressed O O
their O O
role O O
as O O
escape O O
rhythms O O
under O O
physiologically O O
appropriate O O
circumstances O O
. O O

Interstrain O O
variation O O
in O O
acute O O
toxic O O
response O O
to O O
caffeine O O
among O O
inbred O O
mice O O
. O O

Acute O O
toxic O O
dosage O O
- O O
dependent O O
behavioral O O
effects O O
of O O
caffeine O O
were O O
compared O O
in O O
adult O O
males O O
from O O
seven O O
inbred O O
mouse O O
strains O O
( O O
A O O
/ O O
J O O
, O O
BALB O O
/ O O
cJ O O
, O O
CBA O O
/ O O
J O O
, O O
C3H O O
/ O O
HeJ O O
, O O
C57BL O O
/ O O
6J O O
, O O
DBA O O
/ O O
2J O O
, O O
SWR O O
/ O O
J O O
) O O
. O O

C57BL O O
/ O O
6J O O
, O O
chosen O O
as O O
a O O
" O O
prototypic O O
" O O
mouse O O
strain O O
, O O
was O O
used O O
to O O
determine O O
behavioral O O
responses O O
to O O
a O O
broad O O
range O O
( O O
5 O O
- O O
500 O O
mg O O
/ O O
kg O O
) O O
of O O
caffeine O O
doses O O
. O O

Five O O
phenotypic O O
characteristics O O
-- O O
locomotor O O
activity O O
, O O
righting O O
ability O O
, O O
clonic B-Disease B-Disease
seizure I-Disease I-Disease
induction O O
, O O
stress O O
- O O
induced O O
lethality O O
, O O
death O O
without O O
external O O
stress O O
-- O O
were O O
scored O O
at O O
various O O
caffeine O O
doses O O
in O O
drug O O
- O O
naive O O
animals O O
under O O
empirically O O
optimized O O
, O O
rigidly O O
constant O O
experimental O O
conditions O O
. O O

Mice O O
( O O
n O O
= O O
12 O O
for O O
each O O
point O O
) O O
received O O
single O O
IP O O
injections O O
of O O
a O O
fixed O O
volume O O
/ O O
g O O
body O O
weight O O
of O O
physiological O O
saline O O
carrier O O
with O O
or O O
without O O
caffeine O O
in O O
doses O O
ranging O O
from O O
125 O O
- O O
500 O O
mg O O
/ O O
kg O O
. O O

Loss O O
of O O
righting O O
ability O O
was O O
scored O O
at O O
1 O O
, O O
3 O O
, O O
5 O O
min O O
post O O
dosing O O
and O O
at O O
5 O O
min O O
intervals O O
thereafter O O
for O O
20 O O
min O O
. O O

In O O
the O O
same O O
animals O O
the O O
occurrence O O
of O O
clonic B-Disease B-Disease
seizures I-Disease I-Disease
was O O
scored O O
as O O
to O O
time O O
of O O
onset O O
and O O
severity O O
for O O
20 O O
min O O
after O O
drug O O
administration O O
. O O

When O O
these O O
proceeded O O
to O O
tonic B-Disease O
seizures I-Disease B-Disease
, O O
death O O
occurred O O
in O O
less O O
than O O
20 O O
min O O
. O O

Animals O O
surviving O O
for O O
20 O O
min O O
were O O
immediately O O
stressed O O
by O O
a O O
swim O O
test O O
in O O
25 O O
degrees O O
C O O
water O O
, O O
and O O
death O O
- O O
producing O O
tonic B-Disease O
seizures I-Disease B-Disease
were O O
scored O O
for O O
2 O O
min O O
. O O

In O O
other O O
animals O O
locomotor O O
activity O O
was O O
measured O O
15 O O
or O O
60 O O
min O O
after O O
caffeine O O
administration O O
. O O

By O O
any O O
single O O
behavioral O O
criterion O O
or O O
a O O
combination O O
of O O
these O O
criteria O O
, O O
marked O O
differences O O
in O O
response O O
to O O
toxic O O
caffeine O O
doses O O
were O O
observed O O
between O O
strains O O
. O O

These O O
results O O
indicate O O
that O O
behavioral O O
toxicity B-Disease B-Disease
testing O O
of O O
alkylxanthines O O
in O O
a O O
single O O
mouse O O
strain O O
may O O
be O O
misleading O O
and O O
suggest O O
that O O
toxic O O
responses O O
of O O
the O O
central O O
nervous O O
system O O
to O O
this O O
class O O
of O O
compounds O O
are O O
genetically O O
influenced O O
in O O
mammals O O
. O O

Treatment O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
with O O
a O O
combination O O
of O O
cis O O
- O O
platinum O O
, O O
adriamycin O O
, O O
cyclophosphamide O O
and O O
hexamethylmelamine O O
. O O

During O O
the O O
last O O
2 O O
1 O O
/ O O
2 O O
years O O
, O O
38 O O
patients O O
with O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
were O O
treated O O
with O O
a O O
combination O O
of O O
cisplatinum O O
( O O
CPDD O O
) O O
, O O
50 O O
mg O O
/ O O
m2 O O
, O O
adriamycin O O
, O O
30 O O
mg O O
/ O O
m2 O O
, O O
cyclophosphamide O O
, O O
300 O O
mg O O
/ O O
m2 O O
, O O
on O O
day O O
1 O O
; O O
and O O
hexamethylmelamine O O
( O O
HMM O O
) O O
, O O
6 O O
mg O O
/ O O
kg O O
daily O O
, O O
for O O
14 O O
days O O
. O O

Each O O
course O O
was O O
repeated O O
monthly O O
. O O

2 O O
patients O O
had O O
stage O O
II O O
, O O
14 O O
stage O O
III O O
and O O
22 O O
stage O O
IV O O
disease O O
. O O

14 O O
of O O
the O O
38 O O
patients O O
were O O
previously O O
treated O O
with O O
chemotherapy O O
, O O
1 O O
with O O
radiation O O
, O O
6 O O
with O O
both O O
chemotherapy O O
and O O
radiation O O
, O O
and O O
17 O O
did O O
not O O
have O O
any O O
treatment O O
before O O
CPDD O O
combination O O
. O O

31 O O
of O O
the O O
38 O O
cases O O
( O O
81.5 O O
% O O
) O O
demonstrated O O
objective O O
responses O O
lasting O O
for O O
2 O O
months O O
or O O
more O O
. O O

These O O
responses O O
were O O
partial O O
in O O
19 O O
and O O
complete O O
in O O
12 O O
cases O O
. O O

Hematologic B-Disease B-Disease
toxicity I-Disease I-Disease
was O O
moderate O O
and O O
with O O
reversible O O
anemia B-Disease B-Disease
developing O O
in O O
71 O O
% O O
of O O
patients O O
. O O

Gastrointestinal O O
side O O
effects O O
from O O
CPDD O O
were O O
universal O O
. O O

HMM O O
gastrointestinal B-Disease B-Disease
toxicity I-Disease I-Disease
necessitated O O
discontinuation O O
of O O
the O O
drug O O
in O O
5 O O
patients O O
. O O

Severe O O
nephrotoxicity B-Disease B-Disease
was O O
observed O O
in O O
2 O O
patients O O
but O O
was O O
reversible O O
. O O

There O O
were O O
no O O
drug O O
- O O
related O O
deaths O O
. O O

Nontraumatic O O
dissecting B-Disease O
aneurysm I-Disease B-Disease
of O O
the O O
basilar O O
artery O O
. O O

A O O
case O O
of O O
nontraumatic O O
dissecting B-Disease O
aneurysm I-Disease B-Disease
of O O
the O O
basilar O O
artery O O
in O O
association O O
with O O
hypertension B-Disease B-Disease
, O O
smoke O O
, O O
and O O
oral O O
contraceptives O O
is O O
reported O O
in O O
a O O
young O O
female O O
patient O O
with O O
a O O
locked B-Disease B-Disease
- I-Disease I-Disease
in I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

A O O
method O O
for O O
the O O
measurement O O
of O O
tremor B-Disease B-Disease
, O O
and O O
a O O
comparison O O
of O O
the O O
effects O O
of O O
tocolytic O O
beta O O
- O O
mimetics O O
. O O

A O O
method O O
permitting O O
measurement O O
of O O
finger O O
tremor B-Disease B-Disease
as O O
a O O
displacement O O
- O O
time O O
curve O O
is O O
described O O
, O O
using O O
a O O
test O O
system O O
with O O
simple O O
amplitude O O
calibration O O
. O O

The O O
coordinates O O
of O O
the O O
inversion O O
points O O
of O O
the O O
displacement O O
- O O
time O O
curves O O
were O O
transferred O O
through O O
graphical O O
input O O
equipment O O
to O O
punched O O
tape O O
. O O

By O O
means O O
of O O
a O O
computer O O
program O O
, O O
periods O O
and O O
amplitudes O O
of O O
tremor B-Disease B-Disease
oscillations O O
were O O
calculated O O
and O O
classified O O
. O O

The O O
event O O
frequency O O
for O O
each O O
class O O
of O O
periods O O
and O O
amplitudes O O
was O O
determined O O
. O O

The O O
actions O O
of O O
fenoterol O O
- O O
hydrobromide O O
, O O
ritodrin O O
- O O
HCl O O
and O O
placebo O O
given O O
to O O
10 O O
healthy O O
subjects O O
by O O
intravenous O O
infusion O O
in O O
a O O
double O O
- O O
blind O O
crossover O O
study O O
were O O
tested O O
by O O
this O O
method O O
. O O

At O O
therapeutic O O
doses O O
both O O
substances O O
raised O O
the O O
mean O O
tremor B-Disease B-Disease
amplitude O O
to O O
about O O
three O O
times O O
the O O
control O O
level O O
. O O

At O O
the O O
same O O
time O O
, O O
the O O
mean O O
period O O
within O O
each O O
class O O
of O O
amplitudes O O
shortened O O
by O O
10 O O
- O O
-20 O O
ms O O
, O O
whereas O O
the O O
mean O O
periods O O
calculated O O
from O O
all O O
oscillations O O
together O O
did O O
not O O
change O O
significantly O O
. O O

After O O
the O O
end O O
of O O
fenoterol O O
- O O
hydrobromide O O
infusion O O
, O O
tremor B-Disease B-Disease
amplitudes O O
decreased O O
significantly O O
faster O O
than O O
those O O
following O O
ritodrin O O
- O O
HCl O O
infusion O O
. O O

Propylthiouracil O O
- O O
induced O O
hepatic B-Disease B-Disease
damage I-Disease I-Disease
. O O

Two O O
cases O O
of O O
propylthiouracil O O
- O O
induced O O
liver B-Disease B-Disease
damage I-Disease I-Disease
have O O
been O O
observed O O
. O O

The O O
first O O
case O O
is O O
of O O
an O O
acute O O
type O O
of O O
damage O O
, O O
proven O O
by O O
rechallenge O O
; O O
the O O
second O O
presents O O
a O O
clinical O O
and O O
histologic O O
picture O O
resembling O O
chronic B-Disease B-Disease
active I-Disease I-Disease
hepatitis I-Disease I-Disease
, O O
with O O
spontaneous O O
remission O O
. O O

Studies O O
on O O
the O O
bradycardia B-Disease B-Disease
induced O O
by O O
bepridil O O
. O O

Bepridil O O
, O O
a O O
novel O O
active O O
compound O O
for O O
prophylactic O O
treatment O O
of O O
anginal B-Disease B-Disease
attacks I-Disease I-Disease
, O O
induced O O
persistent O O
bradycardia B-Disease B-Disease
and O O
a O O
non O O
- O O
specific O O
anti O O
- O O
tachycardial B-Disease B-Disease
effect O O
, O O
the O O
mechanisms O O
of O O
which O O
were O O
investigated O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

In O O
vitro O O
perfusion O O
of O O
bepridil O O
in O O
the O O
life O O
- O O
support O O
medium O O
for O O
isolated O O
sino O O
- O O
atrial O O
tissue O O
from O O
rabbit O O
heart O O
, O O
caused O O
a O O
reduction O O
in O O
action O O
potential O O
( O O
AP O O
) O O
spike O O
frequency O O
( O O
recorded O O
by O O
KCl O O
microelectrodes O O
) O O
starting O O
at O O
doses O O
of O O
5 O O
X O O
10 O O
( O O
-6 O O
) O O
M. O O
This O O
effect O O
was O O
dose O O
- O O
dependent O O
up O O
to O O
concentrations O O
of O O
5 O O
X O O
10 O O
( O O
-5 O O
) O O
M O O
, O O
whereupon O O
blockade O O
of O O
sinus O O
activity O O
set O O
in O O
. O O

Bepridil O O
at O O
a O O
dose O O
of O O
5 O O
X O O
10 O O
( O O
-6 O O
) O O
M O O
, O O
induced O O
a O O
concomitant O O
reduction O O
in O O
AP O O
amplitude O O
( O O
falling O O
from O O
71 O O
+ O O
/- O O

8 O O
mV O O
to O O
47 O O
+ O O
/- O O

6 O O
mV O O
) O O
, O O
maximum O O
systolic O O
depolarization O O
velocity O O
( O O
phase O O
0 O O
) O O
which O O
fell O O
from O O
1.85 O O
+ O O
/- O O

0.35 O O
V O O
/ O O
s O O
to O O
0.84 O O
+ O O
/- O O

0.28 O O
V O O
/ O O
s O O
, O O
together O O
with O O
maximum O O
diastolic O O
depolarization O O
velocity O O
( O O
phase O O
4 O O
) O O
which O O
fell O O
from O O
38 O O
+ O O
/- O O

3 O O
mV O O
/ O O
s O O
to O O
24 O O
+ O O
/- O O

5 O O
mV O O
/ O O
s O O
. O O

In O O
vivo O O
injection O O
of O O
bepridil O O
at O O
a O O
dose O O
of O O
5 O O
mg O O
/ O O
kg O O
( O O
i.v O O
. O O
) O O
into O O
6 O O
anaesthetized O O
dogs O O
which O O
had O O
undergone O O
ablation O O
of O O
all O O
the O O
extrinsic O O
cardiac O O
afferent O O
nerve O O
supply O O
, O O
together O O
with O O
a O O
bilateral O O
medullo O O
- O O
adrenalectomy O O
, O O
caused O O
a O O
marked O O
reduction O O
in O O
heart O O
rate O O
which O O
fell O O
from O O
98.7 O O
+ O O
/- O O

4.2 O O
beats O O
/ O O
min O O
to O O
76 O O
+ O O
/- O O

5.3 O O
beats O O
/ O O
min O O
sustained O O
for O O
more O O
than O O
45 O O
min O O
. O O

It O O
is O O
concluded O O
that O O
bepridil O O
reduces O O
heart O O
rate O O
by O O
acting O O
directly O O
on O O
the O O
sinus O O
node O O
. O O

This O O
effect O O
, O O
which O O
results O O
in O O
a O O
flattening O O
of O O
the O O
phase O O
0 O O
and O O
phase O O
4 O O
slope O O
, O O
together O O
with O O
a O O
longer O O
AP O O
duration O O
, O O
may O O
be O O
due O O
to O O
an O O
increase O O
in O O
the O O
time O O
constants O O
of O O
slow O O
inward O O
ionic O O
currents O O
( O O
already O O
demonstrated O O
elsewhere O O
) O O
, O O
but O O
also O O
to O O
an O O
increased O O
time O O
constant O O
for O O
deactivation O O
of O O
the O O
outward O O
potassium O O
current O O
( O O
Ip O O
) O O
. O O

Hepatitis B-Disease B-Disease
and O O
renal B-Disease B-Disease
tubular I-Disease I-Disease
acidosis I-Disease I-Disease
after O O
anesthesia O O
with O O
methoxyflurane O O
. O O

A O O
69-year O O
- O O
old O O
man O O
operated O O
for O O
acute B-Disease O
cholecystitis I-Disease B-Disease
under O O
methoxyflurane O O
anesthesia O O
developed O O
postoperatively O O
a O O
hepatic B-Disease B-Disease
insufficiency I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
renal B-Disease B-Disease
tubular I-Disease I-Disease
acidosis I-Disease I-Disease
. O O

Massive O O
bleeding B-Disease B-Disease
appeared O O
during O O
surgery O O
which O O
lasted O O
for O O
six O O
hours O O
. O O

Postoperative O O
evolution O O
under O O
supportive O O
therapy O O
was O O
favourable O O
. O O

Complete O O
recovery O O
was O O
confirmed O O
by O O
repeated O O
controls O O
performed O O
over O O
a O O
period O O
of O O
one O O
year O O
after O O
surgery O O
. O O

Pituitary O O
response O O
to O O
luteinizing O O
hormone O O
- O O
releasing O O
hormone O O
during O O
haloperidol O O
- O O
induced O O
hyperprolactinemia B-Disease B-Disease
. O O

The O O
effects O O
of O O
a O O
6-hour O O
infusion O O
with O O
haloperidol O O
on O O
serum O O
prolactin O O
and O O
luteinizing O O
hormone O O
( O O
LH O O
) O O
levels O O
was O O
studied O O
in O O
a O O
group O O
of O O
male O O
subjects O O
. O O

Five O O
hours O O
after O O
starting O O
the O O
infusions O O
, O O
a O O
study O O
of O O
the O O
pituitary O O
responses O O
to O O
LH O O
- O O
releasing O O
hormone O O
( O O
LH O O
- O O
RH O O
) O O
was O O
carried O O
out O O
. O O

Control O O
patients O O
received O O
infusions O O
of O O
0.9 O O
% O O
NaCl O O
solution O O
. O O

During O O
the O O
course O O
of O O
haloperidol O O
infusions O O
, O O
significant O O
hyperprolactinemia B-Disease B-Disease
was O O
found O O
, O O
together O O
with O O
an O O
abolished O O
pituitary O O
response O O
to O O
LH O O
- O O
RH O O
, O O
as O O
compared O O
with O O
responses O O
of O O
control O O
subjects O O
. O O

Antirifampicin O O
antibodies O O
in O O
acute O O
rifampicin O O
- O O
associated O O
renal B-Disease B-Disease
failure I-Disease I-Disease
. O O

5 O O
patients O O
with O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
( O O
3 O O
with O O
thrombopenia B-Disease B-Disease
and O O
hemolysis B-Disease B-Disease
) O O
induced O O
by O O
the O O
reintroduction O O
of O O
rifampicin O O
are O O
described O O
. O O

No O O
correlation O O
was O O
found O O
between O O
the O O
severity O O
of O O
clinical O O
manifestations O O
and O O
the O O
total O O
dose O O
taken O O
by O O
the O O
patients O O
. O O

In O O
all O O
but O O
1 O O
patient O O
, O O
antirifampicin O O
antibodies O O
were O O
detected O O
. O O

Antibodies O O
suggested O O
to O O
be O O
of O O
the O O
IgM O O
class O O
were O O
detected O O
in O O
all O O
3 O O
patients O O
with O O
hematological B-Disease B-Disease
disorders I-Disease I-Disease
. O O

The O O
pattern O O
of O O
non O O
- O O
specific O O
acute B-Disease B-Disease
tubular I-Disease I-Disease
necrosis I-Disease I-Disease
found O O
in O O
the O O
2 O O
biopsied O O
patients O O
, O O
indistinguishable O O
from O O
that O O
of O O
ischemic O B-Disease
origin O O
, O O
raised O O
the O O
possibility O O
of O O
a O O
vascular O O
- O O
mediated O O
damage O O
. O O

In O O
3 O O
patients O O
, O O
the O O
possibility O O
of O O
a O O
triggering O O
immunoallergic O O
mechanism O O
is O O
discussed O O
. O O

Cardiovascular O O
effects O O
of O O
hypotension B-Disease B-Disease
induced O O
by O O
adenosine O O
triphosphate O O
and O O
sodium O O
nitroprusside O O
on O O
dogs O O
with O O
denervated O O
hearts O O
. O O

Adenosine O O
triphosphate O O
( O O
ATP O O
) O O
and O O
sodium O O
nitroprusside O O
( O O
SNP O O
) O O
are O O
administered O O
to O O
patients O O
to O O
induce O O
and O O
control O O
hypotension B-Disease B-Disease
during O O
anesthesia O O
. O O

SNP O O
is O O
authorized O O
for O O
clinical O O
use O O
in O O
USA O O
and O O
UK O O
, O O
and O O
ATP O O
is O O
clinically O O
used O O
in O O
other O O
countries O O
such O O
as O O
Japan O O
. O O

We O O
investigated O O
how O O
these O O
two O O
drugs O O
act O O
on O O
the O O
cardiovascular O O
systems O O
of O O
20 O O
dogs O O
whose O O
hearts O O
had O O
been O O
denervated O O
by O O
a O O
procedure O O
we O O
had O O
devised O O
. O O

ATP O O
( O O
10 O O
dogs O O
) O O
or O O
SNP O O
( O O
10 O O
dogs O O
) O O
was O O
administered O O
to O O
reduce O O
mean O O
arterial O O
pressure O O
by O O
30 O O
% O O
to O O
70 O O
% O O
of O O
control O O
. O O

Before O O
, O O
during O O
and O O
after O O
induced O O
hypotension B-Disease B-Disease
, O O
we O O
measured O O
major O O
cardiovascular O O
parameters O O
. O O

Hypotension B-Disease B-Disease
induced O O
by O O
ATP O O
was O O
accompanied O O
by O O
significant O O
decreases O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
total O O
body O O
oxygen O O
consumption O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
, O O
and O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
; O O
all O O
these O O
variables O O
returned O O
normal O O
within O O
30 O O
min O O
after O O
ATP O O
was O O
stopped O O
. O O

Cardiac O O
output O O
did O O
not O O
change O O
. O O

During O O
hypotension B-Disease B-Disease
produced O O
by O O
SNP O O
similar O O
decreases O O
were O O
observed O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
, O O
and O O
oxygen O O
content O O
difference O O
between O O
arterial O O
and O O
mixed O O
venous O O
blood O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
, O O
while O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0.001 O O
) O O
and O O
cardiac O O
output O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
were O O
increased O O
. O O

Recoveries O O
of O O
heart O O
rate O O
and O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
were O O
not O O
shown O O
within O O
60 O O
min O O
after O O
SNP O O
had O O
been O O
stopped O O
. O O

Both O O
ATP O O
and O O
SNP O O
should O O
act O O
on O O
the O O
pacemaker O O
tissue O O
of O O
the O O
heart O O
. O O

Comparative O O
study O O
: O O
Endografine O O
( O O
diatrizoate O O
) O O
, O O
Vasurix O O
polyvidone O O
( O O
acetrizoate O O
) O O
, O O
Dimer O O
- O O
X O O
( O O
iocarmate O O
) O O
and O O
Hexabrix O O
( O O
ioxaglate O O
) O O
in O O
hysterosalpingography O O
. O O

Side O O
effects O O
of O O
hysterosalpingography O O
with O O
Dimer O O
- O O
X O O
, O O
Hexabrix O O
, O O
Vasurix O O
polyvidone O O
and O O
Endografine O O
in O O
142 O O
consecutive O O
patients O O
, O O
receiving O O
one O O
of O O
the O O
four O O
tested O O
media O O
were O O
evaluated O O
from O O
replies O O
to O O
postal O O
questionnaires O O
. O O

The O O
Dimer O O
- O O
X O O
group O O
had O O
a O O
higher O O
incidence O O
of O O
nausea B-Disease B-Disease
and O O
dizziness B-Disease B-Disease
. O O

The O O
Endografine O O
group O O
had O O
a O O
higher O O
incidence O O
of O O
abdominal B-Disease B-Disease
pain I-Disease I-Disease
. O O

These O O
differences O O
occur O O
especially O O
in O O
the O O
age O O
groups O O
under O O
30 O O
years O O
. O O

Hexabrix O O
and O O
Vasurix O O
polyvidone O O
are O O
considered O O
the O O
best O O
contrast O O
media O O
for O O
hysterosalpingography O O
and O O
perhaps O O
because O O
of O O
its O O
low O O
toxicity B-Disease O
Hexabrix O O
should O O
be O O
preferred O O
. O O

Post O O
- O O
suxamethonium O O
pains B-Disease B-Disease
in O O
Nigerian O O
surgical O O
patients O O
. O O

Contrary O O
to O O
an O O
earlier O O
report O O
by O O
Coxon O O
, O O
scoline O O
pain B-Disease B-Disease
occurs O O
in O O
African O O
negroes O O
. O O

Its O O
incidence O O
was O O
determined O O
in O O
a O O
prospective O O
study O O
involving O O
a O O
total O O
of O O
100 O O
Nigerian O O
patients O O
( O O
50 O O
out O O
- O O
patients O O
and O O
50 O O
in O O
- O O
patients O O
) O O
. O O

About O O
62 O O
% O O
of O O
the O O
out O O
- O O
patients O O
developed O O
scoline O O
pain B-Disease B-Disease
as O O
compared O O
with O O
about O O
26 O O
% O O
among O O
the O O
in O O
- O O
patients O O
. O O

The O O
abolition O O
of O O
muscle O B-Disease
fasciculations B-Disease I-Disease
( O O
by O O
0.075mg O O
/ O O
kg O O
dose O O
of O O
Fazadinium O O
) O O
did O O
not O O
influence O O
the O O
occurrence O O
of O O
scoline O O
pain B-Disease B-Disease
. O O

Neither O O
the O O
type O O
of O O
induction O O
agent O O
( O O
Althesin O O
or O O
Thiopentone O O
) O O
nor O O
the O O
salt O O
preparation O O
of O O
suxamethonium O O
used O O
( O O
chloride O O
or O O
bromide O O
) O O
, O O
affected O O
the O O
incidence O O
of O O
scoline O O
pain B-Disease B-Disease
. O O

Invasive O B-Disease
carcinoma B-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
renal I-Disease I-Disease
pelvis I-Disease I-Disease
following O O
cyclophosphamide O O
therapy O O
for O O
nonmalignant O O
disease O O
. O O

A O O
47-year O O
- O O
old O O
woman O O
with O O
right O O
hydroureteronephrosis B-Disease B-Disease
due O O
to O O
ureterovesical O B-Disease
junction O I-Disease
obstruction O I-Disease
had O O
gross O O
hematuria B-Disease B-Disease
after O O
being O O
treated O O
for O O
five O O
years O O
wtih O O
cyclophosphamide O O
for O O
cerebral B-Disease B-Disease
vasculitis I-Disease I-Disease
. O O

A O O
right O O
nephroureterectomy O O
was O O
required O O
for O O
control O O
of O O
bleeding B-Disease B-Disease
. O O

The O O
pathology O O
specimen O O
contained O O
clinically O O
occult O O
invasive O B-Disease
carcinoma B-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
renal I-Disease I-Disease
pelvis I-Disease I-Disease
. O O

Although O O
the O O
ability O O
of O O
cyclophosphamide O O
to O O
cause O O
hemorrhagic B-Disease B-Disease
cystitis B-Disease B-Disease
and O O
urine O B-Disease
cytologic O I-Disease
abnormalities O I-Disease
indistinguishable O O
from O O
high O O
grade O O
carcinoma B-Disease B-Disease
is O O
well O O
known O O
, O O
it O O
is O O
less O O
widely O O
appreciated O O
that O O
it O O
is O O
also O O
associated O O
with O O
carcinoma B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
urinary I-Disease I-Disease
tract I-Disease I-Disease
. O O

Twenty O O
carcinomas B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
urinary I-Disease I-Disease
bladder I-Disease I-Disease
and O O
one O O
carcinoma B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
prostate I-Disease I-Disease
have O O
been O O
reported O O
in O O
association O O
with O O
its O O
use O O
. O O

The O O
present O O
case O O
is O O
the O O
first O O
carcinoma B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
renal I-Disease I-Disease
pelvis I-Disease I-Disease
reported O O
in O O
association O O
with O O
cyclophosphamide O O
treatment O O
. O O

It O O
is O O
the O O
third O O
urinary B-Disease B-Disease
tract I-Disease I-Disease
cancer I-Disease I-Disease
reported O O
in O O
association O O
with O O
cyclophosphamide O O
treatment O O
for O O
nonmalignant O O
disease O O
. O O

The O O
association O O
of O O
the O O
tumor B-Disease B-Disease
with O O
preexisting O O
hydroureteronephrosis B-Disease B-Disease
suggests O O
that O O
stasis O O
prolonged O O
and O O
intensified O O
exposure O O
of O O
upper O O
urinary O O
tract O O
epithelium O O
to O O
cyclophosphamide O O
. O O

Patients O O
who O O
are O O
candidates O O
for O O
long O O
- O O
term O O
cyclophosphamide O O
treatment O O
should O O
be O O
routinely O O
evaluated O O
for O O
obstructive B-Disease B-Disease
uropathy I-Disease I-Disease
. O O

Medial O O
changes O O
in O O
arterial O O
spasm B-Disease B-Disease
induced O O
by O O
L O O
- O O
norepinephrine O O
. O O

In O O
normal O O
rats O O
, O O
the O O
media O O
of O O
small O O
arteries O O
( O O
0.4 O O
- O O
-0.2 O O
mm O O
in O O
diameter O O
) O O
previously O O
was O O
shown O O
to O O
contain O O
intracellular O O
vacuoles O O
, O O
identified O O
ultrastructurally O O
as O O
herniations O O
of O O
one O O
smooth O O
muscle O O
cell O O
into O O
another O O
. O O

The O O
hypothesis O O
that O O
intense O O
vasoconstriction O O
would O O
increase O O
the O O
number O O
of O O
such O O
vacuoles O O
has O O
been O O
tested O O
. O O

In O O
the O O
media O O
of O O
the O O
saphenous O O
artery O O
and O O
its O O
distal O O
branch O O
, O O
vasoconstriction O O
induced O O
by O O
L O O
- O O
norepinephrine O O
produced O O
many O O
cell O O
- O O
to O O
- O O
cell O O
hernias B-Disease B-Disease
within O O
15 O O
minutes O O
. O O

At O O
1 O O
day O O
their O O
number O O
was O O
reduced O O
to O O
about O O
1 O O
/ O O
10 O O
of O O
the O O
original O O
number O O
. O O

By O O
7 O O
days O O
the O O
vessel O O
was O O
almost O O
restored O O
to O O
normal O O
. O O

Triple O O
stimulation O O
over O O
1 O O
day O O
induced O O
more O O
severe O O
changes O O
in O O
the O O
media O O
. O O

These O O
findings O O
suggest O O
that O O
smooth O O
muscle O O
cells O O
are O O
susceptible O O
to O O
damage O O
in O O
the O O
course O O
of O O
their O O
specific O O
function O O
. O O

The O O
experimental O O
data O O
are O O
discussed O O
in O O
relation O O
to O O
medial O O
changes O O
observed O O
in O O
other O O
instances O O
of O O
arterial O O
spasm B-Disease B-Disease
. O O

Endothelial O O
changes O O
that O O
developed O O
in O O
the O O
same O O
experimental O O
model O O
were O O
described O O
in O O
a O O
previous O O
paper O O
. O O

Bilateral O O
retinal B-Disease B-Disease
artery I-Disease I-Disease
and I-Disease I-Disease
choriocapillaris I-Disease I-Disease
occlusion I-Disease I-Disease
following O O
the O O
injection O O
of O O
long O O
- O O
acting O O
corticosteroid O O
suspensions O O
in O O
combination O O
with O O
other O O
drugs O O
: O O
I. O O
Clinical O O
studies O O
. O O

Two O O
well O O
- O O
documented O O
cases O O
of O O
bilateral O O
retinal B-Disease B-Disease
artery I-Disease I-Disease
and I-Disease I-Disease
choriocapillaris I-Disease I-Disease
occlusions I-Disease I-Disease
with O O
blindness B-Disease B-Disease
following O O
head O O
and O O
neck O O
soft O O
- O O
tissue O O
injection O O
with O O
methylprednisolone O O
acetate O O
in O O
combination O O
with O O
lidocaine O O
, O O
epinephrine O O
, O O
or O O
penicillin O O
are O O
reported O O
. O O

One O O
case O O
had O O
only O O
a O O
unilateral O O
injection O O
. O O

The O O
acute O O
observations O O
included O O
hazy O O
sensorium O O
, O O
superior O B-Disease
gaze O I-Disease
palsy B-Disease I-Disease
, O O
pupillary B-Disease B-Disease
abnormalities I-Disease I-Disease
, O O
and O O
conjunctival O B-Disease
hemorrhages B-Disease I-Disease
with O O
edema B-Disease B-Disease
. O O

Follow O O
- O O
up O O
changes O O
showed O O
marked O O
visual B-Disease B-Disease
loss I-Disease I-Disease
, O O
constricted O O
visual O O
fields O O
, O O
optic O O
nerve O O
pallor O O
, O O
vascular O O
attenuation O O
, O O
and O O
chorioretinal B-Disease B-Disease
atrophy I-Disease I-Disease
. O O

The O O
literature O O
is O O
reviewed O O
, O O
and O O
possible O O
causes O O
are O O
discussed O O
. O O

Abnormalities O B-Disease
of O I-Disease
the O I-Disease
pupil O I-Disease
and O O
visual O O
- O O
evoked O O
potential O O
in O O
quinine O O
amblyopia B-Disease B-Disease
. O O

Total O O
blindness B-Disease B-Disease
with O O
a O O
transient O O
tonic B-Disease O
pupillary I-Disease O
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
developed O O
in O O
a O O
54-year O O
- O O
old O O
man O O
after O O
the O O
use O O
of O O
quinine O O
sulfate O O
for O O
leg B-Disease B-Disease
cramps I-Disease I-Disease
. O O

He O O
later O O
recovered O O
normal O O
visual O O
acuity O O
. O O

A O O
transient O O
tonic B-Disease O
pupillary I-Disease O
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
in O O
quinine O O
toxicity B-Disease B-Disease
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O
. O O

Suxamethonium O O
- O O
induced O O
jaw B-Disease B-Disease
stiffness I-Disease I-Disease
and O O
myalgia B-Disease B-Disease
associated O O
with O O
atypical O O
cholinesterase O O
: O O
case O O
report O O
. O O

An O O
11-year O O
- O O
old O O
boy O O
was O O
given O O
halothane O O
, O O
nitrous O O
oxide O O
and O O
oxygen O O
, O O
pancuronium O O
0.4 O O
mg O O
and O O
suxamethonium O O
100 O O
mg O O
for O O
induction O O
of O O
anaesthesia O O
. O O

In O O
response O O
to O O
this O O
a O O
marked O O
jaw B-Disease B-Disease
stiffness I-Disease I-Disease
occurred O O
which O O
lasted O O
for O O
two O O
minutes O O
and O O
the O O
anaesthesia O O
were O O
terminated O O
. O O

Four O O
hours O O
of O O
apnoea B-Disease B-Disease
ensued O O
and O O
he O O
suffered O O
generalized O O
severe O O
myalgia B-Disease B-Disease
lasting O O
for O O
one O O
week O O
. O O

He O O
was O O
found O O
to O O
have O O
atypical O O
plasma O O
cholinesterase O O
with O O
a O O
dibucaine O O
number O O
of O O
12 O O
, O O
indicating O O
homozygocity O O
. O O

This O O
was O O
verified O O
by O O
study O O
of O O
the O O
family O O
. O O

The O O
case O O
shows O O
that O O
prolonged B-Disease O
jaw I-Disease B-Disease
rigidity I-Disease I-Disease
and O O
myalgia B-Disease B-Disease
may O O
occur O O
after O O
suxamethonium O O
in O O
patients O O
with O O
atypical O O
cholinesterase O O
despite O O
pretreatment O O
with O O
pancuronium O O
. O O

Indomethacin O O
- O O
induced O O
hyperkalemia B-Disease B-Disease
in O O
three O O
patients O O
with O O
gouty B-Disease B-Disease
arthritis I-Disease I-Disease
. O O

We O O
describe O O
three O O
patients O O
in O O
whom O O
severe O O
, O O
life O O
- O O
threatening O O
hyperkalemia B-Disease B-Disease
and O O
renal B-Disease B-Disease
insufficiency I-Disease I-Disease
developed O O
after O O
treatment O O
of O O
acute O O
gouty B-Disease B-Disease
arthritis I-Disease I-Disease
with O O
indomethacin O O
. O O

This O O
complication O O
may O O
result O O
from O O
an O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
and O O
consequent O O
hyporeninemic B-Disease B-Disease
hypoaidosteronism I-Disease I-Disease
. O O

Careful O O
attention O O
to O O
renal O O
function O O
and O O
potassium O O
balance O O
in O O
patients O O
receiving O O
indomethacin O O
or O O
other O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
agents O O
, O O
particularly O O
in O O
those O O
patients O O
with O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
or O O
preexisting O O
renal B-Disease B-Disease
disease I-Disease I-Disease
, O O
will O O
help O O
prevent O O
this O O
potentially O O
serious O O
complication O O
. O O

Etomidate O O
: O O
a O O
foreshortened O O
clinical O O
trial O O
. O O

A O O
clinical O O
evaluation O O
of O O
etomidate O O
for O O
outpatient O O
cystoscopy O O
was O O
embarked O O
upon O O
. O O

Unpremedicated O O
patients O O
were O O
given O O
fentanyl O O
1 O O
microgram O O
/ O O
kg O O
followed O O
by O O
etomidate O O
0.3 O O
mg O O
/ O O
kg O O
. O O

Anaesthesia O O
was O O
maintained O O
with O O
intermittent O O
etomidate O O
in O O
2 O O
- O O
4 O O
mg O O
doses O O
. O O

Patients O O
were O O
interviewed O O
personally O O
later O O
the O O
same O O
day O O
, O O
and O O
by O O
questionnaire O O
three O O
to O O
four O O
weeks O O
later O O
. O O

The O O
trial O O
was O O
discontinued O O
after O O
20 O O
cases O O
because O O
of O O
an O O
unacceptable O O
incidence O O
of O O
side O O
effects O O
. O O

Venous O B-Disease
pain B-Disease I-Disease
occurred O O
in O O
68 O O
% O O
of O O
patients O O
and O O
50 O O
% O O
had O O
redness O O
, O O
pain B-Disease B-Disease
or O O
swelling B-Disease B-Disease
related O O
to O O
the O O
injection O O
site O O
, O O
in O O
some O O
cases O O
lasting O O
up O O
to O O
three O O
weeks O O
after O O
anaesthesia O O
. O O

Skeletal O O
movements O O
occurred O O
in O O
50 O O
% O O
of O O
patients O O
; O O
30 O O
% O O
experienced O O
respiratory B-Disease O
upset I-Disease O
, O O
one O O
sufficiently O O
severe O O
to O O
necessitate O O
abandoning O O
the O O
technique O O
. O O

Nausea B-Disease B-Disease
and O O
vomiting B-Disease B-Disease
occurred O O
in O O
40 O O
% O O
and O O
25 O O
% O O
had O O
disturbing O O
emergence O O
psychoses B-Disease B-Disease
. O O

Levodopa O O
- O O
induced O O
dyskinesias B-Disease B-Disease
are O O
improved O O
by O O
fluoxetine O O
. O O

We O O
evaluated O O
the O O
severity O O
of O O
motor B-Disease B-Disease
disability I-Disease I-Disease
and O O
dyskinesias B-Disease B-Disease
in O O
seven O O
levodopa O O
- O O
responsive O O
patients O O
with O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
after O O
an O O
acute O O
challenge O O
with O O
the O O
mixed O O
dopamine O O
agonist O O
, O O
apomorphine O O
, O O
before O O
and O O
after O O
the O O
administration O O
of O O
fluoxetine O O
( O O
20 O O
mg O O
twice O O
per O O
day O O
) O O
for O O
11 O O
+ O O
/- O O

1 O O
days O O
. O O

After O O
fluoxetine O O
treatment O O
, O O
there O O
was O O
a O O
significant O O
47 O O
% O O
improvement O O
( O O
p O O
< O O
0.05 O O
) O O
of O O
apomorphine O O
- O O
induced O O
dyskinesias B-Disease B-Disease
without O O
modification O O
of O O
parkinsonian B-Disease B-Disease
motor B-Disease B-Disease
disability I-Disease I-Disease
. O O

The O O
dyskinesias B-Disease B-Disease
were O O
reduced O O
predominantly O O
in O O
the O O
lower O O
limbs O O
during O O
the O O
onset O O
and O O
disappearance O O
of O O
dystonic B-Disease B-Disease
dyskinesias B-Disease B-Disease
( O O
onset- O O
and O O
end O O
- O O
of O O
- O O
dose O O
dyskinesias B-Disease B-Disease
) O O
and O O
in O O
the O O
upper O O
limbs O O
during O O
choreic B-Disease B-Disease
mid B-Disease O
- I-Disease O
dose I-Disease O
dyskinesias I-Disease B-Disease
. O O

The O O
results O O
suggest O O
that O O
increased O O
brain O O
serotoninergic O O
transmission O O
with O O
fluoxetine O O
may O O
reduce O O
levodopa- O O
or O O
dopamine O O
agonist O O
- O O
induced O O
dyskinesias B-Disease B-Disease
without O O
aggravating O O
parkinsonian B-Disease B-Disease
motor B-Disease I-Disease
disability I-Disease I-Disease
. O O

A O O
large O O
population O O
- O O
based O O
follow O O
- O O
up O O
study O O
of O O
trimethoprim O O
- O O
sulfamethoxazole O O
, O O
trimethoprim O O
, O O
and O O
cephalexin O O
for O O
uncommon O O
serious O O
drug B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

We O O
conducted O O
a O O
population O O
- O O
based O O
45-day O O
follow O O
- O O
up O O
study O O
of O O
232,390 O O
people O O
who O O
were O O
prescribed O O
trimethoprim O O
- O O
sulfamethoxazole O O
( O O
TMP O O
- O O
SMZ O O
) O O
, O O
266,951 O O
prescribed O O
trimethoprim O O
alone O O
, O O
and O O
196,397 O O
prescribed O O
cephalexin O O
, O O
to O O
estimate O O
the O O
risk O O
of O O
serious O O
liver B-Disease B-Disease
, I-Disease I-Disease
blood I-Disease I-Disease
, I-Disease I-Disease
skin I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
renal I-Disease I-Disease
disorders I-Disease I-Disease
resulting O O
in O O
referral O O
or O O
hospitalization O O
associated O O
with O O
these O O
drugs O O
. O O

The O O
results O O
were O O
based O O
on O O
information O O
recorded O O
on O O
office O O
computers O O
by O O
selected O O
general O O
practitioners O O
in O O
the O O
United O O
Kingdom O O
, O O
together O O
with O O
a O O
review O O
of O O
clinical O O
records O O
. O O

The O O
risk O O
of O O
clinically O O
important O O
idiopathic O B-Disease
liver B-Disease I-Disease
disease I-Disease I-Disease
was O O
similar O O
for O O
persons O O
prescribed O O
TMP O O
- O O
SMZ O O
( O O
5.2 O O
/ O O
100,000 O O
) O O
and O O
those O O
prescribed O O
trimethoprim O O
alone O O
( O O
3.8 O O
/ O O
100,000 O O
) O O
. O O

The O O
risk O O
for O O
those O O
prescribed O O
cephalexin O O
was O O
somewhat O O
lower O O
( O O
2.0 O O
/ O O
100,000 O O
) O O
. O O

Only O O
five O O
patients O O
experienced O O
blood O B-Disease
disorders O I-Disease
, O O
one O O
of O O
whom O O
was O O
exposed O O
to O O
TMP O O
- O O
SMZ O O
; O O
of O O
seven O O
with O O
erythema B-Disease B-Disease
multiforme I-Disease I-Disease
and O O
Stevens B-Disease B-Disease
- I-Disease I-Disease
Johnson I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
four O O
were O O
exposed O O
to O O
TMP O O
- O O
SMZ O O
. O O

The O O
one O O
case O O
of O O
toxic B-Disease B-Disease
epidermal I-Disease I-Disease
necrolysis I-Disease I-Disease
occurred O O
in O O
a O O
patient O O
who O O
took O O
cephalexin O O
. O O

Finally O O
, O O
only O O
five O O
cases O O
of O O
acute O O
parenchymal O B-Disease
renal B-Disease I-Disease
disease I-Disease I-Disease
occurred O O
, O O
none O O
likely O O
to O O
be O O
caused O O
by O O
a O O
study O O
drug O O
. O O

We O O
conclude O O
that O O
the O O
risk O O
of O O
the O O
serious O O
diseases O O
studied O O
is O O
small O O
for O O
the O O
three O O
agents O O
, O O
and O O
compares O O
reasonably O O
with O O
the O O
risk O O
for O O
many O O
other O O
antibiotics O O
. O O

Clinical O O
safety O O
of O O
lidocaine O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

STUDY O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
safety O O
of O O
lidocaine O O
in O O
the O O
setting O O
of O O
cocaine O O
- O O
induced O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
( O O
MI B-Disease B-Disease
) O O
. O O

DESIGN O O
: O O
A O O
retrospective O O
, O O
multicenter O O
study O O
. O O

SETTING O O
: O O
Twenty O O
- O O
nine O O
university O O
, O O
university O O
- O O
affiliated O O
, O O
or O O
community O O
hospitals O O
during O O
a O O
6-year O O
period O O
( O O
total O O
of O O
117 O O
cumulative O O
hospital O O
- O O
years O O
) O O
. O O

PARTICIPANTS O O
: O O
Patients O O
with O O
cocaine O O
- O O
associated O O
MI B-Disease B-Disease
who O O
received O O
lidocaine O O
in O O
the O O
emergency O O
department O O
. O O

RESULTS O O
: O O
Of O O
29 O O
patients O O
who O O
received O O
lidocaine O O
in O O
the O O
setting O O
of O O
cocaine O O
- O O
associated O O
MI B-Disease B-Disease
, O O
no O O
patient O O
died O O
; O O
exhibited O O
bradydysrhythmias B-Disease B-Disease
, O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
, O O
or O O
ventricular B-Disease B-Disease
fibrillation I-Disease I-Disease
; O O
or O O
experienced O O
seizures B-Disease B-Disease
after O O
administration O O
of O O
lidocaine O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
0 O O
% O O
to O O
11 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
Despite O O
theoretical O O
concerns O O
that O O
lidocaine O O
may O O
enhance O O
cocaine O O
toxicity B-Disease B-Disease
, O O
the O O
use O O
of O O
lidocaine O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
MI B-Disease B-Disease
was O O
not O O
associated O O
with O O
significant O O
cardiovascular B-Disease B-Disease
or I-Disease I-Disease
central I-Disease I-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
toxicity I-Disease I-Disease
. O O

Experimental O O
progressive O O
muscular B-Disease B-Disease
dystrophy I-Disease I-Disease
and O O
its O O
treatment O O
with O O
high O O
doses O O
anabolizing O O
agents O O
. O O

We O O
are O O
still O O
a O O
long O O
way O O
from O O
discovering O O
an O O
unequivocal O O
pathogenetic O O
interpretation O O
of O O
progressive O O
muscular B-Disease B-Disease
dystrophy I-Disease I-Disease
in O O
man O O
. O O

Noteworthy O O
efforts O O
have O O
been O O
made O O
in O O
the O O
experimental O O
field O O
; O O
a O O
recessive O O
autosomic O O
form O O
found O O
in O O
the O O
mouse O O
seems O O
to O O
bear O O
the O O
closest O O
resemblance O O
to O O
the O O
human O O
form O O
from O O
the O O
genetic O O
point O O
of O O
view O O
. O O

Myopathy B-Disease B-Disease
due O O
to O O
lack O O
of O O
vitamin O O
E O O
and O O
myopathy B-Disease B-Disease
induced O O
by O O
certain O O
viruses O O
have O O
much O O
in O O
common O O
anatomically O O
and O O
pathologically O O
with O O
the O O
human O O
form O O
. O O

The O O
authors O O
induced O O
myodystrophy B-Disease B-Disease
in O O
the O O
rat O O
by O O
giving O O
it O O
a O O
diet O O
lacking O O
in O O
vitamin O O
E. O O
The O O
pharmacological O O
characteristics O O
of O O
vitamin O O
E O O
and O O
the O O
degenerative O O
changes O O
brought O O
about O O
by O O
its O O
deficiency O O
, O O
especially O O
in O O
the O O
muscles O O
, O O
are O O
illustrated O O
. O O

It O O
is O O
thus O O
confirmed O O
that O O
the O O
histological O O
characteristics O O
of O O
myopathic B-Disease B-Disease
rat O O
muscle O O
induced O O
experimentally O O
are O O
extraordinarily O O
similar O O
to O O
those O O
of O O
human O O
myopathy B-Disease B-Disease
as O O
confirmed O O
during O O
biopsies O O
performed O O
at O O
the O O
Orthopaedic O O
Traumatological O O
Centre O O
, O O
Florence O O
. O O

The O O
encouraging O O
results O O
obtained O O
in O O
various O O
authoratative O O
departments O O
in O O
myopathic B-Disease B-Disease
patients O O
by O O
using O O
anabolizing O O
steroids O O
have O O
encouraged O O
the O O
authors O O
to O O
investigate O O
the O O
beneficial O O
effects O O
of O O
one O O
anabolizing O O
agent O O
( O O
Dianabol O O
, O O
CIBA O O
) O O
at O O
high O O
doses O O
in O O
rats O O
rendered O O
myopathic B-Disease B-Disease
by O O
a O O
diet O O
deficient O O
in O O
vitamin O O
E. O O
In O O
this O O
way O O
they O O
obtained O O
appreciable O O
changes O O
in O O
body O O
weight O O
( O O
increased O O
from O O
50 O O
to O O
70 O O
g O O
after O O
forty O O
days O O
at O O
a O O
dose O O
of O O
5 O O
mg O O
per O O
day O O
of O O
anabolizing O O
agent O O
) O O
, O O
but O O
most O O
of O O
all O O
they O O
found O O
histological O O
changes O O
due O O
to O O
" O O
regenerative O O
" O O
changes O O
in O O
the O O
muscle O O
tissue O O
, O O
which O O
however O O
maintained O O
its O O
myopathic B-Disease B-Disease
characteristics O O
in O O
the O O
control O O
animals O O
that O O
were O O
not O O
treated O O
with O O
the O O
anabolizing O O
agent O O
. O O

The O O
authors O O
conclude O O
by O O
affirming O O
the O O
undoubted O O
efficacy O O
of O O
the O O
anabolizing O O
steroids O O
in O O
experimental O O
myopathic B-Disease B-Disease
disease I-Disease I-Disease
, O O
but O O
they O O
have O O
reservations O O
as O O
to O O
the O O
transfer O O
of O O
the O O
results O O
into O O
the O O
human O O
field O O
, O O
where O O
high O O
dosage O O
can O O
not O O
be O O
carried O O
out O O
continuously O O
because O O
of O O
the O O
effects O O
of O O
the O O
drug O O
on O O
virility O O
; O O
because O O
the O O
tissue O B-Disease
injury O I-Disease
too O O
often O O
occurs O O
at O O
an O O
irreversible O O
stage O O
vis O O
- O O
a O O
- O O
vis O O
the O O
" O O
regeneration O O
" O O
of O O
the O O
muscle O O
tissue O O
; O O
and O O
finally O O
because O O
the O O
dystrophic O B-Disease
injurious O O
agent O O
is O O
certainly O O
not O O
the O O
lack O O
of O O
vitamin O O
E O O
but O O
something O O
as O O
yet O O
unknown O O
. O O

Paclitaxel O O
3-hour O O
infusion O O
given O O
alone O O
and O O
combined O O
with O O
carboplatin O O
: O O
preliminary O O
results O O
of O O
dose O O
- O O
escalation O O
trials O O
. O O

Paclitaxel O O
( O O
Taxol O O
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
by O O
3-hour O O
infusion O O
was O O
combined O O
with O O
carboplatin O O
in O O
a O O
phase O O
I O O
/ O O
II O O
study O O
directed O O
to O O
patients O O
with O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Carboplatin O O
was O O
given O O
at O O
a O O
fixed O O
target O O
area O O
under O O
the O O
concentration O O
- O O
time O O
curve O O
of O O
6.0 O O
by O O
the O O
Calvert O O
formula O O
, O O
whereas O O
paclitaxel O O
was O O
escalated O O
in O O
patient O O
cohorts O O
from O O
150 O O
mg O O
/ O O
m2 O O
( O O
dose O O
level O O
I O O
) O O
to O O
175 O O
, O O
200 O O
, O O
225 O O
, O O
and O O
250 O O
mg O O
/ O O
m2 O O
. O O

The O O
225 O O
mg O O
/ O O
m2 O O
level O O
was O O
expanded O O
for O O
the O O
phase O O
II O O
study O O
since O O
the O O
highest O O
level O O
achieved O O
( O O
250 O O
mg O O
/ O O
m2 O O
) O O
required O O
modification O O
because O O
of O O
nonhematologic O O
toxicities B-Disease B-Disease
( O O
arthralgia B-Disease B-Disease
and O O
sensory B-Disease B-Disease
neuropathy I-Disease I-Disease
) O O
. O O

Therapeutic O O
effects O O
were O O
noted O O
at O O
all O O
dose O O
levels O O
, O O
with O O
objective O O
responses O O
in O O
17 O O
( O O
two O O
complete O O
and O O
15 O O
partial O O
regressions O O
) O O
of O O
41 O O
previously O O
untreated O O
patients O O
. O O

Toxicities B-Disease B-Disease
were O O
compared O O
with O O
a O O
cohort O O
of O O
patients O O
in O O
a O O
phase O O
I O O
trial O O
of O O
paclitaxel O O
alone O O
at O O
identical O O
dose O O
levels O O
. O O

Carboplatin O O
did O O
not O O
appear O O
to O O
add O O
to O O
the O O
hematologic B-Disease B-Disease
toxicities I-Disease I-Disease
observed O O
, O O
and O O
the O O
paclitaxel O O
/ O O
carboplatin O O
combination O O
could O O
be O O
dosed O O
every O O
3 O O
weeks O O
. O O

The O O
dose O O
- O O
dependent O O
effect O O
of O O
misoprostol O O
on O O
indomethacin O O
- O O
induced O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
in O O
well O O
compensated O O
cirrhosis B-Disease B-Disease
. O O

Misoprostol O O
( O O
200 O O
micrograms O O
) O O
has O O
been O O
shown O O
to O O
acutely O O
counteract O O
the O O
indomethacin O O
- O O
induced O O
renal B-Disease B-Disease
dysfunction I-Disease I-Disease
in O O
well O O
compensated O O
cirrhotic B-Disease B-Disease
patients O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
the O O
prophylactic O O
value O O
of O O
misoprostol O O
was O O
dose O O
- O O
dependent O O
. O O

Parameters O O
of O O
renal O O
hemodynamics O O
and O O
tubular O O
sodium O O
and O O
water O O
handling O O
were O O
assessed O O
by O O
clearance O O
techniques O O
in O O
26 O O
well O O
compensated O O
cirrhotic B-Disease B-Disease
patients O O
before O O
and O O
after O O
an O O
oral O O
combination O O
of O O
50 O O
mg O O
of O O
indomethacin O O
and O O
various O O
doses O O
of O O
misoprostol O O
. O O

The O O
200-micrograms O O
dose O O
was O O
able O O
to O O
totally O O
abolish O O
the O O
deleterious O O
renal O O
effects O O
of O O
indomethacin O O
, O O
whereas O O
the O O
800-micrograms O O
dose O O
resulted O O
in O O
significant O O
worsening O O
of O O
renal O O
hemodynamics O O
and O O
sodium O O
retention O O
. O O

These O O
changes O O
were O O
maximal O O
in O O
the O O
hour O O
immediately O O
after O O
medications O O
and O O
slowly O O
returned O O
toward O O
base O O
- O O
line O O
levels O O
thereafter O O
. O O

These O O
results O O
suggest O O
that O O
the O O
renal O O
protective O O
effects O O
of O O
misoprostol O O
is O O
dose O O
- O O
dependent O O
. O O

However O O
, O O
until O O
this O O
apparent O O
ability O O
of O O
200 O O
micrograms O O
of O O
misoprostol O O
to O O
prevent O O
the O O
adverse O O
effects O O
of O O
indomethacin O O
on O O
renal O O
function O O
is O O
confirmed O O
with O O
chronic O O
frequent O O
dosing O O
, O O
it O O
would O O
be O O
prudent O O
to O O
avoid O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
therapy O O
in O O
patients O O
with O O
cirrhosis B-Disease B-Disease
. O O

Increased O O
frequency O O
and O O
severity O O
of O O
angio B-Disease B-Disease
- I-Disease I-Disease
oedema I-Disease I-Disease
related O O
to O O
long O O
- O O
term O O
therapy O O
with O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitor O O
in O O
two O O
patients O O
. O O

Adverse O O
reactions O O
to O O
drugs O O
are O O
well O O
recognized O O
as O O
a O O
cause O O
of O O
acute O O
or O O
chronic O O
urticaria B-Disease B-Disease
, O O
and O O
angio B-Disease B-Disease
- I-Disease I-Disease
oedema I-Disease I-Disease
. O O

Angiotensin O O
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
, O O
used O O
to O O
treat O O
hypertension B-Disease B-Disease
and O O
congestive B-Disease B-Disease
heart I-Disease I-Disease
failure I-Disease I-Disease
, O O
were O O
introduced O O
in O O
Europe O O
in O O
the O O
middle O O
of O O
the O O
eighties O O
, O O
and O O
the O O
use O O
of O O
these O O
drugs O O
has O O
increased O O
progressively O O
. O O

Soon O O
after O O
the O O
introduction O O
of O O
ACE O O
inhibitors O O
, O O
acute O O
bouts O O
of O O
angio B-Disease B-Disease
- I-Disease I-Disease
oedema I-Disease I-Disease
were O O
reported O O
in O O
association O O
with O O
the O O
use O O
of O O
these O O
drugs O O
. O O

We O O
wish O O
to O O
draw O O
attention O O
to O O
the O O
possibility O O
of O O
adverse O O
reactions O O
to O O
ACE O O
inhibitors O O
after O O
long O O
- O O
term O O
use O O
and O O
in O O
patients O O
with O O
pre O O
- O O
existing O O
angio B-Disease B-Disease
- I-Disease I-Disease
oedema I-Disease I-Disease
. O O

Myoclonus B-Disease B-Disease
associated O O
with O O
lorazepam O O
therapy O O
in O O
very O O
- O O
low O O
- O O
birth O O
- O O
weight O O
infants O O
. O O

Lorazepam O O
is O O
being O O
used O O
with O O
increasing O O
frequency O O
as O O
a O O
sedative O O
in O O
the O O
newborn O O
and O O
the O O
young O O
infant O O
. O O

Concern O O
has O O
been O O
raised O O
with O O
regard O O
to O O
the O O
safety O O
of O O
lorazepam O O
in O O
this O O
age O O
group O O
, O O
especially O O
in O O
very O O
- O O
low O O
- O O
birth O O
- O O
weight O O
( O O
VLBW O O
; O O
< O O
1,500 O O
g O O
) O O
infants O O
. O O

Three O O
young O O
infants O O
, O O
all O O
of O O
birth O O
weight O O
< O O
1,500 O O
g O O
, O O
experienced O O
myoclonus B-Disease B-Disease
following O O
the O O
intravenous O O
administration O O
of O O
lorazepam O O
. O O

The O O
potential O O
neurotoxic B-Disease B-Disease
effects O O
of O O
the O O
drug O O
( O O
and O O
its O O
vehicle O O
) O O
in O O
this O O
population O O
are O O
discussed O O
. O O

Injectable O O
lorazepam O O
should O O
be O O
used O O
with O O
caution O O
in O O
VLBW O O
infants O O
. O O

Transvenous O O
right O O
ventricular O O
pacing O O
during O O
cardiopulmonary O O
resuscitation O O
of O O
pediatric O O
patients O O
with O O
acute O O
cardiomyopathy B-Disease B-Disease
. O O

We O O
describe O O
the O O
cardiopulmonary O O
resuscitation O O
efforts O O
on O O
five O O
patients O O
who O O
presented O O
in O O
acute O O
circulatory B-Disease B-Disease
failure I-Disease I-Disease
from O O
myocardial B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

Three O O
patients O O
had O O
acute O O
viral O O
myocarditis B-Disease B-Disease
, O O
one O O
had O O
a O O
carbamazepine O O
- O O
induced O O
acute O O
eosinophilic B-Disease O
myocarditis B-Disease B-Disease
, O O
and O O
one O O
had O O
cardiac O B-Disease
hemosiderosis O I-Disease
resulting O O
in O O
acute O O
cardiogenic B-Disease B-Disease
shock I-Disease I-Disease
. O O

All O O
patients O O
were O O
continuously O O
monitored O O
with O O
central O O
venous O O
and O O
arterial O O
catheters O O
in O O
addition O O
to O O
routine O O
noninvasive O O
monitoring O O
. O O

An O O
introducer O O
sheath O O
, O O
a O O
pacemaker O O
, O O
and O O
sterile O O
pacing O O
wires O O
were O O
made O O
readily O O
available O O
for O O
the O O
patients O O
, O O
should O O
the O O
need O O
arise O O
to O O
terminate O O
resistant O O
cardiac O B-Disease
dysrhythmias B-Disease I-Disease
. O O

All O O
patients O O
developed O O
cardiocirculatory O B-Disease
arrest O I-Disease
associated O O
with O O
extreme O O
hypotension B-Disease B-Disease
and O O
dysrhythmias B-Disease B-Disease
within O O
the O O
first O O
48 O O
hours O O
of O O
their O O
admission O O
to O O
the O O
pediatric O O
intensive O O
care O O
unit O O
( O O
PICU O O
) O O
. O O

Right O O
ventricular O O
pacemaker O O
wires O O
were O O
inserted O O
in O O
all O O
of O O
them O O
during O O
cardiopulmonary O O
resuscitation O O
( O O
CPR O O
) O O
. O O

In O O
four O O
patients O O
, O O
cardiac O O
pacing O O
was O O
used O O
, O O
resulting O O
in O O
a O O
temporary O O
captured O O
rhythm O O
and O O
restoration O O
of O O
their O O
cardiac O O
output O O
. O O

These O O
patients O O
had O O
a O O
second O O
event O O
of O O
cardiac B-Disease B-Disease
arrest I-Disease I-Disease
, O O
resulting O O
in O O
death O O
, O O
within O O
10 O O
to O O
60 O O
minutes O O
. O O

In O O
one O O
patient O O
, O O
cardiac O O
pacing O O
was O O
not O O
used O O
, O O
because O O
he O O
converted O O
to O O
normal O O
sinus O O
rhythm O O
by O O
electrical O O
defibrillation O O
within O O
three O O
minutes O O
of O O
initiating O O
CPR O O
. O O

We O O
conclude O O
that O O
cardiac O O
pacing O O
during O O
resuscitative O O
efforts O O
in O O
pediatric O O
patients O O
suffering O O
from O O
acute O O
myocardial B-Disease B-Disease
dysfunction I-Disease I-Disease
may O O
not O O
have O O
long O O
- O O
term O O
value O O
in O O
and O O
of O O
itself O O
; O O
however O O
, O O
if O O
temporary O O
hemodynamic O O
stability O O
is O O
achieved O O
by O O
this O O
procedure O O
, O O
it O O
may O O
provide O O
additional O O
time O O
needed O O
to O O
institute O O
other O O
therapeutic O O
modalities O O
. O O

Efficacy O O
and O O
safety O O
of O O
granisetron O O
, O O
a O O
selective O O
5-hydroxytryptamine-3 O O
receptor O O
antagonist O O
, O O
in O O
the O O
prevention O O
of O O
nausea B-Disease B-Disease
and O O
vomiting B-Disease B-Disease
induced O O
by O O
high O O
- O O
dose O O
cisplatin O O
. O O

PURPOSE O O
: O O
To O O
assess O O
the O O
antiemetic O O
effects O O
and O O
safety O O
profile O O
of O O
four O O
different O O
doses O O
of O O
granisetron O O
( O O
Kytril O O
; O O
SmithKline O O
Beecham O O
Pharmaceuticals O O
, O O
Philadelphia O O
, O O
PA O O
) O O
when O O
administered O O
as O O
a O O
single O O
intravenous O O
( O O
IV O O
) O O
dose O O
for O O
prophylaxis O O
of O O
cisplatin O O
- O O
induced O O
nausea B-Disease B-Disease
and O I-Disease
vomiting B-Disease I-Disease
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
One O O
hundred O O
eighty O O
- O O
four O O
chemotherapy O O
- O O
naive O O
patients O O
receiving O O
high O O
- O O
dose O O
cisplatin O O
( O O
81 O O
to O O
120 O O
mg O O
/ O O
m2 O O
) O O
were O O
randomized O O
to O O
receive O O
one O O
of O O
four O O
granisetron O O
doses O O
( O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
or O O
40 O O
micrograms O O
/ O O
kg O O
) O O
administered O O
before O O
chemotherapy O O
. O O

Patients O O
were O O
observed O O
on O O
an O O
inpatient O O
basis O O
for O O
18 O O
to O O
24 O O
hours O O
, O O
and O O
vital O O
signs O O
, O O
nausea B-Disease B-Disease
, O O
vomiting B-Disease B-Disease
, O O
retching O O
, O O
and O O
appetite O O
were O O
assessed O O
. O O

Safety O O
analyses O O
included O O
incidence O O
of O O
adverse O O
experiences O O
and O O
laboratory O O
parameter O O
changes O O
. O O

RESULTS O O
: O O
After O O
granisetron O O
doses O O
of O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
and O O
40 O O
micrograms O O
/ O O
kg O O
, O O
a O O
major O O
response O O
( O O
< O O
or O O
= O O
two O O
vomiting B-Disease B-Disease
or O O
retching O O
episodes O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
was O O
recorded O O
in O O
23 O O
% O O
, O O
57 O O
% O O
, O O
58 O O
% O O
, O O
and O O
60 O O
% O O
of O O
patients O O
, O O
respectively O O
, O O
and O O
a O O
complete O O
response O O
( O O
no O O
vomiting B-Disease B-Disease
or O O
retching O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
in O O
18 O O
% O O
, O O
41 O O
% O O
, O O
40 O O
% O O
, O O
and O O
47 O O
% O O
of O O
patients O O
, O O
respectively O O
. O O

There O O
was O O
a O O
statistically O O
longer O O
time O O
to O O
first O O
episode O O
of O O
nausea B-Disease B-Disease
( O O
P O O
= O O
.0015 O O
) O O
and O O
vomiting B-Disease B-Disease
( O O
P O O
= O O
.0001 O O
) O O
, O O
and O O
fewer O O
patients O O
were O O
administered O O
additional O O
antiemetic O O
medication O O
in O O
the O O
10-micrograms O O
/ O O
kg O O
dosing O O
groups O O
than O O
in O O
the O O
5-micrograms O O
/ O O
kg O O
dosing O O
group O O
. O O

As O O
granisetron O O
dose O O
increased O O
, O O
appetite O O
return O O
increased O O
( O O
P O O
= O O
.040 O O
) O O
. O O

Headache B-Disease B-Disease
was O O
the O O
most O O
frequently O O
reported O O
adverse O O
event O O
( O O
20 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
A O O
single O O
10- O O
, O O
20- O O
, O O
or O O
40-micrograms O O
/ O O
kg O O
dose O O
of O O
granisetron O O
was O O
effective O O
in O O
controlling O O
vomiting B-Disease B-Disease
in O O
57 O O
% O O
to O O
60 O O
% O O
of O O
patients O O
who O O
received O O
cisplatin O O
at O O
doses O O
greater O O
than O O
81 O O
mg O O
/ O O
m2 O O
and O O
totally O O
prevented O O
vomiting B-Disease B-Disease
in O O
40 O O
% O O
to O O
47 O O
% O O
of O O
patients O O
. O O

There O O
were O O
no O O
statistically O O
significant O O
differences O O
in O O
efficacy O O
between O O
the O O
10-micrograms O O
/ O O
kg O O
dose O O
and O O
the O O
20- O O
and O O
40-micrograms O O
/ O O
kg O O
doses O O
. O O

Granisetron O O
was O O
well O O
tolerated O O
at O O
all O O
doses O O
. O O

Adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
two O O
cases O O
of O O
a O O
possible O O
adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
resulting O O
in O O
atrioventricular B-Disease B-Disease
( I-Disease I-Disease
AV I-Disease I-Disease
) I-Disease I-Disease
block I-Disease I-Disease
in O O
both O O
patients O O
and O O
severe O O
hypotension B-Disease B-Disease
in O O
one O O
patient O O
. O O

CASE O O
SUMMARIES O O
: O O
A O O
54-year O O
- O O
old O O
woman O O
with O O
hyperaldosteronism B-Disease B-Disease
was O O
treated O O
with O O
verapamil O O
480 O O
mg O O
/ O O
d O O
and O O
spironolactone O O
100 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
a O O
minimal O O
dose O O
of O O
clonidine O O
( O O
0.15 O O
mg O O
bid O O
) O O
, O O
she O O
developed O O
complete O O
AV B-Disease B-Disease
block I-Disease I-Disease
and O O
severe O O
hypotension B-Disease B-Disease
, O O
which O O
resolved O O
upon O O
cessation O O
of O O
all O O
medications O O
. O O

A O O
65-year O O
- O O
old O O
woman O O
was O O
treated O O
with O O
extended O O
- O O
release O O
verapamil O O
240 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
clonidine O O
0.15 O O
mg O O
bid O O
she O O
developed O O
complete O O
AV B-Disease B-Disease
block I-Disease I-Disease
, O O
which O O
resolved O O
after O O
all O O
therapy O O
was O O
stopped O O
. O O

DISCUSSION O O
: O O
An O O
adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
has O O
not O O
been O O
reported O O
previously O O
. O O

We O O
describe O O
two O O
such O O
cases O O
and O O
discuss O O
the O O
various O O
mechanisms O O
that O O
might O O
cause O O
such O O
an O O
interaction O O
. O O

Clinicians O O
should O O
be O O
acquainted O O
with O O
this O O
possibly O O
fatal O O
interaction O O
between O O
two O O
commonly O O
used O O
antihypertensive O O
drugs O O
. O O

CONCLUSIONS O O
: O O
Caution O O
is O O
recommended O O
in O O
combining O O
clonidine O O
and O O
verapamil O O
therapy O O
, O O
even O O
in O O
patients O O
who O O
do O O
not O O
have O O
sinus O O
or O O
AV O B-Disease
node O I-Disease
dysfunction O I-Disease
. O O

The O O
two O O
drugs O O
may O O
act O O
synergistically O O
on O O
both O O
the O O
AV O O
node O O
and O O
the O O
peripheral O O
circulation O O
. O O

Pharmacological O O
studies O O
on O O
a O O
new O O
dihydrothienopyridine O O
calcium O O
antagonist O O
, O O
S-312-d O O
. O O

5th O O
communication O O
: O O
anticonvulsant O O
effects O O
in O O
mice O O
. O O

S-312 O O
, O O
S-312-d O O
, O O
but O O
not O O
S-312-l O O
, O O
L O O
- O O
type O O
calcium O O
channel O O
antagonists O O
, O O
showed O O
anticonvulsant O O
effects O O
on O O
the O O
audiogenic B-Disease B-Disease
tonic I-Disease O
convulsions I-Disease B-Disease
in O O
DBA O O
/ O O
2 O O
mice O O
; O O
and O O
their O O
ED50 O O
values O O
were O O
18.4 O O
( O O
12.8 O O
- O O
27.1 O O
) O O
mg O O
/ O O
kg O O
, O O
p.o O O
. O O
and O O
15.0 O O
( O O
10.2 O O
- O O
23.7 O O
) O O
mg O O
/ O O
kg O O
, O O
p.o O O
. O O
, O O
respectively O O
, O O
while O O
that O O
of O O
flunarizine O O
was O O
34.0 O O
( O O
26.0 O O
- O O
44.8 O O
) O O
mg O O
/ O O
kg O O
, O O
p.o O O
. O O

Although O O
moderate O O
anticonvulsant O O
effects O O
of O O
S-312-d O O
in O O
higher O O
doses O O
were O O
observed O O
against O O
the O O
clonic O B-Disease
convulsions B-Disease I-Disease
induced O O
by O O
pentylenetetrazole O O
( O O
85 O O
mg O O
/ O O
kg O O
, O O
s.c O O
. O O
) O O
or O O
bemegride O O
( O O
40 O O
mg O O
/ O O
kg O O
, O O
s.c O O
. O O
) O O
, O O
no O O
effects O O
were O O
observed O O
in O O
convulsions B-Disease B-Disease
induced O O
by O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
, O O
picrotoxin O O
, O O
or O O
electroshock O O
in O O
Slc O O
: O O
ddY O O
mice O O
. O O

S-312-d O O
may O O
be O O
useful O O
in O O
the O O
therapy O O
of O O
certain O O
types O O
of O O
human O O
epilepsy B-Disease B-Disease
. O O

Transmural O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
with O O
sumatriptan O O
. O O

For O O
sumatriptan O O
, O O
tightness O O
in O O
the O O
chest O O
caused O O
by O O
an O O
unknown O O
mechanism O O
has O O
been O O
reported O O
in O O
3 O O
- O O
5 O O
% O O
of O O
users O O
. O O

We O O
describe O O
a O O
47-year O O
- O O
old O O
woman O O
with O O
an O O
acute O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
after O O
administration O O
of O O
sumatriptan O O
6 O O
mg O O
subcutaneously O O
for O O
cluster B-Disease B-Disease
headache I-Disease I-Disease
. O O

The O O
patient O O
had O O
no O O
history O O
of O O
underlying O O
ischaemic B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
or O O
Prinzmetal B-Disease B-Disease
's I-Disease I-Disease
angina I-Disease I-Disease
. O O

She O O
recovered O O
without O O
complications O O
. O O

Flumazenil O O
induces O O
seizures B-Disease B-Disease
and O O
death O O
in O O
mixed O O
cocaine O O
- O O
diazepam O O
intoxications O O
. O O

STUDY O O
HYPOTHESIS O O
: O O
Administration O O
of O O
the O O
benzodiazepine O O
antagonist O O
flumazenil O O
may O O
unmask O O
seizures B-Disease B-Disease
in O O
mixed O O
cocaine O O
- O O
benzodiazepine O O
intoxication O O
. O O

DESIGN O O
: O O
Male O O
Sprague O O
- O O
Dawley O O
rats O O
received O O
100 O O
mg O O
/ O O
kg O O
cocaine O O
IP O O
alone O O
, O O
5 O O
mg O O
/ O O
kg O O
diazepam O O
alone O O
, O O
or O O
a O O
combination O O
of O O
diazepam O O
and O O
cocaine O O
. O O

Three O O
minutes O O
later O O
, O O
groups O O
were O O
challenged O O
with O O
vehicle O O
or O O
flumazenil O O
5 O O
or O O
10 O O
mg O O
/ O O
kg O O
IP O O
. O O

Animal O O
behavior O O
, O O
seizures B-Disease B-Disease
( O O
time O O
to O O
and O O
incidence O O
) O O
, O O
death O O
( O O
time O O
to O O
and O O
incidence O O
) O O
, O O
and O O
cortical O O
EEG O O
tracings O O
were O O
recorded O O
. O O

INTERVENTIONS O O
: O O
Administration O O
of O O
flumazenil O O
to O O
animals O O
after O O
they O O
had O O
received O O
a O O
combination O O
dose O O
of O O
cocaine O O
and O O
diazepam O O
. O O

RESULTS O O
: O O
In O O
group O O
1 O O
, O O
animals O O
received O O
cocaine O O
followed O O
by O O
vehicle O O
. O O

This O O
resulted O O
in O O
100 O O
% O O
developing O O
seizures B-Disease B-Disease
and O O
death O O
. O O

Group O O
2 O O
received O O
diazepam O O
alone O O
followed O O
by O O
vehicle O O
. O O

Animals O O
became O O
somnolent O O
and O O
none O O
died O O
. O O

Group O O
3 O O
received O O
diazepam O O
followed O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

Animals O O
became O O
somnolent O O
after O O
diazepam O O
and O O
then O O
active O O
after O O
flumazenil O O
administration O O
. O O

In O O
group O O
4 O O
, O O
a O O
combination O O
of O O
cocaine O O
and O O
diazepam O O
was O O
administered O O
simultaneously O O
. O O

This O O
resulted O O
in O O
no O O
overt O O
or O O
EEG O O
- O O
detectable O O
seizures B-Disease B-Disease
and O O
a O O
50 O O
% O O
incidence O O
of O O
death O O
. O O

Group O O
5 O O
received O O
a O O
similar O O
combination O O
of O O
cocaine O O
and O O
diazepam O O
, O O
followed O O
later O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

This O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
seizures B-Disease B-Disease
, O O
90 O O
% O O
( O O
P O O
< O O
.01 O O
) O O
, O O
and O O
death O O
, O O
100 O O
% O O
( O O
P O O
< O O
or O O
= O O
.01 O O
) O O
, O O
compared O O
with O O
group O O
4 O O
. O O

Group O O
6 O O
received O O
cocaine O O
and O O
diazepam O O
followed O O
by O O
10 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

This O O
also O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
seizures B-Disease B-Disease
, O O
90 O O
% O O
( O O
P O O
< O O
or O O
= O O
.01 O O
) O O
, O O
and O O
death O O
, O O
90 O O
% O O
( O O
P O O
< O O
or O O
= O O
.05 O O
) O O
, O O
compared O O
with O O
group O O
4 O O
. O O

CONCLUSION O O
: O O
Flumazenil O O
can O O
unmask O O
seizures B-Disease B-Disease
and O O
increase O O
the O O
incidence O O
of O O
death O O
in O O
a O O
model O O
of O O
combined O O
cocaine O O
- O O
diazepam O O
intoxications O O
. O O

Mechanisms O O
for O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin O O
- O O
mediated O O
nephropathy B-Disease B-Disease
in O O
rats O O
. O O

Studies O O
were O O
performed O O
to O O
examine O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin O O
( O O
GM O O
) O O
-mediated O O
nephropathy B-Disease B-Disease
. O O

Administration O O
of O O
GM O O
at O O
40 O O
mg O O
/ O O
kg O O
sc O O
for O O
13 O O
days O O
to O O
rats O O
induced O O
a O O
significant O O
reduction O O
in O O
renal O O
blood O O
flow O O
( O O
RBF O O
) O O
and O O
inulin O O
clearance O O
( O O
CIn O O
) O O
as O O
well O O
as O O
marked O O
tubular B-Disease B-Disease
damage I-Disease I-Disease
. O O

A O O
significant O O
reduction O O
in O O
urinary O O
guanosine O O
3',5'-cyclic O O
monophosphate O O
( O O
cGMP O O
) O O
excretion O O
and O O
a O O
significant O O
increase O O
in O O
renal O O
cortical O O
renin O O
and O O
endothelin-1 O O
contents O O
were O O
also O O
observed O O
in O O
GM O O
- O O
mediated O O
nephropathy B-Disease B-Disease
. O O

Superoxide O O
dismutase O O
( O O
SOD O O
) O O
or O O
dimethylthiourea O O
( O O
DMTU O O
) O O
significantly O O
lessened O O
the O O
GM O O
- O O
induced O O
decrement O O
in O O
CIn O O
. O O

The O O
SOD O O
- O O
induced O O
increase O O
in O O
glomerular O O
filtration O O
rate O O
was O O
associated O O
with O O
a O O
marked O O
improvement O O
in O O
RBF O O
, O O
an O O
increase O O
in O O
urinary O O
cGMP O O
excretion O O
, O O
and O O
a O O
decrease O O
in O O
renal O O
renin O O
and O O
endothelin-1 O O
content O O
. O O

SOD O O
did O O
not O O
attenuate O O
the O O
tubular B-Disease B-Disease
damage I-Disease I-Disease
. O O

In O O
contrast O O
, O O
DMTU O O
significantly O O
reduced O O
the O O
tubular B-Disease O
damage I-Disease O
and O O
lipid O O
peroxidation O O
, O O
but O O
it O O
did O O
not O O
affect O O
renal O O
hemodynamics O O
and O O
vasoactive O O
substances O O
. O O

Neither O O
SOD O O
nor O O
DMTU O O
affected O O
the O O
renal O O
cortical O O
GM O O
content O O
in O O
GM O O
- O O
treated O O
rats O O
. O O

These O O
results O O
suggest O O
that O O
1 O O
) O O
both O O
SOD O O
and O O
DMTU O O
have O O
protective O O
effects O O
on O O
GM O O
- O O
mediated O O
nephropathy B-Disease B-Disease
, O O
2 O O
) O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
differ O O
for O O
SOD O O
and O O
DMTU O O
, O O
and O O
3 O O
) O O
superoxide O O
anions O O
play O O
a O O
critical O O
role O O
in O O
GM O O
- O O
induced O O
renal O O
vasoconstriction O O
. O O

Cephalothin O O
- O O
induced O O
immune O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
. O O

A O O
patient O O
with O O
renal B-Disease B-Disease
disease I-Disease I-Disease
developed O O
Coombs O O
- O O
positive O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
while O O
receiving O O
cephalothin O O
therapy O O
. O O

An O O
anti O O
- O O
cephalothin O O
IgG O O
antibody O O
was O O
detected O O
in O O
the O O
patient O O
's O O
serum O O
and O O
in O O
the O O
eluates O O
from O O
her O O
erythrocytes O O
. O O

In O O
addition O O
, O O
nonimmunologic O O
binding O O
of O O
normal O O
and O O
patient O O
's O O
serum O O
proteins O O
to O O
her O O
own O O
and O O
cephalothin O O
- O O
coated O O
normal O O
red O O
cells O O
was O O
demonstrated O O
. O O

Skin O O
tests O O
and O O
in O O
vitro O O
lymphocyte O O
stimulation O O
revealed O O
that O O
the O O
patient O O
was O O
sensitized O O
to O O
cephalothin O O
and O O
also O O
to O O
ampicillin O O
. O O

Careful O O
investigation O O
of O O
drug O O
- O O
induced O O
hemolytic B-Disease B-Disease
anemias I-Disease I-Disease
reveals O O
the O O
complexity O O
of O O
the O O
immune O O
mechanisms O O
involved O O
. O O

Assessment O O
of O O
cardiomyocyte O O
DNA O O
synthesis O O
during O O
hypertrophy B-Disease B-Disease
in O O
adult O O
mice O O
. O O

The O O
ability O O
of O O
cardiomyocytes O O
to O O
synthesize O O
DNA O O
in O O
response O O
to O O
experimentally O O
induced O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
was O O
assessed O O
in O O
adult O O
mice O O
. O O

Isoproterenol O O
delivered O O
by O O
osmotic O O
minipump O O
implantation O O
in O O
adult O O
C3Heb O O
/ O O
FeJ O O
mice O O
resulted O O
in O O
a O O
46 O O
% O O
increase O O
in O O
heart O O
weight O O
and O O
a O O
19.3 O O
% O O
increase O O
in O O
cardiomyocyte O O
area O O
. O O

No O O
DNA O O
synthesis O O
, O O
as O O
assessed O O
by O O
autoradiographic O O
analysis O O
of O O
isolated O O
cardiomyocytes O O
, O O
was O O
observed O O
in O O
control O O
or O O
hypertrophic B-Disease B-Disease
hearts I-Disease I-Disease
. O O

A O O
survey O O
of O O
15 O O
independent O O
inbred O O
strains O O
of O O
mice O O
revealed O O
that O O
ventricular O O
cardiomyocyte O O
nuclear O O
number O O
ranged O O
from O O
3 O O
to O O
13 O O
% O O
mononucleate O O
, O O
suggesting O O
that O O
cardiomyocyte O O
terminal O O
differentiation O O
is O O
influenced O O
directly O O
or O O
indirectly O O
by O O
genetic O O
background O O
. O O

To O O
determine O O
whether O O
the O O
capacity O O
for O O
reactive O O
DNA O O
synthesis O O
was O O
also O O
subject O O
to O O
genetic O O
regulation O O
, O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
was O O
induced O O
in O O
the O O
strains O O
of O O
mice O O
comprising O O
the O O
extremes O O
of O O
the O O
nuclear O O
number O O
survey O O
. O O

These O O
data O O
indicate O O
that O O
adult O O
mouse O O
atrial O O
and O O
ventricular O O
cardiomyocytes O O
do O O
not O O
synthesize O O
DNA O O
in O O
response O O
to O O
isoproterenol O O
- O O
induced O O
cardiac B-Disease B-Disease
hypertrophy I-Disease I-Disease
. O O

Central O O
cardiovascular O O
effects O O
of O O
AVP O O
and O O
ANP O O
in O O
normotensive O O
and O O
spontaneously O O
hypertensive B-Disease B-Disease
rats O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
compare O O
influence O O
of O O
central O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
and O O
of O O
atrial O O
natriuretic O O
peptide O O
( O O
ANP O O
) O O
on O O
control O O
of O O
arterial O O
blood O O
pressure O O
( O O
MAP O O
) O O
and O O
heart O O
rate O O
( O O
HR O O
) O O
in O O
normotensive O O
( O O
WKY O O
) O O
and O O
spontaneously O O
hypertensive B-Disease B-Disease
( O O
SHR O O
) O O
rats O O
. O O

Three O O
series O O
of O O
experiments O O
were O O
performed O O
on O O
30 O O
WKY O O
and O O
30 O O
SHR O O
, O O
chronically O O
instrumented O O
with O O
guide O O
tubes O O
in O O
the O O
lateral O O
ventricle O O
( O O
LV O O
) O O
and O O
arterial O O
and O O
venous O O
catheters O O
. O O

MAP O O
and O O
HR O O
were O O
monitored O O
before O O
and O O
after O O
i.v O O
. O O

injections O O
of O O
either O O
vehicle O O
or O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP O O
and O O
25 O O
, O O
125 O O
and O O
500 O O
ng O O
of O O
ANP O O
. O O

Sensitivity O O
of O O
cardiac O O
component O O
of O O
baroreflex O O
( O O
CCB O O
) O O
, O O
expressed O O
as O O
a O O
slope O O
of O O
the O O
regression O O
line O O
was O O
determined O O
from O O
relationships O O
between O O
systolic O O
arterial O O
pressure O O
( O O
SAP O O
) O O
and O O
HR O O
period O O
( O O
HRp O O
) O O
during O O
phenylephrine O O
( O O
Phe O O
) O O
-induced O O
hypertension B-Disease B-Disease
and O O
sodium O O
nitroprusside O O
( O O
SN O O
) O O
-induced O O
hypotension B-Disease B-Disease
. O O

CCB O O
was O O
measured O O
before O O
and O O
after O O
administration O O
of O O
either O O
vehicle O O
, O O
AVP O O
, O O
ANP O O
, O O
or O O
both O O
peptides O O
together O O
. O O

Increases O O
of O O
MAP O O
occurred O O
after O O
LV O O
administration O O
of O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP O O
in O O
WKY O O
and O O
of O O
10 O O
and O O
50 O O
ng O O
in O O
SHR O O
. O O

ANP O O
did O O
not O O
cause O O
significant O O
changes O O
in O O
MAP O O
in O O
both O O
strains O O
as O O
compared O O
to O O
vehicle O O
, O O
but O O
it O O
abolished O O
AVP O O
- O O
induced O O
MAP O O
increase O O
in O O
WKY O O
and O O
SHR O O
. O O

CCB O O
was O O
reduced O O
in O O
WKY O O
and O O
SHR O O
after O O
LV O O
administration O O
of O O
AVP O O
during O O
SN O O
- O O
induced O O
hypotension B-Disease B-Disease
. O O

In O O
SHR O O
but O O
not O O
in O O
WKY O O
administration O O
of O O
ANP O O
, O O
AVP O O
and O O
ANP O O
+ O O
AVP O O
decreased O O
CCB O O
during O O
Phe O O
- O O
induced O O
MAP O O
elevation O O
. O O

The O O
results O O
indicate O O
that O O
centrally O O
applied O O
AVP O O
and O O
ANP O O
exert O O
differential O O
effects O O
on O O
blood O O
pressure O O
and O O
baroreflex O O
control O O
of O O
heart O O
rate O O
in O O
WKY O O
and O O
SHR O O
and O O
suggest O O
interaction O O
of O O
these O O
two O O
peptides O O
in O O
blood O O
pressure O O
regulation O O
at O O
the O O
level O O
of O O
central O O
nervous O O
system O O
. O O

Cutaneous O O
exposure O O
to O O
warfarin O O
- O O
like O O
anticoagulant O O
causing O O
an O O
intracerebral B-Disease B-Disease
hemorrhage I-Disease I-Disease
: O O
a O O
case O O
report O O
. O O

A O O
case O O
of O O
intercerebral O B-Disease
hematoma B-Disease I-Disease
due O O
to O O
warfarin O O
- O O
induced O O
coagulopathy B-Disease B-Disease
is O O
presented O O
. O O

The O O
39-year O O
- O O
old O O
woman O O
had O O
spread O O
a O O
warfarin O O
- O O
type O O
rat O O
poison O O
around O O
her O O
house O O
weekly O O
using O O
her O O
bare O O
hands O O
, O O
with O O
no O O
washing O O
post O O
application O O
. O O

Percutaneous O O
absorption O O
of O O
warfarin O O
causing O O
coagulopathy B-Disease B-Disease
, O O
reported O O
three O O
times O O
in O O
the O O
past O O
, O O
is O O
a O O
significant O O
risk O O
if O O
protective O O
measures O O
, O O
such O O
as O O
gloves O O
, O O
are O O
not O O
used O O
. O O

An O O
adverse O O
drug O O
interaction O O
with O O
piroxicam O O
, O O
which O O
she O O
took O O
occasionally O O
, O O
may O O
have O O
exacerbated O O
the O O
coagulopathy B-Disease B-Disease
. O O

Pediatric O O
heart O O
transplantation O O
without O O
chronic O O
maintenance O O
steroids O O
. O O

From O O
1986 O O
to O O
February O O
1993 O O
, O O
40 O O
children O O
aged O O
2 O O
months O O
to O O
18 O O
years O O
( O O
average O O
age O O
10.4 O O
+ O O
/- O O

5.8 O O
years O O
) O O
underwent O O
heart O O
transplantation O O
. O O

Indications O O
for O O
transplantation O O
were O O
idiopathic B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
( O O
52 O O
% O O
) O O
, O O
congenital B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
( O O
35 O O
% O O
) O O
with O O
and O O
without O O
prior O O
repair O O
( O O
71 O O
% O O
and O O
29 O O
% O O
, O O
respectively O O
) O O
, O O
hypertrophic B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
( O O
5 O O
% O O
) O O
, O O
valvular B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
( O O
3 O O
% O O
) O O
, O O
and O O
doxorubicin O O
cardiomyopathy B-Disease B-Disease
( O O
5 O O
% O O
) O O
. O O

Patients O O
were O O
managed O O
with O O
cyclosporine O O
and O O
azathioprine O O
. O O

No O O
prophylaxis O O
with O O
antilymphocyte O O
globulin O O
was O O
used O O
. O O

Steroids O O
were O O
given O O
to O O
39 O O
% O O
of O O
patients O O
for O O
refractory O O
rejection O O
, O O
but O O
weaning O O
was O O
always O O
attempted O O
and O O
generally O O
successful O O
( O O
64 O O
% O O
) O O
. O O

Five O O
patients O O
( O O
14 O O
% O O
) O O
received O O
maintenance O O
steroids O O
. O O

Four O O
patients O O
died O O
in O O
the O O
perioperative O O
period O O
and O O
one O O
died O O
4 O O
months O O
later O O
. O O

There O O
have O O
been O O
no O O
deaths O O
related O O
to O O
rejection O O
or O O
infection B-Disease B-Disease
. O O

Average O O
follow O O
- O O
up O O
was O O
36 O O
+ O O
/- O O

19 O O
months O O
( O O
range O O
1 O O
to O O
65 O O
months O O
) O O
. O O

Cumulative O O
survival O O
is O O
88 O O
% O O
at O O
5 O O
years O O
. O O

In O O
patients O O
less O O
than O O
7 O O
years O O
of O O
age O O
, O O
rejection O O
was O O
monitored O O
noninvasively O O
. O O

In O O
the O O
first O O
postoperative O O
month O O
, O O
89 O O
% O O
of O O
patients O O
were O O
treated O O
for O O
rejection O O
. O O

Freedom O O
from O O
serious O O
infections B-Disease B-Disease
was O O
83 O O
% O O
at O O
1 O O
month O O
and O O
65 O O
% O O
at O O
1 O O
year O O
. O O

Cytomegalovirus B-Disease B-Disease
infections I-Disease I-Disease
were O O
treated O O
successfully O O
with O O
ganciclovir O O
in O O
11 O O
patients O O
. O O

No O O
impairment O O
of O O
growth O O
was O O
observed O O
in O O
children O O
who O O
underwent O O
transplantation O O
compared O O
with O O
a O O
control O O
population O O
. O O

Twenty O O
- O O
one O O
patients O O
( O O
60 O O
% O O
) O O
have O O
undergone O O
annual O O
catheterizations O O
and O O
no O O
sign O O
of O O
graft O O
atherosclerosis B-Disease B-Disease
has O O
been O O
observed O O
. O O

Seizures B-Disease B-Disease
occurred O O
in O O
five O O
patients O O
( O O
14 O O
% O O
) O O
and O O
hypertension B-Disease B-Disease
was O O
treated O O
in O O
10 O O
patients O O
( O O
28 O O
% O O
) O O
. O O

No O O
patient O O
was O O
disabled O O
and O O
no O O
lymphoproliferative B-Disease B-Disease
disorder I-Disease I-Disease
was O O
observed. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Delirium B-Disease B-Disease
during O O
fluoxetine O O
treatment O O
. O O

A O O
case O O
report O O
. O O

The O O
correlation O O
between O O
high O O
serum O O
tricyclic O O
antidepressant O O
concentrations O O
and O O
central O O
nervous O O
system O O
side O O
effects O O
has O O
been O O
well O O
established O O
. O O

Only O O
a O O
few O O
reports O O
exist O O
, O O
however O O
, O O
on O O
the O O
relationship O O
between O O
the O O
serum O O
concentrations O O
of O O
selective O O
serotonin O O
reuptake O O
inhibitors O O
( O O
SSRIs O O
) O O
and O O
their O O
toxic O O
effects O O
. O O

In O O
some O O
cases O O
, O O
a O O
high O O
serum O O
concentration O O
of O O
citalopram O O
( O O
> O O
600 O O
nmol O O
/ O O
L O O
) O O
in O O
elderly O O
patients O O
has O O
been O O
associated O O
with O O
increased O O
somnolence B-Disease B-Disease
and O O
movement B-Disease O
difficulties I-Disease O
. O O

Widespread O O
cognitive B-Disease B-Disease
disorders I-Disease I-Disease
, O O
such O O
as O O
delirium B-Disease B-Disease
, O O
have O O
not O O
been O O
previously O O
linked O O
with O O
high O O
blood O O
levels O O
of O O
SSRIs O O
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
acute O O
hyperkinetic B-Disease B-Disease
delirium B-Disease I-Disease
connected O O
with O O
a O O
high O O
serum O O
total O O
fluoxetine O O
( O O
fluoxetine O O
plus O O
desmethylfluoxetine O O
) O O
concentration O O
. O O

Pulmonary B-Disease B-Disease
edema I-Disease I-Disease
and O O
shock B-Disease B-Disease
after O O
high O O
- O O
dose O O
aracytine O O
- O O
C O O
for O O
lymphoma B-Disease B-Disease
; O O
possible O O
role O O
of O O
TNF O O
- O O
alpha O O
and O O
PAF O O
. O O

Four O O
out O O
of O O
23 O O
consecutive O O
patients O O
treated O O
with O O
high O O
- O O
dose O O
Ara O O
- O O
C O O
for O O
lymphomas B-Disease B-Disease
in O O
our O O
institution O O
developed O O
a O O
strikingly O O
similar O O
syndrome O O
during O O
the O O
perfusion O O
. O O

It O O
was O O
characterized O O
by O O
the O O
onset O O
of O O
fever B-Disease B-Disease
, O O
diarrhea B-Disease B-Disease
, O O
shock B-Disease B-Disease
, O O
pulmonary B-Disease B-Disease
edema I-Disease I-Disease
, O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
, O O
metabolic B-Disease O
acidosis I-Disease B-Disease
, O O
weight B-Disease B-Disease
gain I-Disease I-Disease
and O O
leukocytosis B-Disease B-Disease
. O O

Thorough O O
bacteriological O O
screening O O
failed O O
to O O
provide O O
evidence O O
of O O
infection B-Disease B-Disease
. O O

Sequential O O
biological O O
assays O O
of O O
IL-1 O O
, O O
IL-2 O O
, O O
TNF O O
and O O
PAF O O
were O O
performed O O
during O O
Ara O O
- O O
C O O
infusion O O
to O O
ten O O
patients O O
, O O
including O O
the O O
four O O
who O O
developed O O
the O O
syndrome O O
. O O

TNF O O
and O O
PAF O O
activity O O
was O O
found O O
in O O
the O O
serum O O
of O O
respectively O O
two O O
and O O
four O O
of O O
the O O
cases O O
, O O
but O O
not O O
in O O
the O O
six O O
controls O O
. O O

As O O
TNF O O
and O O
PAF O O
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
development O O
of O O
septic O B-Disease
shock B-Disease I-Disease
and O O
adult B-Disease B-Disease
respiratory I-Disease I-Disease
distress I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
we O O
hypothesize O O
that O O
high O O
- O O
dose O O
Ara O O
- O O
C O O
may O O
be O O
associated O O
with O O
cytokine O O
release O O
. O O

Protective O O
effect O O
of O O
clentiazem O O
against O O
epinephrine O O
- O O
induced O O
cardiac B-Disease B-Disease
injury I-Disease I-Disease
in O O
rats O O
. O O

We O O
investigated O O
the O O
effects O O
of O O
clentiazem O O
, O O
a O O
1,5-benzothiazepine O O
calcium O O
antagonist O O
, O O
on O O
epinephrine O O
- O O
induced O O
cardiomyopathy B-Disease B-Disease
in O O
rats O O
. O O

With O O
2-week O O
chronic O O
epinephrine O O
infusion O O
, O O
16 O O
of O O
30 O O
rats O O
died O O
within O O
4 O O
days O O
, O O
and O O
severe O O
ischemic B-Disease B-Disease
lesions I-Disease I-Disease
and O O
fibrosis B-Disease B-Disease
of O O
the O O
left O O
ventricles O O
were O O
observed O O
. O O

In O O
epinephrine O O
- O O
treated O O
rats O O
, O O
left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol O O
were O O
reduced O O
, O O
but O O
responses O O
to O O
calcium O O
were O O
normal O O
or O O
enhanced O O
compared O O
to O O
controls O O
. O O

Left O O
ventricular O O
alpha O O
and O O
beta O O
adrenoceptor O O
densities O O
were O O
also O O
reduced O O
compared O O
to O O
controls O O
. O O

Treatment O O
with O O
clentiazem O O
prevented O O
epinephrine O O
- O O
induced O O
death O O
( O O
P O O
< O O
.05 O O
) O O
, O O
and O O
attenuated O O
the O O
ventricular O B-Disease
ischemic B-Disease I-Disease
lesions I-Disease I-Disease
and O O
fibrosis B-Disease B-Disease
, O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

Left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol O O
were O O
reduced O O
compared O O
to O O
controls O O
in O O
groups O O
treated O O
with O O
clentiazem O O
alone O O
, O O
but O O
combined O O
with O O
epinephrine O O
, O O
clentiazem O O
restored O O
left O O
atrial O O
responses O O
and O O
enhanced O O
left O O
ventricular O O
papillary O O
responses O O
to O O
isoproterenol O O
. O O

On O O
the O O
other O O
hand O O
clentiazem O O
did O O
not O O
prevent O O
epinephrine O O
- O O
induced O O
down O O
- O O
regulation O O
of O O
alpha O O
and O O
beta O O
adrenoceptors O O
. O O

Interestingly O O
, O O
clentiazem O O
, O O
infused O O
alone O O
, O O
resulted O O
in O O
decreased O O
adrenergic O O
receptor O O
densities O O
in O O
the O O
left O O
ventricle O O
. O O

Clentiazem O O
also O O
did O O
not O O
prevent O O
the O O
enhanced O O
responses O O
to O O
calcium O O
seen O O
in O O
the O O
epinephrine O O
- O O
treated O O
animals O O
, O O
although O O
the O O
high O O
dose O O
of O O
clentiazem O O
partially O O
attenuated O O
the O O
maximal O O
response O O
to O O
calcium O O
compared O O
to O O
epinephrine O O
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
clentiazem O O
attenuated O O
epinephrine O O
- O O
induced O O
cardiac B-Disease B-Disease
injury I-Disease I-Disease
, O O
possibly O O
through O O
its O O
effect O O
on O O
the O O
adrenergic O O
pathway O O
. O O

Kaliuretic O O
effect O O
of O O
L O O
- O O
dopa O O
treatment O O
in O O
parkinsonian B-Disease B-Disease
patients O O
. O O

Hypokalemia B-Disease B-Disease
, O O
sometimes O O
severe O O
, O O
was O O
observed O O
in O O
some O O
L O O
- O O
dopa O O
- O O
treated O O
parkinsonian B-Disease B-Disease
patients O O
. O O

The O O
influence O O
of O O
L O O
- O O
dopa O O
on O O
the O O
renal O O
excretion O O
of O O
potassium O O
was O O
studied O O
in O O
3 O O
patients O O
with O O
hypokalemia B-Disease B-Disease
and O O
in O O
5 O O
normokalemic O O
patients O O
by O O
determination O O
of O O
renal O O
plasma O O
flow O O
, O O
glomerular O O
filtration O O
rate O O
, O O
plasma O O
concentration O O
of O O
potassium O O
and O O
sodium O O
as O O
well O O
as O O
urinary O O
excretion O O
of O O
potassium O O
, O O
sodium O O
and O O
aldosterone O O
. O O

L O O
- O O
Dopa O O
intake O O
was O O
found O O
to O O
cause O O
an O O
increased O O
excretion O O
of O O
potassium O O
, O O
and O O
sometimes O O
also O O
of O O
sodium O O
, O O
in O O
the O O
hypokalemic O B-Disease
but O O
not O O
in O O
the O O
normokalemic O B-Disease
patients O O
. O O

This O O
effect O O
on O O
the O O
renal O O
function O O
could O O
be O O
prohibited O O
by O O
the O O
administration O O
of O O
a O O
peripheral O O
dopa O O
decarbodylase O O
inhibitor O O
. O O

It O O
is O O
not O O
known O O
why O O
this O O
effect O O
occurred O O
in O O
some O O
individuals O O
but O O
not O O
in O O
others O O
, O O
but O O
our O O
results O O
indicate O O
a O O
correlation O O
between O O
aldosterone O O
production O O
and O O
this O O
renal O O
effect O O
of O O
L O O
- O O
dopa O O
. O O

Cocaine O O
induced O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
. O O

We O O
report O O
a O O
case O O
of O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
induced O O
by O O
cocaine O O
. O O

The O O
ischemia B-Disease B-Disease
probably O O
induced O O
by O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
spasm I-Disease I-Disease
was O O
reversed O O
by O O
nitroglycerin O O
and O O
calcium O O
blocking O O
agents O O
. O O

Doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
monitored O O
by O O
ECG O O
in O O
freely O O
moving O O
mice O O
. O O

A O O
new O O
model O O
to O O
test O O
potential O O
protectors O O
. O O

In O O
laboratory O O
animals O O
, O O
histology O O
is O O
most O O
commonly O O
used O O
to O O
study O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
. O O

However O O
, O O
for O O
monitoring O O
during O O
treatment O O
, O O
large O O
numbers O O
of O O
animals O O
are O O
needed O O
. O O

Recently O O
we O O
developed O O
a O O
new O O
method O O
to O O
measure O O
ECG O O
values O O
in O O
freely O O
moving O O
mice O O
by O O
telemetry O O
. O O

With O O
this O O
model O O
we O O
investigated O O
the O O
effect O O
of O O
chronic O O
doxorubicin O O
administration O O
on O O
the O O
ECG O O
of O O
freely O O
moving O O
BALB O O
/ O O
c O O
mice O O
and O O
the O O
efficacy O O
of O O
ICRF-187 O O
as O O
a O O
protective O O
agent O O
. O O

The O O
ST O O
interval O O
significantly O O
widened O O
from O O
15.0 O O
+ O O
/- O O

1.5 O O
to O O
56.8 O O
+ O O
/- O O

11.8 O O
ms O O
in O O
week O O
10 O O
( O O
7 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
given O O
i.v O O
. O O

plus O O
3 O O
weeks O O
of O O
observation O O
) O O
. O O

The O O
ECG O O
of O O
the O O
control O O
animals O O
did O O
not O O
change O O
during O O
the O O
entire O O
study O O
. O O

After O O
sacrifice O O
the O O
hearts O O
of O O
doxorubicin O O
- O O
treated O O
animals O O
were O O
enlarged O O
and O O
the O O
atria O O
were O O
hypertrophic B-Disease B-Disease
. O O

As O O
this O O
schedule O O
exerted O O
more O O
toxicity B-Disease B-Disease
than O O
needed O O
to O O
investigate O O
protective O O
agents O O
, O O
the O O
protection O O
of O O
ICRF-187 O O
was O O
determined O O
using O O
a O O
dose O O
schedule O O
with O O
lower O O
general O O
toxicity B-Disease B-Disease
( O O
6 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
given O O
i.v O O
. O O
plus O O
2 O O
weeks O O
of O O
observation O O
) O O
. O O

On O O
this O O
schedule O O
, O O
the O O
animals O O
' O O
hearts O O
appeared O O
normal O O
after O O
sacrifice O O
and O O
ICRF-187 O O
( O O
50 O O
mg O O
/ O O
kg O O
given O O
i.p O O
. O O

1 O O
h O O
before O O
doxorubicin O O
) O O
provided O O
almost O O
full O O
protection O O
. O O

These O O
data O O
were O O
confirmed O O
by O O
histology O O
. O O

The O O
results O O
indicate O O
that O O
this O O
new O O
model O O
is O O
very O O
sensitive O O
and O O
enables O O
monitoring O O
of O O
the O O
development O O
of O O
cardiotoxicity B-Disease B-Disease
with O O
time O O
. O O

These O O
findings O O
result O O
in O O
a O O
model O O
that O O
allows O O
the O O
testing O O
of O O
protectors O O
against O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B-Disease B-Disease
as O O
demonstrated O O
by O O
the O O
protection O O
provided O O
by O O
ICRF-187 O O
. O O

Epinephrine O O
dysrhythmogenicity O O
is O O
not O O
enhanced O O
by O O
subtoxic O O
bupivacaine O O
in O O
dogs O O
. O O

Since O O
bupivacaine O O
and O O
epinephrine O O
may O O
both O O
precipitate O O
dysrhythmias B-Disease B-Disease
, O O
circulating O O
bupivacaine O O
during O O
regional O O
anesthesia O O
could O O
potentiate O O
dysrhythmogenic O O
effects O O
of O O
epinephrine O O
. O O

We O O
therefore O O
examined O O
whether O O
bupivacaine O O
alters O O
the O O
dysrhythmogenicity O O
of O O
subsequent O O
administration O O
of O O
epinephrine O O
in O O
conscious O O
, O O
healthy O O
dogs O O
and O O
in O O
anesthetized O O
dogs O O
with O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

Forty O O
- O O
one O O
conscious O O
dogs O O
received O O
10 O O
micrograms.kg-1.min-1 O O
epinephrine O O
. O O

Seventeen O O
animals O O
responded O O
with O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
( O O
VT B-Disease B-Disease
) O O
within O O
3 O O
min O O
. O O

After O O
3 O O
h O O
, O O
these O O
responders O O
randomly O O
received O O
1 O O
or O O
2 O O
mg O O
/ O O
kg O O
bupivacaine O O
or O O
saline O O
over O O
5 O O
min O O
, O O
followed O O
by O O
10 O O
micrograms.kg-1.min-1 O O
epinephrine O O
. O O

In O O
the O O
bupivacaine O O
groups O O
, O O
epinephrine O O
caused O O
fewer O O
prodysrhythmic O O
effects O O
than O O
without O O
bupivacaine O O
. O O

VT B-Disease B-Disease
appeared O O
in O O
fewer O O
dogs O O
and O O
at O O
a O O
later O O
time O O
, O O
and O O
there O O
were O O
more O O
sinoatrial O O
beats O O
and O O
less O O
ectopies O O
. O O

Epinephrine O O
shortened O O
QT O O
less O O
after O O
bupivacaine O O
than O O
in O O
control O O
animals O O
. O O

One O O
day O O
after O O
experimental O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
, O O
six O O
additional O O
halothane O O
- O O
anesthetized O O
dogs O O
received O O
4 O O
micrograms.kg-1.min-1 O O
epinephrine O O
until O O
VT B-Disease B-Disease
appeared O O
. O O

After O O
45 O O
min O O
, O O
1 O O
mg O O
/ O O
kg O O
bupivacaine O O
was O O
injected O O
over O O
5 O O
min O O
, O O
again O O
followed O O
by O O
4 O O
micrograms.kg-1.min-1 O O
epinephrine O O
. O O

In O O
these O O
dogs O O
, O O
the O O
prodysrhythmic O O
response O O
to O O
epinephrine O O
was O O
also O O
mitigated O O
by O O
preceding O O
bupivacaine O O
. O O

Bupivacaine O O
antagonizes O O
epinephrine O O
dysrhythmogenicity O O
in O O
conscious O O
dogs O O
susceptible O O
to O O
VT B-Disease B-Disease
and O O
in O O
anesthetized O O
dogs O O
with O O
spontaneous O O
postinfarct O B-Disease
dysrhythmias B-Disease I-Disease
. O O

There O O
is O O
no O O
evidence O O
that O O
systemic O O
subtoxic O O
bupivacaine O O
administration O O
enhances O O
the O O
dysrhythmogenicity O O
of O O
subsequent O O
epinephrine O O
. O O

Milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
induced O O
by O O
1,25 O O
( O O
OH O O
) O O
2D O O
in O O
a O O
patient O O
with O O
hypoparathyroidism B-Disease B-Disease
. O O

Milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
was O O
first O O
described O O
70 O O
years O O
ago O O
in O O
the O O
context O O
of O O
the O O
treatment O O
of O O
peptic B-Disease B-Disease
ulcer I-Disease I-Disease
disease I-Disease I-Disease
with O O
large O O
amounts O O
of O O
calcium O O
and O O
alkali O O
. O O

Although O O
with O O
current O O
ulcer B-Disease B-Disease
therapy O O
( O O
H-2 O O
blockers O O
, O O
omeprazole O O
, O O
and O O
sucralfate O O
) O O
, O O
the O O
frequency O O
of O O
milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
has O O
decreased O O
significantly O O
, O O
the O O
classic O O
triad O O
of O O
hypercalcemia B-Disease B-Disease
, O O
alkalosis B-Disease B-Disease
, O O
and O O
renal B-Disease B-Disease
impairment I-Disease I-Disease
remains O O
the O O
hallmark O O
of O O
the O O
syndrome O O
. O O

Milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
can O O
present O O
serious O O
and O O
occasionally O O
life O O
- O O
threatening O O
illness O O
unless O O
diagnosed O O
and O O
treated O O
appropriately O O
. O O

This O O
article O O
presents O O
a O O
patient O O
with O O
hypoparathyroidism B-Disease B-Disease
who O O
was O O
treated O O
with O O
calcium O O
carbonate O O
and O O
calcitriol O O
resulting O O
in O O
two O O
admissions O O
to O O
the O O
hospital O O
for O O
milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

The O O
patient O O
was O O
successfully O O
treated O O
with O O
intravenous O O
pamidronate O O
on O O
his O O
first O O
admission O O
and O O
with O O
hydrocortisone O O
on O O
the O O
second O O
. O O

This O O
illustrates O O
intravenous O O
pamidronate O O
as O O
a O O
valuable O O
therapeutic O O
tool O O
when O O
milk B-Disease B-Disease
- I-Disease I-Disease
alkali I-Disease I-Disease
syndrome I-Disease I-Disease
presents O O
as O O
hypercalcemic B-Disease B-Disease
emergency I-Disease O
. O O

Encephalopathy B-Disease B-Disease
during O O
amitriptyline O O
therapy O O
: O O
are O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
serotonin B-Disease B-Disease
syndrome I-Disease I-Disease
spectrum O O
disorders O O
? O O

This O O
report O O
describes O O
a O O
case O O
of O O
encephalopathy B-Disease B-Disease
developed O O
in O O
the O O
course O O
of O O
amitriptyline O O
therapy O O
, O O
during O O
a O O
remission O O
of O O
unipolar B-Disease B-Disease
depression I-Disease I-Disease
. O O

This O O
patient O O
could O O
have O O
been O O
diagnosed O O
as O O
having O O
either O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
NMS B-Disease B-Disease
) O O
or O O
serotonin B-Disease B-Disease
syndrome I-Disease I-Disease
( O O
SS B-Disease B-Disease
) O O
. O O

The O O
major O O
determinant O O
of O O
the O O
symptoms O O
may O O
have O O
been O O
dopamine O O
/ O O
serotonin O O
imbalance O O
in O O
the O O
central O O
nervous O O
system O O
. O O

The O O
NMS B-Disease B-Disease
- O O
like O O
encephalopathy B-Disease B-Disease
that O O
develops O O
in O O
association O O
with O O
the O O
use O O
of O O
antidepressants O O
indicates O O
that O O
NMS B-Disease B-Disease
and O O
SS B-Disease B-Disease
are O O
spectrum O O
disorders O O
induced O O
by O O
drugs O O
with O O
both O O
antidopaminergic O O
and O O
serotonergic O O
effects O O
. O O

Genetic O O
separation O O
of O O
tumor B-Disease B-Disease
growth O O
and O O
hemorrhagic B-Disease B-Disease
phenotypes O O
in O O
an O O
estrogen O O
- O O
induced O O
tumor B-Disease B-Disease
. O O

Chronic O O
administration O O
of O O
estrogen O O
to O O
the O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rat O O
induces O O
growth O O
of O O
large O O
, O O
hemorrhagic B-Disease B-Disease
pituitary B-Disease B-Disease
tumors I-Disease I-Disease
. O O

Ten O O
weeks O O
of O O
diethylstilbestrol O O
( O O
DES O O
) O O
treatment O O
caused O O
female O O
F344 O O
rat O O
pituitaries O O
to O O
grow O O
to O O
an O O
average O O
of O O
109.2 O O
+ O O
/- O O

6.3 O O
mg O O
( O O
mean O O
+ O O
/- O O
SE O O
) O O
versus O O
11.3 O O
+ O O
/- O O

1.4 O O
mg O O
for O O
untreated O O
rats O O
, O O
and O O
to O O
become O O
highly O O
hemorrhagic B-Disease B-Disease
. O O

The O O
same O O
DES O O
treatment O O
produced O O
no O O
significant O O
growth O O
( O O
8.9 O O
+ O O
/- O O

0.5 O O
mg O O
for O O
treated O O
females O O
versus O O
8.7 O O
+ O O
/- O O

1.1 O O
for O O
untreated O O
females O O
) O O
or O O
morphological O O
changes O O
in O O
Brown O O
Norway O O
( O O
BN O O
) O O
rat O O
pituitaries O O
. O O

An O O
F1 O O
hybrid O O
of O O
F344 O O
and O O
BN O O
exhibited O O
significant O O
pituitary O O
growth O O
after O O
10 O O
weeks O O
of O O
DES O O
treatment O O
with O O
an O O
average O O
mass O O
of O O
26.3 O O
+ O O
/- O O

0.7 O O
mg O O
compared O O
with O O
8.6 O O
+ O O
/- O O

0.9 O O
mg O O
for O O
untreated O O
rats O O
. O O

Surprisingly O O
, O O
the O O
F1 O O
hybrid O O
tumors B-Disease B-Disease
were O O
not O O
hemorrhagic B-Disease B-Disease
and O O
had O O
hemoglobin O O
content O O
and O O
outward O O
appearance O O
identical O O
to O O
that O O
of O O
BN O O
. O O

Expression O O
of O O
both O O
growth O O
and O O
morphological O O
changes O O
is O O
due O O
to O O
multiple O O
genes O O
. O O

However O O
, O O
while O O
DES O O
- O O
induced O O
pituitary O O
growth O O
exhibited O O
quantitative O O
, O O
additive O O
inheritance O O
, O O
the O O
hemorrhagic B-Disease B-Disease
phenotype O O
exhibited O O
recessive O O
, O O
epistatic O O
inheritance O O
. O O

Only O O
5 O O
of O O
the O O
160 O O
F2 O O
pituitaries O O
exhibited O O
the O O
hemorrhagic B-Disease B-Disease
phenotype O O
; O O
36 O O
of O O
the O O
160 O O
F2 O O
pituitaries O O
were O O
in O O
the O O
F344 O O
range O O
of O O
mass O O
, O O
but O O
31 O O
of O O
these O O
were O O
not O O
hemorrhagic B-Disease B-Disease
, O O
indicating O O
that O O
the O O
hemorrhagic B-Disease B-Disease
phenotype O O
is O O
not O O
merely O O
a O O
consequence O O
of O O
extensive O O
growth O O
. O O

The O O
hemorrhagic B-Disease B-Disease
F2 O O
pituitaries O O
were O O
all O O
among O O
the O O
most O O
massive O O
, O O
indicating O O
that O O
some O O
of O O
the O O
genes O O
regulate O O
both O O
phenotypes O O
. O O

Increased O O
expression O O
of O O
neuronal O O
nitric O O
oxide O O
synthase O O
in O O
bladder O O
afferent O O
pathways O O
following O O
chronic O O
bladder B-Disease B-Disease
irritation I-Disease I-Disease
. O O

Immunocytochemical O O
techniques O O
were O O
used O O
to O O
examine O O
alterations O O
in O O
the O O
expression O O
of O O
neuronal O O
nitric O O
oxide O O
synthase O O
( O O
NOS O O
) O O
in O O
bladder O O
pathways O O
following O O
acute O O
and O O
chronic O O
irritation B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
urinary I-Disease I-Disease
tract I-Disease I-Disease
of O O
the O O
rat O O
. O O

Chemical O O
cystitis B-Disease B-Disease
was O O
induced O O
by O O
cyclophosphamide O O
( O O
CYP O O
) O O
which O O
is O O
metabolized O O
to O O
acrolein O O
, O O
an O O
irritant O O
eliminated O O
in O O
the O O
urine O O
. O O

Injection O O
of O O
CYP O O
( O O
n O O
= O O
10 O O
, O O
75 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
) O O
2 O O
hours O O
prior O O
to O O
perfusion O O
( O O
acute O O
treatment O O
) O O
of O O
the O O
animals O O
increased O O
Fos O O
- O O
immunoreactivity O O
( O O
IR O O
) O O
in O O
neurons O O
in O O
the O O
dorsal O O
commissure O O
, O O
dorsal O O
horn O O
, O O
and O O
autonomic O O
regions O O
of O O
spinal O O
segments O O
( O O
L1-L2 O O
and O O
L6-S1 O O
) O O
which O O
receive O O
afferent O O
inputs O O
from O O
the O O
bladder O O
, O O
urethra O O
, O O
and O O
ureter O O
. O O

Fos O O
- O O
IR O O
in O O
the O O
spinal O O
cord O O
was O O
not O O
changed O O
in O O
rats O O
receiving O O
chronic O O
CYP O O
treatment O O
( O O
n O O
= O O
15 O O
, O O
75 O O
mg O O
/ O O
kg O O
, O O
i.p O O
. O O
, O O
every O O
3rd O O
day O O
for O O
2 O O
weeks O O
) O O
. O O

In O O
control O O
animals O O
and O O
in O O
animals O O
treated O O
acutely O O
with O O
CYP O O
, O O
only O O
small O O
numbers O O
of O O
NOS O O
- O O
IR O O
cells O O
( O O
0.5 O O
- O O
0.7 O O
cell O O
profiles O O
/ O O
sections O O
) O O
were O O
detected O O
in O O
the O O
L6-S1 O O
dorsal O O
root O O
ganglia O O
( O O
DRG O O
) O O
. O O

Chronic O O
CYP O O
administration O O
significantly O O
( O O
P O O
< O O
or O O
= O O
.002 O O
) O O
increased O O
bladder O O
weight O O
by O O
60 O O
% O O
and O O
increased O O
( O O
7- O O
to O O
11-fold O O
) O O
the O O
numbers O O
of O O
NOS O O
- O O
immunoreactive O O
( O O
IR O O
) O O
afferent O O
neurons O O
in O O
the O O
L6-S1 O O
DRG O O
. O O

A O O
small O O
increase O O
( O O
1.5-fold O O
) O O
also O O
occurred O O
in O O
the O O
L1 O O
DRG O O
, O O
but O O
no O O
change O O
was O O
detected O O
in O O
the O O
L2 O O
and O O
L5 O O
DRG O O
. O O

Bladder O O
afferent O O
cells O O
in O O
the O O
L6-S1 O O
DRG O O
labeled O O
by O O
Fluorogold O O
( O O
40 O O
microliters O O
) O O
injected O O
into O O
the O O
bladder O O
wall O O
did O O
not O O
exhibit O O
NOS O O
- O O
IR O O
in O O
control O O
animals O O
; O O
however O O
, O O
following O O
chronic O O
CYP O O
administration O O
, O O
a O O
significant O O
percentage O O
of O O
bladder O O
afferent O O
neurons O O
were O O
NOS O O
- O O
IR O O
: O O
L6 O O
( O O
19.8 O O
+ O O
/- O O

4.6 O O
% O O
) O O
and O O
S1 O O
( O O
25.3 O O
+ O O
/- O O

2.9 O O
% O O
) O O
. O O

These O O
results O O
indicate O O
that O O
neuronal O O
gene O O
expression O O
in O O
visceral O O
sensory O O
pathways O O
can O O
be O O
upregulated O O
by O O
chemical O O
irritation O O
of O O
afferent O O
receptors O O
in O O
the O O
urinary O O
tract O O
and/or O O
that O O
pathological O O
changes O O
in O O
the O O
urinary O O
tract O O
can O O
initiate O O
chemical O O
signals O O
that O O
alter O O
the O O
chemical O O
properties O O
of O O
visceral O O
afferent O O
neurons O O
. O O

Effects O O
of O O
a O O
new O O
calcium O O
antagonist O O
, O O
CD-832 O O
, O O
on O O
isoproterenol O O
- O O
induced O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
in O O
dogs O O
with O O
partial O O
coronary B-Disease B-Disease
stenosis I-Disease I-Disease
. O O

Effects O O
of O O
CD-832 O O
on O O
isoproterenol O O
( O O
ISO O O
) O O
-induced O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
were O O
studied O O
in O O
dogs O O
with O O
partial O O
coronary B-Disease B-Disease
stenosis I-Disease I-Disease
of O O
the O O
left O O
circumflex O O
coronary O O
artery O O
and O O
findings O O
were O O
compared O O
with O O
those O O
for O O
nifedipine O O
or O O
diltiazem O O
. O O

In O O
the O O
presence O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
stenosis I-Disease I-Disease
, O O
3-min O O
periods O O
of O O
intracoronary O O
ISO O O
infusion O O
( O O
10 O O
ng O O
/ O O
kg O O
/ O O
min O O
) O O
increased O O
heart O O
rate O O
and O O
maximal O O
rate O O
of O O
left O O
ventricular O O
pressure O O
rise O O
, O O
which O O
resulted O O
in O O
a O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
and O O
ST O O
- O O
segment O O
elevation O O
of O O
the O O
epicardial O O
electrocardiogram O O
. O O

After O O
the O O
control O O
ISO O O
infusion O O
with O O
stenosis B-Disease B-Disease
was O O
performed O O
, O O
equihypotensive O O
doses O O
of O O
CD-832 O O
( O O
3 O O
and O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
, O O
nifedipine O O
( O O
1 O O
and O O
3 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
9 O O
) O O
or O O
diltiazem O O
( O O
10 O O
and O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
were O O
infused O O
5 O O
min O O
before O O
and O O
during O O
the O O
second O O
and O O
third O O
ISO O O
infusion O O
. O O

Both O O
CD-832 O O
and O O
diltiazem O O
, O O
but O O
not O O
nifedipine O O
, O O
significantly O O
reduced O O
the O O
increase O O
in O O
heart O O
rate O O
induced O O
by O O
ISO O O
infusion O O
. O O

In O O
contrast O O
to O O
nifedipine O O
, O O
CD-832 O O
( O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
32 O O
+ O O
/- O O

12 O O
% O O
to O O
115 O O
+ O O
/- O O

26 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
.01 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
5.6 O O
+ O O
/- O O

1.0 O O
mV O O
to O O
1.6 O O
+ O O
/- O O

1.3 O O
mV O O
( O O
P O O
< O O
.01 O O
) O O
at O O
3 O O
min O O
after O O
ISO O O
infusion O O
with O O
stenosis B-Disease B-Disease
. O O

Diltiazem O O
( O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
also O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
34 O O
+ O O
/- O O

14 O O
% O O
to O O
63 O O
+ O O
/- O O

18 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
.05 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
4.7 O O
+ O O
/- O O

0.7 O O
mV O O
to O O
2.1 O O
+ O O
/- O O

0.7 O O
mV O O
( O O
P O O
< O O
.01 O O
) O O
at O O
3 O O
min O O
after O O
ISO O O
infusion O O
with O O
stenosis B-Disease B-Disease
. O O

These O O
data O O
show O O
that O O
CD-832 O O
improves O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
during O O
ISO O O
infusion O O
with O O
stenosis B-Disease B-Disease
and O O
suggest O O
that O O
the O O
negative O O
chronotropic O O
property O O
of O O
CD-832 O O
plays O O
a O O
major O O
role O O
in O O
the O O
beneficial O O
effects O O
of O O
CD-832 O O
. O O

The O O
effect O O
of O O
recombinant O O
human O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
I O O
on O O
chronic O O
puromycin O O
aminonucleoside O O
nephropathy B-Disease B-Disease
in O O
rats O O
. O O

We O O
recently O O
demonstrated O O
that O O
recombinant O O
hGH O O
exacerbates O O
renal O B-Disease
functional O I-Disease
and O I-Disease
structural O I-Disease
injury O I-Disease
in O O
chronic O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
nephropathy B-Disease B-Disease
, O O
an O O
experimental O O
model O O
of O O
glomerular B-Disease B-Disease
disease I-Disease I-Disease
. O O

Therefore O O
, O O
we O O
examined O O
whether O O
recombinant O O
human O O
( O O
rh O O
) O O
IGF O O
- O O
I O O
is O O
a O O
safer O O
alternative O O
for O O
the O O
treatment O O
of O O
growth B-Disease B-Disease
failure I-Disease I-Disease
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B-Disease B-Disease
. O O

The O O
glomerulopathy B-Disease B-Disease
was O O
induced O O
by O O
seven O O
serial O O
injections O O
of O O
PAN O O
over O O
12 O O
wk O O
. O O

Experimental O O
animals O O
( O O
n O O
= O O
6 O O
) O O
received O O
rhIGF O O
- O O
I O O
, O O
400 O O
micrograms O O
/ O O
d O O
, O O
whereas O O
control O O
rats O O
( O O
n O O
= O O
6 O O
) O O
received O O
the O O
vehicle O O
. O O

rhIGF O O
- O O
I O O
improved O O
weight O O
gain O O
by O O
14 O O
% O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
without O O
altering O O
hematocrit O O
or O O
blood O O
pressure O O
in O O
rats O O
with O O
renal B-Disease B-Disease
disease I-Disease I-Disease
. O O

Urinary O O
protein O O
excretion O O
was O O
unaltered O O
by O O
rhIGF O O
- O O
I O O
treatment O O
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B-Disease B-Disease
. O O

After O O
12 O O
wk O O
, O O
the O O
inulin O O
clearance O O
was O O
higher O O
in O O
rhIGF O O
- O O
I O O
- O O
treated O O
rats O O
, O O
0.48 O O
+ O O
/- O O

0.08 O O
versus O O
0.24 O O
+ O O
/- O O

0.06 O O
mL O O
/ O O
min O O
/ O O
100 O O
g O O
of O O
body O O
weight O O
in O O
untreated O O
PAN O O
nephropathy B-Disease B-Disease
animals O O
, O O
p O O
< O O
0.05 O O
. O O

The O O
improvement O O
in O O
GFR O O
was O O
not O O
associated O O
with O O
enhanced O O
glomerular B-Disease B-Disease
hypertrophy I-Disease I-Disease
or O O
increased O O
segmental O O
glomerulosclerosis B-Disease B-Disease
, O O
tubulointerstitial B-Disease B-Disease
injury I-Disease I-Disease
, O O
or O O
renal O O
cortical O O
malondialdehyde O O
content O O
. O O

In O O
rats O O
with O O
PAN O O
nephropathy B-Disease B-Disease
, O O
administration O O
of O O
rhIGF O O
- O O
I O O
increased O O
IGF O O
- O O
I O O
and O O
GH O O
receptor O O
gene O O
expression O O
, O O
without O O
altering O O
the O O
steady O O
state O O
level O O
of O O
IGF O O
- O O
I O O
receptor O O
mRNA O O
. O O

In O O
normal O O
rats O O
with O O
intact O O
kidneys O O
, O O
rhIGF O O
- O O
I O O
administration O O
( O O
n O O
= O O
4 O O
) O O
did O O
not O O
alter O O
weight O O
gain O O
, O O
blood O O
pressure O O
, O O
proteinuria B-Disease B-Disease
, O O
GFR O O
, O O
glomerular O O
planar O O
area O O
, O O
renal O O
cortical O O
malondialdehyde O O
content O O
, O O
or O O
glomerular O O
or O O
tubulointerstitial B-Disease O
damage I-Disease O
, O O
compared O O
with O O
untreated O O
animals O O
( O O
n O O
= O O
4 O O
) O O
. O O

rhIGF O O
- O O
I O O
treatment O O
reduced O O
the O O
steady O O
state O O
renal O O
IGF O O
- O O
I O O
mRNA O O
level O O
but O O
did O O
not O O
modify O O
gene O O
expression O O
of O O
the O O
IGF O O
- O O
I O O
or O O
GH O O
receptors O O
. O O

We O O
conclude O O
that O O
: O O
1 O O
) O O
administration O O
of O O
rhIGF O O
- O O
I O O
improves O O
growth O O
and O O
GFR O O
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B-Disease B-Disease
and O O
2 O O
) O O
unlike O O
rhGH O O
, O O
long O O
- O O
term O O
use O O
of O O
rhIGF O O
- O O
I O O
does O O
not O O
worsen O O
renal O B-Disease
functional O I-Disease
and O I-Disease
structural O I-Disease
injury O I-Disease
in O O
this O O
disease O O
model O O
. O O

Nefiracetam O O
( O O
DM-9384 O O
) O O
reverses O O
apomorphine O O
- O O
induced O O
amnesia B-Disease B-Disease
of O O
a O O
passive O O
avoidance O O
response O O
: O O
delayed O O
emergence O O
of O O
the O O
memory O O
retention O O
effects O O
. O O

Nefiracetam O O
is O O
a O O
novel O O
pyrrolidone O O
derivative O O
which O O
attenuates O O
scopolamine O O
- O O
induced O O
learning B-Disease B-Disease
and I-Disease I-Disease
post I-Disease I-Disease
- I-Disease I-Disease
training I-Disease I-Disease
consolidation I-Disease I-Disease
deficits I-Disease I-Disease
. O O

Given O O
that O O
apomorphine O O
inhibits O O
passive O O
avoidance O O
retention O O
when O O
given O O
during O O
training O O
or O O
in O O
a O O
defined O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
, O O
we O O
evaluated O O
the O O
ability O O
of O O
nefiracetam O O
to O O
attenuate O O
amnesia B-Disease B-Disease
induced O O
by O O
dopaminergic O O
agonism O O
. O O

A O O
step O O
- O O
down O O
passive O O
avoidance O O
paradigm O O
was O O
employed O O
and O O
nefiracetam O O
( O O
3 O O
mg O O
/ O O
kg O O
) O O
and O O
apomorphine O O
( O O
0.5 O O
mg O O
/ O O
kg O O
) O O
were O O
given O O
alone O O
or O O
in O O
combination O O
during O O
training O O
and O O
at O O
the O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
of O O
consolidation O O
. O O

Co O O
- O O
administration O O
of O O
nefiracetam O O
and O O
apomorphine O O
during O O
training O O
or O O
10h O O
thereafter O O
produced O O
no O O
significant O O
anti O O
- O O
amnesic O O
effect O O
. O O

However O O
, O O
administration O O
of O O
nefiracetam O O
during O O
training O O
completely O O
reversed O O
the O O
amnesia B-Disease B-Disease
induced O O
by O O
apomorphine O O
at O O
the O O
10h O O
post O O
- O O
training O O
time O O
and O O
the O O
converse O O
was O O
also O O
true O O
. O O

These O O
effects O O
were O O
not O O
mediated O O
by O O
a O O
dopaminergic O O
mechanism O O
as O O
nefiracetam O O
, O O
at O O
millimolar O O
concentrations O O
, O O
failed O O
to O O
displace O O
either O O
[ O O
3H O O
] O O
SCH O O
23390 O O
or O O
[ O O
3H O O
] O O
spiperone O O
binding O O
from O O
D1 O O
or O O
D2 O O
dopamine O O
receptor O O
subtypes O O
, O O
respectively O O
. O O

It O O
is O O
suggested O O
that O O
nefiracetam O O
augments O O
molecular O O
processes O O
in O O
the O O
early O O
stages O O
of O O
events O O
which O O
ultimately O O
lead O O
to O O
consolidation O O
of O O
memory O O
. O O

Phenytoin O O
encephalopathy B-Disease B-Disease
as O O
probable O O
idiosyncratic O O
reaction O O
: O O
case O O
report O O
. O O

A O O
case O O
of O O
phenytoin O O
( O O
DPH O O
) O O
encephalopathy B-Disease B-Disease
with O O
increasing O O
seizures B-Disease B-Disease
and O O
EEG O O
and O O
mental O O
changes O O
is O O
described O O
. O O

Despite O O
adequate O O
oral O O
dosage O O
of O O
DPH O O
( O O
5 O O
mg O O
/ O O
kg O O
/ O O
daily O O
) O O
the O O
plasma O O
level O O
was O O
very O O
low O O
( O O
2.8 O O
microgramg O O
/ O O
ml O O
) O O
. O O

The O O
encephalopathy B-Disease B-Disease
was O O
probably O O
an O O
idiosyncratic O O
and O O
not O O
toxic O O
or O O
allergic O O
reaction O O
. O O

In O O
fact O O
the O O
concentration O O
of O O
free O O
DPH O O
was O O
normal O O
, O O
the O O
patient O O
presented O O
a O O
retarded O O
morbilliform O O
rash B-Disease B-Disease
during O O
DPH O O
treatment O O
, O O
the O O
protidogram O O
was O O
normal O O
, O O
and O O
an O O
intradermic O O
DPH O O
injection O O
had O O
no O O
local O O
effect O O
. O O

The O O
authors O O
conclude O O
that O O
in O O
a O O
patient O O
starting O O
DPH O O
treatment O O
an O O
unexpected O O
increase O O
in O O
seizures B-Disease B-Disease
, O O
with O O
EEG O O
and O O
mental O O
changes O O
occurring O O
simultaneously O O
, O O
should O O
alert O O
the O O
physician O O
to O O
the O O
possible O O
need O O
for O O
eliminating O O
DPH O O
from O O
the O O
therapeutic O O
regimen O O
, O O
even O O
if O O
plasma O O
concentrations O O
are O O
low O O
. O O

Prevention O O
and O O
treatment O O
of O O
endometrial B-Disease B-Disease
disease I-Disease I-Disease
in O O
climacteric O O
women O O
receiving O O
oestrogen O O
therapy O O
. O O

The O O
treatment O O
regimens O O
are O O
described O O
in O O
74 O O
patients O O
with O O
endometrial B-Disease B-Disease
disease I-Disease I-Disease
among O O
850 O O
climacteric O O
women O O
receiving O O
oestrogen O O
therapy O O
. O O

Cystic O B-Disease
hyperplasia B-Disease I-Disease
was O O
associated O O
with O O
unopposed O O
oestrogen O O
therapy O O
without O O
progestagen O O
. O O

Two O O
courses O O
of O O
21 O O
days O O
of O O
5 O O
mg O O
norethisterone O O
daily O O
caused O O
reversion O O
to O O
normal O O
in O O
all O O
57 O O
cases O O
of O O
cystic O B-Disease
hyperplasia B-Disease I-Disease
and O O
6 O O
of O O
the O O
8 O O
cases O O
of O O
atypical O O
hyperplasia B-Disease B-Disease
. O O

4 O O
cases O O
of O O
endometrial B-Disease B-Disease
carcinoma I-Disease I-Disease
referred O O
from O O
elsewhere O O
demonstrated O O
the O O
problems O O
of O O
inappropriate O O
and O O
unsupervised O O
unopposed O O
oestrogen O O
therapy O O
and O O
the O O
difficulty O O
in O O
distinguishing O O
severe O O
hyperplasia B-Disease B-Disease
from O O
malignancy B-Disease B-Disease
. O O

Cyclical O O
low O O
- O O
dose O O
oestrogen O O
therapy O O
with O O
7 O O
- O O
-13 O O
days O O
of O O
progestagen O O
does O O
not O O
seem O O
to O O
increase O O
the O O
risk O O
of O O
endometrial B-Disease B-Disease
hyperplasia I-Disease I-Disease
or O O
carcinoma B-Disease B-Disease
. O O

Effects O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol O O
- O O
induced O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
. O O

The O O
effect O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol O O
- O O
induced O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
was O O
studied O O
in O O
male O O
rats O O
. O O

Ninety O O
- O O
three O O
rats O O
were O O
randomly O O
divided O O
into O O
three O O
groups O O
. O O

The O O
exercise O O
- O O
isoproterenol O O
( O O
E-1 O O
) O O
and O O
exercise O O
control O O
( O O
EC O O
) O O
groups O O
exercised O O
daily O O
for O O
thirty O O
days O O
on O O
a O O
treadmill O O
at O O
1 O O
mph O O
, O O
2 O O
% O O
grade O O
while O O
animals O O
of O O
the O O
sedentary O O
- O O
isoproterenol O O
( O O
S O O
- O O
I O O
) O O
group O O
remained O O
sedentary O O
. O O

Eight O O
animals O O
were O O
assigned O O
to O O
the O O
sedentary O O
control O O
( O O
SC O O
) O O
group O O
which O O
remained O O
sedentary O O
throughout O O
the O O
experimental O O
period O O
. O O

Forty O O
- O O
eight O O
hours O O
after O O
the O O
final O O
exercise O O
period O O
, O O
S O O
- O O
I O O
and O O
E O O
- O O
I O O
animals O O
received O O
a O O
single O O
subcutaneous O O
injection O O
of O O
isoproterenol O O
( O O
250 O O
mg O O
/ O O
kg O O
body O O
weight O O
) O O
. O O

Animals O O
of O O
the O O
S O O
- O O
I O O
group O O
exhibited O O
significantly O O
( O O
Pp O O
less O O
than O O
0.05 O O
) O O
greater O O
mortality O O
from O O
the O O
effects O O
of O O
isoproterenol O O
than O O
animals O O
of O O
the O O
E O O
- O O
I O O
group O O
. O O

Serum O O
CPK O O
activity O O
for O O
E O O
- O O
I O O
animals O O
was O O
significantly O O
( O O
p O O
less O O
than O O
0.05 O O
) O O
greater O O
than O O
for O O
animals O O
in O O
the O O
S O O
- O O
I O O
and O O
EC O O
groups O O
twenty O O
hours O O
following O O
isoproterenol O O
injection O O
. O O

No O O
statistically O O
significant O O
differences O O
were O O
observed O O
between O O
the O O
two O O
isoproterenol O O
treated O O
groups O O
for O O
severity O O
of O O
the O O
induced O O
lesions O O
, O O
changes O O
in O O
heart O O
weight O O
, O O
or O O
heart O O
weight O O
to O O
body O O
weight O O
ratios O O
. O O

The O O
results O O
indicated O O
that O O
exercise O O
reduced O O
the O O
mortality O O
associated O O
with O O
the O O
effects O O
of O O
large O O
dosages O O
of O O
isoproterenol O O
but O O
had O O
little O O
on O O
the O O
severity O O
of O O
the O O
infarction B-Disease B-Disease
. O O

Human O O
corticotropin O O
- O O
releasing O O
hormone O O
and O O
thyrotropin O O
- O O
releasing O O
hormone O O
modulate O O
the O O
hypercapnic B-Disease B-Disease
ventilatory O O
response O O
in O O
humans O O
. O O

Human O O
corticotropin O O
- O O
releasing O O
hormone O O
( O O
hCRH O O
) O O
and O O
thyrotropin O O
- O O
releasing O O
hormone O O
( O O
TRH O O
) O O
are O O
known O O
to O O
stimulate O O
ventilation O O
after O O
i.v O O
. O O

administration O O
in O O
humans O O
. O O

In O O
a O O
placebo O O
- O O
controlled O O
, O O
single O O
- O O
blind O O
study O O
we O O
aimed O O
to O O
clarify O O
if O O
both O O
peptides O O
act O O
by O O
altering O O
central O O
chemosensitivity O O
. O O

Two O O
subsequent O O
CO2-rebreathing O O
tests O O
were O O
performed O O
in O O
healthy O O
young O O
volunteers O O
. O O

During O O
the O O
first O O
test O O
0.9 O O
% O O
NaCl O O
was O O
given O O
i.v O O
. O O
; O O
during O O
the O O
second O O
test O O
200 O O
micrograms O O
of O O
hCRH O O
( O O
n O O
= O O
12 O O
) O O
or O O
400 O O
micrograms O O
of O O
TRH O O
( O O
n O O
= O O
6 O O
) O O
was O O
administered O O
i.v O O
. O O

Nine O O
subjects O O
received O O
0.9 O O
% O O
NaCl O O
i.v O O
. O O

during O O
both O O
rebreathing O O
manoeuvres O O
. O O

The O O
CO2-response O O
curves O O
for O O
the O O
two O O
tests O O
were O O
compared O O
within O O
the O O
same O O
subject O O
. O O

In O O
the O O
hCRH O O
group O O
a O O
marked O O
parallel O O
shift O O
of O O
the O O
CO2-response O O
curve O O
to O O
the O O
left O O
was O O
observed O O
after O O
hCRH O O
( O O
P O O
< O O
0.01 O O
) O O
. O O

The O O
same O O
effect O O
occurred O O
following O O
TRH O O
but O O
was O O
less O O
striking O O
( O O
P O O
= O O
0.05 O O
) O O
. O O

hCRH O O
and O O
TRH O O
caused O O
a O O
reduction O O
in O O
the O O
CO2 O O
threshold O O
. O O

The O O
CO2-response O O
curves O O
in O O
the O O
control O O
group O O
were O O
nearly O O
identical O O
. O O

The O O
results O O
indicate O O
an O O
additive O O
effect O O
of O O
both O O
releasing O O
hormones O O
on O O
the O O
hypercapnic B-Disease B-Disease
ventilatory O O
response O O
in O O
humans O O
, O O
presumably O O
independent O O
of O O
central O O
chemosensitivity O O
. O O

Lamivudine O O
is O O
effective O O
in O O
suppressing O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
virus O O
DNA O O
in O O
Chinese O O
hepatitis O O
B O O
surface O O
antigen O O
carriers O O
: O O
a O O
placebo O O
- O O
controlled O O
trial O O
. O O

Lamivudine O O
is O O
a O O
novel O O
2',3'-dideoxy O O
cytosine O O
analogue O O
that O O
has O O
potent O O
inhibitory O O
effects O O
on O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
virus O O
replication O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
performed O O
a O O
single O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
to O O
assess O O
its O O
effectiveness O O
and O O
safety O O
in O O
Chinese O O
hepatitis O O
B O O
surface O O
antigen O O
( O O
HBsAg O O
) O O
carriers O O
. O O

Forty O O
- O O
two O O
Chinese O O
HBsAg O O
carriers O O
were O O
randomized O O
to O O
receive O O
placebo O O
( O O
6 O O
patients O O
) O O
or O O
lamivudine O O
orally O O
in O O
dosages O O
of O O
25 O O
mg O O
, O O
100 O O
mg O O
, O O
or O O
300 O O
mg O O
daily O O
( O O
12 O O
patients O O
for O O
each O O
dosage O O
) O O
. O O

The O O
drug O O
was O O
given O O
for O O
4 O O
weeks O O
. O O

The O O
patients O O
were O O
closely O O
monitored O O
clinically O O
, O O
biochemically O O
, O O
and O O
serologically O O
up O O
to O O
4 O O
weeks O O
after O O
drug O O
treatment O O
. O O

All O O
36 O O
patients O O
receiving O O
lamivudine O O
had O O
a O O
decrease O O
in O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
virus O O
( O O
HBV O O
) O O
DNA O O
values O O
of O O
> O O
90 O O
% O O
( O O
P O O
< O O
.001 O O
compared O O
with O O
placebo O O
) O O
. O O

Although O O
25 O O
mg O O
of O O
lamivudine O O
was O O
slightly O O
less O O
effective O O
than O O
100 O O
mg O O
( O O
P O O
= O O
.011 O O
) O O
and O O
300 O O
mg O O
( O O
P O O
= O O
.005 O O
) O O
, O O
it O O
still O O
induced O O
94 O O
% O O
suppression O O
of O O
HBV O O
DNA O O
after O O
the O O
fourth O O
week O O
of O O
therapy O O
. O O

HBV O O
DNA O O
values O O
returned O O
to O O
pretreatment O O
levels O O
within O O
4 O O
weeks O O
of O O
cessation O O
of O O
therapy O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
hepatitis B-Disease B-Disease
B I-Disease I-Disease
e O O
antigen O O
status O O
or O O
in O O
aminotransferase O O
levels O O
. O O

No O O
serious O O
adverse O O
events O O
were O O
observed O O
. O O

In O O
conclusion O O
, O O
a O O
4-week O O
course O O
of O O
lamivudine O O
was O O
safe O O
and O O
effective O O
in O O
suppression O O
of O O
HBV O O
DNA O O
in O O
Chinese O O
HBsAg O O
carriers O O
. O O

The O O
suppression O O
was O O
> O O
90 O O
% O O
but O O
reversible O O
. O O

Studies O O
with O O
long O O
- O O
term O O
lamivudine O O
administration O O
should O O
be O O
performed O O
to O O
determine O O
if O O
prolonged O O
suppression O O
of O O
HBV O O
DNA O O
can O O
be O O
achieved O O
. O O

Population O O
- O O
based O O
study O O
of O O
risk O O
of O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
associated O O
with O O
various O O
oral O O
contraceptives O O
. O O

BACKGROUND O O
: O O
Four O O
studies O O
published O O
since O O
December O O
, O O
1995 O O
, O O
reported O O
that O O
the O O
incidence O O
of O O
venous B-Disease B-Disease
thromboembolism I-Disease I-Disease
( O O
VTE B-Disease B-Disease
) O O
was O O
higher O O
in O O
women O O
who O O
used O O
oral O O
contraceptives O O
( O O
OCs O O
) O O
containing O O
the O O
third O O
- O O
generation O O
progestagens O O
gestodene O O
or O O
desogestrel O O
than O O
in O O
users O O
of O O
OCs O O
containing O O
second O O
- O O
generation O O
progestagens O O
. O O

However O O
, O O
confounding O O
and O O
bias O O
in O O
the O O
design O O
of O O
these O O
studies O O
may O O
have O O
affected O O
the O O
findings O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
re O O
- O O
examine O O
the O O
association O O
between O O
risk O O
of O O
VTE B-Disease B-Disease
and O O
OC O O
use O O
with O O
a O O
different O O
study O O
design O O
and O O
analysis O O
to O O
avoid O O
some O O
of O O
the O O
bias O O
and O O
confounding O O
of O O
the O O
earlier O O
studies O O
. O O

METHODS O O
: O O
We O O
used O O
computer O O
records O O
of O O
patients O O
from O O
143 O O
general O O
practices O O
in O O
the O O
UK O O
. O O

The O O
study O O
was O O
based O O
on O O
the O O
medical O O
records O O
of O O
about O O
540,000 O O
women O O
born O O
between O O
1941 O O
and O O
1981 O O
. O O

All O O
women O O
who O O
had O O
a O O
recorded O O
diagnosis O O
of O O
deep B-Disease B-Disease
- I-Disease I-Disease
vein I-Disease I-Disease
thrombosis I-Disease I-Disease
, O O
venous B-Disease B-Disease
thrombosis I-Disease I-Disease
not O O
otherwise O O
specified O O
, O O
or O O
pulmonary O B-Disease
embolus O I-Disease
during O O
the O O
study O O
period O O
, O O
and O O
who O O
had O O
been O O
treated O O
with O O
an O O
anticoagulant O O
were O O
identified O O
as O O
potential O O
cases O O
of O O
VTE B-Disease B-Disease
. O O

We O O
did O O
a O O
cohort O O
analysis O O
to O O
estimate O O
and O O
compare O O
incidence O O
of O O
VTE B-Disease B-Disease
in O O
users O O
of O O
the O O
main O O
OC O O
preparations O O
, O O
and O O
a O O
nested O O
case O O
- O O
control O O
study O O
to O O
calculate O O
the O O
odds O O
ratios O O
of O O
VTE B-Disease B-Disease
associated O O
with O O
use O O
of O O
different O O
types O O
of O O
OC O O
, O O
after O O
adjustment O O
for O O
potential O O
confounding O O
factors O O
. O O

In O O
the O O
case O O
- O O
control O O
study O O
, O O
we O O
matched O O
cases O O
to O O
controls O O
by O O
exact O O
year O O
of O O
birth O O
, O O
practice O O
, O O
and O O
current O O
use O O
of O O
OCs O O
. O O

We O O
used O O
a O O
multiple O O
logistic O O
regression O O
model O O
that O O
included O O
body O O
- O O
mass O O
index O O
, O O
number O O
of O O
cycles O O
, O O
change O O
in O O
type O O
of O O
OC O O
prescribed O O
within O O
3 O O
months O O
of O O
the O O
event O O
, O O
previous O O
pregnancy O O
, O O
and O O
concurrent O O
disease O O
. O O

FINDINGS O O
: O O
85 O O
women O O
met O O
the O O
inclusion O O
criteria O O
for O O
VTE B-Disease B-Disease
, O O
two O O
of O O
whom O O
were O O
users O O
of O O
progestagen O O
- O O
only O O
OCs O O
. O O

Of O O
the O O
83 O O
cases O O
of O O
VTE B-Disease B-Disease
associated O O
with O O
use O O
of O O
combined O O
OCs O O
, O O
43 O O
were O O
recorded O O
as O O
deep B-Disease B-Disease
- I-Disease I-Disease
vein I-Disease I-Disease
thrombosis I-Disease I-Disease
, O O
35 O O
as O O
pulmonary O B-Disease
thrombosis B-Disease I-Disease
, O O
and O O
five O O
as O O
venous B-Disease B-Disease
thrombosis I-Disease I-Disease
not O O
otherwise O O
specified O O
. O O

The O O
crude O O
rate O O
of O O
VTE B-Disease B-Disease
per O O
10,000 O O
woman O O
- O O
years O O
was O O
4.10 O O
in O O
current O O
users O O
of O O
any O O
OC O O
, O O
3.10 O O
in O O
users O O
of O O
second O O
- O O
generation O O
OCs O O
, O O
and O O
4.96 O O
in O O
users O O
of O O
third O O
- O O
generation O O
preparations O O
. O O

After O O
adjustment O O
for O O
age O O
, O O
the O O
rate O O
ratio O O
of O O
VTE B-Disease B-Disease
in O O
users O O
of O O
third O O
- O O
generation O O
relative O O
to O O
second O O
- O O
generation O O
OCs O O
was O O
1.68 O O
( O O
95 O O
% O O
CI O O
1.04 O O
- O O
2.75 O O
) O O
. O O

Logistic O O
regression O O
showed O O
no O O
significant O O
difference O O
in O O
the O O
risk O O
of O O
VTE B-Disease B-Disease
between O O
users O O
of O O
third O O
- O O
generation O O
and O O
second O O
- O O
generation O O
OCs O O
. O O

Among O O
users O O
of O O
third O O
- O O
generation O O
progestagens O O
, O O
the O O
risk O O
of O O
VTE B-Disease B-Disease
was O O
higher O O
in O O
users O O
of O O
desogestrel O O
with O O
20 O O
g O O
ethinyloestradiol O O
than O O
in O O
users O O
of O O
gestodene O O
or O O
desogestrel O O
with O O
30 O O
g O O
ethinyloestradiol O O
. O O

With O O
all O O
second O O
- O O
generation O O
OCs O O
as O O
the O O
reference O O
, O O
the O O
odds O O
ratios O O
for O O
VTE B-Disease B-Disease
were O O
3.49 O O
( O O
1.21 O O
- O O
10.12 O O
) O O
for O O
desogestrel O O
plus O O
20 O O
g O O
ethinyloestradiol O O
and O O
1.18 O O
( O O
0.66 O O
- O O
2.17 O O
) O O
for O O
the O O
other O O
third O O
- O O
generation O O
progestagens O O
. O O

INTERPRETATION O O
: O O
The O O
previously O O
reported O O
increase O O
in O O
odds O O
ratio O O
associated O O
with O O
third O O
- O O
generation O O
OCs O O
when O O
compared O O
with O O
second O O
- O O
generation O O
products O O
is O O
likely O O
to O O
have O O
been O O
the O O
result O O
of O O
residual O O
confounding O O
by O O
age O O
. O O

The O O
increased O O
odds O O
ratio O O
associated O O
with O O
products O O
containing O O
20 O O
micrograms O O
ethinyloestradiol O O
and O O
desogestrel O O
compared O O
with O O
the O O
30 O O
micrograms O O
product O O
is O O
biologically O O
implausible O O
, O O
and O O
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
preferential O O
prescribing O O
and O O
, O O
thus O O
, O O
confounding O O
. O O

MK-801 O O
augments O O
pilocarpine O O
- O O
induced O O
electrographic O O
seizure B-Disease B-Disease
but O O
protects O O
against O O
brain B-Disease B-Disease
damage I-Disease I-Disease
in O O
rats O O
. O O

1 O O
. O O

The O O
authors O O
examined O O
the O O
anticonvulsant O O
effects O O
of O O
MK-801 O O
on O O
the O O
pilocarpine O O
- O O
induced O O
seizure B-Disease B-Disease
model O O
. O O

Intraperitoneal O O
injection O O
of O O
pilocarpine O O
( O O
400 O O
mg O O
/ O O
kg O O
) O O
induced O O
tonic B-Disease B-Disease
and I-Disease I-Disease
clonic I-Disease I-Disease
seizure I-Disease I-Disease
. O O

Scopolamine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
and O O
pentobarbital O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
prevented O O
development O O
of O O
pilocarpine O O
- O O
induced O O
behavioral O O
seizure B-Disease B-Disease
but O O
MK-801 O O
( O O
0.5 O O
mg O O
/ O O
kg O O
) O O
did O O
not O O
. O O

2 O O
. O O

An O O
electrical O O
seizure B-Disease B-Disease
measured O O
with O O
hippocampal O O
EEG O O
appeared O O
in O O
the O O
pilocarpine O O
- O O
treated O O
group O O
. O O

Scopolamine O O
and O O
pentobarbital O O
blocked O O
the O O
pilocarpine O O
- O O
induced O O
electrographic O O
seizure B-Disease B-Disease
, O O
MK-801 O O
treatment O O
augmented O O
the O O
electrographic O O
seizure B-Disease B-Disease
induced O O
by O O
pilocarpine O O
. O O

3 O O
. O O

Brain B-Disease B-Disease
damage I-Disease I-Disease
was O O
assessed O O
by O O
examining O O
the O O
hippocampus O O
microscopically O O
. O O

Pilocarpine O O
produced O O
neuronal B-Disease O
death I-Disease O
in O O
the O O
hippocampus O O
, O O
which O O
showed O O
pyknotic O O
changes O O
. O O

Pentobarbital O O
, O O
scopolamine O O
and O O
MK-801 O O
protected O O
the O O
brain B-Disease B-Disease
damage I-Disease I-Disease
by O O
pilocarpine O O
, O O
though O O
in O O
the O O
MK-801-treated O O
group O O
, O O
the O O
pyramidal O O
cells O O
of O O
hippocampus O O
appeared O O
darker O O
than O O
normal O O
. O O

In O O
all O O
treatments O O
, O O
granule O O
cells O O
of O O
the O O
dentate O O
gyrus O O
were O O
not O O
affected O O
. O O

4 O O
. O O

These O O
results O O
indicate O O
that O O
status B-Disease B-Disease
epilepticus I-Disease I-Disease
induced O O
by O O
pilocarpine O O
is O O
initiated O O
by O O
cholinergic O O
overstimulation O O
and O O
propagated O O
by O O
glutamatergic O O
transmission O O
, O O
the O O
elevation O O
of O O
which O O
may O O
cause O O
brain B-Disease B-Disease
damage I-Disease I-Disease
through O O
an O O
excitatory O O
NMDA O O
receptor O O
- O O
mediated O O
mechanism O O
. O O

Paclitaxel O O
, O O
5-fluorouracil O O
, O O
and O O
folinic O O
acid O O
in O O
metastatic O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
: O O
BRE-26 O O
, O O
a O O
phase O O
II O O
trial O O
. O O

5-Fluorouracil O O
plus O O
folinic O O
acid O O
and O O
paclitaxel O O
( O O
Taxol O O
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
are O O
effective O O
salvage O O
therapies O O
for O O
metastatic O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
. O O

Paclitaxel O O
and O O
5-fluorouracil O O
have O O
additive O O
cytotoxicity B-Disease B-Disease
in O O
MCF-7 O O
cell O O
lines O O
. O O

We O O
performed O O
a O O
phase O O
II O O
trial O O
of O O
paclitaxel O O
175 O O
mg O O
/ O O
m2 O O
over O O
3 O O
hours O O
on O O
day O O
I O O
followed O O
by O O
folinic O O
acid O O
300 O O
mg O O
over O O
1 O O
hour O O
before O O
5-fluorouracil O O
350 O O
mg O O
/ O O
m2 O O
on O O
days O O
1 O O
to O O
3 O O
every O O
28 O O
days O O
( O O
TFL O O
) O O
in O O
women O O
with O O
metastatic O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Analysis O O
is O O
reported O O
on O O
37 O O
patients O O
with O O
a O O
minimum O O
of O O
6 O O
months O O
follow O O
- O O
up O O
who O O
received O O
a O O
total O O
of O O
192 O O
cycles O O
of O O
TFL O O
: O O
nine O O
cycles O O
( O O
5 O O
% O O
) O O
were O O
associated O O
with O O
grade O O
3 O O
/ O O
4 O O
neutropenia B-Disease B-Disease
requiring O O
hospitalization O O
; O O
seven O O
( O O
4 O O
% O O
) O O
cycles O O
in O O
two O O
patients O O
required O O
granulocyte O O
colony O O
- O O
stimulating O O
factor O O
due O O
to O O
neutropenia B-Disease B-Disease
; O O
no O O
patient O O
required O O
platelet O O
transfusions O O
. O O

Grade O O
3 O O
/ O O
4 O O
nonhematologic O O
toxicities B-Disease B-Disease
were O O
uncommon O O
. O O

Among O O
the O O
34 O O
patients O O
evaluable O O
for O O
response O O
, O O
there O O
were O O
three O O
complete O O
responses O O
( O O
9 O O
% O O
) O O
and O O
18 O O
partial O O
responses O O
( O O
53 O O
% O O
) O O
for O O
an O O
overall O O
response O O
rate O O
of O O
62 O O
% O O
. O O

Of O O
the O O
19 O O
evaluable O O
patients O O
with O O
prior O O
doxorubicin O O
exposure O O
, O O
11 O O
( O O
58 O O
% O O
) O O
responded O O
compared O O
with O O
nine O O
of O O
15 O O
( O O
60 O O
% O O
) O O
without O O
prior O O
doxorubicin O O
. O O

Plasma O O
paclitaxel O O
concentrations O O
were O O
measured O O
at O O
the O O
completion O O
of O O
paclitaxel O O
infusion O O
and O O
at O O
24 O O
hours O O
in O O
19 O O
patients O O
. O O

TFL O O
is O O
an O O
active O O
, O O
well O O
- O O
tolerated O O
regimen O O
in O O
metastatic O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Efficacy O O
and O O
proarrhythmia B-Disease B-Disease
with O O
the O O
use O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
for O O
sustained O O
ventricular B-Disease B-Disease
tachyarrhythmias I-Disease I-Disease
. O O

This O O
study O O
prospectively O O
evaluated O O
the O O
clinical O O
efficacy O O
, O O
the O O
incidence O O
of O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
, O O
and O O
the O O
presumable O O
risk O O
factors O O
for O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
in O O
patients O O
treated O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
for O O
sustained O O
ventricular B-Disease B-Disease
tachyarrhythmias I-Disease I-Disease
. O O

Eighty O O
- O O
one O O
consecutive O O
patients O O
( O O
54 O O
with O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
, O O
and O O
20 O O
with O O
dilated B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
) O O
with O O
inducible O O
sustained O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
or O O
ventricular B-Disease B-Disease
fibrillation I-Disease I-Disease
received O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
to O O
prevent O O
induction O O
of O O
the O O
ventricular B-Disease B-Disease
tachyarrhythmia I-Disease I-Disease
. O O

During O O
oral O O
loading O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
, O O
continuous O O
electrocardiographic O O
( O O
ECG O O
) O O
monitoring O O
was O O
performed O O
. O O

Those O O
patients O O
in O O
whom O O
d O O
, O O
l O O
- O O
sotalol O O
prevented O O
induction O O
of O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
or O O
ventricular B-Disease B-Disease
fibrillation I-Disease I-Disease
were O O
discharged O O
with O O
the O O
drug O O
and O O
followed O O
up O O
on O O
an O O
outpatient O O
basis O O
for O O
21 O O
+ O O
/- O O

18 O O
months O O
. O O

Induction O O
of O O
the O O
ventricular B-Disease B-Disease
tachyarrhythmia I-Disease I-Disease
was O O
prevented O O
by O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
in O O
35 O O
( O O
43 O O
% O O
) O O
patients O O
; O O
the O O
ventricular B-Disease B-Disease
tachyarrhythmia I-Disease I-Disease
remained O O
inducible O O
in O O
40 O O
( O O
49 O O
% O O
) O O
patients O O
; O O
and O O
two O O
( O O
2.5 O O
% O O
) O O
patients O O
did O O
not O O
tolerate O O
even O O
40 O O
mg O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
once O O
daily O O
. O O

Four O O
( O O
5 O O
% O O
) O O
patients O O
had O O
from O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
during O O
the O O
initial O O
oral O O
treatment O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Neither O O
ECG O O
[ O O
sinus O O
- O O
cycle O O
length O O
( O O
SCL O O
) O O
, O O
QT O O
or O O
QTc O O
interval O O
, O O
or O O
U O O
wave O O
] O O
nor O O
clinical O O
parameters O O
identified O O
patients O O
at O O
risk O O
for O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
. O O

However O O
, O O
the O O
oral O O
dose O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
was O O
significantly O O
lower O O
in O O
patients O O
with O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
( O O
200 O O
+ O O
/- O O
46 O O
vs. O O
328 O O
+ O O
/- O O

53 O O
mg O O
/ O O
day O O
; O O
p O O
= O O
0.0017 O O
) O O
. O O

Risk O O
factors O O
associated O O
with O O
the O O
development O O
of O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
were O O
the O O
appearance O O
of O O
an O O
U O O
wave O O
( O O
p O O
= O O
0.049 O O
) O O
, O O
female O O
gender O O
( O O
p O O
= O O
0.015 O O
) O O
, O O
and O O
significant O O
dose O O
- O O
corrected O O
changes O O
of O O
SCL O O
, O O
QT O O
interval O O
, O O
and O O
QTc O O
interval O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

During O O
follow O O
- O O
up O O
, O O
seven O O
( O O
20 O O
% O O
) O O
patients O O
had O O
a O O
nonfatal O O
ventricular B-Disease B-Disease
tachycardia I-Disease I-Disease
recurrence O O
, O O
and O O
two O O
( O O
6 O O
% O O
) O O
patients O O
died O O
suddenly O O
. O O

One O O
female O O
patient O O
with O O
stable O O
cardiac B-Disease B-Disease
disease I-Disease I-Disease
had O O
recurrent O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
after O O
2 O O
years O O
of O O
successful O O
treatment O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
occurred O O
early O O
during O O
treatment O O
even O O
with O O
low O O
doses O O
of O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Pronounced O O
changes O O
in O O
the O O
surface O O
ECG O O
( O O
cycle O O
length O O
, O O
QT O O
, O O
and O O
QTc O O
) O O
in O O
relation O O
to O O
the O O
dose O O
of O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
might O O
identify O O
a O O
subgroup O O
of O O
patients O O
with O O
an O O
increased O O
risk O O
for O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
. O O

Other O O
ECG O O
parameters O O
before O O
the O O
application O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
did O O
not O O
identify O O
patients O O
at O O
increased O O
risk O O
for O O
torsades B-Disease B-Disease
de I-Disease I-Disease
pointes I-Disease I-Disease
. O O

Recurrence O O
rates O O
of O O
ventricular B-Disease B-Disease
tachyarrhythmias I-Disease I-Disease
are O O
high O O
despite O O
complete O O
suppression O O
of O O
the O O
arrhythmia B-Disease B-Disease
during O O
programmed O O
stimulation O O
. O O

Therefore O O
programmed O O
electrical O O
stimulation O O
in O O
the O O
case O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
seems O O
to O O
be O O
of O O
limited O O
prognostic O O
value O O
. O O

Chronic O O
hyperprolactinemia B-Disease B-Disease
and O O
changes O O
in O O
dopamine O O
neurons O O
. O O

The O O
tuberoinfundibular O O
dopaminergic O O
( O O
TIDA O O
) O O
system O O
is O O
known O O
to O O
inhibit O O
prolactin O O
( O O
PRL O O
) O O
secretion O O
. O O

In O O
young O O
animals O O
this O O
system O O
responds O O
to O O
acute O O
elevations O O
in O O
serum O O
PRL O O
by O O
increasing O O
its O O
activity O O
. O O

However O O
, O O
this O O
responsiveness O O
is O O
lost O O
in O O
aging O O
rats O O
with O O
chronically O O
high O O
serum O O
PRL O O
levels O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
induce O O
hyperprolactinemia B-Disease B-Disease
in O O
rats O O
for O O
extended O O
periods O O
of O O
time O O
and O O
examine O O
its O O
effects O O
on O O
dopaminergic O O
systems O O
in O O
the O O
brain O O
. O O

Hyperprolactinemia B-Disease B-Disease
was O O
induced O O
by O O
treatment O O
with O O
haloperidol O O
, O O
a O O
dopamine O O
receptor O O
antagonist O O
, O O
and O O
Palkovits O O
' O O
microdissection O O
technique O O
in O O
combination O O
with O O
high O O
- O O
performance O O
liquid O O
chromatography O O
was O O
used O O
to O O
measure O O
neurotransmitter O O
concentrations O O
in O O
several O O
areas O O
of O O
the O O
brain O O
. O O

After O O
6 O O
months O O
of O O
hyperprolactinemia B-Disease B-Disease
, O O
dopamine O O
( O O
DA O O
) O O
concentrations O O
in O O
the O O
median O O
eminence O O
( O O
ME O O
) O O
increased O O
by O O
84 O O
% O O
over O O
the O O
control O O
group O O
. O O

Nine O O
months O O
of O O
hyperprolactinemia B-Disease B-Disease
produced O O
a O O
50 O O
% O O
increase O O
in O O
DA O O
concentrations O O
in O O
the O O
ME O O
over O O
the O O
control O O
group O O
. O O

However O O
, O O
DA O O
response O O
was O O
lost O O
if O O
a O O
9-month O O
long O O
haloperidol O O
- O O
induced O O
hyperprolactinemia B-Disease B-Disease
was O O
followed O O
by O O
a O O
1 O O
1 O O
/ O O
2 O O
month O O
- O O
long O O
extremely O O
high O O
increase O O
in O O
serum O O
PRL O O
levels O O
produced O O
by O O
implantation O O
of O O
MMQ O O
cells O O
under O O
the O O
kidney O O
capsule O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
levels O O
of O O
DA O O
, O O
norepinephrine O O
( O O
NE O O
) O O
, O O
serotonin O O
( O O
5-HT O O
) O O
, O O
or O O
their O O
metabolites O O
in O O
the O O
arcuate O O
nucleus O O
( O O
AN O O
) O O
, O O
medial O O
preoptic O O
area O O
( O O
MPA O O
) O O
, O O
caudate O O
putamen O O
( O O
CP O O
) O O
, O O
substantia O O
nigra O O
( O O
SN O O
) O O
, O O
and O O
zona O O
incerta O O
( O O
ZI O O
) O O
, O O
except O O
for O O
a O O
decrease O O
in O O
5-hydroxyindoleacetic O O
acid O O
( O O
5-HIAA O O
) O O
in O O
the O O
AN O O
after O O
6-months O O
of O O
hyperprolactinemia B-Disease B-Disease
and O O
an O O
increase O O
in O O
DA O O
concentrations O O
in O O
the O O
AN O O
after O O
9-months O O
of O O
hyperprolactinemia B-Disease B-Disease
. O O

These O O
results O O
demonstrate O O
that O O
hyperprolactinemia B-Disease B-Disease
specifically O O
affects O O
TIDA O O
neurons O O
and O O
these O O
effects O O
vary O O
, O O
depending O O
on O O
the O O
duration O O
and O O
intensity O O
of O O
hyperprolactinemia B-Disease B-Disease
. O O

The O O
age O O
- O O
related O O
decrease O O
in O O
hypothalamic O O
dopamine O O
function O O
may O O
be O O
associated O O
with O O
increases O O
in O O
PRL O O
secretion O O
. O O

Treatment O O
- O O
related O O
disseminated O O
necrotizing O O
leukoencephalopathy B-Disease B-Disease
with O O
characteristic O O
contrast O O
enhancement O O
of O O
the O O
white O O
matter O O
. O O

This O O
report O O
describes O O
unique O O
contrast O O
enhancement O O
of O O
the O O
white O O
matter O O
on O O
T1-weighted O O
magnetic O O
resonance O O
images O O
of O O
two O O
patients O O
with O O
disseminated O O
necrotizing O O
leukoencephalopathy B-Disease B-Disease
, O O
which O O
developed O O
from O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
treated O O
with O O
high O O
- O O
dose O O
methotrexate O O
. O O

In O O
both O O
patients O O
, O O
the O O
enhancement O O
was O O
more O O
pronounced O O
near O O
the O O
base O O
of O O
the O O
brain O O
than O O
at O O
the O O
vertex O O
. O O

Necropsy O O
of O O
the O O
first O O
case O O
revealed O O
loss B-Disease O
of I-Disease O
myelination I-Disease O
and O O
necrosis B-Disease B-Disease
of O I-Disease
the O I-Disease
white O I-Disease
matter O I-Disease
. O O

Possible O O
mechanisms O O
causing O O
such O O
a O O
leukoencephalopathy B-Disease B-Disease
are O O
discussed O O
. O O

Thrombotic B-Disease B-Disease
complications O O
in O O
acute B-Disease B-Disease
promyelocytic I-Disease I-Disease
leukemia I-Disease I-Disease
during O O
all O O
- O O
trans O O
- O O
retinoic O O
acid O O
therapy O O
. O O

A O O
case O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
, O O
due O O
to O O
occlusion B-Disease B-Disease
of I-Disease I-Disease
renal I-Disease I-Disease
vessels I-Disease I-Disease
in O O
a O O
patient O O
with O O
acute B-Disease B-Disease
promyelocytic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
APL B-Disease B-Disease
) O O
treated O O
with O O
all O O
- O O
trans O O
- O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
and O O
tranexamic O O
acid O O
has O O
been O O
described O O
recently O O
. O O

We O O
report O O
a O O
case O O
of O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
in O O
an O O
APL B-Disease B-Disease
patient O O
treated O O
with O O
ATRA O O
alone O O
. O O

This O O
case O O
further O O
supports O O
the O O
concern O O
about O O
thromboembolic B-Disease B-Disease
complications O I-Disease
associated O O
with O O
ATRA O O
therapy O O
in O O
APL B-Disease B-Disease
patients O O
. O O

The O O
patients O O
, O O
a O O
43-year O O
- O O
old O O
man O O
, O O
presented O O
all O O
the O O
signs O O
and O O
symptoms O O
of O O
APL B-Disease B-Disease
and O O
was O O
included O O
in O O
a O O
treatment O O
protocol O O
with O O
ATRA O O
. O O

After O O
10 O O
days O O
of O O
treatment O O
, O O
he O O
developed O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
that O O
was O O
completely O O
reversible O O
after O O
complete O O
remission O O
of O O
APL B-Disease B-Disease
was O O
achieved O O
and O O
therapy O O
discontinued O O
. O O

We O O
conclude O O
that O O
ATRA O O
is O O
a O O
valid O O
therapeutic O O
choice O O
for O O
patients O O
with O O
APL B-Disease B-Disease
, O O
although O O
the O O
procoagulant O O
tendency O O
is O O
not O O
completely O O
corrected O O
. O O

Thrombotic B-Disease B-Disease
events O O
, O O
however O O
, O O
could O O
be O O
avoided O O
by O O
using O O
low O O
- O O
dose O O
heparin O O
. O O

Pupillary O O
changes O O
associated O O
with O O
the O O
development O O
of O O
stimulant O O
- O O
induced O O
mania B-Disease B-Disease
: O O
a O O
case O O
report O O
. O O

A O O
30-year O O
- O O
old O O
cocaine O O
- O O
dependent O O
man O O
who O O
was O O
a O O
subject O O
in O O
a O O
study O O
evaluating O O
the O O
anticraving O O
efficacy O O
of O O
the O O
stimulant O O
medication O O
diethylpropion O O
( O O
DEP O O
) O O
became O O
manic B-Disease B-Disease
during O O
his O O
second O O
week O O
on O O
the O O
study O O
drug O O
. O O

Pupillometric O O
changes O O
while O O
on O O
DEP O O
, O O
especially O O
changes O O
in O O
the O O
total O O
power O O
of O O
pupillary B-Disease B-Disease
oscillation I-Disease I-Disease
, O O
were O O
dramatically O O
different O O
than O O
those O O
observed O O
in O O
the O O
eight O O
other O O
study O O
subjects O O
who O O
did O O
not O O
become O O
manic B-Disease B-Disease
. O O

The O O
large O O
changes O O
in O O
total O O
power O O
of O O
pupillary B-Disease B-Disease
oscillation I-Disease I-Disease
occurred O O
a O O
few O O
days O O
before O O
the O O
patient O O
became O O
fully O O
manic B-Disease B-Disease
. O O

Such O O
medication O O
- O O
associated O O
changes O O
in O O
the O O
total O O
power O O
of O O
pupillary B-Disease B-Disease
oscillation I-Disease I-Disease
might O O
be O O
of O O
utility O O
in O O
identifying O O
persons O O
at O O
risk O O
for O O
manic B-Disease B-Disease
- O O
like O O
adverse O O
effects O O
during O O
the O O
medical O O
use O O
of O O
psychomotor O O
stimulants O O
or O O
sympathomimetic O O
agents O O
. O O

Fetal O O
risks O O
due O O
to O O
warfarin O O
therapy O O
during O O
pregnancy O O
. O O

Two O O
mothers O O
with O O
heart O O
valve O O
prosthesis O O
were O O
treated O O
with O O
warfarin O O
during O O
pregnancy O O
. O O

In O O
the O O
first O O
case O O
a O O
caesarean O O
section O O
was O O
done O O
one O O
week O O
after O O
replacement O O
of O O
warfarin O O
with O O
heparin O O
. O O

The O O
baby O O
died O O
of O O
cerebral B-Disease B-Disease
and I-Disease I-Disease
pulmonary I-Disease I-Disease
hemorrhage I-Disease I-Disease
. O O

The O O
second O O
mother O O
had O O
a O O
male O O
infant O O
by O O
caesarean O O
section O O
. O O

The O O
baby O O
showed O O
warfarin O O
- O O
induced O O
embryopathy B-Disease B-Disease
with O O
nasal B-Disease B-Disease
hypoplasia I-Disease I-Disease
and O O
stippled B-Disease B-Disease
epiphyses I-Disease I-Disease
( O O
chondrodysplasia B-Disease B-Disease
punctata I-Disease I-Disease
) O O
. O O

Nasal B-Disease B-Disease
hypoplasia I-Disease I-Disease
with O O
or O O
without O O
stippled B-Disease B-Disease
epiphyses I-Disease I-Disease
has O O
now O O
been O O
reported O O
in O O
11 O O
infants O O
born O O
to O O
mothers O O
treated O O
with O O
warfarin O O
during O O
the O O
first O O
trimester O O
, O O
and O O
a O O
causal O O
association O O
is O O
probable O O
. O O

In O O
view O O
of O O
the O O
risks O O
to O O
both O O
mother O O
and O O
fetus O O
in O O
women O O
with O O
prosthetic O O
cardiac O O
valves O O
it O O
is O O
recommended O O
that O O
therapeutic O O
abortion O O
be O O
advised O O
as O O
the O O
first O O
alternative O O
. O O

The O O
negative O O
mucosal O O
potential O O
: O O
separating O O
central O O
and O O
peripheral O O
effects O O
of O O
NSAIDs O O
in O O
man O O
. O O

OBJECTIVE O O
: O O
We O O
wanted O O
to O O
test O O
whether O O
assessment O O
of O O
both O O
a O O
central O O
pain B-Disease B-Disease
- O O
related O O
signal O O
( O O
chemo O O
- O O
somatosensory O O
evoked O O
potential O O
, O O
CSSEP O O
) O O
and O O
a O O
concomitantly O O
recorded O O
peripheral O O
signal O O
( O O
negative O O
mucosal O O
potential O O
, O O
NMP O O
) O O
allows O O
for O O
separation O O
of O O
central O O
and O O
peripheral O O
effects O O
of O O
NSAIDs O O
. O O

For O O
this O O
purpose O O
, O O
experimental O O
conditions O O
were O O
created O O
in O O
which O O
NSAIDs O O
had O O
previously O O
been O O
observed O O
to O O
produce O O
effects O O
on O O
phasic O O
and O O
tonic O O
pain B-Disease B-Disease
by O O
either O O
central O O
or O O
peripheral O O
mechanisms O O
. O O

METHODS O O
: O O
According O O
to O O
a O O
double O O
- O O
blind O O
, O O
randomised O O
, O O
controlled O O
, O O
threefold O O
cross O O
- O O
over O O
design O O
, O O
18 O O
healthy O O
subjects O O
( O O
11 O O
males O O
, O O
7 O O
females O O
; O O
mean O O
age O O
26 O O
years O O
) O O
received O O
either O O
placebo O O
, O O
400 O O
mg O O
ibuprofen O O
, O O
or O O
800 O O
mg O O
ibuprofen O O
. O O

Phasic O O
pain B-Disease B-Disease
was O O
applied O O
by O O
means O O
of O O
short O O
pulses O O
of O O
CO2 O O
to O O
the O O
nasal O O
mucosa O O
( O O
stimulus O O
duration O O
500 O O
ms O O
, O O
interval O O
approximately O O
60 O O
s O O
) O O
, O O
and O O
tonic O O
pain B-Disease B-Disease
was O O
induced O O
in O O
the O O
nasal O O
cavity O O
by O O
means O O
of O O
dry O O
air O O
of O O
controlled O O
temperature O O
, O O
humidity O O
and O O
flow O O
rate O O
( O O
22 O O
degrees O O
C O O
, O O
0 O O
% O O
relative O O
humidity O O
, O O
145 O O
ml.s-1 O O
) O O
. O O

Both O O
CSSEPs O O
as O O
central O O
and O O
NMPs O O
as O O
peripheral O O
correlates O O
of O O
pain B-Disease B-Disease
were O O
obtained O O
in O O
response O O
to O O
the O O
CO2 O O
stimuli O O
. O O

Additionally O O
, O O
the O O
subjects O O
rated O O
the O O
intensity O O
of O O
both O O
phasic O O
and O O
tonic O O
pain B-Disease B-Disease
by O O
means O O
of O O
visual O O
analogue O O
scales O O
. O O

RESULTS O O
: O O
As O O
described O O
earlier O O
, O O
administration O O
of O O
ibuprofen O O
was O O
followed O O
by O O
a O O
decrease O O
in O O
tonic O O
pain B-Disease B-Disease
but O O
- O O
relative O O
to O O
placebo O O
- O O
an O O
increase O O
in O O
correlates O O
of O O
phasic O O
pain B-Disease B-Disease
, O O
indicating O O
a O O
specific O O
effect O O
of O O
ibuprofen O O
on O O
the O O
interaction O O
between O O
the O O
pain B-Disease B-Disease
stimuli O O
under O O
these O O
special O O
experimental O O
conditions O O
. O O

Based O O
on O O
the O O
similar O O
behaviour O O
of O O
CSSEP O O
and O O
NMP O O
, O O
it O O
was O O
concluded O O
that O O
the O O
pharmacological O O
process O O
underlying O O
this O O
phenomenon O O
was O O
localised O O
in O O
the O O
periphery O O
. O O

By O O
means O O
of O O
the O O
simultaneous O O
recording O O
of O O
interrelated O O
peripheral O O
and O O
central O O
electrophysiologic O O
correlates O O
of O O
nociception O O
, O O
it O O
was O O
possible O O
to O O
separate O O
central O O
and O O
peripheral O O
effects O O
of O O
an O O
NSAID O O
. O O

The O O
major O O
advantage O O
of O O
this O O
pain B-Disease B-Disease
model O O
is O O
the O O
possibility O O
of O O
obtaining O O
peripheral O O
pain B-Disease B-Disease
- O O
related O O
activity O O
directly O O
using O O
a O O
non O O
- O O
invasive O O
technique O O
in O O
humans O O
. O O

Effect O O
of O O
D O O
- O O
Glucarates O O
on O O
basic O O
antibiotic O O
- O O
induced O O
renal B-Disease B-Disease
damage I-Disease I-Disease
in O O
rats O O
. O O

Dehydrated B-Disease O
rats O O
regularly O O
develop O O
acute B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
following O O
single O O
injection O O
of O O
aminoglycoside O O
antibiotics O O
combined O O
with O O
dextran O O
or O O
of O O
antibiotics O O
only O O
. O O

Oral O O
administration O O
of O O
2,5-di O O
- O O
O O O
- O O
acetyl O O
- O O
D O O
- O O
glucaro-1,4 O O
- O O
6,3-dilactone O O
protected O O
rats O O
against O O
renal B-Disease B-Disease
failure I-Disease I-Disease
induced O O
by O O
kanamycin O O
- O O
dextran O O
. O O

The O O
protective O O
effect O O
was O O
prevalent O O
among O O
D O O
- O O
glucarates O O
, O O
and O O
also O O
to O O
other O O
saccharic O O
acid O O
, O O
hexauronic O O
acids O O
and O O
hexaaldonic O O
acids O O
, O O
although O O
to O O
a O O
lesser O O
degree O O
, O O
but O O
not O O
to O O
a O O
hexaaldose O O
, O O
sugar O O
alcohols O O
, O O
substances O O
inthe O O
TCA O O
cycle O O
and O O
other O O
acidic O O
compounds O O
. O O

D O O
- O O
Glucarates O O
were O O
effective O O
against O O
renal B-Disease B-Disease
damage I-Disease I-Disease
induced O O
by O O
peptide O O
antibiotics O O
as O O
well O O
as O O
various O O
aminoglycoside O O
antibitocis O O
. O O

Dose O O
- O O
responses O O
were O O
observed O O
in O O
the O O
protective O O
effect O O
of O O
D O O
- O O
Glucarates O O
. O O

With O O
a O O
D O O
- O O
glucarate O O
of O O
a O O
fixed O O
size O O
of O O
dose O O
, O O
approximately O O
the O O
same O O
degree O O
of O O
protection O O
was O O
obtained O O
against O O
renal B-Disease B-Disease
damages I-Disease I-Disease
induced O O
by O O
different O O
basic O O
antibiotics O O
despite O O
large O O
disparities O O
in O O
administration O O
doses O O
of O O
different O O
antibiotics O O
. O O

D O O
- O O
Glucarates O O
had O O
the O O
ability O O
to O O
prevent O O
renal B-Disease B-Disease
damage I-Disease I-Disease
but O O
not O O
to O O
cure O O
it O O
. O O

Rats O O
excreted O O
acidic O O
urine O O
when O O
they O O
were O O
spared O O
from O O
renal B-Disease B-Disease
lesions I-Disease I-Disease
by O O
monosaccharides O O
. O O

The O O
reduction O O
effect O O
of O O
D O O
- O O
glucarates O O
against O O
nephrotoxicity B-Disease B-Disease
of O O
basic O O
antibiotics O O
was O O
discussed O O
. O O

Acute O O
severe O O
depression B-Disease B-Disease
following O O
peri O O
- O O
operative O O
ondansetron O O
. O O

A O O
41-year O O
- O O
old O O
woman O O
with O O
a O O
strong O O
history O O
of O O
postoperative B-Disease B-Disease
nausea I-Disease I-Disease
and I-Disease I-Disease
vomiting I-Disease I-Disease
presented O O
for O O
abdominal O O
hysterectomy O O
3 O O
months O O
after O O
a O O
previous O O
anaesthetic O O
where O O
ondansetron O O
prophylaxis O O
had O O
been O O
used O O
. O O

She O O
had O O
developed O O
a O O
severe O O
acute O O
major B-Disease B-Disease
depression I-Disease I-Disease
disorder I-Disease I-Disease
almost O O
immediately O O
thereafter O O
, O O
possibly O O
related O O
to O O
the O O
use O O
of O O
a O O
serotonin O O
antagonist O O
. O O

Nine O O
years O O
before O O
she O O
had O O
experienced O O
a O O
self O O
- O O
limited O O
puerperal O O
depressive B-Disease B-Disease
episode I-Disease I-Disease
. O O

Anaesthesia O O
with O O
a O O
propofol O O
infusion O O
and O O
avoidance O O
of O O
serotonin O O
antagonists O O
provided O O
a O O
nausea B-Disease B-Disease
- O O
free O O
postoperative O O
course O O
without O O
exacerbation O O
of O O
the O O
depression B-Disease B-Disease
disorder I-Disease I-Disease
. O O

Hypertensive B-Disease B-Disease
response O O
during O O
dobutamine O O
stress O O
echocardiography O O
. O O

Among O O
3,129 O O
dobutamine O O
stress O O
echocardiographic O O
studies O O
, O O
a O O
hypertensive B-Disease B-Disease
response O O
, O O
defined O O
as O O
systolic O O
blood O O
pressure O O
( O O
BP O O
) O O
> O O
or O O
= O O
220 O O
mm O O
Hg O O
and/or O O
diastolic O O
BP O O
> O O
or O O
= O O
110 O O
mm O O
Hg O O
, O O
occurred O O
in O O
30 O O
patients O O
( O O
1 O O
% O O
) O O
. O O

Patients O O
with O O
this O O
response O O
more O O
often O O
had O O
a O O
history O O
of O O
hypertension B-Disease B-Disease
and O O
had O O
higher O O
resting O O
systolic O O
and O O
diastolic O O
BP O O
before O O
dobutamine O O
infusion O O
. O O

Continuously O O
nebulized O O
albuterol O O
in O O
severe O O
exacerbations O O
of O O
asthma B-Disease B-Disease
in O O
adults O O
: O O
a O O
case O O
- O O
controlled O O
study O O
. O O

A O O
retrospective O O
, O O
case O O
- O O
controlled O O
analysis O O
comparing O O
patients O O
admitted O O
to O O
a O O
medical O O
intensive O O
care O O
unit O O
with O O
severe O O
exacerbations O O
of O O
asthma B-Disease B-Disease
who O O
received O O
continuously O O
nebulized O O
albuterol O O
( O O
CNA O O
) O O
versus O O
intermittent O O
albuterol O O
( O O
INA O O
) O O
treatments O O
is O O
reported O O
. O O

Forty O O
matched O O
pairs O O
of O O
patients O O
with O O
asthma B-Disease B-Disease
are O O
compared O O
. O O

CNA O O
was O O
administered O O
for O O
a O O
mean O O
of O O
11 O O
+ O O
/- O O

10 O O
hr O O
. O O

The O O
incidence O O
of O O
cardiac B-Disease B-Disease
dysrhythmias I-Disease I-Disease
was O O
similar O O
between O O
groups O O
. O O

Symptomatic O O
hypokalemia B-Disease B-Disease
did O O
not O O
occur O O
. O O

CNA O O
patients O O
had O O
higher O O
heart O O
rates O O
during O O
treatment O O
, O O
which O O
may O O
reflect O O
severity O O
of O O
illness O O
. O O

The O O
incidence O O
of O O
intubation O O
was O O
similar O O
. O O

We O O
conclude O O
that O O
CNA O O
and O O
INA O O
demonstrated O O
similar O O
profiles O O
with O O
regard O O
to O O
safety O O
, O O
morbidity O O
, O O
and O O
mortality O O
. O O

Paraplegia B-Disease B-Disease
following O O
intrathecal O O
methotrexate O O
: O O
report O O
of O O
a O O
case O O
and O O
review O O
of O O
the O O
literature O O
. O O

A O O
patient O O
who O O
developed O O
paraplegia B-Disease B-Disease
following O O
the O O
intrathecal O O
instillation O O
of O O
methotrexate O O
is O O
discribed O O
. O O

The O O
ten O O
previously O O
reported O O
cases O O
of O O
this O O
unusual O O
complication O O
are O O
reviewed O O
. O O

The O O
following O O
factors O O
appear O O
to O O
predispose O O
to O O
the O O
development O O
of O O
this O O
complication O O
: O O
abnormal O O
cerebrospinal O O
dynamics O O
related O O
to O O
the O O
presence O O
of O O
central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
leukemia I-Disease I-Disease
, O O
and O O
epidural O O
cerebrospinal O O
leakage O O
; O O
elevated O O
cerebrospinal O O
fluid O O
methothexate O O
concentration O O
related O O
to O O
abnormal O O
cerebrospinal O O
fluid O O
dynamics O O
and O O
to O O
inappropriately O O
high O O
methotrexate O O
doses O O
based O O
on O O
body O O
surface O O
area O O
calculations O O
in O O
older O O
children O O
and O O
adults O O
; O O
the O O
presence O O
of O O
neurotoxic B-Disease B-Disease
preservatives O O
in O O
commercially O O
available O O
methotrexate O O
preparations O O
and O O
diluents O O
; O O
and O O
the O O
use O O
of O O
methotrexate O O
diluents O O
of O O
unphysiologic O O
pH O O
, O O
ionic O O
content O O
and O O
osmolarity O O
. O O

The O O
role O O
of O O
methotrexate O O
contaminants O O
, O O
local O O
folate B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
and O O
cranial O O
irradiation O O
in O O
the O O
pathogenesis O O
of O O
intrathecal O O
methotrexate O O
toxicity B-Disease B-Disease
is O O
unclear O O
. O O

The O O
incidence O O
of O O
neurotoxicity B-Disease B-Disease
may O O
be O O
reduced O O
by O O
employing O O
lower O O
doses O O
of O O
methotrexate O O
in O O
the O O
presence O O
of O O
central B-Disease B-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
leukemia I-Disease I-Disease
, O O
in O O
older O O
children O O
and O O
adults O O
, O O
and O O
in O O
the O O
presence O O
of O O
epidural O O
leakage O O
. O O

Only O O
preservative O O
- O O
free O O
methotrexate O O
in O O
Elliott O O
's O O
B O O
Solution O O
at O O
a O O
concentration O O
of O O
not O O
more O O
than O O
1 O O
mg O O
/ O O
ml O O
should O O
be O O
used O O
for O O
intrathecal O O
administration O O
. O O

Periodic O O
monitoring O O
of O O
cerebruspinal O O
fluid O O
methotrexate O O
levels O O
may O O
be O O
predictive O O
of O O
the O O
development O O
of O O
serious O O
neurotoxicity B-Disease B-Disease
. O O

Hyperosmolar B-Disease B-Disease
nonketotic I-Disease I-Disease
coma I-Disease I-Disease
precipitated O O
by O O
lithium O O
- O O
induced O O
nephrogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
. O O

A O O
45-year O O
- O O
old O O
man O O
, O O
with O O
a O O
10-year O O
history O O
of O O
manic B-Disease B-Disease
depression I-Disease I-Disease
treated O O
with O O
lithium O O
, O O
was O O
admitted O O
with O O
hyperosmolar B-Disease B-Disease
, I-Disease I-Disease
nonketotic I-Disease I-Disease
coma I-Disease I-Disease
. O O

He O O
gave O O
a O O
five O O
- O O
year O O
history O O
of O O
polyuria B-Disease B-Disease
and O O
polydipsia B-Disease B-Disease
, O O
during O O
which O O
time O O
urinalysis O O
had O O
been O O
negative O O
for O O
glucose O O
. O O

After O O
recovery O O
from O O
hyperglycaemia B-Disease B-Disease
, O O
he O O
remained O O
polyuric B-Disease B-Disease
despite O O
normal O O
blood O O
glucose O O
concentrations O O
; O O
water O O
deprivation O O
testing O O
indicated O O
nephrogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
, O O
likely O O
to O O
be O O
lithium O O
- O O
induced O O
. O O

We O O
hypothesize O O
that O O
when O O
this O O
man O O
developed O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
, O O
chronic O O
polyuria B-Disease B-Disease
due O O
to O O
nephrogenic B-Disease B-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
was O O
sufficient O O
to O O
precipitate O O
hyperosmolar O B-Disease
dehydration B-Disease I-Disease
. O O

Effects O O
of O O
the O O
intracoronary O O
infusion O O
of O O
cocaine O O
on O O
left O O
ventricular O O
systolic O O
and O O
diastolic O O
function O O
in O O
humans O O
. O O

BACKGROUND O O
: O O
In O O
dogs O O
, O O
a O O
large O O
amount O O
of O O
intravenous O O
cocaine O O
causes O O
a O O
profound O O
deterioration B-Disease B-Disease
of I-Disease I-Disease
left I-Disease I-Disease
ventricular I-Disease I-Disease
( I-Disease I-Disease
LV I-Disease I-Disease
) I-Disease I-Disease
systolic I-Disease I-Disease
function I-Disease I-Disease
and O O
an O O
increase O O
in O O
LV O O
end O O
- O O
diastolic O O
pressure O O
. O O

This O O
study O O
was O O
done O O
to O O
assess O O
the O O
influence O O
of O O
a O O
high O O
intracoronary O O
cocaine O O
concentration O O
on O O
LV O O
systolic O O
and O O
diastolic O O
function O O
in O O
humans O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
In O O
20 O O
patients O O
( O O
14 O O
men O O
and O O
6 O O
women O O
aged O O
39 O O
to O O
72 O O
years O O
) O O
referred O O
for O O
cardiac O O
catheterization O O
for O O
the O O
evaluation O O
of O O
chest B-Disease B-Disease
pain I-Disease I-Disease
, O O
we O O
measured O O
heart O O
rate O O
, O O
systemic O O
arterial O O
pressure O O
, O O
LV O O
pressure O O
and O O
its O O
first O O
derivative O O
( O O
dP O O
/ O O
dt O O
) O O
, O O
and O O
LV O O
volumes O O
and O O
ejection O O
fraction O O
before O O
and O O
during O O
the O O
final O O
2 O O
to O O
3 O O
minutes O O
of O O
a O O
15-minute O O
intracoronary O O
infusion O O
of O O
saline O O
( O O
n=10 O O
, O O
control O O
subjects O O
) O O
or O O
cocaine O O
hydrochloride O O
1 O O
mg O O
/ O O
min O O
( O O
n=10 O O
) O O
. O O

No O O
variable O O
changed O O
with O O
saline O O
. O O

With O O
cocaine O O
, O O
the O O
drug O O
concentration O O
in O O
blood O O
obtained O O
from O O
the O O
coronary O O
sinus O O
was O O
3.0+ O O
/ O O
-0.4 O O
( O O
mean+ O O
/ O O
-SD O O
) O O
mg O O
/ O O
L O O
, O O
similar O O
in O O
magnitude O O
to O O
the O O
blood O O
cocaine O O
concentration O O
reported O O
in O O
abusers O O
dying O O
of O O
cocaine O O
intoxication O O
. O O

Cocaine O O
induced O O
no O O
significant O O
change O O
in O O
heart O O
rate O O
, O O
LV O O
dP O O
/ O O
dt O O
( O O
positive O O
or O O
negative O O
) O O
, O O
or O O
LV O O
end O O
- O O
diastolic O O
volume O O
, O O
but O O
it O O
caused O O
an O O
increase O O
in O O
systolic O O
and O O
mean O O
arterial O O
pressures O O
, O O
LV O O
end O O
- O O
diastolic O O
pressure O O
, O O
and O O
LV O O
end O O
- O O
systolic O O
volume O O
, O O
as O O
well O O
as O O
a O O
decrease O O
in O O
LV O O
ejection O O
fraction O O
. O O

CONCLUSIONS O O
: O O
In O O
humans O O
, O O
the O O
intracoronary O O
infusion O O
of O O
cocaine O O
sufficient O O
in O O
amount O O
to O O
achieve O O
a O O
high O O
drug O O
concentration O O
in O O
coronary O O
sinus O O
blood O O
causes O O
a O O
deterioration B-Disease B-Disease
of I-Disease I-Disease
LV I-Disease I-Disease
systolic I-Disease I-Disease
and I-Disease I-Disease
diastolic I-Disease I-Disease
performance I-Disease I-Disease
. O O

Ascending O O
dose O O
tolerance O O
study O O
of O O
intramuscular O O
carbetocin O O
administered O O
after O O
normal O O
vaginal O O
birth O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
maximum O O
tolerated O O
dose O O
( O O
MTD O O
) O O
of O O
carbetocin O O
( O O
a O O
long O O
- O O
acting O O
synthetic O O
analogue O O
of O O
oxytocin O O
) O O
, O O
when O O
administered O O
immediately O O
after O O
vaginal O O
delivery O O
at O O
term O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Carbetocin O O
was O O
given O O
as O O
an O O
intramuscular O O
injection O O
immediately O O
after O O
the O O
birth O O
of O O
the O O
infant O O
in O O
45 O O
healthy O O
women O O
with O O
normal O O
singleton O O
pregnancies O O
who O O
delivered O O
vaginally O O
at O O
term O O
. O O

Dosage O O
groups O O
of O O
15 O O
, O O
30 O O
, O O
50 O O
, O O
75 O O
, O O
100 O O
, O O
125 O O
, O O
150 O O
, O O
175 O O
or O O
200 O O
microg O O
carbetocin O O
were O O
assigned O O
to O O
blocks O O
of O O
three O O
women O O
according O O
to O O
the O O
continual O O
reassessment O O
method O O
( O O
CRM O O
) O O
. O O

RESULTS O O
: O O
All O O
dosage O O
groups O O
consisted O O
of O O
three O O
women O O
, O O
except O O
those O O
with O O
100 O O
microg O O
( O O
n=6 O O
) O O
and O O
200 O O
microg O O
( O O
n=18 O O
) O O
. O O

Recorded O O
were O O
dose O O
- O O
limiting O O
adverse O O
events O O
: O O
hyper- B-Disease O
or I-Disease O
hypotension I-Disease B-Disease
( O O
three O O
) O O
, O O
severe O O
abdominal B-Disease B-Disease
pain I-Disease I-Disease
( O O
0 O O
) O O
, O O
vomiting B-Disease B-Disease
( O O
0 O O
) O O
and O O
retained B-Disease O
placenta I-Disease O
( O O
four O O
) O O
. O O

Serious O O
adverse O O
events O O
occurred O O
in O O
seven O O
women O O
: O O
six O O
cases O O
with O O
blood B-Disease B-Disease
loss I-Disease I-Disease
> O O
or O O
= O O
1000 O O
ml O O
, O O
four O O
cases O O
of O O
manual O O
placenta O O
removal O O
, O O
five O O
cases O O
of O O
additional O O
oxytocics O O
administration O O
and O O
five O O
cases O O
of O O
blood O O
transfusion O O
. O O

Maximum O O
blood B-Disease O
loss I-Disease O
was O O
greatest O O
at O O
the O O
upper O O
and O O
lower O O
dose O O
levels O O
, O O
and O O
lowest O O
in O O
the O O
70 O O
- O O
125 O O
microg O O
dose O O
range O O
. O O

Four O O
out O O
of O O
six O O
cases O O
with O O
blood B-Disease B-Disease
loss I-Disease I-Disease
> O O
or O O
= O O
1000 O O
ml O O
occurred O O
in O O
the O O
200 O O
microg O O
group O O
. O O

The O O
majority O O
of O O
additional O O
administration O O
of O O
oxytocics O O
( O O
4 O O
/ O O
5 O O
) O O
and O O
blood O O
transfusion O O
( O O
3 O O
/ O O
5 O O
) O O
occurred O O
in O O
the O O
dose O O
groups O O
of O O
200 O O
microg O O
. O O

All O O
retained O O
placentae O O
were O O
found O O
in O O
the O O
group O O
of O O
200 O O
microg O O
. O O

CONCLUSION O O
: O O
The O O
MTD O O
was O O
calculated O O
to O O
be O O
at O O
200 O O
microg O O
carbetocin O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
, O O
paradoxical O O
thromboembolism B-Disease B-Disease
, O O
and O O
other O O
side O O
effects O O
of O O
heparin O O
therapy O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin O O
remains O O
the O O
drug O O
of O O
choice O O
for O O
most O O
anticoagulation O O
needs O O
. O O

The O O
clinical O O
effects O O
of O O
heparin O O
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Important O O
untoward O O
effects O O
of O O
heparin O O
therapy O O
including O O
heparin O O
- O O
induced O O
thrombocytopenia B-Disease B-Disease
, O O
heparin O O
- O O
associated O O
osteoporosis B-Disease B-Disease
, O O
eosinophilia B-Disease B-Disease
, O O
skin B-Disease B-Disease
reactions I-Disease I-Disease
, O O
allergic B-Disease B-Disease
reactions I-Disease I-Disease
other O O
than O O
thrombocytopenia B-Disease B-Disease
and O O
alopecia B-Disease B-Disease
will O O
be O O
discussed O O
in O O
this O O
article O O
. O O

Nonopaque O O
crystal O O
deposition O O
causing O O
ureteric B-Disease B-Disease
obstruction I-Disease I-Disease
in O O
patients O O
with O O
HIV O O
undergoing O O
indinavir O O
therapy O O
. O O

OBJECTIVE O O
: O O
We O O
describe O O
the O O
unique O O
CT O O
features O O
of O O
ureteric B-Disease B-Disease
calculi I-Disease I-Disease
in O O
six O O
HIV B-Disease B-Disease
- I-Disease I-Disease
infected I-Disease I-Disease
patients O O
receiving O O
indinavir O O
, O O
the O O
most O O
commonly O O
used O O
HIV O O
protease O O
inhibitor O O
, O O
which O O
is O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
urolithiasis B-Disease B-Disease
. O O

CONCLUSION O O
: O O
Ureteric B-Disease B-Disease
obstruction I-Disease I-Disease
caused O O
by O O
precipitated O O
indinavir O O
crystals O O
may O O
be O O
difficult O O
to O O
diagnose O O
with O O
unenhanced O O
CT O O
. O O

The O O
calculi O O
are O O
not O O
opaque O O
, O O
and O O
secondary O O
signs O O
of O O
obstruction O O
may O O
be O O
absent O O
or O O
minimal O O
and O O
should O O
be O O
sought O O
carefully O O
. O O

Images O O
may O O
need O O
to O O
be O O
obtained O O
using O O
i.v O O
. O O

contrast O O
material O O
to O O
enable O O
diagnosis O O
of O O
ureteric B-Disease B-Disease
stones I-Disease I-Disease
or B-Disease O
obstruction I-Disease O
in O O
patients O O
with O O
HIV B-Disease B-Disease
infection I-Disease I-Disease
who O O
receive O O
indinavir O O
therapy O O
. O O

Ischemic B-Disease B-Disease
colitis I-Disease I-Disease
and O O
sumatriptan O O
use O O
. O O

Sumatriptan O O
succinate O O
, O O
a O O
serotonin-1 O O
( O O
5-hydroxytryptamine-1 O O
) O O
receptor O O
agonist O O
, O O
is O O
an O O
antimigraine O O
drug O O
that O O
is O O
reported O O
to O O
act O O
by O O
selectively O O
constricting O O
intracranial O O
arteries O O
. O O

Recently O O
, O O
vasopressor O O
responses O O
that O O
are O O
distinct O O
from O O
the O O
cranial O O
circulation O O
have O O
been O O
demonstrated O O
to O O
occur O O
in O O
the O O
systemic O O
, O O
pulmonary O O
, O O
and O O
coronary O O
circulations O O
. O O

Cases O O
have O O
been O O
published O O
of O O
coronary B-Disease B-Disease
vasospasm I-Disease I-Disease
, O O
myocardial B-Disease B-Disease
ischemia I-Disease I-Disease
, O O
and O O
myocardial B-Disease B-Disease
infarction I-Disease I-Disease
occurring O O
after O O
sumatriptan O O
use O O
. O O

We O O
report O O
on O O
the O O
development O O
of O O
8 O O
serious O O
cases O O
of O O
ischemic B-Disease B-Disease
colitis I-Disease I-Disease
in O O
patients O O
with O O
migraine B-Disease B-Disease
treated O O
with O O
sumatriptan O O
. O O

Pallidotomy O O
with O O
the O O
gamma O O
knife O O
: O O
a O O
positive O O
experience O O
. O O

51 O O
patients O O
with O O
medically O O
refractory O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
underwent O O
stereotactic O O
posteromedial O O
pallidotomy O O
between O O
August O O
1993 O O
and O O
February O O
1997 O O
for O O
treatment O O
of O O
bradykinesia B-Disease B-Disease
, O O
rigidity B-Disease B-Disease
, O O
and O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B-Disease B-Disease
. O O

In O O
29 O O
patients O O
, O O
the O O
pallidotomies O O
were O O
performed O O
with O O
the O O
Leksell O O
Gamma O O
Knife O O
and O O
in O O
22 O O
they O O
were O O
performed O O
with O O
the O O
standard O O
radiofrequency O O
( O O
RF O O
) O O
method O O
. O O

Clinical O O
assessment O O
as O O
well O O
as O O
blinded O O
ratings O O
of O O
Unified O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
Disease I-Disease I-Disease
Rating O O
Scale O O
( O O
UPDRS O O
) O O
scores O O
were O O
carried O O
out O O
pre- O O
and O O
postoperatively O O
. O O

Mean O O
follow O O
- O O
up O O
time O O
is O O
20.6 O O
months O O
( O O
range O O
6 O O
- O O
48 O O
) O O
and O O
all O O
except O O
4 O O
patients O O
have O O
been O O
followed O O
more O O
than O O
one O O
year O O
. O O

85 O O
percent O O
of O O
patients O O
with O O
dyskinesias B-Disease B-Disease
were O O
relieved O O
of O O
symptoms O O
, O O
regardless O O
of O O
whether O O
the O O
pallidotomies O O
were O O
performed O O
with O O
the O O
Gamma O O
Knife O O
or O O
radiofrequency O O
methods O O
. O O

About O O
2 O O
/ O O
3 O O
of O O
the O O
patients O O
in O O
both O O
Gamma O O
Knife O O
and O O
radiofrequency O O
groups O O
showed O O
improvements O O
in O O
bradykinesia B-Disease B-Disease
and O O
rigidity B-Disease B-Disease
, O O
although O O
when O O
considered O O
as O O
a O O
group O O
neither O O
the O O
Gamma O O
Knife O O
nor O O
the O O
radiofrequency O O
group O O
showed O O
statistically O O
significant O O
improvements O O
in O O
UPDRS O O
scores O O
. O O

One O O
patient O O
in O O
the O O
Gamma O O
Knife O O
group O O
( O O
3.4 O O
% O O
) O O
developed O O
a O O
homonymous B-Disease O
hemianopsia I-Disease B-Disease
9 O O
months O O
following O O
treatment O O
and O O
5 O O
patients O O
( O O
27.7 O O
% O O
) O O
in O O
the O O
radiofrequency O O
group O O
became O O
transiently O O
confused O O
postoperatively O O
. O O

No O O
other O O
complications O O
were O O
seen O O
. O O

Gamma O O
Knife O O
pallidotomy O O
is O O
as O O
effective O O
as O O
radiofrequency O O
pallidotomy O O
in O O
controlling O O
certain O O
of O O
the O O
symptoms O O
of O O
Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

It O O
may O O
be O O
the O O
only O O
practical O O
technique O O
available O O
in O O
certain O O
patients O O
, O O
such O O
as O O
those O O
who O O
take O O
anticoagulants O O
, O O
have O O
bleeding B-Disease B-Disease
diatheses O O
or O O
serious O O
systemic O O
medical O O
illnesses O O
. O O

It O O
is O O
a O O
viable O O
option O O
for O O
other O O
patients O O
as O O
well O O
. O O

Centrally O O
mediated O O
cardiovascular O O
effects O O
of O O
intracisternal O O
application O O
of O O
carbachol O O
in O O
anesthetized O O
rats O O
. O O

The O O
pressor O O
response O O
to O O
the O O
intracisternal O O
( O O
i.c O O
. O O
) O O
injection O O
of O O
carbachol O O
( O O
1 O O
mug O O
) O O
in O O
anesthetized O O
rats O O
was O O
analyzed O O
. O O

This O O
response O O
was O O
significantly O O
reduced O O
by O O
the O O
intravenous O O
( O O
i.v O O
. O O
) O O
injection O O
of O O
guanethidine O O
( O O
5 O O
mg O O
) O O
, O O
hexamethonium O O
( O O
10 O O
mg O O
) O O
or O O
phentolamine O O
( O O
5 O O
mg O O
) O O
, O O
and O O
conversely O O
, O O
potentiated O O
by O O
i.v O O
. O O

desmethylimipramine O O
( O O
0.3 O O
mg O O
) O O
, O O
while O O
propranolol O O
( O O
0.5 O O
mg O O
) O O
i.v O O
. O O
selectively O O
inhibited O O
the O O
enlargement B-Disease O
of I-Disease O
pulse I-Disease O
pressure I-Disease O
and O O
the O O
tachycardia B-Disease B-Disease
following O O
i.c O O
. O O

carbachol O O
( O O
1 O O
mug O O
) O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
pressor O O
response O O
to O O
i.c O O
. O O

carbachol O O
( O O
1 O O
mug O O
) O O
was O O
almost O O
completely O O
blocked O O
by O O
i.c O O
. O O

atropine O O
( O O
3 O O
mug O O
) O O
or O O
hexamethonium O O
( O O
500 O O
mug O O
) O O
, O O
and O O
significantly O O
reduced O O
by O O
i.c O O
. O O

chlorpromazine O O
( O O
50 O O
mug O O
) O O
but O O
significantly O O
potentiated O O
by O O
i.c O O
. O O

desmethylimipramine O O
( O O
30 O O
mug O O
) O O
. O O

The O O
pressor O O
response O O
to O O
i.c O O
. O O

carbachol O O
( O O
1 O O
mug O O
) O O
remained O O
unchanged O O
after O O
sectioning O O
of O O
the O O
bilateral O O
cervical O O
vagal O O
nerves O O
but O O
disappeared O O
after O O
sectioning O O
of O O
the O O
spinal O O
cord O O
( O O
C7-C8 O O
) O O
. O O

From O O
the O O
above O O
result O O
it O O
is O O
suggested O O
that O O
the O O
pressor O O
response O O
to O O
i.c O O
. O O

carbachol O O
ortral O O
and O O
peripheral O O
adrenergic O O
mechanisms O O
, O O
and O O
that O O
the O O
sympathetic O O
trunk O O
is O O
the O O
main O O
pathway O O
. O O

Neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
methylphenidate O O
. O O

A O O
1-year O O
- O O
old O O
female O O
presented O O
with O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
probably O O
caused O O
by O O
methylphenidate O O
. O O

She O O
had O O
defects O O
in O O
the O O
supratentorial O O
brain O O
including O O
the O O
basal O O
ganglia O O
and O O
the O O
striatum O O
( O O
multicystic B-Disease B-Disease
encephalomalacia I-Disease I-Disease
) O O
due O O
to O O
severe O O
perinatal O O
hypoxic B-Disease B-Disease
- I-Disease I-Disease
ischemic I-Disease I-Disease
encephalopathy I-Disease I-Disease
, O O
which O O
was O O
considered O O
to O O
be O O
a O O
possible O O
predisposing O O
factor O O
causing O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

A O O
dopaminergic O O
blockade O O
mechanism O O
generally O O
is O O
accepted O O
as O O
the O O
pathogenesis O O
of O O
this O O
syndrome O O
. O O

However O O
, O O
methylphenidate O O
is O O
a O O
dopamine O O
agonist O O
via O O
the O O
inhibition O O
of O O
uptake O O
of O O
dopamine O O
, O O
and O O
therefore O O
dopaminergic O O
systems O O
in O O
the O O
brainstem O O
( O O
mainly O O
the O O
midbrain O O
) O O
and O O
the O O
spinal O O
cord O O
were O O
unlikely O O
to O O
participate O O
in O O
the O O
onset O O
of O O
this O O
syndrome O O
. O O

A O O
relative O O
gamma O O
- O O
aminobutyric O O
acid O O
- O O
ergic O O
deficiency O O
might O O
occur O O
because O O
diazepam O O
, O O
a O O
gamma O O
- O O
aminobutyric O O
acid O O
- O O
mimetic O O
agent O O
, O O
was O O
strikingly O O
effective O O
. O O

This O O
is O O
the O O
first O O
reported O O
patient O O
with O O
neuroleptic B-Disease B-Disease
malignant I-Disease I-Disease
syndrome I-Disease I-Disease
probably O O
caused O O
by O O
methylphenidate O O
. O O

Differential O O
effects O O
of O O
17alpha O O
- O O
ethinylestradiol O O
on O O
the O O
neutral O O
and O O
acidic O O
pathways O O
of O O
bile O O
salt O O
synthesis O O
in O O
the O O
rat O O
. O O

Effects O O
of O O
17alpha O O
- O O
ethinylestradiol O O
( O O
EE O O
) O O
on O O
the O O
neutral O O
and O O
acidic O O
biosynthetic O O
pathways O O
of O O
bile O O
salt O O
( O O
BS O O
) O O
synthesis O O
were O O
evaluated O O
in O O
rats O O
with O O
an O O
intact O O
enterohepatic O O
circulation O O
and O O
in O O
rats O O
with O O
long O O
- O O
term O O
bile O O
diversion O O
to O O
induce O O
BS O O
synthesis O O
. O O

For O O
this O O
purpose O O
, O O
bile O O
salt O O
pool O O
composition O O
, O O
synthesis O O
of O O
individual O O
BS O O
in O O
vivo O O
, O O
hepatic O O
activities O O
, O O
and O O
expression O O
levels O O
of O O
cholesterol O O
7alpha O O
- O O
hydroxylase O O
( O O
CYP7A O O
) O O
, O O
and O O
sterol O O
27-hydroxylase O O
( O O
CYP27 O O
) O O
, O O
as O O
well O O
as O O
of O O
other O O
enzymes O O
involved O O
in O O
BS O O
synthesis O O
, O O
were O O
analyzed O O
in O O
rats O O
treated O O
with O O
EE O O
( O O
5 O O
mg O O
/ O O
kg O O
, O O
3 O O
days O O
) O O
or O O
its O O
vehicle O O
. O O

BS O O
pool O O
size O O
was O O
decreased O O
by O O
27 O O
% O O
but O O
total O O
BS O O
synthesis O O
was O O
not O O
affected O O
by O O
EE O O
in O O
intact O O
rats O O
. O O

Synthesis O O
of O O
cholate O O
was O O
reduced O O
by O O
68 O O
% O O
in O O
EE O O
- O O
treated O O
rats O O
, O O
while O O
that O O
of O O
chenodeoxycholate O O
was O O
increased O O
by O O
60 O O
% O O
. O O

The O O
recently O O
identified O O
Delta22-isomer O O
of O O
beta O O
- O O
muricholate O O
contributed O O
for O O
5.4 O O
% O O
and O O
18.3 O O
% O O
( O O
P O O
< O O
0.01 O O
) O O
to O O
the O O
pool O O
in O O
control O O
and O O
EE O O
- O O
treated O O
rats O O
, O O
respectively O O
, O O
but O O
could O O
not O O
be O O
detected O O
in O O
bile O O
after O O
exhaustion O O
of O O
the O O
pool O O
. O O

A O O
clear O O
reduction O O
of O O
BS O O
synthesis O O
was O O
found O O
in O O
bile O O
- O O
diverted O O
rats O O
treated O O
with O O
EE O O
, O O
yet O O
biliary O O
BS O O
composition O O
was O O
only O O
minimally O O
affected O O
. O O

Activity O O
of O O
CYP7A O O
was O O
decreased O O
by O O
EE O O
in O O
both O O
intact O O
and O O
bile O O
- O O
diverted O O
rats O O
, O O
whereas O O
the O O
activity O O
of O O
the O O
CYP27 O O
was O O
not O O
affected O O
. O O

Hepatic O O
mRNA O O
levels O O
of O O
CYP7A O O
were O O
significantly O O
reduced O O
by O O
EE O O
in O O
bile O O
- O O
diverted O O
rats O O
only O O
; O O
CYP27 O O
mRNA O O
levels O O
were O O
not O O
affected O O
by O O
EE O O
. O O

In O O
addition O O
, O O
mRNA O O
levels O O
of O O
sterol O O
12alpha O O
- O O
hydroxylase O O
and O O
lithocholate O O
6beta O O
- O O
hydroxylase O O
were O O
increased O O
by O O
bile O O
diversion O O
and O O
suppressed O O
by O O
EE O O
. O O

This O O
study O O
shows O O
that O O
17alpha O O
- O O
ethinylestradiol O O
( O O
EE O O
) O O
-induced O O
intrahepatic B-Disease O
cholestasis I-Disease B-Disease
in O O
rats O O
is O O
associated O O
with O O
selective O O
inhibition O O
of O O
the O O
neutral O O
pathway O O
of O O
bile O O
salt O O
( O O
BS O O
) O O
synthesis O O
. O O

Simultaneous O O
impairment O O
of O O
other O O
enzymes O O
in O O
the O O
BS O O
biosynthetic O O
pathways O O
may O O
contribute O O
to O O
overall O O
effects O O
of O O
EE O O
on O O
BS O O
synthesis O O
. O O

Glibenclamide O O
- O O
sensitive O O
hypotension B-Disease B-Disease
produced O O
by O O
helodermin O O
assessed O O
in O O
the O O
rat O O
. O O

The O O
effects O O
of O O
helodermin O O
, O O
a O O
basic O O
35-amino O O
acid O O
peptide O O
isolated O O
from O O
the O O
venom O O
of O O
a O O
lizard O O
salivary O O
gland O O
, O O
on O O
arterial O O
blood O O
pressure O O
and O O
heart O O
rate O O
were O O
examined O O
in O O
the O O
rat O O
, O O
focusing O O
on O O
the O O
possibility O O
that O O
activation O O
of O O
ATP O O
sensitive O O
K+ O O
( O O
K O O
( O O
ATP O O
) O O
) O O
channels O O
is O O
involved O O
in O O
the O O
responses O O
. O O

The O O
results O O
were O O
also O O
compared O O
with O O
those O O
of O O
vasoactive O O
intestinal O O
polypeptide O O
( O O
VIP O O
) O O
. O O

Helodermin O O
produced O O
hypotension B-Disease B-Disease
in O O
a O O
dose O O
- O O
dependent O O
manner O O
with O O
approximately O O
similar O O
potency O O
and O O
duration O O
to O O
VIP O O
. O O

Hypotension B-Disease B-Disease
induced O O
by O O
both O O
peptides O O
was O O
significantly O O
attenuated O O
by O O
glibenclamide O O
, O O
which O O
abolished O O
a O O
levcromakalim O O
- O O
produced O O
decrease O O
in O O
arterial O O
blood O O
pressure O O
. O O

Oxyhemoglobin O O
did O O
not O O
affect O O
helodermin O O
- O O
induced O O
hypotension B-Disease B-Disease
, O O
whereas O O
it O O
shortened O O
the O O
duration O O
of O O
acetylcholine O O
( O O
ACh O O
) O O
-produced O O
hypotension B-Disease B-Disease
. O O

These O O
findings O O
suggest O O
that O O
helodermin O O
- O O
produced O O
hypotension B-Disease B-Disease
is O O
partly O O
attributable O O
to O O
the O O
activation O O
of O O
glibenclamide O O
- O O
sensitive O O
K+ O O
channels O O
( O O
K O O
( O O
ATP O O
) O O
channels O O
) O O
, O O
which O O
presumably O O
exist O O
on O O
arterial O O
smooth O O
muscle O O
cells O O
. O O

EDRF O O
( O O
endothelium O O
- O O
derived O O
relaxing O O
factor O O
) O O
/ O O
nitric O O
oxide O O
does O O
not O O
seem O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
peptide O O
- O O
produced O O
hypotension B-Disease B-Disease
. O O

Long O O
- O O
term O O
efficacy O O
and O O
adverse O O
event O O
of O O
nifedipine O O
sustained O O
- O O
release O O
tablets O O
for O O
cyclosporin O O
A O O
- O O
induced O O
hypertension B-Disease B-Disease
in O O
patients O O
with O O
psoriasis B-Disease B-Disease
. O O

Thirteen O O
psoriatic B-Disease B-Disease
patients O O
with O O
hypertension B-Disease B-Disease
during O O
the O O
course O O
of O O
cyclosporin O O
A O O
therapy O O
were O O
treated O O
for O O
25 O O
months O O
with O O
a O O
calcium O O
channel O O
blocker O O
, O O
sustained O O
- O O
release O O
nifedipine O O
, O O
to O O
study O O
the O O
clinical O O
antihypertensive O O
effects O O
and O O
adverse O O
events O O
during O O
treatment O O
with O O
both O O
drugs O O
. O O

Seven O O
of O O
the O O
13 O O
patients O O
had O O
exhibited O O
a O O
subclinical O O
hypertensive B-Disease B-Disease
state O O
before O O
cyclosporin O O
A O O
therapy O O
. O O

Both O O
systolic O O
and O O
diastolic O O
blood O O
pressures O O
of O O
these O O
13 O O
patients O O
were O O
decreased O O
significantly O O
after O O
4 O O
weeks O O
of O O
nifedipine O O
therapy O O
, O O
and O O
blood O O
pressure O O
was O O
maintained O O
within O O
the O O
normal O O
range O O
thereafter O O
for O O
25 O O
months O O
. O O

The O O
adverse O O
events O O
during O O
combined O O
therapy O O
with O O
cyclosporin O O
A O O
and O O
nifedipine O O
included O O
an O O
increase O O
in O O
blood O O
urea O O
nitrogen O O
levels O O
in O O
9 O O
of O O
the O O
13 O O
patients O O
and O O
development O O
of O O
gingival B-Disease B-Disease
hyperplasia I-Disease I-Disease
in O O
2 O O
of O O
the O O
13 O O
patients O O
. O O

Our O O
findings O O
indicate O O
that O O
sustained O O
- O O
release O O
nifedipine O O
is O O
useful O O
for O O
hypertensive B-Disease B-Disease
psoriatic B-Disease B-Disease
patients O O
under O O
long O O
- O O
term O O
treatment O O
with O O
cyclosporin O O
A O O
, O O
but O O
that O O
these O O
patients O O
should O O
be O O
monitored O O
for O O
gingival B-Disease B-Disease
hyperplasia I-Disease I-Disease
. O O

Dominant O O
negative O O
effect O O
of O O
the O O
APC1309 O O
mutation O O
: O O
a O O
possible O O
explanation O O
for O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
. O O

Inactivation O O
of O O
the O O
adenomatous B-Disease B-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
( O O
APC B-Disease B-Disease
) O O
gene O O
product O O
initiates O O
colorectal O O
tumorigenesis O O
. O O

Patients O O
with O O
familial B-Disease B-Disease
APC I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
carry O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
APC B-Disease B-Disease
gene O O
and O O
develop O O
multiple O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
and O O
subsequent O O
carcinomas B-Disease B-Disease
early O O
in O O
life O O
. O O

The O O
severity O O
of O O
the O O
disease O O
correlates O O
with O O
the O O
position O O
of O O
the O O
inherited O O
APC B-Disease B-Disease
mutation O O
( O O
genotype O O
- O O
phenotype O O
correlation O O
) O O
. O O

Together O O
with O O
the O O
fact O O
that O O
both O O
germ O O
- O O
line O O
and O O
sporadic O O
APC B-Disease B-Disease
mutations O O
cluster O O
in O O
the O O
central O O
region O O
of O O
the O O
APC B-Disease B-Disease
gene O O
, O O
this O O
points O O
to O O
a O O
dominant O O
negative O O
effect O O
of O O
certain O O
APC B-Disease B-Disease
mutants O O
. O O

Loss O O
of O O
APC B-Disease B-Disease
function O O
was O O
recently O O
shown O O
to O O
result O O
in O O
enhanced O O
beta O O
- O O
catenin- O O
/ O O
Tcf O O
- O O
mediated O O
transcription O O
in O O
colon O O
epithelial O O
cells O O
. O O

Here O O
, O O
we O O
provide O O
experimental O O
evidence O O
for O O
a O O
dominant O O
negative O O
effect O O
of O O
APC B-Disease B-Disease
gene O O
products O O
associated O O
with O O
severe O O
polyposis B-Disease B-Disease
. O O

Wild O O
- O O
type O O
APC B-Disease B-Disease
activity O O
in O O
beta O O
- O O
catenin- O O
/ O O
Tcf O O
- O O
mediated O O
transcription O O
was O O
strongly O O
inhibited O O
by O O
a O O
mutant O O
APC B-Disease B-Disease
that O O
is O O
truncated O O
at O O
codon O O
1309 O O
. O O

In O O
contrast O O
, O O
mutant O O
APC B-Disease B-Disease
gene O O
products O O
that O O
are O O
associated O O
with O O
attenuated B-Disease B-Disease
polyposis I-Disease I-Disease
( O O
codon O O
386 O O
or O O
1465 O O
) O O
interfered O O
only O O
weakly O O
with O O
wild O O
- O O
type O O
APC B-Disease B-Disease
activity O O
. O O

These O O
results O O
suggest O O
a O O
molecular O O
explanation O O
for O O
the O O
genotype O O
- O O
phenotype O O
correlation O O
in O O
FAP B-Disease B-Disease
patients O O
and O O
support O O
the O O
idea O O
that O O
colorectal B-Disease B-Disease
tumor I-Disease I-Disease
growth O O
might O O
be O O
, O O
in O O
part O O
, O O
driven O O
by O O
selection O O
for O O
a O O
mutation O O
in O O
the O O
mutation O O
cluster O O
region O O
.. O O

Overgrowth B-Disease B-Disease
of I-Disease I-Disease
oral I-Disease I-Disease
mucosa I-Disease I-Disease
and I-Disease I-Disease
facial I-Disease I-Disease
skin I-Disease I-Disease
, O O
a O O
novel O O
feature O O
of O O
aspartylglucosaminuria B-Disease B-Disease
. O O

Aspartylglucosaminuria B-Disease B-Disease
( O O
AGU B-Disease B-Disease
) O O
is O O
a O O
lysosomal B-Disease B-Disease
storage I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
aspartylglucosaminidase I-Disease I-Disease
( O O
AGA O O
) O O
. O O

The O O
main O O
symptom O O
is O O
progressive O O
mental B-Disease B-Disease
retardation I-Disease I-Disease
. O O

A O O
spectrum O O
of O O
different O O
mutations O O
has O O
been O O
reported O O
in O O
this O O
disease O O
, O O
one O O
missense O O
mutation O O
( O O
Cys163Ser O O
) O O
being O O
responsible O O
for O O
the O O
majority O O
of O O
Finnish O O
cases O O
. O O

We O O
were O O
able O O
to O O
examine O O
66 O O
Finnish O O
AGU B-Disease B-Disease
patients O O
for O O
changes O O
in O O
the O O
oral O O
mucosa O O
and O O
44 O O
of O O
these O O
for O O
changes O O
in O O
facial O O
skin O O
. O O

Biopsy O O
specimens O O
of O O
16 O O
oral O B-Disease
lesions O I-Disease
, O O
12 O O
of O O
them O O
associated O O
with O O
the O O
teeth O O
, O O
plus O O
two O O
facial B-Disease B-Disease
lesions I-Disease I-Disease
were O O
studied O O
histologically O O
. O O

Immunohistochemical O O
staining O O
for O O
AGA O O
was O O
performed O O
on O O
15 O O
oral O O
specimens O O
. O O

Skin O O
was O O
seborrhoeic O O
in O O
adolescent O O
and O O
adult O O
patients O O
, O O
with O O
erythema B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
facial I-Disease I-Disease
skin I-Disease I-Disease
already O O
common O O
in O O
childhood O O
. O O

Of O O
44 O O
patients O O
, O O
nine O O
( O O
20 O O
% O O
) O O
had O O
facial B-Disease B-Disease
angiofibromas I-Disease I-Disease
, O O
tumours B-Disease B-Disease
primarily O O
occurring O O
in O O
association O O
with O O
tuberous B-Disease B-Disease
sclerosis I-Disease I-Disease
. O O

Oedemic B-Disease B-Disease
buccal I-Disease I-Disease
mucosa I-Disease I-Disease
( O O
leucoedema B-Disease B-Disease
) O O
and O O
gingival B-Disease B-Disease
overgrowths I-Disease I-Disease
were O O
more O O
frequent O O
in O O
AGU B-Disease B-Disease
patients O O
than O O
in O O
controls O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Of O O
16 O O
oral B-Disease B-Disease
mucosal I-Disease I-Disease
lesions I-Disease I-Disease
studied O O
histologically O O
, O O
15 O O
represented O O
fibroepithelial B-Disease B-Disease
or I-Disease I-Disease
epithelial I-Disease I-Disease
hyperplasias I-Disease I-Disease
and O O
were O O
reactive O O
in O O
nature O O
. O O

Cytoplasmic O O
vacuolisation O O
was O O
evident O O
in O O
four O O
. O O

Immunohistochemically O O
, O O
expression O O
of O O
AGA O O
in O O
AGU B-Disease B-Disease
patients O O
mucosal B-Disease B-Disease
lesions I-Disease I-Disease
did O O
not O O
differ O O
from O O
that O O
seen O O
in O O
corresponding O O
lesions O O
of O O
normal O O
subjects O O
. O O

Thus O O
, O O
the O O
high O O
frequency O O
of O O
mucosal B-Disease B-Disease
overgrowth I-Disease I-Disease
in O O
AGU B-Disease B-Disease
patients O O
does O O
not O O
appear O O
to O O
be O O
directly O O
associated O O
with O O
lysosomal O O
storage O O
or O O
with O O
alterations O O
in O O
the O O
level O O
of O O
AGA O O
expression O O
. O O

Sulfate O O
transport O O
is O O
not O O
impaired O O
in O O
pendred B-Disease B-Disease
syndrome I-Disease I-Disease
thyrocytes O O
. O O

Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
is O O
the O O
most O O
common O O
form O O
of O O
syndromic B-Disease B-Disease
deafness I-Disease I-Disease
, O O
characterized O O
by O O
dyshormonogenic B-Disease O
goiter I-Disease B-Disease
associated O O
with O O
sensory B-Disease B-Disease
- I-Disease I-Disease
neural I-Disease I-Disease
deafness I-Disease I-Disease
. O O

The O O
gene O O
responsible O O
for O O
the O O
disease O O
( O O
PDS B-Disease B-Disease
) O O
has O O
been O O
cloned O O
, O O
but O O
its O O
function O O
is O O
as O O
yet O O
unknown O O
and O O
the O O
connection O O
between O O
thyroid B-Disease B-Disease
goiter I-Disease I-Disease
and O O
sensory B-Disease B-Disease
- I-Disease I-Disease
neural I-Disease I-Disease
deafness I-Disease I-Disease
remains O O
an O O
enigma O O
. O O

PDS O O
codes O O
for O O
a O O
novel O O
protein O O
, O O
pendrin O O
, O O
which O O
is O O
closely O O
related O O
to O O
a O O
number O O
of O O
sufate O O
transporters O O
. O O

Mechanisms O O
by O O
which O O
abnormal O O
sulfate O O
transport O O
could O O
deleteriously O O
affect O O
iodide O O
organification O O
have O O
been O O
proposed O O
. O O

We O O
tested O O
sulfate O O
transport O O
in O O
thyrocytes O O
obtained O O
from O O
Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
patients O O
and O O
found O O
that O O
it O O
was O O
not O O
defective O O
. O O

This O O
suggests O O
that O O
pendrin O O
in O O
fact O O
may O O
not O O
be O O
a O O
sulfate O O
transporter O O
, O O
and O O
emphasizes O O
the O O
importance O O
of O O
functional O O
studies O O
on O O
this O O
novel O O
protein O O
.. O O

Mutational O O
analysis O O
of O O
the O O
HGO O O
gene O O
in O O
Finnish O O
alkaptonuria B-Disease B-Disease
patients O O
. O O

Alkaptonuria B-Disease B-Disease
( O O
AKU B-Disease B-Disease
) O O
, O O
the O O
prototypic O O
inborn B-Disease B-Disease
error I-Disease I-Disease
of I-Disease I-Disease
metabolism I-Disease I-Disease
, O O
has O O
recently O O
been O O
shown O O
to O O
be O O
caused O O
by O O
loss O O
of O O
function O O
mutations O O
in O O
the O O
homogentisate-1 O O
, O O
2-dioxygenase O O
gene O O
( O O
HGO O O
) O O
. O O

So O O
far O O
17 O O
mutations O O
have O O
been O O
characterised O O
in O O
AKU B-Disease B-Disease
patients O O
of O O
different O O
ethnic O O
origin O O
. O O

We O O
describe O O
three O O
novel O O
mutations O O
( O O
R58fs O O
, O O
R330S O O
, O O
and O O
H371R O O
) O O
and O O
one O O
common O O
AKU B-Disease B-Disease
mutation O O
( O O
M368V O O
) O O
, O O
detected O O
by O O
mutational O O
and O O
polymorphism O O
analysis O O
of O O
the O O
HGO O O
gene O O
in O O
five O O
Finnish O O
AKU B-Disease B-Disease
pedigrees O O
. O O

The O O
three O O
novel O O
AKU B-Disease B-Disease
mutations O O
are O O
most O O
likely O O
specific O O
for O O
the O O
Finnish O O
population O O
and O O
have O O
originated O O
recently O O
.. O O

Genetic O O
analysis O O
, O O
phenotypic O O
diagnosis O O
, O O
and O O
risk O O
of O O
venous B-Disease B-Disease
thrombosis I-Disease I-Disease
in O O
families O O
with O O
inherited O B-Disease
deficiencies B-Disease I-Disease
of I-Disease I-Disease
protein I-Disease I-Disease
S. I-Disease I-Disease
Protein B-Disease B-Disease
S I-Disease I-Disease
deficiency I-Disease I-Disease
is O O
a O O
recognized O O
risk O O
factor O O
for O O
venous B-Disease B-Disease
thrombosis I-Disease I-Disease
. O O

Of O O
all O O
the O O
inherited O B-Disease
thrombophilic B-Disease I-Disease
conditions I-Disease I-Disease
, O O
it O O
remains O O
the O O
most O O
difficult O O
to O O
diagnose O O
because O O
of O O
phenotypic O O
variability O O
, O O
which O O
can O O
lead O O
to O O
inconclusive O O
results O O
. O O

We O O
have O O
overcome O O
this O O
problem O O
by O O
studying O O
a O O
cohort O O
of O O
patients O O
from O O
a O O
single O O
center O O
where O O
the O O
diagnosis O O
was O O
confirmed O O
at O O
the O O
genetic O O
level O O
. O O

Twenty O O
- O O
eight O O
index O O
patients O O
with O O
protein B-Disease B-Disease
S I-Disease I-Disease
deficiency I-Disease I-Disease
and O O
a O O
PROS1 B-Disease B-Disease
gene I-Disease I-Disease
defect I-Disease I-Disease
were O O
studied O O
, O O
together O O
with O O
109 O O
first O O
- O O
degree O O
relatives O O
. O O

To O O
avoid O O
selection O O
bias O O
, O O
we O O
confined O O
analysis O O
of O O
total O O
and O O
free O O
protein O O
S O O
levels O O
and O O
thrombotic O B-Disease
risk O O
to O O
the O O
patients O O
relatives O O
. O O

In O O
this O O
group O O
of O O
relatives O O
, O O
a O O
low O O
free O O
protein O O
S O O
level O O
was O O
the O O
most O O
reliable O O
predictor O O
of O O
a O O
PROS1 B-Disease B-Disease
gene I-Disease I-Disease
defect I-Disease I-Disease
( O O
sensitivity O O
97 O O
. O O
7 O O
% O O
, O O
specificity O O
100 O O
% O O
) O O
. O O

First O O
- O O
degree O O
relatives O O
with O O
a O O
PROS1 B-Disease B-Disease
gene I-Disease I-Disease
defect I-Disease I-Disease
had O O
a O O
5 O O
. O O

0-fold O O
higher O O
risk O O
of O O
thrombosis B-Disease B-Disease
( O O
95 O O
% O O
confidence O O
interval O O
, O O
1 O O
. O O
5 O O
- O O
16 O O
. O O

8) O O
than O O
those O O
with O O
a O O
normal O O
PROS1 O O
gene O O
and O O
no O O
other O O
recognized O O
thrombophilic B-Disease B-Disease
defect I-Disease I-Disease
. O O

Although O O
pregnancy O O
/ O O
puerperium O O
and O O
immobility O B-Disease
/ O O
trauma B-Disease B-Disease
were O O
important O O
precipitating O O
factors O O
for O O
thrombosis B-Disease B-Disease
, O O
almost O O
half O O
of O O
the O O
events O O
were O O
spontaneous O O
. O O

Relatives O O
with O O
splice O O
- O O
site O O
or O O
major O O
structural O O
defects B-Disease O
in I-Disease O
the I-Disease O
PROS1 I-Disease O
gene I-Disease O
were O O
more O O
likely O O
to O O
have O O
had O O
a O O
thrombotic O B-Disease
event O O
and O O
had O O
significantly O O
lower O O
total O O
and O O
free O O
protein O O
S O O
levels O O
than O O
those O O
relatives O O
having O O
missense O O
mutations O O
. O O

We O O
conclude O O
that O O
persons O O
with O O
PROS1 B-Disease B-Disease
gene I-Disease I-Disease
defects I-Disease I-Disease
and O O
protein B-Disease B-Disease
S I-Disease I-Disease
deficiency I-Disease I-Disease
are O O
at O O
increased O O
risk O O
of O O
thrombosis B-Disease B-Disease
and O O
that O O
free O O
protein O O
S O O
estimation O O
offers O O
the O O
most O O
reliable O O
way O O
of O O
diagnosing O O
the O O
deficiency O O
. O O

( O O
Blood O O
. O O

2000 O O
; O O
95 O O
1935 O O
- O O
1941 O O
) O O
. O O

Autoinhibition O O
and O O
activation O O
mechanisms O O
of O O
the O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
protein O O
. O O

The O O
Rho O O
- O O
family O O
GTPase O O
, O O
Cdc42 O O
, O O
can O O
regulate O O
the O O
actin O O
cytoskeleton O O
through O O
activation O O
of O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
protein O O
( O O
WASP O O
) O O
family O O
members O O
. O O

Activation O O
relieves O O
an O O
autoinhibitory O O
contact O O
between O O
the O O
GTPase O O
- O O
binding O O
domain O O
and O O
the O O
carboxy O O
- O O
terminal O O
region O O
of O O
WASP O O
proteins O O
. O O

Here O O
we O O
report O O
the O O
autoinhibited O O
structure O O
of O O
the O O
GTPase O O
- O O
binding O O
domain O O
of O O
WASP O O
, O O
which O O
can O O
be O O
induced O O
by O O
the O O
C O O
- O O
terminal O O
region O O
or O O
by O O
organic O O
co O O
- O O
solvents O O
. O O

In O O
the O O
autoinhibited O O
complex O O
, O O
intramolecular O O
interactions O O
with O O
the O O
GTPase O O
- O O
binding O O
domain O O
occlude O O
residues O O
of O O
the O O
C O O
terminus O O
that O O
regulate O O
the O O
Arp2 O O
/ O O
3 O O
actin O O
- O O
nucleating O O
complex O O
. O O

Binding O O
of O O
Cdc42 O O
to O O
the O O
GTPase O O
- O O
binding O O
domain O O
causes O O
a O O
dramatic O O
conformational O O
change O O
, O O
resulting O O
in O O
disruption O O
of O O
the O O
hydrophobic O O
core O O
and O O
release O O
of O O
the O O
C O O
terminus O O
, O O
enabling O O
its O O
interaction O O
with O O
the O O
actin O O
regulatory O O
machinery O O
. O O

These O O
data O O
show O O
that O O
intrinsically O O
unstructured O O
peptides O O
such O O
as O O
the O O
GTPase O O
- O O
binding O O
domain O O
of O O
WASP O O
can O O
be O O
induced O O
into O O
distinct O O
structural O O
and O O
functional O O
states O O
depending O O
on O O
context O O
.. O O

Locus O O
heterogeneity O O
in O O
Friedreich B-Disease B-Disease
ataxia I-Disease I-Disease
. O O

Friedreich B-Disease B-Disease
ataxia I-Disease I-Disease
( O O
FRDA B-Disease B-Disease
) O O
is O O
the O O
most O O
common O O
form O O
of O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
ataxia I-Disease I-Disease
. O O

The O O
disease O O
locus O O
was O O
assigned O O
to O O
chromosome O O
9 O O
and O O
the O O
disease O O
gene O O
, O O
STM7 O O
/ O O
X25 O O
, O O
has O O
been O O
isolated O O
. O O

To O O
date O O
most O O
data O O
suggest O O
locus O O
homogeneity O O
in O O
FRDA B-Disease B-Disease
. O O

We O O
now O O
provide O O
strong O O
evidence O O
of O O
a O O
second O O
FRDA B-Disease B-Disease
locus O O
. O O

Studying O O
two O O
siblings O O
with O O
FRDA B-Disease B-Disease
from O O
two O O
families O O
we O O
did O O
not O O
detect O O
a O O
mutation O O
in O O
STM7 O O
/ O O
X25 O O
. O O

Haplotype O O
analysis O O
of O O
the O O
STM7 O O
/ O O
X25 O O
region O O
of O O
chromosome O O
9 O O
demonstrated O O
that O O
the O O
relevant O O
portion O O
of O O
chromosome O O
9 O O
differs O O
in O O
the O O
patients O O
. O O

Although O O
the O O
patients O O
studied O O
had O O
typical O O
FRDA B-Disease B-Disease
, O O
one O O
sibpair O O
had O O
the O O
uncommon O O
symptom O O
of O O
retained O O
tendon O O
reflexes O O
. O O

In O O
order O O
to O O
investigate O O
whether O O
retained O O
tendon O O
reflexes O O
are O O
characteristic O O
of O O
FRDA B-Disease B-Disease
caused O O
by O O
the O O
second O O
locus O O
, O O
FRDA2 O O
, O O
we O O
studied O O
an O O
unrelated O O
FRDA B-Disease B-Disease
patient O O
with O O
retained O O
tendon O O
reflexes O O
. O O

The O O
observation O O
of O O
typical O O
mutations O O
in O O
STM7 O O
/ O O
X25 O O
( O O
GAA O O
expansions O O
) O O
in O O
this O O
patient O O
demonstrates O O
that O O
the O O
two O O
genetically O O
different O O
forms O O
of O O
FRDA B-Disease B-Disease
can O O
not O O
be O O
distinguished O O
clinically O O
.. O O

Restoration O O
of O O
photoreceptor O O
ultrastructure O O
and O O
function O O
in O O
retinal B-Disease B-Disease
degeneration I-Disease I-Disease
slow O O
mice O O
by O O
gene O O
therapy O O
. O O

The O O
gene O O
Prph2 O O
encodes O O
a O O
photoreceptor O O
- O O
specific O O
membrane O O
glycoprotein O O
, O O
peripherin-2 O O
( O O
also O O
known O O
as O O
peripherin O O
/ O O
rds O O
) O O
, O O
which O O
is O O
inserted O O
into O O
the O O
rims O O
of O O
photoreceptor O O
outer O O
segment O O
discs O O
in O O
a O O
complex O O
with O O
rom-1 O O
( O O
ref O O
. O O

2 O O
) O O
. O O

The O O
complex O O
is O O
necessary O O
for O O
the O O
stabilization O O
of O O
the O O
discs O O
, O O
which O O
are O O
renewed O O
constantly O O
throughout O O
life O O
, O O
and O O
which O O
contain O O
the O O
visual O O
pigments O O
necessary O O
for O O
photon O O
capture O O
. O O

Mutations O O
in O O
Prph2 O O
have O O
been O O
shown O O
to O O
result O O
in O O
a O O
variety O O
of O O
photoreceptor B-Disease B-Disease
dystrophies I-Disease I-Disease
, O O
including O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
retinitis I-Disease I-Disease
pigmentosa I-Disease I-Disease
and O O
macular B-Disease B-Disease
dystrophy I-Disease I-Disease
. O O

A O O
common O O
feature O O
of O O
these O O
diseases O O
is O O
the O O
loss O O
of O O
photoreceptor O O
function O O
, O O
also O O
seen O O
in O O
the O O
retinal B-Disease B-Disease
degeneration I-Disease I-Disease
slow O O
( O O
rds O O
or O O
Prph2 O O
Rd2 O O
/ O O
Rd2 O O
) O O
mouse O O
, O O
which O O
is O O
homozygous O O
for O O
a O O
null O O
mutation O O
in O O
Prph2 O O
. O O

It O O
is O O
characterized O O
by O O
a O O
complete O O
failure O O
to O O
develop O O
photoreceptor O O
discs O O
and O O
outer O O
segments O O
, O O
downregulation O O
of O O
rhodopsin O O
and O O
apoptotic O O
loss O O
of O O
photoreceptor O O
cells O O
. O O

The O O
electroretinograms O O
( O O
ERGs O O
) O O
of O O
Prph2Rd2 O O
/ O O
Rd2 O O
mice O O
have O O
greatly O O
diminished O O
a O O
- O O
wave O O
and O O
b O O
- O O
wave O O
amplitudes O O
, O O
which O O
decline O O
to O O
virtually O O
undetectable O O
concentrations O O
by O O
two O O
months O O
. O O

Subretinal O O
injection O O
of O O
recombinant O O
adeno O O
- O O
associated O O
virus O O
( O O
AAV O O
) O O
encoding O O
a O O
Prph2 O O
transgene O O
results O O
in O O
stable O O
generation O O
of O O
outer O O
segment O O
structures O O
and O O
formation O O
of O O
new O O
stacks O O
of O O
discs O O
containing O O
both O O
perpherin-2 O O
and O O
rhodopsin O O
, O O
which O O
in O O
many O O
cases O O
are O O
morphologically O O
similar O O
to O O
normal O O
outer O O
segments O O
. O O

Moreover O O
, O O
the O O
re O O
- O O
establishment O O
of O O
the O O
structural O O
integrity O O
of O O
the O O
photoreceptor O O
layer O O
also O O
results O O
in O O
electrophysiological O O
correction O O
. O O

These O O
studies O O
demonstrate O O
for O O
the O O
first O O
time O O
that O O
a O O
complex O O
ultrastructural O O
cell O O
defect O O
can O O
be O O
corrected O O
both O O
morphologically O O
and O O
functionally O O
by O O
in O O
vivo O O
gene O O
transfer O O
.. O O

Function O O
of O O
an O O
axonal O O
chemoattractant O O
modulated O O
by O O
metalloprotease O O
activity O O
. O O

The O O
axonal O O
chemoattractant O O
netrin-1 O O
guides O O
spinal O O
commissural O O
axons O O
by O O
activating O O
its O O
receptor O O
DCC O O
( O O
Deleted O O
in O O
Colorectal B-Disease B-Disease
Cancer I-Disease I-Disease
) O O
. O O

We O O
have O O
found O O
that O O
chemical O O
inhibitors O O
of O O
metalloproteases O O
potentiate O O
netrin O O
- O O
mediated O O
axon O O
outgrowth O O
in O O
vitro O O
. O O

We O O
have O O
also O O
found O O
that O O
DCC O O
is O O
a O O
substrate O O
for O O
metalloprotease O O
- O O
dependent O O
ectodomain O O
shedding O O
, O O
and O O
that O O
the O O
inhibitors O O
block O O
proteolytic O O
processing O O
of O O
DCC O O
and O O
cause O O
an O O
increase O O
in O O
DCC O O
protein O O
levels O O
on O O
axons O O
within O O
spinal O O
cord O O
explants O O
. O O

Thus O O
, O O
potentiation O O
of O O
netrin O O
activity O O
by O O
inhibitors O O
may O O
result O O
from O O
stabilization O O
of O O
DCC O O
on O O
the O O
axons O O
, O O
and O O
proteolytic O O
activity O O
may O O
regulate O O
axon O O
migration O O
by O O
controlling O O
the O O
number O O
of O O
functional O O
extracellular O O
axon O O
guidance O O
receptors O O
.. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
in O O
transgenic O O
mice O O
expressing O O
an O O
expanded O O
CUG O O
repeat O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
, O O
the O O
most O O
common O O
form O O
of O O
muscular B-Disease B-Disease
dystrophy I-Disease I-Disease
in O O
adult O O
humans O O
, O O
results O O
from O O
expansion O O
of O O
a O O
CTG O O
repeat O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
the O O
DMPK O O
gene O O
. O O

The O O
mutant O O
DMPK O O
messenger O O
RNA O O
( O O
mRNA O O
) O O
contains O O
an O O
expanded O O
CUG O O
repeat O O
and O O
is O O
retained O O
in O O
the O O
nucleus O O
. O O

We O O
have O O
expressed O O
an O O
untranslated O O
CUG O O
repeat O O
in O O
an O O
unrelated O O
mRNA O O
in O O
transgenic O O
mice O O
. O O

Mice O O
that O O
expressed O O
expanded O O
CUG O O
repeats O O
developed O O
myotonia B-Disease B-Disease
and O O
myopathy B-Disease B-Disease
, O O
whereas O O
mice O O
expressing O O
a O O
nonexpanded O O
repeat O O
did O O
not O O
. O O

Thus O O
, O O
transcripts O O
with O O
expanded O O
CUG O O
repeats O O
are O O
sufficient O O
to O O
generate O O
a O O
DM B-Disease B-Disease
phenotype O O
. O O

This O O
result O O
supports O O
a O O
role O O
for O O
RNA O O
gain O O
of O O
function O O
in O O
disease O O
pathogenesis O O
.. O O

Malignant B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
the O O
families O O
of O O
patients O O
with O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
. O O

Ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
syndrome I-Disease I-Disease
associated O O
with O O
a O O
greatly O O
increased O O
incidence O O
of O O
malignant B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
homozygous O O
affected O O
individuals O O
. O O

Heterozygotes O O
for O O
the O O
gene O O
for O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
are O O
thought O O
to O O
comprise O O
about O O
1 O O
% O O
of O O
the O O
general O O
population O O
and O O
, O O
therefore O O
, O O
it O O
is O O
important O O
to O O
know O O
whether O O
this O O
gene O O
also O O
predisposes O O
the O O
heterozygous O O
carrier O O
to O O
cancers B-Disease B-Disease
. O O

Heterozygous O O
carriers O O
of O O
this O O
gene O O
are O O
common O O
among O O
the O O
close O O
relatives O O
of O O
patients O O
with O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
, O O
although O O
individual O O
carriers O O
can O O
not O O
be O O
identified O O
by O O
any O O
clinical O O
criterion O O
or O O
laboratory O O
test O O
. O O

For O O
this O O
reason O O
, O O
we O O
compared O O
the O O
incidence O O
of O O
death O O
from O O
malignant B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
2 O O
families O O
of O O
patients O O
with O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
to O O
that O O
expected O O
in O O
a O O
random O O
sample O O
of O O
the O O
general O O
population O O
. O O

There O O
were O O
59 O O
deaths O O
from O O
malignant B-Disease B-Disease
neoplasms I-Disease I-Disease
in O O
relatives O O
dying O O
before O O
age O O
75 O O
, O O
compared O O
to O O
42 O O
. O O

6 O O
expected O O
( O O
p O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

For O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
heterozygotes O O
younger O O
than O O
age O O
45 O O
, O O
the O O
risk O O
of O O
dying O O
from O O
a O O
malignant B-Disease B-Disease
neoplasm I-Disease I-Disease
was O O
estimated O O
to O O
be O O
greater O O
than O O
5 O O
times O O
the O O
risk O O
for O O
the O O
general O O
population O O
. O O

A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
heterozygotes O O
may O O
comprise O O
more O O
than O O
5 O O
% O O
of O O
all O O
persons O O
dying O O
from O O
a O O
cancer B-Disease B-Disease
before O O
age O O
45 O O
. O O

The O O
incidence O O
of O O
ovarian B-Disease B-Disease
, I-Disease I-Disease
gastric I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
biliary I-Disease I-Disease
system I-Disease I-Disease
carcinomas I-Disease I-Disease
and O O
of O O
leukemia B-Disease B-Disease
and O O
lymphoma B-Disease B-Disease
was O O
increased O O
in O O
these O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
families O O
. O O

Other O O
neoplasms B-Disease B-Disease
that O O
may O O
be O O
associated O O
with O O
this O O
gene O O
in O O
heterozygotes O O
include O O
pancreatic B-Disease B-Disease
, I-Disease I-Disease
basal I-Disease I-Disease
cell I-Disease I-Disease
, I-Disease I-Disease
colonic I-Disease I-Disease
, I-Disease I-Disease
breast I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
cervical I-Disease I-Disease
carcinomas I-Disease I-Disease
. O O

Analbuminemia B-Disease B-Disease
in O O
an O O
American O O
Indian O O
girl O O
. O O

Analbuminemia B-Disease B-Disease
was O O
fortuitously O O
detected O O
in O O
a O O
nonedematous O O
12-year O O
- O O
old O O
American O O
Indian O O
girl O O
with O O
atopic B-Disease B-Disease
dermatitis I-Disease I-Disease
, O O
mild O O
bronchial B-Disease B-Disease
asthma I-Disease I-Disease
, O O
a O O
mild O O
seizure B-Disease B-Disease
disorder I-Disease I-Disease
, O O
and O O
hyperlipoproteinemia B-Disease B-Disease
with O O
a O O
corneal B-Disease B-Disease
arcus I-Disease I-Disease
. O O

Immunologic O O
methods O O
revealed O O
trace O O
amounts O O
( O O
17 O O
mg O O
/ O O
100 O O
ml O O
) O O
of O O
apparently O O
normal O O
serum O O
albumin O O
. O O

The O O
patients O O
parents O O
were O O
remotely O O
related O O
. O O

The O O
pedigree O O
and O O
clinical O O
findings O O
were O O
compatible O O
with O O
autosomal O O
recessive O O
transmission O O
of O O
analbuminemia B-Disease B-Disease
. O O

Heterozygotes O O
had O O
subnormal O O
levels O O
of O O
serum O O
albumin O O
. O O

The O O
Gc O O
- O O
locus O O
is O O
closely O O
linked O O
to O O
the O O
structural O O
albumin O O
locus O O
. O O

Gc O O
- O O
protein O O
levels O O
were O O
normal O O
in O O
the O O
patient O O
and O O
together O O
with O O
normal O O
chromosomal O O
banding O O
studies O O
make O O
it O O
unlikely O O
that O O
a O O
chromosomal O O
deletion O O
caused O O
analbuminemia B-Disease B-Disease
. O O

Gc O O
- O O
types O O
in O O
the O O
family O O
were O O
compatible O O
with O O
, O O
but O O
did O O
not O O
prove O O
, O O
linkage O O
of O O
analbuminemia B-Disease B-Disease
to O O
the O O
Gc O O
- O O
locus O O
. O O

These O O
findings O O
suggest O O
a O O
" O O
thalassemia B-Disease B-Disease
" O O
-like O O
mutation O O
for O O
this O O
disorder O O
.. O O

Detection O O
of O O
a O O
nonsense O O
mutation O O
in O O
the O O
dystrophin O O
gene O O
by O O
multiple O O
SSCP O O
. O O

A O O
combination O O
of O O
multiplex O O
PCR O O
with O O
the O O
single O O
strand O O
conformation O O
polymorphism O O
( O O
SSCP O O
) O O
technique O O
was O O
employed O O
to O O
screen O O
for O O
point O O
mutations O O
in O O
the O O
human O O
dystrophin O O
gene O O
. O O

Co O O
- O O
amplification O O
of O O
11 O O
exons O O
from O O
genomic O O
DNA O O
of O O
Duchenne B-Disease B-Disease
and I-Disease I-Disease
Becker I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
/ O O
BMD B-Disease B-Disease
) O O
patients O O
with O O
no O O
deletion O O
or O O
duplication O O
was O O
performed O O
and O O
the O O
samples O O
subjected O O
to O O
multiple O O
SSCP O O
analysis O O
. O O

We O O
report O O
the O O
case O O
of O O
a O O
nonsense O O
mutation O O
in O O
a O O
Duchenne B-Disease B-Disease
patient O O
identified O O
by O O
this O O
approach O O
. O O

The O O
mutation O O
introduces O O
a O O
termination O O
codon O O
within O O
exon O O
8 O O
of O O
the O O
dystrophin O O
gene O O
. O O

It O O
is O O
predicted O O
to O O
cause O O
a O O
very O O
premature O O
translational O O
termination O O
accounting O O
for O O
the O O
severe O O
phenotype O O
observed O O
. O O

The O O
patient O O
inherited O O
this O O
mutation O O
from O O
his O O
mother O O
. O O

In O O
addition O O
the O O
analysis O O
revealed O O
5 O O
polymorphisms O O
useful O O
for O O
internal O O
control O O
.. O O

Linkage O O
of O O
gene O O
for O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
and O O
the O O
major O O
histocompatibility O O
complex O O
MHC O O
in O O
man O O
. O O

Family O O
study O O
of O O
a O O
further O O
case O O
. O O

Close O O
linkage O O
between O O
HL O O
- O O
A O O
and O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
was O O
first O O
reported O O
by O O
FU O O
and O O
co O O
- O O
workers O O
in O O
1974 O O
. O O

We O O
present O O
here O O
a O O
pedigree O O
of O O
a O O
31-year O O
- O O
old O O
C2-deficient B-Disease B-Disease
individual O O
with O O
clinical O O
manifestations O O
of O O
Hodgkins B-Disease B-Disease
disease I-Disease I-Disease
. O O

The O O
following O O
markers O O
were O O
tested O O
C2 O O
levels O O
, O O
factor O O
B O O
polymorphism O O
, O O
blood O O
groups O O
, O O
and O O
enzyme O O
typing O O
. O O

In O O
addition O O
to O O
close O O
linkage O O
between O O
HL O O
- O O
A O O
and O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
both O O
parents O O
were O O
heterozygous O O
for O O
Bf O O
( O O
HL O O
- O O
A O O
linked O O
, O O
electrophoretic O O
variation O O
of O O
B O O
) O O
. O O

The O O
two O O
HL O O
- O O
A O O
haplotypes O O
closely O O
linked O O
to O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
are O O
different O O
2 O O
, O O
W18 O O
and O O
W24 O O
, O O
W18 O O
. O O

They O O
share O O
, O O
however O O
, O O
the O O
SD2 O O
antigen O O
W18 O O
and O O
the O O
LD O O
type O O
7a O O
.. O O

Late O O
- O O
onset O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
: O O
molecular O O
pathology O O
in O O
two O O
siblings O O
. O O

We O O
report O O
on O O
a O O
new O O
allele O O
at O O
the O O
arylsulfatase O O
A O O
( O O
ARSA O O
) O O
locus O O
causing O O
late O O
- O O
onset O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
( O O
MLD B-Disease B-Disease
) O O
. O O

In O O
that O O
allele O O
arginine84 O O
, O O
a O O
residue O O
that O O
is O O
highly O O
conserved O O
in O O
the O O
arylsulfatase O O
gene O O
family O O
, O O
is O O
replaced O O
by O O
glutamine O O
. O O

In O O
contrast O O
to O O
alleles O O
that O O
cause O O
early O O
- O O
onset O O
MLD B-Disease B-Disease
, O O
the O O
arginine84 O O
to O O
glutamine O O
substitution O O
is O O
associated O O
with O O
some O O
residual O O
ARSA O O
activity O O
. O O

A O O
comparison O O
of O O
genotypes O O
, O O
ARSA O O
activities O O
, O O
and O O
clinical O O
data O O
on O O
4 O O
individuals O O
carrying O O
the O O
allele O O
of O O
81 O O
patients O O
with O O
MLD B-Disease B-Disease
examined O O
, O O
further O O
validates O O
the O O
concept O O
that O O
different O O
degrees O O
of O O
residual O O
ARSA O O
activity O O
are O O
the O O
basis O O
of O O
phenotypical O O
variation O O
in O O
MLD B-Disease B-Disease
.. O O

Trisomy B-Disease B-Disease
15 I-Disease I-Disease
with O O
loss O O
of O O
the O O
paternal O O
15 O O
as O O
a O O
cause O O
of O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
due O O
to O O
maternal B-Disease B-Disease
disomy I-Disease I-Disease
. O O

Uniparental B-Disease B-Disease
disomy I-Disease I-Disease
has O O
recently O O
been O O
recognized O O
to O O
cause O O
human O O
disorders O O
, O O
including O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
PWS B-Disease B-Disease
) O O
. O O

We O O
describe O O
a O O
particularly O O
instructive O O
case O O
which O O
raises O O
important O O
issues O O
concerning O O
the O O
mechanisms O O
producing O O
uniparental B-Disease B-Disease
disomy I-Disease I-Disease
and O O
whose O O
evaluation O O
provides O O
evidence O O
that O O
trisomy O O
may O O
precede O O
uniparental B-Disease B-Disease
disomy I-Disease I-Disease
in O O
a O O
fetus O O
. O O

Chorionic O O
villus O O
sampling O O
performed O O
for O O
advanced O O
maternal O O
age O O
revealed O O
trisomy B-Disease B-Disease
15 I-Disease I-Disease
in O O
all O O
direct O O
and O O
cultured O O
cells O O
, O O
though O O
the O O
fetus O O
appeared O O
normal O O
. O O

Chromosome O O
analysis O O
of O O
amniocytes O O
obtained O O
at O O
15 O O
wk O O
was O O
normal O O
in O O
over O O
100 O O
cells O O
studied O O
. O O

The O O
child O O
was O O
hypotonic B-Disease B-Disease
at O O
birth O O
, O O
and O O
high O O
- O O
resolution O O
banding O O
failed O O
to O O
reveal O O
the O O
deletion O O
of O O
15q11 O O
- O O
13 O O
, O O
a O O
deletion O O
which O O
is O O
found O O
in O O
50 O O
% O O
-70 O O
% O O
of O O
patients O O
with O O
PWS B-Disease B-Disease
. O O

Over O O
time O O
, O O
typical O O
features O O
of O O
PWS B-Disease B-Disease
developed O O
. O O

Molecular O O
genetic O O
analysis O O
using O O
probes O O
for O O
chromosome O O
15 O O
revealed O O
maternal O B-Disease
disomy O I-Disease
. O O

Maternal O O
nondisjunction O O
with O O
fertilization O O
of O O
a O O
disomic O O
egg O O
by O O
a O O
normal O O
sperm O O
, O O
followed O O
by O O
loss O O
of O O
the O O
paternal O O
15 O O
, O O
is O O
a O O
likely O O
cause O O
of O O
confined O O
placental O O
mosaicism O O
and O O
uniparental B-Disease B-Disease
disomy I-Disease I-Disease
in O O
this O O
case O O
of O O
PWS B-Disease B-Disease
, O O
and O O
advanced O O
maternal O O
age O O
may O O
be O O
a O O
predisposing O O
factor O O
.. O O

Genetic O O
heterogeneity O O
in O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
amelogenesis I-Disease I-Disease
imperfecta I-Disease I-Disease
. O O

The O O
AMELX O O
gene O O
located O O
at O O
Xp22 O O
. O O

1-p22 O O
. O O

3 O O
encodes O O
for O O
the O O
enamel O O
protein O O
amelogenin O O
and O O
has O O
been O O
implicated O O
as O O
the O O
gene O O
responsible O O
for O O
the O O
inherited B-Disease B-Disease
dental I-Disease I-Disease
abnormality I-Disease I-Disease
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
amelogenesis I-Disease I-Disease
imperfecta I-Disease I-Disease
( O O
XAI B-Disease B-Disease
) O O
. O O

Three O O
families O O
with O O
XAI B-Disease B-Disease
have O O
been O O
investigated O O
using O O
polymorphic O O
DNA O O
markers O O
flanking O O
the O O
position O O
of O O
AMELX O O
. O O

Using O O
two O O
- O O
point O O
linkage O O
analysis O O
, O O
linkage O O
was O O
established O O
between O O
XAI B-Disease B-Disease
and O O
several O O
of O O
these O O
markers O O
in O O
two O O
families O O
, O O
with O O
a O O
combined O O
lod O O
score O O
of O O
6 O O
. O O

05 O O
for O O
DXS16 O O
at O O
theta O O
= O O
0 O O
. O O
04 O O
04 O O
. O O

This O O
supports O O
the O O
involvement O O
of O O
AMELX O O
, O O
located O O
close O O
to O O
DXS16 O O
, O O
in O O
the O O
XAI B-Disease B-Disease
disease I-Disease I-Disease
process O O
( O O
AIH1 O O
) O O
in O O
those O O
families O O
. O O

Using O O
multipoint O O
linkage O O
analysis O O
, O O
the O O
combined O O
maximum O O
lod O O
score O O
for O O
these O O
two O O
families O O
was O O
7 O O
. O O
30 O O
for O O
a O O
location O O
of O O
AIH1 O O
at O O
2 O O
cM O O
distal O O
to O O
DXS16 O O
. O O

The O O
support O O
interval O O
around O O
this O O
location O O
extended O O
about O O
8 O O
cM O O
proximal O O
to O O
DXS92 O O
, O O
and O O
the O O
AIH1 O O
location O O
could O O
not O O
be O O
precisely O O
defined O O
by O O
multipoint O O
mapping O O
. O O

Study O O
of O O
recombination O O
events O O
indicated O O
that O O
AIH1 O O
lies O O
in O O
the O O
interval O O
between O O
DXS143 O O
and O O
DXS85 O O
. O O

There O O
was O O
significant O O
evidence O O
against O O
linkage O O
to O O
this O O
region O O
in O O
the O O
third O O
family O O
, O O
indicating O O
locus O O
heterogeneity O O
in O O
XAI B-Disease B-Disease
. O O

Further O O
analysis O O
with O O
markers O O
on O O
the O O
long O O
arm O O
of O O
the O O
X O O
chromosome O O
showed O O
evidence O O
of O O
linkage O O
to O O
DXS144E O O
and O O
F9 O O
with O O
no O O
recombination O O
with O O
either O O
of O O
these O O
markers O O
. O O

Two O O
- O O
point O O
analysis O O
gave O O
a O O
peak O O
lod O O
score O O
at O O
DXS144E O O
with O O
a O O
maximum O O
lod O O
score O O
of O O
2 O O
. O O

83 O O
at O O
theta O O
= O O
0 O O
, O O
with O O
a O O
peak O O
lod O O
score O O
in O O
multipoint O O
linkage O O
analysis O O
of O O
2 O O
. O O
84 O O
at O O
theta O O
= O O
0 O O
. O O

The O O
support O O
interval O O
extended O O
9 O O
cM O O
proximal O O
to O O
DXS144E O O
and O O
14 O O
cM O O
distal O O
to O O
F9 O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

Typical O O
and O O
partial O O
cat B-Disease B-Disease
eye I-Disease I-Disease
syndrome I-Disease I-Disease
: O O
identification O O
of O O
the O O
marker O O
chromosome O O
by O O
FISH O O
. O O

Three O O
children O O
are O O
reported O O
with O O
typical O O
cat B-Disease B-Disease
eye I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
CES B-Disease B-Disease
) O O
and O O
three O O
more O O
children O O
with O O
partial O O
CES B-Disease B-Disease
because O O
of O O
absence O O
of O O
coloboma O B-Disease
, O O
in O O
which O O
the O O
supernumerary O O
marker O O
chromosome O O
was O O
studied O O
by O O
FISH O O
. O O

Using O O
a O O
genomic O O
library O O
, O O
and O O
also O O
a O O
centromeric O O
and O O
particularly O O
a O O
cosmid O O
probe O O
of O O
22q11 O O
, O O
partial O O
tetrasomy B-Disease B-Disease
was O O
shown O O
in O O
all O O
cases O O
.. O O

Linkage O O
analysis O O
in O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
adrenoleukodystrophy I-Disease I-Disease
and O O
application O O
in O O
post- O O
and O O
prenatal O O
diagnosis O O
. O O

We O O
have O O
performed O O
linkage O O
analysis O O
with O O
the O O
DNA O O
markers O O
DXS52 O O
and O O
the O O
clotting O O
factor O O
VIII O O
gene O O
( O O
F8C O O
) O O
, O O
in O O
several O O
large O O
families O O
with O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
adrenoleukodystrophy I-Disease I-Disease
( O O
ALD B-Disease B-Disease
) O O
. O O

The O O
tight O O
linkage O O
to O O
DXS52 O O
could O O
be O O
extended O O
giving O O
a O O
maximal O O
LOD O O
score O O
of O O
22 O O
. O O

5 O O
at O O
1 O O
cM. O O
F8C O O
was O O
also O O
tightly O O
linked O O
to O O
ALD B-Disease B-Disease
with O O
a O O
maximal O O
LOD O O
score O O
of O O
7 O O
. O O
8 O O
without O O
recombination O O
. O O

Multipoint O O
linkage O O
analysis O O
with O O
the O O
markers O O
DXS304 O O
, O O
DXS52 O O
, O O
and O O
F8C O O
indicated O O
that O O
both O O
the O O
gene O O
for O O
ALD B-Disease B-Disease
and O O
for O O
F8C O O
are O O
distal O O
to O O
DXS52 O O
. O O

In O O
four O O
patients O O
with O O
ALD B-Disease B-Disease
, O O
no O O
major O O
structural O O
rearrangement O O
in O O
the O O
Xqter O O
region O O
was O O
observed O O
; O O
in O O
particular O O
, O O
there O O
were O O
no O O
abnormalities B-Disease B-Disease
in I-Disease I-Disease
the I-Disease I-Disease
vision I-Disease I-Disease
blindness I-Disease I-Disease
genes I-Disease O
. O O

DNA O O
analysis O O
appeared O O
to O O
be O O
of O O
use O O
in O O
determination O O
of O O
the O O
carrier O O
status O O
of O O
females O O
at O O
risk O O
, O O
for O O
the O O
determination O O
of O O
the O O
origin O O
of O O
the O O
mutation O O
in O O
a O O
particular O O
family O O
, O O
and O O
for O O
prenatal O O
diagnosis O O
. O O

Huntington B-Disease B-Disease
disease I-Disease I-Disease
and O O
childhood O O
- O O
onset O O
Tourette B-Disease B-Disease
syndrome I-Disease I-Disease
. O O

A O O
40-year O O
- O O
old O O
man O O
with O O
childhood O O
- O O
onset O O
Tourette B-Disease B-Disease
syndrome I-Disease I-Disease
( O O
TS B-Disease B-Disease
) O O
developed O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
. O O

We O O
believe O O
this O O
to O O
be O O
the O O
first O O
reported O O
case O O
of O O
childhood O O
- O O
onset O O
TS B-Disease B-Disease
with O O
adult O O
onset O O
HD B-Disease B-Disease
. O O

Discovery O O
of O O
other O O
cases O O
with O O
both O O
disorders O O
may O O
provide O O
clues O O
to O O
the O O
pathophysiology O O
of O O
both O O
conditions O O
.. O O

Linkage O O
of O O
aspartylglucosaminuria B-Disease B-Disease
( O O
AGU B-Disease B-Disease
) O O
to O O
marker O O
loci O O
on O O
the O O
long O O
arm O O
of O O
chromosome O O
4 O O
. O O

Aspartylglucosaminuria B-Disease B-Disease
( O O
AGU B-Disease B-Disease
) O O
is O O
caused O O
by O O
deficient O O
activity O O
of O O
the O O
enzyme O O
aspartylglucosaminidase O O
( O O
AGA O O
) O O
. O O

The O O
structural O O
gene O O
for O O
AGA O O
has O O
been O O
assigned O O
to O O
the O O
region O O
4q21-qter O O
of O O
chromosome O O
4 O O
. O O

We O O
have O O
studied O O
the O O
map O O
position O O
of O O
the O O
AGU O B-Disease
locus O O
in O O
relation O O
to O O
other O O
marker O O
loci O O
on O O
the O O
long O O
arm O O
of O O
chromosome O O
4 O O
using O O
linkage O O
analyses O O
. O O

Restriction O O
fragment O O
length O O
polymorphism O O
alleles O O
for O O
the O O
ADH2 O O
, O O
ADH3 O O
, O O
EGF O O
, O O
FG O O
alpha O O
and O O
FG O O
beta O O
loci O O
and O O
blood O O
group O O
antigens O O
for O O
the O O
MNS O B-Disease
locus O O
were O O
determined O O
in O O
a O O
panel O O
of O O
12 O O
Finnish O O
AGU B-Disease B-Disease
families O O
. O O

The O O
heterozygous O O
family O O
members O O
were O O
identified O O
by O O
reduced O O
activity O O
of O O
AGA O O
in O O
lymphocytes O O
. O O

Linkage O O
studies O O
were O O
performed O O
using O O
both O O
pairwise O O
and O O
multipoint O O
analyses O O
. O O

Loose O O
linkage O O
of O O
the O O
AGU B-Disease B-Disease
locus O O
to O O
the O O
FG O O
and O O
MNS O O
loci O O
was O O
observed O O
( O O
z O O
= O O
1 O O
. O O
16 O O
, O O
z O O
= O O
1 O O
. O O
39 O O
, O O
respectively O O
) O O
. O O

Multipoint O O
analysis O O
to O O
the O O
fixed O O
map O O
[ O O
ADH- O O
( O O
0 O O
. O O
03 O O
) O O
-EGF- O O
( O O
0 O O
. O O
35 O O
) O O
-FG- O O
( O O
0 O O
. O O
11 O O
) O O
-MNS O O
] O O
suggests O O
that O O
the O O
location O O
of O O
the O O
AGU O B-Disease
locus O O
is O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
30 O O
recombination O O
units O O
distal O O
to O O
MNS O O
( O O
z O O
= O O
3 O O
. O O
03 O O
) O O
. O O

The O O
order O O
cen O O
- O O
ADH O O
- O O
EGF O O
- O O
FG O O
- O O
MNS O O
- O O
AGU O O
is O O
35 O O
times O O
more O O
likely O O
than O O
the O O
next O O
best O O
order O O
cen O O
- O O
ADH O O
- O O
EGF O O
- O O
AGU O O
- O O
FG O O
- O O
MNS O O
. O O

Detection O O
of O O
98 O O
% O O
of O O
DMD B-Disease B-Disease
/ O O
BMD B-Disease B-Disease
gene O O
deletions O O
by O O
polymerase O O
chain O O
reaction O O
. O O

We O O
describe O O
oligonucleotide O O
primer O O
sequences O O
that O O
can O O
be O O
used O O
to O O
amplify O O
eight O O
exons O O
plus O O
the O O
muscle O O
promoter O O
of O O
the O O
dystrophin O O
gene O O
in O O
a O O
single O O
multiplex O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
. O O

When O O
used O O
in O O
conjunction O O
with O O
an O O
existing O O
primer O O
set O O
, O O
these O O
two O O
multiplex O O
reactions O O
detect O O
about O O
98 O O
% O O
of O O
deletions O O
in O O
patients O O
with O O
Duchenne B-Disease B-Disease
or I-Disease I-Disease
Becker I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
, O O
BMD B-Disease B-Disease
) O O
. O O

Furthermore O O
, O O
these O O
primers O O
amplify O O
most O O
of O O
the O O
exons O O
in O O
the O O
deletion O O
prone O O
" O O
hot O O
spot O O
" O O
region O O
around O O
exons O O
44 O O
to O O
53 O O
, O O
allowing O O
determination O O
of O O
deletion O O
endpoints O O
and O O
prediction O O
of O O
mutational O O
effects O O
on O O
the O O
translational O O
reading O O
frame O O
. O O

Thus O O
, O O
use O O
of O O
these O O
PCR O O
- O O
based O O
assays O O
will O O
allow O O
deletion O O
detection O O
and O O
prenatal O O
diagnosis O O
for O O
most O O
DMD B-Disease B-Disease
/ O O
BMD B-Disease B-Disease
patients O O
in O O
a O O
fraction O O
of O O
the O O
time O O
required O O
for O O
Southern O O
blot O O
analysis O O
.. O O

Statistical O O
analysis O O
of O O
the O O
two O O
stage O O
mutation O O
model O O
in O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
disease I-Disease I-Disease
, O O
and O O
in O O
sporadic B-Disease B-Disease
cerebellar I-Disease I-Disease
haemangioblastoma I-Disease I-Disease
and O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
. O O

Analysis O O
of O O
the O O
age O O
incidence O O
curves O O
for O O
unilateral B-Disease B-Disease
and I-Disease I-Disease
bilateral I-Disease I-Disease
retinoblastoma I-Disease I-Disease
led O O
Knudson O O
to O O
propose O O
that O O
hereditary B-Disease B-Disease
tumours I-Disease I-Disease
may O O
arise O O
by O O
a O O
single O O
event O O
and O O
sporadic B-Disease B-Disease
tumours I-Disease I-Disease
by O O
a O O
two O O
stage O O
mutation O O
process O O
. O O

It O O
has O O
been O O
suggested O O
recently O O
that O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
may O O
arise O O
from O O
a O O
two O O
stage O O
mutation O O
process O O
. O O

We O O
analysed O O
the O O
age O O
incidence O O
curves O O
for O O
symptomatic O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
( O O
n O O
= O O
26 O O
) O O
and O O
cerebellar B-Disease B-Disease
haemangioblastoma I-Disease I-Disease
( O O
n O O
= O O
68 O O
) O O
in O O
109 O O
patients O O
with O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
( I-Disease I-Disease
VHL I-Disease I-Disease
) I-Disease I-Disease
disease I-Disease I-Disease
, O O
and O O
compared O O
them O O
to O O
104 O O
patients O O
with O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
and O O
43 O O
patients O O
with O O
sporadic B-Disease B-Disease
cerebellar I-Disease I-Disease
haemangioblastoma I-Disease I-Disease
. O O

The O O
age O O
incidence O O
curves O O
for O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
and O O
cerebellar B-Disease B-Disease
haemangioblastoma I-Disease I-Disease
in O O
VHL B-Disease B-Disease
disease I-Disease I-Disease
were O O
compatible O O
with O O
a O O
single O O
mutation O O
model O O
, O O
whereas O O
the O O
age O O
incidence O O
curves O O
for O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
and O O
cerebellar B-Disease B-Disease
haemangioblastoma I-Disease I-Disease
suggested O O
a O O
two O O
stage O O
mutation O O
process O O
. O O

These O O
data O O
are O O
compatible O O
with O O
the O O
VHL B-Disease B-Disease
gene O O
functioning O O
as O O
a O O
recessive O O
tumour B-Disease B-Disease
suppressor O O
gene O O
. O O

Sporadic B-Disease B-Disease
cerebellar I-Disease I-Disease
haemangioblastoma I-Disease I-Disease
and O O
some O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
may O O
arise O O
from O O
somatic O O
mutations O O
inactivating O O
both O O
alleles O O
at O O
the O O
VHL B-Disease B-Disease
locus O O
.. O O

Molecular O O
and O O
phenotypic O O
analysis O O
of O O
patients O O
with O O
deletions O O
within O O
the O O
deletion O O
- O O
rich O O
region O O
of O O
the O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
) O O
gene O O
. O O

Eighty O O
unrelated O O
individuals O O
with O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
) O O
or O O
Becker B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
BMD B-Disease B-Disease
) O O
were O O
found O O
to O O
have O O
deletions O O
in O O
the O O
major O O
deletion O O
- O O
rich O O
region O O
of O O
the O O
DMD B-Disease B-Disease
locus O O
. O O

This O O
region O O
includes O O
the O O
last O O
five O O
exons O O
detected O O
by O O
cDNA5b-7 O O
, O O
all O O
exons O O
detected O O
by O O
cDNA8 O O
, O O
and O O
the O O
first O O
two O O
exons O O
detected O O
by O O
cDNA9 O O
. O O

These O O
80 O O
individuals O O
account O O
for O O
approximately O O
75 O O
% O O
of O O
109 O O
deletions O O
of O O
the O O
gene O O
, O O
detected O O
among O O
181 O O
patients O O
analyzed O O
with O O
the O O
entire O O
dystrophin O O
cDNA O O
. O O

Endpoints O O
for O O
many O O
of O O
these O O
deletions O O
were O O
further O O
characterized O O
using O O
two O O
genomic O O
probes O O
, O O
p20 O O
( O O
DXS269 O O
; O O
Wapenaar O O
et O O
al. O O
) O O
and O O
GMGX11 O O
( O O
DXS239 O O
; O O
present O O
paper O O
) O O
. O O

Clinical O O
findings O O
are O O
presented O O
for O O
all O O
80 O O
patients O O
allowing O O
a O O
correlation O O
of O O
phenotypic O O
severity O O
with O O
the O O
genotype O O
. O O

Thirty O O
- O O
eight O O
independent O O
patients O O
were O O
old O O
enough O O
to O O
be O O
classified O O
as O O
DMD B-Disease B-Disease
, O O
BMD B-Disease B-Disease
, O O
or O O
intermediate O O
phenotype O O
and O O
had O O
deletions O O
of O O
exons O O
with O O
sequenced O O
intron O O
/ O O
exon O O
boundaries O O
. O O

Of O O
these O O
, O O
eight O O
BMD B-Disease B-Disease
patients O O
and O O
one O O
intermediate O O
patient O O
had O O
gene O O
deletions O O
predicted O O
to O O
leave O O
the O O
reading O O
frame O O
intact O O
, O O
while O O
21 O O
DMD B-Disease B-Disease
patients O O
, O O
7 O O
intermediate O O
patients O O
, O O
and O O
1 O O
BMD B-Disease B-Disease
patient O O
had O O
gene O O
deletions O O
predicted O O
to O O
disrupt O O
the O O
reading O O
frame O O
. O O

Thus O O
, O O
with O O
two O O
exceptions O O
, O O
frameshift O O
deletions O O
of O O
the O O
gene O O
resulted O O
in O O
more O O
severe O O
phenotype O O
than O O
did O O
in O O
- O O
frame O O
deletions O O
. O O

This O O
is O O
in O O
agreement O O
with O O
recent O O
findings O O
by O O
Baumbach O O
et O O
al. O O
and O O
Koenig O O
et O O
al. O O
but O O
is O O
in O O
contrast O O
to O O
findings O O
, O O
by O O
Malhotra O O
et O O
al. O O
at O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
. O O

X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
glucose-6-phosphate I-Disease I-Disease
dehydrogenase I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
Mus O O
musculus O O
. O O

A O O
mouse O O
with O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
glucose-6-phosphate I-Disease I-Disease
dehydrogenase I-Disease I-Disease
( I-Disease I-Disease
G6PD I-Disease I-Disease
) I-Disease I-Disease
deficiency I-Disease I-Disease
has O O
been O O
recovered O O
in O O
offspring O O
of O O
1-ethyl-1-nitrosourea O O
- O O
treated O O
male O O
mice O O
. O O

The O O
activity O O
alteration O O
was O O
detected O O
in O O
blood O O
but O O
can O O
also O O
be O O
observed O O
in O O
other O O
tissue O O
extracts O O
. O O

Hemizygous O O
, O O
heterozygous O O
, O O
and O O
homozygous O O
mutants O O
have O O
, O O
respectively O O
, O O
about O O
15 O O
, O O
60 O O
, O O
and O O
15 O O
% O O
G6PD O O
remaining O O
activity O O
in O O
the O O
blood O O
as O O
compared O O
to O O
the O O
wild O O
type O O
. O O

Erythrocyte O O
indices O O
did O O
not O O
show O O
differences O O
between O O
mutants O O
and O O
wild O O
types O O
. O O

The O O
mutation O O
does O O
not O O
affect O O
the O O
electrophoretic O O
migration O O
, O O
the O O
isoelectric O O
point O O
, O O
or O O
the O O
thermal O O
stability O O
. O O

Kinetic O O
properties O O
, O O
such O O
as O O
the O O
Km O O
for O O
glucose-6-phosphate O O
or O O
for O O
NADP O O
and O O
the O O
relative O O
utilization O O
of O O
substrate O O
analogues O O
, O O
showed O O
no O O
differences O O
between O O
wild O O
types O O
and O O
mutants O O
with O O
the O O
exception O O
of O O
the O O
relative O O
utilization O O
of O O
deamino O O
- O O
NADP O O
which O O
was O O
significantly O O
lower O O
in O O
mutants O O
. O O

This O O
is O O
presently O O
the O O
only O O
animal O O
model O O
for O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
G6PD I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
humans O O
.. O O

Genetic O O
analysis O O
in O O
families O O
with O O
van B-Disease B-Disease
der I-Disease I-Disease
Woude I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

We O O
have O O
brought O O
together O O
information O O
on O O
864 O O
affected O O
individuals O O
in O O
164 O O
families O O
( O O
including O O
three O O
new O O
pedigrees O O
) O O
reported O O
in O O
the O O
137 O O
year O O
period O O
since O O
1845 O O
when O O
Demarquay O O
first O O
described O O
a O O
family O O
with O O
what O O
was O O
later O O
called O O
van B-Disease B-Disease
der I-Disease I-Disease
Woude I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
VWS B-Disease B-Disease
) O O
. O O

Both O O
types O O
of O O
oral B-Disease B-Disease
cleft I-Disease I-Disease
, O O
cleft B-Disease B-Disease
palate I-Disease I-Disease
( O O
CP B-Disease B-Disease
) O O
and O O
cleft B-Disease B-Disease
lip I-Disease I-Disease
with O O
or O O
without O O
CP B-Disease B-Disease
( O O
CLP B-Disease B-Disease
) O O
, O O
segregate O O
in O O
these O O
families O O
together O O
with O O
lower O O
lip B-Disease B-Disease
pits I-Disease I-Disease
or O O
fistulae B-Disease B-Disease
in O O
an O O
autosomal O O
dominant O O
mode O O
with O O
high O O
penetrance O O
estimated O O
to O O
be O O
K O O
= O O
. O O

89 O O
and O O
. O O
99 O O
by O O
different O O
methods O O
. O O

Cleft O O
types O O
( O O
CLP B-Disease B-Disease
and O O
CP B-Disease B-Disease
) O O
occur O O
in O O
VWS B-Disease B-Disease
in O O
the O O
same O O
proportions O O
as O O
in O O
the O O
general O O
non O O
- O O
VWS O B-Disease
population O O
, O O
ie O O
, O O
about O O
twice O O
as O O
many O O
cleft O O
- O O
bearing O O
individuals O O
have O O
CLP B-Disease B-Disease
as O O
have O O
CP B-Disease B-Disease
. O O

On O O
the O O
other O O
hand O O
, O O
we O O
do O O
not O O
find O O
the O O
usually O O
observed O O
excess O O
of O O
females O O
with O O
CP B-Disease B-Disease
and O O
excess O O
of O O
males O O
with O O
CLP B-Disease B-Disease
; O O
in O O
VWS B-Disease B-Disease
the O O
sex O O
ratios O O
are O O
more O O
nearly O O
equal O O
. O O

Lip B-Disease B-Disease
pits I-Disease I-Disease
also O O
are O O
equally O O
distributed O O
between O O
the O O
sexes O O
. O O

Affected O O
males O O
and O O
females O O
are O O
equally O O
likely O O
to O O
transmit O O
VWS B-Disease B-Disease
. O O

However O O
, O O
there O O
is O O
an O O
excess O O
of O O
less O O
severely O O
affected O O
individuals O O
among O O
transmitters O O
and O O
a O O
deficiency O O
of O O
more O O
severely O O
affected O O
, O O
brought O O
about O O
by O O
a O O
proband O O
bias O O
and O O
differential O O
fecundity O O
. O O

The O O
expression O O
of O O
VWS B-Disease B-Disease
is O O
significantly O O
modified O O
by O O
the O O
genetic O O
background O O
More O O
extreme O O
phenotypes O O
in O O
parents O O
tend O O
to O O
produce O O
more O O
extreme O O
expression O O
in O O
their O O
children O O
. O O

For O O
a O O
VWS B-Disease B-Disease
gene O O
carrier O O
the O O
relative O O
risk O O
of O O
transmitting O O
a O O
cleft O O
is O O
26 O O
. O O
45 O O
% O O
; O O
that O O
of O O
transmitting O O
lower O O
lip B-Disease B-Disease
pits I-Disease I-Disease
is O O
23 O O
. O O
55 O O
% O O
. O O

Three O O
pedigrees O O
of O O
lip B-Disease B-Disease
pits I-Disease I-Disease
in O O
the O O
literature O O
show O O
no O O
clefts O O
among O O
a O O
significant O O
number O O
of O O
affected O O
individuals O O
. O O

Control O O
of O O
gene O O
expression O O
in O O
VWS B-Disease B-Disease
in O O
the O O
three O O
target O O
tissues O O
appears O O
to O O
be O O
independent O O
and O O
separately O O
designated O O
. O O

Mutation O O
rate O O
of O O
the O O
VWS B-Disease B-Disease
gene O O
is O O
calculated O O
to O O
be O O
1 O O
. O O
8 O O
X O O
10 O O
( O O
-5 O O
) O O

Familial B-Disease B-Disease
discoid I-Disease I-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
associated O O
with O O
heterozygote O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

Two O O
siblings O O
with O O
chronic B-Disease B-Disease
discoid I-Disease I-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
and O O
several O O
family O O
members O O
were O O
found O O
with O O
heterozygous O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

An O O
association O O
with O O
histocompatibility O O
markers O O
HLA O O
- O O
B18 O O
and O O
HLA O O
- O O
Dw2 O O
was O O
demonstrated O O
, O O
and O O
the O O
slow O O
allotype O O
of O O
factor O O
B O O
was O O
present O O
. O O

Linkage O O
studies O O
in O O
this O O
family O O
suggested O O
a O O
close O O
linkage O O
between O O
the O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
gene O O
and O O
genes O O
coding O O
for O O
B18 O O
, O O
Dw2 O O
, O O
and O O
BfS O O
antigens O O
. O O

One O O
HLA O O
- O O
ACB O O
/ O O
DBf O O
recombinant O O
was O O
observed O O
showing O O
closer O O
linkage O O
between O O
HLA O O
- O O
D O O
and O O
Bf O O
than O O
between O O
HLA O O
- O O
B O O
and O O
Bf O O
.. O O

New O O
genetic O O
variants O O
of O O
glucose O O
6-phosphate O O
dehydrogenase O O
( O O
G6PD O O
) O O
in O O
Italy O O
. O O

Six O O
new O O
variants O O
of O O
human O O
erythrocyte O O
G6PD O O
have O O
been O O
characterized O O
. O O

All O O
of O O
them O O
were O O
found O O
in O O
Italian O O
males O O
and O O
all O O
were O O
associated O O
with O O
enzyme B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
but O O
only O O
two O O
with O O
signs O O
of O O
haemolysis B-Disease B-Disease
. O O

These O O
and O O
other O O
variants O O
reported O O
in O O
the O O
literature O O
, O O
which O O
must O O
thus O O
far O O
be O O
regarded O O
as O O
sporadic O O
, O O
are O O
found O O
to O O
map O O
in O O
parts O O
of O O
Italy O O
where O O
common O O
types O O
of O O
G6PD B-Disease B-Disease
deficiency I-Disease I-Disease
are O O
also O O
prevalent O O
.. O O

Aberrant O O
subcellular O O
localization O O
of O O
BRCA1 O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
BRCA1 O O
gene O O
product O O
was O O
identified O O
as O O
a O O
220-kilodalton O O
nuclear O O
phosphoprotein O O
in O O
normal O O
cells O O
, O O
including O O
breast O O
ductal O O
epithelial O O
cells O O
, O O
and O O
in O O
18 O O
of O O
20 O O
tumor B-Disease B-Disease
cell O O
lines O O
derived O O
from O O
tissues O O
other O O
than O O
breast O O
and O O
ovary O O
. O O

In O O
16 O O
of O O
17 O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
lines O O
and O O
17 O O
of O O
17 O O
samples O O
of O O
cells O O
obtained O O
from O O
malignant O O
effusions O O
, O O
however O O
, O O
BRCA1 O O
localized O O
mainly O O
in O O
cytoplasm O O
. O O

Absence O O
of O O
BRCA1 O O
or O O
aberrant O O
subcellular O O
location O O
was O O
also O O
observed O O
to O O
a O O
variable O O
extent O O
in O O
histological O O
sections O O
of O O
many O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
biopsies O O
. O O

These O O
findings O O
suggest O O
that O O
BRCA1 B-Disease B-Disease
abnormalities I-Disease I-Disease
may O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
many O O
breast B-Disease B-Disease
cancers I-Disease I-Disease
, O O
sporadic O O
as O O
well O O
as O O
familial O O
.. O O

The O O
carrier O O
frequency O O
of O O
the O O
BRCA1 O O
185delAG O O
mutation O O
is O O
approximately O O
1 O O
percent O O
in O O
Ashkenazi O O
Jewish O O
individuals O O
. O O

Since O O
BRCA1 O O
, O O
the O O
first O O
major O O
gene O O
responsible O O
for O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
, O O
was O O
cloned O O
, O O
more O O
than O O
50 O O
unique O O
mutations O O
have O O
been O O
detected O O
in O O
the O O
germline O O
of O O
individuals O O
with O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

In O O
high O O
- O O
risk O O
pedigrees O O
, O O
female O O
carriers O O
of O O
BRCA1 O O
mutations O O
have O O
an O O
80 O O
- O O
90 O O
% O O
lifetime O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
and O O
a O O
40 O O
- O O
50 O O
% O O
risk O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
. O O

However O O
, O O
the O O
mutation O O
stats O O
of O O
individuals O O
unselected O O
for O O
breast B-Disease B-Disease
or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
has O O
not O O
been O O
determined O O
, O O
and O O
it O O
is O O
not O O
known O O
whether O O
mutations O O
in O O
such O O
individuals O O
confer O O
the O O
same O O
risk O O
of O O
cancer B-Disease B-Disease
as O O
in O O
individuals O O
from O O
the O O
high O O
- O O
risk O O
families O O
studied O O
so O O
far O O
. O O

Following O O
the O O
finding O O
of O O
a O O
185delAG O O
frameshift O O
mutation O O
in O O
several O O
Ashkenazi O O
Jewish O O
breast O O
/ O O
ovarian O O
families O O
, O O
we O O
have O O
determined O O
the O O
frequency O O
of O O
this O O
mutation O O
in O O
858 O O
Ashkenazim O O
seeking O O
genetic O O
testing O O
for O O
conditions O O
unrelated O O
to O O
cancer B-Disease B-Disease
, O O
and O O
in O O
815 O O
reference O O
individuals O O
not O O
selected O O
for O O
ethnic O O
origin O O
. O O

We O O
observed O O
the O O
185delAG O O
mutation O O
in O O
0 O O
. O O
9 O O
% O O
of O O
Ashkenazim O O
( O O
95 O O
% O O
confidence O O
limit O O
, O O
0 O O
. O O
4 O O
- O O
1 O O
. O O
8 O O
% O O
) O O
and O O
in O O
none O O
of O O
the O O
reference O O
samples O O
. O O

Our O O
results O O
suggest O O
that O O
one O O
in O O
a O O
hundred O O
women O O
of O O
Ashkenazi O O
descent O O
may O O
be O O
at O O
especially O O
high O O
risk O O
of O O
developing O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

The O O
protein O O
deficient O O
in O O
Lowe B-Disease B-Disease
syndrome I-Disease I-Disease
is O O
a O O
phosphatidylinositol-4,5-bisphosphate O O
5-phosphatase O O
. O O

Lowe B-Disease B-Disease
syndrome I-Disease I-Disease
, O O
also O O
known O O
as O O
oculocerebrorenal B-Disease B-Disease
syndrome I-Disease I-Disease
, O O
is O O
caused O O
by O O
mutations O O
in O O
the O O
X O O
chromosome O O
- O O
encoded O O
OCRL O O
gene O O
. O O

The O O
OCRL O O
protein O O
is O O
51 O O
% O O
identical O O
to O O
inositol O O
polyphosphate O O
5-phosphatase O O
II O O
( O O
5-phosphatase O O
II O O
) O O
from O O
human O O
platelets O O
over O O
a O O
span O O
of O O
744 O O
aa O O
, O O
suggesting O O
that O O
OCRL O O
may O O
be O O
a O O
similar O O
enzyme O O
. O O

We O O
engineered O O
a O O
construct O O
of O O
the O O
OCRL O O
cDNA O O
that O O
encodes O O
amino O O
acids O O
homologous O O
to O O
the O O
platelet O O
5-phosphatase O O
for O O
expression O O
in O O
baculovirus O O
- O O
infected O O
Sf9 O O
insect O O
cells O O
. O O

This O O
cDNA O O
encodes O O
aa O O
264 O O
- O O
968 O O
of O O
the O O
OCRL O O
protein O O
. O O

The O O
recombinant O O
protein O O
was O O
found O O
to O O
catalyze O O
the O O
reactions O O
also O O
carried O O
out O O
by O O
platelet O O
5-phosphatase O O
II O O
. O O

Thus O O
OCRL O O
converts O O
inositol O O
1 O O
, O O
4 O O
, O O
5-trisphosphate O O
to O O
inositol O O
1 O O
, O O
4-bisphosphate O O
, O O
and O O
it O O
converts O O
inositol O O
1 O O
, O O
3 O O
, O O
4 O O
, O O
5-tetrakisphosphate O O
to O O
inositol O O
1 O O
, O O
3 O O
, O O
4-trisphosphate O O
. O O

Most O O
important O O
, O O
the O O
enzyme O O
converts O O
phosphatidylinositol O O
4 O O
, O O
5-bisphosphate O O
to O O
phosphatidylinositol O O
4-phosphate O O
. O O

The O O
relative O O
ability O O
of O O
OCRL O O
to O O
catalyze O O
the O O
three O O
reactions O O
is O O
different O O
from O O
that O O
of O O
5-phosphatase O O
II O O
and O O
from O O
that O O
of O O
another O O
5-phosphatase O O
isoenzyme O O
from O O
platelets O O
, O O
5-phosphatase O O
I. O O
The O O
recombinant O O
OCRL O O
protein O O
hydrolyzes O O
the O O
phospholipid O O
substrate O O
10- O O
to O O
30-fold O O
better O O
than O O
5-phosphatase O O
II O O
, O O
and O O
5-phosphatase O O
I O O
does O O
not O O
cleave O O
the O O
lipid O O
at O O
all O O
. O O

We O O
also O O
show O O
that O O
OCRL O O
functions O O
as O O
a O O
phosphatidylinositol O O
4 O O
, O O
5-bisphosphate O O
5-phosphatase O O
in O O
OCRL O O
- O O
expressing O O
Sf9 O O
cells O O
. O O

These O O
results O O
suggest O O
that O O
OCRL O O
is O O
mainly O O
a O O
lipid O O
phosphatase O O
that O O
may O O
control O O
cellular O O
levels O O
of O O
a O O
critical O O
metabolite O O
, O O
phosphatidylinositol O O
4 O O
, O O
5-bisphosphate O O
. O O

Deficiency O B-Disease
of O I-Disease
this O I-Disease
enzyme O I-Disease
apparently O O
causes O O
the O O
protean O O
manifestations O O
of O O
Lowe B-Disease B-Disease
syndrome I-Disease I-Disease
.. O O

A O O
single O O
amino O O
acid O O
substitution O O
( O O
G103D O O
) O O
in O O
the O O
type O O
II O O
collagen O O
triple O O
helix O O
produces O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
. O O

Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
is O O
a O O
moderately O O
severe O O
chondrodysplasia B-Disease B-Disease
phenotype O O
that O O
results O O
from O O
mutations O O
in O O
the O O
gene O O
for O O
type O O
II O O
collagen O O
, O O
COL2A1 O O
. O O

Characteristics O O
of O O
the O O
disorder O O
include O O
a O O
short B-Disease O
trunk I-Disease O
and I-Disease O
extremities I-Disease O
, O O
mid B-Disease B-Disease
- I-Disease I-Disease
face I-Disease I-Disease
hypoplasia I-Disease I-Disease
, O O
cleft B-Disease B-Disease
palate I-Disease I-Disease
, O O
myopia B-Disease B-Disease
, O O
retinal B-Disease B-Disease
detachment I-Disease I-Disease
, O O
and O O
hearing B-Disease B-Disease
loss I-Disease I-Disease
. O O

Recently O O
, O O
deletions O O
of O O
all O O
or O O
part O O
of O O
exon O O
12 O O
have O O
been O O
identified O O
in O O
individuals O O
with O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
, O O
suggesting O O
that O O
mutations O O
within O O
this O O
region O O
of O O
the O O
protein O O
may O O
primarily O O
result O O
in O O
the O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
phenotype O O
. O O

We O O
used O O
SSCP O O
to O O
analyze O O
an O O
amplified O O
genomic O O
DNA O O
fragment O O
containing O O
exon O O
12 O O
from O O
seven O O
individuals O O
with O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
. O O

An O O
abnormality O O
was O O
identified O O
in O O
one O O
patient O O
. O O

DNA O O
sequence O O
analysis O O
demonstrated O O
that O O
the O O
patient O O
was O O
heterozygous O O
for O O
a O O
G O O
to O O
A O O
transition O O
that O O
implied O O
substitution O O
of O O
glycine103 O O
of O O
the O O
triple O O
helical O O
domain O O
by O O
aspartate O O
. O O

The O O
mutation O O
was O O
not O O
observed O O
in O O
DNA O O
from O O
either O O
of O O
the O O
clinically O O
unaffected O O
parents O O
of O O
the O O
proband O O
. O O

Protein O O
microsequencing O O
demonstrated O O
expression O O
of O O
the O O
abnormal O O
allele O O
in O O
cartilage O O
. O O

These O O
data O O
demonstrate O O
that O O
point O O
mutations O O
which O O
result O O
in O O
single O O
amino O O
acid O O
substitutions O O
can O O
produce O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
and O O
further O O
support O O
the O O
hypothesis O O
that O O
alteration O O
of O O
a O O
domain O O
, O O
which O O
includes O O
the O O
region O O
encoded O O
by O O
exon O O
12 O O
, O O
in O O
the O O
type O O
II O O
collagen O O
protein O O
leads O O
to O O
this O O
disorder O O
.. O O

Mutation O O
spectrum O O
in O O
the O O
CHM B-Disease B-Disease
gene O O
of O O
Danish O O
and O O
Swedish O O
choroideremia B-Disease B-Disease
patients O O
. O O

The O O
recent O O
isolation O O
of O O
the O O
complete O O
open O O
reading O O
frame O O
of O O
the O O
choroideremia B-Disease B-Disease
( O O
CHM B-Disease B-Disease
) O O
gene O O
and O O
the O O
characterization O O
of O O
the O O
exon O O
- O O
intron O O
boundaries O O
has O O
paved O O
the O O
way O O
to O O
mutation O O
detection O O
in O O
patients O O
with O O
classical O O
choroideremia B-Disease B-Disease
. O O

We O O
have O O
performed O O
mutation O O
screening O O
in O O
patients O O
from O O
15 O O
Danish O O
and O O
Swedish O O
families O O
by O O
using O O
Southern O O
blot O O
hybridization O O
and O O
the O O
polymerase O O
chain O O
reaction O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
( O O
PCR O O
- O O
SSCP O O
) O O
technique O O
. O O

Causative O O
mutations O O
in O O
the O O
CHM B-Disease B-Disease
gene O O
were O O
detected O O
in O O
at O O
least O O
12 O O
families O O
, O O
indicating O O
that O O
a O O
substantial O O
part O O
of O O
the O O
mutations O O
can O O
be O O
identified O O
by O O
this O O
approach O O
. O O

In O O
four O O
of O O
these O O
families O O
deletions O O
of O O
different O O
sizes O O
were O O
found O O
. O O

Thus O O
, O O
in O O
one O O
patient O O
, O O
the O O
deletion O O
resulted O O
in O O
the O O
absence O O
of O O
only O O
one O O
exon O O
, O O
while O O
in O O
another O O
the O O
deletion O O
comprised O O
the O O
entire O O
CHM B-Disease B-Disease
gene O O
. O O

Mapping O O
of O O
the O O
deletion O O
endpoints O O
in O O
these O O
four O O
patients O O
and O O
in O O
another O O
11 O O
male O O
patients O O
with O O
sizeable O O
deletions O O
enabled O O
us O O
to O O
construct O O
a O O
very O O
detailed O O
map O O
of O O
intervals O O
2 O O
and O O
3 O O
of O O
Xq21 O O
. O O

In O O
the O O
remaining O O
11 O O
Danish O O
and O O
Swedish O O
families O O
at O O
least O O
8 O O
causative O O
mutations O O
were O O
found O O
by O O
PCR O O
- O O
SSCP O O
analysis O O
and O O
direct O O
sequencing O O
. O O

Interestingly O O
, O O
all O O
CHM B-Disease B-Disease
gene O O
mutations O O
detected O O
thus O O
far O O
in O O
choroideremia B-Disease B-Disease
patients O O
give O O
rise O O
to O O
the O O
introduction O O
of O O
a O O
premature O O
stop O O
codon O O
.. O O

X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
spastic I-Disease I-Disease
paraplegia I-Disease I-Disease
and O O
Pelizaeus B-Disease B-Disease
- I-Disease I-Disease
Merzbacher I-Disease I-Disease
disease I-Disease I-Disease
are O O
allelic B-Disease B-Disease
disorders I-Disease I-Disease
at O O
the O O
proteolipid O O
protein O O
locus O O
. O O

Three O O
forms O O
of O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
spastic I-Disease I-Disease
paraplegia I-Disease I-Disease
( O O
SPG B-Disease B-Disease
) O O
have O O
been O O
defined O O
. O O

One O O
locus O O
( O O
SPG O O
1 O O
) O O
maps O O
to O O
Xq28 O O
while O O
two O O
clinically O O
distinct O O
forms O O
map O O
to O O
Xq22 O O
( O O
SPG2 O O
) O O
. O O

A O O
rare O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
dysmyelinating I-Disease I-Disease
disorder I-Disease I-Disease
of O O
the O O
central O O
nervous O O
system O O
, O O
Pelizaeus B-Disease B-Disease
- I-Disease I-Disease
Merzbacher I-Disease I-Disease
disease I-Disease I-Disease
( O O
PMD B-Disease B-Disease
) O O
, O O
has O O
also O O
been O O
mapped O O
to O O
Xq21-q22 O O
, O O
and O O
is O O
caused O O
by O O
mutations O O
in O O
the O O
proteolipid O O
protein O O
gene O O
( O O
PLP O O
) O O
which O O
encodes O O
two O O
myelin O O
proteins O O
, O O
PLP O O
and O O
DM20 O O
. O O

While O O
narrowing O O
the O O
genetic O O
interval O O
containing O O
SPG2 O O
in O O
a O O
large O O
pedigree O O
, O O
we O O
found O O
that O O
PLP O O
was O O
the O O
closest O O
marker O O
to O O
the O O
disease O O
locus O O
, O O
implicating O O
PLP O O
as O O
a O O
possible O O
candidate O O
gene O O
. O O

We O O
have O O
found O O
that O O
a O O
point O O
mutation O O
( O O
His139Tyr O O
) O O
in O O
exon O O
3B O O
of O O
an O O
affected O O
male O O
produces O O
a O O
mutant O O
PLP O O
but O O
a O O
normal O O
DM20 O O
, O O
and O O
segregates O O
with O O
the O O
disease O O
( O O
Zmax O O
= O O
6 O O
. O O
63 O O
, O O
theta O O
= O O
0 O O
. O O
00 O O
) O O
. O O

It O O
appears O O
, O O
therefore O O
, O O
that O O
SPG2 O O
and O O
PMD B-Disease B-Disease
are O O
allelic B-Disease B-Disease
disorders I-Disease I-Disease

Huntington B-Disease B-Disease
disease I-Disease I-Disease
without O O
CAG O O
expansion O O
: O O
phenocopies O O
or O O
errors O O
in O O
assignment O O
? O O

Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
has O O
been O O
shown O O
to O O
be O O
associated O O
with O O
an O O
expanded O O
CAG O O
repeat O O
within O O
a O O
novel O O
gene O O
on O O
4p16 O O
. O O

3 O O
( O O
IT15 O O
) O O
. O O

A O O
total O O
of O O
30 O O
of O O
1 O O
, O O
022 O O
affected O O
persons O O
( O O
2 O O
. O O
9 O O
% O O
of O O
our O O
cohort O O
) O O
did O O
not O O
have O O
an O O
expanded O O
CAG O O
in O O
the O O
disease O O
range O O
. O O

The O O
reasons O O
for O O
not O O
observing O O
expansion O O
in O O
affected O O
individuals O O
are O O
important O O
for O O
determining O O
the O O
sensitivity O O
of O O
using O O
repeat O O
length O O
both O O
for O O
diagnosis O O
of O O
affected O O
patients O O
and O O
for O O
predictive O O
testing O O
programs O O
and O O
may O O
have O O
biological O O
relevance O O
for O O
the O O
understanding O O
of O O
the O O
molecular O O
mechanism O O
underlying O O
HD B-Disease B-Disease
. O O

Here O O
we O O
show O O
that O O
the O O
majority O O
( O O
18 O O
) O O
of O O
the O O
individuals O O
with O O
normal O O
sized O O
alleles O O
represent O O
misdiagnosis O O
, O O
sample O O
mix O O
- O O
up O O
, O O
or O O
clerical O O
error O O
. O O

The O O
remaining O O
12 O O
patients O O
represent O O
possible O O
phenocopies O O
for O O
HD B-Disease B-Disease
. O O

In O O
at O O
least O O
four O O
cases O O
, O O
family O O
studies O O
of O O
these O O
phenocopies O O
excluded O O
4p16 O O
. O O

3 O O
as O O
the O O
region O O
responsible O O
for O O
the O O
phenotype O O
. O O

Mutations O O
in O O
the O O
HD B-Disease B-Disease
gene O O
that O O
are O O
other O O
than O O
CAG O O
expansion O O
have O O
not O O
been O O
excluded O O
for O O
the O O
remaining O O
eight O O
cases O O
; O O
however O O
, O O
in O O
as O O
many O O
as O O
seven O O
of O O
these O O
persons O O
, O O
retrospective O O
review O O
of O O
these O O
patients O O
clinical O O
features O O
identified O O
characteristics O O
not O O
typical O O
for O O
HD B-Disease B-Disease
. O O

This O O
study O O
shows O O
that O O
on O O
rare O O
occasions O O
mutations O O
in O O
other O O
, O O
as O O
- O O
yet O O
- O O
undefined O O
genes O O
can O O
present O O
with O O
a O O
clinical O O
phenotype O O
very O O
similar O O
to O O
that O O
of O O
HD B-Disease B-Disease

Assignment O O
of O O
the O O
human O O
Na+ O O
/ O O
glucose O O
cotransporter O O
gene O O
SGLT1 O O
to O O
chromosome O O
22q13.1 O O
. O O

The O O
Na O O
+ O O
/glucose O O
cotransporter O O
gene O O
SGLT1 O O
encodes O O
the O O
primary O O
carrier O O
protein O O
responsible O O
for O O
the O O
uptake O O
of O O
the O O
dietary O O
sugars O O
glucose O O
and O O
galactose O O
from O O
the O O
intestinal O O
lumen O O
. O O

SGLT1 O O
transport O O
activity O O
is O O
currently O O
exploited O O
in O O
oral O O
rehydration O O
therapy O O
. O O

The O O
75-kDa O O
glycoprotein O O
is O O
localized O O
in O O
the O O
brush O O
border O O
of O O
the O O
intestinal O O
epithelium O O
and O O
is O O
predicted O O
to O O
comprise O O
12 O O
membrane O O
spans O O
. O O

In O O
two O O
patients O O
with O O
the O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
disease I-Disease I-Disease
glucose I-Disease I-Disease
/ I-Disease I-Disease
galactose I-Disease I-Disease
malabsorption I-Disease I-Disease
, O O
the O O
underlying O O
cause O O
was O O
found O O
to O O
be O O
a O O
missense O O
mutation O O
in O O
SGLT1 O O
, O O
and O O
the O O
Asp28 O O
- O O
- O O
> O O
Asn O O
change O O
was O O
demonstrated O O
in O O
vitro O O
to O O
eliminate O O
SGLT1 O O
transport O O
activity O O
. O O

The O O
SGLT1 O O
gene O O
was O O
previously O O
shown O O
to O O
reside O O
on O O
the O O
distal O O
q O O
arm O O
of O O
chromosome O O
22 O O
( O O
11 O O
. O O
2 O O
- O O
- O O
> O O
qter O O
) O O
. O O

We O O
have O O
used O O
a O O
cosmid O O
probe O O
for O O
fluorescence O O
in O O
situ O O
hybridization O O
, O O
which O O
refines O O
the O O
localization O O
to O O
22q13 O O
. O O

1 O O
, O O
and O O
provide O O
an O O
example O O
of O O
the O O
utility O O
of O O
the O O
SGLT1 O O
probe O O
as O O
a O O
diagnostic O O
for O O
genetic B-Disease B-Disease
diseases I-Disease I-Disease
associated O O
with O O
translocations O O
of O O
chromosome O O
22 O O
. O O

Haplotype O O
studies O O
in O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
. O O

In O O
51 O O
families O O
with O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
, O O
we O O
have O O
studied O O
DNA O O
haplotypes O O
of O O
dinucleotide O O
repeat O O
polymorphisms O O
( O O
CA O O
repeats O O
) O O
in O O
the O O
13q14 O O
. O O

3 O O
region O O
, O O
to O O
examine O O
these O O
markers O O
for O O
association O O
with O O
the O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
gene O O
( O O
WND B-Disease B-Disease
) O O
. O O

In O O
addition O O
to O O
a O O
marker O O
( O O
D13S133 O O
) O O
described O O
elsewhere O O
, O O
we O O
have O O
developed O O
three O O
new O O
highly O O
polymorphic O O
markers O O
( O O
D13S314 O O
, O O
D13S315 O O
, O O
and O O
D13S316 O O
) O O
close O O
to O O
the O O
WND B-Disease B-Disease
locus O O
. O O

We O O
have O O
examined O O
the O O
distribution O O
of O O
marker O O
alleles O O
at O O
the O O
loci O O
studied O O
and O O
have O O
found O O
that O O
D13S314 O O
, O O
D13S133 O O
, O O
and O O
D13S316 O O
each O O
show O O
nonrandom O O
distribution O O
on O O
chromosomes O O
carrying O O
the O O
WND B-Disease B-Disease
mutation O O
. O O

We O O
have O O
studied O O
haplotypes O O
of O O
these O O
three O O
markers O O
and O O
have O O
found O O
that O O
there O O
are O O
highly O O
significant O O
differences O O
between O O
WND B-Disease B-Disease
and O O
normal O O
haplotypes O O
in O O
northern O O
European O O
families O O
. O O

These O O
findings O O
have O O
important O O
implications O O
for O O
mutation O O
detection O O
and O O
molecular O O
diagnosis O O
in O O
families O O
with O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
. O O

Brca1 B-Disease B-Disease
deficiency I-Disease I-Disease
results O O
in O O
early O O
embryonic B-Disease B-Disease
lethality I-Disease I-Disease
characterized O O
by O O
neuroepithelial B-Disease B-Disease
abnormalities I-Disease I-Disease
. O O

The O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
susceptibility O O
gene O O
, O O
BRCA1 O O
, O O
has O O
been O O
cloned O O
and O O
shown O O
to O O
encode O O
a O O
zinc O O
- O O
finger O O
protein O O
of O O
unknown O O
function O O
. O O

Mutations O O
in O O
BRCA1 O O
account O O
for O O
at O O
least O O
80 O O
% O O
of O O
families O O
with O O
both O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
, O O
as O O
well O O
as O O
some O O
non O B-Disease
- O I-Disease
familial O I-Disease
sporadic O I-Disease
ovarian B-Disease I-Disease
cancers I-Disease I-Disease
. O O

The O O
loss O O
of O O
wild O O
- O O
type O O
BRCA1 O O
in O O
tumours B-Disease B-Disease
of O O
individuals O O
carrying O O
one O O
nonfunctional O O
BRCA1 O O
allele O O
suggests O O
that O O
BRCA1 O O
encodes O O
a O O
tumour B-Disease B-Disease
suppressor O O
that O O
may O O
inhibit O O
the O O
proliferation O O
of O O
mammary O O
epithelial O O
cells O O
. O O

To O O
examine O O
the O O
role O O
of O O
BRCA1 O O
in O O
normal O O
tissue O O
growth O O
and O O
differentiation O O
, O O
and O O
to O O
generate O O
a O O
potential O O
model O O
for O O
the O O
cancer B-Disease B-Disease
susceptibility O O
associated O O
with O O
loss O O
of O O
BRCA1 O O
function O O
, O O
we O O
have O O
created O O
a O O
mouse O O
line O O
carrying O O
a O O
mutation O O
in O O
one O O
Brca1 O O
allele O O
. O O

Analysis O O
of O O
mice O O
homozygous O O
for O O
the O O
mutant O O
allele O O
indicate O O
that O O
Brca1 O O
is O O
critical O O
for O O
normal O O
development O O
, O O
as O O
these O O
mice O O
died O O
in O O
utero O O
between O O
10 O O
and O O
13 O O
days O O
of O O
gestation O O
( O O
E10-E13 O O
) O O
. O O

Abnormalities O O
in O O
Brca1-deficient B-Disease B-Disease
embryos O O
were O O
most O O
evident O O
in O O
the O O
neural O O
tube O O
, O O
with O O
40 O O
% O O
of O O
the O O
embryos O O
presenting O O
with O O
varying O O
degrees O O
of O O
spina B-Disease B-Disease
bifida I-Disease I-Disease
and O O
anencephaly B-Disease B-Disease
. O O

In O O
addition O O
, O O
the O O
neuroepithelium O O
in O O
Brca1-deficient B-Disease B-Disease
embryos O O
appeared O O
disorganized O O
, O O
with O O
signs O O
of O O
both O O
rapid O O
proliferation O O
and O O
excessive O O
cell O O
death O O
.. O O

BRCA1 O O
is O O
secreted O O
and O O
exhibits O O
properties O O
of O O
a O O
granin O O
. O O

Germline O O
mutations O O
in O O
BRCA1 O O
are O O
responsible O O
for O O
most O O
cases O O
of O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

However O O
, O O
the O O
function O O
of O O
the O O
BRCA1 O O
protein O O
has O O
remained O O
elusive O O
. O O

We O O
now O O
show O O
that O O
BRCA1 O O
encodes O O
a O O
190-kD O O
protein O O
with O O
sequence O O
homology O O
and O O
biochemical O O
analogy O O
to O O
the O O
granin O O
protein O O
family O O
. O O

Interestingly O O
, O O
BRCA2 O O
also O O
includes O O
a O O
motif O O
similar O O
to O O
the O O
granin O O
consensus O O
at O O
the O O
C O O
terminus O O
of O O
the O O
protein O O
. O O

Both O O
BRCA1 O O
and O O
the O O
granins O O
localize O O
to O O
secretory O O
vesicles O O
, O O
are O O
secreted O O
by O O
a O O
regulated O O
pathway O O
, O O
are O O
post O O
- O O
translationally O O
glycosylated O O
and O O
are O O
responsive O O
to O O
hormones O O
. O O

As O O
a O O
regulated O O
secretory O O
protein O O
, O O
BRCA1 O O
appears O O
to O O
function O O
by O O
a O O
mechanism O O
not O O
previously O O
described O O
for O O
tumour B-Disease B-Disease
suppressor O O
gene O O
products O O
.. O O

Ovarian B-Disease B-Disease
cancer I-Disease I-Disease
risk O O
in O O
BRCA1 O O
carriers O O
is O O
modified O O
by O O
the O O
HRAS1 O O
variable O O
number O O
of O O
tandem O O
repeat O O
( O O
VNTR O O
) O O
locus O O
. O O

Women O O
who O O
carry O O
a O O
mutation O O
in O O
the O O
BRCA1 O O
gene O O
( O O
on O O
chromosome O O
17q21 O O
) O O
, O O
have O O
an O O
80 O O
% O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
and O O
a O O
40 O O
% O O
risk O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
by O O
the O O
age O O
of O O
70 O O
( O O
ref O O
. O O

1 O O
) O O
. O O

The O O
variable O O
penetrance O O
of O O
BRCA1 O O
suggests O O
that O O
other O O
genetic O O
and O O
non O O
- O O
genetic O O
factors O O
play O O
a O O
role O O
in O O
tumourigenesis O O
in O O
these O O
individuals O O
. O O

The O O
HRAS1 O O
variable O O
number O O
of O O
tandem O O
repeats O O
( O O
VNTR O O
) O O
polymorphism O O
, O O
located O O
1 O O
kilobase O O
( O O
kb O O
) O O
downstream O O
of O O
the O O
HRAS1 O O
proto O O
- O O
oncogene O O
( O O
chromosome O O
11p15 O O
. O O

5 O O
) O O
is O O
one O O
possible O O
genetic O O
modifier O O
of O O
cancer B-Disease B-Disease
penetrance O O
. O O

Individuals O O
who O O
have O O
rare O O
alleles O O
of O O
the O O
VNTR O O
have O O
an O O
increased O O
risk O O
of O O
certain O O
types O O
of O O
cancers B-Disease B-Disease
, O O
including O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
( O O
2 O O
- O O
4 O O
) O O
. O O

To O O
investigate O O
whether O O
the O O
presence O O
of O O
rare O O
HRAS1 O O
alleles O O
increases O O
susceptibility O O
to O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
, O O
we O O
have O O
typed O O
a O O
panel O O
of O O
307 O O
female O O
BRCA1 O O
carriers O O
at O O
this O O
locus O O
using O O
a O O
PCR O O
- O O
based O O
technique O O
. O O

The O O
risk O O
for O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
was O O
2 O O
. O O
11 O O
times O O
greater O O
for O O
BRCA1 O O
carriers O O
harbouring O O
one O O
or O O
two O O
rare O O
HRAS1 O O
alleles O O
, O O
compared O O
to O O
carriers O O
with O O
only O O
common O O
alleles O O
( O O
P O O
= O O
0 O O
. O O
015 O O
) O O
. O O

The O O
magnitude O O
of O O
the O O
relative O O
risk O O
associated O O
with O O
a O O
rare O O
HRAS1 O O
allele O O
was O O
not O O
altered O O
by O O
adjusting O O
for O O
the O O
other O O
known O O
risk O O
factors O O
for O O
hereditary B-Disease B-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
( O O
5 O O
) O O
. O O

Susceptibility O O
to O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
did O O
not O O
appear O O
to O O
be O O
affected O O
by O O
the O O
presence O O
of O O
rare O O
HRAS1 O O
alleles O O
. O O

This O O
study O O
is O O
the O O
first O O
to O O
show O O
the O O
effect O O
of O O
a O O
modifying O O
gene O O
on O O
the O O
penetrance O O
of O O
an O O
inherited B-Disease B-Disease
cancer I-Disease I-Disease
syndrome I-Disease I-Disease

A O O
novel O O
homeodomain O O
- O O
encoding O O
gene O O
is O O
associated O O
with O O
a O O
large O O
CpG O O
island O O
interrupted O O
by O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
unstable O O
( O O
CTG O O
) O O
n O O
repeat O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
associated O O
with O O
a O O
( O O
CTG O O
) O O
n O O
trinucleotide O O
repeat O O
expansion O O
in O O
the O O
3-untranslated O O
region O O
of O O
a O O
protein O O
kinase O O
- O O
encoding O O
gene O O
, O O
DMPK O O
, O O
which O O
maps O O
to O O
chromosome O O
19q13 O O
. O O

3 O O
. O O
Characterisation O O
of O O
the O O
expression O O
of O O
this O O
gene O O
in O O
patient O O
tissues O O
has O O
thus O O
far O O
generated O O
conflicting O O
data O O
on O O
alterations O O
in O O
the O O
steady O O
state O O
levels O O
of O O
DMPK O O
mRNA O O
, O O
and O O
on O O
the O O
final O O
DMPK O O
protein O O
levels O O
in O O
the O O
presence O O
of O O
the O O
expansion O O
. O O

The O O
DM B-Disease B-Disease
region O O
of O O
chromosome O O
19 O O
is O O
gene O O
rich O O
, O O
and O O
it O O
is O O
possible O O
that O O
the O O
repeat O O
expansion O O
may O O
lead O O
to O O
dysfunction O O
of O O
a O O
number O O
of O O
transcription O O
units O O
in O O
the O O
vicinity O O
, O O
perhaps O O
as O O
a O O
consequence O O
of O O
chromatin O O
disruption O O
. O O

We O O
have O O
searched O O
for O O
genes O O
associated O O
with O O
a O O
CpG O O
island O O
at O O
the O O
3 O O
end O O
of O O
DMPK O O
. O O

Sequencing O O
of O O
this O O
region O O
shows O O
that O O
the O O
island O O
extends O O
over O O
3 O O
. O O
5 O O
kb O O
and O O
is O O
interrupted O O
by O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
. O O

Comparison O O
of O O
genomic O O
sequences O O
downstream O O
( O O
centromeric O O
) O O
of O O
the O O
repeat O O
in O O
human O O
and O O
mouse O O
identified O O
regions O O
of O O
significant O O
homology O O
. O O

These O O
correspond O O
to O O
exons O O
of O O
a O O
gene O O
predicted O O
to O O
encode O O
a O O
homeodomain O O
protein O O
. O O

RT O O
- O O
PCR O O
analysis O O
shows O O
that O O
this O O
gene O O
, O O
which O O
we O O
have O O
called O O
DM B-Disease B-Disease
locus O O
- O O
associated O O
homeodomain O O
protein O O
( O O
DMAHP O O
) O O
, O O
is O O
expressed O O
in O O
a O O
number O O
of O O
human O O
tissues O O
, O O
including O O
skeletal O O
muscle O O
, O O
heart O O
and O O
brain O O
. O O

Germline O O
mutations O O
in O O
the O O
RB1 O O
gene O O
in O O
patients O O
with O O
hereditary B-Disease B-Disease
retinoblastoma I-Disease I-Disease
. O O

We O O
have O O
analyzed O O
the O O
27 O O
exons O O
and O O
the O O
promoter O O
region O O
of O O
the O O
RB1 O O
gene O O
in O O
familial B-Disease B-Disease
or I-Disease I-Disease
sporadic I-Disease I-Disease
bilateral I-Disease I-Disease
retinoblastoma I-Disease I-Disease
by O O
using O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
analysis O O
. O O

For O O
improvement O O
over O O
previous O O
studies O O
, O O
a O O
new O O
set O O
of O O
primers O O
has O O
been O O
designed O O
, O O
which O O
allow O O
for O O
amplification O O
of O O
the O O
coding O O
and O O
splicing O O
sequences O O
only O O
. O O

The O O
positioning O O
of O O
the O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
primers O O
was O O
such O O
that O O
the O O
resulting O O
PCR O O
products O O
were O O
of O O
different O O
sizes O O
, O O
which O O
enabled O O
us O O
to O O
analyze O O
two O O
different O O
exons O O
simultaneously O O
and O O
still O O
distinguish O O
between O O
the O O
banding O O
profiles O O
for O O
both O O
( O O
biplex O O
analysis O O
) O O
. O O

By O O
using O O
this O O
approach O O
, O O
we O O
were O O
able O O
to O O
identify O O
mutation O O
in O O
22 O O
new O O
patients O O
, O O
but O O
the O O
overall O O
efficiency O O
of O O
the O O
procedure O O
when O O
we O O
used O O
a O O
single O O
- O O
pass O O
regimen O O
was O O
only O O
48 O O
% O O
. O O

The O O
mutations O O
were O O
small O O
insertions O O
and O O
deletions O O
and O O
point O O
mutations O O
in O O
roughly O O
equal O O
proportions O O
.. O O

Type B-Disease B-Disease
II I-Disease I-Disease
human I-Disease I-Disease
complement I-Disease I-Disease
C2 I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

Allele O O
- O O
specific O O
amino O O
acid O O
substitutions O O
( O O
Ser189 O O
-- O O
> O O
Phe O O
; O O
Gly444 O O
-- O O
> O O
Arg O O
) O O
cause O O
impaired O O
C2 O O
secretion O O
. O O

Type B-Disease B-Disease
II I-Disease I-Disease
complement I-Disease I-Disease
protein I-Disease I-Disease
C2 I-Disease I-Disease
deficiency I-Disease I-Disease
is O O
characterized O O
by O O
a O O
selective O O
block O O
in O O
C2 O O
secretion O O
. O O

The O O
Type O O
II O O
C2 O O
null O O
allele O O
( O O
C2Q0 O O
) O O
is O O
linked O O
to O O
two O O
major O O
histocompatibility O O
haplotypes O O
( O O
MHC O O
) O O
that O O
differ O O
from O O
the O O
MHC O O
of O O
the O O
more O O
common O O
Type B-Disease B-Disease
I I-Disease I-Disease
C2 I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

To O O
determine O O
the O O
molecular O O
basis O O
of O O
Type B-Disease B-Disease
II I-Disease I-Disease
deficiency I-Disease I-Disease
the O O
two O O
Type O O
II O O
C2Q0 O O
genes O O
were O O
isolated O O
and O O
transfected O O
separately O O
into O O
L O O
- O O
cells O O
. O O

Subsequent O O
molecular O O
biology O O
, O O
biosynthetic O O
, O O
and O O
immunofluorescence O O
studies O O
demonstrated O O
that O O
C2 O O
secretion O O
is O O
impaired O O
in O O
Type B-Disease B-Disease
II I-Disease I-Disease
C2 I-Disease I-Disease
deficiency I-Disease I-Disease
because O O
of O O
different O O
missense O O
mutations O O
at O O
highly O O
conserved O O
residues O O
in O O
each O O
of O O
the O O
C2Q0 O O
alleles O O
. O O

One O O
is O O
in O O
exon O O
5 O O
( O O
nucleotide O O
C566 O O
-- O O
> O O
T O O
; O O
Ser189 O O
-- O O
> O O
Phe O O
) O O
of O O
the O O
C2Q0 O O
gene O O
linked O O
to O O
the O O
MHC O O
haplotype O O
A11 O O
, O O
B35 O O
, O O
DRw1 O O
, O O
BFS O O
, O O
C4A0B1 O O
. O O

The O O
other O O
is O O
in O O
exon O O
11 O O
( O O
G1930 O O
-- O O
> O O
A O O
; O O
Gly444 O O
-- O O
> O O
Arg O O
) O O
of O O
the O O
C2Q0 O O
gene O O
linked O O
to O O
the O O
MHC O O
haplotype O O
A2 O O
, O O
B5 O O
, O O
DRw4 O O
, O O
BFS O O
, O O
C4A3B1 O O
. O O

Each O O
mutant O O
C2 O O
gene O O
product O O
is O O
retained O O
early O O
in O O
the O O
secretory O O
pathway O O
. O O

These O O
mutants O O
provide O O
models O O
for O O
elucidating O O
the O O
C2 O O
secretory O O
pathway O O
.. O O

Defective O O
dimerization O O
of O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
factor O O
subunits O O
due O O
to O O
a O O
Cys- O O
> O O
Arg O O
mutation O O
in O O
type B-Disease B-Disease
IID I-Disease I-Disease
von I-Disease I-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
. O O

The O O
same O O
heterozygous O O
T O O
- O O
> O O
C O O
transition O O
at O O
nt O O
8567 O O
of O O
the O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
factor O O
( O O
vWF O O
) O O
transcript O O
was O O
found O O
in O O
two O O
unrelated O O
patients O O
with O O
type B-Disease B-Disease
IID I-Disease I-Disease
von I-Disease I-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
, O O
with O O
no O O
other O O
apparent O O
abnormality O O
. O O

In O O
one O O
family O O
, O O
both O O
alleles O O
were O O
normal O O
in O O
the O O
parents O O
and O O
one O O
sister O O
; O O
thus O O
, O O
the O O
mutation O O
originated O O
de O O
novo O O
in O O
the O O
proposita O O
. O O

The O O
second O O
patient O O
also O O
had O O
asymptomatic O O
parents O O
who O O
, O O
however O O
, O O
were O O
not O O
available O O
for O O
study O O
. O O

The O O
structural O O
consequences O O
of O O
the O O
identified O O
mutation O O
, O O
resulting O O
in O O
the O O
CyS2010 O O
- O O
> O O
Arg O O
substitution O O
, O O
were O O
evaluated O O
by O O
expression O O
of O O
the O O
vWF O O
carboxyl O O
- O O
terminal O O
domain O O
containing O O
residues O O
1366 O O
- O O
2050 O O
. O O

Insect O O
cells O O
infected O O
with O O
recombinant O O
baculovirus O O
expressing O O
normal O O
vWF O O
sequence O O
secreted O O
a O O
disulfide O O
linked O O
dimeric O O
molecule O O
with O O
an O O
apparent O O
molecular O O
mass O O
of O O
150 O O
kDa O O
before O O
reduction O O
, O O
yielding O O
a O O
single O O
band O O
of O O
80 O O
kDa O O
after O O
disulfide O O
bond O O
reduction O O
. O O

In O O
contrast O O
, O O
cells O O
expressing O O
the O O
mutant O O
fragment O O
secreted O O
a O O
monomeric O O
molecule O O
of O O
apparent O O
molecular O O
mass O O
of O O
80 O O
kDa O O
, O O
which O O
remained O O
unchanged O O
after O O
reduction O O
. O O

We O O
conclude O O
that O O
CyS2010 O O
is O O
essential O O
for O O
normal O O
dimerization O O
of O O
vWF O O
subunits O O
through O O
disulfide O O
bonding O O
of O O
carboxyl O O
- O O
terminal O O
domains O O
and O O
that O O
a O O
heterozygous O O
mutation O O
in O O
the O O
corresponding O O
codon O O
is O O
responsible O O
for O O
defective O O
multimer O O
formation O O
in O O
type B-Disease B-Disease
IID I-Disease I-Disease
von I-Disease I-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
.. O O

Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
protein O O
, O O
a O O
novel O O
effector O O
for O O
the O O
GTPase O O
CDC42Hs O O
, O O
is O O
implicated O O
in O O
actin O O
polymerization O O
. O O

The O O
Rho O O
family O O
of O O
GTPases O O
control O O
diverse O O
biological O O
processes O O
, O O
including O O
cell O O
morphology O O
and O O
mitogenesis O O
. O O

We O O
have O O
identified O O
WASP O O
, O O
the O O
protein O O
that O O
is O O
defective O O
in O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
WAS B-Disease B-Disease
) O O
, O O
as O O
a O O
novel O O
effector O O
for O O
CDC42Hs O O
, O O
but O O
not O O
for O O
the O O
other O O
Rho O O
family O O
members O O
, O O
Rac O O
and O O
Rho O O
. O O

This O O
interaction O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
the O O
G O O
protein O O
- O O
binding O O
domain O O
. O O

Cellular O O
expression O O
of O O
epitope O O
- O O
tagged O O
WASP O O
produces O O
clusters O O
of O O
WASP O O
that O O
are O O
highly O O
enriched O O
in O O
polymerized O O
actin O O
. O O

This O O
clustering O O
is O O
not O O
observed O O
with O O
a O O
C O O
- O O
terminally O O
deleted O O
WASP O O
and O O
is O O
inhibited O O
by O O
coexpression O O
with O O
dominant O O
negative O O
CDC42Hs O O
- O O
N17 O O
, O O
but O O
not O O
with O O
dominant O O
negative O O
forms O O
of O O
Rac O O
or O O
Rho O O
. O O

Thus O O
, O O
WASP O O
provides O O
a O O
novel O O
link O O
between O O
CDC42Hs O O
and O O
the O O
actin O O
cytoskeleton O O
, O O
which O O
suggests O O
a O O
molecular O O
mechanism O O
for O O
many O O
of O O
the O O
cellular O O
abnormalities O O
in O O
WAS B-Disease B-Disease
. O O

The O O
WASP O O
sequence O O
contains O O
two O O
novel O O
domains O O
that O O
are O O
homologous O O
to O O
other O O
proteins O O
involved O O
in O O
action O O
organization O O
.. O O

X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
adrenoleukodystrophy I-Disease I-Disease
is O O
a O O
frequent O O
cause O O
of O O
idiopathic O O
Addison B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
in O O
young O O
adult O O
male O O
patients O O
. O O

X B-Disease B-Disease
- I-Disease I-Disease
Linked I-Disease I-Disease
adrenoleukodystrophy I-Disease I-Disease
( O O
ALD B-Disease B-Disease
) O O
is O O
a O O
genetic B-Disease B-Disease
disease I-Disease I-Disease
associated O O
with O O
demyelination B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
central I-Disease I-Disease
nervous I-Disease I-Disease
system I-Disease I-Disease
, O O
adrenal B-Disease B-Disease
insufficiency I-Disease I-Disease
, O O
and O O
accumulation O O
of O O
very O O
long O O
chain O O
fatty O O
acids O O
in O O
tissue O O
and O O
body O O
fluids O O
. O O

ALD B-Disease B-Disease
is O O
due O O
to O O
mutation O O
of O O
a O O
gene O O
located O O
in O O
Xq28 O O
that O O
encodes O O
a O O
peroxisomal O O
transporter O O
protein O O
of O O
unknown O O
function O O
. O O

The O O
most O O
common O O
phenotype O O
of O O
ALD B-Disease B-Disease
is O O
the O O
cerebral O O
form O O
( O O
45 O O
% O O
) O O
that O O
develops O O
in O O
boys O O
between O O
5 O O
- O O
12 O O
yr O O
. O O

Adrenomyeloneuropathy B-Disease B-Disease
( O O
AMN B-Disease B-Disease
) O O
involves O O
the O O
spinal O O
cord O O
and O O
peripheral O O
nerves O O
in O O
young O O
adults O O
( O O
35 O O
% O O
) O O
. O O

Adrenal B-Disease B-Disease
insufficiency I-Disease I-Disease
( O O
Addisons B-Disease B-Disease
disease I-Disease I-Disease
) O O
is O O
frequently O O
associated O O
with O O
AMN B-Disease B-Disease
or O O
cerebral B-Disease B-Disease
ALD I-Disease I-Disease
and O O
may O O
remain O O
the O O
only O O
clinical O O
expression O O
of O O
ALD B-Disease B-Disease
( O O
8 O O
% O O
of O O
cases O O
) O O
. O O

The O O
prevalence O O
of O O
ALD B-Disease B-Disease
among O O
adults O O
with O O
Addisons B-Disease B-Disease
disease I-Disease I-Disease
remains O O
unknown O O
. O O

To O O
evaluate O O
this O O
prevalence O O
, O O
we O O
performed O O
biochemical O O
analysis O O
of O O
very O O
long O O
chain O O
fatty O O
acids O O
in O O
14 O O
male O O
patients O O
( O O
age O O
ranging O O
from O O
12 O O
- O O
45 O O
yr O O
at O O
diagnosis O O
) O O
previously O O
diagnosed O O
as O O
having O O
primary O O
idiopathic O B-Disease
adrenocortical B-Disease I-Disease
insufficiency I-Disease I-Disease
. O O

In O O
5 O O
of O O
14 O O
patients O O
( O O
35 O O
% O O
) O O
, O O
elevated O O
plasma O O
concentrations O O
of O O
very O O
long O O
chain O O
fatty O O
acids O O
were O O
detected O O
. O O

None O O
of O O
these O O
patients O O
had O O
adrenocortical O O
antibodies O O
. O O

By O O
electrophysiological O O
tests O O
and O O
magnetic O O
resonance O O
imaging O O
it O O
was O O
determined O O
that O O
two O O
patients O O
had O O
cerebral B-Disease B-Disease
ALD I-Disease I-Disease
, O O
one O O
had O O
adrenomyeloneuropathy B-Disease B-Disease
with O O
cerebral O O
involvement O O
, O O
and O O
two O O
had O O
preclinical O O
AMN B-Disease B-Disease
. O O

Our O O
data O O
support O O
the O O
hypothesis O O
that O O
ALD B-Disease B-Disease
is O O
a O O
frequent O O
cause O O
of O O
idiopathic O B-Disease
Addisons B-Disease I-Disease
disease I-Disease I-Disease
in O O
children O O
and O O
adults O O
.. O O

Tumor B-Disease B-Disease
suppression O O
and O O
apoptosis O O
of O O
human O O
prostate B-Disease B-Disease
carcinoma I-Disease I-Disease
mediated O O
by O O
a O O
genetic O O
locus O O
within O O
human O O
chromosome O O
10pter O O
- O O
q11 O O
. O O

Prostate B-Disease B-Disease
cancer I-Disease I-Disease
is O O
the O O
second O O
leading O O
cause O O
of O O
male O B-Disease
cancer B-Disease I-Disease
deaths O O
in O O
the O O
United O O
States O O
. O O

Yet O O
, O O
despite O O
a O O
large O O
international O O
effort O O
, O O
little O O
is O O
known O O
about O O
the O O
molecular O O
mechanisms O O
that O O
underlie O O
this O O
devastating O O
disease O O
. O O

Prostate O O
secretory O O
epithelial O O
cells O O
and O O
androgen O O
- O O
dependent O O
prostate B-Disease B-Disease
carcinomas I-Disease I-Disease
undergo O O
apoptosis O O
in O O
response O O
to O O
androgen O O
deprivation O O
and O O
, O O
furthermore O O
, O O
most O O
prostate B-Disease B-Disease
carcinomas I-Disease I-Disease
become O O
androgen O O
independent O O
and O O
refractory O O
to O O
further O O
therapeutic O O
manipulations O O
during O O
disease O O
progression O O
. O O

Definition O O
of O O
the O O
genetic O O
events O O
that O O
trigger O O
apoptosis O O
in O O
the O O
prostate O O
could O O
provide O O
important O O
insights O O
into O O
critical O O
pathways O O
in O O
normal O O
development O O
as O O
well O O
as O O
elucidate O O
the O O
perturbations O O
of O O
those O O
key O O
pathways O O
in O O
neoplastic O O
transformation O O
. O O

We O O
report O O
the O O
functional O O
definition O O
of O O
a O O
novel O O
genetic O O
locus O O
within O O
human O O
chromosome O O
10pter O O
- O O
q11 O O
that O O
mediates O O
both O O
in O O
vivo O O
tumor O B-Disease
suppression O O
and O O
in O O
vitro O O
apoptosis O O
of O O
prostatic B-Disease B-Disease
adenocarcinoma I-Disease I-Disease
cells O O
. O O

A O O
defined O O
fragment O O
of O O
human O O
chromosome O O
10 O O
was O O
transferred O O
via O O
microcell O O
fusion O O
into O O
a O O
prostate B-Disease B-Disease
adenocarcinoma I-Disease I-Disease
cell O O
line O O
. O O

Microcell O O
hybrids O O
containing O O
only O O
the O O
region O O
10pter O O
- O O
q11 O O
were O O
suppressed O O
for O O
tumorigenicity O O
following O O
injection O O
of O O
microcell O O
hybrids O O
into O O
nude O O
mice O O
. O O

Furthermore O O
, O O
the O O
complemented O O
hybrids O O
undergo O O
programmed O O
cell O O
death O O
in O O
vitro O O
via O O
a O O
mechanism O O
that O O
does O O
not O O
require O O
nuclear O O
localization O O
of O O
p53 O O
. O O

These O O
data O O
functionally O O
define O O
a O O
novel O O
genetic O O
locus O O
, O O
designated O O
PAC1 O O
, O O
for O O
prostate O B-Disease
adenocarcinoma O I-Disease
1 O O
, O O
involved O O
in O O
tumor O B-Disease
suppression O O
of O O
human O O
prostate B-Disease B-Disease
carcinoma I-Disease I-Disease
and O O
furthermore O O
strongly O O
suggest O O
that O O
the O O
cell O O
death O O
pathway O O
can O O
be O O
functionally O O
restored O O
in O O
prostatic B-Disease B-Disease
adenocarcinoma I-Disease I-Disease
.. O O

Low O O
incidence O O
of O O
BRCA2 O O
mutations O O
in O O
breast B-Disease B-Disease
carcinoma I-Disease I-Disease
and O O
other O O
cancers B-Disease B-Disease
. O O

Inherited O O
mutant O O
alleles O O
of O O
familial O B-Disease
tumour B-Disease I-Disease
suppressor O O
genes O O
predispose O O
individuals O O
to O O
particular O O
types O O
of O O
cancer B-Disease B-Disease
. O O

In O O
addition O O
to O O
an O O
involvement O O
in O O
inherited O O
susceptibility O O
to O O
cancer B-Disease B-Disease
, O O
these O O
tumour B-Disease B-Disease
suppressor O O
genes O O
are O O
targets O O
for O O
somatic O O
mutations O O
in O O
sporadic B-Disease B-Disease
cancers I-Disease I-Disease
of O O
the O O
same O O
type O O
found O O
in O O
the O O
familial O O
forms O O
. O O

An O O
exception O O
is O O
BRCA1 O O
, O O
which O O
contributes O O
to O O
a O O
significant O O
fraction O O
of O O
familial B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
, O O
but O O
undergoes O O
mutation O O
at O O
very O O
low O O
rates O O
in O O
sporadic B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancers I-Disease I-Disease
. O O

This O O
finding O O
suggests O O
that O O
other O O
genes O O
may O O
be O O
the O O
principal O O
targets O O
for O O
somatic O O
mutation O O
in O O
breast B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

A O O
second O O
, O O
recently O O
identified O O
familial B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
gene O O
, O O
BRCA2 O O
( O O
refs O O
5 O O
- O O
8 O O
) O O
, O O
accounts O O
for O O
a O O
proportion O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
roughly O O
equal O O
to O O
BRCA1 O O
. O O

Like O O
BRCA1 O O
, O O
BRCA2 O O
behaves O O
as O O
a O O
dominantly O O
inherited O O
tumour B-Disease B-Disease
suppressor O O
gene O O
. O O

Individuals O O
who O O
inherit O O
one O O
mutant O O
allele O O
are O O
at O O
increased O O
risk O O
for O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
and O O
the O O
tumours B-Disease B-Disease
they O O
develop O O
lose O O
the O O
wild O O
- O O
type O O
allele O O
by O O
heterozygous O O
deletion O O
. O O

The O O
BRCA2 O O
coding O O
sequence O O
is O O
huge O O
, O O
composed O O
of O O
26 O O
exons O O
that O O
span O O
10 O O
, O O
443 O O
bp O O
. O O

Here O O
we O O
investigate O O
the O O
rate O O
of O O
BRCA2 O O
mutation O O
in O O
sporadic B-Disease B-Disease
breast I-Disease I-Disease
cancers I-Disease I-Disease
and O O
in O O
a O O
set O O
of O O
cell O O
lines O O
that O O
represent O O
twelve O O
other O O
tumour B-Disease B-Disease
types O O
. O O

Surprisingly O O
, O O
mutations O O
in O O
BRCA2 O O
are O O
infrequent O O
in O O
cancers B-Disease B-Disease
including O O
breast B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

However O O
, O O
a O O
probable O O
germline O O
mutation O O
in O O
a O O
pancreatic B-Disease B-Disease
tumour I-Disease I-Disease
cell O O
line O O
suggests O O
a O O
role O O
for O O
BRCA2 O O
in O O
susceptibility O O
to O O
pancreatic B-Disease B-Disease
cancer I-Disease I-Disease
.. O O

Founding O O
BRCA1 O O
mutations O O
in O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
southern O O
Sweden O O
. O O

Nine O O
different O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
BRCA1 O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
susceptibility O O
gene O O
were O O
identified O O
in O O
15 O O
of O O
47 O O
kindreds O O
from O O
southern O O
Sweden O O
, O O
by O O
use O O
of O O
SSCP O O
and O O
heteroduplex O O
analysis O O
of O O
all O O
exons O O
and O O
flanking O O
intron O O
region O O
and O O
by O O
a O O
protein O O
- O O
truncation O O
test O O
for O O
exon O O
11 O O
, O O
followed O O
by O O
direct O O
sequencing O O
. O O

All O O
but O O
one O O
of O O
the O O
mutations O O
are O O
predicted O O
to O O
give O O
rise O O
to O O
premature O O
translation O O
termination O O
and O O
include O O
seven O O
frameshift O O
insertions O O
or O O
deletions O O
, O O
a O O
nonsense O O
mutation O O
, O O
and O O
a O O
splice O O
acceptor O O
site O O
mutation O O
. O O

The O O
remaining O O
mutation O O
is O O
a O O
missense O O
mutation O O
( O O
Cys61Gly O O
) O O
in O O
the O O
zinc O O
- O O
binding O O
motif O O
. O O

Four O O
novel O O
Swedish O O
founding O O
mutations O O
were O O
identified O O
the O O
nucleotide O O
2595 O O
deletion O O
A O O
was O O
found O O
in O O
five O O
families O O
, O O
the O O
C O O
1806 O O
T O O
nonsense O O
mutation O O
in O O
three O O
families O O
, O O
the O O
3166 O O
insertion O O
TGAGA O O
in O O
three O O
families O O
, O O
and O O
the O O
nucleotide O O
1201 O O
deletion O O
11 O O
in O O
two O O
families O O
. O O

Analysis O O
of O O
the O O
intragenic O O
polymorphism O O
D17S855 O O
supports O O
common O O
origins O O
of O O
the O O
mutations O O
. O O

Eleven O O
of O O
the O O
15 O O
kindreds O O
manifesting O O
BRCA1 O O
mutations O O
were O O
breast B-Disease B-Disease
- I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
, O O
several O O
of O O
them O O
with O O
a O O
predominant O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
phenotype O O
. O O

The O O
set O O
of O O
32 O O
families O O
in O O
which O O
no O O
BRCA1 O O
alterations O O
were O O
detected O O
included O O
1 O O
breast B-Disease B-Disease
- I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
kindred O O
manifesting O O
clear O O
linkage O O
to O O
the O O
BRCA1 O O
region O O
and O O
loss O O
of O O
the O O
wild O O
- O O
type O O
chromosome O O
in O O
associated O O
tumors B-Disease B-Disease
. O O

Other O O
tumor B-Disease B-Disease
types O O
found O O
in O O
BRCA1 O O
mutation O O
/ O O
haplotype O O
carriers O O
included O O
prostatic B-Disease B-Disease
, I-Disease I-Disease
pancreas I-Disease I-Disease
, I-Disease I-Disease
skin I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
, O O
a O O
malignant B-Disease B-Disease
melanoma I-Disease I-Disease
, O O
an O O
oligodendroglioma B-Disease B-Disease
, O O
and O O
a O O
carcinosarcoma B-Disease B-Disease
. O O

In O O
all O O
, O O
12 O O
of O O
16 O O
kindreds O O
manifesting O O
BRCA1 O O
mutation O O
or O O
linkage O O
contained O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
, O O
as O O
compared O O
with O O
only O O
6 O O
of O O
the O O
remaining O O
31 O O
families O O
( O O
P O O
< O O
. O O

001 O O
) O O
. O O

The O O
present O O
study O O
confirms O O
the O O
involvement O O
of O O
BRCA1 O O
in O O
disease O O
predisposition O O
for O O
a O O
subset O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
families O O
often O O
characterized O O
by O O
ovarian B-Disease B-Disease
cancers I-Disease I-Disease
. O O

Rapid O O
detection O O
of O O
regionally O O
clustered O O
germ O O
- O O
line O O
BRCA1 O O
mutations O O
by O O
multiplex O O
heteroduplex O O
analysis O O
. O O

UKCCCR O O
Familial O B-Disease
Ovarian B-Disease I-Disease
Cancer I-Disease I-Disease
Study O O
Group O O
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
BRCA1 O O
gene O O
are O O
responsible O O
for O O
a O O
substantial O O
proportion O O
of O O
families O O
with O O
multiple O O
cases O O
of O O
early O O
- O O
onset O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Since O O
the O O
isolation O O
of O O
BRCA1 O O
last O O
year O O
, O O
> O O
65 O O
distinct O O
mutations O O
scattered O O
throughout O O
the O O
coding O O
region O O
have O O
been O O
detected O O
, O O
making O O
analysis O O
of O O
the O O
gene O O
time O O
consuming O O
and O O
technically O O
challenging O O
. O O

We O O
have O O
developed O O
a O O
multiplex O O
heteroduplex O O
analysis O O
that O O
is O O
designed O O
to O O
analyze O O
one O O
- O O
quarter O O
of O O
the O O
coding O O
sequence O O
in O O
a O O
single O O
- O O
step O O
screening O O
procedure O O
and O O
that O O
will O O
detect O O
approximately O O
50 O O
% O O
of O O
all O O
BRCA1 O O
mutations O O
so O O
far O O
reported O O
in O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
. O O

We O O
have O O
used O O
this O O
technique O O
to O O
analyze O O
BRCA1 O O
in O O
162 O O
families O O
with O O
a O O
history O O
of O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
and O O
identified O O
12 O O
distinct O O
mutations O O
in O O
35 O O
families O O
.. O O

A O O
previously O O
undescribed O O
mutation O O
within O O
the O O
tetramerisation O O
domain O O
of O O
TP53 O O
in O O
a O O
family O O
with O O
Li B-Disease B-Disease
- I-Disease I-Disease
Fraumeni I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

We O O
report O O
details O O
of O O
a O O
family O O
with O O
classic O O
Li B-Disease B-Disease
- I-Disease I-Disease
Fraumeni I-Disease I-Disease
syndrome I-Disease I-Disease
in O O
which O O
there O O
is O O
a O O
mutation O O
in O O
codon O O
344 O O
of O O
the O O
tumour B-Disease B-Disease
suppressor O O
gene O O
TP53 O O
. O O

Codon O O
344 O O
is O O
a O O
key O O
residue O O
within O O
the O O
tetramerisation O O
domain O O
, O O
and O O
the O O
amino O O
acid O O
substitution O O
of O O
a O O
proline O O
for O O
a O O
leucine O O
is O O
predicted O O
to O O
have O O
profound O O
implications O O
for O O
tetramerisation O O
and O O
potentially O O
DNA O O
binding O O
. O O

This O O
is O O
the O O
first O O
report O O
of O O
a O O
mutation O O
at O O
this O O
residue O O
in O O
either O O
sporadic B-Disease B-Disease
tumours I-Disease I-Disease
or O O
in O O
the O O
germline O O
and O O
the O O
first O O
report O O
of O O
a O O
germline O O
mutation O O
within O O
the O O
tetramerisation O O
domain O O
. O O

The O O
family O O
does O O
not O O
appear O O
to O O
be O O
remarkable O O
in O O
the O O
spectrum O O
of O O
tumours B-Disease B-Disease
, O O
and O O
there O O
is O O
loss O O
of O O
the O O
wild O O
- O O
type O O
allele O O
in O O
a O O
leiomyosarcoma B-Disease B-Disease
from O O
the O O
proband O O
. O O

A O O
cell O O
line O O
has O O
been O O
established O O
from O O
the O O
tumour B-Disease B-Disease
of O O
the O O
proband O O
and O O
cytogenetic O O
and O O
molecular O O
studies O O
carried O O
out O O
, O O
providing O O
an O O
extensive O O
analysis O O
in O O
this O O
family O O
.. O O

The O O
spectrum O O
of O O
RB1 O O
germ O O
- O O
line O O
mutations O O
in O O
hereditary B-Disease B-Disease
retinoblastoma I-Disease I-Disease
. O O

We O O
have O O
searched O O
for O O
germ O O
- O O
line O O
RB1 O O
mutations O O
in O O
119 O O
patients O O
with O O
hereditary B-Disease B-Disease
retinoblastoma I-Disease I-Disease
. O O

Previous O O
investigations O O
by O O
Southern O O
blot O O
hybridization O O
and O O
PCR O O
fragment O O
- O O
length O O
analysis O O
had O O
revealed O O
mutations O O
in O O
48 O O
patients O O
. O O

Here O O
we O O
report O O
on O O
the O O
analysis O O
of O O
the O O
remaining O O
71 O O
patients O O
. O O

By O O
applying O O
heteroduplex O O
analysis O O
, O O
nonisotopic O O
SSCP O O
, O O
and O O
direct O O
sequencing O O
, O O
we O O
detected O O
germ O O
- O O
line O O
mutations O O
resulting O O
in O O
premature O O
termination O O
codons O O
or O O
disruption O O
of O O
splice O O
signals O O
in O O
51 O O
( O O
72 O O
% O O
) O O
of O O
the O O
71 O O
patients O O
. O O

Four O O
patients O O
also O O
showed O O
rare O O
sequence O O
variants O O
. O O

No O O
region O O
of O O
the O O
RB1 O O
gene O O
was O O
preferentially O O
involved O O
in O O
single O O
base O O
substitutions O O
. O O

Recurrent O O
transitions O O
were O O
observed O O
at O O
most O O
of O O
the O O
14 O O
codons O O
within O O
the O O
RB1 O O
. O O

No O O
mutation O O
was O O
observed O O
in O O
exons O O
25 O O
- O O
27 O O
, O O
although O O
this O O
region O O
contains O O
two O O
CGA O O
codons O O
. O O

This O O
suggests O O
that O O
mutations O O
within O O
the O O
3-terminal O O
region O O
of O O
the O O
RB1 O O
gene O O
may O O
not O O
be O O
oncogenic O O
. O O

When O O
these O O
data O O
were O O
combined O O
with O O
the O O
results O O
of O O
our O O
previous O O
investigations O O
, O O
mutations O O
were O O
identified O O
in O O
a O O
total O O
of O O
99 O O
( O O
83 O O
% O O
) O O
of O O
119 O O
patients O O
. O O

The O O
spectrum O O
comprises O O
15 O O
% O O
large O O
deletions O O
, O O
26 O O
% O O
small O O
length O O
alterations O O
, O O
and O O
42 O O
% O O
base O O
substitutions O O
. O O

No O O
correlation O O
between O O
the O O
location O O
of O O
frameshift O O
or O O
nonsense O O
mutations O O
and O O
phenotypic O O
features O O
, O O
including O O
age O O
at O O
diagnosis O O
, O O
the O O
number O O
of O O
tumor B-Disease B-Disease
foci O O
, O O
and O O
manifestation O O
of O O
nonocular B-Disease B-Disease
tumors I-Disease I-Disease
was O O
observed O O
.. O O

Phenotypic O O
characterization O O
of O O
individuals O O
with O O
30 O O
- O O
40 O O
CAG O O
repeats O O
in O O
the O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
gene O O
reveals O O
HD B-Disease B-Disease
cases O O
with O O
36 O O
repeats O O
and O O
apparently O O
normal O O
elderly O O
individuals O O
with O O
36 O O
- O O
39 O O
repeats O O
. O O

Abnormal O O
CAG O O
expansions O O
in O O
the O O
IT-15 O O
gene O O
are O O
associated O O
with O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
. O O

In O O
the O O
diagnostic O O
setting O O
it O O
is O O
necessary O O
to O O
define O O
the O O
limits O O
of O O
the O O
CAG O O
size O O
ranges O O
on O O
normal O O
and O O
HD B-Disease B-Disease
- O O
associated O O
chromosomes O O
. O O

Most O O
large O O
analyses O O
that O O
defined O O
the O O
limits O O
of O O
the O O
normal O O
and O O
pathological O O
size O O
ranges O O
employed O O
PCR O O
assays O O
, O O
which O O
included O O
the O O
CAG O O
repeats O O
and O O
a O O
CCG O O
repeat O O
tract O O
that O O
was O O
thought O O
to O O
be O O
invariant O O
. O O

Many O O
of O O
these O O
experiments O O
found O O
an O O
overlap O O
between O O
the O O
normal O O
and O O
disease O O
size O O
ranges O O
. O O

Subsequent O O
findings O O
that O O
the O O
CCG O O
repeats O O
vary O O
by O O
8 O O
trinucleotide O O
lengths O O
suggested O O
that O O
the O O
limits O O
of O O
the O O
normal O O
and O O
disease O O
size O O
ranges O O
should O O
be O O
reevaluated O O
with O O
assays O O
that O O
exclude O O
the O O
CCG O O
polymorphism O O
. O O

Since O O
patients O O
with O O
between O O
30 O O
and O O
40 O O
repeats O O
are O O
rare O O
, O O
a O O
consortium O O
was O O
assembled O O
to O O
collect O O
such O O
individuals O O
. O O

All O O
178 O O
samples O O
were O O
reanalyzed O O
in O O
Cambridge O O
by O O
using O O
assays O O
specific O O
for O O
the O O
CAG O O
repeats O O
. O O

We O O
have O O
optimized O O
methods O O
for O O
reliable O O
sizing O O
of O O
CAG O O
repeats O O
and O O
show O O
cases O O
that O O
demonstrate O O
the O O
dangers O O
of O O
using O O
PCR O O
assays O O
that O O
include O O
both O O
the O O
CAG O O
and O O
CCG O O
polymorphisms O O
. O O

Seven O O
HD B-Disease B-Disease
patients O O
had O O
36 O O
repeats O O
, O O
which O O
confirms O O
that O O
this O O
allele O O
is O O
associated O O
with O O
disease O O
. O O

Individuals O O
without O O
apparent O O
symptoms O O
or O O
signs O O
of O O
HD B-Disease B-Disease
were O O
found O O
at O O
36 O O
repeats O O
( O O
aged O O
74 O O
, O O
78 O O
, O O
79 O O
, O O
and O O
87 O O
years O O
) O O
, O O
37 O O
repeats O O
( O O
aged O O
69 O O
years O O
) O O
, O O
38 O O
repeats O O
( O O
aged O O
69 O O
and O O
90 O O
years O O
) O O
, O O
and O O
39 O O
repeats O O
( O O
aged O O
67 O O
, O O
90 O O
, O O
and O O
95 O O
years O O
) O O
. O O

The O O
detailed O O
case O O
histories O O
of O O
an O O
exceptional O O
case O O
from O O
this O O
series O O
will O O
be O O
presented O O
a O O
95-year O O
- O O
old O O
man O O
with O O
39 O O
repeats O O
who O O
did O O
not O O
have O O
classical O O
features O O
of O O
HD B-Disease B-Disease
. O O

The O O
apparently O O
healthy O O
survival O O
into O O
old O O
age O O
of O O
some O O
individuals O O
with O O
36 O O
- O O
39 O O
repeats O O
suggests O O
that O O
the O O
HD B-Disease B-Disease
mutation O O
may O O
not O O
always O O
be O O
fully O O
penetrant O O
.. O O

Identification O O
and O O
expression O O
of O O
eight O O
novel O O
mutations O O
among O O
non O O
- O O
Jewish O O
patients O O
with O O
Canavan B-Disease B-Disease
disease I-Disease I-Disease
. O O

Canavan B-Disease B-Disease
disease I-Disease I-Disease
is O O
inherited O O
as O O
an O O
autosomal O O
recessive O O
trait O O
that O O
is O O
caused O O
by O O
the O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
aspartoacylase I-Disease I-Disease
( O O
ASPA O O
) O O
. O O

The O O
majority O O
of O O
patients O O
with O O
Canavan B-Disease B-Disease
disease I-Disease I-Disease
are O O
from O O
an O O
Ashkenazi O O
Jewish O O
background O O
. O O

Mutations O O
in O O
ASPA O O
that O O
lead O O
to O O
loss O O
of O O
enzymatic O O
activity O O
have O O
been O O
identified O O
, O O
and O O
E285A O O
and O O
Y231X O O
are O O
the O O
two O O
predominant O O
mutations O O
that O O
account O O
for O O
97 O O
% O O
of O O
the O O
mutant O O
chromosomes O O
in O O
Ashkenazi O O
Jewish O O
patients O O
. O O

The O O
current O O
study O O
was O O
aimed O O
at O O
finding O O
the O O
molecular O O
basis O O
of O O
Canavan B-Disease B-Disease
disease I-Disease I-Disease
in O O
25 O O
independent O O
patients O O
of O O
non O O
- O O
Jewish O O
background O O
. O O

Eight O O
novel O O
and O O
three O O
previously O O
characterized O O
mutations O O
accounted O O
for O O
80 O O
% O O
( O O
40 O O
/ O O
50 O O
) O O
of O O
mutant O O
chromosomes O O
. O O

The O O
A305E O O
missense O O
mutation O O
accounted O O
for O O
48 O O
% O O
( O O
24 O O
/ O O
50 O O
) O O
of O O
mutant O O
chromosomes O O
in O O
patients O O
of O O
western O O
European O O
descent O O
, O O
while O O
the O O
two O O
predominant O O
Jewish O O
mutations O O
each O O
accounted O O
for O O
a O O
single O O
mutant O O
chromosome O O
. O O

The O O
eight O O
novel O O
mutations O O
identified O O
included O O
1- O O
and O O
4-bp O O
deletions O O
( O O
32 O O
deltaT O O
and O O
876 O O
deltaAGAA O O
, O O
respectively O O
) O O
and O O
I16 O O
T O O
, O O
G27R O O
, O O
D114E O O
, O O
G123E O O
, O O
C152Y O O
, O O
and O O
R168C O O
missense O O
mutations O O
. O O

The O O
homozygous O O
32 O O
deltaT O O
deletion O O
was O O
identified O O
in O O
the O O
only O O
known O O
patient O O
of O O
African O O
- O O
American O O
origin O O
with O O
Canavan B-Disease B-Disease
disease I-Disease I-Disease
. O O

The O O
heterozygosity O O
for O O
876 O O
deltaAGAA O O
mutation O O
was O O
identified O O
in O O
three O O
independent O O
patients O O
from O O
England O O
. O O

Six O O
single O O
- O O
base O O
changes O O
leading O O
to O O
missense O O
mutations O O
were O O
identified O O
in O O
patients O O
from O O
Turkey O O
( O O
D114E O O
, O O
R168C O O
) O O
, O O
The O O
Netherlands O O
( O O
I16 O O
T O O
) O O
, O O
Germany O O
( O O
G27R O O
) O O
, O O
Ireland O O
( O O
C152Y O O
) O O
, O O
and O O
Canada O O
( O O
G123E O O
) O O
. O O

A O O
PCR O O
- O O
based O O
protocol O O
is O O
described O O
that O O
was O O
used O O
to O O
introduce O O
mutations O O
in O O
wild O O
- O O
type O O
cDNA O O
. O O

In O O
vitro O O
expression O O
of O O
mutant O O
cDNA O O
clones O O
demonstrated O O
that O O
all O O
of O O
these O O
mutations O O
led O O
to O O
a O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
ASPA I-Disease I-Disease
and O O
should O O
therefore O O
result O O
in O O
Canavan B-Disease B-Disease
disease I-Disease I-Disease
.. O O

Identification O O
and O O
chromosomal O O
localization O O
of O O
Atm O O
, O O
the O O
mouse O O
homolog O O
of O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
gene O O
. O O

Atm O O
, O O
the O O
mouse O O
homolog O O
of O O
the O O
human O O
ATM O O
gene O O
defective O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
, O O
has O O
been O O
identified O O
. O O

The O O
entire O O
coding O O
sequence O O
of O O
the O O
Atm O O
transcript O O
was O O
cloned O O
and O O
found O O
to O O
contain O O
an O O
open O O
reading O O
frame O O
encoding O O
a O O
protein O O
of O O
3066 O O
amino O O
acids O O
with O O
84 O O
% O O
overall O O
identity O O
and O O
91 O O
% O O
similarity O O
to O O
the O O
human O O
ATM O O
protein O O
. O O

Variable O O
levels O O
of O O
expression O O
of O O
Atm O O
were O O
observed O O
in O O
different O O
tissues O O
. O O

Fluorescence O O
in O O
situ O O
hybridization O O
and O O
linkage O O
analysis O O
located O O
the O O
Atm O O
gene O O
on O O
mouse O O
chromosome O O
9 O O
, O O
band O O
9C O O
, O O
in O O
a O O
region O O
homologous O O
to O O
the O O
ATM O O
region O O
on O O
human O O
chromosome O O
11q22-q23 O O
.. O O

The O O
mouse O O
homolog O O
of O O
the O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
protein O O
( O O
WASP O O
) O O
gene O O
is O O
highly O O
conserved O O
and O O
maps O O
near O O
the O O
scurfy O O
( O O
sf O O
) O O
mutation O O
on O O
the O O
X O O
chromosome O O
. O O

The O O
mouse O O
WASP O O
gene O O
, O O
the O O
homolog O O
of O O
the O O
gene O O
mutated O O
in O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
has O O
been O O
isolated O O
and O O
sequenced O O
. O O

the O O
predicted O O
amino O O
acid O O
sequence O O
is O O
86 O O
% O O
identical O O
to O O
the O O
human O O
WASP O O
sequence O O
. O O

A O O
distinct O O
feature O O
of O O
the O O
mouse O O
gene O O
is O O
an O O
expanded O O
polymorphic O O
GGA O O
trinucleotide O O
repeat O O
that O O
codes O O
for O O
polyglycine O O
and O O
varies O O
from O O
15 O O
to O O
17 O O
triplets O O
in O O
different O O
Mus O O
musculus O O
strains O O
. O O

The O O
genomic O O
structure O O
of O O
the O O
mouse O O
WASP O O
gene O O
is O O
expressed O O
as O O
an O O
approximately O O
2 O O
. O O

4-kb O O
mRNA O O
in O O
thymus O O
and O O
spleen O O
. O O

Chromosomal O O
mapping O O
in O O
an O O
interspecific O O
M. O O
Musculus O O
/ O O
M. O O
spretus O O
backcross O O
placed O O
the O O
Wasp O O
locus O O
near O O
the O O
centromere O O
of O O
the O O
mouse O O
X O O
chromosome O O
, O O
inseparable O O
from O O
Gata1 O O
, O O
Tcfe3 O O
, O O
and O O
scurfy O O
( O O
sf O O
) O O
. O O

This O O
localization O O
makes O O
Wasp O O
a O O
candidate O O
for O O
involvement O O
in O O
scurfy O O
, O O
a O O
T O O
cell O O
- O O
mediated O O
fatal B-Disease O
lymphoreticular I-Disease B-Disease
disease I-Disease I-Disease
of O O
mice O O
that O O
has O O
previously O O
been O O
proposed O O
as O O
a O O
mouse O O
homolog O O
of O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Northern O O
analysis O O
of O O
sf O O
tissue O O
samples O O
indicated O O
the O O
presence O O
of O O
WASP O O
mRNA O O
in O O
liver O O
and O O
skin O O
, O O
presumably O O
as O O
a O O
consequence O O
of O O
lymphocytic O O
infiltration O O
, O O
but O O
non O O
abnormalities O O
in O O
the O O
amount O O
or O O
size O O
of O O
mRNA O O
present O O
. O O

Colchicine O O
in O O
breast O O
milk O O
of O O
patients O O
with O O
familial B-Disease B-Disease
Mediterranean I-Disease I-Disease
fever I-Disease I-Disease
. O O

OBJECTIVE O O
. O O

To O O
clarify O O
whether O O
colchicine O O
is O O
excreted O O
in O O
breast O O
milk O O
, O O
and O O
to O O
compare O O
its O O
concentrations O O
in O O
the O O
serum O O
and O O
breast O O
milk O O
of O O
lactating O O
women O O
who O O
have O O
familial B-Disease B-Disease
Mediterranean I-Disease I-Disease
fever I-Disease I-Disease
( O O
FMF B-Disease B-Disease
) O O
. O O

METHODS O O
. O O

Using O O
a O O
specific O O
radioimmunoassay O O
, O O
we O O
determined O O
colchicine O O
concentrations O O
in O O
the O O
serum O O
and O O
breast O O
milk O O
of O O
4 O O
patients O O
at O O
various O O
time O O
points O O
, O O
following O O
oral O O
administration O O
of O O
the O O
drug O O
. O O

The O O
study O O
evaluated O O
4 O O
patients O O
with O O
FMF B-Disease B-Disease
who O O
had O O
been O O
taking O O
colchicine O O
on O O
a O O
long O O
- O O
term O O
basis O O
. O O

RESULTS O O
. O O

Colchicine O O
was O O
found O O
to O O
be O O
excreted O O
in O O
breast O O
milk O O
. O O

Its O O
levels O O
ranged O O
between O O
1 O O
. O O
9 O O
and O O
8 O O
. O O
6 O O
ng O O
/ O O
ml O O
, O O
which O O
were O O
similar O O
to O O
those O O
found O O
in O O
the O O
serum O O
( O O
parallel O O
concentration O O
time O O
curves O O
) O O
. O O

However O O
, O O
there O O
appeared O O
to O O
be O O
a O O
considerable O O
variation O O
in O O
colchicine O O
milk O O
concentration O O
among O O
the O O
different O O
patients O O
, O O
which O O
might O O
be O O
related O O
to O O
individual O O
breast O O
milk O O
composition O O
and O O
, O O
possibly O O
, O O
to O O
other O O
nutritional O O
or O O
metabolic O O
factors O O
. O O

CONCLUSION O O
. O O

The O O
extensive O O
peripheral O O
tissue O O
binding O O
and O O
relatively O O
low O O
concentration O O
of O O
colchicine O O
in O O
breast O O
milk O O
suggests O O
that O O
the O O
amount O O
ingested O O
by O O
the O O
infant O O
is O O
small O O
. O O

Furthermore O O
, O O
based O O
on O O
our O O
clinical O O
experience O O
, O O
nursing O O
appears O O
to O O
be O O
safe O O
for O O
lactating O O
women O O
with O O
FMF B-Disease B-Disease
who O O
continue O O
to O O
take O O
colchicine O O
. O O

Abnormal O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
protein O O
kinase O O
levels O O
produce O O
only O O
mild O O
myopathy B-Disease B-Disease
in O O
mice O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
commonly O O
associated O O
with O O
CTG O O
repeat O O
expansions O O
within O O
the O O
gene O O
for O O
DM O O
- O O
protein O O
kinase O O
( O O
DMPK O O
) O O
. O O

The O O
effect O O
of O O
altered O O
expression O O
levels O O
of O O
DMPK O O
, O O
which O O
is O O
ubiquitously O O
expressed O O
in O O
all O O
muscle O O
cell O O
lineages O O
during O O
development O O
, O O
was O O
examined O O
by O O
disrupting O O
the O O
endogenous O O
Dmpk O O
gene O O
and O O
overexpressing O O
a O O
normal O O
human O O
DMPK O O
transgene O O
in O O
mice O O
. O O

Nullizygous O O
( O O
- O O
/ O O
- O O
) O O
mice O O
showed O O
only O O
inconsistent O O
and O O
minor O O
size O O
changes O O
in O O
head O O
and O O
neck O O
muscle O O
fibres O O
at O O
older O O
age O O
, O O
animals O O
with O O
the O O
highest O O
DMPK O O
transgene O O
expression O O
showed O O
hypertrophic B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
and O O
enhanced O O
neonatal O O
mortality O O
. O O

However O O
, O O
both O O
models O O
lack O O
other O O
frequent O O
DM B-Disease B-Disease
symptoms O O
including O O
the O O
fibre O O
- O O
type O O
dependent O O
atrophy B-Disease B-Disease
, O O
myotonia B-Disease B-Disease
, O O
cataract B-Disease B-Disease
and O O
male B-Disease B-Disease
- I-Disease I-Disease
infertility I-Disease I-Disease
. O O

These O O
results O O
strengthen O O
the O O
contention O O
that O O
simple O O
loss- O O
or O O
gain O O
- O O
of O O
- O O
expression O O
of O O
DMPK O O
is O O
not O O
the O O
only O O
crucial O O
requirement O O
for O O
development O O
of O O
the O O
disease O O
.. O O

Mice O O
lacking O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
protein O O
kinase O O
develop O O
a O O
late O O
onset O O
progressive O O
myopathy B-Disease B-Disease
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disorder I-Disease I-Disease
resulting O O
from O O
the O O
expansion O O
of O O
a O O
CTG O O
repeat O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
a O O
putative O O
protein O O
kinase O O
( O O
DMPK O O
) O O
. O O

To O O
elucidate O O
the O O
role O O
of O O
DMPK O O
in O O
DM B-Disease B-Disease
pathogenesis O O
we O O
have O O
developed O O
Dmpk B-Disease B-Disease
deficient I-Disease I-Disease
( O O
Dmpk- O O
/ O O
- O O
) O O
mice O O
. O O

Dmpk- O O
/ O O
-mice O O
develop O O
a O O
late O O
- O O
onset O O
, O O
progressive B-Disease O
skeletal I-Disease B-Disease
myopathy I-Disease I-Disease
that O O
shares O O
some O O
pathological O O
features O O
with O O
DM B-Disease B-Disease
. O O

Muscles O O
from O O
mature O O
mice O O
show O O
variation O O
in O O
fibre O O
size O O
, O O
increased O O
fibre B-Disease O
degeneration I-Disease O
and O O
fibrosis B-Disease B-Disease
. O O

Adult O O
Dmpk- O O
/ O O
-mice O O
show O O
ultrastructural O O
changes O O
in O O
muscle O O
and O O
a O O
50 O O
% O O
decrease O O
in O O
force O O
generation O O
compared O O
to O O
young O O
mice O O
. O O

Our O O
results O O
indicate O O
that O O
DMPK O O
may O O
be O O
necessary O O
for O O
the O O
maintenance O O
of O O
skeletal O O
muscle O O
structure O O
and O O
function O O
and O O
suggest O O
that O O
a O O
decrease O O
in O O
DMPK O O
levels O O
may O O
contribute O O
to O O
DM B-Disease B-Disease
pathology O O
.. O O

The O O
tumor B-Disease B-Disease
suppressor O O
gene O O
Brca1 O O
is O O
required O O
for O O
embryonic O O
cellular O O
proliferation O O
in O O
the O O
mouse O O
. O O

Mutations O O
of O O
the O O
BRCA1 O O
gone O O
in O O
humans O O
are O O
associated O O
with O O
predisposition O O
to O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancers I-Disease I-Disease
. O O

We O O
show O O
here O O
that O O
Brca1 O O
+ O O
/- O O

mice O O
are O O
normal O O
and O O
fertile O O
and O O
lack O O
tumors B-Disease B-Disease
by O O
age O O
eleven O O
months O O
. O O

Homozygous O O
Brca1 O O
( O O
5 O O
- O O
6 O O
) O O
mutant O O
mice O O
die O O
before O O
day O O
7 O O
. O O

5 O O
of O O
embryogenesis O O
. O O

Mutant O O
embryos O O
are O O
poorly O O
developed O O
, O O
with O O
no O O
evidence O O
of O O
mesoderm O O
formation O O
. O O

The O O
extraembryonic O O
region O O
is O O
abnormal O O
, O O
but O O
aggregation O O
with O O
wild O O
- O O
type O O
tetraploid O O
embryos O O
does O O
not O O
rescue O O
the O O
lethality O O
. O O

In O O
vivo O O
, O O
mutant O O
embryos O O
do O O
not O O
exhibit O O
increased O O
apoptosis O O
but O O
show O O
reduced O O
cell O O
proliferation O O
accompanied O O
by O O
decreased O O
expression O O
of O O
cyclin O O
E O O
and O O
mdm-2 O O
, O O
a O O
regulator O O
of O O
p53 O O
activity O O
. O O

The O O
expression O O
of O O
cyclin O O
- O O
dependent O O
kinase O O
inhibitor O O
p21 O O
is O O
dramatically O O
increased O O
in O O
the O O
mutant O O
embryos O O
. O O

Buttressing O O
these O O
in O O
vivo O O
observations O O
is O O
the O O
fact O O
that O O
mutant O O
blastocyst O O
growth O O
is O O
grossly O O
impaired O O
in O O
vitro O O
. O O

Thus O O
, O O
the O O
death O O
of O O
Brca1 O O
( O O
5 O O
- O O
6 O O
) O O
mutant O O
embryos O O
prior O O
to O O
gastrulation O O
may O O
be O O
due O O
to O O
a O O
failure O O
of O O
the O O
proliferative O O
burst O O
required O O
for O O
the O O
development O O
of O O
the O O
different O O
germ O O
layers O O
. O O

Increased O O
coronary B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
in O O
Japanese O O
- O O
American O O
men O O
with O O
mutation O O
in O O
the O O
cholesteryl O O
ester O O
transfer O O
protein O O
gene O O
despite O O
increased O O
HDL O O
levels O O
. O O

Plasma O O
high O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
levels O O
are O O
strongly O O
genetically O O
determined O O
and O O
show O O
a O O
general O O
inverse O O
relationship O O
with O O
coronary B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
( O O
CHD B-Disease B-Disease
) O O
. O O

The O O
cholesteryl O O
ester O O
transfer O O
protein O O
( O O
CETP O O
) O O
mediates O O
the O O
transfer O O
of O O
cholesteryl O O
esters O O
from O O
HDL O O
to O O
other O O
lipoproteins O O
and O O
is O O
a O O
key O O
participant O O
in O O
the O O
reverse O O
transport O O
of O O
cholesterol O O
from O O
the O O
periphery O O
to O O
the O O
liver O O
. O O

A O O
high O O
prevalence O O
of O O
two O O
different O O
CETP O O
gene O O
mutations O O
( O O
D442 O O
G O O
, O O
5 O O
. O O
1 O O
% O O
; O O
intron O O
14 O O
G O O
A O O
, O O
0 O O
. O O
5 O O
% O O
) O O
, O O
was O O
found O O
in O O
3 O O
, O O
469 O O
men O O
of O O
Japanese O O
ancestry O O
in O O
the O O
Honolulu O O
Heart O O
Program O O
and O O
mutations O O
were O O
associated O O
with O O
decreased O O
CETP O O
( O O
-35 O O
% O O
) O O
and O O
increased O O
HDL O O
chol O O
levels O O
( O O
+ O O
10 O O
% O O
for O O
D442 O O
G O O
) O O
. O O

However O O
, O O
the O O
overall O O
prevalence O O
of O O
definite O O
CHD B-Disease B-Disease
was O O
21 O O
% O O
in O O
men O O
with O O
mutations O O
and O O
16 O O
% O O
in O O
men O O
without O O
mutations O O
. O O

The O O
relative O O
risk O O
( O O
RR O O
) O O
of O O
CHD B-Disease B-Disease
was O O
1 O O
. O O
43 O O
in O O
men O O
with O O
mutations O O
( O O
P O O
< O O
. O O
05 O O
) O O
; O O
after O O
adjustment O O
for O O
CHD B-Disease B-Disease
risk O O
factors O O
, O O
the O O
RR O O
was O O
1 O O
. O O
55 O O
( O O
P O O
= O O
. O O
02 O O
) O O
; O O
after O O
additional O O
adjustment O O
for O O
HDL O O
levels O O
, O O
the O O
RR O O
was O O
1 O O
. O O
68 O O
( O O
P O O
= O O
. O O
008 O O
) O O
. O O

Similar O O
RR O O
values O O
were O O
obtained O O
for O O
the O O
D442 O O
G O O
mutation O O
alone O O
. O O

Increased O O
CHD B-Disease B-Disease
in O O
men O O
with O O
mutations O O
was O O
primarily O O
observed O O
for O O
HDL O O
chol O O
41 O O
- O O
60 O O
mg O O
/ O O
dl O O
; O O
for O O
HDL O O
chol O O
> O O
60 O O
mg O O
/ O O
dl O O
men O O
with O O
and O O
without O O
mutations O O
had O O
low O O
CHD B-Disease B-Disease
prevalence O O
. O O

Thus O O
, O O
genetic O O
CETP B-Disease B-Disease
deficiency I-Disease I-Disease
appears O O
to O O
be O O
an O O
independent O O
risk O O
factor O O
for O O
CHD B-Disease B-Disease
, O O
primarily O O
due O O
to O O
increased O O
CHD B-Disease B-Disease
prevalence O O
in O O
men O O
with O O
the O O
D442 O O
G O O
mutation O O
and O O
HDL O O
cholesterol O O
between O O
41 O O
and O O
60 O O
mg O O
/ O O
dl O O
. O O

The O O
findings O O
suggest O O
that O O
both O O
HDL O O
concentration O O
and O O
the O O
dynamics O O
of O O
cholesterol O O
transport O O
through O O
HDL O O
( O O
i. O O
e. O O
, O O
reverse O O
cholesterol O O
transport O O
) O O
determine O O
the O O
anti O O
- O O
atherogenicity O O
of O O
the O O
HDL O O
fraction O O
. O O

Mapping O O
the O O
homolog O O
of O O
the O O
human O O
Rb1 O O
gene O O
to O O
chromosome O O
14 O O
of O O
higher O O
primates O O
. O O

The O O
Rb1 O O
gene O O
has O O
been O O
implicated O O
with O O
retinoblastoma B-Disease B-Disease
and O O
is O O
located O O
on O O
human O O
Chromosome O O
( O O
Chr O O
) O O
13q14 O O
. O O

2 O O
2 O O
. O O

A O O
unique O O
sequence O O
human O O
Rb1 O O
cosmid O O
DNA O O
probe O O
has O O
been O O
used O O
to O O
localize O O
this O O
region O O
on O O
apes O O
Chr O O
14 O O
by O O
the O O
FISH O O
technique O O
. O O

The O O
conservation O O
of O O
the O O
Rb1 O O
gene O O
in O O
higher O O
primates O O
at O O
the O O
corresponding O O
equivalent O O
chromosome O O
locus O O
( O O
14q14 O O
) O O
of O O
the O O
human O O
may O O
serve O O
as O O
a O O
phylogenetic O O
marker O O
to O O
further O O
trace O O
the O O
evolutionary O O
pathway O O
of O O
human O O
descent O O
. O O

Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
: O O
no O O
strict O O
genotype O O
- O O
phenotype O O
correlations O O
but O O
clustering O O
of O O
missense O O
mutations O O
in O O
the O O
amino O O
- O O
terminal O O
part O O
of O O
the O O
WASP O O
gene O O
product O O
. O O

The O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
protein O O
( O O
WASP O O
) O O
gene O O
was O O
found O O
to O O
be O O
mutated O O
in O O
patients O O
presenting O O
with O O
WAS B-Disease B-Disease
and O O
in O O
patients O O
showing O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
thrombocytopenia I-Disease I-Disease
. O O

Mutation O O
analysis O O
in O O
19 O O
families O O
of O O
German O O
, O O
Swiss O O
and O O
Turkish O O
descent O O
by O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
and O O
sequencing O O
resulted O O
in O O
the O O
detection O O
of O O
seven O O
novel O O
and O O
10 O O
known O O
mutations O O
. O O

A O O
striking O O
clustering O O
of O O
missense O O
mutations O O
in O O
the O O
first O O
four O O
exons O O
contrasted O O
with O O
a O O
random O O
distribution O O
of O O
nonsense O O
mutations O O
. O O

More O O
than O O
85 O O
% O O
of O O
all O O
known O O
missense O O
mutations O O
were O O
localized O O
in O O
the O O
amino O O
- O O
terminal O O
stretch O O
of O O
the O O
WASP O O
gene O O
product O O
; O O
this O O
region O O
contained O O
a O O
mutational O O
hot O O
spot O O
at O O
codon O O
86 O O
. O O

No O O
genotype O O
- O O
phenotype O O
correlation O O
emerged O O
after O O
a O O
comparison O O
of O O
the O O
identified O O
mutations O O
with O O
the O O
resulting O O
clinical O O
picture O O
for O O
a O O
classical O O
WAS B-Disease B-Disease
phenotype O O
. O O

A O O
substitution O O
at O O
codon O O
86 O O
resulted O O
in O O
an O O
extremely O O
variable O O
expression O O
of O O
the O O
disease O O
in O O
a O O
large O O
Swiss O O
family O O
. O O

An O O
extended O O
homology O O
search O O
revealed O O
a O O
distant O O
relationship O O
of O O
this O O
stretch O O
to O O
the O O
vasodilator O O
- O O
stimulated O O
phosphoprotein O O
( O O
VASP O O
) O O
, O O
which O O
is O O
involved O O
in O O
the O O
maintenance O O
of O O
cyto O O
- O O
architecture O O
by O O
interacting O O
with O O
actin O O
- O O
like O O
filaments O O
.. O O

Influence O O
of O O
PAX6 O O
gene O O
dosage O O
on O O
development O O
: O O
overexpression O O
causes O O
severe O O
eye B-Disease B-Disease
abnormalities I-Disease I-Disease
. O O

Aniridia B-Disease B-Disease
in O O
man O O
and O O
Small O O
eye O O
in O O
mice O O
are O O
semidominant B-Disease B-Disease
developmental I-Disease I-Disease
disorders I-Disease I-Disease
caused O O
by O O
mutations O O
within O O
the O O
paired O O
box O O
gene O O
PAX6 O O
. O O

Whereas O O
heterozygotes O O
suffer O O
from O O
iris B-Disease B-Disease
hypoplasia I-Disease I-Disease
, O O
homozygous O O
mice O O
lack O O
eyes O O
and O O
nasal O O
cavities O O
and O O
exhibit O O
brain B-Disease B-Disease
abnormalities I-Disease I-Disease
. O O

To O O
investigate O O
the O O
role O O
of O O
gene O O
dosage O O
in O O
more O O
detail O O
, O O
we O O
have O O
generated O O
yeast O O
artificial O O
chromosome O O
transgenic O O
mice O O
carrying O O
the O O
human O O
PAX6 O O
locus O O
. O O

When O O
crossed O O
onto O O
the O O
Small O O
eye O O
background O O
, O O
the O O
transgene O O
rescues O O
the O O
mutant O O
phenotype O O
. O O

Strikingly O O
, O O
mice O O
carrying O O
multiple O O
copies O O
on O O
a O O
wild O O
- O O
type O O
background O O
show O O
specific O O
developmental B-Disease B-Disease
abnormalities I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
eye I-Disease I-Disease
, O O
but O O
not O O
of O O
other O O
tissues O O
expressing O O
the O O
gene O O
. O O

Thus O O
, O O
at O O
least O O
five O O
different O O
eye O O
phenotypes O O
are O O
associated O O
with O O
changes O O
in O O
PAX6 O O
expression O O
. O O

We O O
provide O O
evidence O O
that O O
not O O
only O O
reduced O O
, O O
but O O
also O O
increased O O
levels O O
of O O
transcriptional O O
regulators O O
can O O
cause O O
developmental B-Disease B-Disease
defects I-Disease I-Disease
.. O O

Heterodimer O O
formation O O
and O O
activity O O
in O O
the O O
human O O
enzyme O O
galactose-1-phosphate O O
uridylyltransferase O O
. O O

One O O
of O O
the O O
fundamental O O
questions O O
concerning O O
expression O O
and O O
function O O
of O O
dimeric O O
enzymes O O
involves O O
the O O
impact O O
of O O
naturally O O
occurring O O
mutations O O
on O O
subunit O O
assembly O O
and O O
heterodimer O O
activity O O
. O O

This O O
question O O
is O O
of O O
particular O O
interest O O
for O O
the O O
human O O
enzyme O O
galactose O O
- O O
l O O
- O O
phosphate O O
uridylyl O O
- O O
transferase O O
( O O
GALT O O
) O O
, O O
impairment O O
of O O
which O O
results O O
in O O
the O O
inherited B-Disease B-Disease
metabolic I-Disease I-Disease
disorder I-Disease I-Disease
galactosemia B-Disease I-Disease
, O O
because O O
many O O
if O O
not O O
most O O
patients O O
studied O O
to O O
date O O
are O O
compound O O
heterozygotes O O
rather O O
than O O
true O O
molecular O O
homozygotes O O
. O O

Furthermore O O
, O O
the O O
broad O O
range O O
of O O
phenotypic O O
severity O O
observed O O
in O O
these O O
patients O O
raises O O
the O O
possibility O O
that O O
allelic O O
combination O O
, O O
not O O
just O O
allelic O O
constitution O O
, O O
may O O
play O O
some O O
role O O
in O O
determining O O
outcome O O
. O O

In O O
the O O
work O O
described O O
herein O O
, O O
we O O
have O O
selected O O
two O O
distinct O O
naturally O O
occurring O O
null O O
mutations O O
of O O
GALT O O
, O O
Q188R O O
and O O
R333W O O
, O O
and O O
asked O O
the O O
questions O O
( O O
i O O
) O O
what O O
are O O
the O O
impacts O O
of O O
these O O
mutations O O
on O O
subunit O O
assembly O O
, O O
and O O
( O O
ii O O
) O O
if O O
heterodimers O O
do O O
form O O
, O O
are O O
they O O
active O O
? O O

To O O
answer O O
these O O
questions O O
, O O
we O O
have O O
established O O
a O O
yeast O O
system O O
for O O
the O O
coexpression O O
of O O
epitope O O
- O O
tagged O O
alleles O O
of O O
human O O
GALT O O
and O O
investigated O O
both O O
the O O
extent O O
of O O
specific O O
GALT O O
subunit O O
interactions O O
and O O
the O O
activity O O
of O O
defined O O
heterodimer O O
pools O O
. O O

We O O
have O O
found O O
that O O
both O O
homodimers O O
and O O
heterodimers O O
do O O
form O O
involving O O
each O O
of O O
the O O
mutant O O
subunits O O
tested O O
and O O
that O O
both O O
heterodimer O O
pools O O
retain O O
substantial O O
enzymatic O O
activity O O
. O O

These O O
results O O
are O O
significant O O
not O O
only O O
in O O
terms O O
of O O
their O O
implications O O
for O O
furthering O O
our O O
understanding O O
of O O
galactosemia B-Disease B-Disease
and O O
GALT O O
holoenzyme O O
structure O O
- O O
function O O
relationships O O
but O O
also O O
because O O
the O O
system O O
described O O
may O O
serve O O
as O O
a O O
model O O
for O O
similar O O
studies O O
of O O
other O O
complexes O O
composed O O
of O O
multiple O O
subunits O O
.. O O

Cleavage O O
of O O
huntingtin O O
by O O
apopain O O
, O O
a O O
proapoptotic O O
cysteine O O
protease O O
, O O
is O O
modulated O O
by O O
the O O
polyglutamine O O
tract O O
. O O

Apoptosis O O
has O O
recently O O
been O O
recognized O O
as O O
a O O
mode O O
of O O
cell O O
death O O
in O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
. O O

Apopain O O
, O O
a O O
human O O
counterpart O O
of O O
the O O
nematode O O
cysteine O O
protease O O
death O O
- O O
gene O O
product O O
, O O
CED-3 O O
, O O
has O O
a O O
key O O
role O O
in O O
proteolytic O O
events O O
leading O O
to O O
apoptosis O O
. O O

Here O O
we O O
show O O
that O O
apoptotic O O
extracts O O
and O O
apopain O O
itself O O
specifically O O
cleave O O
the O O
HD B-Disease B-Disease
gene O O
product O O
, O O
huntingtin O O
. O O

The O O
rate O O
of O O
cleavage O O
increases O O
with O O
the O O
length O O
of O O
the O O
huntingtin O O
polyglutamine O O
tract O O
, O O
providing O O
an O O
explanation O O
for O O
the O O
gain O O
- O O
of O O
- O O
function O O
associated O O
with O O
CAG O O
expansion O O
. O O

Our O O
results O O
show O O
that O O
huntingtin O O
is O O
cleaved O O
by O O
cysteine O O
proteases O O
and O O
suggest O O
that O O
HD B-Disease B-Disease
might O O
be O O
a O O
disorder B-Disease B-Disease
of I-Disease I-Disease
inappropriate I-Disease I-Disease
apoptosis I-Disease I-Disease
.. O O

The O O
5 O O
' O O
end O O
of O O
the O O
BRCA1 O O
gene O O
lies O O
within O O
a O O
duplicated O O
region O O
of O O
human O O
chromosome O O
17q21 O O
. O O

To O O
begin O O
to O O
address O O
the O O
hypothesis O O
that O O
abnormal O O
regulation O O
of O O
the O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
susceptibility O O
gene O O
BRCA1 O O
is O O
a O O
critical O O
step O O
in O O
sporadic O B-Disease
breast O I-Disease
/ O I-Disease
ovarian O I-Disease
tumorigenesis O I-Disease
, O O
we O O
have O O
determined O O
the O O
detailed O O
structure O O
of O O
the O O
BRCA1 O O
genomic O O
region O O
. O O

We O O
show O O
that O O
this O O
region O O
of O O
the O O
genome O O
contains O O
a O O
tandem O O
duplication O O
of O O
approximately O O
30 O O
kilobases O O
, O O
which O O
results O O
in O O
two O O
copies O O
of O O
BRCA1 O O
exons O O
1 O O
and O O
2 O O
, O O
of O O
exons O O
1 O O
and O O
3 O O
of O O
the O O
adjacent O O
1A1 O O
- O O
3B O O
gene O O
and O O
of O O
the O O
previously O O
reported O O
295 O O
base O O
pair O O
intergenic O O
region O O
. O O

Sequence O O
analysis O O
of O O
the O O
duplicated O O
exons O O
of O O
BRCA1 O O
and O O
1A1 O O
- O O
3B O O
and O O
flanking O O
genomic O O
DNA O O
reveals O O
maintenance O O
of O O
the O O
intron O O
- O O
exon O O
structure O O
and O O
a O O
high O O
degree O O
of O O
nucleotide O O
sequence O O
identity O O
, O O
suggesting O O
that O O
these O O
are O O
non O O
- O O
processed O O
pseudogenes O O
and O O
that O O
the O O
duplication O O
is O O
a O O
recent O O
event O O
in O O
evolutionary O O
terms O O
. O O

We O O
also O O
show O O
that O O
a O O
processed O O
pseudogene O O
of O O
the O O
acidic O O
ribosomal O O
phosphoprotein O O
P1 O O
( O O
ARPP1 O O
) O O
is O O
inserted O O
directly O O
upstream O O
of O O
pseudo O O
- O O
BRCA1 O O
exon O O
1A O O
. O O

We O O
believe O O
that O O
these O O
findings O O
could O O
not O O
only O O
confound O O
BRCA1 O O
mutation O O
analysis O O
, O O
but O O
could O O
have O O
implications O O
for O O
the O O
normal O O
and O O
abnormal O O
regulation O O
of O O
BRCA1 O O
transcription O O
, O O
translation O O
and O O
function O O
.. O O

Deletion O O
of O O
small O O
nuclear O O
ribonucleoprotein O O
polypeptide O O
N O O
( O O
SNRPN O O
) O O
in O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
detected O O
by O O
fluorescence O O
in O O
situ O O
hybridization O O
: O O
two O O
sibs O O
with O O
the O O
typical O O
phenotype O O
without O O
a O O
cytogenetic O O
deletion O O
in O O
chromosome O O
15q O O
. O O

The O O
small O O
nuclear O O
ribonucleoprotein O O
polypeptide O O
N O O
( O O
SNRPN O O
) O O
gene O O
is O O
regarded O O
as O O
one O O
of O O
the O O
candidates O O
for O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
PWS B-Disease B-Disease
) O O
. O O

We O O
describe O O
two O O
sibs O O
with O O
typical O O
PWS B-Disease B-Disease
presenting O O
deletion O O
of O O
SNRPN O O
detected O O
by O O
fluorescence O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
. O O

Neither O O
a O O
cytogenetically O O
detectable O O
15q12 O O
deletion O O
nor O O
a O O
deletion O O
for O O
the O O
D15S11 O O
, O O
D15S10 O O
, O O
and O O
GABRB3 O O
cosmid O O
probes O O
were O O
found O O
in O O
either O O
patient O O
. O O

This O O
implies O O
a O O
smaller O O
deletion O O
limited O O
to O O
the O O
PWS B-Disease B-Disease
critical O O
region O O
. O O

FISH O O
with O O
a O O
SNRPN O O
probe O O
will O O
permit O O
analysis O O
of O O
PWS B-Disease B-Disease
patients O O
with O O
limited O O
deletions O O
not O O
detectable O O
with O O
other O O
probes O O
.. O O

Expression O O
of O O
the O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
disease I-Disease I-Disease
tumour I-Disease I-Disease
suppressor O O
gene O O
during O O
human O O
embryogenesis O O
. O O

The O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
( I-Disease I-Disease
VHL I-Disease I-Disease
) I-Disease I-Disease
disease I-Disease I-Disease
product O O
is O O
thought O O
to O O
down O O
- O O
regulate O O
transcription O O
by O O
antagonizing O O
elongin O O
- O O
enhanced O O
transcriptional O O
elongation O O
. O O

Germline O O
VHL B-Disease B-Disease
gene O O
mutations O O
predispose O O
to O O
the O O
development O O
of O O
retinal B-Disease B-Disease
, I-Disease I-Disease
cerebellar I-Disease I-Disease
and I-Disease I-Disease
spinal I-Disease I-Disease
haemangioblastomas I-Disease I-Disease
, O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
and O O
phaeochromocytoma B-Disease B-Disease
. O O

In O O
addition O O
, O O
somatic O O
Inactivation O O
of O O
the O O
VHL B-Disease B-Disease
gene O O
is O O
frequent O O
in O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
and O O
haemangioblastoma B-Disease B-Disease
. O O

Regulation O O
of O O
transcript O O
elongation O O
is O O
an O O
important O O
control O O
mechanism O O
for O O
gene O O
expression O O
and O O
the O O
VHL B-Disease B-Disease
gene O O
might O O
modify O O
the O O
expression O O
of O O
proto O O
- O O
oncogenes O O
and O O
growth O O
suppressor O O
genes O O
during O O
embryogenesis O O
. O O

We O O
therefore O O
investigated O O
the O O
expression O O
of O O
VHL B-Disease B-Disease
mRNA O O
during O O
human O O
embryogenesis O O
by O O
in O O
situ O O
hybridization O O
studies O O
at O O
4 O O
, O O
6 O O
and O O
10 O O
weeks O O
post O O
conception O O
. O O

Although O O
VHL B-Disease B-Disease
mRNA O O
was O O
expressed O O
in O O
all O O
three O O
germ O O
layers O O
, O O
strong O O
expression O O
was O O
noted O O
in O O
the O O
central O O
nervous O O
system O O
, O O
kidneys O O
, O O
testis O O
and O O
lung O O
. O O

Within O O
the O O
kidney O O
, O O
VHL B-Disease B-Disease
mRNA O O
was O O
differentially O O
expressed O O
within O O
renal O O
tubules O O
suggesting O O
that O O
the O O
VHL B-Disease B-Disease
gene O O
product O O
may O O
have O O
a O O
specific O O
role O O
in O O
kidney O O
development O O
. O O

Two O O
alternatively O O
spliced O O
VHL B-Disease B-Disease
mRNAs O O
characterized O O
by O O
inclusion O O
( O O
isoform O O
I O O
) O O
or O O
exclusion O O
( O O
isoform O O
II O O
) O O
of O O
exon O O
2 O O
are O O
transcribed O O
in O O
adult O O
tissues O O
. O O

To O O
investigate O O
if O O
the O O
two O O
isoforms O O
are O O
differentially O O
expressed O O
during O O
embryogenesis O O
, O O
VHL B-Disease B-Disease
mRNA O O
was O O
reverse O O
transcribed O O
from O O
13 O O
fetal O O
tissues O O
( O O
8 O O
- O O
10 O O
weeks O O
gestation O O
) O O
. O O

The O O
quantitative O O
distribution O O
of O O
VHL B-Disease B-Disease
mRNA O O
within O O
fetal O O
tissues O O
reflected O O
that O O
seen O O
by O O
in O O
situ O O
hybridization O O
and O O
the O O
ratio O O
of O O
the O O
two O O
VHL B-Disease B-Disease
isoforms O O
was O O
similar O O
between O O
tissues O O
. O O

Although O O
the O O
genes O O
regulated O O
by O O
the O O
VHL B-Disease B-Disease
gene O O
product O O
have O O
not O O
yet O O
been O O
identified O O
, O O
our O O
findings O O
are O O
compatible O O
with O O
the O O
hypothesis O O
that O O
VHL B-Disease O
- O O
mediated O O
control O O
of O O
transcriptional O O
elongation O O
may O O
have O O
a O O
role O O
in O O
normal O O
human O O
development O O
.. O O

Genetic O O
heterogeneity O O
in O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
: O O
role O O
of O O
BRCA1 O O
and O O
BRCA2 O O
. O O

The O O
common O O
hereditary O O
forms O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
have O O
been O O
largely O O
attributed O O
to O O
the O O
inheritance O O
of O O
mutations O O
in O O
the O O
BRCA1 O O
or O O
BRCA2 O O
genes O O
. O O

However O O
, O O
it O O
is O O
not O O
yet O O
clear O O
what O O
proportion O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
is O O
explained O O
by O O
BRCA1 O O
and O O
BRCA2 O O
or O O
by O O
some O O
other O O
unidentified O O
susceptibility O O
gene O O
( O O
s O O
) O O
. O O

We O O
describe O O
the O O
proportion O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
explained O O
by O O
BRCA1 O O
or O O
BRCA2 O O
in O O
a O O
sample O O
of O O
North O O
American O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancers I-Disease I-Disease
and O O
assess O O
the O O
evidence O O
for O O
additional O O
susceptibility O O
genes O O
that O O
may O O
confer O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
risk O O
. O O

Twenty O O
- O O
three O O
families O O
were O O
identified O O
through O O
two O O
high O O
- O O
risk O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
research O O
programs O O
. O O

Genetic O O
analysis O O
was O O
undertaken O O
to O O
establish O O
linkage O O
between O O
the O O
breast B-Disease B-Disease
or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
and O O
markers O O
on O O
chromosomes O O
17q O O
( O O
BRCA1 O O
) O O
and O O
13q O O
( O O
BRCA2 O O
) O O
. O O

Mutation O O
analysis O O
in O O
the O O
BRCA1 O O
and O O
BRCA2 O O
genes O O
was O O
also O O
undertaken O O
in O O
all O O
families O O
. O O

The O O
pattern O O
of O O
hereditary B-Disease B-Disease
cancer I-Disease I-Disease
in O O
14 O O
( O O
61 O O
% O O
) O O
of O O
the O O
23 O O
families O O
studied O O
was O O
attributed O O
to O O
BRCA1 O O
by O O
a O O
combination O O
of O O
linkage O O
and O O
mutation O O
analyses O O
. O O

No O O
families O O
were O O
attributed O O
to O O
BRCA2 O O
. O O

Five O O
families O O
( O O
22 O O
% O O
) O O
provided O O
evidence O O
against O O
linkage O O
to O O
both O O
BRCA1 O O
and O O
BRCA2 O O
. O O

No O O
BRCA1 O O
or O O
BRCA2 O O
mutations O O
were O O
detected O O
in O O
these O O
five O O
families O O
. O O

The O O
BRCA1 O O
or O O
BRCA2 O O
status O O
of O O
four O O
families O O
( O O
17 O O
% O O
) O O
could O O
not O O
be O O
determined O O
. O O

BRCA1 O O
and O O
BRCA2 O O
probably O O
explain O O
the O O
majority O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
that O O
exists O O
in O O
the O O
North O O
American O O
population O O
. O O

However O O
, O O
one O O
or O O
more O O
additional O O
genes O O
may O O
yet O O
be O O
found O O
that O O
explain O O
some O O
proportion O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
.. O O

An O O
intronic O O
mutation O O
in O O
a O O
lariat O O
branchpoint O O
sequence O O
is O O
a O O
direct O O
cause O O
of O O
an O O
inherited B-Disease B-Disease
human I-Disease I-Disease
disorder I-Disease I-Disease
( O O
fish B-Disease B-Disease
- I-Disease I-Disease
eye I-Disease I-Disease
disease I-Disease I-Disease
) O O
. O O

The O O
first O O
step O O
in O O
the O O
splicing O O
of O O
an O O
intron O O
from O O
nuclear O O
precursors O O
of O O
mRNA O O
results O O
in O O
the O O
formation O O
of O O
a O O
lariat O O
structure O O
. O O

A O O
distinct O O
intronic O O
nucleotide O O
sequence O O
, O O
known O O
as O O
the O O
branchpoint O O
region O O
, O O
plays O O
a O O
central O O
role O O
in O O
this O O
process O O
. O O

We O O
here O O
describe O O
a O O
point O O
mutation O O
in O O
such O O
a O O
sequence O O
. O O

Three O O
sisters O O
were O O
shown O O
to O O
suffer O O
from O O
fish B-Disease B-Disease
- I-Disease I-Disease
eye I-Disease I-Disease
disease I-Disease I-Disease
( O O
FED B-Disease B-Disease
) O O
, O O
a O O
disorder O O
which O O
is O O
caused O O
by O O
mutations O O
in O O
the O O
gene O O
coding O O
for O O
lecithin O O
cholesterol O O
acyltransferase O O
( O O
LCAT O O
) O O
. O O

Sequencing O O
of O O
the O O
LCAT O O
gene O O
of O O
all O O
three O O
probands O O
revealed O O
compound O O
heterozygosity O O
for O O
a O O
missense O O
mutation O O
in O O
exon O O
4 O O
which O O
is O O
reported O O
to O O
underlie O O
the O O
FED B-Disease B-Disease
phenotype O O
, O O
and O O
a O O
point O O
mutation O O
located O O
in O O
intron O O
4 O O
( O O
IVS4 O O
T-22C O O
) O O
. O O

By O O
performing O O
in O O
vitro O O
expression O O
of O O
LCAT O O
minigenes O O
and O O
reverse O O
transcriptase O O
PCR O O
on O O
mRNA O O
isolated O O
from O O
leukocytes O O
of O O
the O O
patient O O
, O O
this O O
gene O O
defect O O
was O O
shown O O
to O O
cause O O
a O O
null O O
allele O O
as O O
the O O
result O O
of O O
complete O O
intron O O
retention O O
. O O

In O O
conclusion O O
, O O
we O O
demonstrated O O
that O O
a O O
point O O
mutation O O
in O O
a O O
lariat O O
branchpoint O O
consensus O O
sequence O O
causes O O
a O O
null O O
allele O O
in O O
a O O
patient O O
with O O
FED B-Disease B-Disease
. O O

In O O
addition O O
, O O
our O O
finding O O
illustrates O O
the O O
importance O O
of O O
this O O
sequence O O
for O O
normal O O
human O O
mRNA O O
processing O O
. O O

Finally O O
, O O
this O O
report O O
provides O O
a O O
widely O O
applicable O O
strategy O O
which O O
ensures O O
fast O O
and O O
effective O O
screening O O
for O O
intronic O O
defects O O
that O O
underlie O O
differential O O
gene O O
expression O O
.. O O

Mutations O O
associated O O
with O O
variant O O
phenotypes O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
. O O

We O O
have O O
identified O O
14 O O
families O O
with O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
in O O
which O O
mutation O O
of O O
the O O
ATM O O
gene O O
is O O
associated O O
with O O
a O O
less O O
severe O O
clinical O O
and O O
cellular O O
phenotype O O
( O O
approximately O O
10 O O
% O O
-15 O O
% O O
of O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
families O O
identified O O
in O O
the O O
United O O
Kingdom O O
) O O
. O O

In O O
10 O O
of O O
these O O
families O O
, O O
all O O
the O O
homozygotes O O
have O O
a O O
137-bp O O
insertion O O
in O O
their O O
cDNA O O
caused O O
by O O
a O O
point O O
mutation O O
in O O
a O O
sequence O O
resembling O O
a O O
splice O O
- O O
donor O O
site O O
. O O

The O O
second O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
allele O O
has O O
a O O
different O O
mutation O O
in O O
each O O
patient O O
. O O

We O O
show O O
that O O
the O O
less O O
severe O O
phenotype O O
in O O
these O O
patients O O
is O O
caused O O
by O O
some O O
degree O O
of O O
normal O O
splicing O O
, O O
which O O
occurs O O
as O O
an O O
alternative O O
product O O
from O O
the O O
insertion O O
- O O
containing O O
allele O O
. O O

The O O
level O O
of O O
the O O
137-bp O O
PCR O O
product O O
containing O O
the O O
insertion O O
was O O
lowest O O
in O O
two O O
patients O O
who O O
showed O O
a O O
later O O
onset O O
of O O
cerebellar B-Disease B-Disease
ataxia I-Disease I-Disease
. O O

A O O
further O O
four O O
families O O
who O O
do O O
not O O
have O O
this O O
insertion O O
have O O
been O O
identified O O
. O O

Mutations O O
detected O O
in O O
two O O
of O O
four O O
of O O
these O O
are O O
missense O O
mutations O O
, O O
normally O O
rare O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
. O O

The O O
demonstration O O
of O O
mutations O O
giving O O
rise O O
to O O
a O O
slightly O O
milder O O
phenotype O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
raises O O
the O O
interesting O O
question O O
of O O
what O O
range O O
of O O
phenotypes O O
might O O
occur O O
in O O
individuals O O
in O O
whom O O
both O O
mutations O O
are O O
milder O O
. O O

One O O
possibility O O
might O O
be O O
that O O
individuals O O
who O O
are O O
compound O O
heterozygotes O O
for O O
ATM O O
mutations O O
are O O
more O O
common O O
than O O
we O O
realize O O
.. O O

Mutation O O
of O O
the O O
VHL O B-Disease
gene O O
is O O
associated O O
exclusively O O
with O O
the O O
development O O
of O O
non B-Disease B-Disease
- I-Disease I-Disease
papillary I-Disease I-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
. O O

To O O
define O O
the O O
possible O O
role O O
of O O
the O O
VHL B-Disease B-Disease
gene O O
in O O
the O O
development O O
of O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
, O O
91 O O
different O O
parenchymal B-Disease B-Disease
tumours I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
kidney I-Disease I-Disease
have O O
been O O
investigated O O
for O O
mutation O O
of O O
the O O
VHL B-Disease B-Disease
gene O O
by O O
single O O
strand O O
conformation O O
polymorphism O O
( O O
SSCP O O
) O O
and/or O O
heteroduplex O O
( O O
HD O O
) O O
techniques O O
. O O

Chromosome O O
3p O O
deletion O O
was O O
detected O O
in O O
98 O O
per O O
cent O O
of O O
non B-Disease B-Disease
- I-Disease I-Disease
papillary I-Disease I-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
and O O
in O O
25 O O
per O O
cent O O
of O O
chromophobe O B-Disease
renal B-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
. O O

In O O
22 O O
of O O
the O O
43 O O
non B-Disease B-Disease
- I-Disease I-Disease
papillary I-Disease I-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
, O O
abnormally O O
migrating O O
DNA O O
bands O O
were O O
detected O O
by O O
SSCP O O
and/or O O
HD O O
analysis O O
. O O

No O O
mobility O O
shift O O
was O O
seen O O
in O O
any O O
of O O
the O O
23 O O
chromophobe O B-Disease
renal B-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
. O O

In O O
addition O O
, O O
15 O O
papillary B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
tumours I-Disease I-Disease
and O O
ten O O
renal B-Disease B-Disease
oncocytomas I-Disease I-Disease
, O O
which O O
are O O
characterized O O
by O O
genetic O O
changes O O
other O O
than O O
loss O O
of O O
chromosome O O
3p O O
sequences O O
, O O
were O O
analysed O O
for O O
mutation O O
of O O
the O O
VHL B-Disease B-Disease
gene O O
. O O

None O O
of O O
these O O
tumours B-Disease B-Disease
showed O O
abnormal O O
migration O O
patterns O O
. O O

The O O
results O O
indicate O O
that O O
mutation O O
of O O
the O O
VHL B-Disease B-Disease
gene O O
is O O
associated O O
exclusively O O
with O O
the O O
development O O
of O O
non B-Disease B-Disease
- I-Disease I-Disease
papillary I-Disease I-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
.. O O

The O O
Emery B-Disease B-Disease
- I-Disease I-Disease
Dreifuss I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
protein O O
, O O
emerin O O
, O O
is O O
a O O
nuclear O O
membrane O O
protein O O
. O O

A O O
large O O
fragment O O
of O O
emerin O O
cDNA O O
was O O
prepared O O
by O O
PCR O O
and O O
expressed O O
as O O
a O O
recombinant O O
protein O O
in O O
Escherichia O O
coli O O
. O O

Using O O
this O O
as O O
immunogen O O
, O O
we O O
prepared O O
a O O
panel O O
of O O
12 O O
monoclonal O O
antibodies O O
which O O
recognise O O
at O O
least O O
four O O
different O O
epitopes O O
on O O
emerin O O
in O O
order O O
to O O
ensure O O
that O O
emerin O O
can O O
be O O
distinguished O O
from O O
non O O
- O O
specific O O
cross O O
- O O
reacting O O
proteins O O
. O O

All O O
the O O
mAbs O O
recognised O O
a O O
34 O O
kDa O O
protein O O
in O O
all O O
tissues O O
tested O O
, O O
though O O
minor O O
emerin O O
- O O
related O O
bands O O
were O O
also O O
detected O O
in O O
some O O
tissues O O
. O O

Immunofluorescence O O
microscopy O O
showed O O
that O O
emerin O O
is O O
located O O
at O O
the O O
nuclear O O
rim O O
in O O
all O O
tissues O O
examined O O
. O O

A O O
muscle O O
biopsy O O
from O O
an O O
Emery B-Disease B-Disease
- I-Disease I-Disease
Dreifuss I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
EMDM B-Disease B-Disease
) O O
patient O O
showed O O
complete O O
absence O O
of O O
emerin O O
by O O
both O O
Western O O
blotting O O
and O O
immunohistochemistry O O
, O O
suggesting O O
a O O
simple O O
diagnostic O O
antibody O O
test O O
for O O
EDMD B-Disease B-Disease
families O O
. O O

Biochemical O O
fractionation O O
of O O
brain O O
and O O
liver O O
tissues O O
showed O O
that O O
emerin O O
was O O
present O O
in O O
nuclei O O
purified O O
by O O
centrifugation O O
through O O
65 O O
% O O
sucrose O O
and O O
was O O
absent O O
from O O
soluble O O
fractions O O
( O O
post-100 O O
, O O
000 O O
g O O
) O O
. O O

From O O
these O O
results O O
, O O
together O O
with O O
sequence O O
and O O
structural O O
homologies O O
between O O
emerin O O
, O O
thymopoietins O O
and O O
the O O
nuclear O O
lamina O O
- O O
associated O O
protein O O
, O O
LAP2 O O
, O O
we O O
suggest O O
that O O
emerin O O
will O O
prove O O
to O O
be O O
one O O
member O O
of O O
a O O
family O O
of O O
inner O O
nuclear O O
membrane O O
proteins O O
.. O O

Mutation O O
of O O
MSH3 O O
in O O
endometrial B-Disease B-Disease
cancer I-Disease I-Disease
and O O
evidence O O
for O O
its O O
functional O O
role O O
in O O
heteroduplex O O
repair O O
. O O

Many O O
human O O
tumours B-Disease B-Disease
have O O
length O O
alterations O O
in O O
repetitive O O
sequence O O
elements O O
. O O

Although O O
this O O
microsatellite B-Disease O
instability I-Disease O
has O O
been O O
attributed O O
to O O
mutations O O
in O O
four O O
DNA O O
mismatch O O
repair O O
genes O O
in O O
hereditary B-Disease B-Disease
nonpolyposis I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
( O O
HNPCC B-Disease B-Disease
) O O
kindreds O O
, O O
many O O
sporadic B-Disease B-Disease
tumours I-Disease I-Disease
exhibit O O
instability O O
but O O
no O O
detectable O O
mutations O O
in O O
these O O
genes O O
. O O

It O O
is O O
therefore O O
of O O
interest O O
to O O
identify O O
other O O
genes O O
that O O
contribute O O
to O O
this O O
instability O O
. O O

In O O
yeast O O
, O O
mutations O O
in O O
several O O
genes O O
, O O
including O O
RTH O O
and O O
MSH3 O O
, O O
cause O O
microsatellite O O
instability O O
. O O

Thus O O
, O O
we O O
screened O O
16 O O
endometrial B-Disease B-Disease
carcinomas I-Disease I-Disease
with O O
microsatellite O O
instability O O
for O O
alterations O O
in O O
FEN1 O O
( O O
the O O
human O O
homolog O O
of O O
RTH O O
) O O
and O O
in O O
MSH3 O O
( O O
refs O O
12 O O
- O O
14 O O
) O O
. O O

Although O O
we O O
found O O
no O O
FEN1 O O
mutations O O
, O O
a O O
frameshift O O
mutation O O
in O O
MSH3 O O
was O O
observed O O
in O O
an O O
endometrial B-Disease B-Disease
carcinoma I-Disease I-Disease
and O O
in O O
an O O
endometrial B-Disease B-Disease
carcinoma I-Disease I-Disease
cell O O
line O O
. O O

Extracts O O
of O O
the O O
cell O O
line O O
were O O
deficient O O
in O O
repair O O
of O O
DNA O O
substrates O O
containing O O
mismatches O O
or O O
extra O O
nucleotides O O
. O O

Introducing O O
chromosome O O
5 O O
, O O
encoding O O
the O O
MSH3 O O
gene O O
, O O
into O O
the O O
mutant O O
cell O O
line O O
increased O O
the O O
stability O O
of O O
some O O
but O O
not O O
all O O
microsatellites O O
. O O

Extracts O O
of O O
these O O
cells O O
repaired O O
certain O O
substrates O O
containing O O
extra O O
nucleotides O O
, O O
but O O
were O O
deficient O O
in O O
repair O O
of O O
those O O
containing O O
mismatches O O
or O O
other O O
extra O O
nucleotides O O
. O O

A O O
subsequent O O
search O O
revealed O O
a O O
second O O
gene O O
mutation O O
in O O
HHUA O O
cells O O
, O O
a O O
missense O O
mutation O O
in O O
the O O
MSH6 O O
gene O O
. O O

Together O O
the O O
data O O
suggest O O
that O O
the O O
MSH3 O O
gene O O
encodes O O
a O O
product O O
that O O
functions O O
in O O
repair O O
of O O
some O O
but O O
not O O
all O O
pre O O
- O O
mutational O O
intermediates O O
, O O
its O O
mutation O O
in O O
tumours B-Disease B-Disease
can O O
result O O
in O O
genomic O O
instability O O
and O O
, O O
as O O
in O O
yeast O O
, O O
MSH3 O O
and O O
MSH6 O O
are O O
partially O O
redundant O O
for O O
mismatch O O
repair O O
.. O O

Comparative O O
genome O O
mapping O O
of O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
region O O
in O O
mouse O O
, O O
rat O O
, O O
and O O
Syrian O O
hamster O O
. O O

Chromosomal O O
locations O O
of O O
the O O
Atm O O
( O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
AT B-Disease B-Disease
) O O
-mutated O O
) O O
and O O
Acat1 O O
( O O
mitochondrial O O
acetoacetyl O O
- O O
CoA O O
thiolase O O
) O O
genes O O
in O O
mouse O O
, O O
rat O O
, O O
and O O
Syrian O O
hamster O O
were O O
determined O O
by O O
direct O O
R O O
- O O
banding O O
FISH O O
. O O

Both O O
genes O O
were O O
colocalized O O
to O O
the O O
C O O
- O O
D O O
band O O
of O O
mouse O O
chromosome O O
9 O O
, O O
the O O
proximal O O
end O O
of O O
q24 O O
. O O

1 O O
of O O
rat O O
chromosome O O
8 O O
, O O
and O O
qa4-qa5 O O
of O O
Syrian O O
hamster O O
chromosome O O
12 O O
. O O

The O O
regions O O
in O O
the O O
mouse O O
and O O
rat O O
were O O
homologous O O
to O O
human O O
chromosome O O
11q O O
. O O

Fine O O
genetic O O
linkage O O
mapping O O
of O O
the O O
mouse O O
AT B-Disease B-Disease
region O O
was O O
performed O O
using O O
the O O
interspecific O O
backcross O O
mice O O
. O O

Atm O O
, O O
Acat1 O O
, O O
and O O
Npat O O
, O O
which O O
is O O
a O O
new O O
gene O O
isolated O O
from O O
the O O
AT O B-Disease
region O O
, O O
and O O
12 O O
flanking O O
microsatellite O O
DNA O O
markers O O
were O O
examined O O
. O O

No O O
recombinations O O
were O O
found O O
among O O
the O O
Atm O O
, O O
Npat O O
, O O
Acat1 O O
, O O
and O O
D9Mit6 O O
loci O O
, O O
and O O
these O O
loci O O
were O O
mapped O O
2 O O
. O O

0 O O
cM O O
distal O O
to O O
D9Mit99 O O
and O O
1 O O
. O O
3 O O
cM O O
proximal O O
to O O
D9Mit102 O O
. O O

Comparison O O
of O O
the O O
linkage O O
map O O
of O O
mouse O O
chromosome O O
9 O O
( O O
MMU9 O O
) O O
and O O
that O O
of O O
human O O
chromosome O O
11 O O
( O O
HSA11 O O
) O O
indicates O O
that O O
there O O
is O O
a O O
chromosomal O O
rearrangement O O
due O O
to O O
an O O
inversion O O
between O O
Ets1 O O
and O O
Atm O O
- O O
Npat O O
- O O
Acat1 O O
and O O
that O O
the O O
inversion O O
of O O
MMU9 O O
originated O O
from O O
the O O
chromosomal O O
breakage O O
at O O
the O O
boundary O O
between O O
Gria4 O O
and O O
Atm O O
- O O
Npat O O
- O O
Acat1 O O
on O O
HSA11 O O
. O O

This O O
type O O
of O O
inversion O O
appeared O O
to O O
be O O
conserved O O
in O O
the O O
three O O
rodent O O
species O O
, O O
mouse O O
, O O
rat O O
, O O
and O O
Syrian O O
hamster O O
, O O
using O O
additional O O
comparative O O
mapping O O
data O O
with O O
the O O
Rck O O
gene O O

An O O
animal O O
model O O
for O O
Norrie B-Disease B-Disease
disease I-Disease I-Disease
( O O
ND B-Disease B-Disease
) O O
: O O
gene O O
targeting O O
of O O
the O O
mouse O O
ND B-Disease B-Disease
gene O O
. O O

In O O
order O O
to O O
elucidate O O
the O O
cellular O O
and O O
molecular O O
processes O O
which O O
are O O
involved O O
in O O
Norrie B-Disease B-Disease
disease I-Disease I-Disease
( O O
ND B-Disease B-Disease
) O O
, O O
we O O
have O O
used O O
gene O O
targeting O O
technology O O
to O O
generate O O
ND B-Disease B-Disease
mutant O O
mice O O
. O O

The O O
murine O O
homologue O O
of O O
the O O
ND B-Disease B-Disease
gene O O
was O O
cloned O O
and O O
shown O O
to O O
encode O O
a O O
polypeptide O O
that O O
shares O O
94 O O
% O O
of O O
the O O
amino O O
acid O O
sequence O O
with O O
its O O
human O O
counterpart O O
. O O

RNA O O
in O O
situ O O
hybridization O O
revealed O O
expression O O
in O O
retina O O
, O O
brain O O
and O O
the O O
olfactory O O
bulb O O
and O O
epithelium O O
of O O
2 O O
week O O
old O O
mice O O
. O O

Hemizygous O O
mice O O
carrying O O
a O O
replacement O O
mutation O O
in O O
exon O O
2 O O
of O O
the O O
ND B-Disease B-Disease
gene O O
developed O O
retrolental O O
structures O O
in O O
the O O
vitreous O O
body O O
and O O
showed O O
an O O
overall O O
disorganization O O
of O O
the O O
retinal O O
ganglion O O
cell O O
layer O O
. O O

The O O
outer O O
plexiform O O
layer O O
disappears O O
occasionally O O
, O O
resulting O O
in O O
a O O
juxtaposed O O
inner O O
and O O
outer O O
nuclear O O
layer O O
. O O

At O O
the O O
same O O
regions O O
, O O
the O O
outer O O
segments O O
of O O
the O O
photoreceptor O O
cell O O
layer O O
are O O
no O O
longer O O
present O O
. O O

These O O
ocular O O
findings O O
are O O
consistent O O
with O O
observations O O
in O O
ND B-Disease B-Disease
patients O O
and O O
the O O
generated O O
mouse O O
line O O
provides O O
a O O
faithful O O
model O O
for O O
study O O
of O O
early O O
pathogenic O O
events O O
in O O
this O O
severe O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
recessive I-Disease I-Disease
neurological I-Disease I-Disease
disorder I-Disease I-Disease
.. O O

The O O
hybrid O O
PAX3-FKHR O O
fusion O O
protein O O
of O O
alveolar B-Disease B-Disease
rhabdomyosarcoma I-Disease I-Disease
transforms O O
fibroblasts O O
in O O
culture O O
. O O

Pediatric B-Disease O
alveolar I-Disease B-Disease
rhabdomyosarcoma I-Disease I-Disease
is O O
characterized O O
by O O
a O O
chromosomal O O
translocation O O
that O O
fuses O O
parts O O
of O O
the O O
PAX3 O O
and O O
FKHR O O
genes O O
. O O

PAX3 O O
codes O O
for O O
a O O
transcriptional O O
regulator O O
that O O
controls O O
developmental O O
programs O O
, O O
and O O
FKHR O O
codes O O
for O O
a O O
forkhead O O
- O O
winged O O
helix O O
protein O O
, O O
also O O
a O O
likely O O
transcription O O
factor O O
. O O

The O O
PAX3-FKHR O O
fusion O O
product O O
retains O O
the O O
DNA O O
binding O O
domains O O
of O O
the O O
PAX3 O O
protein O O
and O O
the O O
putative O O
activator O O
domain O O
of O O
the O O
FKHR O O
protein O O
. O O

The O O
PAX3-FKHR O O
protein O O
has O O
been O O
shown O O
to O O
function O O
as O O
a O O
transcriptional O O
activator O O
. O O

Using O O
the O O
RCAS O O
retroviral O O
vector O O
, O O
we O O
have O O
introduced O O
the O O
PAX3-FKHR O O
gene O O
into O O
chicken O O
embryo O O
fibroblasts O O
. O O

Expression O O
of O O
the O O
PAX3-FKHR O O
protein O O
in O O
these O O
cells O O
leads O O
to O O
transformation O O
the O O
cells O O
become O O
enlarged O O
, O O
grow O O
tightly O O
packed O O
and O O
in O O
multiple O O
layers O O
, O O
and O O
acquire O O
the O O
ability O O
for O O
anchorage O O
- O O
independent O O
growth O O
. O O

This O O
cellular O O
transformation O O
in O O
vitro O O
will O O
facilitate O O
studies O O
on O O
the O O
mechanism O O
of O O
PAX3-FKHR O O
- O O
induced O O
oncogenesis O O
.. O O

Somatic O O
- O O
cell O O
selection O O
is O O
a O O
major O O
determinant O O
of O O
the O O
blood O O
- O O
cell O O
phenotype O O
in O O
heterozygotes O O
for O O
glucose-6-phosphate O O
dehydrogenase O O
mutations O O
causing O O
severe O O
enzyme B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

X O O
- O O
chromosome O O
inactivation O O
in O O
mammals O O
is O O
regarded O O
as O O
an O O
essentially O O
random O O
process O O
, O O
but O O
the O O
resulting O O
somatic O O
- O O
cell O O
mosaicism O O
creates O O
the O O
opportunity O O
for O O
cell O O
selection O O
. O O

In O O
most O O
people O O
with O O
red O O
- O O
blood O O
- O O
cell O O
glucose-6-phosphate B-Disease B-Disease
dehydrogenase I-Disease I-Disease
( I-Disease I-Disease
G6PD I-Disease I-Disease
) I-Disease I-Disease
deficiency I-Disease I-Disease
, O O
the O O
enzyme O O
- O O
deficient O O
phenotype O O
is O O
only O O
moderately O O
expressed O O
in O O
nucleated O O
cells O O
. O O

However O O
, O O
in O O
a O O
small O O
subset O O
of O O
hemizygous O O
males O O
who O O
suffer O O
from O O
chronic B-Disease B-Disease
nonspherocytic I-Disease I-Disease
hemolytic I-Disease I-Disease
anemia I-Disease I-Disease
, O O
the O O
underlying O O
mutations O O
( O O
designated O O
class O O
I O O
) O O
cause O O
more O O
- O O
severe O O
G6PD B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
and O O
this O O
might O O
provide O O
an O O
opportunity O O
for O O
selection O O
in O O
heterozygous O O
females O O
during O O
development O O
. O O

In O O
order O O
to O O
test O O
this O O
possibility O O
we O O
have O O
analyzed O O
four O O
heterozygotes O O
for O O
class O O
I O O
G6PD O O
mutations O O
two O O
with O O
G6PD O O
Portici O O
( O O
1178G-- O O
> O O
A O O
) O O
and O O
two O O
with O O
G6PD O O
Bari O O
( O O
1187C-- O O
> O O
T O O
) O O
. O O

We O O
found O O
that O O
in O O
fractionated O O
blood O O
cell O O
types O O
( O O
including O O
erythroid O O
, O O
myeloid O O
, O O
and O O
lymphoid O O
cell O O
lineages O O
) O O
there O O
was O O
a O O
significant O O
excess O O
of O O
G6PD O O
- O O
normal O O
cells O O
. O O

The O O
significant O O
concordance O O
that O O
we O O
have O O
observed O O
in O O
the O O
degree O O
of O O
imbalance O O
in O O
the O O
different O O
blood O O
- O O
cell O O
lineages O O
indicates O O
that O O
a O O
selective O O
mechanism O O
is O O
likely O O
to O O
operate O O
at O O
the O O
level O O
of O O
pluripotent O O
blood O O
stem O O
cells O O
. O O

Thus O O
, O O
it O O
appears O O
that O O
severe O O
G6PD B-Disease B-Disease
deficiency I-Disease I-Disease
affects O O
adversely O O
the O O
proliferation O O
or O O
the O O
survival O O
of O O
nucleated O O
blood O O
cells O O
and O O
that O O
this O O
phenotypic O O
characteristic O O
is O O
critical O O
during O O
hematopoiesis O O
.. O O

Analysis O O
of O O
meiotic O O
segregation O O
, O O
using O O
single O O
- O O
sperm O O
typing O O
: O O
meiotic O O
drive O O
at O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
locus O O
. O O

Meiotic O O
drive O O
at O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
locus O O
has O O
recently O O
been O O
suggested O O
as O O
being O O
responsible O O
for O O
maintaining O O
the O O
frequency O O
, O O
in O O
the O O
human O O
population O O
, O O
of O O
DM B-Disease B-Disease
chromosomes O O
capable O O
of O O
expansion O O
to O O
the O O
disease O O
state O O
. O O

In O O
order O O
to O O
test O O
this O O
hypothesis O O
, O O
we O O
have O O
studied O O
samples O O
of O O
single O O
sperm O O
from O O
three O O
individuals O O
heterozygous O O
at O O
the O O
DM B-Disease B-Disease
locus O O
, O O
each O O
with O O
one O O
allele O O
larger O O
and O O
one O O
allele O O
smaller O O
than O O
19 O O
CTG O O
repeats O O
. O O

To O O
guard O O
against O O
the O O
possible O O
problem O O
of O O
differential O O
PCR O O
amplification O O
rates O O
based O O
on O O
the O O
lengths O O
of O O
the O O
alleles O O
, O O
the O O
sperm O O
were O O
also O O
typed O O
at O O
another O O
closely O O
linked O O
marker O O
whose O O
allele O O
size O O
was O O
unrelated O O
to O O
the O O
allele O O
size O O
at O O
the O O
DM B-Disease B-Disease
locus O O
. O O

Using O O
statistical O O
models O O
specifically O O
designed O O
to O O
study O O
single O O
- O O
sperm O O
segregation O O
data O O
, O O
we O O
find O O
no O O
evidence O O
of O O
meiotic O O
segregation O O
distortion O O
. O O

The O O
upper O O
limit O O
of O O
the O O
two O O
- O O
sided O O
95 O O
% O O
confidence O O
interval O O
for O O
the O O
estimate O O
of O O
the O O
common O O
segregation O O
probability O O
for O O
the O O
three O O
donors O O
is O O
at O O
or O O
below O O
. O O

515 O O
for O O
all O O
models O O
considered O O
, O O
and O O
no O O
statistically O O
significant O O
difference O O
from O O
. O O

5 O O
is O O
detected O O
in O O
any O O
of O O
the O O
models O O
. O O

This O O
suggests O O
that O O
any O O
greater O O
amount O O
of O O
segregation O O
distortion O O
at O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
locus O O
must O O
result O O
from O O
events O O
following O O
sperm O O
ejaculation O O
. O O

LPP O O
, O O
the O O
preferred O O
fusion O O
partner O O
gene O O
of O O
HMGIC O O
in O O
lipomas B-Disease B-Disease
, O O
is O O
a O O
novel O O
member O O
of O O
the O O
LIM O O
protein O O
gene O O
family O O
. O O

A O O
major O O
cytogenetic O O
subgroup O O
of O O
lipomas B-Disease B-Disease
is O O
characterized O O
by O O
recurrent O O
chromosome O O
aberrations O O
, O O
mainly O O
translocations O O
, O O
that O O
involve O O
chromosome O O
segment O O
12q13-q15 O O
. O O

Multiple O O
chromosomes O O
have O O
been O O
found O O
as O O
the O O
translocation O O
partners O O
of O O
chromosome O O
12 O O
but O O
3q27-q28 O O
is O O
preferentially O O
involved O O
. O O

In O O
previous O O
studies O O
, O O
it O O
has O O
been O O
shown O O
that O O
the O O
high O O
mobility O O
group O O
( O O
HMG O O
) O O
protein O O
gene O O
HMGIC O O
at O O
12q15 O O
is O O
consistently O O
rearranged O O
as O O
a O O
consequence O O
of O O
these O O
translocations O O
. O O

Here O O
, O O
we O O
report O O
the O O
identification O O
and O O
characterization O O
of O O
the O O
chromosome O O
3-derived O O
translocation O O
partner O O
gene O O
, O O
which O O
we O O
have O O
designated O O
LPP O O
( O O
lipoma B-Disease B-Disease
preferred O O
partner O O
gene O O
) O O
. O O

Using O O
3-RACE O O
analysis O O
of O O
HMGIC O O
fusion O O
transcripts O O
in O O
lipoma B-Disease B-Disease
cell O O
line O O
Li-501 O O
/ O O
SV40 O O
, O O
ectopic O O
genetic O O
sequences O O
were O O
obtained O O
, O O
which O O
by O O
CASH O O
( O O
chromosome O O
assignment O O
using O O
somatic O O
cell O O
hybrids O O
) O O
and O O
FISH O O
( O O
fluorescence O O
in O O
situ O O
hybridization O O
) O O
analysis O O
were O O
found O O
to O O
originate O O
from O O
chromosome O O
segment O O
3q27-q28 O O
. O O

In O O
Northern O O
blot O O
analysis O O
, O O
an O O
mRNA O O
of O O
over O O
10 O O
kb O O
was O O
detected O O
by O O
these O O
ectopic O O
sequences O O
in O O
a O O
variety O O
of O O
human O O
tissues O O
but O O
not O O
in O O
brain O O
and O O
peripheral O O
blood O O
leukocytes O O
. O O

Upon O O
partial O O
cDNA O O
cloning O O
, O O
features O O
of O O
the O O
genetic O O
organization O O
of O O
LPP O O
were O O
established O O
. O O

The O O
gene O O
was O O
found O O
to O O
span O O
a O O
genomic O O
region O O
of O O
over O O
400 O O
kb O O
. O O

Nucleotide O O
sequence O O
analysis O O
of O O
a O O
composite O O
cDNA O O
of O O
LPP O O
revealed O O
an O O
open O O
reading O O
frame O O
of O O
1836 O O
nucleotides O O
encoding O O
a O O
proline O O
- O O
rich O O
protein O O
containing O O
a O O
leucine O O
- O O
zipper O O
motif O O
in O O
its O O
amino O O
- O O
terminal O O
region O O
and O O
three O O
LIM O O
domains O O
in O O
its O O
carboxy O O
- O O
terminal O O
region O O
. O O

The O O
LPP O O
- O O
encoded O O
protein O O
should O O
be O O
classified O O
as O O
a O O
novel O O
member O O
of O O
the O O
group O O
3 O O
proteins O O
of O O
the O O
LIM O O
protein O O
gene O O
family O O
. O O

Using O O
reverse O O
transcriptase O O
combined O O
with O O
polymerase O O
chain O O
reactions O O
in O O
the O O
analysis O O
of O O
a O O
number O O
of O O
lipoma B-Disease B-Disease
cell O O
lines O O
and O O
primary B-Disease O
lipomas I-Disease B-Disease
, O O
it O O
appeared O O
that O O
LPP O O
is O O
frequently O O
rearranged O O
also O O
in O O
cases O O
without O O
a O O
cytogenetically O O
detectable O O
involvement O O
of O O
3q27-q28 O O
. O O

Two O O
alternative O O
HMGIC O O
/ O O
LPP O O
hybrid O O
transcripts O O
have O O
been O O
detected O O
; O O
the O O
difference O O
between O O
them O O
is O O
mainly O O
the O O
presence O O
of O O
either O O
two O O
or O O
three O O
LIM O O
domains O O
in O O
the O O
predicted O O
HMGI O O
- O O
C O O
/ O O
LPP O O
fusion O O
proteins O O
.. O O

Absence O O
of O O
disease O O
phenotype O O
and O O
intergenerational O O
stability O O
of O O
the O O
CAG O O
repeat O O
in O O
transgenic O O
mice O O
expressing O O
the O O
human O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
transcript O O
. O O

The O O
mutation O O
underlying O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
is O O
CAG O O
expansion O O
in O O
the O O
first O O
exon O O
of O O
the O O
HD B-Disease B-Disease
gene O O
. O O

In O O
order O O
to O O
investigate O O
the O O
role O O
of O O
CAG O O
expansion O O
in O O
the O O
pathogenesis O O
of O O
HD B-Disease B-Disease
, O O
we O O
have O O
produced O O
transgenic O O
mice O O
containing O O
the O O
full O O
length O O
human O O
HD B-Disease B-Disease
cDNA O O
with O O
44 O O
CAG O O
repeats O O
. O O

By O O
1 O O
year O O
, O O
these O O
mice O O
have O O
no O O
behavioral B-Disease B-Disease
abnormalities I-Disease I-Disease
and O O
morphometric O O
analysis O O
at O O
6 O O
( O O
one O O
animal O O
) O O
and O O
9 O O
( O O
two O O
animals O O
) O O
months O O
age O O
revealed O O
no O O
changes O O
. O O

Despite O O
high O O
levels O O
of O O
mRNA O O
expression O O
, O O
there O O
was O O
no O O
evidence O O
of O O
the O O
HD B-Disease B-Disease
gene O O
product O O
in O O
any O O
of O O
these O O
transgenic O O
mice O O
. O O

In O O
vitro O O
transfection O O
studies O O
indicated O O
that O O
the O O
inclusion O O
of O O
120 O O
bp O O
of O O
the O O
5 O O
UTR O O
in O O
the O O
cDNA O O
construct O O
and O O
the O O
presence O O
of O O
a O O
frameshift O O
mutation O O
at O O
nucleotide O O
2349 O O
prevented O O
expression O O
of O O
the O O
HD B-Disease B-Disease
cDNA O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
pathogenesis O O
of O O
HD B-Disease B-Disease
is O O
not O O
mediated O O
through O O
DNA O O
- O O
protein O O
interaction O O
and O O
that O O
presence O O
of O O
the O O
RNA O O
transcript O O
with O O
an O O
expanded O O
CAG O O
repeat O O
is O O
insufficient O O
to O O
cause O O
the O O
disease O O
. O O

Rather O O
, O O
translation O O
of O O
the O O
CAG O O
is O O
crucial O O
for O O
the O O
pathogenesis O O
of O O
HD B-Disease B-Disease
. O O

In O O
contrast O O
to O O
that O O
seen O O
in O O
humans O O
, O O
the O O
CAG O O
repeat O O
in O O
these O O
mice O O
was O O
remarkably O O
stable O O
in O O
97 O O
meioses O O
. O O

This O O
suggests O O
that O O
genomic O O
sequences O O
may O O
play O O
a O O
critical O O
role O O
in O O
influencing O O
repeat O O
instability O O
.. O O

FISH O O
studies O O
in O O
a O O
patient O O
with O O
sporadic B-Disease O
aniridia I-Disease B-Disease
and O O
t O O
( O O
7;11 O O
) O O
( O O
q31.2;p13 O O
) O O
. O O

A O O
2 O O
year O O
old O O
female O O
presenting O O
with O O
bilateral B-Disease O
sporadic I-Disease O
aniridia I-Disease B-Disease
was O O
found O O
to O O
have O O
an O O
apparently O O
balanced O O
reciprocal O O
translocation O O
with O O
a O O
chromosome O O
11 O O
breakpoint O O
within O O
band O O
p13 O O
. O O

Fluorescence O O
in O O
situ O O
hybridisation O O
( O O
FISH O O
) O O
studies O O
with O O
distal O O
11p13 O O
specific O O
cosmids O O
showed O O
that O O
the O O
chromosome O O
11 O O
breakpoint O O
lay O O
between O O
the O O
aniridia B-Disease B-Disease
( O O
PAX6 O O
) O O
locus O O
and O O
a O O
region O O
approximately O O
100 O O
kb O O
distal O O
to O O
PAX6 O O
defined O O
by O O
the O O
cosmid O O
FO2121 O O
. O O

Although O O
this O O
patient O O
did O O
not O O
have O O
a O O
detectable O O
deletion O O
within O O
PAX6 O O
, O O
her O O
aniridia B-Disease B-Disease
may O O
have O O
resulted O O
from O O
a O O
disruption O O
of O O
the O O
distal O O
chromatin O O
domain O O
containing O O
either O O
enhancers O O
or O O
regulators O O
for O O
PAX6 O O
. O O

This O O
case O O
may O O
therefore O O
be O O
another O O
example O O
of O O
aniridia B-Disease B-Disease
caused O O
by O O
a O O
position O O
effect O O
as O O
recently O O
described O O
in O O
two O O
familial B-Disease B-Disease
aniridia I-Disease I-Disease
patients O O
in O O
which O O
the O O
phenotype O O
cosegregated O O
with O O
chromosome B-Disease B-Disease
abnormalities I-Disease I-Disease
with O O
11p13 O O
breakpoints O O
.. O O

Muscle O O
expression O O
of O O
glucose-6-phosphate B-Disease B-Disease
dehydrogenase I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
different O O
variants O O
. O O

Muscle O O
expression O O
of O O
G6PD B-Disease B-Disease
deficiency I-Disease I-Disease
has O O
been O O
investigated O O
in O O
Mediterranean O O
, O O
Seattle O O
- O O
like O O
and O O
A O O
- O O
variants O O
. O O

G6PD O O
activity O O
was O O
detected O O
in O O
samples O O
obtained O O
from O O
biopsies O O
on O O
the O O
quadriceps O O
muscle O O
of O O
seven O O
males O O
and O O
one O O
female O O
. O O

The O O
type O O
of O O
genetic O O
variant O O
was O O
determined O O
by O O
molecular O O
analysis O O
of O O
DNA O O
, O O
extracted O O
from O O
blood O O
samples O O
. O O

All O O
variants O O
showed O O
the O O
enzyme O O
defect O O
in O O
muscle O O
. O O

A O O
statistically O O
significant O O
relationship O O
was O O
found O O
in O O
the O O
activity O O
of O O
G6PD O O
between O O
erythrocytes O O
and O O
muscle O O
of O O
the O O
male O O
subjects O O
( O O
r O O
= O O
0 O O
. O O
968 O O
; O O
p O O
= O O
0 O O
. O O
00008 O O
) O O
. O O

The O O
equation O O
for O O
the O O
best O O
fit O O
line O O
was O O
Y O O
= O O
0 O O
. O O

390X O O
+ O O
0 O O
. O O
198 O O
198 O O
. O O

The O O
results O O
suggest O O
that O O
, O O
for O O
a O O
given O O
variant O O
, O O
the O O
extent O O
of O O
the O O
enzyme O O
defect O O
in O O
muscle O O
may O O
be O O
determined O O
, O O
using O O
this O O
equation O O
, O O
from O O
the O O
G6PD O O
activity O O
of O O
erythrocytes O O

Gene O O
therapy O O
for O O
phenylketonuria B-Disease B-Disease
. O O

Classical O B-Disease
phenylketonuria B-Disease I-Disease
( O O
PKU B-Disease B-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
a O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
hepatic I-Disease I-Disease
phenylalanine I-Disease I-Disease
hydroxylase I-Disease I-Disease
( O O
PAH O O
) O O
. O O

Limitations O O
of O O
the O O
current O O
dietary O O
treatment O O
for O O
PKU B-Disease B-Disease
have O O
led O O
to O O
the O O
development O O
of O O
potential O O
treatments O O
based O O
on O O
somatic O O
gene O O
transfer O O
. O O

Three O O
different O O
vector O O
systems O O
have O O
been O O
examined O O
. O O

Vectors O O
derived O O
from O O
a O O
recombinant O O
retrovirus O O
or O O
a O O
DNA O O
/ O O
protein O O
complex O O
can O O
efficiently O O
transduce O O
the O O
PAH O O
cDNA O O
into O O
PAH B-Disease O
- I-Disease O
deficient I-Disease O
hepatocytes O O
in O O
vitro O O
, O O
but O O
the O O
application O O
of O O
these O O
vector O O
systems O O
is O O
presently O O
limited O O
by O O
their O O
low O O
transduction O O
efficiency O O
in O O
vivo O O
. O O

In O O
contrast O O
, O O
a O O
vector O O
derived O O
from O O
a O O
recombinant O O
adenovirus O O
can O O
restore O O
10 O O
% O O
-80 O O
% O O
of O O
normal O O
hepatic O O
PAH O O
activity O O
into O O
PAH B-Disease B-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
, O O
which O O
completely O O
normalizes O O
serum O O
phenylalanine O O
levels O O
. O O

This O O
treatment O O
is O O
transient O O
and O O
can O O
not O O
be O O
effectively O O
re O O
- O O
administered O O
due O O
to O O
the O O
presence O O
of O O
neutralizing O O
antibodies O O
directed O O
against O O
the O O
recombinant O O
adenoviral O O
vector O O
. O O

However O O
, O O
these O O
findings O O
suggest O O
that O O
PKU B-Disease B-Disease
can O O
be O O
completely O O
corrected O O
by O O
somatic O O
gene O O
therapy O O
, O O
and O O
provide O O
some O O
direction O O
for O O
the O O
future O O
development O O
of O O
adenoviral O O
vectors O O
.. O O

Exon O O
- O O
intron O O
structure O O
of O O
the O O
human O O
neuronal O O
nicotinic O O
acetylcholine O O
receptor O O
alpha O O
4 O O
subunit O O
( O O
CHRNA4 O O
) O O
. O O

The O O
human O O
neuronal O O
nicotinic O O
acetylcholine O O
receptor O O
alpha O O
4 O O
subunit O O
gene O O
( O O
CHRNA4 O O
) O O
is O O
located O O
in O O
the O O
candidate O O
region O O
for O O
three O O
different O O
phenotypes O O
benign B-Disease O
familial I-Disease B-Disease
neonatal I-Disease I-Disease
convulsions I-Disease I-Disease
, O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
nocturnal I-Disease I-Disease
frontal I-Disease I-Disease
lobe I-Disease I-Disease
epilepsy I-Disease I-Disease
, O O
and O O
low O O
- O O
voltage O O
EEG O O
. O O

Recently O O
, O O
a O O
missense O O
mutation O O
in O O
transmembrane O O
domain O O
2 O O
of O O
CHRNA4 O O
was O O
found O O
to O O
be O O
associated O O
with O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
nocturnal I-Disease I-Disease
frontal I-Disease I-Disease
lobe I-Disease I-Disease
epilepsy I-Disease I-Disease
in O O
one O O
extended O O
pedigree O O
. O O

We O O
have O O
determined O O
the O O
genomic O O
organization O O
of O O
CHRNA4 O O
, O O
which O O
consists O O
of O O
six O O
exons O O
distributed O O
over O O
approximately O O
17 O O
kb O O
of O O
genomic O O
DNA O O
. O O

The O O
nucleotide O O
sequence O O
obtained O O
from O O
the O O
genomic O O
regions O O
adjacent O O
to O O
the O O
exon O O
boundaries O O
enabled O O
us O O
to O O
develop O O
a O O
set O O
of O O
primer O O
pairs O O
for O O
PCR O O
amplification O O
of O O
the O O
complete O O
coding O O
region O O
. O O

The O O
sequence O O
analysis O O
provides O O
the O O
basis O O
for O O
a O O
comprehensive O O
mutation O O
screening O O
of O O
CHRNA4 O O
in O O
the O O
above O O
- O O
mentioned O O
phenotypes O O
and O O
possibly O O
in O O
other O O
types O O
of O O
idiopathic B-Disease B-Disease
epilepsies I-Disease I-Disease
.. O O

Ashkenazi O O
Jewish O O
population O O
frequencies O O
for O O
common O O
mutations O O
in O O
BRCA1 O O
and O O
BRCA2 O O
. O O

BRCA1 O O
and O O
BRCA2 O O
are O O
the O O
two O O
major O O
identified O O
causes O O
of O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
, O O
with O O
mutations O O
in O O
either O O
gene O O
conferring O O
up O O
to O O
80 O O
- O O
90 O O
% O O
lifetime O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
in O O
carrier O O
females O O
. O O

Mutations O O
in O O
BRCA1 O O
account O O
for O O
approximately O O
45 O O
% O O
of O O
familial B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
and O O
90 O O
% O O
of O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
, O O
whereas O O
mutations O O
in O O
BRCA2 O O
account O O
for O O
a O O
comparable O O
percentage O O
of O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
. O O

Over O O
85 O O
distinct O O
BRCA1 O O
mutations O O
and O O
a O O
growing O O
list O O
of O O
BRCA2 O O
mutations O O
have O O
been O O
identified O O
, O O
with O O
the O O
majority O O
resulting O O
in O O
protein O O
truncation O O
. O O

A O O
specific O O
BRCA1 O O
mutation O O
, O O
185delAG O O
, O O
has O O
a O O
reported O O
increased O O
carrier O O
frequency O O
of O O
approximately O O
0 O O
. O O
9 O O
% O O
in O O
the O O
Ashkenazi O O
Jewish O O
population O O
, O O
but O O
is O O
also O O
found O O
in O O
rare O O
non O O
- O O
Jewish O O
patients O O
with O O
a O O
different O O
haplotype O O
. O O

The O O
6174delT O O
mutation O O
in O O
BRCA2 O O
was O O
recently O O
identified O O
as O O
a O O
frequent O O
mutation O O
in O O
8 O O
out O O
of O O
107 O O
Ashkenazi O O
Jewish O O
women O O
diagnosed O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
by O O
age O O
50 O O
( O O
ref O O
. O O

8) O O
, O O
as O O
well O O
as O O
in O O
three O O
Ashkenazi O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
patients O O
. O O

We O O
have O O
conducted O O
a O O
large O O
- O O
scale O O
population O O
study O O
to O O
investigate O O
the O O
prevalence O O
of O O
specific O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
in O O
Ashkenazi O O
Jewish O O
individuals O O
who O O
were O O
unselected O O
for O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

BRCA1 O O
mutation O O
screening O O
on O O
approximately O O
3 O O
, O O
000 O O
Ashkenazi O O
Jewish O O
samples O O
determined O O
a O O
carrier O O
frequency O O
of O O
1 O O
. O O
09 O O
% O O
for O O
the O O
185delAG O O
mutation O O
and O O
0 O O
. O O
13 O O
% O O
for O O
the O O
5382insC O O
mutation O O
. O O

BRCA2 O O
analysis O O
on O O
3 O O
, O O
085 O O
individuals O O
from O O
the O O
same O O
population O O
showed O O
a O O
carrier O O
frequency O O
of O O
1 O O
. O O
52 O O
% O O
for O O
the O O
6174delT O O
mutation O O
. O O

This O O
expanded O O
population O O
- O O
based O O
study O O
confirms O O
that O O
the O O
BRCA1 O O
185delAG O O
mutation O O
and O O
the O O
BRCA2 O O
6174delT O O
mutation O O
constitute O O
the O O
two O O
most O O
frequent O O
mutation O O
alleles O O
predisposing O O
to O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
among O O
the O O
Ashkenazim O O
, O O
and O O
suggests O O
a O O
relatively O O
lower O O
penetrance O O
for O O
the O O
6174delT O O
mutation O O
in O O
BRCA2 O O

Dual O O
roles O O
of O O
ATM O O
in O O
the O O
cellular O O
response O O
to O O
radiation O O
and O O
in O O
cell O O
growth O O
control O O
. O O

The O O
gene O O
mutated O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
AT B-Disease B-Disease
) O O
patients O O
, O O
denoted O O
ATM O O
, O O
encodes O O
a O O
putative O O
protein O O
or O O
lipid O O
kinase O O
. O O

To O O
elucidate O O
the O O
functions O O
of O O
ATM O O
, O O
we O O
disrupted O O
the O O
mouse O O
ATM O O
gene O O
through O O
homologous O O
recombination O O
in O O
mice O O
. O O

Consistent O O
with O O
cellular O O
defects O O
of O O
AT B-Disease B-Disease
patients O O
, O O
the O O
ATM- O O
/ O O
- O O
cells O O
are O O
hypersensitive O O
to O O
gamma O O
- O O
irradiation O O
and O O
defective O O
in O O
cell O O
- O O
cycle O O
arrest O O
following O O
radiation O O
, O O
correlating O O
with O O
a O O
defective O O
up O O
- O O
regulation O O
of O O
p53 O O
. O O

In O O
addition O O
, O O
ATM- O O
/ O O
- O O
mouse O O
thymocytes O O
are O O
more O O
resistant O O
to O O
apoptosis O O
induced O O
by O O
gamma O O
- O O
irradiation O O
than O O
normal O O
thymocytes O O
. O O

ATM- O O
/ O O
- O O
fibroblasts O O
are O O
inefficient O O
in O O
G1 O O
to O O
S O O
- O O
phase O O
progression O O
following O O
serum O O
stimulation O O
and O O
senesce O O
after O O
only O O
a O O
few O O
passages O O
in O O
culture O O
. O O

They O O
have O O
an O O
increased O O
constitutive O O
level O O
of O O
p21CP1 O O
/ O O
WAF1 O O
. O O

The O O
ATM O O
protein O O
is O O
therefore O O
critical O O
both O O
for O O
cellular O O
responses O O
to O O
ionizing O O
radiation O O
and O O
for O O
normal O O
cell O O
- O O
cycle O O
progression O O
. O O

ATM O O
+ O O
/- O O
fibroblasts O O
and O O
thymocytes O O
showed O O
intermediately O O
defective O O
responses O O
to O O
irradiation O O
but O O
no O O
growth O O
defect O O
, O O
suggesting O O
that O O
the O O
increased O O
cancer B-Disease B-Disease
risk O O
of O O
AT B-Disease B-Disease
heterozygotes O O
could O O
be O O
attributable O O
to O O
poor O O
checkpoint O O
function O O
.. O O

Targeted O O
disruption O O
of O O
ATM O O
leads O O
to O O
growth B-Disease B-Disease
retardation I-Disease I-Disease
, O O
chromosomal B-Disease O
fragmentation I-Disease O
during I-Disease O
meiosis I-Disease O
, O O
immune B-Disease B-Disease
defects I-Disease I-Disease
, O O
and O O
thymic B-Disease B-Disease
lymphoma I-Disease I-Disease
. O O

ATM O O
, O O
the O O
gene O O
mutated O O
in O O
the O O
inherited B-Disease B-Disease
human I-Disease I-Disease
disease I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
, O O
is O O
a O O
member O O
of O O
a O O
family O O
of O O
kinases O O
involved O O
in O O
DNA O O
metabolism O O
and O O
cell O O
- O O
cycle O O
checkpoint O O
control O O
. O O

To O O
help O O
clarify O O
the O O
physiological O O
roles O O
of O O
the O O
ATM O O
protein O O
, O O
we O O
disrupted O O
the O O
ATM O O
gene O O
in O O
mice O O
through O O
homologous O O
recombination O O
. O O

Initial O O
evaluation O O
of O O
the O O
ATM O O
knockout O O
animals O O
indicates O O
that O O
inactivation O O
of O O
the O O
mouse O O
ATM O O
gene O O
recreates O O
much O O
of O O
the O O
phenotype O O
of O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
. O O

The O O
homozygous O O
mutant O O
( O O
ATM- O O
/ O O
- O O
) O O
mice O O
are O O
viable O O
, O O
growth O O
- O O
retarded O O
, O O
and O O
infertile O O
. O O

The O O
infertility B-Disease B-Disease
of O O
ATM- O O
/ O O
- O O
mice O O
results O O
from O O
meiotic O O
failure O O
. O O

Meiosis O O
is O O
arrested O O
at O O
the O O
zygotene O O
/ O O
pachytene O O
stage O O
of O O
prophase O O
I O O
as O O
a O O
result O O
of O O
abnormal O O
chromosomal O O
synapsis O O
and O O
subsequent O O
chromosome O O
fragmentation O O
. O O

Immune B-Disease O
defects I-Disease O
also O O
are O O
evident O O
in O O
ATM- O O
/ O O
- O O
mice O O
, O O
including O O
reduced O O
numbers O O
of O O
B220 O O
+ O O
CD43- O O
pre O O
- O O
B O O
cells O O
, O O
thymocytes O O
, O O
and O O
peripheral O O
T O O
cells O O
, O O
as O O
well O O
as O O
functional O O
impairment O O
of O O
T O O
- O O
cell O O
- O O
dependent O O
immune O O
responses O O
. O O

The O O
cerebella O O
of O O
ATM- O O
/ O O
- O O
mice O O
appear O O
normal O O
by O O
histologic O O
examination O O
at O O
3 O O
to O O
4 O O
months O O
and O O
the O O
mice O O
have O O
no O O
gross O O
behavioral B-Disease B-Disease
abnormalities I-Disease I-Disease
. O O

The O O
majority O O
of O O
mutant O O
mice O O
rapidly O O
develop O O
thymic B-Disease B-Disease
lymphomas I-Disease I-Disease
and O O
die O O
before O O
4 O O
months O O
of O O
age O O
. O O

These O O
findings O O
indicate O O
that O O
the O O
ATM O O
gene O O
product O O
plays O O
an O O
essential O O
role O O
in O O
a O O
diverse O O
group O O
of O O
cellular O O
processes O O
, O O
including O O
meiosis O O
, O O
the O O
normal O O
growth O O
of O O
somatic O O
tissues O O
, O O
immune O O
development O O
, O O
and O O
tumor B-Disease B-Disease
suppression O O
.. O O

Cloning O O
and O O
characterization O O
of O O
human O O
very O O
- O O
long O O
- O O
chain O O
acyl O O
- O O
CoA O O
dehydrogenase O O
cDNA O O
, O O
chromosomal O O
assignment O O
of O O
the O O
gene O O
and O O
identification O O
in O O
four O O
patients O O
of O O
nine O O
different O O
mutations O O
within O O
the O O
VLCAD O O
gene O O
. O O

Very O O
- O O
long O O
- O O
chain O O
acyl O O
- O O
CoA O O
dehydrogenase O O
( O O
VLCAD O O
) O O
is O O
one O O
of O O
four O O
straight O O
- O O
chain O O
acyl O O
- O O
CoA O O
dehydrogenase O O
( O O
ACD O O
) O O
enzymes O O
, O O
which O O
are O O
all O O
nuclear O O
encoded O O
mitochondrial O O
flavoproteins O O
catalyzing O O
the O O
initial O O
step O O
in O O
fatty O O
acid O O
beta O O
- O O
oxidation O O
. O O

We O O
have O O
used O O
the O O
very O O
fast O O
, O O
Rapid O O
Amplification O O
of O O
cDNA O O
Ends O O
( O O
RACE O O
) O O
based O O
strategy O O
to O O
obtain O O
the O O
sequence O O
of O O
cDNAs O O
encoding O O
human O O
VLCAD O O
from O O
placenta O O
and O O
fibroblasts O O
. O O

Alignment O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
of O O
human O O
VLCAD O O
with O O
those O O
of O O
the O O
other O O
human O O
ACD O B-Disease
enzymes O O
revealed O O
extensive O O
sequence O O
homology O O
. O O

Moreover O O
, O O
human O O
VLCAD O O
and O O
human O O
acyl O O
- O O
CoA O O
oxidase O O
showed O O
extensive O O
sequence O O
homology O O
corroborating O O
the O O
notion O O
that O O
these O O
genes O O
are O O
evolutionarily O O
related O O
. O O

Southern O O
blot O O
analysis O O
of O O
genomic O O
DNA O O
from O O
hybrid O O
cell O O
lines O O
was O O
used O O
to O O
localize O O
the O O
VLCAD O O
gene O O
to O O
human O O
chromosome O O
17p11 O O
. O O

2-p11 O O
. O O

13105 O O
. O O

Using O O
Northern O O
and O O
Western O O
blot O O
analysis O O
to O O
investigate O O
the O O
tissue O O
specific O O
distribution O O
of O O
VLCAD O O
mRNA O O
and O O
protein O O
in O O
several O O
human O O
tissues O O
we O O
showed O O
that O O
VLCAD O O
is O O
most O O
abundant O O
in O O
heart O O
and O O
skeletal O O
muscle O O
. O O

This O O
agrees O O
well O O
with O O
the O O
fact O O
that O O
cardiac O O
and O O
muscle O O
symptoms O O
are O O
characteristic O O
for O O
patients O O
with O O
VLCAD B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

Northern O O
blot O O
analysis O O
and O O
sequencing O O
of O O
cloned O O
PCR O O
amplified O O
VLCAD O O
cDNA O O
from O O
four O O
unrelated O O
patients O O
with O O
VLCAD B-Disease B-Disease
deficiency I-Disease I-Disease
showed O O
that O O
VLCAD O O
mRNA O O
was O O
undetectable O O
in O O
one O O
patient O O
and O O
that O O
the O O
other O O
three O O
have O O
mutations O O
in O O
both O O
VLCAD O O
alleles O O
. O O

Western O O
blot O O
analysis O O
of O O
patient O O
fibroblasts O O
showed O O
that O O
the O O
identified O O
mutations O O
result O O
in O O
severely O O
reduced O O
amounts O O
of O O
VLCAD O O
protein O O
. O O

Molecular O O
bases O O
of O O
combined B-Disease O
subtotal I-Disease B-Disease
deficiencies I-Disease I-Disease
of I-Disease I-Disease
C6 I-Disease I-Disease
and I-Disease I-Disease
C7 I-Disease I-Disease
: O O
their O O
effects O O
in O O
combination O O
with O O
other O O
C6 B-Disease B-Disease
and I-Disease I-Disease
C7 I-Disease I-Disease
deficiencies I-Disease I-Disease
. O O

Combined B-Disease B-Disease
subtotal I-Disease I-Disease
deficiency I-Disease I-Disease
of I-Disease I-Disease
C6 I-Disease I-Disease
and I-Disease I-Disease
C7 I-Disease I-Disease
, O O
in O O
which O O
both O O
proteins O O
are O O
expressed O O
at O O
very O O
low O O
levels O O
, O O
has O O
been O O
observed O O
in O O
homozygous O O
form O O
in O O
two O O
families O O
. O O

A O O
defect O O
at O O
the O O
5 O O
splice O O
donor O O
site O O
of O O
intron O O
15 O O
of O O
the O O
C6 O O
gene O O
explains O O
the O O
low O O
molecular O O
weight O O
of O O
the O O
C6 O O
protein O O
and O O
is O O
probably O O
responsible O O
for O O
its O O
low O O
expressed O O
concentration O O
. O O

The O O
C7 O B-Disease
defect O I-Disease
is O O
more O O
enigmatic O O
the O O
protein O O
is O O
of O O
normal O O
molecular O O
weight O O
, O O
low O O
circulating O O
concentration O O
, O O
and O O
altered O O
isoelectric O O
point O O
. O O

An O O
Arg O O
> O O
Ser O O
codon O O
substitution O O
in O O
exon O O
11 O O
is O O
the O O
only O O
molecular O O
alteration O O
within O O
the O O
mature O O
C7 O O
protein O O
. O O

These O O
defects O O
are O O
associated O O
with O O
a O O
characteristic O O
set O O
of O O
polymorphic O O
DNA O O
markers O O
in O O
the O O
C6 O O
/ O O
C7 O O
region O O
, O O
forming O O
a O O
distinct O O
haplotype O O
. O O

The O O
haplotype O O
has O O
been O O
found O O
in O O
combination O O
with O O
a O O
number O O
of O O
other O O
haplotypes O O
containing O O
defective O O
genes O O
that O O
lead O O
either O O
to O O
C6 B-Disease B-Disease
or I-Disease I-Disease
C7 I-Disease I-Disease
deficiency I-Disease I-Disease
, O O
but O O
with O O
different O O
consequences O O
. O O

Where O O
it O O
is O O
combined O O
with O O
a O O
C6-deficient B-Disease B-Disease
gene O O
, O O
the O O
serum O O
C7 O O
levels O O
can O O
be O O
surprisingly O O
high O O
, O O
possibly O O
because O O
there O O
is O O
no O O
C6 O O
generating O O
C56 O O
to O O
consume O O
the O O
C7 O O
. O O

In O O
contrast O O
, O O
where O O
the O O
C7 O O
genes O O
are O O
both O O
defective O O
( O O
but O O
still O O
partially O O
functional O O
) O O
, O O
there O O
may O O
be O O
a O O
profound O O
deficit O B-Disease
of O I-Disease
circulating O I-Disease
C7 O I-Disease
because O O
there O O
is O O
ample O O
C6 O O
to O O
produce O O
C56 O O
and O O
consume O O
the O O
already O O
small O O
amount O O
of O O
C7 O O
. O O

Each O O
molecular O O
defect O O
has O O
also O O
been O O
found O O
in O O
isolation O O
and O O
has O O
the O O
expected O O
effect O O
.. O O

Genetic O O
bases O O
of O O
human O O
complement B-Disease B-Disease
C7 I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

Complement B-Disease B-Disease
C7 I-Disease I-Disease
deficiency I-Disease I-Disease
( O O
C7D B-Disease B-Disease
) O O
is O O
associated O O
frequently O O
with O O
recurrent O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
, O O
especially O O
meningitis B-Disease B-Disease
caused O O
by O O
Neisseria B-Disease O
meningitidis I-Disease O
. O O

We O O
report O O
in O O
this O O
work O O
the O O
molecular O O
bases O O
of O O
C7D B-Disease B-Disease
in O O
two O O
unrelated O O
Japanese O O
males O O
. O O

We O O
used O O
exon O O
- O O
specific O O
PCR O O
/ O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
analysis O O
as O O
a O O
screening O O
step O O
for O O
mutations O O
. O O

Subsequent O O
direct O O
sequencing O O
of O O
the O O
target O O
exons O O
identified O O
homozygous O O
mutations O O
in O O
exon O O
16 O O
of O O
case O O
1 O O
and O O
in O O
exon O O
15 O O
of O O
case O O
2 O O
. O O

The O O
mutation O O
of O O
case O O
1 O O
was O O
a O O
homozygous O O
T O O
to O O
A O O
transversion O O
at O O
nucleotide O O
2250 O O
, O O
the O O
third O O
nucleotide O O
of O O
the O O
codon O O
TGT O O
for O O
Cys728 O O
, O O
leading O O
to O O
a O O
stop O O
codon O O
TGA O O
( O O
C728X O O
) O O
. O O

In O O
case O O
2 O O
, O O
a O O
homozygous O O
2-bp O O
deletion O O
( O O
2137delTG O O
/ O O
2138delGT O O
/ O O
2139delTG O O
) O O
caused O O
a O O
frameshift O O
, O O
generating O O
a O O
premature O O
termination O O
codon O O
4 O O
to O O
6 O O
nucleotides O O
downstream O O
. O O

Family O O
study O O
in O O
case O O
1 O O
confirmed O O
the O O
genetic O O
nature O O
of O O
the O O
defect O O
. O O

Moreover O O
, O O
we O O
detected O O
a O O
novel O O
polymorphism O O
in O O
intron O O
11 O O
that O O
presumably O O
is O O
linked O O
to O O
the O O
mutation O O
responsible O O
for O O
C7D B-Disease B-Disease
in O O
case O O
1 O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
pathogenesis O O
of O O
C7D B-Disease B-Disease
is O O
heterogeneous O O
like O O
most O O
of O O
the O O
other O O
deficiencies B-Disease B-Disease
of I-Disease I-Disease
complement I-Disease I-Disease
components I-Disease I-Disease
.. O O

HPRT B-Disease B-Disease
- I-Disease I-Disease
APRT I-Disease I-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
are O O
not O O
a O O
model O O
for O O
lesch B-Disease B-Disease
- I-Disease I-Disease
nyhan I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Complete B-Disease B-Disease
hypoxanthine I-Disease I-Disease
- I-Disease I-Disease
guanine I-Disease I-Disease
phosphoribosyl I-Disease I-Disease
- I-Disease I-Disease
transferase I-Disease I-Disease
( I-Disease I-Disease
HPRT I-Disease I-Disease
) I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
humans O O
results O O
in O O
the O O
Lesch B-Disease B-Disease
- I-Disease I-Disease
Nyhan I-Disease I-Disease
syndrome I-Disease I-Disease
which O O
is O O
characterized O O
, O O
among O O
other O O
features O O
, O O
by O O
compulsive O B-Disease
self O I-Disease
- O I-Disease
injurious O I-Disease
behavior O I-Disease
. O O

HPRT B-Disease B-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
generated O O
using O O
mouse O O
embryonic O O
stem O O
cells O O
exhibit O O
none O O
of O O
the O O
behavioral O O
symptoms O O
associated O O
with O O
the O O
Lesch B-Disease B-Disease
- I-Disease I-Disease
Nyhan I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Administration O O
of O O
drugs O O
that O O
inhibit O O
adenine O O
phosphoribosyltransferase O O
( O O
APRT O O
) O O
in O O
HPRT B-Disease B-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
has O O
produced O O
the O O
suggestion O O
that O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
APRT I-Disease I-Disease
in O O
combination O O
with O O
HPRT B-Disease B-Disease
- I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
mice O O
may O O
lead O O
to O O
self O O
- O O
mutilation O O
behavior O O
[ O O
C. O O
L. O O
Wu O O
and O O
D. O O
W. O O
Melton O O
( O O
1993 O O
) O O
Nature O O
Genet O O
. O O

3 O O
, O O
235 O O
- O O
240 O O
] O O
. O O

To O O
test O O
this O O
proposition O O
, O O
we O O
bred O O
HPRT B-Disease B-Disease
- I-Disease I-Disease
APRT I-Disease I-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
. O O

Although O O
the O O
doubly O B-Disease
- O I-Disease
deficient O I-Disease
mice O O
excrete O O
adenine O O
and O O
its O O
highly O O
insoluble O O
derivative O O
, O O
2 O O
, O O
8-dihydroxyadenine O O
, O O
which O O
are O O
also O O
associated O O
with O O
human O O
APRT B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
additional O O
abnormalities O O
or O O
any O O
self O O
- O O
injurious O O
behavior O O
were O O
not O O
detected O O
. O O

Thus O O
, O O
APRT B-Disease B-Disease
- I-Disease I-Disease
HPRT I-Disease I-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
, O O
which O O
are O O
devoid O O
of O O
any O O
purine O O
salvage O O
pathways O O
, O O
show O O
no O O
novel O O
phenotype O O
and O O
are O O
not O O
a O O
model O O
for O O
the O O
behavioral B-Disease B-Disease
abnormalities I-Disease I-Disease
associated O O
with O O
the O O
Lesch B-Disease B-Disease
- I-Disease I-Disease
Nyhan I-Disease I-Disease
syndrome I-Disease I-Disease
as O O
previously O O
suggested O O

Somatic O O
alterations O O
of O O
the O O
DPC4 O O
gene O O
in O O
human O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
in O O
vivo O O
. O O

BACKGROUND O O
& O O
AIMS O O
The O O
chromosome O O
region O O
18q21 O O
has O O
been O O
shown O O
to O O
be O O
frequently O O
deleted O O
in O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
, O O
and O O
such O O
frequent O O
allelic O O
loss O O
is O O
a O O
hallmark O O
of O O
the O O
presence O O
of O O
a O O
tumor O B-Disease
- O O
suppressor O O
gene O O
. O O

The O O
DPC4 O O
gene O O
, O O
which O O
is O O
located O O
at O O
18q21 O O
, O O
has O O
been O O
identified O O
as O O
a O O
tumor O B-Disease
- O O
suppressor O O
gene O O
from O O
examination O O
of O O
pancreatic B-Disease B-Disease
cancers I-Disease I-Disease
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
if O O
it O O
might O O
also O O
be O O
altered O O
in O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
. O O

METHODS O O
Mutation O O
analyses O O
of O O
the O O
DPC4 O O
gene O O
were O O
performed O O
on O O
complementary O O
DNA O O
samples O O
from O O
31 O O
primary O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
specimens O O
using O O
a O O
combination O O
of O O
polymerase O O
chain O O
reaction O O
, O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
, O O
and O O
DNA O O
sequencing O O
. O O

RESULTS O O
Four O O
missense O O
mutations O O
producing O O
amino O O
acid O O
substitutions O O
and O O
a O O
somatic O O
12-base O O
pair O O
deletion O O
in O O
the O O
coding O O
region O O
of O O
the O O
DPC4 O O
gene O O
were O O
detected O O
in O O
the O O
31 O O
cancers B-Disease B-Disease
( O O
16 O O
% O O
; O O
5 O O
of O O
31 O O
) O O
. O O

CONCLUSIONS O O
The O O
DPC4 O O
gene O O
may O O
play O O
a O O
role O O
as O O
a O O
tumor O B-Disease
- O O
suppressor O O
gene O O
in O O
a O O
fraction O O
of O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
; O O
however O O
, O O
while O O
allelic O O
loss O O
at O O
18q21 O O
is O O
very O O
often O O
seen O O
in O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
, O O
only O O
a O O
minority O O
show O O
DPC4 O O
mutations O O
, O O
suggesting O O
that O O
there O O
might O O
be O O
another O O
tumor O B-Disease
- O O
suppressor O O
gene O O
in O O
this O O
chromosome O O
region O O
.. O O

Pleiotropic O O
defects O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
protein O I-Disease
- O I-Disease
deficient O I-Disease
mice O O
. O O

We O O
have O O
generated O O
a O O
mouse O O
model O O
for O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
by O O
using O O
gene O O
targeting O O
to O O
generate O O
mice O O
that O O
do O O
not O O
express O O
the O O
Atm O O
protein O O
. O O

Atm O O
- O O
deficient O O
mice O O
are O O
retarded O O
in O O
growth O O
, O O
do O O
not O O
produce O O
mature O O
sperm O O
, O O
and O O
exhibit O O
severe O O
defects O O
in O O
T O O
cell O O
maturation O O
while O O
going O O
on O O
to O O
develop O O
thymomas B-Disease B-Disease
. O O

Atm O O
- O O
deficient O O
fibroblasts O O
grow O O
poorly O O
in O O
culture O O
and O O
display O O
a O O
high O O
level O O
of O O
double O O
- O O
stranded O O
chromosome O O
breaks O O
. O O

Atm O O
- O O
deficient O O
thymocytes O O
undergo O O
spontaneous O O
apoptosis O O
in O O
vitro O O
significantly O O
more O O
than O O
controls O O
. O O

Atm O O
- O O
deficient O O
mice O O
then O O
exhibit O O
many O O
of O O
the O O
same O O
symptoms O O
found O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
patients O O
and O O
in O O
cells O O
derived O O
from O O
them O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
the O O
Atm O O
protein O O
exists O O
as O O
two O O
discrete O O
molecular O O
species O O
, O O
and O O
that O O
loss O O
of O O
one O O
or O O
of O O
both O O
of O O
these O O
can O O
lead O O
to O O
the O O
development O O
of O O
the O O
disease O O
.. O O

The O O
DCC O O
protein O O
and O O
prognosis O O
in O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

BACKGROUND O O
Allelic O O
loss O O
of O O
chromosome O O
18q O O
predicts O O
a O O
poor O O
outcome O O
in O O
patients O O
with O O
stage B-Disease B-Disease
II I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Although O O
the O O
specific O O
gene O O
inactivated O O
by O O
this O O
allelic O O
loss O O
has O O
not O O
been O O
elucidated O O
, O O
the O O
DCC O O
( O O
deleted O O
in O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
) O O
gene O O
is O O
a O O
candidate O O
. O O

We O O
investigated O O
whether O O
the O O
expression O O
of O O
the O O
DCC O O
protein O O
in O O
tumor B-Disease B-Disease
cells O O
is O O
a O O
prognostic O O
marker O O
in O O
colorectal B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

METHODS O O
The O O
expression O O
of O O
DCC O O
was O O
evaluated O O
immunohistochemically O O
in O O
132 O O
paraffin O O
- O O
embedded O O
samples O O
from O O
patients O O
with O O
curatively O O
resected O O
stage B-Disease O
II I-Disease O
and I-Disease O
III I-Disease O
colorectal I-Disease B-Disease
carcinomas I-Disease I-Disease
. O O

The O O
Cox O O
proportional O O
- O O
hazards O O
model O O
was O O
used O O
to O O
adjust O O
for O O
covariates O O
including O O
age O O
, O O
sex O O
, O O
tumor B-Disease B-Disease
site O O
, O O
degree O O
of O O
tumor B-Disease B-Disease
differentiation O O
, O O
and O O
use O O
of O O
adjuvant O O
therapy O O
. O O

RESULTS O O
The O O
expression O O
of O O
DCC O O
was O O
a O O
strong O O
positive O O
predictive O O
factor O O
for O O
survival O O
in O O
both O O
stage B-Disease O
II I-Disease O
and I-Disease O
stage I-Disease O
III I-Disease O
colorectal I-Disease B-Disease
carcinomas I-Disease I-Disease
. O O

In O O
patients O O
with O O
stage O O
II O O
disease O O
whose O O
tumors B-Disease B-Disease
expressed O O
DCC O O
, O O
the O O
five O O
- O O
year O O
survival O O
rate O O
was O O
94 O O
. O O
3 O O
percent O O
, O O
whereas O O
in O O
patients O O
with O O
DCC B-Disease B-Disease
- I-Disease I-Disease
negative I-Disease I-Disease
tumors I-Disease I-Disease
, O O
the O O
survival O O
rate O O
was O O
61 O O
. O O
6 O O
percent O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

In O O
patients O O
with O O
stage B-Disease O
III I-Disease O
disease I-Disease O
, O O
the O O
respective O O
survival O O
rates O O
were O O
59 O O
. O O

3 O O
percent O O
and O O
33 O O
. O O

2 O O
percent O O
( O O
P O O
= O O
0 O O
. O O
03 O O
) O O
. O O

CONCLUSIONS O O
DCC O O
is O O
a O O
prognostic O O
marker O O
in O O
patients O O
with O O
stage B-Disease O
II I-Disease O
or I-Disease O
stage I-Disease O
III I-Disease O
colorectal I-Disease B-Disease
cancer I-Disease I-Disease
. O O

In O O
stage B-Disease O
II I-Disease O
colorectal I-Disease B-Disease
carcinomas I-Disease I-Disease
, O O
the O O
absence O O
of O O
DCC O O
identifies O O
a O O
subgroup O O
of O O
patients O O
with O O
lesions O O
that O O
behave O O
like O O
stage B-Disease B-Disease
III I-Disease I-Disease
cancers I-Disease I-Disease
. O O

These O O
findings O O
may O O
thus O O
have O O
therapeutic O O
implications O O
in O O
this O O
group O O
of O O
patients O O

Association O O
of O O
anxiety B-Disease B-Disease
- I-Disease O
related I-Disease O
traits I-Disease O
with O O
a O O
polymorphism O O
in O O
the O O
serotonin O O
transporter O O
gene O O
regulatory O O
region O O
. O O

Transporter O O
- O O
facilitated O O
uptake O O
of O O
serotonin O O
( O O
5-hydroxytryptamine O O
or O O
5-HT O O
) O O
has O O
been O O
implicated O O
in O O
anxiety B-Disease B-Disease
in O O
humans O O
and O O
animal O O
models O O
and O O
is O O
the O O
site O O
of O O
action O O
of O O
widely O O
used O O
uptake O O
- O O
inhibiting O O
antidepressant O O
and O O
antianxiety O O
drugs O O
. O O

Human O O
5-HT O O
transporter O O
( O O
5-HTT O O
) O O
gene O O
transcription O O
is O O
modulated O O
by O O
a O O
common O O
polymorphism O O
in O O
its O O
upstream O O
regulatory O O
region O O
. O O

The O O
short O O
variant O O
of O O
the O O
polymorphism O O
reduces O O
the O O
transcriptional O O
efficiency O O
of O O
the O O
5-HTT O O
gene O O
promoter O O
, O O
resulting O O
in O O
decreased O O
5-HTT O O
expression O O
and O O
5-HT O O
uptake O O
in O O
lymphoblasts O O
. O O

Association O O
studies O O
in O O
two O O
independent O O
samples O O
totaling O O
505 O O
individuals O O
revealed O O
that O O
the O O
5-HTT O O
polymorphism O O
accounts O O
for O O
3 O O
to O O
4 O O
percent O O
of O O
total O O
variation O O
and O O
7 O O
to O O
9 O O
percent O O
of O O
inherited O O
variance O O
in O O
anxiety B-Disease B-Disease
- I-Disease O
related I-Disease O
personality I-Disease O
traits I-Disease O
in O O
individuals O O
as O O
well O O
as O O
sibships O O
.. O O

Phenotypic O O
and O O
genotypic O O
overlap O O
between O O
atelosteogenesis B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
and O O
diastrophic B-Disease B-Disease
dysplasia I-Disease I-Disease
. O O

Mutations O O
in O O
the O O
diastrophic B-Disease B-Disease
dysplasia I-Disease I-Disease
sulfate O O
transporter O O
gene O O
DTDST O O
have O O
been O O
associated O O
with O O
a O O
family O O
of O O
chondrodysplasias B-Disease B-Disease
that O O
comprises O O
, O O
in O O
order O O
of O O
increasing O O
severity O O
, O O
diastrophic B-Disease B-Disease
dysplasia I-Disease I-Disease
( O O
DTD B-Disease B-Disease
) O O
, O O
atelosteogenesis B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
( O O
AO2 B-Disease B-Disease
) O O
, O O
and O O
achondrogenesis B-Disease B-Disease
type I-Disease I-Disease
1B I-Disease I-Disease
( O O
ACG1B B-Disease B-Disease
) O O
. O O

To O O
learn O O
more O O
about O O
the O O
molecular O O
basis O O
of O O
DTDST B-Disease B-Disease
chondrodysplasias I-Disease I-Disease
and O O
about O O
genotype O O
- O O
phenotype O O
correlations O O
, O O
we O O
studied O O
fibroblast O O
cultures O O
of O O
three O O
new O O
patients O O
one O O
with O O
AO-2 B-Disease B-Disease
, O O
one O O
with O O
DTD B-Disease B-Disease
, O O
and O O
one O O
with O O
an O O
intermediate O O
phenotype O O
( O O
AO2 B-Disease B-Disease
/ O O
DTD B-Disease B-Disease
) O O
. O O

Reduced O O
incorporation O O
of O O
inorganic O O
sulfate O O
into O O
macromolecules O O
was O O
found O O
in O O
all O O
three O O
. O O

Each O O
of O O
the O O
three O O
patients O O
was O O
found O O
to O O
be O O
heterozygous O O
for O O
a O O
c862 O O
t O O
transition O O
predicting O O
a O O
R279W O O
substitution O O
in O O
the O O
third O O
extracellular O O
loop O O
of O O
DTDST O O
. O O

In O O
two O O
patients O O
( O O
DTD B-Disease B-Disease
and O O
AO2 B-Disease B-Disease
/ O O
DTD B-Disease B-Disease
) O O
, O O
no O O
other O O
structural O O
mutation O O
was O O
found O O
, O O
but O O
polymerase O O
chain O O
reaction O O
amplification O O
and O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
analysis O O
of O O
fibroblast O O
cDNA O O
showed O O
reduced O O
mRNA O O
levels O O
of O O
the O O
wild O O
- O O
type O O
DTDST O O
allele O O
these O O
two O O
patients O O
may O O
be O O
compound O O
heterozygotes O O
for O O
the O O
" O O
Finnish O O
" O O
mutation O O
( O O
as O O
yet O O
uncharacterized O O
at O O
the O O
DNA O O
level O O
) O O
, O O
which O O
causes O O
reduced O O
expression O O
of O O
DTDST O O
. O O

The O O
third O O
patient O O
( O O
with O O
AO2 B-Disease B-Disease
) O O
had O O
the O O
R279W O O
mutation O O
compounded O O
with O O
a O O
novel O O
mutation O O
, O O
the O O
deletion O O
of O O
cytosine O O
418 O O
( O O
delta O O
c418 O O
) O O
, O O
predicting O O
a O O
frameshift O O
with O O
premature O O
termination O O
. O O

Also O O
the O O
delta O O
c418 O O
allele O O
was O O
underrepresented O O
in O O
the O O
cDNA O O
, O O
in O O
accordance O O
with O O
previous O O
observations O O
that O O
premature O O
stop O O
codons O O
reduce O O
mRNA O O
levels O O
. O O

The O O
presence O O
of O O
the O O
DTDST O O
R279W O O
mutation O O
in O O
a O O
total O O
of O O
11 O O
patients O O
with O O
AO2 B-Disease B-Disease
or O O
DTD B-Disease B-Disease
emphasizes O O
the O O
overlap O O
between O O
these O O
conditions O O
. O O

This O O
mutation O O
has O O
not O O
been O O
found O O
so O O
far O O
in O O
8 O O
analyzed O O
ACG1B B-Disease B-Disease
patients O O
, O O
suggesting O O
that O O
it O O
allows O O
some O O
residual O O
activity O O
of O O
the O O
sulfate O O
transporter O O
.. O O

Identification O O
of O O
WASP O O
mutations O O
, O O
mutation O O
hotspots O O
and O O
genotype O O
- O O
phenotype O O
disparities O O
in O O
24 O O
patients O O
with O O
the O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

The O O
Wiskott B-Disease B-Disease
- I-Disease I-Disease
Aldrich I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
WAS B-Disease B-Disease
) O O
, O O
an O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
immunodeficiency I-Disease I-Disease
disease I-Disease I-Disease
caused O O
by O O
mutation O O
in O O
the O O
recently O O
isolated O O
gene O O
encoding O O
WAS B-Disease B-Disease
protein O O
( O O
WASP O O
) O O
, O O
is O O
known O O
to O O
be O O
associated O O
with O O
extensive O O
clinical O O
heterogeneity O O
. O O

Cumulative O O
mutation O O
data O O
have O O
revealed O O
that O O
WASP O O
genotypes O O
are O O
also O O
highly O O
variable O O
among O O
WAS B-Disease B-Disease
patients O O
, O O
but O O
the O O
relationship O O
of O O
phenotype O O
with O O
genotype O O
in O O
this O O
disease O O
remains O O
unclear O O
. O O

To O O
address O O
this O O
issue O O
we O O
characterized O O
WASP O O
mutations O O
in O O
24 O O
unrelated O O
WAS B-Disease B-Disease
patients O O
, O O
including O O
18 O O
boys O O
with O O
severe O O
classical O O
WAS B-Disease B-Disease
and O O
6 O O
boys O O
expressing O O
mild O O
forms O O
of O O
the O O
disease O O
, O O
and O O
then O O
examined O O
the O O
degree O O
of O O
correlation O O
of O O
these O O
as O O
well O O
as O O
all O O
previously O O
published O O
WASP O O
mutations O O
with O O
disease O O
severity O O
. O O

By O O
analysis O O
of O O
these O O
compiled O O
mutation O O
data O O
, O O
we O O
demonstrated O O
clustering O O
of O O
WASP O O
mutations O O
within O O
the O O
four O O
most O O
N O O
- O O
terminal O O
exons O O
of O O
the O O
gene O O
and O O
also O O
identified O O
several O O
sites O O
within O O
this O O
region O O
as O O
hotspots O O
for O O
WASP O O
mutation O O
. O O

These O O
characteristics O O
were O O
observed O O
, O O
however O O
, O O
in O O
both O O
severe O O
and O O
mild O O
cases O O
of O O
the O O
disease O O
. O O

Similarly O O
, O O
while O O
the O O
cumulative O O
data O O
revealed O O
a O O
predominance O O
of O O
missense O O
mutations O O
among O O
the O O
WASP O O
gene O O
lesions O O
observed O O
in O O
boys O O
with O O
isolated B-Disease B-Disease
thrombocytopenia I-Disease I-Disease
, O O
missense O O
mutations O O
were O O
not O O
exclusively O O
associated O O
with O O
milder O O
WAS B-Disease B-Disease
phenotypes O O
, O O
but O O
also O O
comprised O O
a O O
substantial O O
portion O O
( O O
38 O O
% O O
) O O
of O O
the O O
WASP O O
gene O O
defects O O
found O O
in O O
patients O O
with O O
severe O O
disease O O
. O O

These O O
findings O O
, O O
as O O
well O O
as O O
the O O
detection O O
of O O
identical O O
WASP O O
mutations O O
in O O
patients O O
with O O
disparate O O
phenotypes O O
, O O
reveal O O
a O O
lack O O
of O O
phenotype O O
concordance O O
with O O
genotype O O
in O O
WAS B-Disease B-Disease
and O O
thus O O
imply O O
that O O
phenotypic O O
outcome O O
in O O
this O O
disease O O
can O O
not O O
be O O
reliably O O
predicted O O
solely O O
on O O
the O O
basis O O
of O O
WASP O O
genotypes O O
.. O O

Germline O O
mutations O O
in O O
the O O
3 O O
' O O
part O O
of O O
APC B-Disease B-Disease
exon O O
15 O O
do O O
not O O
result O O
in O O
truncated O O
proteins O O
and O O
are O O
associated O O
with O O
attenuated O B-Disease
adenomatous B-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
. O O

Familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
is O O
an O O
inherited O O
predisposition O O
to O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
characterized O O
by O O
the O O
development O O
of O O
numerous O O
adenomatous B-Disease B-Disease
polyps I-Disease I-Disease
predominantly O O
in O O
the O O
colorectal O O
region O O
. O O

Germline O O
mutations O O
in O O
the O O
adenomatous B-Disease B-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
( O O
APC B-Disease B-Disease
) O O
gene O O
are O O
responsible O O
for O O
most O O
cases O O
of O O
FAP B-Disease B-Disease
. O O

Mutations O O
at O O
the O O
5 O O
end O O
of O O
APC B-Disease B-Disease
are O O
known O O
to O O
be O O
associated O O
with O O
a O O
relatively O O
mild O O
form O O
of O O
the O O
disease O O
, O O
called O O
attenuated B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
( O O
AAPC B-Disease B-Disease
) O O
. O O

We O O
identified O O
a O O
frameshift O O
mutation O O
in O O
the O O
3 O O
part O O
of O O
exon O O
15 O O
, O O
resulting O O
in O O
a O O
stop O O
codon O O
at O O
1862 O O
, O O
in O O
a O O
large O O
Dutch O O
kindred O O
with O O
AAPC B-Disease B-Disease
. O O

Western O O
blot O O
analysis O O
of O O
lymphoblastoid O O
cell O O
lines O O
derived O O
from O O
affected O O
family O O
members O O
from O O
this O O
kindred O O
, O O
as O O
well O O
as O O
from O O
a O O
previously O O
reported O O
Swiss O O
family O O
carrying O O
a O O
frameshift O O
mutation O O
at O O
codon O O
1987 O O
and O O
displaying O O
a O O
similar O O
attenuated O O
phenotype O O
, O O
showed O O
only O O
the O O
wild O O
- O O
type O O
APC B-Disease B-Disease
protein O O
. O O

Our O O
study O O
indicates O O
that O O
chain O O
- O O
terminating O O
mutations O O
located O O
in O O
the O O
3 O O
part O O
of O O
APC B-Disease B-Disease
do O O
not O O
result O O
in O O
detectable O O
truncated O O
polypeptides O O
and O O
we O O
hypothesize O O
that O O
this O O
is O O
likely O O
to O O
be O O
the O O
basis O O
for O O
the O O
observed O O
AAPC B-Disease B-Disease
phenotype O O
.. O O

Complete O O
genomic O O
sequence O O
and O O
analysis O O
of O O
117 O O
kb O O
of O O
human O O
DNA O O
containing O O
the O O
gene O O
BRCA1 O O
. O O

Over O O
100 O O
distinct O O
disease O O
- O O
associated O O
mutations O O
have O O
been O O
identified O O
in O O
the O O
breast B-Disease B-Disease
- I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
susceptibility O O
gene O O
BRCA1 O O
. O O

Loss O O
of O O
the O O
wild O O
- O O
type O O
allele O O
in O O
> O O
90 O O
% O O
of O O
tumors B-Disease B-Disease
from O O
patients O O
with O O
inherited O O
BRCA1 O O
mutations O O
indicates O O
tumor B-Disease B-Disease
suppressive O O
function O O
. O O

The O O
low O O
incidence O O
of O O
somatic O O
mutations O O
suggests O O
that O O
BRCA1 O O
inactivation O O
in O O
sporadic O B-Disease
tumors B-Disease I-Disease
occurs O O
by O O
alternative O O
mechanisms O O
, O O
such O O
as O O
interstitial O O
chromosomal O O
deletion O O
or O O
reduced O O
transcription O O
. O O

To O O
identify O O
possible O O
features O O
of O O
the O O
BRCA1 O O
genomic O O
region O O
that O O
may O O
contribute O O
to O O
chromosomal O O
instability O O
as O O
well O O
as O O
potential O O
transcriptional O O
regulatory O O
elements O O
, O O
a O O
117 O O
, O O
143-bp O O
DNA O O
sequence O O
encompassing O O
BRCA1 O O
was O O
obtained O O
by O O
random O O
sequencing O O
of O O
four O O
cosmids O O
identified O O
from O O
a O O
human O O
chromosome O O
17 O O
specific O O
library O O
. O O

The O O
24 O O
exons O O
of O O
BRCA1 O O
span O O
an O O
81-kb O O
region O O
that O O
has O O
an O O
unusually O O
high O O
density O O
of O O
Alu O O
repetitive O O
DNA O O
( O O
41 O O
. O O
5 O O
% O O
) O O
, O O
but O O
relatively O O
low O O
density O O
( O O
4 O O
. O O
8 O O
% O O
) O O
of O O
other O O
repetitive O O
sequences O O
. O O

BRCA1 O O
intron O O
lengths O O
range O O
in O O
size O O
from O O
403 O O
bp O O
to O O
9 O O
. O O
2 O O
kb O O
and O O
contain O O
the O O
intragenic O O
microsatellite O O
markers O O
D17S1323 O O
, O O
D17S1322 O O
, O O
and O O
D17S855 O O
, O O
which O O
localize O O
to O O
introns O O
12 O O
, O O
19 O O
, O O
and O O
20 O O
, O O
respectively O O
. O O

In O O
addition O O
to O O
BRCA1 O O
, O O
the O O
contig O O
contains O O
two O O
complete O O
genes O O
Rho7 O O
, O O
a O O
member O O
of O O
the O O
rho O O
family O O
of O O
GTP O O
binding O O
proteins O O
, O O
and O O
VAT1 O O
, O O
an O O
abundant O O
membrane O O
protein O O
of O O
cholinergic O O
synaptic O O
vesicles O O
. O O

Partial O O
sequences O O
of O O
the O O
1A1 O O
- O O
3B O O
B O O
- O O
box O O
protein O O
pseudogene O O
and O O
IFP O O
35 O O
, O O
an O O
interferon O O
induced O O
leucine O O
zipper O O
protein O O
, O O
reside O O
within O O
the O O
contig O O
. O O

An O O
L21 O O
ribosomal O O
protein O O
pseudogene O O
is O O
embedded O O
in O O
BRCA1 O O
intron O O
13 O O
. O O

The O O
order O O
of O O
genes O O
on O O
the O O
chromosome O O
is O O
centromere-1FP O O
35-VAT1-Rho7-BRCA1 O O
- O O
1A1 O O
- O O
3B O O
- O O
telomere O O

Identification O O
of O O
a O O
RING O O
protein O O
that O O
can O O
interact O O
in O O
vivo O O
with O O
the O O
BRCA1 O O
gene O O
product O O
. O O

The O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
gene O O
, O O
BRCA1 O O
, O O
encodes O O
a O O
large O O
polypeptide O O
that O O
contains O O
the O O
cysteine O O
- O O
rich O O
RING O O
motif O O
, O O
a O O
zinc O O
- O O
binding O O
domain O O
found O O
in O O
a O O
variety O O
of O O
regulatory O O
proteins O O
. O O

Here O O
we O O
describe O O
a O O
novel O O
protein O O
that O O
interacts O O
in O O
vivo O O
with O O
the O O
N O O
- O O
terminal O O
region O O
of O O
BRCA1 O O
. O O

This O O
BRCA1-associated O O
RING O O
domain O O
( O O
BARD1 O O
) O O
protein O O
contains O O
an O O
N O O
- O O
terminal O O
RING O O
motif O O
, O O
three O O
tandem O O
ankyrin O O
repeats O O
, O O
and O O
a O O
C O O
- O O
terminal O O
sequence O O
with O O
significant O O
homology O O
to O O
the O O
phylogenetically O O
conserved O O
BRCT O O
domains O O
that O O
lie O O
near O O
the O O
C O O
terminus O O
of O O
BRCA1 O O
. O O

The O O
BARD1 O O
/ O O
BRCA1 O O
interaction O O
is O O
disrupted O O
by O O
BRCA1 O O
missense O O
mutations O O
that O O
segregate O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
susceptibility O O
, O O
indicating O O
that O O
BARD1 O O
may O O
be O O
involved O O
in O O
mediating O O
tumour B-Disease B-Disease
suppression O O
by O O
BRCA1 O O
.. O O

Detection O O
of O O
heterozygous O O
mutations O O
in O O
BRCA1 O O
using O O
high O O
density O O
oligonucleotide O O
arrays O O
and O O
two O O
- O O
colour O O
fluorescence O O
analysis O O
. O O

The O O
ability O O
to O O
scan O O
a O O
large O O
gene O O
rapidly O O
and O O
accurately O O
for O O
all O O
possible O O
heterozygous O O
mutations O O
in O O
large O O
numbers O O
of O O
patient O O
samples O O
will O O
be O O
critical O O
for O O
the O O
future O O
of O O
medicine O O
. O O

We O O
have O O
designed O O
high O O
- O O
density O O
arrays O O
consisting O O
of O O
over O O
96 O O
, O O
600 O O
oligonucleotides O O
20-nucleotides O O
( O O
nt O O
) O O
in O O
length O O
to O O
screen O O
for O O
a O O
wide O O
range O O
of O O
heterozygous O O
mutations O O
in O O
the O O
3 O O
. O O

45-kilobases O O
( O O
kb O O
) O O
exon O O
11 O O
of O O
the O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
gene O O
BRCA1 O O
. O O

Reference O O
and O O
test O O
samples O O
were O O
co O O
- O O
hybridized O O
to O O
these O O
arrays O O
and O O
differences O O
in O O
hybridization O O
patterns O O
quantitated O O
by O O
two O O
- O O
colour O O
analysis O O
. O O

Fourteen O O
of O O
fifteen O O
patient O O
samples O O
with O O
known O O
mutations O O
were O O
accurately O O
diagnosed O O
, O O
and O O
no O O
false O O
positive O O
mutations O O
were O O
identified O O
in O O
20 O O
control O O
samples O O
. O O

Eight O O
single O O
nucleotide O O
polymorphisms O O
were O O
also O O
readily O O
detected O O
. O O

DNA O O
chip O O
- O O
based O O
assays O O
may O O
provide O O
a O O
valuable O O
new O O
technology O O
for O O
high O O
- O O
throughput O O
cost O O
- O O
efficient O O
detection O O
of O O
genetic O O
alterations O O
. O O

Autosomal O O
dominant O O
primary O B-Disease
hyperparathyroidism B-Disease I-Disease
and I-Disease O
jaw I-Disease B-Disease
tumor I-Disease I-Disease
syndrome I-Disease I-Disease
associated O O
with O O
renal B-Disease B-Disease
hamartomas I-Disease I-Disease
and O O
cystic B-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
: O O
linkage O O
to O O
1q21-q32 O O
and O O
loss O O
of O O
the O O
wild O O
type O O
allele O O
in O O
renal B-Disease B-Disease
hamartomas I-Disease I-Disease
. O O

Hereditary B-Disease B-Disease
hyperparathyroidism I-Disease I-Disease
- I-Disease I-Disease
jaw I-Disease I-Disease
tumor I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
HPT B-Disease B-Disease
- I-Disease I-Disease
JT I-Disease I-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disease I-Disease I-Disease
( O O
OMIM O O
145001 O O
) O O
that O O
has O O
recently O O
been O O
mapped O O
to O O
chromosomal O O
region O O
1q21-q32 O O
( O O
HRPT2 O O
) O O
. O O

Here O O
we O O
report O O
two O O
families O O
with O O
HPT B-Disease B-Disease
- I-Disease I-Disease
JT I-Disease I-Disease
syndrome I-Disease I-Disease
in O O
which O O
adult B-Disease B-Disease
renal I-Disease I-Disease
hamartomas I-Disease I-Disease
or O O
cystic B-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
were O O
prominent O O
associated O O
features O O
, O O
possibly O O
representing O O
a O O
new O O
phenotypic O O
variant O O
of O O
the O O
HPT B-Disease B-Disease
- I-Disease I-Disease
JT I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

In O O
the O O
first O O
family O O
, O O
renal B-Disease B-Disease
lesions I-Disease I-Disease
were O O
present O O
in O O
five O O
out O O
of O O
six O O
affected O O
individuals O O
, O O
whereas O O
HPT B-Disease B-Disease
and O O
JT B-Disease B-Disease
were O O
seen O O
in O O
four O O
and O O
two O O
cases O O
, O O
respectively O O
. O O

In O O
the O O
second O O
family O O
, O O
JT B-Disease B-Disease
was O O
found O O
in O O
three O O
of O O
the O O
five O O
affected O O
individuals O O
and O O
two O O
affected O O
members O O
also O O
exhibited O O
polycystic B-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
. O O

The O O
possibility O O
of O O
the O O
latter O O
cosegregating O O
as O O
a O O
separate O O
autosomal O O
dominant O O
gene O O
can O O
not O O
be O O
ruled O O
out O O
. O O

A O O
sex O O
- O O
dependent O O
penetrance O O
of O O
primary B-Disease O
HPT I-Disease B-Disease
, O O
resulting O O
in O O
predominantly O O
male O O
- O O
affected O O
cases O O
was O O
evident O O
in O O
the O O
two O O
families O O
. O O

Twenty O O
microsatellite O O
markers O O
in O O
the O O
HRPT2 O O
region O O
were O O
typed O O
, O O
in O O
addition O O
to O O
markers O O
in O O
the O O
multiple B-Disease B-Disease
endocrine I-Disease I-Disease
neoplasia I-Disease I-Disease
( I-Disease O
MEN I-Disease B-Disease
) I-Disease O
types I-Disease O
1 I-Disease O
and I-Disease O
2 I-Disease O
regions O O
at O O
11q13 O O
and O O
10q11 O O
. O O

The O O
disease O O
in O O
these O O
two O O
kindreds O O
was O O
linked O O
to O O
five O O
markers O O
in O O
the O O
1q21-q32 O O
region O O
( O O
logarithm O O
- O O
of O O
- O O
odds O O
scores O O
3 O O
. O O
2 O O
- O O
4 O O
2 O O
- O O
4 O O
. O O
2 O O
) O O
, O O
whereas O O
linkage O O
to O O
the O O
MEN1 B-Disease B-Disease
and O O
MEN2 B-Disease B-Disease
regions O O
was O O
excluded O O
. O O

Meiotic O O
recombinations O O
detected O O
in O O
affected O O
individuals O O
placed O O
the O O
locus O O
telomeric O O
of O O
D1S215 O O
, O O
thus O O
narrowing O O
the O O
HRPT2 O O
region O O
from O O
> O O
60 O O
to O O
approximately O O
34 O O
centimorgans O O
. O O

Loss O O
of O O
heterozygosity O O
was O O
studied O O
in O O
seven O O
renal B-Disease B-Disease
hamartomas I-Disease I-Disease
from O O
two O O
affected O O
individuals O O
in O O
the O O
first O O
family O O
, O O
as O O
well O O
as O O
in O O
a O O
jaw B-Disease B-Disease
tumor I-Disease I-Disease
and O O
a O O
parathyroid B-Disease B-Disease
tumor I-Disease I-Disease
from O O
the O O
second O O
family O O
. O O

All O O
renal B-Disease B-Disease
hamartomas I-Disease I-Disease
showed O O
loss O O
of O O
heterozygosity O O
at O O
the O O
1q21-q32 O O
region O O
. O O

The O O
losses O O
invariably O O
involved O O
the O O
wild O O
type O O
allele O O
derived O O
from O O
the O O
unaffected O O
parent O O
, O O
suggesting O O
the O O
inactivation O O
of O O
a O O
tumor B-Disease B-Disease
suppressor O O
gene O O
in O O
this O O
region O O

Independent O O
origin O O
of O O
single O O
and O O
double O O
mutations O O
in O O
the O O
human O O
glucose O O
6-phosphate O O
dehydrogenase O O
gene O O
. O O

The O O
vast O O
majority O O
of O O
both O O
polymorphic O O
and O O
sporadic O O
G6PD O O
variants O O
are O O
due O O
to O O
single O O
missense O O
mutations O O
. O O

In O O
the O O
four O O
polymorphic O O
variants O O
that O O
have O O
two O O
point O O
mutations O O
, O O
one O O
of O O
the O O
mutations O O
is O O
always O O
376 O O
A-- O O
> O O
G O O
( O O
126 O O
Asn-- O O
> O O
Asp O O
) O O
, O O
which O O
on O O
its O O
own O O
gives O O
rise O O
to O O
the O O
nondeficient O O
polymorphic O O
variant O O
, O O
G6PD O O
A. O O
In O O
a O O
study O O
of O O
G6PD B-Disease B-Disease
deficient I-Disease I-Disease
patients O O
who O O
presented O O
with O O
clinical O O
favism B-Disease B-Disease
in O O
Spain O O
, O O
we O O
have O O
found O O
a O O
new O O
polymorphic O O
variant O O
that O O
we O O
have O O
called O O
G6PD O O
Malaga O O
, O O
whose O O
only O O
abnormality O O
is O O
a O O
542 O O
A-- O O
> O O
T O O
( O O
181 O O
Asp-- O O
> O O
Val O O
) O O
mutation O O
. O O

This O O
is O O
the O O
same O O
mutation O O
as O O
previously O O
found O O
in O O
association O O
with O O
the O O
mutation O O
of O O
G6PD O O
A O O
in O O
the O O
double O O
mutant O O
, O O
G6PD O O
Santamaria O O
. O O

G6PD O O
Malaga O O
is O O
associated O O
with O O
enzyme B-Disease B-Disease
deficiency I-Disease I-Disease
( O O
class O O
III O O
) O O
, O O
and O O
the O O
enzymic O O
properties O O
of O O
G6PD O O
Malaga O O
and O O
G6PD O O
Santamaria O O
are O O
quite O O
similar O O
, O O
indicating O O
that O O
in O O
this O O
case O O
the O O
effects O O
of O O
the O O
two O O
mutations O O
are O O
additive O O
rather O O
than O O
synergistic O O
. O O

G6PD O O
Santamaria O O
might O O
have O O
been O O
produced O O
by O O
recombination O O
between O O
G6PD O O
A O O
and O O
G6PD O O
Malaga O O
; O O
however O O
haplotype O O
analysis O O
, O O
including O O
the O O
use O O
of O O
a O O
new O O
silent O O
polymorphism O O
, O O
suggests O O
that O O
the O O
same O O
542 O O
A-- O O
> O O
T O O
mutation O O
has O O
taken O O
place O O
independently O O
in O O
a O O
G6PD O O
B O O
gene O O
to O O
give O O
G6PD O O
Malaga O O
and O O
in O O
a O O
G6PD O O
A O O
gene O O
to O O
give O O
G6PD O O
Santamaria O O
. O O

These O O
findings O O
help O O
to O O
outline O O
the O O
relationship O O
and O O
evolution O O
of O O
mutations O O
in O O
the O O
human O O
G6PD O O
locus O O
.. O O

BRCA1 O O
R841W O O
: O O
a O O
strong O O
candidate O O
for O O
a O O
common O O
mutation O O
with O O
moderate O O
phenotype O O
. O O

BRCA1 O O
mutations O O
cause O O
increased O O
risk O O
for O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
, O O
frequently O O
of O O
early O O
onset O O
. O O

Many O O
different O O
mutations O O
occur O O
in O O
BRCA1 O O
, O O
including O O
several O O
examples O O
of O O
recurrent O O
mutations O O
, O O
each O O
of O O
which O O
accounts O O
for O O
a O O
significant O O
number O O
of O O
families O O
with O O
heritable O O
cancer B-Disease B-Disease
predisposition O O
. O O

These O O
common O O
mutations O O
have O O
an O O
etiological O O
role O O
in O O
many O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
and O O
provide O O
the O O
opportunity O O
to O O
examine O O
genotype O O
- O O
phenotype O O
correlations O O
and O O
genotype O O
- O O
environment O O
interactions O O
in O O
individuals O O
with O O
the O O
identical O O
BRCA1 O O
lesion O O
. O O

We O O
report O O
a O O
novel O O
missense O O
change O O
in O O
BRCA1 O O
, O O
2640 O O
C-- O O
> O O
T O O
( O O
R841W O O
) O O
, O O
found O O
in O O
3 O O
cases O O
from O O
a O O
subject O O
group O O
of O O
305 O O
breast B-Disease B-Disease
and I-Disease I-Disease
79 I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
from O O
Orange O O
County O O
, O O
CA O O
. O O

These O O
are O O
consecutive O O
, O O
population O O
- O O
based O O
cases O O
not O O
selected O O
for O O
age O O
or O O
family O O
history O O
. O O

In O O
all O O
three O O
cases O O
, O O
there O O
is O O
a O O
strong O O
family O O
history O O
of O O
breast B-Disease B-Disease
, I-Disease I-Disease
ovarian I-Disease I-Disease
, I-Disease I-Disease
or I-Disease I-Disease
other I-Disease I-Disease
cancers I-Disease I-Disease
possibly O O
related O O
to O O
a O O
BRCA1 O O
defect O O
and O O
family O O
members O O
showed O O
a O O
high O O
concordance O O
of O O
cancer B-Disease B-Disease
incidence O O
with O O
the O O
presence O O
of O O
R841W O O
. O O

The O O
age O O
of O O
cancer B-Disease B-Disease
onset O O
was O O
not O O
always O O
distinct O O
from O O
typical O O
sporadic O O
cases O O
. O O

Testing O O
of O O
a O O
sample O O
of O O
413 O O
unrelated O O
individuals O O
to O O
examine O O
the O O
hypothesis O O
that O O
R841W O O
might O O
be O O
a O O
rare O O
polymorphism O O
detected O O
one O O
additional O O
instance O O
in O O
a O O
woman O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
diagnosed O O
at O O
age O O
77 O O
years O O
, O O
and O O
cancer B-Disease B-Disease
in O O
one O O
parent O O
. O O

R841W O O
is O O
likely O O
to O O
be O O
an O O
etiologically O O
significant O O
lesion O O
with O O
involvement O O
in O O
close O O
to O O
1 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
of O O
0 O O
- O O
1 O O
. O O
7 O O
% O O
) O O
of O O
all O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancers I-Disease I-Disease
in O O
this O O
population O O
. O O

Ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
: O O
founder O O
effect O O
among O O
north O O
African O O
Jews O O
. O O

The O O
ATM O O
gene O O
is O O
responsible O O
for O O
the O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
disorder I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
, O O
characterized O O
by O O
cerebellar B-Disease B-Disease
degeneration I-Disease I-Disease
, O O
immunodeficiency B-Disease B-Disease
and O O
cancer B-Disease B-Disease
predisposition I-Disease O
. O O

A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
carriers O O
were O O
reported O O
to O O
be O O
moderately O O
cancer B-Disease B-Disease
- I-Disease O
prone I-Disease O
. O O

A O O
wide O O
variety O O
of O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
mutations O O
, O O
most O O
of O O
which O O
are O O
unique O O
to O O
single O O
families O O
, O O
were O O
identified O O
in O O
various O O
ethnic O O
groups O O
, O O
precluding O O
carrier O O
screening O O
with O O
mutation O O
- O O
specific O O
assays O O
. O O

However O O
, O O
a O O
single O O
mutation O O
was O O
observed O O
in O O
32 O O
/ O O
33 O O
defective O O
ATM O O
alleles O O
in O O
Jewish O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
families O O
of O O
North O O
African O O
origin O O
, O O
coming O O
from O O
various O O
regions O O
of O O
Morocco O O
and O O
Tunisia O O
. O O

This O O
mutation O O
, O O
103C-- O O
> O O
T O O
, O O
results O O
in O O
a O O
stop O O
codon O O
at O O
position O O
35 O O
of O O
the O O
ATM O O
protein O O
. O O

In O O
keeping O O
with O O
the O O
nature O O
of O O
this O O
mutation O O
, O O
various O O
antibodies O O
directed O O
against O O
the O O
ATM O O
protein O O
failed O O
to O O
defect O O
this O O
protein O O
in O O
patient O O
cells O O
. O O

A O O
rapid O O
carrier O O
detection O O
assay O O
detected O O
this O O
mutation O O
in O O
three O O
out O O
of O O
488 O O
ATM O O
alleles O O
of O O
Jewish O O
Moroccan O O
or O O
Tunisian O O
origin O O
. O O

This O O
founder O O
effect O O
provides O O
a O O
unique O O
opportunity O O
for O O
population O O
- O O
based O O
screening O O
for O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
carriers O O
in O O
a O O
large O O
Jewish O O
community O O
.. O O

Mutation O O
analysis O O
of O O
BRCA1 O O
and O O
BRCA2 O O
in O O
a O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
population O O
. O O

A O O
population O O
- O O
based O O
series O O
of O O
54 O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
from O O
Southern O O
California O O
were O O
analyzed O O
for O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
genes O O
, O O
BRCA1 O O
and O O
BRCA2 O O
. O O

Nine O O
( O O
17 O O
% O O
) O O
of O O
the O O
patients O O
had O O
a O O
family O O
history O O
of O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
at O O
least O O
one O O
first O O
- O O
degree O O
relative O O
. O O

A O O
further O O
seven O O
( O O
13 O O
% O O
) O O
of O O
the O O
patients O O
reported O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
at O O
least O O
one O O
second O O
- O O
degree O O
relative O O
and O O
in O O
no O O
first O O
- O O
degree O O
relatives O O
. O O

No O O
germ O O
- O O
line O O
BRCA1 O O
mutations O O
were O O
found O O
. O O

Two O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
patients O O
( O O
4 O O
% O O
of O O
the O O
total O O
) O O
were O O
found O O
to O O
carry O O
novel O O
truncating O O
mutations O O
in O O
the O O
BRCA2 O O
gene O O
. O O

Only O O
one O O
of O O
the O O
two O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
patients O O
carrying O O
a O O
BRCA2 O O
mutation O O
had O O
a O O
family O O
history O O
of O O
cancer B-Disease B-Disease
, O O
with O O
one O O
case O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
in O O
a O O
first O O
- O O
degree O O
relative O O
. O O

The O O
remaining O O
eight O O
cases O O
( O O
89 O O
% O O
) O O
of O O
male B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
with O O
a O O
family O O
history O O
of O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
first O O
- O O
degree O O
relatives O O
remain O O
unaccounted O O
for O O
by O O
mutations O O
in O O
either O O
the O O
BRCA1 O O
gene O O
or O O
the O O
BRCA2 O O
gene O O
.. O O

Molecular O O
basis O O
for O O
Duarte B-Disease B-Disease
and I-Disease I-Disease
Los I-Disease I-Disease
Angeles I-Disease I-Disease
variant I-Disease I-Disease
galactosemia I-Disease I-Disease
. O O

Human O O
orythrocytes O O
that O O
are O O
homozygous O O
for O O
the O O
Duarte B-Disease B-Disease
enzyme I-Disease I-Disease
variant I-Disease I-Disease
of I-Disease I-Disease
galactosemia I-Disease I-Disease
( O O
D O O
/ O O
D O O
) O O
have O O
a O O
characteristic O O
isoform O O
on O O
isoelectric O O
focusing O O
and O O
50 O O
% O O
reduction O O
in O O
galactose-1-phosphate O O
uridyltransferase O O
( O O
GALT O O
) O O
enzyme O O
activity O O
. O O

The O O
Duarte O O
biochemical O O
phenotype O O
has O O
a O O
molecular O O
genotype O O
of O O
N314D O O
/ O O
N314D O O
. O O

The O O
characteristic O O
Duarte O O
isoform O O
is O O
also O O
associated O O
with O O
a O O
variant O O
called O O
the O O
" O O
Los O O
Angeles O O
( O O
LA O O
) O O
phenotype O O
, O O
" O O
which O O
has O O
increased O O
GALT O O
enzyme O O
activity O O
. O O

We O O
evaluated O O
GALT O O
enzyme O O
activity O O
and O O
screened O O
the O O
GALT O O
genes O O
of O O
145 O O
patients O O
with O O
one O O
or O O
more O O
N314D O O
- O O
containing O O
alleles O O
. O O

We O O
found O O
seven O O
with O O
the O O
LA O O
biochemical O O
phenotype O O
, O O
and O O
all O O
had O O
a O O
1721C-- O O
> O O
T O O
transition O O
in O O
exon O O
7 O O
in O O
cis O O
with O O
the O O
N314D O O
missense O O
mutation O O
. O O

The O O
1721C-- O O
> O O
T O O
transition O O
is O O
a O O
neutral O O
polymorphism O O
for O O
leucine O O
at O O
amino O O
acid O O
218 O O
( O O
L218L O O
) O O
. O O

In O O
pedigree O O
analyses O O
, O O
this O O
1721C-- O O
> O O
T O O
transition O O
segregated O O
with O O
the O O
LA O O
phenotype O O
of O O
increased O O
GALT O O
activity O O
in O O
three O O
different O O
biochemical O O
phenotypes O O
( O O
LA O O
/ O O
N O O
, O O
LA O O
/ O O
G O O
, O O
and O O
LA O O
/ O O
D O O
) O O
. O O

To O O
determine O O
the O O
mechanism O O
for O O
increased O O
activity O O
of O O
the O O
LA O O
variant O O
, O O
we O O
compared O O
GALT O O
mRNA O O
, O O
protein O O
abundance O O
, O O
and O O
enzyme O O
thermal O O
stability O O
in O O
lymphoblast O O
cell O O
lines O O
of O O
D O O
and O O
LA O O
phenotypes O O
with O O
comparable O O
genotypes O O
. O O

GALT O O
protein O O
abundance O O
was O O
increased O O
in O O
LA O O
compared O O
to O O
D O O
alleles O O
, O O
but O O
mRNA O O
was O O
similar O O
among O O
all O O
genotypes O O
. O O

When O O
LA O O
/ O O
D O O
and O O
D O O
/ O O
D O O
GALT O O
biochemical O O
phenotypes O O
were O O
compared O O
to O O
N O O
/ O O
N O O
GALT O O
phenotypes O O
, O O
both O O
had O O
50 O O
% O O
, O O
as O O
compared O O
to O O
21 O O
% O O
, O O
reduction O O
in O O
GALT O O
activity O O
in O O
the O O
wild O O
type O O
( O O
N O O
/ O O
N O O
) O O
after O O
exposure O O
at O O
identical O O
initial O O
enzyme O O
activity O O
to O O
50 O O
degrees O O
C O O
for O O
15 O O
min O O
. O O

We O O
conclude O O
that O O
the O O
codon O O
change O O
N314D O O
in O O
cis O O
with O O
the O O
base O O
- O O
pair O O
transition O O
1721C-- O O
> O O
T O O
produces O O
the O O
LA B-Disease O
variant I-Disease O
of I-Disease O
galactosemia I-Disease B-Disease
and O O
that O O
this O O
nucleotide O O
change O O
increases O O
GALT O O
activity O O
by O O
increasing O O
GALT O O
protein O O
abundance O O
without O O
increasing O O
transcription O O
or O O
decreasing O O
thermal O O
lability O O
. O O

A O O
favorable O O
codon O O
bias O O
for O O
the O O
mutated O O
codon O O
with O O
consequently O O
increased O O
translation O O
rates O O
is O O
postulated O O
as O O
the O O
mechanism O O
.. O O

The O O
TSG101 O O
tumor B-Disease B-Disease
susceptibility O O
gene O O
is O O
located O O
in O O
chromosome O O
11 O O
band O O
p15 O O
and O O
is O O
mutated O O
in O O
human O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Recent O O
work O O
has O O
identified O O
a O O
mouse O O
gene O O
( O O
tsg101 O O
) O O
whose O O
inactivation O O
in O O
fibroblasts O O
results O O
in O O
cellular O O
transformation O O
and O O
the O O
ability O O
to O O
produce O O
metastatic B-Disease B-Disease
tumors I-Disease I-Disease
in O O
nude O O
mice O O
. O O

Here O O
, O O
we O O
report O O
that O O
the O O
human O O
homolog O O
, O O
TSG101 O O
, O O
which O O
we O O
isolated O O
and O O
mapped O O
to O O
chromosome O O
11 O O
, O O
bands O O
15 O O
. O O
1 O O
- O O
15 O O
1 O O
- O O
15 O O
. O O
2 O O
, O O
a O O
region O O
proposed O O
to O O
contain O O
tumor B-Disease B-Disease
suppressor O O
gene O O
( O O
s O O
) O O
, O O
is O O
mutated O O
at O O
high O O
frequency O O
in O O
human O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

In O O
7 O O
of O O
15 O O
uncultured O O
primary O O
human O O
breast B-Disease B-Disease
carcinomas I-Disease I-Disease
, O O
intragenic O O
deletions O O
were O O
shown O O
in O O
TSG101 O O
genomic O O
DNA O O
and O O
transcripts O O
by O O
gel O O
and O O
sequence O O
analysis O O
, O O
and O O
mutations O O
affecting O O
two O O
TSG101 O O
alleles O O
were O O
identified O O
in O O
four O O
of O O
these O O
cancers B-Disease B-Disease
. O O

No O O
TSG101 O O
defects O O
were O O
found O O
in O O
matched O O
normal O O
breast O O
tissue O O
from O O
the O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
. O O

These O O
findings O O
strongly O O
implicate O O
TSG101 O O
mutations O O
in O O
human O O
breast B-Disease B-Disease
cancer I-Disease I-Disease

Moderate O O
intergenerational O O
and O O
somatic O O
instability O O
of O O
a O O
55-CTG O O
repeat O O
in O O
transgenic O O
mice O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
associated O O
with O O
the O O
expansion O O
of O O
a O O
( O O
CTG O O
) O O
n O O
trinucleotide O O
repeat O O
in O O
the O O
3 O O
untranslated O O
region O O
( O O
UTR O O
) O O
of O O
the O O
DM B-Disease B-Disease
protein O O
kinase O O
gene O O
( O O
DMPK O O
) O O
. O O

The O O
( O O
CTG O O
) O O
n O O
repeat O O
is O O
polymorphic O O
and O O
varies O O
in O O
size O O
between O O
5 O O
and O O
37 O O
repeats O O
in O O
unaffected O O
individuals O O
whereas O O
in O O
affected O O
patients O O
there O O
are O O
between O O
50 O O
and O O
4 O O
, O O
000 O O
CTGs O O
. O O

The O O
size O O
of O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
, O O
which O O
increases O O
through O O
generations O O
, O O
generally O O
correlates O O
with O O
clinical O O
severity O O
and O O
age O O
of O O
onset O O
. O O

The O O
instability O O
of O O
the O O
CTG O O
repeat O O
appears O O
to O O
depend O O
on O O
its O O
size O O
as O O
well O O
as O O
on O O
the O O
sex O O
of O O
the O O
transmitting O O
parent O O
. O O

Moreover O O
, O O
mitotic O O
instability O O
analysis O O
of O O
different O O
human O O
DM B-Disease B-Disease
tissues O O
shows O O
length O O
mosaicism O O
between O O
different O O
cell O O
lineages O O
. O O

The O O
molecular O O
mechanisms O O
of O O
triplet O O
instability O O
remain O O
elusive O O
. O O

To O O
investigate O O
the O O
role O O
of O O
genomic O O
sequences O O
in O O
instability O O
, O O
we O O
produced O O
transgenic O O
mice O O
containing O O
a O O
45-kb O O
genomic O O
segment O O
with O O
a O O
55-CTG O O
repeat O O
cloned O O
from O O
a O O
mildly O O
affected O O
patient O O
. O O

In O O
contrast O O
to O O
other O O
mouse O O
models O O
containing O O
CAG O O
repeats O O
within O O
cDNAs O O
, O O
these O O
mice O O
showed O O
both O O
intergenerational O O
and O O
somatic O O
repeat O O
instability O O
.. O O

Missense O O
mutations O O
in O O
the O O
Fas O O
gene O O
resulting O O
in O O
autoimmune B-Disease B-Disease
lymphoproliferative I-Disease I-Disease
syndrome I-Disease I-Disease
: O O
a O O
molecular O O
and O O
immunological O O
analysis O O
. O O

Programmed O O
cell O O
death O O
( O O
or O O
apoptosis O O
) O O
is O O
a O O
physiological O O
process O O
essential O O
to O O
the O O
normal O O
development O O
and O O
homeostatic O O
maintenance O O
of O O
the O O
immune O O
system O O
. O O

The O O
Fas O O
/ O O
Apo-1 O O
receptor O O
plays O O
a O O
crucial O O
role O O
in O O
the O O
regulation O O
of O O
apoptosis O O
, O O
as O O
demonstrated O O
by O O
lymphoproliferation O O
in O O
MRL O O
- O O
lpr O O
/ O O
lpr O O
mice O O
and O O
by O O
the O O
recently O O
described O O
autoimmune B-Disease B-Disease
lymphoproliferative I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
ALPS B-Disease B-Disease
) O O
in O O
humans O O
, O O
both O O
of O O
which O O
are O O
due O O
to O O
mutations O O
in O O
the O O
Fas O O
gene O O
. O O

We O O
describe O O
a O O
novel O O
family O O
with O O
ALPS B-Disease B-Disease
in O O
which O O
three O O
affected O O
siblings O O
carry O O
two O O
distinct O O
missense O O
mutations O O
on O O
both O O
the O O
Fas O O
gene O O
alleles O O
and O O
show O O
lack O O
of O O
Fas O O
- O O
induced O O
apoptosis O O
. O O

The O O
children O O
share O O
common O O
clinical O O
features O O
including O O
splenomegaly B-Disease B-Disease
and O O
lymphadenopathy B-Disease B-Disease
, O O
but O O
only O O
one O O
developed O O
severe O O
autoimmune B-Disease O
manifestations I-Disease O
. O O

In O O
all O O
three O O
siblings O O
, O O
we O O
demonstrated O O
the O O
presence O O
of O O
anergic O O
CD3 O O
+ O O
CD4-CD8- O O
( O O
double O O
negative O O
, O O
[ O O
DN O O
] O O
) O O
T O O
cells O O
; O O
moreover O O
, O O
a O O
chronic O O
lymphocyte O O
activation O O
was O O
found O O
, O O
as O O
demonstrated O O
by O O
the O O
presence O O
of O O
high O O
levels O O
of O O
HLA O O
- O O
DR O O
expression O O
on O O
peripheral O O
CD3 O O
+ O O
cells O O
and O O
by O O
the O O
presence O O
of O O
high O O
levels O O
of O O
serum O O
activation O O
markers O O
such O O
as O O
soluble O O
interleukin-2 O O
receptor O O
( O O
slL-2R O O
) O O
and O O
soluble O O
CD30 O O
( O O
sCD30 O O
) O O
.. O O

The O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
gene O O
product O O
, O O
a O O
constitutively O O
expressed O O
nuclear O O
protein O O
that O O
is O O
not O O
up O O
- O O
regulated O O
following O O
genome O O
damage O O
. O O

The O O
product O O
of O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
gene O O
( O O
ATM O O
) O O
was O O
identified O O
by O O
using O O
an O O
antiserum O O
developed O O
to O O
a O O
peptide O O
corresponding O O
to O O
the O O
deduced O O
amino O O
acid O O
sequence O O
. O O

The O O
ATM O O
protein O O
is O O
a O O
single O O
, O O
high O O
- O O
molecular O O
weight O O
protein O O
predominantly O O
confined O O
to O O
the O O
nucleus O O
of O O
human O O
fibroblasts O O
, O O
but O O
is O O
present O O
in O O
both O O
nuclear O O
and O O
microsomal O O
fractions O O
from O O
human O O
lymphoblast O O
cells O O
and O O
peripheral O O
blood O O
lymphocytes O O
. O O

ATM O O
protein O O
levels O O
and O O
localization O O
remain O O
constant O O
throughout O O
all O O
stages O O
of O O
the O O
cell O O
cycle O O
. O O

Truncated O O
ATM O O
protein O O
was O O
not O O
detected O O
in O O
lymphoblasts O O
from O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
patients O O
homozygous O O
for O O
mutations O O
leading O O
to O O
premature O O
protein O O
termination O O
. O O

Exposure O O
of O O
normal O O
human O O
cells O O
to O O
gamma O O
- O O
irradiation O O
and O O
the O O
radiomimetic O O
drug O O
neocarzinostatin O O
had O O
no O O
effect O O
on O O
ATM O O
protein O O
levels O O
, O O
in O O
contrast O O
to O O
a O O
noted O O
rise O O
in O O
p53 O O
levels O O
over O O
the O O
same O O
time O O
interval O O
. O O

These O O
findings O O
are O O
consistent O O
with O O
a O O
role O O
for O O
the O O
ATM O O
protein O O
in O O
ensuring O O
the O O
fidelity O O
of O O
DNA O O
repair O O
and O O
cell O O
cycle O O
regulation O O
following O O
genome O O
damage O O
.. O O

Type O O
III O O
collagen O O
is O O
crucial O O
for O O
collagen O O
I O O
fibrillogenesis O O
and O O
for O O
normal O O
cardiovascular O O
development O O
. O O

Type O O
III O O
collagen O O
is O O
a O O
fibrillar O O
forming O O
collagen O O
comprising O O
three O O
alpha1 O O
( O O
III O O
) O O
chains O O
and O O
is O O
expressed O O
in O O
early O O
embryos O O
and O O
throughout O O
embryogenesis O O
. O O

In O O
the O O
adult O O
, O O
type O O
III O O
collagen O O
is O O
a O O
major O O
component O O
of O O
the O O
extracellular O O
matrix O O
in O O
a O O
variety O O
of O O
internal O O
organs O O
and O O
skin O O
. O O

Mutations O O
in O O
the O O
COL3A1 O O
gene O O
have O O
been O O
implicated O O
as O O
a O O
cause O O
of O O
type B-Disease B-Disease
IV I-Disease I-Disease
Ehlers I-Disease I-Disease
- I-Disease I-Disease
Danlos I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
a O O
disease O O
leading O O
to O O
aortic B-Disease B-Disease
rupture I-Disease I-Disease
in O O
early O O
adult O O
life O O
. O O

To O O
directly O O
study O O
the O O
role O O
of O O
Col3a1 O O
in O O
development O O
and O O
disease O O
, O O
we O O
have O O
inactivated O O
the O O
Col3a1 O O
gene O O
in O O
embryonic O O
stem O O
cells O O
by O O
homologous O O
recombination O O
. O O

The O O
mutated O O
allele O O
was O O
transmitted O O
through O O
the O O
mouse O O
germ O O
line O O
and O O
homozygous O O
mutant O O
animals O O
were O O
derived O O
from O O
heterozygous O O
intercrosses O O
. O O

About O O
10 O O
% O O
of O O
the O O
homozygous O O
mutant O O
animals O O
survived O O
to O O
adulthood O O
but O O
have O O
a O O
much O O
shorter O O
life O O
span O O
compared O O
with O O
wild O O
- O O
type O O
mice O O
. O O

The O O
major O O
cause O O
of O O
death O O
of O O
mutant O O
mice O O
was O O
rupture O B-Disease
of O I-Disease
the O I-Disease
major O I-Disease
blood O I-Disease
vessels O I-Disease
, O O
similar O O
to O O
patients O O
with O O
type B-Disease B-Disease
IV I-Disease I-Disease
Ehlers I-Disease I-Disease
- I-Disease I-Disease
Danlos I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Ultrastructural O O
analysis O O
of O O
tissues O O
from O O
mutant O O
mice O O
revealed O O
that O O
type O O
III O O
collagen O O
is O O
essential O O
for O O
normal O O
collagen O O
I O O
fibrillogenesis O O
in O O
the O O
cardiovascular O O
system O O
and O O
other O O
organs O O
.. O O

Nonsense O O
mutation O O
in O O
exon O O
3 O O
of O O
the O O
proteolipid O O
protein O O
gene O O
( O O
PLP O O
) O O
in O O
a O O
family O O
with O O
an O O
unusual O O
form O O
of O O
Pelizaeus B-Disease B-Disease
- I-Disease I-Disease
Merzbacher I-Disease I-Disease
disease I-Disease I-Disease
. O O

We O O
report O O
a O O
G-- O O
> O O
A O O
transition O O
at O O
nucleotide O O
431 O O
of O O
the O O
proteolipid O O
protein O O
gene O O
( O O
PLP O O
) O O
results O O
in O O
a O O
nonsense O O
codon O O
in O O
a O O
family O O
with O O
an O O
unusual O O
form O O
of O O
Pelizaeus B-Disease B-Disease
- I-Disease I-Disease
Merzbacher I-Disease I-Disease
disease I-Disease I-Disease
( O O
PMD B-Disease B-Disease
) O O
. O O

The O O
mutation O O
, O O
which O O
creates O O
a O O
second O O
AluI O O
restriction O O
site O O
, O O
results O O
in O O
a O O
nonsense O O
mutation O O
in O O
PLP O O
. O O

The O O
clinical O O
picture O O
resembles O O
somewhat O O
that O O
of O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
spastic I-Disease I-Disease
paraplegia I-Disease I-Disease
( O O
SPG B-Disease B-Disease
) O O
. O O

It O O
differs O O
from O O
this O O
and O O
both O O
the O O
classical O O
and O O
connatal O O
forms O O
of O O
PMD B-Disease B-Disease
in O O
that O O
it O O
is O O
relatively O O
mild O O
in O O
form O O
, O O
onset O O
is O O
delayed O O
beyond O O
age O O
2 O O
years O O
, O O
nystagmus B-Disease B-Disease
is O O
absent O O
, O O
tremors B-Disease B-Disease
are O O
prominent O O
, O O
mental B-Disease B-Disease
retardation I-Disease I-Disease
is O O
not O O
severe O O
, O O
some O O
patients O O
show O O
dementia B-Disease B-Disease
or O O
personality B-Disease B-Disease
disorders I-Disease I-Disease
, O O
the O O
disease O O
is O O
progressive O O
rather O O
than O O
static O O
in O O
some O O
, O O
and O O
several O O
females O O
show O O
signs O O
of O O
disease O O
. O O

The O O
nonsense O O
mutation O O
, O O
which O O
is O O
in O O
exon O O
3B O O
, O O
should O O
block O O
the O O
synthesis O O
of O O
normal O O
PLP O O
but O O
spare O O
DM20 O O
, O O
the O O
isoform O O
whose O O
persistence O O
has O O
been O O
associated O O
with O O
mild O O
forms O O
of O O
PLP B-Disease B-Disease
- I-Disease I-Disease
associated I-Disease I-Disease
disease I-Disease I-Disease
in O O
both O O
humans O O
and O O
mice O O
.. O O

Common O O
BRCA1 O O
variants O O
and O O
susceptibility O O
to O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
the O O
general O O
population O O
. O O

Most O O
multiple O O
case O O
families O O
of O O
young O O
onset O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
and O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
are O O
thought O O
to O O
be O O
due O O
to O O
highly O O
penetrant O O
mutations O O
in O O
the O O
predisposing O O
genes O O
BRCA1 O O
and O O
BRCA2 O O
. O O

However O O
, O O
these O O
mutations O O
are O O
uncommon O O
in O O
the O O
population O O
and O O
they O O
probably O O
account O O
for O O
only O O
a O O
few O O
percent O O
of O O
all O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
incidence O O
. O O

A O O
much O O
larger O O
fraction O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
might O O
, O O
in O O
principle O O
, O O
be O O
due O O
to O O
common O O
variants O O
which O O
confer O O
more O O
modest O O
individual O O
risks O O
. O O

There O O
are O O
several O O
common O O
polymorphisms O O
in O O
the O O
BRCA1 O O
gene O O
which O O
generate O O
amino O O
acid O O
substitutions O O
. O O

We O O
have O O
examined O O
the O O
frequency O O
of O O
four O O
of O O
these O O
polymorphisms O O
Gln356Arg O O
, O O
Pro871Leu O O
, O O
Glu1038Gly O O
and O O
Ser1613Gly O O
in O O
large O O
series O O
of O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
cases O O
and O O
matched O O
controls O O
. O O

Due O O
to O O
strong O O
linkage O O
disequilibrium O O
, O O
these O O
four O O
sites O O
generate O O
only O O
three O O
haplotypes O O
with O O
a O O
frequency O O
> O O
1 O O
. O O
3 O O
% O O
. O O

The O O
most O O
common O O
haplotypes O O
, O O
defined O O
by O O
the O O
alleles O O
Gln356Pro871Glu1038Ser1613 O O
and O O
Gln356Leu871Gly1038Gly1613 O O
, O O
have O O
frequencies O O
of O O
0 O O
. O O
57 O O
and O O
0 O O
. O O
32 O O
respectively O O
, O O
and O O
these O O
frequencies O O
do O O
not O O
differ O O
significantly O O
between O O
patient O O
and O O
control O O
groups O O
. O O

Thus O O
the O O
most O O
common O O
polymorphisms O O
of O O
the O O
BRCA1 O O
gene O O
do O O
not O O
make O O
a O O
significant O O
contribution O O
to O O
breast B-Disease B-Disease
or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
risk O O
. O O

However O O
, O O
our O O
data O O
suggest O O
that O O
the O O
Arg356 O O
allele O O
may O O
have O O
a O O
different O O
genotype O O
distribution O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
from O O
that O O
in O O
controls O O
( O O
Arg356 O O
homozygotes O O
are O O
more O O
frequent O O
in O O
the O O
control O O
groups O O
, O O
P O O
= O O
0 O O
. O O
01 O O
) O O
, O O
indicating O O
that O O
it O O
may O O
be O O
protective O O
against O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

If O O
this O O
finding O O
can O O
be O O
confirmed O O
, O O
it O O
may O O
provide O O
an O O
insight O O
into O O
the O O
structural O O
features O O
of O O
the O O
BRCA1 O O
protein O O
that O O
are O O
important O O
for O O
its O O
function O O
. O O

Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
: O O
Dr. O O
W. O O
Kniest O O
, O O
his O O
patient O O
, O O
the O O
molecular O O
defect O O
. O O

Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
is O O
a O O
severe O O
chondrodysplasia B-Disease B-Disease
caused O O
by O O
the O O
defective B-Disease O
formation I-Disease O
of I-Disease O
type I-Disease O
II I-Disease O
collagen I-Disease O
. O O

We O O
report O O
about O O
Dr. O O
Kniest O O
, O O
who O O
first O O
described O O
the O O
condition O O
in O O
1952 O O
, O O
and O O
his O O
patient O O
, O O
who O O
, O O
at O O
the O O
age O O
of O O
50 O O
years O O
is O O
severely B-Disease O
handicapped I-Disease O
with O O
short B-Disease B-Disease
stature I-Disease I-Disease
, O O
restricted B-Disease O
joint I-Disease O
mobility I-Disease O
, O O
and O O
blindness B-Disease B-Disease
but O O
is O O
mentally O O
alert O O
and O O
leads O O
an O O
active O O
life O O
. O O

Molecular O O
analysis O O
of O O
the O O
patients O O
DNA O O
showed O O
a O O
single O O
base O O
( O O
G O O
) O O
deletion O O
involving O O
the O O
GT O O
dinucleotide O O
at O O
the O O
start O O
of O O
intron O O
18 O O
destroying O O
a O O
splice O O
site O O
of O O
the O O
COL2A1 O O
gene O O
. O O

This O O
is O O
in O O
accordance O O
with O O
molecular O O
findings O O
in O O
other O O
patients O O
with O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
and O O
confirms O O
, O O
in O O
the O O
original O O
patient O O
, O O
that O O
the O O
disorder O O
is O O
caused O O
by O O
small O O
inframe O O
deletions O O
often O O
due O O
to O O
exon O O
skipping O O
as O O
a O O
result O O
of O O
COL2A1 O O
splice O O
site O O
mutations O O
.. O O

Cloning O O
of O O
the O O
homogentisate O O
1,2-dioxygenase O O
gene O O
, O O
the O O
key O O
enzyme O O
of O O
alkaptonuria B-Disease B-Disease
in O O
mouse O O
. O O

We O O
determined O O
48 O O
amino O O
acid O O
residues O O
from O O
five O O
peptides O O
from O O
the O O
homogeneous O O
monomer O O
of O O
homogentisate O O
1 O O
, O O
2-dioxygenase O O
( O O
HGO O O
; O O
E. O O
C. O O
1 O O
. O O
13 O O
. O O
11 O O
. O O
15 O O
) O O
of O O
mouse O O
liver O O
. O O

After O O
digestion O O
with O O
trypsin O O
, O O
peptides O O
were O O
separated O O
by O O
reversed O O
phase O O
chromatography O O
and O O
amino O O
acid O O
sequenced O O
. O O

The O O
deduced O O
codon O O
sequence O O
of O O
three O O
peptides O O
was O O
used O O
to O O
derive O O
degenerated O O
oligomeres O O
. O O

By O O
combining O O
these O O
oligos O O
, O O
we O O
were O O
able O O
to O O
amplify O O
fragments O O
from O O
100 O O
to O O
300 O O
bases O O
( O O
b O O
) O O
from O O
mouse O O
liver O O
cDNA O O
by O O
polymerase O O
chain O O
reaction O O
after O O
reverse O O
transcription O O
( O O
RT O O
- O O
PCR O O
) O O
. O O

A O O
fragment O O
of O O
200 O O
b O O
was O O
cloned O O
and O O
used O O
as O O
a O O
probe O O
to O O
screen O O
a O O
mouse O O
liver O O
cDNA O O
library O O
. O O

One O O
clone O O
from O O
this O O
library O O
contained O O
the O O
complete O O
cDNA O O
- O O
insert O O
for O O
HGO O O
as O O
determined O O
by O O
sequencing O O
. O O

The O O
cDNA O O
encodes O O
for O O
a O O
protein O O
of O O
50 O O
kDa O O
, O O
as O O
predicted O O
. O O

The O O
cDNA O O
of O O
mouse O O
HGO O O
has O O
an O O
overall O O
identity O O
of O O
41 O O
% O O
to O O
the O O
corresponding O O
gene O O
hmgA O O
from O O
Aspergillus O O
. O O

Sequence O O
similarities O O
to O O
human O O
expressed O O
sequence O O
tags O O
( O O
EST O O
) O O
clones O O
ranged O O
from O O
70 O O
% O O
to O O
20 O O
% O O
. O O

The O O
positions O O
of O O
122 O O
conserved O O
amino O O
acids O O
could O O
be O O
determined O O
by O O
multiple O O
sequence O O
alignment O O
. O O

We O O
identified O O
one O O
first O O
intron O O
of O O
928 O O
b O O
in O O
the O O
mouse O O
gene O O
. O O

The O O
gene O O
for O O
HGO O O
seems O O
to O O
be O O
expressed O O
in O O
various O O
tissues O O
, O O
as O O
shown O O
by O O
RT O O
- O O
PCR O O
on O O
different O O
cDNAs O O
. O O

FISH O O
experiments O O
with O O
the O O
whole O O
murine O O
cDNA O O
as O O
probe O O
clearly O O
revealed O O
signals O O
at O O
the O O
human O O
chromosomal O O
band O O
3q13 O O
. O O

3-q21 O O
. O O

This O O
corresponds O O
well O O
to O O
the O O
previous O O
assignment O O
of O O
the O O
locus O O
for O O
the O O
human O O
alkaptonuria B-Disease B-Disease
gene O O
( O O
AKU O B-Disease
) O O
to O O
the O O
same O O
chromosomal O O
region O O
by O O
multipoint O O
linkage O O
analysis O O
. O O

We O O
therefore O O
conclude O O
that O O
the O O
HGO O O
cDNA O O
encodes O O
the O O
gene O O
responsible O O
for O O
alkaptonuria B-Disease B-Disease
. O O

PTEN O O
, O O
a O O
putative O O
protein O O
tyrosine O O
phosphatase O O
gene O O
mutated O O
in O O
human O O
brain B-Disease B-Disease
, I-Disease I-Disease
breast I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
prostate I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Mapping O O
of O O
homozygous O O
deletions O O
on O O
human O O
chromosome O O
10q23 O O
has O O
led O O
to O O
the O O
isolation O O
of O O
a O O
candidate O O
tumor B-Disease B-Disease
suppressor O O
gene O O
, O O
PTEN O O
, O O
that O O
appears O O
to O O
be O O
mutated O O
at O O
considerable O O
frequency O O
in O O
human O O
cancers B-Disease B-Disease
. O O

In O O
preliminary O O
screens O O
, O O
mutations O O
of O O
PTEN O O
were O O
detected O O
in O O
31 O O
% O O
( O O
13 O O
/ O O
42 O O
) O O
of O O
glioblastoma B-Disease B-Disease
cell O O
lines O O
and O O
xenografts O O
, O O
100 O O
% O O
( O O
4 O O
/ O O
4 O O
) O O
of O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
cell O O
lines O O
, O O
6 O O
% O O
( O O
4 O O
/ O O
65 O O
) O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
cell O O
lines O O
and O O
xenografts O O
, O O
and O O
17 O O
% O O
( O O
3 O O
/ O O
18 O O
) O O
of O O
primary B-Disease O
glioblastomas I-Disease B-Disease
. O O

The O O
predicted O O
PTEN O O
product O O
has O O
a O O
protein O O
tyrosine O O
phosphatase O O
domain O O
and O O
extensive O O
homology O O
to O O
tensin O O
, O O
a O O
protein O O
that O O
interacts O O
with O O
actin O O
filaments O O
at O O
focal O O
adhesions O O
. O O

These O O
homologies O O
suggest O O
that O O
PTEN O O
may O O
suppress O O
tumor B-Disease B-Disease
cell O O
growth O O
by O O
antagonizing O O
protein O O
tyrosine O O
kinases O O
and O O
may O O
regulate O O
tumor B-Disease B-Disease
cell O O
invasion O O
and O O
metastasis B-Disease B-Disease
through O O
interactions O O
at O O
focal O O
adhesions O O
.. O O

Heterogeneity O O
in O O
Schwartz B-Disease B-Disease
- I-Disease I-Disease
Jampel I-Disease I-Disease
chondrodystrophic I-Disease I-Disease
myotonia I-Disease I-Disease
. O O

The O O
Schwartz B-Disease B-Disease
- I-Disease I-Disease
Jampel I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
SJS B-Disease B-Disease
; O O
chondrodystrophic B-Disease B-Disease
myotonia I-Disease I-Disease
; O O
McK O O
255 O O
, O O
800 O O
) O O
is O O
a O O
recessively B-Disease B-Disease
inherited I-Disease I-Disease
condition I-Disease I-Disease
defined O O
by O O
myotonia B-Disease B-Disease
, O O
short B-Disease B-Disease
stature I-Disease I-Disease
, O O
and O O
bone B-Disease B-Disease
dysplasia I-Disease I-Disease
. O O

Genetic O O
linkage O O
between O O
SJS B-Disease B-Disease
and O O
chromosomal O O
region O O
1q36 O O
- O O
34 O O
has O O
been O O
observed O O
in O O
several O O
families O O
, O O
but O O
the O O
gene O O
has O O
not O O
yet O O
been O O
identified O O
. O O

We O O
studied O O
the O O
clinical O O
and O O
radiological O O
features O O
in O O
81 O O
patients O O
from O O
the O O
literature O O
and O O
5 O O
own O O
patients O O
trying O O
to O O
identify O O
distinct O O
subgroups O O
. O O

In O O
addition O O
, O O
we O O
tested O O
genetic O O
linkage O O
to O O
the O O
SJS B-Disease B-Disease
locus O O
on O O
chromosome O O
1 O O
in O O
one O O
family O O
with O O
two O O
affected O O
sibs O O
. O O

We O O
found O O
that O O
a O O
group O O
of O O
patients O O
have O O
mild O O
skeletal O O
changes O O
which O O
may O O
be O O
secondary O O
consequences O O
of O O
myotonia B-Disease B-Disease
, O O
while O O
another O O
group O O
of O O
patients O O
appear O O
to O O
have O O
primary O B-Disease
bone B-Disease I-Disease
dysplasia I-Disease I-Disease
with O O
myotonia B-Disease B-Disease
. O O

Within O O
this O O
latter O O
group O O
, O O
there O O
are O O
differences O O
in O O
age O O
of O O
manifestation O O
, O O
clinical O O
course O O
and O O
pattern O O
of O O
bone O O
changes O O
. O O

We O O
tentatively O O
isolate O O
three O O
different O O
types O O
of O O
SJS B-Disease B-Disease
type I-Disease I-Disease
1A I-Disease I-Disease
, O O
usually O O
recognized O O
in O O
childhood O O
, O O
with O O
moderate O O
bone B-Disease B-Disease
dysplasia I-Disease I-Disease
, O O
corresponding O O
to O O
the O O
original O O
descriptions O O
of O O
Schwartz O O
, O O
Jampel O O
and O O
Aberfeld O O
; O O
type O O
1B O O
, O O
similar O O
to O O
type O O
1A O O
but O O
recognizable O O
at O O
birth O O
, O O
with O O
more O O
pronounced O O
bone B-Disease B-Disease
dysplasia I-Disease I-Disease
resembling O O
Kniest B-Disease B-Disease
dysplasia I-Disease I-Disease
; O O
and O O
type O O
2 O O
, O O
manifest O O
at O O
birth O O
, O O
with O O
increased O O
mortality O O
and O O
bone B-Disease B-Disease
dysplasia I-Disease I-Disease
resembling O O
Pyle B-Disease B-Disease
disease I-Disease I-Disease
. O O

Genetic O O
analysis O O
of O O
the O O
family O O
with O O
two O O
sibs O O
affected O O
by O O
SJS B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
showed O O
evidence O O
against O O
linkage O O
to O O
chromosome O O
1p36 O O
- O O
34 O O
. O O

CONCLUSIONS O O
SJS B-Disease B-Disease
is O O
clinically O O
and O O
radiologically O O
heterogeneous O O
. O O

The O O
causes O O
of O O
heterogeneity O O
are O O
not O O
known O O
yet O O
but O O
are O O
likely O O
to O O
include O O
both O O
different O O
mutations O O
at O O
the O O
SJS B-Disease B-Disease
locus O O
on O O
chromosome O O
1 O O
and O O
the O O
presence O O
of O O
a O O
second O O
SJS B-Disease B-Disease
locus O O
. O O

A O O
tentative O O
clinico O O
- O O
radiological O O
classification O O
can O O
be O O
useful O O
for O O
the O O
characterization O O
of O O
patients O O
and O O
the O O
development O O
of O O
genotype O O
- O O
phenotype O O
correlations O O
.. O O

A O O
clinical O O
overview O O
of O O
WT1 O O
gene O O
mutations O O
. O O

Mutations O O
in O O
the O O
WT1 O O
gene O O
were O O
anticipated O O
to O O
explain O O
the O O
genetic O O
basis O O
of O O
the O O
childhood O O
kidney B-Disease B-Disease
cancer I-Disease I-Disease
, O O
Wilms B-Disease B-Disease
tumour I-Disease I-Disease
( O O
WT B-Disease B-Disease
) O O
. O O

Six O O
years O O
on O O
, O O
we O O
review O O
100 O O
reports O O
of O O
intragenic O O
WT1 O O
mutations O O
and O O
examine O O
the O O
accompanying O O
clinical O O
phenotypes O O
. O O

While O O
only O O
5 O O
% O O
of O O
sporadic B-Disease O
Wilms I-Disease B-Disease
tumours I-Disease I-Disease
have O O
intragenic O O
WT1 O O
mutations O O
, O O
> O O
90 O O
% O O
of O O
patients O O
with O O
the O O
Denys B-Disease B-Disease
- I-Disease I-Disease
Drash I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
renal B-Disease B-Disease
nephropathy I-Disease I-Disease
, O O
gonadal B-Disease B-Disease
anomaly I-Disease I-Disease
, O O
predisposition B-Disease O
to I-Disease O
WT I-Disease B-Disease
) O O
carry O O
constitutional O O
intragenic O O
WT1 O O
mutations O O
. O O

WT1 O O
mutations O O
have O O
also O O
been O O
reported O O
in O O
juvenile B-Disease B-Disease
granulosa I-Disease I-Disease
cell I-Disease I-Disease
tumour I-Disease I-Disease
, O O
non B-Disease B-Disease
- I-Disease I-Disease
asbestos I-Disease I-Disease
related I-Disease I-Disease
mesothelioma I-Disease I-Disease
, O O
desmoplastic B-Disease B-Disease
small I-Disease I-Disease
round I-Disease I-Disease
cell I-Disease I-Disease
tumour I-Disease I-Disease
and O O
, O O
most O O
recently O O
, O O
acute B-Disease B-Disease
myeloid I-Disease I-Disease
leukemia I-Disease I-Disease
.. O O

A O O
mutation O O
in O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
myotonia I-Disease I-Disease
congenita I-Disease I-Disease
affects O O
pore O O
properties O O
of O O
the O O
muscle O O
chloride O O
channel O O
. O O

Autosomal B-Disease B-Disease
dominant I-Disease I-Disease
myotonia I-Disease I-Disease
congenita I-Disease I-Disease
is O O
an O O
inherited B-Disease B-Disease
disorder I-Disease I-Disease
of I-Disease I-Disease
skeletal I-Disease I-Disease
muscle I-Disease I-Disease
caused O O
by O O
mutations O O
in O O
a O O
voltage O O
- O O
gated O O
Cl- O O
channel O O
gene O O
( O O
CLCN1 O O
, O O
7q35 O O
) O O
. O O

Here O O
, O O
we O O
report O O
that O O
a O O
mutation O O
predicting O O
the O O
substitution O O
of O O
Gly O O
230 O O
by O O
glutamic O O
acid O O
( O O
G230E O O
) O O
between O O
segments O O
D3 O O
and O O
D4 O O
dramatically O O
alters O O
the O O
pore O O
properties O O
of O O
a O O
recombinant O O
human O O
muscle O O
Cl- O O
channel O O
( O O
hCIC-1 O O
) O O
expressed O O
in O O
a O O
mammalian O O
cell O O
line O O
( O O
tsA201 O O
) O O
. O O

The O O
G230E O O
mutation O O
causes O O
substantial O O
changes O O
in O O
anion O O
and O O
cation O O
selectivity O O
as O O
well O O
as O O
a O O
fundamental O O
change O O
in O O
rectification O O
of O O
the O O
current O O
- O O
voltage O O
relationship O O
. O O

Whereas O O
wild O O
- O O
type O O
channels O O
are O O
characterized O O
by O O
pronounced O O
inward O O
rectification O O
and O O
a O O
Cl O O
> O O
thiocyanate O O
> O O
Br O O
> O O
NO O O
( O O
3 O O
) O O
> O O
I O O
> O O
CH O O
( O O
3 O O
) O O
SO O O
( O O
3 O O
) O O
selectivity O O
, O O
G230E O O
exhibits O O
outward O O
rectification O O
at O O
positive O O
potentials O O
and O O
a O O
thiocyanate O O
> O O
NO O O
( O O
3 O O
) O O
> O O

I O O
> O O
Br O O
> O O
Cl O O
> O O
CH O O
( O O
3 O O
) O O
SO O O
( O O
3 O O
) O O
selectivity O O
. O O

Furthermore O O
, O O
the O O
cation O O
- O O
to O O
- O O
anion O O
permeability O O
ratio O O
of O O
the O O
mutant O O
is O O
much O O
greater O O
than O O
that O O
of O O
the O O
wild O O
- O O
type O O
channel O O
. O O

Voltage O O
- O O
dependent O O
blocks O O
by O O
intracellular O O
and O O
extracellular O O
iodide O O
help O O
to O O
distinguish O O
two O O
distinct O O
ion O O
binding O O
sites O O
within O O
the O O
hClC-1 O O
conduction O O
pathway O O
. O O

Both O O
binding O O
sites O O
are O O
preserved O O
in O O
the O O
mutant O O
but O O
have O O
decreased O O
affinities O O
for O O
iodide O O
. O O

These O O
findings O O
suggest O O
that O O
Gly O O
230 O O
is O O
critical O O
for O O
normal O O
ion O O
conductance O O
in O O
hClC-1 O O
and O O
that O O
this O O
residue O O
resides O O
within O O
the O O
channel O O
pore O O
.. O O

The O O
incidence O O
of O O
PAX6 O O
mutation O O
in O O
patients O O
with O O
simple O O
aniridia B-Disease B-Disease
: O O
an O O
evaluation O O
of O O
mutation O O
detection O O
in O O
12 O O
cases O O
. O O

Twelve O O
aniridia B-Disease B-Disease
patients O O
, O O
five O O
with O O
a O O
family O O
history O O
and O O
seven O O
presumed O O
to O O
be O O
sporadic O O
, O O
were O O
exhaustively O O
screened O O
in O O
order O O
to O O
test O O
what O O
proportion O O
of O O
people O O
with O O
aniridia B-Disease B-Disease
, O O
uncomplicated O O
by O O
associated O O
anomalies O O
, O O
carry O O
mutations O O
in O O
the O O
human O O
PAX6 O O
gene O O
. O O

Mutations O O
were O O
detected O O
in O O
90 O O
% O O
of O O
the O O
cases O O
. O O

Three O O
mutation O O
detection O O
techniques O O
were O O
used O O
to O O
determine O O
if O O
one O O
method O O
was O O
superior O O
for O O
this O O
gene O O
. O O

The O O
protein O O
truncation O O
test O O
( O O
PTT O O
) O O
was O O
used O O
on O O
RT O O
- O O
PCR O O
products O O
, O O
SSCP O O
on O O
genomic O O
PCR O O
amplifications O O
, O O
and O O
chemical O O
cleavage O O
of O O
mismatch O O
on O O
both O O
RT O O
- O O
PCR O O
and O O
genomic O O
amplifications O O
. O O

For O O
RT O O
- O O
PCR O O
products O O
, O O
only O O
the O O
translated O O
portion O O
of O O
the O O
gene O O
was O O
screened O O
. O O

On O O
genomic O O
products O O
exons O O
1 O O
to O O
13 O O
( O O
including O O
740 O O
bp O O
of O O
the O O
3 O O
untranslated O O
sequence O O
and O O
all O O
intron O O
/ O O
exon O O
boundaries O O
) O O
were O O
screened O O
, O O
as O O
was O O
a O O
neuroretina O O
specific O O
enhancer O O
in O O
intron O O
4 O O
. O O

Ten O O
of O O
the O O
possible O O
12 O O
mutations O O
in O O
the O O
five O O
familial O O
cases O O
and O O
five O O
of O O
the O O
sporadic O O
patients O O
were O O
found O O
, O O
all O O
of O O
which O O
conformed O O
to O O
a O O
functional O O
outcome O O
of O O
haploinsufficiency O O
. O O

Five O O
were O O
splice O O
site O O
mutations O O
( O O
one O O
in O O
the O O
donor O O
site O O
of O O
intron O O
4 O O
, O O
two O O
in O O
the O O
donor O O
site O O
of O O
intron O O
6 O O
, O O
one O O
in O O
each O O
of O O
the O O
acceptor O O
sites O O
of O O
introns O O
8 O O
and O O
9 O O
) O O
and O O
five O O
were O O
nonsense O O
mutations O O
in O O
exons O O
8 O O
, O O
9 O O
, O O
10 O O
, O O
11 O O
, O O
and O O
12 O O
. O O

SSCP O O
analysis O O
of O O
individually O O
amplified O O
exons O O
, O O
with O O
which O O
nine O O
of O O
the O O
10 O O
mutations O O
were O O
seen O O
, O O
was O O
the O O
most O O
useful O O
detection O O
method O O
for O O
PAX6 O O
.. O O

Insulin O O
gene O O
region O O
contributes O O
to O O
genetic O O
susceptibility O O
to O O
, O O
but O O
may O O
not O O
to O O
low O O
incidence O O
of O O
, O O
insulin B-Disease B-Disease
- I-Disease I-Disease
dependent I-Disease I-Disease
diabetes I-Disease I-Disease
mellitus I-Disease I-Disease
in O O
Japanese O O
. O O

In O O
the O O
Caucasian O O
population O O
, O O
it O O
has O O
been O O
demonstrated O O
that O O
the O O
insulin O O
gene O O
( O O
INS O O
) O O
region O O
contains O O
the O O
insulin B-Disease B-Disease
- I-Disease I-Disease
dependent I-Disease I-Disease
diabetes I-Disease I-Disease
mellitus I-Disease I-Disease
locus O O
( O O
IDDM2 O O
) O O
. O O

In O O
the O O
Japanese O O
population O O
, O O
however O O
, O O
there O O
has O O
been O O
no O O
report O O
demonstrating O O
the O O
contribution O O
of O O
IDDM2 O O
to O O
the O O
pathogenesis O O
of O O
IDDM B-Disease B-Disease
. O O

We O O
conducted O O
an O O
association O O
study O O
of O O
IDDM B-Disease B-Disease
in O O
a O O
large O O
number O O
of O O
Japanese O O
subjects O O
with O O
multiple O O
polymorphisms O O
in O O
INS O O
region O O
. O O

We O O
found O O
a O O
significant O O
association O O
of O O
the O O
INS O O
region O O
with O O
IDDM B-Disease B-Disease
. O O

Alleles O O
positively O O
associated O O
with O O
IDDM B-Disease B-Disease
in O O
INS O O
region O O
were O O
the O O
same O O
as O O
those O O
positively O O
- O O
associated O O
with O O
IDDM B-Disease B-Disease
in O O
Caucasian O O
population O O
, O O
although O O
positively O O
- O O
associated O O
alleles O O
are O O
very O O
common O O
( O O
allele O O
frequencies O O
> O O
0 O O
. O O
9 O O
) O O
in O O
the O O
Japanese O O
general O O
population O O
. O O

These O O
data O O
suggest O O
that O O
IDDM2 O O
is O O
involved O O
in O O
the O O
genetic O O
susceptibility O O
to O O
IDDM B-Disease B-Disease
in O O
Japanese O O
. O O

The O O
high O O
frequencies O O
of O O
disease O O
- O O
associated O O
alleles O O
in O O
the O O
general O O
population O O
suggest O O
that O O
IDDM2 O O
locus O O
is O O
not O O
responsible O O
for O O
the O O
low O O
incidence O O
of O O
IDDM B-Disease B-Disease
in O O
Japanese O O
. O O

The O O
human O O
complement O O
C9 O O
gene O O
: O O
identification O O
of O O
two O O
mutations O O
causing O O
deficiency O O
and O O
revision O O
of O O
the O O
gene O O
structure O O
. O O

The O O
ninth O O
component O O
of O O
human O O
complement O O
( O O
C9 O O
) O O
is O O
the O O
last O O
of O O
the O O
terminal O O
complement O O
components O O
creating O O
the O O
membrane O O
attack O O
complex O O
. O O

C9 O O
is O O
a O O
single O O
- O O
chain O O
serum O O
protein O O
that O O
is O O
encoded O O
by O O
a O O
gene O O
located O O
on O O
chromosome O O
5p O O
. O O

Deficiency B-Disease B-Disease
of I-Disease I-Disease
terminal I-Disease I-Disease
complement I-Disease I-Disease
components I-Disease I-Disease
is O O
generally O O
associated O O
with O O
recurrent O O
neisseria B-Disease B-Disease
infections I-Disease I-Disease
. O O

We O O
studied O O
a O O
previously O O
described O O
Swiss O O
family O O
with O O
inherited B-Disease B-Disease
C9 I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

To O O
identify O O
the O O
genetic O O
basis O O
of O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
we O O
developed O O
an O O
approach O O
using O O
exon O O
- O O
specific O O
PCR O O
and O O
direct O O
DNA O O
sequencing O O
. O O

As O O
a O O
cause O O
of O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
we O O
found O O
two O O
different O O
point O O
mutations O O
, O O
both O O
generating O O
TGA O O
stop O O
codons O O
in O O
the O O
coding O O
sequence O O
. O O

One O O
mutation O O
, O O
a O O
C O O
to O O
A O O
exchange O O
, O O
was O O
detected O O
in O O
exon O O
2 O O
at O O
cDNA O O
position O O
166 O O
, O O
the O O
other O O
, O O
a O O
C O O
to O O
T O O
exchange O O
, O O
was O O
located O O
in O O
exon O O
4 O O
( O O
cDNA O O
position O O
464 O O
) O O
. O O

In O O
family O O
studies O O
of O O
three O O
first O O
- O O
degree O O
relatives O O
with O O
heterozygous O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
we O O
demonstrated O O
that O O
the O O
two O O
mutations O O
are O O
segregating O O
independently O O
. O O

Therefore O O
, O O
these O O
mutations O O
are O O
sufficient O O
to O O
explain O O
the O O
complete O O
deficiency O O
of O O
both O O
the O O
probands O O
studied O O
. O O

DNA O O
sequencing O O
of O O
the O O
exon O O
- O O
intron O O
junctions O O
revealed O O
a O O
number O O
of O O
revisions O O
regarding O O
the O O
boundaries O O
between O O
exons O O
4 O O
, O O
5 O O
, O O
and O O
6 O O
as O O
well O O
as O O
between O O
exons O O
10 O O
and O O
11 O O
. O O

No O O
additional O O
introns O O
were O O
detected O O
in O O
exons O O
6 O O
and O O
10 O O
. O O

Furthermore O O
, O O
DNA O O
marker O O
studies O O
were O O
conducted O O
using O O
known O O
polymorphisms O O
of O O
the O O
C6 O O
, O O
C7 O O
, O O
and O O
C9 O O
genes O O
, O O
confirming O O
the O O
linkage O O
of O O
the O O
observed O O
C9 O O
mutations O O
with O O
defined O O
haplotypes O O
.. O O

BRCA1 O O
mutations O O
in O O
women O O
attending O O
clinics O O
that O O
evaluate O O
the O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

BACKGROUND O O
To O O
define O O
the O O
incidence O O
of O O
BRCA1 O O
mutations O O
among O O
patients O O
seen O O
in O O
clinics O O
that O O
evaluate O O
the O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
we O O
analyzed O O
DNA O O
samples O O
from O O
women O O
seen O O
in O O
this O O
setting O O
and O O
constructed O O
probability O O
tables O O
to O O
provide O O
estimates O O
of O O
the O O
likelihood O O
of O O
finding O O
a O O
BRCA1 O O
mutation O O
in O O
individual O O
families O O
. O O

METHODS O O
Clinical O O
information O O
, O O
family O O
histories O O
, O O
and O O
blood O O
for O O
DNA O O
analysis O O
were O O
obtained O O
from O O
263 O O
women O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Conformation O O
- O O
sensitive O O
gel O O
electrophoresis O O
and O O
DNA O O
sequencing O O
were O O
used O O
to O O
identify O O
BRCA1 O O
mutations O O
. O O

RESULTS O O
BRCA1 O O
mutations O O
were O O
identified O O
in O O
16 O O
percent O O
of O O
women O O
with O O
a O O
family O O
history O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Only O O
7 O O
percent O O
of O O
women O O
from O O
families O O
with O O
a O O
history O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
but O O
not O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
had O O
BRCA1 O O
mutations O O
. O O

The O O
rates O O
were O O
higher O O
among O O
women O O
from O O
families O O
with O O
a O O
history O O
of O O
both O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Among O O
family O O
members O O
, O O
an O O
average O O
age O O
of O O
less O O
than O O
55 O O
years O O
at O O
the O O
diagnosis O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
the O O
presence O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
, O O
the O O
presence O O
of O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
in O O
the O O
same O O
woman O O
, O O
and O O
Ashkenazi O O
Jewish O O
ancestry O O
were O O
all O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
detecting O O
a O O
BRCA1 O O
mutation O O
. O O

No O O
association O O
was O O
found O O
between O O
the O O
presence O O
of O O
bilateral O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
or O O
the O O
number O O
of O O
breast B-Disease B-Disease
cancers I-Disease I-Disease
in O O
a O O
family O O
and O O
the O O
detection O O
of O O
a O O
BRCA1 O O
mutation O O
, O O
or O O
between O O
the O O
position O O
of O O
the O O
mutation O O
in O O
the O O
BRCA1 O O
gene O O
and O O
the O O
presence O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
in O O
a O O
family O O
. O O

CONCLUSIONS O O
Among O O
women O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
and O O
a O O
family O O
history O O
of O O
the O O
disease O O
, O O
the O O
percentage O O
with O O
BRCA1 O O
coding O O
- O O
region O O
mutations O O
is O O
less O O
than O O
the O O
45 O O
percent O O
predicted O O
by O O
genetic O O
- O O
linkage O O
analysis O O
. O O

These O O
results O O
suggest O O
that O O
even O O
in O O
a O O
referral O O
clinic O O
specializing O O
in O O
screening O O
women O O
from O O
high O O
- O O
risk O O
families O O
, O O
the O O
majority O O
of O O
tests O O
for O O
BRCA1 O O
mutations O O
will O O
be O O
negative O O
and O O
therefore O O
uninformative O O
.. O O

Mutations O O
in O O
the O O
arginine O O
- O O
rich O O
protein O O
gene O O
( O O
ARP O O
) O O
in O O
pancreatic B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
ARP O O
gene O O
encodes O O
a O O
highly O O
conserved O O
arginine O O
- O O
rich O O
protein O O
from O O
chromosomal O O
band O O
3p21 O O
. O O

1 O O
1 O O
. O O

At O O
the O O
cytogenetic O O
level O O
this O O
region O O
is O O
frequently O O
deleted O O
in O O
a O O
variety O O
of O O
different O O
solid B-Disease B-Disease
tumors I-Disease I-Disease
, O O
although O O
not O O
in O O
pancreatic B-Disease B-Disease
cancer I-Disease I-Disease
. O O

We O O
have O O
reported O O
the O O
presence O O
of O O
a O O
specific O O
mutation O O
( O O
ATG50 O O
- O O
- O O
> O O
AGG O O
) O O
or O O
deletion O O
of O O
codon O O
50 O O
of O O
the O O
ARP O O
gene O O
in O O
different O O
tumor B-Disease B-Disease
types I-Disease O
( O O
Shridhar O O
et O O
al. O O
, O O
1996 O O
, O O
1996a O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
observed O O
mutations O O
involving O O
codon O O
50 O O
in O O
11 O O
of O O
37 O O
pancreatic B-Disease B-Disease
tumors I-Disease I-Disease
. O O

The O O
frequency O O
of O O
codon O O
50 O O
mutation O O
is O O
roughly O O
the O O
same O O
in O O
pancreatic B-Disease B-Disease
tumors I-Disease I-Disease
as O O
in O O
the O O
other O O
types O O
of O O
tumors B-Disease B-Disease
previously O O
examined O O
. O O

In O O
addition O O
, O O
we O O
have O O
detected O O
mutations O O
at O O
codon O O
51 O O
in O O
multiple O O
PCR O O
subclones O O
in O O
two O O
other O O
pancreatic B-Disease B-Disease
tumors I-Disease I-Disease
. O O

Mutations O O
in O O
the O O
ARP O O
gene O O
are O O
thus O O
commonly O O
observed O O
in O O
pancreatic B-Disease B-Disease
cancer I-Disease I-Disease
, O O
as O O
well O O
as O O
many O O
other O O
cancers B-Disease B-Disease
. O O

Difficulties O O
in O O
the O O
ascertainment O O
of O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
: O O
lessons O O
to O O
be O O
drawn O O
from O O
a O O
compound O O
heterozygote O O
C9-deficient B-Disease B-Disease
subject O O
. O O

A O O
group O O
of O O
patients O O
with O O
long O O
- O O
surviving O O
mismatched O O
kidney O O
allografts O O
were O O
investigated O O
for O O
complement O O
function O O
using O O
haemolytic O O
assays O O
in O O
agarose O O
gels O O
. O O

One O O
patient O O
was O O
found O O
to O O
have O O
no O O
alternative O O
pathway O O
activity O O
but O O
a O O
low O O
normal O O
classical O O
pathway O O
. O O

Surprisingly O O
, O O
investigation O O
revealed O O
that O O
the O O
patients O O
complement O O
was O O
normal O O
for O O
all O O
components O O
except O O
C9 O O
, O O
which O O
was O O
functionally O O
absent O O
. O O

The O O
patient O O
was O O
shown O O
to O O
be O O
heterozygous O O
for O O
DNA O O
markers O O
in O O
the O O
C6 O O
, O O
C7 O O
and O O
C9 O O
region O O
of O O
chromosome O O
5 O O
and O O
therefore O O
appears O O
to O O
be O O
a O O
compound O O
heterozygote O O
for O O
two O O
uncharacterized O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
genes O O
. O O

Serological O O
analysis O O
by O O
ELISA O O
revealed O O
that O O
he O O
has O O
trace O O
concentrations O O
of O O
a O O
non O O
- O O
functional O O
C9 O O
molecule O O
. O O

Western O O
blot O O
analysis O O
was O O
not O O
sufficiently O O
sensitive O O
to O O
permit O O
detection O O
of O O
this O O
molecule O O
. O O

We O O
hypothesize O O
that O O
the O O
patient O O
is O O
heterozygous O O
for O O
a O O
complete B-Disease O
deficiency I-Disease B-Disease
of I-Disease I-Disease
C9 I-Disease I-Disease
and O O
for O O
a O O
gene O O
directing O O
hyposynthesis O O
of O O
a O O
defective O O
C9 O O
. O O

We O O
also O O
suggest O O
that O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
may O O
be O O
more O O
common O O
among O O
Caucasians O O
than O O
has O O
been O O
reported O O
.. O O

Screening O O
for O O
ESR O O
mutations O O
in O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
patients O O
. O O

In O O
the O O
present O O
study O O
, O O
leukocyte O O
DNA O O
from O O
143 O O
patients O O
with O O
familial O O
clustering O O
of O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
and O O
tumour B-Disease B-Disease
DNA O O
from O O
96 O O
breast B-Disease B-Disease
carcinomas I-Disease I-Disease
were O O
screened O O
for O O
base O O
mutations O O
in O O
the O O
estrogen O O
receptor O O
gene O O
( O O
ESR O O
) O O
. O O

Three O O
patients O O
with O O
a O O
family O O
history O O
of O O
cancer B-Disease B-Disease
were O O
carrying O O
a O O
Gly160Cys O O
germline O O
substitution O O
. O O

This O O
alteration O O
was O O
also O O
detected O O
in O O
eight O O
( O O
four O O
females O O
and O O
four O O
males O O
) O O
of O O
729 O O
controls O O
( O O
366 O O
female O O
, O O
363 O O
males O O
) O O
, O O
indicating O O
that O O
the O O
substitution O O
probably O O
represents O O
a O O
polymorphism O O
. O O

However O O
, O O
in O O
the O O
229 O O
female O O
controls O O
in O O
whom O O
family O O
history O O
of O O
cancer B-Disease B-Disease
was O O
known O O
, O O
one O O
of O O
two O O
who O O
had O O
a O O
sister O O
with O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
was O O
carrying O O
the O O
variant O O
allele O O
. O O

Hence O O
, O O
a O O
possible O O
clinical O O
significance O O
of O O
the O O
glycine O O
into O O
cysteine O O
can O O
not O O
be O O
completely O O
ruled O O
out O O
and O O
should O O
be O O
further O O
investigated O O
. O O

Somatic O O
mutations O O
were O O
not O O
detected O O
in O O
any O O
of O O
the O O
tumours B-Disease B-Disease
studied O O
, O O
and O O
the O O
present O O
data O O
do O O
not O O
provide O O
support O O
for O O
somatic O O
ESR O O
base O O
mutations O O
as O O
an O O
important O O
mechanism O O
for O O
hormonal O O
therapy O O
resistance O O
in O O
estrogen B-Disease O
receptor I-Disease O
- I-Disease O
positive I-Disease O
breast I-Disease B-Disease
carcinomas I-Disease I-Disease
.. O O

Molecular O O
bases O O
of O O
C7 B-Disease B-Disease
deficiency I-Disease I-Disease
: O O
three O O
different O O
defects O O
. O O

The O O
molecular O O
basis O O
of O O
C7 B-Disease B-Disease
deficiency I-Disease I-Disease
has O O
been O O
investigated O O
in O O
two O O
Irish O O
families O O
and O O
a O O
number O O
of O O
Israeli O O
families O O
of O O
Moroccan O O
Sephardic O O
Jewish O O
origin O O
. O O

Exon O O
PCR O O
and O O
sequencing O O
revealed O O
a O O
heterozygous O O
point O O
mutation O O
at O O
the O O
3 O O
splice O O
acceptor O O
site O O
of O O
intron O O
1 O O
in O O
one O O
Irish O O
family O O
. O O

In O O
the O O
other O O
Irish O O
family O O
, O O
exons O O
7 O O
and O O
8 O O
failed O O
to O O
amplify O O
and O O
they O O
were O O
shown O O
to O O
be O O
deleted O O
. O O

Marker O O
haplotype O O
studies O O
of O O
the O O
C6 O O
and O O
C7 O O
gene O O
region O O
and O O
Southern O O
blots O O
show O O
that O O
the O O
Irish O O
family O O
with O O
the O O
splice O O
defect O O
also O O
segregate O O
for O O
the O O
deletion O O
, O O
which O O
is O O
not O O
easily O O
detected O O
in O O
heterozygotes O O
. O O

The O O
Israeli O O
C7-deficient B-Disease B-Disease
cases O O
all O O
share O O
a O O
C7 O O
haplotype O O
and O O
are O O
homozygous O O
for O O
a O O
mis O O
- O O
sense O O
mutation O O
in O O
exon O O
9 O O
. O O

However O O
, O O
one O O
individual O O
is O O
heterozygous O O
for O O
markers O O
at O O
adjacent O O
C6 O O
loci O O
, O O
showing O O
that O O
there O O
has O O
been O O
an O O
intergenic O O
recombination O O
and O O
suggesting O O
that O O
the O O
deficiency O O
mutation O O
is O O
of O O
appreciable O O
antiquity O O
.. O O

Molecular O O
heterogeneity O O
of O O
classical B-Disease B-Disease
and I-Disease I-Disease
Duarte I-Disease I-Disease
galactosemia I-Disease I-Disease
: O O
mutation O O
analysis O O
by O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
. O O

Classical B-Disease B-Disease
galactosemia I-Disease I-Disease
is O O
caused O O
by O O
one O O
common O O
missense O O
mutation O O
( O O
Q188R O O
) O O
and O O
by O O
several O O
rare O O
mutations O O
in O O
the O O
galactose-1-phosphate O O
uridyltransferase O O
( O O
GALT O O
) O O
gene O O
. O O

The O O
most O O
common O O
variant O O
of O O
GALT O O
, O O
the O O
Duarte O O
variant O O
, O O
occurs O O
as O O
two O O
types O O
, O O
Duarte-1 O O
( O O
D-1 O O
) O O
and O O
Duarte-2 O O
( O O
D-2 O O
) O O
, O O
both O O
of O O
which O O
carry O O
the O O
sequence O O
change O O
N314D O O
. O O

D-1 O O
increases O O
, O O
whereas O O
D-2 O O
decreases O O
GALT O O
activity O O
. O O

To O O
study O O
the O O
molecular O O
genetics O O
of O O
classical B-Disease B-Disease
and I-Disease I-Disease
Duarte I-Disease I-Disease
galactosemia I-Disease I-Disease
, O O
we O O
analyzed O O
the O O
GALT O O
mutations O O
in O O
30 O O
families O O
with O O
classical B-Disease B-Disease
galactosemia I-Disease I-Disease
, O O
in O O
10 O O
families O O
with O O
the O O
D-2 O O
variant O O
and O O
in O O
3 O O
individuals O O
carrying O O
the O O
D-1 O O
allele O O
by O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
. O O

DGGE O O
detected O O
59 O O
of O O
the O O
60 O O
classical O O
galactosemia B-Disease B-Disease
alleles O O
. O O

Q188R O O
accounted O O
for O O
60 O O
% O O
, O O
K285N O O
accounted O O
for O O
28 O O
% O O
of O O
these O O
alleles O O
. O O

Eight O O
novel O O
candidate O O
galactosemia B-Disease B-Disease
mutations O O
were O O
found O O
. O O

On O O
all O O
D-2 O O
alleles O O
N314D O O
occurred O O
in O O
cis O O
with O O
two O O
intronic O O
sequence O O
changes O O
, O O
on O O
the O O
D-1 O O
alleles O O
in O O
cis O O
with O O
a O O
neutral O O
mutation O O
in O O
exon O O
7 O O
. O O

We O O
conclude O O
that O O
the O O
mutations O O
causing O O
galactosemia B-Disease B-Disease
are O O
highly O O
heterogeneous O O
and O O
that O O
K285N O O
is O O
a O O
second O O
common O O
galactosemia B-Disease B-Disease
mutation O O
in O O
our O O
population O O
.. O O

Isolation O O
of O O
full O O
- O O
length O O
ATM O O
cDNA O O
and O O
correction O O
of O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
cellular O O
phenotype O O
. O O

A O O
gene O O
mutated O O
in O O
the O O
human O O
genetic B-Disease B-Disease
disorder I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
, O O
ATM O O
, O O
was O O
recently O O
identified O O
by O O
positional O O
cloning O O
. O O

ATM O O
is O O
a O O
member O O
of O O
the O O
phosphatidylinositol-3-kinase O O
superfamily O O
, O O
some O O
of O O
which O O
are O O
protein O O
kinases O O
and O O
appear O O
to O O
have O O
important O O
roles O O
in O O
cell O O
cycle O O
control O O
and O O
radiation O O
signal O O
transduction O O
. O O

We O O
describe O O
herein O O
, O O
to O O
our O O
knowledge O O
, O O
for O O
the O O
first O O
time O O
, O O
the O O
cloning O O
of O O
a O O
full O O
- O O
length O O
cDNA O O
for O O
ATM O O
and O O
correction O O
of O O
multiple O O
aspects O O
of O O
the O O
radio O O
- O O
sensitive O O
phenotype O O
of O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
cells O O
by O O
transfection O O
with O O
this O O
cDNA O O
. O O

Overexpression O O
of O O
ATM O O
cDNA O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
cells O O
enhanced O O
the O O
survival O O
of O O
these O O
cells O O
in O O
response O O
to O O
radiation O O
exposure O O
, O O
decreased O O
radiation O O
- O O
induced O O
chromosome O O
aberrations O O
, O O
reduced O O
radio O O
- O O
resistant O O
DNA O O
synthesis O O
, O O
and O O
partially O O
corrected O O
defective O O
cell O O
cycle O O
checkpoints O O
and O O
induction O O
of O O
stress O O
- O O
activated O O
protein O O
kinase O O
. O O

This O O
correction O O
of O O
the O O
defects O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
cells O O
provides O O
further O O
evidence O O
of O O
the O O
multiplicity O O
of O O
effector O O
functions O O
of O O
the O O
ATM O O
protein O O
and O O
suggests O O
possible O O
approaches O O
to O O
gene O O
therapy O O
.. O O

Fusion O O
genes O O
resulting O O
from O O
alternative O O
chromosomal O O
translocations O O
are O O
overexpressed O O
by O O
gene O O
- O O
specific O O
mechanisms O O
in O O
alveolar B-Disease B-Disease
rhabdomyosarcoma I-Disease I-Disease
. O O

Chromosomal O O
translocations O O
identified O O
in O O
hematopoietic B-Disease B-Disease
and I-Disease I-Disease
solid I-Disease I-Disease
tumors I-Disease I-Disease
result O O
in O O
deregulated O O
expression O O
of O O
protooncogenes O O
or O O
creation O O
of O O
chimeric O O
proteins O O
with O O
tumorigenic O O
potential O O
. O O

In O O
the O O
pediatric O O
solid B-Disease B-Disease
tumor I-Disease I-Disease
alveolar B-Disease B-Disease
rhabdomyosarcoma I-Disease I-Disease
, O O
a O O
consistent O O
t O O
( O O
2 O O
; O O
13 O O
) O O
( O O
q35 O O
; O O
q14 O O
) O O
or O O
variant O O
t O O
( O O
1 O O
; O O
13 O O
) O O
( O O
p36 O O
; O O
q14 O O
) O O
translocation O O
generates O O
PAX3-FKHR O O
or O O
PAX7-FKHR O O
fusion O O
proteins O O
, O O
respectively O O
. O O

In O O
this O O
report O O
, O O
we O O
demonstrate O O
that O O
in O O
addition O O
to O O
functional O O
alterations O O
these O O
translocations O O
are O O
associated O O
with O O
fusion O O
product O O
overexpression O O
. O O

Furthermore O O
, O O
PAX3-FKHR O O
and O O
PAX7-FKHR O O
overexpression O O
occurs O O
by O O
distinct O O
mechanisms O O
. O O

Transcription O O
of O O
PAX3-FKHR O O
is O O
increased O O
relative O O
to O O
wild O O
- O O
type O O
PAX3 O O
by O O
a O O
copy O O
number O O
- O O
independent O O
process O O
. O O

In O O
contrast O O
, O O
PAX7-FKHR O O
overexpression O O
results O O
from O O
fusion O O
gene O O
amplification O O
. O O

Thus O O
, O O
gene O O
- O O
specific O O
mechanisms O O
were O O
selected O O
to O O
overexpress O O
PAX3-FKHR O O
and O O
PAX7-FKHR O O
in O O
alveolar B-Disease B-Disease
rhabdomyosarcoma I-Disease I-Disease
, O O
presumably O O
due O O
to O O
differences O O
in O O
regulation O O
between O O
the O O
wild O O
- O O
type O O
loci O O
. O O

We O O
postulate O O
that O O
these O O
overexpression O O
mechanisms O O
ensure O O
a O O
critical O O
level O O
of O O
gene O O
product O O
for O O
the O O
oncogenic O O
effects O O
of O O
these O O
fusions O O
.. O O

atm O O
and O O
p53 O O
cooperate O O
in O O
apoptosis O O
and O O
suppression O O
of O O
tumorigenesis O O
, O O
but O O
not O O
in O O
resistance O O
to O O
acute B-Disease B-Disease
radiation I-Disease I-Disease
toxicity I-Disease I-Disease
. O O

Mutations O O
in O O
atm O O
and O O
p53 O O
cause O O
the O O
human O O
cancer B-Disease B-Disease
- I-Disease I-Disease
associated I-Disease I-Disease
diseases I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
and O O
Li B-Disease B-Disease
- I-Disease I-Disease
Fraumeni I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
respectively O O
. O O

The O O
two O O
genes O O
are O O
believed O O
to O O
interact O O
in O O
a O O
number O O
of O O
pathways O O
, O O
including O O
regulation O O
of O O
DNA O O
damage O O
- O O
induced O O
cell O O
- O O
cycle O O
checkpoints O O
, O O
apoptosis O O
and O O
radiation O O
sensitivity O O
, O O
and O O
cellular O O
proliferation O O
. O O

Atm O O
- O O
null O O
mice O O
, O O
as O O
well O O
as O O
those O O
null O O
for O O
p53 O O
, O O
develop O O
mainly O O
T B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
lymphomas I-Disease I-Disease
, O O
supporting O O
the O O
view O O
that O O
these O O
genes O O
have O O
similar O O
roles O O
in O O
thymocyte O O
development O O
. O O

To O O
study O O
the O O
interactions O O
of O O
these O O
two O O
genes O O
on O O
an O O
organismal O O
level O O
, O O
we O O
bred O O
mice O O
heterozygous O O
for O O
null O O
alleles O O
of O O
both O O
atm O O
and O O
p53 O O
to O O
produce O O
all O O
genotypic O O
combinations O O
. O O

Mice O O
doubly O O
null O O
for O O
atm O O
and O O
p53 O O
exhibited O O
a O O
dramatic O O
acceleration O O
of O O
tumour B-Disease B-Disease
formation O O
relative O O
to O O
singly O O
null O O
mice O O
, O O
indicating O O
that O O
both O O
genes O O
collaborate O O
in O O
a O O
significant O O
manner O O
to O O
prevent O O
tumorigenesis O O
. O O

With O O
respect O O
to O O
their O O
roles O O
in O O
apoptosis O O
, O O
loss O O
of O O
atm O O
rendered O O
thymocytes O O
only O O
partly O O
resistant O O
to O O
irradiation O O
- O O
induced O O
apoptosis O O
, O O
whereas O O
additional O O
loss O O
of O O
p53 O O
engendered O O
complete O O
resistance O O
. O O

This O O
implies O O
that O O
the O O
irradiation O O
- O O
induced O O
atm O O
and O O
p53 O O
apoptotic O O
pathways O O
are O O
not O O
completely O O
congruent O O
. O O

Finally O O
- O O
and O O
in O O
contrast O O
to O O
prior O O
predictions O O
- O O
atm O O
and O O
p53 O O
do O O
not O O
appear O O
to O O
interact O O
in O O
acute B-Disease B-Disease
radiation I-Disease I-Disease
toxicity I-Disease I-Disease
, O O
suggesting O O
a O O
separate O O
atm O O
effector O O
pathway O O
for O O
this O O
DNA O O
damage O O
response O O
and O O
having O O
implications O O
for O O
the O O
prognosis O O
and O O
treatment O O
of O O
human O O
tumours B-Disease B-Disease
.. O O

Trinucleotide O O
repeat O O
expansion O O
at O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
locus O O
reduces O O
expression O O
of O O
DMAHP O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
, O O
or O O
dystrophia B-Disease B-Disease
myotonica I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
, O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
multisystem I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
the O O
expansion O O
of O O
a O O
CTG O O
trinucleotide O O
repeat O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
the O O
DMPK O O
protein O O
kinase O O
gene O O
on O O
chromosome O O
19q13 O O
. O O

3 O O
( O O
refs O O
1 O O
- O O
3 O O
) O O
. O O

Although O O
the O O
DM B-Disease B-Disease
mutation O O
was O O
identified O O
more O O
than O O
five O O
years O O
ago O O
, O O
the O O
pathogenic O O
mechanisms O O
underlying O O
this O O
most O O
prevalent O O
form O O
of O O
hereditary O B-Disease
adult O I-Disease
neuromuscular B-Disease I-Disease
disease I-Disease I-Disease
remain O O
elusive O O
. O O

Previous O O
work O O
from O O
our O O
laboratory O O
demonstrated O O
that O O
a O O
DNase O O
l O O
- O O
hypersensitive O O
site O O
located O O
adjacent O O
to O O
the O O
repeats O O
on O O
the O O
wild O O
- O O
type O O
allele O O
is O O
eliminated O O
by O O
repeat O O
expansion O O
, O O
indicating O O
that O O
large O O
CTG O O
- O O
repeat O O
arrays O O
may O O
be O O
associated O O
with O O
a O O
local O O
chromatin O O
environment O O
that O O
represses O O
gene O O
expression O O
. O O

Here O O
we O O
report O O
that O O
the O O
hypersensitive O O
site O O
contains O O
an O O
enhancer O O
element O O
that O O
regulates O O
transcription O O
of O O
the O O
adjacent O O
DMAHP O O
homeobox O O
gene O O
. O O

Analysis O O
of O O
DMAHP O O
expression O O
in O O
the O O
cells O O
of O O
DM B-Disease B-Disease
patients O O
with O O
loss O O
of O O
the O O
hypersensitive O O
site O O
revealed O O
a O O
two- O O
to O O
fourfold O O
reduction O O
in O O
steady O O
- O O
state O O
DMAHP O O
transcript O O
levels O O
relative O O
to O O
wild O O
- O O
type O O
controls O O
. O O

Allele O O
- O O
specific O O
analysis O O
of O O
DMAHP O O
expression O O
showed O O
that O O
steady O O
- O O
state O O
transcript O O
levels O O
from O O
the O O
expanded O O
allele O O
were O O
greatly O O
reduced O O
in O O
comparison O O
to O O
those O O
from O O
the O O
wild O O
- O O
type O O
allele O O
. O O

Together O O
, O O
these O O
results O O
demonstrate O O
that O O
CTG O O
- O O
repeat O O
expansions O O
can O O
suppress O O
local O O
gene O O
expression O O
and O O
implicate O O
DMAHP O O
in O O
DM B-Disease B-Disease
pathogenesis O O
. O O

Constitutively O O
methylated O O
CpG O O
dinucleotides O O
as O O
mutation O O
hot O O
spots O O
in O O
the O O
retinoblastoma B-Disease B-Disease
gene O O
( O O
RB1 O O
) O O
. O O

A O O
wide O O
spectrum O O
of O O
mutations O O
, O O
ranging O O
from O O
point O O
mutations O O
to O O
large O O
deletions O O
, O O
have O O
been O O
described O O
in O O
the O O
retinoblastoma B-Disease B-Disease
gene O O
( O O
RB1 O O
) O O
. O O

Mutations O O
have O O
been O O
found O O
throughout O O
the O O
gene O O
; O O
however O O
, O O
these O O
genetic O O
alterations O O
do O O
not O O
appear O O
to O O
be O O
homogeneously O O
distributed O O
. O O

In O O
particular O O
, O O
a O O
significant O O
proportion O O
of O O
disease O O
- O O
causing O O
mutations O O
results O O
in O O
the O O
premature O O
termination O O
of O O
protein O O
synthesis O O
, O O
and O O
the O O
majority O O
of O O
these O O
mutations O O
occur O O
as O O
C-- O O
> O O
T O O
transitions O O
at O O
CpG O O
dinucleotides O O
( O O
CpGs O O
) O O
. O O

Such O O
recurrent O O
CpG O O
mutations O O
, O O
including O O
those O O
found O O
in O O
RB1 O O
, O O
are O O
likely O O
the O O
result O O
of O O
the O O
deamination O O
of O O
5-methylcytosine O O
within O O
these O O
CpGs O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
used O O
the O O
sodiumbisulfite O O
conversion O O
method O O
to O O
detect O O
cytosine O O
methylation O O
in O O
representative O O
exons O O
of O O
RB1 O O
. O O

We O O
analyzed O O
DNA O O
from O O
a O O
variety O O
of O O
tissues O O
and O O
specifically O O
targeted O O
CGA O O
codons O O
in O O
RB1 O O
, O O
where O O
recurrent O O
premature O O
termination O O
mutations O O
have O O
been O O
reported O O
. O O

We O O
found O O
that O O
DNA O O
methylation O O
within O O
RB1 O O
exons O O
8 O O
, O O
14 O O
, O O
25 O O
, O O
and O O
27 O O
appeared O O
to O O
be O O
restricted O O
to O O
CpGs O O
, O O
including O O
six O O
CGA O O
codons O O
. O O

Other O O
codons O O
containing O O
methylated O O
cytosines O O
have O O
not O O
been O O
reported O O
to O O
be O O
mutated O O
. O O

Therefore O O
, O O
disease O O
- O O
causing O O
mutations O O
at O O
CpGs O O
in O O
RB1 O O
appear O O
to O O
be O O
determined O O
by O O
several O O
factors O O
, O O
including O O
the O O
constitutive O O
presence O O
of O O
DNA O O
methylation O O
at O O
cytosines O O
within O O
CpGs O O
, O O
the O O
specific O O
codon O O
within O O
which O O
the O O
methylated O O
cytosine O O
is O O
located O O
, O O
and O O
the O O
particular O O
region O O
of O O
the O O
gene O O
within O O
which O O
that O O
codon O O
resides O O
.. O O

The O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
tumor I-Disease I-Disease
suppressor O O
gene O O
product O O
interacts O O
with O O
Sp1 O O
to O O
repress O O
vascular O O
endothelial O O
growth O O
factor O O
promoter O O
activity O O
. O O

The O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
tumor I-Disease I-Disease
suppressor O O
gene O O
( O O
VHL O B-Disease
) O O
has O O
a O O
critical O O
role O O
in O O
the O O
pathogenesis O O
of O O
clear B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
( O O
RCC B-Disease B-Disease
) O O
, O O
as O O
VHL O B-Disease
mutations O O
have O O
been O O
found O O
in O O
both O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
disease I-Disease I-Disease
- I-Disease O
associated I-Disease O
and I-Disease O
sporadic I-Disease B-Disease
RCCs I-Disease I-Disease
. O O

Recent O O
studies O O
suggest O O
that O O
vascular O O
endothelial O O
growth O O
factor O O
( O O
VEGF O O
) O O
mRNA O O
is O O
upregulated O O
in O O
RCC- B-Disease B-Disease
and I-Disease O
von I-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
disease I-Disease I-Disease
- I-Disease O
associated I-Disease O
tumors I-Disease B-Disease
. O O

We O O
have O O
therefore O O
assessed O O
the O O
effect O O
of O O
the O O
VHL O B-Disease
gene O O
product O O
on O O
VEGF O O
expression O O
. O O

VEGF O O
promoter O O
- O O
luciferase O O
constructs O O
were O O
transiently O O
cotransfected O O
with O O
a O O
wild O O
- O O
type O O
VHL O O
( O O
wt O O
- O O
VHL O O
) O O
vector O O
in O O
several O O
cell O O
lines O O
, O O
including O O
293 O O
embryonic O O
kidney O O
and O O
RCC B-Disease B-Disease
cell O O
lines O O
. O O

wt O O
- O O
VHL O B-Disease
protein O O
inhibited O O
VEGF O O
promoter O O
activity O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
up O O
to O O
5- O O
to O O
10-fold O O
. O O

Deletion O O
analysis O O
defined O O
a O O
144-bp O O
region O O
of O O
the O O
VEGF O O
promoter O O
necessary O O
for O O
VHL O B-Disease
repression O O
. O O

This O O
VHL O O
- O O
responsive O O
element O O
is O O
GC O O
rich O O
and O O
specifically O O
binds O O
the O O
transcription O O
factor O O
Sp1 O O
in O O
crude O O
nuclear O O
extracts O O
. O O

In O O
Drosophila O O
cells O O
, O O
cotransfected O O
VHL O B-Disease
represses O O
Sp1-mediated O O
activation O O
but O O
not O O
basal O O
activity O O
of O O
the O O
VEGF O O
promoter O O
. O O

We O O
next O O
demonstrated O O
in O O
coimmunoprecipitates O O
that O O
VHL O B-Disease
and O O
Sp1 O O
were O O
part O O
of O O
the O O
same O O
complex O O
and O O
, O O
by O O
using O O
a O O
glutathione O O
- O O
S O O
- O O
transferase O O
- O O
VHL O O
fusion O O
protein O O
and O O
purified O O
Sp1 O O
, O O
that O O
VHL O O
and O O
Sp1 O O
directly O O
interact O O
. O O

Furthermore O O
, O O
endogenous O O
VEGF O O
mRNA O O
levels O O
were O O
suppressed O O
in O O
permanent O O
RCC B-Disease B-Disease
cell O O
lines O O
expressing O O
wt O O
- O O
VHL O O
, O O
and O O
nuclear O O
run O O
- O O
on O O
studies O O
indicated O O
that O O
VHL O B-Disease
regulation O O
of O O
VEGF O O
occurs O O
at O O
least O O
partly O O
at O O
the O O
transcriptional O O
level O O
. O O

These O O
observations O O
support O O
a O O
new O O
mechanism O O
for O O
VHL O O
- O O
mediated O O
transcriptional O O
repression O O
via O O
a O O
direct O O
inhibitory O O
action O O
on O O
Sp1 O O
and O O
suggest O O
that O O
loss O O
of O O
Sp1 O O
inhibition O O
may O O
be O O
important O O
in O O
the O O
pathogenesis O O
of O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
disease I-Disease I-Disease
and O O
RCC B-Disease B-Disease
.. O O

Adult B-Disease O
onset I-Disease O
globoid I-Disease B-Disease
cell I-Disease I-Disease
leukodystrophy I-Disease I-Disease
( O O
Krabbe B-Disease B-Disease
disease I-Disease I-Disease
) O O
: O O
analysis O O
of O O
galactosylceramidase O O
cDNA O O
from O O
four O O
Japanese O O
patients O O
. O O

We O O
examined O O
galactosylceramidase O O
( O O
GALC O O
) O O
cDNA O O
in O O
four O O
Japanese O O
patients O O
with O O
adult B-Disease O
onset I-Disease O
globoid I-Disease B-Disease
cell I-Disease I-Disease
leukodystrophy I-Disease I-Disease
( O O
Krabbe B-Disease B-Disease
disease I-Disease I-Disease
; O O
AO B-Disease B-Disease
- I-Disease I-Disease
GLD I-Disease I-Disease
) O O
by O O
polymerase O O
chain O O
reaction O O
/ O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
( O O
PCR O O
- O O
SSCP O O
) O O
analysis O O
, O O
subsequent O O
sequence O O
determination O O
, O O
and O O
restriction O O
enzyme O O
digestion O O
of O O
PCR O O
products O O
, O O
initial O O
symptoms O O
were O O
the O O
onset O O
of O O
slowly O O
progressive O O
spastic B-Disease B-Disease
paraplegia I-Disease I-Disease
from O O
the O O
middle O O
of O O
the O O
second O O
decade O O
, O O
and O O
all O O
patients O O
had O O
diminished B-Disease O
GALC I-Disease O
activity I-Disease O
in O O
their O O
leukocytes O O
. O O

We O O
identified O O
three O O
missense O O
mutations O O
( O O
I66 O O
M O O
, O O
G270D O O
, O O
L618S O O
) O O
and O O
one O O
exon-6 O O
skipping O O
( O O
535 O O
- O O
573del O O
) O O
. O O

Two O O
of O O
the O O
patients O O
had O O
only O O
the O O
I66 O O
M O O
mutant O O
mRNA O O
, O O
and O O
one O O
only O O
the O O
G27OD O O
mutant O O
mRNA O O
. O O

The O O
fourth O O
patient O O
carried O O
a O O
compound O O
heterozygous O O
mutation O O
of O O
535 O O
- O O
573del O O
and O O
L618S O O
. O O

To O O
determine O O
the O O
enzymatic O O
activities O O
produced O O
by O O
these O O
mutations O O
, O O
we O O
constructed O O
mutated O O
GALC O O
cDNAs O O
and O O
expressed O O
them O O
in O O
COS-1 O O
cells O O
. O O

Three O O
mutations O O
, O O
viz O O
. O O
, O O
G270D O O
, O O
L618S O O
, O O
and O O
exon-6 O O
skipping O O
( O O
535 O O
- O O
573del O O
) O O
, O O
produced O O
diminished B-Disease O
GALC I-Disease O
activity I-Disease O
as O O
expected O O
. O O

The O O
I66 O O
M O O
mutation O O
in O O
the O O
wild O O
- O O
type O O
GALC O O
cDNA O O
( O O
I289 O O
) O O
had O O
normal O O
activity O O
, O O
but O O
when O O
this O O
mutation O O
and O O
the O O
V289 O O
polymorphism O O
were O O
introduced O O
into O O
the O O
same O O
allele O O
, O O
it O O
had O O
decreased O O
activity O O
. O O

Thus O O
, O O
the O O
combination O O
of O O
a O O
unique O O
mutation O O
and O O
polymorphism O O
causes O O
conformational O O
change O O
in O O
the O O
GALC O O
enzyme O O
, O O
resulting O O
in O O
low O O
enzymatic O O
activity O O
. O O

AO B-Disease B-Disease
- I-Disease I-Disease
GLD I-Disease I-Disease
mutations O O
, O O
including O O
those O O
found O O
here O O
, O O
are O O
located O O
in O O
the O O
N O O
- O O
terminus O O
( O O
I66 O O
M O O
, O O
G270D O O
, O O
535 O O
- O O
573del O O
) O O
or O O
C O O
- O O
terminus O O
( O O
L618S O O
) O O
of O O
the O O
GALC O O
enzyme O O
, O O
whereas O O
the O O
reported O O
mutations O O
in O O
the O O
infantile O O
form O O
( O O
IF B-Disease B-Disease
- I-Disease I-Disease
GLD I-Disease I-Disease
) O O
are O O
in O O
the O O
central O O
domain O O
. O O

This O O
difference O O
in O O
mutation O O
sites O O
may O O
affect O O
the O O
clinical O O
features O O
of O O
GLD B-Disease B-Disease
. O O

Clustering O O
of O O
missense O O
mutations O O
in O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
gene O O
in O O
a O O
sporadic B-Disease B-Disease
T I-Disease I-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
leukaemia I-Disease I-Disease
. O O

Ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
is O O
a O O
recessive B-Disease B-Disease
multi I-Disease I-Disease
- I-Disease I-Disease
system I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
mutations O O
in O O
the O O
ATM O O
gene O O
at O O
11q22-q23 O O
( O O
ref O O
. O O

3 O O
) O O
. O O

The O O
risk O O
of O O
cancer B-Disease B-Disease
, O O
especially O O
lymphoid B-Disease B-Disease
neoplasias I-Disease I-Disease
, O O
is O O
substantially O O
elevated O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
and O O
has O O
long O O
been O O
associated O O
with O O
chromosomal O O
instability O O
. O O

By O O
analysing O O
tumour B-Disease B-Disease
DNA O O
from O O
patients O O
with O O
sporadic B-Disease B-Disease
T I-Disease I-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
prolymphocytic I-Disease I-Disease
leukaemia I-Disease I-Disease
( O O
T B-Disease B-Disease
- I-Disease I-Disease
PLL I-Disease I-Disease
) O O
, O O
a O O
rare O O
clonal B-Disease O
malignancy I-Disease B-Disease
with O O
similarities O O
to O O
a O O
mature B-Disease O
T I-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
leukaemia I-Disease I-Disease
seen O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
, O O
we O O
demonstrate O O
a O O
high O O
frequency O O
of O O
ATM O O
mutations O O
in O O
T B-Disease B-Disease
- I-Disease I-Disease
PLL I-Disease I-Disease
. O O

In O O
marked O O
contrast O O
to O O
the O O
ATM O O
mutation O O
pattern O O
in O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
, O O
the O O
most O O
frequent O O
nucleotide O O
changes O O
in O O
this O O
leukaemia B-Disease B-Disease
were O O
missense O O
mutations O O
. O O

These O O
clustered O O
in O O
the O O
region O O
corresponding O O
to O O
the O O
kinase O O
domain O O
, O O
which O O
is O O
highly O O
conserved O O
in O O
ATM O O
- O O
related O O
proteins O O
in O O
mouse O O
, O O
yeast O O
and O O
Drosophila O O
. O O

The O O
resulting O O
amino O O
- O O
acid O O
substitutions O O
are O O
predicted O O
to O O
interfere O O
with O O
ATP O O
binding O O
or O O
substrate O O
recognition O O
. O O

Two O O
of O O
seventeen O O
mutated O O
T B-Disease B-Disease
- I-Disease I-Disease
PLL I-Disease I-Disease
samples O O
had O O
a O O
previously O O
reported O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
allele O O
. O O

In O O
contrast O O
, O O
no O O
mutations O O
were O O
detected O O
in O O
the O O
p53 O O
gene O O
, O O
suggesting O O
that O O
this O O
tumour B-Disease B-Disease
suppressor O O
is O O
not O O
frequently O O
altered O O
in O O
this O O
leukaemia B-Disease B-Disease
. O O

Occasional O O
missense O O
mutations O O
in O O
ATM O O
were O O
also O O
found O O
in O O
tumour B-Disease B-Disease
DNA O O
from O O
patients O O
with O O
B B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
non I-Disease I-Disease
- I-Disease I-Disease
Hodgkins I-Disease I-Disease
lymphomas I-Disease I-Disease
( O O
B B-Disease B-Disease
- I-Disease I-Disease
NHL I-Disease I-Disease
) O O
and O O
a O O
B B-Disease B-Disease
- I-Disease I-Disease
NHL I-Disease I-Disease
cell O O
line O O
. O O

The O O
evidence O O
of O O
a O O
significant O O
proportion O O
of O O
loss O O
- O O
of O O
- O O
function O O
mutations O O
and O O
a O O
complete O O
absence O O
of O O
the O O
normal O O
copy O O
of O O
ATM O O
in O O
the O O
majority O O
of O O
mutated O O
tumours B-Disease B-Disease
establishes O O
somatic O O
inactivation O O
of O O
this O O
gene O O
in O O
the O O
pathogenesis O O
of O O
sporadic B-Disease B-Disease
T I-Disease I-Disease
- I-Disease I-Disease
PLL I-Disease I-Disease
and O O
suggests O O
that O O
ATM O O
acts O O
as O O
a O O
tumour B-Disease B-Disease
suppressor O O
. O O

As O O
constitutional O O
DNA O O
was O O
not O O
available O O
, O O
a O O
putative O O
hereditary O O
predisposition O O
to O O
T B-Disease B-Disease
- I-Disease I-Disease
PLL I-Disease I-Disease
will O O
require O O
further O O
investigation O O
.. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
protein O O
kinase O O
is O O
involved O O
in O O
the O O
modulation O O
of O O
the O O
Ca2 O O
+ O O
homeostasis O O
in O O
skeletal O O
muscle O O
cells O O
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
, O O
the O O
most O O
prevalent O O
muscular B-Disease B-Disease
disorder I-Disease I-Disease
in O O
adults O O
, O O
is O O
caused O O
by O O
( O O
CTG O O
) O O
n O O
- O O
repeat O O
expansion O O
in O O
a O O
gene O O
encoding O O
a O O
protein O O
kinase O O
( O O
DM B-Disease B-Disease
protein O O
kinase O O
; O O
DMPK O O
) O O
and O O
involves O O
changes O O
in O O
cytoarchitecture O O
and O O
ion O O
homeostasis O O
. O O

To O O
obtain O O
clues O O
to O O
the O O
normal O O
biological O O
role O O
of O O
DMPK O O
in O O
cellular O O
ion O O
homeostasis O O
, O O
we O O
have O O
compared O O
the O O
resting O O
[ O O
Ca2 O O
+ O O
] O O
i O O
, O O
the O O
amplitude O O
and O O
shape O O
of O O
depolarization O O
- O O
induced O O
Ca2 O O
+ O O
transients O O
, O O
and O O
the O O
content O O
of O O
ATP O O
- O O
driven O O
ion O O
pumps O O
in O O
cultured O O
skeletal O O
muscle O O
cells O O
of O O
wild O O
- O O
type O O
and O O
DMPK O O
[ O O
- O O
/ O O
- O O
] O O
knockout O O
mice O O
. O O

In O O
vitro O O
- O O
differentiated O O
DMPK O O
[ O O
- O O
/ O O
- O O
] O O
myotubes O O
exhibit O O
a O O
higher O O
resting O O
[ O O
Ca2 O O
+ O O
] O O
i O O
than O O
do O O
wild O O
- O O
type O O
myotubes O O
because O O
of O O
an O O
altered O O
open O O
probability O O
of O O
voltage O O
- O O
dependent O O
l O O
- O O
type O O
Ca2 O O
+ O O
and O O
Na O O
+ O O
channels O O
. O O

The O O
mutant O O
myotubes O O
exhibit O O
smaller O O
and O O
slower O O
Ca2 O O
+ O O
responses O O
upon O O
triggering O O
by O O
acetylcholine O O
or O O
high O O
external O O
K O O
+ O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
these O O
Ca2 O O
+ O O
transients O O
partially O O
result O O
from O O
an O O
influx O O
of O O
extracellular O O
Ca2 O O
+ O O
through O O
the O O
l O O
- O O
type O O
Ca2 O O
+ O O
channel O O
. O O

Neither O O
the O O
content O O
nor O O
the O O
activity O O
of O O
Na O O
+ O O
/K O O
+ O O
ATPase O O
and O O
sarcoplasmic O O
reticulum O O
Ca2 O O
+ O O
-ATPase O O
are O O
affected O O
by O O
DMPK O O
absence O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
DMPK O O
is O O
involved O O
in O O
modulating O O
the O O
initial O O
events O O
of O O
excitation O O
- O O
contraction O O
coupling O O
in O O
skeletal O O
muscle O O
.. O O

Constitutional O O
RB1-gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B-Disease B-Disease
retinoblastoma I-Disease I-Disease
. O O

In O O
most O O
patients O O
with O O
isolated O O
unilateral B-Disease B-Disease
retinoblastoma I-Disease I-Disease
, O O
tumor B-Disease B-Disease
development O O
is O O
initiated O O
by O O
somatic O O
inactivation O O
of O O
both O O
alleles O O
of O O
the O O
RB1 O O
gene O O
. O O

However O O
, O O
some O O
of O O
these O O
patients O O
can O O
transmit O O
retinoblastoma B-Disease B-Disease
predisposition O O
to O O
their O O
offspring O O
. O O

To O O
determine O O
the O O
frequency O O
and O O
nature O O
of O O
constitutional O O
RB1-gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B-Disease B-Disease
retinoblastoma I-Disease I-Disease
, O O
we O O
analyzed O O
DNA O O
from O O
peripheral O O
blood O O
and O O
from O O
tumor B-Disease B-Disease
tissue O O
. O O

The O O
analysis O O
of O O
tumors B-Disease B-Disease
from O O
54 O O
( O O
71 O O
% O O
) O O
of O O
76 O O
informative O O
patients O O
showed O O
loss O O
of O O
constitutional O O
heterozygosity O O
( O O
LOH O O
) O O
at O O
intragenic O O
loci O O
. O O

Three O O
of O O
13 O O
uninformative O O
patients O O
had O O
constitutional O O
deletions O O
. O O

For O O
39 O O
randomly O O
selected O O
tumors B-Disease B-Disease
, O O
SSCP O O
, O O
hetero O O
- O O
duplex O O
analysis O O
, O O
sequencing O O
, O O
and O O
Southern O O
blot O O
analysis O O
were O O
used O O
to O O
identify O O
mutations O O
. O O

Mutations O O
were O O
detected O O
in O O
21 O O
( O O
91 O O
% O O
) O O
of O O
23 O O
tumors B-Disease B-Disease
with O O
LOH O O
. O O

In O O
6 O O
( O O
38 O O
% O O
) O O
of O O
16 O O
tumors B-Disease B-Disease
without O O
LOH O O
, O O
one O O
mutation O O
was O O
detected O O
, O O
and O O
in O O
9 O O
( O O
56 O O
% O O
) O O
of O O
the O O
tumors B-Disease B-Disease
without O O
LOH O O
, O O
both O O
mutations O O
were O O
found O O
. O O

Thus O O
, O O
a O O
total O O
of O O
45 O O
mutations O O
were O O
identified O O
in O O
tumors B-Disease B-Disease
of O O
36 O O
patients O O
. O O

Thirty O O
- O O
nine O O
of O O
the O O
mutations O O
- O O
including O O
34 O O
small O O
mutations O O
, O O
2 O O
large O O
structural O O
alterations O O
, O O
and O O
hypermethylation O O
in O O
3 O O
tumors O B-Disease
- O O
were O O
not O O
detected O O
in O O
the O O
corresponding O O
peripheral O O
blood O O
DNA O O
. O O

In O O
6 O O
( O O
17 O O
% O O
) O O
of O O
the O O
36 O O
patients O O
, O O
a O O
mutation O O
was O O
detected O O
in O O
constitutional O O
DNA O O
, O O
and O O
1 O O
of O O
these O O
mutations O O
is O O
known O O
to O O
be O O
associated O O
with O O
reduced O O
expressivity O O
. O O

The O O
presence O O
of O O
a O O
constitutional O O
mutation O O
was O O
not O O
associated O O
with O O
an O O
early O O
age O O
at O O
treatment O O
. O O

In O O
1 O O
patient O O
, O O
somatic O O
mosaicism O O
was O O
demonstrated O O
by O O
molecular O O
analysis O O
of O O
DNA O O
and O O
RNA O O
from O O
peripheral O O
blood O O
. O O

In O O
2 O O
patients O O
without O O
a O O
detectable O O
mutation O O
in O O
peripheral O O
blood O O
, O O
mosaicism O O
was O O
suggested O O
because O O
1 O O
of O O
the O O
patients O O
showed O O
multifocal O O
tumors B-Disease B-Disease
and O O
the O O
other O O
later O O
developed O O
bilateral B-Disease O
retinoblastoma I-Disease B-Disease
. O O

In O O
conclusion O O
, O O
our O O
results O O
emphasize O O
that O O
the O O
manifestation O O
and O O
transmissibility O O
of O O
retinoblastoma B-Disease B-Disease
depend O O
on O O
the O O
nature O O
of O O
the O O
first O O
mutation O O
, O O
its O O
time O O
in O O
development O O
, O O
and O O
the O O
number O O
and O O
types O O
of O O
cells O O
that O O
are O O
affected O O
.. O O

Hereditary B-Disease B-Disease
deficiency I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
fifth I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
complement I-Disease I-Disease
in O O
man O O
. O O

I. O O
Clinical O O
, O O
immunochemical O O
, O O
and O O
family O O
studies O O
. O O

The O O
first O O
recognized O O
human O O
kindred O O
with O O
hereditary B-Disease B-Disease
deficiency I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
fifth I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
complement I-Disease I-Disease
( O O
C5 O O
) O O
is O O
described O O
. O O

The O O
proband O O
, O O
a O O
20-year O O
- O O
old O O
black O O
female O O
with O O
systemic B-Disease B-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
since O O
age O O
11 O O
, O O
lacked O O
serum O O
hemolytic O O
complement O O
activity O O
, O O
even O O
during O O
remission O O
. O O

C5 O O
was O O
undetectable O O
in O O
her O O
serum O O
by O O
both O O
immunodiffusion O O
and O O
hemolytic O O
assays O O
. O O

Other O O
complement O O
components O O
were O O
normal O O
during O O
remission O O
of O O
lupus O B-Disease
, O O
but O O
C1 O O
, O O
C4 O O
, O O
C2 O O
, O O
and O O
C3 O O
levels O O
fell O O
during O O
exacerbations O O
. O O

A O O
younger O O
half O O
- O O
sister O O
, O O
who O O
had O O
no O O
underlying O O
disease O O
, O O
was O O
also O O
found O O
to O O
lack O O
immunochemically O O
detectable O O
C5 O O
. O O

By O O
hemolytic O O
assay O O
, O O
she O O
exhibited O O
1 O O
- O O
2 O O
% O O
of O O
the O O
normal O O
serum O O
C5 O O
level O O
and O O
normal O O
concentrations O O
of O O
other O O
complement O O
components O O
. O O

C5 O O
levels O O
of O O
other O O
family O O
members O O
were O O
either O O
normal O O
or O O
approximately O O
half O O
- O O
normal O O
, O O
consistent O O
with O O
autosomal O O
codominant O O
inheritance O O
of O O
the O O
gene O O
determining O O
C5 B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

Normal O O
hemolytic O O
titers O O
were O O
restored O O
to O O
both O O
homozygous O O
C5-deficient B-Disease B-Disease
( O O
C5D B-Disease B-Disease
) O O
sera O O
by O O
addition O O
of O O
highly O O
purified O O
human O O
C5 O O
. O O

In O O
specific O O
C5 O O
titrations O O
, O O
however O O
, O O
it O O
was O O
noted O O
that O O
when O O
limited O O
amounts O O
of O O
C5 O O
were O O
assayed O O
in O O
the O O
presence O O
of O O
low O O
dilutions O O
of O O
either O O
C5D B-Disease B-Disease
serum O O
, O O
curving O O
rather O O
than O O
linear O O
dose O O
- O O
response O O
plots O O
were O O
consistently O O
obtained O O
, O O
suggesting O O
some O O
inhibitory O O
effect O O
. O O

Further O O
studies O O
suggested O O
that O O
low O O
dilutions O O
of O O
C5D B-Disease B-Disease
serum O O
contain O O
a O O
factor O O
( O O
or O O
factors O O
) O O
interfering O O
at O O
some O O
step O O
in O O
the O O
hemolytic O O
assay O O
of O O
C5 O O
, O O
rather O O
than O O
a O O
true O O
C5 O O
inhibitor O O
or O O
inactivator O O
. O O

Of O O
clinical O O
interest O O
are O O
( O O
a O O
) O O
the O O
documentation O O
of O O
membranous O O
glomerulonephritis B-Disease B-Disease
, O O
vasculitis B-Disease B-Disease
, O O
and O O
arthritis B-Disease B-Disease
in O O
an O O
individual O O
lacking O O
C5 O O
( O O
and O O
its O O
biologic O O
functions O O
) O O
, O O
and O O
( O O
b O O
) O O
a O O
remarkable O O
propensity O O
to O O
bacterial B-Disease B-Disease
infections I-Disease I-Disease
in O O
the O O
proband O O
, O O
even O O
during O O
periods O O
of O O
low O O
- O O
dose O O
or O O
alternate O O
- O O
day O O
corticosteroid O O
therapy O O
. O O

Other O O
observations O O
indicate O O
that O O
the O O
C5D B-Disease B-Disease
state O O
is O O
compatible O O
with O O
normal O O
coagulation O O
function O O
and O O
the O O
capacity O O
to O O
mount O O
a O O
neutrophilic O O
leukocytosis O B-Disease
during O O
pyogenic B-Disease B-Disease
infection I-Disease I-Disease
.. O O

Susceptibility O O
to O O
ankylosing B-Disease B-Disease
spondylitis I-Disease I-Disease
in O O
twins O O
: O O
the O O
role O O
of O O
genes O O
, O O
HLA O O
, O O
and O O
the O O
environment O O
. O O

OBJECTIVE O O
To O O
determine O O
the O O
relative O O
effects O O
of O O
genetic O O
and O O
environmental O O
factors O O
in O O
susceptibility O O
to O O
ankylosing B-Disease B-Disease
spondylitis I-Disease I-Disease
( O O
AS B-Disease B-Disease
) O O
. O O

METHODS O O
Twins O O
with O O
AS B-Disease B-Disease
were O O
identified O O
from O O
the O O
Royal O O
National O O
Hospital O O
for O O
Rheumatic B-Disease B-Disease
Diseases I-Disease I-Disease
database O O
. O O

Clinical O O
and O O
radiographic O O
examinations O O
were O O
performed O O
to O O
establish O O
diagnoses O O
, O O
and O O
disease O O
severity O O
was O O
assessed O O
using O O
a O O
combination O O
of O O
validated O O
scoring O O
systems O O
. O O

HLA O O
typing O O
for O O
HLA O O
- O O
B27 O O
, O O
HLA O O
- O O
B60 O O
, O O
and O O
HLA O O
- O O
DR1 O O
was O O
performed O O
by O O
polymerase O O
chain O O
reaction O O
with O O
sequence O O
- O O
specific O O
primers O O
, O O
and O O
zygosity O O
was O O
assessed O O
using O O
microsatellite O O
markers O O
. O O

Genetic O O
and O O
environmental O O
variance O O
components O O
were O O
assessed O O
with O O
the O O
program O O
Mx O O
, O O
using O O
data O O
from O O
this O O
and O O
previous O O
studies O O
of O O
twins O O
with O O
AS B-Disease B-Disease
. O O

RESULTS O O
Six O O
of O O
8 O O
monozygotic O O
( O O
MZ O O
) O O
twin O O
pairs O O
were O O
disease O O
concordant O O
, O O
compared O O
with O O
4 O O
of O O
15 O O
B27-positive O O
dizygotic O O
( O O
DZ O O
) O O
twin O O
pairs O O
( O O
27 O O
% O O
) O O
and O O
4 O O
of O O
32 O O
DZ O O
twin O O
pairs O O
overall O O
( O O
12 O O
. O O
5 O O
% O O
) O O
. O O

Nonsignificant O O
increases O O
in O O
similarity O O
with O O
regard O O
to O O
age O O
at O O
disease O O
onset O O
and O O
all O O
of O O
the O O
disease O O
severity O O
scores O O
assessed O O
were O O
noted O O
in O O
disease O O
- O O
concordant O O
MZ O O
twins O O
compared O O
with O O
concordant O O
DZ O O
twins O O
. O O

HLA O O
- O O
B27 O O
and O O
B60 O O
were O O
associated O O
with O O
the O O
disease O O
in O O
probands O O
, O O
and O O
the O O
rate O O
of O O
disease O O
concordance O O
was O O
significantly O O
increased O O
among O O
DZ O O
twin O O
pairs O O
in O O
which O O
the O O
co O O
- O O
twin O O
was O O
positive O O
for O O
both O O
B27 O O
and O O
DR1 O O
. O O

Additive O O
genetic O O
effects O O
were O O
estimated O O
to O O
contribute O O
97 O O
% O O
of O O
the O O
population O O
variance O O
. O O

CONCLUSION O O
Susceptibility O O
to O O
AS B-Disease B-Disease
is O O
largely O O
genetically O O
determined O O
, O O
and O O
the O O
environmental O O
trigger O O
for O O
the O O
disease O O
is O O
probably O O
ubiquitous O O
. O O

HLA O O
- O O
B27 O O
accounts O O
for O O
a O O
minority O O
of O O
the O O
overall O O
genetic O O
susceptibility O O
to O O
AS B-Disease B-Disease
. O O

Cell O O
cycle O O
- O O
dependent O O
colocalization O O
of O O
BARD1 O O
and O O
BRCA1 O O
proteins O O
in O O
discrete O O
nuclear O O
domains O O
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
BRCA1 O O
gene O O
predispose O O
women O O
to O O
early O O
- O O
onset O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
by O O
compromising O O
the O O
genes O O
presumptive O O
function O O
as O O
a O O
tumor B-Disease B-Disease
suppressor O O
. O O

Although O O
the O O
biochemical O O
properties O O
of O O
BRCA1 O O
polypeptides O O
are O O
not O O
understood O O
, O O
their O O
expression O O
pattern O O
and O O
subcellular O O
localization O O
suggest O O
a O O
role O O
in O O
cell O O
- O O
cycle O O
regulation O O
. O O

When O O
resting O O
cells O O
are O O
induced O O
to O O
proliferate O O
, O O
the O O
steady O O
- O O
state O O
levels O O
of O O
BRCA1 O O
increase O O
in O O
late O O
G1 O O
and O O
reach O O
a O O
maximum O O
during O O
S O O
phase O O
. O O

Moreover O O
, O O
in O O
S O O
phase O O
cells O O
, O O
BRCA1 O O
polypeptides O O
are O O
hyperphosphorylated O O
and O O
accumulate O O
into O O
discrete O O
subnuclear O O
foci O O
termed O O
" O O
BRCA1 O O
nuclear O O
dots O O
. O O
" O O
BRCA1 O O
associates O O
in O O
vivo O O
with O O
a O O
structurally O O
related O O
protein O O
termed O O
BARD1 O O
. O O

Here O O
we O O
show O O
that O O
the O O
steady O O
- O O
state O O
levels O O
of O O
BARD1 O O
, O O
unlike O O
those O O
of O O
BRCA1 O O
, O O
remain O O
relatively O O
constant O O
during O O
cell O O
cycle O O
progression O O
. O O

However O O
, O O
immunostaining O O
revealed O O
that O O
BARD1 O O
resides O O
within O O
BRCA1 O O
nuclear O O
dots O O
during O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
, O O
but O O
not O O
during O O
the O O
G1 O O
phase O O
. O O

Nevertheless O O
, O O
BARD1 O O
polypeptides O O
are O O
found O O
exclusively O O
in O O
the O O
nuclear O O
fractions O O
of O O
both O O
G1- O O
and O O
S O O
- O O
phase O O
cells O O
. O O

Therefore O O
, O O
progression O O
to O O
S O O
phase O O
is O O
accompanied O O
by O O
the O O
aggregation O O
of O O
nuclear O O
BARD1 O O
polypeptides O O
into O O
BRCA1 O O
nuclear O O
dots O O
. O O

This O O
cell O O
cycle O O
- O O
dependent O O
colocalization O O
of O O
BARD1 O O
and O O
BRCA1 O O
indicates O O
a O O
role O O
for O O
BARD1 O O
in O O
BRCA1-mediated O O
tumor B-Disease B-Disease
suppression O O
. O O

Ethnic O O
differences O O
in O O
the O O
HFE O O
codon O O
282 O O
( O O
Cys O O
/ O O
Tyr O O
) O O
polymorphism O O
. O O

Recent O O
studies O O
have O O
shown O O
that O O
hereditary B-Disease B-Disease
hemochromatosis I-Disease I-Disease
( O O
HH B-Disease B-Disease
) O O
is O O
likely O O
to O O
be O O
caused O O
by O O
homozygosity O O
for O O
a O O
Cys282Tyr O O
mutation O O
in O O
the O O
HFE O O
gene O O
located O O
4 O O
. O O

5 O O
Mb O O
telomeric O O
to O O
HLA O O
- O O
A. O O
Population O O
studies O O
of O O
this O O
polymorphism O O
are O O
facilitated O O
by O O
the O O
fact O O
that O O
the O O
Cys282Tyr O O
mutation O O
creates O O
a O O
Rsal O O
restriction O O
site O O
. O O

We O O
have O O
studied O O
the O O
codon O O
282 O O
( O O
Cys O O
/ O O
Tyr O O
) O O
polymorphism O O
in O O
different O O
ethnic O O
groups O O
. O O

In O O
agreement O O
with O O
previous O O
observations O O
the O O
Tyr O O
allele O O
appeared O O
to O O
be O O
rare O O
or O O
absent O O
in O O
Asiatic O O
( O O
Indian O O
, O O
Chinese O O
) O O
populations O O
. O O

The O O
highest O O
allele O O
frequency O O
( O O
7 O O
. O O
5 O O
% O O
) O O
was O O
found O O
in O O
Swedes O O
. O O

Saamis O O
( O O
2 O O
% O O
) O O
and O O
Mordvinians O O
( O O
1 O O
. O O
8 O O
% O O
) O O
had O O
significantly O O
lower O O
frequencies O O
of O O
the O O
Tyr O O
allele O O
. O O

Comparisons O O
with O O
allele O O
frequencies O O
based O O
on O O
prevalence O O
estimates O O
of O O
HH B-Disease B-Disease
showed O O
some O O
disagreements O O
with O O
the O O
RFLP O O
data O O
, O O
particularly O O
in O O
Finns O O
. O O

The O O
newly O O
described O O
HFE O O
marker O O
provides O O
a O O
new O O
approach O O
to O O
the O O
screening O O
of O O
HH B-Disease B-Disease
as O O
well O O
as O O
studies O O
of O O
the O O
relationship O O
between O O
the O O
HFE O O
Tyr O O
allele O O
and O O
different O O
disorders O O
including O O
cancer B-Disease B-Disease

Autosomal B-Disease B-Disease
dominant I-Disease I-Disease
neurohypophyseal I-Disease I-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
associated O O
with O O
a O O
missense O O
mutation O O
encoding O O
Gly23 O O
- O O
->Val O O
in O O
neurophysin O O
II O O
. O O

Autosomal B-Disease B-Disease
dominant I-Disease I-Disease
neurohypophyseal I-Disease I-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
( O O
ADNDI B-Disease B-Disease
) O O
is O O
an O O
inherited B-Disease B-Disease
disease I-Disease I-Disease
caused O O
by O O
progressive O O
degeneration O O
of O O
the O O
magnocellular O O
neurons O O
of O O
the O O
hypothalamus O O
leading O O
to O O
decreased O O
ability O O
to O O
produce O O
the O O
hormone O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
. O O

Affected O O
individuals O O
are O O
not O O
symptomatic O O
at O O
birth O O
, O O
but O O
usually O O
develop O O
diabetes B-Disease B-Disease
insipidus I-Disease I-Disease
at O O
1 O O
- O O
6 O O
yr O O
of O O
age O O
. O O

The O O
genetic O O
locus O O
of O O
the O O
disease O O
is O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
NPII O O
) O O
gene O O
, O O
and O O
mutations O O
that O O
cause O O
ADNDI B-Disease B-Disease
have O O
been O O
found O O
in O O
both O O
the O O
signal O O
peptide O O
of O O
the O O
prepro O O
- O O
AVP O O
- O O
NPII O O
precursor O O
and O O
within O O
NPII O O
itself O O
. O O

An O O
affected O O
girl O O
who O O
presented O O
at O O
9 O O
months O O
of O O
age O O
and O O
her O O
similarly O O
affected O O
younger O O
brother O O
and O O
father O O
were O O
all O O
found O O
to O O
have O O
a O O
novel O O
missense O O
mutation O O
( O O
G1758 O O
- O O
- O O
> O O
T O O
) O O
encoding O O
the O O
amino O O
acid O O
substitution O O
Gly23 O O
- O O
- O O
> O O
Val O O
within O O
NPII O O
. O O

The O O
mutation O O
was O O
confirmed O O
by O O
restriction O O
endonuclease O O
analysis O O
. O O

A O O
T1-weighted O O
magnetic O O
resonance O O
imaging O O
of O O
the O O
fathers O O
pituitary O O
gland O O
demonstrates O O
an O O
attenuated O O
posterior O O
pituitary O O
bright O O
spot O O
. O O

This O O
mutation O O
may O O
be O O
valuable O O
for O O
developing O O
models O O
of O O
dominantly B-Disease O
inherited I-Disease B-Disease
neurodegeneration I-Disease I-Disease
, O O
as O O
the O O
early O O
age O O
of O O
onset O O
of O O
symptoms O O
suggests O O
that O O
this O O
mutation O O
may O O
be O O
particularly O O
deleterious O O
to O O
the O O
magnocellular O O
neuron O O
.. O O

Frequent O O
inactivation O O
of O O
PTEN O O
/ O O
MMAC1 O O
in O O
primary O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Sporadic B-Disease B-Disease
prostate I-Disease I-Disease
carcinoma I-Disease I-Disease
is O O
the O O
most O O
common O O
male B-Disease B-Disease
cancer I-Disease I-Disease
in O O
the O O
Western O O
world O O
, O O
yet O O
many O O
of O O
the O O
major O O
genetic O O
events O O
involved O O
in O O
the O O
progression O O
of O O
this O O
often O O
fatal O O
cancer B-Disease B-Disease
remain O O
to O O
be O O
elucidated O O
. O O

Numerous O O
cytogenetic O O
and O O
allelotype O O
studies O O
have O O
reported O O
frequent O O
loss O O
of O O
heterozygosity O O
on O O
chromosomal O O
arm O O
10q O O
in O O
sporadic B-Disease B-Disease
prostate I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Deletion O O
mapping O O
studies O O
have O O
unambiguously O O
identified O O
a O O
region O O
of O O
chromosome O O
10q23 O O
to O O
be O O
the O O
minimal O O
area O O
of O O
loss O O
. O O

A O O
new O O
tumor B-Disease B-Disease
suppressor O O
gene O O
, O O
PTEN O O
/ O O
MMAC1 O O
, O O
was O O
isolated O O
recently O O
at O O
this O O
region O O
of O O
chromosome O O
10q23 O O
and O O
found O O
to O O
be O O
inactivated O O
by O O
mutation O O
in O O
three O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
cell O O
lines O O
. O O

We O O
screened O O
80 O O
prostate B-Disease B-Disease
tumors I-Disease I-Disease
by O O
microsatellite O O
analysis O O
and O O
found O O
chromosome O O
10q23 O O
to O O
be O O
deleted O O
in O O
23 O O
cases O O
. O O

We O O
then O O
proceeded O O
with O O
sequence O O
analysis O O
of O O
the O O
entire O O
PTEN O O
/ O O
MMAC1 O O
coding O O
region O O
and O O
tested O O
for O O
homozygous O O
deletion O O
with O O
new O O
intragenic O O
markers O O
in O O
these O O
23 O O
cases O O
with O O
10q23 O O
loss O O
of O O
heterozygosity O O
. O O

The O O
identification O O
of O O
the O O
second O O
mutational O O
event O O
in O O
10 O O
( O O
43 O O
% O O
) O O
tumors B-Disease B-Disease
establishes O O
PTEN O O
/ O O
MMAC1 O O
as O O
a O O
main O O
inactivation O O
target O O
of O O
10q O O
loss O O
in O O
sporadic B-Disease B-Disease
prostate I-Disease I-Disease
cancer I-Disease I-Disease
.. O O

Risk O O
reversals O O
in O O
predictive O O
testing O O
for O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
. O O

The O O
first O O
predictive O O
testing O O
for O O
Huntington B-Disease B-Disease
disease I-Disease I-Disease
( O O
HD B-Disease B-Disease
) O O
was O O
based O O
on O O
analysis O O
of O O
linked O O
polymorphic O O
DNA O O
markers O O
to O O
estimate O O
the O O
likelihood O O
of O O
inheriting O O
the O O
mutation O O
for O O
HD B-Disease B-Disease
. O O

Limits O O
to O O
accuracy O O
included O O
recombination O O
between O O
the O O
DNA O O
markers O O
and O O
the O O
mutation O O
, O O
pedigree O O
structure O O
, O O
and O O
whether O O
DNA O O
samples O O
were O O
available O O
from O O
family O O
members O O
. O O

With O O
direct O O
tests O O
for O O
the O O
HD B-Disease B-Disease
mutation O O
, O O
we O O
have O O
assessed O O
the O O
accuracy O O
of O O
results O O
obtained O O
by O O
linkage O O
approaches O O
when O O
requested O O
to O O
do O O
so O O
by O O
the O O
test O O
individuals O O
. O O

For O O
six O O
such O O
individuals O O
, O O
there O O
was O O
significant O O
disparity O O
between O O
the O O
tests O O
. O O

Three O O
went O O
from O O
a O O
decreased O O
risk O O
to O O
an O O
increased O O
risk O O
, O O
while O O
in O O
another O O
three O O
the O O
risk O O
was O O
decreased O O
. O O

Knowledge O O
of O O
the O O
potential O O
reasons O O
for O O
these O O
changes O O
in O O
results O O
and O O
impact O O
of O O
these O O
risk O O
reversals O O
on O O
both O O
patients O O
and O O
the O O
counseling O O
team O O
can O O
assist O O
in O O
the O O
development O O
of O O
strategies O O
for O O
the O O
prevention O O
and O O
, O O
where O O
necessary O O
, O O
management O O
of O O
a O O
risk O O
reversal O O
in O O
any O O
predictive O O
testing O O
program O O
.. O O

A O O
novel O O
common O O
missense O O
mutation O O
G301C O O
in O O
the O O
N O O
- O O
acetylgalactosamine-6-sulfate O O
sulfatase O O
gene O O
in O O
mucopolysaccharidosis B-Disease B-Disease
IVA I-Disease I-Disease
. O O

Mucopolysaccharidosis B-Disease B-Disease
IVA I-Disease I-Disease
( O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
lysosomal I-Disease I-Disease
storage I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
a O O
genetic B-Disease B-Disease
defect I-Disease I-Disease
in O O
N O O
- O O
acetylgalactosamine-6-sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

In O O
previous O O
studies O O
, O O
we O O
have O O
found O O
two O O
common O O
mutations O O
in O O
Caucasians O O
and O O
Japanese O O
, O O
respectively O O
. O O

To O O
characterize O O
the O O
mutational O O
spectrum O O
in O O
various O O
ethnic O O
groups O O
, O O
mutations O O
in O O
the O O
GALNS O O
gene O O
in O O
Colombian O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
patients O O
were O O
investigated O O
, O O
and O O
genetic O O
backgrounds O O
were O O
extensively O O
analyzed O O
to O O
identify O O
racial O O
origin O O
, O O
based O O
on O O
mitochondrial O O
DNA O O
( O O
mtDNA O O
) O O
lineages O O
. O O

Three O O
novel O O
missense O O
mutations O O
never O O
identified O O
previously O O
in O O
other O O
populations O O
and O O
found O O
in O O
16 O O
out O O
of O O
19 O O
Colombian O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
unrelated O O
alleles O O
account O O
for O O
84 O O
. O O

2 O O
% O O
of O O
the O O
alleles O O
in O O
this O O
study O O
. O O

The O O
G301C O O
and O O
S162F O O
mutations O O
account O O
for O O
68 O O
. O O
4 O O
% O O
and O O
10 O O
. O O
5 O O
% O O
of O O
mutations O O
, O O
respectively O O
, O O
whereas O O
the O O
remaining O O
F69V O O
is O O
limited O O
to O O
a O O
single O O
allele O O
. O O

The O O
skewed O O
prevalence O O
of O O
G301C O O
in O O
only O O
Colombian O O
patients O O
and O O
haplotype O O
analysis O O
by O O
restriction O O
fragment O O
length O O
polymorphisms O O
in O O
the O O
GALNS O O
gene O O
suggest O O
that O O
G301C O O
originated O O
from O O
a O O
common O O
ancestor O O
. O O

Investigation O O
of O O
the O O
genetic O O
background O O
by O O
means O O
of O O
mtDNA O O
lineages O O
indicate O O
that O O
all O O
our O O
patients O O
are O O
probably O O
of O O
native O O
American O O
descent O O

Low O O
frequency O O
of O O
BRCA1 O O
germline O O
mutations O O
in O O
45 O O
German O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
. O O

In O O
this O O
study O O
we O O
investigated O O
45 O O
German O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
for O O
germline O O
mutations O O
in O O
the O O
BRCA1 O O
gene O O
. O O

We O O
identified O O
four O O
germline O O
mutations O O
in O O
three O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
families O O
and O O
in O O
one O O
breast B-Disease B-Disease
- I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
family O O
. O O

among O O
these O O
were O O
one O O
frameshift O O
mutation O O
, O O
one O O
nonsense O O
mutation O O
, O O
one O O
novel O O
splice O O
site O O
mutation O O
, O O
and O O
one O O
missense O O
mutation O O
. O O

The O O
missense O O
mutation O O
was O O
also O O
found O O
in O O
2 O O
. O O
8 O O
% O O
of O O
the O O
general O O
population O O
, O O
suggesting O O
that O O
it O O
is O O
not O O
disease O O
associated O O
. O O

The O O
average O O
age O O
of O O
disease O O
onset O O
in O O
those O O
families O O
harbouring O O
causative O O
mutations O O
was O O
between O O
32 O O
. O O

3 O O
and O O
37 O O
. O O
4 O O
years O O
, O O
whereas O O
the O O
family O O
harbouring O O
the O O
missense O O
mutation O O
had O O
an O O
average O O
age O O
of O O
onset O O
of O O
51 O O
. O O

2 O O
years O O
. O O

These O O
findings O O
show O O
that O O
BRCA1 O O
is O O
implicated O O
in O O
a O O
small O O
fraction O O
of O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
suggesting O O
the O O
involvement O O
of O O
another O O
susceptibility O O
gene O O
( O O
s O O
) O O

Paternal O O
transmission O O
of O O
congenital B-Disease B-Disease
myotonic I-Disease I-Disease
dystrophy I-Disease I-Disease
. O O

We O O
report O O
a O O
rare O O
case O O
of O O
paternally O O
transmitted O O
congenital B-Disease B-Disease
myotonic I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
. O O

The O O
proband O O
is O O
a O O
23 O O
year O O
old O O
, O O
mentally B-Disease B-Disease
retarded I-Disease I-Disease
male O O
who O O
suffers O O
severe O O
muscular B-Disease B-Disease
weakness I-Disease I-Disease
. O O

He O O
presented O O
with O O
respiratory O O
and O O
feeding O O
difficulties O O
at O O
birth O O
. O O

His O O
two O O
sibs O O
suffer O O
from O O
childhood O O
onset O O
DM B-Disease B-Disease
. O O

Their O O
late O O
father O O
had O O
the O O
adult O O
type O O
of O O
DM B-Disease B-Disease
, O O
with O O
onset O O
around O O
30 O O
years O O
. O O

Only O O
six O O
other O O
cases O O
of O O
paternal O O
transmission O O
of O O
congenital B-Disease B-Disease
DM I-Disease I-Disease
have O O
been O O
reported O O
recently O O
. O O

We O O
review O O
the O O
sex O O
related O O
effects O O
on O O
transmission O O
of O O
congenital B-Disease B-Disease
DM I-Disease I-Disease
. O O

Decreased O O
fertility O O
of O O
males O O
with O O
adult O O
onset O O
DM B-Disease B-Disease
and O O
contraction O O
of O O
the O O
repeat O O
upon O O
male O O
transmission O O
contribute O O
to O O
the O O
almost O O
absent O O
occurrence O O
of O O
paternal O O
transmission O O
of O O
congenital B-Disease B-Disease
DM I-Disease I-Disease
. O O

Also O O
the O O
fathers O O
of O O
the O O
reported O O
congenitally O O
affected O O
children O O
showed O O
, O O
on O O
average O O
, O O
shorter O O
CTG O O
repeat O O
lengths O O
and O O
hence O O
less O O
severe O O
clinical O O
symptoms O O
than O O
the O O
mothers O O
of O O
children O O
with O O
congenital B-Disease B-Disease
DM I-Disease I-Disease
. O O

We O O
conclude O O
that O O
paternal O O
transmission O O
of O O
congenital B-Disease B-Disease
DM I-Disease I-Disease
is O O
rare O O
and O O
preferentially O O
occurs O O
with O O
onset O O
of O O
DM B-Disease B-Disease
past O O
30 O O
years O O
in O O
the O O
father O O
.. O O

The O O
RB1 O O
gene O O
mutation O O
in O O
a O O
child O O
with O O
ectopic B-Disease B-Disease
intracranial I-Disease I-Disease
retinoblastoma I-Disease I-Disease
. O O

The O O
RB1 O O
gene O O
mutation O O
was O O
investigated O O
in O O
a O O
child O O
with O O
ectopic B-Disease B-Disease
intracranial I-Disease I-Disease
retinoblastoma I-Disease I-Disease
using O O
DNA O O
obtained O O
from O O
both O O
the O O
pineal B-Disease B-Disease
and I-Disease I-Disease
retinal I-Disease I-Disease
tumours I-Disease I-Disease
of O O
the O O
patient O O
. O O

A O O
nonsense O O
mutation O O
in O O
exon O O
17 O O
( O O
codon O O
556 O O
) O O
of O O
the O O
RB1 O O
gene O O
was O O
found O O
to O O
be O O
present O O
homozygously O O
in O O
both O O
the O O
retinal B-Disease B-Disease
and I-Disease I-Disease
the I-Disease I-Disease
pineal I-Disease I-Disease
tumours I-Disease I-Disease
. O O

The O O
same O O
mutation O O
was O O
present O O
heterozygously O O
in O O
the O O
DNA O O
from O O
the O O
constitutional O O
cells O O
of O O
the O O
patient O O
, O O
proving O O
it O O
to O O
be O O
of O O
germline O O
origin O O
. O O

The O O
initial O O
mutation O O
was O O
shown O O
to O O
have O O
occurred O O
in O O
the O O
paternally O O
derived O O
RB1 O O
allele O O
. O O

The O O
mutation O O
is O O
in O O
an O O
area O O
of O O
the O O
gene O O
that O O
encodes O O
the O O
protein O O
- O O
binding O O
region O O
known O O
as O O
the O O
pocket O O
region O O
and O O
has O O
been O O
detected O O
in O O
other O O
cases O O
of O O
retinoblastoma B-Disease B-Disease
.. O O

Low O O
levels O O
of O O
beta O O
hexosaminidase O O
A O O
in O O
healthy O O
individuals O O
with O O
apparent O O
deficiency O O
of O O
this O O
enzyme O O
. O O

Appreciable O O
beta O O
hexosaminidase O O
A O O
( O O
hex O O
A O O
) O O
activity O O
has O O
been O O
detected O O
in O O
cultured O O
skin O O
fibroblasts O O
and O O
melanoma B-Disease B-Disease
tissue O O
from O O
healthy O O
individuals O O
previously O O
reported O O
as O O
having O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
hex I-Disease I-Disease
A I-Disease I-Disease
activity O O
indistinguishable O O
from O O
that O O
of O O
patients O O
with O O
Tay B-Disease B-Disease
- I-Disease I-Disease
Sachs I-Disease I-Disease
disease I-Disease I-Disease
( O O
TSD B-Disease B-Disease
) O O
. O O

Identification O O
and O O
quantitation O O
of O O
hex O O
A O O
, O O
amounting O O
to O O
3 O O
. O O
5 O O
% O O
-6 O O
. O O

9 O O
% O O
of O O
total O O
beta O O
hexosaminidase O O
activity O O
, O O
has O O
been O O
obtained O O
by O O
cellulose O O
acetate O O
gel O O
electrophoresis O O
, O O
DEAE O O
- O O
cellulose O O
ion O O
- O O
exchange O O
chromatography O O
, O O
radial O O
immunodiffusion O O
, O O
and O O
radioimmunoassay O O
. O O

Previous O O
family O O
studies O O
suggested O O
that O O
these O O
individuals O O
may O O
be O O
compound O O
heterozygotes O O
for O O
the O O
common O O
mutant O O
TSD B-Disease B-Disease
gene O O
and O O
a O O
rare O O
( O O
allelic O O
) O O
mutant O O
gene O O
. O O

Thus O O
, O O
the O O
postulated O O
rate O O
mutant O O
gene O O
appears O O
to O O
code O O
for O O
the O O
expression O O
of O O
low O O
amounts O O
of O O
hex O O
A. O O
Heterozygotes O O
for O O
the O O
rare O O
mutant O O
may O O
be O O
indistinguishable O O
from O O
heterozygotes O O
for O O
the O O
common O O
TSD B-Disease B-Disease
mutant O O
. O O

However O O
, O O
direct O O
visualization O O
and O O
quantitation O O
of O O
hex O O
A O O
by O O
the O O
methods O O
described O O
may O O
prevent O O
false O O
- O O
positive O O
prenatal O O
diagnosis O O
of O O
TSD B-Disease B-Disease
in O O
fetuses O O
having O O
the O O
incomplete O O
hex B-Disease B-Disease
A I-Disease I-Disease
deficiency I-Disease I-Disease
of O O
the O O
type O O
described O O
in O O
the O O
four O O
healthy O O
individuals O O

The O O
tumor B-Disease B-Disease
suppressor O O
gene O O
Smad4 O O
/ O O
Dpc4 O O
is O O
required O O
for O O
gastrulation O O
and O O
later O O
for O O
anterior O O
development O O
of O O
the O O
mouse O O
embryo O O
. O O

Mutations O O
in O O
the O O
SMAD4 O O
/ O O
DPC4 O O
tumor B-Disease B-Disease
suppressor O O
gene O O
, O O
a O O
key O O
signal O O
transducer O O
in O O
most O O
TGFbeta O O
- O O
related O O
pathways O O
, O O
are O O
involved O O
in O O
50 O O
% O O
of O O
pancreatic B-Disease B-Disease
cancers I-Disease I-Disease
. O O

Homozygous O O
Smad4 O O
mutant O O
mice O O
die O O
before O O
day O O
7 O O
. O O

5 O O
of O O
embryogenesis O O
. O O

Mutant O O
embryos O O
have O O
reduced O O
size O O
, O O
fail O O
to O O
gastrulate O O
or O O
express O O
a O O
mesodermal O O
marker O O
, O O
and O O
show O O
abnormal O O
visceral O O
endoderm O O
development O O
. O O

Growth B-Disease B-Disease
retardation I-Disease I-Disease
of O O
the O O
Smad4-deficient O O
embryos O O
results O O
from O O
reduced O O
cell O O
proliferation O O
rather O O
than O O
increased O O
apoptosis O O
. O O

Aggregation O O
of O O
mutant O O
Smad4 O O
ES O O
cells O O
with O O
wild O O
- O O
type O O
tetraploid O O
morulae O O
rescues O O
the O O
gastrulation B-Disease B-Disease
defect I-Disease I-Disease
. O O

These O O
results O O
indicate O O
that O O
Smad4 O O
is O O
initially O O
required O O
for O O
the O O
differentiation O O
of O O
the O O
visceral O O
endoderm O O
and O O
that O O
the O O
gastrulation B-Disease B-Disease
defect I-Disease I-Disease
in O O
the O O
epiblast O O
is O O
secondary O O
and O O
non O O
- O O
cell O O
autonomous O O
. O O

Rescued O O
embryos O O
show O O
severe O O
anterior O O
truncations O O
, O O
indicating O O
a O O
second O O
important O O
role O O
for O O
Smad4 O O
in O O
anterior O O
patterning O O
during O O
embryogenesis O O
. O O

Prevalence O O
of O O
p16 O O
and O O
CDK4 O O
germline O O
mutations O O
in O O
48 O O
melanoma B-Disease B-Disease
- O O
prone O O
families O O
in O O
France O O
. O O

The O O
French O O
Familial B-Disease B-Disease
Melanoma I-Disease I-Disease
Study O O
Group O O
. O O

Germline O O
mutations O O
in O O
the O O
p16 O O
and O O
CDK4 O O
genes O O
have O O
been O O
reported O O
in O O
a O O
subset O O
of O O
melanoma B-Disease B-Disease
pedigrees O O
, O O
but O O
their O O
prevalence O O
is O O
not O O
well O O
known O O
. O O

We O O
searched O O
for O O
such O O
germline O O
mutations O O
in O O
48 O O
French O O
melanoma B-Disease B-Disease
- O O
prone O O
families O O
selected O O
according O O
to O O
two O O
major O O
criteria O O
families O O
with O O
at O O
least O O
three O O
affected O O
members O O
( O O
n O O
= O O
20 O O
) O O
or O O
families O O
with O O
two O O
affected O O
members O O
, O O
one O O
of O O
them O O
affected O O
before O O
the O O
age O O
of O O
50 O O
( O O
n O O
= O O
28 O O
) O O
, O O
and O O
one O O
additional O O
minor O O
criterion O O
. O O

Sixteen O O
different O O
p16 O O
germline O O
mutations O O
were O O
found O O
in O O
21 O O
families O O
, O O
while O O
one O O
germline O O
mutation O O
, O O
Arg24His O O
, O O
was O O
detected O O
in O O
the O O
CDK4 O O
gene O O
. O O

The O O
frequency O O
of O O
p16 O O
gene O O
mutation O O
in O O
our O O
sample O O
( O O
44 O O
% O O
) O O
is O O
among O O
the O O
highest O O
rates O O
yet O O
reported O O
and O O
the O O
CDK4 O O
mutation O O
is O O
the O O
second O O
mutation O O
detected O O
in O O
this O O
gene O O
worldwide O O
. O O

In O O
summary O O
, O O
our O O
results O O
show O O
frequent O O
involvement O O
of O O
the O O
p16 O O
gene O O
in O O
familial B-Disease B-Disease
melanoma I-Disease I-Disease
and O O
confirm O O
the O O
role O O
of O O
the O O
CDK4 O O
gene O O
as O O
a O O
melanoma B-Disease B-Disease
- O O
predisposing O O
gene O O
.. O O

Progression O O
of O O
somatic O O
CTG O O
repeat O O
length O O
heterogeneity O O
in O O
the O O
blood O O
cells O O
of O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
patients O O
. O O

The O O
genetic O O
basis O O
of O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
the O O
expansion O O
of O O
an O O
unstable O O
CTG O O
repeat O O
in O O
the O O
34 O O
UTR O O
of O O
the O O
DM B-Disease B-Disease
protein O O
kinase O O
gene O O
on O O
chromosome O O
19 O O
. O O

One O O
of O O
the O O
principal O O
features O O
of O O
the O O
DM B-Disease B-Disease
mutation O O
is O O
an O O
extraordinarily O O
high O O
level O O
of O O
somatic O O
mosaicism O O
, O O
due O O
to O O
an O O
extremely O O
high O O
degree O O
of O O
somatic O O
instability O O
both O O
within O O
and O O
between O O
different O O
tissues O O
. O O

This O O
instability O O
appears O O
to O O
be O O
biased O O
towards O O
further O O
expansion O O
and O O
continuous O O
throughout O O
the O O
life O O
of O O
an O O
individual O O
, O O
features O O
that O O
could O O
be O O
associated O O
with O O
the O O
progressive O O
nature O O
of O O
the O O
disease O O
. O O

Although O O
increasing O O
measured O O
allele O O
size O O
between O O
patients O O
clearly O O
correlates O O
with O O
an O O
increased O O
severity O O
of O O
symptoms O O
and O O
an O O
earlier O O
age O O
of O O
onset O O
, O O
this O O
correlation O O
is O O
not O O
precise O O
and O O
measured O O
allele O O
length O O
can O O
not O O
be O O
used O O
as O O
an O O
accurate O O
predictor O O
of O O
age O O
of O O
onset O O
. O O

In O O
order O O
to O O
further O O
characterize O O
the O O
dynamics O O
of O O
DM B-Disease B-Disease
CTG O O
repeat O O
somatic O O
instability O O
, O O
we O O
have O O
studied O O
repeat O O
length O O
changes O O
over O O
time O O
in O O
111 O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
patients O O
with O O
varying O O
clinical O O
severity O O
and O O
CTG O O
repeat O O
size O O
over O O
time O O
intervals O O
of O O
1 O O
- O O
7 O O
years O O
. O O

We O O
have O O
found O O
a O O
direct O O
progression O O
of O O
the O O
size O O
heterogeneity O O
over O O
time O O
related O O
to O O
initial O O
CTG O O
repeat O O
size O O
and O O
the O O
time O O
interval O O
and O O
always O O
biased O O
towards O O
further O O
expansion O O
. O O

Attempts O O
to O O
mathematically O O
model O O
the O O
dynamics O O
have O O
proved O O
only O O
partially O O
successful O O
suggesting O O
that O O
individual O O
specific O O
genetic O O
and/or O O
environmental O O
factors O O
also O O
play O O
a O O
role O O
in O O
somatic O O
mosaicism O O
.. O O

Aspartylglucosaminuria B-Disease B-Disease
among O O
Palestinian O O
Arabs O O
. O O

Aspartylglucosaminuria B-Disease B-Disease
( O O
AGU B-Disease B-Disease
) O O
is O O
a O O
rare O O
disorder B-Disease B-Disease
of I-Disease I-Disease
glycoprotein I-Disease I-Disease
metabolism I-Disease I-Disease
caused O O
by O O
the O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
lysosomal I-Disease I-Disease
enzyme I-Disease I-Disease
aspartylglucosaminidase I-Disease I-Disease
( O O
AGA O O
) O O
. O O

AGU B-Disease B-Disease
is O O
inherited O O
as O O
an O O
autosomal O O
recessive O O
trait O O
and O O
occurs O O
with O O
a O O
high O O
frequency O O
in O O
Finland O O
because O O
of O O
a O O
founder O O
effect O O
. O O

While O O
very O O
few O O
patients O O
with O O
AGU B-Disease B-Disease
have O O
been O O
reported O O
from O O
non O O
- O O
Finnish O O
origin O O
, O O
we O O
diagnosed O O
the O O
disorder O O
in O O
8 O O
patients O O
originating O O
from O O
3 O O
unrelated O O
families O O
, O O
all O O
Palestinian O O
Arabs O O
from O O
the O O
region O O
of O O
Jerusalem O O
. O O

The O O
clinical O O
diagnosis O O
of O O
AGU B-Disease B-Disease
is O O
often O O
difficult O O
, O O
in O O
particular O O
early O O
in O O
the O O
course O O
of O O
the O O
disease O O
, O O
and O O
most O O
of O O
the O O
patients O O
are O O
diagnosed O O
after O O
the O O
age O O
of O O
5 O O
years O O
. O O

However O O
, O O
since O O
these O O
patients O O
excrete O O
early O O
large O O
amounts O O
of O O
aspartylglucosamine O O
in O O
urine O O
, O O
biochemical O O
screening O O
is O O
easy O O
by O O
urine O O
chromatography O O
.. O O

Detection O O
of O O
heterozygous O O
carriers O O
of O O
the O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
ATM O O
) O O
gene O O
by O O
G2 O O
phase O O
chromosomal O O
radiosensitivity O O
of O O
peripheral O O
blood O O
lymphocytes O O
. O O

In O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
patients O O
, O O
mutations O O
in O O
a O O
single O O
gene O O
, O O
ATM O O
, O O
result O O
in O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
syndrome I-Disease I-Disease
that O O
embraces O O
a O O
variety O O
of O O
clinical O O
features O O
and O O
manifests O O
extreme O O
radiosensitivity O O
and O O
a O O
strong O O
pre O O
- O O
disposition O O
to O O
malignancy B-Disease B-Disease
. O O

Heterozygotes O O
for O O
the O O
ATM O O
gene O O
have O O
no O O
clinical O O
expression O O
of O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
but O O
may O O
be O O
cancer B-Disease B-Disease
prone O O
with O O
a O O
moderate O O
increase O O
in O O
in O O
vitro O O
radiosensitivity O O
. O O

We O O
performed O O
a O O
blind O O
chromosomal O O
analysis O O
on O O
G2-phase O O
lymphocytes O O
from O O
7 O O
unrelated O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
, O O
13 O O
obligate O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
heterozygotes O O
( O O
parents O O
of O O
the O O
patients O O
) O O
, O O
and O O
14 O O
normal O O
controls O O
following O O
X O O
- O O
irradiation O O
with O O
1 O O
Gy O O
in O O
order O O
to O O
evaluate O O
this O O
cytogenetic O O
method O O
as O O
a O O
tool O O
for O O
detection O O
of O O
ATM O O
carriers O O
. O O

Both O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
homozygotes O O
and O O
heterozygotes O O
showed O O
significantly O O
increased O O
levels O O
of O O
radiation O O
- O O
induced O O
chromatid O B-Disease
damage O I-Disease
relative O O
to O O
that O O
of O O
normal O O
controls O O
. O O

These O O
results O O
show O O
that O O
the O O
G2-phase O O
chromosomal O O
radiosensitivity O O
assay O O
can O O
be O O
used O O
for O O
the O O
detection O O
of O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
heterozygotes O O
. O O

In O O
combination O O
with O O
molecular O O
genetic O O
analyses O O
, O O
this O O
test O O
may O O
be O O
of O O
value O O
in O O
studies O O
of O O
familial B-Disease B-Disease
and I-Disease I-Disease
sporadic I-Disease I-Disease
cancers I-Disease I-Disease
aimed O O
at O O
determination O O
of O O
the O O
potential O O
involvement O O
of O O
ATM O O
mutations O O
in O O
tumor B-Disease B-Disease
risk O O
or O O
development O O
.. O O

Ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
: O O
identification O O
and O O
detection O O
of O O
founder O O
- O O
effect O O
mutations O O
in O O
the O O
ATM O O
gene O O
in O O
ethnic O O
populations O O
. O O

To O O
facilitate O O
the O O
evaluation O O
of O O
ATM O O
heterozygotes O O
for O O
susceptibility O O
to O O
other O O
diseases O O
, O O
such O O
as O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
we O O
have O O
attempted O O
to O O
define O O
the O O
most O O
common O O
mutations O O
and O O
their O O
frequencies O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
homozygotes O O
from O O
10 O O
ethnic O O
populations O O
. O O

Both O O
genomic O O
mutations O O
and O O
their O O
effects O O
on O O
cDNA O O
were O O
characterized O O
. O O

Protein O O
- O O
truncation O O
testing O O
of O O
the O O
entire O O
ATM O O
cDNA O O
detected O O
92 O O
( O O
66 O O
% O O
) O O
truncating O O
mutations O O
in O O
140 O O
mutant O O
alleles O O
screened O O
. O O

The O O
haplotyping O O
of O O
patients O O
with O O
identical O O
mutations O O
indicates O O
that O O
almost O O
all O O
of O O
these O O
represent O O
common O O
ancestry O O
and O O
that O O
very O O
few O O
spontaneously O O
recurring O O
ATM O O
mutations O O
exist O O
. O O

Assays O O
requiring O O
minimal O O
amounts O O
of O O
genomic O O
DNA O O
were O O
designed O O
to O O
allow O O
rapid O O
screening O O
for O O
common O O
ethnic O O
mutations O O
. O O

These O O
rapid O O
assays O O
detected O O
mutations O O
in O O
76 O O
% O O
of O O
Costa O O
Rican O O
patients O O
( O O
3 O O
) O O
, O O
50 O O
% O O
of O O
Norwegian O O
patients O O
( O O
1 O O
) O O
, O O
25 O O
% O O
of O O
Polish O O
patients O O
( O O
4 O O
) O O
, O O
and O O
14 O O
% O O
of O O
Italian O O
patients O O
( O O
1 O O
) O O
, O O
as O O
well O O
as O O
in O O
patients O O
of O O
Amish O O
/ O O
Mennonite O O
and O O
Irish O O
English O O
backgrounds O O
. O O

Additional O O
mutations O O
were O O
observed O O
in O O
Japanese O O
, O O
Utah O O
Mormon O O
, O O
and O O
African O O
American O O
patients O O
. O O

These O O
assays O O
should O O
facilitate O O
screening O O
for O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
heterozygotes O O
in O O
the O O
populations O O
studied O O
.. O O

The O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
tumor I-Disease I-Disease
suppressor O O
gene O O
is O O
required O O
for O O
cell O O
cycle O O
exit O O
upon O O
serum O O
withdrawal O O
. O O

The O O
inactivation O O
of O O
the O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
( I-Disease I-Disease
VHL I-Disease I-Disease
) I-Disease I-Disease
tumor I-Disease I-Disease
suppressor O O
gene O O
predisposes O O
affected O O
individuals O O
to O O
the O O
human O O
VHL B-Disease B-Disease
cancer I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
is O O
associated O O
with O O
sporadic B-Disease B-Disease
renal I-Disease I-Disease
cell I-Disease I-Disease
carcinomas I-Disease I-Disease
( O O
RCC B-Disease B-Disease
) O O
and O O
brain B-Disease B-Disease
hemangioblastomas I-Disease I-Disease
. O O

VHL O O
- O O
negative O O
786 O O
- O O
0 O O
RCC B-Disease B-Disease
cells O O
are O O
tumorigenic O O
in O O
nude O O
mice O O
which O O
is O O
suppressed O O
by O O
the O O
reintroduction O O
of O O
VHL B-Disease B-Disease
. O O

Remarkably O O
, O O
this O O
occurs O O
without O O
affecting O O
the O O
growth O O
rate O O
and O O
cell O O
cycle O O
profile O O
of O O
these O O
cells O O
in O O
culture O O
. O O

The O O
786 O O
- O O
0 O O
cell O O
line O O
, O O
like O O
many O O
cancer B-Disease O
cells O O
, O O
fails O O
to O O
exit O O
the O O
cell O O
cycle O O
upon O O
serum O O
withdrawal O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
reintroduction O O
of O O
the O O
wild O O
- O O
type O O
VHL B-Disease B-Disease
gene O O
restores O O
the O O
ability O O
of O O
VHL O O
- O O
negative O O
RCC B-Disease O
cancer I-Disease O
cells O O
to O O
exit O O
the O O
cell O O
cycle O O
and O O
enter O O
G0 O O
/ O O
quiescence O O
in O O
low O O
serum O O
. O O

Both O O
VHL O O
- O O
positive O O
and O O
VHL O O
- O O
negative O O
RCC B-Disease B-Disease
cells O O
exit O O
the O O
cell O O
cycle O O
by O O
contact O O
inhibition O O
. O O

The O O
cyclin O O
- O O
dependent O O
kinase O O
inhibitor O O
, O O
p27 O O
, O O
accumulates O O
upon O O
serum O O
withdrawal O O
, O O
only O O
in O O
the O O
presence O O
of O O
VHL B-Disease B-Disease
, O O
as O O
a O O
result O O
of O O
the O O
stabilization O O
of O O
the O O
protein O O
. O O

We O O
propose O O
that O O
the O O
loss O O
of O O
wild O O
- O O
type O O
VHL B-Disease B-Disease
gene O O
results O O
in O O
a O O
specific O O
cellular O O
defect O O
in O O
serum O O
- O O
dependent O O
growth O O
control O O
, O O
which O O
may O O
initiate O O
tumor B-Disease B-Disease
formation O O
. O O

This O O
is O O
corrected O O
by O O
the O O
reintroduction O O
of O O
wild O O
- O O
type O O
VHL B-Disease B-Disease
, O O
implicating O O
VHL B-Disease B-Disease
as O O
the O O
first O O
tumor B-Disease B-Disease
suppressor O O
involved O O
in O O
the O O
regulation O O
of O O
cell O O
cycle O O
exit O O
, O O
which O O
is O O
consistent O O
with O O
its O O
gatekeeper O O
function O O
in O O
the O O
kidney O O
.. O O

Piebaldism B-Disease B-Disease
with O O
deafness B-Disease B-Disease
: O O
molecular O O
evidence O O
for O O
an O O
expanded O O
syndrome O O
. O O

In O O
a O O
South O O
African O O
girl O O
of O O
Xhosa O O
stock O O
with O O
severe O O
piebaldism B-Disease B-Disease
and O O
profound O O
congenital O B-Disease
sensorineural B-Disease I-Disease
deafness I-Disease I-Disease
we O O
identified O O
a O O
novel O O
missense O O
substitution O O
at O O
a O O
highly O O
conserved O O
residue O O
in O O
the O O
intracellular O O
kinase O O
domain O O
of O O
the O O
KIT O O
proto O O
- O O
oncogene O O
, O O
R796 O O
G O O
. O O

Though O O
auditory B-Disease B-Disease
anomalies I-Disease I-Disease
have O O
been O O
observed O O
in O O
mice O O
with O O
dominant O O
white O O
spotting O O
( O O
W O O
) O O
due O O
to O O
KIT O O
mutations O O
, O O
deafness B-Disease B-Disease
is O O
not O O
typical O O
in O O
human O O
piebaldism B-Disease B-Disease
. O O

Thus O O
, O O
the O O
occurrence O O
of O O
sensorineural B-Disease B-Disease
deafness I-Disease I-Disease
in O O
this O O
patient O O
extends O O
considerably O O
the O O
phenotypic O O
range O O
of O O
piebaldism B-Disease B-Disease
due O O
to O O
KIT O O
gene O O
mutation O O
in O O
humans O O
and O O
tightens O O
the O O
clinical O O
similarity O O
between O O
piebaldism B-Disease B-Disease
and O O
the O O
various O O
forms O O
of O O
Waardenburg B-Disease B-Disease
syndrome I-Disease I-Disease
.. O O

Cycloheximide O O
facilitates O O
the O O
identification O O
of O O
aberrant O O
transcripts O O
resulting O O
from O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
. O O

Patients O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
often O O
show O O
decreased O O
expression O O
of O O
type O O
XVII O O
collagen O O
, O O
a O O
transmembrane O O
hemidesmosomal O O
protein O O
encoded O O
by O O
COL17A1 O O
. O O

This O O
report O O
documents O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
, O O
and O O
applies O O
a O O
new O O
methodology O O
to O O
define O O
and O O
characterize O O
the O O
resulting O O
mRNA O O
splice O O
variants O O
. O O

Mutational O O
analysis O O
of O O
COL17A1 O O
identified O O
a O O
maternally O O
inherited O O
G O O
- O O
to O O
- O O
T O O
transversion O O
at O O
the O O
-1 O O
position O O
of O O
exon O O
32 O O
. O O

This O O
acceptor O O
splice O O
- O O
site O O
mutation O O
led O O
to O O
the O O
formation O O
of O O
aberrant O O
transcripts O O
present O O
at O O
extremely O O
low O O
levels O O
. O O

Based O O
on O O
our O O
recent O O
finding O O
that O O
cycloheximide O O
stabilized O O
mutant O O
COL17A1 O O
transcripts O O
in O O
keratinocytes O O
homozygous O O
for O O
a O O
frameshift O O
mutation O O
, O O
the O O
effects O O
of O O
the O O
splice O O
- O O
site O O
mutation O O
on O O
splicing O O
of O O
COL17A1 O O
transcripts O O
were O O
determined O O
using O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
of O O
total O O
RNA O O
from O O
keratinocytes O O
incubated O O
for O O
2 O O
. O O
5 O O
h O O
in O O
the O O
presence O O
or O O
absence O O
of O O
10 O O
microg O O
cycloheximide O O
per O O
ml O O
. O O

Using O O
this O O
approach O O
, O O
an O O
abnormally O O
spliced O O
transcript O O
was O O
identified O O
that O O
contains O O
an O O
extra O O
264 O O
bases O O
upstream O O
from O O
exon O O
32 O O
, O O
resulting O O
in O O
a O O
premature O O
termination O O
codon O O
27 O O
bp O O
downstream O O
from O O
the O O
cryptic O O
splice O O
site O O
. O O

Three O O
other O O
splice O O
variants O O
, O O
including O O
one O O
derived O O
from O O
the O O
skipping O O
of O O
exon O O
32 O O
, O O
were O O
also O O
identified O O
. O O

These O O
results O O
indicate O O
the O O
usefulness O O
of O O
cycloheximide O O
treatment O O
in O O
evaluating O O
the O O
abnormal O O
processing O O
of O O
mRNA O O
due O O
to O O
splice O O
- O O
site O O
mutations O O
, O O
because O O
( O O
i O O
) O O
aberrant O O
splicing O O
often O O
generates O O
a O O
premature O O
termination O O
codon O O
, O O
( O O
ii O O
) O O
transcripts O O
with O O
premature O O
termination O O
codons O O
can O O
occur O O
at O O
low O O
or O O
undetectable O O
levels O O
due O O
to O O
nonsense O O
- O O
mediated O O
mRNA O O
decay O O
, O O
and O O
( O O
iii O O
) O O
the O O
levels O O
of O O
these O O
transcripts O O
can O O
be O O
increased O O
by O O
cycloheximide O O
. O O

A O O
deletion O O
mutation O O
in O O
COL17A1 O O
in O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
represents O O
propagation O O
of O O
an O O
ancestral O O
allele O O
. O O

Patients O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
, O O
a O O
usually O O
nonlethal O O
form O O
of O O
junctional B-Disease B-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
, O O
have O O
generalized O O
blistering B-Disease B-Disease
, O O
nail B-Disease B-Disease
dystrophy I-Disease I-Disease
, O O
patchy B-Disease O
alopecia I-Disease B-Disease
, O O
and O O
dental B-Disease B-Disease
abnormalities I-Disease I-Disease
. O O

Skin B-Disease B-Disease
fragility I-Disease I-Disease
in O O
most O O
cases O O
is O O
due O O
to O O
mutations O O
in O O
the O O
gene O O
encoding O O
type O O
XVII O O
collagen O O
( O O
COL17A1 O O
) O O
. O O

Recently O O
, O O
we O O
reported O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B-Disease B-Disease
benign I-Disease I-Disease
epidermolysis I-Disease I-Disease
bullosa I-Disease I-Disease
who O O
share O O
the O O
same O O
COL17A1 O O
mutation O O
. O O

Affected O O
individuals O O
in O O
three O O
families O O
are O O
homozygous O O
for O O
4003delTC O O
, O O
whereas O O
those O O
in O O
two O O
others O O
are O O
compound O O
heterozygotes O O
. O O

To O O
determine O O
if O O
the O O
occurrence O O
of O O
4003delTC O O
in O O
these O O
unrelated O O
families O O
signifies O O
propagation O O
of O O
an O O
ancestral O O
allele O O
or O O
a O O
mutational O O
hot O O
spot O O
, O O
haplotypes O O
were O O
determined O O
for O O
polymorphisms O O
both O O
within O O
and O O
flanking O O
COL17A1 O O
. O O

Five O O
intragenic O O
polymorphisms O O
were O O
chosen O O
based O O
on O O
their O O
informativeness O O
. O O

One O O
of O O
these O O
, O O
not O O
previously O O
reported O O
, O O
was O O
2988 O O
A O O
or O O
C O O
that O O
introduces O O
a O O
new O O
restriction O O
site O O
for O O
Eco0109 O O
I. O O
All O O
the O O
4003delTC O O
alleles O O
showed O O
the O O
same O O
haplotype O O
for O O
these O O
five O O
polymorphic O O
markers O O
. O O

Fourteen O O
microsatellite O O
polymorphisms O O
were O O
selected O O
based O O
on O O
their O O
high O O
heterozygosity O O
and O O
their O O
location O O
within O O
10q23-q25 O O
near O O
COL17A1 O O
. O O

Three O O
families O O
shared O O
microsatellite O O
polymorphisms O O
covering O O
at O O
most O O
19 O O
cM O O
, O O
whereas O O
the O O
others O O
shared O O
smaller O O
regions O O
consistent O O
with O O
cross O O
- O O
over O O
events O O
during O O
passage O O
of O O
this O O
mutation O O
through O O
several O O
generations O O
. O O

These O O
results O O
indicate O O
that O O
4003delTC O O
occurs O O
on O O
a O O
single O O
ancestral O O
allele O O
.. O O

The O O
haptoglobin O O
- O O
gene O O
deletion O O
responsible O O
for O O
anhaptoglobinemia B-Disease B-Disease
. O O

We O O
have O O
found O O
an O O
allelic O O
deletion O O
of O O
the O O
haptoglobin O O
( O O
Hp O O
) O O
gene O O
from O O
an O O
individual O O
with O O
anhaptoglobinemia B-Disease B-Disease
. O O

The O O
Hp O O
gene O O
cluster O O
consists O O
of O O
coding O O
regions O O
of O O
the O O
alpha O O
chain O O
and O O
beta O O
chain O O
of O O
the O O
haptoglobin O O
gene O O
( O O
Hp O O
) O O
and O O
of O O
the O O
alpha O O
chain O O
and O O
beta O O
chain O O
of O O
the O O
haptoglobin O O
- O O
related O O
gene O O
( O O
Hpr O O
) O O
, O O
in O O
tandem O O
from O O
the O O
5 O O
side O O
. O O

Southern O O
blot O O
and O O
PCR O O
analyses O O
have O O
indicated O O
that O O
the O O
individual O O
with O O
anhaptoglobinemia B-Disease B-Disease
was O O
homozygous O O
for O O
the O O
gene O O
deletion O O
and O O
that O O
the O O
gene O O
deletion O O
was O O
included O O
at O O
least O O
from O O
the O O
promoter O O
region O O
of O O
Hp O O
to O O
Hpr O O
alpha O O
but O O
not O O
to O O
Hpr O O
beta O O
( O O
Hpdel O O
) O O
. O O

In O O
addition O O
, O O
we O O
found O O
seven O O
individuals O O
with O O
hypohaptoglobinemia B-Disease B-Disease
in O O
three O O
families O O
, O O
and O O
the O O
genotypes O O
of O O
six O O
of O O
the O O
seven O O
individuals O O
were O O
found O O
to O O
be O O
Hp2 O O
/ O O
Hpdel O O
. O O

The O O
phenotypes O O
and O O
genotypes O O
in O O
one O O
of O O
these O O
three O O
families O O
showed O O
the O O
father O O
to O O
be O O
hypohaptoglobinemic B-Disease B-Disease
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
the O O
mother O O
to O O
be O O
Hp2 O O
- O O
1 O O
and O O
Hp1 O O
/ O O
Hp2 O O
, O O
one O O
of O O
the O O
two O O
children O O
to O O
be O O
hypohaptoglobinemic B-Disease B-Disease
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
and O O
the O O
other O O
child O O
to O O
be O O
Hp1 O O
and O O
Hp1 O O
/ O O
Hpdel O O
, O O
showing O O
an O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
in O O
the O O
child O O
with O O
Hp1 O O
. O O

The O O
Hp2 O O
/ O O
Hpdel O O
individuals O O
had O O
an O O
extremely O O
low O O
level O O
of O O
Hp O O
( O O
mean O O
+ O O
/-SD O O
= O O
0 O O
. O O
049 O O
+ O O
/-0 O O
. O O

043 O O
mg O O
/ O O
ml O O
; O O
n O O
= O O
6 O O
) O O
, O O
compared O O
with O O
the O O
level O O
( O O
1 O O
. O O
64 O O
+ O O
/-1 O O
. O O

07 O O
mg O O
/ O O
ml O O
) O O
obtained O O
from O O
52 O O
healthy O O
volunteers O O
having O O
phenotype O O
Hp2 O O
, O O
whereas O O
the O O
serum O O
Hp O O
level O O
of O O
an O O
individual O O
with O O
Hp1 O O
/ O O
Hpdel O O
was O O
0 O O
. O O
50 O O
mg O O
/ O O
ml O O
, O O
which O O
was O O
approximately O O
half O O
the O O
level O O
of O O
Hp O O
in O O
control O O
sera O O
from O O
the O O
Hp1 O O
phenotype O O
( O O
1 O O
. O O
26 O O
+ O O
/-0 O O
. O O

33 O O
mg O O
/ O O
ml O O
; O O
n O O
= O O
9 O O
) O O
, O O
showing O O
a O O
gene O O
- O O
dosage O O
effect O O
. O O

The O O
other O O
allele O O
( O O
Hp2 O O
) O O
of O O
individuals O O
with O O
Hp2 O O
/ O O
Hpdel O O
was O O
found O O
to O O
have O O
, O O
in O O
all O O
exons O O
, O O
no O O
mutation O O
, O O
by O O
DNA O O
sequencing O O
. O O

On O O
the O O
basis O O
of O O
the O O
present O O
study O O
, O O
the O O
mechanism O O
of O O
anhaptoglobinemia B-Disease B-Disease
and O O
the O O
mechanism O O
of O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
were O O
well O O
explained O O
. O O

However O O
, O O
the O O
mechanism O O
of O O
hypohaptoglobinemia B-Disease B-Disease
remains O O
unknown O O

ATM O O
mutations O O
and O O
phenotypes O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
families O O
in O O
the O O
British O O
Isles O O
: O O
expression O O
of O O
mutant O O
ATM O O
and O O
the O O
risk O O
of O O
leukemia B-Disease B-Disease
, O O
lymphoma B-Disease B-Disease
, O O
and O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

We O O
report O O
the O O
spectrum O O
of O O
59 O O
ATM O O
mutations O O
observed O O
in O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
patients O O
in O O
the O O
British O O
Isles O O
. O O

Of O O
51 O O
ATM O O
mutations O O
identified O O
in O O
families O O
native O O
to O O
the O O
British O O
Isles O O
, O O
11 O O
were O O
founder O O
mutations O O
, O O
and O O
2 O O
of O O
these O O
11 O O
conferred O O
a O O
milder O O
clinical O O
phenotype O O
with O O
respect O O
to O O
both O O
cerebellar B-Disease B-Disease
degeneration I-Disease I-Disease
and O O
cellular O O
features O O
. O O

We O O
report O O
, O O
in O O
two O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
families O O
, O O
an O O
ATM O O
mutation O O
( O O
7271T-- O O
> O O
G O O
) O O
that O O
may O O
be O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
in O O
both O O
homozygotes O O
and O O
heterozygotes O O
( O O
relative O O
risk O O
12 O O
. O O
7 O O
; O O
P O O
= O O
. O O
0025 O O
) O O
, O O
although O O
there O O
is O O
a O O
less O O
severe O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
phenotype O O
in O O
terms O O
of O O
the O O
degree O O
of O O
cerebellar B-Disease B-Disease
degeneration I-Disease I-Disease
. O O

This O O
mutation O O
( O O
7271T-- O O
> O O
G O O
) O O
also O O
allows O O
expression O O
of O O
full O O
- O O
length O O
ATM O O
protein O O
at O O
a O O
level O O
comparable O O
with O O
that O O
in O O
unaffected O O
individuals O O
. O O

In O O
addition O O
, O O
we O O
have O O
studied O O
18 O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
, O O
in O O
15 O O
families O O
, O O
who O O
developed O O
leukemia B-Disease B-Disease
, O O
lymphoma B-Disease B-Disease
, O O
preleukemic O O
T O O
- O O
cell O O
proliferation O O
, O O
or O O
Hodgkin B-Disease B-Disease
lymphoma I-Disease I-Disease
, O O
mostly O O
in O O
childhood O O
. O O

A O O
wide O O
variety O O
of O O
ATM O O
mutation O O
types O O
, O O
including O O
missense O O
mutations O O
and O O
in O O
- O O
frame O O
deletions O O
, O O
were O O
seen O O
in O O
these O O
patients O O
. O O

We O O
also O O
show O O
that O O
25 O O
% O O
of O O
all O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
carried O O
in O O
- O O
frame O O
deletions O O
or O O
missense O O
mutations O O
, O O
many O O
of O O
which O O
were O O
also O O
associated O O
with O O
expression O O
of O O
mutant O O
ATM O O
protein O O
. O O

The O O
DMPK O O
gene O O
of O O
severely O O
affected O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
patients O O
is O O
hypermethylated O O
proximal O O
to O O
the O O
largely O O
expanded O O
CTG O O
repeat O O
. O O

Using O O
methylation O O
- O O
sensitive O O
restriction O O
enzymes O O
, O O
we O O
characterized O O
the O O
methylation O O
pattern O O
on O O
the O O
5 O O
side O O
of O O
the O O
CTG O O
repeat O O
in O O
the O O
DMPK O O
gene O O
of O O
normal O O
individuals O O
and O O
of O O
patients O O
affected O O
with O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
, O O
showing O O
expansions O O
of O O
the O O
repetitive O O
sequence O O
. O O

The O O
gene O O
segment O O
analyzed O O
corresponds O O
to O O
the O O
genomic O O
SacI O O
- O O
HindIII O O
fragment O O
carrying O O
exons O O
11 O O
- O O
15 O O
. O O

There O O
is O O
constitutive O O
methylation O O
in O O
intron O O
12 O O
at O O
restriction O O
sites O O
of O O
SacII O O
and O O
HhaI O O
, O O
localized O O
1 O O
, O O
159 O O
- O O
1 O O
, O O
232 O O
bp O O
upstream O O
of O O
the O O
CTG O O
repeat O O
, O O
whereas O O
most O O
, O O
if O O
not O O
all O O
, O O
of O O
the O O
other O O
sites O O
of O O
SacII O O
, O O
HhaI O O
, O O
and O O
HpaII O O
in O O
this O O
region O O
are O O
unmethylated O O
, O O
in O O
normal O O
individuals O O
and O O
most O O
of O O
the O O
patients O O
. O O

In O O
a O O
number O O
of O O
young O O
and O O
severely O O
affected O O
patients O O
, O O
however O O
, O O
complete O O
methylation O O
of O O
these O O
restriction O O
sites O O
was O O
found O O
in O O
the O O
mutated O O
allele O O
. O O

In O O
most O O
of O O
these O O
patients O O
, O O
the O O
onset O O
of O O
the O O
disease O O
was O O
congenital O O
. O O

Preliminary O O
in O O
vivo O O
footprinting O O
data O O
gave O O
evidence O O
for O O
protein O O
- O O
DNA O O
contact O O
in O O
normal O O
genes O O
at O O
an O O
Sp1 O O
consensus O O
binding O O
site O O
upstream O O
of O O
the O O
CTG O O
repeat O O
and O O
for O O
a O O
significant O O
reduction O O
of O O
this O O
interaction O O
in O O
cells O O
with O O
a O O
hypermethylated O O
DMPK O O
gene O O
.. O O

The O O
hemochromatosis B-Disease B-Disease
gene O O
product O O
complexes O O
with O O
the O O
transferrin O O
receptor O O
and O O
lowers O O
its O O
affinity O O
for O O
ligand O O
binding O O
. O O

We O O
recently O O
reported O O
the O O
positional O O
cloning O O
of O O
a O O
candidate O O
gene O O
for O O
hereditary B-Disease B-Disease
hemochromatosis I-Disease I-Disease
called O O
HFE O O
. O O

The O O
gene O O
product O O
, O O
a O O
member O O
of O O
the O O
major O O
histocompatibility O O
complex O O
class O O
I O O
- O O
like O O
family O O
, O O
was O O
found O O
to O O
have O O
a O O
mutation O O
, O O
Cys-282 O O
-- O O
> O O
Tyr O O
( O O
C282Y O O
) O O
, O O
in O O
85 O O
% O O
of O O
patient O O
chromosomes O O
. O O

This O O
mutation O O
eliminates O O
the O O
ability O O
of O O
HFE O O
to O O
associate O O
with O O
beta2-microglobulin O O
( O O
beta2 O O
m O O
) O O
and O O
prevents O O
cell O O
- O O
surface O O
expression O O
. O O

A O O
second O O
mutation O O
that O O
has O O
no O O
effect O O
on O O
beta2 O O
m O O
association O O
, O O
H63D O O
, O O
was O O
found O O
in O O
eight O O
out O O
of O O
nine O O
patients O O
heterozygous O O
for O O
the O O
C282Y O O
mutant O O
. O O

In O O
this O O
report O O
, O O
we O O
demonstrate O O
in O O
cultured O O
293 O O
cells O O
overexpressing O O
wild O O
- O O
type O O
or O O
mutant O O
HFE O O
proteins O O
that O O
both O O
the O O
wild O O
- O O
type O O
and O O
H63D O O
HFE O O
proteins O O
form O O
stable O O
complexes O O
with O O
the O O
transferrin O O
receptor O O
( O O
TfR O O
) O O
. O O

The O O
C282Y O O
mutation O O
nearly O O
completely O O
prevents O O
the O O
association O O
of O O
the O O
mutant O O
HFE O O
protein O O
with O O
the O O
TfR. O O
Studies O O
on O O
cell O O
- O O
associated O O
transferrin O O
at O O
37 O O
degrees O O
C O O
suggest O O
that O O
the O O
overexpressed O O
wild O O
- O O
type O O
HFE O O
protein O O
decreases O O
the O O
affinity O O
of O O
the O O
TfR O O
for O O
transferrin O O
. O O

The O O
overexpressed O O
H63D O O
protein O O
does O O
not O O
have O O
this O O
effect O O
, O O
providing O O
the O O
first O O
direct O O
evidence O O
for O O
a O O
functional O O
consequence O O
of O O
the O O
H63D O O
mutation O O
. O O

Addition O O
of O O
soluble O O
wild O O
- O O
type O O
HFE O O
/ O O
beta2 O O
m O O
heterodimers O O
to O O
cultured O O
cells O O
also O O
decreased O O
the O O
apparent O O
affinity O O
of O O
the O O
TfR O O
for O O
its O O
ligand O O
under O O
steady O O
- O O
state O O
conditions O O
, O O
both O O
in O O
293 O O
cells O O
and O O
in O O
HeLa O O
cells O O
. O O

Furthermore O O
, O O
at O O
4 O O
degrees O O
C O O
, O O
the O O
added O O
soluble O O
complex O O
of O O
HFE O O
/ O O
beta2 O O
m O O
inhibited O O
binding O O
of O O
transferrin O O
to O O
HeLa O O
cell O O
TfR O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Scatchard O O
plots O O
of O O
these O O
data O O
indicate O O
that O O
the O O
added O O
heterodimer O O
substantially O O
reduced O O
the O O
affinity O O
of O O
TfR O O
for O O
transferrin O O
. O O

These O O
results O O
establish O O
a O O
molecular O O
link O O
between O O
HFE O O
and O O
a O O
key O O
protein O O
involved O O
in O O
iron O O
transport O O
, O O
the O O
TfR O O
, O O
and O O
raise O O
the O O
possibility O O
that O O
alterations O O
in O O
this O O
regulatory O O
mechanism O O
may O O
play O O
a O O
role O O
in O O
the O O
pathogenesis O O
of O O
hereditary B-Disease B-Disease
hemochromatosis I-Disease I-Disease
.. O O

Genomic O O
organization O O
of O O
the O O
UBE3A O O
/ O O
E6-AP O O
gene O O
and O O
related O O
pseudogenes O O
. O O

The O O
UBE3A O O
gene O O
encodes O O
the O O
E6-AP O O
ubiquitin O O
- O O
protein O O
ligase O O
and O O
has O O
recently O O
been O O
shown O O
to O O
be O O
mutated O O
in O O
Angelman B-Disease B-Disease
syndrome I-Disease I-Disease
patients O O
who O O
lack O O
15q11-q13 O O
deletions O O
or O O
chromosome O O
15 O O
paternal O O
uniparental B-Disease B-Disease
disomy I-Disease I-Disease
. O O

Previous O O
UBE3A O O
cDNA O O
analysis O O
has O O
shown O O
a O O
coding O O
region O O
of O O
approximately O O
2 O O
. O O
6 O O
kb O O
and O O
a O O
3-untranslated O O
region O O
( O O
UTR O O
) O O
of O O
< O O
50 O O
bp O O
, O O
whereas O O
Northern O O
analysis O O
has O O
indicated O O
mRNA O O
sizes O O
of O O
5 O O
- O O
8 O O
kb O O
. O O

We O O
have O O
analyzed O O
additional O O
cDNA O O
clones O O
and O O
provide O O
evidence O O
for O O
an O O
additional O O
0 O O
. O O
5 O O
kb O O
of O O
5-UTR O O
and O O
> O O
2 O O
kb O O
of O O
3-UTR O O
. O O

We O O
have O O
established O O
the O O
genomic O O
organization O O
of O O
UBE3A O O
and O O
the O O
sequence O O
of O O
intron O O
- O O
exon O O
borders O O
. O O

We O O
have O O
also O O
mapped O O
two O O
highly O O
homologous O O
processed O O
pseudogenes O O
, O O
UBE3AP1 O O
and O O
UBE3AP2 O O
, O O
to O O
chromosomes O O
2 O O
and O O
21 O O
, O O
respectively O O
, O O
and O O
determined O O
their O O
genomic O O
organization O O
. O O

These O O
results O O
will O O
form O O
the O O
basis O O
for O O
studies O O
of O O
mutation O O
and O O
imprinting O O
of O O
UBE3A O O
. O O

Mutation O O
spectrum O O
and O O
genotype O O
- O O
phenotype O O
analyses O O
in O O
Cowden B-Disease B-Disease
disease I-Disease I-Disease
and O O
Bannayan B-Disease B-Disease
- I-Disease I-Disease
Zonana I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
two O O
hamartoma B-Disease B-Disease
syndromes I-Disease I-Disease
with O O
germline O O
PTEN O O
mutation O O
. O O

The O O
tumour B-Disease B-Disease
suppressor O O
gene O O
PTEN O O
, O O
which O O
maps O O
to O O
10q23 O O
. O O

3 O O
and O O
encodes O O
a O O
403 O O
amino O O
acid O O
dual O O
specificity O O
phosphatase O O
( O O
protein O O
tyrosine O O
phosphatase O O
; O O
PTPase O O
) O O
, O O
was O O
shown O O
recently O O
to O O
play O O
a O O
broad O O
role O O
in O O
human O O
malignancy B-Disease B-Disease
. O O

Somatic O O
PTEN O O
deletions O O
and O O
mutations O O
were O O
observed O O
in O O
sporadic B-Disease B-Disease
breast I-Disease I-Disease
, I-Disease I-Disease
brain I-Disease I-Disease
, I-Disease I-Disease
prostate I-Disease I-Disease
and I-Disease I-Disease
kidney I-Disease I-Disease
cancer I-Disease I-Disease
cell O O
lines O O
and O O
in O O
several O O
primary O O
tumours B-Disease B-Disease
such O O
as O O
endometrial B-Disease B-Disease
carcinomas I-Disease I-Disease
, O O
malignant B-Disease B-Disease
melanoma I-Disease I-Disease
and O O
thyroid B-Disease B-Disease
tumours I-Disease I-Disease
. O O

In O O
addition O O
, O O
PTEN O O
was O O
identified O O
as O O
the O O
susceptibility O O
gene O O
for O O
two O O
hamartoma B-Disease B-Disease
syndromes I-Disease I-Disease
Cowden B-Disease B-Disease
disease I-Disease I-Disease
( O O
CD B-Disease B-Disease
; O O
MIM O O
158350 O O
) O O
and O O
Bannayan B-Disease B-Disease
- I-Disease I-Disease
Zonana I-Disease I-Disease
( I-Disease O
BZS I-Disease B-Disease
) I-Disease O
or I-Disease O
Ruvalcaba I-Disease B-Disease
- I-Disease I-Disease
Riley I-Disease I-Disease
- I-Disease I-Disease
Smith I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
MIM O O
153480 O O
) O O
. O O

Constitutive O O
DNA O O
from O O
37 O O
CD B-Disease B-Disease
families O O
and O O
seven O O
BZS B-Disease B-Disease
families O O
was O O
screened O O
for O O
germline O O
PTEN O O
mutations O O
. O O

PTEN O O
mutations O O
were O O
identified O O
in O O
30 O O
of O O
37 O O
( O O
81 O O
% O O
) O O
CD B-Disease B-Disease
families O O
, O O
including O O
missense O O
and O O
nonsense O O
point O O
mutations O O
, O O
deletions O O
, O O
insertions O O
, O O
a O O
deletion O O
/ O O
insertion O O
and O O
splice O O
site O O
mutations O O
. O O

These O O
mutations O O
were O O
scattered O O
over O O
the O O
entire O O
length O O
of O O
PTEN O O
, O O
with O O
the O O
exception O O
of O O
the O O
first O O
, O O
fourth O O
and O O
last O O
exons O O
. O O

A O O
hot O O
spot O O
for O O
PTEN O O
mutation O O
in O O
CD B-Disease B-Disease
was O O
identified O O
in O O
exon O O
5 O O
that O O
contains O O
the O O
PTPase O O
core O O
motif O O
, O O
with O O
13 O O
of O O
30 O O
( O O
43 O O
% O O
) O O
CD B-Disease B-Disease
mutations O O
identified O O
in O O
this O O
exon O O
. O O

Seven O O
of O O
30 O O
( O O
23 O O
% O O
) O O
were O O
within O O
the O O
core O O
motif O O
, O O
the O O
majority O O
( O O
five O O
of O O
seven O O
) O O
of O O
which O O
were O O
missense O O
mutations O O
, O O
possibly O O
pointing O O
to O O
the O O
functional O O
significance O O
of O O
this O O
region O O
. O O

Germline O O
PTEN O O
mutations O O
were O O
identified O O
in O O
four O O
of O O
seven O O
( O O
57 O O
% O O
) O O
BZS B-Disease B-Disease
families O O
studied O O
. O O

Interestingly O O
, O O
none O O
of O O
these O O
mutations O O
was O O
observed O O
in O O
the O O
PTPase O O
core O O
motif O O
. O O

It O O
is O O
also O O
worthy O O
of O O
note O O
that O O
a O O
single O O
nonsense O O
point O O
mutation O O
, O O
R233X O O
, O O
was O O
observed O O
in O O
the O O
germline O O
DNA O O
from O O
two O O
unrelated O O
CD B-Disease B-Disease
families O O
and O O
one O O
BZS B-Disease B-Disease
family O O
. O O

Genotype O O
- O O
phenotype O O
studies O O
were O O
not O O
performed O O
on O O
this O O
small O O
group O O
of O O
BZS B-Disease B-Disease
families O O
. O O

However O O
, O O
genotype O O
- O O
phenotype O O
analysis O O
inthe O O
group O O
of O O
CD B-Disease B-Disease
families O O
revealed O O
two O O
possible O O
associations O O
worthy O O
of O O
follow O O
- O O
up O O
in O O
independent O O
analyses O O
. O O

The O O
first O O
was O O
an O O
association O O
noted O O
in O O
the O O
group O O
of O O
CD B-Disease B-Disease
families O O
with O O
breast B-Disease B-Disease
disease I-Disease I-Disease
. O O

A O O
correlation O O
was O O
observed O O
between O O
the O O
presence O O
/ O O
absence O O
of O O
a O O
PTEN O O
mutation O O
and O O
the O O
type O O
of O O
breast O B-Disease
involvement O I-Disease
( O O
unaffected O O
versus O O
benign O O
versus O O
malignant O O
) O O
. O O

Specifically O O
and O O
more O O
directly O O
, O O
an O O
association O O
was O O
also O O
observed O O
between O O
the O O
presence O O
of O O
a O O
PTEN O O
mutation O O
and O O
malignant B-Disease B-Disease
breast I-Disease I-Disease
disease I-Disease I-Disease
. O O

Secondly O O
, O O
there O O
appeared O O
to O O
be O O
an O O
interdependent O O
association O O
between O O
mutations O O
upstream O O
and O O
within O O
the O O
PTPase O O
core O O
motif O O
, O O
the O O
core O O
motif O O
containing O O
the O O
majority O O
of O O
missense O O
mutations O O
, O O
and O O
the O O
involvement O O
of O O
all O O
major O O
organ O O
systems O O
( O O
central O O
nervous O O
system O O
, O O
thyroid O O
, O O
breast O O
, O O
skin O O
and O O
gastrointestinal O O
tract O O
) O O
. O O

However O O
, O O
these O O
observations O O
would O O
need O O
to O O
be O O
confirmed O O
by O O
studying O O
a O O
larger O O
number O O
of O O
CD B-Disease B-Disease
families O O
. O O

Molecular O O
defects O O
leading O O
to O O
human O O
complement B-Disease B-Disease
component I-Disease I-Disease
C6 I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
an O O
African O O
- O O
American O O
family O O
. O O

Complement B-Disease B-Disease
component I-Disease I-Disease
C6 I-Disease I-Disease
deficiency I-Disease I-Disease
( O O
C6D B-Disease B-Disease
) O O
was O O
diagnosed O O
in O O
a O O
16-year O O
- O O
old O O
African O O
- O O
American O O
male O O
with O O
meningococcal B-Disease B-Disease
meningitis I-Disease I-Disease
. O O

The O O
patients O O
father O O
and O O
two O O
brothers O O
also O O
had O O
C6D B-Disease B-Disease
, O O
but O O
gave O O
no O O
history O O
of O O
meningitis B-Disease B-Disease
or O O
other O O
neisserial B-Disease B-Disease
infection I-Disease I-Disease
. O O

By O O
using O O
exon O O
- O O
specific O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
/ O O
single O O
- O O
strand O O
conformation O O
polymorphism O O
as O O
a O O
screening O O
step O O
and O O
nucleotide O O
sequencing O O
of O O
target O O
exons O O
, O O
we O O
determined O O
that O O
the O O
proband O O
was O O
a O O
compound O O
heterozygote O O
for O O
two O O
C6 O O
gene O O
mutations O O
. O O

The O O
first O O
, O O
1195delC O O
located O O
in O O
exon O O
7 O O
, O O
is O O
a O O
novel O O
mutation O O
, O O
while O O
the O O
second O O
, O O
1936delG O O
in O O
exon O O
12 O O
, O O
has O O
been O O
described O O
before O O
to O O
cause O O
C6D B-Disease B-Disease
in O O
an O O
unrelated O O
African O O
- O O
American O O
individual O O
. O O

Both O O
mutations O O
result O O
in O O
premature O O
termination O O
codons O O
and O O
C6 O O
null O O
alleles O O
. O O

Allele O O
- O O
specific O O
PCR O O
indicated O O
that O O
the O O
probands O O
two O O
brothers O O
also O O
inherited O O
the O O
1195delC O O
mutation O O
from O O
their O O
heterozygous O O
mother O O
and O O
the O O
1936delG O O
mutation O O
from O O
their O O
homozygous O O
father O O
.. O O

PAX6 O O
mutations O O
reviewed O O
. O O

Mutations O O
in O O
PAX6 O O
are O O
responsible O O
for O O
human O O
aniridia B-Disease B-Disease
and O O
have O O
also O O
been O O
found O O
in O O
patients O O
with O O
Peters B-Disease B-Disease
anomaly I-Disease I-Disease
, O O
with O O
congenital B-Disease B-Disease
cataracts I-Disease I-Disease
, O O
with O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
keratitis I-Disease I-Disease
, O O
and O O
with O O
isolated B-Disease O
foveal I-Disease B-Disease
hypoplasia I-Disease I-Disease
. O O

No O O
locus O O
other O O
than O O
chromosome O O
11p13 O O
has O O
been O O
implicated O O
in O O
aniridia B-Disease B-Disease
, O O
and O O
PAX6 O O
is O O
clearly O O
the O O
major O O
, O O
if O O
not O O
only O O
, O O
gene O O
responsible O O
. O O

Twenty O O
- O O
eight O O
percent O O
of O O
identified O O
PAX6 O O
mutations O O
are O O
C O O
- O O
T O O
changes O O
at O O
CpG O O
dinucleotides O O
, O O
20 O O
% O O
are O O
splicing O O
errors O O
, O O
and O O
more O O
than O O
30 O O
% O O
are O O
deletion O O
or O O
insertion O O
events O O
. O O

There O O
is O O
a O O
noticeably O O
elevated O O
level O O
of O O
mutation O O
in O O
the O O
paired O O
domain O O
compared O O
with O O
the O O
rest O O
of O O
the O O
gene O O
. O O

Increased O O
mutation O O
in O O
the O O
homeodomain O O
is O O
accounted O O
for O O
by O O
the O O
hypermutable O O
CpG O O
dinucleotide O O
in O O
codon O O
240 O O
. O O

Very O O
nearly O O
all O O
mutations O O
appear O O
to O O
cause O O
loss O O
of O O
function O O
of O O
the O O
mutant O O
allele O O
, O O
and O O
more O O
than O O
80 O O
% O O
of O O
exonic O O
substitutions O O
result O O
in O O
nonsense O O
codons O O
. O O

In O O
a O O
gene O O
with O O
such O O
extraordinarily O O
high O O
sequence O O
conservation O O
throughout O O
evolution O O
, O O
there O O
are O O
presumed O O
undiscovered O O
missense O O
mutations O O
, O O
these O O
are O O
hypothesized O O
to O O
exist O O
in O O
as O O
- O O
yet O O
unidentified O O
phenotypes O O
.. O O

Genetic O O
heterogeneity O O
and O O
penetrance O O
analysis O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
genes O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
families O O
. O O

The O O
Breast B-Disease B-Disease
Cancer I-Disease I-Disease
Linkage O O
Consortium O O
. O O

The O O
contribution O O
of O O
BRCA1 O O
and O O
BRCA2 O O
to O O
inherited B-Disease B-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
was O O
assessed O O
by O O
linkage O O
and O O
mutation O O
analysis O O
in O O
237 O O
families O O
, O O
each O O
with O O
at O O
least O O
four O O
cases O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
, O O
collected O O
by O O
the O O
Breast B-Disease B-Disease
Cancer I-Disease I-Disease
Linkage O O
Consortium O O
. O O

Families O O
were O O
included O O
without O O
regard O O
to O O
the O O
occurrence O O
of O O
ovarian B-Disease B-Disease
or I-Disease I-Disease
other I-Disease I-Disease
cancers I-Disease I-Disease
. O O

Overall O O
, O O
disease O O
was O O
linked O O
to O O
BRCA1 O O
in O O
an O O
estimated O O
52 O O
% O O
of O O
families O O
, O O
to O O
BRCA2 O O
in O O
32 O O
% O O
of O O
families O O
, O O
and O O
to O O
neither O O
gene O O
in O O
16 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
6 O O
% O O
-28 O O
% O O
) O O
, O O
suggesting O O
other O O
predisposition O O
genes O O
. O O

The O O
majority O O
( O O
81 O O
% O O
) O O
of O O
the O O
breast B-Disease B-Disease
- I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
were O O
due O O
to O O
BRCA1 O O
, O O
with O O
most O O
others O O
( O O
14 O O
% O O
) O O
due O O
to O O
BRCA2 O O
. O O

Conversely O O
, O O
the O O
majority O O
of O O
families O O
with O O
male B-Disease B-Disease
and I-Disease I-Disease
female I-Disease I-Disease
breast I-Disease I-Disease
cancer I-Disease I-Disease
were O O
due O O
to O O
BRCA2 O O
( O O
76 O O
% O O
) O O
. O O

The O O
largest O O
proportion O O
( O O
67 O O
% O O
) O O
of O O
families O O
due O O
to O O
other O O
genes O O
was O O
found O O
in O O
families O O
with O O
four O O
or O O
five O O
cases O O
of O O
female O B-Disease
breast B-Disease I-Disease
cancer I-Disease I-Disease
only O O
. O O

These O O
estimates O O
were O O
not O O
substantially O O
affected O O
either O O
by O O
changing O O
the O O
assumed O O
penetrance O O
model O O
for O O
BRCA1 O O
or O O
by O O
including O O
or O O
excluding O O
BRCA1 O O
mutation O O
data O O
. O O

Among O O
those O O
families O O
with O O
disease O O
due O O
to O O
BRCA1 O O
that O O
were O O
tested O O
by O O
one O O
of O O
the O O
standard O O
screening O O
methods O O
, O O
mutations O O
were O O
detected O O
in O O
the O O
coding O O
sequence O O
or O O
splice O O
sites O O
in O O
an O O
estimated O O
63 O O
% O O
( O O
95 O O
% O O
CI O O
51 O O
% O O
-77 O O
% O O
) O O
. O O

The O O
estimated O O
sensitivity O O
was O O
identical O O
for O O
direct O O
sequencing O O
and O O
other O O
techniques O O
. O O

The O O
penetrance O O
of O O
BRCA2 O O
was O O
estimated O O
by O O
maximizing O O
the O O
LOD O O
score O O
in O O
BRCA2-mutation O O
families O O
, O O
over O O
all O O
possible O O
penetrance O O
functions O O
. O O

The O O
estimated O O
cumulative O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
reached O O
28 O O
% O O
( O O
95 O O
% O O
CI O O
9 O O
% O O
-44 O O
% O O
) O O
by O O
age O O
50 O O
years O O
and O O
84 O O
% O O
( O O
95 O O
% O O
CI O O
43 O O
% O O
-95 O O
% O O
) O O
by O O
age O O
70 O O
years O O
. O O

The O O
corresponding O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
risks O O
were O O
0 O O
. O O
4 O O
% O O
( O O
95 O O
% O O
CI O O
0 O O
% O O
-1 O O
% O O
) O O
by O O
age O O
50 O O
years O O
and O O
27 O O
% O O
( O O
95 O O
% O O
CI O O
0 O O
% O O
-47 O O
% O O
) O O
by O O
age O O
70 O O
years O O
. O O

The O O
lifetime O O
risk O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
appears O O
similar O O
to O O
the O O
risk O O
in O O
BRCA1 O O
carriers O O
, O O
but O O
there O O
was O O
some O O
suggestion O O
of O O
a O O
lower O O
risk O O
in O O
BRCA2 O O
carriers O O
< O O
50 O O
years O O
of O O
age O O
. O O

Eye B-Disease B-Disease
movement I-Disease I-Disease
abnormalities I-Disease I-Disease
correlate O O
with O O
genotype O O
in O O
autosomal O B-Disease
dominant O I-Disease
cerebellar B-Disease I-Disease
ataxia I-Disease I-Disease
type I-Disease I-Disease
I. I-Disease I-Disease
We O O
compared O O
horizontal O O
eye O O
movements O O
( O O
visually O O
guided O O
saccades O O
, O O
antisaccades O O
, O O
and O O
smooth O O
pursuit O O
) O O
in O O
control O O
subjects O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
with O O
three O O
forms O O
of O O
autosomal O B-Disease
dominant O I-Disease
cerebellar B-Disease I-Disease
ataxias I-Disease I-Disease
type I-Disease B-Disease
I I-Disease I-Disease
spinocerebellar B-Disease B-Disease
ataxias I-Disease I-Disease
1 I-Disease I-Disease
and I-Disease I-Disease
2 I-Disease I-Disease
( O O
SCA1 B-Disease B-Disease
, O O
n O O
= O O
11 O O
; O O
SCA2 B-Disease B-Disease
, O O
n O O
= O O
10 O O
) O O
and O O
SCA3 B-Disease B-Disease
/ O O
Machado B-Disease B-Disease
- I-Disease I-Disease
Joseph I-Disease I-Disease
disease I-Disease I-Disease
( O O
MJD B-Disease B-Disease
) O O
( O O
n O O
= O O
16 O O
) O O
. O O

In O O
SCA1 B-Disease B-Disease
, O O
saccade O O
amplitude O O
was O O
significantly O O
increased O O
, O O
resulting O O
in O O
hypermetria B-Disease B-Disease
. O O

The O O
smooth O O
pursuit O O
gain O O
was O O
decreased O O
. O O

In O O
SCA2 B-Disease B-Disease
, O O
saccade O O
velocity O O
was O O
markedly O O
decreased O O
. O O

The O O
percentage O O
of O O
errors O O
in O O
antisaccades O O
was O O
greatly O O
increased O O
and O O
was O O
significantly O O
correlated O O
with O O
age O O
at O O
disease O O
onset O O
. O O

In O O
addition O O
, O O
a O O
correlation O O
between O O
smooth O O
pursuit O O
gain O O
and O O
the O O
number O O
of O O
trinucleotide O O
repeats O O
was O O
found O O
. O O

In O O
SCA3 B-Disease B-Disease
, O O
gaze B-Disease B-Disease
- I-Disease I-Disease
evoked I-Disease I-Disease
nystagmus I-Disease I-Disease
was O O
often O O
present O O
as O O
was O O
saccade O O
hypometria O O
and O O
smooth O O
pursuit O O
gain O O
was O O
markedly O O
decreased O O
. O O

Three O O
major O O
criteria O O
, O O
saccade O O
amplitude O O
, O O
saccade O O
velocity O O
, O O
and O O
presence O O
of O O
gaze B-Disease O
- I-Disease O
evoked I-Disease O
nystagmus I-Disease B-Disease
, O O
permitted O O
the O O
correct O O
assignment O O
of O O
90 O O
% O O
of O O
the O O
SCA1 B-Disease B-Disease
, O O
90 O O
% O O
of O O
the O O
SCA2 B-Disease B-Disease
, O O
and O O
93 O O
% O O
of O O
the O O
patients O O
with O O
SCA3 B-Disease B-Disease
to O O
their O O
genetically O O
confirmed O O
patient O O
group O O
and O O
, O O
therefore O O
, O O
may O O
help O O
orient O O
diagnoses O O
of O O
SCA1 B-Disease B-Disease
, O O
SCA2 B-Disease B-Disease
, O O
and O O
SCA3 B-Disease B-Disease
at O O
early O O
clinical O O
stages O O
of O O
the O O
diseases O O
.. O O

Genetic O O
basis O O
and O O
molecular O O
mechanism O O
for O O
idiopathic B-Disease O
ventricular I-Disease B-Disease
fibrillation I-Disease I-Disease
. O O

Ventricular B-Disease B-Disease
fibrillation I-Disease I-Disease
causes O O
more O O
than O O
300 O O
, O O
000 O O
sudden O O
deaths O O
each O O
year O O
in O O
the O O
USA O O
alone O O
. O O

In O O
approximately O O
5 O O
- O O
12 O O
% O O
of O O
these O O
cases O O
, O O
there O O
are O O
no O O
demonstrable O O
cardiac O O
or O O
non O O
- O O
cardiac O O
causes O O
to O O
account O O
for O O
the O O
episode O O
, O O
which O O
is O O
therefore O O
classified O O
as O O
idiopathic B-Disease O
ventricular I-Disease B-Disease
fibrillation I-Disease I-Disease
( O O
IVF B-Disease B-Disease
) O O
. O O

A O O
distinct O O
group O O
of O O
IVF B-Disease B-Disease
patients O O
has O O
been O O
found O O
to O O
present O O
with O O
a O O
characteristic O O
electrocardiographic O O
pattern O O
. O O

Because O O
of O O
the O O
small O O
size O O
of O O
most O O
pedigrees O O
and O O
the O O
high O O
incidence O O
of O O
sudden B-Disease B-Disease
death I-Disease I-Disease
, O O
however O O
, O O
molecular O O
genetic O O
studies O O
of O O
IVF B-Disease B-Disease
have O O
not O O
yet O O
been O O
done O O
. O O

Because O O
IVF B-Disease B-Disease
causes O O
cardiac O B-Disease
rhythm O I-Disease
disturbance O I-Disease
, O O
we O O
investigated O O
whether O O
malfunction O O
of O O
ion O O
channels O O
could O O
cause O O
the O O
disorder O O
by O O
studying O O
mutations O O
in O O
the O O
cardiac O O
sodium O O
channel O O
gene O O
SCN5A O O
. O O

We O O
have O O
now O O
identified O O
a O O
missense O O
mutation O O
, O O
a O O
splice O O
- O O
donor O O
mutation O O
, O O
and O O
a O O
frameshift O O
mutation O O
in O O
the O O
coding O O
region O O
of O O
SCN5A O O
in O O
three O O
IVF B-Disease B-Disease
families O O
. O O

We O O
show O O
that O O
sodium O O
channels O O
with O O
the O O
missense O O
mutation O O
recover O O
from O O
inactivation O O
more O O
rapidly O O
than O O
normal O O
and O O
that O O
the O O
frameshift O O
mutation O O
causes O O
the O O
sodium O O
channel O O
to O O
be O O
non O O
- O O
functional O O
. O O

Our O O
results O O
indicate O O
that O O
mutations O O
in O O
cardiac O O
ion O O
- O O
channel O O
genes O O
contribute O O
to O O
the O O
risk O O
of O O
developing O O
IVF B-Disease B-Disease
.. O O

Molecular O O
heterogeneity O O
in O O
mucopolysaccharidosis B-Disease B-Disease
IVA I-Disease I-Disease
in O O
Australia O O
and O O
Northern O O
Ireland O O
: O O
nine O O
novel O O
mutations O O
including O O
T312S O O
, O O
a O O
common O O
allele O O
that O O
confers O O
a O O
mild O O
phenotype O O
. O O

Mucopolysaccharidosis B-Disease B-Disease
IVA I-Disease I-Disease
( O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
lysosomal I-Disease I-Disease
storage I-Disease I-Disease
disorder I-Disease I-Disease
caused O O
by O O
a O O
genetic B-Disease B-Disease
defect I-Disease I-Disease
in O O
N O O
- O O
acetylgalactosamine-6-sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

Previous O O
studies O O
of O O
patients O O
from O O
a O O
British O O
- O O
Irish O O
population O O
showed O O
that O O
the O O
I113F O O
mutation O O
is O O
the O O
most O O
common O O
single O O
mutation O O
among O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
patients O O
and O O
produces O O
a O O
severe O O
clinical O O
phenotype O O
. O O

We O O
studied O O
mutations O O
in O O
the O O
GALNS O O
gene O O
from O O
23 O O
additional O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
patients O O
( O O
15 O O
from O O
Australia O O
, O O
8 O O
from O O
Northern O O
Ireland O O
) O O
, O O
with O O
various O O
clinical O O
phenotypes O O
( O O
severe O O
, O O
16 O O
cases O O
; O O
intermediate O O
, O O
4 O O
cases O O
; O O
mild O O
, O O
3 O O
cases O O
) O O
. O O

We O O
found O O
two O O
common O O
mutations O O
that O O
together O O
accounted O O
for O O
32 O O
% O O
of O O
the O O
44 O O
unrelated O O
alleles O O
in O O
these O O
patients O O
. O O

One O O
is O O
the O O
T312S O O
mutation O O
, O O
a O O
novel O O
mutation O O
found O O
exclusively O O
in O O
milder O O
patients O O
. O O

The O O
other O O
is O O
the O O
previously O O
described O O
I113F O O
that O O
produces O O
a O O
severe O O
phenotype O O
. O O

The O O
I113F O O
and O O
T312S O O
mutations O O
accounted O O
for O O
8 O O
( O O
18 O O
% O O
) O O
and O O
6 O O
( O O
14 O O
% O O
) O O
of O O
44 O O
unrelated O O
alleles O O
, O O
respectively O O
. O O

The O O
relatively O O
high O O
residual O O
GALNS O O
activity O O
seen O O
when O O
the O O
T312S O O
mutant O O
cDNA O O
is O O
overexpressed O O
in O O
mutant O O
cells O O
provides O O
an O O
explanation O O
for O O
the O O
mild O O
phenotype O O
in O O
patients O O
with O O
this O O
mutation O O
. O O

The O O
distribution O O
and O O
relative O O
frequencies O O
of O O
the O O
I113F O O
and O O
T312S O O
mutations O O
in O O
Australia O O
corresponded O O
to O O
those O O
observed O O
in O O
Northern O O
Ireland O O
and O O
are O O
unique O O
to O O
these O O
two O O
populations O O
, O O
suggesting O O
that O O
both O O
mutations O O
were O O
probably O O
introduced O O
to O O
Australia O O
by O O
Irish O O
migrants O O
during O O
the O O
19th O O
century O O
. O O

Haplotype O O
analysis O O
using O O
6 O O
RFLPs O O
provides O O
additional O O
data O O
that O O
the O O
I113F O O
mutation O O
originated O O
from O O
a O O
common O O
ancestor O O
. O O

The O O
other O O
9 O O
novel O O
mutations O O
identified O O
in O O
these O O
23 O O
patients O O
were O O
each O O
limited O O
to O O
a O O
single O O
family O O
. O O

These O O
data O O
provide O O
further O O
evidence O O
for O O
extensive O O
allelic O O
heterogeneity O O
in O O
MPS B-Disease B-Disease
IVA I-Disease I-Disease
in O O
British O O
- O O
Irish O O
patients O O
and O O
provide O O
evidence O O
for O O
their O O
transmission O O
to O O
Australia O O
by O O
British O O
- O O
Irish O O
migrants O O
.. O O

Identification O O
of O O
constitutional O O
WT1 O O
mutations O O
, O O
in O O
patients O O
with O O
isolated O O
diffuse B-Disease O
mesangial I-Disease B-Disease
sclerosis I-Disease I-Disease
, O O
and O O
analysis O O
of O O
genotype O O
/ O O
phenotype O O
correlations O O
by O O
use O O
of O O
a O O
computerized O O
mutation O O
database O O
. O O

Constitutional O O
mutations O O
of O O
the O O
WT1 O O
gene O O
, O O
encoding O O
a O O
zinc O O
- O O
finger O O
transcription O O
factor O O
involved O O
in O O
renal O O
and O O
gonadal O O
development O O
, O O
are O O
found O O
in O O
most O O
patients O O
with O O
Denys B-Disease B-Disease
- I-Disease I-Disease
Drash I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
DDS B-Disease B-Disease
) O O
, O O
or O O
diffuse B-Disease B-Disease
mesangial I-Disease I-Disease
sclerosis I-Disease I-Disease
( O O
DMS B-Disease B-Disease
) O O
associated O O
with O O
pseudohermaphroditism B-Disease B-Disease
and/or O O
Wilms B-Disease B-Disease
tumor I-Disease I-Disease
( O O
WT B-Disease B-Disease
) O O
. O O

Most O O
mutations O O
in O O
DDS B-Disease B-Disease
patients O O
lie O O
in O O
exon O O
8 O O
or O O
exon O O
9 O O
, O O
encoding O O
zinc O O
finger O O
2 O O
or O O
zinc O O
finger O O
3 O O
, O O
respectively O O
, O O
with O O
a O O
hot O O
spot O O
( O O
R394W O O
) O O
in O O
exon O O
9 O O
. O O

We O O
analyzed O O
a O O
series O O
of O O
24 O O
patients O O
, O O
10 O O
with O O
isolated B-Disease O
DMS I-Disease B-Disease
( O O
IDMS B-Disease B-Disease
) O O
, O O
10 O O
with O O
DDS B-Disease B-Disease
, O O
and O O
4 O O
with O O
urogenital B-Disease B-Disease
abnormalities I-Disease I-Disease
and/or O O
WT B-Disease B-Disease
. O O

We O O
report O O
WT1 O O
heterozygous O O
mutations O O
in O O
16 O O
patients O O
, O O
4 O O
of O O
whom O O
presented O O
with O O
IDMS B-Disease B-Disease
. O O

One O O
male O O
and O O
two O O
female O O
IDMS B-Disease B-Disease
patients O O
with O O
WT1 O O
mutations O O
underwent O O
normal O O
puberty O O
. O O

Two O O
mutations O O
associated O O
with O O
IDMS B-Disease B-Disease
are O O
different O O
from O O
those O O
described O O
in O O
DDS B-Disease B-Disease
patients O O
. O O

No O O
WT1 O O
mutations O O
were O O
detected O O
in O O
the O O
six O O
other O O
IDMS B-Disease B-Disease
patients O O
, O O
suggesting O O
genetic O O
heterogeneity O O
of O O
this O O
disease O O
. O O

We O O
analyzed O O
genotype O O
/ O O
phenotype O O
correlations O O
, O O
on O O
the O O
basis O O
of O O
the O O
constitution O O
of O O
a O O
WT1 O O
mutation O O
database O O
of O O
84 O O
germ O O
- O O
line O O
mutations O O
, O O
to O O
compare O O
the O O
distribution O O
and O O
type O O
of O O
mutations O O
, O O
according O O
to O O
the O O
different O O
symptoms O O
. O O

This O O
demonstrated O O
( O O
1 O O
) O O
the O O
association O O
between O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
and O O
DMS B-Disease B-Disease
; O O
( O O
2 O O
) O O
among O O
patients O O
with O O
DMS B-Disease B-Disease
, O O
a O O
higher O O
frequency O O
of O O
exon O O
8 O O
mutations O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
female O O
phenotype O O
than O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
sexual O O
ambiguity O O
or O O
male O O
phenotype O O
; O O
and O O
( O O
3 O O
) O O
statistically O O
significant O O
evidence O O
that O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
preferentially O O
affect O O
amino O O
acids O O
with O O
different O O
functions O O
.. O O

The O O
185delAG O O
BRCA1 O O
mutation O O
originated O O
before O O
the O O
dispersion O O
of O O
Jews O O
in O O
the O O
diaspora O O
and O O
is O O
not O O
limited O O
to O O
Ashkenazim O O
. O O

The O O
185delAG O O
mutation O O
in O O
BRCA1 O O
is O O
detected O O
in O O
Ashkenazi O O
Jews O O
both O O
in O O
familial B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
and O O
in O O
the O O
general O O
population O O
. O O

All O O
tested O O
Ashkenazi O O
mutation O O
carriers O O
share O O
the O O
same O O
allelic O O
pattern O O
at O O
the O O
BRCA1 O O
locus O O
. O O

Our O O
previous O O
study O O
showed O O
that O O
this O O
Ashkenazi O O
mutation O O
also O O
occurs O O
in O O
Iraqi O O
Jews O O
with O O
a O O
similar O O
allelic O O
pattern O O
. O O

We O O
extended O O
our O O
analysis O O
to O O
other O O
non O O
- O O
Ashkenazi O O
subsets O O
354 O O
of O O
Moroccan O O
origin O O
, O O
200 O O
Yemenites O O
and O O
150 O O
Iranian O O
Jews O O
. O O

Heteroduplex O O
analysis O O
complemented O O
by O O
direct O O
DNA O O
sequencing O O
of O O
abnormally O O
migrating O O
bands O O
were O O
employed O O
. O O

Four O O
of O O
Moroccan O O
origin O O
( O O
1 O O
. O O
1 O O
% O O
) O O
and O O
none O O
of O O
the O O
Yemenites O O
or O O
Iranians O O
was O O
a O O
carrier O O
of O O
the O O
185delAG O O
mutation O O
. O O

BRCA1 O O
allelic O O
patterns O O
were O O
determined O O
for O O
four O O
of O O
these O O
individuals O O
and O O
for O O
12 O O
additional O O
non O O
- O O
Ashkenazi O O
185delAG O O
mutation O O
carriers O O
who O O
had O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Six O O
non O O
- O O
Ashkenazi O O
individuals O O
shared O O
the O O
common O O
Ashkenazi O O
haplotype O O
, O O
four O O
had O O
a O O
closely O O
related O O
pattern O O
, O O
and O O
the O O
rest O O
( O O
n O O
= O O
6 O O
) O O
displayed O O
a O O
distinct O O
BRCA1 O O
allelic O O
pattern O O
. O O

We O O
conclude O O
that O O
the O O
185delAG O O
BRCA1 O O
mutation O O
occurs O O
in O O
some O O
non O O
- O O
Ashkenazi O O
populations O O
at O O
rates O O
comparable O O
with O O
that O O
of O O
Ashkenazim O O
. O O

The O O
majority O O
of O O
Jewish O O
185delAG O O
mutation O O
carriers O O
have O O
a O O
common O O
allelic O O
pattern O O
, O O
supporting O O
the O O
founder O O
effect O O
notion O O
, O O
but O O
dating O O
the O O
mutations O O
origin O O
to O O
an O O
earlier O O
date O O
than O O
currently O O
estimated O O
. O O

However O O
, O O
the O O
different O O
allelic O O
pattern O O
at O O
the O O
BRCA1 O O
locus O O
even O O
in O O
some O O
Jewish O O
mutation O O
carriers O O
, O O
might O O
suggest O O
that O O
the O O
mutation O O
arose O O
independently O O
.. O O

Crystal O O
structure O O
of O O
the O O
hemochromatosis B-Disease B-Disease
protein O O
HFE O O
and O O
characterization O O
of O O
its O O
interaction O O
with O O
transferrin O O
receptor O O
. O O

HFE O O
is O O
an O O
MHC O O
- O O
related O O
protein O O
that O O
is O O
mutated O O
in O O
the O O
iron B-Disease B-Disease
- I-Disease I-Disease
overload I-Disease I-Disease
disease I-Disease I-Disease
hereditary B-Disease B-Disease
hemochromatosis I-Disease I-Disease
. O O

HFE O O
binds O O
to O O
transferrin O O
receptor O O
( O O
TfR O O
) O O
and O O
reduces O O
its O O
affinity O O
for O O
iron O O
- O O
loaded O O
transferrin O O
, O O
implicating O O
HFE O O
in O O
iron O O
metabolism O O
. O O

The O O
2 O O
. O O
6 O O
A O O
crystal O O
structure O O
of O O
HFE O O
reveals O O
the O O
locations O O
of O O
hemochromatosis B-Disease B-Disease
mutations O O
and O O
a O O
patch O O
of O O
histidines O O
that O O
could O O
be O O
involved O O
in O O
pH O O
- O O
dependent O O
interactions O O
. O O

We O O
also O O
demonstrate O O
that O O
soluble O O
TfR O O
and O O
HFE O O
bind O O
tightly O O
at O O
the O O
basic O O
pH O O
of O O
the O O
cell O O
surface O O
, O O
but O O
not O O
at O O
the O O
acidic O O
pH O O
of O O
intracellular O O
vesicles O O
. O O

TfR O O
HFE O O
stoichiometry O O
( O O
2 O O
1 O O
) O O
differs O O
from O O
TfR O O
transferrin O O
stoichiometry O O
( O O
2 O O
2 O O
) O O
, O O
implying O O
a O O
different O O
mode O O
of O O
binding O O
for O O
HFE O O
and O O
transferrin O O
to O O
TfR O O
, O O
consistent O O
with O O
our O O
demonstration O O
that O O
HFE O O
, O O
transferrin O O
, O O
and O O
TfR O O
form O O
a O O
ternary O O
complex O O
. O O

Identification O O
of O O
three O O
novel O O
mutations O O
and O O
a O O
high O O
frequency O O
of O O
the O O
Arg778Leu O O
mutation O O
in O O
Korean O O
patients O O
with O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
. O O

Four O O
mutations O O
-- O O
R778L O O
, O O
A874V O O
, O O
L1083F O O
, O O
and O O
2304delC O O
-- O O
in O O
the O O
copper O O
- O O
transporting O O
enzyme O O
, O O
P O O
- O O
type O O
ATPase O O
( O O
ATP7B O O
) O O
, O O
were O O
identified O O
in O O
Korean O O
Patients O O
with O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
. O O

Arg778Leu O O
, O O
the O O
most O O
frequently O O
reported O O
mutation O O
of O O
this O O
enzyme O O
, O O
was O O
found O O
in O O
six O O
of O O
eight O O
unrelated O O
patients O O
studied O O
, O O
an O O
allele O O
frequency O O
of O O
37 O O
. O O
5 O O
% O O
, O O
which O O
is O O
considerably O O
higher O O
than O O
those O O
in O O
other O O
Asian O O
populations O O
. O O

The O O
novel O O
single O O
nucleotide O O
deletion O O
, O O
2304delC O O
, O O
was O O
found O O
in O O
one O O
patient O O
. O O

Since O O
a O O
mutation O O
at O O
cDNA O O
nucleotide O O
2302 O O
( O O
2302insC O O
) O O
had O O
been O O
previously O O
described O O
, O O
this O O
region O O
of O O
the O O
ATP7B O O
gene O O
may O O
be O O
susceptible O O
to O O
gene O O
rearrangements O O
causing O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
. O O

Disruption O O
of O O
splicing O O
regulated O O
by O O
a O O
CUG O O
- O O
binding O O
protein O O
in O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
caused O O
by O O
a O O
CTG O O
expansion O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
the O O
DM B-Disease B-Disease
gene O O
. O O

One O O
model O O
of O O
DM B-Disease B-Disease
pathogenesis O O
suggests O O
that O O
RNAs O O
from O O
the O O
expanded O O
allele O O
create O O
a O O
gain O O
- O O
of O O
- O O
function O O
mutation O O
by O O
the O O
inappropriate O O
binding O O
of O O
proteins O O
to O O
the O O
CUG O O
repeats O O
. O O

Data O O
presented O O
here O O
indicate O O
that O O
the O O
conserved O O
heterogeneous O O
nuclear O O
ribonucleoprotein O O
, O O
CUG O O
- O O
binding O O
protein O O
( O O
CUG O O
- O O
BP O O
) O O
, O O
may O O
mediate O O
the O O
trans O O
- O O
dominant O O
effect O O
of O O
the O O
RNA O O
. O O

CUG O O
- O O
BP O O
was O O
found O O
to O O
bind O O
to O O
the O O
human O O
cardiac O O
troponin O O
T O O
( O O
cTNT O O
) O O
pre O O
- O O
messenger O O
RNA O O
and O O
regulate O O
its O O
alternative O O
splicing O O
. O O

Splicing O O
of O O
cTNT O O
was O O
disrupted O O
in O O
DM B-Disease B-Disease
striated O O
muscle O O
and O O
in O O
normal O O
cells O O
expressing O O
transcripts O O
that O O
contain O O
CUG O O
repeats O O
. O O

Altered O O
expression O O
of O O
genes O O
regulated O O
posttranscriptionally O O
by O O
CUG O O
- O O
BP O O
therefore O O
may O O
contribute O O
to O O
DM B-Disease B-Disease
pathogenesis O O
.. O O

Identification O O
of O O
a O O
novel O O
nonsense O O
mutation O O
and O O
a O O
missense O O
substitution O O
in O O
the O O
vasopressin O O
- O O
neurophysin O O
II O O
gene O O
in O O
two O O
Spanish O O
kindreds O O
with O O
familial B-Disease B-Disease
neurohypophyseal I-Disease I-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
. O O

Familial B-Disease B-Disease
neurohypophyseal I-Disease I-Disease
diabetes I-Disease I-Disease
insipidus I-Disease I-Disease
( O O
FNDI B-Disease B-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disease I-Disease I-Disease
caused O O
by O O
deficiency O B-Disease
in O I-Disease
the O I-Disease
antidiuretic O I-Disease
hormone O I-Disease
arginine O O
vasopressin O O
( O O
AVP O O
) O O
encoded O O
by O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
AVP O O
- O O
NPII O O
) O O
gene O O
on O O
chromosome O O
20p13 O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
two O O
families O O
with O O
FNDI B-Disease B-Disease
using O O
direct O O
automated O O
fluorescent O O
, O O
solid O O
phase O O
, O O
single O O
- O O
stranded O O
DNA O O
sequencing O O
of O O
PCR O O
- O O
amplified O O
AVP O O
- O O
NPII O O
DNA O O
. O O

In O O
one O O
of O O
the O O
families O O
, O O
affected O O
individuals O O
presented O O
a O O
novel O O
nonsense O O
mutation O O
in O O
exon O O
3 O O
of O O
the O O
gene O O
, O O
consisting O O
in O O
a O O
G O O
to O O
T O O
transition O O
at O O
nucleotide O O
2101 O O
, O O
which O O
produces O O
a O O
stop O O
signal O O
in O O
codon O O
82 O O
( O O
Glu O O
) O O
of O O
NPII O O
. O O

The O O
premature O O
termination O O
eliminates O O
part O O
of O O
the O O
C O O
- O O
terminal O O
domain O O
of O O
NPII O O
, O O
including O O
a O O
cysteine O O
residue O O
in O O
position O O
85 O O
, O O
which O O
could O O
be O O
involved O O
in O O
the O O
correct O O
folding O O
of O O
the O O
prohormone O O
. O O

In O O
the O O
second O O
family O O
, O O
a O O
G279A O O
substitution O O
at O O
position O O
-1 O O
of O O
the O O
signal O O
peptide O O
was O O
observed O O
in O O
all O O
affected O O
individuals O O
. O O

This O O
missense O O
mutation O O
, O O
which O O
replaces O O
Ala O O
with O O
Thr O O
, O O
is O O
frequent O O
among O O
FNDI B-Disease B-Disease
patients O O
and O O
is O O
thought O O
to O O
reduce O O
the O O
efficiency O O
of O O
cleavage O O
by O O
signal O O
peptidases O O
.. O O

Genetic O O
heterogeneity O O
of O O
Saethre B-Disease B-Disease
- I-Disease I-Disease
Chotzen I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
due O O
to O O
TWIST O O
and O O
FGFR O O
mutations O O
. O O

Thirty O O
- O O
two O O
unrelated O O
patients O O
with O O
features O O
of O O
Saethre B-Disease B-Disease
- I-Disease I-Disease
Chotzen I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
a O O
common O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
condition I-Disease I-Disease
of O O
craniosynostosis B-Disease B-Disease
and O O
limb B-Disease B-Disease
anomalies I-Disease I-Disease
, O O
were O O
screened O O
for O O
mutations O O
in O O
TWIST O O
, O O
FGFR2 O O
, O O
and O O
FGFR3 O O
. O O

Nine O O
novel O O
and O O
three O O
recurrent O O
TWIST O O
mutations O O
were O O
found O O
in O O
12 O O
families O O
. O O

Seven O O
families O O
were O O
found O O
to O O
have O O
the O O
FGFR3 O O
P250R O O
mutation O O
, O O
and O O
one O O
individual O O
was O O
found O O
to O O
have O O
an O O
FGFR2 O O
VV269 O O
- O O
270 O O
deletion O O
. O O

To O O
date O O
, O O
our O O
detection O O
rate O O
for O O
TWIST O O
or O O
FGFR O O
mutations O O
is O O
68 O O
% O O
in O O
our O O
Saethre B-Disease B-Disease
- I-Disease I-Disease
Chotzen I-Disease I-Disease
syndrome I-Disease I-Disease
patients O O
, O O
including O O
our O O
five O O
patients O O
elsewhere O O
reported O O
with O O
TWIST O O
mutations O O
. O O

More O O
than O O
35 O O
different O O
TWIST O O
mutations O O
are O O
now O O
known O O
in O O
the O O
literature O O
. O O

The O O
most O O
common O O
phenotypic O O
features O O
, O O
present O O
in O O
more O O
than O O
a O O
third O O
of O O
our O O
patients O O
with O O
TWIST O O
mutations O O
, O O
are O O
coronal B-Disease B-Disease
synostosis I-Disease I-Disease
, O O
brachycephaly B-Disease B-Disease
, O O
low B-Disease B-Disease
frontal I-Disease I-Disease
hairline I-Disease I-Disease
, O O
facial B-Disease B-Disease
asymmetry I-Disease I-Disease
, O O
ptosis B-Disease B-Disease
, O O
hypertelorism B-Disease B-Disease
, O O
broad B-Disease B-Disease
great I-Disease I-Disease
toes I-Disease I-Disease
, O O
and O O
clinodactyly B-Disease B-Disease
. O O

Significant O O
intra- O O
and O O
interfamilial O O
phenotypic O O
variability O O
is O O
present O O
for O O
either O O
TWIST O O
mutations O O
or O O
FGFR O O
mutations O O
. O O

The O O
overlap O O
in O O
clinical O O
features O O
and O O
the O O
presence O O
, O O
in O O
the O O
same O O
genes O O
, O O
of O O
mutations O O
for O O
more O O
than O O
one O O
craniosynostotic B-Disease B-Disease
condition I-Disease I-Disease
- O O
such O O
as O O
Saethre B-Disease B-Disease
- I-Disease I-Disease
Chotzen I-Disease I-Disease
, I-Disease I-Disease
Crouzon I-Disease I-Disease
, I-Disease I-Disease
and I-Disease I-Disease
Pfeiffer I-Disease I-Disease
syndromes I-Disease I-Disease
- O O
support O O
the O O
hypothesis O O
that O O
TWIST O O
and O O
FGFRs O O
are O O
components O O
of O O
the O O
same O O
molecular O O
pathway O O
involved O O
in O O
the O O
modulation O O
of O O
craniofacial O O
and O O
limb O O
development O O
in O O
humans O O
.. O O

Mutation O O
analysis O O
of O O
UBE3A O O
in O O
Angelman B-Disease B-Disease
syndrome I-Disease I-Disease
patients O O
. O O

Angelman B-Disease B-Disease
syndrome I-Disease I-Disease
( O O
AS B-Disease B-Disease
) O O
is O O
caused O O
by O O
chromosome O O
15q11-q13 O O
deletions O O
of O O
maternal O O
origin O O
, O O
by O O
paternal O O
uniparental B-Disease B-Disease
disomy I-Disease I-Disease
( O O
UPD B-Disease B-Disease
) O O
15 O O
, O O
by O O
imprinting O O
defects O O
, O O
and O O
by O O
mutations O O
in O O
the O O
UBE3A O O
gene O O
. O O

UBE3A O O
encodes O O
a O O
ubiquitin O O
- O O
protein O O
ligase O O
and O O
shows O O
brain O O
- O O
specific O O
imprinting O O
. O O

Here O O
we O O
describe O O
UBE3A O O
coding O O
- O O
region O O
mutations O O
detected O O
by O O
SSCP O O
analysis O O
in O O
13 O O
AS B-Disease B-Disease
individuals O O
or O O
families O O
. O O

Two O O
identical O O
de O O
novo O O
5-bp O O
duplications O O
in O O
exon O O
16 O O
were O O
found O O
. O O

Among O O
the O O
other O O
11 O O
unique O O
mutations O O
, O O
8 O O
were O O
small O O
deletions O O
or O O
insertions O O
predicted O O
to O O
cause O O
frameshifts O O
, O O
1 O O
was O O
a O O
mutation O O
to O O
a O O
stop O O
codon O O
, O O
1 O O
was O O
a O O
missense O O
mutation O O
, O O
and O O
1 O O
was O O
predicted O O
to O O
cause O O
insertion O O
of O O
an O O
isoleucine O O
in O O
the O O
hect O O
domain O O
of O O
the O O
UBE3A O O
protein O O
, O O
which O O
functions O O
in O O
E2 O O
binding O O
and O O
ubiquitin O O
transfer O O
. O O

Eight O O
of O O
the O O
cases O O
were O O
familial O O
, O O
and O O
five O O
were O O
sporadic O O
. O O

In O O
two O O
familial O O
cases O O
and O O
one O O
sporadic O O
case O O
, O O
mosaicism O O
for O O
UBE3A O O
mutations O O
was O O
detected O O
in O O
the O O
mother O O
of O O
three O O
AS B-Disease B-Disease
sons O O
, O O
in O O
the O O
maternal O O
grandfather O O
of O O
two O O
AS B-Disease B-Disease
first O O
cousins O O
, O O
and O O
in O O
the O O
mother O O
of O O
an O O
AS B-Disease B-Disease
daughter O O
. O O

The O O
frequencies O O
with O O
which O O
we O O
detected O O
mutations O O
were O O
5 O O
( O O
14 O O
% O O
) O O
of O O
35 O O
in O O
sporadic O O
cases O O
and O O
8 O O
( O O
80 O O
% O O
) O O
of O O
10 O O
in O O
familial O O
cases O O
.. O O

The O O
hemochromatosis B-Disease B-Disease
845 O O
G-->A O O
and O O
187 O O
C-->G O O
mutations O O
: O O
prevalence O O
in O O
non O O
- O O
Caucasian O O
populations O O
. O O

Hemochromatosis B-Disease B-Disease
, O O
the O O
inherited B-Disease B-Disease
disorder I-Disease I-Disease
of I-Disease I-Disease
iron I-Disease I-Disease
metabolism I-Disease I-Disease
, O O
leads O O
, O O
if O O
untreated O O
, O O
to O O
progressive O O
iron B-Disease B-Disease
overload I-Disease I-Disease
and O O
premature B-Disease B-Disease
death I-Disease I-Disease
. O O

The O O
hemochromatosis B-Disease B-Disease
gene O O
, O O
HFE O O
, O O
recently O O
has O O
been O O
identified O O
, O O
and O O
characterization O O
of O O
this O O
gene O O
has O O
shown O O
that O O
it O O
contains O O
two O O
mutations O O
that O O
result O O
in O O
amino O O
acid O O
substitutions O O
- O O
cDNA O O
nucleotides O O
845 O O
G-- O O
> O O
A O O
( O O
C282Y O O
) O O
and O O
187 O O
C-- O O
> O O
G O O
( O O
H63D O O
) O O
. O O

Although O O
hemochromatosis B-Disease B-Disease
is O O
common O O
in O O
Caucasians O O
, O O
affecting O O
> O O
= O O
1 O O
/ O O
300 O O
individuals O O
of O O
northern O O
European O O
origin O O
, O O
it O O
has O O
not O O
been O O
recognized O O
in O O
other O O
populations O O
. O O

The O O
present O O
study O O
used O O
PCR O O
and O O
restriction O O
- O O
enzyme O O
digestion O O
to O O
analyze O O
the O O
frequency O O
of O O
the O O
845 O O
G-- O O
> O O
A O O
and O O
187 O O
C-- O O
> O O
G O O
mutations O O
in O O
HLA O O
- O O
typed O O
samples O O
from O O
non O O
- O O
Caucasian O O
populations O O
, O O
comprising O O
Australian O O
Aboriginal O O
, O O
Chinese O O
, O O
and O O
Pacific O O
Islanders O O
. O O

Results O O
showed O O
that O O
the O O
845 O O
G-- O O
> O O
A O O
mutation O O
was O O
present O O
in O O
these O O
populations O O
( O O
allele O O
frequency O O
0 O O
. O O
32 O O
% O O
) O O
, O O
and O O
, O O
furthermore O O
, O O
it O O
was O O
always O O
seen O O
in O O
conjunction O O
with O O
HLA O O
haplotypes O O
common O O
in O O
Caucasians O O
, O O
suggesting O O
that O O
845 O O
G-- O O
> O O
A O O
may O O
have O O
been O O
introduced O O
into O O
these O O
populations O O
by O O
Caucasian O O
admixture O O
. O O

187 O O
C-- O O
> O O
G O O
was O O
present O O
at O O
an O O
allele O O
frequency O O
of O O
2 O O
. O O
68 O O
% O O
in O O
the O O
two O O
populations O O
analyzed O O
( O O
Australian O O
Aboriginal O O
and O O
Chinese O O
) O O
. O O

In O O
the O O
Australian O O
Aboriginal O O
samples O O
, O O
187 O O
C-- O O
> O O
G O O
was O O
found O O
to O O
be O O
associated O O
with O O
HLA O O
haplotypes O O
common O O
in O O
Caucasians O O
, O O
suggesting O O
that O O
it O O
was O O
introduced O O
by O O
recent O O
admixture O O
. O O

In O O
the O O
Chinese O O
samples O O
analyzed O O
, O O
187 O O
C-- O O
> O O
G O O
was O O
present O O
in O O
association O O
with O O
a O O
wide O O
variety O O
of O O
HLA O O
haplotypes O O
, O O
showing O O
this O O
mutation O O
to O O
be O O
widespread O O
and O O
likely O O
to O O
predate O O
the O O
more O O
genetically O O
restricted O O
845 O O
G-- O O
> O O
A O O
mutation O O
. O O

Genotype O O
- O O
phenotype O O
correlations O O
in O O
attenuated B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
tumor B-Disease B-Disease
suppressor O O
APC O B-Disease
are O O
implicated O O
in O O
attenuated B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
( O O
AAPC B-Disease B-Disease
) O O
, O O
a O O
variant O O
of O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
. O O

AAPC B-Disease B-Disease
is O O
recognized O O
by O O
the O O
occurrence O O
of O O
< O O
100 O O
colonic B-Disease B-Disease
adenomas I-Disease I-Disease
and O O
a O O
later O O
onset O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
( O O
age O O
> O O
40 O O
years O O
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
AAPC B-Disease B-Disease
families O O
. O O

By O O
protein O O
- O O
truncation O O
test O O
( O O
PTT O O
) O O
assay O O
, O O
the O O
entire O O
coding O O
region O O
of O O
the O O
APC B-Disease B-Disease
gene O O
was O O
screened O O
in O O
affected O O
individuals O O
from O O
11 O O
AAPC B-Disease B-Disease
kindreds O O
, O O
and O O
their O O
phenotypic O O
differences O O
were O O
examined O O
. O O

Five O O
novel O O
germ O O
- O O
line O O
APC B-Disease B-Disease
mutations O O
were O O
identified O O
in O O
seven O O
kindreds O O
. O O

Mutations O O
were O O
located O O
in O O
three O O
different O O
regions O O
of O O
the O O
APC B-Disease B-Disease
gene O O
( O O
1 O O
) O O
at O O
the O O
5 O O
end O O
spanning O O
exons O O
4 O O
and O O
5 O O
, O O
( O O
2 O O
) O O
within O O
exon O O
9 O O
, O O
and O O
( O O
3 O O
) O O
at O O
the O O
3 O O
distal O O
end O O
of O O
the O O
gene O O
. O O

Variability O O
in O O
the O O
number O O
of O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
was O O
most O O
apparent O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
and O O
upper O O
- O O
gastrointestinal O O
manifestations O O
were O O
more O O
severe O O
in O O
them O O
. O O

In O O
individuals O O
with O O
mutations O O
in O O
either O O
region O O
2 O O
or O O
region O O
3 O O
, O O
the O O
average O O
number O O
of O O
adenomas B-Disease B-Disease
tended O O
to O O
be O O
lower O O
than O O
those O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
although O O
age O O
at O O
diagnosis O O
was O O
similar O O
. O O

In O O
all O O
AAPC B-Disease B-Disease
kindreds O O
, O O
a O O
predominance O O
of O O
right O O
- O O
sided O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
and O O
rectal B-Disease B-Disease
polyp I-Disease I-Disease
sparing O O
was O O
observed O O
. O O

No O O
desmoid B-Disease B-Disease
tumors I-Disease I-Disease
were O O
found O O
in O O
these O O
kindreds O O
. O O

Our O O
data O O
suggest O O
that O O
, O O
in O O
AAPC B-Disease B-Disease
families O O
, O O
the O O
location O O
of O O
the O O
APC B-Disease B-Disease
mutation O O
may O O
partially O O
predict O O
specific O O
phenotypic O O
expression O O
. O O

This O O
should O O
help O O
in O O
the O O
design O O
of O O
tailored O O
clinical O O
- O O
management O O
protocols O O
in O O
this O O
subset O O
of O O
FAP B-Disease B-Disease
patients O O
.. O O

Wilms B-Disease B-Disease
' I-Disease I-Disease
tumor I-Disease I-Disease
1 O O
and O O
Dax-1 O O
modulate O O
the O O
orphan O O
nuclear O O
receptor O O
SF-1 O O
in O O
sex O O
- O O
specific O O
gene O O
expression O O
. O O

Products O O
of O O
steroidogenic O O
factor O O
1 O O
( O O
SF-1 O O
) O O
and O O
Wilms B-Disease B-Disease
tumor I-Disease I-Disease
1 O O
( O O
WT1 O O
) O O
genes O O
are O O
essential O O
for O O
mammalian O O
gonadogenesis O O
prior O O
to O O
sexual O O
differentiation O O
. O O

In O O
males O O
, O O
SF-1 O O
participates O O
in O O
sexual O O
development O O
by O O
regulating O O
expression O O
of O O
the O O
polypeptide O O
hormone O O
Mullerian O O
inhibiting O O
substance O O
( O O
MIS O O
) O O
. O O

Here O O
, O O
we O O
show O O
that O O
WT1 O O
-KTS O O
isoforms O O
associate O O
and O O
synergize O O
with O O
SF-1 O O
to O O
promote O O
MIS O O
expression O O
. O O

In O O
contrast O O
, O O
WT1 O O
missense O O
mutations O O
, O O
associated O O
with O O
male B-Disease O
pseudohermaphroditism I-Disease B-Disease
in O O
Denys B-Disease B-Disease
- I-Disease I-Disease
Drash I-Disease I-Disease
syndrome I-Disease I-Disease
, O O
fail O O
to O O
synergize O O
with O O
SF-1 O O
. O O

Additionally O O
, O O
the O O
X O O
- O O
linked O O
, O O
candidate O O
dosage O O
- O O
sensitive O O
sex O O
- O O
reversal O O
gene O O
, O O
Dax-1 O O
, O O
antagonizes O O
synergy O O
between O O
SF-1 O O
and O O
WT1 O O
, O O
most O O
likely O O
through O O
a O O
direct O O
interaction O O
with O O
SF-1 O O
. O O

We O O
propose O O
that O O
WT1 O O
and O O
Dax-1 O O
functionally O O
oppose O O
each O O
other O O
in O O
testis O O
development O O
by O O
modulating O O
SF-1-mediated O O
transactivation O O
.. O O

A O O
mouse O O
model O O
for O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
imprinting O O
- O O
centre O O
mutations O O
. O O

Imprinting O O
in O O
the O O
15q11-q13 O O
region O O
involves O O
an O O
imprinting O O
centre O O
( O O
IC O O
) O O
, O O
mapping O O
in O O
part O O
to O O
the O O
promoter O O
and O O
first O O
exon O O
of O O
SNRPN O O
. O O

Deletion O O
of O O
this O O
IC O O
abolishes O O
local O O
paternally O O
derived O O
gene O O
expression O O
and O O
results O O
in O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
PWS B-Disease B-Disease
) O O
. O O

We O O
have O O
created O O
two O O
deletion O O
mutations O O
in O O
mice O O
to O O
understand O O
PWS B-Disease B-Disease
and O O
the O O
mechanism O O
of O O
this O O
IC O O
. O O

Mice O O
harbouring O O
an O O
intragenic O O
deletion O O
in O O
Snrpn O O
are O O
phenotypically O O
normal O O
, O O
suggesting O O
that O O
mutations O O
of O O
SNRPN O O
are O O
not O O
sufficient O O
to O O
induce O O
PWS B-Disease B-Disease
. O O

Mice O O
with O O
a O O
larger O O
deletion O O
involving O O
both O O
Snrpn O O
and O O
the O O
putative O O
PWS O B-Disease
- O O
IC O O
lack O O
expression O O
of O O
the O O
imprinted O O
genes O O
Zfp127 O O
( O O
mouse O O
homologue O O
of O O
ZNF127 O O
) O O
, O O
Ndn O O
and O O
Ipw O O
, O O
and O O
manifest O O
several O O
phenotypes O O
common O O
to O O
PWS B-Disease B-Disease
infants O O
. O O

These O O
data O O
demonstrate O O
that O O
both O O
the O O
position O O
of O O
the O O
IC O O
and O O
its O O
role O O
in O O
the O O
coordinate O O
expression O O
of O O
genes O O
is O O
conserved O O
between O O
mouse O O
and O O
human O O
, O O
and O O
indicate O O
that O O
the O O
mouse O O
is O O
a O O
suitable O O
model O O
system O O
in O O
which O O
to O O
investigate O O
the O O
molecular O O
mechanisms O O
of O O
imprinting O O
in O O
this O O
region O O
of O O
the O O
genome O O
.. O O

Mutations O O
of O O
the O O
ATM O O
gene O O
detected O O
in O O
Japanese O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
patients O O
: O O
possible O O
preponderance O O
of O O
the O O
two O O
founder O O
mutations O O
4612del165 O O
and O O
7883del5 O O
. O O

The O O
ATM O O
( O O
A O B-Disease
- O I-Disease
T O I-Disease
, O O
mutated O O
) O O
gene O O
on O O
human O O
chromosome O O
11q22 O O
. O O

3 O O
has O O
recently O O
been O O
identified O O
as O O
the O O
gene O O
responsible O O
for O O
the O O
human O O
recessive B-Disease B-Disease
disease I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
. O O

In O O
order O O
to O O
define O O
the O O
types O O
of O O
disease O O
- O O
causing O O
ATM O O
mutations O O
in O O
Japanese O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
as O O
well O O
as O O
to O O
look O O
for O O
possible O O
mutational O O
hotspots O O
, O O
reverse O O
- O O
transcribed O O
RNA O O
derived O O
from O O
ten O O
patients O O
belonging O O
to O O
eight O O
unrelated O O
Japanese O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
families O O
was O O
analyzed O O
for O O
mutations O O
by O O
the O O
restriction O O
endonuclease O O
fingerprinting O O
method O O
. O O

As O O
has O O
been O O
reported O O
by O O
others O O
, O O
mutations O O
that O O
lead O O
to O O
exon O O
skipping O O
or O O
premature O O
protein O O
truncation O O
were O O
also O O
predominant O O
in O O
our O O
mutants O O
. O O

Six O O
different O O
mutations O O
were O O
identified O O
on O O
12 O O
of O O
the O O
16 O O
alleles O O
examined O O
. O O

Four O O
were O O
deletions O O
involving O O
a O O
loss O O
of O O
a O O
single O O
exon O O
exon O O
7 O O
, O O
exon O O
16 O O
, O O
exon O O
33 O O
or O O
exon O O
35 O O
. O O

The O O
others O O
were O O
minute O O
deletions O O
, O O
4649delA O O
in O O
exon O O
33 O O
and O O
7883del5 O O
in O O
exon O O
55 O O
. O O

The O O
mutations O O
4612del165 O O
and O O
7883del5 O O
were O O
found O O
in O O
more O O
than O O
two O O
unrelated O O
families O O
; O O
44 O O
% O O
( O O
7 O O
of O O
16 O O
) O O
of O O
the O O
mutant O O
alleles O O
had O O
one O O
of O O
the O O
two O O
mutations O O
. O O

The O O
4612del165 O O
mutations O O
in O O
three O O
different O O
families O O
were O O
all O O
ascribed O O
to O O
the O O
same O O
T-- O O
> O O
A O O
substitution O O
at O O
the O O
splice O O
donor O O
site O O
in O O
intron O O
33 O O
. O O

Microsatellite O O
genotyping O O
around O O
the O O
ATM O O
locus O O
also O O
indicated O O
that O O
a O O
common O O
haplotype O O
was O O
shared O O
by O O
the O O
mutant O O
alleles O O
in O O
both O O
mutations O O
. O O

This O O
suggests O O
that O O
these O O
two O O
founder O O
mutations O O
may O O
be O O
predominant O O
among O O
Japanese O O
ATM O O
mutant O O
alleles O O
. O O

W474C O O
amino O O
acid O O
substitution O O
affects O O
early O O
processing O O
of O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
and O O
is O O
associated O O
with O O
subacute O O
G B-Disease B-Disease
( I-Disease I-Disease
M2 I-Disease I-Disease
) I-Disease I-Disease
gangliosidosis I-Disease I-Disease
. O O

Mutations O O
in O O
the O O
HEXA O O
gene O O
, O O
encoding O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
( O O
Hex O O
A O O
) O O
, O O
that O O
abolish O O
Hex O O
A O O
enzyme O O
activity O O
cause O O
Tay B-Disease B-Disease
- I-Disease I-Disease
Sachs I-Disease I-Disease
disease I-Disease I-Disease
( O O
TSD B-Disease B-Disease
) O O
, O O
the O O
fatal O O
infantile B-Disease O
form I-Disease O
of I-Disease O
G I-Disease B-Disease
( I-Disease I-Disease
M2 I-Disease I-Disease
) I-Disease I-Disease
gangliosidosis I-Disease I-Disease
, I-Disease O
Type I-Disease B-Disease
1 I-Disease I-Disease
. O O

Less O O
severe O O
, O O
subacute O O
( O O
juvenile O O
- O O
onset O O
) O O
and O O
chronic O O
( O O
adult O O
- O O
onset O O
) O O
variants O O
are O O
characterized O O
by O O
a O O
broad O O
spectrum O O
of O O
clinical O O
manifestations O O
and O O
are O O
associated O O
with O O
residual O O
levels O O
of O O
Hex O O
A O O
enzyme O O
activity O O
. O O

We O O
identified O O
a O O
1422 O O
G-- O O
> O O
C O O
( O O
amino O O
acid O O
W474C O O
) O O
substitution O O
in O O
the O O
first O O
position O O
of O O
exon O O
13 O O
of O O
HEXA O O
of O O
a O O
non O O
- O O
Jewish O O
proband O O
who O O
manifested O O
a O O
subacute O O
variant O O
of O O
G B-Disease B-Disease
( I-Disease I-Disease
M2 I-Disease I-Disease
) I-Disease I-Disease
gangliosidosis I-Disease I-Disease
. O O

On O O
the O O
second O O
maternally O O
inherited O O
allele O O
, O O
we O O
identified O O
the O O
common O O
infantile O B-Disease
disease O I-Disease
- O O
causing O O
4-bp O O
insertion O O
, O O
+ O O
TATC O O
1278 O O
, O O
in O O
exon O O
11 O O
. O O

Pulse O O
- O O
chase O O
analysis O O
using O O
proband O O
fibroblasts O O
revealed O O
that O O
the O O
W474C O O
- O O
containing O O
alpha O O
- O O
subunit O O
precursor O O
was O O
normally O O
synthesized O O
, O O
but O O
not O O
phosphorylated O O
or O O
secreted O O
, O O
and O O
the O O
mature O O
lysosomal O O
alpha O O
- O O
subunit O O
was O O
not O O
detected O O
. O O

When O O
the O O
W474C O O
- O O
containing O O
alpha O O
- O O
subunit O O
was O O
transiently O O
co O O
- O O
expressed O O
with O O
the O O
beta O O
- O O
subunit O O
to O O
produce O O
Hex O O
A O O
( O O
alphabeta O O
) O O
in O O
COS-7 O O
cells O O
, O O
the O O
mature O O
alpha O O
- O O
subunit O O
was O O
present O O
, O O
but O O
its O O
level O O
was O O
much O O
lower O O
than O O
that O O
from O O
normal O O
alpha O O
- O O
subunit O O
transfections O O
, O O
although O O
higher O O
than O O
in O O
those O O
cells O O
transfected O O
with O O
an O O
alpha O O
- O O
subunit O O
associated O O
with O O
infantile O O
TSD B-Disease B-Disease
. O O

Furthermore O O
, O O
the O O
precursor O O
level O O
of O O
the O O
W474C O O
alpha O O
- O O
subunit O O
was O O
found O O
to O O
accumulate O O
in O O
comparison O O
to O O
the O O
normal O O
alpha O O
- O O
subunit O O
precursor O O
levels O O
. O O

We O O
conclude O O
that O O
the O O
1422 O O
G-- O O
> O O
C O O
mutation O O
is O O
the O O
cause O O
of O O
Hex B-Disease B-Disease
A I-Disease I-Disease
enzyme I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
the O O
proband O O
. O O

The O O
resulting O O
W474C O O
substitution O O
clearly O O
interferes O O
with O O
alpha O O
- O O
subunit O O
processing O O
, O O
but O O
because O O
the O O
base O O
substitution O O
falls O O
at O O
the O O
first O O
position O O
of O O
exon O O
13 O O
, O O
aberrant O O
splicing O O
may O O
also O O
contribute O O
to O O
Hex B-Disease B-Disease
A I-Disease I-Disease
deficiency I-Disease I-Disease
in O O
this O O
proband O O
.. O O

Two O O
frequent O O
missense O O
mutations O O
in O O
Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
. O O

Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
disorder I-Disease I-Disease
characterized O O
by O O
early O O
childhood O O
deafness B-Disease B-Disease
and O O
goiter B-Disease B-Disease
. O O

A O O
century O O
after O O
its O O
recognition O O
as O O
a O O
syndrome O O
by O O
Vaughan O O
Pendred O O
, O O
the O O
disease O O
gene O O
( O O
PDS O O
) O O
was O O
mapped O O
to O O
chromosome O O
7q22-q31 O O
. O O

1 O O
and O O
, O O
recently O O
, O O
found O O
to O O
encode O O
a O O
putative O O
sulfate O O
transporter O O
. O O

We O O
performed O O
mutation O O
analysis O O
of O O
the O O
PDS B-Disease B-Disease
gene O O
in O O
patients O O
from O O
14 O O
Pendred B-Disease B-Disease
families O O
originating O O
from O O
seven O O
countries O O
and O O
identified O O
all O O
mutations O O
. O O

The O O
mutations O O
include O O
three O O
single O O
base O O
deletions O O
, O O
one O O
splice O O
site O O
mutation O O
and O O
10 O O
missense O O
mutations O O
. O O

One O O
missense O O
mutation O O
( O O
L236P O O
) O O
was O O
found O O
in O O
a O O
homozygous O O
state O O
in O O
two O O
consanguineous O O
families O O
and O O
in O O
a O O
heterozygous O O
state O O
in O O
five O O
additional O O
non O O
- O O
consanguineous O O
families O O
. O O

Another O O
missense O O
mutation O O
( O O
T416P O O
) O O
was O O
found O O
in O O
a O O
homozygous O O
state O O
in O O
one O O
family O O
and O O
in O O
a O O
heterozygous O O
state O O
in O O
four O O
families O O
. O O

Pendred B-Disease B-Disease
patients O O
in O O
three O O
non O O
- O O
consanguineous O O
families O O
were O O
shown O O
to O O
be O O
compound O O
heterozygotes O O
for O O
L236P O O
and O O
T416P O O
. O O

In O O
total O O
, O O
one O O
or O O
both O O
of O O
these O O
mutations O O
were O O
found O O
in O O
nine O O
of O O
the O O
14 O O
families O O
analyzed O O
. O O

The O O
identification O O
of O O
two O O
frequent O O
PDS B-Disease B-Disease
mutations O O
will O O
facilitate O O
the O O
molecular O O
diagnosis O O
of O O
Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
. O O

Insertional O O
mutation O O
by O O
transposable O O
element O O
, O O
L1 O O
, O O
in O O
the O O
DMD B-Disease B-Disease
gene O O
results O O
in O O
X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
dilated I-Disease I-Disease
cardiomyopathy I-Disease I-Disease
. O O

X B-Disease B-Disease
- I-Disease I-Disease
linked I-Disease I-Disease
dilated I-Disease I-Disease
cardiomyopathy I-Disease I-Disease
( O O
XLDCM B-Disease B-Disease
) O O
is O O
a O O
clinical O O
phenotype O O
of O O
dystrophinopathy B-Disease B-Disease
which O O
is O O
characterized O O
by O O
preferential O O
myocardial B-Disease O
involvement I-Disease O
without O O
any O O
overt O O
clinical O O
signs O O
of O O
skeletal B-Disease B-Disease
myopathy I-Disease I-Disease
. O O

To O O
date O O
, O O
several O O
mutations O O
in O O
the O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
gene O O
, O O
DMD O B-Disease
, O O
have O O
been O O
identified O O
in O O
patients O O
with O O
XLDCM B-Disease B-Disease
, O O
but O O
a O O
pathogenic O O
correlation O O
of O O
these O O
cardiospecific O O
mutations O O
in O O
DMD O B-Disease
with O O
the O O
XLDCM B-Disease B-Disease
phenotype O O
has O O
remained O O
to O O
be O O
elucidated O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
unique O O
de O O
novo O O
L1 O O
insertion O O
in O O
the O O
muscle O O
exon O O
1 O O
in O O
DMD O B-Disease
in O O
three O O
XLDCM B-Disease B-Disease
patients O O
from O O
two O O
unrelated O O
Japanese O O
families O O
. O O

The O O
insertion O O
was O O
a O O
5-truncated O O
form O O
of O O
human O O
L1 O O
inversely O O
integrated O O
in O O
the O O
5-untranslated O O
region O O
in O O
the O O
muscle O O
exon O O
1 O O
, O O
which O O
affected O O
the O O
transcription O O
or O O
the O O
stability O O
of O O
the O O
muscle O O
form O O
of O O
dystrophin O O
transcripts O O
but O O
not O O
that O O
of O O
the O O
brain O O
or O O
Purkinje O O
cell O O
form O O
, O O
probably O O
due O O
to O O
its O O
unique O O
site O O
of O O
integration O O
. O O

We O O
speculate O O
that O O
this O O
insertion O O
of O O
an O O
L1 O O
sequence O O
in O O
DMD O B-Disease
is O O
responsible O O
for O O
some O O
of O O
the O O
population O O
of O O
Japanese O O
patients O O
with O O
XLDCM B-Disease B-Disease
.. O O

Severe O O
early O O
- O O
onset O O
obesity B-Disease B-Disease
, O O
adrenal B-Disease B-Disease
insufficiency I-Disease I-Disease
and O O
red O O
hair O O
pigmentation O O
caused O O
by O O
POMC O O
mutations O O
in O O
humans O O
. O O

Sequential O O
cleavage O O
of O O
the O O
precursor O O
protein O O
pre O O
- O O
pro O O
- O O
opiomelanocortin O O
( O O
POMC O O
) O O
generates O O
the O O
melanocortin O O
peptides O O
adrenocorticotrophin O O
( O O
ACTH O O
) O O
, O O
melanocyte O O
- O O
stimulating O O
hormones O O
( O O
MSH O O
) O O
alpha O O
, O O
beta O O
and O O
gamma O O
as O O
well O O
as O O
the O O
opioid O O
- O O
receptor O O
ligand O O
beta O O
- O O
endorphin O O
. O O

While O O
a O O
few O O
cases O O
of O O
isolated O B-Disease
ACTH B-Disease I-Disease
deficiency I-Disease I-Disease
have O O
been O O
reported O O
( O O
OMIM O O
201400 O O
) O O
, O O
an O O
inherited O O
POMC O O
defect O O
has O O
not O O
been O O
described O O
so O O
far O O
. O O

Recent O O
studies O O
in O O
animal O O
models O O
elucidated O O
a O O
central O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
the O O
regulation O O
of O O
food O O
intake O O
by O O
activation O O
of O O
the O O
brain O O
melanocortin-4-receptor O O
( O O
MC4-R O O
; O O
refs O O
3 O O
- O O
5 O O
) O O
and O O
the O O
linkage O O
of O O
human O O
obesity B-Disease B-Disease
to O O
chromosome O O
2 O O
in O O
close O O
proximity O O
to O O
the O O
POMC O O
locus O O
, O O
led O O
to O O
the O O
proposal O O
of O O
an O O
association O O
of O O
POMC O O
with O O
human O O
obesity B-Disease B-Disease
. O O

The O O
dual O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
regulating O O
food O O
intake O O
and O O
influencing O O
hair O O
pigmentation O O
predicts O O
that O O
the O O
phenotype O O
associated O O
with O O
a O O
defect O O
in O O
POMC O O
function O O
would O O
include O O
obesity B-Disease B-Disease
, O O
alteration O O
in O O
pigmentation O O
and O O
ACTH B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

The O O
observation O O
of O O
these O O
symptoms O O
in O O
two O O
probands O O
prompted O O
us O O
to O O
search O O
for O O
mutations O O
within O O
their O O
POMC O O
genes O O
. O O

Patient O O
1 O O
was O O
found O O
to O O
be O O
a O O
compound O O
heterozygote O O
for O O
two O O
mutations O O
in O O
exon O O
3 O O
( O O
G7013 O O
T O O
, O O
C7133delta O O
) O O
which O O
interfere O O
with O O
appropriate O O
synthesis O O
of O O
ACTH O O
and O O
alpha O O
- O O
MSH O O
. O O

Patient O O
2 O O
was O O
homozygous O O
for O O
a O O
mutation O O
in O O
exon O O
2 O O
( O O
C3804A O O
) O O
which O O
abolishes O O
POMC O O
translation O O
. O O

These O O
findings O O
represent O O
the O O
first O O
examples O O
of O O
a O O
genetic B-Disease B-Disease
defect I-Disease I-Disease
within O O
the O O
POMC O O
gene O O
and O O
define O O
a O O
new O O
monogenic B-Disease B-Disease
endocrine I-Disease I-Disease
disorder I-Disease I-Disease
resulting O O
in O O
early O O
- O O
onset O O
obesity B-Disease B-Disease
, O O
adrenal B-Disease B-Disease
insufficiency I-Disease I-Disease
and O O
red O O
hair O O
pigmentation O O
.. O O

A O O
European O O
multicenter O O
study O O
of O O
phenylalanine B-Disease B-Disease
hydroxylase I-Disease I-Disease
deficiency I-Disease I-Disease
: O O
classification O O
of O O
105 O O
mutations O O
and O O
a O O
general O O
system O O
for O O
genotype O O
- O O
based O O
prediction O O
of O O
metabolic O O
phenotype O O
. O O

Phenylketonuria B-Disease B-Disease
( O O
PKU B-Disease B-Disease
) O O
and O O
mild B-Disease O
hyperphenylalaninemia I-Disease B-Disease
( O O
MHP B-Disease B-Disease
) O O
are O O
allelic B-Disease B-Disease
disorders I-Disease I-Disease
caused O O
by O O
mutations O O
in O O
the O O
gene O O
encoding O O
phenylalanine O O
hydroxylase O O
( O O
PAH O O
) O O
. O O

Previous O O
studies O O
have O O
suggested O O
that O O
the O O
highly O O
variable O O
metabolic O O
phenotypes O O
of O O
PAH B-Disease B-Disease
deficiency I-Disease I-Disease
correlate O O
with O O
PAH O O
genotypes O O
. O O

We O O
identified O O
both O O
causative O O
mutations O O
in O O
686 O O
patients O O
from O O
seven O O
European O O
centers O O
. O O

On O O
the O O
basis O O
of O O
the O O
phenotypic O O
characteristics O O
of O O
297 O O
functionally O O
hemizygous O O
patients O O
, O O
105 O O
of O O
the O O
mutations O O
were O O
assigned O O
to O O
one O O
of O O
four O O
arbitrary O O
phenotype O O
categories O O
. O O

We O O
proposed O O
and O O
tested O O
a O O
simple O O
model O O
for O O
correlation O O
between O O
genotype O O
and O O
phenotypic O O
outcome O O
. O O

The O O
observed O O
phenotype O O
matched O O
the O O
predicted O O
phenotype O O
in O O
79 O O
% O O
of O O
the O O
cases O O
, O O
and O O
in O O
only O O
5 O O
of O O
184 O O
patients O O
was O O
the O O
observed O O
phenotype O O
more O O
than O O
one O O
category O O
away O O
from O O
that O O
expected O O
. O O

Among O O
the O O
seven O O
contributing O O
centers O O
, O O
the O O
proportion O O
of O O
patients O O
for O O
whom O O
the O O
observed O O
phenotype O O
did O O
not O O
match O O
the O O
predicted O O
phenotype O O
was O O
4 O O
% O O
-23 O O
% O O
( O O
P O O
< O O
. O O
0001 O O
) O O
, O O
suggesting O O
that O O
differences O O
in O O
methods O O
used O O
for O O
mutation O O
detection O O
or O O
phenotype O O
classification O O
may O O
account O O
for O O
a O O
considerable O O
proportion O O
of O O
genotype O O
- O O
phenotype O O
inconsistencies O O
. O O

Our O O
data O O
indicate O O
that O O
the O O
PAH O O
- O O
mutation O O
genotype O O
is O O
the O O
main O O
determinant O O
of O O
metabolic O O
phenotype O O
in O O
most O O
patients O O
with O O
PAH B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

In O O
the O O
present O O
study O O
, O O
the O O
classification O O
of O O
105 O O
PAH O O
mutations O O
may O O
allow O O
the O O
prediction O O
of O O
the O O
biochemical O O
phenotype O O
in O O
> O O
10 O O
, O O
000 O O
genotypes O O
, O O
which O O
may O O
be O O
useful O O
for O O
the O O
management O O
of O O
hyperphenylalaninemia B-Disease B-Disease
in O O
newborns O O
. O O

Somatic O O
instability O O
of O O
the O O
CTG O O
repeat O O
in O O
mice O O
transgenic O O
for O O
the O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
region O O
is O O
age O O
dependent O O
but O O
not O O
correlated O O
to O O
the O O
relative O O
intertissue O O
transcription O O
levels O O
and O O
proliferative O O
capacities O O
. O O

A O O
( O O
CTG O O
) O O
nexpansion O O
in O O
the O O
3-untranslated O O
region O O
( O O
UTR O O
) O O
of O O
the O O
DM O B-Disease
protein O O
kinase O O
gene O O
( O O
DMPK O O
) O O
is O O
responsible O O
for O O
causing O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
. O O

Major O O
instability O O
, O O
with O O
very O O
large O O
expansions O O
between O O
generations O O
and O O
high O O
levels O O
of O O
somatic O O
mosaicism O O
, O O
is O O
observed O O
in O O
patients O O
. O O

There O O
is O O
a O O
good O O
correlation O O
between O O
repeat O O
size O O
( O O
at O O
least O O
in O O
leucocytes O O
) O O
, O O
clinical O O
severity O O
and O O
age O O
of O O
onset O O
. O O

The O O
trinucleotide O O
repeat O O
instability O O
mechanisms O O
involved O O
in O O
DM B-Disease B-Disease
and O O
other O O
human O O
genetic B-Disease B-Disease
diseases I-Disease I-Disease
are O O
unknown O O
. O O

We O O
studied O O
somatic O O
instability O O
by O O
measuring O O
the O O
CTG O O
repeat O O
length O O
at O O
several O O
ages O O
in O O
various O O
tissues O O
of O O
transgenic O O
mice O O
carrying O O
a O O
( O O
CTG O O
) O O
55expansion O O
surrounded O O
by O O
45 O O
kb O O
of O O
the O O
human O O
DM B-Disease B-Disease
region O O
, O O
using O O
small O O
- O O
pool O O
PCR O O
. O O

These O O
mice O O
have O O
been O O
shown O O
to O O
reproduce O O
the O O
intergenerational O O
and O O
somatic O O
instability O O
of O O
the O O
55 O O
CTG O O
repeat O O
suggesting O O
that O O
surrounding O O
sequences O O
and O O
the O O
chromatin O O
environment O O
are O O
involved O O
in O O
instability O O
mechanisms O O
. O O

As O O
observed O O
in O O
some O O
of O O
the O O
tissues O O
of O O
DM B-Disease B-Disease
patients O O
, O O
there O O
is O O
a O O
tendency O O
for O O
repeat O O
length O O
and O O
somatic O O
mosaicism O O
to O O
increase O O
with O O
the O O
age O O
of O O
the O O
mouse O O
. O O

Furthermore O O
, O O
we O O
observed O O
no O O
correlation O O
between O O
the O O
somatic O O
mutation O O
rate O O
and O O
tissue O O
proliferation O O
capacity O O
. O O

The O O
somatic O O
mutation O O
rates O O
in O O
different O O
tissues O O
were O O
also O O
not O O
correlated O O
to O O
the O O
relative O O
inter O O
- O O
tissue O O
difference O O
in O O
transcriptional O O
levels O O
of O O
the O O
three O O
genes O O
( O O
DMAHP O O
, O O
DMPK O O
and O O
59 O O
) O O
surrounding O O
the O O
repeat O O
.. O O

A O O
novel O O
missense O O
mutation O O
in O O
patients O O
from O O
a O O
retinoblastoma B-Disease B-Disease
pedigree O O
showing O O
only O O
mild O O
expression O O
of O O
the O O
tumor B-Disease B-Disease
phenotype O O
. O O

We O O
have O O
used O O
single O O
strand O O
conformation O O
polymorphism O O
analysis O O
to O O
study O O
the O O
27 O O
exons O O
of O O
the O O
RB1 O O
gene O O
in O O
individuals O O
from O O
a O O
family O O
showing O O
mild O O
expression O O
of O O
the O O
retinoblastoma B-Disease B-Disease
phenotype O O
. O O

In O O
this O O
family O O
affected O O
individuals O O
developed O O
unilateral B-Disease B-Disease
tumors I-Disease I-Disease
and O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
, O O
unaffected O O
mutation O O
carriers O O
were O O
also O O
identified O O
within O O
the O O
pedigree O O
. O O

A O O
single O O
band O O
shift O O
using O O
SSCP O O
was O O
identified O O
in O O
exon O O
21 O O
which O O
resulted O O
in O O
a O O
missense O O
mutation O O
converting O O
a O O
cys-- O O
> O O
arg O O
at O O
nucleotide O O
position O O
28 O O
in O O
the O O
exon O O
. O O

The O O
mutation O O
destroyed O O
an O O
NdeI O O
restriction O O
enzyme O O
site O O
. O O

Analysis O O
of O O
all O O
family O O
members O O
demonstrated O O
that O O
the O O
missense O O
mutation O O
co O O
- O O
segregated O O
with O O
patients O O
with O O
tumors B-Disease B-Disease
or O O
who O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
had O O
been O O
predicted O O
to O O
carry O O
the O O
predisposing O O
mutation O O
. O O

These O O
observations O O
point O O
to O O
another O O
region O O
of O O
the O O
RB1 O O
gene O O
where O O
mutations O O
only O O
modify O O
the O O
function O O
of O O
the O O
gene O O
and O O
raise O O
important O O
questions O O
for O O
genetic O O
counseling O O
in O O
families O O
with O O
these O O
distinctive O O
phenotypes O O
.. O O

Maternal B-Disease B-Disease
disomy I-Disease I-Disease
and O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
consistent O O
with O O
gamete O O
complementation O O
in O O
a O O
case O O
of O O
familial O O
translocation O O
( O O
3;15 O O
) O O
( O O
p25;q11.2 O O
) O O
. O O

Maternal B-Disease B-Disease
uniparental I-Disease I-Disease
disomy I-Disease I-Disease
( I-Disease O
UPD I-Disease B-Disease
) I-Disease O
for I-Disease O
chromosome I-Disease O
15 I-Disease O
is O O
responsible O O
for O O
an O O
estimated O O
30 O O
% O O
of O O
cases O O
of O O
Prader B-Disease B-Disease
- I-Disease I-Disease
Willi I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
PWS B-Disease B-Disease
) O O
. O O

We O O
report O O
on O O
an O O
unusual O O
case O O
of O O
maternal B-Disease B-Disease
disomy I-Disease I-Disease
15 I-Disease I-Disease
in O O
PWS B-Disease B-Disease
that O O
is O O
most O O
consistent O O
with O O
adjacent-1 O O
segregation O O
of O O
a O O
paternal O O
t O O
( O O
3 O O
; O O
15 O O
) O O
( O O
p25 O O
; O O
q11 O O
. O O

2 O O
) O O
with O O
simultaneous O O
maternal O O
meiotic O O
nondisjunction O O
for O O
chromosome O O
15 O O
. O O

The O O
patient O O
( O O
J. O O
B. O O
) O O
, O O
a O O
17-year O O
- O O
old O O
white O O
male O O
with O O
PWS B-Disease B-Disease
, O O
was O O
found O O
to O O
have O O
47 O O
chromosomes O O
with O O
a O O
supernumerary O O
, O O
paternal O O
der O O
( O O
15 O O
) O O
consisting O O
of O O
the O O
short O O
arm O O
and O O
the O O
proximal O O
long O O
arm O O
of O O
chromosome O O
15 O O
, O O
and O O
distal O O
chromosome O O
arm O O
3p O O
. O O

The O O
t O O
( O O
3 O O
; O O
15 O O
) O O
was O O
present O O
in O O
the O O
balanced O O
state O O
in O O
the O O
patients O O
father O O
and O O
a O O
sister O O
. O O

Fluorescent O O
in O O
situ O O
hybridization O O
analysis O O
demonstrated O O
that O O
the O O
PWS B-Disease B-Disease
critical O O
region O O
resided O O
on O O
the O O
derivative O O
chromosome O O
3 O O
and O O
that O O
there O O
was O O
no O O
deletion O O
of O O
the O O
PWS B-Disease B-Disease
region O O
on O O
the O O
normal O O
pair O O
of O O
15s O O
present O O
in O O
J. O O
B. O O
Methylation O O
analysis O O
at O O
exon O O
alpha O O
of O O
the O O
small O O
nuclear O O
ribonucleoprotein O O
- O O
associated O O
polypeptide O O
N O O
( O O
SNRPN O O
) O O
gene O O
showed O O
a O O
pattern O O
characteristic O O
of O O
only O O
the O O
maternal O O
chromosome O O
15 O O
in O O
J. O O
B. O O
Maternal B-Disease B-Disease
disomy I-Disease I-Disease
was O O
confirmed O O
by O O
polymerase O O
chain O O
reaction O O
analysis O O
of O O
microsatellite O O
repeats O O
at O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
receptor O O
beta3 O O
subunit O O
( O O
GABRB3 O O
) O O
locus O O
. O O

A O O
niece O O
( O O
B. O O
B. O O
) O O
with O O
45 O O
chromosomes O O
and O O
the O O
derivative O O
3 O O
but O O
without O O
the O O
der O O
( O O
15 O O
) O O
demonstrated O O
a O O
phenotype O O
consistent O O
with O O
that O O
reported O O
for O O
haploinsufficiency O O
of O O
distal O O
3 O O
p. O O
Uniparental B-Disease B-Disease
disomy I-Disease I-Disease
associated O O
with O O
unbalanced O O
segregation O O
of O O
non O O
- O O
Robertsonian O O
translocations O O
has O O
been O O
reported O O
previously O O
but O O
has O O
not O O
, O O
to O O
our O O
knowledge O O
, O O
been O O
observed O O
in O O
a O O
case O O
of O O
PWS B-Disease B-Disease
. O O

Furthermore O O
, O O
our O O
findings O O
are O O
best O O
interpreted O O
as O O
true O O
gamete O O
complementation O O
resulting O O
in O O
maternal B-Disease B-Disease
UPD I-Disease I-Disease
15 I-Disease I-Disease
and O O
PWS B-Disease B-Disease

Schwartz B-Disease B-Disease
- I-Disease I-Disease
Jampel I-Disease I-Disease
syndrome I-Disease I-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
and O O
Stuve B-Disease B-Disease
- I-Disease I-Disease
Wiedemann I-Disease I-Disease
syndrome I-Disease I-Disease
: O O
a O O
case O O
for O O
" O O
lumping O O
" O O
. O O

Recent O O
studies O O
demonstrated O O
the O O
existence O O
of O O
a O O
genetically O O
distinct O O
, O O
usually O O
lethal O O
form O O
of O O
the O O
Schwartz B-Disease B-Disease
- I-Disease I-Disease
Jampel I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
SJS B-Disease B-Disease
) O O
of O O
myotonia B-Disease B-Disease
and O O
skeletal B-Disease B-Disease
dysplasia I-Disease I-Disease
, O O
which O O
we O O
called O O
SJS B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
. O O

This O O
disorder O O
is O O
reminiscent O O
of O O
another O O
rare O O
condition O O
, O O
the O O
Stuve B-Disease B-Disease
- I-Disease I-Disease
Wiedemann I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
SWS B-Disease B-Disease
) O O
, O O
which O O
comprises O O
campomelia B-Disease B-Disease
at O O
birth O O
with O O
skeletal B-Disease B-Disease
dysplasia I-Disease I-Disease
, O O
contractures B-Disease B-Disease
, O O
and O O
early B-Disease O
death I-Disease O
. O O

To O O
test O O
for O O
possible O O
nosologic O O
identity O O
between O O
these O O
disorders O O
, O O
we O O
reviewed O O
the O O
literature O O
and O O
obtained O O
a O O
follow O O
- O O
up O O
of O O
the O O
only O O
two O O
surviving O O
patients O O
, O O
one O O
with O O
SJS B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
at O O
age O O
10 O O
years O O
and O O
another O O
with O O
SWS B-Disease B-Disease
at O O
age O O
7 O O
years O O
. O O

Patients O O
reported O O
as O O
having O O
either O O
neonatal O O
SJS B-Disease B-Disease
or O O
SWS B-Disease B-Disease
presented O O
a O O
combination O O
of O O
a O O
severe O O
, O O
prenatal O O
- O O
onset O O
neuromuscular B-Disease B-Disease
disorder I-Disease I-Disease
( O O
with O O
congenital B-Disease B-Disease
joint I-Disease I-Disease
contractures I-Disease I-Disease
, O O
respiratory O O
and O O
feeding O O
difficulties O O
, O O
tendency O O
to O O
hyperthermia B-Disease B-Disease
, O O
and O O
frequent O O
death O O
in O O
infancy O O
) O O
with O O
a O O
distinct O O
campomelic B-Disease B-Disease
- I-Disease I-Disease
metaphyseal I-Disease I-Disease
skeletal I-Disease I-Disease
dysplasia I-Disease I-Disease
. O O

The O O
similarity O O
of O O
the O O
clinical O O
and O O
radiographic O O
findings O O
is O O
so O O
extensive O O
that O O
these O O
disorders O O
appear O O
to O O
be O O
a O O
single O O
entity O O
. O O

The O O
follow O O
- O O
up O O
observation O O
of O O
an O O
identical O O
and O O
unique O O
pattern O O
of O O
progressive O O
bone B-Disease B-Disease
dysplasia I-Disease I-Disease
in O O
the O O
two O O
patients O O
( O O
one O O
with O O
SJS B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
, O O
one O O
with O O
SWS B-Disease B-Disease
) O O
surviving O O
beyond O O
infancy O O
adds O O
to O O
the O O
evidence O O
in O O
favor O O
of O O
identity O O
. O O

The O O
hypothesis O O
that O O
SWS B-Disease B-Disease
and O O
SJS B-Disease B-Disease
type I-Disease I-Disease
2 I-Disease I-Disease
are O O
the O O
same O O
disorder O O
should O O
be O O
testable O O
by O O
molecular O O
methods O O
.. O O

A O O
mouse O O
model O O
of O O
severe O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
: O O
defects O O
in O O
hemostasis O O
and O O
thrombosis B-Disease B-Disease
. O O

von B-Disease B-Disease
Willebrand I-Disease I-Disease
factor I-Disease I-Disease
( I-Disease I-Disease
vWf I-Disease I-Disease
) I-Disease I-Disease
deficiency I-Disease I-Disease
causes O O
severe O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
in O O
humans O O
. O O

We O O
generated O O
a O O
mouse O O
model O O
for O O
this O O
disease O O
by O O
using O O
gene O O
targeting O O
. O O

vWf B-Disease B-Disease
- I-Disease I-Disease
deficient I-Disease I-Disease
mice O O
appeared O O
normal O O
at O O
birth O O
; O O
they O O
were O O
viable O O
and O O
fertile O O
. O O

Neither O O
vWf O O
nor O O
vWf O O
propolypeptide O O
( O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
antigen O O
II O O
) O O
were O O
detectable O O
in O O
plasma O O
, O O
platelets O O
, O O
or O O
endothelial O O
cells O O
of O O
the O O
homozygous O O
mutant O O
mice O O
. O O

The O O
mutant O O
mice O O
exhibited O O
defects O O
in O O
hemostasis O O
with O O
a O O
highly O O
prolonged O O
bleeding O B-Disease
time O O
and O O
spontaneous O O
bleeding O B-Disease
events O O
in O O
approximately O O
10 O O
% O O
of O O
neonates O O
. O O

As O O
in O O
the O O
human O O
disease O O
, O O
the O O
factor O O
VIII O O
level O O
in O O
these O O
mice O O
was O O
reduced O O
strongly O O
as O O
a O O
result O O
of O O
the O O
lack O O
of O O
protection O O
provided O O
by O O
vWf O O
. O O

Defective O O
thrombosis B-Disease B-Disease
in O O
mutant O O
mice O O
was O O
also O O
evident O O
in O O
an O O
in O O
vivo O O
model O O
of O O
vascular B-Disease B-Disease
injury I-Disease I-Disease
. O O

In O O
this O O
model O O
, O O
the O O
exteriorized O O
mesentery O O
was O O
superfused O O
with O O
ferric O O
chloride O O
and O O
the O O
accumulation O O
of O O
fluorescently O O
labeled O O
platelets O O
was O O
observed O O
by O O
intravital O O
microscopy O O
. O O

We O O
conclude O O
that O O
these O O
mice O O
very O O
closely O O
mimic O O
severe O O
human O O
von B-Disease B-Disease
Willebrand I-Disease I-Disease
disease I-Disease I-Disease
and O O
will O O
be O O
very O O
useful O O
for O O
investigating O O
the O O
role O O
of O O
vWf O O
in O O
normal O O
physiology O O
and O O
in O O
disease O O
models O O
.. O O

Oral O O
contraceptives O O
and O O
the O O
risk O O
of O O
hereditary B-Disease B-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
. O O

Hereditary B-Disease B-Disease
Ovarian I-Disease I-Disease
Cancer I-Disease I-Disease
Clinical O O
Study O O
Group O O
. O O

BACKGROUND O O
Women O O
with O O
mutations O O
in O O
either O O
the O O
BRCA1 O O
or O O
the O O
BRCA2 O O
gene O O
have O O
a O O
high O O
lifetime O O
risk O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Oral O O
contraceptives O O
protect O O
against O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
in O O
general O O
, O O
but O O
it O O
is O O
not O O
known O O
whether O O
they O O
also O O
protect O O
against O O
hereditary B-Disease O
forms I-Disease O
of I-Disease O
ovarian I-Disease B-Disease
cancer I-Disease I-Disease
. O O

METHODS O O
We O O
enrolled O O
207 O O
women O O
with O O
hereditary B-Disease B-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
and O O
161 O O
of O O
their O O
sisters O O
as O O
controls O O
in O O
a O O
case O O
- O O
control O O
study O O
. O O

All O O
the O O
patients O O
carried O O
a O O
pathogenic O O
mutation O O
in O O
either O O
BRCA1 O O
( O O
179 O O
women O O
) O O
or O O
BRCA2 O O
( O O
28 O O
women O O
) O O
. O O

The O O
control O O
women O O
were O O
enrolled O O
regardless O O
of O O
whether O O
or O O
not O O
they O O
had O O
either O O
mutation O O
. O O

Lifetime O O
histories O O
of O O
oral O O
- O O
contraceptive O O
use O O
were O O
obtained O O
by O O
interview O O
or O O
by O O
written O O
questionnaire O O
and O O
were O O
compared O O
between O O
patients O O
and O O
control O O
women O O
, O O
after O O
adjustment O O
for O O
year O O
of O O
birth O O
and O O
parity O O
. O O

RESULTS O O
The O O
adjusted O O
odds O O
ratio O O
for O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
associated O O
with O O
any O O
past O O
use O O
of O O
oral O O
contraceptives O O
was O O
0 O O
. O O
5 O O
( O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
3 O O
to O O
0 O O
. O O

8) O O
. O O

The O O
risk O O
decreased O O
with O O
increasing O O
duration O O
of O O
use O O
( O O
P O O
for O O
trend O O
, O O
< O O
0 O O
. O O
001 O O
) O O
; O O
use O O
for O O
six O O
or O O
more O O
years O O
was O O
associated O O
with O O
a O O
60 O O
percent O O
reduction O O
in O O
risk O O
. O O

Oral O O
- O O
contraceptive O O
use O O
protected O O
against O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
both O O
for O O
carriers O O
of O O
the O O
BRCA1 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
5 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
3 O O
to O O
0 O O
. O O
9 O O
) O O
and O O
for O O
carriers O O
of O O
the O O
BRCA2 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
4 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
2 O O
to O O
1 O O
. O O
1 O O
) O O
. O O

CONCLUSIONS O O
Oral O O
- O O
contraceptive O O
use O O
may O O
reduce O O
the O O
risk O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
in O O
women O O
with O O
pathogenic O O
mutations O O
in O O
the O O
BRCA1 O O
or O O
BRCA2 O O
gene O O

A O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B-Disease B-Disease
with O O
a O O
codon O O
291 O O
deletion O O
: O O
a O O
clinical O O
, O O
biochemical O O
, O O
pathological O O
, O O
and O O
genetic O O
report O O
. O O

We O O
report O O
a O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B-Disease B-Disease
( O O
ALD B-Disease B-Disease
) O O
with O O
a O O
three O O
base O O
pair O O
deletion O O
( O O
delGAG O O
291 O O
) O O
in O O
the O O
ALD B-Disease B-Disease
gene O O
. O O

A O O
variety O O
of O O
phenotypes O O
were O O
observed O O
within O O
this O O
family O O
. O O

While O O
the O O
proband O O
( O O
patient O O
1 O O
) O O
was O O
classified O O
as O O
having O O
a O O
rare O O
intermediate O O
type O O
of O O
adult O O
cerebral O O
and O O
cerebello O O
- O O
brain O O
stem O O
forms O O
, O O
his O O
younger O O
brother O O
( O O
patient O O
2 O O
) O O
and O O
nephew O O
( O O
patient O O
3 O O
) O O
had O O
a O O
childhood O O
ALD B-Disease B-Disease
type O O
. O O

Another O O
nephew O O
( O O
patient O O
4 O O
) O O
of O O
patient O O
1 O O
was O O
classified O O
as O O
having O O
an O O
adolescent O O
form O O
. O O

The O O
tau O O
level O O
in O O
the O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
in O O
patient O O
1 O O
was O O
as O O
high O O
as O O
that O O
of O O
patients O O
with O O
Alzheimers B-Disease B-Disease
disease I-Disease I-Disease
( O O
AD B-Disease B-Disease
) O O
. O O

His O O
brain O O
magnetic O O
resonance O O
image O O
( O O
MRI O O
) O O
showed O O
abnormalities B-Disease O
in I-Disease O
the I-Disease O
bilateral I-Disease O
cerebellar I-Disease O
hemispheres I-Disease O
and O O
brain O O
stem O O
, O O
but O O
not O O
in O O
the O O
cerebral O O
white O O
matter O O
, O O
where O O
marked O O
reductions O O
of O O
the O O
cerebral O O
blood O O
flow O O
and O O
oxygen O O
metabolism O O
were O O
clearly O O
demonstrated O O
by O O
positron O O
emission O O
tomography O O
( O O
PET O O
) O O
. O O

In O O
patients O O
2 O O
and O O
3 O O
, O O
the O O
autopsy O O
findings O O
showed O O
massive O O
demyelination B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
cerebral I-Disease I-Disease
white I-Disease I-Disease
matter I-Disease I-Disease
with O O
sparing O O
of O O
the O O
U O O
- O O
fibers O O
, O O
compatible O O
with O O
the O O
findings O O
of O O
childhood O O
ALD B-Disease B-Disease
. O O

Oleic O O
and O O
erucic O O
acids O O
( O O
Lorenzos O O
Oil O O
) O O
were O O
administered O O
to O O
patients O O
1 O O
and O O
4 O O
, O O
but O O
sufficient O O
effectiveness O O
was O O
not O O
obtained O O
. O O

The O O
findings O O
in O O
this O O
family O O
suggest O O
that O O
delGAG291 O O
is O O
part O O
of O O
the O O
cause O O
of O O
Japanese O O
ALD B-Disease B-Disease
with O O
phenotypic O O
variations O O
. O O

Moreover O O
, O O
although O O
the O O
scale O O
of O O
the O O
study O O
is O O
limited O O
, O O
there O O
is O O
a O O
possibility O O
that O O
PET O O
can O O
detect O O
an O O
insidious B-Disease O
lesion I-Disease O
which O O
is O O
undetectable O O
by O O
computed O O
tomogram O O
( O O
CT O O
) O O
or O O
MRI O O
analysis O O
, O O
and O O
that O O
the O O
higher O O
level O O
of O O
tau O O
reflects O O
the O O
process O O
of O O
neuronal B-Disease B-Disease
degeneration I-Disease I-Disease
in O O
ALD B-Disease B-Disease
. O O

Lorenzos O O
Oil O O
should O O
be O O
given O O
in O O
the O O
early O O
stage O O
.. O O

Nonsense O O
mutation O O
in O O
exon O O
4 O O
of O O
human O O
complement O O
C9 O O
gene O O
is O O
the O O
major O O
cause O O
of O O
Japanese O O
complement B-Disease B-Disease
C9 I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

Deficiency B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
ninth I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
human I-Disease I-Disease
complement I-Disease I-Disease
( O O
C9 O O
) O O
is O O
the O O
most O O
common O O
complement B-Disease B-Disease
deficiency I-Disease I-Disease
in O O
Japan O O
but O O
is O O
rare O O
in O O
other O O
countries O O
. O O

We O O
studied O O
the O O
molecular O O
basis O O
of O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
in O O
four O O
Japanese O O
C9-deficient B-Disease B-Disease
patients O O
who O O
had O O
suffered O O
from O O
meningococcal B-Disease B-Disease
meningitis I-Disease I-Disease
. O O

Direct O O
sequencing O O
of O O
amplified O O
C9 O O
cDNA O O
and O O
DNA O O
revealed O O
a O O
nonsense O O
substitution O O
( O O
CGA-- O O
> O O
TGA O O
) O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
in O O
the O O
four O O
C9-deficient B-Disease B-Disease
individuals O O
. O O

An O O
allele O O
- O O
specific O O
polymerase O O
chain O O
reaction O O
system O O
designed O O
to O O
detect O O
exclusively O O
only O O
one O O
of O O
the O O
normal O O
and O O
mutant O O
alleles O O
indicated O O
that O O
all O O
the O O
four O O
patients O O
were O O
homozygous O O
for O O
the O O
mutation O O
in O O
exon O O
4 O O
and O O
that O O
the O O
parents O O
of O O
patient O O
2 O O
were O O
heterozygous O O
. O O

The O O
common O O
mutation O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
might O O
be O O
responsible O O
for O O
most O O
Japanese O O
C9 B-Disease B-Disease
deficiency I-Disease I-Disease
.. O O

BRCA1 O O
required O O
for O O
transcription O O
- O O
coupled O O
repair O O
of O O
oxidative O O
DNA O O
damage O O
. O O

The O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
susceptibility O O
gene O O
BRCA1 O O
encodes O O
a O O
zinc O O
finger O O
protein O O
of O O
unknown O O
function O O
. O O

Association O O
of O O
the O O
BRCA1 O O
protein O O
with O O
the O O
DNA O O
repair O O
protein O O
Rad51 O O
and O O
changes O O
in O O
the O O
phosphorylation O O
and O O
cellular O O
localization O O
of O O
the O O
protein O O
after O O
exposure O O
to O O
DNA O O
- O O
damaging O O
agents O O
are O O
consistent O O
with O O
a O O
role O O
for O O
BRCA1 O O
in O O
DNA O O
repair O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
mouse O O
embryonic O O
stem O O
cells O O
deficient B-Disease O
in I-Disease O
BRCA1 I-Disease O
are O O
defective O O
in O O
the O O
ability O O
to O O
carry O O
out O O
transcription O O
- O O
coupled O O
repair O O
of O O
oxidative O O
DNA O O
damage O O
, O O
and O O
are O O
hypersensitive O O
to O O
ionizing O O
radiation O O
and O O
hydrogen O O
peroxide O O
. O O

These O O
results O O
suggest O O
that O O
BRCA1 O O
participates O O
, O O
directly O O
or O O
indirectly O O
, O O
in O O
transcription O O
- O O
coupled O O
repair O O
of O O
oxidative O O
DNA O O
damage O O
.. O O

Truncation O O
mutations O O
in O O
the O O
transactivation O O
region O O
of O O
PAX6 O O
result O O
in O O
dominant O O
- O O
negative O O
mutants O O
. O O

PAX6 O O
is O O
a O O
transcription O O
factor O O
with O O
two O O
DNA O O
- O O
binding O O
domains O O
( O O
paired O O
box O O
and O O
homeobox O O
) O O
and O O
a O O
proline O O
- O O
serine O O
- O O
threonine O O
( O O
PST O O
) O O
-rich O O
transactivation O O
domain O O
. O O

PAX6 O O
regulates O O
eye O O
development O O
in O O
animals O O
ranging O O
from O O
jellyfish O O
to O O
Drosophila O O
to O O
humans O O
. O O

Heterozygous O O
mutations O O
in O O
the O O
human O O
PAX6 O O
gene O O
result O O
in O O
various O O
phenotypes O O
, O O
including O O
aniridia B-Disease B-Disease
, O O
Peters B-Disease B-Disease
anomaly I-Disease I-Disease
, O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
keratitis I-Disease I-Disease
, O O
and O O
familial B-Disease B-Disease
foveal I-Disease I-Disease
dysplasia I-Disease I-Disease
. O O

It O O
is O O
believed O O
that O O
the O O
mutated O O
allele O O
of O O
PAX6 O O
produces O O
an O O
inactive O O
protein O O
and O O
aniridia B-Disease B-Disease
is O O
caused O O
due O O
to O O
genetic O O
haploinsufficiency O O
. O O

However O O
, O O
several O O
truncation O O
mutations O O
have O O
been O O
found O O
to O O
occur O O
in O O
the O O
C O O
- O O
terminal O O
half O O
of O O
PAX6 O O
in O O
patients O O
with O O
Aniridia B-Disease B-Disease
resulting O O
in O O
mutant O O
proteins O O
that O O
retain O O
the O O
DNA O O
- O O
binding O O
domains O O
but O O
have O O
lost O O
most O O
of O O
the O O
transactivation O O
domain O O
. O O

It O O
is O O
not O O
clear O O
whether O O
such O O
mutants O O
really O O
behave O O
as O O
loss O O
- O O
of O O
- O O
function O O
mutants O O
as O O
predicted O O
by O O
haploinsufficiency O O
. O O

Contrary O O
to O O
this O O
theory O O
, O O
our O O
data O O
showed O O
that O O
these O O
mutants O O
are O O
dominant O O
- O O
negative O O
in O O
transient O O
transfection O O
assays O O
when O O
they O O
are O O
coexpressed O O
with O O
wild O O
- O O
type O O
PAX6 O O
. O O

We O O
found O O
that O O
the O O
dominant O O
- O O
negative O O
effects O O
result O O
from O O
the O O
enhanced O O
DNA O O
binding O O
ability O O
of O O
these O O
mutants O O
. O O

Kinetic O O
studies O O
of O O
binding O O
and O O
dissociation O O
revealed O O
that O O
various O O
truncation O O
mutants O O
have O O
3 O O
- O O
5-fold O O
higher O O
affinity O O
to O O
various O O
DNA O O
- O O
binding O O
sites O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
PAX6 O O
. O O

These O O
results O O
provide O O
a O O
new O O
insight O O
into O O
the O O
role O O
of O O
mutant O O
PAX6 O O
in O O
causing O O
aniridia B-Disease B-Disease
.. O O

Reversal O O
of O O
severe O O
hypertrophic B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
and O O
excellent O O
neuropsychologic O O
outcome O O
in O O
very B-Disease B-Disease
- I-Disease I-Disease
long I-Disease I-Disease
- I-Disease I-Disease
chain I-Disease I-Disease
acyl I-Disease I-Disease
- I-Disease I-Disease
coenzyme I-Disease I-Disease
A I-Disease I-Disease
dehydrogenase I-Disease I-Disease
deficiency I-Disease I-Disease
. O O

Very B-Disease B-Disease
- I-Disease I-Disease
long I-Disease I-Disease
- I-Disease I-Disease
chain I-Disease I-Disease
acyl I-Disease I-Disease
- I-Disease I-Disease
coenzyme I-Disease I-Disease
A I-Disease I-Disease
dehydrogenase I-Disease I-Disease
( I-Disease I-Disease
VLCAD I-Disease I-Disease
) I-Disease I-Disease
deficiency I-Disease I-Disease
is O O
a O O
disorder O B-Disease
of O I-Disease
fatty O I-Disease
acid O I-Disease
beta O I-Disease
oxidation O I-Disease
that O O
reportedly O O
has O O
high O O
rates O O
of O O
morbidity O O
and O O
mortality O O
. O O

We O O
describe O O
the O O
outcome O O
of O O
a O O
5-year O O
- O O
old O O
girl O O
with O O
VLCAD B-Disease B-Disease
deficiency I-Disease I-Disease
who O O
was O O
first O O
seen O O
at O O
5 O O
months O O
of O O
age O O
with O O
severe O O
hypertrophic B-Disease B-Disease
cardiomyopathy I-Disease I-Disease
, O O
hepatomegaly B-Disease B-Disease
, O O
encephalopathy B-Disease B-Disease
, O O
and O O
hypotonia B-Disease B-Disease
. O O

Biochemical O O
studies O O
indicated O O
VLCAD B-Disease B-Disease
deficiency I-Disease I-Disease
caused O O
by O O
a O O
stable O O
yet O O
inactive O O
enzyme O O
. O O

Molecular O O
genetic O O
analysis O O
of O O
her O O
VLCAD O O
gene O O
revealed O O
a O O
T1372C O O
( O O
F458L O O
) O O
missense O O
mutation O O
and O O
a O O
1668 O O
ACAG O O
1669 O O
splice O O
site O O
mutation O O
. O O

After O O
initial O O
treatment O O
with O O
intravenous O O
glucose O O
and O O
carnitine O O
, O O
the O O
patient O O
has O O
thrived O O
on O O
a O O
low O O
- O O
fat O O
diet O O
supplemented O O
with O O
medium O O
- O O
chain O O
triglyceride O O
oil O O
and O O
carnitine O O
and O O
avoidance O O
of O O
fasting O O
. O O

Her O O
ventricular O B-Disease
hypertrophy O I-Disease
resolved O O
significantly O O
over O O
1 O O
year O O
, O O
and O O
cognitively O O
, O O
she O O
is O O
in O O
the O O
superior O O
range O O
for O O
age O O
. O O

Clinical O O
recognition O O
of O O
VLCAD B-Disease B-Disease
deficiency I-Disease I-Disease
is O O
important O O
because O O
it O O
is O O
one O O
of O O
the O O
few O O
directly O O
treatable O O
causes O O
of O O
cardiomyopathy B-Disease B-Disease
in O O
children O O
.. O O

Cloning O O
of O O
a O O
novel O O
member O O
of O O
the O O
low O O
- O O
density O O
lipoprotein O O
receptor O O
family O O
. O O

A O O
gene O O
encoding O O
a O O
novel O O
transmembrane O O
protein O O
was O O
identified O O
by O O
DNA O O
sequence O O
analysis O O
within O O
the O O
insulin B-Disease B-Disease
- I-Disease I-Disease
dependent I-Disease I-Disease
diabetes I-Disease I-Disease
mellitus I-Disease I-Disease
( O O
IDDM B-Disease B-Disease
) O O
locus O O
IDDM4 O O
on O O
chromosome O O
11q13 O O
. O O

Based O O
on O O
its O O
chromosomal O O
position O O
, O O
this O O
gene O O
is O O
a O O
candidate O O
for O O
conferring O O
susceptibility O O
to O O
diabetes B-Disease B-Disease
. O O

The O O
gene O O
, O O
termed O O
low O O
- O O
density O O
lipoprotein O O
receptor O O
related O O
protein O O
5 O O
( O O
LRP5 O O
) O O
, O O
encodes O O
a O O
protein O O
of O O
1615 O O
amino O O
acids O O
that O O
contains O O
conserved O O
modules O O
which O O
are O O
characteristic O O
of O O
the O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
receptor O O
family O O
. O O

These O O
modules O O
include O O
a O O
putative O O
signal O O
peptide O O
for O O
protein O O
export O O
, O O
four O O
epidermal O O
growth O O
factor O O
( O O
EGF O O
) O O
repeats O O
with O O
associated O O
spacer O O
domains O O
, O O
three O O
LDL O O
- O O
receptor O O
( O O
LDLR O O
) O O
repeats O O
, O O
a O O
single O O
transmembrane O O
spanning O O
domain O O
, O O
and O O
a O O
cytoplasmic O O
domain O O
. O O

The O O
encoded O O
protein O O
has O O
a O O
unique O O
organization O O
of O O
EGF O O
and O O
LDLR O O
repeats O O
; O O
therefore O O
, O O
LRP5 O O
likely O O
represents O O
a O O
new O O
category O O
of O O
the O O
LDLR O O
family O O
. O O

Both O O
human O O
and O O
mouse O O
LRP5 O O
cDNAs O O
have O O
been O O
isolated O O
and O O
the O O
encoded O O
mature O O
proteins O O
are O O
95 O O
% O O
identical O O
, O O
indicating O O
a O O
high O O
degree O O
of O O
evolutionary O O
conservation O O
.. O O

The O O
APC B-Disease B-Disease
variants O O
I1307 O O
K O O
and O O
E1317Q O O
are O O
associated O O
with O O
colorectal B-Disease B-Disease
tumors I-Disease I-Disease
, O O
but O O
not O O
always O O
with O O
a O O
family O O
history O O
. O O

Classical O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
is O O
a O O
high O O
- O O
penetrance O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disease I-Disease I-Disease
that O O
predisposes O O
to O O
hundreds O O
or O O
thousands O O
of O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
and I-Disease O
carcinoma I-Disease B-Disease
and O O
that O O
results O O
from O O
truncating O O
mutations O O
in O O
the O O
APC B-Disease B-Disease
gene O O
. O O

A O O
variant O O
of O O
FAP B-Disease B-Disease
is O O
attenuated B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
, O O
which O O
results O O
from O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
5 O O
and O O
3 O O
regions O O
of O O
the O O
APC B-Disease B-Disease
gene O O
. O O

Attenuated B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
patients O O
have O O
" O O
multiple O O
" O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
( O O
typically O O
fewer O O
than O O
100 O O
) O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B-Disease B-Disease
. O O

Another O O
group O O
of O O
patients O O
with O O
multiple O O
adenomas B-Disease B-Disease
has O O
no O O
mutations O O
in O O
the O O
APC B-Disease B-Disease
gene O O
, O O
and O O
their O O
phenotype O O
probably O O
results O O
from O O
variation O O
at O O
a O O
locus O O
, O O
or O O
loci O O
, O O
elsewhere O O
in O O
the O O
genome O O
. O O

Recently O O
, O O
however O O
, O O
a O O
missense O O
variant O O
of O O
APC B-Disease B-Disease
( O O
I1307 O O
K O O
) O O
was O O
described O O
that O O
confers O O
an O O
increased O O
risk O O
of O O
colorectal B-Disease B-Disease
tumors I-Disease I-Disease
, O O
including O O
multiple O O
adenomas B-Disease B-Disease
, O O
in O O
Ashkenazim O O
. O O

We O O
have O O
studied O O
a O O
set O O
of O O
164 O O
patients O O
with O O
multiple O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
and/or I-Disease O
carcinoma I-Disease B-Disease
and O O
analyzed O O
codons O O
1263 O O
- O O
1377 O O
( O O
exon O O
15 O O
G O O
) O O
of O O
the O O
APC B-Disease B-Disease
gene O O
for O O
germ O O
- O O
line O O
variants O O
. O O

Three O O
patients O O
with O O
the O O
I1307 O O
K O O
allele O O
were O O
detected O O
, O O
each O O
of O O
Ashkenazi O O
descent O O
. O O

Four O O
patients O O
had O O
a O O
germ O O
- O O
line O O
E1317Q O O
missense O O
variant O O
of O O
APC O B-Disease
that O O
was O O
not O O
present O O
in O O
controls O O
; O O
one O O
of O O
these O O
individuals O O
had O O
an O O
unusually O O
large O O
number O O
of O O
metaplastic B-Disease B-Disease
polyps I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
colorectum I-Disease I-Disease
. O O

There O O
is O O
increasing O O
evidence O O
that O O
there O O
exist O O
germ O O
- O O
line O O
variants O O
of O O
the O O
APC B-Disease B-Disease
gene O O
that O O
predispose O O
to O O
the O O
development O O
of O O
multiple O O
colorectal B-Disease B-Disease
adenomas I-Disease I-Disease
and I-Disease O
carcinoma I-Disease B-Disease
, O O
but O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B-Disease B-Disease
, O O
and O O
possibly O O
with O O
importance O O
for O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
risk O O
in O O
the O O
general O O
population O O
.. O O

Genomic O O
structure O O
of O O
the O O
human O O
congenital B-Disease B-Disease
chloride I-Disease I-Disease
diarrhea I-Disease I-Disease
( O O
CLD B-Disease B-Disease
) O O
gene O O
. O O

Congenital B-Disease B-Disease
chloride I-Disease I-Disease
diarrhea I-Disease I-Disease
( O O
CLD B-Disease B-Disease
) O O
is O O
caused O O
by O O
mutations O O
in O O
a O O
gene O O
which O O
encodes O O
an O O
intestinal O O
anion O O
transporter O O
. O O

We O O
report O O
here O O
the O O
complete O O
genomic O O
organization O O
of O O
the O O
human O O
CLD B-Disease B-Disease
gene O O
which O O
spans O O
approximately O O
39 O O
kb O O
, O O
and O O
comprises O O
21 O O
exons O O
. O O

All O O
exon O O
/ O O
intron O O
boundaries O O
conform O O
to O O
the O O
GT O O
/ O O
AG O O
rule O O
. O O

An O O
analysis O O
of O O
the O O
putative O O
promoter O O
region O O
sequence O O
shows O O
a O O
putative O O
TATA O O
box O O
and O O
predicts O O
multiple O O
transcription O O
factor O O
binding O O
sites O O
. O O

The O O
genomic O O
structure O O
was O O
determined O O
using O O
DNA O O
from O O
several O O
sources O O
including O O
multiple O O
large O O
- O O
insert O O
libaries O O
and O O
genomic O O
DNA O O
from O O
Finnish O O
CLD B-Disease B-Disease
patients O O
and O O
controls O O
. O O

Exon O O
- O O
specific O O
primers O O
developed O O
in O O
this O O
study O O
will O O
facilitate O O
mutation O O
screening O O
studies O O
of O O
patients O O
with O O
the O O
disease O O
. O O

Genomic O O
sequencing O O
of O O
a O O
BAC O O
clone O O
H_RG364P16 O O
revealed O O
the O O
presence O O
of O O
another O O
, O O
highly O O
homologous O O
gene O O
3 O O
of O O
the O O
CLD B-Disease B-Disease
gene O O
, O O
with O O
a O O
similar O O
genomic O O
structure O O
, O O
recently O O
identified O O
as O O
the O O
Pendred B-Disease B-Disease
syndrome I-Disease I-Disease
gene O O
( O O
PDS B-Disease B-Disease
) O O
.. O O

The O O
APCI1307 O O
K O O
allele O O
and O O
cancer B-Disease B-Disease
risk O O
in O O
a O O
community O O
- O O
based O O
study O O
of O O
Ashkenazi O O
Jews O O
. O O

Mutations O O
in O O
APC O B-Disease
are O O
classically O O
associated O O
with O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
, O O
a O O
highly O O
penetrant O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disorder I-Disease I-Disease
characterized O O
by O O
multiple O O
intestinal O B-Disease
polyps B-Disease I-Disease
and O O
, O O
without O O
surgical O O
intervention O O
, O O
the O O
development O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
( O O
CRC B-Disease B-Disease
) O O
. O O

APC B-Disease B-Disease
is O O
a O O
tumour O B-Disease
- O O
suppressor O O
gene O O
, O O
and O O
somatic O O
loss O O
occurs O O
in O O
tumours B-Disease B-Disease
. O O

The O O
germline O O
T O O
- O O
to O O
- O O
A O O
transversion O O
responsible O O
for O O
the O O
APC O B-Disease
I1307 O O
K O O
allele O O
converts O O
the O O
wild O O
- O O
type O O
sequence O O
to O O
a O O
homopolymer O O
tract O O
( O O
A8 O O
) O O
that O O
is O O
genetically O O
unstable O O
and O O
prone O O
to O O
somatic O O
mutation O O
. O O

The O O
I1307 O O
K O O
allele O O
was O O
found O O
in O O
6 O O
. O O
1 O O
% O O
of O O
unselected O O
Ashkenazi O O
Jews O O
and O O
higher O O
proportions O O
of O O
Ashkenazim O O
with O O
family O O
or O O
personal O O
histories O O
of O O
CRC B-Disease B-Disease
( O O
ref O O
. O O

2 O O
) O O
. O O

To O O
evaluate O O
the O O
role O O
of O O
I1307 O O
K O O
in O O
cancer B-Disease B-Disease
, O O
we O O
genotyped O O
5 O O
, O O
081 O O
Ashkenazi O O
volunteers O O
in O O
a O O
community O O
survey O O
. O O

Risk O O
of O O
developing O O
colorectal B-Disease B-Disease
, I-Disease I-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
other I-Disease I-Disease
cancers I-Disease I-Disease
were O O
compared O O
between O O
genotyped O O
I1307 O O
K O O
carriers O O
and O O
non O O
- O O
carriers O O
and O O
their O O
first O O
- O O
degree O O
relatives O O
. O O

Sperm O O
DNA O O
analysis O O
in O O
a O O
Friedreich B-Disease B-Disease
ataxia I-Disease I-Disease
premutation O O
carrier O O
suggests O O
both O O
meiotic O O
and O O
mitotic O O
expansion O O
in O O
the O O
FRDA B-Disease B-Disease
gene O O
. O O

Friedreich B-Disease B-Disease
ataxia I-Disease I-Disease
is O O
usually O O
caused O O
by O O
an O O
expansion O O
of O O
a O O
GAA O O
trinucleotide O O
repeat O O
in O O
intron O O
1 O O
of O O
the O O
FRDA B-Disease B-Disease
gene O O
. O O

Occasionally O O
, O O
a O O
fully O O
expanded O O
allele O O
has O O
been O O
found O O
to O O
arise O O
from O O
a O O
premutation O O
of O O
100 O O
or O O
less O O
triplet O O
repeats O O
. O O

We O O
have O O
examined O O
the O O
sperm O O
DNA O O
of O O
a O O
premutation O O
carrier O O
. O O

This O O
mans O O
leucocyte O O
DNA O O
showed O O
one O O
normal O O
allele O O
and O O
one O O
allele O O
of O O
approximately O O
100 O O
repeats O O
. O O

His O O
sperm O O
showed O O
an O O
expanded O O
allele O O
in O O
a O O
tight O O
range O O
centering O O
on O O
a O O
size O O
of O O
approximately O O
320 O O
trinucleotide O O
repeats O O
. O O

His O O
affected O O
son O O
has O O
repeat O O
sizes O O
of O O
1040 O O
and O O
540 O O
. O O

These O O
data O O
suggest O O
that O O
expansion O O
occurs O O
in O O
two O O
stages O O
, O O
the O O
first O O
during O O
meiosis O O
followed O O
by O O
a O O
second O O
mitotic O O
expansion O O
. O O

We O O
also O O
show O O
that O O
in O O
all O O
informative O O
carrier O O
father O O
to O O
affected O O
child O O
transmissions O O
, O O
with O O
the O O
notable O O
exception O O
of O O
the O O
premutation O O
carrier O O
, O O
the O O
expansion O O
size O O
decreases O O
.. O O

The O O
R496H O O
mutation O O
of O O
arylsulfatase O O
A O O
does O O
not O O
cause O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
. O O

Deficiency B-Disease B-Disease
of I-Disease I-Disease
arylsulfatase I-Disease I-Disease
A I-Disease I-Disease
( O O
ARSA O O
) O O
enzyme O O
activity O O
causes O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
( O O
MLD B-Disease B-Disease
) O O
. O O

A O O
number O O
of O O
ARSA O O
gene O O
mutations O O
responsible O O
for O O
MLD B-Disease B-Disease
have O O
been O O
identified O O
. O O

Recently O O
, O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
was O O
proposed O O
to O O
be O O
a O O
cause O O
of O O
MLD B-Disease B-Disease
( O O
Draghia O O
et O O
al. O O
, O O
1997 O O
) O O
. O O

We O O
have O O
investigated O O
the O O
R496H O O
mutation O O
and O O
found O O
this O O
mutation O O
at O O
a O O
relatively O O
high O O
frequency O O
in O O
an O O
African O O
American O O
population O O
( O O
f O O
= O O
0 O O
. O O
09 O O
, O O
n O O
= O O
61 O O
subjects O O
) O O
. O O

The O O
ARSA O O
enzyme O O
activity O O
in O O
subjects O O
with O O
and O O
without O O
the O O
R496H O O
mutation O O
was O O
determined O O
and O O
found O O
to O O
be O O
normal O O
. O O

It O O
is O O
therefore O O
concluded O O
that O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
does O O
not O O
negatively O O
influence O O
the O O
activity O O
of O O
ARSA O O
and O O
is O O
not O O
a O O
cause O O
of O O
MLD B-Disease B-Disease

Down O O
- O O
regulation O O
of O O
transmembrane O O
carbonic O O
anhydrases O O
in O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
cell O O
lines O O
by O O
wild O O
- O O
type O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
transgenes O O
. O O

To O O
discover O O
genes O O
involved O O
in O O
von B-Disease B-Disease
Hippel I-Disease I-Disease
- I-Disease I-Disease
Lindau I-Disease I-Disease
( O O
VHL B-Disease B-Disease
) O O
-mediated O O
carcinogenesis O O
, O O
we O O
used O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
cell O O
lines O O
stably O O
transfected O O
with O O
wild O O
- O O
type O O
VHL O O
- O O
expressing O O
transgenes O O
. O O

Large O O
- O O
scale O O
RNA O O
differential O O
display O O
technology O O
applied O O
to O O
these O O
cell O O
lines O O
identified O O
several O O
differentially O O
expressed O O
genes O O
, O O
including O O
an O O
alpha O O
carbonic O O
anhydrase O O
gene O O
, O O
termed O O
CA12 O O
. O O

The O O
deduced O O
protein O O
sequence O O
was O O
classified O O
as O O
a O O
one O O
- O O
pass O O
transmembrane O O
CA O O
possessing O O
an O O
apparently O O
intact O O
catalytic O O
domain O O
in O O
the O O
extracellular O O
CA O O
module O O
. O O

Reintroduced O O
wild O O
- O O
type O O
VHL B-Disease B-Disease
strongly O O
inhibited O O
the O O
overexpression O O
of O O
the O O
CA12 O O
gene O O
in O O
the O O
parental O O
renal B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
cell O O
lines O O
. O O

Similar O O
results O O
were O O
obtained O O
with O O
CA9 O O
, O O
encoding O O
another O O
transmembrane O O
CA O O
with O O
an O O
intact O O
catalytic O O
domain O O
. O O

Although O O
both O O
domains O O
of O O
the O O
VHL B-Disease B-Disease
protein O O
contribute O O
to O O
regulation O O
of O O
CA12 O O
expression O O
, O O
the O O
elongin O O
binding O O
domain O O
alone O O
could O O
effectively O O
regulate O O
CA9 O O
expression O O
. O O

We O O
mapped O O
CA12 O O
and O O
CA9 O O
loci O O
to O O
chromosome O O
bands O O
15q22 O O
and O O
17q21 O O
. O O

2 O O
respectively O O
, O O
regions O O
prone O O
to O O
amplification O O
in O O
some O O
human O O
cancers B-Disease B-Disease
. O O

Additional O O
experiments O O
are O O
needed O O
to O O
define O O
the O O
role O O
of O O
CA O O
IX O O
and O O
CA O O
XII O O
enzymes O O
in O O
the O O
regulation O O
of O O
pH O O
in O O
the O O
extracellular O O
microenvironment O O
and O O
its O O
potential O O
impact O O
on O O
cancer B-Disease O
cell O O
growth O O
. O O

A O O
gene O O
encoding O O
a O O
transmembrane O O
protein O O
is O O
mutated O O
in O O
patients O O
with O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
and O O
optic B-Disease B-Disease
atrophy I-Disease I-Disease
( O O
Wolfram B-Disease B-Disease
syndrome I-Disease I-Disease
) O O
. O O

Wolfram B-Disease B-Disease
syndrome I-Disease I-Disease
( O O
WFS B-Disease B-Disease
; O O
OMIM O O
222300 O O
) O O
is O O
an O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
neurodegenerative I-Disease I-Disease
disorder I-Disease I-Disease
defined O O
by O O
young O O
- O O
onset O O
non O O
- O O
immune O O
insulin B-Disease B-Disease
- I-Disease I-Disease
dependent I-Disease I-Disease
diabetes I-Disease I-Disease
mellitus I-Disease I-Disease
and O O
progressive O O
optic B-Disease B-Disease
atrophy I-Disease I-Disease
. O O

Linkage O O
to O O
markers O O
on O O
chromosome O O
4p O O
was O O
confirmed O O
in O O
five O O
families O O
. O O

On O O
the O O
basis O O
of O O
meiotic O O
recombinants O O
and O O
disease O O
- O O
associated O O
haplotypes O O
, O O
the O O
WFS B-Disease B-Disease
gene O O
was O O
localized O O
to O O
a O O
BAC O O
/ O O
P1 O O
contig O O
of O O
less O O
than O O
250 O O
kb O O
. O O

Mutations O O
in O O
a O O
novel O O
gene O O
( O O
WFS1 O O
) O O
encoding O O
a O O
putative O O
transmembrane O O
protein O O
were O O
found O O
in O O
all O O
affected O O
individuals O O
in O O
six O O
WFS B-Disease B-Disease
families O O
, O O
and O O
these O O
mutations O O
were O O
associated O O
with O O
the O O
disease O O
phenotype O O
. O O

WFS1 O O
appears O O
to O O
function O O
in O O
survival O O
of O O
islet O O
beta O O
- O O
cells O O
and O O
neurons O O
.. O O

Stable O O
interaction O O
between O O
the O O
products O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
tumor B-Disease B-Disease
suppressor O O
genes O O
in O O
mitotic O O
and O O
meiotic O O
cells O O
. O O

BRCA1 O O
and O O
BRCA2 O O
account O O
for O O
most O O
cases O O
of O O
familial O O
, O O
early O O
onset O O
breast B-Disease B-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
and O O
encode O O
products O O
that O O
each O O
interact O O
with O O
hRAD51 O O
. O O

Results O O
presented O O
here O O
show O O
that O O
BRCA1 O O
and O O
BRCA2 O O
coexist O O
in O O
a O O
biochemical O O
complex O O
and O O
colocalize O O
in O O
subnuclear O O
foci O O
in O O
somatic O O
cells O O
and O O
on O O
the O O
axial O O
elements O O
of O O
developing O O
synaptonemal O O
complexes O O
. O O

Like O O
BRCA1 O O
and O O
RAD51 O O
, O O
BRCA2 O O
relocates O O
to O O
PCNA O O
+ O O
replication O O
sites O O
following O O
exposure O O
of O O
S O O
phase O O
cells O O
to O O
hydroxyurea O O
or O O
UV O O
irradiation O O
. O O

Thus O O
, O O
BRCA1 O O
and O O
BRCA2 O O
participate O O
, O O
together O O
, O O
in O O
a O O
pathway O O
( O O
s O O
) O O
associated O O
with O O
the O O
activation O O
of O O
double O O
- O O
strand O O
break O O
repair O O
and/or O O
homologous O O
recombination O O
. O O

Dysfunction O O
of O O
this O O
pathway O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
the O O
majority O O
of O O
cases O O
of O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and/or I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
.. O O

A O O
novel O O
Arg362Ser O O
mutation O O
in O O
the O O
sterol O O
27-hydroxylase O O
gene O O
( O O
CYP27 O O
) O O
: O O
its O O
effects O O
on O O
pre O O
- O O
mRNA O O
splicing O O
and O O
enzyme O O
activity O O
. O O

A O O
novel O O
C O O
to O O
A O O
mutation O O
in O O
the O O
sterol O O
27-hydroxylase O O
gene O O
( O O
CYP27 O O
) O O
was O O
identified O O
by O O
sequencing O O
amplified O O
CYP27 O O
gene O O
products O O
from O O
a O O
patient O O
with O O
cerebrotendinous B-Disease B-Disease
xanthomatosis I-Disease I-Disease
( O O
CTX B-Disease B-Disease
) O O
. O O

The O O
mutation O O
changed O O
the O O
adrenodoxin O O
cofactor O O
binding O O
residue O O
362Arg O O
to O O
362Ser O O
( O O
CGT O O
362Arg O O
to O O
AGT O O
362Ser O O
) O O
, O O
and O O
was O O
responsible O O
for O O
deficiency O B-Disease
in O I-Disease
the O I-Disease
sterol O I-Disease
27-hydroxylase O I-Disease
activity O I-Disease
, O O
as O O
confirmed O O
by O O
expression O O
of O O
mutant O O
cDNA O O
into O O
COS-1 O O
cells O O
. O O

Quantitative O O
analysis O O
showed O O
that O O
the O O
expression O O
of O O
CYP27 O O
gene O O
mRNA O O
in O O
the O O
patient O O
represented O O
52 O O
. O O
5 O O
% O O
of O O
the O O
normal O O
level O O
. O O

As O O
the O O
mutation O O
occurred O O
at O O
the O O
penultimate O O
nucleotide O O
of O O
exon O O
6 O O
( O O
-2 O O
position O O
of O O
exon O O
6-intron O O
6 O O
splice O O
site O O
) O O
of O O
the O O
gene O O
, O O
we O O
hypothesized O O
that O O
the O O
mutation O O
may O O
partially O O
affect O O
the O O
normal O O
splicing O O
efficiency O O
in O O
exon O O
6 O O
and O O
cause O O
alternative O O
splicing O O
elsewhere O O
, O O
which O O
resulted O O
in O O
decreased O O
transcript O O
in O O
the O O
patient O O
. O O

Transfection O O
of O O
constructed O O
minigenes O O
, O O
with O O
or O O
without O O
the O O
mutation O O
, O O
into O O
COS-1 O O
cells O O
confirmed O O
that O O
the O O
mutant O O
minigene O O
was O O
responsible O O
for O O
a O O
mRNA O O
species O O
alternatively O O
spliced O O
at O O
an O O
activated O O
cryptic O O
5 O O
splice O O
site O O
88 O O
bp O O
upstream O O
from O O
the O O
3 O O
end O O
of O O
exon O O
6 O O
. O O

Our O O
data O O
suggest O O
that O O
the O O
C O O
to O O
A O O
mutation O O
at O O
the O O
penultimate O O
nucleotide O O
of O O
exon O O
6 O O
of O O
the O O
CYP27 O O
gene O O
not O O
only O O
causes O O
the O O
deficiency B-Disease B-Disease
in I-Disease I-Disease
the I-Disease I-Disease
sterol I-Disease I-Disease
27-hydroxylase I-Disease I-Disease
activity I-Disease I-Disease
, O O
but O O
also O O
partially O O
leads O O
to O O
alternative O O
pre O O
- O O
mRNA O O
splicing O O
of O O
the O O
gene O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
regarding O O
effects O O
on O O
pre O O
- O O
mRNA O O
splicing O O
of O O
a O O
mutation O O
at O O
the O O
-2 O O
position O O
of O O
a O O
5 O O
splice O O
site O O
. O O

ATM O O
germline O O
mutations O O
in O O
classical O O
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
patients O O
in O O
the O O
Dutch O O
population O O
. O O

Germline O O
mutations O O
in O O
the O O
ATM O O
gene O O
are O O
responsible O O
for O O
the O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
disorder I-Disease I-Disease
ataxia B-Disease B-Disease
- I-Disease I-Disease
telangiectasia I-Disease I-Disease
( O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
) O O
. O O

In O O
our O O
study O O
, O O
we O O
have O O
determined O O
the O O
ATM O O
mutation O O
spectrum O O
in O O
19 O O
classical O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
patients O O
, O O
including O O
some O O
immigrant O O
populations O O
, O O
as O O
well O O
as O O
12 O O
of O O
Dutch O O
ethnic O O
origin O O
. O O

Both O O
the O O
protein O O
truncation O O
test O O
( O O
PTT O O
) O O
and O O
the O O
restriction O O
endonuclease O O
fingerprinting O O
( O O
REF O O
) O O
method O O
were O O
used O O
and O O
compared O O
for O O
their O O
detection O O
efficiency O O
, O O
identifying O O
76 O O
% O O
and O O
60 O O
% O O
of O O
the O O
mutations O O
, O O
respectively O O
. O O

Most O O
patients O O
were O O
found O O
to O O
be O O
compound O O
heterozygote O O
. O O

Seventeen O O
mutations O O
were O O
distinct O O
, O O
of O O
which O O
10 O O
were O O
not O O
reported O O
previously O O
. O O

Mutations O O
are O O
small O O
deletions O O
or O O
point O O
mutations O O
frequently O O
affecting O O
splice O O
sites O O
. O O

Moreover O O
, O O
a O O
16 O O
. O O

7-kb O O
genomic O O
deletion O O
of O O
the O O
3 O O
end O O
of O O
the O O
gene O O
, O O
most O O
likely O O
a O O
result O O
of O O
recombination O O
between O O
two O O
LINE O O
elements O O
, O O
was O O
identified O O
. O O

The O O
most O O
frequently O O
found O O
mutation O O
, O O
identified O O
in O O
three O O
unrelated O O
Turkish O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
individuals O O
, O O
was O O
previously O O
described O O
to O O
be O O
a O O
Turkish O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
founder O O
mutation O O
. O O

The O O
presence O O
of O O
a O O
founder O O
mutation O O
among O O
relatively O O
small O O
ethnic O O
population O O
groups O O
in O O
Western O O
Europe O O
could O O
indicate O O
a O O
high O O
carrier O O
frequency O O
in O O
such O O
communities O O
. O O

In O O
patients O O
of O O
Dutch O O
ethnic O O
origin O O
, O O
however O O
, O O
no O O
significant O O
founder O O
effect O O
could O O
be O O
identified O O
. O O

The O O
observed O O
genetic O O
heterogeneity O O
including O O
the O O
relative O O
high O O
percentage O O
of O O
splice O O
- O O
site O O
mutations O O
had O O
no O O
reflection O O
on O O
the O O
phenotype O O
. O O

All O O
patients O O
manifested O O
classical O O
A B-Disease B-Disease
- I-Disease I-Disease
T I-Disease I-Disease
and O O
increased O O
cellular O O
radioresistant O O
DNA O O
synthesis O O
. O O

Determination O O
of O O
the O O
genomic O O
structure O O
of O O
the O O
COL4A4 O O
gene O O
and O O
of O O
novel O O
mutations O O
causing O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
Alport I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Autosomal B-Disease B-Disease
recessive I-Disease I-Disease
Alport I-Disease I-Disease
syndrome I-Disease I-Disease
is O O
a O O
progressive O O
hematuric B-Disease B-Disease
glomerulonephritis I-Disease I-Disease
characterized O O
by O O
glomerular B-Disease B-Disease
basement I-Disease I-Disease
membrane I-Disease I-Disease
abnormalities I-Disease I-Disease
and O O
associated O O
with O O
mutations O O
in O O
either O O
the O O
COL4A3 O O
or O O
the O O
COL4A4 O O
gene O O
, O O
which O O
encode O O
the O O
alpha3 O O
and O O
alpha4 O O
type O O
IV O O
collagen O O
chains O O
, O O
respectively O O
. O O

To O O
date O O
, O O
mutation O O
screening O O
in O O
the O O
two O O
genes O O
has O O
been O O
hampered O O
by O O
the O O
lack O O
of O O
genomic O O
structure O O
information O O
. O O

We O O
report O O
here O O
the O O
complete O O
characterization O O
of O O
the O O
48 O O
exons O O
of O O
the O O
COL4A4 O O
gene O O
, O O
a O O
comprehensive O O
gene O O
screen O O
, O O
and O O
the O O
subsequent O O
detection O O
of O O
10 O O
novel O O
mutations O O
in O O
eight O O
patients O O
diagnosed O O
with O O
autosomal B-Disease B-Disease
recessive I-Disease I-Disease
Alport I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

Furthermore O O
, O O
we O O
identified O O
a O O
glycine O O
to O O
alanine O O
substitution O O
in O O
the O O
collagenous O O
domain O O
that O O
is O O
apparently O O
silent O O
in O O
the O O
heterozygous O O
carriers O O
, O O
in O O
11 O O
. O O
5 O O
% O O
of O O
all O O
control O O
individuals O O
, O O
and O O
in O O
one O O
control O O
individual O O
homozygous O O
for O O
this O O
glycine O O
substitution O O
. O O

There O O
has O O
been O O
no O O
previous O O
finding O O
of O O
a O O
glycine O O
substitution O O
that O O
is O O
not O O
associated O O
with O O
any O O
obvious O O
phenotype O O
in O O
homozygous O O
individuals O O
. O O

Founder O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
in O O
French O O
Canadian O O
breast B-Disease B-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
. O O

We O O
have O O
identified O O
four O O
mutations O O
in O O
each O O
of O O
the O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
- O O
susceptibility O O
genes O O
, O O
BRCA1 O O
and O O
BRCA2 O O
, O O
in O O
French O O
Canadian O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
and O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
from O O
Quebec O O
. O O

To O O
identify O O
founder O O
effects O O
, O O
we O O
examined O O
independently O O
ascertained O O
French O O
Canadian O O
cancer B-Disease B-Disease
families O O
for O O
the O O
distribution O O
of O O
these O O
eight O O
mutations O O
. O O

Mutations O O
were O O
found O O
in O O
41 O O
of O O
97 O O
families O O
. O O

Six O O
of O O
eight O O
mutations O O
were O O
observed O O
at O O
least O O
twice O O
. O O

The O O
BRCA1 O O
C4446 O O
T O O
mutation O O
was O O
the O O
most O O
common O O
mutation O O
found O O
, O O
followed O O
by O O
the O O
BRCA2 O O
8765delAG O O
mutation O O
. O O

Together O O
, O O
these O O
mutations O O
were O O
found O O
in O O
28 O O
of O O
41 O O
families O O
identified O O
to O O
have O O
a O O
mutation O O
. O O

The O O
odds O O
of O O
detection O O
of O O
any O O
of O O
the O O
four O O
BRCA1 O O
mutations O O
was O O
18 O O
. O O

7x O O
greater O O
if O O
one O O
or O O
more O O
cases O O
of O O
ovarian B-Disease B-Disease
cancer I-Disease I-Disease
were O O
also O O
present O O
in O O
the O O
family O O
. O O

The O O
odds O O
of O O
detection O O
of O O
any O O
of O O
the O O
four O O
BRCA2 O O
mutations O O
was O O
5 O O
. O O

3x O O
greater O O
if O O
there O O
were O O
at O O
least O O
five O O
cases O O
of O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
in O O
the O O
family O O
. O O

Interestingly O O
, O O
the O O
presence O O
of O O
a O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
case O O
< O O
36 O O
years O O
of O O
age O O
was O O
strongly O O
predictive O O
of O O
the O O
presence O O
of O O
any O O
of O O
the O O
eight O O
mutations O O
screened O O
. O O

Carriers O O
of O O
the O O
same O O
mutation O O
, O O
from O O
different O O
families O O
, O O
shared O O
similar O O
haplotypes O O
, O O
indicating O O
that O O
the O O
mutant O O
alleles O O
were O O
likely O O
to O O
be O O
identical O O
by O O
descent O O
for O O
a O O
mutation O O
in O O
the O O
founder O O
population O O
. O O

The O O
identification O O
of O O
common O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
will O O
facilitate O O
carrier O O
detection O O
in O O
French O O
Canadian O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
and O O
breast B-Disease B-Disease
/ I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
families O O
. O O

Are O O
Dp71 O O
and O O
Dp140 O O
brain O O
dystrophin O O
isoforms O O
related O O
to O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
in O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
? O O

Molecular O O
study O O
and O O
neuropsychological O O
analysis O O
were O O
performed O O
concurrently O O
on O O
49 O O
patients O O
with O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
) O O
in O O
order O O
to O O
find O O
a O O
molecular O O
explanation O O
for O O
the O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
observed O O
in O O
most O O
DMD B-Disease B-Disease
patients O O
. O O

Complete O O
analysis O O
of O O
the O O
dystrophin O O
gene O O
was O O
performed O O
to O O
define O O
the O O
localization O O
of O O
deletions O O
and O O
duplications O O
in O O
relation O O
to O O
the O O
different O O
DMD B-Disease B-Disease
promoters O O
. O O

Qualitative O O
analysis O O
of O O
the O O
Dp71 O O
transcript O O
and O O
testing O O
for O O
the O O
specific O O
first O O
exon O O
of O O
Dp140 O O
were O O
also O O
carried O O
out O O
. O O

Neuropsychological O O
analysis O O
assessed O O
verbal O O
and O O
visuospatial O O
intelligence O O
, O O
verbal O O
memory O O
, O O
and O O
reading O O
skills O O
. O O

Comparison O O
of O O
molecular O O
and O O
psychometric O O
findings O O
demonstrated O O
that O O
deletions O O
and O O
duplications O O
that O O
were O O
localized O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
seemed O O
to O O
be O O
preferentially O O
associated O O
with O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
. O O

Two O O
altered O O
Dp71 O O
transcripts O O
and O O
two O O
deleted O O
Dp140 O O
DNA O O
sequences O O
were O O
found O O
in O O
four O O
patients O O
with O O
severe O O
cerebral B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

These O O
findings O O
suggest O O
that O O
some O O
sequences O O
located O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
and O O
, O O
in O O
particular O O
, O O
some O O
DMD B-Disease B-Disease
isoforms O O
expressed O O
in O O
the O O
brain O O
may O O
be O O
related O O
to O O
the O O
cognitive B-Disease B-Disease
impairment I-Disease I-Disease
associated O O
with O O
DMD B-Disease B-Disease
.. O O

I1307 O O
K O O
APC O O
and O O
hMLH1 O O
mutations O O
in O O
a O O
non O O
- O O
Jewish O O
family O O
with O O
hereditary B-Disease B-Disease
non I-Disease I-Disease
- I-Disease I-Disease
polyposis I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
. O O

We O O
describe O O
a O O
French O O
Canadian O O
hereditary B-Disease B-Disease
non I-Disease I-Disease
- I-Disease I-Disease
polyposis I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
( O O
HNPCC B-Disease B-Disease
) O O
kindred O O
which O O
carries O O
a O O
novel O O
truncating O O
mutation O O
in O O
hMLH1 O O
. O O

Interestingly O O
, O O
the O O
I1307 O O
K O O
APC O B-Disease
polymorphism O O
, O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
, O O
is O O
also O O
present O O
in O O
this O O
family O O
. O O

The O O
I1307 O O
K O O
polymorphism O O
has O O
previously O O
only O O
been O O
identified O O
in O O
individuals O O
of O O
self O O
- O O
reported O O
Ashkenazi O O
Jewish O O
origins O O
. O O

In O O
addition O O
, O O
in O O
this O O
family O O
, O O
there O O
appears O O
to O O
be O O
no O O
relationship O O
between O O
the O O
I1307 O O
K O O
polymorphism O O
and O O
the O O
presence O O
or O O
absence O O
of O O
cancer B-Disease B-Disease
.. O O

Identification O O
of O O
a O O
novel O O
mutation O O
of O O
the O O
CPO O O
gene O O
in O O
a O O
Japanese O O
hereditary B-Disease B-Disease
coproporphyria I-Disease I-Disease
family O O
. O O

Hereditary B-Disease B-Disease
coproporphyria I-Disease I-Disease
( O O
HCP B-Disease B-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disease I-Disease I-Disease
characterized O O
by O O
a O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
coproporphyrinogen I-Disease I-Disease
oxidase I-Disease I-Disease
( O O
CPO O O
) O O
caused O O
by O O
a O O
mutation O O
in O O
the O O
CPO O O
gene O O
. O O

Only O O
11 O O
mutations O O
of O O
the O O
gene O O
have O O
been O O
reported O O
in O O
HCP B-Disease B-Disease
patients O O
. O O

We O O
report O O
another O O
mutation O O
in O O
a O O
Japanese O O
family O O
. O O

Polymerase O O
chain O O
reaction O O
- O O
single O O
strand O O
conformational O O
polymorphism O O
and O O
direct O O
sequence O O
analyses O O
demonstrated O O
a O O
C O O
to O O
T O O
substitution O O
in O O
exon O O
1 O O
of O O
the O O
CPO O O
gene O O
at O O
nucleotide O O
position O O
85 O O
, O O
which O O
lies O O
in O O
the O O
putative O O
presequence O O
for O O
targeting O O
to O O
mitochondria O O
. O O

This O O
mutation O O
changes O O
the O O
codon O O
for O O
glutamine O O
to O O
a O O
termination O O
codon O O
at O O
amino O O
acid O O
position O O
29 O O
. O O

MaeI O O
restriction O O
analysis O O
showed O O
two O O
other O O
carriers O O
in O O
the O O
family O O
. O O

The O O
C O O
- O O
T O O
mutation O O
is O O
located O O
within O O
a O O
recently O O
proposed O O
putative O O
alternative O O
translation O O
initiation O O
codon O O
( O O
TIC-1 O O
) O O
, O O
supporting O O
that O O
TIC-1 O O
is O O
the O O
real O O
TIC O O
rather O O
than O O
TIC-2 O O
.. O O

Human B-Disease O
complement I-Disease B-Disease
factor I-Disease I-Disease
H I-Disease I-Disease
deficiency I-Disease I-Disease
associated O O
with O O
hemolytic B-Disease B-Disease
uremic I-Disease I-Disease
syndrome I-Disease I-Disease
. O O

This O O
study O O
reports O O
on O O
six O O
cases O O
of O O
deficiency B-Disease B-Disease
in I-Disease I-Disease
the I-Disease I-Disease
human I-Disease I-Disease
complement I-Disease I-Disease
regulatory I-Disease I-Disease
protein I-Disease I-Disease
Factor I-Disease I-Disease
H I-Disease I-Disease
( O O
FH O O
) O O
in O O
the O O
context O O
of O O
an O O
acute B-Disease B-Disease
renal I-Disease I-Disease
disease I-Disease I-Disease
. O O

Five O O
of O O
the O O
cases O O
were O O
observed O O
in O O
children O O
presenting O O
with O O
idiopathic O B-Disease
hemolytic B-Disease I-Disease
uremic I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
HUS B-Disease B-Disease
) O O
. O O

Two O O
of O O
the O O
children O O
exhibited O O
a O O
homozygous O O
deficiency O O
characterized O O
by O O
the O O
absence O O
of O O
the O O
150-kD O O
form O O
of O O
Factor O O
H O O
and O O
the O O
presence O O
, O O
upon O O
immunoblotting O O
, O O
of O O
the O O
42-kD O O
Factor O O
H O O
- O O
like O O
protein O O
1 O O
( O O
FHL-1 O O
) O O
and O O
other O O
FH O O
- O O
related O O
protein O O
( O O
FHR O O
) O O
bands O O
. O O

Southern O O
blot O O
and O O
PCR O O
analysis O O
of O O
DNA O O
of O O
one O O
patient O O
with O O
homozygous O O
deficiency O O
ruled O O
out O O
the O O
presence O O
of O O
a O O
large O O
deletion O O
of O O
the O O
FH O B-Disease
gene O O
as O O
the O O
underlying O O
defect O O
for O O
the O O
deficiency O O
. O O

The O O
other O O
four O O
children O O
presented O O
with O O
heterozygous O O
deficiency O O
and O O
exhibited O O
a O O
normal O O
immunoblotting O O
pattern O O
of O O
proteins O O
of O O
the O O
FH O B-Disease
family O O
. O O

Factor B-Disease B-Disease
H I-Disease I-Disease
deficiency I-Disease I-Disease
is O O
the O O
only O O
complement B-Disease B-Disease
deficiency I-Disease I-Disease
associated O O
with O O
HUS B-Disease B-Disease
. O O

These O O
observations O O
suggest O O
a O O
role O O
for O O
FH O O
and/or O O
FH O O
receptors O O
in O O
the O O
pathogenesis O O
of O O
idiopathic O O
HUS B-Disease B-Disease
.. O O

Further O O
evidence O O
for O O
a O O
major O O
ancient O O
mutation O O
underlying O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
from O O
linkage O O
disequilibrium O O
studies O O
in O O
the O O
Japanese O O
population O O
. O O

The O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
mutation O O
is O O
an O O
unstable O O
( O O
CTG O O
) O O
n O O
repeat O O
, O O
present O O
at O O
a O O
copy O O
number O O
of O O
5 O O
- O O
37 O O
repeats O O
on O O
normal O O
chromosomes O O
but O O
amplified O O
to O O
50 O O
- O O
3000 O O
copies O O
on O O
DM B-Disease B-Disease
chromosomes O O
. O O

Previous O O
findings O O
in O O
Caucasian O O
populations O O
of O O
a O O
DM B-Disease B-Disease
founder O O
chromosome O O
raise O O
a O O
question O O
about O O
the O O
molecular O O
events O O
involved O O
in O O
the O O
expansion O O
mutation O O
. O O

To O O
investigate O O
whether O O
a O O
founder O O
chromosome O O
for O O
the O O
DM B-Disease B-Disease
mutation O O
exists O O
in O O
the O O
Japanese O O
population O O
, O O
we O O
genotyped O O
families O O
using O O
polymorphic O O
markers O O
near O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
region O O
and O O
constructed O O
haplotypes O O
. O O

Six O O
different O O
haplotypes O O
were O O
found O O
and O O
DM B-Disease B-Disease
alleles O O
were O O
always O O
haplotype O O
A. O O
To O O
find O O
an O O
origin O O
of O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
mutation O O
and O O
to O O
investigate O O
the O O
mechanism O O
of O O
the O O
expansion O O
mutation O O
in O O
the O O
Japanese O O
population O O
we O O
have O O
studied O O
90 O O
Japanese O O
DM B-Disease B-Disease
families O O
comprising O O
190 O O
affected O O
and O O
130 O O
unaffected O O
members O O
. O O

The O O
results O O
suggest O O
that O O
a O O
few O O
common O O
ancestral O O
mutations O O
in O O
both O O
Caucasian O O
and O O
Japanese O O
populations O O
have O O
originated O O
by O O
expansion O O
of O O
an O O
ancestral O O
n O O
= O O
5 O O
repeat O O
to O O
n O O
= O O
19 O O
- O O
37 O O
copies O O
. O O

These O O
data O O
support O O
multistep O O
models O O
of O O
triplet O O
repeat O O
expansion O O
that O O
have O O
been O O
proposed O O
for O O
both O O
DM B-Disease B-Disease
and O O
Friedreichs B-Disease B-Disease
ataxia I-Disease I-Disease
.. O O

The O O
molecular O O
basis O O
of O O
C6 B-Disease B-Disease
deficiency I-Disease I-Disease
in O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Deficiency B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
sixth I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
human I-Disease I-Disease
complement I-Disease I-Disease
( O O
C6 O O
) O O
has O O
been O O
reported O O
in O O
a O O
number O O
of O O
families O O
from O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Meningococcal B-Disease B-Disease
disease I-Disease I-Disease
is O O
endemic O O
in O O
the O O
Cape O O
and O O
almost O O
all O O
pedigrees O O
of O O
total O O
C6 B-Disease B-Disease
deficiency I-Disease I-Disease
( O O
C6Q0 O B-Disease
) O O
have O O
been O O
ascertained O O
because O O
of O O
recurrent O O
disease O O
. O O

We O O
have O O
sequenced O O
the O O
expressed O O
exons O O
of O O
the O O
C6 O O
gene O O
from O O
selected O O
cases O O
and O O
have O O
found O O
three O O
molecular O O
defects O O
leading O O
to O O
total O O
deficiency O O
879delG O O
, O O
which O O
is O O
the O O
common O O
defect O O
in O O
the O O
Cape O O
and O O
hitherto O O
unreported O O
, O O
and O O
1195delC O O
and O O
1936delG O O
, O O
which O O
have O O
been O O
previously O O
reported O O
in O O
African O O
- O O
Americans O O
. O O

We O O
also O O
show O O
that O O
the O O
879delG O O
and O O
1195delC O O
defects O O
are O O
associated O O
with O O
characteristic O O
C6 O O
/ O O
C7 O O
region O O
DNA O O
marker O O
haplotypes O O
, O O
although O O
small O O
variations O O
were O O
observed O O
. O O

The O O
1936delG O O
defect O O
was O O
observed O O
only O O
once O O
in O O
the O O
Cape O O
, O O
but O O
its O O
associated O O
haplotype O O
could O O
be O O
deduced O O
. O O

The O O
data O O
from O O
the O O
haplotypes O O
indicate O O
that O O
these O O
three O O
molecular O O
defects O O
account O O
for O O
the O O
defects O O
in O O
all O O
the O O
38 O O
unrelated O O
C6Q0 O O
individuals O O
we O O
have O O
studied O O
from O O
the O O
Cape O O
. O O

We O O
have O O
also O O
observed O O
the O O
879delG O O
defect O O
in O O
two O O
Dutch O O
C6-deficient B-Disease B-Disease
kindreds O O
, O O
but O O
the O O
879delG O O
defect O O
in O O
the O O
Cape O O
probably O O
did O O
not O O
come O O
from O O
The O O
Netherlands O O
.. O O

Complement B-Disease B-Disease
C7 I-Disease I-Disease
deficiency I-Disease I-Disease
: O O
seven O O
further O O
molecular O O
defects O O
and O O
their O O
associated O O
marker O O
haplotypes O O
. O O

Seven O O
further O O
molecular O O
bases O O
of O O
C7 B-Disease B-Disease
deficiency I-Disease I-Disease
are O O
described O O
. O O

All O O
these O O
new O O
molecular O O
defects O O
involve O O
single O O
- O O
nucleotide O O
events O O
, O O
deletions O O
and O O
substitutions O O
, O O
some O O
of O O
which O O
alter O O
splice O O
sites O O
, O O
and O O
others O O
codons O O
. O O

They O O
are O O
distributed O O
along O O
the O O
C7 O O
gene O O
, O O
but O O
predominantly O O
towards O O
the O O
3 O O
end O O
. O O

All O O
were O O
found O O
in O O
compound O O
heterozygous O O
individuals O O
. O O

The O O
C6 O O
/ O O
C7 O O
marker O O
haplotypes O O
associated O O
with O O
most O O
C7 B-Disease B-Disease
defects I-Disease I-Disease
are O O
tabulated O O
.. O O

A O O
genome O O
- O O
wide O O
search O O
for O O
chromosomal O O
loci O O
linked O O
to O O
mental O O
health O O
wellness O O
in O O
relatives O O
at O O
high O O
risk O O
for O O
bipolar B-Disease B-Disease
affective I-Disease I-Disease
disorder I-Disease I-Disease
among O O
the O O
Old O O
Order O O
Amish O O
. O O

Bipolar B-Disease B-Disease
affective I-Disease I-Disease
disorder I-Disease I-Disease
( O O
BPAD B-Disease B-Disease
; O O
manic B-Disease B-Disease
- I-Disease I-Disease
depressive I-Disease I-Disease
illness I-Disease I-Disease
) O O
is O O
characterized O O
by O O
episodes O O
of O O
mania B-Disease B-Disease
and/or O O
hypomania B-Disease B-Disease
interspersed O O
with O O
periods O O
of O O
depression B-Disease B-Disease
. O O

Compelling O O
evidence O O
supports O O
a O O
significant O O
genetic O O
component O O
in O O
the O O
susceptibility O O
to O O
develop O O
BPAD B-Disease B-Disease
. O O

To O O
date O O
, O O
however O O
, O O
linkage O O
studies O O
have O O
attempted O O
only O O
to O O
identify O O
chromosomal O O
loci O O
that O O
cause O O
or O O
increase O O
the O O
risk O O
of O O
developing O O
BPAD B-Disease B-Disease
. O O

To O O
determine O O
whether O O
there O O
could O O
be O O
protective O O
alleles O O
that O O
prevent O O
or O O
reduce O O
the O O
risk O O
of O O
developing O O
BPAD B-Disease B-Disease
, O O
similar O O
to O O
what O O
is O O
observed O O
in O O
other O O
genetic B-Disease B-Disease
disorders I-Disease I-Disease
, O O
we O O
used O O
mental O O
health O O
wellness O O
( O O
absence O O
of O O
any O O
psychiatric B-Disease B-Disease
disorder I-Disease I-Disease
) O O
as O O
the O O
phenotype O O
in O O
our O O
genome O O
- O O
wide O O
linkage O O
scan O O
of O O
several O O
large O O
multigeneration O O
Old O O
Order O O
Amish O O
pedigrees O O
exhibiting O O
an O O
extremely O O
high O O
incidence O O
of O O
BPAD B-Disease B-Disease
. O O

We O O
have O O
found O O
strong O O
evidence O O
for O O
a O O
locus O O
on O O
chromosome O O
4p O O
at O O
D4S2949 O O
( O O
maximum O O
GENEHUNTER O O
- O O
PLUS O O
nonparametric O O
linkage O O
score O O
= O O
4 O O
. O O
05 O O
, O O
P O O
= O O
5 O O
. O O
22 O O
x O O
10 O O
( O O
-4 O O
) O O
; O O
SIBPAL O O
Pempirical O O
value O O
< O O
3 O O
x O O
10 O O
( O O
-5 O O
) O O
) O O
and O O
suggestive O O
evidence O O
for O O
a O O
locus O O
on O O
chromosome O O
4q O O
at O O
D4S397 O O
( O O
maximum O O
GENEHUNTER O O
- O O
PLUS O O
nonparametric O O
linkage O O
score O O
= O O
3 O O
. O O
29 O O
, O O
P O O
= O O
2 O O
. O O
57 O O
x O O
10 O O
( O O
-3 O O
) O O
; O O
SIBPAL O O
Pempirical O O
value O O
< O O
1 O O
x O O
10 O O
( O O
-3 O O
) O O
) O O
that O O
are O O
linked O O
to O O
mental O O
health O O
wellness O O
. O O

These O O
findings O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
certain O O
alleles O O
could O O
prevent O O
or O O
modify O O
the O O
clinical O O
manifestations O O
of O O
BPAD B-Disease B-Disease
and O O
perhaps O O
other O O
related O O
affective B-Disease B-Disease
disorders I-Disease I-Disease
. O O

Segregation O O
distortion O O
in O O
myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
. O O

Myotonic B-Disease B-Disease
dystrophy I-Disease I-Disease
( O O
DM B-Disease B-Disease
) O O
is O O
an O O
autosomal B-Disease B-Disease
dominant I-Disease I-Disease
disease I-Disease I-Disease
which O O
, O O
in O O
the O O
typical O O
pedigree O O
, O O
shows O O
a O O
three O O
generation O O
anticipation O O
cascade O O
. O O

This O O
results O O
in O O
infertility B-Disease B-Disease
and O O
congenital B-Disease B-Disease
myotonic I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
CDM B-Disease B-Disease
) O O
with O O
the O O
disappearance O O
of O O
DM B-Disease B-Disease
in O O
that O O
pedigree O O
. O O

The O O
concept O O
of O O
segregation O O
distortion O O
, O O
where O O
there O O
is O O
preferential O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B-Disease B-Disease
locus O O
, O O
has O O
been O O
put O O
forward O O
to O O
explain O O
partially O O
the O O
maintenance O O
of O O
DM B-Disease B-Disease
in O O
the O O
population O O
. O O

In O O
a O O
survey O O
of O O
DM B-Disease B-Disease
in O O
Northern O O
Ireland O O
, O O
59 O O
pedigrees O O
were O O
ascertained O O
. O O

Sibships O O
where O O
the O O
status O O
of O O
all O O
the O O
members O O
had O O
been O O
identified O O
were O O
examined O O
to O O
determine O O
the O O
transmission O O
of O O
the O O
DM B-Disease B-Disease
expansion O O
from O O
affected O O
parents O O
to O O
their O O
offspring O O
. O O

Where O O
the O O
transmitting O O
parent O O
was O O
male O O
, O O
58 O O
. O O
3 O O
% O O
of O O
the O O
offspring O O
were O O
affected O O
, O O
and O O
in O O
the O O
case O O
of O O
a O O
female O O
transmitting O O
parent O O
, O O
68 O O
. O O
7 O O
% O O
were O O
affected O O
. O O

Studies O O
on O O
meiotic O O
drive O O
in O O
DM B-Disease B-Disease
have O O
shown O O
increased O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B-Disease B-Disease
locus O O
in O O
non O O
- O O
DM O B-Disease
heterozygotes O O
for O O
CTGn O O
. O O

This O O
study O O
provides O O
further O O
evidence O O
that O O
the O O
DM B-Disease B-Disease
expansion O O
tends O O
to O O
be O O
transmitted O O
preferentially O O
. O O

Diagnosis O O
of O O
hemochromatosis B-Disease B-Disease
. O O

If O O
untreated O O
, O O
hemochromatosis B-Disease B-Disease
can O O
cause O O
serious O O
illness O O
and O O
early B-Disease O
death I-Disease O
, O O
but O O
the O O
disease O O
is O O
still O O
substantially O O
under O O
- O O
diagnosed O O
. O O

The O O
cornerstone O O
of O O
screening O O
and O O
case O O
detection O O
is O O
the O O
measurement O O
of O O
serum O O
transferrin O O
saturation O O
and O O
the O O
serum O O
ferritin O O
level O O
. O O

Once O O
the O O
diagnosis O O
is O O
suspected O O
, O O
physicians O O
must O O
use O O
serum O O
ferritin O O
levels O O
and O O
hepatic O O
iron O O
stores O O
on O O
liver O O
biopsy O O
specimens O O
to O O
assess O O
patients O O
for O O
the O O
presence O O
of O O
iron B-Disease B-Disease
overload I-Disease I-Disease
. O O

Liver O O
biopsy O O
is O O
also O O
used O O
to O O
establish O O
the O O
presence O O
or O O
absence O O
of O O
cirrhosis B-Disease B-Disease
, O O
which O O
can O O
affect O O
prognosis O O
and O O
management O O
. O O

A O O
DNA O O
- O O
based O O
test O O
for O O
the O O
HFE O O
gene O O
is O O
commercially O O
available O O
, O O
but O O
its O O
place O O
in O O
the O O
diagnosis O O
of O O
hemochromatosis B-Disease B-Disease
is O O
still O O
being O O
evaluated O O
. O O

Currently O O
, O O
the O O
most O O
useful O O
role O O
for O O
this O O
test O O
is O O
in O O
the O O
detection O O
of O O
hemochromatosis B-Disease B-Disease
in O O
the O O
family O O
members O O
of O O
patients O O
with O O
a O O
proven O O
case O O
of O O
the O O
disease O O
. O O

It O O
is O O
crucial O O
to O O
diagnose O O
hemochromatosis B-Disease B-Disease
before O O
hepatic B-Disease B-Disease
cirrhosis I-Disease I-Disease
develops O O
because O O
phlebotomy O O
therapy O O
can O O
avert O O
serious O O
chronic O O
disease O O
and O O
can O O
even O O
lead O O
to O O
normal O O
life O O
expectancy O O
.. O O

Prevalence O O
of O O
the O O
I1307 O O
K O O
APC B-Disease B-Disease
gene O O
variant O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

BACKGROUND O O
& O O
AIMS O O
Israeli O O
Jews O O
of O O
European O O
birth O O
, O O
i. O O
e. O O
, O O
Ashkenazim O O
, O O
have O O
the O O
highest O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
incidence O O
of O O
any O O
Israeli O O
ethnic O O
group O O
. O O

The O O
I1307 O O
K O O
APC B-Disease B-Disease
gene O O
variant O O
was O O
found O O
in O O
6 O O
. O O
1 O O
% O O
of O O
American O O
Jews O O
, O O
28 O O
% O O
of O O
their O O
familial O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
cases O O
, O O
but O O
not O O
in O O
non O O
- O O
Jews O O
. O O

We O O
assessed O O
the O O
I1307 O O
K O O
prevalence O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

METHODS O O
DNA O O
samples O O
from O O
500 O O
unrelated O O
Jews O O
of O O
European O O
or O O
non O O
- O O
European O O
origin O O
, O O
with O O
or O O
without O O
a O O
personal O O
and/or O O
family O O
history O O
of O O
neoplasia B-Disease B-Disease
, O O
were O O
examined O O
for O O
the O O
I1307 O O
K O O
variant O O
by O O
the O O
allele O O
- O O
specific O O
oligonucleotide O O
( O O
ASO O O
) O O
method O O
. O O

RESULTS O O
In O O
persons O O
at O O
average O O
risk O O
for O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
, O O
I1307 O O
K O O
was O O
found O O
in O O
5 O O
. O O
0 O O
% O O
of O O
120 O O
European O O
and O O
1 O O
. O O
6 O O
% O O
of O O
188 O O
non O O
- O O
European O O
Jews O O
( O O
P O O
= O O
0 O O
. O O
08 O O
) O O
. O O

It O O
occurred O O
in O O
15 O O
. O O
4 O O
% O O
of O O
52 O O
Ashkenazi O O
Israelis O O
with O O
familial O B-Disease
cancer B-Disease I-Disease
( O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
was O O
not O O
detected O O
in O O
51 O O
non O O
- O O
European O O
Jews O O
at O O
increased O O
cancer B-Disease B-Disease
risk O O
. O O

Colorectal B-Disease B-Disease
neoplasia I-Disease I-Disease
occurred O O
personally O O
or O O
in O O
the O O
families O O
of O O
13 O O
of O O
20 O O
Ashkenazi O O
I1307 O O
K O O
carriers O O
, O O
8 O O
of O O
whom O O
also O O
had O O
a O O
personal O O
or O O
family O O
history O O
of O O
noncolonic O B-Disease
neoplasia B-Disease I-Disease
. O O

CONCLUSIONS O O
The O O
I1307 O O
K O O
APC O B-Disease
variant O O
may O O
represent O O
a O O
susceptibility O O
gene O O
for O O
colorectal B-Disease B-Disease
, I-Disease I-Disease
or I-Disease I-Disease
other I-Disease I-Disease
, I-Disease I-Disease
cancers I-Disease I-Disease
in O O
Ashkenazi O O
Jews O O
, O O
and O O
partially O O
explains O O
the O O
higher O O
incidence O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
in O O
European O O
Israelis O O
. O O

Systematic O O
analysis O O
of O O
coproporphyrinogen O O
oxidase O O
gene O O
defects O O
in O O
hereditary B-Disease B-Disease
coproporphyria I-Disease I-Disease
and O O
mutation O O
update O O
. O O

Hereditary B-Disease B-Disease
coproporphyria I-Disease I-Disease
( O O
HC B-Disease B-Disease
) O O
is O O
an O O
acute O B-Disease
hepatic B-Disease I-Disease
porphyria I-Disease I-Disease
with O O
autosomal O O
dominant O O
inheritance O O
caused O O
by O O
deficient B-Disease O
activity I-Disease O
of I-Disease O
coproporphyrinogen I-Disease O
III I-Disease O
oxidase I-Disease O
( O O
CPO O O
) O O
. O O

Clinical O O
manifestations O O
of O O
the O O
disease O O
are O O
characterized O O
by O O
acute O O
attacks O O
of O O
neurological B-Disease B-Disease
dysfunction I-Disease I-Disease
often O O
precipitated O O
by O O
drugs O O
, O O
fasting O O
, O O
cyclical O O
hormonal O O
changes O O
, O O
or O O
infectious B-Disease B-Disease
diseases I-Disease I-Disease
. O O

Skin O B-Disease
photosensitivity O I-Disease
may O O
also O O
be O O
present O O
. O O

The O O
seven O O
exons O O
, O O
the O O
exon O O
/ O O
intron O O
boundaries O O
and O O
part O O
of O O
3 O O
noncoding O O
sequence O O
of O O
the O O
CPO O O
gene O O
were O O
systematically O O
analyzed O O
by O O
an O O
exon O O
- O O
by O O
- O O
exon O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
strategy O O
followed O O
by O O
direct O O
sequencing O O
in O O
seven O O
unrelated O O
heterozygous O O
HC B-Disease B-Disease
patients O O
from O O
France O O
, O O
Holland O O
, O O
and O O
Czech O O
Republic O O
. O O

Seven O O
novel O O
mutations O O
and O O
two O O
new O O
polymorphisms O O
were O O
detected O O
. O O

Among O O
these O O
mutations O O
two O O
are O O
missense O O
( O O
G197W O O
, O O
W427R O O
) O O
, O O
two O O
are O O
nonsense O O
( O O
Q306X O O
, O O
Q385X O O
) O O
, O O
two O O
are O O
small O O
deletions O O
( O O
662de14bp O O
; O O
1168del3bp O O
removing O O
a O O
glycine O O
at O O
position O O
390 O O
) O O
, O O
and O O
one O O
is O O
a O O
splicing O O
mutation O O
( O O
IVS1 O O
- O O
15c-- O O
> O O
g O O
) O O
which O O
creates O O
a O O
new O O
acceptor O O
splice O O
site O O
. O O

The O O
pathological O O
significance O O
of O O
the O O
point O O
mutations O O
G197W O O
, O O
W427R O O
, O O
and O O
the O O
in O O
- O O
frame O O
deletion O O
390delGly O O
were O O
assessed O O
by O O
their O O
respective O O
expression O O
in O O
a O O
prokaryotic O O
system O O
using O O
site O O
- O O
directed O O
mutagenesis O O
. O O

These O O
mutations O O
resulted O O
in O O
the O O
absence O O
or O O
a O O
dramatic O O
decrease O O
of O O
CPO O O
activity O O
. O O

The O O
two O O
polymorphisms O O
were O O
localized O O
in O O
noncoding O O
part O O
of O O
the O O
gene O O
1 O O
) O O
a O O
C O O
/ O O
G O O
polymorphism O O
in O O
the O O
promotor O O
region O O
, O O
142 O O
bp O O
upstream O O
from O O
the O O
transcriptional O O
initiation O O
site O O
( O O
-142C O O
/ O O
G O O
) O O
, O O
and O O
2 O O
) O O
a O O
6 O O
bp O O
deletion O O
polymorphism O O
in O O
the O O
3 O O
noncoding O O
part O O
of O O
the O O
CPO O O
gene O O
, O O
574 O O
bp O O
downstream O O
of O O
the O O
last O O
base O O
of O O
the O O
normal O O
termination O O
codon O O
( O O
+ O O
574 O O
delATTCTT O O
) O O
. O O

Five O O
intragenic O O
dimorphisms O O
are O O
now O O
well O O
characterized O O
and O O
the O O
high O O
degree O O
of O O
allelic O O
heterogeneity O O
in O O
HC B-Disease B-Disease
is O O
demonstrated O O
with O O
seven O O
new O O
different O O
mutations O O
making O O
a O O
total O O
of O O
nineteen O O
CPO O B-Disease
gene B-Disease I-Disease
defects I-Disease I-Disease
reported O O
so O O
far O O
.. O O

Coincidence O O
of O O
two O O
novel O O
arylsulfatase O O
A O O
alleles O O
and O O
mutation O O
459 O O
+ O O
1G O O
> O O
A O O
within O O
a O O
family O O
with O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
: O O
molecular O O
basis O O
of O O
phenotypic O O
heterogeneity O O
. O O

In O O
a O O
family O O
with O O
three O O
siblings O O
, O O
one O O
developed O O
classical O O
late O O
infantile O O
metachromatic B-Disease B-Disease
leukodystrophy I-Disease I-Disease
( O O
MLD B-Disease B-Disease
) O O
, O O
fatal O O
at O O
age O O
5 O O
years O O
, O O
with O O
deficient O O
arylsulfatase O O
A O O
( O O
ARSA O O
) O O
activity O O
and O O
increased O O
galactosylsulfatide O O
( O O
GS O O
) O O
excretion O O
. O O

The O O
two O O
other O O
siblings O O
, O O
apparently O O
healthy O O
at O O
12 O O
( O O
1 O O
/ O O
2 O O
) O O
and O O
15 O O
years O O
, O O
respectively O O
, O O
and O O
their O O
father O O
, O O
apparently O O
healthy O O
as O O
well O O
, O O
presented O O
ARSA O O
and O O
GS O O
values O O
within O O
the O O
range O O
of O O
MLD B-Disease B-Disease
patients O O
. O O

Mutation O O
screening O O
and O O
sequence O O
analysis O O
disclosed O O
the O O
involvement O O
of O O
three O O
different O O
ARSA O O
mutations O O
being O O
the O O
molecular O O
basis O O
of O O
intrafamilial O O
phenotypic O O
heterogeneity O O
. O O

The O O
late O O
infantile O O
patient O O
inherited O O
from O O
his O O
mother O O
the O O
frequent O O
0-type O O
mutation O O
459 O O
+ O O
1 O O
G O O
> O O
A O O
, O O
and O O
from O O
his O O
father O O
a O O
novel O O
, O O
single O O
basepair O O
microdeletion O O
of O O
guanine O O
at O O
nucleotide O O
7 O O
in O O
exon O O
1 O O
( O O
7delG O O
) O O
. O O

The O O
two O O
clinically O O
unaffected O O
siblings O O
carried O O
the O O
maternal O O
mutation O O
459 O O
+ O O
1 O O
G O O
> O O
A O O
and O O
, O O
on O O
their O O
paternal O O
allele O O
, O O
a O O
novel O O
cytosine O O
to O O
thymidine O O
transition O O
at O O
nucleotide O O
2435 O O
in O O
exon O O
8 O O
, O O
resulting O O
in O O
substitution O O
of O O
alanine O O
464 O O
by O O
valine O O
( O O
A464V O O
) O O
. O O

The O O
fathers O O
genotype O O
thus O O
was O O
7delG O O
/ O O
A464V O O
. O O

Mutation O O
A464V O O
was O O
not O O
found O O
in O O
18 O O
unrelated O O
MLD B-Disease B-Disease
patients O O
and O O
50 O O
controls O O
. O O

A464V O O
, O O
although O O
clearly O O
modifying O O
ARSA O O
and O O
GS O O
levels O O
, O O
apparently O O
bears O O
little O O
significance O O
for O O
clinical O O
manifestation O O
of O O
MLD B-Disease B-Disease
, O O
mimicking O O
the O O
frequent O O
ARSA O B-Disease
pseudodeficiency O I-Disease
allele O O
. O O

Our O O
results O O
demonstrate O O
that O O
in O O
certain O O
genetic O O
conditions O O
MLD B-Disease B-Disease
- O O
like O O
ARSA O O
and O O
GS O B-Disease
values O O
need O O
not O O
be O O
paralleled O O
by O O
clinical O O
disease O O
, O O
a O O
finding O O
with O O
serious O O
diagnostic O O
and O O
prognostic O O
implications O O
. O O

Moreover O O
, O O
further O O
ARSA O O
alleles O O
functionally O O
similar O O
to O O
A464V O O
might O O
exist O O
which O O
, O O
together O O
with O O
0-type O O
mutations O O
, O O
may O O
cause O O
pathological O O
ARSA O O
and O O
GS O B-Disease
levels O O
, O O
but O O
not O O
clinical O O
outbreak O O
of O O
the O O
disease O O
.. O O

Human O O
MLH1 O B-Disease
deficiency O I-Disease
predisposes O O
to O O
hematological B-Disease B-Disease
malignancy I-Disease I-Disease
and O O
neurofibromatosis B-Disease B-Disease
type I-Disease I-Disease
1 I-Disease I-Disease
. O O

Heterozygous O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
DNA O O
mismatch O O
repair O O
genes O O
lead O O
to O O
hereditary B-Disease B-Disease
nonpolyposis I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
. O O

The O O
disease O O
susceptibility O O
of O O
individuals O O
who O O
constitutionally O O
lack O O
both O O
wild O O
- O O
type O O
alleles O O
is O O
unknown O O
. O O

We O O
have O O
identified O O
three O O
offspring O O
in O O
a O O
hereditary B-Disease B-Disease
nonpolyposis I-Disease I-Disease
colorectal I-Disease I-Disease
cancer I-Disease I-Disease
family O O
who O O
developed O O
hematological B-Disease B-Disease
malignancy I-Disease I-Disease
at O O
a O O
very O O
early O O
age O O
, O O
and O O
at O O
least O O
two O O
of O O
them O O
displayed O O
signs O O
of O O
neurofibromatosis B-Disease B-Disease
type I-Disease I-Disease
1 I-Disease I-Disease
( O O
NF1 B-Disease B-Disease
) O O
. O O

DNA O O
sequence O O
analysis O O
and O O
allele O O
- O O
specific O O
amplification O O
in O O
two O O
siblings O O
revealed O O
a O O
homozygous O O
MLH1 O O
mutation O O
( O O
C676T-- O O
> O O
Arg226Stop O O
) O O
. O O

Thus O O
, O O
a O O
homozygous O O
germ O O
- O O
line O O
MLH1 O O
mutation O O
and O O
consequent O O
mismatch O O
repair O O
deficiency O O
results O O
in O O
a O O
mutator O O
phenotype O O
characterized O O
by O O
leukemia B-Disease B-Disease
and/or O O
lymphoma B-Disease B-Disease
associated O O
with O O
neurofibromatosis B-Disease B-Disease
type I-Disease I-Disease
1 I-Disease I-Disease
.. O O

Missense O O
mutations O O
in O O
the O O
most O O
ancient O O
residues O O
of O O
the O O
PAX6 O O
paired O O
domain O O
underlie O O
a O O
spectrum O O
of O O
human O O
congenital B-Disease B-Disease
eye I-Disease I-Disease
malformations I-Disease I-Disease
. O O

Mutations O O
of O O
the O O
human O O
PAX6 O O
gene O O
underlie O O
aniridia B-Disease B-Disease
( O O
congenital B-Disease B-Disease
absence I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
iris I-Disease I-Disease
) O O
, O O
a O O
rare O O
dominant O O
malformation B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
eye I-Disease I-Disease
. O O

The O O
spectrum O O
of O O
PAX6 O O
mutations O O
in O O
aniridia B-Disease B-Disease
patients O O
is O O
highly O O
biased O O
, O O
with O O
92 O O
% O O
of O O
all O O
reported O O
mutations O O
leading O O
to O O
premature O O
truncation O O
of O O
the O O
protein O O
( O O
nonsense O O
, O O
splicing O O
, O O
insertions O O
and O O
deletions O O
) O O
and O O
just O O
2 O O
% O O
leading O O
to O O
substitution O O
of O O
one O O
amino O O
acid O O
by O O
another O O
( O O
missense O O
) O O
. O O

The O O
extraordinary O O
conservation O O
of O O
the O O
PAX6 O O
protein O O
at O O
the O O
amino O O
acid O O
level O O
amongst O O
vertebrates O O
predicts O O
that O O
pathological O O
missense O O
mutations O O
should O O
in O O
fact O O
be O O
common O O
even O O
though O O
they O O
are O O
hardly O O
ever O O
seen O O
in O O
aniridia B-Disease B-Disease
patients O O
. O O

This O O
indicates O O
that O O
there O O
is O O
a O O
heavy O O
ascertainment O O
bias O O
in O O
the O O
selection O O
of O O
patients O O
for O O
PAX6 O O
mutation O O
analysis O O
and O O
that O O
the O O
missing O O
PAX6 O O
missense O O
mutations O O
frequently O O
may O O
underlie O O
phenotypes O O
distinct O O
from O O
textbook O O
aniridia B-Disease B-Disease
. O O

Here O O
we O O
present O O
four O O
novel O O
PAX6 O O
missense O O
mutations O O
, O O
two O O
in O O
association O O
with O O
atypical O O
phenotypes O O
ectopia B-Disease B-Disease
pupillae I-Disease I-Disease
( O O
displaced B-Disease B-Disease
pupils I-Disease I-Disease
) O O
and O O
congenital B-Disease B-Disease
nystagmus I-Disease I-Disease
( O O
searching B-Disease O
gaze I-Disease O
) O O
, O O
and O O
two O O
in O O
association O O
with O O
more O O
recognizable O O
aniridia B-Disease B-Disease
phenotypes O O
. O O

Strikingly O O
, O O
all O O
four O O
mutations O O
are O O
located O O
within O O
the O O
PAX6 O O
paired O O
domain O O
and O O
affect O O
amino O O
acids O O
which O O
are O O
highly O O
conserved O O
in O O
all O O
known O O
paired O O
domain O O
proteins O O
. O O

Our O O
results O O
support O O
the O O
hypothesis O O
that O O
the O O
under O O
- O O
representation O O
of O O
missense O O
mutations O O
is O O
caused O O
by O O
ascertainment O O
bias O O
and O O
suggest O O
that O O
a O O
substantial O O
burden O O
of O O
PAX6 B-Disease B-Disease
-related I-Disease I-Disease
disease I-Disease I-Disease
remains O O
to O O
be O O
uncovered O O
.. O O

The O O
chromosomal O O
order O O
of O O
genes O O
controlling O O
the O O
major O O
histocompatibility O O
complex O O
, O O
properdin O O
factor O O
B O O
, O O
and O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
second I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
complement I-Disease I-Disease
. O O

The O O
relationship O O
of O O
the O O
genes O O
coding O O
for O O
HLA O O
to O O
those O O
coding O O
for O O
properdin O O
Factor O O
B O O
allotypes O O
and O O
for O O
deficiency B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
second I-Disease I-Disease
component I-Disease I-Disease
of I-Disease I-Disease
complement I-Disease I-Disease
( O O
C2 O O
) O O
was O O
studied O O
in O O
families O O
of O O
patients O O
with O O
connective O B-Disease
tissue O I-Disease
disorders O I-Disease
. O O

Patients O O
were O O
selected O O
because O O
they O O
were O O
heterozygous O O
or O O
homozygous O O
for O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
. O O

12 O O
families O O
with O O
15 O O
matings O O
informative O O
for O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
were O O
found O O
. O O

Of O O
57 O O
informative O O
meioses O O
, O O
two O O
crossovers O O
were O O
noted O O
between O O
the O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
gene O O
and O O
the O O
HLA O O
- O O
B O O
gene O O
, O O
with O O
a O O
recombinant O O
fraction O O
of O O
0 O O
. O O
035 O O
. O O

A O O
lod O O
score O O
of O O
13 O O
was O O
calculated O O
for O O
linkage O O
between O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
and O O
HLA O O
- O O
B O O
at O O
a O O
maximum O O
likelihood O O
value O O
of O O
the O O
recombinant O O
fraction O O
of O O
0 O O
. O O
04 O O
. O O
18 O O
families O O
with O O
21 O O
informative O O
matings O O
for O O
both O O
properdin O O
Factor O O
B O O
allotype O O
and O O
HLA O O
- O O
B O O
were O O
found O O
. O O

Of O O
72 O O
informative O O
meioses O O
, O O
three O O
recombinants O O
were O O
found O O
, O O
giving O O
a O O
recombinant O O
fraction O O
of O O
0 O O
. O O
042 O O
. O O

A O O
lod O O
score O O
of O O
16 O O
between O O
HLA O O
- O O
B O O
and O O
Factor O O
B O O
allotypes O O
was O O
calculated O O
at O O
a O O
maximum O O
likelihood O O
value O O
of O O
the O O
recombinant O O
fraction O O
of O O
0 O O
. O O
04 O O
. O O

A O O
crossover O O
was O O
shown O O
to O O
have O O
occurred O O
between O O
genes O O
for O O
Factor O O
B O O
and O O
HLA O O
- O O
D O O
, O O
in O O
which O O
HLA O O
- O O
D O O
segregared O O
with O O
HLA O O
- O O
A O O
and O O
B. O O
These O O
studies O O
suggest O O
that O O
the O O
genes O O
for O O
Factor O O
B O O
and O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
are O O
located O O
outside O O
those O O
for O O
HLA O O
, O O
that O O
the O O
order O O
of O O
genese O O
is O O
HLA O O
- O O
A O O
, O O
-B O O
, O O
-D O O
, O O
Factor O O
B O O
allotype O O
, O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
, O O
that O O
the O O
genes O O
coding O O
for O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
and O O
Factor O O
B O O
allotypes O O
are O O
approximately O O
3 O O
- O O
-5 O O
centimorgans O O
from O O
the O O
HLA O O
- O O
A O O
and O O
HLA O O
- O O
B O O
loci O O
, O O
and O O
that O O
the O O
apparent O O
lack O O
of O O
recombinants O O
between O O
the O O
Factor O O
B O O
gene O O
and O O
C2 B-Disease B-Disease
deficiency I-Disease I-Disease
gene O O
suggests O O
that O O
these O O
two O O
genes O O
lie O O
in O O
close O O
proximity O O
to O O
one O O
another O O
. O O

Distribution O O
of O O
emerin O O
and O O
lamins O O
in O O
the O O
heart O O
and O O
implications O O
for O O
Emery B-Disease B-Disease
- I-Disease I-Disease
Dreifuss I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
. O O

Emerin O O
is O O
a O O
nuclear O O
membrane O O
protein O O
which O O
is O O
missing O O
or O O
defective O O
in O O
Emery B-Disease B-Disease
- I-Disease I-Disease
Dreifuss I-Disease I-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
EDMD B-Disease B-Disease
) O O
. O O

It O O
is O O
one O O
member O O
of O O
a O O
family O O
of O O
lamina O O
- O O
associated O O
proteins O O
which O O
includes O O
LAP1 O O
, O O
LAP2 O O
and O O
lamin O O
B O O
receptor O O
( O O
LBR O O
) O O
. O O

A O O
panel O O
of O O
16 O O
monoclonal O O
antibodies O O
( O O
mAbs O O
) O O
has O O
been O O
mapped O O
to O O
six O O
specific O O
sites O O
throughout O O
the O O
emerin O O
molecule O O
using O O
phage O O
- O O
displayed O O
peptide O O
libraries O O
and O O
has O O
been O O
used O O
to O O
localize O O
emerin O O
in O O
human O O
and O O
rabbit O O
heart O O
. O O

Several O O
mAbs O O
against O O
different O O
emerin O O
epitopes O O
did O O
not O O
recognize O O
intercalated O O
discs O O
in O O
the O O
heart O O
, O O
though O O
they O O
recognized O O
cardiomyocyte O O
nuclei O O
strongly O O
, O O
both O O
at O O
the O O
rim O O
and O O
in O O
intranuclear O O
spots O O
or O O
channels O O
. O O

A O O
polyclonal O O
rabbit O O
antiserum O O
against O O
emerin O O
did O O
recognize O O
both O O
nuclear O O
membrane O O
and O O
intercalated O O
discs O O
but O O
, O O
after O O
affinity O O
purification O O
against O O
a O O
pure O O
- O O
emerin O O
band O O
on O O
a O O
western O O
blot O O
, O O
it O O
stained O O
only O O
the O O
nuclear O O
membrane O O
. O O

These O O
results O O
would O O
not O O
be O O
expected O O
if O O
immunostaining O O
at O O
intercalated O O
discs O O
were O O
due O O
to O O
a O O
product O O
of O O
the O O
emerin O O
gene O O
and O O
, O O
therefore O O
, O O
cast O O
some O O
doubt O O
upon O O
the O O
hypothesis O O
that O O
cardiac B-Disease B-Disease
defects I-Disease I-Disease
in O O
EDMD B-Disease B-Disease
are O O
caused O O
by O O
absence O O
of O O
emerin O O
from O O
intercalated O O
discs O O
. O O

Although O O
emerin O O
was O O
abundant O O
in O O
the O O
membranes O O
of O O
cardiomyocyte O O
nuclei O O
, O O
it O O
was O O
absent O O
from O O
many O O
non O O
- O O
myocyte O O
cells O O
in O O
the O O
heart O O
. O O

This O O
distribution O O
of O O
emerin O O
was O O
similar O O
to O O
that O O
of O O
lamin O O
A O O
, O O
a O O
candidate O O
gene O O
for O O
an O O
autosomal O O
form O O
of O O
EDMD B-Disease B-Disease
. O O

In O O
contrast O O
, O O
lamin O O
B1 O O
was O O
absent O O
from O O
cardiomyocyte O O
nuclei O O
, O O
showing O O
that O O
lamin O O
B1 O O
is O O
not O O
essential O O
for O O
localization O O
of O O
emerin O O
to O O
the O O
nuclear O O
lamina O O
. O O

Lamin O O
B1 O O
is O O
also O O
almost O O
completely O O
absent O O
from O O
skeletal O O
muscle O O
nuclei O O
. O O

In O O
EDMD B-Disease B-Disease
, O O
the O O
additional O O
absence O O
of O O
lamin O O
B1 O O
from O O
heart O O
and O O
skeletal O O
muscle O O
nuclei O O
which O O
already O O
lack O O
emerin O O
may O O
offer O O
an O O
alternative O O
explanation O O
of O O
why O O
these O O
tissues O O
are O O
particularly O O
affected O O
.. O O

Genetic O O
mapping O O
of O O
the O O
copper B-Disease B-Disease
toxicosis I-Disease I-Disease
locus O O
in O O
Bedlington O O
terriers O O
to O O
dog O O
chromosome O O
10 O O
, O O
in O O
a O O
region O O
syntenic O O
to O O
human O O
chromosome O O
region O O
2p13-p16 O O
. O O

Abnormal O O
hepatic B-Disease O
copper I-Disease O
accumulation I-Disease O
is O O
recognized O O
as O O
an O O
inherited B-Disease B-Disease
disorder I-Disease I-Disease
in O O
man O O
, O O
mouse O O
, O O
rat O O
and O O
dog O O
. O O

The O O
major O O
cause O O
of O O
hepatic B-Disease B-Disease
copper I-Disease I-Disease
accumulation I-Disease I-Disease
in O O
man O O
is O O
a O O
dysfunctional O O
ATP7B O O
gene O O
, O O
causing O O
Wilson B-Disease B-Disease
disease I-Disease I-Disease
( O O
WD B-Disease B-Disease
) O O
. O O

Mutations O O
in O O
the O O
ATP7B O O
genes O O
have O O
also O O
been O O
demonstrated O O
in O O
mouse O O
and O O
rat O O
. O O

The O O
ATP7B O O
gene O O
has O O
been O O
excluded O O
in O O
the O O
much O O
rarer O O
human O O
copper B-Disease B-Disease
overload I-Disease I-Disease
disease O I-Disease
non B-Disease O
- I-Disease O
Indian I-Disease O
childhood I-Disease O
cirrhosis I-Disease B-Disease
, O O
indicating O O
genetic O O
heterogeneity O O
. O O

By O O
investigating O O
the O O
common O O
autosomal O B-Disease
recessive O I-Disease
copper B-Disease I-Disease
toxicosis I-Disease I-Disease
( O O
CT B-Disease B-Disease
) O O
in O O
Bedlington O O
terriers O O
, O O
we O O
have O O
identified O O
a O O
new O O
locus O O
involved O O
in O O
progressive O O
liver B-Disease B-Disease
disease I-Disease I-Disease
. O O

We O O
examined O O
whether O O
the O O
WD B-Disease B-Disease
gene O O
ATP7B O O
was O O
also O O
causative O O
for O O
CT B-Disease B-Disease
by O O
investigating O O
the O O
chromosomal O O
co O O
- O O
localization O O
of O O
ATP7B O O
and O O
C04107 O O
, O O
using O O
fluorescence O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
. O O

C04107 O O
is O O
an O O
anonymous O O
microsatellite O O
marker O O
closely O O
linked O O
to O O
CT B-Disease B-Disease
. O O

However O O
, O O
BAC O O
clones O O
containing O O
ATP7B O O
and O O
C04107 O O
mapped O O
to O O
the O O
canine O O
chromosome O O
regions O O
CFA22q11 O O
and O O
CFA10q26 O O
, O O
respectively O O
, O O
demonstrating O O
that O O
WD B-Disease B-Disease
can O O
not O O
be O O
homologous O O
to O O
CT B-Disease B-Disease
. O O

The O O
copper O O
transport O O
genes O O
CTR1 O O
and O O
CTR2 O O
were O O
also O O
excluded O O
as O O
candidate O O
genes O O
for O O
CT B-Disease B-Disease
since O O
they O O
both O O
mapped O O
to O O
canine O O
chromosome O O
region O O
CFA11q22 O O
. O O

2 O O
- O O
22 O O
. O O
5 O O
. O O

A O O
transcribed O O
sequence O O
identified O O
from O O
the O O
C04107-containing O O
BAC O O
was O O
found O O
to O O
be O O
homologous O O
to O O
a O O
gene O O
expressed O O
from O O
human O O
chromosome O O
2p13-p16 O O
, O O
a O O
region O O
devoid O O
of O O
any O O
positional O O
candidate O O
genes O O
. O O

Molecular O O
analysis O O
of O O
the O O
APC B-Disease B-Disease
gene O O
in O O
205 O O
families O O
: O O
extended O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
FAP B-Disease B-Disease
and O O
evidence O O
for O O
the O O
role O O
of O O
APC B-Disease B-Disease
amino O O
acid O O
changes O O
in O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
predisposition O O
. O O

BACKGROUND O O
/ O O
AIMS O O
The O O
development O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
and O O
a O O
variable O O
range O O
of O O
extracolonic O O
manifestations O O
in O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
( O O
FAP B-Disease B-Disease
) O O
is O O
the O O
result O O
of O O
the O O
dominant O O
inheritance O O
of O O
adenomatous B-Disease B-Disease
polyposis I-Disease I-Disease
coli I-Disease I-Disease
( O O
APC B-Disease B-Disease
) O O
gene O O
mutations O O
. O O

In O O
this O O
study O O
, O O
direct O O
mutation O O
analysis O O
of O O
the O O
APC B-Disease B-Disease
gene O O
was O O
performed O O
to O O
determine O O
genotype O O
- O O
phenotype O O
correlations O O
for O O
nine O O
extracolonic O O
manifestations O O
and O O
to O O
investigate O O
the O O
incidence O O
of O O
APC B-Disease B-Disease
mutations O O
in O O
non O B-Disease
- O I-Disease
FAP O I-Disease
colorectal B-Disease I-Disease
cancer I-Disease I-Disease
. O O

METHODS O O
The O O
APC B-Disease B-Disease
gene O O
was O O
analysed O O
in O O
190 O O
unrelated O O
FAP B-Disease B-Disease
and O O
15 O O
non O B-Disease
- O I-Disease
FAP O I-Disease
colorectal B-Disease I-Disease
cancer I-Disease I-Disease
patients O O
using O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
, O O
the O O
protein O O
truncation O O
test O O
, O O
and O O
direct O O
sequencing O O
. O O

RESULTS O O
Chain O O
terminating O O
signals O O
were O O
only O O
identified O O
in O O
patients O O
belonging O O
to O O
the O O
FAP B-Disease B-Disease
group O O
( O O
105 O O
patients O O
) O O
. O O

Amino O O
acid O O
changes O O
were O O
identified O O
in O O
four O O
patients O O
, O O
three O O
of O O
whom O O
belonged O O
to O O
the O O
non O O
- O O
FAP O O
group O O
of O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
. O O

Genotype O O
- O O
phenotype O O
correlations O O
identified O O
significant O O
differences O O
in O O
the O O
nature O O
of O O
certain O O
extracolonic O O
manifestations O O
in O O
FAP B-Disease B-Disease
patients O O
belonging O O
to O O
three O O
mutation O O
subgroups O O
. O O

CONCLUSIONS O O
Extended O O
genotype O O
- O O
phenotype O O
correlations O O
made O O
in O O
this O O
study O O
may O O
have O O
the O O
potential O O
to O O
determine O O
the O O
most O O
appropriate O O
surveillance O O
and O O
prophylactic O O
treatment O O
regimens O O
for O O
those O O
patients O O
with O O
mutations O O
associated O O
with O O
life O O
threatening O O
conditions O O
. O O

This O O
study O O
also O O
provided O O
evidence O O
for O O
the O O
pathological O O
nature O O
of O O
amino O O
acid O O
changes O O
in O O
APC O B-Disease
associated O O
with O O
both O O
FAP B-Disease B-Disease
and O O
non O B-Disease
- O I-Disease
FAP O I-Disease
colorectal B-Disease I-Disease
cancer I-Disease I-Disease
patients O O
.. O O

Inherited B-Disease B-Disease
colorectal I-Disease I-Disease
polyposis I-Disease I-Disease
and O O
cancer B-Disease B-Disease
risk O O
of O O
the O O
APC O O
I1307 O O
K O O
polymorphism O O
. O O

Germ O O
- O O
line O O
and O O
somatic O O
truncating O O
mutations O O
of O O
the O O
APC B-Disease B-Disease
gene O O
are O O
thought O O
to O O
initiate O O
colorectal B-Disease B-Disease
tumor I-Disease I-Disease
formation O O
in O O
familial B-Disease B-Disease
adenomatous I-Disease I-Disease
polyposis I-Disease I-Disease
syndrome I-Disease I-Disease
and O O
sporadic O B-Disease
colorectal O I-Disease
carcinogenesis O I-Disease
, O O
respectively O O
. O O

Recently O O
, O O
an O O
isoleucine-- O O
> O O
lysine O O
polymorphism O O
at O O
codon O O
1307 O O
( O O
I1307 O O
K O O
) O O
of O O
the O O
APC B-Disease B-Disease
gene O O
has O O
been O O
identified O O
in O O
6 O O
% O O
-7 O O
% O O
of O O
the O O
Ashkenazi O O
Jewish O O
population O O
. O O

To O O
assess O O
the O O
risk O O
of O O
this O O
common O O
APC B-Disease B-Disease
allelic O O
variant O O
in O O
colorectal O B-Disease
carcinogenesis O I-Disease
, O O
we O O
have O O
analyzed O O
a O O
large O O
cohort O O
of O O
unselected O O
Ashkenazi O O
Jewish O O
subjects O O
with O O
adenomatous B-Disease B-Disease
polyps I-Disease I-Disease
and O O
. O O
or O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
, I-Disease O
for O O
the O O
APC O O
I1307 O O
K O O
polymorphism O O
. O O

The O O
APC O O
I1307 O O
K O O
allele O O
was O O
identified O O
in O O
48 O O
( O O
10 O O
. O O
1 O O
% O O
) O O
of O O
476 O O
patients O O
. O O

Compared O O
with O O
the O O
frequency O O
in O O
two O O
separate O O
population O O
control O O
groups O O
, O O
the O O
APC O O
I1307 O O
K O O
allele O O
is O O
associated O O
with O O
an O O
estimated O O
relative O O
risk O O
of O O
1 O O
. O O

5 O O
- O O
1 O O
. O O
7 O O
for O O
colorectal B-Disease B-Disease
neoplasia I-Disease I-Disease
( O O
both O O
P O O
= O O
. O O

01 O O
) O O
. O O

Furthermore O O
, O O
compared O O
with O O
noncarriers O O
, O O
APC O O
I1307 O O
K O O
carriers O O
had O O
increased O O
numbers O O
of O O
adenomas B-Disease B-Disease
and O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
per O O
patient O O
( O O
P O O
= O O
. O O
03 O O
) O O
, O O
as O O
well O O
as O O
a O O
younger O O
age O O
at O O
diagnosis O O
. O O

We O O
conclude O O
that O O
the O O
APC O O
I1307 O O
K O O
variant O O
leads O O
to O O
increased O O
adenoma B-Disease B-Disease
formation O O
and O O
directly O O
contributes O O
to O O
3 O O
% O O
-4 O O
% O O
of O O
all O O
Ashkenazi O O
Jewish O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
estimated O O
relative O O
risk O O
for O O
carriers O O
may O O
justify O O
specific O O
clinical O O
screening O O
for O O
the O O
360 O O
, O O
000 O O
Americans O O
expected O O
to O O
harbor O O
this O O
allele O O
, O O
and O O
genetic O O
testing O O
in O O
the O O
setting O O
of O O
long O O
- O O
term O O
- O O
outcome O O
studies O O
may O O
impact O O
significantly O O
on O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
prevention O O
in O O
this O O
population O O
. O O

Localization O O
of O O
human O O
BRCA1 O O
and O O
its O O
loss O O
in O O
high O O
- O O
grade O O
, O O
non B-Disease B-Disease
- I-Disease I-Disease
inherited I-Disease I-Disease
breast I-Disease I-Disease
carcinomas I-Disease I-Disease
. O O

Although O O
the O O
link O O
between O O
the O O
BRCA1 O O
tumour B-Disease B-Disease
- O O
suppressor O O
gene O O
and O O
hereditary B-Disease B-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancer I-Disease I-Disease
is O O
established O O
, O O
the O O
role O O
, O O
if O O
any O O
, O O
of O O
BRCA1 O O
in O O
non B-Disease B-Disease
- I-Disease I-Disease
familial I-Disease I-Disease
cancers I-Disease I-Disease
is O O
unclear O O
. O O

BRCA1 O O
mutations O O
are O O
rare O O
in O O
sporadic B-Disease B-Disease
cancers I-Disease I-Disease
, O O
but O O
loss O O
of O O
BRCA1 O O
resulting O O
from O O
reduced O O
expression O O
or O O
incorrect O O
subcellular O O
localization O O
is O O
postulated O O
to O O
be O O
important O O
in O O
non B-Disease B-Disease
- I-Disease I-Disease
familial I-Disease I-Disease
breast I-Disease I-Disease
and I-Disease I-Disease
ovarian I-Disease I-Disease
cancers I-Disease I-Disease
. O O

Epigenetic O O
loss O O
, O O
however O O
, O O
has O O
not O O
received O O
general O O
acceptance O O
due O O
to O O
controversy O O
regarding O O
the O O
subcellular O O
localization O O
of O O
BRCA1 O O
proteins O O
, O O
reports O O
of O O
which O O
have O O
ranged O O
from O O
exclusively O O
nuclear O O
, O O
to O O
conditionally O O
nuclear O O
, O O
to O O
the O O
ER O O
/ O O
golgi O O
, O O
to O O
cytoplasmic O O
invaginations O O
into O O
the O O
nucleus O O
. O O

In O O
an O O
attempt O O
to O O
resolve O O
this O O
issue O O
, O O
we O O
have O O
comprehensively O O
characterized O O
19 O O
anti O O
- O O
BRCA1 O O
antibodies O O
. O O

These O O
reagents O O
detect O O
a O O
220-kD O O
protein O O
localized O O
in O O
discrete O O
nuclear O O
foci O O
in O O
all O O
epithelial O O
cell O O
lines O O
, O O
including O O
those O O
derived O O
from O O
breast B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

Immunohistochemical O O
staining O O
of O O
human O O
breast O O
specimens O O
also O O
revealed O O
BRCA1 O O
nuclear O O
foci O O
in O O
benign O B-Disease
breast O I-Disease
, O I-Disease
invasive B-Disease I-Disease
lobular I-Disease I-Disease
cancers I-Disease I-Disease
and O O
low B-Disease O
- I-Disease O
grade I-Disease O
ductal I-Disease B-Disease
carcinomas I-Disease I-Disease
. O O

Conversely O O
, O O
BRCA1 O O
expression O O
was O O
reduced O O
or O O
undetectable O O
in O O
the O O
majority O O
of O O
high O O
- O O
grade O O
, O O
ductal B-Disease B-Disease
carcinomas I-Disease I-Disease
, O O
suggesting O O
that O O
absence O O
of O O
BRCA1 O O
may O O
contribute O O
to O O
the O O
pathogenesis O O
of O O
a O O
significant O O
percentage O O
of O O
sporadic B-Disease B-Disease
breast I-Disease I-Disease
cancers I-Disease I-Disease
.. O O

Prolactin O O
and O O
dopamine O O
: O O
what O O
is O O
the O O
connection O O
? O O

A O O
review O O
article O O
. O O

Dopamine O O
( O O
DA O O
) O O
holds O O
a O O
predominant O O
role O O
in O O
the O O
regulation O O
of O O
prolactin O O
( O O
PRL O O
) O O
secretion O O
. O O

Through O O
a O O
direct O O
effect O O
on O O
anterior O O
pituitary O O
lactotrophs O O
, O O
DA O O
inhibits O O
the O O
basally O O
high O O
- O O
secretory O O
tone O O
of O O
the O O
cell O O
. O O

It O O
accomplishes O O
this O O
by O O
binding O O
to O O
D2 O O
receptors O O
expressed O O
on O O
the O O
cell O O
membrane O O
of O O
the O O
lactotroph O O
, O O
activation O O
of O O
which O O
results O O
in O O
a O O
reduction O O
of O O
PRL O O
exocytosis O O
and O O
gene O O
expression O O
by O O
a O O
variety O O
of O O
intracellular O O
signalling O O
mechanisms O O
. O O

The O O
hypothalamic O O
dopaminergic O O
neurons O O
, O O
which O O
provide O O
DA O O
to O O
the O O
anterior O O
pituitary O O
gland O O
, O O
are O O
themselves O O
regulated O O
by O O
feedback O O
from O O
PRL O O
through O O
a O O
's O O
hort O O
- O O
loop O O
feedback O O
mechanism O O
' O O
. O O

A O O
variety O O
of O O
other O O
modulators O O
of O O
prolactin O O
secretion O O
act O O
at O O
the O O
hypothalamic O O
level O O
by O O
either O O
disinhibition O O
of O O
the O O
dopaminergic O O
tone O O
( O O
e.g. O O
serotonin O O
, O O
GABA O O
, O O
oestrogens O O
and O O
opioids O O
) O O
or O O
by O O
reinforcing O O
it O O
( O O
e.g. O O
substance O O
P O O
) O O
. O O

All O O
typical O O
antipsychotic O O
medications O O
are O O
associated O O
with O O
sustained B-Disease O
hyperprolactinaemia I-Disease B-Disease
due O O
to O O
their O O
high O O
affinity O O
for O O
the O O
D2 O O
receptor O O
and O O
their O O
slow O O
dissociation O O
from O O
the O O
receptor O O
once O O
bound O O
, O O
but O O
atypicals O O
differ O O
quite O O
dramatically O O
in O O
their O O
propensity O O
to O O
cause O O
prolonged O O
high O O
prolactin O O
levels O O
. O O

Of O O
those O O
atypicals O O
that O O
are O O
associated O O
with O O
prolactin O O
elevation O O
, O O
the O O
main O O
causative O O
factor O O
appears O O
to O O
be O O
a O O
higher O O
peripheral O O
- O O
to O O
- O O
central O O
dopamine O O
receptor O O
potency O O
of O O
either O O
the O O
parent O O
drug O O
or O O
its O O
active O O
metabolite O O
( O O
e.g. O O
risperidone O O
, O O
9 O O
- O O
hydroxy O O
- O O
risperidone O O
and O O
amisulpride O O
) O O
. O O

Antipsychotics O O
that O O
easily O O
cross O O
the O O
blood O O
- O O
brain O O
barrier O O
and O O
exhibit O O
fast O O
dissociation O O
from O O
the O O
dopamine O O
receptor O O
once O O
bound O O
do O O
not O O
result O O
in O O
sustained B-Disease O
hyperprolactinaemia I-Disease B-Disease
. O O

Arsenic O O
upregulates O O
MMP O O
- O O
9 O O
and O O
inhibits O O
wound B-Disease B-Disease
repair O O
in O O
human O O
airway O O
epithelial O O
cells O O
. O O

As O O
part O O
of O O
the O O
innate O O
immune O O
defense O O
, O O
the O O
polarized O O
conducting O O
lung O O
epithelium O O
acts O O
as O O
a O O
barrier O O
to O O
keep O O
particulates O O
carried O O
in O O
respiration O O
from O O
underlying O O
tissue O O
. O O

Arsenic O O
is O O
a O O
metalloid O O
toxicant O O
that O O
can O O
affect O O
the O O
lung O O
via O O
inhalation O O
or O O
ingestion O O
. O O

We O O
have O O
recently O O
shown O O
that O O
chronic O O
exposure O O
of O O
mice O O
or O O
humans O O
to O O
arsenic O O
( O O
10 O O
- O O
50 O O
ppb O O
) O O
in O O
drinking O O
water O O
alters O O
bronchiolar O O
lavage O O
or O O
sputum O O
proteins O O
consistent O O
with O O
reduced O O
epithelial O O
cell O O
migration O O
and O O
wound B-Disease B-Disease
repair O O
in O O
the O O
airway O O
. O O

In O O
this O O
report O O
, O O
we O O
used O O
an O O
in O O
vitro O O
model O O
to O O
examine O O
effects O O
of O O
acute O O
exposure O O
of O O
arsenic O O
( O O
15 O O
- O O
290 O O
ppb O O
) O O
on O O
conducting O O
airway O O
lung O O
epithelium O O
. O O

We O O
found O O
that O O
arsenic O O
at O O
concentrations O O
as O O
low O O
as O O
30 O O
ppb O O
inhibits O O
reformation O O
of O O
the O O
epithelial O O
monolayer O O
following O O
scrape O O
wounds O O
of O O
monolayer O O
cultures O O
. O O

In O O
an O O
effort O O
to O O
understand O O
functional O O
contributions O O
to O O
epithelial O O
wound B-Disease B-Disease
repair O O
altered O O
by O O
arsenic O O
, O O
we O O
showed O O
that O O
acute O O
arsenic O O
exposure O O
increases O O
activity O O
and O O
expression O O
of O O
matrix O O
metalloproteinase O O
( O O
MMP O O
) O O
- O O
9 O O
, O O
an O O
important O O
protease O O
in O O
lung O O
function O O
. O O

Furthermore O O
, O O
inhibition O O
of O O
MMP O O
- O O
9 O O
in O O
arsenic O O
- O O
treated O O
cells O O
improved O O
wound B-Disease B-Disease
repair O O
. O O

We O O
propose O O
that O O
arsenic O O
in O O
the O O
airway O O
can O O
alter O O
the O O
airway O O
epithelial O O
barrier O O
by O O
restricting O O
proper O O
wound B-Disease B-Disease
repair O O
in O O
part O O
through O O
the O O
upregulation O O
of O O
MMP O O
- O O
9 O O
by O O
lung O O
epithelial O O
cells O O
. O O

Stem O O
cell O O
mobilization O O
with O O
cyclophosphamide O O
overcomes O O
the O O
suppressive O O
effect O O
of O O
lenalidomide O O
therapy O O
on O O
stem O O
cell O O
collection O O
in O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
. O O

A O O
total O O
of O O
28 O O
treatment O O
- O O
na O O
? O O

ve O O
patients O O
with O O
stage O O
II O O
or O O
III O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
( O O
MM B-Disease B-Disease
) O O
were O O
treated O O
with O O
the O O
combination O O
of O O
clarithromycin O O
, O O
lenalidomide O O
, O O
and O O
dexamethasone O O
( O O
BiRD O O
) O O
. O O

Stem O O
cells O O
were O O
collected O O
following O O
granulocyte O O
- O O
colony O O
stimulating O O
factor O O
( O O
G O O
- O O
CSF O O
) O O
or O O
cyclophosphamide O O
( O O
Cy O O
) O O
plus O O
G O O
- O O
CSF O O
mobilization O O
at O O
maximum O O
response O O
. O O

Sufficient O O
stem O O
cells O O
for O O
2 O O
autologous O O
stem O O
cell O O
transplants O O
were O O
collected O O
from O O
all O O
patients O O
mobilized O O
with O O
Cy O O
plus O O
G O O
- O O
CSF O O
, O O
versus O O
33 O O
% O O
mobilized O O
with O O
G O O
- O O
CSF O O
alone O O
( O O
P O O
< O O
.0001 O O
) O O
. O O

The O O
duration O O
of O O
prior O O
lenalidomide O O
therapy O O
did O O
not O O
correlate O O
with O O
success O O
of O O
stem O O
cell O O
harvests O O
( O O
P O O
= O O
.91 O O
) O O
. O O

In O O
conclusion O O
, O O
Cy O O
can O O
be O O
added O O
to O O
G O O
- O O
CSF O O
for O O
stem O O
cell O O
mobilization O O
to O O
successfully O O
overcome O O
the O O
suppressive O O
effect O O
of O O
prior O O
treatment O O
with O O
lenalidomide O O
. O O

Fluctuating O O
functions O O
related O O
to O O
quality O O
of O O
life O O
in O O
advanced O O
Parkinson O B-Disease
disease O I-Disease
: O O
effects O O
of O O
duodenal O O
levodopa O O
infusion O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
fluctuations O O
in O O
quality O O
of O O
life O O
( O O
QoL O O
) O O
and O O
motor O O
performance O O
in O O
patients O O
with O O
advanced O O
Parkinson O B-Disease
disease O I-Disease
( O O
PD O B-Disease
) O O
treated O O
with O O
continuous O O
daytime O O
duodenal O O
levodopa O O
/ O O
carbidopa O O
infusion O O
or O O
conventional O O
therapy O O
. O O

METHODS O O
: O O
Of O O
18 O O
patients O O
completing O O
a O O
6 O O
- O O
week O O
trial O O
( O O
DIREQT O O
) O O
, O O
12 O O
were O O
followed O O
for O O
up O O
to O O
6 O O
months O O
and O O
assessed O O
using O O
electronic O O
diaries O O
and O O
the O O
PD O O
Questionnaire O O
- O O
39 O O
( O O
PDQ O O
- O O
39 O O
) O O
. O O

RESULTS O O
: O O
During O O
the O O
trial O O
and O O
follow O O
- O O
up O O
, O O
major O O
diurnal O O
fluctuations O O
were O O
observed O O
, O O
especially O O
for O O
hyperkinesia B-Disease B-Disease
, O O
' O O
off O O
' O O
time O O
, O O
ability O O
to O O
walk O O
and O O
depression B-Disease B-Disease
. O O

Duodenal O O
infusion O O
was O O
associated O O
with O O
significantly O O
more O O
favourable O O
outcomes O O
compared O O
with O O
conventional O O
treatment O O
for O O
satisfaction O O
with O O
overall O O
functioning O O
, O O
' O O
off O O
' O O
time O O
and O O
ability O O
to O O
walk O O
, O O
with O O
improved O O
outcomes O O
with O O
PDQ O O
- O O
39 O O
. O O

CONCLUSIONS O O
: O O
Relative O O
to O O
conventional O O
treatment O O
, O O
infusion O O
therapy O O
may O O
stabilize O O
and O O
significantly O O
improve O O
motor O O
function O O
and O O
patient O O
's O O
QoL O O
. O O

The O O
potential O O
for O O
daily O O
fluctuation O O
in O O
PD O B-Disease
symptoms O O
means O O
single O O
measures O O
of O O
treatment O O
effectiveness O O
can O O
result O O
in O O
bias O O
in O O
effect O O
estimates O O
and O O
hence O O
repeated O O
measures O O
are O O
recommended O O
. O O

Apaziquone O O
for O O
non B-Disease B-Disease
- I-Disease I-Disease
muscle I-Disease I-Disease
invasive I-Disease I-Disease
bladder I-Disease I-Disease
cancer I-Disease I-Disease
: O O
a O O
critical O O
review O O
. O O

OBJECTIVE O O
: O O
To O O
describe O O
clinical O O
needs O O
in O O
non B-Disease B-Disease
- I-Disease I-Disease
muscle I-Disease I-Disease
invasive I-Disease I-Disease
bladder I-Disease I-Disease
cancer I-Disease I-Disease
( O O
NMIBC B-Disease B-Disease
) O O
and O O
review O O
the O O
potential O O
of O O
apaziquone O O
in O O
this O O
respect O O
. O O

METHODS O O
: O O
Epidemiology O O
and O O
clinical O O
practice O O
in O O
NMIBC B-Disease B-Disease
, O O
as O O
well O O
as O O
new O O
drugs O O
and O O
strategies O O
are O O
reviewed O O
. O O

RESULTS O O
: O O
Bladder B-Disease B-Disease
cancer I-Disease I-Disease
is O O
a O O
heterogeneous O O
and O O
frequent O O
disease O O
. O O

Clinical O O
risk O O
factors O O
help O O
in O O
determining O O
additional O O
therapy O O
after O O
initial O O
resection O O
. O O

However O O
, O O
current O O
treatments O O
have O O
clear O O
limitations O O
with O O
regard O O
to O O
efficacy O O
and O O
/ O O
or O O
toxicity O O
. O O

New O O
drugs O O
and O O
strategies O O
have O O
been O O
tested O O
recently O O
and O O
are O O
in O O
( O O
pre O O
) O O
clinical O O
use O O
. O O

Intravesical O O
apaziquone O O
( O O
EOquin O O
) O O
is O O
a O O
new O O
drug O O
. O O

It O O
has O O
theoretical O O
advantages O O
for O O
intravesical O O
use O O
, O O
has O O
proven O O
safety O O
and O O
is O O
presently O O
under O O
further O O
clinical O O
evaluation O O
. O O

CONCLUSION O O
: O O
Apaziquone O O
is O O
a O O
promising O O
drug O O
for O O
intravesical O O
use O O
in O O
patients O O
with O O
NMIBC B-Disease B-Disease
. O O

Allopregnanolone O O
impairs O O
episodic O O
memory O O
in O O
healthy O O
women O O
. O O

OBJECTIVE O O
: O O
Allopregnanolone O O
is O O
an O O
endogenous O O
neuroactive O O
steroid O O
that O O
, O O
through O O
its O O
binding O O
to O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
A O O
receptor O O
, O O
has O O
GABA O O
- O O
active O O
properties O O
. O O

Animal O O
studies O O
indicate O O
that O O
allopregnanolone O O
administration O O
results O O
in O O
diminished B-Disease O
learning I-Disease O
and O O
memory B-Disease B-Disease
impairment I-Disease I-Disease
. O O

The O O
aim O O
of O O
the O O
current O O
study O O
was O O
to O O
investigate O O
the O O
effect O O
of O O
intravenously O O
administered O O
allopregnanolone O O
on O O
episodic O O
memory O O
, O O
semantic O O
memory O O
, O O
and O O
working O O
memory O O
in O O
healthy O O
women O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Twenty O O
- O O
eight O O
healthy O O
women O O
were O O
included O O
in O O
the O O
study O O
. O O

The O O
participants O O
were O O
scheduled O O
for O O
the O O
memory O O
tests O O
twice O O
in O O
the O O
follicular O O
phase O O
. O O

During O O
the O O
test O O
sessions O O
, O O
an O O
intravenous O O
allopregnanolone O O
and O O
placebo O O
infusion O O
were O O
administered O O
in O O
a O O
double O O
- O O
blinded O O
, O O
randomized O O
order O O
at O O
intervals O O
of O O
48 O O
h O O
. O O

Before O O
and O O
10 O O
min O O
after O O
the O O
allopregnanolone O O
/ O O
placebo O O
injections O O
, O O
memory O O
tasks O O
were O O
performed O O
. O O

RESULTS O O
: O O
The O O
study O O
demonstrated O O
that O O
allopregnanolone O O
impaired O B-Disease
episodic O I-Disease
memory O I-Disease
in O O
healthy O O
women O O
. O O

There O O
was O O
a O O
significant O O
difference O O
between O O
pre O O
- O O
and O O
postallopregnanolone O O
injection O O
episodic O O
memory O O
scores O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
whereas O O
there O O
was O O
no O O
change O O
in O O
episodic O O
memory O O
performance O O
following O O
the O O
placebo O O
injections O O
. O O

There O O
was O O
also O O
a O O
significant O O
difference O O
between O O
allopregnanolone O O
and O O
placebo O O
postinjection O O
episodic O O
memory O O
scores O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

There O O
were O O
no O O
effects O O
of O O
allopregnanolone O O
on O O
the O O
semantic O O
memory O O
task O O
or O O
working O O
memory O O
task O O
. O O

CONCLUSION O O
: O O
Intravenous O O
allopregnanolone O O
impairs O O
episodic O O
memory O O
in O O
healthy O O
women O O
, O O
but O O
there O O
is O O
a O O
high O O
degree O O
of O O
individual O O
variability O O
. O O

Effect O O
of O O
carbocisteine O O
on O O
acute O O
exacerbation O O
of O O
chronic B-Disease B-Disease
obstructive I-Disease I-Disease
pulmonary I-Disease I-Disease
disease I-Disease I-Disease
( O O
PEACE O O
Study O O
) O O
: O O
a O O
randomised O O
placebo O O
- O O
controlled O O
study O O
. O O

BACKGROUND O O
: O O
Chronic B-Disease B-Disease
obstructive I-Disease I-Disease
pulmonary I-Disease I-Disease
disease I-Disease I-Disease
( O O
COPD B-Disease B-Disease
) O O
is O O
characterised O O
by O O
airflow O O
limitation O O
, O O
and O O
has O O
many O O
components O O
including O O
mucus O O
hypersecretion O O
, O O
oxidative O O
stress O O
, O O
and O O
airway O B-Disease
inflammation O I-Disease
. O O

We O O
aimed O O
to O O
assess O O
whether O O
carbocisteine O O
, O O
a O O
mucolytic O O
agent O O
with O O
anti O O
- O O
inflammatory O O
and O O
antioxidation O O
activities O O
, O O
could O O
reduce O O
the O O
yearly O O
exacerbation O O
rate O O
in O O
patients O O
with O O
COPD B-Disease B-Disease
. O O

METHODS O O
: O O
We O O
did O O
a O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
of O O
709 O O
patients O O
from O O
22 O O
centres O O
in O O
China O O
. O O

Participants O O
were O O
eligible O O
if O O
they O O
were O O
diagnosed O O
as O O
having O O
COPD B-Disease B-Disease
with O O
a O O
postbronchodilator O O
forced O O
expiratory O O
volume O O
in O O
1 O O
s O O
( O O
FEV O O
( O O
1 O O
) O O
) O O
to O O
forced O O
vital O O
capacity O O
( O O
FVC O O
) O O
ratio O O
( O O
FEV O O
( O O
1 O O
) O O
/ O O
FVC O O
) O O
of O O
less O O
than O O
0.7 O O
and O O
an O O
FEV O O
( O O
1 O O
) O O
between O O
25 O O
% O O
and O O
79 O O
% O O
of O O
the O O
predicted O O
value O O
, O O
were O O
aged O O
between O O
40 O O
and O O
80 O O
years O O
, O O
had O O
a O O
history O O
of O O
at O O
least O O
two O O
COPD B-Disease B-Disease
exacerbations O O
within O O
the O O
previous O O
2 O O
years O O
, O O
and O O
had O O
remained O O
clinically O O
stable O O
for O O
over O O
4 O O
weeks O O
before O O
the O O
study O O
. O O

Patients O O
were O O
randomly O O
assigned O O
to O O
receive O O
1500 O O
mg O O
carbocisteine O O
or O O
placebo O O
per O O
day O O
for O O
a O O
year O O
. O O

The O O
primary O O
endpoint O O
was O O
exacerbation O O
rate O O
over O O
1 O O
year O O
, O O
and O O
analysis O O
was O O
by O O
intention O O
to O O
treat O O
. O O

This O O
trial O O
is O O
registered O O
with O O
the O O
Japan O O
Clinical O O
Trials O O
Registry O O
( O O
http://umin.ac.jp/ctr/index/htm O O
) O O
number O O
UMIN O O
- O O
CRT O O
C000000233 O O
. O O

FINDINGS O O
: O O
354 O O
patients O O
were O O
assigned O O
to O O
the O O
carbocisteine O O
group O O
and O O
355 O O
to O O
the O O
placebo O O
group O O
. O O

Numbers O O
of O O
exacerbations O O
per O O
patient O O
per O O
year O O
declined O O
significantly O O
in O O
the O O
carbocisteine O O
group O O
compared O O
with O O
the O O
placebo O O
group O O
( O O
1.01 O O
[ O O
SE O O
0.06 O O
] O O
vs O O
1.35 O O
[ O O
SE O O
0.06 O O
] O O
) O O
, O O
risk O O
ratio O O
0.75 O O
( O O
95 O O
% O O
CI O O
0.62 O O
- O O
0.92 O O
, O O
p O O
= O O
0.004 O O
) O O
. O O

Non O O
- O O
significant O O
interactions O O
were O O
found O O
between O O
the O O
preventive O O
effects O O
and O O
COPD B-Disease B-Disease
severity O O
, O O
smoking O O
, O O
as O O
well O O
as O O
concomitant O O
use O O
of O O
inhaled O O
corticosteroids O O
. O O

Carbocisteine O O
was O O
well O O
tolerated O O
. O O

INTERPRETATION O O
: O O
Mucolytics O O
, O O
such O O
as O O
carbocisteine O O
, O O
should O O
be O O
recognised O O
as O O
a O O
worthwhile O O
treatment O O
for O O
prevention O O
of O O
exacerbations O O
in O O
Chinese O O
patients O O
with O O
COPD B-Disease B-Disease
. O O

Induction O O
of O O
the O O
multixenobiotic O O
/ O O
multidrug O O
resistance O O
system O O
in O O
various O O
cell O O
lines O O
in O O
response O O
to O O
perfluorinated O O
carboxylic O O
acids O O
. O O

The O O
multixenobiotic O O
resistance O O
( O O
closely O O
related O O
to O O
multidrug O O
resistance O O
) O O
system O O
controls O O
transport O O
across O O
the O O
plasma O O
membrane O O
as O O
a O O
defense O O
against O O
toxic O O
molecules O O
. O O

Multixenobiotic O O
resistance O O
system O O
consists O O
of O O
an O O
efflux O O
pump O O
, O O
ABCB1 O O
( O O
also O O
named O O
P O O
- O O
glycoprotein O O
, O O
P O O
- O O
gp O O
) O O
, O O
and O O
/ O O
or O O
a O O
molecule O O
of O O
the O O
ABCC O O
family O O
( O O
also O O
named O O
multiple O O
resistance O O
associated O O
protein O O
, O O
MRP O O
) O O
. O O

ABCB1 O O
is O O
able O O
to O O
increase O O
efflux O O
of O O
many O O
low O O
- O O
molecular O O
foreign O O
molecules O O
. O O

Measuring O O
system O O
induction O O
may O O
be O O
used O O
as O O
a O O
biomarker O O
of O O
cell O O
/ O O
organism O O
exposure O O
to O O
foreign O O
substances O O
. O O

Various O O
established O O
cell O O
lines O O
were O O
tested O O
for O O
constitutive O O
and O O
induced O O
multixenobiotic O O
resistance O O
proteins O O
by O O
Western O O
blotting O O
immunodetection O O
. O O

The O O
pumping O O
function O O
was O O
indirectly O O
assayed O O
with O O
Rhodamine O O
B O O
by O O
visualization O O
of O O
cell O O
fluorescence O O
in O O
the O O
presence O O
of O O
verapamil O O
. O O

Changes O O
in O O
ABC O O
proteins O O
were O O
measured O O
by O O
flow O O
cytometry O O
after O O
exposition O O
to O O
various O O
perfluorinated O O
carboxylic O O
acids O O
. O O

MCF7 O O
and O O
HeLa O O
cells O O
were O O
found O O
to O O
contain O O
the O O
highest O O
constitutive O O
level O O
of O O
both O O
ABCB1 O O
and O O
ABCC1 O O
. O O

HEK293 O O
exhibited O O
much O O
less O O
ABCB1 O O
and O O
no O O
activity O O
of O O
pumping O O
out O O
Rhodamine O O
B O O
. O O

The O O
pumping O O
activity O O
was O O
found O O
to O O
be O O
related O O
to O O
the O O
amount O O
of O O
the O O
cell O O
- O O
type O O
specific O O
170 O O
kDa O O
ABCB1 O O
protein O O
. O O

An O O
8 O O
- O O
day O O
exposure O O
to O O
10 O O
( O O
- O O
4 O O
) O O
M O O
perfluorononanoic O O
acid O O
resulted O O
in O O
about O O
2 O O
- O O
2.5 O O
- O O
fold O O
increase O O
of O O
ABCB1 O O
level O O
. O O

That O O
was O O
confirmed O O
also O O
for O O
short O O
times O O
by O O
flow O O
cytometry O O
of O O
cells O O
exposed O O
to O O
perfluorinated O O
acids O O
and O O
its O O
natural O O
congeners O O
. O O

Both O O
ABCB1 O O
- O O
and O O
ABCC1 O O
- O O
related O O
fluorescence O O
increased O O
along O O
with O O
the O O
carbon O O
chain O O
in O O
acids O O
from O O
C O O
( O O
6 O O
) O O
up O O
to O O
C O O
( O O
9 O O
) O O
and O O
decreased O O
for O O
C O O
( O O
10 O O
) O O
. O O

Measuring O O
of O O
multixenobiotic O O
resistance O O
changes O O
in O O
vitro O O
induced O O
by O O
chemicals O O
may O O
be O O
a O O
convenient O O
test O O
for O O
screening O O
for O O
their O O
potential O O
toxicity O O
. O O

Phase O O
I O O
/ O O
II O O
study O O
of O O
biweekly O O
paclitaxel O O
and O O
radiation O O
in O O
androgen O O
- O O
ablated O O
locally O O
advanced O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
maximum O O
- O O
tolerated O O
dose O O
( O O
MTD O O
) O O
of O O
concurrent O O
paclitaxel O O
and O O
radiation O O
therapy O O
( O O
RT O O
) O O
in O O
patients O O
with O O
locally O O
advanced O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Eligible O O
patients O O
had O O
T2 O O
- O O
4 O O
tumors B-Disease B-Disease
with O O
Gleason O O
scores O O
greater O O
than O O
7 O O
and O O
/ O O
or O O
PSA O O
levels O O
greater O O
than O O
10 O O
ng O O
/ O O
mL O O
and O O
/ O O
or O O
had O O
tumors B-Disease B-Disease
with O O
pathologic O O
stage O O
TxN1 O O
. O O

Hormonal O O
ablation O O
was O O
initiated O O
3 O O
months O O
before O O
RT O O
and O O
was O O
given O O
for O O
9 O O
months O O
. O O

RT O O
was O O
delivered O O
daily O O
( O O
1.8 O O
Gy O O
) O O
with O O
concurrent O O
twice O O
- O O
weekly O O
paclitaxel O O
( O O
30 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
. O O

The O O
whole O O
pelvis O O
was O O
irradiated O O
to O O
39.6 O O
Gy O O
. O O

The O O
radiation O O
dose O O
was O O
escalated O O
as O O
follows O O
: O O
63 O O
Gy O O
, O O
66.6 O O
Gy O O
, O O
70.2 O O
Gy O O
, O O
and O O
73.8 O O
Gy O O
. O O

The O O
last O O
RT O O
dose O O
level O O
was O O
fixed O O
at O O
73.8 O O
Gy O O
. O O

RESULTs O O
: O O
Between O O
January O O
2000 O O
and O O
October O O
2006 O O
, O O
22 O O
patients O O
were O O
enrolled O O
. O O

The O O
median O O
age O O
was O O
59 O O
years O O
( O O
range O O
, O O
48 O O
to O O
72 O O
years O O
) O O
; O O
the O O
median O O
PSA O O
level O O
was O O
22.4 O O
ng O O
/ O O
mL O O
( O O
range O O
, O O
2.8 O O
to O O
113 O O
ng O O
/ O O
mL O O
) O O
. O O

The O O
number O O
of O O
patients O O
per O O
stage O O
was O O
as O O
follows O O
: O O
three O O
with O O
T1 O O
, O O
eight O O
with O O
T2 O O
, O O
11 O O
with O O
T3 O O
, O O
and O O
five O O
with O O
pN1 O O
= O O
5 O O
. O O

No O O
grade O O
3 O O
toxicities O O
occurred O O
at O O
63 O O
Gy O O
. O O

Grade O O
3 O O
diarrhea B-Disease B-Disease
occurred O O
in O O
three O O
patients O O
at O O
66.6 O O
Gy O O
. O O

The O O
protocol O O
then O O
was O O
amended O O
to O O
treat O O
the O O
prostate O O
volume O O
first O O
followed O O
by O O
the O O
whole O O
pelvis O O
. O O

No O O
grade O O
3 O O
toxicities O O
were O O
observed O O
at O O
70.2 O O
Gy O O
. O O

One O O
patient O O
experienced O O
grade O O
3 O O
diarrhea B-Disease B-Disease
at O O
73.8 O O
Gy O O
. O O

Five O O
additional O O
patients O O
were O O
treated O O
to O O
73.8 O O
Gy O O
without O O
grade O O
3 O O
toxicity O B-Disease
, O O
which O O
established O O
the O O
MTD O O
for O O
combined O O
paclitaxel O O
and O O
RT O O
at O O
73.8 O O
Gy O O
. O O

At O O
38 O O
months O O
median O O
follow O O
- O O
up O O
( O O
range O O
, O O
9 O O
to O O
87 O O
months O O
) O O
, O O
21 O O
( O O
95 O O
% O O
) O O
of O O
22 O O
patients O O
are O O
alive O O
. O O

Six O O
( O O
27 O O
% O O
) O O
of O O
22 O O
experienced O O
recurrence O O
. O O

CONCLUSION O O
: O O
Concurrent O O
biweekly O O
paclitaxel O O
with O O
RT O O
is O O
feasible O O
, O O
with O O
an O O
MTD O O
of O O
73.8 O O
Gy O O
. O O

Recovery O O
of O O
gonadal O O
function O O
occurs O O
in O O
the O O
majority O O
of O O
patients O O
. O O

These O O
results O O
encourage O O
testing O O
in O O
a O O
phase O O
III O O
setting O O
. O O

Application O O
of O O
a O O
high O O
- O O
content O O
multiparameter O O
cytotoxicity B-Disease B-Disease
assay O O
to O O
prioritize O O
compounds O O
based O O
on O O
toxicity O O
potential O O
in O O
humans O O
. O O

Prioritization O O
of O O
compounds O O
based O O
on O O
human O O
hepatotoxicity B-Disease B-Disease
potential O O
is O O
currently O O
a O O
key O O
unmet O O
need O O
in O O
drug O O
discovery O O
, O O
as O O
it O O
can O O
become O O
a O O
major O O
problem O O
for O O
several O O
lead O O
compounds O O
in O O
later O O
stages O O
of O O
the O O
drug O O
discovery O O
pipeline O O
. O O

The O O
authors O O
report O O
the O O
validation O O
and O O
implementation O O
of O O
a O O
high O O
- O O
content O O
multiparametric O O
cytotoxicity B-Disease B-Disease
assay O O
based O O
on O O
simultaneous O O
measurement O O
of O O
8 O O
key O O
cell O O
health O O
indicators O O
associated O O
with O O
nuclear O O
morphology O O
, O O
plasma O O
membrane O O
integrity O O
, O O
mitochondrial O O
function O O
, O O
and O O
cell O O
proliferation O O
. O O

Compounds O O
are O O
prioritized O O
by O O
( O O
a O O
) O O
computing O O
an O O
in O O
vitro O O
safety O O
margin O O
using O O
the O O
minimum O O
cytotoxic O O
concentration O O
( O O
IC O O
( O O
20 O O
) O O
) O O
across O O
all O O
8 O O
indicators O O
and O O
cell O O
- O O
based O O
efficacy O O
data O O
and O O
( O O
b O O
) O O
using O O
the O O
minimal O O
cytotoxic O O
concentration O O
alone O O
to O O
take O O
into O O
account O O
concentration O O
of O O
drug O O
in O O
tissues O O
. O O

Feasibility O O
data O O
using O O
selected O O
compounds O O
, O O
including O O
quinolone O O
antibiotics O O
, O O
thiazolidinediones O O
, O O
and O O
statins O O
, O O
suggest O O
the O O
viability O O
of O O
this O O
approach O O
. O O

To O O
increase O O
overall O O
throughput O O
of O O
compound O O
prioritization O O
, O O
the O O
authors O O
have O O
identified O O
the O O
higher O O
throughput O O
, O O
plate O O
reader O O
- O O
based O O
CyQUANT O O
assay O O
that O O
is O O
similar O O
to O O
the O O
high O O
- O O
content O O
screening O O
( O O
HCS O O
) O O
assay O O
in O O
sensitivity O O
of O O
measuring O O
inhibition O O
of O O
cell O O
proliferation O O
. O O

It O O
is O O
expected O O
that O O
the O O
phenotypic O O
output O O
from O O
the O O
multiparametric O O
HCS O O
assay O O
in O O
combination O O
with O O
other O O
highly O O
sensitive O O
approaches O O
, O O
such O O
as O O
microarray O O
- O O
based O O
expression O O
analysis O O
of O O
toxic O O
signatures O O
, O O
will O O
contribute O O
to O O
a O O
better O O
understanding O O
and O O
predictivity O O
of O O
human O O
hepatotoxicity B-Disease B-Disease
potential O O
. O O

Amended O O
final O O
report O O
of O O
the O O
safety O O
assessment O O
of O O
cocamidopropylamine O O
oxide O O
. O O

Cocamidopropylamine O O
Oxide O O
is O O
a O O
tertiary O O
amine O O
oxide O O
which O O
functions O O
as O O
a O O
hair O O
- O O
conditioning O O
agent O O
and O O
as O O
a O O
surfactant O O
, O O
currently O O
used O O
in O O
60 O O
cosmetic O O
formulations O O
at O O
concentrations O O
between O O
0.07 O O
% O O
and O O
4.0 O O
% O O
. O O

In O O
an O O
earlier O O
safety O O
assessment O O
, O O
the O O
Cosmetic O O
Ingredient O O
Review O O
( O O
CIR O O
) O O
Expert O O
Panel O O
had O O
determined O O
that O O
the O O
available O O
data O O
were O O
insufficient O O
to O O
support O O
the O O
safety O O
of O O
this O O
ingredient O O
in O O
cosmetic O O
products O O
. O O

Additional O O
data O O
have O O
now O O
been O O
provided O O
and O O
reviewed O O
. O O

Cocamidopropylamine O O
Oxide O O
was O O
determined O O
to O O
have O O
an O O
acute O O
oral O O
LD O O
( O O
50 O O
) O O
between O O
500 O O
and O O
1000 O O
mg O O
/ O O
kg O O
day O O
( O O
- O O
1 O O
) O O
using O O
rats O O
. O O

The O O
acute O O
dermal O O
LD O O
( O O
50 O O
) O O
in O O
rats O O
was O O
> O O
2174 O O
mg O O
/ O O
kg O O
day O O
( O O
- O O
1 O O
) O O
. O O

A O O
28 O O
- O O
day O O
repeated O O
oral O O
dose B-Disease O
toxicity I-Disease B-Disease
study O O
in O O
rats O O
found O O
hemolytic B-Disease B-Disease
anemia I-Disease I-Disease
at O O
150 O O
and O O
1000 O O
mg O O
/ O O
kg O O
day O O
( O O
- O O
1 O O
) O O
, O O
with O O
a O O
no O O
observed O O
effect O O
level O O
( O O
NOEL O O
) O O
of O O
15 O O
mg O O
/ O O
kg O O
day O O
( O O
- O O
1 O O
) O O
. O O

At O O
5 O O
% O O
, O O
Cocamidopropylamine O O
Oxide O O
solution O O
was O O
not O O
a O O
primary O O
dermal O O
irritant O O
. O O

Application O O
of O O
81.5 O O
% O O
Cocamidopropylamine O O
Oxide O O
to O O
rabbit O O
skin O O
caused O O
moderate O O
irritation B-Disease B-Disease
under O O
Draize O O
classification O O
scale O O
, O O
but O O
81.5 O O
% O O
Cocamidopropylamine O O
Oxide O O
in O O
rabbit O O
eyes O O
caused O O
severe O O
irritation B-Disease B-Disease
. O O

A O O
maximization O O
study O O
classified O O
Cocamidopropylamine O O
Oxide O O
as O O
a O O
nonsensitizer O O
to O O
guinea O O
pig O O
skin O O
. O O

Cocamidopropylamine O O
Oxide O O
was O O
not O O
mutagenic O O
in O O
an O O
Ames O O
test O O
, O O
with O O
and O O
without O O
metabolic O O
activation O O
. O O

No O O
evidence O O
of O O
increased O O
chromosomal O O
aberrations O O
were O O
noted O O
in O O
human O O
lymphocytes O O
treated O O
with O O
81.5 O O
% O O
Cocamidopropylamine O O
Oxide O O
. O O

In O O
a O O
clinical O O
study O O
, O O
7.5 O O
% O O
Cocamidopropylamine O O
Oxide O O
was O O
not O O
a O O
sensitizer O O
, O O
although O O
it O O
did O O
produce O O
some O O
reactions O O
typical O O
of O O
mild O O
irritation B-Disease B-Disease
. O O

Although O O
the O O
impurities O O
, O O
amidoamine O O
and O O
dimethylaminopropylamine O O
, O O
have O O
been O O
implicated O O
in O O
contact B-Disease B-Disease
allergy I-Disease I-Disease
reactions O O
to O O
products O O
containing O O
cocamidopropylamine O O
betaine O O
, O O
clinical O O
testing O O
of O O
a O O
product O O
with O O
cocamidopropylamine O O
betaine O O
containing O O
these O O
impurities O O
, O O
at O O
levels O O
comparable O O
to O O
those O O
found O O
in O O
Cocamidopropylamine O O
Oxide O O
, O O
failed O O
to O O
produce O O
a O O
reaction O O
in O O
10 O O
individuals O O
known O O
to O O
be O O
sensitive O O
to O O
cocamidopropylamine O O
betaine O O
. O O

Two O O
repeat O O
- O O
insult O O
patch O O
tests O O
using O O
a O O
facial O O
wash O O
with O O
1 O O
% O O
raw O O
material O O
containing O O
35 O O
% O O
to O O
36.5 O O
% O O
Cocamidopropylamine O O
Oxide O O
did O O
not O O
find O O
evidence O O
of O O
dermal B-Disease O
sensitization I-Disease O
. O O

Tests O O
for O O
dermal B-Disease B-Disease
phototoxicity I-Disease I-Disease
and O O
photoallergenicity B-Disease B-Disease
with O O
the O O
same O O
facial O O
wash O O
product O O
also O O
did O O
not O O
produce O O
evidence O O
of O O
effect O O
. O O

The O O
CIR O O
Expert O O
Panel O O
recognizes O O
that O O
there O O
are O O
data O O
gaps O O
regarding O O
the O O
use O O
and O O
concentration O O
of O O
this O O
ingredient O O
. O O

However O O
, O O
the O O
overall O O
information O O
available O O
on O O
types O O
of O O
products O O
in O O
which O O
this O O
ingredient O O
is O O
used O O
and O O
at O O
what O O
concentration O O
indicate O O
a O O
pattern O O
of O O
use O O
, O O
which O O
was O O
considered O O
by O O
the O O
Expert O O
Panel O O
in O O
assessing O O
safety O O
. O O

Overall O O
, O O
these O O
data O O
demonstrate O O
that O O
Cocamidopropylamine O O
Oxide O O
has O O
low O O
toxicity O O
in O O
animal O O
and O O
in O O
vitro O O
tests O O
. O O

Although O O
there O O
are O O
no O O
available O O
carcinogenicity B-Disease B-Disease
data O O
, O O
the O O
available O O
genotoxicity B-Disease B-Disease
data O O
, O O
combined O O
with O O
the O O
absence O O
of O O
any O O
structural O O
alerts O O
, O O
suggest O O
no O O
carcinogenic O O
potential O O
. O O

The O O
Panel O O
noted O O
the O O
absence O O
of O O
reproductive O O
and O O
developmental B-Disease B-Disease
toxicity I-Disease I-Disease
data O O
. O O

Because O O
this O O
ingredient O O
has O O
a O O
highly O O
polarized O O
molecular O O
structure O O
, O O
the O O
Panel O O
considered O O
that O O
it O O
would O O
be O O
, O O
at O O
most O O
, O O
slowly O O
absorbed O O
. O O

Given O O
that O O
most O O
of O O
the O O
uses O O
and O O
the O O
highest O O
use O O
concentration O O
of O O
4 O O
% O O
is O O
found O O
in O O
rinse O O
- O O
off O O
products O O
, O O
the O O
Panel O O
determined O O
that O O
the O O
available O O
data O O
suggest O O
that O O
Cocamidopropylamine O O
Oxide O O
is O O
safe O O
as O O
used O O
in O O
rinse O O
- O O
off O O
products O O
. O O

Although O O
dermal O O
penetration O O
may O O
be O O
slow O O
, O O
data O O
on O O
the O O
extent O O
of O O
dermal O O
penetration O O
of O O
Cocamidopropylamine O O
Oxide O O
are O O
needed O O
to O O
support O O
the O O
safety O O
of O O
leave O O
- O O
on O O
uses O O
. O O

If O O
there O O
is O O
significant O O
dermal O O
absorption O O
, O O
dermal O O
reproductive O O
and O O
developmental B-Disease B-Disease
toxicity I-Disease I-Disease
data O O
may O O
be O O
needed O O
. O O

Intravenous O O
fat O O
emulsion O O
: O O
a O O
potential O O
novel O O
antidote O O
. O O

Intravenous O O
fat O O
emulsions O O
( O O
IFE O O
) O O
are O O
traditionally O O
used O O
as O O
a O O
component O O
of O O
parenteral O O
nutrition O O
therapy O O
. O O

Recently O O
, O O
IFE O O
was O O
used O O
to O O
resuscitate O O
severe O O
local B-Disease O
anesthetic I-Disease O
drug I-Disease B-Disease
toxicity I-Disease I-Disease
. O O

This O O
review O O
focuses O O
on O O
the O O
potential O O
role O O
of O O
IFE O O
in O O
treatment O O
of O O
toxicity O B-Disease
due O O
to O O
local O O
anesthetics O O
and O O
other O O
lipid O O
- O O
soluble O O
drugs O O
. O O

The O O
general O O
properties O O
of O O
IFE O O
, O O
metabolic O O
fate O O
, O O
and O O
associated O O
adverse O O
events O O
are O O
described O O
. O O

Cases O O
of O O
local B-Disease B-Disease
anesthetic I-Disease I-Disease
toxicity I-Disease I-Disease
treated O O
with O O
IFE O O
are O O
presented O O
along O O
with O O
a O O
discussion O O
of O O
the O O
possible O O
antidotal O O
mechanisms O O
. O O

Initial O O
investigations O O
into O O
the O O
antidotal O O
use O O
of O O
IFE O O
for O O
lipophilic O O
central O O
nervous O O
and O O
cardiovascular B-Disease B-Disease
drug I-Disease I-Disease
toxicity I-Disease I-Disease
are O O
also O O
reviewed O O
. O O

The O O
use O O
of O O
ultrasound O O
and O O
micelles O O
in O O
cancer B-Disease B-Disease
treatment O O
. O O

The O O
high O O
toxicity O O
of O O
potent O O
chemotherapeutic O O
drugs O O
like O O
Doxorubicin O O
( O O
Dox O O
) O O
limits O O
the O O
therapeutic O O
window O O
in O O
which O O
they O O
can O O
be O O
applied O O
. O O

This O O
window O O
can O O
be O O
expanded O O
by O O
controlling O O
the O O
drug O O
delivery O O
in O O
both O O
space O O
and O O
time O O
such O O
that O O
non O O
- O O
targeted O O
tissues O O
are O O
not O O
adversely O O
affected O O
. O O

Recent O O
research O O
has O O
shown O O
that O O
ultrasound O O
( O O
US O O
) O O
can O O
be O O
used O O
to O O
control O O
the O O
release O O
of O O
Dox O O
and O O
other O O
hydrophobic O O
drugs O O
from O O
polymeric O O
micelles O O
in O O
both O O
time O O
and O O
space O O
. O O

It O O
has O O
also O O
been O O
shown O O
using O O
an O O
in O O
vivo O O
rat O O
tumor O B-Disease
model O O
that O O
Dox O O
activity O O
can O O
be O O
enhanced O O
by O O
ultrasound O O
in O O
one O O
region O O
, O O
while O O
in O O
an O O
adjacent O O
region O O
there O O
is O O
little O O
or O O
no O O
effect O O
of O O
the O O
drug O O
. O O

In O O
this O O
article O O
, O O
we O O
review O O
the O O
in O O
vivo O O
and O O
in O O
vitro O O
research O O
being O O
conducted O O
in O O
the O O
area O O
of O O
using O O
ultrasound O O
to O O
enhance O O
and O O
target O O
micellar O O
drug O O
delivery O O
to O O
cancerous O O
tissues O O
. O O

Additionally O O
, O O
we O O
summarize O O
our O O
previously O O
published O O
mathematical O O
models O O
that O O
attempt O O
to O O
represent O O
the O O
release O O
and O O
re O O
- O O
encapsulation O O
phenomena O O
of O O
Dox O O
from O O
Pluronic O O
P105 O O
micelles O O
upon O O
the O O
application O O
of O O
ultrasound O O
. O O

The O O
potential O O
benefits O O
of O O
such O O
controlled O O
chemotherapy O O
compels O O
a O O
thorough O O
investigation O O
of O O
the O O
role O O
of O O
ultrasound O O
( O O
US O O
) O O
and O O
the O O
mechanisms O O
by O O
which O O
US O O
accomplishes O O
drug O O
release O O
and O O
/ O O
or O O
enhances O O
drug O O
potency O O
. O O

Therefore O O
we O O
will O O
summarize O O
our O O
findings O O
related O O
to O O
the O O
mechanism O O
involved O O
in O O
acoustically O O
activated O O
micellar O O
drug O O
delivery O O
to O O
tumors B-Disease B-Disease
. O O

Drug O O
insight O O
: O O
aggrecanases O O
as O O
therapeutic O O
targets O O
for O O
osteoarthritis B-Disease B-Disease
. O O

In O O
healthy O O
cartilage O O
, O O
effective O O
weight O O
- O O
bearing O O
requires O O
a O O
high O O
concentration O O
of O O
intact O O
aggrecan O O
. O O

Degradation O O
and O O
loss O O
of O O
aggrecan O O
are O O
features O O
of O O
osteoarthritis B-Disease B-Disease
( O O
OA B-Disease B-Disease
) O O
. O O

It O O
is O O
unclear O O
whether O O
ADAMTS O O
- O O
4 O O
, O O
ADAMTS O O
- O O
5 O O
, O O
or O O
both O O
of O O
these O O
aggrecanases O O
from O O
the O O
ADAMTS O O
( O O
a O O
disintegrin O O
and O O
metalloproteinase O O
with O O
thrombospondin O O
motifs O O
) O O
enzyme O O
family O O
, O O
are O O
responsible O O
for O O
aggrecanolysis O O
in O O
human O O
OA B-Disease B-Disease
, O O
and O O
at O O
what O O
stage O O
of O O
disease O O
these O O
enzymes O O
are O O
active O O
. O O

Several O O
potential O O
disease O O
- O O
modifying O O
agents O O
for O O
OA B-Disease B-Disease
include O O
glucosamine O O
and O O
chondroitin O O
sulfate O O
, O O
diacerhein O O
, O O
and O O
pentosan O O
polysulfate O O
; O O
although O O
their O O
mechanisms O O
of O O
action O O
in O O
vivo O O
are O O
unknown O O
, O O
data O O
from O O
in O O
vitro O O
studies O O
and O O
animal O O
models O O
suggest O O
that O O
their O O
efficacy O O
might O O
be O O
partly O O
due O O
to O O
inhibition O O
of O O
proinflammatory O O
pathways O O
that O O
lead O O
to O O
downregulation O O
of O O
ADAMTS O O
enzymes O O
. O O

Some O O
histone O O
deacetylase O O
inhibitors O O
that O O
are O O
successfully O O
used O O
to O O
treat O O
cancer B-Disease B-Disease
can O O
block O O
ADAMTS O O
- O O
5 O O
expression O O
; O O
however O O
, O O
these O O
inhibitors O O
will O O
only O O
be O O
considered O O
as O O
potential O O
therapies O O
for O O
OA B-Disease B-Disease
if O O
their O O
toxicity O O
is O O
markedly O O
reduced O O
. O O

ADAMTS O O
inhibitors O O
currently O O
in O O
development O O
are O O
expected O O
to O O
show O O
excellent O O
specificity O O
now O O
that O O
crystal O O
structures O O
for O O
several O O
ADAMTS O O
enzymes O O
are O O
available O O
to O O
guide O O
drug O O
design O O
. O O

ADAMTS O O
- O O
4 O O
and O O
ADAMTS O O
- O O
5 O O
are O O
appropriate O O
targets O O
for O O
OA B-Disease O
therapies O O
, O O
but O O
ultimately O O
, O O
inhibitors O O
of O O
these O O
enzymes O O
will O O
form O O
only O O
part O O
of O O
a O O
larger O O
arsenal O O
of O O
therapies O O
. O O

Long O O
- O O
term O O
clinical O O
and O O
surrogate O O
marker O O
effects O O
of O O
subcutaneous O O
intermittent O O
interleukin O O
- O O
2 O O
without O O
antiretroviral O O
therapy O O
in O O
HIV O B-Disease
- O I-Disease
infected O I-Disease
patients O O
. O O

OBJECTIVES O O
: O O
Subcutaneous O O
administration O O
of O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
has O O
been O O
shown O O
to O O
increase O O
CD4 O O
counts O O
in O O
HIV O B-Disease
- O I-Disease
infected O I-Disease
patients O O
. O O

It O O
remains O O
unclear O O
whether O O
this O O
effect O O
is O O
associated O O
with O O
a O O
clinical O O
benefit O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
We O O
conducted O O
a O O
long O O
- O O
term O O
follow O O
- O O
up O O
in O O
the O O
cohort O O
of O O
the O O
UK O O
- O O
Vanguard O O
study O O
in O O
which O O
three O O
groups O O
of O O
12 O O
antiretroviral O O
- O O
naive O O
subjects O O
with O O
CD4 O O
cell O O
counts O O
> O O
350 O O
cells O O
/ O O
mm O O
( O O
3 O O
) O O
received O O
no O O
treatment O O
or O O
IL O O
- O O
2 O O
at O O
either O O
4.5 O O
or O O
7.5 O O
MIU O O
twice O O
daily O O
in O O
5 O O
day O O
cycles O O
, O O
respectively O O
. O O

RESULTS O O
: O O
Mean O O
follow O O
- O O
up O O
was O O
376 O O
weeks O O
. O O

IL O O
- O O
2 O O
therapy O O
was O O
associated O O
with O O
a O O
higher O O
area O O
under O O
the O O
curve O O
of O O
CD4 O O
cell O O
count O O
change O O
from O O
baseline O O
at O O
week O O
48 O O
but O O
not O O
thereafter O O
. O O

HIV O O
- O O
RNA O O
levels O O
were O O
unaffected O O
. O O

Highly O O
active O O
antiretroviral O O
therapy O O
( O O
HAART O O
) O O
was O O
initiated O O
after O O
a O O
mean O O
of O O
172 O O
, O O
175 O O
and O O
152 O O
weeks O O
in O O
the O O
control O O
group O O
, O O
low O O
- O O
dose O O
and O O
high O O
- O O
dose O O
IL O O
- O O
2 O O
treatment O O
group O O
, O O
respectively O O
, O O
a O O
statistically O O
non O O
- O O
significant O O
difference O O
. O O

There O O
was O O
a O O
tendency O O
to O O
start O O
HAART O O
soon O O
after O O
discontinuation O O
of O O
IL O O
- O O
2 O O
therapy O O
which O O
may O O
have O O
been O O
triggered O O
by O O
the O O
steep O O
decay O O
of O O
CD4 O O
counts O O
. O O

There O O
were O O
two O O
serious O O
adverse O O
events O O
in O O
the O O
control O O
group O O
, O O
seven O O
in O O
the O O
low O O
- O O
dose O O
IL O O
- O O
2 O O
group O O
and O O
eight O O
in O O
the O O
high O O
- O O
dose O O
IL O O
- O O
2 O O
group O O
. O O

No O O
pattern O O
of O O
disease O O
was O O
detected O O
, O O
making O O
an O O
association O O
with O O
IL O O
- O O
2 O O
therapy O O
unlikely O O
. O O

CONCLUSIONS O O
: O O
We O O
could O O
detect O O
neither O O
a O O
benefit O O
of O O
IL O O
- O O
2 O O
therapy O O
after O O
week O O
48 O O
nor O O
delayed O O
initiation O O
of O O
HAART O O
. O O

This O O
is O O
currently O O
the O O
longest O O
follow O O
- O O
up O O
data O O
comparing O O
IL O O
- O O
2 O O
therapy O O
with O O
no O O
therapy O O
in O O
antiretroviral O O
- O O
naive O O
HIV O O
- O O
infected O O
patients O O
and O O
does O O
not O O
show O O
a O O
persistent O O
benefit O O
of O O
the O O
intervention O O
. O O

Altered O O
first O O
- O O
pass O O
effects O O
in O O
a O O
liver O O
transplant O O
recipient O O
explained O O
intraindividual O O
variation O O
in O O
calcineurin O O
inhibitor O O
concentrations O O
: O O
a O O
case O O
report O O
. O O

BACKGROUND O O
: O O
The O O
significant O O
interindividual O O
and O O
intraindividual O O
variability O O
in O O
the O O
blood O O
concentrations O O
of O O
the O O
most O O
commonly O O
used O O
calcineurin O O
inhibitors O O
such O O
as O O
tacrolimus O O
and O O
cyclosporine O O
makes O O
the O O
exact O O
dosing O O
of O O
these O O
agents O O
in O O
transplant O O
recipients O O
very O O
challenging O O
. O O

As O O
both O O
of O O
these O O
drugs O O
have O O
narrow O O
therapeutic O O
index O O
and O O
are O O
metabolized O O
by O O
hepatic O O
and O O
intestinal O O
cytochrome O O
P450 O O
3A O O
, O O
we O O
tested O O
the O O
hypothesis O O
that O O
these O O
variations O O
are O O
secondary O O
to O O
varying O O
first O O
- O O
pass O O
effects O O
in O O
the O O
gut O O
and O O
the O O
liver O O
over O O
a O O
period O O
of O O
time O O
. O O

CASE O O
REPORT O O
: O O
A O O
liver O O
transplant O O
recipient O O
, O O
who O O
had O O
previously O O
presented O O
with O O
tacrolimus B-Disease O
toxicity I-Disease B-Disease
on O O
his O O
usual O O
dosing O O
regimen O O
and O O
intolerant O O
to O O
standard O O
doses O O
of O O
cyclosporine O O
, O O
was O O
selected O O
to O O
undergo O O
the O O
study O O
. O O

Oral O O
and O O
intravenous O O
midazolam O O
was O O
used O O
as O O
the O O
probe O O
to O O
measure O O
hepatic O O
and O O
intestinal O O
CYP3A4 O O
activities O O
at O O
two O O
different O O
time O O
points O O
( O O
phases O O
one O O
and O O
two O O
) O O
. O O

Small O O
intestinal O O
biopsies O O
were O O
also O O
obtained O O
for O O
measuring O O
CYP3A4 O O
activity O O
for O O
in O O
vitro O O
studies O O
. O O

On O O
serially O O
determining O O
the O O
patient O O
's O O
hepatic O O
and O O
intestinal O O
CYP3A O O
activities O O
, O O
we O O
concluded O O
that O O
the O O
variability O O
in O O
the O O
dosing O O
requirements O O
is O O
due O O
to O O
altered O O
first O O
- O O
pass O O
effects O O
in O O
the O O
intestine O O
. O O

DISCUSSION O O
: O O
Transplant O O
recipients O O
receive O O
multiple O O
medications O O
that O O
may O O
inhibit O O
or O O
induce O O
these O O
metabolizing O O
enzymes O O
, O O
which O O
eventually O O
determine O O
the O O
concentrations O O
of O O
these O O
narrow O O
therapeutic O O
agents O O
. O O

If O O
no O O
obvious O O
etiology O O
of O O
intolerance O O
to O O
calcineurin O O
inhibitors O O
in O O
a O O
transplant O O
recipient O O
is O O
identified O O
, O O
one O O
should O O
consider O O
altered O O
first O O
- O O
pass O O
effects O O
in O O
the O O
gut O O
and O O
the O O
liver O O
contributing O O
to O O
intraindividual O O
variations O O
in O O
the O O
blood O O
concentrations O O
. O O

AIDS B-Disease B-Disease
- I-Disease I-Disease
related I-Disease I-Disease
malignancies I-Disease I-Disease
: O O
state O O
of O O
the O O
art O O
and O O
therapeutic O O
challenges O O
. O O

Despite O O
the O O
impact O O
of O O
combination O O
antiretroviral O O
therapy O O
( O O
cART O O
) O O
on O O
HIV O O
- O O
related O O
mortality O O
, O O
malignancy O B-Disease
remains O O
an O O
important O O
cause O O
of O O
death O O
in O O
the O O
current O O
era O O
. O O

Although O O
the O O
advent O O
of O O
cART O O
has O O
resulted O O
in O O
reductions O O
in O O
the O O
incidence O O
of O O
Kaposi B-Disease B-Disease
's I-Disease I-Disease
sarcoma I-Disease I-Disease
and O O
non B-Disease B-Disease
- I-Disease I-Disease
Hodgkin I-Disease I-Disease
's I-Disease I-Disease
lymphoma I-Disease I-Disease
, O O
non B-Disease B-Disease
- I-Disease I-Disease
AIDS I-Disease I-Disease
- I-Disease I-Disease
defining I-Disease I-Disease
malignancies I-Disease I-Disease
present O O
an O O
increased O O
risk O O
for O O
HIV O B-Disease
- O I-Disease
infected O I-Disease
patients O O
, O O
characterized O O
by O O
some O O
common O O
clinical O O
features O O
, O O
generally O O
with O O
a O O
more O O
aggressive B-Disease O
behavior I-Disease O
and O O
a O O
more O O
advanced O O
disease O O
at O O
diagnosis O O
, O O
which O O
is O O
responsible O O
for O O
poorer O O
patient O O
outcomes O O
. O O

Specific O O
therapeutic O O
recommendations O O
are O O
lacking O O
for O O
these O O
new O O
nonopportunistic O O
malignancies B-Disease B-Disease
, O O
such O O
as O O
Hodgkin B-Disease B-Disease
's I-Disease I-Disease
lymphoma I-Disease I-Disease
, O O
anal B-Disease B-Disease
cancer I-Disease I-Disease
, O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
, O O
hepatocarcinoma B-Disease B-Disease
, O O
and O O
many O O
others O O
. O O

Antiretroviral O O
agents O O
have O O
a O O
propensity O O
for O O
causing O O
drug O O
interactions O O
as O O
a O O
result O O
of O O
their O O
ability O O
to O O
either O O
inhibit O O
or O O
induce O O
the O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
enzyme O O
system O O
. O O

Because O O
many O O
antineoplastic O O
drugs O O
are O O
also O O
metabolized O O
by O O
the O O
CYP O O
system O O
, O O
coadministration O O
with O O
cART O O
could O O
result O O
in O O
either O O
drug O O
accumulation O O
with O O
increased O O
toxicity O O
, O O
or O O
decreased O O
efficacy O O
of O O
one O O
or O O
both O O
classes O O
of O O
drugs O O
. O O

Further O O
research O O
delineating O O
the O O
combined O O
safety O O
and O O
pharmacokinetics O O
of O O
antiretrovirals O O
and O O
antineoplastic O O
therapy O O
is O O
necessary O O
. O O

Special O O
considerations O O
of O O
these O O
AIDS O O
- O O
related O O
and O O
non B-Disease B-Disease
- I-Disease I-Disease
AIDS I-Disease I-Disease
- I-Disease I-Disease
related I-Disease I-Disease
malignancies I-Disease I-Disease
and O O
their O O
clinical O O
and O O
therapeutic O O
aspects O O
constitute O O
the O O
subject O O
of O O
this O O
review O O
. O O

Doxorubicin O O
, O O
cardiac O O
risk O O
factors O O
, O O
and O O
cardiac B-Disease B-Disease
toxicity I-Disease I-Disease
in O O
elderly O O
patients O O
with O O
diffuse O O
B B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
non I-Disease I-Disease
- I-Disease I-Disease
Hodgkin I-Disease I-Disease
's I-Disease I-Disease
lymphoma I-Disease I-Disease
. O O

PURPOSE O O
: O O
Anthracycline O O
- O O
based O O
chemotherapy O O
, O O
which O O
improves O O
survival O O
for O O
patients O O
with O O
non B-Disease B-Disease
- I-Disease I-Disease
Hodgkin I-Disease I-Disease
's I-Disease I-Disease
lymphoma I-Disease I-Disease
, O O
is O O
often O O
withheld O O
from O O
elderly O O
patients O O
because O O
of O O
its O O
cardiotoxicity B-Disease B-Disease
. O O

We O O
studied O O
the O O
cardiac O O
effects O O
of O O
doxorubicin O O
in O O
a O O
population O O
- O O
based O O
sample O O
of O O
older O O
patients O O
with O O
diffuse B-Disease B-Disease
large I-Disease I-Disease
B I-Disease I-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
lymphoma I-Disease I-Disease
( O O
DLBCL B-Disease B-Disease
) O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Among O O
patients O O
age O O
> O O
or O O
= O O
65 O O
years O O
diagnosed O O
with O O
DLBCL B-Disease B-Disease
from O O
1991 O O
to O O
2002 O O
in O O
the O O
Surveillance O O
, O O
Epidemiology O O
, O O
and O O
End O O
Results O O
- O O
Medicare O O
database O O
, O O
we O O
developed O O
logistic O O
regression O O
models O O
of O O
the O O
associations O O
of O O
doxorubicin O O
with O O
demographic O O
, O O
clinical O O
, O O
and O O
cardiac O O
variables O O
. O O

We O O
then O O
developed O O
Cox O O
proportional O O
hazards O O
models O O
of O O
the O O
association O O
between O O
doxorubicin O O
and O O
subsequent O O
congestive B-Disease B-Disease
heart I-Disease I-Disease
failure I-Disease I-Disease
( O O
CHF B-Disease B-Disease
) O O
, O O
taking O O
predictors O O
of O O
CHF B-Disease B-Disease
into O O
account O O
. O O

RESULTS O O
: O O
Of O O
9,438 O O
patients O O
with O O
DLBCL B-Disease B-Disease
, O O
3,164 O O
( O O
42 O O
% O O
) O O
received O O
doxorubicin O O
- O O
based O O
chemotherapy O O
. O O

Any O O
doxorubicin O O
use O O
was O O
associated O O
with O O
a O O
29 O O
% O O
increase O O
in O O
risk O O
of O O
CHF B-Disease B-Disease
( O O
95 O O
% O O
CI O O
, O O
1.02 O O
to O O
1.62 O O
) O O
; O O
CHF B-Disease B-Disease
risk O O
increased O O
with O O
number O O
of O O
doxorubicin O O
claims O O
, O O
increasing O O
age O O
, O O
prior B-Disease O
heart I-Disease B-Disease
disease I-Disease I-Disease
, O O
comorbidities O O
, O O
diabetes B-Disease B-Disease
, O O
and O O
hypertension B-Disease B-Disease
; O O
hypertension B-Disease B-Disease
intensified O O
the O O
effect O O
of O O
doxorubicin O O
on O O
risk O O
of O O
CHF B-Disease B-Disease
( O O
hazard O O
ratio O O
= O O
1.8 O O
; O O
P O O
< O O
.01 O O
) O O
. O O

In O O
the O O
8 O O
years O O
after O O
diagnosis O O
, O O
the O O
adjusted O O
CHF O B-Disease
- O O
free O O
survival O O
rate O O
was O O
74 O O
% O O
in O O
doxorubicin O O
- O O
treated O O
patients O O
versus O O
79 O O
% O O
in O O
patients O O
not O O
treated O O
with O O
doxorubicin O O
. O O

CONCLUSION O O
: O O
Among O O
patients O O
receiving O O
chemotherapy O O
for O O
DLBCL B-Disease B-Disease
, O O
those O O
with O O
prior B-Disease O
heart I-Disease B-Disease
disease I-Disease I-Disease
were O O
less O O
likely O O
than O O
others O O
to O O
be O O
treated O O
with O O
doxorubicin O O
, O O
and O O
those O O
who O O
received O O
doxorubicin O O
were O O
more O O
likely O O
than O O
others O O
to O O
develop O O
CHF B-Disease B-Disease
. O O

Various O O
cardiac O O
risk O O
factors O O
increased O O
CHF B-Disease B-Disease
risk O O
, O O
but O O
only O O
hypertension B-Disease B-Disease
was O O
synergistic O O
with O O
doxorubicin O O
. O O

Doxorubicin O O
has O O
dramatically O O
improved O O
survival O O
of O O
DLBCL B-Disease B-Disease
patients O O
; O O
nonetheless O O
, O O
some O O
subgroups O O
may O O
benefit O O
from O O
efforts O O
to O O
reduce O O
doxorubicin O O
- O O
related O O
CHF B-Disease B-Disease
risk O O
. O O

A O O
high O O
throughput O O
in O O
vitro O O
analytical O O
approach O O
to O O
screen O O
for O O
oxidative O O
stress O O
potential O O
exerted O O
by O O
nanomaterials O O
using O O
a O O
biologically O O
relevant O O
matrix O O
: O O
human O O
blood O O
serum O O
. O O

Limited O O
studies O O
have O O
shown O O
that O O
selected O O
nanomaterials O O
( O O
NMs O O
) O O
impart O O
various O O
forms O O
of O O
toxicity O O
in O O
biological O O
systems O O
; O O
however O O
, O O
a O O
common O O
metric O O
to O O
screen O O
for O O
potential O O
toxicity O O
is O O
needed O O
. O O

This O O
study O O
optimized O O
and O O
utilized O O
a O O
' O O
Ferric O O
reducing O O
ability O O
of O O
serum O O
( O O
FRAS O O
) O O
' O O
assay O O
as O O
a O O
screening O O
tool O O
to O O
quantitate O O
the O O
degree O O
of O O
oxidative O O
damage O O
induced O O
by O O
NMs O O
on O O
human O O
blood O O
serum O O
. O O

Antioxidants O O
in O O
blood O O
protect O O
against O O
oxidative O O
damage O O
caused O O
by O O
free O O
radicals O O
via O O
chemical O O
quenching O O
and O O
will O O
decrease O O
when O O
exposed O O
to O O
oxidatively O O
stressful O O
materials O O
. O O

Using O O
this O O
approach O O
, O O
the O O
antioxidant O O
capacity O O
of O O
NM O O
treated O O
serum O O
was O O
significantly O O
decreased O O
by O O
nano O O
- O O
silver O O
, O O
a O O
series O O
of O O
nano O O
- O O
carbon O O
blacks O O
, O O
fullerene O O
soot O O
, O O
and O O
nano O O
- O O
TiO O O
( O O
2 O O
) O O
( O O
anatase O O
, O O
p O O
< O O
0.05 O O
) O O
, O O
but O O
not O O
with O O
nano O O
- O O
alumina O O
, O O
fullerite O O
, O O
purified O O
fullerene O O
, O O
fine O O
TiO O O
( O O
2 O O
) O O
( O O
rutile O O
) O O
and O O
Min O O
- O O
U O O
- O O
Sil O O
5 O O
. O O

Particle O O
surface O O
area O O
and O O
not O O
biological O O
particle O O
size O O
was O O
highly O O
associated O O
with O O
the O O
degree O O
of O O
oxidative O O
stress O O
observed O O
. O O

This O O
approach O O
appears O O
responsive O O
to O O
multiple O O
determinants O O
of O O
oxidative O O
damage O O
, O O
including O O
particle O O
chemistry O O
, O O
surface O O
area O O
and O O
impurities O O
, O O
and O O
may O O
be O O
a O O
valid O O
screening O O
method O O
to O O
determine O O
oxidative O O
damage O O
imparted O O
by O O
nanomaterials O O
. O O

Efficacy O O
and O O
safety O O
of O O
two O O
doses O O
of O O
pemetrexed O O
supplemented O O
with O O
folic O O
acid O O
and O O
vitamin O O
B12 O O
in O O
previously O O
treated O O
patients O O
with O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
. O O

PURPOSE O O
: O O
The O O
objective O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
two O O
doses O O
of O O
pemetrexed O O
supplemented O O
with O O
folic O O
acid O O
and O O
vitamin O O
B O O
( O O
12 O O
) O O
in O O
pretreated O O
Japanese O O
patients O O
with O O
advanced O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
( O O
NSCLC B-Disease B-Disease
) O O
. O O

EXPERIMENTAL O O
DESIGN O O
: O O
Patients O O
with O O
an O O
Eastern O O
Cooperative O O
Oncology O O
Group O O
performance O O
status O O
0 O O
to O O
2 O O
, O O
stage O O
III O O
or O O
IV O O
, O O
and O O
who O O
received O O
previously O O
one O O
or O O
two O O
chemotherapy O O
regimens O O
were O O
randomized O O
to O O
receive O O
500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
pemetrexed O O
( O O
P500 O O
) O O
or O O
1,000 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
pemetrexed O O
( O O
P1000 O O
) O O
on O O
day O O
1 O O
every O O
3 O O
weeks O O
. O O

The O O
primary O O
endpoint O O
was O O
response O O
rate O O
. O O

RESULTS O O
: O O
Of O O
the O O
216 O O
patients O O
evaluable O O
for O O
efficacy O O
( O O
108 O O
in O O
each O O
arm O O
) O O
, O O
response O O
rates O O
were O O
18.5 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
, O O
12.6 O O
- O O
25.8 O O
% O O
) O O
and O O
14.8 O O
% O O
( O O
90 O O
% O O
confidence O O
interval O O
, O O
9.5 O O
- O O
21.6 O O
% O O
) O O
, O O
median O O
survival O O
times O O
were O O
16.0 O O
and O O
12.6 O O
months O O
, O O
1 O O
- O O
year O O
survival O O
rates O O
were O O
59.2 O O
% O O
and O O
53.7 O O
% O O
, O O
and O O
median O O
progression O O
- O O
free O O
survival O O
were O O
3.0 O O
and O O
2.5 O O
months O O
for O O
the O O
P500 O O
and O O
P1000 O O
, O O
respectively O O
. O O

Cox O O
multiple O O
regression O O
analysis O O
indicated O O
that O O
pemetrexed O O
dose O O
was O O
not O O
a O O
significant O O
prognostic O O
factor O O
. O O

Drug B-Disease B-Disease
- I-Disease I-Disease
related I-Disease I-Disease
toxicity I-Disease I-Disease
was O O
generally O O
tolerable O O
for O O
both O O
doses O O
; O O
however O O
, O O
the O O
safety O O
profile O O
of O O
P500 O O
showed O O
generally O O
milder O O
toxicity O O
. O O

Main O O
adverse O O
drug O O
reactions O O
of O O
severity O O
grade O O
3 O O
or O O
4 O O
were O O
neutrophil B-Disease O
count I-Disease O
decreased I-Disease O
( O O
20.2 O O
% O O
) O O
and O O
alanine B-Disease O
aminotransferase I-Disease O
( I-Disease O
glutamine I-Disease O
pyruvic I-Disease O
transaminase I-Disease O
) I-Disease O
increased I-Disease O
( O O
15.8 O O
% O O
) O O
in O O
P500 O O
and O O
neutrophil B-Disease O
count I-Disease O
decreased I-Disease O
( O O
24.3 O O
% O O
) O O
, O O
WBC B-Disease O
count I-Disease O
decreased I-Disease O
( O O
20.7 O O
% O O
) O O
, O O
and O O
lymphocyte B-Disease O
count I-Disease O
decreased I-Disease O
( O O
18.0 O O
% O O
) O O
in O O
P1000 O O
. O O

One O O
drug O O
- O O
related O O
death O O
from O O
interstitial B-Disease B-Disease
lung I-Disease I-Disease
disease I-Disease I-Disease
occurred O O
in O O
the O O
P500 O O
. O O

CONCLUSION O O
: O O
P500 O O
and O O
P1000 O O
are O O
similarly O O
active O O
with O O
promising O O
efficacy O O
and O O
acceptable O O
safety O O
outcomes O O
in O O
pretreated O O
patients O O
with O O
NSCLC B-Disease B-Disease
. O O

These O O
results O O
support O O
the O O
use O O
of O O
P500 O O
as O O
a O O
second O O
- O O
and O O
third O O
- O O
line O O
treatment O O
of O O
NSCLC B-Disease B-Disease
. O O

Pharmacogenetics O O
of O O
analgesics O O
: O O
toward O O
the O O
individualization O O
of O O
prescription O O
. O O

The O O
use O O
of O O
analgesics O O
is O O
based O O
on O O
the O O
empiric O O
administration O O
of O O
a O O
given O O
drug O O
with O O
clinical O O
monitoring O O
for O O
efficacy O O
and O O
toxicity O O
. O O

However O O
, O O
individual O O
responses O O
to O O
drugs O O
are O O
influenced O O
by O O
a O O
combination O O
of O O
pharmacokinetic O O
and O O
pharmacodynamic O O
factors O O
that O O
can O O
sometimes O O
be O O
regulated O O
by O O
genetic O O
factors O O
. O O

Whereas O O
polymorphic O O
drug O O
- O O
metabolizing O O
enzymes O O
and O O
drug O O
transporters O O
may O O
affect O O
the O O
pharmacokinetics O O
of O O
drugs O O
, O O
polymorphic O O
drug O O
targets O O
and O O
disease O O
- O O
related O O
pathways O O
may O O
influence O O
the O O
pharmacodynamic O O
action O O
of O O
drugs O O
. O O

After O O
a O O
usual O O
dose O O
, O O
variations O O
in O O
drug B-Disease B-Disease
toxicity I-Disease I-Disease
and O O
inefficacy O O
can O O
be O O
observed O O
depending O O
on O O
the O O
polymorphism O O
, O O
the O O
analgesic O O
considered O O
and O O
the O O
presence O O
or O O
absence O O
of O O
active O O
metabolites O O
. O O

For O O
opioids O O
, O O
the O O
most O O
studied O O
being O O
morphine O O
, O O
mutations O O
in O O
the O O
ABCB1 O O
gene O O
, O O
coding O O
for O O
P O O
- O O
glycoprotein O O
( O O
P O O
- O O
gp O O
) O O
, O O
and O O
in O O
the O O
micro O O
- O O
opioid O O
receptor O O
reduce O O
morphine O O
potency O O
. O O

Cytochrome O O
P450 O O
( O O
CYP O O
) O O
2D6 O O
mutations O O
influence O O
the O O
analgesic O O
effect O O
of O O
codeine O O
and O O
tramadol O O
, O O
and O O
polymorphism O O
of O O
CYP2C9 O O
is O O
potentially O O
linked O O
to O O
an O O
increase O O
in O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
- O O
induced O O
adverse O O
events O O
. O O

Furthermore O O
, O O
drug O O
interactions O O
can O O
mimic O O
genetic O B-Disease
deficiency O I-Disease
and O O
contribute O O
to O O
the O O
variability O O
in O O
response O O
to O O
analgesics O O
. O O

This O O
review O O
summarizes O O
the O O
available O O
data O O
on O O
the O O
pharmacokinetic O O
and O O
pharmacodynamic O O
consequences O O
of O O
known O O
polymorphisms O O
of O O
drug O O
- O O
metabolizing O O
enzymes O O
, O O
drug O O
transporters O O
, O O
drug O O
targets O O
and O O
other O O
nonopioid O O
biological O O
systems O O
on O O
central O O
and O O
peripheral O O
analgesics O O
. O O

Effect O O
of O O
repeated O O
doses O O
of O O
darunavir O O
plus O O
low O O
- O O
dose O O
ritonavir O O
on O O
the O O
pharmacokinetics O O
of O O
sildenafil O O
in O O
healthy O O
male O O
subjects O O
: O O
phase O O
I O O
randomized O O
, O O
open O O
- O O
label O O
, O O
two O O
- O O
way O O
crossover O O
study O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
Darunavir O O
( O O
DRV O O
, O O
TMC114 O O
) O O
is O O
a O O
novel O O
protease O O
inhibitor O O
administered O O
in O O
combination O O
with O O
low O O
- O O
dose O O
ritonavir O O
( O O
DRV O O
/ O O
r O O
) O O
and O O
is O O
highly O O
active O O
against O O
both O O
wild O O
- O O
type O O
and O O
multidrug O O
- O O
resistant O O
HIV O O
- O O
1 O O
strains O O
. O O

Sildenafil O O
is O O
an O O
oral O O
therapy O O
for O O
erectile B-Disease B-Disease
dysfunction I-Disease I-Disease
. O O

Concomitant O O
administration O O
of O O
protease O O
inhibitors O O
and O O
sildenafil O O
increases O O
sildenafil O O
plasma O O
concentrations O O
. O O

The O O
potential O O
for O O
a O O
pharmacokinetic O O
drug O O
interaction O O
exists O O
when O O
sildenafil O O
and O O
DRV O O
/ O O
r O O
are O O
co O O
- O O
administered O O
, O O
as O O
these O O
drugs O O
are O O
primarily O O
metabolized O O
by O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
3A O O
, O O
and O O
darunavir O O
and O O
ritonavir O O
are O O
CYP3A O O
inhibitors O O
. O O

The O O
primary O O
objective O O
of O O
this O O
open O O
- O O
label O O
, O O
crossover O O
, O O
phase O O
I O O
study O O
was O O
to O O
assess O O
the O O
effect O O
of O O
multiple O O
doses O O
of O O
DRV O O
/ O O
r O O
on O O
the O O
pharmacokinetics O O
of O O
sildenafil O O
and O O
its O O
active O O
metabolite O O
N O O
- O O
desmethyl O O
sildenafil O O
. O O

The O O
secondary O O
objective O O
was O O
to O O
assess O O
the O O
short O O
- O O
term O O
safety O O
and O O
tolerability O O
of O O
co O O
- O O
administration O O
of O O
sildenafil O O
and O O
DRV O O
/ O O
r O O
. O O

METHODS O O
: O O
Sixteen O O
HIV O O
- O O
negative O O
healthy O O
male O O
subjects O O
were O O
randomized O O
to O O
one O O
of O O
two O O
sequences O O
. O O

In O O
two O O
sessions O O
each O O
subject O O
received O O
treatments O O
A O O
and O O
B O O
. O O

In O O
treatment O O
A O O
, O O
a O O
single O O
dose O O
of O O
sildenafil O O
100 O O
mg O O
was O O
administered O O
. O O

In O O
treatment O O
B O O
, O O
the O O
subjects O O
received O O
DRV O O
/ O O
r O O
400 O O
/ O O
100 O O
mg O O
twice O O
daily O O
for O O
8 O O
days O O
and O O
on O O
day O O
7 O O
a O O
single O O
dose O O
of O O
sildenafil O O
25 O O
mg O O
was O O
co O O
- O O
administered O O
. O O

Full O O
pharmacokinetic O O
profiles O O
of O O
sildenafil O O
, O O
N O O
- O O
desmethyl O O
sildenafil O O
, O O
darunavir O O
and O O
ritonavir O O
were O O
determined O O
. O O

Safety O O
and O O
tolerability O O
were O O
also O O
assessed O O
. O O

RESULTS O O
: O O
Sildenafil O O
exposure O O
( O O
area O O
under O O
the O O
plasma O O
concentration O O
- O O
time O O
curve O O
[ O O
AUC O O
] O O
) O O
was O O
comparable O O
between O O
the O O
two O O
treatments O O
despite O O
administration O O
of O O
a O O
lower O O
dose O O
of O O
sildenafil O O
( O O
25 O O
mg O O
) O O
with O O
DRV O O
/ O O
r O O
than O O
when O O
sildenafil O O
( O O
100 O O
mg O O
) O O
was O O
administered O O
alone O O
. O O

When O O
sildenafil O O
25 O O
mg O O
was O O
co O O
- O O
administered O O
with O O
DRV O O
/ O O
r O O
, O O
the O O
sildenafil O O
maximum O O
plasma O O
concentration O O
( O O
Cmax O O
) O O
was O O
38 O O
% O O
lower O O
compared O O
with O O
Cmax O O
after O O
administration O O
of O O
sildenafil O O
alone O O
at O O
a O O
dose O O
of O O
100 O O
mg O O
. O O

N O O
- O O
desmethyl O O
sildenafil O O
Cmax O O
and O O
AUC O O
from O O
the O O
time O O
of O O
administration O O
until O O
the O O
last O O
time O O
point O O
with O O
a O O
measurable O O
concentration O O
after O O
dosing O O
( O O
calculated O O
by O O
linear O O
trapezoidal O O
summation O O
[ O O
AUClast O O
] O O
) O O
values O O
decreased O O
by O O
approximately O O
95 O O
% O O
when O O
sildenafil O O
25 O O
mg O O
was O O
co O O
- O O
administered O O
with O O
DRV O O
/ O O
r O O
compared O O
with O O
sildenafil O O
100 O O
mg O O
alone O O
. O O

Combined O O
treatment O O
with O O
DRV O O
/ O O
r O O
and O O
sildenafil O O
was O O
generally O O
safe O O
and O O
well O O
tolerated O O
. O O

CONCLUSION O O
: O O
Sildenafil O O
exposure O O
is O O
increased O O
in O O
the O O
presence O O
of O O
DRV O O
/ O O
r O O
. O O

In O O
this O O
setting O O
, O O
a O O
dose O O
adjustment O O
for O O
sildenafil O O
is O O
warranted O O
; O O
no O O
more O O
than O O
25 O O
mg O O
of O O
sildenafil O O
is O O
recommended O O
over O O
a O O
48 O O
- O O
hour O O
period O O
when O O
co O O
- O O
administered O O
with O O
DRV O O
/ O O
r O O
. O O

Paternal O O
exposure O O
and O O
counselling O O
: O O
experience O O
of O O
a O O
Teratology O O
Information O O
Service O O
. O O

We O O
describe O O
paternal O O
exposure O O
and O O
counselling O O
in O O
a O O
selected O O
population O O
calling O O
to O O
an O O
Italian O O
Teratology O O
Information O O
Service O O
( O O
TIS O O
) O O
. O O

The O O
majority O O
of O O
callers O O
asked O O
for O O
paternal O O
drug O O
exposure O O
( O O
76 O O
% O O
, O O
drugs O O
except O O
chemotherapy O O
) O O
and O O
treatment O O
for O O
cancer B-Disease B-Disease
( O O
17 O O
% O O
, O O
chemotherapy O O
and O O
/ O O
or O O
radiotherapy O O
) O O
. O O

Others O O
asked O O
for O O
exposure O O
to O O
diagnostic O O
radiations O O
( O O
4 O O
% O O
) O O
, O O
recreational O O
drugs O O
( O O
2 O O
% O O
) O O
and O O
occupational O O
chemicals O O
( O O
1 O O
% O O
) O O
. O O

Among O O
paternal O O
drugs O O
neurological O O
compounds O O
, O O
immunosuppressive O O
drugs O O
and O O
antiviral O O
agents O O
were O O
the O O
main O O
reasons O O
for O O
calling O O
. O O

In O O
humans O O
, O O
there O O
are O O
no O O
evidences O O
of O O
birth B-Disease B-Disease
defects I-Disease I-Disease
after O O
paternal O O
exposures O O
, O O
but O O
to O O
minimize O O
any O O
possible O O
risk O O
, O O
counselling O O
in O O
men O O
exposed O O
to O O
radio O O
and O O
chemotherapy O O
should O O
recommend O O
delaying O O
conception O O
for O O
at O O
least O O
3 O O
months O O
after O O
the O O
end O O
of O O
the O O
therapy O O
. O O

Male O O
patients O O
treated O O
with O O
drugs O O
, O O
whose O O
teratogenic O O
potential O O
has O O
been O O
well O O
assessed O O
or O O
suspected O O
for O O
maternal O O
exposure O O
, O O
should O O
be O O
advised O O
to O O
practice O O
effective O O
birth O O
control O O
during O O
therapy O O
and O O
up O O
to O O
one O O
or O O
two O O
cycles O O
of O O
spermatogenesis O O
and O O
to O O
avoid O O
semen O O
contact O O
with O O
vaginal O O
walls O O
during O O
first O O
trimester O O
of O O
pregnancy O O
. O O

A O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
crossover O O
study O O
of O O
once O O
- O O
daily O O
dexmethylphenidate O O
in O O
children O O
with O O
attention B-Disease B-Disease
- I-Disease I-Disease
deficit I-Disease I-Disease
hyperactivity I-Disease I-Disease
disorder I-Disease I-Disease
: O O
rapid O O
onset O O
of O O
effect O O
. O O

BACKGROUND O O
: O O
Long O O
- O O
acting O O
methylphenidate O O
formulations O O
provide O O
control O O
of O O
attention B-Disease B-Disease
- I-Disease I-Disease
deficit I-Disease I-Disease
hyperactivity I-Disease I-Disease
disorder I-Disease I-Disease
( O O
ADHD B-Disease B-Disease
) O O
symptoms O O
for O O
up O O
to O O
12 O O
hours O O
; O O
however O O
, O O
not O O
all O O
formulations O O
have O O
rapid O O
onset O O
of O O
therapeutic O O
effect O O
, O O
which O O
is O O
essential O O
for O O
providing O O
symptom O O
control O O
during O O
morning O O
hours O O
. O O

The O O
primary O O
objective O O
of O O
this O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
crossover O O
study O O
was O O
to O O
assess O O
the O O
efficacy O O
of O O
dexmethylphenidate O O
extended O O
release O O
( O O
ER O O
) O O
versus O O
placebo O O
by O O
measuring O O
the O O
change O O
from O O
pre O O
- O O
dose O O
to O O
0.5 O O
hours O O
post O O
- O O
dose O O
on O O
the O O
Swanson O O
, O O
Kotkin O O
, O O
Agler O O
, O O
M O O
- O O
Flynn O O
and O O
Pelham O O
( O O
SKAMP O O
) O O
rating O O
scale O O
. O O

METHODS O O
: O O
Eighty O O
- O O
six O O
children O O
( O O
6 O O
- O O
12 O O
years O O
) O O
with O O
ADHD B-Disease B-Disease
diagnosed O O
using O O
the O O
DSM O O
- O O
IV O O
criteria O O
were O O
randomized O O
to O O
receive O O
dexmethylphenidate O O
ER O O
20 O O
mg O O
/ O O
day O O
or O O
placebo O O
, O O
sequentially O O
, O O
for O O
7 O O
days O O
, O O
with O O
the O O
final O O
dose O O
administered O O
in O O
a O O
laboratory O O
classroom O O
setting O O
on O O
day O O
7 O O
of O O
each O O
treatment O O
period O O
. O O

The O O
primary O O
efficacy O O
comparison O O
was O O
change O O
in O O
the O O
SKAMP O O
- O O
Combined O O
score O O
from O O
pre O O
- O O
dose O O
to O O
0.5 O O
hours O O
post O O
- O O
dose O O
, O O
with O O
additional O O
secondary O O
assessments O O
at O O
1 O O
, O O
2 O O
, O O
4 O O
, O O
6 O O
and O O
8 O O
hours O O
post O O
- O O
dose O O
. O O

Secondary O O
efficacy O O
measures O O
included O O
change O O
from O O
pre O O
- O O
dose O O
at O O
all O O
timepoints O O
in O O
the O O
SKAMP O O
- O O
Attention O O
and O O
SKAMP O O
- O O
Deportment O O
, O O
Math O O
Test O O
- O O
Attempted O O
and O O
Math O O
Test O O
- O O
Correct O O
scores O O
, O O
and O O
change O O
from O O
baseline O O
on O O
the O O
Conners O O
' O O
ADHD B-Disease B-Disease
/ O O
DSM O O
- O O
IV O O
Scale O O
for O O
Parents O O
( O O
CADS O O
- O O
P O O
) O O
. O O

In O O
an O O
exploratory O O
analysis O O
, O O
a O O
daily O O
diary O O
card O O
was O O
completed O O
by O O
parents O O
on O O
the O O
children O O
's O O
in O O
- O O
home O O
behaviour O O
before O O
school O O
. O O

Safety O O
was O O
assessed O O
by O O
occurrence O O
of O O
adverse O O
events O O
, O O
monitoring O O
of O O
vital O O
signs O O
and O O
interpretation O O
of O O
ECGs O O
. O O

RESULTS O O
: O O
Significant O O
improvements O O
were O O
noted O O
at O O
0.5 O O
hours O O
and O O
at O O
all O O
timepoints O O
post O O
- O O
dose O O
throughout O O
the O O
8 O O
- O O
hour O O
laboratory O O
classroom O O
day O O
for O O
dexmethylphenidate O O
ER O O
vs O O
placebo O O
in O O
the O O
primary O O
outcome O O
measure O O
of O O
the O O
SKAMP O O
- O O
Combined O O
scores O O
( O O
p O O
< O O
0.001 O O
) O O
, O O
as O O
well O O
as O O
SKAMP O O
- O O
Attention O O
, O O
SKAMP O O
- O O
Deportment O O
, O O
Math O O
Test O O
- O O
Attempted O O
and O O
Math O O
Test O O
- O O
Correct O O
scores O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

The O O
changes O O
from O O
baseline O O
in O O
CADS O O
- O O
P O O
scores O O
were O O
significantly O O
greater O O
with O O
dexmethylphenidate O O
ER O O
than O O
placebo O O
( O O
- O O
16.382 O O
vs O O
- O O
4.622 O O
; O O
p O O
< O O
0.001 O O
) O O
. O O

Responses O O
to O O
all O O
diary O O
questions O O
indicated O O
significant O O
improvement O O
with O O
dexmethylphenidate O O
ER O O
treatment O O
versus O O
placebo O O
( O O
all O O
p O O
< O O
0.001 O O
) O O
. O O

The O O
most O O
common O O
adverse O O
events O O
were O O
abdominal B-Disease B-Disease
pain I-Disease I-Disease
( O O
dexmethylphenidate O O
ER O O
3.5 O O
% O O
; O O
placebo O O
4.7 O O
% O O
) O O
, O O
headache B-Disease B-Disease
( O O
dexmethylphenidate O O
ER O O
3.5 O O
% O O
; O O
placebo O O
2.3 O O
% O O
) O O
and O O
increased B-Disease B-Disease
appetite I-Disease I-Disease
( O O
dexmethylphenidate O O
ER O O
0 O O
% O O
; O O
placebo O O
3.5 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
Compared O O
with O O
placebo O O
, O O
once O O
- O O
daily O O
dexmethylphenidate O O
ER O O
20 O O
mg O O
provided O O
rapid O O
and O O
significant O O
improvement O O
at O O
0.5 O O
hours O O
post O O
- O O
dose O O
in O O
attention O O
, O O
deportment O O
and O O
academic O O
performance O O
, O O
which O O
was O O
sustained O O
for O O
8 O O
hours O O
post O O
- O O
dose O O
. O O

Overall O O
, O O
once O O
- O O
daily O O
dexmethylphenidate O O
ER O O
20 O O
mg O O
was O O
well O O
tolerated O O
. O O

In O O
an O O
analysis O O
of O O
parental O O
assessment O O
of O O
diary O O
responses O O
, O O
children O O
appeared O O
more O O
organized O O
, O O
and O O
morning O O
preparation O O
for O O
school O O
was O O
smoother O O
and O O
less O O
frustrating O O
with O O
once O O
- O O
daily O O
dexmethylphenidate O O
ER O O
compared O O
with O O
placebo O O
. O O

Clostridium O O
perfringens O O
enterotoxin O O
in O O
antibiotic B-Disease O
- I-Disease O
associated I-Disease O
diarrhea I-Disease B-Disease
. O O

Clostridium O O
perfringens O O
type O O
A O O
is O O
associated O O
with O O
5 O O
- O O
20 O O
% O O
cases O O
of O O
antibiotic B-Disease O
- I-Disease O
associated I-Disease O
diarrhea I-Disease B-Disease
( O O
AAD O B-Disease
) O O
even O O
though O O
Clostridium O O
difficile O O
is O O
implicated O O
in O O
the O O
most O O
severe O O
cases O O
. O O

Fecal O O
specimens O O
from O O
one O O
hundred O O
hospitalized O O
patients O O
, O O
who O O
developed O O
diarrhea B-Disease B-Disease
regardless O O
of O O
antibiotic O O
intake O O
and O O
who O O
were O O
negative O O
for O O
C O O
. O O

difficile O O
toxin O O
assay O O
, O O
were O O
investigated O O
for O O
C O O
. O O

perfringens O O
enterotoxin O O
( O O
CPE O O
) O O
. O O

Simultaneously O O
, O O
cultures O O
were O O
set O O
up O O
for O O
other O O
possible O O
aetiological O O
factors O O
. O O

Ten B-Disease O
healthy O O
controls O O
were O O
also O O
similarly O O
investigated O O
. O O

CPE O O
was O O
positive O O
in O O
2 O O
/ O O
100 O O
( O O
2 O O
% O O
) O O
of O O
the O O
patients O O
and O O
the O O
samples O O
were O O
also O O
positive O O
for O O
the O O
organism O O
in O O
culture O O
. O O

Other O O
organisms O O
isolated O O
were O O
non O O
- O O
toxigenic O O
C O O
. O O

difficile O O
( O O
4 O O
% O O
) O O
, O O
staphylococci O O
( O O
6 O O
% O O
) O O
, O O
Candida O O
( O O
18 O O
% O O
) O O
and O O
Klebsiella O O
pneumoniae O O
( O O
1 O O
% O O
) O O
. O O

Stool O O
samples O O
from O O
healthy O O
controls O O
grew O O
mixed O O
growth O O
of O O
no O O
significance O O
and O O
CPE O O
was O O
negative O O
in O O
all O O
of O O
them O O
. O O

Detection O O
of O O
CPE O O
is O O
not O O
part O O
of O O
routine O O
laboratory O O
investigation O O
due O O
to O O
resource O O
implication O O
. O O

Criteria O O
for O O
initiating O O
investigations O O
have O O
to O O
be O O
therefore O O
established O O
by O O
understanding O O
the O O
true O O
burden O O
of O O
C O O
. O O

perfringens O O
- O O
associated O O
AAD O B-Disease
by O O
further O O
research O O
. O O

Should O O
we O O
abandon O O
corticosteroids O O
during O O
septic B-Disease B-Disease
shock I-Disease I-Disease
? O O

No O O
. O O

PURPOSE O O
OF O O
REVIEW O O
: O O
With O O
the O O
publication O O
of O O
the O O
results O O
of O O
the O O
recent O O
CORTICUS O O
trial O O
, O O
stress O O
( O O
' O O
low O O
' O O
) O O
doses O O
of O O
corticosteroids O O
for O O
the O O
treatment O O
of O O
vasopressor O O
- O O
dependent O O
septic B-Disease B-Disease
shock I-Disease I-Disease
in O O
adults O O
can O O
still O O
be O O
considered O O
controversial O O
. O O

The O O
purpose O O
of O O
this O O
narrative O O
review O O
is O O
to O O
elaborate O O
the O O
pros O O
and O O
cons O O
of O O
this O O
treatment O O
in O O
clinical O O
practice O O
and O O
to O O
formulate O O
clinical O O
and O O
research O O
directions O O
. O O

RECENT O O
FINDINGS O O
: O O
The O O
recent O O
CORTICUS O O
study O O
only O O
shows O O
a O O
beneficial O O
effect O O
of O O
stress O O
doses O O
of O O
corticosteroids O O
in O O
the O O
time O O
interval O O
to O O
shock O B-Disease
reversal O O
and O O
not O O
on O O
mortality O O
, O O
potentially O O
explained O O
by O O
an O O
increased O O
risk O O
for O O
superinfection B-Disease B-Disease
. O O

The O O
mortality O O
in O O
the O O
placebo O O
arm O O
was O O
relatively O O
low O O
and O O
lower O O
than O O
in O O
earlier O O
randomized O O
studies O O
in O O
which O O
stress O O
doses O O
of O O
corticosteroids O O
had O O
a O O
favorable O O
hemodynamic O O
effect O O
and O O
conferred O O
a O O
survival O O
benefit O O
in O O
septic B-Disease B-Disease
shock I-Disease I-Disease
. O O

SUMMARY O O
: O O
Treatment O O
by O O
stress O O
doses O O
of O O
corticosteroids O O
should O O
not O O
be O O
abandoned O O
during O O
septic B-Disease B-Disease
shock I-Disease I-Disease
. O O

Additional O O
studies O O
are O O
needed O O
, O O
however O O
, O O
to O O
better O O
delineate O O
the O O
patient O O
group O O
with O O
the O O
highest O O
likelihood O O
to O O
benefit O O
from O O
this O O
therapy O O
, O O
as O O
a O O
function O O
of O O
severity O O
of O O
illness O O
, O O
response O O
to O O
adrenocorticotrophic O O
hormone O O
testing O O
or O O
both O O
. O O

For O O
now O O
, O O
results O O
of O O
the O O
CORTICUS O O
study O O
should O O
not O O
change O O
current O O
clinical O O
practice O O
of O O
administering O O
200 O O
- O O
300 O O
mg O O
of O O
hydrocortisone O O
daily O O
( O O
in O O
divided O O
doses O O
) O O
in O O
case O O
of O O
fluid O O
and O O
vasopressor O O
- O O
insensitive O O
septic B-Disease B-Disease
shock I-Disease I-Disease
and O O
rapid O O
tapering O O
of O O
this O O
treatment O O
on O O
the O O
basis O O
of O O
a O O
hemodynamic O O
response O O
. O O

Inhibition O O
of O O
cell O O
- O O
cycle O O
progression O O
in O O
human O O
colorectal O O
carcinoma O O
Lovo O O
cells O O
by O O
andrographolide O O
. O O

In O O
recent O O
years O O
, O O
attention O O
has O O
been O O
focused O O
on O O
the O O
anti O O
- O O
cancer O O
properties O O
of O O
pure O O
components O O
, O O
an O O
important O O
role O O
in O O
the O O
prevention O O
of O O
disease O O
. O O

Andrographolide O O
( O O
Andro O O
) O O
, O O
the O O
major O O
constituent O O
of O O
Andrographis O O
paniculata O O
( O O
Burm O O
. O O
F O O
. O O
) O O

Nees O O
plant O O
, O O
is O O
implicated O O
towards O O
its O O
pharmacological O O
activity O O
. O O

To O O
investigate O O
the O O
mechanism O O
basis O O
for O O
the O O
anti O O
- O O
tumor O O
properties O O
of O O
Andro O O
, O O
Andro O O
was O O
used O O
to O O
examine O O
its O O
effect O O
on O O
cell O O
- O O
cycle O O
progression O O
in O O
human O O
colorectal O O
carcinoma O O
Lovo O O
cells O O
. O O

The O O
data O O
from O O
cell O O
growth O O
experiment O O
showed O O
that O O
Andro O O
exhibited O O
the O O
anti O O
- O O
proliferation O O
effect O O
on O O
Lovo O O
cells O O
in O O
a O O
time O O
- O O
and O O
dose O O
- O O
dependent O O
manner O O
. O O

This O O
event O O
was O O
accompanied O O
the O O
arrest O O
of O O
the O O
cells O O
at O O
the O O
G1 O O
- O O
S O O
phase O O
by O O
Andro O O
at O O
the O O
tested O O
concentrations O O
of O O
0 O O
- O O
30 O O
microM O O
. O O

Cellular O O
uptake O O
of O O
Andro O O
and O O
Andro O O
was O O
confirmed O O
by O O
capillary O O
electrophoresis O O
analysis O O
and O O
the O O
intracellular O O
accumulation O O
of O O
Andro O O
( O O
0.61 O O
+ O O
/ O O
- O O
0.07 O O
microM O O
/ O O
mg O O
protein O O
) O O
was O O
observed O O
when O O
treatment O O
of O O
Lovo O O
cells O O
with O O
Andro O O
for O O
12h O O
. O O

In O O
addition O O
, O O
an O O
accumulation O O
of O O
the O O
cells O O
in O O
G1 O O
phase O O
( O O
15 O O
% O O
increase O O
for O O
10 O O
microM O O
of O O
Andro O O
) O O
was O O
observed O O
as O O
well O O
as O O
by O O
the O O
association O O
with O O
a O O
marked O O
decrease O O
in O O
the O O
protein O O
expression O O
of O O
Cyclin O O
A O O
, O O
Cyclin O O
D1 O O
, O O
Cdk2 O O
and O O
Cdk4 O O
. O O

Andro O O
also O O
inducted O O
the O O
content O O
of O O
Cdk O O
inhibitor O O
p21 O O
and O O
p16 O O
, O O
and O O
the O O
phosphorylation O O
of O O
p53 O O
. O O

Further O O
immunoprecipitation O O
studies O O
found O O
that O O
, O O
in O O
response O O
to O O
the O O
treatment O O
, O O
the O O
formation O O
of O O
Cyclin O O
D1 O O
/ O O
Cdk4 O O
and O O
Cyclin O O
A O O
/ O O
Cdk2 O O
complexes O O
had O O
declined O O
, O O
preventing O O
the O O
phosphorylation O O
of O O
Rb O O
and O O
the O O
subsequent O O
dissociation O O
of O O
Rb O O
/ O O
E2F O O
complex O O
. O O

These O O
results O O
suggested O O
Andro O O
can O O
inhibit O O
Lovo O O
cell O O
growth O O
by O O
G1 O O
- O O
S O O
phase O O
arrest O O
, O O
and O O
was O O
exerted O O
by O O
inducing O O
the O O
expression O O
of O O
p53 O O
, O O
p21 O O
and O O
p16 O O
that O O
, O O
in O O
turn O O
, O O
repressed O O
the O O
activity O O
of O O
Cyclin O O
D1 O O
/ O O
Cdk4 O O
and O O
/ O O
or O O
Cyclin O O
A O O
/ O O
Cdk2 O O
, O O
as O O
well O O
as O O
Rb O O
phosphorylation O O
. O O

Impact O O
of O O
antioxidant O O
supplementation O O
on O O
chemotherapeutic B-Disease B-Disease
toxicity I-Disease I-Disease
: O O
a O O
systematic O O
review O O
of O O
the O O
evidence O O
from O O
randomized O O
controlled O O
trials O O
. O O

Much O O
debate O O
has O O
focused O O
on O O
whether O O
antioxidants O O
interfere O O
with O O
the O O
efficacy O O
of O O
cancer B-Disease B-Disease
chemotherapy O O
. O O

The O O
objective O O
of O O
this O O
study O O
is O O
to O O
systematically O O
review O O
the O O
randomized O O
, O O
controlled O O
clinical O O
trial O O
evidence O O
evaluating O O
the O O
effects O O
of O O
concurrent O O
use O O
of O O
antioxidants O O
with O O
chemotherapy O O
on O O
toxic O O
side O O
effects O O
. O O

We O O
performed O O
a O O
search O O
of O O
literature O O
from O O
1966 O O
- O O
October O O
2007 O O
using O O
MEDLINE O O
, O O
Cochrane O O
, O O
CinAhl O O
, O O
AMED O O
, O O
AltHealthWatch O O
and O O
EMBASE O O
databases O O
. O O

Randomized O O
, O O
controlled O O
clinical O O
trials O O
reporting O O
antioxidant O O
- O O
based O O
mitigation O O
of O O
chemotherapy B-Disease B-Disease
toxicity I-Disease I-Disease
were O O
included O O
in O O
the O O
final O O
tally O O
. O O

Searches O O
were O O
performed O O
following O O
a O O
standardized O O
protocol O O
for O O
systematic O O
reviews O O
. O O

Only O O
33 O O
of O O
965 O O
articles O O
considered O O
, O O
including O O
2,446 O O
subjects O O
, O O
met O O
the O O
inclusion O O
criteria O O
. O O

Antioxidants O O
evaluated O O
were O O
: O O
glutathione O O
( O O
11 O O
) O O
, O O
melatonin O O
( O O
7 O O
) O O
, O O
vitamin O O
A O O
( O O
1 O O
) O O
, O O
an O O
antioxidant O O
mixture O O
( O O
2 O O
) O O
, O O
N O O
- O O
acetylcysteine O O
( O O
2 O O
) O O
, O O
vitamin O O
E O O
( O O
5 O O
) O O
, O O
selenium O O
( O O
2 O O
) O O
, O O
L O O
- O O
carnitine O O
( O O
1 O O
) O O
, O O
Co O O
- O O
Q10 O O
( O O
1 O O
) O O
and O O
ellagic O O
acid O O
( O O
1 O O
) O O
. O O

The O O
majority O O
( O O
24 O O
) O O
of O O
the O O
33 O O
studies O O
included O O
reported O O
evidence O O
of O O
decreased O O
toxicities O O
from O O
the O O
concurrent O O
use O O
of O O
antioxidants O O
with O O
chemotherapy O O
. O O

Nine O O
studies O O
reported O O
no O O
difference O O
in O O
toxicities O O
between O O
the O O
2 O O
groups O O
. O O

Only O O
1 O O
study O O
( O O
vitamin O O
A O O
) O O
reported O O
a O O
significant O O
increase O O
in O O
toxicity O O
in O O
the O O
antioxidant O O
group O O
. O O

Five O O
studies O O
reported O O
the O O
antioxidant O O
group O O
completed O O
more O O
full O O
doses O O
of O O
chemotherapy O O
or O O
had O O
less O O
- O O
dose O O
reduction O O
than O O
control O O
groups O O
. O O

Statistical O O
power O O
and O O
poor O O
study O O
quality O O
were O O
concerns O O
with O O
some O O
studies O O
. O O

This O O
review O O
provides O O
the O O
first O O
systematically O O
reviewed O O
evidence O O
that O O
antioxidant O O
supplementation O O
during O O
chemotherapy O O
holds O O
potential O O
for O O
reducing O O
dose O O
- O O
limiting O O
toxicities O O
. O O

However O O
, O O
well O O
- O O
designed O O
studies O O
evaluating O O
larger O O
populations O O
of O O
patients O O
given O O
specific O O
antioxidants O O
defined O O
by O O
dose O O
and O O
schedule O O
relative O O
to O O
chemotherapy O O
are O O
warranted O O
. O O

Optimizing O O
docetaxel O O
chemotherapy O O
in O O
patients O O
with O O
cancer B-Disease B-Disease
of I-Disease I-Disease
the I-Disease I-Disease
gastric I-Disease I-Disease
and I-Disease I-Disease
gastroesophageal I-Disease I-Disease
junction I-Disease I-Disease
: O O
evolution O O
of O O
the O O
docetaxel O O
, O O
cisplatin O O
, O O
and O O
5 O O
- O O
fluorouracil O O
regimen O O
. O O

Advanced O O
gastroesophageal B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
are O O
often O O
treated O O
with O O
systemic O O
combination O O
chemotherapy O O
. O O

The O O
V O O
- O O
325 O O
study O O
demonstrated O O
that O O
adding O O
docetaxel O O
( O O
D O O
) O O
to O O
a O O
frequently O O
used O O
regimen O O
of O O
cisplatin O O
and O O
5 O O
- O O
fluorouracil O O
( O O
CF O O
) O O
provided O O
benefits O O
with O O
regard O O
to O O
overall O O
survival O O
, O O
response O O
rate O O
, O O
time O O
- O O
to O O
- O O
disease O O
progression O O
, O O
clinical O O
benefit O O
, O O
and O O
health O O
- O O
related O O
quality O O
of O O
life O O
. O O

Although O O
the O O
DCF O O
regimen O O
provides O O
these O O
advantages O O
, O O
it O O
is O O
accompanied O O
by O O
an O O
increase O O
in O O
toxicity O O
compared O O
with O O
the O O
doublet O O
regimen O O
. O O

The O O
toxicity O O
profile O O
of O O
DCF O O
is O O
acceptable O O
only O O
with O O
appropriately O O
selected O O
patients O O
and O O
comprehensive O O
toxicity O O
management O O
strategies O O
. O O

The O O
objective O O
of O O
the O O
current O O
review O O
was O O
to O O
identify O O
trials O O
that O O
investigated O O
modifications O O
to O O
the O O
original O O
DCF O O
regimen O O
to O O
improve O O
its O O
toxicity O O
profile O O
and O O
summarize O O
response O O
rate O O
and O O
toxicities O O
. O O

An O O
attempt O O
was O O
also O O
made O O
to O O
summarize O O
ongoing O O
modifications O O
of O O
the O O
DCF O O
regimen O O
. O O

MEDLINE O O
, O O
major O O
meeting O O
proceedings O O
, O O
and O O
the O O
government O O
clinical O O
trials O O
website O O
were O O
searched O O
until O O
2007 O O
. O O

The O O
modified O O
DCF O O
regimens O O
appear O O
to O O
improve O O
the O O
toxicity O O
profile O O
when O O
compared O O
with O O
the O O
original O O
DCF O O
regimen O O
. O O

The O O
docetaxel O O
- O O
based O O
triplet O O
combinations O O
appear O O
to O O
have O O
a O O
higher O O
response O O
rate O O
than O O
the O O
doublet O O
combinations O O
. O O

Many O O
institutions O O
and O O
cooperative O O
groups O O
continue O O
to O O
study O O
docetaxel O O
- O O
based O O
modifications O O
of O O
the O O
DCF O O
regimen O O
to O O
treat O O
patients O O
with O O
gastroesophageal B-Disease B-Disease
carcinoma I-Disease I-Disease
. O O

However O O
, O O
although O O
modified O O
DCF O O
reduces O O
the O O
frequency O O
of O O
severe O O
toxicities O O
previously O O
reported O O
with O O
DCF O O
, O O
considerably O O
more O O
advances O O
are O O
needed O O
to O O
improve O O
the O O
safety O O
, O O
survival O O
, O O
and O O
convenience O O
of O O
patients O O
with O O
advanced O O
gastroesophageal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Pentachlorophenol O O
decreases O O
ATP O O
levels O O
in O O
human O O
natural O O
killer O O
cells O O
. O O

Pentachlorophenol O O
( O O
PCP O O
) O O
is O O
used O O
as O O
a O O
wood O O
preservative O O
and O O
is O O
found O O
in O O
human O O
blood O O
and O O
urine O O
. O O

PCP O O
causes O O
significant O O
decreases O O
in O O
the O O
tumor O B-Disease
- O O
killing O O
( O O
lytic O O
) O O
function O O
of O O
human O O
natural O O
killer O O
( O O
NK O O
) O O
cells O O
, O O
a O O
critical O O
immune O O
defense O O
. O O

The O O
current O O
study O O
examined O O
the O O
association O O
between O O
decreased O O
lytic O O
function O O
and O O
decreased O O
ATP O O
levels O O
, O O
as O O
well O O
as O O
the O O
ability O O
of O O
antioxidants O O
( O O
vitamin O O
E O O
and O O
reduced O O
glutathione O O
) O O
to O O
prevent O O
PCP O O
- O O
induced O O
decreases O O
in O O
either O O
ATP O O
levels O O
or O O
lytic O O
function O O
. O O

Exposure O O
of O O
NK O O
cells O O
to O O
10 O O
microm O O
PCP O O
decreased O O
ATP O O
levels O O
by O O
15 O O
% O O
at O O
24 O O
h O O
, O O
and O O
exposure O O
to O O
5 O O
microm O O
PCP O O
decreased O O
ATP O O
levels O O
by O O
32 O O
% O O
at O O
48 O O
h O O
. O O

No O O
effects O O
were O O
seen O O
with O O
0.5 O O
microm O O
at O O
48 O O
h O O
or O O
with O O
5 O O
microm O O
at O O
24 O O
h O O
. O O

However O O
, O O
10 O O
microm O O
PCP O O
decreased O O
lytic O O
function O O
by O O
69 O O
% O O
at O O
24 O O
h O O
and O O
5 O O
microm O O
decreased O O
it O O
by O O
90 O O
% O O
at O O
48 O O
h O O
. O O

Even O O
0.5 O O
microm O O
PCP O O
decreased O O
lytic O O
function O O
by O O
46 O O
% O O
at O O
48 O O
h O O
. O O

None O O
of O O
these O O
effects O O
were O O
prevented O O
by O O
pretreatment O O
with O O
1 O O
mm O O
vitamin O O
E O O
or O O
reduced O O
glutathione O O
. O O

Using O O
dietary O O
exposure O O
and O O
physiologically O O
based O O
pharmacokinetic O O
/ O O
pharmacodynamic O O
modeling O O
in O O
human O O
risk O O
extrapolations O O
for O O
acrylamide B-Disease O
toxicity I-Disease B-Disease
. O O

The O O
discovery O O
of O O
acrylamide O O
( O O
AA O O
) O O
in O O
many O O
common O O
cooked O O
starchy O O
foods O O
has O O
presented O O
significant O O
challenges O O
to O O
toxicologists O O
, O O
food O O
scientists O O
, O O
and O O
national O O
regulatory O O
and O O
public O O
health O O
organizations O O
because O O
of O O
the O O
potential O O
for O O
producing O O
neurotoxicity B-Disease B-Disease
and O O
cancer B-Disease B-Disease
. O O

This O O
paper O O
reviews O O
some O O
of O O
the O O
underlying O O
experimental O O
bases O O
for O O
AA B-Disease B-Disease
toxicity I-Disease I-Disease
and O O
earlier O O
risk O O
assessments O O
. O O

Then O O
, O O
dietary O O
exposure O O
modeling O O
is O O
used O O
to O O
estimate O O
probable O O
AA O O
intake O O
in O O
the O O
U O O
. O O

S O O
. O O

population O O
, O O
and O O
physiologically O O
based O O
pharmacokinetic O O
/ O O
pharmacodynamic O O
( O O
PBPK O O
/ O O
PD O O
) O O
modeling O O
is O O
used O O
to O O
integrate O O
the O O
findings O O
of O O
rodent O O
neurotoxicity B-Disease B-Disease
and O O
cancer B-Disease B-Disease
into O O
estimates O O
of O O
risks O O
from O O
human O O
AA O O
exposure O O
through O O
the O O
diet O O
. O O

The O O
goal O O
of O O
these O O
modeling O O
techniques O O
is O O
to O O
reduce O O
the O O
uncertainty O O
inherent O O
in O O
extrapolating O O
toxicological O O
findings O O
across O O
species O O
and O O
dose O O
by O O
comparing O O
common O O
exposure O O
biomarkers O O
. O O

PBPK O O
/ O O
PD O O
modeling O O
estimated O O
population O O
- O O
based O O
lifetime O O
excess O O
cancer B-Disease B-Disease
risks O O
from O O
average O O
AA O O
consumption O O
in O O
the O O
diet O O
in O O
the O O
range O O
of O O
1 O O
- O O
4 O O
x O O
10 O O
( O O
- O O
4 O O
) O O
; O O
however O O
, O O
modeling O O
did O O
not O O
support O O
a O O
link O O
between O O
dietary O O
AA O O
exposure O O
and O O
human O O
neurotoxicity B-Disease B-Disease
because O O
marginal O O
exposure O O
ratios O O
were O O
50 O O
- O O
300 O O
lower O O
than O O
in O O
rodents O O
. O O

In O O
addition O O
, O O
dietary O O
exposure O O
modeling O O
suggests O O
that O O
because O O
AA O O
is O O
found O O
in O O
so O O
many O O
common O O
foods O O
, O O
even O O
big O O
changes O O
in O O
concentration O O
for O O
single O O
foods O O
or O O
groups O O
of O O
foods O O
would O O
probably O O
have O O
a O O
small O O
impact O O
on O O
overall O O
population O O
- O O
based O O
intake O O
and O O
risk O O
. O O

These O O
results O O
suggest O O
that O O
a O O
more O O
holistic O O
analysis O O
of O O
dietary B-Disease B-Disease
cancer I-Disease I-Disease
risks O O
may O O
be O O
appropriate O O
, O O
by O O
which O O
potential O O
risks O O
from O O
AA O O
should O O
be O O
considered O O
in O O
conjunction O O
with O O
other O O
risks O O
and O O
benefits O O
from O O
foods O O
. O O

Review O O
article O O
: O O
new O O
drug O O
formulations O O
, O O
chemical O O
entities O O
and O O
therapeutic O O
approaches O O
for O O
the O O
management O O
of O O
ulcerative B-Disease B-Disease
colitis I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Treatment O O
options O O
for O O
ulcerative B-Disease B-Disease
colitis I-Disease I-Disease
( O O
UC B-Disease B-Disease
) O O
are O O
expanding O O
with O O
the O O
development O O
of O O
novel O O
drug O O
formulations O O
and O O
dosing O O
regimens O O
and O O
new O O
chemical O O
entities O O
. O O

Although O O
the O O
goals O O
of O O
medical O O
therapy O O
for O O
UC B-Disease B-Disease
remain O O
unchanged O O
, O O
that O O
is O O
to O O
induce O O
and O O
to O O
maintain O O
remission O O
, O O
focus O O
has O O
also O O
centred O O
on O O
improving O O
patient O O
compliance O O
, O O
modifying O O
the O O
natural O O
course O O
of O O
disease O O
and O O
healing O O
the O O
mucosa O O
. O O

AIM O O
: O O
To O O
examine O O
novel O O
formulations O O
, O O
new O O
chemical O O
entities O O
and O O
novel O O
therapeutic O O
approaches O O
to O O
the O O
management O O
of O O
UC B-Disease B-Disease
. O O

METHODS O O
: O O
Searches O O
for O O
all O O
studies O O
related O O
to O O
UC B-Disease B-Disease
treatment O O
in O O
Medline O O
and O O
abstracts O O
from O O
major O O
national O O
and O O
international O O
meetings O O
published O O
in O O
the O O
last O O
10 O O
years O O
. O O

RESULTS O O
: O O
5 O O
- O O
Aminosalicylic O O
acids O O
( O O
5 O O
- O O
ASA O O
) O O
remain O O
the O O
standard O O
first O O
- O O
line O O
treatment O O
for O O
patients O O
with O O
mild O O
to O O
moderately O O
active O O
UC B-Disease B-Disease
. O O

New O O
formulations O O
with O O
altered O O
delivery O O
, O O
and O O
new O O
dosing O O
regimens O O
have O O
demonstrated O O
possible O O
improvements O O
in O O
efficacy O O
compared O O
with O O
historically O O
available O O
preparations O O
and O O
dosing O O
patterns O O
. O O

Once O O
- O O
daily O O
dosing O O
, O O
micropellet O O
formulations O O
, O O
and O O
high O O
- O O
dose O O
tablets O O
offer O O
enhanced O O
efficacy O O
and O O
improved O O
compliance O O
. O O

5 O O
- O O
ASA O O
is O O
now O O
recognized O O
as O O
a O O
ligand O O
for O O
peroxisome O O
proliferator O O
activated O O
receptor O O
- O O
gamma O O
( O O
PPAR O O
- O O
gamma O O
) O O
and O O
it O O
has O O
a O O
role O O
as O O
a O O
chemo O O
- O O
preventive O O
agent O O
in O O
long O O
- O O
standing O O
UC B-Disease B-Disease
. O O

New O O
colonic O O
release O O
corticosteroid O O
formulations O O
help O O
to O O
limit O O
systemic B-Disease B-Disease
toxicity I-Disease I-Disease
; O O
turmeric O O
, O O
tacrolimus O O
and O O
infliximab O O
have O O
shown O O
promising O O
results O O
. O O

New O O
anti O O
- O O
inflammatory O O
targeted O O
therapies O O
include O O
an O O
anti O O
- O O
CD3 O O
antibody O O
, O O
selective O O
integrin O O
blockers O O
, O O
anti O O
- O O
IL O O
- O O
2 O O
antibody O O
and O O
PPAR O O
- O O
gamma O O
agonists O O
. O O

CONCLUSION O O
: O O
The O O
evolution O O
of O O
novel O O
oral O O
5 O O
- O O
ASA O O
formulations O O
and O O
dosage O O
regimens O O
, O O
and O O
recent O O
development O O
of O O
new O O
molecules O O
have O O
expanded O O
the O O
therapeutic O O
armamentarium O O
of O O
UC B-Disease B-Disease
. O O

Dietary O O
flavonoids O O
inhibit O O
the O O
anticancer O O
effects O O
of O O
the O O
proteasome O O
inhibitor O O
bortezomib O O
. O O

Dietary O O
flavonoids O O
have O O
many O O
health O O
- O O
promoting O O
actions O O
, O O
including O O
anticancer O O
activity O O
via O O
proteasome O O
inhibition O O
. O O

Bor O O
- O O
tezomib O O
is O O
a O O
dipeptide O O
boronate O O
proteasome O O
inhibitor O O
that O O
has O O
activity O O
in O O
the O O
treatment O O
of O O
multiple B-Disease B-Disease
myeloma I-Disease I-Disease
but O O
is O O
not O O
effective O O
in O O
chronic B-Disease B-Disease
lymphocytic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
CLL B-Disease B-Disease
) O O
. O O

Although O O
CLL B-Disease O
cells O O
are O O
sensitive O O
in O O
vitro O O
to O O
bortezomib O O
- O O
induced O O
apoptosis B-Disease O
when O O
cultured O O
in O O
medium O O
, O O
the O O
killing O O
activity O O
was O O
blocked O O
when O O
cultured O O
in O O
50 O O
% O O
fresh O O
autologous O O
plasma O O
. O O

Dietary O O
flavonoids O O
, O O
quercetin O O
and O O
myricetin O O
, O O
which O O
are O O
abundant O O
in O O
plasma O O
, O O
inhibited O O
bortezomib O O
- O O
induced O O
apoptosis B-Disease O
of O O
primary O O
CLL B-Disease B-Disease
and O O
malignant O O
B O O
- O O
cell O O
lines O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

This O O
inhibitory O O
effect O O
was O O
associated O O
with O O
chemical O O
reactions O O
between O O
quercetin O O
and O O
the O O
boronic O O
acid O O
group O O
, O O
- O O
RB O O
( O O
OH O O
) O O
2 O O
, O O
in O O
bortezomib O O
. O O

The O O
addition O O
of O O
boric O O
acid O O
diminished O O
the O O
inhibitory O O
effect O O
of O O
both O O
quercetin O O
and O O
plasma O O
on O O
bortezomib O O
- O O
induced O O
apoptosis B-Disease O
. O O

The O O
protective O O
effect O O
was O O
also O O
reduced O O
when O O
myeloma B-Disease B-Disease
cell O O
lines O O
, O O
but O O
not O O
B O O
- O O
cell O O
lines O O
, O O
were O O
preincubated O O
with O O
quercetin O O
, O O
indicating O O
a O O
direct O O
effect O O
of O O
quercetin O O
on O O
myeloma B-Disease B-Disease
cells O O
. O O

At O O
high O O
doses O O
, O O
quercetin O O
itself O O
induced O O
tumor O B-Disease
cell B-Disease O
death I-Disease O
. O O

These O O
data O O
indicate O O
that O O
dietary O O
flavonoids O O
limit O O
the O O
efficacy O O
of O O
bortezomib O O
, O O
whereas O O
supplemental O O
inorganic O O
boric O O
acid O O
is O O
able O O
to O O
reverse O O
this O O
. O O

The O O
complex O O
interactions O O
between O O
quercetin O O
, O O
tumor O O
cells O O
, O O
and O O
bortezomib O O
mean O O
caution O O
is O O
required O O
when O O
giving O O
dietary O O
advice O O
to O O
patients O O
. O O

Nitrate O O
- O O
induced O O
toxicity O B-Disease
and O O
preconditioning O O
: O O
a O O
rationale O O
for O O
reconsidering O O
the O O
use O O
of O O
these O O
drugs O O
. O O

Although O O
organic O O
nitrates O O
have O O
been O O
clinically O O
used O O
for O O
more O O
than O O
a O O
century O O
, O O
findings O O
in O O
the O O
last O O
decade O O
have O O
radically O O
challenged O O
our O O
traditional O O
view O O
concerning O O
the O O
mechanism O O
( O O
s O O
) O O
of O O
their O O
clinical O O
effects O O
and O O
implications O O
. O O

While O O
their O O
hemodynamic O O
properties O O
are O O
well O O
known O O
, O O
the O O
knowledge O O
that O O
nitrates O O
possess O O
previously O O
unexpected O O
nonhemodynamic O O
effects O O
is O O
a O O
unique O O
opportunity O O
of O O
which O O
clinicians O O
should O O
be O O
aware O O
but O O
, O O
at O O
the O O
same O O
time O O
, O O
it O O
also O O
provides O O
a O O
rationale O O
to O O
worry O O
about O O
previously O O
unanticipated O O
clinical O O
consequences O O
of O O
long O O
- O O
term O O
treatment O O
with O O
these O O
drugs O O
. O O

The O O
effect O O
of O O
QuYuHuaTanTongLuo O O
Decoction O O
on O O
the O O
non B-Disease B-Disease
- I-Disease I-Disease
alcoholic I-Disease I-Disease
steatohepatitis I-Disease I-Disease
. O O

Non B-Disease B-Disease
- I-Disease I-Disease
alcoholic I-Disease I-Disease
steatohepatitis I-Disease I-Disease
( O O
NASH O B-Disease
) O O
is O O
the O O
most O O
common O O
cause O O
of O O
cryptogenic B-Disease B-Disease
cirrhosis I-Disease I-Disease
, O O
is O O
becoming O O
more O O
prevalent O O
in O O
China O O
. O O

However O O
, O O
there O O
is O O
as O O
yet O O
no O O
clearly O O
established O O
therapy O O
for O O
reversing O O
fatty B-Disease B-Disease
liver I-Disease I-Disease
. O O

Our O O
aim O O
is O O
to O O
explore O O
the O O
effect O O
of O O
traditional O O
Chinese O O
herbs O O
QuYuHuaTanTongLuo O O
Decoction O O
( O O
QYHTTLD O O
) O O
on O O
non B-Disease B-Disease
- I-Disease I-Disease
alcoholic I-Disease I-Disease
steatohepatitis I-Disease I-Disease
. O O

Sixty O O
- O O
nine O O
non B-Disease O
- I-Disease O
alcoholic I-Disease O
steatohepatitis I-Disease B-Disease
patients O O
were O O
randomly O O
divided O O
into O O
two O O
groups O O
. O O

One O O
group O O
of O O
35 O O
patients O O
were O O
treated O O
by O O
QYHTTLD O O
, O O
another O O
group O O
of O O
34 O O
patients O O
were O O
treated O O
by O O
Ursodeoxycholic O O
acid O O
( O O
UDCA O O
) O O
. O O

The O O
TNF O O
- O O
alpha O O
, O O
IL O O
- O O
8 O O
, O O
MDA O O
level O O
, O O
SOD O O
activity O O
and O O
liver O O
function O O
, O O
as O O
well O O
as O O
B O O
ultrasonic O O
image O O
were O O
detected O O
before O O
and O O
after O O
being O O
treated O O
. O O

The O O
results O O
showed O O
: O O
after O O
6 O O
months O O
treatment O O
, O O
MBI O O
of O O
the O O
treatment O O
group O O
was O O
obviously O O
decreased O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

The O O
levels O O
of O O
TC O O
, O O
TG O O
and O O
LDL O O
- O O
C O O
were O O
significantly O O
decreased O O
whereas O O
the O O
level O O
of O O
HDL O O
- O O
C O O
increased O O
( O O
p O O
< O O
0.01 O O
, O O
p O O
< O O
0.05 O O
, O O
p O O
< O O
0.05 O O
, O O
and O O
p O O
< O O
0.05 O O
, O O
respectively O O
) O O
in O O
the O O
treatment O O
group O O
, O O
the O O
levels O O
of O O
TC O O
, O O
TG O O
, O O
LDL O O
- O O
C O O
and O O
HDL O O
- O O
C O O
had O O
no O O
significant O O
difference O O
in O O
the O O
control O O
group O O
( O O
p O O
> O O
0.05 O O
) O O
. O O

The O O
levels O O
of O O
TNF O O
- O O
alpha O O
, O O
IL O O
- O O
8 O O
and O O
MDA O O
were O O
significantly O O
decreased O O
whereas O O
SOD O O
activity O O
was O O
significantly O O
increased O O
( O O
p O O
< O O
0.01 O O
, O O
p O O
< O O
0.05 O O
, O O
p O O
< O O
0.01 O O
, O O
and O O
p O O
< O O
0.01 O O
, O O
respectively O O
) O O
in O O
the O O
treatment O O
group O O
, O O
the O O
level O O
of O O
MDA O O
was O O
significantly O O
decreased O O
in O O
the O O
control O O
group O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

B O O
ultrasonic O O
images O O
were O O
ameliorated O O
in O O
different O O
degree O O
( O O
p O O
< O O
0.01 O O
and O O
p O O
< O O
0.01 O O
, O O
respectively O O
) O O
. O O

Both O O
QYHTTLD O O
and O O
UDCA O O
had O O
the O O
effect O O
in O O
improving O O
the O O
scores O O
of O O
symptoms O O
and O O
signs O O
of O O
patients O O
, O O
however O O
, O O
the O O
difference O O
value O O
of O O
the O O
scores O O
in O O
treatment O O
group O O
were O O
significantly O O
higher O O
than O O
that O O
in O O
control O O
group O O
after O O
being O O
treated O O
for O O
6 O O
months O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

Conclusion O O
: O O
QYHTTLD O O
is O O
effective O O
for O O
treating O O
non B-Disease B-Disease
- I-Disease I-Disease
alcoholic I-Disease I-Disease
steatohepatitis I-Disease I-Disease
, O O
and O O
its O O
effect O O
seems O O
to O O
relate O O
with O O
the O O
ways O O
of O O
QYHTTL O O
down O O
- O O
regulating O O
inflammation B-Disease B-Disease
cytokine O O
IL O O
- O O
8 O O
level O O
and O O
relieving O O
lipid O O
peroxidation O O
of O O
liver O O
. O O

Fragrance O O
material O O
review O O
on O O
sclareol O O
. O O

A O O
toxicologic O O
and O O
dermatologic O O
review O O
of O O
sclareol O O
when O O
used O O
as O O
a O O
fragrance O O
ingredient O O
is O O
presented O O
. O O

Fragrance O O
Material O O
Review O O
on O O
isopulegol O O
. O O

A O O
toxicologic O O
and O O
dermatologic O O
review O O
of O O
isopulegol O O
when O O
used O O
as O O
a O O
fragrance O O
ingredient O O
is O O
presented O O
. O O

Fragrance O O
material O O
review O O
on O O
ocimenol O O
. O O

A O O
toxicologic O O
and O O
dermatologic O O
review O O
of O O
ocimenol O O
when O O
used O O
as O O
a O O
fragrance O O
ingredient O O
is O O
presented O O
. O O

Topical O O
pyrethrin B-Disease O
toxicity I-Disease B-Disease
leading O O
to O O
acute B-Disease O
- I-Disease O
onset I-Disease O
stuttering I-Disease B-Disease
in O O
a O O
toddler O O
. O O

Pyrethrin O O
compounds O O
can O O
cause O O
neurotoxicity B-Disease B-Disease
when O O
used O O
in O O
an O O
excessive O O
dose O O
. O O

A O O
case O O
of O O
stuttering B-Disease B-Disease
and O O
general O O
clumsiness B-Disease B-Disease
in O O
a O O
toddler O O
associated O O
with O O
topical O O
pyrethrin O O
use O O
is O O
described O O
. O O

Antitumor O O
properties O O
of O O
a O O
sulfated O O
polysaccharide O O
from O O
the O O
red O O
seaweed O O
Champia O O
feldmannii O O
( O O
Diaz O O
- O O
Pifferer O O
) O O
. O O

In O O
recent O O
years O O
, O O
much O O
attention O O
has O O
been O O
focused O O
on O O
polysaccharides O O
isolated O O
from O O
natural O O
sources O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
in O O
vitro O O
and O O
in O O
vivo O O
antitumor O O
properties O O
of O O
a O O
sulfated O O
polysaccharide O O
isolated O O
from O O
the O O
seaweed O O
C O O
. O O

feldmannii O O
( O O
Cf O O
- O O
PLS O O
) O O
. O O

Hematological O O
, O O
biochemical O O
and O O
histopathological O O
analyses O O
were O O
performed O O
in O O
order O O
to O O
evaluate O O
the O O
toxicological O O
aspects O O
related O O
to O O
Cf O O
- O O
PLS O O
treatment O O
. O O

Its O O
effects O O
on O O
the O O
immunological O O
system O O
were O O
also O O
investigated O O
. O O

The O O
Cf O O
- O O
PLS O O
did O O
not O O
show O O
any O O
significant O O
in O O
vitro O O
cytotoxicity B-Disease B-Disease
at O O
the O O
experimental O O
exposure O O
levels O O
that O O
were O O
used O O
, O O
but O O
showed O O
in O O
vivo O O
antitumor O O
effect O O
. O O

The O O
inhibition O O
rates O O
of O O
sarcoma B-Disease B-Disease
180 O O
tumor B-Disease B-Disease
development O O
were O O
48.62 O O
and O O
48.16 O O
% O O
at O O
the O O
doses O O
of O O
10 O O
and O O
25 O O
mg O O
kg O O
( O O
- O O
1 O O
) O O
, O O
respectively O O
. O O

In O O
addition O O
, O O
Cf O O
- O O
PLS O O
was O O
also O O
able O O
to O O
increase O O
the O O
response O O
elicited O O
by O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
from O O
48.66 O O
to O O
68.32 O O
% O O
. O O

The O O
histopathological O O
analysis O O
of O O
liver O O
and O O
kidney O O
showed O O
that O O
both O O
organs O O
were O O
moderately O O
affected O O
by O O
Cf O O
- O O
PLS O O
- O O
treatment O O
. O O

Neither O O
enzymatic O O
activity O O
of O O
alanine O O
aminotransferase O O
nor O O
urea O O
or O O
creatinine O O
levels O O
were O O
significantly O O
altered O O
. O O

In O O
hematological O O
analysis O O
, O O
leucopeny B-Disease B-Disease
was O O
observed O O
after O O
5 O O
- O O
FU O O
treatment O O
, O O
but O O
this O O
effect O O
was O O
prevented O O
when O O
the O O
treatment O O
was O O
associated O O
with O O
the O O
Cf O O
- O O
PLS O O
. O O

It O O
was O O
also O O
demonstrated O O
that O O
Cf O O
- O O
PLS O O
acts O O
as O O
an O O
immunomodulatory O O
agent O O
, O O
raising O O
the O O
production O O
of O O
specific O O
antibodies O O
, O O
and O O
increasing O O
the O O
production O O
of O O
OVA O O
- O O
specific O O
antibodies O O
. O O

It O O
also O O
induced O O
a O O
discreet O O
hyperplasia B-Disease B-Disease
of I-Disease I-Disease
lymphoid I-Disease I-Disease
folicules I-Disease I-Disease
of O O
the O O
white O O
pulp O O
in O O
the O O
spleen O O
of O O
treated O O
mice O O
. O O

In O O
conclusion O O
, O O
Cf O O
- O O
PLS O O
has O O
some O O
interesting O O
anticancer O O
activity O O
that O O
could O O
be O O
associated O O
with O O
its O O
immunostimulating O O
properties O O
. O O

A O O
multi O O
- O O
centre O O
dose O O
- O O
escalation O O
and O O
pharmacokinetic O O
study O O
of O O
diflomotecan O O
in O O
patients O O
with O O
advanced O O
malignancy B-Disease B-Disease
. O O

PURPOSE O O
: O O
Diflomotecan O O
, O O
a O O
homocamptothecin O O
, O O
targets O O
DNA O O
topoisomerase O O
I O O
. O O

Previous O O
clinical O O
trials O O
have O O
demonstrated O O
a O O
variable O O
degree O O
of O O
dose B-Disease B-Disease
limiting I-Disease I-Disease
toxicity I-Disease I-Disease
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
further O O
evaluate O O
the O O
safety O O
and O O
pharmacokinetic O O
profile O O
of O O
a O O
range O O
of O O
diflomotecan O O
doses O O
administered O O
intravenously O O
. O O

METHODS O O
: O O
Patients O O
with O O
advanced O O
solid O O
malignant B-Disease B-Disease
tumours I-Disease I-Disease
, O O
refractory O O
to O O
standard O O
therapies O O
, O O
with O O
adequate O O
haematologic O O
, O O
renal O O
and O O
hepatic O O
function O O
, O O
received O O
diflomotecan O O
administered O O
as O O
a O O
20 O O
min O O
intravenous O O
infusion O O
every O O
21 O O
days O O
. O O

Cohorts O O
of O O
six O O
patients O O
were O O
recruited O O
sequentially O O
to O O
one O O
of O O
three O O
fixed O O
starting O O
dose O O
groups O O
- O O
2 O O
, O O
4 O O
, O O
or O O
7 O O
mg O O
, O O
with O O
drug O O
administered O O
by O O
fixed O O
- O O
dose O O
rather O O
than O O
dosing O O
by O O
body O O
surface O O
area O O
. O O

Pharmacokinetic O O
analyses O O
were O O
performed O O
on O O
serial O O
blood O O
samples O O
taken O O
over O O
the O O
first O O
24 O O
h O O
after O O
diflomotecan O O
administration O O
( O O
cycles O O
1 O O
and O O
2 O O
) O O
. O O

Cytochrome O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
activity O O
was O O
determined O O
by O O
an O O
erythromycin O O
breath O O
test O O
( O O
EBT O O
) O O
prior O O
to O O
diflomotecan O O
administration O O
in O O
cycles O O
1 O O
and O O
2 O O
. O O

RESULTS O O
: O O
Thirteen O O
patients O O
, O O
were O O
treated O O
with O O
a O O
starting O O
dose O O
of O O
either O O
2 O O
mg O O
( O O
n O O
= O O
8 O O
) O O
or O O
4 O O
mg O O
( O O
n O O
= O O
5 O O
) O O
of O O
diflomotecan O O
. O O

Dose O O
limiting O O
toxicities O B-Disease
( O O
DLTs O O
) O O
were O O
observed O O
in O O
1 O O
patient O O
in O O
the O O
2 O O
mg O O
starting O O
dose O O
level O O
( O O
grade O O
4 O O
neutropenia B-Disease B-Disease
which O O
lasted O O
for O O
8 O O
days O O
) O O
, O O
and O O
in O O
2 O O
of O O
5 O O
patients O O
enrolled O O
at O O
the O O
4 O O
mg O O
starting O O
dose O O
level O O
( O O
grade O O
4 O O
neutropenia B-Disease B-Disease
for O O
11 O O
days O O
; O O
grade O O
4 O O
neutropenia B-Disease B-Disease
leading O O
to O O
withdrawal O O
from O O
the O O
study O O
) O O
, O O
and O O
no O O
further O O
dose O O
escalation O O
was O O
performed O O
. O O

Pharmacokinetic O O
analyses O O
revealed O O
a O O
less O O
than O O
dose O O
- O O
proportional O O
increase O O
in O O
diflomotecan O O
and O O
for O O
the O O
two O O
metabolites O O
BN80942 O O
and O O
P O O
- O O
20 O O
, O O
with O O
a O O
magnitude O O
of O O
P O O
- O O
20 O O
exposure O O
similar O O
to O O
the O O
parent O O
drug O O
. O O

There O O
was O O
a O O
high O O
inter O O
- O O
patient O O
variability O O
in O O
diflomotecan O O
exposure O O
similar O O
to O O
that O O
observed O O
with O O
other O O
camptothecin O O
derivatives O O
. O O

One O O
minor O O
response O O
was O O
observed O O
in O O
a O O
patient O O
with O O
oesophageal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

CONCLUSIONS O O
: O O
Diflomotecan O O
administered O O
as O O
a O O
20 O O
- O O
min O O
intravenous O O
infusion O O
3 O O
- O O
weekly O O
is O O
characterised O O
by O O
a O O
variable O O
pharmacokinetic O O
profile O O
. O O

Alternative O O
oral O O
dosing O O
schedules O O
of O O
diflomotecan O O
have O O
been O O
shown O O
to O O
display O O
a O O
more O O
predictable O O
PK O O
/ O O
PD O O
and O O
safety O O
profile O O
and O O
should O O
be O O
selected O O
for O O
further O O
evaluation O O
in O O
Phase O O
II O O
clinical O O
trials O O
. O O

Hepatic O O
protection O O
by O O
noni O O
fruit O O
juice O O
against O O
CCl O O
( O O
4 O O
) O O
- O O
induced O O
chronic B-Disease B-Disease
liver I-Disease I-Disease
damage I-Disease I-Disease
in O O
female O O
SD O O
rats O O
. O O

Morinda O O
citrifolia O O
L O O
. O O

( O O
noni O O
) O O
has O O
been O O
used O O
throughout O O
the O O
Pacific O O
, O O
Southeast O O
Asia O O
, O O
Central O O
America O O
, O O
and O O
the O O
Caribbean O O
for O O
a O O
variety O O
of O O
health O O
conditions O O
, O O
including O O
heart O B-Disease
and O I-Disease
liver O I-Disease
ailments O I-Disease
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
the O O
hepatoprotective O O
effects O O
of O O
TAHITIAN O O
NONI O O
Juice O O
( O O
TNJ O O
) O O
against O O
CCl O O
( O O
4 O O
) O O
- O O
induced O O
chronic B-Disease B-Disease
liver I-Disease I-Disease
damage I-Disease I-Disease
in O O
female O O
Sprague O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

Twelve O O
female O O
SD O O
rats O O
were O O
divided O O
into O O
control O O
, O O
placebo O O
and O O
TNJ O O
( O O
6 O O
mL O O
/ O O
rat O O
/ O O
day O O
) O O
groups O O
. O O

On O O
day O O
15 O O
, O O
animals O O
in O O
the O O
placebo O O
and O O
TNJ O O
groups O O
received O O
0.25 O O
mL O O
/ O O
kg O O
CCl O O
( O O
4 O O
) O O
in O O
corn O O
oil O O
once O O
a O O
week O O
for O O
12 O O
successive O O
weeks O O
. O O

All O O
animals O O
were O O
sacrificed O O
at O O
week O O
16 O O
. O O

Blood O O
and O O
liver O O
were O O
collected O O
for O O
liver O O
function O O
, O O
lipid O O
panel O O
tests O O
, O O
and O O
histological O O
observation O O
. O O

Histopathological O O
examination O O
revealed O O
that O O
liver O O
sections O O
from O O
the O O
TNJ O O
+ O O
CCl O O
( O O
4 O O
) O O
appeared O O
similar O O
to O O
controls O O
, O O
whereas O O
typical O O
hepatic B-Disease B-Disease
steatosis I-Disease I-Disease
was O O
observed O O
in O O
the O O
placebo O O
+ O O
CCl O O
( O O
4 O O
) O O
group O O
. O O

Serum O O
alkaline O O
phosphatase O O
( O O
ALP O O
) O O
, O O
aspartate O O
aminotransferase O O
( O O
AST O O
) O O
, O O
alanine O O
transaminase O O
( O O
ALT O O
) O O
, O O
total O O
cholesterol O O
( O O
TC O O
) O O
, O O
triglycerides O O
( O O
TG O O
) O O
, O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
, O O
and O O
very O O
low O O
- O O
density O O
lipoprotein O O
( O O
VLDL O O
) O O
levels O O
were O O
increased O O
in O O
the O O
placebo O O
group O O
compared O O
with O O
the O O
TNJ O O
group O O
. O O

In O O
contrast O O
, O O
high O O
- O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
was O O
increased O O
in O O
the O O
TNJ O O
group O O
and O O
decreased O O
in O O
the O O
placebo O O
group O O
. O O

Thus O O
, O O
TNJ O O
juice O O
appears O O
to O O
protect O O
the O O
liver O O
from O O
chronic O O
exogenous O O
CCl O O
( O O
4 O O
) O O
exposures O O
. O O

Such O O
protective O O
mechanisms O O
are O O
supportive O O
evidence O O
for O O
the O O
utility O O
of O O
noni O O
in O O
traditional O O
medicine O O
for O O
liver O O
ailments O O
. O O

Chronopharmacology O O
and O O
antimicrobial O O
therapeutics O O
. O O

Chronobiology O O
studies O O
the O O
phenomenon O O
of O O
rhythmicity O O
in O O
living O O
organisms O O
. O O

Circadian O O
rhythms O O
are O O
genetically O O
determined O O
and O O
are O O
regulated O O
by O O
external O O
synchronizers O O
( O O
i.e. O O
light O O
/ O O
day O O
cycle O O
) O O
. O O

Several O O
biological O O
processes O O
involved O O
in O O
the O O
pharmacokinetics O O
and O O
pharmacodynamics O O
of O O
drugs O O
are O O
subject O O
to O O
circadian O O
variations O O
. O O

Chronopharmacology O O
studies O O
how O O
biological O O
rhythms O O
impact O O
on O O
drug O O
pharmacokinetic O O
( O O
chronokinetics O O
) O O
, O O
pharmacodynamics O O
( O O
chronoesthesy O O
) O O
and O O
toxicity O O
and O O
determines O O
whether O O
time O O
of O O
day O O
administration O O
modifies O O
drug O O
's O O
pharmacological O O
characteristics O O
. O O

Chronotherapy O O
applies O O
chronopharmacological O O
studies O O
to O O
clinical O O
treatments O O
, O O
determining O O
the O O
best O O
biological O O
time O O
for O O
its O O
dosing O O
, O O
i.e. O O
when O O
beneficial O O
effects O O
are O O
maximal O O
and O O
incidence O O
and O O
/ O O
or O O
intensity O O
of O O
related O O
side O O
- O O
effects O O
and O O
toxicity O O
are O O
minimal O O
. O O

Significant O O
variations O O
in O O
the O O
pharmacokinetics O O
and O O
toxicity O B-Disease
of O O
antibiotics O O
( O O
aminoglycosides O O
, O O
beta O O
- O O
lactams O O
and O O
fluoroquinolones O O
) O O
related O O
to O O
administration O O
time O O
are O O
well O O
known O O
. O O

The O O
aims O O
of O O
this O O
review O O
are O O
to O O
discuss O O
, O O
briefly O O
, O O
the O O
currently O O
accepted O O
model O O
of O O
the O O
circadian O O
system O O
that O O
substantiates O O
endogenous O O
rhythmicity O O
and O O
to O O
provide O O
an O O
update O O
on O O
the O O
knowledge O O
of O O
circadian O O
rhythms O O
applied O O
to O O
drugs O O
used O O
as O O
medicines O O
, O O
with O O
a O O
special O O
mention O O
to O O
the O O
possible O O
impact O O
on O O
antimicrobial O O
treatments O O
. O O

It O O
is O O
concluded O O
that O O
the O O
dosing O O
time O O
of O O
an O O
antimicrobial O O
agent O O
might O O
be O O
clinically O O
relevant O O
in O O
some O O
treatments O O
, O O
thus O O
, O O
clinicians O O
should O O
be O O
aware O O
that O O
the O O
dosing O O
time O O
might O O
affect O O
the O O
clinical O O
response O O
of O O
a O O
drug O O
. O O

Chemoimmunotherapy O O
reinduction O O
with O O
epratuzumab O O
in O O
children O O
with O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
in O O
marrow O O
relapse O O
: O O
a O O
Children O O
's O O
Oncology O O
Group O O
Pilot O O
Study O O
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
tolerability O O
and O O
serum O O
concentration O O
of O O
epratuzumab O O
, O O
a O O
humanized O O
monoclonal O O
antibody O O
targeting O O
CD22 O O
, O O
administered O O
alone O O
and O O
in O O
combination O O
with O O
reinduction O O
chemotherapy O O
in O O
children O O
with O O
relapsed O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
ALL B-Disease B-Disease
) O O
, O O
and O O
to O O
preliminarily O O
assess O O
tumor O B-Disease
targeting O O
and O O
efficacy O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Therapy O O
consisted O O
of O O
a O O
single O O
- O O
agent O O
phase O O
( O O
epratuzumab O O
360 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
dose O O
intravenously O O
twice O O
weekly O O
x O O
four O O
doses O O
) O O
, O O
followed O O
by O O
four O O
weekly O O
doses O O
of O O
epratuzumab O O
in O O
combination O O
with O O
standard O O
reinduction O O
chemotherapy O O
. O O

Morphologic O O
and O O
minimal O O
residual O O
disease O O
( O O
MRD O O
) O O
responses O O
were O O
determined O O
at O O
the O O
end O O
of O O
this O O
6 O O
- O O
week O O
period O O
. O O

Serum O O
concentrations O O
of O O
epratuzumab O O
were O O
determined O O
before O O
and O O
30 O O
minutes O O
after O O
infusions O O
, O O
and O O
CD22 O O
targeting O O
efficiency O O
was O O
determined O O
by O O
quantifying O O
changes O O
in O O
CD22 O O
expression O O
after O O
epratuzumab O O
administration O O
. O O

RESULTS O O
: O O
Fifteen O O
patients O O
( O O
12 O O
fully O O
assessable O O
for O O
toxicity O O
) O O
with O O
first O O
or O O
later O O
CD22 O O
- O O
positive O O
ALL B-Disease B-Disease
marrow O O
relapse O O
enrolled O O
on O O
the O O
feasibility O O
portion O O
of O O
this O O
study O O
from O O
December O O
2005 O O
to O O
June O O
2006 O O
. O O

Two O O
dose O O
- O O
limiting O O
toxicities O O
occurred O O
: O O
one O O
grade O O
4 O O
seizure B-Disease B-Disease
of O O
unclear O O
etiology O O
and O O
one O O
asymptomatic O O
grade O O
3 O O
ALT O O
elevation O O
. O O

In O O
all O O
but O O
one O O
patient O O
, O O
surface O O
CD22 O O
was O O
not O O
detected O O
by O O
flow O O
cytometry O O
on O O
peripheral O O
blood O O
leukemic O O
blasts O O
within O O
24 O O
hours O O
of O O
drug O O
administration O O
, O O
indicating O O
effective O O
targeting O O
of O O
leukemic O O
cells O O
by O O
epratuzumab O O
. O O

Nine O O
patients O O
achieved O O
a O O
complete O O
remission O O
after O O
chemoimmunotherapy O O
, O O
seven O O
of O O
whom O O
were O O
MRD O O
negative O O
. O O

CONCLUSION O O
: O O
Treatment O O
with O O
epratuzumab O O
plus O O
standard O O
reinduction O O
chemotherapy O O
is O O
feasible O O
and O O
acceptably O O
tolerated O O
in O O
children O O
with O O
relapsed O O
CD22 O O
- O O
positive O O
ALL B-Disease B-Disease
. O O

CD22 O O
targeting O O
was O O
efficient O O
, O O
and O O
the O O
majority O O
of O O
patients O O
achieved O O
favorable O O
early O O
responses O O
. O O

Pharmacokinetic O O
interaction O O
between O O
ethinyl O O
estradiol O O
, O O
norethindrone O O
and O O
darunavir O O
with O O
low O O
- O O
dose O O
ritonavir O O
in O O
healthy O O
women O O
. O O

BACKGROUND O O
: O O
An O O
open O O
- O O
label O O
, O O
randomized O O
, O O
crossover O O
study O O
was O O
performed O O
to O O
investigate O O
the O O
effect O O
of O O
multiple O O
doses O O
of O O
darunavir O O
co O O
- O O
administered O O
with O O
low O O
- O O
dose O O
ritonavir O O
( O O
DRV O O
/ O O
r O O
) O O
on O O
the O O
steady O O
- O O
state O O
pharmacokinetics O O
of O O
the O O
oral O O
contraceptives O O
ethinyl O O
estradiol O O
( O O
EE O O
) O O
and O O
norethindrone O O
( O O
NE O O
) O O
( O O
commercial O O
name O O
of O O
the O O
combined O O
drug O O
Ortho O O
- O O
Novum O O
1 O O
/ O O
35 O O
) O O
in O O
19 O O
HIV O O
- O O
negative O O
healthy O O
women O O
. O O

METHODS O O
: O O
In O O
session O O
1 O O
, O O
participants O O
received O O
35 O O
microg O O
EE O O
and O O
1.0 O O
mg O O
NE O O
from O O
days O O
1 O O
to O O
21 O O
. O O

In O O
session O O
2 O O
, O O
participants O O
received O O
the O O
same O O
oral O O
contraceptive O O
treatment O O
as O O
in O O
session O O
1 O O
on O O
days O O
1 O O
to O O
21 O O
plus O O
DRV O O
/ O O
r O O
( O O
600 O O
mg O O
/ O O
100 O O
mg O O
twice O O
daily O O
) O O
on O O
days O O
1 O O
to O O
14 O O
. O O

Pharmacokinetic O O
assessments O O
were O O
performed O O
on O O
day O O
14 O O
for O O
each O O
session O O
. O O

RESULTS O O
: O O
Steady O O
- O O
state O O
systemic O O
exposure O O
to O O
EE O O
and O O
NE O O
decreased O O
when O O
DRV O O
/ O O
r O O
was O O
co O O
- O O
administered O O
, O O
based O O
on O O
the O O
ratio O O
of O O
least O O
square O O
means O O
of O O
the O O
minimum O O
plasma O O
concentration O O
( O O
Cmin O O
) O O
, O O
the O O
maximum O O
plasma O O
concentration O O
( O O
Cmax O O
) O O
, O O
and O O
the O O
area O O
under O O
the O O
curve O O
( O O
AUC24h O O
) O O
of O O
EE O O
( O O
which O O
decreased O O
by O O
62 O O
% O O
, O O
32 O O
% O O
and O O
44 O O
% O O
, O O
respectively O O
) O O
and O O
NE O O
( O O
which O O
decreased O O
by O O
30 O O
% O O
, O O
10 O O
% O O
and O O
14 O O
% O O
, O O
respectively O O
) O O
compared O O
with O O
administration O O
of O O
EE O O
and O O
NE O O
alone O O
. O O

Five O O
participants O O
discontinued O O
the O O
study O O
due O O
to O O
grade O O
2 O O
cutaneous O O
events O O
, O O
as O O
required O O
per O O
protocol O O
, O O
during O O
treatment O O
with O O
EE O O
and O O
NE O O
in O O
combination O O
with O O
DRV O O
/ O O
r O O
. O O

There O O
were O O
no O O
clinically O O
relevant O O
findings O O
for O O
laboratory O O
and O O
cardiovascular O O
parameters O O
. O O

CONCLUSIONS O O
: O O
The O O
pharmacokinetic O O
interaction O O
observed O O
here O O
is O O
considered O O
to O O
be O O
clinically O O
relevant O O
as O O
EE O O
concentrations O O
are O O
considerably O O
reduced O O
when O O
DRV O O
/ O O
r O O
is O O
co O O
- O O
administered O O
with O O
EE O O
and O O
NE O O
. O O

Alternative O O
or O O
additional O O
contraceptive O O
measures O O
should O O
be O O
used O O
when O O
oestrogen O O
- O O
based O O
contraceptives O O
are O O
co O O
- O O
administered O O
with O O
DRV O O
/ O O
r O O
. O O

Eosinophil O O
- O O
derived O O
neurotoxin O O
/ O O
RNase O O
2 O O
: O O
connecting O O
the O O
past O O
, O O
the O O
present O O
and O O
the O O
future O O
. O O

The O O
eosinophil O O
- O O
derived O O
neurotoxin O O
( O O
EDN O O
, O O
also O O
known O O
as O O
eosinophil O O
protein O O
- O O
X O O
) O O
is O O
best O O
- O O
known O O
as O O
one O O
of O O
the O O
four O O
major O O
proteins O O
found O O
in O O
the O O
large O O
specific O O
granules O O
of O O
human O O
eosinophilic O O
leukocytes O O
. O O

Although O O
it O O
was O O
named O O
for O O
its O O
discovery O O
and O O
initial O O
characterization O O
as O O
a O O
neurotoxin O O
, O O
it O O
is O O
also O O
expressed O O
constitutively O O
in O O
human O O
liver O O
tissue O O
and O O
its O O
expression O O
can O O
be O O
induced O O
in O O
macrophages O O
by O O
proinflammatory O O
stimuli O O
. O O

EDN O O
and O O
its O O
divergent O O
orthologs O O
in O O
rodents O O
have O O
ribonuclease O O
activity O O
, O O
and O O
are O O
members O O
of O O
the O O
extensive O O
RNase O O
A O O
superfamily O O
, O O
although O O
the O O
relationship O O
between O O
the O O
characterized O O
physiologic O O
functions O O
and O O
enzymatic O O
activity O O
remains O O
poorly O O
understood O O
. O O

Recent O O
explorations O O
into O O
potential O O
physiologic O O
functions O O
for O O
EDN O O
have O O
provided O O
us O O
with O O
some O O
insights O O
into O O
its O O
role O O
in O O
antiviral O O
host O O
defense O O
, O O
as O O
a O O
chemoattractant O O
for O O
human O O
dendritic O O
cells O O
, O O
and O O
most O O
recently O O
, O O
as O O
an O O
endogenous O O
ligand O O
for O O
toll O O
- O O
like O O
receptor O O
( O O
TLR O O
) O O
2 O O
. O O

Endogenous O O
alpha O O
- O O
calcitonin O O
gene O O
- O O
related O O
peptide O O
mitigates O O
liver B-Disease B-Disease
fibrosis I-Disease I-Disease
in O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
induced O O
by O O
repeated O O
administration O O
of O O
concanavalin O O
A O O
. O O

BACKGROUND O O
: O O
Alpha O O
- O O
calcitonin O O
gene O O
- O O
related O O
peptide O O
( O O
alphaCGRP O O
) O O
is O O
a O O
37 O O
- O O
amino O O
acid O O
pleiotropic O O
peptide O O
that O O
we O O
previously O O
showed O O
to O O
exert O O
a O O
hepatoprotective O O
effect O O
during O O
concanavalin O O
A B-Disease O
( I-Disease O
Con I-Disease O
A I-Disease O
) I-Disease O
- I-Disease O
induced I-Disease O
acute I-Disease O
hepatitis I-Disease B-Disease
. O O

In O O
the O O
present O O
study O O
, O O
we O O
used O O
alphaCGRP O O
( O O
- O O
/ O O
- O O
) O O
mice O O
to O O
further O O
investigate O O
the O O
antifibrogenic O O
and O O
hepatoprotective O O
effects O O
of O O
endogenous O O
alphaCGRP O O
in O O
Con O O
A O O
- O O
induced O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
. O O

METHODS O O
: O O
Chronic B-Disease O
hepatitis I-Disease B-Disease
was O O
induced O O
in O O
alphaCGRP O O
( O O
- O O
/ O O
- O O
) O O
and O O
wild O O
- O O
type O O
mice O O
by O O
repeated O O
administration O O
of O O
Con O O
A O O
. O O

Serum O O
transaminases O O
were O O
measured O O
to O O
assess O O
hepatic O B-Disease
injury B-Disease I-Disease
. O O

The O O
severity O O
of O O
fibrosis B-Disease B-Disease
and O O
the O O
activation O O
of O O
hepatic O O
stellate O O
cells O O
( O O
HSCs O O
) O O
were O O
analysed O O
by O O
Masson O O
trichrome O O
staining O O
and O O
immunohistochemical O O
staining O O
of O O
alpha O O
- O O
smooth O O
muscle O O
actin O O
( O O
alpha O O
- O O
SMA O O
) O O
respectively O O
. O O

Altered O O
expression O O
of O O
fibrosis O B-Disease
- O O
and O O
inflammation O B-Disease
- O O
related O O
genes O O
was O O
evaluated O O
using O O
a O O
quantitative O O
real O O
- O O
time O O
polymerase O O
chain O O
reaction O O
. O O

Activation O O
and O O
proliferation O O
of O O
HSCs O O
were O O
analysed O O
using O O
both O O
primary O O
cultured O O
HSCs O O
from O O
the O O
mice O O
and O O
the O O
LI90 O O
HSC O O
cell O O
line O O
. O O

RESULTS O O
: O O
alphaCGRP O O
( O O
- O O
/ O O
- O O
) O O
mice O O
showed O O
more O O
severe O O
liver B-Disease O
fibrosis I-Disease B-Disease
than O O
wild O O
- O O
type O O
mice O O
in O O
a O O
Con O O
A O O
- O O
induced O O
chronic B-Disease O
hepatitis I-Disease B-Disease
model O O
. O O

In O O
histological O O
and O O
gene O O
expression O O
analyses O O
, O O
alphaCGRP O O
( O O
- O O
/ O O
- O O
) O O
mice O O
showed O O
greater O O
inflammatory O O
and O O
fibrotic O O
changes O O
, O O
greater O O
HSC O O
activation O O
and O O
a O O
higher O O
incidence O O
of O O
apoptosis B-Disease O
among O O
nonparenchymal O O
cells O O
than O O
wild O O
- O O
type O O
mice O O
. O O

CONCLUSIONS O O
: O O
Endogenous O O
alphaCGRP O O
mitigates O O
liver B-Disease B-Disease
fibrosis I-Disease I-Disease
in O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
induced O O
by O O
repeated O O
administration O O
of O O
Con O O
A O O
. O O

alphaCGRP O O
could O O
be O O
a O O
useful O O
therapeutic O O
target O O
for O O
the O O
treatment O O
of O O
chronic B-Disease B-Disease
hepatitis I-Disease I-Disease
. O O

Novel O O
roles O O
for O O
ceramides O O
, O O
calpains O O
and O O
caspases O O
in O O
kidney O O
proximal O O
tubule O O
cell O O
apoptosis O O
: O O
lessons O O
from O O
in O O
vitro O O
cadmium B-Disease O
toxicity I-Disease B-Disease
studies O O
. O O

Apoptosis O O
is O O
a O O
tightly O O
regulated O O
physiological O O
process O O
, O O
which O O
can O O
be O O
initiated O O
by O O
toxic O O
stimuli O O
, O O
such O O
as O O
cadmium O O
( O O
Cd2 O O
+ O O
) O O
. O O

Cd2 O O
+ O O
( O O
10 O O
- O O
50 O O
microM O O
) O O
induces O O
a O O
rapid O O
increase O O
in O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
( O O
> O O
or O O
= O O
30 O O
min O O
) O O
in O O
a O O
cell O O
line O O
derived O O
from O O
the O O
S1 O O
segment O O
of O O
rat O O
kidney O O
proximal O O
tubule O O
, O O
without O O
any O O
apparent O O
mitochondrial O B-Disease
dysfunction O I-Disease
. O O

The O O
sphingolipid O O
ceramide O O
is O O
an O O
important O O
second O O
messenger O O
in O O
apoptosis O O
. O O

Short O O
exposure O O
to O O
Cd2 O O
+ O O
( O O
3h O O
) O O
causes O O
an O O
increase O O
in O O
ceramides O O
, O O
which O O
occurs O O
downstream O O
of O O
ROS O O
formation O O
, O O
and O O
may O O
interact O O
with O O
cellular O O
components O O
, O O
such O O
as O O
endoplasmic O O
reticulum O O
and O O
mitochondria O O
. O O

Following O O
apoptosis O O
initiation O O
, O O
execution O O
must O O
take O O
place O O
. O O

The O O
classical O O
executioners O O
of O O
apoptosis O O
are O O
caspases O O
, O O
a O O
family O O
of O O
cysteine O O
proteases O O
. O O

However O O
, O O
increasing O O
studies O O
report O O
caspase O O
- O O
independent O O
apoptosis O O
, O O
which O O
questions O O
the O O
essentiality O O
of O O
caspases O O
for O O
apoptosis O O
implementation O O
. O O

With O O
low O O
micromolar O O
Cd2 O O
+ O O
concentrations O O
( O O
< O O
10 O O
microM O O
) O O
, O O
caspases O O
are O O
only O O
activated O O
after O O
24h O O
and O O
not O O
at O O
earlier O O
time O O
points O O
, O O
which O O
supports O O
the O O
notion O O
of O O
caspase O O
- O O
independent O O
apoptosis O O
. O O

Due O O
to O O
increased O O
cytosolic O O
Ca O O
( O O
2 O O
+ O O
) O O
under O O
pathological O O
conditions O O
, O O
a O O
role O O
for O O
the O O
Ca2 O O
+ O O
- O O
dependent O O
proteases O O
, O O
calpains O O
, O O
has O O
emerged O O
. O O

Calpain O O
activation O O
by O O
Cd2 O O
+ O O
( O O
3 O O
- O O
6 O O
h O O
) O O
seems O O
to O O
be O O
regulated O O
by O O
ceramide O O
levels O O
, O O
in O O
order O O
to O O
induce O O
apoptosis O O
. O O

Calpain O O
and O O
caspase O O
substrates O O
overlap O O
but O O
yield O O
different O O
fragments O O
, O O
which O O
may O O
explain O O
their O O
diverse O O
downstream O O
targets O O
. O O

Furthermore O O
, O O
calpains O O
and O O
caspases O O
may O O
interact O O
with O O
one O O
another O O
to O O
enhance O O
, O O
as O O
seen O O
by O O
Cd2 O O
+ O O
, O O
or O O
diminish O O
apoptosis O O
. O O

In O O
this O O
review O O
, O O
we O O
discuss O O
novel O O
roles O O
for O O
ceramides O O
, O O
calpains O O
and O O
caspases O O
as O O
part O O
of O O
Cd2 O O
+ O O
- O O
induced O O
apoptotic O O
signalling O O
pathways O O
in O O
the O O
kidney O O
proximal O O
tubule O O
and O O
their O O
in O O
vivo O O
relevance O O
to O O
Cd2 O O
+ O O
- O O
induced O O
nephrotoxicity B-Disease B-Disease
. O O

Effect O O
of O O
darbepoetin O O
alfa O O
administered O O
once O O
monthly O O
on O O
maintaining O O
hemoglobin O O
levels O O
in O O
older O O
patients O O
with O O
chronic B-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
. O O

BACKGROUND O O
: O O
The O O
anemia B-Disease B-Disease
of I-Disease O
chronic I-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
( O O
CKD B-Disease B-Disease
) O O
is O O
associated O O
with O O
increased O O
hospitalizations O O
, O O
increased O O
cardiovascular O O
morbidity O O
and O O
mortality O O
, O O
and O O
diminished O O
quality O O
of O O
life O O
in O O
the O O
elderly O O
. O O

Darbepoetin O O
alfa O O
is O O
an O O
erythropoiesis O O
- O O
stimulating O O
agent O O
that O O
has O O
been O O
shown O O
to O O
be O O
effective O O
in O O
treating O O
anemia B-Disease B-Disease
in O O
patients O O
with O O
CKD B-Disease B-Disease
( O O
but O O
not O O
on O O
dialysis O O
) O O
when O O
administered O O
using O O
extended O O
- O O
dosing O O
regimens O O
. O O

OBJECTIVE O O
: O O
The O O
purpose O O
of O O
this O O
post O O
hoc O O
analysis O O
was O O
to O O
examine O O
the O O
efficacy O O
and O O
safety O O
profile O O
of O O
once O O
- O O
monthly O O
( O O
QM O O
) O O
darbepoetin O O
alfa O O
in O O
study O O
patients O O
stratified O O
according O O
to O O
age O O
( O O
ie O O
, O O
< O O
65 O O
, O O
65 O O
- O O
74 O O
, O O
and O O
> O O
or O O
= O O
75 O O
years O O
) O O
. O O

METHODS O O
: O O
Patients O O
with O O
CKD B-Disease B-Disease
but O O
not O O
on O O
dialysis O O
, O O
receiving O O
darbepoetin O O
alfa O O
every O O
other O O
week O O
( O O
Q2W O O
) O O
, O O
and O O
with O O
stable O O
hemoglobin O O
( O O
Hb O O
) O O
levels O O
between O O
11 O O
and O O
13 O O
g O O
/ O O
dL O O
, O O
inclusive O O
, O O
were O O
enrolled O O
in O O
this O O
33 O O
- O O
week O O
, O O
multicenter O O
, O O
open O O
- O O
label O O
, O O
single O O
- O O
arm O O
study O O
. O O

The O O
study O O
was O O
carried O O
out O O
at O O
36 O O
US O O
centers O O
and O O
consisted O O
of O O
a O O
24 O O
- O O
week O O
QM O O
darbepoetin O O
alfa O O
dose O O
- O O
titration O O
period O O
followed O O
by O O
an O O
8 O O
- O O
week O O
evaluation O O
period O O
. O O

Hb O O
levels O O
were O O
measured O O
Q2W O O
. O O

Study O O
results O O
were O O
stratified O O
according O O
to O O
patient O O
age O O
( O O
< O O
65 O O
, O O
65 O O
- O O
74 O O
, O O
and O O
> O O
or O O
= O O
75 O O
years O O
) O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
152 O O
patients O O
( O O
79 O O
women O O
, O O
73 O O
men O O
) O O
were O O
enrolled O O
; O O
55 O O
patients O O
( O O
36 O O
% O O
) O O
were O O
< O O
65 O O
years O O
of O O
age O O
, O O
46 O O
( O O
30 O O
% O O
) O O
were O O
65 O O
to O O
74 O O
years O O
of O O
age O O
, O O
and O O
51 O O
( O O
34 O O
% O O
) O O
were O O
> O O
or O O
= O O
75 O O
years O O
of O O
age O O
. O O

In O O
patients O O
who O O
received O O
> O O
or O O
= O O
1 O O
dose O O
of O O
darbepoetin O O
alfa O O
, O O
Hb O O
levels O O
> O O
or O O
= O O
11 O O
g O O
/ O O
dL O O
were O O
maintained O O
in O O
76 O O
% O O
, O O
80 O O
% O O
, O O
and O O
71 O O
% O O
of O O
patients O O
aged O O
< O O
65 O O
, O O
65 O O
to O O
74 O O
, O O
and O O
> O O
or O O
= O O
75 O O
years O O
, O O
respectively O O
. O O

For O O
patients O O
who O O
completed O O
the O O
study O O
, O O
the O O
proportions O O
who O O
maintained O O
Hb O O
levels O O
> O O
or O O
= O O
11 O O
g O O
/ O O
dL O O
were O O
83 O O
% O O
, O O
88 O O
% O O
, O O
and O O
85 O O
% O O
, O O
respectively O O
, O O
for O O
the O O
3 O O
age O O
groups O O
. O O

The O O
safety O O
profile O O
of O O
QM O O
darbepoetin O O
alfa O O
in O O
this O O
study O O
was O O
consistent O O
with O O
that O O
expected O O
in O O
patients O O
with O O
CKD B-Disease B-Disease
not O O
receiving O O
dialysis O O
. O O

CONCLUSIONS O O
: O O
Darbepoetin O O
alfa O O
administered O O
QM O O
maintained O O
Hb O O
levels O O
> O O
or O O
= O O
11 O O
g O O
/ O O
dL O O
in O O
patients O O
with O O
CKD B-Disease B-Disease
( O O
not O O
on O O
dialysis O O
) O O
aged O O
< O O
65 O O
, O O
65 O O
to O O
74 O O
, O O
and O O
> O O
or O O
= O O
75 O O
years O O
. O O

This O O
treatment O O
regimen O O
may O O
help O O
optimize O O
anemia B-Disease B-Disease
management O O
for O O
older O O
community O O
- O O
dwelling O O
and O O
long O O
- O O
term O O
care O O
patients O O
. O O

EF24 O O
, O O
a O O
novel O O
curcumin O O
analog O O
, O O
disrupts O O
the O O
microtubule O O
cytoskeleton O O
and O O
inhibits O O
HIF O O
- O O
1 O O
. O O

Curcumin O O
, O O
the O O
yellow O O
pigment O O
of O O
the O O
spice O O
turmeric O O
, O O
has O O
emerged O O
as O O
a O O
promising O O
anticancer O O
agent O O
due O O
to O O
its O O
antiproliferative O O
and O O
antiangiogenic O O
properties O O
. O O

However O O
, O O
the O O
molecular O O
mechanism O O
of O O
action O O
of O O
this O O
compound O O
remains O O
a O O
subject O O
of O O
debate O O
. O O

In O O
addition O O
, O O
curcumin O O
's O O
low O O
bioavailability O O
and O O
efficacy O O
profile O O
in O O
vivo O O
further O O
hinders O O
its O O
clinical O O
development O O
. O O

This O O
study O O
focuses O O
on O O
the O O
mechanism O O
of O O
action O O
of O O
EF24 O O
, O O
a O O
novel O O
curcumin O O
analog O O
with O O
greater O O
than O O
curcumin O O
biological O O
activity O O
and O O
bioavailability O O
, O O
but O O
no O O
increased O O
toxicity O O
. O O

Treatment O O
of O O
MDA O O
- O O
MB231 O O
breast O O
and O O
PC3 O O
prostate B-Disease O
cancer I-Disease O
cells O O
with O O
EF24 O O
or O O
curcumin O O
led O O
to O O
inhibition O O
of O O
HIF O O
- O O
1alpha O O
protein O O
levels O O
and O O
, O O
consequently O O
, O O
inhibition O O
of O O
HIF O O
transcriptional O O
activity O O
. O O

This O O
drug O O
- O O
induced O O
HIF O O
inhibition O O
occurred O O
in O O
a O O
VHL O O
- O O
dependent O O
but O O
proteasome O O
- O O
independent O O
manner O O
. O O

We O O
found O O
that O O
, O O
while O O
curcumin O O
inhibited O O
HIF O O
- O O
1alpha O O
gene O O
transcription O O
, O O
EF24 O O
exerted O O
its O O
activity O O
by O O
inhibiting O O
HIF O O
- O O
1alpha O O
posttranscriptionally O O
. O O

This O O
result O O
suggested O O
that O O
the O O
two O O
compounds O O
are O O
structurally O O
similar O O
but O O
mechanistically O O
distinct O O
. O O

Another O O
cellular O O
effect O O
that O O
further O O
differentiated O O
the O O
two O O
compounds O O
was O O
the O O
ability O O
of O O
EF24 O O
, O O
but O O
not O O
curcumin O O
, O O
to O O
induce O O
microtubule O O
stabilization O O
in O O
cells O O
. O O

EF24 O O
had O O
no O O
stabilizing O O
effect O O
on O O
tubulin O O
polymerization O O
in O O
an O O
in O O
vitro O O
assay O O
using O O
purified O O
bovine O O
brain O O
tubulin O O
, O O
suggesting O O
that O O
the O O
EF24 O O
- O O
induced O O
cytoskeletal O O
disruption O O
in O O
cells O O
may O O
be O O
the O O
result O O
of O O
upstream O O
signaling O O
events O O
rather O O
than O O
EF24 O O
direct O O
binding O O
to O O
tubulin O O
. O O

In O O
summary O O
, O O
our O O
study O O
identifies O O
EF24 O O
as O O
a O O
novel O O
curcumin O O
- O O
related O O
compound O O
possessing O O
a O O
distinct O O
mechanism O O
of O O
action O O
, O O
which O O
we O O
believe O O
contributes O O
to O O
the O O
potent O O
anticancer O O
activity O O
of O O
this O O
agent O O
and O O
can O O
be O O
further O O
exploited O O
to O O
investigate O O
the O O
therapeutic O O
potential O O
of O O
EF24 O O
. O O

How O O
can O O
biologically O O
- O O
based O O
modeling O O
of O O
arsenic O O
kinetics O O
and O O
dynamics O O
inform O O
the O O
risk O O
assessment O O
process O O
? O O

- O O
A O O
workshop O O
review O O
. O O

Quantitative O O
biologically O O
- O O
based O O
models O O
describing O O
key O O
events O O
in O O
the O O
continuum O O
from O O
arsenic O O
exposure O O
to O O
the O O
development O O
of O O
adverse O O
health O O
effects O O
provide O O
a O O
framework O O
to O O
integrate O O
information O O
obtained O O
across O O
diverse O O
research O O
areas O O
. O O

For O O
example O O
, O O
genetic O O
polymorphisms O O
in O O
arsenic O O
metabolizing O O
enzymes O O
can O O
lead O O
to O O
differences O O
in O O
target O O
tissue O O
dosimetry O O
for O O
key O O
metabolites O O
causative O O
in O O
toxic O O
and O O
carcinogenic B-Disease O
response I-Disease O
. O O

This O O
type O O
of O O
variation O O
can O O
be O O
quantitatively O O
incorporated O O
into O O
pharmacokinetic O O
( O O
PK O O
) O O
models O O
and O O
used O O
together O O
with O O
population O O
- O O
based O O
modeling O O
approaches O O
to O O
evaluate O O
the O O
impact O O
of O O
genetic O O
variation O O
in O O
methylation O O
capacity O O
on O O
dose O O
of O O
key O O
metabolites O O
to O O
target O O
tissue O O
. O O

The O O
PK O O
model O O
is O O
an O O
essential O O
bridge O O
to O O
the O O
pharmacodynamic O O
( O O
PD O O
) O O
models O O
. O O

A O O
particular O O
benefit O O
of O O
PD O O
modeling O O
for O O
arsenic O O
is O O
that O O
alternative O O
models O O
can O O
be O O
constructed O O
for O O
multiple O O
proposed O O
modes O O
of O O
action O O
for O O
arsenicals O O
. O O

Genomics O O
data O O
will O O
prove O O
useful O O
for O O
identifying O O
the O O
key O O
pathways O O
involved O O
in O O
particular O O
responses O O
and O O
aid O O
in O O
determining O O
other O O
types O O
of O O
data O O
needed O O
for O O
quantitative O O
modeling O O
. O O

These O O
models O O
, O O
when O O
linked O O
with O O
PK O O
models O O
, O O
can O O
be O O
used O O
to O O
better O O
understand O O
and O O
explain O O
dose O O
- O O
and O O
time O O
- O O
response O O
behaviors O O
. O O

This O O
in O O
turn O O
assists O O
in O O
prioritizing O O
modes O O
of O O
action O O
with O O
respect O O
to O O
their O O
risk O O
assessment O O
relevance O O
and O O
future O O
research O O
. O O

This O O
type O O
of O O
integrated O O
modeling O O
approach O O
can O O
form O O
the O O
basis O O
for O O
a O O
highly O O
informative O O
mode O O
- O O
of O O
- O O
action O O
directed O O
risk O O
assessment O O
for O O
inorganic O O
arsenic O O
( O O
iAs O O
) O O
. O O

This O O
paper O O
will O O
address O O
both O O
practical O O
and O O
theoretical O O
aspects O O
of O O
integrating O O
PK O O
and O O
PD O O
data O O
in O O
a O O
modeling O O
framework O O
, O O
including O O
practical O O
barriers O O
to O O
its O O
application O O
. O O

Enhanced O O
PDE4B O O
expression O O
augments O O
LPS O O
- O O
inducible O O
TNF O O
expression O O
in O O
ethanol O O
- O O
primed O O
monocytes O O
: O O
relevance O O
to O O
alcoholic B-Disease B-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
. O O

Increased O O
plasma O O
and O O
hepatic O O
TNF O O
- O O
alpha O O
expression O O
is O O
well O O
documented O O
in O O
patients O O
with O O
alcoholic B-Disease B-Disease
hepatitis I-Disease I-Disease
and O O
is O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
alcoholic B-Disease B-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
. O O

We O O
have O O
previously O O
shown O O
that O O
monocytes O O
from O O
patients O O
with O O
alcoholic B-Disease B-Disease
hepatitis I-Disease I-Disease
show O O
increased O O
constitutive O O
and O O
LPS O O
- O O
induced O O
NF O O
- O O
kappaB O O
activation O O
and O O
TNF O O
- O O
alpha O O
production O O
. O O

Our O O
recent O O
studies O O
showed O O
that O O
chronic O O
ethanol O O
exposure O O
significantly O O
decreased O O
cellular O O
cAMP O O
levels O O
in O O
both O O
LPS O O
- O O
stimulated O O
and O O
unstimulated O O
monocytes O O
and O O
Kupffer O O
cells O O
, O O
leading O O
to O O
an O O
increase O O
in O O
LPS O O
- O O
inducible O O
TNF O O
- O O
alpha O O
production O O
by O O
affecting O O
NF O O
- O O
kappaB O O
activation O O
and O O
induction O O
of O O
TNF O O
mRNA O O
expression O O
. O O

Accordingly O O
, O O
the O O
mechanisms O O
underlying O O
this O O
ethanol O O
- O O
induced O O
decrease O O
in O O
cellular O O
cAMP O O
leading O O
to O O
an O O
increase O O
in O O
TNF O O
expression O O
were O O
examined O O
in O O
monocytes O O
/ O O
macrophages O O
. O O

In O O
this O O
study O O
, O O
chronic O O
ethanol O O
exposure O O
was O O
observed O O
to O O
significantly O O
increase O O
LPS O O
- O O
inducible O O
expression O O
of O O
cAMP O O
- O O
specific O O
phosphodiesterase O O
( O O
PDE O O
) O O
4B O O
that O O
degrades O O
cellular O O
cAMP O O
. O O

Increased O O
PDE4B O O
expression O O
was O O
associated O O
with O O
enhanced O O
NF O O
- O O
kappaB O O
activation O O
and O O
transcriptional O O
activity O O
and O O
subsequent O O
priming O O
of O O
monocytes O O
/ O O
macrophages O O
leading O O
to O O
enhanced O O
LPS O O
- O O
inducible O O
TNF O O
- O O
alpha O O
production O O
. O O

Selective O O
inhibition O O
of O O
PDE4 O O
by O O
rolipram O O
abrogated O O
LPS O O
- O O
mediated O O
TNF O O
- O O
alpha O O
expression O O
at O O
both O O
protein O O
and O O
mRNA O O
levels O O
in O O
control O O
and O O
ethanol O O
- O O
treated O O
cells O O
. O O

Notably O O
, O O
PDE4 O O
inhibition O O
did O O
not O O
affect O O
LPS O O
- O O
inducible O O
NF O O
- O O
kappaB O O
activation O O
but O O
significantly O O
decreased O O
NF O O
- O O
kappaB O O
transcriptional O O
activity O O
. O O

These O O
findings O O
strongly O O
support O O
the O O
pathogenic O O
role O O
of O O
PDE4B O O
in O O
the O O
ethanol O O
- O O
mediated O O
priming O O
of O O
monocytes O O
/ O O
macrophages O O
and O O
increased O O
LPS O O
- O O
inducible O O
TNF O O
production O O
and O O
the O O
subsequent O O
development O O
of O O
alcoholic B-Disease B-Disease
liver I-Disease I-Disease
disease I-Disease I-Disease
( O O
ALD B-Disease B-Disease
) O O
. O O

Since O O
enhanced O O
TNF O O
expression O O
plays O O
a O O
significant O O
role O O
in O O
the O O
evolution O O
of O O
clinical O O
and O O
experimental O O
ALD B-Disease B-Disease
, O O
its O O
downregulation O O
via O O
selective O O
PDE4B O O
inhibitors O O
could O O
constitute O O
a O O
novel O O
therapeutic O O
approach O O
in O O
the O O
treatment O O
of O O
ALD B-Disease B-Disease
. O O

The O O
molecular O O
basis O O
of O O
class O O
side O O
effects O O
due O O
to O O
treatment O O
with O O
inhibitors O O
of O O
the O O
VEGF O O
/ O O
VEGFR O O
pathway O O
. O O

Vascular O O
Endothelial O O
Growth O O
Factor O O
( O O
VEGF O O
) O O
is O O
considered O O
to O O
be O O
one O O
of O O
the O O
most O O
important O O
regulators O O
of O O
angiogenesis O O
and O O
a O O
new O O
key O O
target O O
in O O
anti O O
- O O
cancer O O
treatment O O
. O O

Various O O
clinical O O
trials O O
have O O
validated O O
the O O
clinical O O
importance O O
of O O
anti O O
- O O
VEGF O O
or O O
anti O O
- O O
VEGF O O
receptor O O
( O O
VEGFR O O
) O O
therapy O O
. O O

Currently O O
the O O
humanized O O
monoclonal O O
antibody O O
bevacizumab O O
( O O
blocks O O
VEGF O O
- O O
A O O
) O O
, O O
and O O
the O O
tyrosine O O
kinase O O
inhibitors O O
sunitinib O O
and O O
sorafenib O O
( O O
inhibit O O
VEGFRs O O
) O O
are O O
approved O O
for O O
patients O O
with O O
various O O
malignancies B-Disease B-Disease
and O O
several O O
others O O
are O O
expected O O
in O O
the O O
coming O O
years O O
. O O

Unfortunately O O
, O O
anti O O
- O O
VEGF O O
/ O O
VEGFR O O
treatment O O
is O O
not O O
void O O
of O O
side O O
effects O O
. O O

An O O
array O O
of O O
unexpected O O
side O O
effects O O
is O O
now O O
seen O O
in O O
clinical O O
practice O O
. O O

Management O O
of O O
these O O
side O O
effects O O
is O O
extremely O O
important O O
in O O
the O O
development O O
of O O
the O O
various O O
anti O O
- O O
VEGF O O
/ O O
VEGFR O O
therapies O O
and O O
their O O
optimal O O
use O O
. O O

This O O
review O O
provides O O
an O O
overview O O
of O O
the O O
toxicity O O
profile O O
of O O
this O O
class O O
of O O
agents O O
, O O
the O O
molecular O O
basis O O
behind O O
these O O
side O O
effects O O
and O O
indicates O O
potential O O
options O O
for O O
management O O
. O O

VEGF O O
and O O
its O O
receptors O O
play O O
an O O
important O O
role O O
in O O
normal O O
tissues O O
and O O
are O O
widely O O
expressed O O
. O O

It O O
is O O
likely O O
that O O
interference O O
with O O
this O O
pathway O O
induces O O
an O O
array O O
of O O
side O O
effects O O
due O O
to O O
the O O
lack O O
of O O
normal O O
function O O
of O O
VEGF O O
. O O

A O O
consistent O O
pattern O O
of O O
side O O
effects O O
is O O
now O O
emerging O O
. O O

Hypertension B-Disease B-Disease
, O O
gastro B-Disease B-Disease
- I-Disease I-Disease
intestinal I-Disease I-Disease
toxicity I-Disease I-Disease
, O O
hypothyroidism B-Disease B-Disease
, O O
proteinuria B-Disease B-Disease
, O O
coagulation B-Disease B-Disease
disorders I-Disease I-Disease
and O O
neurotoxicity B-Disease B-Disease
are O O
side O O
effects O O
observed O O
with O O
both O O
anti O O
- O O
VEGF O O
and O O
anti O O
- O O
VEGFR O O
inhibitors O O
. O O

For O O
these O O
side O O
effects O O
the O O
role O O
of O O
VEGF O O
/ O O
VEGFR O O
pathway O O
in O O
normal O O
tissue O O
was O O
reviewed O O
in O O
order O O
to O O
provide O O
a O O
molecular O O
mechanism O O
that O O
linked O O
side O O
effect O O
with O O
physiological O O
activity O O
of O O
VEGF O O
/ O O
VEGFR O O
. O O

Insight O O
into O O
the O O
molecular O O
basis O O
may O O
aid O O
specific O O
supportive O O
care O O
measures O O
to O O
ensure O O
optimal O O
use O O
of O O
this O O
class O O
of O O
agents O O
. O O

Conclusion O O
: O O
Inhibiting O O
the O O
VEGF O O
/ O O
VEGFR O O
pathway O O
is O O
an O O
effective O O
approach O O
to O O
treat O O
cancer B-Disease B-Disease
. O O

It O O
has O O
also O O
provided O O
new O O
insight O O
into O O
the O O
physiological O O
role O O
of O O
this O O
pathway O O
in O O
various O O
organs O O
. O O

Integrating O O
the O O
knowledge O O
in O O
daily O O
oncological O O
practice O O
will O O
be O O
a O O
challenge O O
for O O
the O O
future O O
. O O

Safety O O
of O O
drug O O
eluting O O
stents O O
: O O
current O O
concerns O O
and O O
controversies O O
. O O

Coronary O O
artery O O
stenting O O
is O O
currently O O
the O O
most O O
frequently O O
performed O O
percutaneous O O
coronary O O
intervention O O
for O O
the O O
treatment O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
. O O

Recently O O
, O O
drug O O
- O O
eluting O O
stents O O
, O O
loaded O O
with O O
anti O O
- O O
inflammatory O O
, O O
anti O O
- O O
migratory O O
, O O
anti O O
- O O
proliferative O O
or O O
pro O O
- O O
healing O O
drugs O O
, O O
have O O
revolutionized O O
the O O
management O O
of O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
by O O
markedly O O
reducing O O
in O O
- O O
stent O O
restenosis O B-Disease
. O O

Despite O O
the O O
excellent O O
short O O
- O O
and O O
mid O O
- O O
term O O
results O O
of O O
randomized O O
controlled O O
trials O O
observed O O
with O O
drug O O
- O O
eluting O O
stents O O
, O O
there O O
remain O O
a O O
number O O
of O O
unresolved O O
issues O O
and O O
valid O O
concerns O O
about O O
long O O
- O O
term O O
safety O O
and O O
efficacy O O
of O O
this O O
revolutionary O O
technology O O
. O O

Important O O
safety O O
issues O O
such O O
as O O
thrombosis B-Disease B-Disease
, O O
late O O
stent B-Disease O
malapposition I-Disease O
, O O
aneurysm B-Disease B-Disease
formation O O
, O O
edge B-Disease O
effect I-Disease O
, O O
late O O
inflammation B-Disease B-Disease
due O O
to O O
choice O O
of O O
polymer O O
used O O
to O O
bind O O
the O O
drug O O
, O O
the O O
release O O
of O O
toxins O O
, O O
and O O
potential O O
interactions O O
with O O
brachytherapy O O
and O O
drugs O O
have O O
not O O
been O O
completely O O
addressed O O
. O O

This O O
review O O
article O O
evaluates O O
current O O
available O O
scientific O O
evidence O O
on O O
the O O
various O O
safety O O
issues O O
related O O
to O O
the O O
use O O
of O O
drug O O
- O O
eluting O O
stents O O
. O O

Evidence O O
for O O
altered O O
hippocampal O O
volume O O
and O O
brain O O
metabolites O O
in O O
workers O O
occupationally O O
exposed O O
to O O
lead O O
: O O
a O O
study O O
by O O
magnetic O O
resonance O O
imaging O O
and O O
( O O
1 O O
) O O
H O O
magnetic O O
resonance O O
spectroscopy O O
. O O

Environmental O O
and O O
occupational O O
exposure O O
to O O
lead O O
( O O
Pb O O
) O O
remains O O
to O O
be O O
a O O
major O O
public O O
health O O
issue O O
. O O

The O O
purpose O O
of O O
this O O
cross O O
- O O
sectional O O
study O O
was O O
to O O
use O O
non O O
- O O
invasive O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
and O O
proton O O
magnetic O O
resonance O O
spectroscopy O O
( O O
( O O
1 O O
) O O
H O O
MRS O O
) O O
techniques O O
to O O
investigate O O
whether O O
chronic O O
exposure O O
to O O
Pb O O
in O O
an O O
occupational O O
setting O O
altered O O
brain O O
structure O O
and O O
function O O
of O O
Pb O O
- O O
exposed O O
workers O O
. O O

The O O
Pb O O
- O O
exposed O O
group O O
consisted O O
of O O
15 O O
workers O O
recruited O O
from O O
either O O
a O O
Pb O O
- O O
smelting O O
factory O O
or O O
a O O
Pb O O
- O O
battery O O
manufacturer O O
. O O

The O O
control O O
group O O
had O O
19 O O
healthy O O
volunteers O O
who O O
had O O
no O O
history O O
of O O
Pb O O
exposure O O
in O O
working O O
environment O O
or O O
at O O
home O O
. O O

The O O
average O O
airborne O O
Pb O O
concentrations O O
in O O
fume O O
and O O
dust O O
were O O
0.43 O O
and O O
0.44 O O
mg O O
/ O O
m O O
( O O
3 O O
) O O
, O O
respectively O O
, O O
in O O
the O O
smeltery O O
, O O
and O O
0.10 O O
and O O
1.06 O O
mg O O
/ O O
m O O
( O O
3 O O
) O O
, O O
respectively O O
, O O
in O O
the O O
Pb O O
battery O O
workshop O O
. O O

The O O
average O O
blood O O
Pb O O
concentrations O O
( O O
BPb O O
) O O
in O O
Pb O O
- O O
exposed O O
and O O
control O O
workers O O
were O O
63.5 O O
and O O
8.7 O O
microg O O
/ O O
dL O O
, O O
respectively O O
. O O

The O O
MRI O O
examination O O
showed O O
that O O
brain O O
hippocampal O O
volume O O
among O O
Pb O O
- O O
exposed O O
workers O O
was O O
significantly O O
diminished O O
in O O
comparison O O
to O O
age O O
- O O
matched O O
control O O
subjects O O
( O O
p O O
< O O
0.01 O O
) O O
, O O
although O O
the O O
extent O O
of O O
this O O
reduction O O
was O O
relatively O O
small O O
( O O
5 O O
- O O
6 O O
% O O
of O O
the O O
control O O
values O O
) O O
. O O

Linear O O
regression O O
analyses O O
revealed O O
significant O O
inverse O O
associations O O
between O O
BPb O O
and O O
the O O
decreased O O
hippocampal O O
volume O O
on O O
both O O
sides O O
of O O
brain O O
hemisphere O O
. O O

Among O O
five O O
brain O O
metabolites O O
investigated O O
by O O
MRS O O
, O O
i.e. O O
, O O
N O O
- O O
acetyl O O
- O O
aspartate O O
( O O
NAA O O
) O O
, O O
creatine O O
( O O
Cr O O
) O O
, O O
choline O O
( O O
Cho O O
) O O
, O O
inosine O O
( O O
mI O O
) O O
, O O
glutamate O O
/ O O
glutamine O O
( O O
Glx O O
) O O
and O O
lipids O O
( O O
Lip O O
) O O
, O O
a O O
significant O O
decrease O O
in O O
NAA O O
/ O O
Cr O O
ratio O O
( O O
7 O O
% O O
of O O
controls O O
, O O
p O O
< O O
0.05 O O
) O O
and O O
a O O
remarkable O O
increase O O
in O O
Lip O O
/ O O
Cr O O
ratio O O
( O O
40 O O
% O O
, O O
p O O
< O O
0.01 O O
) O O
were O O
observed O O
in O O
the O O
brains O O
of O O
Pb O O
- O O
exposed O O
workers O O
as O O
compared O O
to O O
controls O O
. O O

Furthermore O O
, O O
the O O
increased O O
Lip O O
/ O O
Cr O O
ratio O O
was O O
significantly O O
associated O O
with O O
BPb O O
( O O
r O O
= O O
0.46 O O
, O O
p O O
< O O
0.01 O O
) O O
. O O

Taken O O
together O O
, O O
this O O
study O O
suggests O O
that O O
occupational O O
exposure O O
to O O
Pb O O
may O O
cause O O
subtle O O
structural O O
and O O
functional O O
alteration O O
in O O
human O O
brains O O
. O O

The O O
MRI O O
and O O
MRS O O
brain O O
imaging O O
techniques O O
can O O
be O O
used O O
as O O
the O O
non O O
- O O
invasive O O
means O O
to O O
evaluate O O
Pb O O
- O O
induced O O
neurotoxicity B-Disease B-Disease
. O O

Anemia B-Disease B-Disease
during O O
sequential O O
induction O O
chemotherapy O O
and O O
chemoradiation O O
for O O
head B-Disease B-Disease
and I-Disease I-Disease
neck I-Disease I-Disease
cancer I-Disease I-Disease
: O O
the O O
impact O O
of O O
blood O O
transfusion O O
on O O
treatment O O
outcome O O
. O O

PURPOSE O O
: O O
Sequential O O
treatment O O
( O O
chemotherapy O O
followed O O
by O O
concomitant O O
chemoradiation O O
; O O
CCRT O O
) O O
is O O
increasingly O O
being O O
used O O
for O O
radical O O
treatment O O
of O O
squamous B-Disease B-Disease
cell I-Disease I-Disease
cancer I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
head I-Disease I-Disease
and I-Disease I-Disease
neck I-Disease I-Disease
( O O
SCCHN B-Disease B-Disease
) O O
, O O
which O O
results O O
in O O
increased O O
myelosuppression B-Disease B-Disease
. O O

In O O
this O O
study O O
, O O
we O O
review O O
the O O
incidence O O
of O O
anemia B-Disease B-Disease
and O O
the O O
effect O O
of O O
a O O
policy O O
of O O
hemoglobin O O
( O O
Hb O O
) O O
maintenance O O
by O O
blood O O
transfusion O O
on O O
disease O O
outcomes O O
in O O
these O O
patients O O
. O O

METHODS O O
AND O O
MATERIALS O O
: O O
Retrospective O O
review O O
of O O
the O O
records O O
of O O
patients O O
with O O
SCCHN B-Disease B-Disease
treated O O
with O O
sequential O O
CCRT O O
formed O O
the O O
basis O O
of O O
this O O
study O O
. O O

The O O
incidence O O
of O O
anemia B-Disease B-Disease
and O O
statistics O O
on O O
blood O O
transfusion O O
were O O
documented O O
. O O

For O O
the O O
purpose O O
of O O
outcome O O
analyses O O
, O O
patients O O
were O O
divided O O
into O O
four O O
categories O O
by O O
( O O
1 O O
) O O
transfusion O O
status O O
, O O
( O O
2 O O
) O O
nadir O O
Hb O O
concentration O O
, O O
( O O
3 O O
) O O
number O O
of O O
transfusion O O
episodes O O
, O O
and O O
( O O
4 O O
) O O
number O O
of O O
units O O
of O O
blood O O
transfused O O
( O O
NOUT O O
) O O
. O O

Data O O
on O O
3 O O
- O O
year O O
locoregional O O
control O O
( O O
LRC O O
) O O
, O O
relapse O O
- O O
free O O
survival O O
( O O
RFS O O
) O O
, O O
disease O O
- O O
specific O O
survival O O
( O O
DSS O O
) O O
, O O
and O O
overall O O
survival O O
( O O
OS O O
) O O
were O O
analyzed O O
. O O

RESULTS O O
: O O
One O O
hundred O O
and O O
sixty O O
- O O
nine O O
patients O O
were O O
identified O O
. O O

The O O
median O O
follow O O
- O O
up O O
was O O
23.6 O O
months O O
. O O

The O O
RFS O O
( O O
52 O O
% O O
vs. O O
41 O O
% O O
, O O
p O O
= O O
0.03 O O
) O O
, O O
DSS O O
( O O
71 O O
% O O
vs. O O
66 O O
% O O
, O O
p O O
= O O
0.02 O O
) O O
, O O
and O O
OS O O
( O O
58 O O
% O O
vs. O O
42 O O
% O O
p O O
= O O
0.005 O O
) O O
were O O
significantly O O
better O O
for O O
patients O O
who O O
did O O
not O O
have O O
a O O
transfusion O O
vs. O O
those O O
who O O
did O O
. O O

The O O
LRC O O
, O O
RFS O O
, O O
DSS O O
, O O
and O O
OS O O
were O O
also O O
significantly O O
better O O
for O O
patients O O
with O O
nadir O O
Hb O O
level O O
> O O
12 O O
vs. O O
< O O
12 O O
g O O
/ O O
dL O O
and O O
NOUT O O
1 O O
- O O
4 O O
vs. O O
> O O
4 O O
. O O

CONCLUSION O O
: O O
Our O O
study O O
seems O O
to O O
suggest O O
that O O
blood O O
transfusion O O
during O O
radical O O
treatment O O
for O O
SCCHN B-Disease B-Disease
might O O
be O O
detrimental O O
. O O

Further O O
research O O
should O O
be O O
undertaken O O
into O O
the O O
complex O O
interactions O O
among O O
tumor B-Disease B-Disease
hypoxia I-Disease B-Disease
, O O
anemia B-Disease B-Disease
, O O
and O O
the O O
treatment O O
of O O
anemia B-Disease B-Disease
before O O
making O O
treatment O O
recommendations O O
. O O

Disparities O O
in O O
the O O
use O O
of O O
chemotherapy O O
and O O
monoclonal O O
antibody O O
therapy O O
for O O
elderly O O
advanced O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
patients O O
in O O
the O O
community O O
oncology O O
setting O O
. O O

BACKGROUND O O
: O O
The O O
clinical O O
trials O O
on O O
which O O
the O O
treatment O O
of O O
advanced O O
colorectal B-Disease B-Disease
( O O
CRC B-Disease B-Disease
) O O
is O O
based O O
enroll O O
few O O
elderly O O
patients O O
. O O

Furthermore O O
, O O
few O O
investigations O O
have O O
determined O O
the O O
use O O
and O O
outcomes O O
of O O
the O O
treatment O O
of O O
advanced O O
CRC B-Disease B-Disease
in O O
practice O O
. O O

This O O
study O O
evaluated O O
the O O
treatment O O
of O O
advanced O O
CRC B-Disease B-Disease
in O O
community O O
oncology O O
practices O O
, O O
focusing O O
on O O
age O O
- O O
related O O
differences O O
in O O
treatment O O
and O O
outcome O O
. O O

METHODS O O
: O O
A O O
national O O
, O O
retrospective O O
chart O O
review O O
was O O
conducted O O
to O O
evaluate O O
the O O
management O O
of O O
advanced O O
CRC B-Disease B-Disease
in O O
10 O O
community O O
practices O O
across O O
the O O
U O O
. O O

S O O
. O O

All O O
medical O O
records O O
of O O
patients O O
diagnosed O O
with O O
advanced O O
CRC B-Disease B-Disease
initiating O O
chemotherapy O O
treatment O O
after O O
January O O
1 O O
, O O
2003 O O
through O O
2006 O O
were O O
included O O
. O O

The O O
primary O O
aim O O
was O O
to O O
compare O O
the O O
proportion O O
receiving O O
doublet O O
chemotherapy O O
( O O
irinotecan O O
or O O
oxaliplatin O O
with O O
a O O
fluoropyrimidine O O
) O O
as O O
initial O O
therapy O O
in O O
young O O
( O O
age O O
< O O
or O O
= O O
65 O O
years O O
) O O
and O O
elderly O O
( O O
age O O
> O O
65 O O
years O O
) O O
patients O O
. O O

Additional O O
aims O O
included O O
age O O
- O O
based O O
comparisons O O
of O O
the O O
addition O O
of O O
bevacizumab O O
to O O
chemotherapy O O
, O O
overall O O
chemotherapy O O
use O O
, O O
all O O
- O O
cause O O
mortality O O
, O O
and O O
toxicity O O
- O O
related O O
events O O
. O O

RESULTS O O
: O O
Overall O O
, O O
520 O O
patients O O
( O O
56 O O
% O O
elderly O O
) O O
received O O
6,253 O O
cycles O O
of O O
chemotherapy O O
. O O

Of O O
the O O
younger O O
patients O O
, O O
84 O O
% O O
received O O
doublet O O
chemotherapy O O
first O O
- O O
line O O
, O O
compared O O
with O O
58 O O
% O O
of O O
elderly O O
patients O O
( O O
p O O
< O O
.001 O O
) O O
. O O

The O O
use O O
of O O
each O O
of O O
the O O
medications O O
- O O
- O O
irinotecan O O
, O O
oxaliplatin O O
, O O
and O O
bevacizumab O O
- O O
- O O
was O O
lower O O
in O O
elderly O O
patients O O
( O O
p O O
< O O
.001 O O
) O O
. O O

Independent O O
predictors O O
of O O
a O O
higher O O
risk O O
for O O
mortality O O
were O O
age O O
> O O
65 O O
( O O
adjusted O O
hazards O O
ratio O O
[ O O
HR O O
] O O
, O O
1.19 O O
; O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
, O O
1.02 O O
- O O
1.39 O O
) O O
and O O
performance O O
status O O
score O O
> O O
or O O
= O O
2 O O
( O O
HR O O
, O O
1.65 O O
; O O
95 O O
% O O
CI O O
, O O
1.41 O O
- O O
1.91 O O
) O O
. O O

CONCLUSION O O
: O O
Elderly O O
patients O O
are O O
less O O
likely O O
to O O
receive O O
first O O
- O O
line O O
doublet O O
chemotherapy O O
than O O
younger O O
patients O O
. O O

Age O O
and O O
performance O O
status O O
are O O
independent O O
predictors O O
of O O
treatment O O
and O O
overall O O
survival O O
. O O

Pharmacological O O
profile O O
, O O
efficacy O O
and O O
safety O O
of O O
rupatadine O O
in O O
allergic B-Disease B-Disease
rhinitis I-Disease I-Disease
. O O

Allergic B-Disease B-Disease
rhinitis I-Disease I-Disease
( O O
AR B-Disease B-Disease
) O O
is O O
a O O
disease O O
with O O
high O O
prevalence O O
. O O

In O O
AR B-Disease B-Disease
, O O
exposure O O
to O O
airborne O O
allergens O O
elicits O O
an O O
allergic O O
response O O
which O O
involves O O
epithelial O O
accumulation O O
of O O
effector O O
cells O O
- O O
e.g. O O
mast O O
cells O O
and O O
basophils O O
- O O
and O O
subsequent O O
inflammation B-Disease B-Disease
. O O

During O O
the O O
early O O
response O O
in O O
AR B-Disease B-Disease
, O O
histamine O O
has O O
been O O
found O O
to O O
be O O
the O O
most O O
abundant O O
mediator O O
and O O
it O O
is O O
associated O O
with O O
many O O
symptoms O O
of O O
this O O
disease O O
mediated O O
through O O
the O O
histamine O O
H1 O O
receptor O O
. O O

Therefore O O
, O O
anti O O
- O O
histamines O O
have O O
a O O
role O O
to O O
play O O
in O O
the O O
management O O
of O O
AR B-Disease B-Disease
. O O

However O O
, O O
the O O
available O O
antihistamines O O
have O O
certain O O
well O O
- O O
known O O
side O O
effects O O
like O O
sedation B-Disease O
and O O
potential O O
pro B-Disease O
- I-Disease O
arrythmic I-Disease O
effects I-Disease O
owing O O
to O O
their O O
interactions O O
with O O
other O O
drugs O O
, O O
as O O
well O O
as O O
having O O
poor O O
or O O
no O O
effect O O
on O O
platelet O O
activating O O
factor O O
( O O
PAF O O
) O O
which O O
also O O
plays O O
an O O
important O O
role O O
in O O
AR B-Disease B-Disease
. O O

This O O
article O O
is O O
a O O
qualitative O O
systematic O O
literature O O
review O O
on O O
the O O
pharmacological O O
profile O O
of O O
rupatadine O O
in O O
order O O
to O O
evaluate O O
its O O
safety O O
and O O
efficacy O O
in O O
AR B-Disease B-Disease
as O O
compared O O
to O O
other O O
anti O O
- O O
histamines O O
. O O

Rupatadine O O
is O O
a O O
once O O
- O O
daily O O
non O O
- O O
sedative O O
, O O
selective O O
, O O
long O O
- O O
acting O O
H1 O O
anti O O
- O O
histamine O O
with O O
antagonistic O O
PAF O O
effects O O
through O O
its O O
interaction O O
with O O
specific O O
receptors O O
. O O

Rupatadine O O
significantly O O
improves O O
nasal O O
symptoms O O
in O O
patients O O
with O O
AR B-Disease B-Disease
. O O

It O O
has O O
a O O
good O O
safety O O
profile O O
and O O
is O O
devoid O O
of O O
arrythmogenic B-Disease O
effects I-Disease O
. O O

These O O
properties O O
make O O
rupatadine O O
a O O
suitable O O
first O O
line O O
anti O O
- O O
histamine O O
for O O
the O O
treatment O O
of O O
AR B-Disease B-Disease
. O O

Variability O O
in O O
platelet O O
response O O
to O O
a O O
single O O
daily O O
dose O O
of O O
150 O O
mg O O
enteric O O
coated O O
aspirin O O
in O O
a O O
high O O
risk O O
population O O
. O O

PURPOSE O O
: O O
Previous O O
studies O O
have O O
reported O O
inadequate O O
anti O O
- O O
platelet O O
effect O O
in O O
0.4 O O
- O O
35 O O
% O O
of O O
patients O O
taking O O
aspirin O O
. O O

Such O O
studies O O
have O O
arbitrarily O O
defined O O
the O O
terms O O
" O O
semi O O
- O O
responders O O
" O O
, O O
" O O
non O O
- O O
responders O O
" O O
or O O
" O O
resistant O O
" O O
to O O
variable O O
doses O O
of O O
aspirin O O
on O O
the O O
basis O O
of O O
absolute O O
values O O
derived O O
from O O
different O O
ex O O
- O O
vivo O O
platelet O O
aggregation O O
( O O
PA O O
) O O
methods O O
. O O

Our O O
objective O O
was O O
to O O
define O O
response O O
to O O
150 O O
- O O
mg O O
dose O O
of O O
aspirin O O
in O O
terms O O
of O O
normally O O
distributed O O
values O O
using O O
an O O
ex O O
- O O
vivo O O
measure O O
of O O
PA O O
in O O
a O O
population O O
at O O
high O O
risk O O
for O O
vascular O O
events O O
. O O

METHODS O O
: O O
We O O
prospectively O O
studied O O
high O O
risk O O
patients O O
with O O
either O O
established O O
coronary B-Disease B-Disease
artery I-Disease I-Disease
disease I-Disease I-Disease
( O O
CAD B-Disease B-Disease
) O O
or O O
stroke B-Disease B-Disease
or O O
transient B-Disease B-Disease
ischemic I-Disease I-Disease
attack I-Disease I-Disease
( O O
TIA B-Disease B-Disease
) O O
or O O
peripheral B-Disease B-Disease
vascular I-Disease I-Disease
disease I-Disease I-Disease
or O O
with O O
multiple O O
atherothrombotic O B-Disease
risk O O
factors O O
like O O
diabetes B-Disease B-Disease
plus O O
one O O
of O O
the O O
following O O
- O O
- O O
hypertension B-Disease B-Disease
, O O
increased O O
total O O
cholesterol O O
, O O
cigarette O O
smoking O O
, O O
micro O O
- O O
albuminuria O B-Disease
, O O
low O O
- O O
high O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
, O O
family O O
history O O
of O O
CAD B-Disease B-Disease
and O O
receiving O O
single O O
150 O O
mg O O
dose O O
of O O
aspirin O O
daily O O
. O O

PA O O
was O O
assessed O O
by O O
chronolog O O
lumi O O
- O O
aggregometer O O
( O O
490 O O
- O O
2 O O
D O O
) O O
using O O
arachidonic O O
acid O O
( O O
AA O O
) O O
reagent O O
. O O

RESULTS O O
: O O
130 O O
patients O O
were O O
studied O O
. O O

The O O
response O O
of O O
subjects O O
to O O
aspirin O O
followed O O
a O O
normal O O
, O O
bell O O
shaped O O
distribution O O
curve O O
with O O
a O O
mean O O
and O O
standard O O
deviation O O
( O O
S O O
. O O

D O O
. O O
) O O
of O O
13.1 O O
+ O O
/ O O
- O O
4.4 O O
% O O
. O O

3.1 O O
% O O
patients O O
had O O
PA O O
values O O
more O O
than O O
2 O O
S O O
. O O

D O O
. O O
of O O
the O O
mean O O
, O O
hence O O
termed O O
as O O
hypo O O
- O O
responders O O
to O O
aspirin O O
while O O
another O O
3.1 O O
% O O
patients O O
had O O
PA O O
values O O
less O O
than O O
2 O O
S O O
. O O

D O O
. O O
of O O
the O O
mean O O
, O O
hence O O
termed O O
as O O
hyper O O
- O O
responders O O
to O O
aspirin O O
. O O

CONCLUSION O O
: O O
There O O
is O O
minimal O O
inter O O
- O O
individual O O
variability O O
in O O
the O O
response O O
to O O
aspirin O O
when O O
tested O O
with O O
AA O O
as O O
the O O
reagent O O
. O O

The O O
response O O
to O O
aspirin O O
follows O O
a O O
normal O O
Gaussian O O
distribution O O
. O O

The O O
prevalence O O
of O O
hypo O O
- O O
responders O O
to O O
aspirin O O
in O O
high O O
risk O O
population O O
is O O
only O O
3.1 O O
% O O
. O O

This O O
is O O
the O O
first O O
study O O
to O O
document O O
" O O
hypo O O
" O O
and O O
" O O
hyper O O
- O O
responders O O
" O O
to O O
single O O
daily O O
dose O O
of O O
150 O O
mg O O
aspirin O O
. O O

The O O
clinical O O
relevance O O
of O O
these O O
findings O O
remains O O
to O O
be O O
determined O O
. O O

Effect O O
of O O
2 O O
- O O
hydroxyethyl O O
- O O
methacrylate O O
( O O
HEMA O O
) O O
on O O
the O O
phagocytic O O
and O O
respiratory O O
burst O O
activity O O
of O O
human O O
neutrophils O O
and O O
monocytes O O
. O O

Neutrophils O O
and O O
monocytes O O
/ O O
macrophages O O
( O O
M O O
? O O
) O O
, O O
found O O
in O O
oral O O
mucosa O O
and O O
gingival O O
sulcus O O
, O O
phagocytose O O
and O O
kill O O
bacteria O O
using O O
products O O
produced O O
during O O
a O O
respiratory O O
burst O O
. O O

2 O O
- O O
Hydroxyethyl O O
- O O
methacrylate O O
( O O
HEMA O O
) O O
is O O
a O O
major O O
component O O
released O O
from O O
resin O O
glass O O
ionomer O O
and O O
dental O O
adhesives O O
. O O

Hence O O
, O O
in O O
pulp O O
and O O
gingiva O O
, O O
phagocytes O O
can O O
come O O
into O O
contact O O
with O O
unpolymerized O O
HEMA O O
monomers O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
examine O O
the O O
effects O O
of O O
exposure O O
to O O
HEMA O O
on O O
neutrophil O O
and O O
monocyte O O
bactericidal O O
function O O
. O O

Blood O O
collected O O
from O O
five O O
female O O
volunteers O O
was O O
exposed O O
in O O
vitro O O
to O O
HEMA O O
for O O
2 O O
h O O
and O O
then O O
phagocytosis O O
, O O
respiratory O O
burst O O
, O O
and O O
cellular O O
integrity O O
were O O
measured O O
using O O
flow O O
cytometry O O
. O O

Respiratory O O
burst O O
was O O
quantified O O
by O O
measuring O O
fluorescent O O
rhodamine O O
123 O O
generated O O
via O O
oxidation O O
of O O
dihydrorhodamine O O
123 O O
. O O

Cellular O O
membrane O O
integrity O O
was O O
evaluated O O
by O O
staining O O
with O O
propidium O O
iodide O O
. O O

The O O
respiratory O O
burst O O
activity O O
of O O
the O O
neutrophils O O
was O O
significantly O O
decreased O O
by O O
exposure O O
to O O
7.5 O O
and O O
15 O O
mM O O
HEMA O O
. O O

No O O
significant O O
effect O O
of O O
HEMA O O
was O O
seen O O
on O O
the O O
number O O
of O O
granulocytes O O
or O O
monocytes O O
capable O O
of O O
performing O O
respiratory O O
burst O O
. O O

Furthermore O O
, O O
there O O
was O O
no O O
significant O O
effect O O
of O O
HEMA O O
on O O
the O O
phagocytic O O
activity O O
of O O
the O O
monocytes O O
or O O
the O O
granulocytes O O
. O O

In O O
conclusion O O
, O O
HEMA O O
did O O
not O O
affect O O
the O O
phagocytosis O O
activity O O
of O O
neutrophils O O
; O O
however O O
, O O
the O O
ability O O
of O O
the O O
cells O O
to O O
kill O O
internalized O O
prey O O
was O O
significantly O O
reduced O O
. O O

Methods O O
in O O
safety O O
pharmacology O O
in O O
focus O O
. O O

This O O
focused O O
issue O O
of O O
the O O
Journal O O
of O O
Pharmacological O O
and O O
Toxicological O O
Methods O O
is O O
the O O
fifth O O
to O O
highlight O O
Methods O O
in O O
Safety O O
Pharmacology O O
and O O
includes O O
a O O
number O O
of O O
articles O O
from O O
the O O
7th O O
Annual O O
Safety O O
Pharmacology O O
Society O O
( O O
SPS O O
) O O
meeting O O
that O O
was O O
held O O
in O O
Edinburgh O O
, O O
Scotland O O
, O O
September O O
19 O O
- O O
21 O O
, O O
2007 O O
. O O

However O O
, O O
unlike O O
issues O O
of O O
the O O
past O O
, O O
in O O
which O O
content O O
predominantly O O
focused O O
on O O
cardiovascular O O
issues O O
( O O
specifically O O
QT O O
interval O O
prolongation O O
, O O
QT O O
- O O
HR O O
correction O O
methods O O
and O O
validation O O
of O O
non O O
- O O
clinical O O
cardiovascular O O
models O O
) O O
this O O
issue O O
is O O
composed O O
of O O
a O O
number O O
of O O
non O O
- O O
cardiovascular O O
methods O O
papers O O
and O O
review O O
articles O O
. O O

Of O O
particular O O
interest O O
to O O
readers O O
will O O
be O O
articles O O
related O O
to O O
CNS O O
studies O O
, O O
in O O
particular O O
neurobehavioral O O
assessments O O
in O O
non O O
- O O
human O O
primates O O
and O O
the O O
effects O O
of O O
drugs O O
in O O
juvenile O O
and O O
adult O O
rats O O
( O O
an O O
article O O
that O O
may O O
be O O
relevant O O
in O O
light O O
of O O
recent O O
EU O O
/ O O
US O O
pediatric O O
legislation O O
) O O
. O O

While O O
cardiovascular O O
function O O
may O O
not O O
dominate O O
there O O
are O O
several O O
useful O O
methodological O O
papers O O
including O O
an O O
assessment O O
of O O
cardiovascular O O
sensitivity O O
of O O
drugs O O
in O O
conscious O O
and O O
anesthetized O O
non O O
- O O
human O O
primates O O
, O O
and O O
a O O
mathematical O O
model O O
( O O
fractal O O
analysis O O
) O O
applied O O
to O O
canine O O
heartbeat O O
dynamics O O
. O O

A O O
first O O
for O O
the O O
journal O O
is O O
a O O
paper O O
by O O
Vargas O O
et O O
al. O O
, O O
( O O
2008 O O
- O O
this O O
issue O O
) O O
in O O
which O O
members O O
of O O
the O O
SPS O O
formed O O
a O O
working O O
group O O
in O O
order O O
to O O
assess O O
and O O
review O O
safety O O
pharmacology O O
testing O O
of O O
biological O O
therapeutic O O
agents O O
( O O
specifically O O
monoclonal O O
antibodies O O
, O O
mAbs O O
) O O
. O O

The O O
group O O
provides O O
recommendations O O
that O O
will O O
likely O O
shape O O
regulatory O O
strategy O O
and O O
discussions O O
in O O
the O O
yet O O
to O O
be O O
fully O O
discussed O O
area O O
of O O
biological O O
safety O O
testing O O
. O O

In O O
the O O
tradition O O
of O O
obtaining O O
a O O
perspective O O
on O O
industry O O
safety O O
pharmacology O O
program O O
practices O O
Lindgren O O
et O O
al. O O
, O O
( O O
2008 O O
- O O
this O O
issue O O
) O O
provide O O
the O O
results O O
of O O
a O O
recent O O
SPS O O
survey O O
that O O
examines O O
ICH O B-Disease
S7A O O
and O O
S7B O O
trends O O
, O O
aspects O O
of O O
early O O
' O O
frontloading O O
' O O
safety O O
studies O O
, O O
abuse O O
and O O
dependence O O
liability O O
and O O
Contract O O
Research O O
Organization O O
( O O
CRO O O
) O O
tests O O
/ O O
assays O O
used O O
in O O
safety O O
assessment O O
of O O
core O O
battery O O
and O O
supplementary O O
organ O O
systems O O
. O O

In O O
keeping O O
with O O
the O O
translation O O
track O O
aspect O O
of O O
the O O
2007 O O
meeting O O
is O O
an O O
overview O O
of O O
the O O
Distinguished O O
Service O O
Award O O
lecture O O
to O O
Dr. O O
T O O
. O O

Hammond O O
that O O
discusses O O
many O O
aspects O O
of O O
safety O O
pharmacology O O
including O O
its O O
evolution O O
, O O
impact O O
, O O
value O O
and O O
translation O O
of O O
non O O
- O O
clinical O O
findings O O
to O O
humans O O
. O O

Finally O O
, O O
perspectives O O
are O O
presented O O
on O O
the O O
use O O
of O O
the O O
zebrafish O O
as O O
an O O
early O O
safety O O
pharmacology O O
- O O
screening O O
assay O O
. O O

Intensity O O
- O O
modulated O O
radiotherapy O O
in O O
postoperative O O
treatment O O
of O O
oral B-Disease B-Disease
cavity I-Disease I-Disease
cancers I-Disease I-Disease
. O O

PURPOSE O O
: O O
To O O
present O O
our O O
single O O
- O O
institution O O
experience O O
of O O
intensity O O
- O O
modulated O O
radiotherapy O O
( O O
IMRT O O
) O O
for O O
oral B-Disease B-Disease
cavity I-Disease I-Disease
cancer I-Disease I-Disease
. O O

METHODS O O
AND O O
MATERIALS O O
: O O
Between O O
September O O
2000 O O
and O O
December O O
2006 O O
, O O
35 O O
patients O O
with O O
histologically O O
confirmed O O
squamous B-Disease B-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
of I-Disease I-Disease
the I-Disease I-Disease
oral I-Disease I-Disease
cavity I-Disease I-Disease
underwent O O
surgery O O
followed O O
by O O
postoperative O O
IMRT O O
. O O

The O O
sites O O
included O O
were O O
buccal O O
mucosa O O
in O O
8 O O
, O O
oral O O
tongue O O
in O O
11 O O
, O O
floor O O
of O O
the O O
mouth O O
in O O
9 O O
, O O
gingiva O O
in O O
4 O O
, O O
hard O O
palate O O
in O O
2 O O
, O O
and O O
retromolar O O
trigone O O
in O O
1 O O
. O O

Most O O
patients O O
had O O
Stage O O
III O O
- O O
IV O O
disease O O
( O O
80 O O
% O O
) O O
. O O

Ten O O
patients O O
( O O
29 O O
% O O
) O O
also O O
received O O
concurrent O O
postoperative O O
chemotherapy O O
with O O
IMRT O O
. O O

The O O
median O O
prescribed O O
radiation O O
dose O O
was O O
60 O O
Gy O O
. O O

RESULTS O O
: O O
The O O
median O O
follow O O
- O O
up O O
for O O
surviving O O
patients O O
was O O
28.1 O O
months O O
( O O
range O O
, O O
11.9 O O
- O O
85.1 O O
) O O
. O O

Treatment O O
failure O O
occurred O O
in O O
11 O O
cases O O
as O O
follows O O
: O O
local O O
in O O
4 O O
, O O
regional O O
in O O
2 O O
, O O
and O O
distant O O
metastases O B-Disease
in O O
5 O O
. O O

Of O O
the O O
5 O O
patients O O
with O O
distant O O
metastases O O
, O O
2 O O
presented O O
with O O
dermal O O
metastases O O
. O O

The O O
2 O O
- O O
and O O
3 O O
- O O
year O O
estimates O O
of O O
locoregional O O
progression O O
- O O
free O O
survival O O
, O O
distant O O
metastasis O O
- O O
free O O
survival O O
, O O
disease O O
- O O
free O O
survival O O
, O O
and O O
overall O O
survival O O
were O O
84 O O
% O O
and O O
77 O O
% O O
, O O
85 O O
% O O
and O O
85 O O
% O O
, O O
70 O O
% O O
and O O
64 O O
% O O
, O O
and O O
74 O O
% O O
and O O
74 O O
% O O
, O O
respectively O O
. O O

Acute O O
Grade O O
2 O O
or O O
greater O O
dermatitis B-Disease B-Disease
, O O
mucositis B-Disease B-Disease
, O O
and O O
esophageal B-Disease B-Disease
reactions I-Disease I-Disease
were O O
experienced O O
by O O
54 O O
% O O
, O O
66 O O
% O O
, O O
and O O
40 O O
% O O
of O O
the O O
patients O O
, O O
respectively O O
. O O

Documented O O
late O O
complications O O
included O O
trismus B-Disease B-Disease
( O O
17 O O
% O O
) O O
and O O
osteoradionecrosis B-Disease B-Disease
( O O
5 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
IMRT O O
as O O
an O O
adjuvant O O
treatment O O
after O O
surgical O O
resection O O
for O O
oral B-Disease B-Disease
cavity I-Disease I-Disease
tumors I-Disease I-Disease
is O O
feasible O O
and O O
effective O O
, O O
with O O
promising O O
results O O
and O O
acceptable O O
toxicity O O
. O O

Breakthrough O O
cryptococcosis B-Disease B-Disease
in O O
a O O
patient O O
with O O
systemic B-Disease B-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
( O O
SLE B-Disease B-Disease
) O O
receiving O O
micafungin O O
. O O

A O O
67 O O
- O O
year O O
- O O
old O O
woman O O
with O O
systemic B-Disease B-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
( O O
SLE B-Disease B-Disease
) O O
was O O
admitted O O
to O O
our O O
hospital O O
because O O
of O O
lupus B-Disease B-Disease
nephritis I-Disease I-Disease
. O O

Methylprednisolone O O
minipulse O O
therapy O O
dramatically O O
reduced O O
her O O
proteinuria B-Disease B-Disease
; O O
however O O
; O O
she O O
then O O
complained O O
of O O
general O O
fatigue B-Disease B-Disease
with O O
low O O
- O O
grade O O
fever B-Disease B-Disease
. O O

Radiological O O
and O O
culture O O
studies O O
revealed O O
no O O
infectious O O
focus O O
, O O
but O O
she O O
was O O
treated O O
with O O
meropenem O O
and O O
micafungin O O
, O O
considering O O
her O O
immunosuppressive O O
state O O
. O O

Cytomegalovirus O B-Disease
antigenemia O I-Disease
was O O
later O O
determined O O
and O O
ganciclovir O O
was O O
added O O
. O O

She O O
became O O
afebrile O O
, O O
but O O
complained O O
of O O
nausea B-Disease B-Disease
and O O
headache B-Disease B-Disease
, O O
and O O
disorientation B-Disease B-Disease
, O O
without O O
meningeal B-Disease O
signs I-Disease O
. O O

Because O O
a O O
brain O O
computed O O
tomography O O
( O O
CT O O
) O O
scan O O
showed O O
no O O
abnormality O O
, O O
we O O
initially O O
suspected O O
some O O
kind O O
of O O
drug O O
interaction O O
. O O

Despite O O
the O O
discontinuation O O
of O O
all O O
drugs O O
, O O
however O O
, O O
she O O
still O O
suffered O O
from O O
disturbance O B-Disease
of O I-Disease
consciousness O I-Disease
. O O

A O O
lumbar O O
puncture O O
revealed O O
yeast O O
cells O O
stained O O
by O O
India O O
ink O O
. O O

A O O
diagnosis O O
of O O
cryptococcal B-Disease B-Disease
meningitis I-Disease I-Disease
was O O
confirmed O O
. O O

Though O O
fluconazole O O
and O O
meropenem O O
were O O
administered O O
, O O
the O O
patient O O
died O O
. O O

Autopsy O O
findings O O
revealed O O
disseminated B-Disease O
cryptococcosis I-Disease B-Disease
concomitant O O
with O O
pulmonary B-Disease B-Disease
aspergillosis I-Disease I-Disease
. O O

Micafungin O O
is O O
a O O
recently O O
approved O O
echinocandin O O
- O O
class O O
antifungal O O
agent O O
that O O
is O O
now O O
widely O O
used O O
in O O
Japan O O
because O O
of O O
its O O
minimal O O
toxicity O O
and O O
broadspectrum O O
activity O O
. O O

However O O
, O O
such O O
echinocandins O O
have O O
limited O O
activity O O
against O O
a O O
number O O
of O O
fungi O O
. O O

Indeed O O
, O O
breakthrough O O
trichosporonosis O B-Disease
is O O
becoming O O
a O O
significant O O
problem O O
in O O
patients O O
with O O
hematological B-Disease B-Disease
malignancies I-Disease I-Disease
who O O
are O O
receiving O O
echinocandins O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
breakthrough O O
cryptococcosis B-Disease B-Disease
, O O
as O O
seen O O
in O O
our O O
patient O O
, O O
has O O
not O O
been O O
reported O O
previously O O
in O O
patients O O
who O O
were O O
receiving O O
micafungin O O
as O O
an O O
empiric O O
antifungal O O
therapy O O
. O O

This O O
case O O
highlights O O
that O O
cryptococcosis B-Disease B-Disease
should O O
be O O
kept O O
in O O
mind O O
as O O
a O O
possible O O
breakthrough O O
infection B-Disease B-Disease
during O O
the O O
administration O O
of O O
echinocandins O O
, O O
especially O O
in O O
patients O O
with O O
cellular B-Disease B-Disease
immunodeficiency I-Disease I-Disease
. O O

Multicenter O O
clinical O O
study O O
on O O
the O O
efficacy O O
and O O
safety O O
of O O
inhalable O O
insulin O O
aerosol O O
in O O
the O O
treatment O O
of O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
. O O

BACKGROUND O O
: O O
A O O
new O O
inhalable O O
insulin O O
aerosol O O
( O O
Inh O O
- O O
Ins O O
) O O
was O O
developed O O
in O O
China O O
. O O

The O O
aim O O
of O O
this O O
multicenter O O
clinical O O
study O O
was O O
to O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
this O O
new O O
Inh O O
- O O
Ins O O
as O O
a O O
treatment O O
of O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
. O O

Regular O O
porcine O O
insulin O O
( O O
RI O O
) O O
was O O
used O O
as O O
a O O
control O O
. O O

METHODS O O
: O O
This O O
study O O
is O O
a O O
prospective O O
, O O
randomized O O
, O O
open O O
- O O
label O O
, O O
parallel O O
- O O
group O O
multicenter O O
clinical O O
trial O O
in O O
which O O
253 O O
qualified O O
patients O O
with O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
received O O
the O O
insulin O O
Glargine O O
daily O O
at O O
bedtime O O
plus O O
either O O
a O O
pre O O
- O O
meal O O
Inh O O
- O O
Ins O O
or O O
a O O
pre O O
- O O
meal O O
subcutaneous O O
RI O O
for O O
12 O O
weeks O O
. O O

HbA1c O O
, O O
fasting O O
plasma O O
glucose O O
( O O
FPG O O
) O O
, O O
the O O
1 O O
- O O
hour O O
- O O
postprandial O O
blood O O
glucose O O
( O O
1hPBG O O
) O O
and O O
the O O
2 O O
- O O
hour O O
- O O
postprandial O O
blood O O
glucose O O
( O O
2hPBG O O
) O O
were O O
measured O O
. O O

Events O O
were O O
monitored O O
for O O
adverse O O
effects O O
. O O

RESULTS O O
: O O
After O O
12 O O
weeks O O
, O O
the O O
HbA1c O O
decreased O O
significantly O O
from O O
baseline O O
in O O
both O O
treatment O O
groups O O
, O O
with O O
no O O
significant O O
difference O O
between O O
the O O
two O O
regimens O O
. O O

In O O
the O O
Inh O O
- O O
Ins O O
group O O
, O O
FPG O O
, O O
both O O
1hPBG O O
and O O
2hPBG O O
significantly O O
declined O O
from O O
baseline O O
after O O
the O O
8th O O
- O O
and O O
12th O O
- O O
weeks O O
of O O
treatment O O
. O O

The O O
reduced O O
values O O
of O O
FPG O O
or O O
1hPBG O O
between O O
the O O
two O O
groups O O
showed O O
a O O
more O O
significant O O
hypoglycemic O B-Disease
effect O O
with O O
the O O
Inh O O
- O O
Ins O O
than O O
the O O
RI O O
. O O

After O O
12 O O
weeks O O
, O O
the O O
pulmonary O O
carbon O O
monoxide O O
diffusing O O
capacity O O
( O O
DLco O O
) O O
was O O
significantly O O
lower O O
in O O
Inh O O
- O O
Ins O O
group O O
than O O
in O O
the O O
RI O O
. O O

The O O
main O O
side O O
effects O O
of O O
Inh O O
- O O
Ins O O
were O O
coughing B-Disease B-Disease
, O O
excessive B-Disease B-Disease
sputum I-Disease I-Disease
, O O
and O O
hypoglycemia B-Disease B-Disease
. O O

CONCLUSIONS O O
: O O
Inh O O
- O O
Ins O O
was O O
effective O O
in O O
decreasing O O
HbA1c O O
like O O
the O O
RI O O
. O O

It O O
was O O
better O O
in O O
lowering O O
the O O
FPG O O
and O O
the O O
1hPBG O O
than O O
the O O
RI O O
. O O

Its O O
main O O
side O O
effects O O
were O O
coughing B-Disease B-Disease
, O O
excessive B-Disease B-Disease
sputum I-Disease I-Disease
, O O
and O O
hypoglycemia B-Disease B-Disease
. O O

Also O O
, O O
Inh O O
- O O
Ins O O
slightly O O
impaired O O
DLco O O
. O O

Choosing O O
a O O
skeletal O O
muscle O O
relaxant O O
. O O

Skeletal O O
muscle O O
relaxants O O
are O O
widely O O
used O O
in O O
treating O O
musculoskeletal O O
conditions O O
. O O

However O O
, O O
evidence O O
of O O
their O O
effectiveness O O
consists O O
mainly O O
of O O
studies O O
with O O
poor O O
methodologic O O
design O O
. O O

In O O
addition O O
, O O
these O O
drugs O O
have O O
not O O
been O O
proven O O
to O O
be O O
superior O O
to O O
acetaminophen O O
or O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
for O O
low B-Disease B-Disease
back I-Disease I-Disease
pain I-Disease I-Disease
. O O

Systematic O O
reviews O O
and O O
meta O O
- O O
analyses O O
support O O
using O O
skeletal O O
muscle O O
relaxants O O
for O O
short O O
- O O
term O O
relief O O
of O O
acute B-Disease O
low I-Disease B-Disease
back I-Disease I-Disease
pain I-Disease I-Disease
when O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
or O O
acetaminophen O O
are O O
not O O
effective O O
or O O
tolerated O O
. O O

Comparison O O
studies O O
have O O
not O O
shown O O
one O O
skeletal O O
muscle O O
relaxant O O
to O O
be O O
superior O O
to O O
another O O
. O O

Cyclobenzaprine O O
is O O
the O O
most O O
heavily O O
studied O O
and O O
has O O
been O O
shown O O
to O O
be O O
effective O O
for O O
various O O
musculoskeletal O O
conditions O O
. O O

The O O
sedative O O
properties O O
of O O
tizanidine O O
and O O
cyclobenzaprine O O
may O O
benefit O O
patients O O
with O O
insomnia B-Disease B-Disease
caused O O
by O O
severe O O
muscle B-Disease B-Disease
spasms I-Disease I-Disease
. O O

Methocarbamol O O
and O O
metaxalone O O
are O O
less O O
sedating O O
, O O
although O O
effectiveness O O
evidence O O
is O O
limited O O
. O O

Adverse O O
effects O O
, O O
particularly O O
dizziness B-Disease B-Disease
and O O
drowsiness B-Disease B-Disease
, O O
are O O
consistently O O
reported O O
with O O
all O O
skeletal O O
muscle O O
relaxants O O
. O O

The O O
potential O O
adverse O O
effects O O
should O O
be O O
communicated O O
clearly O O
to O O
the O O
patient O O
. O O

Because O O
of O O
limited O O
comparable O O
effectiveness O O
data O O
, O O
choice O O
of O O
agent O O
should O O
be O O
based O O
on O O
side O O
- O O
effect O O
profile O O
, O O
patient O O
preference O O
, O O
abuse B-Disease O
potential O O
, O O
and O O
possible O O
drug O O
interactions O O
. O O

Two O O
rare O O
cases O O
of O O
methotrexate O O
- O O
induced O O
pneumonitis B-Disease B-Disease
and O O
pleurisy B-Disease B-Disease
in O O
patients O O
with O O
gestational B-Disease B-Disease
trophoblastic I-Disease I-Disease
neoplasms I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Pneumonitis B-Disease B-Disease
is O O
a O O
serious O O
and O O
unpredictable O O
side O O
- O O
effect O O
of O O
treatment O O
with O O
methotrexate O O
( O O
MTX O O
) O O
that O O
may O O
result O O
in O O
a O O
life O O
- O O
threatening O O
outcome O O
. O O

Pulmonary B-Disease B-Disease
toxicity I-Disease I-Disease
of O O
methotrexate O O
in O O
patients O O
with O O
a O O
gestational B-Disease B-Disease
trophoblastic I-Disease I-Disease
neoplasm I-Disease I-Disease
( O O
GTN B-Disease B-Disease
) O O
has O O
rarely O O
been O O
reported O O
before O O
. O O

CASE O O
REPORTS O O
: O O
For O O
the O O
first O O
time O O
two O O
cases O O
of O O
methotrexate O O
- O O
induced O O
pneumonitis B-Disease B-Disease
and O O
pleurisy B-Disease B-Disease
in O O
GTN B-Disease B-Disease
patients O O
of O O
Chinese O O
ethnicity O O
are O O
presented O O
. O O

Two O O
patients O O
were O O
both O O
categorized O O
as O O
the O O
low O O
- O O
risk O O
group O O
, O O
and O O
underwent O O
a O O
single O O
regimen O O
therapy O O
of O O
methotrexate O O
. O O

Their O O
symptoms O O
, O O
such O O
as O O
fever B-Disease B-Disease
, O O
chest B-Disease B-Disease
pain I-Disease I-Disease
, O O
acute B-Disease O
nonproductive I-Disease O
cough I-Disease B-Disease
, O O
dyspnea B-Disease B-Disease
and O O
hypoxemia B-Disease B-Disease
did O O
not O O
respond O O
to O O
antibiotics O O
immediately O O
. O O

Treatment O O
with O O
corticosteroids O O
may O O
be O O
helpful O O
. O O

CONCLUSION O O
: O O
Awareness O O
of O O
pneumonitis B-Disease B-Disease
and O O
pleurisy B-Disease B-Disease
, O O
potentially O O
life O O
- O O
threatening O O
complications O O
of O O
MTX O O
, O O
is O O
very O O
necessary O O
and O O
important O O
to O O
early O O
recognition O O
and O O
treatment O O
. O O

Reduced O O
weight O O
gain O O
with O O
insulin O O
detemir O O
compared O O
to O O
NPH O O
insulin O O
is O O
not O O
explained O O
by O O
a O O
reduction O O
in O O
hypoglycemia B-Disease B-Disease
. O O

BACKGROUND O O
: O O
Weight O O
gain O O
often O O
occurs O O
when O O
insulin O O
therapy O O
is O O
initiated O O
. O O

The O O
long O O
- O O
acting O O
insulin O O
analog O O
insulin O O
detemir O O
has O O
been O O
shown O O
to O O
be O O
effective O O
and O O
well O O
tolerated O O
when O O
used O O
in O O
basal O O
- O O
bolus O O
regimens O O
or O O
as O O
an O O
add O O
- O O
on O O
to O O
oral O O
antidiabetic O O
drugs O O
( O O
OADs O O
) O O
and O O
causes O O
less O O
weight O B-Disease
gain O I-Disease
than O O
other O O
insulins O O
. O O

The O O
aim O O
of O O
this O O
exploratory O O
analysis O O
was O O
to O O
investigate O O
any O O
correlations O O
between O O
weight O O
change O O
and O O
occurrence O O
of O O
hypoglycemia B-Disease B-Disease
with O O
NPH O O
insulin O O
and O O
insulin O O
detemir O O
. O O

METHODS O O
: O O
The O O
analysis O O
was O O
based O O
on O O
a O O
26 O O
- O O
week O O
, O O
randomized O O
, O O
multicenter O O
, O O
open O O
- O O
label O O
, O O
parallel O O
- O O
group O O
trial O O
in O O
which O O
glycemic O O
control O O
, O O
hypoglycemia B-Disease B-Disease
, O O
and O O
weight O O
change O O
were O O
compared O O
between O O
insulin O O
detemir O O
and O O
NPH O O
insulin O O
. O O

A O O
total O O
of O O
476 O O
insulin O O
- O O
naive O O
patients O O
with O O
type B-Disease B-Disease
2 I-Disease I-Disease
diabetes I-Disease I-Disease
treated O O
with O O
one O O
or O O
two O O
OADs O O
added O O
insulin O O
detemir O O
( O O
n O O
= O O
237 O O
) O O
or O O
NPH O O
insulin O O
( O O
n O O
= O O
239 O O
) O O
morning O O
and O O
evening O O
to O O
their O O
current O O
oral O O
treatment O O
. O O

Weight O O
gain O O
data O O
from O O
this O O
study O O
were O O
analyzed O O
as O O
a O O
function O O
of O O
hypoglycemia B-Disease B-Disease
frequency O O
. O O

RESULTS O O
: O O
Both O O
groups O O
achieved O O
excellent O O
glycosylated O O
hemoglobin O O
control O O
( O O
insulin O O
detemir O O
, O O
6.6 O O
% O O
; O O
NPH O O
insulin O O
, O O
6.5 O O
% O O
[ O O
difference O O
not O O
significant O O
] O O
) O O
. O O

Weight O O
gain O O
with O O
insulin O O
detemir O O
was O O
less O O
than O O
half O O
that O O
of O O
NPH O O
insulin O O
( O O
1.2 O O
vs. O O
2.8 O O
kg O O
, O O
respectively O O
[ O O
P O O
< O O
0.001 O O
] O O
) O O
, O O
and O O
the O O
overall O O
risk O O
of O O
hypoglycemia B-Disease B-Disease
was O O
47 O O
% O O
lower O O
with O O
insulin O O
detemir O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

No O O
significant O O
relationship O O
between O O
hypoglycemia B-Disease B-Disease
and O O
weight O B-Disease
gain O I-Disease
was O O
seen O O
with O O
insulin O O
detemir O O
( O O
P O O
= O O
0.2 O O
) O O
, O O
while O O
a O O
statistically O O
significant O O
correlation O O
was O O
found O O
for O O
NPH O O
insulin O O
( O O
P O O
= O O
0.003 O O
) O O
. O O

CONCLUSIONS O O
: O O
Hypoglycemia B-Disease B-Disease
is O O
predictive O O
of O O
weight O B-Disease
gain O I-Disease
with O O
NPH O O
insulin O O
, O O
but O O
the O O
same O O
relationship O O
is O O
not O O
seen O O
with O O
insulin O O
detemir O O
. O O

It O O
is O O
therefore O O
likely O O
that O O
the O O
weight O O
- O O
sparing O O
effect O O
of O O
insulin O O
detemir O O
involves O O
other O O
mechanisms O O
. O O

Lung B-Disease B-Disease
fibrosis I-Disease I-Disease
10 O O
years O O
after O O
cessation O O
of O O
bleomycin O O
therapy O O
. O O

Bleomycin O O
( O O
BLM O O
) O O
is O O
a O O
chemotherapeutic O O
agent O O
used O O
for O O
the O O
treatment O O
of O O
several O O
types O O
of O O
malignancy O B-Disease
, O O
including O O
germ B-Disease B-Disease
cell I-Disease I-Disease
tumors I-Disease I-Disease
, O O
lymphoma B-Disease B-Disease
, O O
and O O
certain O O
types O O
of O O
squamous B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
carcinoma I-Disease I-Disease
. O O

The O O
common O O
adverse O O
effect O O
of O O
BLM O O
is O O
interstitial B-Disease B-Disease
pneumonitis I-Disease I-Disease
, O O
followed O O
by O O
pulmonary B-Disease B-Disease
fibrosis I-Disease I-Disease
. O O

BLM O O
- O O
induced O O
pneumonitis B-Disease B-Disease
occurs O O
in O O
up O O
to O O
46 O O
% O O
of O O
patients O O
treated O O
with O O
BLM O O
- O O
containing O O
chemotherapy O O
and O O
lung B-Disease B-Disease
toxicity I-Disease I-Disease
usually O O
appears O O
during O O
treatment O O
. O O

Here O O
we O O
describe O O
a O O
patient O O
with O O
lung B-Disease B-Disease
fibrosis I-Disease I-Disease
, O O
who O O
presented O O
with O O
slow O O
progressive B-Disease O
breathlessness I-Disease B-Disease
and O O
pneumothorax B-Disease B-Disease
more O O
than O O
10 O O
years O O
after O O
cessation O O
of O O
BLM O O
therapy O O
. O O

A O O
15 O O
year O O
- O O
old O O
girl O O
presented O O
with O O
abnormal O O
shadows O O
on O O
chest O O
X O O
- O O
ray O O
. O O

The O O
patient O O
had O O
a O O
yolk B-Disease B-Disease
sac I-Disease I-Disease
carcinoma I-Disease I-Disease
in O O
the O O
sacral O O
region O O
at O O
1 O O
year O O
of O O
age O O
and O O
obtained O O
complete O O
remission O O
after O O
being O O
treated O O
with O O
tumor B-Disease B-Disease
resection O O
, O O
radiation O O
, O O
and O O
several O O
anti O O
- O O
cancer O O
drugs O O
including O O
BLM O O
. O O

There O O
were O O
no O O
abnormal O O
findings O O
in O O
chest O O
X O O
- O O
ray O O
until O O
she O O
reached O O
3 O O
years O O
of O O
age O O
, O O
when O O
she O O
had O O
developed O O
respiratory B-Disease B-Disease
distress I-Disease I-Disease
that O O
worsened O O
with O O
age O O
. O O

The O O
patient O O
had O O
experienced O O
an O O
episode O O
of O O
pneumothorax B-Disease B-Disease
at O O
13 O O
years O O
of O O
age O O
. O O

Chest O O
CT O O
at O O
the O O
time O O
revealed O O
interstitial O O
reticular O O
opacities O O
. O O

Radiological O O
findings O O
and O O
pathological O O
examination O O
of O O
the O O
lung O O
tissue O O
obtained O O
during O O
bullectomy O O
with O O
video O O
- O O
assisted O O
thoracic O O
surgery O O
were O O
compatible O O
with O O
BLM O O
- O O
induced O O
pneumonitis B-Disease B-Disease
. O O

The O O
present O O
study O O
suggests O O
that O O
lung B-Disease B-Disease
fibrosis I-Disease I-Disease
may O O
surface O O
more O O
than O O
10 O O
years O O
after O O
cessation O O
of O O
BLM O O
therapy O O
at O O
the O O
age O O
of O O
1 O O
year O O
, O O
with O O
no O O
chest O O
radiographic O O
findings O O
1 O O
year O O
after O O
completion O O
of O O
chemotherapy O O
. O O

The O O
use O O
of O O
BLM O O
in O O
infants O O
requires O O
strict O O
supervision O O
and O O
observation O O
and O O
careful O O
long O O
- O O
term O O
follow O O
up O O
. O O

Riluzole O O
in O O
psychiatry O O
: O O
a O O
systematic O O
review O O
of O O
the O O
literature O O
. O O

BACKGROUND O O
: O O
The O O
glutamate O O
system O O
seems O O
to O O
be O O
an O O
important O O
contributor O O
to O O
the O O
pathophysiology O O
of O O
mood O O
and O O
anxiety B-Disease B-Disease
disorders I-Disease I-Disease
. O O

Thus O O
, O O
glutamatergic O O
modulators O O
are O O
reasonable O O
candidate O O
drugs O O
to O O
test O O
in O O
patients O O
with O O
mood O O
and O O
anxiety B-Disease B-Disease
disorders I-Disease I-Disease
. O O

Riluzole O O
, O O
a O O
neuroprotective O O
agent O O
with O O
anticonvulsant O O
properties O O
approved O O
for O O
the O O
treatment O O
of O O
amyotrophic B-Disease B-Disease
lateral I-Disease I-Disease
sclerosis I-Disease I-Disease
( O O
ALS B-Disease B-Disease
) O O
is O O
one O O
such O O
agent O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
the O O
potential O O
risks O O
and O O
benefits O O
of O O
riluzole O O
treatment O O
in O O
psychiatric O B-Disease
patients O O
. O O

METHODS O O
: O O
A O O
PubMed O O
search O O
was O O
performed O O
using O O
the O O
keywords O O
' O O
riluzole O O
' O O
, O O
' O O
inhibitor O O
of O O
glutamate O O
release O O
' O O
and O O
' O O
glutamatergic O O
modulator O O
' O O
to O O
identify O O
all O O
clinical O O
studies O O
and O O
case O O
reports O O
involving O O
riluzole O O
in O O
psychiatric O B-Disease
patients O O
. O O

RESULTS O O
/ O O
CONCLUSION O O
: O O
Riluzole O O
's O O
side O O
effect O O
profile O O
is O O
favorable O O
and O O
preliminary O O
results O O
regarding O O
riluzole O O
for O O
the O O
treatment O O
of O O
severe O O
mood O O
, O O
anxiety B-Disease B-Disease
and O O
impulsive B-Disease B-Disease
disorders I-Disease I-Disease
are O O
encouraging O O
. O O

Estimates O O
of O O
cancer B-Disease B-Disease
potency O O
of O O
2,3,4,7,8 O O
- O O
pentachlorodibenzofuran O O
using O O
both O O
nonlinear O O
and O O
linear O O
approaches O O
. O O

Cancer B-Disease B-Disease
potency O O
estimates O O
were O O
derived O O
for O O
2,3,4,7,8 O O
- O O
pentachlorodibenzofuran O O
( O O
4 O O
- O O
PeCDF O O
) O O
using O O
data O O
collected O O
from O O
the O O
recently O O
published O O
National O O
Toxicology O O
Program O O
bioassay O O
in O O
female O O
Sprague O O
- O O
Dawley O O
rats O O
. O O

By O O
using O O
a O O
toxicokinetic O O
model O O
for O O
4 O O
- O O
PeCDF O O
, O O
the O O
dose O O
- O O
response O O
relationship O O
for O O
combined O O
liver B-Disease B-Disease
tumors I-Disease I-Disease
( O O
hepatocellular B-Disease B-Disease
adenomas I-Disease I-Disease
and O O
cholangiocarcinomas B-Disease B-Disease
) O O
in O O
rats O O
was O O
assessed O O
in O O
terms O O
of O O
lifetime O O
average O O
liver O O
concentration O O
and O O
lifetime O O
average O O
adipose O O
concentration O O
with O O
data O O
from O O
both O O
the O O
lifetime O O
and O O
the O O
stop O O
- O O
exposure O O
components O O
of O O
the O O
bioassay O O
. O O

Benchmark O O
dose O O
modeling O O
was O O
performed O O
to O O
estimate O O
tissue O O
concentrations O O
at O O
two O O
points O O
of O O
departure O O
( O O
EC O O
( O O
10 O O
) O O
and O O
EC O O
( O O
01 O O
) O O
and O O
their O O
95 O O
% O O
upper O O
and O O
lower O O
confidence O O
limits O O
) O O
. O O

The O O
same O O
toxicokinetic O O
model O O
with O O
human O O
input O O
values O O
was O O
then O O
used O O
to O O
back O O
- O O
extrapolate O O
human O O
equivalent O O
doses O O
that O O
corresponded O O
to O O
the O O
internal O O
tissue O O
concentration O O
measures O O
at O O
the O O
points O O
of O O
departure O O
. O O

Information O O
regarding O O
the O O
cancer B-Disease B-Disease
mode O O
of O O
action O O
was O O
used O O
to O O
support O O
the O O
development O O
of O O
several O O
toxicity O O
criterion O O
values O O
based O O
on O O
a O O
nonlinear O O
method O O
, O O
e.g. O O
, O O
reference O O
dose O O
or O O
tolerable O O
daily O O
intake O O
. O O

Nonlinear O O
estimates O O
of O O
toxicity O O
criteria O O
based O O
on O O
observed O O
noncancer O O
toxic O O
events O O
as O O
possible O O
precursors O O
to O O
tumor B-Disease B-Disease
formation O O
were O O
also O O
derived O O
and O O
were O O
similar O O
in O O
value O O
to O O
those O O
based O O
on O O
combined O O
liver B-Disease B-Disease
tumors I-Disease I-Disease
. O O

For O O
comparison O O
purposes O O
, O O
linear O O
estimates O O
of O O
cancer B-Disease B-Disease
potency O O
were O O
also O O
derived O O
. O O

Phase O O
II O O
preradiation O O
R115777 O O
( O O
tipifarnib O O
) O O
in O O
newly O O
diagnosed O O
GBM O B-Disease
with O O
residual O O
enhancing O O
disease O O
. O O

Glioblastoma B-Disease B-Disease
multiforme I-Disease I-Disease
( O O
GBM B-Disease B-Disease
) O O
is O O
a O O
lethal O O
primary O O
malignant B-Disease O
brain I-Disease B-Disease
tumor I-Disease I-Disease
in O O
adults O O
. O O

R115777 O O
( O O
tipifarnib O O
) O O
is O O
an O O
oral O O
agent O O
with O O
antiproliferative O O
effects O O
, O O
being O O
a O O
potent O O
and O O
selective O O
inhibitor O O
of O O
farnesyltransferase O O
. O O

This O O
multicenter O O
, O O
open O O
- O O
label O O
phase O O
II O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
R115777 O O
given O O
after O O
surgery O O
and O O
prior O O
to O O
radiation O O
in O O
patients O O
with O O
newly O O
diagnosed O O
and O O
residual O O
enhancing O O
GBM B-Disease B-Disease
. O O

Following O O
surgery O O
, O O
an O O
MRI O O
confirmed O O
the O O
presence O O
of O O
residual O O
enhancing O O
tumor O B-Disease
. O O

Patients O O
on O O
enzyme O O
- O O
inducing O O
antiseizure O O
drugs O O
( O O
EIASDs O O
) O O
received O O
600 O O
mg O O
twice O O
per O O
day O O
, O O
and O O
those O O
not O O
on O O
EIASDs O O
received O O
300 O O
mg O O
twice O O
per O O
day O O
. O O

One O O
to O O
three O O
monthly O O
cycles O O
of O O
R115777 O O
were O O
administered O O
, O O
and O O
radiation O O
was O O
initiated O O
with O O
progression O O
or O O
after O O
three O O
cycles O O
. O O

A O O
cycle O O
consisted O O
of O O
3 O O
weeks O O
of O O
continuous O O
R115777 O O
followed O O
by O O
a O O
1 O O
- O O
week O O
rest O O
. O O

MRI O O
was O O
done O O
monthly O O
. O O

The O O
primary O O
end O O
point O O
was O O
overall O O
survival O O
; O O
secondary O O
end O O
points O O
were O O
tumor B-Disease B-Disease
response O O
rate O O
and O O
toxicity O O
. O O

A O O
total O O
of O O
28 O O
confirmed O O
GBM O B-Disease
patients O O
entered O O
the O O
study O O
; O O
15 O O
patients O O
( O O
54 O O
% O O
) O O
were O O
on O O
EIASDs O O
. O O

The O O
overall O O
median O O
time O O
of O O
survival O O
was O O
7.7 O O
months O O
. O O

There O O
were O O
no O O
tumor B-Disease B-Disease
responses O O
. O O

Eight O O
patients O O
( O O
29 O O
% O O
) O O
had O O
stable O O
disease O O
as O O
the O O
best O O
response O O
. O O

The O O
study O O
was O O
stopped O O
early O O
due O O
to O O
progression O O
of O O
the O O
disease O O
in O O
12 O O
patients O O
( O O
48 O O
% O O
) O O
. O O

A O O
total O O
of O O
24 O O
patients O O
( O O
85 O O
% O O
) O O
were O O
off O O
study O O
before O O
the O O
planned O O
treatment O O
schedule O O
for O O
radiation O O
therapy O O
. O O

R115777 O O
administered O O
prior O O
to O O
radiation O O
therapy O O
in O O
patients O O
with O O
newly O O
diagnosed O O
GBM B-Disease B-Disease
and O O
residual O O
enhancing O O
disease O O
did O O
not O O
result O O
in O O
any O O
measurable O O
responses O O
or O O
improvement O O
in O O
survival O O
. O O

R115777 O O
administered O O
prior O O
to O O
radiation O O
therapy O O
is O O
not O O
recommended O O
for O O
patients O O
with O O
newly O O
diagnosed O O
GBM B-Disease B-Disease
. O O

Effect O O
of O O
calpain O O
and O O
proteasome O O
inhibition O O
on O O
Ca2 O O
+ O O
- O O
dependent O O
proteolysis O O
and O O
muscle O O
histopathology O O
in O O
the O O
mdx O O
mouse O O
. O O

Dystrophin O B-Disease
deficiency O I-Disease
is O O
the O O
underlying O O
molecular O O
cause O O
of O O
progressive B-Disease O
muscle I-Disease B-Disease
weakness I-Disease I-Disease
observed O O
in O O
Duchenne B-Disease B-Disease
muscular I-Disease I-Disease
dystrophy I-Disease I-Disease
( O O
DMD B-Disease B-Disease
) O O
. O O

Loss O O
of O O
functional O O
dystrophin O O
leads O O
to O O
elevated O O
levels O O
of O O
intracellular O O
Ca O O
( O O
2 O O
+ O O
) O O
, O O
a O O
key O O
step O O
in O O
the O O
cellular O O
pathology O O
of O O
DMD B-Disease B-Disease
. O O

The O O
cysteine O O
protease O O
calpain O O
is O O
activated O O
in O O
dystrophin O O
- O O
deficient O O
muscle O O
, O O
and O O
its O O
inhibition O O
is O O
regarded O O
as O O
a O O
potential O O
therapeutic O O
approach O O
. O O

In O O
addition O O
, O O
previous O O
work O O
has O O
shown O O
that O O
the O O
ubiquitin O O
- O O
proteasome O O
system O O
also O O
contributes O O
to O O
muscle O O
protein O O
breakdown O O
in O O
dystrophic O B-Disease
muscle O O
and O O
, O O
therefore O O
, O O
also O O
qualifies O O
as O O
a O O
potential O O
target O O
for O O
therapeutic O O
intervention O O
in O O
DMD B-Disease B-Disease
. O O

The O O
relative O O
contribution O O
of O O
calpain O O
- O O
and O O
proteasome O O
- O O
mediated O O
proteolysis O O
induced O O
by O O
increased O O
Ca O O
( O O
2 O O
+ O O
) O O
levels O O
was O O
characterized O O
in O O
cultured O O
muscle O O
cells O O
and O O
revealed O O
initial O O
Ca O O
( O O
2 O O
+ O O
) O O
influx O O
- O O
dependent O O
calpain O O
activity O O
and O O
subsequent O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
independent O O
activity O O
of O O
the O O
ubiquitin O O
- O O
proteasome O O
system O O
. O O

We O O
then O O
set O O
out O O
to O O
optimize O O
novel O O
small O O
- O O
molecule O O
inhibitors O O
that O O
inhibit O O
both O O
calpain O O
as O O
well O O
as O O
the O O
20S O O
proteasome O O
in O O
a O O
cellular O O
system O O
with O O
impaired O O
Ca O O
( O O
2 O O
+ O O
) O O
homeostasis O O
. O O

On O O
administration O O
of O O
such O O
inhibitors O O
to O O
mdx O O
mice O O
, O O
quantitative O O
histological O O
parameters O O
improved O O
significantly O O
, O O
in O O
particular O O
with O O
compounds O O
strongly O O
inhibiting O O
the O O
20S O O
proteasome O O
. O O

To O O
investigate O O
the O O
role O O
of O O
calpain O O
inhibition O O
without O O
interfering O O
with O O
the O O
ubiquitin O O
- O O
proteasome O O
system O O
, O O
we O O
crossed O O
mdx O O
mice O O
with O O
transgenic O O
mice O O
, O O
overexpressing O O
the O O
endogenous O O
calpain O O
inhibitor O O
calpastatin O O
. O O

Although O O
our O O
data O O
show O O
that O O
proteolysis O O
by O O
calpain O O
is O O
strongly O O
inhibited O O
in O O
the O O
transgenic O O
mdx O O
mouse O O
, O O
this O O
calpain O O
inhibition O O
did O O
not O O
ameliorate O O
muscle O O
histology O O
. O O

Our O O
results O O
indicate O O
that O O
inhibition O O
of O O
the O O
proteasome O O
rather O O
than O O
calpain O O
is O O
required O O
for O O
histological O O
improvement O O
of O O
dystrophin O O
- O O
deficient O O
muscle O O
. O O

In O O
conclusion O O
, O O
we O O
have O O
identified O O
novel O O
proteasome O O
inhibitors O O
that O O
qualify O O
as O O
potential O O
candidates O O
for O O
pharmacological O O
intervention O O
in O O
muscular B-Disease B-Disease
dystrophy I-Disease I-Disease
. O O

Effects O O
of O O
in O O
vitro O O
brevetoxin O O
exposure O O
on O O
apoptosis O O
and O O
cellular O O
metabolism O O
in O O
a O O
leukemic O O
T O O
cell O O
line O O
( O O
Jurkat O O
) O O
. O O

Harmful O O
algal O O
blooms O O
( O O
HABs O O
) O O
of O O
the O O
toxic O O
dinoflagellate O O
, O O
Karenia O O
brevis O O
, O O
produce O O
red O O
tide O O
toxins O O
, O O
or O O
brevetoxins O O
. O O

Significant O O
health O O
effects O O
associated O O
with O O
red O O
tide O O
toxin O O
exposure O O
have O O
been O O
reported O O
in O O
sea O O
life O O
and O O
in O O
humans O O
, O O
with O O
brevetoxins O O
documented O O
within O O
immune O O
cells O O
from O O
many O O
species O O
. O O

The O O
objective O O
of O O
this O O
research O O
was O O
to O O
investigate O O
potential O O
immunotoxic O O
effects O O
of O O
brevetoxins O O
using O O
a O O
leukemic O O
T O O
cell O O
line O O
( O O
Jurkat O O
) O O
as O O
an O O
in O O
vitro O O
model O O
system O O
. O O

Viability O O
, O O
cell O O
proliferation O O
, O O
and O O
apoptosis O O
assays O O
were O O
conducted O O
using O O
brevetoxin O O
congeners O O
PbTx O O
- O O
2 O O
, O O
PbTx O O
- O O
3 O O
, O O
and O O
PbTx O O
- O O
6 O O
. O O

The O O
effects O O
of O O
in O O
vitro O O
brevetoxin O O
exposure O O
on O O
cell O O
viability O O
and O O
cellular O O
metabolism O O
or O O
proliferation O O
were O O
determined O O
using O O
trypan O O
blue O O
and O O
MTT O O
( O O
1 O O
- O O
( O O
4,5 O O
- O O
dimethylthiazol O O
- O O
2 O O
- O O
yl O O
) O O
- O O
3,5 O O
- O O
diphenylformazan O O
) O O
, O O
respectively O O
. O O

Using O O
MTT O O
, O O
cellular O O
metabolic O O
activity O O
was O O
decreased O O
in O O
Jurkat O O
cells O O
exposed O O
to O O
5 O O
- O O
10 O O
microg O O
/ O O
ml O O
PbTx O O
- O O
2 O O
or O O
PbTx O O
- O O
6 O O
. O O

After O O
3 O O
h O O
, O O
no O O
significant O O
effects O O
on O O
cell O O
viability O O
were O O
observed O O
with O O
any O O
toxin O O
congener O O
in O O
concentrations O O
up O O
to O O
10 O O
microg O O
/ O O
ml O O
. O O

Viability O O
decreased O O
dramatically O O
after O O
24 O O
h O O
in O O
cells O O
treated O O
with O O
PbTx O O
- O O
2 O O
or O O
- O O
6 O O
. O O

Apoptosis O O
, O O
as O O
measured O O
by O O
caspase O O
- O O
3 O O
activity O O
, O O
was O O
significantly O O
increased O O
in O O
cells O O
exposed O O
to O O
PbTx O O
- O O
2 O O
or O O
PbTx O O
- O O
6 O O
. O O

In O O
summary O O
, O O
brevetoxin O O
congeners O O
varied O O
in O O
effects O O
on O O
Jurkat O O
cells O O
, O O
with O O
PbTx O O
- O O
2 O O
and O O
PbTx O O
- O O
6 O O
eliciting O O
greater O O
cellular O O
effects O O
compared O O
to O O
PbTx O O
- O O
3 O O
. O O

Influence O O
of O O
valproic O O
acid O O
on O O
outcome O O
of O O
high O O
- O O
grade O O
gliomas O B-Disease
in O O
children O O
. O O

BACKGROUND O O
: O O
Chemotherapy O O
has O O
limited O O
effects O O
in O O
the O O
treatment O O
of O O
high O O
- O O
grade O O
gliomas B-Disease B-Disease
( O O
HGGs B-Disease B-Disease
) O O
. O O

Valproic O O
acid O O
( O O
VPA O O
) O O
, O O
a O O
histone O O
deacetylase O O
( O O
HDAC O O
) O O
inhibitor O O
, O O
may O O
sensitize O O
HGGs O B-Disease
to O O
radiochemotherapy O O
. O O

As O O
the O O
drug O O
has O O
been O O
given O O
frequently O O
as O O
an O O
antiepileptic O O
drug O O
, O O
a O O
retrospective O O
analysis O O
was O O
conducted O O
to O O
ensure O O
relevant O O
information O O
was O O
not O O
missed O O
before O O
a O O
prospective O O
study O O
was O O
launched O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
An O O
analysis O O
of O O
66 O O
pediatric O O
patients O O
( O O
range O O
, O O
1 O O
- O O
19 O O
years O O
of O O
age O O
) O O
with O O
glioblastoma B-Disease B-Disease
multiforme I-Disease I-Disease
( O O
GBM B-Disease B-Disease
) O O
( O O
n O O
= O O
40 O O
) O O
or O O
anaplastic B-Disease B-Disease
astrocytoma I-Disease I-Disease
( O O
AA B-Disease B-Disease
) O O
( O O
n O O
= O O
26 O O
) O O
was O O
retrospectively O O
conducted O O
for O O
predictors O O
of O O
survival O O
and O O
response O O
and O O
for O O
effects O O
of O O
VPA O O
on O O
outcome O O
or O O
toxicity O O
. O O

RESULTS O O
: O O
The O O
overall O O
survival O O
( O O
OS O O
) O O
was O O
better O O
for O O
AA B-Disease B-Disease
( O O
p O O
= O O
0.0114 O O
) O O
and O O
complete O O
resection O O
( O O
p O O
< O O
0.00005 O O
) O O
and O O
event O O
- O O
free O O
survival O O
( O O
EFS O O
) O O
was O O
better O O
for O O
complete O O
resection O O
( O O
p O O
= O O
0.0049 O O
) O O
. O O

Nine O O
patients O O
received O O
VPA O O
( O O
for O O
seizure B-Disease B-Disease
) O O
plus O O
further O O
oncological O O
treatment O O
. O O

The O O
most O O
severe O O
adverse O O
effect O O
was O O
a O O
pulmonary B-Disease B-Disease
embolism I-Disease I-Disease
( O O
n O O
= O O
1 O O
) O O
; O O
no O O
other O O
severe O O
side O O
- O O
effects O O
were O O
noted O O
. O O

The O O
response O O
to O O
nonsurgical O O
treatment O O
after O O
8 O O
weeks O O
was O O
: O O
complete O O
response O O
( O O
CR O O
) O O
: O O
0 O O
, O O
partial O O
response O O
( O O
PR O O
) O O
: O O
3 O O
, O O
stable O O
disease O O
( O O
SD O O
) O O
: O O
4 O O
, O O
progressive O O
disease O O
( O O
PD O B-Disease
) O O
: O O
2 O O
. O O

Some O O
of O O
the O O
patients O O
with O O
SD O B-Disease
responded O O
later O O
resulting O O
in O O
best O O
response O O
: O O
CR O O
: O O
0 O O
, O O
PR O O
: O O
5 O O
, O O
SD O O
: O O
2 O O
, O O
PD O O
: O O
2 O O
. O O

CONCLUSION O O
: O O
Treatment O O
with O O
VPA O O
plus O O
radiochemotherapy O O
is O O
well O O
tolerated O O
with O O
an O O
encouraging O O
response O O
rate O O
. O O

Tacrolimus O O
for O O
the O O
treatment O O
of O O
systemic B-Disease B-Disease
lupus I-Disease I-Disease
erythematosus I-Disease I-Disease
with O O
pure O O
class O O
V O O
nephritis B-Disease B-Disease
. O O

OBJECTIVES O O
: O O
The O O
treatment O O
of O O
pure O O
membranous O O
( O O
class O O
V O O
) O O
lupus B-Disease B-Disease
nephropathy I-Disease I-Disease
remains O O
unsatisfactory O O
. O O

We O O
studied O O
the O O
efficacy O O
and O O
safety O O
of O O
tacrolimus O O
in O O
the O O
treatment O O
of O O
membranous B-Disease B-Disease
nephritis I-Disease I-Disease
secondary O O
to O O
SLE B-Disease B-Disease
. O O

METHODS O O
: O O
We O O
recruited O O
18 O O
consecutive O O
SLE B-Disease B-Disease
patients O O
( O O
tacrolimus O O
group O O
) O O
with O O
recently O O
confirmed O O
biopsy O O
- O O
proven O O
class O O
V O O
lupus B-Disease B-Disease
nephritis I-Disease I-Disease
. O O

They O O
were O O
treated O O
with O O
a O O
tailing O O
dose O O
of O O
oral O O
prednisolone O O
and O O
tacrolimus O O
0.1 O O
- O O
0.2 O O
mg O O
/ O O
kg O O
/ O O
day O O
for O O
6 O O
months O O
, O O
followed O O
by O O
maintenance O O
prednisolone O O
and O O
AZA O O
. O O

The O O
rate O O
of O O
resolution O O
of O O
proteinuria B-Disease B-Disease
and O O
SLEDAI O O
were O O
compared O O
with O O
19 O O
historical O O
controls O O
treated O O
with O O
oral O O
cyclophosphamide O O
or O O
AZA O O
( O O
control O O
group O O
) O O
. O O

All O O
patients O O
were O O
followed O O
for O O
12 O O
months O O
. O O

RESULTS O O
: O O
Baseline O O
clinical O O
characteristics O O
were O O
comparable O O
between O O
the O O
groups O O
. O O

For O O
the O O
tacrolimus O O
group O O
, O O
the O O
complete O O
and O O
partial O O
remission O O
rates O O
were O O
27.8 O O
and O O
50.0 O O
% O O
, O O
respectively O O
at O O
12 O O
weeks O O
; O O
for O O
the O O
control O O
group O O
, O O
they O O
were O O
15.8 O O
and O O
47.4 O O
% O O
, O O
respectively O O
( O O
overall O O
chi O O
- O O
square O O
test O O
, O O
P O O
= O O
0.5 O O
) O O
. O O

However O O
, O O
tacrolimus O O
group O O
had O O
faster O O
resolution O O
of O O
proteinuria B-Disease B-Disease
than O O
the O O
control O O
group O O
by O O
the O O
general O O
linear O O
model O O
with O O
repeated O O
measures O O
( O O
P O O
= O O
0.032 O O
) O O
. O O

At O O
12 O O
weeks O O
, O O
proteinuria B-Disease B-Disease
was O O
reduced O O
by O O
76.2 O O
+ O O
/ O O
- O O
17.0 O O
% O O
for O O
the O O
tacrolimus O O
group O O
and O O
47.1 O O
+ O O
/ O O
- O O
51.1 O O
% O O
for O O
the O O
control O O
group O O
( O O
P O O
= O O
0.028 O O
) O O
. O O

Serial O O
change O O
in O O
renal O O
function O O
and O O
SLEDAI O O
score O O
did O O
not O O
differ O O
between O O
the O O
groups O O
. O O

During O O
the O O
study O O
period O O
, O O
four O O
patients O O
of O O
the O O
tacrolimus O O
group O O
, O O
and O O
11 O O
of O O
the O O
control O O
group O O
, O O
developed O O
lupus B-Disease B-Disease
flare I-Disease I-Disease
( O O
P O O
= O O
0.027 O O
) O O
. O O

There O O
was O O
no O O
serious O O
adverse O O
effect O O
in O O
the O O
tacrolimus O O
group O O
. O O

CONCLUSIONS O O
: O O
A O O
6 O O
- O O
month O O
course O O
of O O
tacrolimus O O
is O O
a O O
safe O O
and O O
effective O O
treatment O O
of O O
pure O O
class O O
V O O
( O O
membranous O O
) O O
lupus B-Disease B-Disease
nephritis I-Disease I-Disease
. O O

As O O
compared O O
with O O
conventional O O
cytotoxic O O
treatment O O
, O O
tacrolimus O O
possibly O O
results O O
in O O
a O O
faster O O
resolution O O
of O O
proteinuria B-Disease B-Disease
, O O
and O O
a O O
lower O O
risk O O
of O O
lupus B-Disease B-Disease
flare I-Disease I-Disease
within O O
1 O O
yr O O
. O O

The O O
long O O
- O O
term O O
effect O O
and O O
optimal O O
regimen O O
of O O
tacrolimus O O
require O O
further O O
study O O
. O O

7 O O
- O O
Deaza O O
- O O
6 O O
- O O
benzylthioinosine O O
analogues O O
as O O
subversive O O
substrate O O
of O O
Toxoplasma O O
gondii O O
adenosine O O
kinase O O
: O O
activities O O
and O O
selective O O
toxicities O O
. O O

Toxoplasma O O
gondii O O
adenosine O O
kinase O O
( O O
EC O O
.2 O O
.7 O O
.1 O O
.20 O O
) O O
is O O
the O O
major O O
route O O
of O O
adenosine O O
metabolism O O
in O O
this O O
parasite O O
. O O

The O O
enzyme O O
is O O
significantly O O
more O O
active O O
than O O
any O O
other O O
enzyme O O
of O O
the O O
purine O O
salvage O O
in O O
T O O
. O O

gondii O O
and O O
has O O
been O O
established O O
as O O
a O O
potential O O
chemotherapeutic O O
target O O
for O O
the O O
treatment O O
of O O
toxoplasmosis B-Disease B-Disease
. O O

Certain O O
6 O O
- O O
benzylthioinosines O O
act O O
as O O
subversive O O
substrates O O
of O O
T O O
. O O

gondii O O
, O O
but O O
not O O
human O O
, O O
adenosine O O
kinase O O
. O O

Therefore O O
, O O
these O O
compounds O O
are O O
preferentially O O
metabolized O O
to O O
their O O
respective O O
nucleotides O O
and O O
become O O
selectively O O
toxic O O
against O O
the O O
parasites O O
but O O
not O O
their O O
host O O
. O O

Moreover O O
, O O
7 O O
- O O
deazaadenosine O O
( O O
tubercidin O O
) O O
was O O
shown O O
to O O
be O O
an O O
excellent O O
ligand O O
of O O
T O O
. O O

gondii O O
adenosine O O
kinase O O
. O O

Therefore O O
, O O
we O O
synthesized O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosine O O
, O O
and O O
analogues O O
with O O
various O O
substitutions O O
at O O
their O O
phenyl O O
ring O O
, O O
to O O
increase O O
the O O
binding O O
affinity O O
of O O
the O O
6 O O
- O O
benzylthioinosines O O
to O O
T O O
. O O

gondii O O
adenosine O O
kinase O O
. O O

Indeed O O
, O O
the O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosine O O
analogues O O
were O O
better O O
ligands O O
of O O
T O O
. O O

gondii O O
adenosine O O
kinase O O
than O O
the O O
parent O O
compounds O O
, O O
6 O O
- O O
benzylthioinosine O O
and O O
7 O O
- O O
deazainosine O O
. O O

Herein O O
, O O
we O O
report O O
the O O
testing O O
of O O
the O O
metabolism O O
of O O
these O O
newly O O
synthesized O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosines O O
, O O
as O O
well O O
as O O
their O O
efficacy O O
as O O
anti O O
- O O
toxoplasmic O O
agents O O
in O O
cell O O
culture O O
. O O

All O O
the O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosine O O
analogues O O
were O O
metabolized O O
to O O
their O O
5 O O
' O O
- O O
monophosphate O O
derivatives O O
, O O
albeit O O
to O O
different O O
degrees O O
. O O

These O O
results O O
indicate O O
that O O
these O O
compounds O O
are O O
not O O
only O O
ligands O O
but O O
also O O
substrates O O
of O O
T O O
. O O

gondii O O
adenosine O O
kinase O O
. O O

All O O
the O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosine O O
analogues O O
showed O O
a O O
selective O O
antitoxoplasmic O O
effect O O
against O O
wild O O
type O O
parasites O O
, O O
but O O
not O O
mutants O O
lacking O O
adenosine O O
kinase O O
. O O

The O O
efficacy O O
of O O
these O O
compounds O O
varied O O
with O O
the O O
position O O
and O O
nature O O
of O O
the O O
substitution O O
on O O
their O O
phenyl O O
ring O O
. O O

Moreover O O
, O O
none O O
of O O
these O O
analogues O O
exhibited O O
host O O
toxicity O B-Disease
. O O

The O O
best O O
compounds O O
were O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
( O O
p O O
- O O
methoxybenzylthio O O
) O O
inosine O O
( O O
IC O O
( O O
50 O O
) O O
= O O
4.6 O O
microM O O
) O O
, O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
( O O
p O O
- O O
methoxycarbonylbenzylthio O O
) O O
inosine O O
( O O
IC O O
( O O
50 O O
) O O
= O O
5.0 O O
microM O O
) O O
, O O
and O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
( O O
p O O
- O O
cyanobenzylthio O O
) O O
inosine O O
( O O
IC O O
( O O
50 O O
) O O
= O O
5.3 O O
microM O O
) O O
. O O

These O O
results O O
further O O
confirm O O
that O O
T O O
. O O

gondii O O
adenosine O O
kinase O O
is O O
an O O
excellent O O
target O O
for O O
chemotherapy O O
and O O
that O O
7 O O
- O O
deaza O O
- O O
6 O O
- O O
benzylthioinosines O O
are O O
potential O O
antitoxoplasmic O O
agents O O
. O O

INN O O
- O O
toxin O O
, O O
a O O
highly O O
lethal O O
peptide O O
from O O
the O O
venom O O
of O O
Indian O O
cobra O O
( O O
Naja O O
naja O O
) O O
venom O O
- O O
Isolation O O
, O O
characterization O O
and O O
pharmacological O O
actions O O
. O O

A O O
novel O O
toxic O O
polypeptide O O
, O O
INN O O
- O O
toxin O O
, O O
is O O
purified O O
from O O
the O O
venom O O
of O O
Naja O O
naja O O
using O O
combination O O
of O O
gel O O
- O O
permeation O O
and O O
ion O O
- O O
exchange O O
chromatography O O
. O O

It O O
has O O
a O O
molecular O O
mass O O
of O O
6951.6 O O
Da O O
as O O
determined O O
by O O
MALDI O O
- O O
TOF O O
/ O O
MS O O
and O O
the O O
N O O
- O O
terminal O O
sequence O O
of O O
LKXNKLVPLF O O
. O O

It O O
showed O O
both O O
neurotoxic O B-Disease
as O O
well O O
as O O
cytotoxic B-Disease O
activities I-Disease O
. O O

INN O O
- O O
toxin O O
is O O
lethal O O
to O O
mice O O
with O O
a O O
LD O O
( O O
50 O O
) O O
of O O
1.2 O O
mg O O
/ O O
kg O O
body O O
weight O O
. O O

IgY O O
raised O O
in O O
chicks O O
against O O
basic O O
peptide O O
pool O O
neutralized O O
the O O
toxicity O O
of O O
INN O O
- O O
toxin O O
. O O

INN O O
- O O
toxin O O
did O O
not O O
inhibit O O
cholinesterase O O
activity O O
. O O

It O O
is O O
toxic O O
to O O
Ehrlich O B-Disease
ascites O I-Disease
tumor O I-Disease
( O O
EAT O O
) O O
cells O O
, O O
but O O
it O O
is O O
not O O
toxic O O
to O O
leukocyte O O
culture O O
. O O

The O O
toxin O O
appears O O
to O O
be O O
specific O O
in O O
its O O
mode O O
of O O
action O O
. O O

Interaction O O
of O O
N O O
- O O
bromosuccinamide O O
( O O
NBS O O
) O O
with O O
the O O
peptide O O
resulted O O
in O O
the O O
modification O O
of O O
tryptophan O O
residues O O
and O O
loss O O
of O O
lethal O O
toxicity O O
of O O
INN O O
- O O
toxin O O
. O O

Role O O
and O O
relevance O O
of O O
PEPT2 O O
in O O
drug O O
disposition O O
, O O
dynamics O O
, O O
and O O
toxicity O O
. O O

Pept2 O O
knockout O O
mice O O
are O O
an O O
important O O
tool O O
to O O
evaluate O O
the O O
evolving O O
role O O
and O O
relevance O O
of O O
this O O
proton O O
- O O
coupled O O
oligopeptide O O
transporter O O
beyond O O
drug O O
disposition O O
, O O
where O O
the O O
transporter O O
also O O
modulates O O
the O O
pharmacodynamic O O
and O O
toxicodynamic O O
effects O O
of O O
drug O O
substrates O O
. O O

Our O O
in O O
vivo O O
studies O O
with O O
glycylsarcosine O O
in O O
Pept2 O O
knockout O O
mice O O
have O O
established O O
" O O
proof O O
of O O
concept O O
" O O
that O O
PEPT2 O O
can O O
have O O
a O O
significant O O
effect O O
on O O
dipeptide O O
disposition O O
. O O

Subsequent O O
studies O O
with O O
the O O
aminocephalosporin O O
antibiotic O O
cefadroxil O O
have O O
shown O O
relevance O O
to O O
pharmacology O O
and O O
infectious O B-Disease
disease O I-Disease
. O O

Finally O O
, O O
studies O O
with O O
the O O
endogenous O O
peptidomimetic O O
5 O O
- O O
aminolevulinic O O
acid O O
have O O
demonstrated O O
relevance O O
to O O
toxicology O O
in O O
the O O
framework O O
of O O
porphyria O B-Disease
- O O
and O O
lead O O
- O O
induced O O
neurotoxicity B-Disease B-Disease
. O O

These O O
studies O O
have O O
consistently O O
demonstrated O O
the O O
dual O O
action O O
of O O
PEPT2 O O
with O O
respect O O
to O O
its O O
apical O O
localization O O
in O O
choroid O O
plexus O O
epithelium O O
and O O
kidney O O
in O O
: O O
1 O O
) O O
effluxing O O
substrates O O
from O O
CSF O O
into O O
choroid O O
plexus O O
, O O
thereby O O
affecting O O
regional O O
pharmacokinetics O O
in O O
brain O O
; O O
and O O
2 O O
) O O
reabsorbing O O
substrates O O
from O O
renal O O
tubular O O
fluid O O
into O O
proximal O O
tubules O O
, O O
thereby O O
affecting O O
systemic O O
pharmacokinetics O O
and O O
exposure O O
. O O

Moreover O O
, O O
these O O
studies O O
have O O
shown O O
that O O
the O O
regional O O
effect O O
of O O
PEPT2 O O
in O O
limiting O O
substrate O O
concentrations O O
in O O
the O O
CSF O O
is O O
more O O
dramatic O O
than O O
its O O
effect O O
in O O
increasing O O
systemic O O
exposure O O
. O O

In O O
the O O
case O O
of O O
5 O O
- O O
aminolevulinic O O
acid O O
, O O
such O O
regional O O
modulation O O
of O O
drug O O
disposition O O
translates O O
directly O O
into O O
significant O O
changes O O
in O O
neurotoxicity B-Disease B-Disease
. O O

Amiodarone O O
pulmonary B-Disease B-Disease
toxicity I-Disease I-Disease
after O O
lung O O
transplantation O O
. O O

Atrial B-Disease B-Disease
fibrillation I-Disease I-Disease
occurs O O
frequently O O
after O O
lung O O
transplantation O O
and O O
is O O
commonly O O
treated O O
with O O
amiodarone O O
. O O

Pulmonary B-Disease B-Disease
toxicity I-Disease I-Disease
may O O
result O O
from O O
amiodarone O O
exposure O O
and O O
is O O
characterized O O
by O O
non O O
- O O
specific O O
respiratory O O
manifestations O O
. O O

To O O
our O O
knowledge O O
, O O
there O O
are O O
no O O
reports O O
of O O
this O O
complication O O
occurring O O
after O O
lung O O
transplantation O O
. O O

We O O
present O O
a O O
patient O O
who O O
developed O O
radiologic O O
evidence O O
of O O
amiodarone O O
deposition O O
in O O
the O O
lungs O O
after O O
bilateral O O
lung O O
transplantation O O
. O O

The O O
phenomenology O O
of O O
the O O
psychotic O B-Disease
break O O
and O O
Huxley O O
's O O
trip O O
: O O
substance O O
use O O
and O O
the O O
onset O O
of O O
psychosis B-Disease B-Disease
. O O

BACKGROUND O O
: O O
While O O
considerable O O
research O O
attention O O
has O O
been O O
devoted O O
to O O
the O O
causal O O
relationship O O
between O O
substance O O
use O O
and O O
psychosis B-Disease B-Disease
, O O
the O O
phenomenology O O
of O O
the O O
association O O
between O O
the O O
two O O
has O O
largely O O
been O O
ignored O O
. O O

This O O
is O O
a O O
significant O O
shortcoming O O
, O O
because O O
it O O
blinds O O
researchers O O
to O O
the O O
possibility O O
that O O
there O O
may O O
be O O
elements O O
of O O
the O O
subjective O O
experience O O
of O O
substance O O
use O O
and O O
psychosis B-Disease B-Disease
that O O
contribute O O
to O O
their O O
apparent O O
relationship O O
in O O
empirical O O
studies O O
. O O

SAMPLING O O
AND O O
METHODS O O
: O O
The O O
current O O
paper O O
examines O O
the O O
phenomenology O O
of O O
the O O
onset O O
of O O
psychosis B-Disease B-Disease
and O O
the O O
phenomenology O O
of O O
substance O O
intoxication O O
through O O
consideration O O
of O O
two O O
texts O O
: O O
Sass O O
's O O
account O O
of O O
the O O
phenomenology O O
of O O
psychosis B-Disease B-Disease
onset O O
and O O
Huxley O O
's O O
account O O
of O O
the O O
experience O O
of O O
hallucinogenic B-Disease B-Disease
intoxication I-Disease I-Disease
. O O

Sass O O
's O O
account O O
of O O
psychosis B-Disease B-Disease
onset O O
includes O O
four O O
components O O
: O O
Unreality O O
, O O
Fragmentation O O
, O O
Mere O O
Being O O
, O O
and O O
Apophany O O
. O O

RESULTS O O
: O O
The O O
analysis O O
reveals O O
significant O O
parallels O O
- O O
and O O
also O O
some O O
differences O O
- O O
between O O
this O O
account O O
and O O
the O O
phenomenology O O
of O O
substance O O
intoxication O O
. O O

CONCLUSIONS O O
: O O
We O O
discuss O O
the O O
implications O O
of O O
this O O
for O O
the O O
causal O O
relationship O O
between O O
psychosis B-Disease B-Disease
and O O
substance O O
use O O
and O O
suggest O O
several O O
ways O O
of O O
understanding O O
the O O
overlapping O O
phenomenologies O O
. O O

This O O
includes O O
the O O
suggestion O O
of O O
a O O
shared O O
factor O O
, O O
perhaps O O
best O O
described O O
as O O
psychotic O B-Disease
- O O
like O O
experience O O
, O O
which O O
seems O O
to O O
involve O O
a O O
breakdown O O
of O O
the O O
sign O O
- O O
referent O O
relationship O O
and O O
relationship O O
with O O
the O O
common O O
- O O
sense O O
, O O
practical O O
world O O
. O O

However O O
, O O
in O O
the O O
onset O O
of O O
psychosis B-Disease B-Disease
, O O
this O O
breakdown O O
is O O
primarily O O
experienced O O
as O O
a O O
sense O O
of O O
alienation O O
from O O
self O O
and O O
world O O
, O O
whereas O O
in O O
the O O
hallucinogenic O O
state O O
a O O
sense O O
of O O
mystical O O
union O O
and O O
revelation O O
seems O O
predominant O O
. O O

Further O O
research O O
may O O
extend O O
this O O
analysis O O
by O O
looking O O
at O O
experiences O O
with O O
other O O
drugs O O
, O O
particularly O O
cannabis O O
, O O
and O O
by O O
examining O O
the O O
phenomenology O O
of O O
psychotic B-Disease B-Disease
disorder I-Disease I-Disease
beyond O O
the O O
first O O
episode O O
. O O

Phase O O
I O O
study O O
of O O
capecitabine O O
in O O
combination O O
with O O
cisplatin O O
and O O
irinotecan O O
in O O
patients O O
with O O
advanced O O
solid B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

PURPOSE O O
: O O
This O O
phase O O
I O O
trial O O
assessed O O
the O O
safety O O
and O O
the O O
maximum O O
tolerated O O
dose O O
of O O
capecitabine O O
given O O
for O O
10 O O
days O O
prior O O
to O O
a O O
combination O O
of O O
cisplatin O O
and O O
irinotecan O O
in O O
patients O O
with O O
advanced O O
solid B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

It O O
also O O
evaluated O O
the O O
changes O O
in O O
cisplatin O O
DNA O O
adducts O O
induced O O
by O O
capecitabine O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Patients O O
with O O
refractory O O
solid O B-Disease
tumors O I-Disease
who O O
had O O
not O O
failed O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
analogs O O
or O O
topoisomerase O O
I O O
inhibitors O O
were O O
eligible O O
. O O

All O O
cohorts O O
of O O
patients O O
first O O
received O O
a O O
28 O O
- O O
day O O
cycle O O
of O O
cisplatin O O
and O O
irinotecan O O
. O O

Both O O
drugs O O
were O O
given O O
at O O
a O O
dose O O
of O O
50 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
intravenously O O
on O O
day O O
1 O O
, O O
followed O O
by O O
irinotecan O O
on O O
days O O
8 O O
and O O
15 O O
at O O
the O O
same O O
dose O O
. O O

The O O
first O O
cycle O O
served O O
as O O
an O O
internal O O
control O O
. O O

Starting O O
from O O
the O O
second O O
cycle O O
, O O
patients O O
received O O
increasing O O
doses O O
per O O
cohort O O
of O O
capecitabine O O
from O O
day O O
1 O O
to O O
10 O O
of O O
each O O
cycle O O
, O O
followed O O
by O O
cisplatin O O
on O O
day O O
11 O O
and O O
irinotecan O O
on O O
days O O
11 O O
, O O
18 O O
and O O
25 O O
, O O
both O O
at O O
same O O
doses O O
as O O
the O O
first O O
cycle O O
. O O

Cycles O O
were O O
repeated O O
every O O
38 O O
days O O
. O O

The O O
starting O O
dose O O
of O O
capecitabine O O
was O O
500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
which O O
was O O
escalated O O
by O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
in O O
the O O
subsequent O O
cohort O O
of O O
patients O O
to O O
reach O O
the O O
maximum O O
tolerated O O
dose O O
( O O
MTD O O
) O O
. O O

Later O O
, O O
additional O O
patients O O
were O O
treated O O
at O O
the O O
MTD O O
of O O
capecitabine O O
to O O
further O O
evaluate O O
the O O
safety O O
, O O
pharmacodynamics O O
, O O
and O O
tumor O B-Disease
response O O
. O O

Patients O O
blood O O
was O O
tested O O
for O O
cisplatin O O
- O O
DNA O O
adducts O O
to O O
determine O O
the O O
impact O O
of O O
capecitabine O O
on O O
cisplatin O O
- O O
based O O
therapy O O
. O O

RESULTS O O
: O O
Fifteen O O
patients O O
received O O
at O O
least O O
2 O O
cycles O O
of O O
treatment O O
. O O

At O O
1,250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
, O O
two O O
DLT O O
of O O
prolonged O O
neutropenia B-Disease B-Disease
of O O
grade O O
> O O
or O O
= O O
3 O O
were O O
observed O O
. O O

The O O
MTD O O
for O O
capecitabine O O
was O O
thus O O
determined O O
to O O
be O O
1000 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
. O O

Fatigue B-Disease B-Disease
and O O
diarrhea B-Disease B-Disease
of O O
grade O O
1 O O
or O O
2 O O
were O O
the O O
most O O
frequent O O
toxicities O O
at O O
this O O
dose O O
level O O
. O O

No O O
significant O O
hematologic B-Disease B-Disease
toxicity I-Disease I-Disease
was O O
observed O O
at O O
the O O
MTD O O
. O O

Two O O
complete O O
and O O
three O O
partial O O
remissions O O
were O O
observed O O
. O O

Four O O
of O O
the O O
responders O O
had O O
received O O
a O O
platinum O O
agent O O
and O O
/ O O
or O O
5 O O
- O O
FU O O
in O O
the O O
past O O
. O O

CONCLUSIONS O O
: O O
A O O
sequential O O
treatment O O
with O O
capecitabine O O
followed O O
by O O
cisplatin O O
and O O
irinotecan O O
is O O
well O O
tolerated O O
and O O
demonstrates O O
clinical O O
activity O O
in O O
patients O O
with O O
advanced O O
solid B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

The O O
influence O O
of O O
capecitabine O O
, O O
if O O
any O O
, O O
on O O
the O O
efficacy O O
of O O
the O O
cisplatin O O
- O O
irinotecan O O
combination O O
is O O
not O O
related O O
to O O
a O O
variation O O
in O O
cisplatin O O
- O O
DNA O O
adducts O O
. O O

The O O
safety O O
of O O
long O O
- O O
acting O O
beta O O
- O O
agonists O O
among O O
patients O O
with O O
asthma B-Disease B-Disease
using O O
inhaled O O
corticosteroids O O
: O O
systematic O O
review O O
and O O
metaanalysis O O
. O O

RATIONALE O O
: O O
Inhaled O O
long O O
- O O
acting O O
beta O O
- O O
agonists O O
( O O
LABAs O O
) O O
, O O
when O O
used O O
as O O
monotherapy O O
in O O
asthma B-Disease B-Disease
, O O
may O O
increase O O
asthma O B-Disease
- O O
related O O
hospitalizations O O
, O O
life O O
threatening O O
events O O
requiring O O
intubation O O
/ O O
mechanical O O
ventilation O O
, O O
and O O
asthma O B-Disease
- O O
related O O
deaths O O
, O O
but O O
concomitant O O
use O O
of O O
inhaled O O
corticosteroids O O
( O O
ICS O O
) O O
may O O
modify O O
this O O
effect O O
. O O

Objectives O O
: O O
To O O
determine O O
the O O
safety O O
of O O
long O O
- O O
acting O O
beta O O
- O O
agonists O O
among O O
patients O O
with O O
asthma B-Disease B-Disease
using O O
corticosteroids O O
. O O

METHODS O O
: O O
We O O
conducted O O
a O O
systematic O O
review O O
and O O
metaanalysis O O
of O O
parallel O O
- O O
group O O
, O O
blinded O O
, O O
randomized O O
, O O
controlled O O
trials O O
with O O
at O O
least O O
12 O O
weeks O O
of O O
treatment O O
addressing O O
the O O
impact O O
of O O
LABA O O
on O O
asthma B-Disease B-Disease
- O O
related O O
and O O
total O O
morbidity O O
and O O
mortality O O
in O O
patients O O
concomitantly O O
using O O
ICS O O
. O O

We O O
searched O O
MEDLINE O O
, O O
EMBASE O O
, O O
ACPJC O O
, O O
and O O
Cochrane O O
( O O
Central O O
) O O
databases O O
, O O
and O O
contacted O O
authors O O
and O O
sponsors O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
We O O
used O O
a O O
random O O
effects O O
model O O
to O O
pool O O
results O O
from O O
different O O
studies O O
as O O
odds O O
ratios O O
( O O
ORs O O
) O O
( O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
) O O
( O O
OR O O
< O O
1.0 O O
favors O O
LABA O O
) O O
. O O

The O O
search O O
yielded O O
62 O O
relevant O O
studies O O
included O O
in O O
this O O
analysis O O
. O O

Among O O
over O O
29,000 O O
participants O O
( O O
15,710 O O
taking O O
LABA O O
, O O
with O O
over O O
8,000 O O
patient O O
- O O
years O O
observed O O
in O O
the O O
LABA O O
groups O O
) O O
, O O
there O O
were O O
three O O
asthma B-Disease B-Disease
- O O
related O O
deaths O O
and O O
two O O
asthma B-Disease B-Disease
- O O
related O O
, O O
nonfatal O O
intubations O O
( O O
all O O
in O O
LABA O O
groups O O
; O O
< O O
or O O
= O O
one O O
event O O
per O O
study O O
) O O
. O O

Differences O O
in O O
asthma O O
- O O
related O O
hospitalizations O O
( O O
OR O O
, O O
0.74 O O
; O O
95 O O
% O O
CI O O
, O O
0.53 O O
- O O
1.03 O O
) O O
and O O
asthma O B-Disease
- O O
related O O
serious O O
adverse O O
events O O
( O O
mostly O O
hospitalizations O O
; O O
OR O O
, O O
0.75 O O
; O O
95 O O
% O O
CI O O
, O O
0.54 O O
- O O
1.03 O O
) O O
failed O O
to O O
reach O O
statistical O O
significance O O
. O O

The O O
OR O O
for O O
total O O
mortality O O
was O O
1.26 O O
( O O
95 O O
% O O
CI O O
, O O
0.58 O O
- O O
2.74 O O
) O O
, O O
reflecting O O
14 O O
deaths O O
in O O
LABA O O
groups O O
and O O
eight O O
deaths O O
in O O
control O O
groups O O
, O O
respectively O O
. O O

CONCLUSIONS O O
: O O
In O O
patients O O
with O O
asthma B-Disease B-Disease
using O O
ICS O O
, O O
LABA O O
did O O
not O O
increase O O
the O O
risk O O
of O O
asthma O B-Disease
- O O
related O O
hospitalizations O O
. O O

There O O
were O O
very O O
few O O
asthma O B-Disease
- O O
related O O
deaths O O
and O O
intubations O O
, O O
and O O
events O O
were O O
too O O
infrequent O O
to O O
establish O O
LABA O O
's O O
relative O O
effect O O
on O O
these O O
outcomes O O
. O O

Adjuvant O O
treatment O O
with O O
vindesine O O
in O O
comparison O O
to O O
observation O O
alone O O
in O O
patients O O
with O O
metastasized B-Disease B-Disease
melanoma I-Disease I-Disease
after O O
complete O O
metastasectomy O O
: O O
a O O
randomized O O
multicenter O O
trial O O
of O O
the O O
German O O
Dermatologic O O
Cooperative O O
Oncology O O
Group O O
. O O

To O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
vindesine O O
in O O
patients O O
with O O
metastatic B-Disease B-Disease
melanoma I-Disease I-Disease
after O O
complete O O
metastasectomy O O
. O O

One O O
hundred O O
and O O
forty O O
- O O
two O O
patients O O
with O O
metastatic O O
spread O O
to O O
regional O O
sites O O
, O O
lymph O O
nodes O O
, O O
and O O
distant O O
sites O O
after O O
complete O O
metastasectomy O O
were O O
randomized O O
to O O
receive O O
either O O
treatment O O
with O O
vindesine O O
for O O
2 O O
years O O
or O O
observation O O
alone O O
. O O

Vindesine O O
3 O O
mg O O
/ O O
m O O
intravenously O O
was O O
administered O O
biweekly O O
for O O
the O O
first O O
26 O O
weeks O O
following O O
3 O O
- O O
week O O
intervals O O
for O O
an O O
additional O O
26 O O
weeks O O
and O O
thereafter O O
every O O
4 O O
weeks O O
for O O
52 O O
weeks O O
. O O

One O O
hundred O O
and O O
thirty O O
- O O
nine O O
patients O O
were O O
eligible O O
for O O
intent O O
- O O
to O O
- O O
treat O O
analysis O O
. O O

Median O O
follow O O
- O O
up O O
time O O
was O O
46 O O
months O O
. O O

Median O O
recurrence O O
free O O
survival O O
was O O
7.9 O O
months O O
in O O
the O O
vindesine O O
group O O
and O O
7.6 O O
months O O
in O O
the O O
observational O O
group O O
( O O
P O O
= O O
0.40 O O
) O O
. O O

Three O O
- O O
year O O
overall O O
survival O O
rate O O
was O O
54.9 O O
% O O
( O O
37 O O
patients O O
) O O
for O O
patients O O
receiving O O
vindesine O O
in O O
comparison O O
to O O
43.6 O O
% O O
( O O
31 O O
patients O O
) O O
in O O
the O O
observation O O
arm O O
( O O
P O O
= O O
0.07 O O
) O O
. O O

No O O
grade O O
IV O O
toxicity O O
was O O
observed O O
. O O

The O O
two O O
major O O
side O O
effects O O
in O O
the O O
vindesine O O
group O O
were O O
alopecia B-Disease B-Disease
and O O
peripheral B-Disease B-Disease
neuropathy I-Disease I-Disease
. O O

Ten O O
patients O O
went O O
off O O
treatment O O
because O O
of O O
grade O O
III O O
toxicity O O
. O O

Adjuvant O O
treatment O O
with O O
vindesine O O
did O O
not O O
significantly O O
prolong O O
disease O O
free O O
or O O
overall O O
survival O O
in O O
high O O
- O O
risk O O
melanoma B-Disease B-Disease
patients O O
. O O

Thus O O
, O O
this O O
randomized O O
trial O O
did O O
not O O
confirm O O
earlier O O
reports O O
of O O
beneficial O O
effects O O
of O O
adjuvant O O
vindesine O O
and O O
can O O
therefore O O
not O O
be O O
recommended O O
. O O

Risk O O
assessment O O
of O O
khat O O
use O O
in O O
the O O
Netherlands O O
: O O
a O O
review O O
based O O
on O O
adverse O O
health O O
effects O O
, O O
prevalence O O
, O O
criminal O O
involvement O O
and O O
public O O
order O O
. O O

In O O
preparing O O
a O O
decision O O
about O O
the O O
legal O O
status O O
of O O
khat O O
in O O
the O O
Netherlands O O
, O O
the O O
Dutch O O
Minister O O
of O O
Health O O
requested O O
CAM O O
( O O
Coordination O O
point O O
Assessment O O
and O O
Monitoring O O
new O O
drugs O O
) O O
to O O
assess O O
the O O
overall O O
risk O O
of O O
khat O O
in O O
the O O
Netherlands O O
. O O

The O O
present O O
paper O O
is O O
a O O
redraft O O
of O O
a O O
report O O
which O O
formed O O
the O O
scientific O O
basis O O
of O O
the O O
risk O O
evaluation O O
procedure O O
( O O
October O O
2007 O O
) O O
. O O

This O O
report O O
reviews O O
the O O
scientific O O
data O O
about O O
khat O O
available O O
in O O
the O O
international O O
literature O O
. O O

In O O
addition O O
, O O
the O O
report O O
contains O O
some O O
information O O
specific O O
for O O
the O O
Netherlands O O
( O O
prevalence O O
, O O
availability O O
of O O
khat O O
and O O
public O O
order O O
aspects O O
) O O
. O O

The O O
main O O
psychoactive O O
compounds O O
in O O
khat O O
leaves O O
are O O
cathine O O
and O O
cathinone O O
, O O
which O O
are O O
some O O
2 O O
- O O
to O O
10 O O
- O O
fold O O
less O O
active O O
than O O
amphetamine O O
. O O

Acute O O
health O O
problems O O
are O O
rarely O O
seen O O
, O O
and O O
are O O
usually O O
related O O
with O O
malnutrition O B-Disease
, O O
social O O
and O O
financial O O
problems O O
. O O

Khat O O
has O O
a O O
low O O
addictive O O
potential O O
. O O

Chronic B-Disease B-Disease
toxicity I-Disease I-Disease
of O O
khat O O
is O O
modest O O
when O O
used O O
in O O
low O O
amounts O O
, O O
whereas O O
at O O
high O O
levels O O
, O O
khat O O
use O O
is O O
associated O O
with O O
adverse O O
effects O O
, O O
like O O
hypertension B-Disease B-Disease
, O O
heart B-Disease B-Disease
rhythm I-Disease I-Disease
disorders I-Disease I-Disease
, O O
insomnia B-Disease B-Disease
and O O
loss B-Disease B-Disease
of I-Disease I-Disease
appetite I-Disease I-Disease
. O O

In O O
addition O O
, O O
khat O O
users O O
show O O
a O O
higher O O
prevalence O O
of O O
cancers B-Disease B-Disease
in O O
the O O
digestive O O
tract O O
. O O

At O O
population O O
level O O
, O O
khat O O
does O O
not O O
lead O O
to O O
specific O O
health O O
risks O O
in O O
the O O
Netherlands O O
, O O
as O O
its O O
use O O
is O O
confined O O
to O O
East O O
- O O
African O O
immigrants O O
. O O

A O O
relationship O O
between O O
khat O O
use O O
and O O
psychiatric O B-Disease
disorders O I-Disease
has O O
been O O
suggested O O
, O O
but O O
the O O
reports O O
are O O
contradictory O O
, O O
and O O
such O O
studies O O
are O O
presumably O O
heavily O O
confounded O O
by O O
posttraumatic O O
and O O
social O O
stress O O
. O O

In O O
the O O
Netherlands O O
( O O
and O O
other O O
countries O O
) O O
, O O
khat O O
use O O
occasionally O O
leads O O
to O O
minor O O
disturbance O O
of O O
civil O O
order O O
in O O
the O O
public O O
domain O O
( O O
loud O O
talking O O
, O O
spitting O O
) O O
, O O
but O O
is O O
not O O
related O O
to O O
criminal O O
activities O O
. O O

Following O O
the O O
assessment O O
, O O
CAM O O
estimated O O
the O O
overall O O
risk O O
potential O O
of O O
khat O O
use O O
in O O
the O O
Netherlands O O
as O O
very O O
low O O
. O O

A O O
similar O O
conclusion O O
may O O
be O O
drawn O O
for O O
countries O O
with O O
a O O
comparable O O
prevalence O O
of O O
khat O O
use O O
and O O
khat O O
related O O
public O O
order O O
disturbance O O
. O O

High O O
- O O
dose O O
methylprednisolone O O
in O O
a O O
pregnant O O
woman O O
with O O
Crohn B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
and O O
adrenal B-Disease B-Disease
suppression I-Disease I-Disease
in O O
her O O
newborn O O
. O O

BACKGROUND O O
: O O
The O O
synthetic O O
corticosteroid O O
methylprednisolone O O
is O O
used O O
for O O
the O O
treatment O O
of O O
acute O O
exacerbations O O
of O O
Crohn B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
, O O
also O O
in O O
pregnancy O O
. O O

Its O O
use O O
is O O
considered O O
to O O
be O O
less O O
harmful O O
than O O
the O O
effect O O
of O O
active O O
disease O O
on O O
the O O
fetus O O
. O O

Adrenal B-Disease B-Disease
suppression I-Disease I-Disease
in O O
a O O
fetus O O
due O O
to O O
administration O O
of O O
methylprednisolone O O
has O O
hitherto O O
been O O
rarely O O
published O O
. O O

OBJECTIVE O O
: O O
To O O
present O O
a O O
case O O
of O O
neonatal B-Disease O
adrenal I-Disease B-Disease
suppression I-Disease I-Disease
due O O
to O O
the O O
use O O
of O O
high O O
- O O
dose O O
methylprednisolone O O
in O O
late O O
pregnancy O O
of O O
a O O
woman O O
with O O
Crohn B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Clinical O O
signs O O
of O O
adrenal B-Disease B-Disease
suppression I-Disease I-Disease
were O O
observed O O
in O O
the O O
newborn O O
3 O O
h O O
after O O
birth O O
. O O

After O O
hydrocortisone O O
supplementation O O
and O O
intensive O O
therapy O O
the O O
baby O O
recovered O O
completely O O
. O O

CONCLUSIONS O O
: O O
Life O O
- O O
threatening O O
adrenal B-Disease B-Disease
suppression I-Disease I-Disease
, O O
requiring O O
hydrocortisone O O
supplementation O O
and O O
intensive O O
therapy O O
, O O
was O O
observed O O
and O O
successfully O O
treated O O
in O O
a O O
newborn O O
, O O
whose O O
mother O O
had O O
received O O
high O O
- O O
dose O O
methylprednisolone O O
in O O
late O O
pregnancy O O
. O O

Effect O O
of O O
ranitidine O O
on O O
the O O
pharmacokinetics O O
and O O
pharmacodynamics O O
of O O
prasugrel O O
and O O
clopidogrel O O
. O O

OBJECTIVE O O
: O O
Clopidogrel O O
is O O
an O O
oral O O
thienopyridine O O
antiplatelet O O
agent O O
indicated O O
for O O
the O O
treatment O O
of O O
atherothrombotic O B-Disease
events O I-Disease
in O O
patients O O
with O O
acute B-Disease B-Disease
coronary I-Disease I-Disease
syndrome I-Disease I-Disease
( O O
ACS O B-Disease
) O O
. O O

Prasugrel O O
, O O
a O O
novel O O
oral O O
thienopyridine O O
, O O
is O O
under O O
investigation O O
for O O
the O O
reduction O O
of O O
atherothrombotic O B-Disease
events O O
in O O
patients O O
with O O
ACS O B-Disease
undergoing O O
percutaneous O O
coronary O O
intervention O O
. O O

Prasugrel O O
's O O
solubility O O
decreases O O
with O O
increasing O O
pH O O
, O O
suggesting O O
that O O
concomitantly O O
- O O
administered O O
medications O O
that O O
increase O O
gastric O O
pH O O
may O O
lower O O
the O O
rate O O
and O O
/ O O
or O O
extent O O
of O O
prasugrel O O
absorption O O
. O O

This O O
study O O
evaluated O O
the O O
influence O O
of O O
ranitidine O O
coadministration O O
on O O
the O O
pharmacokinetics O O
and O O
pharmacodynamics O O
of O O
the O O
respective O O
active O O
metabolite O O
of O O
prasugrel O O
and O O
clopidogrel O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
In O O
this O O
open O O
- O O
label O O
, O O
two O O
- O O
period O O
, O O
two O O
- O O
treatment O O
, O O
crossover O O
study O O
, O O
47 O O
healthy O O
male O O
subjects O O
were O O
randomized O O
to O O
one O O
of O O
two O O
study O O
arms O O
, O O
receiving O O
either O O
prasugrel O O
( O O
60 O O
- O O
mg O O
loading O O
dose O O
[ O O
LD O O
] O O
, O O
10 O O
- O O
mg O O
maintenance O O
dose O O
[ O O
MD O O
] O O
for O O
7 O O
days O O
; O O
n O O
= O O
23 O O
) O O
or O O
clopidogrel O O
( O O
600 O O
- O O
mg O O
LD O O
, O O
75 O O
- O O
mg O O
MD O O
for O O
7 O O
days O O
; O O
n O O
= O O
24 O O
) O O
. O O

In O O
one O O
treatment O O
period O O
, O O
subjects O O
received O O
prasugrel O O
or O O
clopidogrel O O
alone O O
, O O
and O O
in O O
the O O
alternate O O
period O O
received O O
the O O
same O O
thienopyridine O O
with O O
ranitidine O O
( O O
150 O O
mg O O
twice O O
daily O O
, O O
starting O O
1 O O
day O O
before O O
the O O
LD O O
) O O
. O O

Pharmacokinetic O O
parameter O O
estimates O O
( O O
AUC O O
( O O
0 O O
- O O
t O O
last O O
) O O
, O O
C O O
( O O
max O O
) O O
, O O
and O O
t O O
( O O
max O O
) O O
) O O
and O O
inhibition O O
of O O
platelet O O
aggregation O O
( O O
IPA O O
) O O
by O O
light O O
transmission O O
aggregometry O O
were O O
assessed O O
at O O
multiple O O
time O O
points O O
after O O
the O O
LD O O
and O O
final O O
MD O O
. O O

RESULTS O O
: O O
Ranitidine O O
had O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
area O O
under O O
the O O
plasma O O
- O O
concentration O O
- O O
time O O
curve O O
( O O
AUC O O
) O O
and O O
did O O
not O O
affect O O
the O O
time O O
to O O
C O O
( O O
max O O
) O O
( O O
t O O
( O O
max O O
) O O
) O O
for O O
active O O
metabolites O O
of O O
either O O
prasugrel O O
or O O
clopidogrel O O
. O O

It O O
reduced O O
the O O
geometric O O
mean O O
maximum O O
concentrations O O
of O O
active O O
metabolite O O
( O O
C O O
( O O
max O O
) O O
) O O
after O O
a O O
prasugrel O O
and O O
clopidogrel O O
LD O O
by O O
14 O O
% O O
and O O
10 O O
% O O
, O O
respectively O O
, O O
but O O
these O O
differences O O
were O O
not O O
statistically O O
significant O O
. O O

When O O
coadministered O O
with O O
a O O
60 O O
- O O
mg O O
prasugrel O O
LD O O
, O O
ranitidine O O
did O O
not O O
affect O O
the O O
time O O
to O O
, O O
or O O
magnitude O O
of O O
, O O
peak O O
IPA O O
, O O
but O O
did O O
result O O
in O O
a O O
modest O O
reduction O O
at O O
0.5 O O
h O O
from O O
67.4 O O
to O O
55.1 O O
% O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

Ranitidine O O
did O O
not O O
affect O O
prasugrel O O
IPA O O
during O O
MD O O
. O O

For O O
clopidogrel O O
, O O
IPA O O
was O O
not O O
affected O O
by O O
ranitidine O O
. O O

Prasugrel O O
and O O
clopidogrel O O
were O O
both O O
well O O
- O O
tolerated O O
, O O
with O O
/ O O
without O O
ranitidine O O
. O O

CONCLUSIONS O O
: O O
Results O O
from O O
this O O
study O O
suggest O O
that O O
there O O
is O O
no O O
significant O O
drug O O
- O O
drug O O
interaction B-Disease O
between O O
oral O O
ranitidine O O
therapy O O
and O O
concomitantly O O
- O O
administered O O
prasugrel O O
or O O
clopidogrel O O
. O O

Dielectrophoretic O O
field O O
- O O
flow O O
fractionation O O
system O O
for O O
detection O O
of O O
aquatic O O
toxicants O O
. O O

Dielectrophoretic O O
field O O
- O O
flow O O
fractionation O O
( O O
dFFF O O
) O O
was O O
applied O O
as O O
a O O
contact O O
- O O
free O O
way O O
to O O
sense O O
changes O O
in O O
the O O
plasma O O
membrane O O
capacitances O O
and O O
conductivities O O
of O O
cultured O O
human O O
HL O O
- O O
60 O O
cells O O
in O O
response O O
to O O
toxicant O O
exposure O O
. O O

A O O
micropatterned O O
electrode O O
imposed O O
electric O O
forces O O
on O O
cells O O
in O O
suspension O O
in O O
a O O
parabolic O O
flow O O
profile O O
as O O
they O O
moved O O
through O O
a O O
thin O O
chamber O O
. O O

Relative O O
changes O O
in O O
the O O
dFFF O O
peak O O
elution O O
time O O
, O O
reflecting O O
changes O O
in O O
cell O O
membrane O O
area O O
and O O
ion O O
permeability O O
, O O
were O O
measured O O
as O O
indices O O
of O O
response O O
during O O
the O O
first O O
150 O O
min O O
of O O
exposure O O
to O O
eight O O
toxicants O O
having O O
different O O
single O O
or O O
mixed O O
modes O O
of O O
action O O
( O O
acrylonitrile O O
, O O
actinomycin O O
D O O
, O O
carbon O O
tetrachloride O O
, O O
endosulfan O O
, O O
N O O
- O O
nitroso O O
- O O
N O O
- O O
methylurea O O
( O O
NMU O O
) O O
, O O
paraquat O O
dichloride O O
, O O
puromycin O O
, O O
and O O
styrene O O
oxide O O
) O O
. O O

The O O
dFFF O O
method O O
was O O
compared O O
with O O
the O O
cell O O
viability O O
assay O O
for O O
all O O
toxicants O O
and O O
with O O
the O O
mitochondrial O O
potentiometric O O
dye O O
assay O O
or O O
DNA O O
alkaline O O
comet O O
assay O O
according O O
to O O
the O O
mode O O
of O O
action O O
of O O
the O O
specific O O
agents O O
. O O

Except O O
for O O
low O O
doses O O
of O O
nucleic O O
acid O O
- O O
targeting O O
agents O O
( O O
actinomycin O O
D O O
and O O
NMU O O
) O O
, O O
the O O
dFFF O O
method O O
detected O O
all O O
toxicants O O
more O O
sensitively O O
than O O
other O O
assays O O
, O O
in O O
some O O
cases O O
up O O
to O O
10 O O
( O O
5 O O
) O O
times O O
more O O
sensitively O O
than O O
the O O
viability O O
approach O O
. O O

The O O
results O O
suggest O O
the O O
dFFF O O
method O O
merits O O
additional O O
study O O
for O O
possible O O
applicability O O
in O O
toxicology O O
. O O

Hyperthermia B-Disease B-Disease
adds O O
to O O
chemotherapy O O
. O O

The O O
hallmarks O O
of O O
hyperthermia B-Disease B-Disease
and O O
its O O
pleotropic O O
effects O O
are O O
in O O
favour O O
of O O
its O O
combined O O
use O O
with O O
chemotherapy O O
. O O

Preclinical O O
research O O
reveals O O
that O O
for O O
heat O O
killing O O
and O O
synergistic O O
effects O O
the O O
thermal O O
dose O O
is O O
most O O
critical O O
. O O

Thermal O O
enhancement O O
of O O
drug B-Disease B-Disease
cytotoxicity I-Disease I-Disease
is O O
accompanied O O
by O O
cellular O O
death O O
and O O
necrosis O B-Disease
without O O
increasing O O
its O O
oncogenic O O
potential O O
. O O

The O O
induction O O
of O O
genetically O O
defined O O
stress O O
responses O O
can O O
deliver O O
danger O O
signals O O
to O O
activate O O
the O O
host O O
's O O
immune O O
system O O
. O O

The O O
positive O O
results O O
of O O
randomised O O
trials O O
have O O
definitely O O
established O O
hyperthermia B-Disease B-Disease
in O O
combination O O
with O O
chemotherapy O O
as O O
a O O
novel O O
clinical O O
modality O O
for O O
the O O
treatment O O
of O O
cancer B-Disease B-Disease
. O O

Hyperthermia B-Disease B-Disease
targets O O
the O O
action O O
of O O
chemotherapy O O
within O O
the O O
heated O O
tumour B-Disease B-Disease
region O O
without O O
affecting O O
systemic B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

In O O
specific O O
clinical O O
settings O O
regional B-Disease B-Disease
hyperthermia I-Disease I-Disease
( O O
RHT B-Disease B-Disease
) O O
or O O
hyperthermic O O
perfusion O O
has O O
proved O O
its O O
value O O
and O O
deserve O O
a O O
greater O O
focus O O
and O O
investigation O O
in O O
other O O
malignancies O B-Disease
. O O

In O O
Europe O O
, O O
more O O
specialised O O
centres O O
should O O
be O O
created O O
and O O
maintained O O
as O O
network O O
of O O
excellence O O
for O O
hyperthermia B-Disease B-Disease
in O O
the O O
field O O
of O O
oncology O O
. O O

Multiple O O
- O O
pool O O
cell O O
lifespan O O
models O O
for O O
neutropenia B-Disease B-Disease
to O O
assess O O
the O O
population O O
pharmacodynamics O O
of O O
unbound O O
paclitaxel O O
from O O
two O O
formulations O O
in O O
cancer B-Disease B-Disease
patients O O
. O O

PURPOSE O O
: O O
Our O O
objective O O
was O O
to O O
build O O
a O O
mechanism O O
- O O
based O O
pharmacodynamic O O
model O O
for O O
the O O
time O O
course O O
of O O
neutropenia B-Disease B-Disease
in O O
cancer B-Disease B-Disease
patients O O
following O O
paclitaxel O O
treatment O O
with O O
a O O
tocopherol O O
- O O
based O O
Cremophor O O
- O O
free O O
formulation O O
( O O
Tocosol O O
Paclitaxel O O
) O O
and O O
Cremophor O O
EL O O
- O O
formulated O O
paclitaxel O O
( O O
Taxol O O
) O O
. O O

METHODS O O
: O O
A O O
randomized O O
two O O
- O O
way O O
crossover O O
trial O O
was O O
performed O O
with O O
35 O O
adult O O
patients O O
who O O
received O O
175 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
paclitaxel O O
as O O
either O O
15 O O
min O O
( O O
Tocosol O O
Paclitaxel O O
) O O
or O O
3 O O
h O O
( O O
Taxol O O
) O O
intravenous O O
infusions O O
. O O

Paclitaxel O O
concentrations O O
were O O
measured O O
by O O
LC O O
- O O
MS O O
/ O O
MS O O
. O O

NONMEM O O
VI O O
was O O
used O O
for O O
population O O
pharmacodynamics O O
. O O

RESULTS O O
: O O
The O O
cytotoxic B-Disease O
effect I-Disease O
on O O
neutrophils O O
was O O
described O O
by O O
four O O
mechanism O O
- O O
based O O
models O O
predicated O O
on O O
known O O
properties O O
of O O
paclitaxel O O
that O O
used O O
unbound O O
concentrations O O
in O O
the O O
central O O
, O O
deep O O
peripheral O O
or O O
an O O
intracellular O O
compartment O O
as O O
forcing O O
functions O O
. O O

Tocosol O O
Paclitaxel O O
was O O
estimated O O
to O O
release O O
9.8 O O
% O O
of O O
the O O
dose O O
directly O O
into O O
the O O
deep O O
peripheral O O
compartment O O
( O O
DPC O O
) O O
. O O

All O O
models O O
provided O O
reasonable O O
fitting O O
of O O
neutropenic O O
effects O O
. O O

The O O
model O O
with O O
the O O
best O O
predictive O O
performance O O
assumed O O
that O O
this O O
dose O O
fraction O O
was O O
released O O
into O O
22.5 O O
% O O
of O O
the O O
DPC O O
which O O
included O O
the O O
site O O
of O O
toxicity O O
. O O

The O O
second O O
- O O
order O O
cytotoxic O O
rate O O
constant O O
was O O
0.00211 O O
mL O O
/ O O
ng O O
per O O
hour O O
( O O
variability O O
: O O
52 O O
% O O
CV O O
) O O
. O O

The O O
relative O O
exposure O O
at O O
the O O
site O O
of O O
toxicity O B-Disease
was O O
2.21 O O
+ O O
/ O O
- O O
0.41 O O
times O O
( O O
average O O
+ O O
/ O O
- O O
SD O O
) O O
larger O O
for O O
Tocosol O O
Paclitaxel O O
compared O O
to O O
Taxol O O
. O O

Lifespan O O
was O O
11.0 O O
days O O
for O O
progenitor O O
cells O O
, O O
1.95 O O
days O O
for O O
maturating O O
cells O O
, O O
and O O
4.38 O O
days O O
for O O
neutrophils O O
. O O

Total O O
drug O O
exposure O O
in O O
blood O O
explained O O
half O O
of O O
the O O
variance O O
in O O
nadir O O
to O O
baseline O O
neutrophil O O
count O O
ratio O O
. O O

CONCLUSIONS O O
: O O
The O O
relative O O
exposure O O
of O O
unbound O O
paclitaxel O O
at O O
the O O
site O O
of O O
toxicity O B-Disease
was O O
twice O O
as O O
large O O
for O O
Tocosol O O
Paclitaxel O O
compared O O
to O O
Taxol O O
. O O

The O O
proposed O O
mechanism O O
- O O
based O O
models O O
explained O O
the O O
extent O O
and O O
time O O
course O O
of O O
neutropenia B-Disease B-Disease
jointly O O
for O O
both O O
formulations O O
. O O

Effect O O
of O O
ABCG2 O O
on O O
cytotoxicity B-Disease B-Disease
of O O
platinum O O
drugs O O
: O O
interference O O
of O O
EGFP O O
. O O

ATP O O
- O O
binding O O
drug O O
efflux O O
transporters O O
decrease O O
intracellular O O
concentrations O O
of O O
cytotoxic O O
drugs O O
, O O
causing O O
multidrug O O
resistance O O
in O O
cancer B-Disease B-Disease
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
possible O O
interactions O O
of O O
ABCG2 O O
transporter O O
with O O
platinum O O
cytotoxic O O
drugs O O
. O O

We O O
demonstrate O O
here O O
an O O
interference O O
of O O
platinum O O
drugs O O
with O O
enhanced O O
green O O
fluorescence O O
protein O O
( O O
EGFP O O
) O O
in O O
the O O
cellular O O
models O O
, O O
where O O
EGFP O O
was O O
employed O O
as O O
a O O
reporter O O
gene O O
. O O

Cytotoxicity B-Disease B-Disease
of O O
cisplatin O O
( O O
CIP O O
) O O
, O O
carboplatin O O
( O O
CAP O O
) O O
and O O
oxaliplatin O O
( O O
OXP O O
) O O
was O O
significantly O O
lowered O O
in O O
MDCKII O O
cells O O
transfected O O
with O O
ABCG2 O O
transporter O O
and O O
EGFP O O
reporter O O
. O O

The O O
IC O O
( O O
50 O O
) O O
values O O
in O O
MDCKII O O
- O O
ABCG2 O O
were O O
25.7 O O
, O O
164 O O
and O O
165 O O
microM O O
for O O
CIP O O
, O O
CAP O O
and O O
OXP O O
, O O
respectively O O
, O O
whereas O O
IC O O
( O O
50 O O
) O O
for O O
the O O
same O O
cytostatics O O
in O O
MDCKII O O
cells O O
were O O
as O O
follows O O
: O O
15.4 O O
, O O
133 O O
and O O
50.3 O O
microM O O
. O O

Addition O O
of O O
fumitremorgin O O
C O O
( O O
FTC O O
) O O
, O O
a O O
potent O O
ABCG2 O O
inhibitor O O
, O O
significantly O O
suppressed O O
the O O
resistance O O
of O O
MDCKII O O
- O O
ABCG2 O O
to O O
OXP O O
, O O
suggesting O O
that O O
OXP O O
interacts O O
with O O
ABCG2 O O
. O O

However O O
, O O
FTC O O
did O O
not O O
change O O
the O O
sensitivity O O
of O O
the O O
cells O O
to O O
CIP O O
and O O
CAP O O
. O O

We O O
assume O O
that O O
EGFP O O
rather O O
than O O
ABCG2 O O
causes O O
the O O
diminished O O
toxicity O O
of O O
the O O
platinum O O
cytostatics O O
in O O
the O O
transfected O O
cells O O
. O O

This O O
hypothesis O O
was O O
confirmed O O
in O O
human O O
Hep2 O O
cells O O
expressing O O
EGFP O O
: O O
using O O
MTT O O
test O O
, O O
IC O O
( O O
50 O O
) O O
of O O
30.0 O O
, O O
247 O O
and O O
27.9 O O
microM O O
were O O
obtained O O
for O O
CIP O O
, O O
CAP O O
and O O
OXP O O
, O O
respectively O O
, O O
while O O
12.3 O O
, O O
106 O O
and O O
20.5 O O
microM O O
were O O
observed O O
in O O
the O O
parent O O
Hep2 O O
cells O O
. O O

Employing O O
neutral O O
red O O
cytotoxicity B-Disease B-Disease
assay O O
, O O
similar O O
data O O
were O O
obtained O O
( O O
IC O O
( O O
50 O O
) O O
7.73 O O
, O O
685 O O
and O O
112 O O
microM O O
for O O
CIP O O
, O O
CAP O O
, O O
and O O
OXP O O
, O O
respectively O O
, O O
in O O
the O O
Hep2 O O
- O O
EGFP O O
cells O O
and O O
1.65 O O
, O O
79.4 O O
and O O
24.5 O O
microM O O
in O O
the O O
parent O O
Hep2 O O
cells O O
) O O
. O O

Caspase O O
- O O
3 O O
/ O O
7 O O
assay O O
revealed O O
lower O O
susceptibility O O
of O O
EGFP O O
expressing O O
Hep2 O O
cells O O
to O O
apoptosis O O
induced O O
by O O
CIP O O
when O O
compared O O
to O O
the O O
parent O O
cell O O
line O O
. O O

We O O
therefore O O
conclude O O
that O O
EGFP O O
in O O
transfected O O
cells O O
interferes O O
with O O
cytotoxicity B-Disease B-Disease
of O O
platinum O O
drugs O O
by O O
hindering O O
the O O
drug O O
induced O O
apoptosis O O
and O O
could O O
cause O O
misinterpretation O O
of O O
results O O
obtained O O
in O O
cytotoxicity B-Disease B-Disease
studies O O
. O O

Protective O O
effects O O
of O O
asiatic O O
acid O O
on O O
rotenone O O
- O O
or O O
H2O2 O O
- O O
induced O O
injury O O
in O O
SH O O
- O O
SY5Y O O
cells O O
. O O

Parkinson B-Disease B-Disease
's I-Disease I-Disease
disease I-Disease I-Disease
( O O
PD B-Disease B-Disease
) O O
is O O
a O O
progressive B-Disease O
neurodegenerative I-Disease B-Disease
disorder I-Disease I-Disease
with O O
a O O
prevalence O O
of O O
1 O O
- O O
2 O O
% O O
in O O
people O O
over O O
the O O
age O O
of O O
50 O O
. O O

Mitochondrial O B-Disease
dysfunction O I-Disease
occurred O O
in O O
PD B-Disease B-Disease
patients O O
showing O O
a O O
15 O O
- O O
30 O O
% O O
loss O O
of O O
activity O O
in O O
complex O O
I O O
. O O

Asiatic O O
acid O O
( O O
AA O O
) O O
, O O
a O O
triterpenoid O O
, O O
is O O
an O O
antioxidant O O
and O O
used O O
for O O
depression B-Disease B-Disease
treatment O O
, O O
but O O
the O O
effect O O
of O O
AA O O
against O O
PD B-Disease B-Disease
- O O
like O O
damage O O
has O O
never O O
been O O
reported O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
protective O O
effects O O
of O O
AA O O
against O O
H O O
( O O
2 O O
) O O
O O O
( O O
2 O O
) O O
or O O
rotenone O O
- O O
induced O O
cellular B-Disease B-Disease
injury I-Disease I-Disease
and O O
mitochondrial O B-Disease
dysfunction O I-Disease
in O O
SH O O
- O O
SY5Y O O
cells O O
. O O

Mitochondrial O O
membrane O O
potential O O
( O O
MMP O O
) O O
and O O
the O O
expression O O
of O O
voltage O O
- O O
dependent O O
anion O O
channel O O
( O O
VDAC O O
) O O
were O O
detected O O
with O O
or O O
without O O
AA O O
pretreatment O O
following O O
cellular B-Disease O
injury I-Disease O
to O O
address O O
the O O
possible O O
mechanisms O O
of O O
AA O O
neuroprotection O O
. O O

The O O
results O O
showed O O
that O O
pre O O
- O O
treatment O O
of O O
AA O O
( O O
0.01 O O
- O O
100 O O
nM O O
) O O
protected O O
cells O O
against O O
the O O
toxicity O O
induced O O
by O O
rotenone O O
or O O
H O O
( O O
2 O O
) O O
O O O
( O O
2 O O
) O O
. O O

In O O
addition O O
, O O
MMP O O
dissipation O O
occurred O O
following O O
the O O
exposure O O
of O O
rotenone O O
, O O
which O O
could O O
be O O
prevented O O
by O O
AA O O
treatment O O
. O O

More O O
interestingly O O
, O O
pre O O
- O O
administration O O
of O O
AA O O
inhibited O O
the O O
elevation O O
of O O
VDAC O O
mRNA O O
and O O
protein O O
levels O O
induced O O
by O O
rotenone O O
( O O
100 O O
nM O O
) O O
or O O
H O O
( O O
2 O O
) O O
O O O
( O O
2 O O
) O O
( O O
300 O O
microM O O
) O O
. O O

These O O
data O O
indicate O O
that O O
AA O O
could O O
protect O O
neuronal O O
cells O O
against O O
mitochondrial O B-Disease
dysfunctional O I-Disease
injury O I-Disease
and O O
suggest O O
that O O
AA O O
might O O
be O O
developed O O
as O O
an O O
agent O O
for O O
PD O O
prevention O O
or O O
therapy O O
. O O

Efficient O O
telomerase O O
inhibition O O
in O O
human O O
non O O
- O O
small O O
cell O O
lung O O
cancer O O
cells O O
by O O
liposomal O O
delivery O O
of O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
. O O

The O O
antisense O O
oligonucleotide O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
is O O
a O O
selective O O
telomerase O O
inhibitor O O
targeting O O
the O O
telomerase O O
RNA O O
component O O
and O O
represents O O
a O O
potential O O
candidate O O
for O O
anticancer O O
therapy O O
. O O

The O O
poor O O
cellular O O
uptake O O
of O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
is O O
a O O
limiting O O
factor O O
that O O
may O O
contribute O O
to O O
the O O
lack O O
of O O
functional O O
efficacy O O
. O O

To O O
improve O O
delivery O O
of O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
and O O
consequently O O
antitumoral O O
efficiency O O
in O O
human O O
lung O O
cancer O O
cells O O
, O O
we O O
have O O
investigated O O
several O O
transfection O O
reagents O O
. O O

The O O
transfection O O
reagents O O
DOTAP O O
, O O
MegaFectin O O
60 O O
, O O
SuperFect O O
, O O
FuGENE O O
6 O O
and O O
MATra O O
- O O
A O O
were O O
tested O O
for O O
intracellular O O
delivery O O
. O O

A O O
FAM O O
- O O
labeled O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
was O O
used O O
to O O
assess O O
the O O
intracellular O O
distribution O O
by O O
confocal O O
laser O O
scanning O O
microscopy O O
in O O
A549 O O
human O O
non O O
- O O
small O O
cell O O
lung O O
cancer O O
cells O O
. O O

Telomerase O O
activity O O
was O O
measured O O
using O O
the O O
telomeric O O
repeat O O
amplification O O
protocol O O
. O O

Cell O O
viability O O
after O O
transfection O O
was O O
quantified O O
by O O
the O O
MTT O O
assay O O
. O O

All O O
transfection O O
reagents O O
enhanced O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
uptake O O
in O O
A549 O O
cells O O
but O O
the O O
cationic O O
lipid O O
reagents O O
DOTAP O O
and O O
MegaFectin O O
60 O O
were O O
most O O
efficient O O
in O O
the O O
delivery O O
of O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
resulting O O
in O O
telomerase O O
inhibition O O
. O O

Among O O
both O O
DOTAP O O
exhibited O O
the O O
lowest O O
cytotoxicity B-Disease B-Disease
. O O

Our O O
experiments O O
show O O
that O O
DOTAP O O
is O O
the O O
most O O
suitable O O
transfection O O
reagent O O
for O O
the O O
delivery O O
of O O
2 O O
' O O
- O O
O O O
- O O
methyl O O
- O O
RNA O O
in O O
human O O
lung O O
cancer O O
cells O O
according O O
to O O
its O O
relatively O O
low O O
cytotoxicity B-Disease B-Disease
and O O
its O O
ability O O
to O O
promote O O
efficient O O
uptake O O
leading O O
to O O
the O O
inhibition O O
of O O
telomerase O O
. O O

Particulate O O
matter O O
inhibits O O
DNA O O
repair O O
and O O
enhances O O
mutagenesis O O
. O O

Exposure O O
to O O
ambient O O
air O O
pollution O O
has O O
been O O
associated O O
with O O
adverse O O
health O O
effects O O
including O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
. O O

A O O
recent O O
epidemiology O O
study O O
has O O
established O O
that O O
each O O
10 O O
microg O O
/ O O
m3 O O
elevation O O
in O O
long O O
- O O
term O O
exposure O O
to O O
average O O
PM2 O O
.5 O O
ambient O O
concentration O O
was O O
associated O O
with O O
approximately O O
8 O O
% O O
of O O
lung B-Disease B-Disease
cancer I-Disease I-Disease
mortality O O
. O O

The O O
underlying O O
mechanisms O O
of O O
how O O
PM O O
contributes O O
to O O
lung O O
carcinogenesis O O
, O O
however O O
, O O
remain O O
to O O
be O O
elucidated O O
. O O

We O O
have O O
recently O O
found O O
that O O
transition O O
metals O O
such O O
as O O
nickel O O
and O O
chromium O O
and O O
oxidative O O
stress O O
induced O O
lipid O O
peroxidation O O
metabolites O O
such O O
as O O
aldehydes O O
can O O
greatly O O
inhibit O O
nucleotide O O
excision O O
repair O O
( O O
NER O O
) O O
and O O
enhance O O
carcinogen O O
- O O
induced O O
mutations O O
. O O

Because O O
PM O O
is O O
rich O O
in O O
metal O O
and O O
aldehyde O O
content O O
and O O
can O O
induce O O
oxidative O O
stress O O
, O O
we O O
tested O O
the O O
effect O O
of O O
PM O O
on O O
DNA O O
repair O O
capacity O O
in O O
cultured O O
human O O
lung O O
cells O O
using O O
in O O
vitro O O
DNA O O
repair O O
synthesis O O
and O O
host O O
cell O O
reactivation O O
assays O O
. O O

We O O
found O O
that O O
PM O O
greatly O O
inhibits O O
NER O O
for O O
ultraviolet O O
( O O
UV O O
) O O
light O O
and O O
benzo O O
( O O
a O O
) O O
pyrene O O
diol O O
epoxide O O
( O O
BPDE O O
) O O
induced O O
DNA O O
damage O O
in O O
human O O
lung O O
cells O O
. O O

We O O
further O O
demonstrated O O
that O O
PM O O
exposure O O
can O O
significantly O O
increase O O
both O O
spontaneous O O
and O O
UV O O
- O O
induced O O
mutagenesis O O
. O O

These O O
results O O
together O O
suggest O O
that O O
the O O
carcinogenicity B-Disease O
of O O
PM O O
may O O
act O O
through O O
its O O
combined O O
effect O O
on O O
suppression O O
of O O
DNA O O
repair O O
and O O
enhancement O O
of O O
DNA O O
replication O O
errors O O
. O O

Nicotine O O
and O O
4 O O
- O O
( O O
methylnitrosamino O O
) O O
- O O
1 O O
- O O
( O O
3 O O
- O O
pyridyl O O
) O O
- O O
1 O O
- O O
butanone O O
induce O O
cyclooxygenase O O
- O O
2 O O
activity O O
in O O
human O O
gastric O O
cancer O O
cells O O
: O O
Involvement O O
of O O
nicotinic O O
acetylcholine O O
receptor O O
( O O
nAChR O O
) O O
and O O
beta O O
- O O
adrenergic O O
receptor O O
signaling O O
pathways O O
. O O

Induction O O
of O O
cyclooxygenase O O
- O O
2 O O
( O O
COX O O
- O O
2 O O
) O O
associates O O
with O O
cigarette O O
smoke O O
exposure O O
in O O
many O O
malignancies O B-Disease
. O O

Nicotine O O
and O O
its O O
derivative O O
, O O
4 O O
- O O
( O O
methylnitrosamino O O
) O O
- O O
1 O O
- O O
( O O
3 O O
- O O
pyridyl O O
) O O
- O O
1 O O
- O O
butanone O O
( O O
NNK O O
) O O
, O O
are O O
the O O
two O O
important O O
components O O
in O O
cigarette O O
smoke O O
that O O
contributes O O
to O O
cancer B-Disease B-Disease
development O O
. O O

However O O
, O O
the O O
molecular O O
mechanism O O
( O O
s O O
) O O
by O O
which O O
nicotine O O
or O O
NNK O O
promotes O O
gastric O B-Disease
carcinogenesis O I-Disease
remains O O
largely O O
unknown O O
. O O

We O O
found O O
that O O
nicotine O O
and O O
NNK O O
significantly O O
enhanced O O
cell O O
proliferation O O
in O O
AGS O O
cells O O
that O O
expressed O O
both O O
alpha7 O O
nicotinic O O
acetylcholine O O
receptor O O
( O O
alpha7 O O
nAChR O O
) O O
and O O
beta O O
- O O
adrenergic O O
receptors O O
. O O

Treatment O O
of O O
cells O O
with O O
alpha O O
- O O
bungarotoxin O O
( O O
alpha O O
- O O
BTX O O
, O O
alpha7nAChR O O
antagonist O O
) O O
or O O
propranolol O O
( O O
beta O O
- O O
adrenergic O O
receptor O O
antagonist O O
) O O
blocked O O
NNK O O
- O O
induced O O
COX O O
- O O
2 O O
/ O O
PGE O O
( O O
2 O O
) O O
and O O
cell O O
proliferation O O
, O O
while O O
nicotine O O
- O O
mediated O O
cell O O
growth O O
and O O
COX O O
- O O
2 O O
/ O O
PGE O O
( O O
2 O O
) O O
induction O O
can O O
only O O
be O O
suppressed O O
by O O
propranolol O O
, O O
but O O
not O O
alpha O O
- O O
BTX O O
. O O

Moreover O O
, O O
in O O
contrast O O
to O O
the O O
dependence O O
of O O
growth O O
promoting O O
effect O O
of O O
nicotine O O
on O O
Erk O O
activation O O
, O O
inhibitor O O
of O O
p38 O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
( O O
MAPK O O
) O O
repressed O O
NNK O O
- O O
induced O O
COX O O
- O O
2 O O
upregulation O O
and O O
resulted O O
in O O
suppression O O
of O O
cell O O
growth O O
. O O

In O O
addition O O
, O O
nicotine O O
and O O
NNK O O
mediated O O
COX O O
- O O
2 O O
induction O O
via O O
different O O
receptors O O
to O O
modulate O O
several O O
G1 O O
/ O O
S O O
transition O O
regulatory O O
proteins O O
and O O
promote O O
gastric O O
cancer O O
cell O O
growth O O
. O O

Selective O O
COX O O
- O O
2 O O
inhibitor O O
( O O
SC O O
- O O
236 O O
) O O
caused O O
G1 O O
arrest O O
and O O
abrogated O O
nicotine O O
/ O O
NNK O O
- O O
induced O O
cell O O
proliferation O O
. O O

Aberrant O O
expression O O
of O O
cyclin O O
D1 O O
and O O
other O O
G1 O O
regulatory O O
proteins O O
are O O
reversed O O
by O O
blockade O O
of O O
COX O O
- O O
2 O O
. O O

These O O
results O O
pointed O O
to O O
the O O
importance O O
of O O
adrenergic O O
and O O
nicotinic O O
receptors O O
in O O
gastric B-Disease B-Disease
tumor I-Disease I-Disease
growth O O
through O O
MAPK O O
/ O O
COX O O
- O O
2 O O
activation O O
, O O
which O O
may O O
perhaps O O
provide O O
a O O
chemoprevention O O
strategy O O
for O O
cigarette O O
smoke O O
- O O
related O O
gastric B-Disease B-Disease
carcinogenesis I-Disease I-Disease
. O O

Selenium O O
nanoparticles O O
fabricated O O
in O O
Undaria O O
pinnatifida O O
polysaccharide O O
solutions O O
induce O O
mitochondria O O
- O O
mediated O O
apoptosis O O
in O O
A375 O O
human O O
melanoma O O
cells O O
. O O

Selenium O O
nanoparticle O O
( O O
Nano O O
- O O
Se O O
) O O
is O O
a O O
novel O O
Se O O
species O O
with O O
novel O O
biological O O
activities O O
and O O
low O O
toxicity O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrated O O
a O O
simple O O
method O O
for O O
synthesis O O
of O O
size O O
- O O
controlled O O
Nano O O
- O O
Se O O
by O O
adding O O
Undaria O O
pinnatifida O O
polysaccharides O O
to O O
the O O
redox O O
system O O
of O O
selenite O O
and O O
ascorbic O O
acid O O
. O O

A O O
panel O O
of O O
four O O
human O O
cancer O O
cell O O
lines O O
was O O
shown O O
to O O
be O O
susceptible O O
to O O
Nano O O
- O O
Se O O
, O O
with O O
IC O O
( O O
50 O O
) O O
values O O
ranging O O
from O O
3.0 O O
to O O
14.1 O O
microM O O
. O O

Treatment O O
of O O
A375 O O
human O O
melanoma O O
cells O O
with O O
the O O
Nano O O
- O O
Se O O
resulted O O
in O O
dose O O
- O O
dependent O O
cell O O
apoptosis O O
as O O
indicated O O
by O O
DNA O O
fragmentation O O
and O O
phosphatidylserine O O
translocation O O
. O O

Further O O
investigation O O
on O O
intracellular O O
mechanisms O O
found O O
that O O
Nano O O
- O O
Se O O
treatment O O
triggered O O
apoptotic O O
cell O O
death O O
in O O
A375 O O
cells O O
with O O
the O O
involvement O O
of O O
oxidative O O
stress O O
and O O
mitochondrial O B-Disease
dysfunction O I-Disease
. O O

Our O O
results O O
suggest O O
that O O
Nano O O
- O O
Se O O
may O O
be O O
a O O
candidate O O
for O O
further O O
evaluation O O
as O O
a O O
chemopreventive O O
and O O
chemotherapeutic O O
agent O O
for O O
human O O
cancers O B-Disease
, O O
especially O O
melanoma B-Disease B-Disease
cancer I-Disease I-Disease
. O O

An O O
EORTC O O
phase O O
I O O
study O O
of O O
Bortezomib O O
in O O
combination O O
with O O
oxaliplatin O O
, O O
leucovorin O O
and O O
5 O O
- O O
fluorouracil O O
in O O
patients O O
with O O
advanced O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
. O O

The O O
combination O O
of O O
oxaliplatin O O
, O O
leucovorin O O
and O O
5 O O
- O O
fluorouracil O O
( O O
FOLFOX O O
- O O
4 O O
) O O
is O O
still O O
a O O
reference O O
regimen O O
in O O
advanced O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
; O O
however O O
, O O
the O O
addition O O
of O O
new O O
biologic O O
compounds O O
represents O O
a O O
significant O O
way O O
forward O O
. O O

Bortezomib O O
is O O
an O O
inhibitor O O
of O O
proteasome O O
, O O
a O O
multicatalytic O O
enzyme O O
complex O O
that O O
degrades O O
several O O
intracellular O O
proteins O O
. O O

In O O
this O O
study O O
, O O
escalating O O
doses O O
of O O
Bortezomib O O
were O O
administered O O
along O O
with O O
the O O
standard O O
FOLFOX O O
- O O
4 O O
doses O O
, O O
in O O
order O O
to O O
evaluate O O
the O O
dose B-Disease O
- I-Disease O
limiting I-Disease O
toxicity I-Disease B-Disease
( O O
DLT B-Disease O
) O O
, O O
toxicity O O
profile O O
and O O
activity O O
of O O
the O O
combination O O
. O O

Patients O O
with O O
advanced O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
, O O
unpretreated O O
for O O
metastatic B-Disease B-Disease
disease I-Disease I-Disease
, O O
were O O
enroled O O
in O O
the O O
study O O
. O O

Bortezomib O O
starting O O
dose O O
was O O
1.3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
, O O
which O O
was O O
to O O
be O O
escalated O O
in O O
the O O
subsequent O O
steps O O
according O O
to O O
the O O
toxicities O O
observed O O
after O O
first O O
cycle O O
. O O

Exploratory O O
pharmacogenetics O O
research O O
was O O
conducted O O
by O O
analysing O O
the O O
association O O
between O O
clinical O O
outcomes O O
and O O
polymorphisms O O
in O O
candidate O O
genes O O
for O O
response O O
to O O
each O O
of O O
the O O
used O O
drugs O O
. O O

Correlation O O
between O O
tumour O B-Disease
marker O O
changes O O
and O O
response O O
was O O
also O O
investigated O O
. O O

One O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
( O O
DL O O
- O O
1 O O
) O O
was O O
defined O O
as O O
being O O
the O O
maximum O O
tolerated O O
dose O O
since O O
only O O
1 O O
DLT O O
was O O
observed O O
in O O
6 O O
patients O O
. O O

The O O
main O O
toxicities O O
were O O
haematologic O O
, O O
neuropathy B-Disease B-Disease
, O O
diarrhoea B-Disease B-Disease
and O O
fatigue B-Disease B-Disease
. O O

Amongst O O
13 O O
evaluable O O
patients O O
, O O
five O O
had O O
a O O
partial O O
response O O
, O O
five O O
had O O
a O O
stable O O
disease O O
and O O
three O O
patients O O
progressed O O
. O O

Two O O
patients O O
are O O
long O O
- O O
term O O
survivors O O
after O O
a O O
combined O O
chemosurgical O O
approach O O
. O O

Further O O
trials O O
of O O
the O O
current O O
combination O O
may O O
be O O
justified O O
. O O

Derivation O O
of O O
a O O
chronic O O
reference O O
dose O O
and O O
reference O O
concentration O O
for O O
trimethylbenzenes O O
and O O
C9 O O
aromatic O O
hydrocarbon O O
solvents O O
. O O

Trimethylbenzenes O O
( O O
TMBs O O
) O O
and O O
C9 O O
aromatic O O
hydrocarbon O O
solvents O O
are O O
structurally O O
similar O O
and O O
have O O
similar O O
toxicity O O
. O O

Based O O
on O O
a O O
review O O
of O O
the O O
entire O O
TMB O O
and O O
C9 O O
aromatic O O
hydrocarbon O O
solvents O O
toxicology O O
database O O
, O O
oral O O
and O O
inhalation O O
studies O O
were O O
identified O O
to O O
serve O O
as O O
the O O
basis O O
for O O
a O O
Reference O O
dose O O
( O O
RfD O O
) O O
and O O
Reference O O
concentrations O O
( O O
RfC O O
) O O
. O O

The O O
RfD O O
and O O
RfC O O
were O O
derived O O
using O O
standard O O
USEPA O O
methods O O
and O O
assumptions O O
. O O

The O O
RfD O O
was O O
calculated O O
to O O
be O O
0.4 O O
mg O O
/ O O
kg O O
/ O O
day O O
using O O
a O O
90 O O
- O O
day O O
oral O O
study O O
that O O
resulted O O
in O O
a O O
NOAEL O O
of O O
600 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
based O O
on O O
a O O
lack O O
of O O
adverse O O
effects O O
at O O
the O O
highest O O
dose O O
level O O
( O O
reversible O O
effects O O
such O O
as O O
increased O O
serum O O
phosphorus O O
levels O O
and O O
liver O O
and O O
kidney O O
weights O O
) O O
, O O
along O O
with O O
a O O
total O O
uncertainty O O
factor O O
of O O
1000 O O
. O O

For O O
the O O
RfC O O
, O O
three O O
studies O O
were O O
considered O O
based O O
on O O
different O O
study O O
designs O O
and O O
toxicological O O
endpoints O O
, O O
including O O
neurotoxicity B-Disease B-Disease
, O O
systemic B-Disease B-Disease
toxicity I-Disease I-Disease
, O O
and O O
potential O O
developmental O O
and O O
reproductive B-Disease B-Disease
toxicity I-Disease I-Disease
. O O

For O O
all O O
three O O
studies O O
, O O
as O O
the O O
calculated O O
RfCs O O
were O O
consistent O O
( O O
3 O O
- O O
4 O O
mg O O
/ O O
m3 O O
) O O
, O O
the O O
most O O
conservative O O
RfC O O
, O O
3 O O
mg O O
/ O O
m3 O O
, O O
was O O
selected O O
. O O

The O O
C9 O O
aromatic O O
hydrocarbon O O
solvents O O
referred O O
to O O
herein O O
are O O
based O O
on O O
chemistries O O
assessed O O
as O O
part O O
of O O
the O O
TSCA O O
Section O O
4 O O
Test O O
Rule O O
. O O

These O O
solvents O O
contain O O
primarily O O
ethyl O O
toluene O O
and O O
tri O O
- O O
methyl O O
benzene O O
isomers O O
, O O
but O O
the O O
specific O O
compositions O O
can O O
vary O O
based O O
on O O
feedstock O O
and O O
manufacturing O O
process O O
, O O
thus O O
, O O
it O O
is O O
important O O
to O O
consider O O
the O O
composition O O
of O O
any O O
specific O O
solvent O O
to O O
assess O O
similarity O O
to O O
that O O
assessed O O
in O O
the O O
TSCA O O
Section O O
4 O O
Test O O
Rule O O
program O O
. O O

Fatal O O
toxic B-Disease B-Disease
epidermal I-Disease I-Disease
necrolysis I-Disease I-Disease
and O O
severe O O
granulocytopenia B-Disease B-Disease
following O O
therapy O O
with O O
cefuroxime O O
. O O

Toxic B-Disease B-Disease
epidermal I-Disease I-Disease
necrolysis I-Disease I-Disease
( O O
TEN B-Disease B-Disease
) O O
is O O
one O O
of O O
the O O
most O O
threatening O O
adverse O O
reactions O O
to O O
various O O
drugs O O
. O O

No O O
case O O
of O O
concomitant O O
occurrence O O
TEN B-Disease B-Disease
and O O
severe O O
granulocytopenia B-Disease B-Disease
following O O
the O O
treatment O O
with O O
cefuroxime O O
has O O
been O O
reported O O
to O O
date O O
. O O

Herein O O
we O O
present O O
a O O
case O O
of O O
TEN B-Disease B-Disease
that O O
developed O O
eighteen O O
days O O
of O O
the O O
initiation O O
of O O
cefuroxime O O
axetil O O
therapy O O
for O O
urinary B-Disease B-Disease
tract I-Disease I-Disease
infection I-Disease I-Disease
in O O
a O O
73 O O
- O O
year O O
- O O
old O O
woman O O
with O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
and O O
no O O
previous O O
history O O
of O O
allergic B-Disease B-Disease
diathesis I-Disease I-Disease
. O O

The O O
condition O O
was O O
associated O O
with O O
severe O O
granulocytopenia B-Disease B-Disease
and O O
followed O O
by O O
gastrointestinal B-Disease B-Disease
hemorrhage I-Disease I-Disease
, O O
severe O O
sepsis B-Disease B-Disease
and O O
multiple B-Disease B-Disease
organ I-Disease I-Disease
failure I-Disease I-Disease
syndrome I-Disease I-Disease
development O O
. O O

Despite O O
intensive O O
medical O O
treatment O O
the O O
patient O O
died O O
. O O

The O O
present O O
report O O
underlines O O
the O O
potential O O
of O O
cefuroxime O O
to O O
simultaneously O O
induce O O
life O O
threatening O O
adverse O O
effects O O
such O O
as O O
TEN B-Disease B-Disease
and O O
severe O O
granulocytopenia B-Disease B-Disease
. O O

Further O O
on O O
, O O
because O O
the O O
patient O O
was O O
also O O
taking O O
furosemide O O
for O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
, O O
the O O
possible O O
unfavorable O O
interactions O O
between O O
the O O
two O O
drugs O O
could O O
be O O
hypothesized O O
. O O

Therefore O O
, O O
awareness O O
of O O
the O O
possible O O
drug O O
interaction O O
is O O
necessary O O
, O O
especially O O
when O O
given O O
in O O
conditions O O
of O O
their O O
altered O O
pharmacokinetics O O
as O O
in O O
case O O
of O O
chronic B-Disease B-Disease
renal I-Disease I-Disease
failure I-Disease I-Disease
. O O

Spatial O O
and O O
temporal O O
aspects O O
of O O
muscle B-Disease B-Disease
hyperalgesia I-Disease I-Disease
induced O O
by O O
nerve O O
growth O O
factor O O
in O O
humans O O
. O O

Intramuscular O O
injection O O
of O O
nerve O O
growth O O
factor O O
( O O
NGF O O
) O O
has O O
been O O
shown O O
to O O
induce O O
long O O
- O O
term O O
sensitisation O O
and O O
time O O
- O O
dependent O O
hyperalgesia B-Disease B-Disease
indicating O O
potential O O
involvement O O
of O O
both O O
central O O
and O O
peripheral O O
pain B-Disease B-Disease
mechanisms O O
. O O

This O O
double O O
- O O
blind O O
placebo O O
- O O
controlled O O
study O O
was O O
designed O O
to O O
describe O O
the O O
spatial O O
distribution O O
of O O
muscle B-Disease B-Disease
hyperalgesia I-Disease I-Disease
over O O
time O O
( O O
immediately O O
after O O
, O O
3 O O
h O O
, O O
1 O O
, O O
4 O O
, O O
7 O O
and O O
21 O O
days O O
) O O
after O O
injecting O O
NGF O O
( O O
5 O O
mug O O
) O O
into O O
the O O
tibialis O O
anterior O O
( O O
TA O O
) O O
muscle O O
, O O
to O O
explore O O
possibly O O
involved O O
central O O
pain B-Disease B-Disease
mechanisms O O
and O O
to O O
investigate O O
the O O
effect O O
of O O
gender O O
on O O
development O O
of O O
hyperalgesia B-Disease B-Disease
. O O

Totally O O
20 O O
healthy O O
volunteers O O
( O O
10 O O
men O O
and O O
10 O O
women O O
) O O
participated O O
in O O
the O O
study O O
. O O

An O O
isotonic O O
saline O O
injection O O
into O O
the O O
contralateral O O
TA O O
muscle O O
served O O
as O O
a O O
control O O
condition O O
for O O
the O O
NGF O O
injection O O
. O O

Pressure O O
pain B-Disease B-Disease
thresholds O O
( O O
PPT O O
) O O
were O O
used O O
to O O
test O O
for O O
muscle B-Disease B-Disease
hyperalgesia I-Disease I-Disease
along O O
the O O
TA O O
( O O
seven O O
sites O O
) O O
muscle O O
at O O
the O O
extensor O O
digitorum O O
longus O O
and O O
at O O
the O O
web O O
between O O
1st O O
and O O
2nd O O
metatarsal O O
( O O
central O O
involvement O O
) O O
. O O

One O O
day O O
after O O
the O O
NGF O O
/ O O
control O O
injections O O
, O O
hypertonic O O
saline O O
( O O
0.5 O O
ml O O
, O O
5.8 O O
% O O
) O O
was O O
injected O O
into O O
the O O
left O O
and O O
right O O
TA O O
to O O
study O O
the O O
pain B-Disease B-Disease
response O O
to O O
chemical O O
stimulation O O
of O O
the O O
hyperalgesic O B-Disease
muscle O O
tissue O O
. O O

Scores O O
on O O
a O O
modified O O
Likert O O
scale O O
were O O
used O O
to O O
assess O O
soreness O O
during O O
muscle O O
function O O
. O O

An O O
area O O
of O O
hyperalgesia B-Disease B-Disease
was O O
observed O O
locally O O
at O O
the O O
injected O O
site O O
3 O O
h O O
after O O
injection O O
of O O
NGF O O
, O O
which O O
expanded O O
both O O
proximally O O
and O O
distally O O
on O O
day O O
1 O O
; O O
this O O
effect O O
subsided O O
on O O
day O O
4 O O
. O O

Decreased O O
PPT O O
was O O
also O O
found O O
between O O
1st O O
and O O
2nd O O
metatarsal O O
on O O
day O O
1 O O
. O O

Hypertonic O O
saline O O
evoked O O
more O O
pain B-Disease B-Disease
in O O
men O O
when O O
injected O O
in O O
the O O
NGF O O
treated O O
TA O O
compared O O
to O O
the O O
control O O
leg O O
. O O

Injection O O
of O O
NGF O O
increased O O
muscle B-Disease B-Disease
soreness I-Disease I-Disease
during O O
muscle O O
activity O O
for O O
7 O O
days O O
. O O

In O O
this O O
material O O
there O O
was O O
no O O
gender O O
effect O O
of O O
NGF O O
- O O
induced O O
muscle B-Disease B-Disease
hyperalgesia I-Disease I-Disease
. O O

The O O
expansion O O
of O O
muscle B-Disease B-Disease
hyperalgesia I-Disease I-Disease
to O O
distant O O
areas O O
indicates O O
that O O
central O O
mechanisms O O
are O O
involved O O
. O O

Occupational O O
hazard O O
: O O
treating O O
cocaine O O
body O O
packers O O
in O O
Caribbean O O
countries O O
. O O

Body O O
packing O O
is O O
a O O
common O O
method O O
of O O
smuggling O O
cocaine O O
where O O
individuals O O
ingest O O
several O O
drug O O
- O O
filled O O
parcels O O
for O O
transport O O
. O O

When O O
identified O O
by O O
the O O
authorities O O
, O O
body O O
packers O O
are O O
usually O O
taken O O
to O O
hospital O O
for O O
evaluation O O
. O O

There O O
are O O
several O O
points O O
during O O
management O O
of O O
these O O
patients O O
when O O
the O O
health O O
care O O
team O O
may O O
be O O
placed O O
at O O
risk O O
. O O

We O O
explore O O
the O O
hazards O O
encountered O O
during O O
the O O
management O O
of O O
these O O
patients O O
in O O
developing O O
Caribbean O O
nations O O
. O O

The O O
addition O O
of O O
rituximab O O
to O O
front O O
- O O
line O O
therapy O O
with O O
CHOP O O
( O O
R O O
- O O
CHOP O O
) O O
results O O
in O O
a O O
higher O O
response O O
rate O O
and O O
longer O O
time O O
to O O
treatment O O
failure O O
in O O
patients O O
with O O
lymphoplasmacytic B-Disease B-Disease
lymphoma I-Disease I-Disease
: O O
results O O
of O O
a O O
randomized O O
trial O O
of O O
the O O
German O O
Low O O
- O O
Grade O O
Lymphoma B-Disease B-Disease
Study O O
Group O O
( O O
GLSG O O
) O O
. O O

Lymphoplasmacytic B-Disease B-Disease
lymphoma I-Disease I-Disease
( O O
LPL B-Disease B-Disease
) O O
is O O
an O O
indolent O O
lymphoma B-Disease B-Disease
with O O
moderate O O
sensitivity O O
to O O
conventional O O
chemotherapy O O
. O O

This O O
study O O
investigated O O
whether O O
the O O
addition O O
of O O
rituximab O O
to O O
standard O O
chemotherapy O O
improves O O
treatment O O
outcome O O
in O O
LPL B-Disease B-Disease
and O O
the O O
subgroup O O
of O O
LPL B-Disease B-Disease
patients O O
fulfilling O O
the O O
criteria O O
of O O
Waldenstroem B-Disease B-Disease
's I-Disease I-Disease
macroglobulinemia I-Disease I-Disease
( O O
WM B-Disease B-Disease
) O O
. O O

A O O
total O O
of O O
69 O O
patients O O
with O O
previously O O
untreated O O
LPL B-Disease B-Disease
were O O
enrolled O O
into O O
the O O
trial O O
; O O
64 O O
patients O O
were O O
evaluable O O
for O O
treatment O O
outcome O O
. O O

In O O
all O O
, O O
48 O O
of O O
the O O
64 O O
LPL B-Disease B-Disease
patients O O
fulfilled O O
the O O
criteria O O
of O O
WM O O
. O O

Patients O O
were O O
randomly O O
assigned O O
to O O
R O O
- O O
CHOP O O
( O O
rituximab O O
, O O
cyclophosphamide O O
, O O
doxorubicin O O
, O O
vincristine O O
and O O
prednisone O O
, O O
n O O
= O O
34 O O
) O O
or O O
CHOP O O
( O O
n O O
= O O
30 O O
) O O
. O O

R O O
- O O
CHOP O O
resulted O O
in O O
significantly O O
higher O O
overall O O
response O O
( O O
OR O O
) O O
rate O O
( O O
94 O O
vs O O
67 O O
% O O
, O O
P O O
= O O
0.0085 O O
) O O
in O O
the O O
LPL B-Disease B-Disease
patients O O
and O O
in O O
the O O
WM B-Disease B-Disease
subgroup O O
( O O
91 O O
vs O O
60 O O
% O O
, O O
P O O
= O O
0.0188 O O
) O O
. O O

With O O
a O O
median O O
observation O O
time O O
of O O
42 O O
months O O
, O O
R O O
- O O
CHOP O O
induced O O
a O O
significantly O O
longer O O
time O O
to O O
treatment O O
failure O O
( O O
TTF O O
) O O
with O O
a O O
median O O
of O O
63 O O
months O O
for O O
R O O
- O O
CHOP O O
vs O O
22 O O
months O O
in O O
the O O
CHOP O O
arm O O
in O O
the O O
LPL B-Disease B-Disease
patients O O
( O O
P O O
= O O
0.0033 O O
) O O
and O O
in O O
the O O
WM B-Disease B-Disease
subgroup O O
( O O
P O O
= O O
0.0241 O O
) O O
. O O

There O O
was O O
no O O
major O O
difference O O
of O O
treatment B-Disease O
- I-Disease O
associated I-Disease O
toxicity I-Disease B-Disease
between O O
both O O
treatment O O
groups O O
. O O

These O O
data O O
indicate O O
that O O
the O O
addition O O
of O O
rituximab O O
to O O
front O O
- O O
line O O
chemotherapy O O
improves O O
treatment O O
outcome O O
in O O
patients O O
with O O
LPL B-Disease B-Disease
or O O
WM B-Disease B-Disease
. O O

Novel O O
therapeutic O O
agents O O
targeting O O
the O O
glucocorticoid O O
receptor O O
for O O
inflammation B-Disease B-Disease
and O O
cancer B-Disease B-Disease
. O O

Glucocorticoids O O
, O O
through O O
their O O
interaction O O
with O O
the O O
ubiquitous O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
, O O
have O O
extensive O O
and O O
disparate O O
effects O O
on O O
different O O
cells O O
and O O
tissues O O
. O O

They O O
have O O
long O O
been O O
used O O
in O O
the O O
treatment O O
of O O
asthma B-Disease B-Disease
, O O
arthritis B-Disease B-Disease
and O O
autoimmune B-Disease B-Disease
diseases I-Disease I-Disease
based O O
on O O
their O O
anti O O
- O O
inflammatory O O
and O O
immunosuppressive O O
effects O O
. O O

For O O
these O O
reasons O O
, O O
as O O
well O O
as O O
for O O
their O O
ability O O
to O O
induce O O
massive O O
apoptosis O O
in O O
hematological B-Disease B-Disease
malignancies I-Disease I-Disease
, O O
they O O
are O O
also O O
commonly O O
used O O
as O O
cotreatment O O
in O O
cancers B-Disease B-Disease
. O O

Despite O O
their O O
wide O O
usage O O
, O O
chronic O O
glucocorticoid O O
therapy O O
has O O
deleterious O O
side O O
effects O O
, O O
including O O
weight O B-Disease
gain O I-Disease
, O O
osteoporosis B-Disease B-Disease
and O O
diabetes B-Disease B-Disease
mellitus I-Disease I-Disease
, O O
and O O
has O O
been O O
shown O O
to O O
diminish O O
the O O
tumor B-Disease B-Disease
toxicity I-Disease I-Disease
of O O
chemotherapy O O
, O O
preventing O O
the O O
full O O
potential O O
of O O
glucocorticoid O O
treatment O O
from O O
being O O
realized O O
. O O

Technological O O
advances O O
have O O
contributed O O
to O O
a O O
better O O
understanding O O
of O O
the O O
mechanism O O
of O O
glucocorticoid O O
action O O
, O O
prompting O O
the O O
development O O
of O O
tailored O O
therapeutics O O
targeting O O
the O O
desired O O
outcomes O O
of O O
GR O O
signaling O O
. O O

This O O
review O O
discusses O O
recent O O
advances O O
in O O
the O O
development O O
of O O
novel O O
therapeutic O O
agents O O
for O O
inflammation B-Disease B-Disease
and O O
cancer B-Disease B-Disease
through O O
targeting O O
the O O
GR O O
. O O

Inhibition O O
of O O
hydroxyapatite O O
dissolution O O
by O O
whole O O
casein O O
: O O
the O O
effects O O
of O O
pH O O
, O O
protein O O
concentration O O
, O O
calcium O O
, O O
and O O
ionic O O
strength O O
. O O

Formulating O O
drinks O O
with O O
reduced O O
erosive O O
potential O O
is O O
one O O
approach O O
for O O
reducing O O
dental O B-Disease
erosion O I-Disease
. O O

In O O
this O O
study O O
, O O
whole O O
casein O O
was O O
added O O
to O O
citric O O
acid O O
solutions O O
representative O O
of O O
soft O O
drinks O O
, O O
and O O
the O O
hydroxyapatite O O
dissolution O O
rate O O
was O O
assessed O O
. O O

Adding O O
0.02 O O
% O O
( O O
w O O
/ O O
v O O
) O O
casein O O
to O O
acid O O
solutions O O
significantly O O
reduced O O
the O O
hydroxyapatite O O
dissolution O O
rate O O
by O O
51 O O
+ O O
/ O O
- O O
4 O O
% O O
at O O
pH O O
values O O
of O O
2.80 O O
, O O
3.00 O O
, O O
3.20 O O
, O O
3.40 O O
, O O
and O O
3.60 O O
, O O
although O O
the O O
baseline O O
dissolution O O
rates O O
of O O
course O O
varied O O
as O O
a O O
function O O
of O O
pH O O
. O O

The O O
protein O O
concentration O O
[ O O
0.002 O O
, O O
0.02 O O
, O O
and O O
0.2 O O
% O O
( O O
w O O
/ O O
v O O
) O O
casein O O
] O O
had O O
no O O
significant O O
effect O O
on O O
dissolution O O
inhibition O O
. O O

Adding O O
both O O
casein O O
and O O
calcium O O
to O O
citric O O
acid O O
resulted O O
in O O
a O O
further O O
reduction O O
in O O
the O O
dissolution O O
rate O O
at O O
low O O
and O O
intermediate O O
calcium O O
concentrations O O
( O O
5 O O
and O O
10 O O
mM O O
) O O
but O O
not O O
at O O
higher O O
calcium O O
concentrations O O
( O O
20 O O
and O O
50 O O
mM O O
) O O
. O O

Ionic O O
strength O O
had O O
no O O
significant O O
impact O O
on O O
the O O
efficacy O O
of O O
casein O O
. O O

Casein O O
also O O
significantly O O
reduced O O
the O O
hydroxyapatite O O
dissolution O O
rate O O
when O O
the O O
hydroxyapatite O O
was O O
coated O O
with O O
a O O
salivary O O
pellicle O O
. O O

The O O
reduction O O
in O O
dissolution O O
rate O O
is O O
ascribed O O
to O O
firmly O O
adsorbed O O
casein O O
on O O
the O O
hydroxyapatite O O
surface O O
, O O
which O O
stabilizes O O
the O O
crystal O O
surface O O
and O O
inhibits O O
ion O O
detachment O O
. O O

A O O
phase O O
II O O
study O O
of O O
oxaliplatin O O
, O O
pemetrexed O O
, O O
and O O
bevacizumab O O
in O O
previously O O
treated O O
advanced O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
. O O

INTRODUCTION O O
: O O
Single O O
agent O O
chemotherapy O O
is O O
standard O O
for O O
second O O
and O O
third O O
line O O
treatment O O
of O O
non B-Disease B-Disease
- I-Disease I-Disease
small I-Disease I-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
( O O
NSCLC B-Disease B-Disease
) O O
. O O

Combination O O
therapy O O
to O O
date O O
has O O
not O O
proven O O
to O O
be O O
superior O O
to O O
single O O
agents O O
in O O
this O O
setting O O
, O O
often O O
adding O O
toxicity O O
without O O
any O O
additional O O
efficacy O O
. O O

We O O
investigated O O
the O O
activity O O
and O O
tolerability O O
of O O
the O O
combination O O
of O O
oxaliplatin O O
, O O
pemetrexed O O
, O O
and O O
bevacizumab O O
in O O
patients O O
with O O
previously O O
treated O O
advanced O O
NSCLC B-Disease B-Disease
. O O

METHODS O O
: O O
This O O
multicenter O O
phase O O
II O O
trial O O
evaluated O O
the O O
safety O O
and O O
efficacy O O
of O O
the O O
combination O O
of O O
pemetrexed O O
( O O
500 O O
mg O O
/ O O
m O O
) O O
, O O
oxaliplatin O O
( O O
120 O O
mg O O
/ O O
m O O
) O O
, O O
and O O
bevacizumab O O
( O O
15 O O
mg O O
/ O O
kg O O
) O O
, O O
given O O
every O O
21 O O
days O O
, O O
in O O
patients O O
with O O
previously O O
treated O O
advanced O O
NSCLC B-Disease B-Disease
. O O

Eligibility O O
criteria O O
included O O
performance O O
status O O
0 O O
to O O
1 O O
, O O
nonsquamous O O
histology O O
, O O
and O O
at O O
least O O
one O O
prior O O
chemotherapy O O
regimen O O
. O O

Patients O O
with O O
treated O O
brain B-Disease B-Disease
metastases I-Disease I-Disease
were O O
allowed O O
. O O

The O O
primary O O
end O O
point O O
was O O
response O O
rate O O
, O O
with O O
secondary O O
endpoints O O
of O O
progression O O
- O O
free O O
survival O O
and O O
overall O O
survival O O
. O O

RESULTS O O
: O O
Thirty O O
- O O
six O O
patients O O
were O O
enrolled O O
on O O
this O O
study O O
. O O

Treatment O O
was O O
well O O
tolerated O O
; O O
the O O
most O O
common O O
grade O O
3 O O
toxicity O B-Disease
was O O
hypertension B-Disease B-Disease
, O O
which O O
was O O
easily O O
managed O O
with O O
oral O O
medications O O
. O O

The O O
nine O O
( O O
25 O O
% O O
) O O
patients O O
with O O
treated O O
brain B-Disease B-Disease
metastases I-Disease I-Disease
had O O
no O O
episodes O O
of O O
cerebral B-Disease B-Disease
hemorrhage I-Disease I-Disease
. O O

Of O O
the O O
34 O O
patients O O
evaluable O O
for O O
tumor B-Disease B-Disease
response O O
, O O
none O O
had O O
complete O O
response O O
, O O
nine O O
( O O
27 O O
% O O
) O O
had O O
partial O O
response O O
, O O
15 O O
( O O
44 O O
% O O
) O O
had O O
stable O O
disease O O
, O O
and O O
10 O O
( O O
29 O O
% O O
) O O
had O O
progressive O O
disease O O
. O O

Median O O
progression O O
- O O
free O O
survival O O
was O O
5.8 O O
months O O
( O O
95 O O
% O O
confidence O O
interval O O
4.1 O O
- O O
7.8 O O
months O O
) O O
and O O
median O O
overall O O
survival O O
was O O
12.5 O O
months O O
( O O
95 O O
% O O
confidence O O
interval O O
7.3 O O
- O O
17 O O
months O O
) O O
. O O

CONCLUSIONS O O
: O O
Treatment O O
with O O
oxaliplatin O O
and O O
pemetrexed O O
in O O
combination O O
with O O
the O O
targeted O O
antiangiogenic O O
agent O O
bevacizumab O O
yielded O O
promising O O
efficacy O O
with O O
manageable O O
toxicity O O
in O O
the O O
previously O O
treated O O
advanced O O
NSCLC B-Disease B-Disease
population O O
. O O

Early O O
- O O
onset O O
pancytopenia B-Disease B-Disease
and O O
skin B-Disease B-Disease
ulcer I-Disease I-Disease
following O O
low O O
- O O
dose O O
methotrexate O O
therapy O O
. O O

Pancytopenia B-Disease B-Disease
is O O
a O O
rare O O
but O O
serious O O
adverse O O
effect O O
of O O
low O O
- O O
dose O O
methotrexate O O
( O O
MTX O O
) O O
sodium O O
therapy O O
, O O
and O O
this O O
case O O
report O O
describes O O
a O O
very O O
early O O
- O O
onset O O
of O O
pancytopenia B-Disease B-Disease
and O O
cutaneous B-Disease O
lesions I-Disease O
after O O
three O O
days O O
of O O
ingestion O O
. O O

A O O
64 O O
- O O
year O O
- O O
old O O
man O O
was O O
presented O O
to O O
Emergency O O
Department O O
with O O
weakness B-Disease B-Disease
, O O
fever B-Disease B-Disease
, O O
poor B-Disease B-Disease
appetite I-Disease I-Disease
, O O
nausea B-Disease B-Disease
, O O
and O O
vomiting B-Disease B-Disease
after O O
he O O
had O O
had O O
accidentally O O
ingested O O
MTX O O
tablets O O
( O O
2.5 O O
mg O O
) O O
twice O O
a O O
day O O
for O O
the O O
last O O
three O O
days O O
. O O

On O O
initial O O
examination O O
, O O
several O O
painful B-Disease O
lesions I-Disease O
in O O
his O O
oral O O
mucosa O O
and O O
a O O
cutaneous B-Disease O
ulceration I-Disease B-Disease
on O O
his O O
right O O
foot O O
were O O
also O O
observed O O
. O O

He O O
had O O
severe O O
pancytopenia B-Disease B-Disease
, O O
poor O O
kidney O O
functions O O
, O O
and O O
abnormal B-Disease B-Disease
coagulation I-Disease I-Disease
parameters O O
. O O

The O O
blood O O
level O O
of O O
MTX O O
was O O
found O O
to O O
be O O
within O O
therapeutic O O
range O O
. O O

He O O
was O O
treated O O
with O O
leucovorine O O
, O O
intravenous O O
antibiotics O O
, O O
and O O
appropriate O O
blood O O
transfusions O O
; O O
he O O
was O O
discharged O O
from O O
hospital O O
without O O
any O O
sequela O O
. O O

Pancytopenia B-Disease B-Disease
associated O O
with O O
low O O
- O O
dose O O
( O O
cumulative O O
dose O O
of O O
15 O O
mg O O
in O O
3 O O
days O O
) O O
MTX O O
therapy O O
had O O
not O O
been O O
reported O O
previously O O
. O O

The O O
Naranjo O O
probability O O
scale O O
showed O O
pancytopenia B-Disease B-Disease
and O O
skin B-Disease B-Disease
ulcer I-Disease I-Disease
associated O O
with O O
low O O
- O O
dose O O
MTX O O
therapy O O
as O O
probable O O
adverse O O
reactions O O
. O O

Risk O O
factors O O
for O O
pancytopenia B-Disease B-Disease
such O O
as O O
renal B-Disease B-Disease
insufficiency I-Disease I-Disease
, O O
hypoalbuminemia B-Disease B-Disease
, O O
low O O
folate O O
levels O O
, O O
concomitant B-Disease O
infections I-Disease B-Disease
, O O
concomitant O O
use O O
of O O
drugs O O
, O O
and O O
folate O O
supplementation O O
were O O
not O O
identified O O
in O O
our O O
patient O O
. O O

Although O O
pancytopenia B-Disease B-Disease
associated O O
with O O
low O O
- O O
dose O O
MTX O O
therapy O O
is O O
not O O
expected O O
as O O
early O O
as O O
3 O O
days O O
after O O
initiation O O
of O O
the O O
therapy O O
, O O
physicians O O
should O O
also O O
be O O
aware O O
of O O
this O O
life O O
threatening O O
adverse O O
effect O O
during O O
the O O
very O O
first O O
days O O
of O O
MTX O O
therapy O O
for O O
rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
patients O O
. O O

Limited O O
place O O
for O O
plasma O O
monitoring O O
of O O
new O O
antiepileptic O O
drugs O O
in O O
clinical O O
practice O O
. O O

Therapeutic O O
drug O O
monitoring O O
( O O
TDM O O
) O O
has O O
been O O
recognized O O
as O O
a O O
useful O O
guide O O
in O O
the O O
clinical O O
management O O
of O O
patients O O
with O O
epilepsy B-Disease B-Disease
, O O
in O O
particular O O
those O O
on O O
therapy O O
with O O
traditional O O
antiepileptic O O
drugs O O
( O O
AEDs O O
) O O
. O O

The O O
demonstration O O
of O O
significant O O
drug O O
interactions O O
and O O
the O O
introduction O O
of O O
the O O
concept O O
" O O
therapeutic O O
range O O
" O O
have O O
also O O
contributed O O
to O O
the O O
view O O
that O O
monotherapy O O
should O O
be O O
considered O O
the O O
" O O
gold O O
standard O O
" O O
in O O
the O O
treatment O O
of O O
epilepsy B-Disease B-Disease
. O O

Ten O O
new O O
AEDs O O
have O O
been O O
approved O O
and O O
released O O
to O O
the O O
market O O
in O O
the O O
last O O
fifteen O O
years O O
. O O

The O O
most O O
obvious O O
consequence O O
has O O
been O O
an O O
increased O O
number O O
of O O
patients O O
on O O
polytherapy O O
. O O

In O O
general O O
, O O
newer O O
AEDs O O
have O O
better O O
and O O
more O O
predictable O O
pharmacokinetics O O
than O O
older O O
AEDs O O
and O O
usually O O
show O O
lower O O
risk O O
of O O
interactions O O
leading O O
to O O
toxicity O O
as O O
well O O
as O O
large O O
therapeutic O O
indexes O O
. O O

This O O
pragmatic O O
review O O
focuses O O
on O O
practical O O
suggestions O O
about O O
the O O
potential O O
clinical O O
usefulness O O
of O O
TDM O O
of O O
newer O O
AEDs O O
in O O
relation O O
to O O
their O O
mechanism O O
of O O
action O O
and O O
pharmacokinetic O O
characteristics O O
and O O
in O O
response O O
to O O
patient O O
- O O
specific O O
problems O O
. O O

Overall O O
, O O
the O O
usefulness O O
of O O
TDM O O
of O O
newer O O
AEDs O O
seems O O
to O O
be O O
limited O O
and O O
its O O
indiscriminate O O
use O O
is O O
not O O
justified O O
. O O

However O O
, O O
in O O
selected O O
cases O O
or O O
in O O
response O O
to O O
a O O
specific O O
clinical O O
question O O
, O O
a O O
wise O O
use O O
of O O
TDM O O
of O O
some O O
new O O
AEDs O O
could O O
represent O O
a O O
useful O O
tool O O
in O O
the O O
management O O
of O O
epileptic O B-Disease
patients O O
. O O

Exceptions O O
are O O
thus O O
represented O O
by O O
special O O
conditions O O
such O O
as O O
renal B-Disease B-Disease
failure I-Disease I-Disease
, O O
dialysis O O
, O O
ascertainment O O
of O O
non O O
- O O
compliance O O
, O O
and O O
pregnancy O O
. O O

For O O
some O O
new O O
AEDs O O
, O O
TDM O O
could O O
be O O
selectively O O
and O O
properly O O
used O O
in O O
response O O
to O O
a O O
single O O
patient O O
- O O
specific O O
pharmacokinetic O O
or O O
pharmacodynamic O O
issue O O
. O O

Synthesis O O
and O O
biological O O
evaluation O O
of O O
bile O O
acid O O
dimers O O
linked O O
with O O
1,2,3 O O
- O O
triazole O O
and O O
bis O O
- O O
beta O O
- O O
lactam O O
. O O

We O O
report O O
herein O O
the O O
synthesis O O
and O O
biological O O
evaluation O O
of O O
bile O O
acid O O
dimers O O
linked O O
through O O
1,2,3 O O
- O O
triazole O O
and O O
bis O O
- O O
beta O O
- O O
lactam O O
. O O

The O O
dimers O O
were O O
synthesized O O
using O O
1,3 O O
- O O
dipolar O O
cycloaddition O O
reaction O O
of O O
diazido O O
bis O O
- O O
beta O O
- O O
lactams O O
, O O
and O O
terminal O O
alkynes O O
derived O O
from O O
cholic O O
acid O O
/ O O
deoxycholic O O
acid O O
in O O
the O O
presence O O
of O O
Cu O O
( O O
i O O
) O O
catalyst O O
( O O
click O O
chemistry O O
) O O
. O O

These O O
novel O O
molecules O O
were O O
evaluated O O
in O O
vitro O O
for O O
their O O
antifungal O O
and O O
antibacterial O O
activity O O
. O O

Most O O
of O O
the O O
compounds O O
exhibited O O
significant O O
antifungal O O
as O O
well O O
as O O
antibacterial O O
activity O O
against O O
all O O
the O O
tested O O
fungal O O
and O O
bacterial O O
strains O O
. O O

Moreover O O
, O O
their O O
in O O
vitro O O
cytotoxicities B-Disease B-Disease
towards O O
HEK O O
- O O
293 O O
and O O
MCF O O
- O O
7 O O
cells O O
were O O
also O O
established O O
. O O

Platinum O O
versus O O
non O O
- O O
platinum O O
chemotherapy O O
regimens O O
for O O
small B-Disease B-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
. O O

BACKGROUND O O
: O O
Small B-Disease B-Disease
cell I-Disease I-Disease
lung I-Disease I-Disease
cancer I-Disease I-Disease
( O O
SCLC B-Disease B-Disease
) O O
is O O
a O O
very O O
fast O O
growing O O
form O O
of O O
cancer B-Disease B-Disease
and O O
is O O
characterised O O
by O O
early O O
metastasis B-Disease O
. O O

As O O
a O O
result O O
, O O
chemotherapy O O
is O O
the O O
mainstay O O
of O O
treatment O O
. O O

A O O
number O O
of O O
different O O
platinum O O
- O O
based O O
chemotherapy O O
regimens O O
and O O
non O O
- O O
platinum O O
- O O
based O O
chemotherapy O O
regimens O O
have O O
been O O
used O O
for O O
the O O
treatment O O
of O O
SCLC B-Disease B-Disease
, O O
with O O
varying O O
results O O
. O O

This O O
review O O
was O O
conducted O O
to O O
analyse O O
the O O
data O O
from O O
these O O
trials O O
in O O
order O O
to O O
compare O O
their O O
effectiveness O O
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
effectiveness O O
of O O
platinum O O
chemotherapy O O
regimens O O
compared O O
with O O
non O O
- O O
platinum O O
chemotherapy O O
regimens O O
in O O
the O O
treatment O O
of O O
SCLC B-Disease B-Disease
with O O
respect O O
to O O
survival O O
, O O
tumour B-Disease B-Disease
response O O
, O O
toxicity O O
and O O
quality O O
of O O
life O O
. O O

SEARCH O O
STRATEGY O O
: O O
We O O
searched O O
the O O
biomedical O O
literature O O
databases O O
CENTRAL O O
( O O
The O O
Cochrane O O
Library O O
2007 O O
, O O
Issue O O
2 O O
) O O
, O O
MEDLINE O O
, O O
EMBASE O O
and O O
CINAHL O O
from O O
1966 O O
to O O
April O O
2007 O O
. O O

In O O
addition O O
, O O
we O O
handsearched O O
reference O O
lists O O
from O O
relevant O O
resources O O
. O O

SELECTION O O
CRITERIA O O
: O O
All O O
randomised O O
controlled O O
trials O O
involving O O
patients O O
with O O
pathologically O O
confirmed O O
( O O
cytological O O
or O O
histological O O
) O O
SCLC B-Disease B-Disease
and O O
the O O
use O O
of O O
a O O
platinum O O
- O O
based O O
chemotherapy O O
regimen O O
in O O
at O O
least O O
one O O
treatment O O
arm O O
and O O
a O O
non O O
- O O
platinum O O
- O O
based O O
chemotherapy O O
regimen O O
in O O
a O O
separate O O
arm O O
. O O

DATA O O
COLLECTION O O
AND O O
ANALYSIS O O
: O O
Two O O
authors O O
independently O O
assessed O O
search O O
results O O
. O O

We O O
assessed O O
included O O
studies O O
for O O
methodological O O
quality O O
and O O
recorded O O
the O O
following O O
outcome O O
data O O
: O O
survival O O
, O O
tumour B-Disease B-Disease
response O O
, O O
toxicity O O
and O O
quality O O
of O O
life O O
. O O

We O O
combined O O
the O O
results O O
of O O
the O O
survival O O
, O O
tumour B-Disease B-Disease
response O O
and O O
toxicity O O
data O O
in O O
a O O
meta O O
- O O
analysis O O
. O O

MAIN O O
RESULTS O O
: O O
A O O
total O O
of O O
29 O O
trials O O
involving O O
5530 O O
patients O O
were O O
included O O
in O O
this O O
systematic O O
review O O
. O O

There O O
was O O
no O O
statistically O O
significant O O
difference O O
between O O
treatment O O
groups O O
in O O
terms O O
of O O
survival O O
at O O
6 O O
months O O
, O O
12 O O
months O O
and O O
24 O O
months O O
. O O

There O O
was O O
also O O
no O O
statistically O O
significant O O
difference O O
in O O
terms O O
of O O
overall O O
tumour B-Disease B-Disease
response O O
. O O

However O O
, O O
platinum O O
- O O
based O O
treatment O O
regimens O O
did O O
have O O
a O O
significantly O O
higher O O
rate O O
of O O
complete O O
response O O
. O O

Platinum O O
- O O
based O O
chemotherapy O O
regimens O O
had O O
significantly O O
higher O O
rates O O
of O O
nausea B-Disease B-Disease
and O O
vomiting B-Disease B-Disease
, O O
anaemia B-Disease B-Disease
and O O
thrombocytopenia B-Disease B-Disease
toxicity O O
. O O

Three O O
trials O O
presented O O
quality O O
of O O
life O O
data O O
but O O
the O O
data O O
presented O O
were O O
not O O
complete O O
and O O
therefore O O
could O O
not O O
be O O
combined O O
in O O
a O O
meta O O
- O O
analysis O O
. O O

AUTHORS O O
' O O
CONCLUSIONS O O
: O O
Platinum O O
- O O
based O O
chemotherapy O O
regimens O O
did O O
not O O
offer O O
a O O
statistically O O
significant O O
benefit O O
in O O
survival O O
or O O
overall O O
tumour B-Disease B-Disease
response O O
compared O O
with O O
non O O
- O O
platinum O O
- O O
based O O
regimens O O
. O O

However O O
, O O
platinum O O
- O O
based O O
chemotherapy O O
regimens O O
did O O
increase O O
complete O O
response O O
rates O O
, O O
at O O
the O O
cost O O
of O O
higher O O
adverse O O
events O O
including O O
nausea B-Disease B-Disease
and O O
vomiting B-Disease B-Disease
, O O
anaemia B-Disease B-Disease
and O O
thrombocytopenia B-Disease B-Disease
toxicity O O
. O O

These O O
data O O
suggest O O
non O O
- O O
platinum O O
chemotherapy O O
regimens O O
have O O
a O O
more O O
advantageous O O
risk O O
- O O
benefit O O
profile O O
. O O

This O O
systematic O O
review O O
highlights O O
the O O
lack O O
of O O
quality O O
of O O
life O O
data O O
in O O
trials O O
involving O O
chemotherapy O O
treatment O O
for O O
SCLC B-Disease B-Disease
. O O

With O O
poor O O
long O O
- O O
term O O
survival O O
associated O O
with O O
both O O
treatment O O
groups O O
, O O
the O O
issue O O
of O O
the O O
quality O O
of O O
the O O
survival O O
period O O
takes O O
on O O
even O O
more O O
significance O O
. O O

It O O
would O O
be O O
beneficial O O
for O O
future O O
trials O O
in O O
this O O
area O O
to O O
include O O
a O O
quality O O
of O O
life O O
assessment O O
. O O

Blood O O
pressure B-Disease O
lowering O O
efficacy O O
of O O
renin O O
inhibitors O O
for O O
primary B-Disease O
hypertension I-Disease B-Disease
. O O

BACKGROUND O O
: O O
Hypertension B-Disease B-Disease
is O O
a O O
chronic O O
condition O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
mortality O O
and O O
morbidity O O
. O O

The O O
renin O O
- O O
angiotensin O O
- O O
aldosterone O O
system O O
is O O
an O O
important O O
target O O
site O O
for O O
five O O
antihypertensive O O
drug O O
classes O O
: O O
beta O O
blockers O O
, O O
renin O O
inhibitors O O
, O O
ACE O O
inhibitors O O
, O O
angiotensin O O
receptor O O
blockers O O
( O O
ARBs O O
) O O
and O O
aldosterone O O
inhibitors O O
. O O

Renin O O
is O O
the O O
enzyme O O
responsible O O
for O O
converting O O
angiotensinogen O O
to O O
angiotensin O O
I O O
, O O
which O O
is O O
then O O
converted O O
to O O
angiotensin O O
II O O
. O O

Renin O O
inhibitors O O
prevent O O
the O O
formation O O
of O O
both O O
angiotensin O O
I O O
and O O
angiotensin O O
II O O
. O O

Renin O O
inhibitors O O
do O O
not O O
affect O O
kinin O O
metabolism O O
and O O
may O O
produce O O
fewer O O
adverse O O
effects O O
than O O
ACE O O
inhibitors O O
such O O
as O O
dry B-Disease B-Disease
cough I-Disease I-Disease
or O O
angioedema B-Disease B-Disease
. O O

OBJECTIVES O O
: O O
To O O
quantify O O
the O O
dose O O
- O O
related O O
blood O O
pressure B-Disease O
lowering O O
efficacy O O
of O O
renin O O
inhibitors O O
versus O O
placebo O O
in O O
the O O
treatment O O
of O O
primary B-Disease B-Disease
hypertension I-Disease I-Disease
. O O

SEARCH O O
STRATEGY O O
: O O
We O O
searched O O
the O O
following O O
databases O O
for O O
randomised O O
, O O
double O O
blind B-Disease O
, O O
placebo O O
- O O
controlled O O
trials O O
of O O
renin O O
inhibitors O O
: O O
Medline O O
( O O
1966 O O
- O O
March O O
2008 O O
) O O
, O O
EMBASE O O
( O O
1988 O O
- O O
March O O
2008 O O
) O O
, O O
Cochrane O O
CENTRAL O O
, O O
and O O
bibliographic O O
citations O O
from O O
retrieved O O
references O O
. O O

No O O
language O O
restrictions O O
were O O
applied O O
. O O

SELECTION O O
CRITERIA O O
: O O
Study O O
design O O
had O O
to O O
meet O O
the O O
following O O
criteria O O
: O O
double O O
- O O
blinded O O
, O O
placebo O O
- O O
controlled O O
; O O
random O O
allocation O O
to O O
a O O
specific O O
dose O O
of O O
renin O O
inhibitor O O
group O O
and O O
parallel O O
placebo O O
group O O
; O O
duration O O
of O O
follow O O
- O O
up O O
of O O
at O O
least O O
three O O
weeks O O
. O O

DATA O O
COLLECTION O O
AND O O
ANALYSIS O O
: O O
Two O O
reviewers O O
independently O O
extracted O O
data O O
and O O
assessed O O
trial O O
quality O O
using O O
risk O O
of O O
bias O O
tables O O
. O O

Disagreements O O
were O O
resolved O O
by O O
discussion O O
or O O
a O O
third O O
reviewer O O
. O O

Data O O
synthesis O O
and O O
analyses O O
were O O
done O O
using O O
the O O
Cochrane O O
Review O O
Manager O O
software O O
, O O
RevMan O O
5 O O
. O O

Data O O
for O O
continuous O O
variables O O
were O O
combined O O
using O O
a O O
weighted O O
mean O O
difference O O
method O O
. O O

Dichotomous O O
variables O O
were O O
analysed O O
using O O
relative O O
risk O O
. O O

MAIN O O
RESULTS O O
: O O
Six O O
trials O O
( O O
N O O
= O O
3694 O O
) O O
met O O
the O O
inclusion O O
criteria O O
for O O
this O O
review O O
. O O

Aliskiren O O
was O O
the O O
only O O
renin O O
inhibitor O O
studied O O
in O O
these O O
studies O O
. O O

The O O
meta O O
- O O
analysis O O
shows O O
that O O
aliskiren O O
has O O
a O O
dose O O
- O O
related O O
both O O
systolic O O
/ O O
diastolic O O
blood O O
pressure B-Disease O
lowering O O
effect O O
as O O
compared O O
to O O
placebo O O
: O O
aliskiren O O
75 O O
mg O O
- O O
2.9 O O
/ O O
- O O
2.3 O O
mmHg O O
, O O
aliskiren O O
150 O O
mg O O
- O O
5.5 O O
/ O O
- O O
3.0 O O
mmHg O O
, O O
aliskiren O O
300 O O
mg O O
- O O
8.7 O O
/ O O
- O O
5.0 O O
, O O
aliskiren O O
600 O O
mg O O
- O O
11.4 O O
/ O O
- O O
6.6 O O
mmHg O O
. O O

Aliskiren O O
300 O O
mg O O
significantly O O
lowered O O
both O O
SBP O O
and O O
DBP O O
as O O
compared O O
to O O
aliskiren O O
150 O O
mg O O
( O O
SBP O O
: O O
- O O
2.97 O O
( O O
95 O O
% O O
CI O O
- O O
3.99 O O
, O O
- O O
1.95 O O
) O O
and O O
DBP O O
: O O
- O O
1.66 O O
( O O
95 O O
% O O
CI O O
- O O
2.32 O O
, O O
- O O
1.0 O O
) O O
. O O

Aliskiren O O
has O O
no O O
effect O O
on O O
blood O O
pressure B-Disease O
variability O O
. O O

No O O
data O O
was O O
available O O
to O O
assess O O
the O O
effect O O
of O O
aliskiren O O
on O O
heart O O
rate O O
and O O
pulse O O
pressure B-Disease O
. O O

This O O
review O O
found O O
weak O O
evidence O O
that O O
with O O
short O O
- O O
term O O
use O O
, O O
aliskiren O O
does O O
not O O
increase O O
withdrawals O O
due O O
to O O
adverse O O
effects O O
as O O
compared O O
to O O
placebo O O
. O O

AUTHORS O O
' O O
CONCLUSIONS O O
: O O
Aliskiren O O
has O O
a O O
dose O O
- O O
related O O
blood O O
pressure B-Disease O
lowering O O
effect O O
better O O
than O O
placebo O O
. O O

This O O
effect O O
is O O
similar O O
to O O
that O O
determined O O
for O O
ACE O O
inhibitors O O
and O O
ARBs O O
. O O

Fragrance O O
material O O
review O O
on O O
tricyclodecanyl O O
acetate O O
. O O

A O O
toxicologic O O
and O O
dermatologic O O
review O O
of O O
tricyclodecanyl O O
acetate O O
when O O
used O O
as O O
a O O
fragrance O O
ingredient O O
is O O
presented O O
. O O

NRF2 O O
as O O
a O O
determinant O O
of O O
cellular O O
resistance O O
in O O
retinoic O O
acid O O
cytotoxicity B-Disease B-Disease
. O O

Clinical O O
use O O
of O O
retinoic O O
acids O O
( O O
RA O O
) O O
is O O
hindered O O
by O O
toxicity O O
possibly O O
related O O
to O O
oxidative O O
stress O O
. O O

Recently O O
, O O
RA O O
at O O
relatively O O
low O O
concentrations O O
was O O
shown O O
to O O
inhibit O O
NRF2 O O
and O O
the O O
expression O O
of O O
its O O
target O O
antioxidative O O
genes O O
. O O

This O O
raises O O
the O O
possibility O O
that O O
RA B-Disease B-Disease
toxicity I-Disease I-Disease
may O O
result O O
from O O
cellular O O
inability O O
to O O
cope O O
with O O
resultant O O
oxidative O O
stress O O
. O O

Using O O
in O O
vitro O O
cell O O
and O O
in O O
vivo O O
mouse O O
models O O
, O O
we O O
report O O
that O O
RA O O
, O O
specifically O O
all O O
- O O
trans O O
- O O
RA O O
( O O
atRA O O
) O O
at O O
concentrations O O
implicated O O
in O O
toxicity O O
, O O
can O O
activate O O
NRF2 O O
and O O
induce O O
NRF2 O O
target O O
genes O O
, O O
particularly O O
the O O
subunits O O
of O O
the O O
rate O O
- O O
limiting O O
enzyme O O
of O O
glutathione O O
biosynthesis O O
, O O
glutamate O O
cysteine O O
ligase O O
( O O
GCLM O O
/ O O
GCLC O O
) O O
. O O

RNA O O
interference O O
- O O
mediated O O
silencing O O
of O O
NRF2 O O
, O O
but O O
not O O
of O O
retinoid O O
X O O
receptor O O
- O O
alpha O O
and O O
- O O
beta O O
, O O
reduced O O
basal O O
and O O
atRA O O
- O O
induced O O
GCLM O O
/ O O
GCLC O O
gene O O
expression O O
. O O

Moreover O O
, O O
RA O O
increased O O
nuclear O O
accumulation O O
of O O
NRF2 O O
, O O
antioxidant O O
response O O
element O O
( O O
ARE O O
) O O
reporter O O
activity O O
, O O
and O O
NRF2 O O
occupancy O O
at O O
AREs O O
. O O

4 O O
- O O
Hydroxynonenal O O
, O O
a O O
lipid O O
peroxidation O O
product O O
, O O
was O O
increased O O
by O O
RA O O
. O O

Inhibition O O
of O O
MEK1 O O
/ O O
ERK O O
mitogen O O
- O O
activated O O
protein O O
kinases O O
significantly O O
suppressed O O
atRA O O
- O O
induced O O
NRF2 O O
activation O O
and O O
ARE O O
- O O
regulated O O
gene O O
expression O O
, O O
reducing O O
cell O O
resistance O O
against O O
toxic O O
concentrations O O
of O O
RA O O
. O O

NRF2 O O
- O O
silenced O O
cells O O
were O O
vulnerable O O
to O O
atRA O O
- O O
induced O O
mitochondrial B-Disease B-Disease
toxicity I-Disease I-Disease
and O O
apoptosis O O
. O O

In O O
conclusion O O
, O O
toxic O O
RA O O
activates O O
NRF2 O O
, O O
thereby O O
triggering O O
an O O
adaptive O O
response O O
against O O
the O O
resultant O O
oxidative O O
stress O O
. O O

NRF2 O O
enhancement O O
as O O
a O O
therapeutic O O
target O O
of O O
retinoid O O
toxicity O B-Disease
awaits O O
further O O
investigation O O
. O O

Renin O O
- O O
angiotensin O O
- O O
aldosterone O O
responsiveness O O
to O O
low O O
sodium O O
and O O
blood O O
pressure O O
reactivity O O
to O O
angiotensin O O
- O O
II O O
are O O
unrelated O O
to O O
cholesteryl O O
ester O O
transfer O O
protein O O
mass O O
in O O
healthy O O
subjects O O
. O O

BACKGROUND O O
: O O
The O O
blood O O
pressure O O
increase O O
associated O O
with O O
the O O
cholesteryl O O
ester O O
transfer O O
protein O O
( O O
CETP O O
) O O
inhibitor O O
, O O
torcetrapib O O
is O O
probably O O
attributable O O
to O O
an O O
off O O
- O O
target O O
effect O O
but O O
it O O
is O O
unknown O O
whether O O
activation O O
of O O
the O O
renin O O
- O O
angiotensin O O
- O O
aldosterone O O
system O O
( O O
RAAS O O
) O O
may O O
be O O
related O O
to O O
variation O O
in O O
the O O
plasma O O
CETP O O
level O O
. O O

We O O
questioned O O
whether O O
the O O
plasma O O
CETP O O
level O O
would O O
affect O O
RAAS O O
responsiveness O O
to O O
low O O
sodium O O
diet O O
and O O
the O O
blood O O
pressure O O
response O O
to O O
angiotensin O O
- O O
II O O
infusion O O
in O O
healthy O O
subjects O O
. O O

METHODS O O
: O O
RAAS O O
parameters O O
and O O
blood O O
pressure O O
were O O
determined O O
during O O
liberal O O
sodium O O
diet O O
( O O
200 O O
mmol O O
/ O O
24 O O
h O O
) O O
and O O
low O O
sodium O O
diet O O
( O O
50 O O
mmol O O
/ O O
24 O O
h O O
) O O
in O O
67 O O
healthy O O
men O O
. O O

Blood O O
pressure O O
response O O
to O O
incremental O O
angiotensin O O
- O O
II O O
infusion O O
was O O
assessed O O
in O O
34 O O
subjects O O
during O O
liberal O O
sodium O O
diet O O
. O O

Correlation O O
analysis O O
was O O
performed O O
to O O
test O O
whether O O
RAAS O O
responsiveness O O
and O O
blood O O
pressure O O
were O O
related O O
to O O
plasma O O
CETP O O
mass O O
, O O
high O O
- O O
density O O
lipoprotein O O
- O O
cholesterol O O
( O O
HDL O O
- O O
C O O
) O O
and O O
apolipoprotein O O
A O O
- O O
I O O
measured O O
during O O
liberal O O
sodium O O
diet O O
. O O

RESULTS O O
: O O
CETP O O
mass O O
ranged O O
from O O
1.29 O O
to O O
2.95 O O
mg O O
/ O O
l O O
. O O

No O O
significant O O
differences O O
in O O
( O O
changes O O
) O O
in O O
mean O O
arterial O O
pressure O O
, O O
aldosterone O O
and O O
active O O
plasma O O
renin O O
concentration O O
in O O
response O O
to O O
low O O
sodium O O
were O O
observed O O
between O O
the O O
lowest O O
and O O
highest O O
tertiles O O
of O O
CETP O O
mass O O
, O O
HDL O O
- O O
C O O
and O O
apolipoprotein O O
A O O
- O O
I O O
. O O

These O O
outcome O O
variables O O
were O O
also O O
not O O
significantly O O
correlated O O
with O O
CETP O O
, O O
HDL O O
- O O
C O O
and O O
apolipoprotein O O
A O O
- O O
I O O
, O O
except O O
for O O
a O O
modest O O
relation O O
of O O
aldosterone O O
measured O O
during O O
low O O
sodium O O
with O O
apolipoprotein O O
A O O
- O O
I O O
( O O
r O O
= O O
0.28 O O
, O O
p O O
= O O
0.022 O O
) O O
. O O

Blood O O
pressure O O
response O O
to O O
angiotensin O O
- O O
II O O
was O O
similar O O
between O O
CETP O O
tertiles O O
. O O

CONCLUSIONS O O
: O O
Mineralocorticoid O O
and O O
blood O O
pressure O O
responsiveness O O
to O O
dietary O O
salt O O
intake O O
are O O
not O O
significantly O O
related O O
to O O
physiological O O
interindividual O O
differences O O
in O O
plasma O O
CETP O O
. O O

We O O
suggest O O
that O O
a O O
lower O O
CETP O O
mass O O
does O O
not O O
exert O O
adverse O O
effects O O
on O O
blood O O
pressure O O
regulation O O
. O O

D O O
- O O
chiro O O
- O O
inositol O O
- O O
enriched O O
tartary O O
buckwheat O O
bran O O
extract O O
lowers O O
the O O
blood O O
glucose O O
level O O
in O O
KK O O
- O O
Ay O O
mice O O
. O O

D O O
- O O
chiro O O
- O O
inositol O O
( O O
DCI O O
) O O
is O O
an O O
active O O
compound O O
in O O
tartary O O
buckwheat O O
[ O O
Fagopyrum O O
tataricum O O
( O O
L O O
. O O
) O O

Gaench O O
] O O
with O O
an O O
insulin O O
- O O
like O O
bioactivity O O
. O O

The O O
present O O
study O O
was O O
performed O O
to O O
( O O
i O O
) O O
prepare O O
DCI O O
- O O
enriched O O
tartary O O
buckwheat O O
bran O O
extract O O
( O O
TBBE O O
) O O
, O O
( O O
ii O O
) O O
evaluate O O
its O O
acute B-Disease B-Disease
toxicity I-Disease I-Disease
in O O
mice O O
, O O
and O O
( O O
iii O O
) O O
examine O O
its O O
blood O O
glucose O O
lowering O O
activity O O
in O O
diabetic O B-Disease
mice O O
. O O

It O O
was O O
found O O
that O O
steaming O O
buckwheat O O
bran O O
in O O
an O O
autoclave O O
at O O
1.6 O O
MPa O O
and O O
120 O O
degrees O O
C O O
for O O
60 O O
min O O
could O O
significantly O O
enrich O O
the O O
DCI O O
level O O
in O O
TBBE O O
from O O
0.03 O O
to O O
0.22 O O
% O O
and O O
further O O
to O O
22 O O
% O O
after O O
passage O O
of O O
the O O
TBBE O O
through O O
activated O O
carbon O O
and O O
ion O O
exchange O O
resins O O
. O O

An O O
acute B-Disease B-Disease
toxicity I-Disease I-Disease
test O O
demonstrated O O
that O O
the O O
LD O O
50 O O
of O O
TBBE O O
was O O
> O O
20 O O
g O O
/ O O
kg O O
of O O
body O O
weight O O
in O O
mice O O
, O O
suggesting O O
that O O
TBBE O O
was O O
in O O
general O O
nontoxic O O
and O O
safe O O
in O O
mice O O
. O O

Male O O
KK O O
- O O
A O O
( O O
y O O
) O O
mice O O
( O O
type B-Disease O
2 I-Disease O
diabetic I-Disease B-Disease
) O O
and O O
C57BL O O
/ O O
6 O O
mice O O
( O O
the O O
control O O
) O O
were O O
used O O
to O O
investigate O O
the O O
antidiabetic O O
activity O O
of O O
TBBE O O
. O O

In O O
KK O O
- O O
A O O
( O O
y O O
) O O
mice O O
, O O
the O O
blood O O
glucose O O
, O O
plasma O O
C O O
- O O
peptide O O
, O O
glucagon O O
, O O
total O O
cholesterol O O
, O O
triglyceride O O
, O O
and O O
blood O O
urea O O
nitrogen O O
( O O
BUN O O
) O O
levels O O
were O O
significantly O O
higher O O
than O O
those O O
in O O
the O O
C57BL O O
/ O O
6 O O
mice O O
. O O

In O O
addition O O
, O O
KK O O
- O O
A O O
( O O
y O O
) O O
mice O O
showed O O
an O O
obvious O O
decrease O O
in O O
insulin O O
immunoreactivity O O
in O O
the O O
pancreas O O
. O O

The O O
present O O
study O O
clearly O O
demonstrated O O
that O O
oral O O
administration O O
of O O
DCI O O
- O O
enriched O O
TBBE O O
could O O
lower O O
plasma O O
glucose O O
, O O
C O O
- O O
peptide O O
, O O
glucagon O O
, O O
triglyceride O O
, O O
and O O
BUN O O
, O O
improve O O
glucose O O
tolerance B-Disease O
, O O
and O O
enhance O O
insulin O O
immunoreactivity O O
in O O
KK O O
- O O
A O O
( O O
y O O
) O O
mice O O
. O O

Optimal O O
timing O O
for O O
adjuvant O O
radiation O O
therapy O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
: O O
a O O
comprehensive O O
review O O
and O O
perspectives O O
. O O

PURPOSE O O
: O O
The O O
optimal O O
sequence O O
of O O
modalities O O
involved O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
treatment O O
with O O
respect O O
to O O
radiotherapy O O
and O O
the O O
maximum O O
acceptable O O
interval O O
between O O
radiotherapy O O
and O O
surgery O O
need O O
to O O
be O O
determined O O
. O O

DESIGN O O
: O O
This O O
review O O
attempts O O
a O O
critical O O
reading O O
of O O
the O O
literature O O
. O O

RESULTS O O
: O O
A O O
delay O O
of O O
radiotherapy O O
more O O
than O O
8 O O
- O O
12 O O
weeks O O
after O O
surgery O O
adversely O O
affects O O
local O O
recurrence O O
. O O

Radiotherapy O O
should O O
be O O
administered O O
within O O
7 O O
months O O
after O O
surgery O O
, O O
when O O
chemotherapy O O
is O O
administered O O
first O O
. O O

Several O O
chemotherapy O O
regimens O O
can O O
be O O
safely O O
administered O O
concurrently O O
with O O
radiotherapy O O
. O O

The O O
concurrent O O
use O O
of O O
tamoxifen O O
with O O
chemotherapy O O
should O O
be O O
avoided O O
, O O
but O O
not O O
with O O
radiotherapy O O
. O O

Data O O
is O O
insufficient O O
with O O
regard O O
to O O
concurrent O O
use O O
of O O
aromatase O O
inhibitors O O
with O O
radiotherapy O O
. O O

The O O
use O O
of O O
trastuzumab O O
concomitantly O O
with O O
radiotherapy O O
may O O
enhance O O
toxicities O O
but O O
may O O
also O O
improve O O
its O O
efficacy O O
. O O

CONCLUSIONS O O
: O O
Although O O
the O O
issue O O
of O O
radiotherapy O O
delay O O
and O O
that O O
of O O
sequence O O
with O O
chemotherapy O O
or O O
tamoxifen O O
are O O
clarified O O
, O O
the O O
sequence O O
of O O
radiotherapy O O
with O O
aromatase O O
inhibitors O O
and O O
trastuzumab O O
needs O O
to O O
be O O
defined O O
. O O

Individual O O
radiosensitivity O O
may O O
influence O O
toxicity O O
. O O

New O O
biologic O O
markers O O
have O O
to O O
be O O
determined O O
in O O
the O O
future O O
for O O
tailoring O O
radiotherapy O O
in O O
breast B-Disease B-Disease
cancer I-Disease I-Disease
. O O

Determinants O O
of O O
negative O O
white O O
- O O
coat O O
effect O O
in O O
treated O O
hypertensive O B-Disease
patients O O
: O O
the O O
Jichi O O
Morning O O
Hypertension B-Disease B-Disease
Research O O
( O O
J O O
- O O
MORE O O
) O O
study O O
. O O

BACKGROUND O O
: O O
The O O
negative O O
white O O
- O O
coat O O
effect O O
( O O
WCE O O
) O O
, O O
a O O
phenomenon O O
in O O
which O O
out O O
- O O
of O O
- O O
office O O
blood O O
pressure O O
( O O
BP O O
) O O
is O O
higher O O
than O O
clinic O O
BP O O
, O O
has O O
not O O
been O O
well O O
examined O O
, O O
unlike O O
the O O
WCE O O
. O O

METHODS O O
: O O
As O O
part O O
of O O
the O O
Jichi O O
Morning O O
Hypertension B-Disease B-Disease
Research O O
study O O
, O O
in O O
which O O
clinic O O
and O O
home O O
BP O O
were O O
measured O O
in O O
969 O O
hypertensive O B-Disease
outpatients O O
, O O
405 O O
patients O O
with O O
normal O O
clinic O O
BP O O
were O O
separately O O
analyzed O O
. O O

Clinic O O
BP O O
was O O
measured O O
on O O
two O O
different O O
occasions O O
, O O
and O O
home O O
BP O O
was O O
measured O O
twice O O
in O O
the O O
morning O O
and O O
twice O O
in O O
the O O
evening O O
for O O
three O O
consecutive O O
days O O
. O O

Clinic O O
and O O
home O O
BP O O
were O O
each O O
averaged O O
from O O
all O O
readings O O
, O O
and O O
negative O O
WCE O O
was O O
defined O O
as O O
clinic O O
systolic O O
BP O O
( O O
SBP O O
) O O
lower O O
than O O
home O O
SBP O O
. O O

RESULTS O O
: O O
Negative O O
WCE O O
was O O
observed O O
in O O
324 O O
( O O
33 O O
% O O
) O O
of O O
the O O
patients O O
overall O O
and O O
in O O
173 O O
( O O
42 O O
% O O
) O O
of O O
the O O
patients O O
with O O
controlled O O
BP O O
( O O
clinic O O
BP O O
< O O
140 O O
/ O O
90 O O
mm O O
Hg O O
) O O
. O O

In O O
multiple O O
logistic O O
regression O O
analysis O O
adjusting O O
for O O
covariates O O
including O O
home O O
SBP O O
and O O
pulse O O
rate O O
, O O
negative O O
WCE O O
was O O
correlated O O
with O O
older O O
age O O
( O O
odds O O
ratio O O
( O O
OR O O
) O O
1.03 O O
, O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
1.01 O O
- O O
1.06 O O
) O O
and O O
male O O
gender O O
( O O
OR O O
1.08 O O
, O O
95 O O
% O O
CI O O
1.01 O O
- O O
1.14 O O
) O O
in O O
overall O O
subjects O O
. O O

Among O O
patients O O
with O O
well O O
- O O
controlled O O
clinic O O
BP O O
, O O
negative O O
WCE O O
was O O
significantly O O
correlated O O
with O O
the O O
presence O O
of O O
ischemic B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
( O O
OR O O
1.17 O O
, O O
95 O O
% O O
CI O O
1.04 O O
- O O
1.31 O O
) O O
. O O

The O O
association O O
of O O
negative O O
WCE O O
with O O
age O O
and O O
male O O
gender O O
remained O O
significant O O
under O O
stringent O O
criteria O O
( O O
negative O O
WCE O O
< O O
- O O
10.2 O O
mm O O
Hg O O
( O O
the O O
mean O O
- O O
1 O O
s O O
. O O

d O O
. O O
) O O
) O O
. O O

CONCLUSIONS O O
: O O
Negative O O
WCE O O
remaining O O
even O O
after O O
clinic O O
BP O O
is O O
controlled O O
may O O
be O O
related O O
to O O
cardiovascular O O
risk O O
factors O O
such O O
as O O
older O O
age O O
, O O
male O O
gender O O
, O O
and O O
a O O
history O O
of O O
ischemic B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
. O O

Addition O O
of O O
sildenafil O O
to O O
long O O
- O O
term O O
intravenous O O
epoprostenol O O
therapy O O
in O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
: O O
a O O
randomized O O
trial O O
. O O

BACKGROUND O O
: O O
Oral O O
sildenafil O O
and O O
intravenous O O
epoprostenol O O
have O O
independently O O
been O O
shown O O
to O O
be O O
effective O O
in O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
To O O
investigate O O
the O O
effect O O
of O O
adding O O
oral O O
sildenafil O O
to O O
long O O
- O O
term O O
intravenous O O
epoprostenol O O
in O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
. O O

DESIGN O O
: O O
A O O
16 O O
- O O
week O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
parallel O O
- O O
group O O
study O O
. O O

SETTING O O
: O O
Multinational O O
study O O
at O O
41 O O
centers O O
in O O
11 O O
countries O O
from O O
3 O O
July O O
2003 O O
to O O
27 O O
January O O
2006 O O
. O O

PATIENTS O O
: O O
267 O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
( O O
idiopathic O O
, O O
associated O O
anorexigen O O
use O O
or O O
connective B-Disease B-Disease
tissue I-Disease I-Disease
disease I-Disease I-Disease
, O O
or O O
corrected O O
congenital B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
) O O
who O O
were O O
receiving O O
long O O
- O O
term O O
intravenous O O
epoprostenol O O
therapy O O
. O O

INTERVENTION O O
: O O
Patients O O
were O O
randomly O O
assigned O O
to O O
receive O O
placebo O O
or O O
sildenafil O O
, O O
20 O O
mg O O
three O O
times O O
daily O O
, O O
titrated O O
to O O
40 O O
mg O O
and O O
80 O O
mg O O
three O O
times O O
daily O O
, O O
as O O
tolerated O O
, O O
at O O
4 O O
- O O
week O O
intervals O O
. O O

Of O O
265 O O
patients O O
who O O
received O O
treatment O O
, O O
256 O O
( O O
97 O O
% O O
) O O
patients O O
( O O
123 O O
in O O
the O O
placebo O O
group O O
and O O
133 O O
in O O
the O O
sildenafil O O
group O O
) O O
completed O O
the O O
study O O
. O O

MEASUREMENTS O O
: O O
Change O O
from O O
baseline O O
in O O
exercise O O
capacity O O
measured O O
by O O
6 O O
- O O
minute O O
walk O O
distance O O
( O O
primary O O
end O O
point O O
) O O
and O O
hemodynamic O O
measurements O O
, O O
time O O
to O O
clinical O O
worsening O O
, O O
and O O
Borg O O
dyspnea B-Disease B-Disease
score O O
( O O
secondary O O
end O O
points O O
) O O
. O O

RESULTS O O
: O O
A O O
placebo O O
- O O
adjusted O O
increase O O
of O O
28.8 O O
meters O O
( O O
95 O O
% O O
CI O O
, O O
13.9 O O
to O O
43.8 O O
meters O O
) O O
in O O
the O O
6 O O
- O O
minute O O
walk O O
distance O O
occurred O O
in O O
patients O O
in O O
the O O
sildenafil O O
group O O
; O O
these O O
improvements O O
were O O
most O O
prominent O O
among O O
patients O O
with O O
baseline O O
distances O O
of O O
325 O O
meters O O
or O O
more O O
. O O

Relative O O
to O O
epoprostenol O O
monotherapy O O
, O O
addition O O
of O O
sildenafil O O
resulted O O
in O O
a O O
greater O O
change O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
by O O
- O O
3.8 O O
mm O O
Hg O O
( O O
CI O O
, O O
- O O
5.6 O O
to O O
- O O
2.1 O O
mm O O
Hg O O
) O O
; O O
cardiac O O
output O O
by O O
0.9 O O
L O O
/ O O
min O O
( O O
CI O O
, O O
0.5 O O
to O O
1.2 O O
L O O
/ O O
min O O
) O O
; O O
and O O
longer O O
time O O
to O O
clinical O O
worsening O O
, O O
with O O
a O O
smaller O O
proportion O O
of O O
patients O O
experiencing O O
a O O
worsening O O
event O O
in O O
the O O
sildenafil O O
group O O
( O O
0.062 O O
) O O
than O O
in O O
the O O
placebo O O
group O O
( O O
0.195 O O
) O O
by O O
week O O
16 O O
( O O
P O O
= O O
0.002 O O
) O O
. O O

Health O O
- O O
related O O
quality O O
of O O
life O O
also O O
improved O O
in O O
patients O O
who O O
received O O
combined O O
therapy O O
compared O O
with O O
those O O
who O O
received O O
epoprostenol O O
monotherapy O O
. O O

There O O
was O O
no O O
effect O O
on O O
the O O
Borg O O
dyspnea O B-Disease
score O O
. O O

Of O O
the O O
side O O
effects O O
generally O O
associated O O
with O O
sildenafil O O
treatment O O
, O O
the O O
most O O
commonly O O
reported O O
in O O
the O O
placebo O O
and O O
sildenafil O O
groups O O
, O O
respectively O O
, O O
were O O
headache B-Disease B-Disease
( O O
34 O O
% O O
and O O
57 O O
% O O
; O O
difference O O
, O O
23 O O
percentage O O
points O O
[ O O
CI O O
, O O
12 O O
to O O
35 O O
percentage O O
points O O
] O O
) O O
, O O
dyspepsia B-Disease B-Disease
( O O
2 O O
% O O
and O O
16 O O
% O O
; O O
difference O O
, O O
13 O O
percentage O O
points O O
[ O O
CI O O
, O O
7 O O
to O O
20 O O
percentage O O
points O O
] O O
) O O
, O O
pain B-Disease B-Disease
in O O
extremity O O
( O O
18 O O
% O O
and O O
25 O O
% O O
; O O
difference O O
, O O
8 O O
percentage O O
points O O
[ O O
CI O O
, O O
- O O
2 O O
to O O
18 O O
percentage O O
points O O
] O O
) O O
, O O
and O O
nausea B-Disease B-Disease
( O O
18 O O
% O O
and O O
25 O O
% O O
; O O
difference O O
, O O
8 O O
percentage O O
points O O
[ O O
CI O O
, O O
- O O
2 O O
to O O
18 O O
percentage O O
points O O
] O O
) O O
. O O

LIMITATIONS O O
: O O
The O O
study O O
excluded O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
associated O O
with O O
other O O
causes O O
. O O

There O O
was O O
an O O
imbalance O O
in O O
missing O O
data O O
between O O
groups O O
, O O
with O O
8 O O
placebo O O
recipients O O
having O O
no O O
postbaseline O O
walk O O
assessment O O
compared O O
with O O
1 O O
sildenafil O O
recipient O O
. O O

These O O
patients O O
were O O
excluded O O
from O O
the O O
analysis O O
. O O

CONCLUSION O O
: O O
In O O
some O O
patients O O
with O O
pulmonary B-Disease B-Disease
arterial I-Disease I-Disease
hypertension I-Disease I-Disease
, O O
the O O
addition O O
of O O
sildenafil O O
to O O
long O O
- O O
term O O
intravenous O O
epoprostenol O O
therapy O O
improves O O
exercise O O
capacity O O
, O O
hemodynamic O O
measurements O O
, O O
time O O
to O O
clinical O O
worsening O O
, O O
and O O
quality O O
of O O
life O O
, O O
but O O
not O O
Borg O O
dyspnea B-Disease B-Disease
score O O
. O O

Increased O O
rates O O
of O O
headache B-Disease B-Disease
and O O
dyspepsia B-Disease B-Disease
occurred O O
with O O
the O O
addition O O
of O O
sildenafil O O
. O O

Capecitabine O O
: O O
have O O
we O O
got O O
the O O
dose O O
right O O
? O O

In O O
the O O
past O O
5 O O
- O O
10 O O
years O O
there O O
has O O
been O O
a O O
growing O O
trend O O
for O O
substituting O O
conventional O O
5 O O
- O O
fluorouracil O O
with O O
the O O
oral O O
prodrug O O
of O O
5 O O
- O O
fluorouracil O O
, O O
capecitabine O O
, O O
in O O
chemotherapy O O
regimens O O
. O O

This O O
regimen O O
change O O
is O O
based O O
on O O
evidence O O
of O O
the O O
efficacy O O
equivalence O O
of O O
these O O
two O O
drugs O O
and O O
the O O
lack O O
of O O
an O O
increase O O
in O O
overall O O
toxic O O
effects O O
when O O
capecitabine O O
is O O
used O O
. O O

Many O O
investigators O O
in O O
different O O
parts O O
of O O
the O O
world O O
have O O
determined O O
their O O
own O O
starting O O
dose O O
for O O
capecitabine O O
, O O
usually O O
based O O
on O O
their O O
experience O O
of O O
toxic O O
events O O
within O O
the O O
population O O
of O O
patients O O
they O O
treat O O
. O O

This O O
starting O O
dose O O
is O O
usually O O
between O O
1,000 O O
- O O
1,250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
, O O
which O O
is O O
generally O O
administered O O
twice O O
daily O O
for O O
14 O O
days O O
followed O O
by O O
7 O O
days O O
rest O O
. O O

This O O
Review O O
summarizes O O
why O O
there O O
may O O
indeed O O
not O O
be O O
a O O
universally O O
applicable O O
starting O O
dose O O
for O O
capecitabine O O
because O O
of O O
interpatient O O
differences O O
in O O
basic O O
physiology O O
, O O
pharmacogenomics O O
and O O
diet O O
. O O

This O O
article O O
also O O
explores O O
which O O
of O O
these O O
factors O O
contribute O O
to O O
the O O
observed O O
inter O O
- O O
regional O O
geographical O O
variation O O
in O O
capecitabine O O
toxicity O B-Disease
, O O
and O O
explains O O
why O O
even O O
within O O
a O O
region O O
various O O
factors O O
should O O
prompt O O
a O O
clinician O O
to O O
modify O O
the O O
starting O O
dose O O
. O O

Predicting O O
and O O
preventing O O
acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
after O O
cardiac O O
surgery O O
. O O

PURPOSE O O
OF O O
REVIEW O O
: O O
Acute B-Disease B-Disease
kidney I-Disease I-Disease
injury I-Disease I-Disease
( O O
AKI B-Disease B-Disease
) O O
after O O
cardiac O O
surgery O O
is O O
associated O O
with O O
significant O O
morbidity O O
and O O
mortality O O
. O O

Despite O O
the O O
proliferation O O
of O O
predictive O O
clinical O O
scoring O O
models O O
of O O
renal O O
risk O O
after O O
cardiac O O
surgery O O
, O O
limitations O O
in O O
preventing O O
AKI O B-Disease
through O O
the O O
use O O
of O O
pharmacological O O
agents O O
remain O O
. O O

Here O O
we O O
review O O
the O O
evolution O O
of O O
predictive O O
models O O
of O O
renal O O
risk O O
after O O
cardiac O O
surgery O O
, O O
and O O
highlight O O
the O O
important O O
gains O O
made O O
in O O
preventing O O
its O O
occurrence O O
. O O

RECENT O O
FINDINGS O O
: O O
Simple O O
risk O O
indices O O
predicting O O
AKI O B-Disease
after O O
cardiac O O
surgery O O
have O O
been O O
developed O O
and O O
can O O
now O O
be O O
readily O O
applied O O
clinically O O
. O O

However O O
, O O
studies O O
focusing O O
on O O
preventing O O
AKI O B-Disease
after O O
surgery O O
have O O
yet O O
to O O
demonstrate O O
any O O
consistent O O
renoprotective O O
effect O O
. O O

SUMMARY O O
: O O
Clinical O O
scoring O O
systems O O
predicting O O
AKI O B-Disease
risk O O
after O O
cardiac O O
surgery O O
are O O
available O O
and O O
should O O
be O O
employed O O
in O O
the O O
preoperative O O
assessment O O
. O O

Elucidation O O
of O O
beneficial O O
preventive O O
strategies O O
of O O
AKI O B-Disease
after O O
cardiac O O
surgery O O
requires O O
ongoing O O
research O O
. O O

Transient O O
gene O O
delivery O O
for O O
functional O O
enrichment O O
of O O
differentiating O O
embryonic O O
stem O O
cells O O
. O O

There O O
is O O
a O O
critical O O
need O O
for O O
new O O
sources O O
of O O
hepatocytes O O
, O O
both O O
clinically O O
to O O
provide O O
support O O
for O O
patients O O
with O O
liver B-Disease B-Disease
failure I-Disease I-Disease
and O O
in O O
drug O O
discovery O O
for O O
toxicity O O
, O O
metabolic O O
and O O
pharmacokinetic O O
screening O O
of O O
new O O
drug O O
entities O O
. O O

We O O
have O O
reported O O
previously O O
a O O
variety O O
of O O
methods O O
for O O
differentiating O O
murine O O
embryonic O O
stem O O
( O O
ES O O
) O O
cells O O
into O O
hepatocyte O O
- O O
like O O
cells O O
. O O

One O O
major O O
challenge O O
of O O
our O O
work O O
and O O
others O O
in O O
the O O
field O O
has O O
been O O
the O O
ability O O
to O O
selectively O O
purify O O
and O O
enrich O O
these O O
cells O O
from O O
a O O
heterogeneous O O
population O O
. O O

Traditional O O
approaches O O
for O O
inserting O O
new O O
genes O O
( O O
e.g. O O
, O O
stable O O
transfection O O
, O O
knock O O
- O O
in O O
, O O
retroviral O O
transduction O O
) O O
involve O O
permanent O O
alterations O O
in O O
the O O
genome O O
. O O

These O O
approaches O O
can O O
lead O O
to O O
mutations O O
and O O
involve O O
the O O
extra O O
costs O O
and O O
time O O
of O O
developing O O
, O O
validating O O
and O O
maintaining O O
new O O
cell O O
lines O O
. O O

We O O
have O O
developed O O
a O O
transient O O
gene O O
delivery O O
system O O
that O O
uses O O
fluorescent O O
gene O O
reporters O O
for O O
purification O O
of O O
the O O
cells O O
. O O

Following O O
a O O
transient O O
transfection O O
, O O
the O O
cells O O
are O O
purified O O
through O O
a O O
fluorescence O O
- O O
activated O O
cell O O
sorter O O
( O O
FACS O O
) O O
, O O
re O O
- O O
plated O O
in O O
secondary O O
culture O O
and O O
subsequent O O
phenotypic O O
analysis O O
is O O
performed O O
. O O

In O O
an O O
effort O O
to O O
test O O
the O O
ability O O
of O O
the O O
reporters O O
to O O
work O O
in O O
a O O
transient O O
environment O O
for O O
our O O
differentiation O O
system O O
, O O
we O O
engineered O O
two O O
non O O
- O O
viral O O
plasmid O O
reporters O O
, O O
the O O
first O O
driven O O
by O O
the O O
mouse O O
albumin O O
enhancer O O
/ O O
promoter O O
and O O
the O O
second O O
by O O
the O O
mouse O O
cytochrome O O
P450 O O
7A1 O O
( O O
Cyp7A1 O O
) O O
promoter O O
. O O

We O O
optimized O O
the O O
transfection O O
efficiency O O
of O O
delivering O O
these O O
genes O O
into O O
spontaneously O O
differentiated O O
ES O O
cells O O
and O O
sorted O O
independent O O
fractions O O
positive O O
for O O
each O O
reporter O O
17 O O
days O O
after O O
inducing O O
differentiation O O
. O O

We O O
found O O
that O O
cells O O
sorted O O
based O O
on O O
the O O
Cyp7A1 O O
promoter O O
showed O O
significant O O
enrichment O O
in O O
terms O O
of O O
albumin O O
secretion O O
, O O
urea O O
secretion O O
and O O
cytochrome O O
P450 O O
1A2 O O
detoxification O O
activity O O
as O O
compared O O
to O O
enrichment O O
garnered O O
by O O
the O O
albumin O O
promoter O O
- O O
based O O
cell O O
sort O O
. O O

Development O O
of O O
gene O O
reporter O O
systems O O
that O O
allow O O
us O O
to O O
identify O O
, O O
purify O O
and O O
assess O O
homogeneous O O
populations O O
of O O
cells O O
is O O
important O O
in O O
better O O
understanding O O
stem O O
cell O O
differentiation O O
pathways O O
. O O

And O O
engineering O O
cellular O O
systems O O
without O O
making O O
permanent O O
gene O O
changes O O
will O O
be O O
critical O O
for O O
the O O
generation O O
of O O
clinically O O
acceptable O O
cellular O O
material O O
in O O
the O O
future O O
. O O

